<SEC-DOCUMENT>0001178913-19-000985.txt : 20190328
<SEC-HEADER>0001178913-19-000985.hdr.sgml : 20190328
<ACCEPTANCE-DATETIME>20190328171714
ACCESSION NUMBER:		0001178913-19-000985
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190328
DATE AS OF CHANGE:		20190328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Check-Cap Ltd
		CENTRAL INDEX KEY:			0001610590
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36848
		FILM NUMBER:		19712947

	BUSINESS ADDRESS:	
		STREET 1:		ABBA HUSHI AVENUE
		STREET 2:		P.O. BOX 1271
		CITY:			ISFIYA
		STATE:			L3
		ZIP:			3009000
		BUSINESS PHONE:		972-4-8303400

	MAIL ADDRESS:	
		STREET 1:		ABBA HUSHI AVENUE
		STREET 2:		P.O. BOX 1271
		CITY:			ISFIYA
		STATE:			L3
		ZIP:			3009000
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>zk1922847.htm
<DESCRIPTION>20-F
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.5.0.0
    Copyright 1995 - 2019 Broadridge-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" text="#000000" bgcolor="#ffffff">
<div>
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 1px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">UNITED STATES</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Washington, D.C. 20549</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 14pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">FORM 20-F</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc0a2a4f490bb49ad9982f46db092ad3d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 6.57%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#9744;</div>
</td>
<td style="WIDTH: 93.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">OR</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc362a6a8155d401b8c41467f507f3bd7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 6.57%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#9744;</div>
</td>
<td style="WIDTH: 93.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">For the fiscal year ended December 31, 2018</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">OR</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zec9e39bcac524a6980ff410b667ef0f6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 6.57%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#9744;</div>
</td>
<td style="WIDTH: 93.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">OR</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1d7ae0e095b34c9ba0c14dc53b94fb0c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 6.57%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#9744;</div>
</td>
<td style="WIDTH: 93.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">for the transition period from __________ to ___________</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Commission file number<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"> 001-36848</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 16pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Check-Cap Ltd.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z835acf28ecdc4f6996e5d14eab8b33c8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 33.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 33.33%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 33.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(Exact name of the Registrant as specified in its charter)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Israel</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9ca0b511241a492ea931104e9e205cc9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 33.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 33.33%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 33.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(Jurisdiction of incorporation or organization)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Check-Cap Building</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">29 Abba Hushi Avenue</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">P.O. Box 1271</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Isfiya, 3009000, Israel</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0fc6a8e31f8a45e6ad1061192497960c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 33.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 33.33%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 33.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(Address of principal executive offices)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Securities registered or to be registered pursuant to Section 12(b) of the Act:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><u>Title of Each Class</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Ordinary Shares, par value NIS 2.40</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><u>Name of each exchange on which registered</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Nasdaq Capital Market</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Securities registered or to be registered pursuant to Section 12(g) of the Act:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">None</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">As of December 31, 2018, the registrant had 5,328,700 ordinary shares outstanding, NIS 2.40 par value per share.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Yes&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9746;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Yes <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9746;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Yes <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9746;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Yes <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9746;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z33d43ed079d34c2495c72411c35ba0c8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 25.75%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font>&#160;&#160; Large Accelerated filer</div>
</td>
<td style="WIDTH: 20.75%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font>&#160;&#160; Accelerated filer</div>
</td>
<td style="WIDTH: 23.75%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9746;</font>&#160; Non-accelerated filer</div>
</td>
<td style="WIDTH: 29.75%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9746;</font>&#160;&#160; Emerging growth company</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z67003c021b5f478ea84f0c432a9799e9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 21.65%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; MARGIN-LEFT: 8.8pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -8.8pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9746;</font>&#160;&#160; US GAAP</div>
</td>
<td style="WIDTH: 62.17%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font>&#160;&#160; International Financial Reporting</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Standards as issued by the International Accounting Standards Board</div>
</td>
<td style="WIDTH: 16.19%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font>&#160;&#160; Other</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font>&#160;&#160; Item 17&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font>&#160;&#160; Item 18</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Yes <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9746;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of the securities under a plan confirmed by a court.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Yes <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Segoe UI Symbol', sans-serif">&#9744;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always; TEXT-ALIGN: center">ii

<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">TABLE OF CONTENTS </div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3e41654967804ebd9e1c0da2337c0dae" style="FONT-SIZE: 10pt; BORDER-TOP: medium none; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#PARTI">PART I</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">Page</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM1">Item 1.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM1">Identity of Directors, Senior Management and Advisers</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;3</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM2">Item 2.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM2">Offer Statistics and Expected Timetable</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;3</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM3">Item 3.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM3">Key Information</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;3</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Selected financial data</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">3</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Capitalization and indebtedness</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">4</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Reasons for the offer and use of proceeds</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">4</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Risk factors</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">4</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM4">Item 4.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM4">Information on Our Company</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;33</td>
</tr>

<tr style="HEIGHT: 15px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">History and Development of the Company</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">33</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Business Overview</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">33</td>
</tr>

<tr style="HEIGHT: 15px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Organizational Structure</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">54</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Property, Plants and Equipment</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">54</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM4A">Item 4A.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM4A">Unresolved Staff Comments</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">54</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM5">Item 5.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM5">Operating and Financial Review and Prospects</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">55</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Operating Results</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">56</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Liquidity and Capital Resources</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">60</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Research and development, patents and licenses, etc.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">64</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Trend Information</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">65</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">E.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Off-balance Sheet Arrangements</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">65</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">F.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Tabular Disclosure of Contractual Obligations.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">65</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM6">Item 6.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM6">Directors, Senior Management and Employees</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">65</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Directors and senior management</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">65</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Compensation</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">68</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Board Practices</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">71</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Employees</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">81</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">E.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Share Ownership</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">81</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM7">Item 7.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM7">Major Shareholders and Related Transactions</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">85</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Major shareholders</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">85</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Related party transactions</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">86</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Interests of experts and counsel</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">88</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM8">Item 8.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM8">Financial Information</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">88</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Statements and Other Financial Information</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">88</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Significant Changes</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">89</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM9">Item 9.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM9">The Offer and Listing</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">89</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Offer and listing details</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">89</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Plan of distribution</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">89</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Markets</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">89</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Selling shareholders</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">89</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">E.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Dilution</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">89</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">F.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Expenses of the issue</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">90</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM10">Item 10.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM10">Additional Information</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">90</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Share capital</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">90</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Memorandum and articles of association</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">90</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Material contracts</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">94</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Exchange controls</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">94</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">E.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Taxation</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">94</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9294054c76644f82a9424372cc66c7d3" style="FONT-SIZE: 10pt; BORDER-TOP: medium none; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">F.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Dividends and paying agents</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;105</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">G.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Statement by experts</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;105</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">H.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Documents on display</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;105</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: right; LINE-HEIGHT: 1.25">I.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Subsidiary Information</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;106</td>
</tr>
</table>

<div>&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always; TEXT-ALIGN: center">iii

<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z82cfdeadbe0c45968f2e8bccb35814c4" style="FONT-SIZE: 10pt; BORDER-TOP: medium none; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM11">Item 11.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM11">Quantitative and Qualitative Disclosure About Market Risk</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">106</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM12">Item 12.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM12">Description of Securities Other Than Equity Securities</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">106</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none" colspan="4">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#PARTII">PART II</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM13">Item 13.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM13">Defaults, Dividend Arrearages and Delinquencies</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">106</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM14">Item 14.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM14">Material Modifications to The Rights of Security Holders and Use Of Proceeds</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">106</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM15">Item 15.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM15">Controls and Procedures</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">107</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16">Item 16</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16">[Reserved]</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">107</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16">Item 16A</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16A">Audit Committee Financial Expert</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">107</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16B">Item 16B</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16B">Code of Ethics</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">107</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16C">Item 16C</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16C">Principal Accountant Fees and Services</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">107</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16D">Item 16D</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16D">Exemption from the Listing Standards for Audit Committees</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">108</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16E">Item 16E</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16E">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">108</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16F">Item 16F</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16F">Change in Registrant&#8217;s Certifying Accountant</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">108</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16G">Item 16G</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16G">Corporate Governance</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">108</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16H">Item 16H</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM16H">Mine Safety Disclosure</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">109</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none" colspan="4">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#PARTIII">PART III</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM17">Item 17</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM17">Financial Statements</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">109</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM18">Item 18.</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM18">Financial Statements</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">109</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM19">Item 19</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#ITEM19">Exhibits</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">110</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 2%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 78%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">&#160;</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none" colspan="3">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a href="#SIGNATURES">Signatures</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; TEXT-ALIGN: right; BORDER-LEFT: medium none">112</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always; TEXT-ALIGN: center">iv

<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CERTAIN INFORMATION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Beginning with the fourth quarter of 2015, we have prepared our consolidated financial statements in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP.&#160;We recast the comparative amounts included in our 2015 financial statements to U.S. GAAP.&#160;Prior to the fourth quarter of 2015, we prepared our financial reports in accordance with International Financial Reporting Standards as issued by International Accounting Standard Board, or IFRS. We elected to use U.S. GAAP to increase the transparency and comparability of our financial reports and facilitate research and analysis by shareholders, analysts and other participants in the U.S. capital markets.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In this Annual Report on Form 20-F, or the Annual Report, unless the context indicates otherwise, references to &#8220;NIS&#8221; are to the legal currency of Israel, &#8220;U.S. dollars,&#8221; &#8220;$&#8221; or &#8220;dollars&#8221; are to United States dollars, and the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our company,&#8221; &#8220;our,&#8221; and &#8220;Check-Cap&#8221; refer to Check-Cap Ltd. Unless otherwise indicated, U.S. dollar translation of NIS amounts presented in this Annual Report are translated using the rate of $1.00 = NIS 3.748, the exchange rate published by the Bank of Israel on December 31, 2018, and U.S. dollar translation of Euro amounts presented in this Annual Report are translated using the rate of $1.00 = Euro 1.1469, the exchange rates published by the Wall Street Journal on December 31, 2018.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We effected a 1-for-12 reverse stock split of our ordinary shares effective as of April 4, 2018, in accordance with the approval of our shareholders at a meeting held on April 2, 2018.&#160; All share numbers in this Annual Report are reflected on a post-reverse stock split basis.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; MARGIN-LEFT: 86.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -86.9pt">USE OF TRADE NAMES AND TRADEMARKS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Throughout this Annual Report, we refer to various trademarks, service marks and trade names that we use in our business.&#160; The &#8220;CHECK-CAP&#8221; and &#8220;C-Scan&#8221; trademarks and design logos are the property of Check-Cap Ltd.&#160; Other trademarks and service marks appearing in this Annual Report are the property of their respective holders.&#160; We do not intend our use or display of other companies&#8217; tradenames, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by these other companies.&#160; Solely for convenience, trademarks and trade names referred to in this Annual Report appear without the &#174; or <sup style="vertical-align: text-top; line-height: 1; font-size: smaller">TM</sup> &#160; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">FORWARD-LOOKING STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">This Annual Report contains forward-looking statements, about our expectations, beliefs or intentions regarding, among other things, our ongoing and planned product development and clinical trials; the timing of, and our ability to make, regulatory filings and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; the degree of clinical utility of our products, particularly in specific patient populations; our ability to develop commercial functions; expectations regarding product launch and revenue; our results of operations, cash needs; financial condition, liquidity, prospects, growth and strategies; the industry in which we operate; and the trends that may affect the industry or us. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should&#8221; or &#8220;anticipate&#8221; or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the U.S. Securities and Exchange Commission, or the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">This Annual Report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements, particularly those set forth under the heading &#8220;Risk Factors.&#8221; The risk factors included in this Annual Report are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="zcb452ca28f5e414a86606f81f2d028d8" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our history of losses and our ability to continue as a going concern;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="z904d591fca9d4444b09e4748a6f0140e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="zdaddf46fff04430b98b6aec14218a229" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">the initiation, timing, progress and results of our clinical trials and other product development efforts;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="z1b0c006b0e79453e8958f605098b4b87" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our reliance on one product or product line;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<!--PROfilePageNumberReset%Num%2%%%-->
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="z1bc5b446c13f4697ae22f568413c1e3c" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">the clinical development, commercialization and market acceptance of our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="z9bed9dd1e71c46aa91e9ad9b3a814497" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our ability to receive de novo classification and other regulatory approvals for our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="zc3d792ed96c4416286d250464b5cc795" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our ability to successfully complete clinical trials;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -26.6pt"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="z4baf4a9b149d4453b292f0c78f48c458" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our reliance on single-source suppliers;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="zab527a8327e24767a4454f3b507e4186" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our reliance on third parties<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, such as for purposes of our clinical trials and clinical development and the marketing and distribution of our C-Scan system;</font></div>
</td>
</tr>
</table>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 9.4pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our ability to establish and maintain strategic partnerships and other corporate collaborations;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="z37222118f68d4ab7bdf000b82f982d73" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our ability to achieve reimbursement and coverage from government and private third-party payors;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="z4c62b0f2cd914de4a89ead84161fea3c" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#160;&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">the implementation of our business model and strategic plans for our business;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -26.6pt"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="z5042a75b49464e209b1132527e217917" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#160;&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">the scope of protection we are able to establish and maintain for intellectual property rights covering our C-Scan system and our ability to operate our business without infringing the intellectual property rights of others;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="z758d27cb03e54eb09aed777cc4f0cb3c" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#160;&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">competitive companies, technologies and our industry;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="zce230d371b424760aa554b7f464607c4" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#160;&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">statements as to the impact of the political and security situation in Israel on our business; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="zfa7968fb197e46c5849209605719dd00" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 45.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 26.6pt; VERTICAL-ALIGN: top; align: right">&#9679;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">those factors referred to in &#8220;Item 3. Key Information &#8211; D. Risk Factors,&#8221; &#8220;Item 4. Information on the Company,&#8221; and &#8220;Item 5. Operating and Financial Review and Prospects&#8221;, as well as in this Annual Report generally.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 72pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -26.6pt"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this Annual Report and are expressly qualified in their entirety by the cautionary statements included in this Annual Report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">EXPLANATORY NOTE</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 36pt">Market data and certain industry data and forecasts used throughout this Annual Report were obtained from internal company surveys, market research, consultant surveys commissioned by the Company, publicly available information, reports of governmental agencies and industry publications and surveys. Industry surveys, publications, consultant surveys commissioned by the Company and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable. However, this information may prove to be inaccurate because of the method by which some of the data for the estimates is obtained or because this information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. As a result, the market and industry data and forecasts included or incorporated by reference in this Annual Report, and estimates and beliefs based on that data, may not be reliable. We have relied on certain data from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be reliable based on our management&#8217;s knowledge of the industry. However, we have not ascertained the underlying economic assumptions relied upon therein. Forecasts are particularly likely to be inaccurate, especially over long periods of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing the forecasts we cite. Statements as to our market position are based to the best of our knowledge on the most currently available data. While we are not aware of any misstatements regarding the industry data presented in this Annual Report, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; in this Annual Report.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">2</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="PARTI" name="PARTI"><!--Anchor--></a>PART I</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM1" name="ITEM1"><!--Anchor--></a>ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf0fe911d86434d58b472e5d8ba42a6f4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.12%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 8.8pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -8.8pt">A.</div>
</td>
<td style="WIDTH: 96.88%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 8.8pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -8.8pt">Directors and Senior Management</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not required.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2b105046b1494dd0b548fb071114573e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Advisers</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not required.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z77c74c48a94a416dae4a385effbcf2e2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Auditors</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not required.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM2" name="ITEM2"><!--Anchor--></a>ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not required.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM3" name="ITEM3"><!--Anchor--></a>ITEM 3. KEY INFORMATION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7d8434e7b8d941218548ceada8e7df6e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Selected financial data</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following selected consolidated financial data should be read in conjunction with Item 5 &#8220;Operating and Financial Review and Prospects&#8221; and the consolidated Financial Statements and Notes thereto included elsewhere in this Annual Report.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following table summarizes our historical consolidated financial data. We have derived the selected consolidated statements of operations data for the years ended December 31, 2018, 2017 and 2016 and the selected consolidated balance sheet data as of December 31, 2018 and 2017 from our audited consolidated financial statements included elsewhere in this Annual Report. We have derived the selected consolidated statements of operations data for the years ended December 31, 2015 and 2014 and the selected consolidated financial data as of December 31, 2016, 2015 and 2014 from our audited consolidated financial statements not included in this Annual Report. Our&#160;Consolidated Financial Statements have been prepared in accordance with U.S. GAAP.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Certain factors that affect the comparability of the information set forth in the following table are described in Item 5 &#8220;Operating and Financial Review and Prospects&#8221; and the Consolidated Financial Statements and related notes thereto included elsewhere in this Annual Report.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Consolidated Statements of Operations Data</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z04acb3062b64419aae1f6cb1ae238428" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="18">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year Ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2014</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="18">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(US$ in thousands, except per share data)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Operating expenses<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Research and development expenses, net</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,618</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,837</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,491</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,837</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,832</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">General and administrative expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,445</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,164</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,571</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,626</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,703</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Operating loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">11,063</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,001</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,062</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12,463</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,535</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Finance income, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">473</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">236</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">244</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">173</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,925</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Loss before income tax&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,590</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,765</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,818</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12,290</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">610</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Taxes on income&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(1</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Net loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,589</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12,290</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">610</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Comprehensive loss:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;Net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,589</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12,290</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">610</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;Change in fair value of cash flow hedge</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">13</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: bold; FONT-STYLE: normal; BACKGROUND-COLOR: #ffffff"><u>Comprehensive loss</u></font></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,602</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12,290</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">610</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Net loss per ordinary share of NIS 2.40 par value, basic and diluted</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160; (3)</sup></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.61</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6.72</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7.31</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12.67</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">14.12</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Weighted average&#160;number of ordinary shares outstanding &#8211; basic and diluted (in thousands)</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160; (3)</sup></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,058</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,455</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,208</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">993</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">182</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">3</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Consolidated Balance Sheet Data</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb0a2e21a2a9d43a9b7a752e15c8b4ca2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="18">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">As of December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2015</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2014</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="18">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(US$ in thousands, except per share data)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Cash and cash equivalents&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,572</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,997</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">11,639</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,392</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,075</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Working capital<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(4)</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12,763</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,841</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,514</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12,856</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(1,622</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total assets&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15,436</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,906</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12,295</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15,298</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,985</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Capital stock&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">76,344</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">58,617</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">53,348</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">46,763</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">20,999</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total shareholders&#8217; equity (deficiency)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">13,030</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,905</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,407</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12,648</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 20.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -20.9pt">______________________________</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6ce23ea431aa4372883ed4a3c36bfed9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(1)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Operating expenses include share-based compensation expense in the total amount of $0.7 million, $1.2 million, $3.7 million and $0.3 million for the years ended December&#160;31, 2017, 2016, 2015 and 2014, respectively and a negative share-based compensation expense of $65,000 as a result of forfeitures of awards for the year ended December 31, 2018. For additional information, see Item 5B &#8220;Operating and Financial Review and Prospects&#8212;Liquidity and Capital Resources&#8212;Application of Critical Accounting Policies and Estimates-Share-based compensation.&#8221;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;(2)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Research and development expenses, net is presented net of the amount of grants received from the Israel Innovation Authority, or IIA, of the Ministry of Economy and Industry (formerly the Office of the Chief Scientist, or OCS, of the Ministry of Economy and Industry), and the Israel-United States Binational Industrial Research and Development Foundation, or the BIRD Foundation.&#160; The effect of the participation by the IIA and the BIRD Foundation totaled $0.2 million, $1.1 million, $0.3 million and $0.6 million for the years ended December 31, 2018, 2017, 2016, 2015 and 2014, respectively. See Item 5A &#8220;Operating and Financial Review and Prospects&#8212;Operating Results - Financial Operations Overview&#8212;Research and Development, Expenses, Net&#8221; for more information.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(3)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Basic and diluted loss per ordinary share is computed based on the basic and diluted weighted average number of ordinary shares outstanding during each period.&#160; For purposes of these calculations, the following ordinary shares were deemed to be outstanding: (i) 8,315 ordinary shares that were issuable to Guy Neev upon exercise of options, referred to as the Neev Options, which options were exercised immediately prior to the consummation of our initial public offering on February 24, 2015; (ii) 32,174 ordinary shares that were issuable under warrants that were subject to automatic exercise, for no consideration (unless the holder thereof objected to such exercise), upon the exercise by Guy Neev of the Neev Options, of which warrants to purchase&#160;7,724, 56 and 17,149 ordinary shares were exercised during the years ended December 31, 2018, 2016 and 2015, respectively.&#160; No such warrants were exercised during the year ended December 31, 2017; (iii) since October 14, 2014, 221,556 ordinary shares issuable upon the exercise of outstanding warrants with an exercise price of NIS 2.40 per share, of which warrants to purchase 22,501, 9,912, 43,739 and 129,797 ordinary shares were exercised during the years ended December 31, 2018, 2017, 2016 and 2015, respectively, and warrants to purchase 5,192, 243, 761 and 2,022 ordinary shares expired during the years ended December 31, 2018, 2017, 2016 and 2015, respectively; (iv) since August 11, 2016, 209,524 ordinary shares issuable upon the exercise of outstanding pre-funded warrants with an exercise price of NIS 2.40 per share, of which pre-funded warrants to purchase 24,167 and 185,357 ordinary shares were exercised during the years ended December 31, 2017 and 2016, respectively; and&#160;(v) since May 8, 2018, 450,909 ordinary shares issuable upon the exercise of outstanding pre-funded warrants with an exercise price of $0.01 per share; these pre-funded warrants were fully exercised between May 8, 2018 and May 17, 2018.&#160; For additional information, see Note&#160;9 to our Consolidated Financial Statements for the year ended December 31, 2018 included elsewhere in this Annual Report.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(4)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Working capital is defined as total current assets minus total current liabilities.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z756387fc891f4c3faad4134d1434631a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Capitalization and Indebtedness</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not required.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0ecfb493055d4c19b68d18dfd79f766c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Reasons for the Offer and Use of Proceeds</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not required.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze7a20b9aa1314449b4c2add873365d93" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Risk factors</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In conducting our business, we face many risks that may interfere with our business objectives. Some of these risks could materially and adversely affect our business, financial condition and results of operations. In particular, we are subject to various risks resulting from changing economic, political, industry, business and financial conditions. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">You should carefully consider the following factors and other information in this Annual Report before you decide to invest in our ordinary shares. If any of the risks referred to below occur, our business, financial condition and results of operations could suffer. In any such case, the trading price of our ordinary shares could decline, and you may lose all or part of your investment.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">4</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Risks Related to Our Financial Position</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We have a history of losses, may incur future losses and may not achieve profitability.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are a clinical and development-stage medical diagnostics company with a limited operating history.&#160;We have incurred net losses in each fiscal year since we commenced operations in 2009.&#160; We incurred net losses of $10.6 million in 2018, $9.8 million in 2017 and $8.8 million in 2016.&#160; As of December 31, 2018, our accumulated deficit was $63.3&#160;million.&#160; Our losses could continue for the foreseeable future as we continue our investment in research and development and clinical trials to complete the development of our technology and to attain regulatory approvals, begin the commercialization efforts for our C-Scan system, increase our marketing and selling expenses, and incur additional costs as a result of being a public company in the United States. Successful completion of our development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill our development activities and our ability to successfully commercialize our C-Scan system and achieve a level of sales adequate to support our cost structure. The extent of our future operating losses and the timing of becoming profitable are highly uncertain, and we may never achieve or sustain profitability.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Our recurring operating losses have raised substantial doubt regarding our ability to continue as a going concern.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As of December 31, 2018, we had an accumulated deficit of $63.3 million. Our recurring operating losses raise substantial doubt about our ability to continue as a going concern. Our financial statements include a note describing the conditions which raise this substantial doubt. As a result, our independent registered public accounting firm included a &#8220;going concern&#8221; explanatory paragraph in its report on our financial statements as of and for the year ended December 31, 2018 with respect to this uncertainty. Our ability to continue as a going concern will require us to obtain additional financing to fund our operations. The perception of our ability to continue as a going concern may make it more difficult for us to obtain financing or obtain financing on favorable terms for the continuation of our operations and could result in the loss of confidence by investors, suppliers and employees. If we are not successful in raising capital through equity offerings, debt financings, collaborations, licensing arrangements or any other means or are not successful in reducing our expenses, we may exhaust our cash resources and will be unable to continue our operations. If we cannot continue as a viable entity, our shareholders would likely lose most or all of their investment in us.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We will require additional funding in order to complete the development and commercialization of our C-Scan system, which may cause dilution to our existing shareholders, restrict our operations or require us to relinquish rights to our C-Scan system or intellectual property. If additional capital is not available, we may have to delay, reduce or cease the development or commercialization of our C-Scan system.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our operations have consumed substantial amounts of cash. We expect that we will need to continue to raise and spend substantial amounts in order to complete the clinical development, regulatory approval and commercialization of our C-Scan system. We intend to use the remaining proceeds of our May 2018 and February 2019 public offerings to finance these efforts and believe that we have sufficient capital to fund our operations into February 2020, and we will therefore need to raise additional funds to obtain the required capital prior to completing the development and commercialization of our C-Scan system (see Item 5B &#8220;Operating and Financial Review and Prospects &#8212; Liquidity and Capital Resources &#8212; Sources of Liquidity&#8221;). We may seek additional funding through equity offerings, debt financings, collaborations, licensing arrangements or any other means to conduct clinical trials and develop and market our C-Scan system or for our general corporate purposes. Securing additional financing may divert our management&#8217;s attention from its day-to-day activities, which may adversely affect our ability to develop and commercialize our C-Scan system. Additional financing may not be available to us on a timely basis on terms acceptable to us, or at all.&#160; In addition, if we raise additional funds by issuing equity securities, you may experience significant dilution of your ownership interest and the newly issued securities may have rights senior to those of the holders of our ordinary shares. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our ordinary shares to decline.&#160; Alternatively, if we raise funds by obtaining loans from third parties, the terms of those financing arrangements may include negative covenants, may require us to grant a lender a security interest in our assets or may include other restrictions on our business that could impair our operational flexibility, and could also result in interest expense. If we raise additional funds through collaborations,&#160;licensing arrangements&#160;or other structured financing transactions, we may relinquish rights to certain of our technologies or products, grant security interests in our assets&#160;or grant licenses to third parties on terms that are unfavorable to us. If adequate additional financing on acceptable terms is not available, we may not be able to develop our C-Scan system at the rate or to the stage we desire and we may have to delay or abandon the commercialization of our C-Scan system. Any of these factors could materially adversely affect our business, financial condition and results of operations.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">5</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Risks Related to Our Business</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">We may not succeed in completing the development of our product, commercializing our product and generating significant revenues</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Since commencing our operations, we have focused on the research and development and limited clinical trials of our C-Scan system. Although we have received CE Mark approval for the marketing and sale of our C-Scan system in the European Union, we have not commenced marketing and sales in the European Union and may require additional regulatory approval in each of the local jurisdictions in the European Union before we can commence marketing and sale of our C-Scan system, such as from the Swiss National Cooperative for the Disposal of Radioactive Waste (Nagra) and the German Federal Office for Radiation Protection (Bundesamt f&#252;r Strahlenschutz, BfS). In Israel we received approval <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">from the Medical Devices and Accessories Division of the Israeli Ministry of Health, or AMAR,</font> for the marketing and sale of the C-Scan system in Israel, which was valid until February 28, 2019. We have submitted a request to the Israeli Ministry of Health for the extension of the AMAR approval, which is currently pending. We have not received approvals in other jurisdictions, including the United States, and there can be no assurance that we will be able to receive regulatory approvals to commence marketing and sales for our C-Scan system in the foreseeable future or ever.&#160;Our ability to generate revenues and achieve profitability depends on our ability to successfully complete the development of our product, demonstrate sufficient clinical evidence, obtain required regulatory approvals and commercial licenses, generate significant revenues and manufacture commercial quantities of our C-Scan system at an acceptable cost. The future success of our business cannot be determined at this time, and we do not anticipate generating revenues from product sales for the foreseeable future.&#160;In addition, we have no experience in commercializing our C-Scan system and face a number of challenges with respect to our commercialization efforts, including, among others, that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf2f6c5d73db44ee09e6a6a17ad747435" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may not have adequate financial or other resources to complete the development of our product, demonstrate adequate clinical results, attain required regulatory approvals and licensures, and begin the commercialization efforts for our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z49015fe882124e3894160e3f3916f76f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may fail to obtain or maintain required regulatory approvals and licensures for our C-Scan system in our target markets or may face adverse regulatory or legal actions relating to our system even if regulatory approval is obtained;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za330bf0705c94e389dedba59c2e4a5c7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may not demonstrate adequate clinical safety and clinical effectiveness results to support regulatory body approval or market acceptance and adoption;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zefeafe4275964c0298a103d1ea69501f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may not be able to scale up the manufacture of our C-Scan system to commercial quantities at an adequate quality or at an acceptable cost;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc02d389d4a064448a8670af4717b7171" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may not be able to establish adequate sales, marketing and distribution channels;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z46aee3820c8f492ba4182746d889d4c0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">healthcare professionals and patients may not accept our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z033c2b6f1a2b4735976e2d72ebc032c9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may not be aware of possible complications from the continued use of our C-Scan system because we have limited clinical experience with respect to the actual use of our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z98657db645d641889b5b3687c812b0ec" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">other technological breakthroughs in CRC screening, treatment and prevention may reduce the demand for our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za83e755fd0f049bcb65dd98d0727f9bf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">changes in the market for CRC screening, new alliances between existing market participants and the entrance of new market participants may interfere with our market penetration efforts;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7cc154d91ad946e791fcd01c5fcfebba" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">government and private third-party payors may not agree to provide coding, coverage and payment adequate to reimburse healthcare providers and patients for any or all of the purchase price of our C-Scan system, which may adversely affect healthcare providers&#8217; and patients&#8217; willingness to purchase our C-Scan system;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">uncertainty as to market demand may result in inefficient pricing of our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze16c381577d2499b8b48f7d7e01ac78c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may not be able to adequately protect our intellectual property or may face third-party claims of intellectual property infringement; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8214389f237b41baba9a757ed1e34cf0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we are dependent upon the results of ongoing clinical studies relating to our C-Scan system and the products of our competitors.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If we are unable to meet any one or more of these challenges successfully, our ability to effectively commercialize our C-Scan system could be limited, which in turn could have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Clinical failure can occur at any stage of clinical development. Our clinical experience to date does not necessarily predict future results and may not have revealed certain potential limitations of the technology and potential complications from our C-Scan system and may require further clinical validation. Any product version we advance through clinical trials may not have favorable results in later clinical trials or receive regulatory approval.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Clinical failure can occur at any stage of clinical development. To date, we have performed clinical studies with iterative versions of both scanning and non-scanning capsules, in conjunction with iterative versions of the C-Scan Track tracking and recording systems and the C-Scan View application and we are continuing to develop further iterative versions of our C-Scan capsule. Our clinical trials have been conducted under differing protocols and using specific inclusion criteria and limited groups of patients. Therefore, we have a limited ability to identify potential problems and/or inefficiencies concerning current and future versions of our C-Scan system in advance of its use in general and expanded groups of patients and we cannot assure you that its actual clinical performances will be satisfactory to support proposed indications and regulatory approvals and clinical acceptance and adoption, or that its use will not result in unanticipated complications. For example, we have experienced technical failures of the C-Scan capsule in the current version of the C-Scan system and are currently engaged in implementing a plan to ensure greater reliability in the future. However, there can be no assurance that the implementation of our plan will be successful. Furthermore, the results from laboratory, pre-clinical, and completed clinical studies, as well as preliminary analyses or interim results of the currently ongoing clinical studies, may not be indicative of final clinical results obtained from our current C-Scan system or future versions of our C-Scan system on expanded screening populations. In addition, the results of our clinical trials are subject to human analyses and interpretation of the data accumulated, which could be affected by various errors due to, among others, lack of sufficient clinical experience with our C-Scan system, interpretation errors in the analysis of the clinical trials results, including the reconstructed images by our C-Scan system, or due to uncertainty in the actual efficacy of our C-Scan system in its current clinical stage. Therefore, the safety and efficacy of our C-Scan system and the clinical results to date will require further independent professional validation and require further clinical study. If our C-Scan system does not function as expected over time, we may not be able to develop our C-Scan system at the rate or to the stage we desire, we could be subject to liability claims, our reputation may be harmed, our C-Scan system may not achieve regulatory clearances, and our C-Scan system may not be widely adopted by healthcare providers and patients.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">6</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We expect to derive most of our revenues from sales of one product or product line.&#160; Our inability to successfully commercialize this product, or any subsequent decline in demand for this product, could severely harm our ability to generate revenues.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are currently dependent on the successful commercialization of our C-Scan system to generate revenues. As a result, factors adversely affecting our ability to successfully commercialize, or the pricing of or demand for, this product could have a material adverse effect on our financial condition and results of operations. If we are unable to successfully commercialize or create market demand for our C-Scan system, we will have limited ability to generate revenues.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Furthermore, we may be vulnerable to fluctuations in demand for our C-Scan system. Such fluctuations in demand may be due to many factors, many of which are beyond our control, including, among others:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1531d2c939284195a6b72c71cc3214ff" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">market acceptance of a new product, including healthcare professionals&#8217; and patients&#8217; preferences;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1b7789397c7d4cfcb572ab61d7938f7a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">market acceptance of the clinical safety and performance of our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z53b0ba92bb2544c2a7406b3c39aa10c6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">development of similarly cost-effective products by our competitors;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zbdec8392d517406ba33a12d5c3e0f828" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">development delays of our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0d421c469fec4da8ab689cb4065a71bb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">technological innovations in CRC screening, treatment and prevention;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zbc2e46a47dec4c03b28297bd40fee0ba" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">adverse medical side effects suffered by patients using our C-Scan system, whether actually resulting from the use of our C-Scan system or not;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6116c8b305f7472481c35567311a40dd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">changes in regulatory policies toward CRC screening or imaging technologies;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5d4614cf3b604f408dd33fd09096af12" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">changes in regulatory approval, clearance requirements and licensure for our product;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc71a15c40eb84bd29d2b500728eba92d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">third-party claims of intellectual property infringement;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z577ccd86c5994357bd08d9b150a7cedc" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">budget constraints and the availability of reimbursement or insurance coverage from third-party payors for our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z483aaac46f9f4e1f946eb8f21804dbec" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">increases in market acceptance of other technologies;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0215994d821441e0b96eada266c65eb4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">adverse responses from certain of our competitors to the offering of our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zde68f5cba52d4640b83e9fa726f9ab70" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">licensure and perceived risk of manufacturing and using a product containing a radioactive source; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9c07aa71fee74169bf956fcb5c361700" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the shelf life of our C-Scan Cap.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">If healthcare professionals do not recommend our product to their patients, our C-Scan</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">system may not achieve market acceptance and we may not become profitable.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">CRC screening candidates are generally referred by their healthcare professional to approved tests and screening technology options. If healthcare professionals, including physicians, do not recommend or prescribe our product to their patients, our C-Scan system may not achieve market acceptance and we may not become profitable. In addition, physicians have historically been slow to change their medical diagnostic and treatment practices because of perceived liability risks arising from the use of new products. Delayed adoption of our C-Scan system by healthcare professionals could lead to a delayed adoption by patients and government and private third-party payors. Healthcare professionals may not recommend or prescribe our C-Scan system until certain conditions have been satisfied including, among others:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z85f26d0eb5874a16a3a950d485e4f498" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">there is sufficient long-term clinical and health-economic evidence to convince them to alter their existing screening methods and device recommendations;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z91374414f3da4381bd5dfdd4cff650a1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">there are recommendations from other prominent physicians, educators and/or associations that our C-Scan system is safe and effective;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">7</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd9bc8285c25840c083bfd9cba482c51f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we obtain favorable data from clinical and health-economic studies for our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z251b963e3d47433f9530acd42ab64dcd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">reimbursement or insurance coverage from government and private third-party payors is available;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za287d40516a64ba3aa6b0ccb1916936e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">healthcare professionals obtain required approvals and licensures for the handling, storage, dispensing, and disposal of&#160; our C-Scan system; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z41e32a299e2040e7bf77328fa998d0f1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">healthcare professionals become familiar with the complexities of our C-Scan system.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We cannot predict when, if ever, healthcare professionals and patients may adopt the use of our C-Scan system. Even if favorable data is obtained from clinical and health-economic studies for the regulatory approval of our C-Scan system, there can be no assurance that prominent physicians would endorse it or that future clinical studies will continue to produce favorable data regarding our C-Scan system. In addition, prolonged market exposure may also be a pre-requisite to reimbursement or insurance coverage from government and private third-party payors. If our C-Scan system does not achieve an adequate level of acceptance by patients, healthcare professionals and government&#160;and private third-party payors, we may not generate significant product revenues and we may not become profitable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">We expect to face competition from large, well-established manufacturers of traditional technologies for CRC screening and detection of gastrointestinal disorders, as well as from new competitive technologies</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 7.3pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 5.2pt; TEXT-INDENT: 30.25pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 5.2pt; TEXT-INDENT: 30.25pt">Competition for our C-Scan system comes from traditional well-entrenched manufacturers of tests and equipment for CRC screening, such as colonoscopy, sigmoidoscopy, CTC, optical capsule endoscopy, fecal occult blood tests, or FOBTs, and fecal immunochemical tests, or FITs. The principal manufacturers of equipment for optical colonoscopy and sigmoidoscopy include Olympus, Pentax, Hoya and Fuji Film. The principal manufacturers of equipment for CTC include General Electric Healthcare Systems, Siemens Medical Solutions, Philips Medical Systems Ltd. and Toshiba Corporation.&#160; The principal manufacturer of equipment for optical capsule endoscopy includes Medtronic plc. All of these companies have substantially greater&#160;&#160; financial resources than we do, and they have established reputations as well as worldwide distribution channels for providing medical instruments to physicians.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Several companies have developed or are developing non-invasive technologies based on stool, serum, or molecular diagnostics (from blood and other bodily fluids), or MDx, tests that are used to indicate the presence of CRC and polyps in the colon. These companies include Polymedco, Exact Sciences, Epigenomics AG, Gene News, EDP Biotech Corporation, Illumina, Inc., Quest Diagnostics and VolitionRx Nu.Q diagnostic. In August 2018, Exact Sciences announced that it entered into a U.S. promotion agreement with Pfizer for the promotion of Cologuard<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#174;</sup>, a non-invasive stool DNA screening test for colorectal cancer.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Procedures for bowel cleansing that are less onerous are constantly being developed, which could make our entry into the market more difficult.&#160; For instance, bowel cleansing initiated by the ingestion of pills or food-substitute diet regimes rather than through drinking large amounts of distasteful liquids may be viewed as an improvement to the cleansing process, but other screening methods may be even more palatable to patients.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If we are unable to convince patients and physicians to adopt our C-Scan system over the current technologies marketed by our competitors, our business and results of operations may suffer.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">We are planning to rely on local distributors and/or strategic partners&#160;to market and distribute our C-Scan</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">system in those countries where we intend to market and distribute our C-Scan system.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are planning to rely on local distributors and/or strategic partners for the marketing and distribution of our C-Scan system. Our success in generating sales in countries or regions where we will engage local distributors and/or strategic partners will depend in large part on the efforts of these third parties over whom we have limited control. If we are unable to identify and engage with suitable local distributors and/or strategic partners in the countries where we intend to market and distribute our C-Scan system, our business, financial condition and results of operations could be negatively affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We have limited manufacturing capabilities and if we are unable to scale our manufacturing operations to meet anticipated market demand, our growth could be limited and our business, financial condition and results of operations could be materially adversely affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We currently have limited resources, facilities and experience in commercially manufacturing sufficient quantities of our C-Scan system to meet the demand we may expect from commercialization efforts. We expect to face certain technical challenges as we increase manufacturing capacity, including, among others, logistics associated with the handling of radioactive materials, equipment design and automation, material procurement, lower than expected yields and increased scrap costs, as well as challenges related to maintaining quality control and&#160; assurance standards and manufacturing commercial quantities of C-Scan capsules at an acceptable cost. Despite our continuing cost-cutting efforts to scale-up our manufacturing capabilities of our C-Scan capsule in commercial quantities, we may not be able to achieve adequate quality at an acceptable cost. Our C-Scan system includes several components that are based on new technologies&#160; &#160; and are difficult to manufacture and some are being supplied to us by single source suppliers (see &#8220;Risk Factors &#8211; Risks Related to Our Business &#8211; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Our reliance on single source suppliers could harm our ability to conduct clinical trials and meet demand for our product in a timely manner or within budget</font>.&#8221;). Furthermore, we may encounter similar or unforeseen challenges initiating and later expanding production of any new products. If we are unable to scale our manufacturing capabilities to meet market demand, our growth could be limited and our business, financial condition and results of operations could be materially adversely affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, we have received and may receive in the future grants from the Government of the State of Israel through the IIA (formerly the OCS) for the financing of a portion of our research and development expenditures pursuant to the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Encouragement of Industrial Research and Development Law 5744-1984), or the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law.&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The terms of the IIA grants subject us to certain restrictions relating to (among other things) the transfer of the manufacturing of IIA-funded products outside Israel. </font>See &#8220;Risk Factors &#8211; Risks Related to Our <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Operations in Israel</font> &#8211; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Pursuant to the terms of the Israeli government grants we received for research and development expenditures, we are obligated to pay certain royalties on our revenues to the Israeli government. The terms of the grants require us to satisfy specified conditions and to make additional payments in addition to repayment of the grants upon certain events</font>.&#8221; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Such</font> restrictions may impair our ability to outsource or transfer development or manufacturing activities with respect to any product or technology outside of Israel.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">8</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Our reliance on single source suppliers could harm our ability to conduct clinical trials and meet demand for our product in a timely manner or within budget.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We currently depend on single source suppliers for some of the components necessary for the production of our C-Scan system. For example, for the current version of the C-Scan system used in clinical trials, we currently have a single supplier for the motor used to rotate the collimated X-ray source in our C-Scan system and for each of the customized X-ray detectors, X-ray source and batteries used in our C-Scan system. There are a limited number of manufacturers worldwide who are capable of manufacturing the motor and the customized X-ray detectors and X-ray source that we currently use in our C-Scan system.&#160;In addition, the application-specific integrated circuit, or ASIC, residing in our C-Scan system is currently manufactured for us by a single semiconductor fabrication plant, or FAB.&#160; Furthermore, we do not currently have written contracts with all of such suppliers.&#160; While our current suppliers have been able to supply the required quantities of such components to date, if the supply of these components is disrupted or terminated or if our current suppliers are unable to supply required quantities of components, we may not be able to find alternative sources for these key components in a timely manner.&#160; Although we are planning to maintain strategic inventory of key components, the inventory may not be sufficient to satisfy the demand for our C-Scan system if such supply is interrupted, or may be subject to risk of loss due do catastrophic events, such as a fire at our storage facility. In addition, to partially mitigate the risks of reliance on single source suppliers, we are seeking alternate manufacturers for some of our components which requires us to dedicate significant resources and investment. There can be no assurance that we will be successful in seeking alternate suppliers.&#160;As a result of the foregoing, we may be unable to meet the demand for our C-Scan system, which could harm our ability to generate revenues, lead to customer dissatisfaction and damage our reputation.&#160; If we are required to change the supplier of any of these key components, there may be a significant delay in locating a suitable alternative manufacturer. In addition, we may be required to verify that the new manufacturer maintains facilities and procedures that comply with FDA and other applicable quality standards and with all applicable regulations and guidelines. For example, our agreement with the supplier of the X-ray source used in our C-Scan system terminated on December 31, 2018 and while we and the X-ray source supplier have continued to perform the contract on the same terms and are currently negotiating the extension of the contract, we cannot assure you that we will be able to negotiate a new agreement on commercially acceptable terms or at all. We have been informed that the supplier of the batteries used in our C-Scan system shall cease to manufacture the batteries by mid-2019 and may cease to accept new orders at any time and, therefore, although we have acquired sufficient batteries for the foreseeable future, we will be required to find an alternative source for the X-ray source and batteries, which we may not be able to do in a timely manner. &#160; The delays associated with the identification of a new manufacturer could delay our ability to manufacture our C-Scan system in a timely manner or within budget. Furthermore, in the event that the manufacturer of a key component of our C-Scan system ceases operations or otherwise ceases to do business with us, we may not have access to the information necessary to enable another supplier to manufacture the component. The occurrence of any of these events could harm our ability to meet demand for our C-Scan system in a timely manner or within budget.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">The use of any of our C-Scan Cap, C-Scan Track or C-Scan View could result in product liability or similar claims that could be expensive, damage our reputation and harm our business</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our business exposes us to an inherent risk of potential product liability or similar claims related to the manufacturing, marketing and sale of medical devices. The medical device industry has historically been litigious, and we face financial exposure to product liability or similar claims if the use of any of our C-Scan Cap, C-Scan Track or C-Scan View were to cause or contribute to injury or death, including, without limitation, harm to the body caused by the procedure or inaccurate diagnoses from the procedure that could affect treatment options. There is also the possibility that defects in the design or manufacture of any of these products might necessitate a product recall. Although we plan to maintain product liability insurance, the coverage limits of these policies may not be adequate to cover future claims. In the future, we may be unable to maintain product liability insurance on acceptable terms or at reasonable costs and such insurance may not provide us with adequate coverage against potential liabilities. A product liability claim, regardless of merit or ultimate outcome, or any product recall could result in substantial costs to us, damage to our reputation, customer dissatisfaction and frustration, and a substantial diversion of management attention. A successful claim brought against us in excess of, or outside of, our insurance coverage could have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Our C-Scan</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">system is a complex medical device that requires training for qualified personal and care for data analysis</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan system is a complex medical device that requires training for qualified personal, including physicians, and care for data analysis. Although our distributors will be required to ensure that our C-Scan system is prescribed only by trained clinicians, the potential for misuse of our C-Scan system still exists due to its complexity. Such misuse could result in adverse medical consequences for patients that could damage our reputation, subject us to costly product liability litigation and otherwise have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">9</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">We depend on third parties to manage our clinical studies and trials, perform related data collection and analysis, and to enroll patients for our clinical trials, and, as a result, we may face costs and delays that are beyond our control</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We rely on third parties, such as third-party clinical research organizations, or CROs, clinical investigators and clinical sites, to manage our clinical trials and perform data collection and analysis, and to enroll patients for our clinical trials. Although we have and expect to continue to have contractual arrangements with these third parties, we control only certain aspects of their activities.&#160; Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on such third parties does not relieve us of our regulatory responsibilities.&#160; If such third parties fail to comply with applicable regulatory requirements, the clinical data generated in our clinical trials may be deemed unreliable and regulatory authorities may require us to perform additional clinical trials before approving our marketing applications, which would delay the regulatory approval process.&#160; Furthermore, we may not be able to control the amount and timing of resources that these parties devote to our studies and trials or the quality of these resources. If these third parties fail to properly manage our studies and trials or enroll patients for our clinical trials, we will be unable to complete them at all or in a satisfactory or timely manner, which could delay or prevent us from obtaining regulatory approvals for, or achieving market acceptance of, our product.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, termination of relationships with third parties may result in delays, inability to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional clinical sites involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new clinical site commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">We currently intend to sell our products in the United States, Europe and Japan and, if we are unable to manage our operations in these territories, our business, financial condition and results of operations could be materially adversely affected</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our headquarters and substantially all of our operations and employees are presently located in Israel, but we currently intend to market our products in the United States, Europe and Japan. Accordingly, we are subject to risks associated with international operations, and our international sales and operations will require significant management attention and financial resources. In addition, our international sales and operations will subject us to risks inherent in international business activities, many of which are beyond our control and include, among others:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb6f43b8d281348ecbbd1d7c49b4e3e31" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">foreign certification, registration and other regulatory requirements;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5fd1edd2f59f4f599800b2cce5b3814f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">customs clearance and shipping delays;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0a003143e21c46e292eeacf11d8c258d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">import and export controls;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zccc4dfb2bab5426d85e9cb98ee1abb32" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">trade restrictions;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z02fd9ab4ada544ffac447f3cd58149f7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">multiple and possibly overlapping tax structures;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z021404ff1e4f44be9b5f2557ad617a65" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">difficulty forecasting the results of our international operations and managing our inventory due to our reliance on third-party distributors;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zbfa2d0410b4d48e7a31e1207c685f917" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.21%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.64%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">differing laws and regulations, business and clinical practices, licensures, government and private third-party payor reimbursement policies and patient preferences;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z4791737fc54d43eb94ad9c86d45c4a99" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">differing standards of intellectual property protection among countries;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z77fdfa0e035f4bcda7b7d876f31baf1d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">difficulties in staffing and managing our international operations;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zed21b9b98b8c45069c0ab1700ae76e7e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">difficulties in penetrating markets in which our competitors&#8217; products are more established and achieving a competitive sale price for our product;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zdf966b558c564ef0892537972c23ac09" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">currency exchange rate fluctuations and foreign currency exchange controls and tax rates; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5382333f131547f2a4b674c79f5a735f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">political and economic instability, war or acts of terrorism.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If we are unable to manage our international operations effectively, our business, financial condition and results of operations could be materially adversely affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">10</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff">We may not be successful in establishing and maintaining strategic partnerships, which could adversely affect our ability to develop and commercialize our C-Scan system.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">A part of our strategy is to evaluate and, as deemed appropriate, enter into partnerships in the future when strategically attractive, including potentially with major medical device companies. We face significant competition in seeking appropriate partners for our C-Scan system, and the negotiation process is time-consuming and complex. In order for us to successfully partner our C-Scan system, potential partners must view our C-Scan system as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Even if we are successful in our efforts to establish strategic partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic partnerships if, for example, development or approval of a product is delayed or sales of an approved product are disappointing. Any delay in entering into strategic partnership agreements related to our C-Scan system could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">In addition, our strategic partners may breach any future agreement with us, and we may not be able to adequately protect our rights under these agreements. Furthermore, our strategic partners will likely negotiate for certain rights to control decisions regarding the development and commercialization of our C-Scan system, if approved, and may not conduct those activities in the same manner as we would do so.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">If we fail to&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">establish</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">maintain</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">strategic</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">partnerships</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;related to our C-Scan system, we will bear all of the risk and costs related to the development and commercialization of our C-Scan system, and we will need to seek additional financing, hire additional employees and otherwise develop expertise which we do not have and for which we have not budgeted.</font></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">If we lose our key personnel or are unable to attract and retain additional personnel, our business and ability to compete will be harmed</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Our success relies upon the continued service and performance of the principal members of our management and research and development team, including Alex Ovadia and Yoav Kimchy. In order to implement our business strategy, we will need to retain our key personnel with expertise in the areas of research and development, clinical testing, government regulation, manufacturing, finance, marketing and sales. Our product development plans depend in part on our ability to retain engineers with expertise in a variety of technical fields. The loss of a number of these persons or our inability to attract and retain qualified personnel could harm our business and our ability to compete.</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">We do not maintain key man insurance for Alex Ovadia or Yoav Kimchy.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Substantially all of our operations are currently conducted at a single location near Haifa, Israel, and any disruption at our facility could materially adversely affect our business, financial condition and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Substantially all of our operations are currently conducted at a single location near Haifa, Israel. We take precautions to safeguard our facility, including obtaining insurance coverage and implementing health and safety protocols. However, a natural or other disaster, such as a fire, flood, an armed conflict involving Israel (as detailed further under &#8220;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Risks Related to Our Operations in Israel</font>&#8221;) or a terrorist attack, could damage or destroy our facility and our manufacturing equipment or inventory, cause substantial delays in our operations and otherwise cause us to incur additional unanticipated expenses.&#160;In addition, the insurance we maintain against fires, floods and other natural disasters and the war and terrorism insurance we maintain may not be adequate to cover our losses in any particular case.&#160;Damage to our facility or our other property or to any of our suppliers&#8217; facilities and properties, whether located in Israel or elsewhere, due to fire, a natural disaster or casualty event or an armed conflict or terrorist attack, could materially adversely affect our business, financial condition and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">A security breach or disruption or failure in a computer or communications systems could adversely affect us.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, natural disasters, fire, terrorism, war, and telecommunication and electrical failures.&#160; If such an event were to occur and interrupt our operations, it could result in a material disruption of our clinical program.&#160; For example, the loss of clinical trial data from ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.&#160; To the extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets or inappropriate disclosure of confidential or proprietary information, including protected health information or personal data of clinical trial participants or employees or former employees, access to our clinical data, or disruption of the manufacturing process, we could incur liability and the further development of our C-Scan system could be delayed.&#160; We may also be vulnerable to cyber-attacks by hackers or other malfeasance.&#160; This type of breach of our cybersecurity may compromise our confidential information and/or our financial information and adversely affect our business or result in legal proceedings.&#160; Further, these cybersecurity breaches may inflict reputational harm upon us that may result in decreased market value and erode public trust.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">11</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Risks Related to Regulations</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">If we are unable to obtain, or experience significant delays in obtaining, FDA clearances or approvals, or equivalent third country approvals for our C-Scan system or future products or product enhancements, our ability to commercially distribute and market our products could suffer</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our products are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities and notified bodies. The process of obtaining regulatory clearances or approvals, or equivalent third-country approvals to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals, or equivalent third-country approvals on a timely basis, if at all. In particular, we expect to eventually generate a portion of our revenues from sales of our C-Scan system and future products in the United States, the European Union, or third countries. Before a new medical device, or a new use of, or claim for, an existing product can be marketed in the United States, it must first receive clearance under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or FDA approval of a premarket approval application, or PMA, unless an exemption applies. The FDA will clear marketing of a low or moderate risk medical device through the 510(k) process if sufficiently similar predicate devices have previously been cleared via this pathway. In the 510(k) clearance process, the FDA must only determine that the proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, with respect to intended use/indications for use, technological characteristics and principles of operation in order to clear the proposed device for marketing. Clinical data is sometimes required to support substantial equivalence.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">High risk devices deemed to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices, or devices not deemed substantially equivalent to a previously cleared device, require approval of a PMA. The PMA process is more costly, lengthy and uncertain than the 510(k) clearance process. The PMA pathway requires an applicant to demonstrate the safety and effectiveness of the device based, in part, on the data obtained in clinical trials. A PMA application must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data, to demonstrate to the FDA&#8217;s satisfaction the safety and efficacy of the device for its intended use.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In instances where a device is novel and there is no suitable predicate device, but that device is deemed to be of low or moderate risk, the FDA can reclassify the device to class I or class II via de novo reclassification. This process involves the submission of a reclassification petition, and the FDA accepting that &#8220;special controls&#8221; are adequate to ensure the product&#8217;s performance and safety. The FDA now allows &#8220;direct&#8221; de novo reclassification petitions, a mechanism by which a sponsor can directly submit a detailed de novo reclassification petition as the device&#8217;s initial submission without having to first receive a not substantially equivalent, or NSE, decision on a 510(k) submission.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">These processes can be expensive and lengthy. FDA&#8217;s 510(k) clearance process may take 6 to 9 months, but it can last longer. Direct de novo reclassification typically takes at least 9 to 12 months from filing to clearance. The PMA pathway is much more costly and uncertain than the 510(k) clearance process or de novo reclassification, and generally takes at least 12 to 18 months, or even longer, from the time the application is filed with FDA to ultimate approval.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are not aware of any legally marketed predicate device upon which FDA could base a determination of substantial equivalence under a 510(k) clearance process. Our proposed strategy, therefore, is to submit a direct de novo reclassification petition for our C-Scan system. To support this petition, our objective is to demonstrate that the device poses a low or moderate risk to patients. We cannot assure you that FDA will not demand that we obtain PMA approval of our C-Scan system.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">FDA can delay, limit or deny clearance or approval of an application for many reasons, including, among others:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zae5e10e3ceb64fbabb27421582053a52" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may not be able to demonstrate to FDA&#8217;s satisfaction that our products are safe and effective for their intended use;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z52cca3cb9e494a0bb4eb2ebcff3615e2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1c03190c12174def81fdaaaab7bced29" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">in the case of a PMA submission, that the manufacturing process or facilities we use may not meet applicable requirements; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z54ef2b2817fc4334a9dacbf0b6c87388" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">changes in FDA&#8217;s 510(k) clearance, de novo reclassification, or PMA approval processes and policies, or the adoption of new regulations may require additional data.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We may not obtain the necessary regulatory clearances, approvals or equivalent third country approvals to market our C-Scan system or future products in the United States or elsewhere. Any delay in, or failure to receive or maintain, clearance, approval for our C-Scan system or other products under development could prevent us from generating revenue from these products or achieving profitability.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">12</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">There is no guarantee that the FDA will grant de novo reclassification or PMA approval of our C-Scan system and failure to obtain necessary 510(k) clearances or approvals for our future products would adversely affect our ability to grow our business</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan system and some of our future products will require FDA clearance of a 510(k), de novo reclassification, or may require FDA approval of a PMA. The FDA may not approve or clear our C-Scan system or our future products for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance, de novo reclassification or&#160;PMA for our C-Scan system or any other future product, new intended uses or modifications to these products once they are cleared or approved for marketing.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our strategy is to submit a direct de novo reclassification petition for our C-Scan system following completion of a U.S. pivotal study. A de novo reclassification generally applies where there is no predicate device and the FDA believes the device poses a low to moderate risk. De novo reclassifications can either be submitted in lieu of a 510(k) notice, such as in our case, or after a 510(k) notice has been filed and found NSE. If a 510(k) notice is found NSE, a de novo petition must be submitted within 30 days from the receipt of the NSE determination.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">To support our direct de novo reclassification petition, our objective is to demonstrate that the device poses a low to moderate risk to patients. If the FDA determines that our C-Scan system is not a candidate for de novo reclassification, it will require approval of the device for market through the PMA process. A PMA application must be supported by extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data, to demonstrate to the FDA&#8217;s satisfaction the safety and efficacy of the device for its intended use. By statute, the FDA has 180 days to review the &#8220;accepted application,&#8221; although, generally, review of the application can take between one and three years. During this review period, the FDA may request additional information or clarification of information already provided or even request new data that may require us to conduct additional tests. Also during the review period, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA will conduct a preapproval inspection of the manufacturing facility to ensure compliance with quality system regulations. The FDA&#8217;s review of a PMA could significantly delay our plans to get to market. There is also no guarantee that the FDA would approve a PMA. Failure to receive clearance or approval for our C-Scan system or future products would have an adverse effect on our ability to expand our business.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Even if the FDA ultimately accepts our de novo reclassification petition, to support our petition, we may be still may be required to conduct</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">additional clinical trials before a petition can be filed. For example, we may be required to conduct a pre-pivotal study in the U.S. prior to commencing a pivotal study in the U.S. We are currently evaluating whether such pre-pivotal study is required. Such studies or trials can be costly and the results uncertain. If we are unable to successfully complete required clinical studies or trials, we will not receive FDA clearance or approval.&#160;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">If we or our future distributors do not obtain and maintain the necessary regulatory clearances or approvals, or equivalent third country approvals in a specific country or region, we will not be able to market and sell our C-Scan system or future products in that country or region</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We intend to market our C-Scan system in a number of international markets. To be able to market and sell our C-Scan system in a specific country or region, we and/or our distributors must comply with the regulations of that country or region. While the regulations of some countries do not impose barriers to marketing and selling part or all of our products or only require notification, others require that we and/or our distributors obtain the approval of a specified regulatory authorities such as the Swiss National Cooperative for the Disposal of Radioactive Waste (Nagra) and the German Federal Office for Radiation Protection (Bundesamt f&#252;r Strahlenschutz, BfS), in addition to the CE mark that is required for medical devices throughout the EU. We are engaged with Dekra Certification as our Notified Body for such purposes. These regulations, and the time required for regulatory review, vary from country to country. Obtaining regulatory approvals is expensive and time-consuming, and we cannot be certain that we or our distributors will receive regulatory approvals for our C-Scan system or any future products in each country or region in which we plan to market such products. If we modify our C-Scan system or any future products, we or our distributors may need to apply for new regulatory approvals or our Notified Body may need to review the planned changes before we are permitted to sell them. We may not meet the quality and safety standards required to maintain the authorizations that we or our distributors have received. If we or our distributors are unable to maintain our authorizations or CE Certificates in a particular country or region, we will no longer be able to sell our C-Scan system or any future products in that country or region, and our ability to generate revenues will be materially and adversely affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Our</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">C-Scan system may be considered a drug-device combination product because of the preparatory use of iodinated oral contrast medium to provide a coating for colonic imaging. We cannot be sure how the FDA or the competent regulatory authorities of foreign countries will regulate this product. The review of combination products is often more complex and more time consuming than the review of products under the jurisdiction of only one center within the FDA</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan system may be considered a combination product because of the preparatory use of iodinated oral contrast medium to provide a coating for colonic imaging. A combination product is the combination of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are combined or mixed and produced as a single entity; packaged together in a single package or as a unit; or a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication or effect. For a combination product, the FDA must determine which center or centers within the FDA will review the product and under what legal authority the product candidate will be reviewed. The combination product&#8217;s primary mode of action is used to determine which center within the FDA has primary regulatory jurisdiction over the product. The other centers within the agency also may provide consulting or collaborative reviews of the product as necessary. We believe that we will put forth a reasonable argument to the FDA that our C-Scan system should be regulated as a device and/or a combination product with a device primary mode of action. However, we cannot be sure as to whether the FDA will treat our C-Scan system as a device or a combination product. The review of combination products is often more complex and more time consuming than the review of a product under the jurisdiction of only one center within the FDA. In the case of the system, should the FDA determine that the iodinated oral contrast medium is not being used in accordance with its approved labeling, the Center for Drug Evaluation and Research may take a prominent role it its regulation. If the FDA does not approve or clear our C-Scan system, or any future products, in a timely fashion, or at all, our business and financial condition will be adversely affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Similar obstacles may be encountered in foreign countries should our C-Scan system be considered as a combination product.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">13</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">If the indications for use or instructions for use for which the iodinated oral contrast medium is approved are not sufficiently broad to support its use prior to the ingestion of our capsules, the FDA or the competent regulatory authorities in the EU Member States and other foreign countries may consider that contrast agent is being used off-label.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Ingestion of our C-Scan system requires the preparatory use of iodinated oral contrast medium to provide a coating for colonic imaging. We cannot be sure that the indications for which iodinated oral contrast medium are approved in the United States, or in other countries is sufficiently broad to cover such use. If the FDA or the competent regulatory authorities in other countries consider that iodinated oral contrast medium is not approved for the purpose for which it is used with the system, we may be considered to promote the off-label use of the iodinated oral contrast medium. Because the promotion of off-label use of drugs or medicinal products is prohibited in the United States, and in other countries, we could face both related issues with the FDA and/or the competent authorities of and/or other countries. In these circumstances, the FDA and/or the competent regulatory authorities and/or other countries may require us to obtain appropriate regulatory approvals for the iodinated oral contrast medium prior to marketing our C-Scan system with such substances. Under such circumstances, should we fail to obtain approval of the contrast agent for use with our C-Scan system, in a timely fashion, or at all, our business and financial condition will be adversely affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">If we are unable to successfully complete clinical trials with respect to our C-Scan system, we may be unable to receive regulatory approvals or clearances for our C-Scan system and/or our ability to achieve market acceptance of our C-Scan system will be harmed.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The development of medical devices typically includes pre-clinical studies. Certain other devices require the submission of data generated from clinical trials, which can be long, expensive and uncertain processes, subject to delays and failure at any stage. The data obtained from the studies and trials may be inadequate to support regulatory clearances or approvals, or equivalent third-country approval, or to allow market acceptance of the products being studied. Our C-Scan system technology is currently undergoing clinical development and clinical trials. To date, we have performed clinical studies with several versions of our C-Scan system and with several versions of our non-scanning capsules.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The development of sufficient and appropriate clinical protocols to demonstrate safety, clinical performance and clinical effectiveness are required, and we may not adequately develop such protocols to support clearance, approval, or equivalent third country approval. The clinical trials that were conducted using prior versions of our C-Scan system, were conducted under differing protocols and used groups of patients different and/or smaller in size from those we intend to study in future clinical trials. Further, the FDA, the competent regulatory authorities of other countries, or our Notified Body in the EU may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or they may change the data collection requirements or data analysis applicable to our clinical trials.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The commencement or completion of any of our clinical studies or trials may be delayed or halted, or be inadequate to support regulatory clearance, approval or product acceptance, or equivalent third country approval, for numerous reasons, including, among others:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zbb46728d408b4495bda5bf969930d588" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">patients do not enroll in the clinical trial at the rate we expect;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zebbe406dc4ca456abc402daeb1a4b364" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">patients do not comply with trial protocols;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z60b506f20112431e8668b4e962916620" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">patient follow-up is not at the rate we expect;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3e93e350edfc4cc39dcead3b8a863a9f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">undetected capsule retention in patients;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zea15c13debd443ba9a48964c665c7ab6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">patients experience adverse side effects, including related to excessive radiation exposure as a result of capsule malfunction or break down;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z24c0055f237343dd84dab841f60cccc4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">patient death during a clinical trial, even though their death may be unrelated to our product;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7c7f1d92eabb47048d7ff7bc3c558500" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">FDA, institutional review boards, or IRBs, or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">14</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zcad990e1a53c43e2921e2890b1618c76" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">IRBs, Ethics Committees and third-party clinical investigators may delay or reject our trial protocol and Informed Consent Form;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc2ff2e47a1784a67862f422c173f97bf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">third-party clinical investigators decline to participate in a study or trial or do not perform a study or trial on our anticipated schedule or consistent with the investigator agreements, study or trial protocol, good clinical practices or other FDA or IRBs, Ethics Committees, or any other applicable requirements;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7d627efe75b0460294a890e500852d81" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the study or trial protocol or investigational or statistical plans;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z424fdfaba8334028b75c6a460c737823" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">regulatory inspections of our studies, trials or manufacturing facilities may require us to, among other things, undertake corrective action or suspend or terminate our studies or clinical trials;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z54cf8e998c5d44d4a2ce5b2d9e56b2bf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">changes in governmental regulations or administrative actions;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9289dcb0ed904c249c637b5884604996" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may not be able to develop our C-Scan system at the rate or to the stage we desire:</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z79d489c1a35f4b0595b81cd46363528a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the interim or final results of the study or clinical trial are inconclusive or unfavorable as to safety or efficacy; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc9cb9166d7134302ac160688dcf7aa81" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a regulatory agency or our Notified Body concludes that our trial design is or was inadequate to demonstrate safety and efficacy.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The results of pre-clinical and clinical studies do not necessarily predict future clinical trial results, and predecessor clinical trial results may not be repeated in subsequent clinical trials. Additionally, the FDA, other third country regulatory entities may disagree with our interpretation of the data from our pre-clinical studies and clinical trials, or may find the clinical trial design, conduct or results inadequate to demonstrate safety or efficacy, and may require us to pursue additional pre-clinical studies or clinical trials, which could further delay the clearance, approval of our products. The data we collect from our non-clinical testing, our pre-clinical studies and other clinical trials may not be sufficient to support regulatory clearance and approval.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">If the third parties on which we rely to conduct our clinical trials and clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval, or equivalent third country approval for, or commercialize, our C-Scan system or future products</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We do not have the ability to independently conduct our clinical trials for our C-Scan system and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory clearance, approval for, or successfully commercialize, our C-Scan system or future products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">The results of our current or future clinical trials may not support our product candidate requirements or intended use claims or may result in the discovery of adverse side effects</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Even if our current or future clinical trials are completed as planned, we cannot be certain that their results will support our product requirements or intended use claims, which could inhibit our marketing strategies, or that the FDA, foreign authorities or our Notified Body will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that clinical trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our C-Scan system, or any future products, are safe and effective for the desired or proposed indicated uses, which could cause us to abandon a product and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to commercialize our C-Scan system, or any future products, and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the product candidate&#8217;s profile.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">15</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Even if our C-Scan system or future products are cleared or approved by regulatory authorities or after obtaining CE Certificates from our Notified Body, modifications to our C-Scan system or future products may require new regulatory clearances or approvals, new CE Certificates, or may require us to recall or cease marketing it until the necessary clearances, approvals or CE Certificates are obtained</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Once cleared, approved or marketed, modifications to our C-Scan system or future products may require new regulatory approvals, clearances, including CE Certificates from our Notified Body, 510(k) clearances or premarket approvals, or require us to recall or cease marketing the modified devices until these clearances or approvals are obtained. Any modification to a 510(k)-cleared device that could significantly affect its safety or efficacy, or that would constitute a major change in its intended use, requires a new 510(k) clearance or, possibly, a PMA. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. However, the FDA can review a manufacturer&#8217;s decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required. We may make modifications to our C-Scan system in the future that we believe do not or will not require additional clearances or approvals. Further, our products could be subject to recall if the FDA determines, for any reason, that our products are not safe or effective. Any recall or FDA requirement that we seek additional approvals or clearances could result in significant delays, fines, increased costs associated with modification of a product, loss of revenue and potential operating restrictions imposed by the FDA.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If a manufacturer determines that a modification to an FDA-cleared device could significantly affect its safety or efficacy, or would constitute a major change in its intended use, then the manufacturer must file for a new 510(k) clearance or possibly a premarket approval application. Where we determine that modifications to our products require a new 510(k) clearance or premarket approval application, we may not be able to obtain those additional clearances or approvals for the modifications or additional indications in a timely manner, or at all.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Any modification to a PMA-approved device must either be approved in a PMA Supplement, or if the modification does not impact the device&#8217;s safety or effectiveness, described in a 30-Day Notice or in the device&#8217;s Annual Report. The FDA may not approve a modification described in a PMA Supplement, in which case the modified device cannot be marketed. The FDA can also disagree that a change described in a 30-Day Notice or Annual Report is appropriately described in either filing, and request that the company file a PMA Supplement and/or request that the company cease marketing the modified device until the PMA Supplement is approved.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Similar rules also apply in foreign jurisdictions. In the European Union, or the EU, we must inform the Notified Body that was involved in the conformity assessment of the medical devices we market or sell in the EU of any planned substantial changes to our quality C-Scan system or changes to our devices which could affect compliance with the Essential Requirements laid down in the Annexes to the Council Directive 93/42/EC concerning medical devices, or Medical Devices Directive, or the devices&#8217; intended purpose. The Notified Body will then assess the changes and verify whether they affect the products&#8217; conformity with the Essential Requirements laid down in the Annexes to the Medical Devices Directive. If the assessment is favorable, the Notified Body will issue a new CE Certificate or an addendum to the existing CE Certificate attesting compliance with the Essential Requirements laid down in Annexes to the Medical Devices Directive.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If the Notified Body or relevant regulatory authorities disagree with our assessments and require modifications to an existing CE Certificate, the preparation of a new CE Certificate or other new regulatory clearances or approvals for modifications, we may be required to recall and to stop marketing the modified devices.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Obtaining clearances and approvals, or new or amended CE Certificates for device modifications can be a time-consuming process, and delays in obtaining required future clearances, approvals, or CE Certificates could adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn could harm our future growth.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Even if our C-Scan</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">system and future products are cleared or approved by regulatory authorities or after obtaining CE Certificates from our Notified Body, if we or our suppliers fail to comply with ongoing FDA or other foreign regulatory authority requirements, or if we experience unanticipated problems with our products, our products could be subject to restrictions or withdrawal from the market</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The manufacturing processes, reporting requirements, post-approval clinical data and promotional activities associated with any product for which we obtain clearance or approval CE Certificates, or equivalent third country approval will be subject to continuous regulatory review, oversight and periodic inspections by the FDA other domestic and foreign regulatory authorities and our Notified Body. In particular, we and certain of our suppliers are required to comply with the FDA&#8217;s Quality System Regulations, or QSR, as well as current good manufacturing practices, or cGMP. In the EU, we will also be subject to the quality system requirements laid down in the Annexes to the Medical Devices Directive. Such compliance can be facilitated by, among other things, a certificate of compliance with ISO 13485:2016. Through compliance with the ISO 13485:2016 standard, we will benefit from a presumption of conformity with the relevant quality system requirements laid down in the Annexes to the Medical Devices Directive. These regulations and standards govern the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which we obtain clearance or approval, CE Certificates, or equivalent third country approval. Regulatory authorities, such as the FDA, and our Notified Body enforce the QSR and other regulations through periodic inspections. The failure by us or one of our suppliers to comply with applicable statutes and regulations falling within the competence of the FDA and other regulatory authorities or our Notified Body, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcement actions:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>
</div>

<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z928ecccc9d714c9f8b4e5f1012e24810" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">untitled letters, warning letters, fines, injunctions, corporate integrity agreements, consent decrees and civil penalties;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">unanticipated expenditures to address or defend such actions;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="FONT-SIZE: 10pt; MARGIN-BOTTOM: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; MARGIN-TOP: 10pt; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">16</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z32f76bfb35bf481a985a37b503cc2fa2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">customer notifications for repair, replacement or refunds;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1c4e32e9eb7746dfb260eee5a255e54f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">recall, detention or seizure of our products;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z018705bfbca34270865e3f9345607ca9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">operating restrictions or partial suspension or total shutdown of production;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd46cd54a937a4fd7b920e71ebf462118" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">refusing or delaying our requests for 510(k) clearance or premarket approval of new products or modified products;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">operating restrictions;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z17fcaba296bf497290325bafb9cc8904" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">withdrawing 510(k) clearances on PMA approvals that have already been granted;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zbe5ef95a84bd487292cec564b2d4c534" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">suspension or withdrawal of our CE Certificates;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze6e183894789490ab39979296d81c151" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">refusal to grant export approval for our products; or</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zde1bc4e8ada84daa80ca49d1e544d32f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">criminal prosecution.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If any of these actions were to occur, our reputation would be harmed, our product sales and profitability would suffer and we may not be able to generate revenue. Furthermore, our key suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our products on a timely basis and in the required quantities, if at all.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Even if regulatory clearance or approval of a product is granted, or after obtaining CE Certificates, such clearance or approval, or CE Certificates may be subject to limitations on the intended uses for which the product may be marketed and reduce our potential to successfully commercialize the product and generate revenue from the product. If FDA or the competent regulatory authorities of foreign countries determines that our promotional materials, labeling, training or other marketing or educational activities constitute the promotion of an unapproved use or the promotion of an intended purpose not covered by our CE mark, they could request that we cease or modify our training or promotional materials or subject us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our training or other promotional materials to constitute promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 39.55pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, we may be required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with our products, including unanticipated adverse side effects or adverse side effects of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension or withdrawal of regulatory approvals or CE Certificates of Conformity, product seizures, injunctions or the imposition of civil or criminal penalties, all of which would adversely affect our business, financial condition and operating results and prospects.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">If we fail to maintain necessary regulatory clearances or CE Certificates for our C-Scan&#160;system and indications in our target foreign markets, if clearances or approvals, or CE Certificates for future products and indications are delayed or not issued, or if there are regulatory changes in our existing or future target markets, our commercial operations could be harmed</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan system is a medical device that is subject to extensive regulations that are intended to assure its safety, effectiveness and compliance with applicable consumer laws. If we fail to obtain and maintain these regulatory approvals or clearances, our ability to sell our C-Scan system and generate revenues will be materially harmed.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt">These laws and regulations relate to the design, development, testing, manufacturing, storage, labeling, packaging, content and language of the instructions for use of the device, sale, promotion, distribution, importing and exporting, shipping, post-sale surveillance and recall from our C-Scan system&#8217;s markets, and all countries in which we intend to sell our C-Scan system apply some form of regulations of this kind. Most notably, we must comply with the Medical Devices Directive and EU Member States&#8217; laws implementing it, and we are subject to extensive regulation in the United States by the FDA and other federal, state and local authorities.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We will be subject to audits by a Notified Body under the Medical Devices Directive. During this audit, the third-party assessor or Notified Body will examine the maintenance and implementation of our quality control system, device post-marketing vigilance system and any changes or modifications made to our products.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">On May 27, 2020, the new Regulation Reg. EU No. 745/2017 on Medical Devices (Medical Devices Regulation) will become applicable and replace the existing regulatory framework for medical devices in the EU. The Medical Devices Regulation strengthens the medical devices rules in the EU. In particular, the Medical Devices Regulation will result in several medical devices being classified in higher risk classes and therefore face elevated regulatory requirements. In addition, the Medical Devices Regulation will generally elevate regulatory requirements to medical devices. As a result, it is likely that it will become more difficult to market medical devices and costs incurred for clinical evaluation, conformity assessment and post marketing surveillance will increase <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and </font>such regulatory changes may adversely affect our business, financial condition and results of operations or restrict our operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">17</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Our failure to comply with radiation safety or radio frequency regulations in a specific country or region could impair our ability to commercially distribute and market our C-Scan</font> &#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic"> system in that country or region</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Our C-Scan system includes a small X-ray source and wireless radio frequency transmitter and receiver, and is therefore subject to equipment authorization requirements in a number of countries and regions. In the United States, the EU and Japan, authorities often require advance clearance of all radiation and radio frequency devices before they can be sold or marketed in these jurisdictions, subject to limited exceptions.</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Competent authorities for such additional approval requirements include the Swiss National Cooperative for the Disposal of Radioactive Waste (Nagra) and the German Federal Office for Radiation Protection (Bundesamt f&#252;r Strahlenschutz, BfS).&#160; Modifications to the approved C-Scan system design and specifications may require new or further regulatory clearances or approvals before we are permitted to market and sell a modified C-Scan system. If we are unable to obtain any required clearances or approvals from the authorities responsible for the radiation as well as the radio frequency regulations in these and other jurisdictions, the sale or use of our C-Scan system could be prevented in these countries. Any such action could negatively affect our business, financial condition and results of operations.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Our C-Scan system may in the future be subject to product recalls that could harm our reputation, business and financial results.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture or a public health/safety issue. In the case of the FDA, the authority to require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause injury or death. In addition, foreign governmental bodies have the authority to require the recall of our products in the event of material deficiencies or defects in design or manufacture. Manufacturers may, under their own initiative, recall a product if any material deficiency in a device is found. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Once marketed, recalls of any of our products, including our C-Scan system, would divert managerial and financial resources and have an adverse effect on our business, financial condition and results of operations. FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to FDA. We may initiate voluntary recalls involving our products in the future that we determine do not require us to notify the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively affect our sales. In addition, the FDA could take enforcement action against us based on our failure to report the recalls when they were conducted.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">If our C-Scan system or future products cause or contribute to a death or a serious injury, or malfunction in such a way that causes or contributes to a death or serious injury, we will be subject to medical device reporting regulations, which can result in corrective actions or enforcement actions from regulatory authorities.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under FDA medical device reporting regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of our device (or any similar future product) were to recur. If we fail to investigate and report these events to FDA within the required timeframes, or at all, the FDA could take enforcement action against us. Any such adverse event involving our products also could result in future corrective actions, such as recalls or customer notifications, or agency action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, including any legal action taken against us, will require us to devote sufficient time and capital to the matter, distract management from operating our business, and may harm our reputation and financial results.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, we must also comply with the EU Medical Device Vigilance System (MEDDEV 2.12/1 rev.8), which is intended to protect the health and safety of patients, users and others by establishing reporting procedures. Under this system, incidents (which are defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, may lead to or may have led to the death of a patient, or user or of other persons or to a serious deterioration in their state of health) must be reported by manufacturers through a Manufacturer&#8217;s Incident Reports to competent authorities within periods of time specified in the MEDDEV 2.12/1 rev. 8. Such incidents are evaluated and, where appropriate, information is disseminated between the competent authorities of the EU Member States. The MEDDEV 2.12/1 rev. 8 is also intended to facilitate a direct, early and harmonized establishment of Field Safety Corrective Actions, or FSCAs, across the EU Member States in which the device is being marketed. An FSCA is an action taken by a manufacturer to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An FSCA may include device recall, modification, exchange, or destruction. FSCAs must be reported by the manufacturer or the manufacturer&#8217;s European Authorized Representative, to its customers and/or the end users of the device through a Field Safety Notice. FSCAs must also be reported to the competent authorities of the EU Member States.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">18</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Our business is subject to complex environmental legislation that may increase our costs and our risk of noncompliance.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our research and development and manufacturing processes involve the handling of potentially harmful radioactive and other hazardous materials. We are subject to local laws and regulations governing the use, shipping, handling, storage and disposal of these materials, and we incur expenses related to compliance with these laws and regulations. If we are found to have violated environmental, health and safety laws, whether as a result of human error, equipment failure or other causes, we could be held liable for damages, penalties and costs of remedial actions which could materially adversely affect our business, financial condition and results of operations. In the future, we could be subject to additional environmental requirements or existing environmental laws could become more stringent, which could lead to greater compliance costs and increasing risks and penalties associated with violations. For example, changes to, or restrictions on, permitting requirements or processes, hazardous or radioactive material storage or handling might require an unplanned capital investment or relocation. If we fail to comply with existing or new environmental laws or regulations, our business, financial condition and results of operations could be materially adversely affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">If we are unable to achieve reimbursement and coverage from government and private third-party payors for procedures using our C-Scan system, or if reimbursement is insufficient to create an economic benefit for purchasing or using our C-Scan</font> &#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic"> system when compared to alternative procedures, demand for our products may not grow at the rate we expect</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The demand for our C-Scan system will depend significantly on the eligibility of the procedures performed using our C-Scan system for reimbursement through government-sponsored healthcare payment systems and private third-party payors. Reimbursement practices vary significantly from country to country and within some countries, by region, and we must obtain reimbursement approvals on a country-by-country and/or region-by-region basis. In general, the process of obtaining reimbursement and coverage approvals has been longer outside of the United States. We may not be able to obtain reimbursement approvals in a timely manner or at all and existing reimbursement and coverage policies may be revised from time to time by government and private third-party payors. If physicians, hospitals and other healthcare providers are unable to obtain sufficient coverage and reimbursement from government and private third-party payors for procedures using our C-Scan system, if reimbursement is, or is perceived by our customers to be, insufficient to create an economic incentive for purchasing or using our C-Scan system, or if such reimbursement does not adequately compensate physicians and health care providers compared to the other procedures they offer, demand for our products may not grow at the rate we expect.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Federal and state privacy laws, and equivalent laws of third countries, may increase our costs of operation and expose us to civil and criminal sanction</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">s</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Health Insurance Portability and Accountability Act of 1996, as amended, and the regulations that have been issued under it, to which we refer collectively as HIPAA, and similar laws outside the United States, contain substantial restrictions and requirements with respect to the use and disclosure of individuals&#8217; protected health information. The HIPAA privacy rules prohibit &#8220;covered entities,&#8221; such as healthcare providers and health plans, from using or disclosing an individual&#8217;s protected health information, unless the use or disclosure is authorized by the individual or is specifically required or permitted under the privacy rules. Under the HIPAA security rules, covered entities must establish administrative, physical and technical safeguards to protect the confidentiality, integrity and availability of electronic protected health information maintained or transmitted by them or by others on their behalf. While we do not believe that we are a covered entity under HIPAA, many of our customers are covered entities subject to HIPAA. Such customers may require us to enter into business associate agreements, which will obligate us to safeguard certain health information we obtain in the course of our relationship with them, restrict the manner in which we use and disclose such information and impose liability on us for failure to meet our contractual obligations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, under The Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which was signed into law as part of the U.S. stimulus package in February 2009, certain of HIPAA&#8217;s privacy and security requirements are now also directly applicable to &#8220;business associates&#8221; of covered entities and subject them to direct governmental enforcement for failure to comply with these requirements. We may be deemed as a &#8220;business associate&#8221; of some of our customers. As a result, we may be subject as a &#8220;business associate&#8221; to civil and criminal penalties for failure to comply with applicable privacy and security rule requirements. Moreover, HITECH created a new requirement obligating &#8220;business associates&#8221; to report any breach of unsecured, individually identifiable health information to their covered entity customers and imposes penalties for failing to do so.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition to HIPAA, most U.S. states have enacted patient confidentiality laws that protect against the disclosure of confidential medical information, and many U.S. states have adopted or are considering adopting further legislation in this area, including privacy safeguards, security standards, and data security breach notification requirements. These U.S. state laws, which may be even more stringent than the HIPAA requirements, are not preempted by the federal requirements, and we are therefore required to comply with them to the extent they are applicable to our operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">These and other possible changes to HIPAA or other U.S. federal or state laws or regulations, or comparable laws and regulations in countries where we conduct business, could affect our business and the costs of compliance could be significant. Failure by us to comply with any of the standards regarding patient privacy, identity theft prevention and detection, and data security may subject us to penalties, including civil monetary penalties and in some circumstances, criminal penalties. In addition, such failure may damage our reputation and adversely affect our ability to retain customers and attract new customers.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">19</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The protection of personal data, particularly patient data, is subject to strict laws and regulations in many countries. The collection and use of personal health data in the EU is governed by the General Data Protection Regulation Reg. EU 2016/769, which became applicable on May 25, 2018, or the GDPR. The GDPR imposes a number of requirements, including an obligation to seek the consent of individuals to whom the personal data relates, the information that must be provided to the individuals, notification of data processing obligations to the competent national data protection authorities of individual EU Member States and the security and confidentiality of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU to the U.S. Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU Member States may result in fines and other administrative penalties and harm our business. We may incur extensive costs in ensuring compliance with these laws and regulations, particularly if we are considered to be a data controller within the meaning of the GDPR.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">The adoption of healthcare reform and deficit reduction measures in the United States may adversely affect our business and financial results</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Patient Protection and Affordable Care Act of 2010, or the PPACA, which was modified on March 30, 2010 by the enactment of the Health Care and Education Reconciliation Act of 2010, affects the way healthcare is financed by both governmental and private insurers, and significantly impacts the device industry. The PPACA is intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers, and impose additional health policy reforms. The PPACA imposes, among other things, an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States beginning in 2013, resulting in an anticipated cost to the medical device industry of up to $20 billion over the next decade. We likely will be subject to the excise tax with respect to our C-Scan system if it is approved for sale in the United States. The PPACA also limits the rate of growth in Medicare payments to providers and authorizes certain voluntary demonstration projects beginning no later than 2013 around development of bundling payments for acute, inpatient hospital services, physician services, and post-acute services for episodes of hospital care. In addition, the PPACA provides for the establishment of an Independent Payment Advisory Board, or IPAB, that, beginning in 2014, could recommend changes in Medicare payments to physicians and other providers that would take effect unless Congress passes an alternative measure to achieve the same amount of savings. The IPAB has not yet been created. The PPACA also increases fraud and abuse penalties and expands the scope and reach of the Federal Civil False Claims Act and government enforcement tools, which may adversely impact healthcare companies.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">There have been judicial and congressional challenges to the PPACA, as well as efforts by the Trump Administration to repeal or replace certain aspects of the PPACA . The U.S. Supreme Court heard a constitutional challenge to the PPACA and in June 2012 held that the PPACA is constitutional. However, states are allowed to opt out of the expansion of eligibility criteria for Medicaid under the PPACA and many states have chosen to do so, causing many uninsured patients to remain without coverage. In addition to the PPACA, the effect of which cannot presently be quantified given its recent enactment, various healthcare reform proposals have also emerged at the state level. We cannot predict whether future healthcare initiatives will be implemented at the federal or state level or the effect any future legislation or regulation will have on us. However, we anticipate that the PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and an additional downward pressure on the price that we receive for any approved product, and could adversely affect our business. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Insurers may also refuse to provide any coverage of uses of approved products for medical indications other than those for which the FDA has granted market approvals, all of which may adversely affect our business, financial condition and results of operations, possibly materially.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements for health insurance mandated by the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">PPACA</font>. However, to date, the Executive Orders have had limited effect and the Congressional activities have not resulted in the passage of a law repealing or replacing the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">PPACA</font>. If a law is enacted, many if not all of the provisions of the PPACA may no longer apply to prescription drugs. While we are unable to predict what changes may ultimately be enacted, to the extent that future changes affect how any future products are paid for and reimbursed by government and private payers our business could be adversely impacted.&#160; On December 14, 2018, a federal district court in Texas ruled that the PPACA is unconstitutional as a result of the Tax Cuts and Jobs Act, the federal income tax reform legislation previously passed by Congress and signed by President Trump on December 22, 2017, that eliminated the individual mandate portion of the PPACA.&#160; The case, Texas, et al, v. United States of America, et al., (N.D. Texas), is an outlier, and the ruling has been stayed by the ruling judge.&#160; We are not able to state with any certainty what will be the&#160;impact of this court decision on our business pending further court action and possible appeals.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount greater than $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, starting in 2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If we ever obtain regulatory approval and commercialization of our C-Scan system or any future product candidates, these laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our C-Scan system or any future product candidates may be.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">20</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Although we cannot predict the full effect on our business of the implementation of existing legislation or the enactment of additional legislation pursuant to healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of, our C-Scan system or any future product candidates, could adversely affect how much or under what circumstances healthcare providers will prescribe or administer our products. This could materially and adversely affect our business by reducing our ability to generate revenue, raise capital, obtain additional collaborators and market our C-Scan system or any future product candidates. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact any future product sales.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition to healthcare reform, other deficit reduction measures could affect reimbursement for our device and related procedures. For example, beginning April 1, 2013, Medicare payments for all items and services have been reduced by 2% under the sequestration (i.e., automatic spending reductions) required by the Budget Control Act of 2011, as amended by the American Taxpayer Relief Act of 2012. These cuts will remain in effect until 2024 unless Congress enacts legislation to cancel or delay the cuts. These payment reductions, or similar efforts to reduce Medicare spending to control the federal deficit, could adversely affect our business by reducing reimbursement to the providers who purchase and use our devices and perform related procedures.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The implementation of the reporting and disclosure obligations of the Physician Payment Sunshine Act's provisions relating to healthcare reform could adversely affect our business. A health care reform provision, generally referred to as the Physician Payment Sunshine Act or Open Payments Program, has imposed new reporting and disclosure requirements for drug and device manufacturers with regard to payments or other transfers of value made to certain practitioners (including physicians, dentists and teaching hospitals), and for such manufacturers and for group purchasing organizations, with regard to certain ownership interests held by physicians in the reporting entity. On February 1, 2013, the Centers for Medicare and Medicaid Services, or CMS, released the final rule to implement the Physician Payment Sunshine Act. As required under the Physician Payment Sunshine Act, CMS will publish information from these reports on a publicly available website, including amounts transferred and physician, dentist and teaching hospital identities.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The final rule implementing the Physician Payment Sunshine Act is complex, ambiguous, and broad in scope. If we participate in federal healthcare programs, meaning our product is reimbursed by a federal healthcare program such as Medicare, Medicaid, or Children&#8217;s Health Insurance Program, our product would be considered a &#8220;covered device.&#8221; Within 180 days of becoming &#8220;covered,&#8221; we would be required to collect and report detailed information regarding certain financial relationships we have with physicians and teaching hospitals. The Physician Payment Sunshine Act preempts similar state reporting laws, although we may be required to report under certain of such state laws. Our compliance with the new final rule imposes additional costs on us and requires additional resources including dedicated personnel with experience and expertise in this area. Failure to comply may expose us to federal and/or state enforcement action and fines.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">If we fail to comply with the U.S. federal Anti-Kickback Statute and similar state and third-country laws, we could be subject to criminal and civil penalties and exclusion from federally funded healthcare programs including the Medicare and Medicaid programs and equivalent third-country programs, which would have a material adverse effect on our business and results of </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">operations</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">A provision of the Social Security Act, commonly referred to as the federal Anti-Kickback Statute, prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration, directly or indirectly, in cash or in kind, to induce or reward the referring, ordering, leasing, purchasing or arranging for, or recommending the ordering, purchasing or leasing of, items or services payable, in whole or in part, by Medicare, Medicaid or any other federal healthcare program. PPACA, among other things, clarified that a person or entity needs not to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exemption or safe harbor may be subject to scrutiny. The federal Anti-Kickback Statute is very broad in scope and many of its provisions have not been uniformly or definitively interpreted by existing case law or regulations. In addition, most of the states have adopted laws similar to the federal Anti-Kickback Statute, and some of these laws are even broader than the federal Anti-Kickback Statute in that their prohibitions may apply to items or services reimbursed under Medicaid and other state programs or, in several states, apply regardless of the source of payment. Violations of the federal Anti-Kickback Statute may result in substantial criminal, civil or administrative penalties, damages, fines and exclusion from participation in federal healthcare programs.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">All of our financial relationships with healthcare providers, purchasers, formulary managers, and others who provide products or services to federal healthcare program beneficiaries are potentially governed by the federal Anti-Kickback Statute and similar state laws. We believe our operations are in compliance with the federal Anti-Kickback Statute and similar state laws. However, we cannot be certain that we will not be subject to investigations or litigation alleging violations of these laws, which could be time-consuming and costly to us and could divert management&#8217;s attention from operating our business, which in turn could have a material adverse effect on our business. In addition, if our arrangements were found to violate the federal Anti-Kickback Statute or similar state laws, the consequences of such violations would likely have a material adverse effect on our business, results of operations and financial condition.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">21</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">There are other federal and state laws that may affect our ability to operate, including the federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. PPACA amended the Social Security Act to provide that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Moreover, we may be subject to other federal false claim laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government healthcare benefit programs. Moreover, there are analogous state laws. Violations of these laws can result in substantial criminal, civil or administrative penalties, damages, fines and exclusion from participation in federal healthcare programs.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Similar restrictions are imposed by the national legislation of many third countries in which our medical devices will be marketed. Moreover, the provisions of the Foreign Corrupt Practices Act of 1997 and other similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from providing money or anything of value to officials of foreign governments, foreign political parties, or international organizations with the intent to obtain or retain business or seek a business advantage. Recently, there has been a substantial increase in anti-bribery law enforcement activity by U.S. regulators, with more aggressive and frequent investigations and enforcement by both the U.S. Securities and Exchange Commission and the Department of Justice. A determination that our operations or activities violated United States or foreign laws or regulations could result in imposition of substantial fines, interruption of business, loss of supplier, vendor or other third-party relationships, termination of necessary licenses and permits, and other legal or equitable sanctions. In addition, lawsuits brought by private litigants may also follow as a consequence.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Our failure to comply with the necessary regulatory approval regarding the use of radioactive materials could significantly impair our ability to develop, manufacture and/or sell our C-Scan system.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The manufacture of our C-Scan system requires the use and storage of radioactive materials. In order to use such materials in the development and manufacture of our C-Scan system in Israel, we are required to obtain a permit from the Israeli Commissioner for Environmental Radiation, or the Commissioner, pursuant to the Israeli Pharmaceutical Regulations (Radioactive Elements and By-Products), 5740&#8211;1980. Should we fail to comply with the conditions of our currently existing permit, the Commissioner would have authority to cancel our permit. Should the Commissioner determine that our activities or facilities constitute a danger to the health and well-being of a person, the public or the environment, the cancellation of our permit could be immediate and without prior notice. Furthermore, we cannot guarantee the annual renewal of our permit and/or annual renewal subject to identical conditions, as the approval of an annual application and the conditions thereof are at the discretion of the Commissioner. Similar requirements and regulations may apply to the manufacture of our C-Scan system in other countries. Cancellation of or failure to renew our permit could have materially adverse consequences on our ability to manufacture and sell our products and therefore on our ability to continue our business and operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Risks Related to Our Intellectual Property</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">If we are unable to protect our intellectual property rights, our competitive position could be harmed</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our success and ability to compete depends in large part upon our ability to protect our intellectual property. Although we have patents issued in Israel, Europe, United States, Japan, China, India, Hong Kong, Canada, South Korea and Australia, we continue to file and prosecute in many of the same countries and additional countries such as Brazil. We face several risks and uncertainties in connection with our intellectual property rights, including, among others:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z760e372a1d6c416db83c7de8c90f636e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">pending and future patent applications may not result in the issuance of patents or, if issued, may not be issued in a form that will be advantageous to us;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z734c9d38d91f47e6827c0a1da6198116" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.61%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.17%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">our issued patents may be challenged, invalidated or legally circumvented by third parties;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze6c97d153e06442a9a2870e654ad1ede" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">our patents may not be upheld as valid and enforceable or prevent the development of competitive products;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z18b240aa9d71440993ac51e4e4d07fd5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the eligibility of certain inventions related to diagnostic medicine, more specifically diagnostic methods and processes, for patent protection in the United States has been limited recently which may affect our ability to enforce our issued patents in the United States or may make it difficult to obtain broad patent protection going forward in the United States;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd940b528033d44479525e91a64f7287c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">for a variety of reasons, we may decide not to file for patent protection on various improvements or additional features; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze013404e2abd450cbcef77761445353c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">intellectual property protection and/or enforcement may be unavailable or limited in some countries where laws or law enforcement practices may not protect our proprietary rights to the same extent as the laws of the United States, the European Union, Canada or Israel.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">22</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Consequently, our competitors could develop, manufacture and sell products that directly compete with our products, which could decrease our sales and diminish our ability to compete. In addition, competitors could attempt to develop their own competitive technologies that fall outside of our intellectual property rights. If our intellectual property does not adequately protect us from our competitors&#8217; products and methods, our competitive position could be materially adversely affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Because the medical device industry is litigious, we are susceptible to intellectual property suits that could cause us to incur substantial costs or pay substantial damages or prohibit us from selling our C-Scan system</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">There is a substantial amount of litigation over patent and other intellectual property rights in the medical device industry. Whether a product infringes a patent involves complex legal and factual issues, the determination of which is often uncertain. We are presently unaware of any other parties&#8217; valid patents and proprietary rights which our evolving product designs would infringe. Searches typically performed to identify potentially infringed patents of third parties are often not conclusive and because patent applications can take many years to issue, there may be applications now pending, which may later result in issued patents which our current or future products may infringe. In addition, our competitors or other parties may assert that our C-Scan system and the methods it employs may be covered by patents held by them. If our C-Scan system infringes a valid patent, we could be prevented from manufacturing or selling it unless we can obtain a license or redesign the product to avoid infringement. A license may not always be available or may require us to pay substantial royalties. We also may not be successful in any attempt to redesign our product to avoid infringement. Infringement and other intellectual property claims, with or without merit, can be expensive and time-consuming to litigate and could divert our management&#8217;s attention from operating our business.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">The steps we have taken to protect our intellectual property may not be adequate, which could have a material adverse effect on our ability to compete in the market</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition to patents, we rely on confidentiality, non-compete, non-disclosure and assignment of inventions provisions, as appropriate, with our employees, consultants and, to some extent, our distributors, to protect and otherwise seek to control access to, and distribution of, our proprietary information. These measures may not be adequate to protect our intellectual property from unauthorized disclosure, third-party infringement or misappropriation, for the following reasons:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb0f448dd039d41b5842ca44dee8a0bc8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the agreements may be breached, may not provide the scope of protection we believe they provide or may be determined to be unenforceable;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0170d8e6562e4bc697bab1bc70783377" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may have inadequate remedies for any breach;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z90242c9f7a6b45fd8427c55f4e867725" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">proprietary information could be disclosed to our competitors; or</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze2c84ac44bbd47f08bc9d29dd8f3f2a1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">others may independently develop substantially equivalent or superior proprietary information and techniques or otherwise gain access to our trade secrets or disclose such technologies.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Specifically with respect to non-compete agreements, under current United States and Israeli law, we may be unable to enforce these agreements, in whole or in part, and it may be difficult for us to restrict our competitors from gaining the expertise that our former employees gained while working for us. For example, Israeli courts have recently required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy of a company&#8217;s confidential commercial information or its intellectual property. If we cannot demonstrate that harm would be caused to us, we may be unable to prevent our competitors from benefiting from the expertise of our former employees. In addition, some states in the United States, such as California, have laws which severely restrict the use of non-compete undertakings.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If, for any of the above reasons, our intellectual property is disclosed or misappropriated, it could harm our ability to protect our rights and could have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Furthermore, although our employees and consultants have agreed to assign to us all rights to any intellectual property created in the scope of their employment or engagement with us and most of our current employees and consultants, have agreed to waive their economic rights with respect to our intellectual property, we cannot assure you that such claims will not be brought against us by current or former employees or consultants, despite their contractual representations and obligations toward us, or by any of the medical and/or governmental institutions that employ or engage such consultants, claiming alleged rights to our intellectual property or demanding remuneration in consideration for assigned intellectual property rights, which could result in litigation and adversely affect our business, financial condition and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">23</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Third-party claims of infringement or other claims against us could require us to redesign our C-Scan system, seek licenses, or engage in future costly intellectual property litigation, which could negatively affect our future business and financial performance.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Substantial litigation over intellectual property rights exists in the medical device industry in general and in the medical imaging or screening sectors in particular. We expect that we may be subject to third-party infringement claims as our revenues increase, the number of competitors grows and the functionality of products and technology in different industry segments converges. Third parties may currently have, or may eventually be issued, patents on which our current or future products or technologies may infringe.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, litigation in which we are accused of infringement may cause negative publicity, adversely impact prospective customers, cause product shipment delays, prohibit us from manufacturing, marketing or selling our current or future products, require us to develop non-infringing technology, make substantial payments to third parties or enter into royalty or license agreements, which may not be available on acceptable terms, or at all. If a successful claim of infringement were made against us and we could not develop non-infringing technology or license the infringed or similar technology in a timely and cost-effective manner, our ability to generate significant revenues may be substantially harmed and we could be exposed to significant liability. A court could enter orders that temporarily, preliminarily or permanently enjoin us or our customers from making, using, selling, offering to sell or importing our current or future products, or could enter an order mandating that we undertake certain remedial activities. Claims that we have misappropriated the confidential information or trade secrets of third parties can have a similar negative impact on our reputation, business, financial condition or results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We may also become involved in litigation in connection with our brand name rights. We do not know whether others will assert that our brand name infringes their trademark rights. In addition, names we choose for our products may be claimed to infringe names held by others. If we have to change the names we use, we may experience a loss in goodwill associated with our brand name, customer confusion and a loss of sales.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Third parties may challenge the validity of our issued patents or challenge patent applications in administrative proceedings before various patent offices which, if successful, could negatively affect our future business and financial performance</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Various patent offices, including in the United States and Europe, provide administrative proceedings by which a third party can challenge the validity of an issued patent or challenge an application that is being examined absent any threat of litigation. In some instances, including in the United States, the administrative proceedings provide a more efficient and favorable forum to challenge our patents which may lead to more opportunities for competitors to do so, particularly smaller competitors with limited resources. Moreover, the standards utilized in these administrative proceedings, at least in the United States, provide certain legal advantages versus challenging the validity of a patent in a district court. If a third party is successful in one of these administrative proceedings, the patent will no longer be enforceable in the corresponding jurisdiction. With this loss in patent rights, we will not be able to prevent third parties from offering identical or similar competing products which may result in lower profits and a less substantial market share.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">We may need to initiate lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive and, if we lose, could cause us to lose some of our intellectual property rights, which would harm our ability to compete in the market</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We rely on patents to protect a portion of our intellectual property and our competitive position. Patent law relating to the scope of claims in the technology fields in which we operate is still evolving and, consequently, patent positions in the medical device industry are generally uncertain. In order to protect or enforce our patent rights, we may initiate patent and related litigation against third parties, such as infringement suits or interference proceedings. Any lawsuits that we initiate could be expensive, take significant time and divert our management&#8217;s attention from other business concerns and the outcome of litigation to enforce our intellectual property rights in patents, copyrights, trade secrets or trademarks is highly unpredictable. Litigation also puts our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not being issued. In addition, we may provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, including attorney fees, if any, may not be commercially valuable. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We rely on trademark protection to distinguish our products from the products of our competitors; however, if a third party is entitled to use our trademark, we could be forced to rebrand, which could result in loss of brand recognition and our ability to distinguish our products may be impaired, which could adversely affect our business.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We rely on trademark protection to distinguish our products from the products of our competitors.&#160;In jurisdictions where we have not registered our trademarks and logos and are using them, and as permitted by applicable local law, we rely on common law trademark protection.&#160; Third parties may oppose our trademark applications, or otherwise challenge our use of the trademarks, and may be able to use our trademarks in jurisdictions where they are not registered or otherwise protected by law.&#160; If our trademarks are successfully challenged or if a third party is using confusingly similar or identical trademarks in particular jurisdictions before we do, we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote additional resources to marketing new brands. If others are able to use our trademarks, our ability to distinguish our products may be impaired, which could adversely affect our business. Further, we cannot assure you that competitors will not infringe upon our trademarks, or that we will have adequate resources to enforce our trademarks.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">24</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We may not be able to enforce covenants not to compete at all or, we may be unable to enforce them for the duration contemplated in our employment contracts and may, therefore, be unable to prevent competitors from benefiting from the expertise of some of our former employees involved in research and development activities.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We currently have non-compete agreements with substantially all of our employees who are involved in research and development, all of whom are located in Israel. These agreements prohibit our employees, if they cease working for us, from directly competing with us or working for our competitors for a limited period of time following termination of employment. In many jurisdictions, courts are increasingly refusing to enforce restrictions on competition by former employees or have interpreted them narrowly. For example, in Israel, where all of our employees reside, courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy of a company&#8217;s confidential commercial information or its intellectual property. If we cannot demonstrate that harm would be caused to us, an Israeli court may refuse to enforce our non-compete restrictions or reduce the contemplated period of non-competition such that we may be unable to prevent our competitors from benefiting from the expertise of our former employees.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Risks Related to Our Operations in Israel</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Our principal offices, research and development facilities and some of our suppliers are located in Israel and, therefore, our business, financial condition and results of operation may be adversely affected by political, economic and military instability in Israel</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our principal offices and research and development facilities are located in northern Israel. In addition, substantially all of our employees and officers, and one of our directors, are residents of Israel. Accordingly, political, economic and military conditions in Israel may directly affect our business. Since the establishment of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">During the Second Lebanon War of 2006, between Israel and Hezbollah, a militant Islamic movement, rockets were fired from Lebanon into Israel, including into the Haifa area, where our facility is located, causing casualties and major disruption of economic activities in northern Israel. An escalation in tension and violence between Israel and the militant Hamas movement (which controls the Gaza Strip) and other Palestinian Arab groups, culminated with Israel&#8217;s military campaign in Gaza in December 2008, in November 2012 and again in July and August 2014 in an endeavor to prevent continued rocket attacks against Israel&#8217;s southern towns, as well as other tension and violence between Israel and Palestinian Arab groups and individuals. It is unclear whether any negotiations that may occur between Israel and the Palestinian Authority will result in an agreement. In addition, Israel faces threats from more distant neighbors, in particular, Iran, an ally of Hezbollah and Hamas, and the militant group known as the Islamic State of Iraq and Syria.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Popular uprisings in various countries in the Middle East and North Africa are affecting the political stability of those countries. Such instability may lead to deterioration in the political and trade relationships that exist between the State of Israel and these countries. Furthermore, several countries, principally in the Middle East, restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions on doing business with Israel and Israeli companies if hostilities in the region continue or intensify. Such restrictions may seriously limit our ability to sell our products to customers in those countries. Similarly, Israeli corporations are limited in conducting business with entities from several countries. Parties with whom we may do business could decline to travel to Israel during periods of heightened unrest or tension. In addition, the political and security situation in Israel may result in parties with whom we may have agreements involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to force majeure provisions in such agreements. In addition, any hostilities involving Israel could have a material adverse effect on our facilities including our corporate office or on the facilities of our local suppliers, in which event all or a portion of our inventory may be damaged, and our ability to deliver products to customers could be materially adversely affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Furthermore, the war and terrorism insurance we maintain may not be adequate to cover our losses associated with armed conflicts and terrorist attacks.&#160;Although the Israeli government in the past covered the reinstatement value of certain damages that were caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our operations could also be disrupted by the obligations of personnel to perform military service. As of December 31, 2018, we had 56 employees and independent contractors, all of whom were based in Israel. Some of these employees may be called upon to perform up to 54 days in each three year period (and in the case of military officers, up to 84 days in each three year period) of military reserve duty until they reach the age of 40 (and in some cases, depending on their specific military profession up to 45 or even 49 years of age) and, in certain emergency circumstances, may be called to immediate and unlimited active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists and it is possible that there will be similar large-scale military reserve duty call-ups in the future. Our operations could be disrupted by the absence of a significant number of employees related to military service, which could materially adversely affect our business and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">25</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Any hostilities involving Israel, terrorist activities or political instability in the region or the interruption or curtailment of trade between Israel and its present trading partners, or significant downturns in the economic or financial condition of Israel, could adversely affect our operations and product development, cause our revenues to decrease and adversely affect our share price.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Pursuant to the terms of the Israeli government grants we received for research and development expenditures, we are obligated to pay certain royalties on our revenues to the Israeli government. The terms of the grants require us to satisfy specified conditions and to make additional payments in addition to repayment of the grants upon certain events</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have received grants from the Government of the State of Israel through the IIA (formerly the OCS) for the financing of a portion of our research and development expenditures pursuant to the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law and related regulations and guidelines.&#160;As of December 31, 2018, we had received funding from the IIA in the aggregate amount of approximately $5.3 million.&#160; As of December 31, 2018, we had not paid any royalties to the IIA and had a contingent obligation to the IIA in the amount of approximately $5.6 million.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> In</font> December 2018, we applied for an additional IIA grant, and our application <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">was</font> rejected<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font> We may apply for additional IIA grants in the future; however, there is no assurance that such applications will be approved in the amount requested or at all. Furthermore, the funds available for IIA grants out of the annual budget of the State of Israel have been reduced in the past and may be further reduced in the future.&#160; We cannot predict whether we will be entitled to any future grants, or the amounts of any such grants.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the terms of the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law as currently in effect, products developed with IIA grants are required to be manufactured in Israel<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, unless approval for transferring such manufacturing</font> outside Israel is received from the IIA<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> (however, only a notice to the IIA</font>, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">as opposed to </font>approval<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, is required for the transfer outside Israel of up to 10% of the manufacturing). </font>Such approval may be provided by the IIA in connection with the approval of the grant application itself (as we requested in certain of our grant applications<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">),</font> in which case the royalty repayment rate is increased<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, typically</font> by 1<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">%,</font> with respect to any such approved percentage.&#160; If manufacturing of IIA-funded products is transferred outside Israel (following IIA approval) in excess of the percentage approved by the IIA in connection with the grant approval, then the royalty repayment rate is increased by 1% and the royalty repayment amount with respect to such products may be increased to up to three times the amount of the grants received, depending on the percentage manufactured outside Israel (plus accrued interest).&#160; IIA prior approval is also required for the transfer of IIA-funded know-how to a third party outside of Israel (including by way of license), which we may not receive (and any such approval would <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">typically be subject to payment of a redemption fee, calculated according to a formula under the Innovation Law, which may be in the amount</font> of up to six times the amount of the grants received, plus accrued interest). We are exploring whether certain components of our C-Scan system can be assembled outside of Israel. In particular, we are continuing to explore whether it would be possible to assemble the capsule without the X-ray source in Israel, and have the X-ray source subsequently assembled into our C-Scan system at a reactor site or at a distribution center outside Israel.&#160; Even following the full repayment of any IIA grants, we must nevertheless continue to comply with the requirements of the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law and related regulations and guidelines. The foregoing restrictions and requirements for payment may impair our ability to sell our technology assets outside of Israel or to outsource or transfer development or manufacturing activities with respect to any product or technology outside of Israel. Furthermore, the consideration available to our shareholders in a transaction involving the transfer outside of Israel of technology or know-how developed with IIA funding (such as a merger or similar transaction) may be reduced by any amounts that we are required to pay to the IIA.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If we fail to comply with any of the conditions and restrictions imposed by the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law and related regulations and guidelines, or by the specific terms under which we received the grants, we may be required to refund any grants previously received together with interest and penalties, and, in certain circumstances, may be subject to criminal charges.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Your rights and responsibilities as a shareholder are governed by Israeli law, which differ in some material respects from the rights and responsibilities of shareholders of U.S. companies.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The rights and responsibilities of the holders of our ordinary shares are governed by our amended articles of association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, in voting at a general meeting of shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and certain related party transactions requiring shareholder approval under Israeli law. In addition, </font>a controlling shareholder of an Israeli company or<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> a shareholder who is aware that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive officer in the company or has other powers towards the company, has a duty of fairness toward the company. There is limited case law available to assist us in understanding the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">26</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">It may be difficult to enforce a judgment of a U.S. court against us, certain of our officers and directors or the Israeli experts named in this Annual Report in Israel or the United States, to assert U.S. securities laws claims in Israel or to serve process on certain of our officers and directors and these experts</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are incorporated in Israel. All of our executive officers, one of our directors and our Israeli experts, reside in Israel, and substantially all of our assets and a substantial portion of the assets of these persons are located in Israel. Therefore, a judgment obtained against us, or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It also may be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws on the grounds that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Provisions of Israeli law and our amended articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, us, even when the terms of such a transaction are favorable to us and our shareholders</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example, a full tender offer for all of a public company&#8217;s issued and outstanding shares can only be completed if the acquirer receives positive responses from the holders of at least 95% of the issued share capital and the approval of a majority of the offerees that do not have a personal interest in the tender offer, unless at least 98% of the company&#8217;s outstanding shares are tendered. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer (unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek appraisal rights), may, at any time within six months following the completion of the tender offer, petition an Israeli court for an appraisal right, to alter the consideration for the acquisition. In addition, a statutory merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We may become subject to claims for payment of compensation for assigned service inventions by our current or former employees, which could result in litigation and adversely affect our business.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Patents Law, 5727-1967, or the Patents Law, inventions conceived by an employee during the scope of his or her employment are regarded as &#8220;service inventions&#8221; and are owned by the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. Section 134 of the Patents Law provides that if no agreement between an employer and an employee exists that prescribes whether, to what extent, and on what conditions the employee is entitled to remuneration for his or her service inventions, then such matters may, upon application by the employee, be decided by a government-appointed compensation and royalties committee established under the Patents Law, or the Committee.&#160; Although our employees have agreed to assign to us all rights to any intellectual property created in the scope of their employment and most of our current employees, including all those involved in the development of our intellectual property, have agreed to waive their economic rights with respect to service inventions, we cannot assure you that claims will not be brought against us by current or former employees demanding remuneration in consideration for assigned service inventions. If any such claims were filed, we could potentially be required to pay remuneration to our current or former employees for such assigned service inventions, or be forced to litigate such claims, which could negatively affect our business.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Risks Related to Ownership of our Ordinary Shares</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Our corporate actions are significantly influenced by&#160;our&#160;principal&#160;shareholders, who have the ability to exert significant influence over important corporate matters that require approval of shareholders, which may deprive you of an opportunity to receive a premium for your ordinary shares and materially reduce the value of your investment.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Based on recently filed Section 13 filings and a Non-Objecting Beneficial Owner list</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, each of </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our four largest shareholders </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">beneficially owned</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> approximately</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> 9</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">%, 8</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">%, 8</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">% and </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">7</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">% of our ordinary shares, respectively, representing in </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">the </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">aggregate </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">32</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">% of our ordinary shares</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> As a result, such shareholders </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">may</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> be able to significantly influence the outcome of matters required to be submitted to our shareholders for approval, including decisions relating to the election of our board of directors (which has the authority to direct our business and to appoint and remove our officers), approving or rejecting any proposed merger or consolidation of our company and amending our articles of association (which govern the rights attached to our ordinary shares). The interests of our principal shareholders may not always be aligned with those of our other shareholders. In addition, conflict of interests may exist or occur between our principal shareholders. Any material conflicts of interests between our major shareholders and other stakeholders may have a material adverse effect on our business, financial condition and results of operations.&#160; Furthermore, these parties&#8217; significant interest in us may discourage, delay or prevent a change in control of our company, which could have the dual effect of depriving our shareholders of an opportunity to receive a premium for their shares as part of a sale of our company and reducing the price of the ordinary shares. As a result of the foregoing, the value of your investment could be materially reduced.</font></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">27</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">We have and will continue to incur significant costs as a result of operating as a public company in the United States, and our management is required to devote substantial time to compliance initiatives</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As a public company whose securities are traded in the United States, we have and will continue to incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002, as well as rules and regulations implemented by the U.S. Securities and Exchange Commission and the Nasdaq Stock Market, impose various requirements on public companies, including requiring the establishment and maintenance of effective disclosure and financial controls. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Changes in the laws, rules and regulations affecting public companies would result in increased costs to us as we respond to their requirements. These rules and regulations could make it more difficult or more expensive for us to obtain certain types of insurance, including director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantial costs to obtain or maintain the same or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. We cannot predict or estimate the amount or timing of additional costs we may incur in order to comply with such requirements.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">We are required to develop and maintain proper and effective internal controls over financial reporting. We may not complete our analysis of our internal controls over financial reporting in a timely manner, or these internal controls may have one or more material weaknesses, which may adversely affect investor confidence in our company and, as a result, the value of our securities</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Section 404 of the Sarbanes-Oxley Act requires the management of public companies to conduct an annual review and evaluation of their internal controls and to obtain an attestation report from their registered public accounting firm regarding the effectiveness of internal controls. However, so long as we qualify as an emerging growth company, we will be exempt from the auditors&#8217; attestation requirement under Section 404 of the Sarbanes-Oxley Act. We would no longer qualify as an emerging growth company at such time as described in the risk factor below.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">To maintain the effectiveness of our disclosure controls and procedures and our internal control over financial reporting, we expect that we will need to continue enhancing existing, and implement new, financial reporting and management systems, procedures and controls to manage our business effectively and support our growth in the future. The process of evaluating our internal control over financial reporting requires an investment of substantial time and resources, including by our Chief Financial Officer and other members of our senior management. The determination and any remedial actions required could divert internal resources and take a significant amount of time and effort to complete and could result in us incurring additional costs that we did not anticipate, including the hiring of outside consultants. During the evaluation and testing process, if we identify one or more additional material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. If we are unable to assert that our internal control over financial reporting is effective, we could lose investor confidence in the accuracy and completeness of our financial reports, which could cause the price of our securities to decline.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Our ordinary shares could be delisted from the Nasdaq Capital Market.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Nasdaq has established certain standards for the continued listing of a security on the Nasdaq Capital Market.&#160; The standards for continued listing include, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">inter&#160; alia</font>, that the minimum bid price for the listed securities be at least $1.00 per share. Under these rules, a security is considered deficient if it fails to achieve at least a $1.00 closing bid price for a continuous period of 30 business days. On January 18, 2018, we received a notification from Nasdaq stating that the bid price for our ordinary shares had closed below the minimum $1.00 per share for 30 consecutive business days, which is not in compliance with the Nasdaq rules for continued listing. We were provided by Nasdaq with a compliance period of 180 calendar days (i.e., until July 17, 2018) in which to regain compliance pursuant to Nasdaq Listing Rules. In order to regain compliance, on April 2, 2018, our shareholders approved a reverse share split of our ordinary shares within a range of 1:8 to 1:12, the exact ratio to be determined by further action of our Board of Directors, to be effective on a date to be determined by our Board of Directors and announced by us, and to amend our Articles of Association accordingly. On April 2, 2018, our Board approved a reverse share split of our ordinary shares at a ratio of 1-for-12, effective as of April 4, 2018. On April 18, 2018, Nasdaq provided confirmation that we regained compliance with the minimum bid price listing requirements.</div>

<br style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If we are delisted from Nasdaq, our ordinary shares may be eligible for trading on an over-the-counter market in the United States. In the event that we are not able to obtain a listing on another U.S. stock exchange or quotation service for our ordinary shares, it may be extremely difficult or impossible for shareholders to sell their ordinary shares in the United States. Moreover, if we are delisted from Nasdaq, but obtain a substitute listing for our ordinary shares in the United States, it will likely be on a market with less liquidity, and therefore, experience potentially more price volatility than experienced on Nasdaq. Shareholders may not be able to sell their ordinary shares on any such substitute U.S. market in the quantities, at the times, or at the prices that could potentially be available on a more liquid trading market. As a result of these factors, if our ordinary shares are delisted from Nasdaq, the price of our ordinary shares is likely to decline. A delisting of our ordinary shares from Nasdaq could also adversely affect our ability to obtain financing for our operations and/or result in a loss of confidence by investors, or employees.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">28</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">While we currently qualify as an &#8220;emerging growth company&#8221; under the JOBS Act, we will cease to be an emerging growth company on or before the end of 2020, and at such time our costs and the demands placed upon our management will increase</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may choose to take advantage of certain exemptions from reporting requirements applicable to other public companies that are not emerging growth companies. We will continue to be deemed an emerging growth company until the earliest of (i) the last day of the fiscal year in which our annual gross revenues exceed $1.07 billion (as indexed for inflation); (ii) the last day of the fiscal year following the fifth anniversary of the date of our<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font>initial public offering; (iii) the date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt; or (iv) the date on which we are deemed to be a &#8216;large accelerated filer,&#8217; as defined by the U.S. Securities and Exchange Commission, which would generally occur upon our attaining a public float of at least $700 million. Once we lose emerging growth company status, we expect the costs and demands placed upon our management to increase, as we will be required to comply with additional disclosure and accounting requirements.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">We are a foreign private issuer and, as a result, we are not be subject to U.S. proxy rules and are subject to the Securities Exchange Act of 1934 reporting obligations that, to some extent, are more lenient and less frequent than those applicable to a U.S. issuer</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We report under the Securities Exchange Act of 1934, as amended, or the Exchange Act as a foreign private issuer. Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. public companies, including (i) the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii) the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iii) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. We intend to furnish quarterly reports to the SEC on Form 6-K for so long as we are subject to the reporting requirements of Section 13(g) or 15(d) of the Exchange Act, although the information we furnish may not be the same as the information that is required in quarterly reports on Form 10-Q for U.S. domestic issuers. In addition, while U.S. domestic issuers that are not large accelerated filers or accelerated filers are required to file their annual reports on Form 10-K within 90 days after the end of each fiscal year, foreign private issuers are not required to file their annual report on Form 20-F until 120 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation FD (Fair Disclosure), aimed at preventing issuers from making selective disclosures of material information. Although we intend to make interim reports available to our shareholders in a timely manner, you may not have the same protections afforded to shareholders of companies that are not foreign private issuers.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">As a foreign private issuer, we are permitted, to follow, and follow certain home country corporate governance practices instead of otherwise applicable Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of those otherwise required under the Listing Rules of the Nasdaq Stock Market for domestic U.S. issuers.&#160; For instance, we follow home country practice in Israel with regard to, among other things, director nomination procedures, the approval of compensation of officers and quorum requirements at general meetings of our shareholders. In addition, we intend to follow our home country law instead of the Listing Rules of the Nasdaq Stock Market that require us to obtain shareholder approval for certain dilutive events, such as the establishment or amendment of certain equity based compensation plans, an issuance that will result in a change of control of the company, certain transactions other than a public offering involving issuances of a 20% or greater interest in the company, and certain acquisitions of the stock or assets of another company. Following our home country governance practices as opposed to the requirements that would otherwise apply to a United States company listed on Nasdaq may provide less protection to you than what is accorded to investors under the Listing Rules of the Nasdaq Stock Market applicable to domestic U.S. issuers.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">If we lose our status as a foreign private issuer under the SEC&#8217;s rules, our compliance costs will increase.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We would lose our foreign private issuer status if more than 50 percent of our outstanding voting securities are directly or indirectly held of record by residents of the United States and if a majority of our directors or executive officers are U.S. citizens or residents and we fail to meet additional requirements necessary to avoid loss of foreign private issuer status.&#160; Although we have elected to comply with certain U.S. regulatory provisions, our loss of foreign private issuer status would make such provisions mandatory. The regulatory and compliance costs for us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. We would also be required to follow U.S. proxy disclosure requirements, including the requirement to disclose more detailed information about the compensation of our senior executive officers on an individual basis. We may also be required to modify certain of our policies to comply with corporate governance practices associated with U.S. domestic issuers. Such conversion and modifications will involve additional costs. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">29</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Exchange rate fluctuations between the U.S. dollar and the NIS and the Euro and inflation may negatively affect our earnings and we may not be able to hedge our currency exchange risks successfully.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The dollar is our functional and reporting currency. However, a significant portion of our operating expenses, including personnel and facilities related expenses, are incurred in NIS. As a result, we are exposed to the risks that the NIS may appreciate relative to the U.S. dollar, or, if the NIS instead devalues relative to the U.S. dollar, that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely affected. The Israeli rate of inflation has not had a material adverse effect on our financial condition during the years 2018, 2017 and 2016.&#160; In addition, we expect to incur operating expenses denominated in Euros, and therefore, our operating results are also subject to fluctuations due to changes in the U.S. dollar/Euro exchange rate. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS, the Euro and other foreign currencies against the U.S. dollar. While we have recently begun to engage in currency hedging arrangements, these measures may not adequately protect us from fluctuations in the exchange rates of the NIS, the Euro and other foreign currencies in relation to the U.S. dollar (and/or from inflation of such foreign currencies), and involve costs and risk of their own.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">We have never declared or paid a dividend and currently do not intend to pay cash dividends in the foreseeable future. Any return on investment may be limited to the value of our securities</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have never declared and do not anticipate paying cash dividends on our ordinary shares in the foreseeable future. Our board of directors has discretion to declare and pay dividends on our ordinary shares and will make any determination to do so based on a number of factors, such as our operating results, financial condition, current and anticipated cash needs and other business and economic factors that our board of directors may deem relevant. In addition, we are only permitted to pay dividends out of &#8220;profits&#8221; (as defined by the Israeli Companies Law, 1999, or the Israeli Companies Law), provided that there is no reasonable concern that the dividend distribution will prevent us from meeting our existing and foreseeable obligations, as they become due. If we do not pay dividends, our ordinary shares may be less valuable because a return on your investment will only occur if the trading price of our securities appreciates. Further, you should not rely on an investment in us if you require dividend income from your investments.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">If securities or industry analysts do not publish research or reports about us or our business or publish unfavorable research about us or our business, the price of our securities and their trading volume could decline</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The trading market for our securities will depend in part on the research and reports that securities or industry analysts publish about us or our business. We currently have limited research coverage by securities and industry analysts. If one or more of the analysts who covers us downgrades our securities, the price of our securities would likely decline. We do not have control over these analysts and we do not have commitments from them to continue to write research reports about us or our business. The price of our ordinary shares could decline if one or more equity research analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Our stock price has and may be subject to fluctuation, and purchasers of our securities could incur substantial losses</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our stock price has been subject to considerable fluctuation since our initial public offering in February 2015, with the closing price per share having varied from a low of $1.62 to a high of $70.56, and may be subject to fluctuation in the future. The stock market in general has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their securities at or above the purchase price. The market price for our ordinary shares on the Nasdaq Capital Market may fluctuate as a result of a number of factors, some of which are beyond our control, including, among others:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd4c60b89f9bf4625a7433dc8532a858e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we may not be able to develop our C-Scan system at the rate or to the stage we desire;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc64db0bc06d64f0bb2c82fdb05c985aa" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">inability to obtain the approvals necessary to commence further clinical trials;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze841e26d90594f7c8633c68f3d8fc151" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">unsatisfactory results of clinical trials;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z356d9ab668ee4dca9c107f94a2de428a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">announcements of regulatory approval or the failure to obtain it, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0f09459f67ed4d018f1035cdde090c1f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">any intellectual property infringement actions in which we may become involved;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7331d0777dbe42a897a040ecb38ff1e4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">announcements concerning our competitors or the medical device industry in general;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z45b34d74d4134e909abe13d32ddaff9b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">achievement of expected product sales and profitability or our failure to meet expectations;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8ec6d967f34f443a8cf1e5d971b3f8ff" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">our commencement of, or involvement in, litigation;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">30</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb3d738a337594130bb1532eb4b92ab9b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">any major changes in our board of directors or management;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z58b2291e9c4e4909acb02075c4d57909" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">legislation in the United States relating to the sale or pricing of medical device;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze83c98c473714617b5881d4a14daa84d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">future substantial sales of our ordinary shares;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf51103726a5742228abdbbef5660db7c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares are covered by analysts; or</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6fa33bfc6fc04a22b987e11cf377390e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the trading volume of our ordinary shares.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, the stock market in general, and Nasdaq Stock Market in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of small companies. Broad market and industry factors may negatively affect the market price of our ordinary shares, regardless of our actual operating performance. Further, a systemic decline in the financial markets and related factors beyond our control may cause our share price to decline rapidly and unexpectedly.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The trading market for our ordinary shares is not always active, liquid and orderly, which may inhibit the ability of our shareholders to sell ordinary shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Prior to our initial public offering in February 2015, there was no public market for our ordinary shares. Since that time, the trading market for our ordinary shares has not always been active, liquid or orderly. The lack of an active market at times may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. An inactive market may also impair our ability to raise capital by selling shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">We have broad discretion in how we use the net proceeds from our financings, and we may not use these proceeds effectively</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our management has broad discretion as to the application of the net proceeds of our financings. Our shareholders may not agree with the manner in which our management chooses to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that may not increase our profitability or our market value.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Risks Related to Taxation</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">There is a risk that we could be treated as a domestic (U.S.) corporation for U.S. federal income tax purposes by reason of the transactions related to our acquisition of all of the business operations and substantially all of the assets of Check-Cap LLC on May 31, 2009 (hereinafter sometimes referred to as the &#8220;reorganization&#8221;)</font> .</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Section 7874(b) of the Internal Revenue Code of 1986, as amended, or the Code, generally provides that a foreign corporation (i.e., a corporation created or organized under the laws of a jurisdiction outside of the United States) would be treated as a domestic (U.S.) corporation for U.S. federal income tax purposes if, pursuant to a plan or a series of related transactions, (1) the foreign corporation acquires, directly or indirectly, substantially all of the assets of a domestic corporation (or substantially all of the properties constituting a trade or business of a domestic partnership), (2) after the acquisition, the former shareholders of the acquired corporation by reason of holding shares of the acquired corporation (or, in the case of an acquisition with respect to a domestic partnership, the former partners of the domestic partnership by reason of holding a capital or profits interest in the domestic partnership) own at least 80% of the stock (by vote or value) of the acquiring corporation, and (3) after the acquisition, the expanded affiliated group that includes the acquiring corporation does not have substantial business activities in the foreign country in which, or under the laws of which, the acquiring corporation is created or organized when compared to the total business activities of such expanded affiliated group. On the basis of analysis of the relevant facts and circumstances and the relevant law (including the temporary regulations under Section 7874 applicable at the time of the reorganization), it was determined that the third condition described in the preceding sentence was not met with respect to the reorganization and, therefore, that the inversion tax rules of Section 7874(b) would not apply to treat us as a domestic corporation for U.S. federal income tax purposes. However, since this determination was made on the basis of all of the relevant facts and circumstances, and it is not clear which facts and circumstances the Internal Revenue Service, or the IRS, may consider more important than others, this conclusion is not free from doubt.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If Section 7874(b) were to apply to the reorganization (and we were to be treated as a domestic corporation for U.S. federal income tax purposes), then, among other things, (i) we would be subject to U.S. federal income tax on our worldwide taxable income (if and when we have taxable income); (ii) certain payments (e.g., interest and dividends) that we make (or have made) to our foreign investors may be (or may have been) subject to U.S. withholding taxes; (iii) we may be subject to significant penalties for the failure to file certain tax returns and reports, including reports with respect to our foreign bank accounts; and (iv) the U.S. unitholders of Check-Cap LLC would not have been subject to U.S. federal income tax on royalties that are deemed to be paid to them under Section 367(d) of the Code as a result of the reorganization. As discussed under Item 5B &#8220;Operating and Financial Review and Prospects &#8211; Liquidity and Capital Resources &#8211; Application of Critical Accounting Policies and Estimates &#8211; Royalties provision &#8211; Reimbursement liability to Check-Cap LLC unitholders,&#8221; and Item 5F &#8220;Operating and Financial Review and Prospects-Tabular Disclosure of Contractual Obligations,&#8221; as part of the reorganization, we committed to reimburse the unitholders of Check-Cap LLC for any tax burdens that may be imposed on them due to the reorganization, including royalties that are deemed to be paid to the U.S. unitholders under Section 367(d) of the Code.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">31</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Prospective investors are urged to consult their own advisors on these issues. The balance of this discussion, including the discussion under Item 10E &#8220;Additional Information &#8211; Taxation &#8211; U.S. Federal Income Taxation,&#8221; assumes that we will be and have been treated as a foreign corporation for U.S. federal income tax purposes.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">We may be eligible for tax benefits from government programs, which require us to meet certain conditions, including regarding the location of our property, plant and equipment and manufacturing in Israel. We can provide no assurance that we would continue to be eligible for such benefits and/or that any such benefits will not be terminated in the future</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our manufacturing facilities in Israel may qualify as a &#8220;Benefited Enterprise&#8221; under the Israeli Law for Encouragement of Capital Investments, 5719-1959, which would entitle us to receive certain tax benefits. In order to be eligible for such benefits, we would be required to meet certain conditions, including the making of a minimum capital investment in our productive assets and the carrying on of a required portion of our manufacturing in Israel. The amount of the benefit will be determined in accordance with various conditions, including the location of our property, plant and equipment and the location of certain of our sub-contractors. If we cease to meet the required conditions for eligibility, the tax benefits could be cancelled and we could be required to pay increased taxes or to refund the amounts of the benefits received with interest and penalties. We can provide no assurance as to the amount of future capital investment in our productive assets, our future manufacturing location and the future location of our property, plant and equipment and certain of our sub-contractors, and therefore, we cannot provide assurance that we will be eligible for such tax benefits or assurance as to the amount of such tax benefits. Even if we continue to meet the relevant requirements, the tax benefits that Benefited Enterprises receive may not be continued in the future at their current levels or at all. If these tax benefits were reduced or eliminated, the amount of taxes that we would be required to pay would likely increase, as all of our operations would consequently be subject to corporate tax at the standard rate, which could adversely affect our results of operations. See Item 10E &#8220;Additional Information&#8212;Taxation&#8212;Israeli Tax Considerations and Government Programs&#8212;Law for the Encouragement of Capital Investments, 5719-1959&#8221; for additional information concerning these tax benefits.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">There is a risk that we may be classified as a passive foreign investment company, or PFIC, which could result in adverse U.S. federal income tax consequences to U.S. investors</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In general, we will be treated as a PFIC for any taxable year in which either (1) at least 75% of our gross income (including our pro rata share of the gross income of our 25% or more-owned corporate subsidiaries) is passive income or (2) at least 50% of the average value of our assets (including our pro rata share of the assets of our 25% or more-owned corporate subsidiaries) is attributable to assets that produce, or are held for the production of, passive income. Passive income generally includes dividends, interest, rents, royalties, and gains from the disposition of passive assets. If we are determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder (as defined in Item 10E &#8220;Additional Information&#8212;Taxation&#8212;U.S. Federal Income Taxation&#8212;General&#8221;) of our securities, the U.S. Holder may be subject to increased U.S. federal income tax liability upon a sale or other disposition of our securities or the receipt of certain excess distributions from us and may be subject to additional reporting requirements. We believe that we <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">were a</font> PFIC for the taxable year ended December 31, 2018<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and may be a PFIC for the taxable year ending December 31, 2019</font>.&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">O</font>ur actual PFIC status for our current taxable year or any subsequent taxable year is uncertain and will not be determinable until after the end of such taxable year. Accordingly, there can be no assurance with respect to our status as a PFIC for our taxable year end<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">ing</font> December 31, 201<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">9</font> or any subsequent taxable year.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">U.S. investors are urged to consult their own tax advisors regarding the possible application of the PFIC rules. For more information, see Item 10E &#8220;Additional Information&#8212;Taxation&#8212;U.S. Federal Income Taxation&#8212;U.S. Holders&#8212;Passive Foreign Investment Company Rules.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">There is a risk that a holder of Long Term Incentive Warrants will recognize ordinary compensation income on the exercise of the Long Term Incentive Warrants, which may result in U.S. federal and Israeli income tax liability to such holder without the receipt of cash.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">While not free from doubt, the Long Term Incentive Warrants may be treated for U.S. federal and Israeli income tax purposes as compensatory warrants (i.e., warrants issued to compensate an original purchaser of units in our initial public offering for holding the ordinary shares underlying the units for a certain period of time after the closing date of our initial public offering). Based on this characterization, a holder may recognize ordinary compensation income for U.S. federal and Israeli income tax purposes on the exercise of the Long Term Incentive Warrants, as described under Item 10E &#8220;Additional Information&#8212;Taxation&#8212;Israeli Tax Considerations and Government Programs&#8212;Taxation of our Shareholders&#8212;Taxation of Non-Israeli Shareholders upon Exercise of Long Term Incentive Warrants&#8221; and Item 10E &#8220;Additional Information&#8212;Taxation&#8212;U.S. Federal Income Taxation&#8212;U.S. Holders&#8212;Exercise of Long Term Incentive Warrants&#8221; and &#8220;Non-U.S. Holders.&#8221; Such compensation income may result in U.S. federal or Israeli income tax liability to such holder without the receipt of cash. Holders of Long Term Incentive Warrants are urged to consult their own tax advisors with respect to the U.S. federal and Israeli income tax consequences that may arise with respect to the Long Term Incentive Warrants.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">32</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM4" name="ITEM4"><!--Anchor--></a>ITEM 4. INFORMATION ON OUR COMPANY</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z36f2942281ce42c0acb95092969b4c5e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">History and Development of the Company</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Our History</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our legal and commercial name is Check-Cap Ltd. We were formed as a company in Israel on April 5, 2009. On May 31, 2009, we acquired all of the business operations and substantially all of the assets of Check-Cap LLC, a Delaware limited liability company formed in December 2004. On May 15, 2015, we formed our wholly-owned subsidiary Check-Cap US, Inc., a Delaware corporation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">On February 24, 2015, we successfully completed an initial public offering in the United States and the listing of our securities on the Nasdaq Capital Market.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are subject to the provisions of the Israeli Companies Law. Our principal executive offices are located at Check-Cap Building, 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, 3009000, Israel. Our telephone number is +972-4-8303400 and our website is located at <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>www.check-cap.com</u></font> (the information contained therein or linked thereto shall not be considered incorporated by reference in this Annual Report). Our U.S. agent is Puglisi &amp; Associates, located at 850 Library Avenue, Suite 204, Newark, Delaware 19711.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt">We use our website (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><u>http://www.check-cap.com</u></font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">) as a channel of distribution of company information. The information we post through this channel may be deemed material. Accordingly, investors should monitor our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. The contents of our website are not, however, a part of this Annual Report.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Principal Capital Expenditures</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For a discussion of our capital expenditures, see Item 5 &#8220;Operating and Financial Review and Prospects&#8212;Liquidity and Capital Resources.&#8221;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zef61f1f0d72046aea1f7f4a19cded16b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Business Overview</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Our Company</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are a clinical stage medical diagnostics company engaged in the development of a capsule-based system that utilizes ultra-low-dose X-rays to generate structural information on the endoluminal surface of the colon that may be used for screening of the colon to detect polyps, masses and CRC. While CRC is the second leading cause of death from cancer for both sexes combined in the United States and is preventable with early screening and intervention, according to the National Health Interview Survey, in 2015, only 63% of Americans over the age of 50 reported being current with CRC screening recommendations. Unlike other screening modalities that are designed for direct visualization and imaging of the internal colon, such as optical colonoscopy, CTC and other capsule-based technologies, our C-Scan system is designed to function without any cathartic preparation of the colon, and to transit the gastrointestinal tract by natural motility while the patient continues his or her normal daily routine. Furthermore, the C-Scan system does not require fasting prior to or during capsule transit. Our C-Scan system is comprised of three main components: (1) C-Scan Cap, an ingestible X-ray scanning capsule; (2) C-Scan Track, a biocompatible unit worn on the patient&#8217;s back for capsule control, tracking and data recording; and (3) C-Scan View, a PC-based, standalone application used to process and display structural information of the colon.&#160;We believe that this solution will be attractive to both physicians and patients, with the potential to increase the number of people completing CRC screening.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan Cap <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">is</font> swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Unlike other existing CRC screening methods, this process should not disrupt a patient&#8217;s normal activities or require fasting. Our C-Scan Cap employs ultra-low-dose X-rays, which allow the C-Scan system to image the interior lining of the colon even when surrounded by intestinal content. As such, we believe that patients using our C-Scan system will not be required to undergo any prior bowel preparation.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan Cap is being designed to transmit position, motility and the data it collects to the C-Scan Track that will be worn on the patient&#8217;s back. The external data recorder is being designed to enable the transfer of the data to our C-Scan View application to allow physicians to analyze the data collected by our C-Scan Cap. The C-Scan Track is being designed to provide the physician with accurate localization data aligned with a reconstructed image. We intend for physicians to be able to review the colon&#8217;s inner images in less time than is required to perform an optical colonoscopy.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Colonic polyps are tissue growths that occur on the lining of the colon. Polyps in the colon are common, and certain types of polyps may become cancerous over time. In the event that polyps are identified by our C-Scan system, the patient may be advised to undergo a subsequent traditional colonoscopy procedure to examine, remove and biopsy the polyps. For those patients who require a subsequent colonoscopy, concerns regarding pain, discomfort and embarrassment may still remain. We do not, however, believe that these concerns will make the use of our C-Scan system any less attractive to physicians and patients. Although patients who are initially screened utilizing a traditional colonoscopy could avoid the need for a second colonoscopy if polyps are discovered, we believe that our C-Scan system will still be attractive to physicians and patients as a large number of patients who are screened will not require a subsequent colonoscopy. Published data from a multi-center CT colonography screening study of 2,531 asymptomatic adults published in The New England Journal of Medicine in 2008 showed that if all patients with a lesion measuring 5mm or more on CT colonography were referred for colonoscopy, the colonoscopy-referral rate would have been 17%.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">33</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We initiated our first clinical studies in 2010, consisting of two single-center feasibility studies with non-scanning (no X-ray source) capsules for the purposes of measuring gastrointestinal tract activity, colon contractions and associated capsule motility, and shortening capsule transit time.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In 2013, we initiated a multi-center prospective clinical feasibility study, designed to allow for the recruitment of 100 subjects, to establish clinical proof of concept, safety and functionality of our C-Scan system in patients eligible for CRC screening.&#160;Analysis conducted on the first 66 capsules swallowed by participants showed that 65 of 66 capsules swallowed were naturally eliminated, without major or minor side effects, after 62&#177;40.7 hours. The average calculated radiation exposure was 0.06 &#177; 0.04 mSv (similar to a single chest radiograph). Both pedunculated and sessile polyps were detected in several patients and validated later by colonoscopy.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In September 2017, we completed a multi-center study of the C-Scan system in support of CE Mark submission.&#160; The objective of the study was to assess safety and the clinical performance of the C-Scan system in detecting patients with polyps. The three-center trial enrolled 66 patients, with a mean age of 59 years. Following capsule ingestion, subjects swallowed small doses of contrast agent and fiber supplements with each meal throughout capsule passage. Average capsule transit time was 52&#177;32 hours, and the average total X-ray dose was 0.05 mSv (CT colonography effective dose is ~ 6.0 mSv).&#160; No bowel preparation, sedation, or change in diet was required.&#160; Both confirmatory colonoscopy, performed by an independent investigator, and C-Scan review, performed by a central review group, were blinded to results. The study demonstrated a 44% sensitivity in the 45 subjects included in the analysis for polyps, with specificity (ability to correctly identify lack of polyps) of 89%.&#160; Sensitivity strongly correlated (R-squared = 0.98) to the percentage of the colon scanned.&#160; Sensitivity was 78% (p&lt;0.05) and 100% (p&lt;0.05) for subjects where greater than 50% and 70% of the colon was scanned, respectively.&#160; Specificity was consistent for all subjects.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In the fourth quarter of 2017, we initiated a clinical study for the purpose of introducing an advanced version of the C-Scan system, Version 3 (formerly referred to as Advanced C-Scan system), which incorporates the latest algorithms and system optimization and tailors scanning of the colon to the patient&#8217;s natural colonic movements to maximize the amount of the colon that is tracked and imaged.&#160; Evaluable results of 21 patients showed average colon imaging coverage of 64%, a 40% improvement over 46% average colon imaging coverage in the multi-center study. Sensitivity was 78% (p&lt;0.05) for subjects with greater than 50% colon imaging coverage and 100% (p&lt;0.05) for subjects with greater than 70% colon imaging coverage. Specificity&#160; was consistent at around 89%.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Following our certification to ISO 13485:2016 by our Notified Body, and completion of our multi-center clinical study and achievement of compliance with the requirements of the Medical Devices Directive, in September 2017, we submitted a request for CE marking for the marketing and sale of our C-Scan system in the European Union.&#160; We received the CE Mark approval on January 9, 2018.&#160; In September 2018, we received approval <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">from the Medical Devices and Accessories Division of the Israeli Ministry of Health, or AMAR,</font> for the marketing and sale of C-Scan system in Israel, which was valid until February 28, 2019. We have submitted a request to the Israeli Ministry of Health for the extension of the AMAR approval, which is currently pending.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">During the first quarter of 2018, we initiated a multi-center EU post-approval study using our C-Scan system Version 3 for the purpose of collecting additional evidence of clinical effectiveness and clinical utility to support market adoption. In September 2018, we announced interim results </font>from our ongoing post-CE approval study of our C-Scan&#174; System Version 3, demonstrating 76% sensitivity (P=0.0038) and 80% specificity, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and we expect to announce final results in the second quarter of 2019.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We conducted pre-submission meetings with the FDA during the period of December 2016 and February 2017 for the purpose of receiving feedback on the regulatory pathway for our system in the United States.&#160;We also sought feedback on a proposed protocol for a feasibility or pilot study, the primary purposes of which is to establish the safety of the C-Scan system and evaluate user compliance and satisfaction. In December 2018, we received from the FDA conditional approval of our IDE application to initiate a U.S. pilot study of the C-Scan system and received final approval from the FDA in February 2019. The U.S. pilot study (NCT03735407<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</font> is a single-arm study enrolling <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">up to 45 </font>subjects considered to be of average risk for polyps and colon cancer. The study will evaluate the safety, usability, and subject compliance of the C-Scan system.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Following successful completion of the pilot study, receipt of required approvals and available capital, we plan to initiate during 2020, a pivotal study in the United States to (i) demonstrate device safety&#160;as evidenced by a lack of device-related serious adverse events; and (ii) provide efficacy data concerning our C-Scan system&#8217;s performance.&#160;We anticipate that FDA approval for the pivotal study will be subject to our providing sufficient clinical data from previous clinical studies, which may include the multi-center clinical feasibility study, the multicenter safety and clinical performance study, and U.S. pilot study. However, there can be no assurance that we will receive approvals for the pivotal study to be conducted in the United States.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">34</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are considering clinical trials for regulatory approvals in Japan and China in parallel to the U.S. pivotal study, subject to available capital and engagement with strategic partners. Pivotal studies are expected, among other things, to compare polyps identified by our C-Scan system with the polyps identified by traditional optical colonoscopy.&#160;These clinical findings may be analyzed in comparison with results obtained from FOBTs and FITs.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Following and subject to the successful completion of our pivotal trial and available capital, our current strategy is to submit a direct de novo reclassification petition, which we anticipate submitting in 2021, for initial FDA approval for the marketing of our C-Scan system in the United States. Direct de novo reclassification typically takes at least 9 to 12 months from filing to clearance. If the FDA determines that our C-Scan system is not a candidate for de novo reclassification, it will require approval of the device for market through the PMA process. The PMA pathway is much more costly and uncertain than the 510(k) clearance process or de novo reclassification, and generally takes at least 12 to 18 months, or even longer, from the time the application is filed with FDA to ultimate approval.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Since our formation, we have not generated any revenue. We do not anticipate generating any revenue for the foreseeable future and we do not yet have any specific launch dates for our product. We incurred net losses of $10.6 million in 2018, $9.8 million in 2017 and $8.8 million in 2016.&#160; As of December 31, 2018, we had an accumulated deficit of $63.3 million and a total shareholders&#8217; equity of $13 million.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Our Solution</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">CRC screening can reduce the incidence of and mortality from the disease by detecting polyps at an earlier, more treatable stage. CRC is one of the few cancers that can be prevented through screening because pre-cancerous polyps, from which colon cancers often develop, can be identified and removed. Today, there is a range of options for CRC screening in the average-risk population, with current technology falling into two general categories: (i) structural exams, such as optical colonoscopy (which is currently regarded as the &#8220;gold standard&#8221; for CRC screening), sigmoidoscopy, CTC and optical capsules (all of which require aggressive bowel preparation), which are invasive exams that enable physicians to visualize the colon for abnormalities; and (ii) stool and serum based tests, such as FOBTs, FITs, stool DNA, and blood tests, which test for blood in stool and irregularities in blood and DNA. Notwithstanding the many CRC screening alternatives, despite the fact that the tests are encouraged by clinicians and insurers and the clinical value of screening for CRC, a large portion of the population is still reticent to go for CRC screening and are not satisfied with the currently available alternatives.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We believe that our C-Scan system could represent a potential breakthrough in CRC screening by providing structural information on the endoluminal surface of the colon without the discomfort and embarrassment experienced by some patients undergoing a traditional optical colonoscopy and other currently available screening methods by offering the following benefits:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7510f7ee83b84f6e8b58de0f6cfa6039" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">eliminating the need for fasting and prior bowel preparation, which would differentiate our system from every other currently available structural screening exam;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc863355487644b8ca7615bc0e644dfc4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">providing patients with a procedure that requires them to swallow our C-Scan Cap and small amounts of a contrast agent, thereby minimizing any disruption to their normal activities;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6e4688f235b9416c9c5ccc0a5180de45" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">eliminating the need to sedate patients;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z87131504b2a141dbb4d004fc505cba68" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">obviating the requirement for the insufflation (the forcing of air into the gastrointestinal tract) of patients; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze4630aa5d7d2484285289199137a11d0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">providing digital reporting, storage and remote consulting capabilities.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Although our C-Scan system utilizes radiation that is less than one mSv, we believe that the potential risks associated with such radiation exposure are low compared to the potential risks associated with other procedures such as perforation, bleeding or sedation related effects (optical colonoscopy and sigmoidoscopy) and dehydration and damage to kidneys. Unlike FOBTs, FITs and stool DNA tests, our capsule-based imaging modality generates structural information on the colon, which could assist in the detection of pre-cancerous polyps. We therefore do not believe that the ultra-low-dose radiation in our capsule will make our C-Scan system less attractive to physicians and patients than other less-effective products that do not employ any radiation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Radiation Safety Division of the Soreq Nuclear Research Center found, as set forth in its report of November 2010 that was prepared at our request and based on the information provided by us and the relevant methods and principles known at such time, or the Report, that the radiation dose to the patient in the proposed screening procedure utilizing the scanning device developed by us at that time in routine operation and normal conditions is low relative to the radiation dose involved in conventional imaging procedures using X-rays (such as fluoroscopy and CT) and is also low when compared to the radiation dose involved in established screening procedures such as mammography, all as more fully described in the Report. In addition, Michael S. Gossman, M.S., DABR, FAAPM, FACR, the Chief Medical Physicist in Radiation Oncology and Radiation Safety Officer, Regulation Directive Medical Physics, concluded, as set forth in his report dated November 14,&#160;2018 that&#160;was prepared at our request and submitted to the FDA in connection with the IDE application for the U.S. pilot study, following analysis of both normal capsule transit and extreme conditions, that the C-Scan system is safe for medical diagnostics and exposes patients to very low dose radiation during&#160;normal operation and that even in extreme and unlikely scenarios, patient exposure to radiation is unlikely to cause severe harm to patients undergoing the C-Scan procedure.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">35</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We believe that gastroenterologists will adopt our technology and encourage the use of our capsule. This may increase the number of people undergoing CRC screening and may cause more people with polyps to obtain a polypectomy &#8211; a therapeutic procedure during which polyps are removed.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our goal is to become a leading supplier of CRC screening technology and to establish our technology as a leading CRC screening method. Key elements of our strategy include:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z4bc88e4dd88e49799f79aac21c32b590" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">seeking to obtain regulatory approvals for the sale of our C-Scan system initially in the United States and Japan following receipt of CE marking for the marketing and sale of our C-Scan system in the European Union;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z148a35f5aeee401b89f332deebb06f46" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">in Europe and Japan, we intend to offer our C-Scan system as an imaging and screening tool for the general population. In the United States, we may choose to first obtain regulatory clearance/approval for our C-Scan system in a screening sub-population, and after we have conducted more extensive clinical studies in the United States, we would anticipate applying to the FDA for the use of our C-Scan system as a primary screening tool;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf44df910d48944e4948c4fff99b2b2c4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">obtaining government and private third-party reimbursement for our technology;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6210e7b29e4247338c10db8cf66d2c5e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">improving and enhancing our existing technology portfolio and developing new technologies; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf7cdeeb13fa94ef19abdf21f0837be55" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">successfully marketing our product to establish a large customer base.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Our Technology</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our technology is based on an ingestible capsule (C-Scan Cap), which is swallowed by the patient and propelled by natural motility through the gastrointestinal tract. Our capsule transmits information to a receiving device (C-Scan Track) worn on the patient&#8217;s body that stores the information for off-line analysis. Our C-Scan Cap consists of an X-ray source and several X-ray detectors. The X-ray source is contained in a rotating radiation shield, enabling the generation of 360-degree angular scans. The collection of successive angular scans is intended to enable the virtual reconstruction of a portion of the colon&#8217;s inner surface. During movement of our capsule longitudinally through the colon, successive images of portions of the colon enable the three-dimensional reconstruction of the colon. Our C-Scan system is also intended to enable identification of polyps, masses, and colorectal cancers which protrude inward into the colon, through the detection of irregularities in the topography of the colon's inner surface.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan system is intended to be prescribed to patients by physicians. Immediately prior to capsule ingestion, patients will swallow 15ml of iodinated oral contrast medium, combined with oral fiber, and continue to do so with normal daily meals in order to enhance the contrast of the colon surface. The capsule is propelled by natural motility through the gastrointestinal tract. During transit, information is transmitted to the C-Scan Track, which stores the information for off-line analysis. After our C-Scan Cap is expelled from a patient&#8217;s body, the C-Scan Track data will be downloaded into our workstation (C-Scan View) through which physicians will utilize our data viewer software application to analyze the data collected by our C-Scan system. Our proprietary software is being designed to process the data and produce a two and three-dimensional visualization of the colon&#8217;s inner surface. A physician will then analyze the visualization to determine whether any anatomical anomalies are present on the inner surface of the colon.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan system consists of the following three main subsystems that together enable the generation of high-resolution 3D imaging of the colon&#8217;s inner surface, further described below: (i) an ultra-low-dose X-ray based colon scanning capsule (C-Scan Cap); (ii) C-Scan Track; and (iii) a PC-based standalone application (C-Scan-View).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">C-Scan Cap</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">C-Scan Cap is an X-ray scanning capsule, designed to measure, collect and transmit structural information, and is comprised of the following components:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z35dc30b2260f4efea6b33add805cf832" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">X-ray Source &#8211; Including radioactive material sealed in a cylindrical housing.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z297a3b53bf214040b248ad448353ffaf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Collimator &#8211; Radiation shield around the source, which absorbs most of the radiation. Several radial holes enable emission&#160;of radiation in defined directions.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">36</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z53d298737d204e458e6240e1d0b929cb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">X-ray Sensor &#8211; Comprised of several solid state X-ray detectors for measuring the scattered radiation intensity.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Tilt Sensor &#8211; Indication of capsule motion (3D acceleration).</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb24db79595e640a896919a11b90d8ee8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Rotation Motor &#8211; For rotating the collimator and X-ray Source.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb095639a168b4d35b13d4fa54a8f7bd9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Compass sensor &#8211; Indication of true north (reference coordinate system).</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0ad0ae37e4e342febb41fd3bd7f21530" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.61%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.17%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Pressure sensor &#8211; indicating the hydrostatic pressure inside the colon.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z55573bc45ff94dbbb94d95417416d21b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.61%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.17%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Source Concealment Mechanism &#8211; Conceals the source inside the radiation shield.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze6225b6859284a41ad72e69cb5f9b77f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">R-T &#8211; Radio frequency transceiver device to communicate with the receiver.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd6a09e0005424ab2a9a05d5684955665" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Batteries &#8211; Electrical power supply for the capsule.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z916c6ca88f414bf6a3f14fa60d5454c3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Memory &#8211; Data storage. The capsule should be able to store up to an hour of measured data.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z311845acf7844d39b34b8b2754c1b868" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">C-Scan Track Coil &#8211; Transmits a continuous electromagnetic field utilized by an external localization system to track 3D position.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><img style="HEIGHT: 367px; WIDTH: 426px" src="image00001.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Image for illustration purpose only</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">C-Scan Track</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">C-Scan Track is a small, disposable system of biocompatible stickers which are designed to automatically track the imaging capsule&#8217;s positioning and orientation throughout the gastrointestinal tract transit, control the capsule scan mechanism through an embedded scan control algorithm or SCA, capture imaging data from the capsule through radio frequency communication to a non-volatile memory device, and enable data retrieval, through either wired or wireless communication, to an external processor.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The C-Scan Track is comprised of the following components:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z524cd2aefed7458390511183db5f3ed4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Sticker Housings &#8211; Biocompatible and water-resistant stickers and housing integrating all functional components, attached to the patient&#8217;s back, enabling five days of continuous operation.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zafed32bb6f6843a9b77ed4afd18a2e6c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Recorder &#8211; Consists of receiver electronics embedded software and nonvolatile memory.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z13bbe85b098949578a7465eafe67b273" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Antennas &#8211; Radio frequency antennas are embedded into the sticker housings and used to communicate with the capsule.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">37</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zcab18a3cfeeb49e587c78b717cce4ffa" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Activation/Deactivation Circuit &#8211; Used to activate/deactivate the C-Scan Track through a specialized protocol.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">UI Indicators &#8211; Provides user with vocal and vibration indication as required.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc97c45f29c7e4ec4abfae284f81cf99d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">PCB &#8211; Electronics&#8217; printed circuit boards.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z51e2fe1f58ff4357843457ee39b4bb8b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Microcontroller &#8211; Runs embedded software, logic that manages the C-Scan Track and SCA.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf67b554a9b5f4b628ed4abc87b4b9049" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">RF Transceivers &#8211; Several transceivers used to communicate with the capsule.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z855d93710180465ebbd2019076b41e0f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">TILT/Compass Sensors &#8211; To determine the patient&#8217;s body movements.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3bee02ba14144606b53e10233c12d96f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Batteries &#8211; Electrical power supply for the C-Scan Track.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze8062af04a0e411681a3dd4c016f4583" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.35%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.43%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Memory &#8211; Non-volatile data storage to store data acquired by the system.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><img style="HEIGHT: 115px; WIDTH: 153px" src="image1.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Image for illustration purpose only</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">C-Scan View</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">C-Scan View is a specialized, user friendly, personal computer-based software package designed to retrieve and process clinical data from the C-Scan Track and to reconstruct and produce 3D visualization and 2D maps of the colon&#8217;s inner surface. The C-Scan Track is comprised of the following software components:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z26384b725d5043ceb29655ba4612efcf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Communication Driver Software &#8211; to communicate with the C-Scan Track and retrieve collected data following procedure completion.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf1979b8f33f841b78172f9a72e164af3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Data Processing Software &#8211; to process and reconstruct clinical data into a 3D structure.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z605a650cf74448cea3f0b4b051928ad7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Data Display and Management Software &#8211; includes the following functions:</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc63ab0ba6ea8452fa7af81aaed046fff" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 13.89%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#9675;</div>
</td>
<td style="WIDTH: 79.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">3D visualization and 2D maps of the reconstructed colon surface.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z63dc45bf8c514de79db46de0a4984acf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 13.89%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#9675;</div>
</td>
<td style="WIDTH: 79.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Annotation tools.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1c5c0dc1b1384efe9aa8d0a2cfc4d4bb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 13.89%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#9675;</div>
</td>
<td style="WIDTH: 79.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Registration of patient and capsule data and management of the patient database.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zce0bcba3f21545b4b45fb8dea893a97c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 13.89%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#9675;</div>
</td>
<td style="WIDTH: 79.96%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Report &#8211; to enable generation of clinical results report out.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><img style="HEIGHT: 86px; WIDTH: 102px" src="image2.jpg">Image for illustration purpose only</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">C-Scan</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">System Non-Clinical, Pre-Clinical and Clinical History</font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have developed and validated our capsule-based imaging modality&#160;for providing structural information on colonic polypoid lesions and masses for CRC screening. Below is a summary of the validation tests carried out by us in the laboratory, in phantoms, animals and humans, which were designed to evaluate this new imaging modality&#8217;s performance and potential clinical value.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">38</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Non-Clinical and Pre-Clinical Testing</font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Imaging Performance Testing</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The C-Scan Cap transmits data as it transits the colon. This data consists of imaged slices perpendicular to the capsule&#8217;s longitudinal axis; slices are then reconstructed by the C-Scan View<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font>to produce 2D and 3D images of the inner surface&#160;of the colon. Following are performance measurements of the capsule imaging.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Modulation Transfer Function, or MTF</font>. The capsule was moved along a longitudinal-edge phantom setup in 3mm steps. The figure below shows a typical raw signal after filtering for peak detection. The same test was carried out using an angular-edge phantom setup, which demonstrated similar results to those shown below. These tests do not take into account noise characteristics.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><img style="HEIGHT: 100px; WIDTH: 102px" src="image3.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Image for illustration purpose only</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For each position of the capsule in the phantom, the mean signal intensity (peak) was measured, the result of&#160;which is shown in the right figure below. Resulting line spread function, or LSF, which is the differential of the curve in the left figure below.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><img style="HEIGHT: 100px; WIDTH: 230px" src="image4.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Image for illustration purpose only</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The graphs above demonstrate that the existing design of our C-Scan system can detect objects of approximately 2-3mm when noise is not taken into account.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 39.55pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Resolution Limit: Estimation of the Smallest Visible Object Size.</font> In order to estimate the size of the smallest visible object, both spatial resolution and noise characteristics must be taken into account. The graph below presents the estimated MTF of our C-Scan system. Noise analysis indicates MTF 1/3 for minimum visibility, which demonstrates that the smallest visible object that can be detected with the existing design of our C-Scan system (in the conditions used, which included a colon diameter of 30mm) is of approximately 5-6 mm (see graph below).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><img style="HEIGHT: 100px; WIDTH: 102px" src="image5.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Image for illustration purpose only</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Image Reconstruction</font>&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Two main characteristics of our C-Scan system contribute to the image reconstruction performance:&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zbc217f0d265c46a4a436a2dd461a2ad7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="WIDTH: 88.05%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The number of photons hitting the detector per time frame.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3ca68e94e64d4784abc6c75c18cb4655" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 5.81%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#8226;</div>
</td>
<td style="WIDTH: 88.05%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The angular spread of the photon beam coming out of the capsule collimator.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Based on the laboratory tests performed with the previous version of our C-Scan system, polyps of 6 mm and larger should be visible and 10 mm polyps and larger are expected to be detected at high sensitivity. To further enhance the visibility of 6 mm - 9 mm polyps, a new design of the collimator was successfully tested in a prototype version of our C-Scan Cap, which is expected to enable 2.5 times the number of photons to be detected by the detectors, allowing the implementation of an image enhancement algorithm, which is expected to improve the imaging performance.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">39</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Animal Testing and Tissue Equivalent Phantom Image Reconstruction</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The physics of our imaging modality was tested in the laboratory on phantoms with tissue equivalent material and in animals to ensure that laboratory conditions mimic real life clinical scenarios.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Following the initial proof of concept, we performed a series of studies in order to evaluate the feasibility and preliminary safety of our technology. All studies were performed in pigs ranging from 60 to 90 kg. Pigs, which are commonly used in gastrointestinal studies, were selected as the animal model for preliminary evaluation of our C-Scan system based on the resemblance of the porcine colon size and morphology to the human colon. However, there are marked differences between the colon of pigs and that of humans. The pig colon is much longer and has a larger diameter, in addition to other anatomical differences. In the pig model, the pressure waves of peristalsis are believed to be more frequent and shorter than in humans. As a result, we believe that colon content movement is substantially slower and more frequent in pigs than in humans. In these studies, we did not intend to collect statistically significant data; hence, the tests were repeated a limited number of times until adequate data was collected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The first test was performed to demonstrate imaging proof-of-concept using a wired C-Scan system. This technology included all the basic features intended to be included in the clinical C-Scan system, but on a larger scale due to the use of off-the-shelf components. The subsequent studies used versions of the C-Scan system that integrated most of the imaging components, software and electronics of the C-Scan system that we used with humans. Since off-the-shelf components were used, the animal capsules were larger and heavier than the version of our C-Scan system that are used clinically.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Raw data from an animal colon showing a decrease in X-ray florescence, or XRF, photon signals and an increase in Compton backscattering, or CMT, signals corresponding to the position of a polyp that was detected when our C-Scan Cap passed over the polyp is shown in the image below. These two signals are combined in order to form a three dimensional image below.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><img style="HEIGHT: 100px; WIDTH: 243px" src="image6.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Image for illustration purpose only</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The animal studies conducted to date demonstrate that our technology provides sufficient resolution, in these studies, for the detection of 10 mm polyps which is the size of clinically significant polyps. The animal studies also demonstrated that 5 mm polyps can be detected, though with lower resolution than 10 mm polyps in the first animal capsule. Animal health was maintained throughout the studies. No adverse effects related to passage of our capsule were noted.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The capsules evaluated in the animal studies were significantly larger than the capsules that we are using with humans. The differences in anatomy, physiology, and capsules may have several effects on the data compared to use in the human population. Motility of the capsules through the digestive C-Scan system was slow due to the specific shape of the porcine gastrointestinal tract. In addition, because of the size of the capsule, it was retained in the stomach for many hours and even days. Accordingly, the animal model required that normal ingestion be replaced by direct insertion of the capsule into the small bowel. In order to simplify the development and animal testing, we used Tungsten radiation source with long half-life (120 days).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Following the success of the animal testing, a series of in-vitro tests were conducted to simulate different clinical scenarios in the laboratory using a miniaturized human capsule. Polyps were created and reconstruction of the laboratory phantoms with a human capsule was generated to assess the ability to detect polyps as the capsule advances in the colon. The in-vitro tests demonstrated the imaging capabilities of our imaging technology. Below is the reconstruction of a laboratory phantom image.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><img style="HEIGHT: 93px; WIDTH: 217px" src="image7.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Image for illustration purpose only</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font>&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">40</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Polyp Detection Analysis</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Laboratory tests were carried out to estimate the capsule&#8217;s ability to detect polyps in phantoms and demonstrate sensitivity and specificity of such detection. Below is an example of the reconstruction of a scan composed of three slices: XRF, CMT and a fused (combined) image.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><img style="HEIGHT: 115px; WIDTH: 255px" src="image8.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Receiver Operating Characteristics</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Standard receiver operating characteristics, or ROC, curves were generated from phantom data with 8 mm polyp in a 30 mm barrel phantom with 3% iodine concentration mimicking the colon contents. CMT, XRF and fused (combined) data were analyzed based on 2D slices that were generated and standard deviation indicator. There were a few cases where the noise in the phantoms was high enough to generate polyp false positive condition separately for each data type, especially in CMT. However, fusion of CMT and XRF data contributed to noise reduction and enabled to demonstrate 100% true positive and 0% false positive.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><img style="HEIGHT: 129px; WIDTH: 115px" src="image9.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Clinical Trials</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We initiated our first clinical study at University Hospital, Hamburg, Germany in 2010. The purpose of this study was to monitor and record the colon contractions and the associated motility of the capsule in the colon.&#160; This study was conducted with a passive capsule that contained no X-ray source or detectors. It included several electronic components of the C-Scan system and had similar dimensions to the current capsule.&#160; 63 healthy volunteers were enrolled and no adverse events were reported.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We completed a limited, single-center, feasibility study at Rambam Medical Center, Haifa, Israel to assess the motility of a non-scanning capsule in healthy subjects. The objective of the study was optimizing the daily routine of the subjects in order to shorten the transit time of our capsule. 15 subjects participated and swallowed a capsule with the same weight and dimensions as our current C-Scan capsule. No adverse events were reported and all capsules were retrieved. A structured daily routine determined the timing of the following: capsule ingestion, the subjects&#8217; daily meals, the contrast agent ingestion and one evening dose of 10 mg of Bisacodyl, and all subjects continued their regular active lifestyles (such as work and exercise). The average transit time of the capsule in the 15 subjects was approximately 38 &#177; 19 hours, which is comparable to the average transit time of our capsule in subjects participating in the multi-center feasibility study, in which the participants do not ingest a daily dose of Bisacodyl, and participants are released to their homes and continue their regular lifestyles during the study.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">A 10 subject clinical proof-of-concept study, conducted at Tel Aviv Sourasky Medical Center in Israel and using a prior version of our C-Scan system, did not identify any material safety or feasibility issues. The study demonstrated the applicability of our C-Scan system to the human colon, generating images of the colon without any prior bowel preparation. All subjects ingested the capsule easily with smooth passage within the designated transit time, on average, within 48-72 hours. There were no reported device-related adverse events. Mild effects on bowel movements were noted, which were determined to be related to the contrast agent and passed within one to two days after the capsule excretion.&#160; Estimated total radiation exposure was calculated using standard established factors for calculating effective radiation exposure, such as the duration of the capsule inside the body, and was based on the activity of the radiation source inside the C-Scan Cap and radiation energy, both of which were measured for each case study. The average calculated exposure for the entire procedure in the 10-case study, from ingestion of the capsule to excretion, was 0.03 mSv (STD 0.007 mSv). This level of radiation exposure is similar to a single chest X-ray (approximately 0.06mSv) and two orders of magnitude less than a CTC.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">41</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The 10-subject study constituted the initial phase of a multi-center, prospective clinical feasibility study to establish the safety, functionality and preliminary efficacy of our C-Scan system in patients eligible for CRC screening, by comparing results from the clinical feasibility study with those from non-invasive, low-sensitivity FITs, as well as from optical colonoscopies. The feasibility study has been designed to allow for the recruitment of 100 subjects. The study was conducted at multiple centers in Israel. The clinical feasibility study was used to evaluate the image resolution generated by the capsule in a human colon without cathartic preparation, assess polyp imaging in various shapes and in different segments of the colon, and evaluated the safety of the device in terms of total and segmental transit time and analyze the effects of the presence of polyps and variable colon dimensions on these parameters. During the feasibility study we collected data regarding the overall imaging of the colon&#8217;s internal surfaces during the passage of the capsule to support the development of a correlation map of polyps identified through our imaging system with polyps imaged by optical colonoscopy and CTC.&#160;Additionally, the feasibility study allowed for the measurement of total radiation exposure and the distribution of contrast material within the colon.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Analysis conducted on the first 66 capsules swallowed by participants enrolled in the multi-center, prospective clinical feasibility study showed that 65 of 66 capsules swallowed were naturally eliminated, without major or minor side effects, after 62&#177;40.7 hours. The average calculated radiation exposure was 0.06 &#177; 0.04 mSv (similar to a single chest radiograph). Image reconstructions allowed 2D/3D views of the colonic wall and lumen with the typical contour of different segments (hepatic flexure, triangular shape of the transverse colon). Both pedunculated and sessile polyps were detected in several patients and validated later by colonoscopy.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In September 2017, we completed a multi-center study of the C-Scan system in support of CE Mark submission.&#160;The objective of the study was to assess safety and the clinical performance of C-Scan in detecting patients with polyps. The three-center trial enrolled 66 patients, with a mean age of 59 years. Following capsule ingestion, subjects swallowed small doses of contrast agent and fiber supplements with each meal throughout capsule passage. Average capsule transit time was 52&#177;32 hours, and the average total X-ray dose was 0.05 mSv (CT colonography effective dose is ~ 6.0 mSv).&#160;No bowel preparation, sedation, or change in diet was required.&#160;Both confirmatory colonoscopy, performed by an independent investigator, and C-Scan review, performed by a central review group, were blinded to results.&#160; The study demonstrated a 44% sensitivity in the 45 subjects included in the analysis for polyps, with specificity (ability to correctly identify lack of polyps) of 89%.&#160;Sensitivity strongly correlated (R-squared = 0.98) to the percentage of the colon scanned.&#160;Sensitivity was 78% (p&lt;0.05) and 100% (p&lt;0.05) for subjects where greater than 50% and 70% of the colon was scanned, respectively.&#160;Specificity was consistent for all subjects.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In the fourth quarter of 2017, we initiated a clinical study for the purpose of introducing an advanced C-Scan version with improved colon scan coverage, Version 3 (formerly referred to as Advanced C-Scan system), which incorporates the latest algorithms and system optimization and tailors scanning of the colon to the patient&#8217;s natural colonic movements to maximize the amount of the colon that is tracked and imaged.&#160; Evaluable results of 21 patients showed average colon imaging coverage of 64%, a 40% improvement over 46% average colon imaging coverage in the multi-center study. Sensitivity was 78% (p&lt;0.05) for subjects with greater than 50% colon imaging coverage and 100% (p&lt;0.05) for subjects with greater than 70% colon imaging coverage. Specificity was consistent at around 89%.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">During the first quarter of 2018, we initiated a multi-center EU post-approval study using our C-Scan system Version 3 for the purpose of collecting additional evidence of clinical effectiveness and clinical utility to support market adoption.</font> The objective of the study is to assess safety and clinical performance of the C-Scan system Version 3 in detecting patients with polyps. In September 2018, we announced interim results on 31 evaluable patients. The C-Scan system Version 3, equipped with improved algorithms, demonstrated a sensitivity (ability to correctly identify polyps) of 76% (P=0.0038), with specificity (ability to correctly identify lack of polyps) of 80% for polyp detection, when using the full patient population with a gender-based analysis. Confirmatory colonoscopy and C-Scan system results analysis were performed by independent expert investigators who were blinded to corresponding test&#8217;s results.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> Improvements to the C-Scan system Version 3 include better scan imaging density, 2D/3D imaging and a new motility analysis algorithm that was recently tested during two years of continued clinical study.&#160; We expect to announce final results in the second quarter of 2019.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In December 2018, we received from the FDA conditional approval of our IDE application to initiate a U.S. pilot study of the C-Scan system, and received final approval from the FDA in February 2019. The U.S. pilot study (NCT03735407<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">)</font> is a single-arm study enrolling<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> up to 45</font> subjects considered to be of average risk for polyps and colon cancer. The study will evaluate the safety, usability, and subject compliance of the C-Scan system.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Research and Development</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our research and development strategy is centered on developing our C-Scan system. Our research and development team is located at our facilities in Isfiya, Israel, and consists of 34 individuals employed on a full-time basis and 6 individuals on a part-time basis as of March 1, 2019.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have received grants from the Government of the State of Israel through the IIA (formerly the OCS) for the financing of a portion of our research and development expenditures pursuant to the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law and related regulations and guidelines. As of December 31, 2018, we had received funding from the IIA in the aggregate amount of approximately $5.3 million and had a contingent obligation to the IIA in the amount of approximately $5.6 million. As of December 31, 2018, we had not paid any royalties to the IIA.&#160; We may apply for additional IIA grants in the future; however, there is no assurance that such applications will be approved in the amount requested or at all.&#160; Furthermore, the funds available for IIA grants out of the annual budget of the State of Israel have been reduced in the past and may be further reduced in the future.&#160; We cannot predict whether we will be entitled to any future grants, or the amounts of any such grants.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We incurred approximately $7.6 million, $6.8 million, and $5.5 million in research and development expenses, net (after deducting participation by others and government grants) for the years ended December 31, 2018, 2017 and 2016, respectively. For additional information, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Financial Operations Overview&#8212;Research and Development Expenses, Net.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">42</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Intellectual Property</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">An important part of our competitive strategy is to seek, when appropriate, protection for our products and proprietary technology through a combination of U.S. and foreign patents, trademarks, trade secrets and non-disclosure and confidentiality, assignment of invention and other contractual arrangements with our employees, consultants and suppliers. These measures, however, may not be adequate to protect our technology from unauthorized disclosure, third-party infringement or misappropriation as these parties may breach these agreements, and we may not have adequate remedies for any such breach. We intend to prosecute and defend our proprietary technology. The primary test for patent protection eligibility includes novelty, non-obviousness and usefulness.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We submit applications under the Patent Cooperation Treaty, or PCT, which is an international patent law treaty that provides a unified procedure for filing a single initial patent application to seek patent protection for an invention simultaneously in each of the member states. Although a PCT application is not itself examined and cannot issue as a patent, it allows the applicant to seek protection in any of the member states through national-phase applications.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt">As of December 31, 2018, we had 36 granted patents (not including separate validations in Europe), 1 allowed patent application and 23 pending patent applications worldwide relating to various elements and functions of our products and related enhancements. We have submitted patent applications covering our technology in the United States, member states of the European Patent Organisation, Australia, Brazil, Canada, China, Hong Kong, India, Israel, Japan and South Korea. We have received patent grants for our core patent by the United States Patent and Trademark Office as well as from the European Patent Office, Australia, China, Hong Kong, Israel, India, Canada, South Korea and Japan.&#160; We also filed patent applications describing the use of our technology in several other medical applications.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt">Our registered U.S. Patent Number 7,787,926 discloses an ingestible capsule with a radiation source and radiation detectors that, when used in conjunction with a radio opaque contrast agent, is adapted to detect clinically relevant findings in the colon. Utilizing X-ray fluorescence and Compton back scatterings, the capsule is able to measure the distance between the capsule and the colon wall and to distinguish between gas, intestinal contents, and clinically significant findings in the gastrointestinal tract.&#160; If the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended patent term for this patent will expire on August 28, 2026.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">A second PCT patent application (PCT/IL2008/000163), granted in Europe, Israel, United States, Australia, India, China, Canada and Hong Kong, discloses additional features such as a rotating collimator and improved scanning mechanisms, the capability to determine tissue density to differentiate between different types of polyps, as well as the capability to determine capsule movement in the colon. If the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended patent term for all national phases will expire on February 6, 2028, other than the U.S. patent that will expire on April 4, 2030.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Another PCT application (PCT/IL2011/000462), which is pending in Brazil in the PCT national-phase and granted in Europe, Israel, United States, Canada, Australia and South Korea, discloses a number of alternate fail safe concealment mechanisms that can be utilized in the capsule to ensure that the X-ray source is blocked when the capsule is not scanning and is open when it is scanning, allowing the capsule to image the colon. The fail-safe feature ensures that in the event of power failure, the radiation source is blocked and X-rays do not escape. If the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended patent term for all national phases will expire on June 9, 2031, other than the U.S. patent that will expire on July 5, 2032.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In another PCT patent application (PCT/IL2008/000765), which was granted in the United States, Europe, Israel and Japan, we disclose an imaging catheter that utilizes X-ray fluorescence, Compton back scattering and electron back scattering. The imaging catheter is designed for use in cardiac applications as well as intra-operative imaging applications such as imaging inside blood vessels where optical imaging cannot be performed because of obscuring circumstances. If the appropriate maintenance, renewal, annuity or other governmental fees are paid, the non-extended patent term for all national phases will expire on June 4, 2028, other than the U.S. patent that will expire on July 28, 2028.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">While our policy is to obtain patents by application, to maintain trade secrets and to seek to operate without infringing on the intellectual property rights of third parties, technologies related to our business have been rapidly developing in recent years. Additionally, patent applications that we may file may not result in the issuance of patents, and our issued patents and any issued patents that we may receive in the future may be challenged, invalidated or circumvented. For example, we cannot predict the extent of claims that may be allowed or enforced in our patents nor be certain of the priority of inventions covered by pending third-party patent applications. If third parties prepare and file patent applications that also claim technology or therapeutics to which we have rights, we may have to partake in proceedings to determine priority of invention, which could result in substantial costs to us, even if the eventual outcome is favorable to us. Moreover, because of the extensive time required for clinical development and regulatory review of a product we may develop, it is possible that, before our C-Scan system can be commercialized, related patents will have expired or will expire a short period following commercialization, thereby reducing the advantage of such patent. Loss or invalidation of certain of our patents, or a finding of unenforceability or limited scope of certain of our intellectual property, could have a material adverse effect on us. See &#8220;Item 3D &#8220;Key Information&#8212;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">In addition to patent protection, we rely on trade secrets, including unpatented know-how, technology innovation, drawings, technical specifications and other proprietary. We also rely on protection available under trademark laws, and hold the following registered trademarks in the United States and Hong Kong: &#8220;CHECK CAP&#8221;, CHECK CAP (logo), &#8220;C-Scan&#8221; and C-Scan (logo) and the following registered trademarks in the European Union: CHECK CAP (logo), &#8220;C-Scan&#8221; and C-Scan (logo), and the following trademark applications are pending in China: &#8220;CHECK CAP&#8221;, CHECK CAP (logo), &#8220;C-Scan&#8221; and C-Scan (logo).</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">43</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Competition</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Competition for our C-Scan system comes from traditional well-entrenched manufacturers of tests and equipment for CRC screening, such as colonoscopy, sigmoidoscopy, CTC, optical capsule endoscopy, FOBTs and FITs. The principal manufacturers of equipment for optical colonoscopy and sigmoidoscopy include Olympus, Pentax, Hoya and Fuji Film. The principal manufacturers of equipment for CTC include General Electric Healthcare Systems, Siemens Medical Solutions, Philips Medical Systems Ltd. and Toshiba Corporation.&#160; The principal manufacturer of equipment for optical capsule endoscopy includes Medtronic plc.&#160; All of these companies have substantially greater financial resources than we do, and they have established reputations as well as worldwide distribution channels for providing medical instruments to physicians.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Several companies have developed or are developing non-invasive technologies based on stool, serum, or molecular diagnostics (from blood and other bodily fluids), or MDx, tests that are used to indicate the presence of CRC and polyps in the colon. These companies include Polymedco, Exact Sciences, Epigenomics AG, Gene News, EDP Biotech Corporation, Illumina, Inc., Quest Diagnostics and VolitionRx Nu.Q diagnostic.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Procedures for bowel cleansing that are less onerous are constantly being developed, which could make our entry into the market more difficult.&#160; For instance, bowel cleansing initiated by the ingestion of pills or food-substitute diet regimes rather than through drinking large amounts of distasteful liquids may be viewed as an improvement to the cleansing process, but other screening methods may be even more palatable to patients.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Sales and Marketing</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our goal is to establish our position as a leading player in the CRC screening market. Although we do not currently generate revenues, we expect to generate revenues through sales of our C-Scan system following demonstration of acceptable clinical safety and effectiveness and obtaining required regulatory approvals and licensures.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt">Because we are still in the clinical and development stage, we are subject to certain challenges, including, among others, that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1ad94eb9516a4f3fa1111ac2c54e1e6b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">our technology has been tested on a limited basis and therefore we cannot assure the product&#8217;s clinical value;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">following the receipt of CE Mark of conformity to protection </font>standards for sale of the<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> C-Scan system in the European Union, we may need to obtain additional regulatory approvals in certain local jurisdictions in the European Union before we can commence marketing and sale of our C-Scan system and will need to obtain the requisite regulatory approvals in the United States, Japan and other markets where we plan to focus our commercialization efforts;</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8e007cbf7ede4ffdadf316ac098448a4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we need to raise an amount of capital sufficient to complete the development of our technology, obtain the requisite regulatory approvals and commercialize our current and future products;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zda1dc2ec322d406c9c45b5d71ed41f07" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we need to obtain reimbursement coverage from third-party payors for procedures using our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5f40445593554d1086c9bc4dbd2bc6bf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we need to scale-up our manufacturing capabilities of our C-Scan system in commercial quantities at an adequate quality and at an acceptable cost; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf0c4cb0fcf4b4baba9e670ab0976784d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">we need to establish and expand our user base while competing against other sellers of capsule endoscopy systems as well as other current and future CRC screening technologies and methods.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our ability to operate our business and achieve our goals and strategies is subject to numerous risks as described more fully in &#8220;Risk Factors.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Subject to our receipt of regulatory approvals, available capital, and engagement with strategic partners, we plan to initiate commercialization of our C-Scan system during the second half of 2019 in selected markets in Europe and Israel. We intend to target major markets in Europe. In these markets, we are planning to work with strategic partners and/or local distributors who are active in the gastroenterology field and who have already demonstrated excellent performance in introducing new and innovative technologies.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">44</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In Europe and Japan, we intend to offer our C-Scan system as an imaging and screening tool for the general population. In the United States, we may choose to first obtain regulatory clearance/approval for our C-Scan system in a screening sub-population, and after we have conducted more extensive clinical studies in the United States, we would anticipate applying to the FDA for the use of our C-Scan system as a primary screening tool.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Subject to the successful completion of our clinical trials and the receipt of our initial FDA clearance/approval, we expect to launch the product in the U.S. market, where we will consider setting up our own sales force or aligning with a strategic partner. Initially, we are planning to sell our C-Scan system to the private sector. Simultaneously, we intend to work intensively to obtain reimbursement by Medicare and private insurers within the shortest possible time frame.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Subject to local regulatory approval, we also intend to market our C-Scan system in key markets in Asia. Initial efforts are expected in Japan, in view of its developed CRC screening market.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Manufacturing and Suppliers</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our manufacturing operations are conducted at a facility located in Isfiya, Israel. We lease approximately 900 square meters at this facility under a lease agreement expiring on May 31, 2022. We have the right to terminate the agreement at any time, upon as least 60 days prior written notice. We currently have sufficient space to manufacture our C-Scan system for the clinical studies, but have limited resources, facilities and experience in commercially manufacturing large quantities of our C-Scan system and software application to meet the demand we expect from our expanded commercialization efforts. We expect to face certain technical challenges as we increase manufacturing capacity, including, among others, logistics associated with the handling of radioactive materials, equipment design and automation, material procurement, lower than expected yields and increased scrap costs, as well as challenges related to maintaining quality control and assurance standards, while maintaining commercially efficient pricing for our C-Scan system. Our production objective is to establish a scalable capacity in order to meet such expanded demand for our C-Scan system and market expansion. If we are unable to scale our manufacturing capabilities to meet market demand, our growth could be limited and our business, financial condition and results of operations could be materially adversely affected.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are continuing to upgrade and expand our production system and capacity and developing supply chain systems to support production for clinical trials and to meet standards for CE post-marketing. Our current capacity was built to accommodate our clinical phase. We have integrated a product life management system to enable overall life cycle tracking and documentation including full configuration management control and manufacturing documentation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">In July 2016, we entered into an agreement with GE Healthcare to develop and demonstrate proof of principle of the process for high-volume manufacturing for the production of the X-ray source and its assembly into our C-Scan capsule. The agreement was amended in </font>November 2017 in order to further our manufacturing collaboration with GE. The agreement involves GE&#8217;s final assembly, packaging and shipping of C-Scan capsules, initially to support our U.S. pilot trial that we initiated in March 2019.&#160; We will supply GE with supporting calibration and final assembly methodology and equipment.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We do not currently have any sales. We are planning to develop a scale-up plan to meet our expected commercial supply needs. We are also working on a plan to expand our manufacturing capacity to support the expected larger clinical volume and subsequent higher volumes expected in the early commercialization stage. We are considering, among other options, the expansion of our assembly line in Israel, the buildup of new assembly lines in the United States and Europe, and alternative sources for the key capsule components (such as the motor, X-ray detectors, electrical components and PCBs). All of the facilities in which manufacturing and assembly of our products will be conducted will need to comply with applicable regulations and standards for medical devices.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;

<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have received grants from Government of the State of Israel through the IIA (formerly the OCS) for the financing of a portion of our research and development expenditures pursuant to the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law and related regulations and guidelines.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> The</font> terms of the IIA grants <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">subject us to certain restrictions relating to the transfer of the manufacturing of IIA-funded products outside </font>Israel and the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">transfer of IIA-funded know-how</font> outside Israel<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font> We are exploring whether certain components of our C-Scan system can be assembled outside of Israel. In particular, we are continuing to explore whether it would be possible to assemble the capsule without the X-ray source in Israel, and have the X-ray source subsequently assembled into our C-Scan system at a reactor site or at a distribution center outside Israel. Even following the full repayment of any IIA grants, we must nevertheless continue to comply with the requirements of the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law and regulations and guidelines thereunder. The foregoing restrictions may impair our ability to outsource or transfer development or manufacturing activities with respect to any product or technology outside of Israel. See &#8220;Risk Factors &#8211; Risks Related to Our Operations in Israel<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> &#8211;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Pursuant to the terms of the Israeli government grants we received for research and development expenditures, we are obligated to pay certain royalties on our revenues to the Israeli government. The terms of the grants require us to satisfy specified conditions and to make additional payments in addition to repayment of the grants upon certain events</font>.&#8221;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">45</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We currently depend on single source suppliers for some of the components necessary for the production of our C-Scan system. For example, for the current version of the C-Scan system used in clinical trials, we currently have a single supplier for the motor used to rotate the collimated X-ray source in our C-Scan system and for each of the customized X-ray detectors, X-ray source and batteries used in our C-Scan system. There are a limited number of manufacturers worldwide who are capable of manufacturing the motor and the customized X-ray detectors and X-ray source that we currently use in our C-Scan system.&#160;In addition, the ASIC residing in our C-Scan system is currently manufactured for us by a single FAB.&#160;However, there are many alternative FABs worldwide and the design of our current ASIC could be adapted in the event it became necessary to use an alternative FAB.&#160; Furthermore, we do not currently have written contracts with all of such suppliers.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"> &#160;</font> While our current suppliers have been able to supply the required quantities of such components to date, if the supply of these components is disrupted or terminated or if our current suppliers are unable to supply required quantities of components, we may not be able to find alternative sources for these key components in a timely manner. Although we are planning to maintain strategic inventory of key components, the inventory may not be sufficient to satisfy the demand for our C-Scan system if such supply is interrupted, or subject to risk of loss due to catastrophic events such as a fire at our storage facility.&#160; In addition, to partially mitigate the risks of reliance on single source suppliers, we are seeking alternate manufacturers for some of our components which requires us to dedicate significant resources and investment. There can be no assurance that we will be successful in seeking alternate suppliers.&#160; As a result of the foregoing, we may be unable to meet the demand for our C-Scan system, which could harm our ability to generate revenues, lead to customer dissatisfaction and damage our reputation. If we are required to change the supplier of any of these key components, there may be a significant delay in locating a suitable alternative manufacturer. In addition, we may be required to verify that the new manufacturer maintains facilities and procedures that comply with FDA and other applicable quality standards and with all applicable regulations and guidelines. For example, our agreement with the supplier of the X-ray source used in our C-Scan system terminated on December 31, 2018 and while we and the X-ray source supplier have continued to perform the agreement on the same terms and are currently negotiating the agreement of the agreement, we cannot assure you that we will be able to negotiate a new agreement on acceptable terms. We have been informed that the supplier of the batteries used in our C-Scan system shall cease to manufacture the batteries by mid-2019 and may cease to accept new orders at any time and, therefore, although we acquired sufficient batteries for the foreseeable future, we will be required to find an alternative source for the X-ray source and batteries, which we may not be able to do in a timely manner.&#160; The delays associated with the identification of a new manufacturer could delay our ability to manufacture our C-Scan system in a timely manner or within budget. Furthermore, in the event that the manufacturer of a key component of our C-Scan system ceases operations or otherwise ceases to do business with us, we may not have access to the information necessary to enable another supplier to manufacture the component. The occurrence of any of these events could harm our ability to meet demand for our C-Scan system in a timely manner or within budget.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Environmental Health and Safety Matters</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are subject to environmental health and safety laws and regulations in Israel, governing, among other things, the use of radioactive materials, including the Israeli Radioactive Elements and their Products, Regulation, 1980, the Israeli Work Safety Regulations (Occupational Safety and Health of Ionizing Radiation Practitioners) 1992-5753 and Women Employment Regulations (Work with Ionizing Radiation), 1979-5739. Our current research and development activities require, and our currently contemplated commercial activities will require, permits from various governmental authorities including, Israel&#8217;s Ministry of Environmental Protection, Israel&#8217;s Ministry of Health and local municipal authorities. Failure to obtain or maintain any such permits could have a material adverse effect on our business, financial condition and results of operations. The Ministry of Environmental Protection and the Ministry of Health conduct from time to time periodic inspections in order to review and ensure our compliance with the various regulations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">These laws, regulations and permits could potentially require expenditure by us for compliance or remediation. If we fail to comply with such laws, regulations or permits, we may be subject to fines and other civil, administrative or criminal sanctions, including the revocation of permits and licenses necessary to continue our business activities. In addition, we may be required to pay damages or civil judgments in respect of third-party claims, including those relating to personal injury (including exposure to radioactive materials) or contribution claims. Some environmental, health and safety laws apply strict, joint and several liability. We may be identified as a responsible party under such laws. Such developments could have a material adverse effect on our business, financial condition and results of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, laws and regulations relating to environmental, health and safety matters are often subject to change. In the event of any changes or new laws or regulations, we could be subject to new compliance measures or to liabilities for activities which were previously permitted.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">U.S. Government Regulation</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan system is a medical device subject to extensive regulation by FDA and other U.S. federal and state regulatory bodies. To ensure that medical products distributed in the United States are safe and effective for their intended use, FDA has imposed regulations that govern, among other things, the following activities that we or our partners perform and will continue to perform:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2afaeb9e89e344d992e6474a46391fee" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">product design and development;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd0946452c281424d99f914986024b472" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">product testing;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z19b67d86d2944042aeb3b858cf44f4d4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">validation and verifications;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z15cfbd884f764a658a6ace8f05471b7e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">product manufacturing;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">46</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z70f4a467776c46a7b5be9e1cc0039020" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">product labeling;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd9b54e8cb0de412a9c9fea3d9068e630" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">product storage, shipping and handling;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zdfd42dddff684cecbdd764c717c80895" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">premarket clearance or approval;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc78eb734a7db4dc38e6d9966d58a2be8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">advertising and promotion;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z53b736d7b54e4fe9a71f5b4fa8ef1ee3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">product marketing, sales and distribution; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z06c7c369fc5748258225b03f7b4208f8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">post-market surveillance reporting death or serious injuries and medical device reporting.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">FDA&#8217;s Premarket Clearance and Approval Requirements</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Unless an exemption applies, before we can commercially distribute medical devices in the United States, we must obtain, depending on the type of device, either prior 510(k) clearance or PMA approval from the FDA. The FDA classifies medical devices into one of three classes:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z89f55b5ec17a4f1f8e89aae83d56306d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Class I devices, which are subject to only general controls (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">e.g.</font>, labeling, medical devices reporting, and prohibitions against adulteration and misbranding) and, in some cases, to the 510(k) premarket clearance requirements;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zec80e39619334588902317ff9358911c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Class II devices, generally requiring 510(k) premarket clearance before they may be commercially marketed in the United States; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0061cb9ca3b64adcaca0082536eb3b59" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Class III devices, consisting of devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a predicate device, generally requiring the submission of a PMA approval supported by clinical trial data.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">510(k) Clearance Pathway</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">To obtain 510(k) clearance, we must submit a premarket notification, or 510(k) notice, demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of premarket approval applications. The FDA&#8217;s 510(k) clearance pathway may take approximately between 6 to 9 months, but it can take significantly longer. FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a new or major change in its intended use, will require a new 510(k) clearance or, depending on the modification, require premarket approval. The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), or a premarket approval, but the FDA can review any such decision and can disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s determination, the FDA can require the manufacturer to cease marketing and/or recall the modified device until 510(k) clearance or premarket approval is obtained. If the FDA requires us to seek 510(k) clearance or premarket approval for any modifications to a previously cleared product, we may be required to cease marketing or recall the modified device until we obtain this clearance or approval. Also, in these circumstances, we may be subject to significant regulatory fines or penalties.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">De Novo Reclassification</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If the FDA finds that there is no suitable predicate device for our C-Scan system, it will automatically be considered a class III device. However, in instances where a device is novel and there is no suitable predicate device, but that device is deemed to be of low to moderate risk, the FDA can reclassify the device to class I or class II via de novo reclassification. This process involves the submission of a reclassification petition, and the FDA's acceptance that &#8220;special controls&#8221; are adequate to ensure the product&#8217;s performance and safety.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The FDA now allows &#8220;direct&#8221; de novo reclassification petitions, a mechanism by which a sponsor can directly submit a detailed de novo reclassification petition as the device&#8217;s initial submission without having to first receive a not substantially equivalent, or NSE, decision on a 510(k) submission. The direct de novo pathway takes at least 9 to 12 months from submission of the petition to device clearance.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our current strategy is to submit a direct de novo reclassification petition for our C-Scan system. To support a direct de novo reclassification petition, our objective is to demonstrate that the device poses a low to moderate risk to patients. If the FDA determines that our C-Scan system is not a candidate for de novo reclassification, it will require approval of the device for market through the PMA process.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">47</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Alternatively, if we seek 510(k) clearance and our device is found not substantially equivalent, or NSE, a de novo petition must be filed within 30 days from the receipt of the NSE determination. The request should include a description of the device, labeling for the device, reasons for the recommended classification and information to support the recommendation. The de novo process following an NSE determination has a 60-day review period, although it is typical for the review to take far longer. If the FDA classifies the device into class II, the company will then receive an approval order to market the device. This device type can then be used as a predicate device for future 510(k) submissions. However, if the FDA subsequently determines that the device will remain in the class III category, then the device may not be marketed until the company has obtained an approved PMA.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Premarket Approval Pathway</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">A premarket approval application must be submitted if the device cannot be cleared through the 510(k) process or is found ineligible for de novo reclassification. The premarket approval application process is generally more costly and time consuming than the 510(k) process. A premarket approval application must be supported by extensive data including, but not limited to, technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device for its intended use.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">After a premarket approval application is sufficiently complete, the FDA will accept the application and begin an in-depth review of the submitted information. By statute, the FDA has 180 days to review the &#8220;accepted application,&#8221; although, generally, review of the application can take at least 12 to 18 months, but it may take significantly longer. During this review period, the FDA may request additional information or clarification of information already provided. Also during the review period, an advisory panel of experts from outside FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA will conduct a preapproval inspection of the manufacturing facility to ensure compliance with quality system regulations. New premarket approval applications or premarket approval application supplements are required for modifications that affect the safety or effectiveness of the device, including, for example, certain types of modifications to the device&#8217;s indication for use, manufacturing process, labeling and design. Premarket approval supplements often require the submission of the same type of information as a premarket approval application, except that the supplement is limited to information needed to support any changes from the device covered by the original premarket approval application, and may not require as extensive clinical data or the convening of an advisory panel.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Clinical Trials</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Clinical trials are almost always required to support a premarket approval application or de novo reclassification petition and are sometimes required for a 510(k) premarket notification. If the device presents a &#8220;significant risk,&#8221; as defined by the FDA, to human health, the FDA requires the device sponsor to file an IDE application with the FDA and obtain IDE approval prior to commencing the human clinical trials. The investigational device exemption application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. The investigational device exemption application must be approved in advance by the FDA for a specified number of patients, unless the product is deemed a &#8220;non-significant risk&#8221; device and eligible for more abbreviated investigational device exemption requirements. Clinical trials for a significant risk device may begin once the investigational device exemption application is approved by the FDA and the appropriate institutional review boards at the clinical trial sites. Future clinical trials of our motion preservation designs will require that we obtain an investigational device exemption from the FDA prior to commencing clinical trials and that the trial be conducted under the oversight of an institutional review board at the clinical trial site. Our clinical trials must be conducted in accordance with FDA regulations and federal and state regulations concerning human subject protection, including informed consent and healthcare privacy. A clinical trial may be suspended by the FDA or the investigational review board at any time for various reasons, including a belief that the risks to the study participants outweigh the benefits of participation in the study. Even if a study is completed, the results of our clinical testing may not demonstrate the safety and efficacy of the device, or may be equivocal or otherwise not be sufficient to obtain approval of our product. Similarly, in Europe the clinical study must be approved by the local ethics committee and in some cases, including studies of high-risk devices, by the Ministry of Health in the applicable country.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Pervasive and Continuing FDA Regulation</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">After a device is placed on the market, numerous regulatory requirements continue to apply. These include:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3efaa5e6dcb743288391a4d2125fcee0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">product listing and establishment registration, which helps facilitate FDA inspections and other regulatory action;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Quality System Regulation, or QSR, and current good manufacturing practices, or cGMP, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z82c98b21e33f409981996aee8a27f39c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">labeling regulations and FDA prohibitions against the promotion of products for uncleared, unapproved or off-label use or indication;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze305d5d1c4ca423facee7973d51d9228" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">clearance of product modifications that could significantly affect safety or efficacy or that would constitute a major change in intended use of one of our cleared devices;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">48</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zda41f208d44b4e6ca188251fc18b6446" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">approval of product modifications that affect the safety or effectiveness of one of our approved devices;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5104a5deba964a08954ff32ba7bb8a3c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">medical device reporting regulations, which require that manufacturers comply with FDA requirements to report if their device may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction of the device or a similar device were to recur;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf3a01a57cdf346389d2a9d1fb38a6e9c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">post-approval restrictions or conditions, including post-approval study commitments;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z82dade782e2246e68307fb705b871c0c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z4e302348fb53402b8d7f05465569992d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">FDA&#8217;s recall authority, whereby it can ask, or under certain conditions order, device manufacturers to recall from the market a product that is in violation of governing laws and regulations;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z351b46ff60ef44cd9c9dc142986ea57d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">regulations pertaining to voluntary recalls; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zdfcaddbd0ba548f7b92924df29a95591" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">notices of corrections or removals.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We and our third-party manufacturers must register with the FDA as medical device manufacturers and must obtain all necessary state permits or licenses to operate our business. As manufacturers, we and our third-party manufacturers are subject to announced and unannounced inspections by the FDA to determine our compliance with quality system regulation and other regulations. We have not yet been inspected by the FDA.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z63b25feaedad434e90f7f31959f96891" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z701a3df1b4304a449bab818a583832fb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">unanticipated expenditures to address or defend such actions;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z44879ffb6c5f412cbe8f14f6ed5f0aa2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">customer notifications for repair, replacement, refunds;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z62275572a9ea41e2882fa1c712721877" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">recall, detention or seizure of our products;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0aed817e4e824aef81be01de28aa6698" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">operating restrictions or partial suspension or total shutdown of production;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3ec0cf5496064736853ced35ea71807f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">refusing or delaying our requests for 510(k) clearance or premarket approval of new products or modified products;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">operating restrictions;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za2b5c0fc22a94aa9974fab2e14fd767a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">withdrawing 510(k) clearances on PMA approvals that have already been granted;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zacc940840a2440a7b18b359887739a6d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">refusal to grant export approval for our products; or</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z123bc40e6ef74ec1bfe2845a8e0e6c2c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">criminal prosecution.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Regulatory Pathway for our C-Scan&#160;System</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have established a clinical and regulatory strategy with our advisors and have conducted a pre-IDE meeting, now referred to as a pre-submission meeting, with FDA (an informal interaction to facilitate a clearer understanding of FDA&#8217;s expectations). During this process, we received the FDA&#8217;s feedback on our submission and our questions and we are planning to continue the dialogue with FDA before the submission of a formal request for the IDE that is necessary for us to conduct the U.S. pivotal clinical trial.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our current strategy is to submit a direct de novo reclassification petition for our system. Although the FDA could require us to submit a PMA, we believe that the device could be considered for evaluation under the FDA&#8217;s de novo reclassification provisions, which allow a novel device to be reclassified into class I or class II. To support this, our objective is to demonstrate that the device poses a low to moderate risk to patients.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">49</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We believe that important potential benefits of our C-Scan system for CRC screening are the elimination of the need for bowel preparation, the elimination of the need for conscious sedation, the minimally invasive, painless nature of the examination, and the ability to pursue normal daily activities immediately following the procedure. Furthermore, the C-Scan system is being designed to generate information from segments of the colon (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">e.g.</font>, cecum and ascending colon) that are difficult to access by conventional optical colonoscopy (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">i.e.</font>, incomplete colonoscopies) without the risks and discomforts of operative examination or other invasive methods. We believe these benefits will be attractive to a large number of patients from the target populations that so far refrained from any screening tests. Thus, we anticipate that our capsule will increase the public compliance to screening recommendation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If FDA determines that our C-Scan system is not a candidate for de novo reclassification, it will require approval of the device for market through the PMA process. Because of the technological characteristics of this device, the non-clinical tests (including lab and animals) and clinical data required may not be significantly different between de novo and PMA regulatory processes. We believe that under both scenarios, we will be required to conduct a multi-center clinical study to establish the safety and efficacy and to demonstrate sensitivity and specificity of our C-Scan system in several hundreds of patients.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">FCC Clearance and Regulation</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Because our C-Scan system includes a wireless radio frequency transmitter and receiver, it is subject to equipment authorization requirements in the United States. The U.S. Federal Communications Commission, or FCC, requires authorization of radio frequency devices before they can be sold or marketed in the United States, subject to limited exceptions. The authorization requirements are intended to confirm that the proposed products comply with FCC radio frequency emission, power level standards, and other technical requirements and will not cause interference. Our system is using the same frequency band as other approved capsules, and we expect that it will comply with the FCC&#8217;s technical requirements, so it is expected that it will be authorized by the FCC as well.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Third-Party Coverage and Reimbursement</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Coverage of and reimbursement for our C-Scan system and related procedures, after approval, will be subject to the requirements of various third-party payors, including government-sponsored healthcare payment systems and private third-party payors. Coverage policies and reimbursement methodologies vary significantly from program-to-program and may be subject to federal and state regulations. For example, the Medicare statute requires all items and services to be &#8220;reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member&#8221; in order to be covered. Medicare currently does not provide separate reimbursement for many devices, but may include payment for the device in the payment for the related procedure. Third-party payors&#8217; coverage and reimbursement policies, including their interpretations of whether an item or service is &#8220;reasonable and necessary&#8221; or experimental and their payment methodologies, are subject to change pursuant to legislation, regulation, or, in the case of private payors, negotiations with providers.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Fraud and Abuse Laws</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In the United States, the healthcare industry is subject to extensive federal, state, and local regulation. Both federal and state governmental agencies subject the healthcare industry to intense regulatory scrutiny, including heightened civil and criminal enforcement efforts. These laws constrain the sales, marketing and other promotional activities of manufacturers of medical devices, by limiting the kinds of financial arrangements (including sales programs) we may have with hospitals, physicians and other potential purchasers of the medical devices. The laws and regulations that may affect our ability to operate include, but are not limited to:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1b312a566758492884ff95b46c95d4e9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly or willingly offering, paying, soliciting or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any health care items or service for which payment may be made, in whole or in part, by federal healthcare programs such as Medicare and Medicaid. This statute has been interpreted to apply to arrangements between medical device manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Further, PPACA, among other things, clarified that a person or entity needs not to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it. Although there are a number of statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exemptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exemption or safe harbor may be subject to scrutiny;</div>
</td>
</tr>
</table>

<div>&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">50</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<table id="z1f57a885b88949d28770fa5afcf07373" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The federal civil False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of government funds or knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. In addition, PPACA amended the Social Security Act to provide that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Many medical device manufacturers and other healthcare companies have been investigated and have reached substantial financial settlements with the federal government under the civil False Claims Act for a variety of alleged improper marketing activities, including providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting fees, grants, free travel, and other benefits to physicians to induce them to use the company&#8217;s products. In addition, in recent years the government has pursued civil False Claims Act cases against a number of manufacturers for causing false claims to be submitted as a result of the marketing of their products for unapproved, and thus non-reimbursable, uses. Device manufacturers also are subject to other federal false claim laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to non-government health benefit programs;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to items or services reimbursed under Medicaid and other state programs or, in several states, apply regardless of the payor. Several states now require medical device manufacturers to report expenses relating to the marketing and promotion or require them to implement compliance programs or marketing codes. For example, California, Connecticut and Nevada mandate the implementation of corporate compliance programs, while Massachusetts and Vermont impose more detailed restrictions on device manufacturers' marketing practices and tracking and reporting of gifts, compensation and other remuneration to healthcare providers;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The federal Foreign Corrupt Practices Act of 1997 and other similar anti-bribery laws in other jurisdictions generally prohibit companies and their intermediaries from providing money or anything of value to officials of foreign governments, foreign political parties, or international organizations with the intent to obtain or retain business or seek a business advantage. Recently, there has been a substantial increase in anti-bribery law enforcement activity by U.S. regulators, with more frequent and aggressive investigations and enforcement proceedings by both the Department of Justice and the U.S. Securities and Exchange Commission. Violations of these laws can result in the imposition of substantial fines, interruptions of business, loss of supplier, vendor or other third-party relationships, termination of necessary licenses and permits, and other legal or equitable sanctions. Other internal or government investigations or legal or regulatory proceedings, including lawsuits brought by private litigants, may also follow as a consequence; and</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">&#160;</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The federal Physician Payment Sunshine Act, being implemented as the Open Payments Program, requires manufacturers of &#8220;covered products&#8221; (drugs, devices, biologics, or medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program) to track and publicly report payments and other transfers of value that they provide to U.S. physicians and teaching hospitals, as well as any ownership interests that U.S. physicians hold in applicable manufacturer. Applicable manufacturers must submit a report to the Centers for Medicare &amp; Medicaid Services, or CMS, by the 90th day of each calendar year disclosing payments and transfers of value made in the preceding calendar year.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Violations of any of the laws described above or any other governmental regulations that apply to us, may cause us to be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, like Medicare and Medicaid, and the curtailment or restructuring of our operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Privacy Laws</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">HIPAA/HITECH and related U.S. federal and state laws protect the confidentiality of certain patient health information, including patient records, and restrict the use and disclosure of that protected information. In particular, the U.S. Department of Health and Human Services promulgated patient privacy rules under HIPAA.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">These privacy rules protect medical records and other personal health information by limiting their use and disclosure, giving individuals the right to access, amend and seek accounting of their protected health information and limiting most use and disclosures of health information to the minimum degree reasonably necessary to accomplish the intended purpose. Because we intend to sell products, once approved, to persons and entities subject to HIPAA and are exposed to personally-identifiable health information in the course of our operations, we also may be subject to certain elements of HIPAA, particularly as a business associate to covered entities, as well as similar state laws. HIPAA imposes civil and criminal penalties for violations of its provisions, which could be substantial. State privacy laws have their own penalty provisions which may be applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">51</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">NRC Regulatory Issues</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As our C-Scan system includes an ingestible capsule with a radioactive source, the company must address Nuclear Regulatory Commission, or NRC, regulations, or relevant Agreement State regulations, in addition to FDA requirements as well as regulations of other nuclear regulatory commissions in jurisdictions in which we intend to commercialize our C-Scan system. An Agreement State is a state that has signed an agreement with the NRC authorizing the state to regulate certain uses of radioactive materials within the state. Agreement State regulations are substantially similar to the NRC&#8217;s regulations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan system is loaded with the X-ray source, sealed and then ingested by the patient. Although the NRC places conditions and limitations on the disposal of radioactive material in the sanitary sewer, such conditions and limitations do not apply to radioactive material contained in the excreta of individuals that are undergoing medical diagnosis or therapy with radioactive material. However, there is no assurance that the NRC or other regulatory commissions worldwide will take a similar position in relation to our C-Scan system and we may face limitations by the NRC or other nuclear regulatory commissions in jurisdictions in which we intend to commercialize our C-Scan system in relation to the disposal of our C-Scan Cap in the sanitary system, such as requiring patients to retrieve our C-Scan system after use, which could make our C-Scan system less attractive.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The capsule is loaded with the X-ray source, sealed and then ingested by the patient. The capsule is excreted naturally through the patient&#8217;s system and is not intended to be recovered and therefore is disposed of in the sanitary sewer system. Although the NRC regulations in 10 CFR Part 20 place certain conditions and limitations on the disposal of radioactive material in the sanitary sewer, such conditions and limitations do not apply to radioactive material contained in excreta of individuals that are undergoing medical diagnosis or therapy with radioactive material. Our regulatory advisors have advised us that the NRC staff likely would take the position that a capsule containing radioactive material can be passed in excreta into the sanitary sewer system without limitation. If, however, the NRC were to find that our C-Scan system could not be passed in excreta into the sanitary sewer system without limitation pursuant to 10 CFR 20.2003(b) the NRC may place restrictions on the disposal of the C-Scan system in the sanitary sewer system.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">An entity which manufactures, prepares, or transfers a medical capsule containing radioactive byproduct material needs to be licensed or covered by a license issued by the NRC or an Agreement State. An NRC or Agreement State licensee authorized to possess and/or distribute byproduct material can transfer the byproduct material only to another NRC, or Agreement State, approved entity or licensee. The NRC&#8217;s regulations permit only individuals who are authorized users (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">e.g.</font>, individuals who meet certain training and experience criteria regarding the safe use of radioactive drugs) or persons working under the supervision of an authorized user to administer radioactive drugs for medical use.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The NRC regulations do exempt certain products from the NRC&#8217;s regulations. Existing exemptions from licensing requirements for the use of byproduct material include exemptions for specific products (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">e.g.</font>, time pieces), exemptions for classes of products (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">e.g.</font>, gas or aerosol detectors), and broader materials exemptions for &#8220;exempt concentrations&#8221; and &#8220;exempt quantities&#8221; of radioactive material. These two broad materials exemptions specifically exclude the transfer of byproduct material contained in any food, drug, or product designed for ingestion by a human being. Capsules containing our X-ray source would not qualify as an &#8220;exempt quantity&#8221; because of their intended use (<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">i.e.</font>, for ingestion) even though they may contain a smaller quantity of the source than the exempt quantities set forth in the regulations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Accordingly, we will need to obtain the appropriate licenses from the NRC or an Agreement State prior to the clinical investigation and/or marketing of the device. We intend to engage a radiopharmaceutical company to manufacture our C-Scan Cap. The fact that another company will be manufacturing the capsule, however, does not exempt us from also obtaining radioactive materials licenses from the NRC or an Agreement State. Distribution activities are generally classified by the NRC as either &#8220;distribution&#8221; or &#8220;redistribution&#8221;, and both types of activities require a specific license. &#8220;Distribution&#8221; refers to the initial transfer from the manufacturing radiopharmacy, while &#8220;redistribution&#8221; refers to a subsequent transfer of the drug by an NRC licensee to an authorized user. In order to distribute the capsule commercially, we will need to obtain an NRC or Agreement State &#8220;medical distribution&#8221; radioactive materials license and may also need to obtain a radioactive materials license authorizing the possession of the radioactive material. Both types of licenses may be obtained by submitting a license application request to the NRC or an Agreement State. In the event that we develop the capsule outside the United States, we would be required to have one of our U.S. offices apply for and receive both the possession and medical distribution radioactive materials licenses. If we do not have an office in the United States, then we can contract with a company with a U.S. office to apply for and obtain these licenses, and that company would be the licensed U.S. distributor of the capsule.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We may be able to petition the NRC to carve out an exemption for the distribution licensing requirement to permit distribution to all health care professionals and not just those licensed by the NRC. This has been done successfully by other medical device companies. For example, Tri-Med, Inc. manufactures an ingestible capsule containing radioactive material for testing of H. Pylori. The company petitioned the NRC in 1994 for an exemption from the distribution licensing regulation. The NRC evaluated the petition and issued a proposed ruling for comments. After receiving comments on the proposed ruling, the NRC issued a final ruling, in 1997, providing for the exemption. This exemption is narrowly drawn, and specific to the distribution of a &#8220;radioactive drug containing one microcurie of carbon-14 urea to any person for &#8216;in vivo&#8217; diagnostic use.&#8221; In creating the exemption, the NRC noted the importance of bringing an inexpensive and effective diagnostic tool to a large number of people, along with the minimum radiation contained in the capsule.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We may consider petitioning the NRC in a similar manner to make the device more widely available. As our C-Scan system imparts comparable radiation exposure to the Tri-Med device described above, and has the potential to be used widely for diagnosis, our C-Scan system may be a candidate for such an exemption.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">52</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Regulation in Europe, Israel, Japan and Other Countries</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">The European Union has adopted numerous directives and standards regulating the design, manufacture, clinical trials, labeling and adverse event reporting for medical devices. Each European Union member state has implemented legislation applying these directives and standards at the national level. Other countries, such as Switzerland, have voluntarily adopted laws and regulations that mirror those of the European Union with respect to medical devices. Devices that comply with the requirements of the laws of the relevant member state applying the applicable European Union directive are entitled to bear CE conformity marking and, accordingly, can be commercially distributed throughout the member states of the European Union and other countries that comply with or mirror these directives. The method of assessing conformity varies depending on the type and class of the product, but normally involves a combination of self-assessment by the manufacturer and a third-party assessment by a &#8220;Notified Body,&#8221; an independent and neutral institution appointed to conduct conformity assessment. This third-party assessment consists of an audit of the manufacturer&#8217;s quality system and clinical information, as well as technical review of the manufacturer&#8217;s product. An assessment by a Notified Body in one country within the European Union is required in order for a manufacturer to commercially distribute the product throughout the European Union. In addition, compliance with ISO 13845:2016 on quality systems issued by the International Organization for Standards, among other standards, establishes the presumption of conformity with the essential requirements for a CE marking. In addition, many countries apply requirements in their reimbursement, pricing or health care systems that affect companies&#8217; ability to market products.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">We obtained as of January 9, 2018 the CE mark of conformity for the C-Scan system.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Our C-Scan system and operations are also subject to regulation by AMAR, which is responsible for the registration of medical devices in Israel, issuance of import licenses and monitoring of marketing of medical equipment.</font> In <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">September 2018, </font>we received approval <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">AMAR</font> for the marketing and sale of the C-Scan system in Israel, which was valid until February 28, 2019. We have submitted a request to the Israeli Ministry of Health for the extension of the AMAR approval, which is currently pending.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">In Japan, manufacturing and marketing medical devices are regulated by the Pharmaceutical Affairs Law, or PAL. In accordance with the PAL, manufacturers must obtain a license for manufacturing medical devices from the Ministry of Health, Labour and Welfare, or MHLW. A license is required for each manufacturing plant specified by an MHLW Ministerial Ordinance.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">A licensed manufacturer is responsible only for manufacturing medical devices. In regard to the marketing of medical devices, the PAL specifies that a Marketing Authorization Holder, or MAH, licensed by MHLW is responsible for putting medical devices into marketplace. Licenses for marketing medical devices are divided into the following 3 types, which correspond to the classifications below:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6c2dd427ece140a99aa979211dc4b37b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">No. 1 type license for marketing &#8211; Specially controlled medical devices (Class III, IV)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze0034223ba8b423db4dfb96900b52a69" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">No. 2 type license for marketing &#8211; Controlled medical devices (Class II)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf7e3dc54f320492980ce9d917c940bce" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">No. 3 type license for marketing &#8211; General medical devices (Class I)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Generally, the process for obtaining marketing clearance for medical devices in Japan ranges from twelve months (for products with only very minor modifications from previously cleared product versions) to a few years in the case of a completely new device.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In order for us to market our products in countries other than the United States, Israel, the EU and Japan (which were described above), we must obtain regulatory approvals and comply with extensive safety and quality regulations in these countries. These regulations, including the requirements for approvals or clearance and the time required for regulatory review varies from country to country. It is customary that once a product has been cleared for sales in the US and is CE marked in the EU, many other countries will follow. Failure to obtain regulatory approval or clearance in any foreign country in which we plan to market our product may harm our ability to generate revenue and harm our business.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Third-Party Reimbursement</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Reimbursement in the United States</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In the United States, healthcare providers that purchase medical devices generally rely on third-party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations, to reimburse all or a portion of the cost of the devices, as well as any related healthcare services utilizing the devices.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">53</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Coverage is not guaranteed simply because a product has received FDA clearance or approval. Medicare&#8217;s general definition of a medically necessary service is one that is reasonable and necessary for the diagnosis or treatment of an illness or injury, or that improves the functioning of a malformed body member.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The cost-effectiveness of a device (or the service in which a device is used) may be a key factor in obtaining third-party payer reimbursement for such device or service.&#160; According to various studies and publications, a key factor affecting the cost-effectiveness of colorectal cancer screening is patient adherence (for instance, see &#8220;Cost-Effectiveness of Colonoscopy in Screening for CRC,&#8221; Annals of Internal Medicine, October 17, 2000 vol. 133 no. 8 573-584). Adherence is strongly affected by patients&#8217; willingness to use the device (or service incorporating a device) as a screening tool for CRC. Several models have been designed to demonstrate the cost effectiveness of optical colonoscopy, CTC, fecal testing and optical capsule endoscopy. Today, several technologies for CRC Screening - including: FOBT / FIT, Flexible Sigmoidoscopy, Optical Colonoscopy Barium Enema, and stool DNA</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#8211; are covered for Medicare patients meeting certain eligibility criteria.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In 2009, the Centers for Medicare and Medicaid Services issued a decision memorandum concluding that the evidence was inadequate to support Medicare coverage CTC screening for CRC. Their main argument for the decision was that based on available evidence, screening with CTC would not necessarily result in cost saving, at least at current screening compliance rates. CTC was not seen as a tool which could potentially increase patients&#8217; adherence. This procedure involves bowel preparation, as well as insufflations of the colon and the exposure of patients to very significant amount of radiation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">An important European study (C. Hassan et al, &#8220;Cost-Effectiveness of Capsule Endoscopy in Screening for Colorectal Cancer,&#8221; Endoscopy 2008, 40, 414-421) assessed the potential cost effectiveness of screening with optical capsule endoscopy and compared its cost-effectiveness with that of optical colonoscopy. Cost-effectiveness of screening was measured in terms of cost per life-year saved through prevention or down staging of CRC. The conclusion was that the cost effectiveness of capsule endoscopy in CRC screening will depend mainly on its ability to improve compliance in the general population.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Third-party payors in the United States began issuing coverage policies for optical capsule endoscopy in early 2002. Initially, all reimbursement policies provided coverage for optical capsule endoscopy of the small bowel only for the diagnosis of obscure gastrointestinal bleeding. Subsequently, reimbursement coverage has been expanded to include other diagnoses and as of December 31, 2012, approximately 220 million people in the United States are covered with most reimbursement policies providing coverage for a number of small bowel indications, including obscure gastrointestinal bleeding, suspected Crohn&#8217;s disease, suspected small bowel tumors and other small bowel pathologies.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Currently, there is no optical capsule endoscopy reimbursement available for the colon in the United States, nor is there a CPT code for such capsule or related method of screening. There can be no assurance that coverage will be obtained in the near future or at all. Third-party payors may deny coverage if they determine that a procedure was not reasonable or necessary as determined by the payor, was experimental or was used for an unapproved indication (among other factors). During the past several years, the major third-party payors have substantially revised their reimbursement methodologies in an attempt to contain or reduce their healthcare reimbursement costs.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Coverage Outside the United States</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In countries outside the United States, coverage for CRC screening may be obtained from various sources, including governmental authorities, private health insurance plans, and labor unions. In some countries, private insurance systems may also offer payments for some therapies. Although not as prevalent as in the United States, health maintenance organizations are emerging in certain European countries. Coverage systems in international markets vary significantly by country and, within some countries, by region. Coverage approvals must be obtained on a country-by-country or region-by-region basis.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z99fa46967c014a2b913a5d9a9b7991a6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Organizational Structure</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">On May 15, 2015, we formed our wholly-owned subsidiary Check-Cap US, Inc., a Delaware corporation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7737ac739f5f4c499ffbe9cfa2ae595c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Property, Plants and Equipment</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our principal executive offices and operations are conducted at a facility located in Isfiya, Israel since June 1, 2009.&#160;We lease approximately 900 square meters at this facility under a lease agreement expiring on May 31, 2022, unless earlier terminated by us upon at least 60 days prior written notice. We believe that our current facilities are adequate to meet our current needs for the clinical phase of our development.&#160; See Item 4B &#8220;Information on Our Company &#8211; Business Overview &#8211; Manufacturing and Suppliers.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM4A" name="ITEM4A"><!--Anchor--></a>ITEM 4A. UNRESOLVED STAFF COMMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">None.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">54</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a id="ITEM5" name="ITEM5"><!--Anchor--></a>ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and related notes included in this Annual Report beginning on page F-1. The following discussion and analysis contain forward-looking statements that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Item 3D &#8220;Key Information - Risk factors&#8221; and elsewhere in this Annual Report.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Overview</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are a clinical stage medical diagnostics company engaged in the development of a capsule-based system that utilizes ultra-low-dose X-rays to generate structural information on the endoluminal surface of the colon that may be used for screening of the colon to detect polyps, masses and CRC. While CRC is the second leading cause of death from cancer for both sexes combined in the United States and is preventable with early screening and intervention, according to the National Health Interview Survey, in 2015, only 63% of Americans over the age of 50 reported being current with CRC screening recommendations. Unlike other screening modalities that are designed for direct visualization and imaging of the internal colon, such as optical colonoscopy, CTC and other capsule-based technologies, our C-Scan system is designed to function without any cathartic preparation of the colon, and to transit the gastrointestinal tract by natural motility while the patient continues his or her normal daily routine. Furthermore, the C-Scan system does not require fasting prior to or during capsule transit. Our C-Scan system is comprised of three main components: (1) C-Scan Cap, a ingestible X-ray scanning capsule; (2) C-Scan Track, a biocompatible unit worn on the patient&#8217;s back for capsule control, tracking and data recording; and (3) C-Scan View, a PC-based, standalone application used to process and display structural information of the colon.&#160; We believe that this solution will be attractive to both physicians and patients, with the potential to increase the number of people completing CRC screening.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Check-Cap LLC was formed in&#160;2004 as a Delaware limited liability company to develop a novel and superior solution for colon cancer screening. In 2009, all of the business operations and substantially all of the assets of Check-Cap LLC were transferred to Check Cap Ltd., a newly-incorporated Israeli company. Our offices are located near Haifa, in the northern part of Israel. Our management team includes an experienced group of executives in the business, research, clinical and regulatory fields. As of March 30, 2019, our research and development team consists of 39 experienced professionals (including employees and independent contractors) in a variety of fields such as clinics, physics, algorithms, electronics, software, mechanical engineering, verification and validation, and manufacturing.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our C-Scan system is being designed to create a reconstructed three-dimensional image of the interior surface of the colon and to enable detection of clinically significant polyps with a high degree of sensitivity. Colonic polyps are tissue growths that occur on the lining of the colon. Polyps in the colon are extremely common and certain types of polyps can become cancerous over time.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For the past several years, we have focused on the research and development of our imaging technology. <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>For details regarding our clinical trials, see Item 4B &#8220;Business Overview&#8212;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font>C-Scan&#160;System Non-Clinical, Pre-Clinical and Clinical History.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have generated significant losses to date, and we expect to continue to generate losses for at least the next several years as we continue our investment in research and development and clinical trials in order to complete the development of our C-Scan system and to attain regulatory approvals, begin the commercialization efforts for our products, increase our marketing and selling expenses, and incur additional costs as a result of being a public company in the United States. The extent of our future operating losses and the timing of becoming profitable are highly uncertain, and we may never achieve or sustain profitability. As of December 31, 2018, we had accumulated losses of approximately $63.3 million.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our financing activities are described below under &#8220;Liquidity and Capital Resources.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our management plans to continue the development, clinical development and regulatory activities of our C-Scan system in 2019 and that costs associated with such activities are expected to increase in 2019, to reach market in a timely manner. Management plans include additional fund raising in the next year. If we are not successful in raising capital through public or private offerings or are unable to reduce our expenses, we may exhaust our cash resources and will be unable to continue our operations beyond February 2020. See &#8220;Item 3D &#8220;Key Information - Risk Factors&#8212; Risks Related to Our Financial Position.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For a more detailed description of our business and plans, see Item 4B &#8220;Information on Our Company &#8211; Business Overview.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">55</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1511caa5c7af484984bd7388ffd35674" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Operating Results</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Financial Operations Overview</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Revenue</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have not generated any revenue since our inception. To date, we have funded our operations primarily through equity financings, as well as from grants that we received from the IIA (formerly the OCS). If our product development efforts result in clinical success, regulatory approval and the successful commercialization of our imaging system, we expect to generate revenue from sales of our C-Scan system.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Operating Cost and Expenses</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our operating costs and expenses are classified into two categories: research and development expenses and general and administrative expenses. For each category, the largest component is personnel costs, which consists of salaries, employee benefits and share-based compensation. Operating costs and expenses also include allocated overhead costs for depreciation of equipment. Operating costs and expenses are generally recognized as incurred. We expect personnel costs to continue to increase as we hire new employees to continue to grow our business.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Research and Development Expenses, Net</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Research and development activities are central to our business model. We intend to increase our research and development operations in order to complete the development of our C-Scan system and to attain regulatory approvals.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Since 2016, we have spent approximately $21.5 million on research and development expenses as of December 31, 2018, of which $1.5 million was funded by government grants. Our total research and development expenses, net of participations in the years ended December 31, 2018, 2017, and 2016 were approximately $7.6 million, $6.8 million, and $5.5 million, respectively. All research and development expenses are expensed as incurred. We expect research and development expenses to increase in absolute terms in the near term.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Research and development expenses consist primarily of costs incurred for our research activities, including:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd6dc82c56226447cb6ff17c4dfa64a16" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">employee-related expenses for research and development staff, including salaries, benefits and related expenses, including share-based compensation and travel expenses;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8ba00bf8208148c088ffe183ab8db94e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">payments made to third-party contract research organizations, contract manufacturers, investigative sites and consultants;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2de2580f846c4cffbc158bc807d7049b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">manufacturing development costs;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc18861a87d4f47b0afcb7a89883ec84b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">costs associated with preclinical and clinical activities and regulatory operations;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze390ba074ab54c92bcfd1d9949242c1f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb1ecb74c83f6432390275136022b0302" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">costs associated with obtaining and maintaining patents.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our research and development expenses, net are net of grants we have received from the Government of Israel through the IIA (formerly the OCS).&#160;Under the terms of the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law as currently in effect, in exchange for these grants, we are required to pay the IIA royalties from our revenues up to an aggregate of 100% (which may be increased under certain circumstances) of the U.S. dollar-linked value of the grant, plus interest at the rate of 12-month LIBOR. Pursuant to regulations under the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law, the rate of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">royalty </font>repayment <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">are</font> 3% <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">or</font> 5% of revenues (and at an increased rate under certain circumstances<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">) from sales of products and services based on IIA-funded know-how.</font> As of December 31, 2018, we had received funding from the IIA (formerly the OCS) in the aggregate amount of approximately $5.3 million.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>As of December 31, 2018, we had not paid any royalties to the IIA and had a contingent obligation to the IIA in the amount of approximately $5.6 million. For additional information regarding the IIA grants, see Item 10E &#8220;Additional Information - Taxation - Israeli Tax Considerations and Government Programs - The Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly the Encouragement of Industrial Research and Development Law, 5744-1984).&#8221; There can be no assurance that we will continue to receive grants from the OCS in amounts sufficient for our operations, if at all.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">56</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">General and Administrative Expenses</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our general and administrative expenses consist primarily of salaries and other related costs, including share-based compensation expense, for persons serving as our executive, finance, legal, human resources and administrative personnel, professional service fees and other general corporate expenses, such as communication, office and travel expenses. We expect that our general and administrative expenses will increase in line with the future growth of our overall operations and, in part, due to costs associated with being a public company in the United States, including compliance under the Sarbanes-Oxley Act of 2002 and rules promulgated by the U.S. Securities and Exchange Commission. These public company-related expense increases will likely include costs of additional legal fees, accounting and audit fees, directors&#8217; and officers&#8217; liability insurance premiums and costs related to investor relations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Financial Income and Finance Expenses</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our finance income and finance expenses in 2018, 2017 and 2016 consist primarily of interest earned on our cash, cash equivalents and short-term investments and changes in provision for royalties primarily to Check&#8211;Cap LLC unitholders.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Foreign currency transactions are translated into U.S. dollars using the exchange rates prevailing at the dates of the transactions or valuation where items are re-measured. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of operations to &#8220;finance expenses&#8221;/&#8221;finance income.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Taxes on Income</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The standard corporate tax rate in Israel was 25% for the 2016 tax year, 24% for the 2017 tax year and 23% for the 2018 tax year and thereafter.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We do not generate taxable income in Israel, as we have historically incurred operating losses resulting in carryforward tax losses totaling approximately $54.5 million as of December 31, 2018.&#160; We anticipate that we will be able to carry forward these tax losses indefinitely to future tax years. However, a tax loss that can be utilized in a certain tax year cannot be carried forward to future tax years. Accordingly, we do not expect to pay taxes in Israel until we have taxable income after the full utilization of our carry forward tax losses.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Law for the Encouragement of Capital Investments, 5719-1959 and other Israeli legislation, we may be entitled to certain additional tax benefits, including reduced tax rates, accelerated depreciation and amortization rates for tax purposes on certain assets, deduction of public offering expenses in three equal annual installments and amortization of other intangible property rights for tax purposes. See Item 10E &#8220;Additional Information &#8212; Taxation&#8212; Israeli Tax Considerations and Government Programs&#8221; for additional information concerning these tax benefits.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Results of Operations</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For convenience purposes, the numbers set forth in the management&#8217;s discussion and analysis below are, where applicable, rounded up and presented in millions, whereas the numbers in the tables below are presented in thousands. As result, the percentages set forth in the year-over-year comparisons below are based on numbers that have (where applicable) been rounded up to millions, which may slightly differ than the percentages that would result from the corresponding numbers set forth in the table that are presented in thousands.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Year Ended December 31, 2018 Compared to Year Ended December 31, 2017</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2aa4c096cf6441348e0bb3f6e3b8edf9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year Ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(US$ in thousands, except</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">per</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">share data)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Research and development expenses, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,618</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,837</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">General and administrative expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,445</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,164</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Operating loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">11,063</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">10,001</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Finance income, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">473</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">236</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Loss before income tax&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">10,590</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">9,765</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Taxes on income&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(1</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Net loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">10,589</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Research and Development Expenses, net</font>.&#160; Our research and development expenses, net for the year ended December 31, 2018 were $7.62 million, as compared with $6.84 million for the year ended December 31, 2017, an increase of $781,000 or 11.4%. The increase in research and development, net expenses between 2018 and 2017 was primarily due to a $894,000 increase in materials and a $206,000 increase in other research and development expenses, both relating to our clinical trials, primarily in connection with our post-CE Mark clinical study and the preparation for the U.S. pilot study, including obtaining FDA approval.&#160; The increase in&#160;research and development expenses, net between 2018 and 2017&#160;was partially offset by a $246,000 decrease in salaries and related expenses, primarily due to the decrease in expenses associated with the position of our Vice President, Research and Development following the appointment of Mr. Shpigelman to such position instead of Mr. Ovadia, who was appointed as our CEO in February 2018, and a $145,000 decrease in fees to subcontractors and consultants.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">57</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7ae6c68dbd49464da508c0e528952426" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Change</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(US$ in thousands)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Salaries and related expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,410</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,656</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(246</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Share-based compensation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">234</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">116</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">118</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Materials&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,508</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">614</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">894</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Subcontractors and consultants&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">311</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">456</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(145</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Depreciation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">138</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">147</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(9</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Cost for registration of patents&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">126</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">157</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(31</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Other research and development expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,099</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">893</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">206</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">7,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">7,039</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">787</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Less participation of the IIA (formerly the OCS) and the BIRD Foundation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(208</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(202</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(6</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Total research and development expenses, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">7,618</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">6,837</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">781</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">General and Administrative Expenses</font>. Our general and administrative expenses for the year ended December 31, 2018 were $3.45 million, as compared to $3.16 million for the year ended December 31, 2017, an increase of $281,000, or 8.9%.&#160; The increase in general and administrative expenses is primarily due to the following: a $444,000 increase in salaries and related expenses primarily due to a $ 281,000 in severance paid to our former CEO, a $419,000 increase in professional fees primarily due to a $202,000 increase in legal fees, and a $325,000 increase in other general and administrative expenses, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">primarily associated with consulting fees and servic</font>es incurred as a result of being a public company. The increase in&#160;general and administrative expenses net between 2018 and 2017&#160;was partially offset by: a $909,000 decrease in <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">share-based compensation, of which $502,000 relates to reversal of expenses associated with an equity award to our former CEO which was forfeited as a result of his separation from employment.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za288fe093da94cfd98e8b78e998ddd06" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Change</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(US$ in thousands)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Salaries and related expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,839</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,395</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">444</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Share-based compensation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(299</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">610</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(909</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Professional services&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">833</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">414</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">419</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Office rent and maintenance&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">163</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">161</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Depreciation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Other general and administrative expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">899</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">574</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">325</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Total general and administrative expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,445</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,164</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">281</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Operating Loss</font>.&#160; Our operating loss for the year ended December 31, 2018 was $11.1 million, as compared with $10.0 million for the year ended December 31, 2017, an increase of $1.1, or 11%.&#160; The increase was as a result of the $781,000 increase in research and development expenses, net for the year ended December 31, 2018 compared to the year ended December 31, 2017 and the $281,000 increase in general and administrative expenses in the same period.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Finance Income, net</font>. Our finance income, net for the year ended December 31, 2018 was $473,000, as compared to $236,000 for the year ended December 31, 2017, an increase of $237,000.&#160; The change in our finance income, net is primarily due to the following:&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z532c5e13c9f4401aa8d3c6ba3244ca99" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.84%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 7.07%; VERTICAL-ALIGN: top; TEXT-ALIGN: center">&#8226;</td>
<td style="WIDTH: 89.08%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">For the year ended December 31, 2018, we recorded $243,000 of interest income on short-term deposits as compared to $66,000, for the year ended December 31, 2017, an increase of $177,000 resulting from a higher average short-term deposits balance in 2018 as a result of our May 2018 underwritten public offering and an increase in interest rates on these short-term deposits.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb04da84eb6ee4c5e959f1019acdff1b5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.83%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 7.07%; VERTICAL-ALIGN: top; TEXT-ALIGN: center">&#8226;</td>
<td style="WIDTH: 89.09%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">For the year ended December 31, 2018, we recorded finance income of $255,000 as a result of changes in provision for royalties, primarily to Check&#8211;Cap LLC unitholders, as compared to finance income of $82,000 for the year ended December 31, 2017, an increase of $173,000.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb9bce70ab8c74155a9b39c94ca00f6d0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.84%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 7.07%; VERTICAL-ALIGN: top; TEXT-ALIGN: center">&#8226;</td>
<td style="WIDTH: 89.08%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">For the year ended December 31, 2018, we recorded $27,000 finance expense as a result of exchange rate differences as compared to finance income of $95,000 for the year ended December 31, 2017, a decrease of $122,000.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Loss before income tax</font>. Our loss before income tax for the year ended December 31, 2018 was $10.59 million, as compared to $9.77 million for the year ended December 31, 2017, an increase of $825,000.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Net Loss</font>. Our net loss for the year ended December 31, 2018 was $10.59 million, as compared to $9.77 million for the year ended December 31, 2017, an increase of $818,000.</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">58</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Year Ended December 31, 2017 Compared to Year Ended December 31, 2016</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zfde458d2b4bb42c6b3cb355e2f6eaf97" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year Ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(US$ in thousands, except</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">per share data)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Research and development expenses, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,837</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,491</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">General and administrative expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,164</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,571</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Operating loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">10,001</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">9,062</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Finance income, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">236</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">244</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Loss before income tax&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">9,765</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">8,818</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Taxes on income&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Net loss&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Research and Development Expenses, net</font>.&#160; Our research and development expenses, net for the year ended December 31, 2017 were $6.84 million, as compared with $5.49 million for the year ended December 31, 2016, an increase of $1.35 million or 24.6%.&#160; The increase in research and development, net expenses between 2017 and 2016 was primarily due to: a $922,000 decrease in grants from the IIA; a $136,000 increase in fees to subcontractors and consultants; and a $382,000 increase in other research and development expenses relating to our clinical trials and regulatory expenses, primarily in connection with the application for CE Mark approval for our C-Scan system and preparation for the U.S. pilot study. The increase in&#160;research and development expenses, net between 2017 and 2016&#160;was partially offset by: a $118,000 decrease in share-based compensation expenses relating to awards to directors, officers and employees in 2015, the expenses for which are recognized over a three to four year period, with the majority of the expenses recognized in 2016.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zad7aaece36f74f5cae3a5687cb8b84bd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Change</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(US$ in thousands)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Salaries and related expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,656</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,683</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(27</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Share-based compensation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">116</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">234</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(118</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Materials&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">614</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">596</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">18</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Subcontractors and consultants&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">456</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">320</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">136</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Depreciation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">147</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">121</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">26</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Cost for registration of patents&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">157</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">150</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Other research and development expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">893</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">511</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">382</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,039</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,615</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">424</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Less participation of the IIA (formerly the OCS) and the BIRD Foundation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(202</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(1,124</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">922</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Total research and development expenses, net&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,837</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,491</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,346</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">General and Administrative Expenses</font>. Our general and administrative expenses for the year ended December 31, 2017 were $3.16 million, as compared to $3.57 million for the year ended December 31, 2016, a decrease of $407,000, or 11.4%.&#160; The decrease in general and administrative expenses is primarily due to the following: a $365,000 decrease in 2017 of share-based compensation expenses relating to awards to directors, officers and employees in 2015, the expenses for which are recognized over a three to four year period, with the majority of the expenses recognized in 2016, and a $104,000 decrease in other general and administrative expenses primarily due to decreased public relation expenses.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za2f95fb2d2d94141bcb75ef29ff9425e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Change</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(US$ in thousands)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Salaries and related expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,395</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,411</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(16</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Share-based compensation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">610</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">975</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(365</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Professional services&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">414</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">354</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">60</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Office rent and maintenance&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">161</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">144</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">17</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Depreciation&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Other general and administrative expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">574</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">678</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(104</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Total general and administrative expenses&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,164</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,571</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(407</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Operating Loss</font>.&#160; Our operating loss for the year ended December 31, 2017 was $10.0 million, as compared with $9.06 million for the year ended December 31, 2016, an increase of $939,000, or 10.4%.&#160; The increase was as a result of the $1.35 million increase in research and development expenses, net for the year ended December 31, 2017 compared to the year ended December 31, 2016, offset by the $407,000 decrease in general and administrative expenses in the same period.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">59</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Finance Income, net</font>. Our finance income, net for the year ended December 31, 2017 was $236,000, as compared to $244,000 for the year ended December 31, 2016, a decrease of $8,000.&#160; The change in our finance income, net is primarily due to the following:&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z99ec53f944f0461d8cbb3315c24952e5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.84%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 7.07%; VERTICAL-ALIGN: top; TEXT-ALIGN: center">&#8226;</td>
<td style="WIDTH: 89.08%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">For the year ended December 31, 2017, we recorded $66,000 of interest income on short-term deposits as compared to $139,000, for the year ended December 31, 2016, a decrease of $73,000 resulting from a lower average short-term deposits balance in 2017.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9547d081857e44a581b90f1d06775299" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.83%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 7.07%; VERTICAL-ALIGN: top; TEXT-ALIGN: center">&#8226;</td>
<td style="WIDTH: 89.09%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">For the year ended December 31, 2017, we recorded finance income of $82,000 as a result of changes in provision for royalties, primarily to Check&#8211;Cap LLC unitholders, as compared to a finance income of $56,000 in the year ended December 31, 2016, a decrease of $26,000.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z29bf9da337a248f1944042fdc59c4ba1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.84%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 7.07%; VERTICAL-ALIGN: top; TEXT-ALIGN: center">&#8226;</td>
<td style="WIDTH: 89.08%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">For the year ended December 31, 2017, we recorded $95,000 finance income as a result of exchange rate differences as compared to $56,000, for the year ended December 31, 2016, an increase of $39,000.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Loss before income tax</font>. Our loss before income tax for the year ended December 31, 2017 was $9.76 million, as compared to $8.82 million for the year ended December 31, 2016, an increase of $947,000.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Net Loss</font>. Our net loss for the year ended December 31, 2017 was $9.77 million, as compared to $8.83 million for the year ended December 31, 2016, an increase of $945,000.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z4693d0a478014dc48ec1da4a31c79667" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Liquidity and Capital Resources</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Sources of Liquidity</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">To date, we have funded our operations primarily with the approximately $24.5 million raised through equity financings consummated prior to our initial public offering, $13.5 million through our initial public offering (including the over-allotment exercise), $12.0 million through the private placement consummated concurrently with our initial public offering, $39.0 million through our registered direct and underwritten public offerings (including through the exercise of pre-funded warrants issued in the August 2016 and February 2019 registered direct offerings), $5.3 million through grants that we received from the IIA (formerly the OCS) and the BIRD Foundation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">On August 11, 2016, we consummated a registered direct offering of 53,365 ordinary shares at a price of $22.80 per share and pre-funded warrants to purchase 209,524 ordinary shares at a purchase price of $22.20 per pre-funded warrant. The pre-funded warrants had an exercise price of $0.60 per share, subject to certain adjustments and an expiration date of August 11, 2023, unless otherwise extended in accordance with the terms of the pre-funded warrants.&#160;We received gross proceeds from the August 2016 registered direct offering of approximately $5.9 million (including proceeds from the exercise of 47,917 pre-funded warrants at the closing of the offering). As of December 31, 2016, additional pre-funded warrants to purchase an aggregate 137,441 ordinary shares had been exercised, for additional proceeds of $82,500.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"> &#160;</font> As of January 23, 2017, all of the remaining pre-funded warrants to purchase an aggregate 24,166 ordinary shares had been exercised, for additional proceeds of $14,500.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">60</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">On June 2, 2017, we consummated a registered direct offering of 112,460 ordinary shares at a price of $24.00 per share and a simultaneous private placement of one-year warrants to purchase an aggregate of up to 112,460 ordinary shares. The warrants have an exercise price of $25.50 per share and are immediately exercisable.&#160;We received gross proceeds from the June 2017 registered direct offering of approximately $2.69. On June 2, 2018, </font>all of the warrants expired without being exercised.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">On November 22, 2017, we consummated a registered direct offering of 189,387 ordinary shares at a price of $13.20 per share and a simultaneous private placement of five-year warrants to purchase an aggregate of up to 142,042 ordinary shares. The warrants have an exercise price of $15.00 per share and are immediately exercisable. We received approximately $2.5 million gross proceeds from the November 2017 registered direct offering. </font>During the year ended December 31, 2018, 43,238 warrants were cashless exercised into 13,574 ordinary shares.&#160; We may receive <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">up to approximately $1.3 million total additional gross proceeds in the event that the remaining outstanding warrants are exercised in full for cash.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">On May 8, 2018, we issued 2,738,472 units, at a public offering price of $5.50 per unit, and 450,909 pre-funded units, at a public offering price of $5.49 per pre-funded unit, in an underwritten offering. Each unit consisted of one ordinary share</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and one Series C warrant to purchase one ordinary share. Each pre-funded unit consisted of one pre-funded warrant to purchase one ordinary share and one Series C Warrant to purchase one ordinary share. The exercise price of each pre-funded warrant included in the pre-funded unit was $0.01 per share. </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The Series C warrants have an exercise price of $5.50 per share, are exercisable immediately and will expire five years from the date of issuance. </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">On May 8, 2018, we issued an additional 478,407 ordinary shares and Series C Warrants to purchase up to an additional 478,407 ordinary shares at $5.50 per share to the underwriter. We received gross proceeds from the May 2018 underwritten public offering of approximately $20.2 million (including proceeds from the exercise of 450,909 pre-funded warrants) and we may receive up to approximately $20.2 million </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">of additional </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">total gross proceeds in the event that the warrants are exercised in full for cash.</font></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">On February 6, 2019, we consummated a registered direct offering of </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1,881,500</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> units at a purchase price of $2.58 per unit</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and 1,024,876 pre-funded units, at a purchase price of $2.57 per pre-funded unit.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> Each unit consisted of </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">one ordinary share </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and one Series D Warrant to purchase 0.5</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> ordinary share</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">. Each pre-funded unit consisted of one pre-funded </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">warrant to purchase one </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">ordinary share </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and one Series D Warrant to purchase 0.5 ordinary share. The exercise price of each pre-funded warrant included in</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> the </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">pre-funded unit was $0.01 per share.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> The Series D warrants have an exercise price of $2.58 per ordinary share</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> are immediately exercisable</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and will expire five years from the date of issuance</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">. We received gross proceeds of approximately of $7.5 million from the offering.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For the years ended December 31, 2018, 2017 and 2016, we received $208,000 and $205,000, and $1.5 million, respectively, in grants from the IIA (formerly the OCS) for the financing of a portion of our research and development expenditure.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">On July 13, 2014, we entered into a Cooperation and Project Funding Agreement with the BIRD Foundation and Synergy, pursuant to which the BIRD Foundation agreed to award a grant to Synergy and us in the maximum amount of the lesser of (i) $900,000; and (ii) 50% of the actual expenditures for the funding of a project entitled &#8220;Collection &amp; Analysis of Gastrointestinal Images for Diagnostic Adenomatic Polyps and Colorectal Cancer.&#8221;&#160; The development work was to be performed over a 24 month period by Synergy (or a subcontractor on its behalf) and us. In 2014, we, together with Synergy, received funding from the BIRD Foundation in the aggregate amount of approximately $127,000.&#160; We shall not be receiving additional funding from the BIRD Foundation for such project, which is no longer active.&#160; Based on the aggregate expenses that we incurred for such project, we refunded to the BIRD Foundation an amount of approximately $13,300.&#160; We are required to repay the total sum granted to us and Synergy by the BIRD Foundation, linked to the U.S. Consumer Price Index from date of receipt of each payment, up to 100%, 113%, 125%, 138% and 150% of the linked sum granted by the BIRD Foundation if repaid within one year, two years, three years, four years and five or more years, respectively, of the original project completion date in accordance with the project proposal. Repayments are made at the rate of 5% of gross revenues derived from the product funded by the project. Under the terms of the agreement, if any portion of the product funded by the project is sold outright to a third party prior to full repayment of the grant to the BIRD Foundation, one-half of the sale proceeds will be applied to the repayment of the grant. If the funded product is licensed to a third party, 30% of all payments received under the respective license agreement must be paid to the BIRD Foundation in repayment of the grant. As of December 31, 2018, we had not paid any royalties to the BIRD Foundation and had a contingent obligation to the BIRD foundation in the amount of $180,000.&#160; Our research and development expenses, net is presented net of the grant amount received from the BIRD Foundation.&#160; &#160;</div>

<br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are a clinical and development-stage medical diagnostics company with a limited operating history.&#160;We have incurred net losses in each fiscal year since we commenced operations in 2009.&#160;We incurred net losses of $10.6 million, $9.8 million and $8.8 million in 2018, 2017 and 2016, respectively.&#160;As of December 31, 2018, our accumulated deficit was $63.3&#160;million.&#160; Our losses could continue for the foreseeable future as we continue our investment in research and development and clinical trials to complete the development of our technology and to attain regulatory approvals, begin the commercialization efforts for our C-Scan system, increase our marketing and selling expenses, and incur additional costs as a result of being a public company in the United States. Successful completion of our development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill our development activities and our ability to successfully commercialize our C-Scan system and achieve a level of sales adequate to support our cost structure. The extent of our future operating losses and the timing of becoming profitable are highly uncertain, and we may never achieve or sustain profitability.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt">Our <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">accumulated</font> losses <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and the additional funds needed to maintain our operation </font>raise substantial doubt about our ability to continue as a going concern. Our financial statements include a note describing the conditions which raise this substantial doubt. As a result, our independent registered public accounting firm included a &#8220;going concern&#8221; explanatory paragraph in its report on our financial statements as of and for the year ended December 31, 2018 with respect to this uncertainty. Our ability to continue as a going concern will require us to obtain additional financing to fund our operations. The perception of our ability to continue as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of confidence by investors, suppliers and employees. If we are not successful in raising capital through public or private offerings or reducing our expenses, we may exhaust our cash resources and will be unable to continue our operations. If we cannot continue as a viable entity, our shareholders would likely lose most or all of their investment in us.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 44pt">To meet our capital needs, we are considering multiple alternatives, including, but not limited to, additional equity financings and other funding transactions. While we have been successful in raising financing in the past, there can be no assurance that we will be able to do so in the future on a timely basis on terms acceptable to us, or at all. Uncertain market conditions and approval by regulatory bodies and adverse results from clinical trials may (among other reasons) adversely impact our ability to raise capital in the future.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 44pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 44pt">Management expects that we will continue to generate losses from the development, clinical development and regulatory activities of the C-Scan system, which will result in a negative cash flow from operating activity. We believe that current cash on hand will be sufficient to fund operations into February 2020. This has led management to conclude that substantial doubt about our ability to continue as a going concern exists. In the event we are unable to successfully raise additional capital during or before the end of 2019, we will not have sufficient cash flows and liquidity to finance our business operations as currently contemplated. Accordingly, in such circumstances we would be compelled to immediately reduce general and administrative expenses and delay research and development projects and clinical trials, until we are able to obtain sufficient financing. If such sufficient financing is not received timely, we would then need to pursue a plan to license or sell our assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. </div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">61</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Historical Cash Flows</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following table summarizes our statement of cash flows for the years ended December 31, 2018, 2017 and 2016.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6a16bb78d4c3451f947057e372b76213" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year Ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(US$ in thousands)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Net cash used in operating activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(10,034</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(9,150</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(7,923</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Net cash provided by (used in) investing activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(5,723</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(231</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,645</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Net cash provided by financing activities&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">17,762</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,575</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,424</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Operating Activities</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Net cash used in operating activities for the year ended December 31, 2018 was $10.1 million, as compared to $9.2 million for the year ended December 31, 2017. The increase in net cash used in operating activities in 2018 was attributable primarily to a $1.1 million increase in operating loss, as compared to 2017. Net cash used in operating activities for the year ended December 31, 2017 was $9.2 million, as compared to $7.9 million for the year ended December 31, 2016. The increase in net cash used in operating activities in 2017 was attributable primarily to a $939,000 increase in operating loss, as compared to 2016.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Investing Activities</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Net cash used in investing activities for the year ended December 31, 2018 <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">was $5.7 million, comprised</font> primarily of investment in short-term bank deposits in the amount of $5.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">6 million and purchase of property and equipment in the amount of $94,000</font>. Net cash used in investing activities for the year ended December 31, 2017 consists of purchase of property and equipment in the amount of $231,000.&#160;Net cash provided by investing activities for the year ended December 31, 2016 consists primarily of proceeds from short-term bank deposits in the amount of $4.8 million, which was partially offset by purchase of property and equipment in the amount of $166,000.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Financing Activities</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Net cash provided by financing activities for the year ended December 31, 2018 was $17.8 million, comprised of proceeds from the issuance of ordinary shares in the underwritten public offering, net of issuance expenses.&#160;Net cash provided by financing activities for the year ended December 31, 2017 was $4.6 million, comprised primarily of proceeds from the issuance of ordinary shares in the June 2017 and November 2017 registered direct offerings, net of issuance expenses.&#160;Net cash provided by financing activities for the year ended December 31, 2016 was $5.4 million, comprised primarily of proceeds from the issuance of ordinary shares in the August 2016 registered direct offering, net of issuance expenses.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Funding Requirements</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We expect to incur losses from operations for the foreseeable future. We expect to incur increasing research and development expenses, including expenses related to the hiring of personnel and conducting additional clinical trials. We expect that our general and administrative expenses will also increase as we expand our finance and administrative staff, add infrastructure, and incur additional costs related to being a public company in the United States, including directors&#8217; and officers&#8217; insurance, investor relations programs, and increased professional fees. Our future capital requirements will depend on a number of factors, including the timing and outcome of clinical trials and regulatory approvals, the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims and other intellectual property rights, the availability of financing, the costs involved in manufacturing our product, and our success in developing markets for our products.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our expected future expenditures related to product, clinical and regulatory clearances includes the following:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc36765f6387f4d50acb81e300b5df054" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">completion of the clinical development of our C-Scan system;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za4b4c7172cc94f7e8ca1cf4bdd2c6a37" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">conducting clinical trials in Europe, the United States and other territories for purposes of regulatory approval and post-marketing validation;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd23278942c094d25a509478817793175" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">development of future generations of our C-Scan system and future products;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z4b224e954f3445558b26bfd70494a5d2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">FDA and additional regulatory filing activities in countries we intend to commercialize our system; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z25c88a8c30b54ec9b283f4eb93123a6f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">patent maintenance fees.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">See &#8220;Item 3D &#8220;Key Information - Risk Factors&#8212; Risks Related to Our Financial Position.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">62</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Application of Critical Accounting Policies and Estimates</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our financial statements requires us to make estimates, judgments and assumptions that can affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. We base our estimates, judgments and assumptions on historical experience and other factors that we believe to be reasonable under the circumstances. Materially different results can occur as circumstances change and additional information becomes known. Besides the estimates identified above that are considered critical, we make many other accounting estimates in preparing our financial statements and related disclosures. See Note&#160;2 to our audited consolidated financial statements presented elsewhere in this Annual Report for a description of the significant accounting policies that we used to prepare our consolidated financial statements. The critical accounting policies that were impacted by the estimates, judgments and assumptions used in the preparation of our consolidated financial statements are discussed below.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Share-based compensation</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our share-based compensation plans provide for the award of stock options and restricted stock units. We account for share-based compensation in accordance with ASC No.&#160;718, &#8220;Compensation-Stock Compensation.&#8221; ASC No.&#160;718 requires companies to estimate the fair value of equity-based payment awards on the date of grant using an Option-Pricing Model, or OPM. We recognize compensation expenses for the value of our awards granted based on the graded-vesting method in our consolidated statements of operations over the requisite service period for each separately vesting portion of the award. ASU 2016-09, Compensation-Stock Compensation (Topic 718) allows companies to account for forfeitures when they occur.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We selected the Black-Scholes-Merton option-pricing model as the most appropriate method for computing the fair value of our share-based awards, using the standard parameters established in that model including estimates relating to the fair value of our ordinary shares, volatility, estimated life of the instruments, risk-free interest rates and dividends yield as described below.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Option Valuations</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The determination of the grant date fair value of options using an option pricing-model is affected by estimates and assumptions with respect to a number of complex and subjective variables. These variables include the expected volatility of our share price over the expected term of the options, share option exercise and cancellation behaviors, risk-free interest rates and expected dividends, which are estimated as follows:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.4pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.4pt">
<div id="DSPFPageHeader" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z106a6ee41d0846edb4c9bbc5a21e589f" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 39.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.5pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">&#8226;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Fair Value of our Ordinary Shares.</font>&#160;Following our initial public offering, the fair value of our ordinary shares is determined based on the trading price of our ordinary shares on the Nasdaq Capital Market.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<table id="zb9940e123dd246fe893d10fdc61ac631" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 39.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.5pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">&#8226;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: justify">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Expected Volatility.</font>&#160; In the year ended December 31, 2018, we estimated the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">expected volatility </font>for our ordinary shares<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff"> based upon actual historical stock price movements of the share price </font>of our ordinary shares on the Nasdaq Capital Market<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff"> over the most recent periods ending on the grant date, equal to the expected term of the options. </font>In the years ended December 31, 2017 and 2016, due to the lack of history of trading information of our shares, we estimated the expected share price volatility for our ordinary shares by considering the historic price volatility for industry peers based on price observations over a period equivalent to the expected term of the share option grants. Industry peers consist of public companies in the medical device and healthcare industries.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc5222d9a9bbc41b8a247cefd520a10ed" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 39.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.5pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">&#8226;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Expected Term.</font>&#160; The expected term of options granted represents the period of time that options granted are expected to be outstanding, and is determined based on the simplified method in accordance with ASC No.&#160;718-10-S99-1 (SAB No.&#160;110), as adequate historical experience is not available to provide a reasonable estimate. ASU 2016-09, Compensation-Stock Compensation (Topic 718) permits forfeitures to be accounted for when they occur.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za605743c2714463a92e525268eab44ed" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 39.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.5pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">&#8226;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Risk-Free Rate.</font>&#160; The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with a term equivalent to the contractual life of the options.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1b98b8f1e03946efaca7395ec2b63c7c" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 39.4pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.5pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">&#8226;</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Expected</font> <font style="FONT-STYLE: italic">Dividend</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic"><font style="FONT-STYLE: italic"> </font>Yield.</font>&#160; We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero.</div>
</td>
</tr>
</table>
</div>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If any of the estimates and assumptions used in the Black-Scholes-Merton option-pricing model will change significantly, our share-based compensation for future awards may differ materially from those projected and recorded previously.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">63</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The fair value for options granted in 2018, 2017 and 2016 is estimated at the date of grant using a Black-Scholes-Merton option-pricing model with the following assumptions:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z4b3a9c36f3504edfad0dd05d0b72ecc3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 54.88%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Parameters</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 14.04%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Year 2018 Grants</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 13.59%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Year 2017 Grants</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Year 2016 Grants</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 54.88%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Expected volatility (in %)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 14.04%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">104-108</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 13.85%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">58-60</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.86%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">59-60</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 54.88%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Expected term (in years)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 14.04%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">5.5-7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 13.85%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">5.5-7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.86%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">5.5-7</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 54.88%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Risk free interest rate (in %)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 14.04%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">2.67-3.15</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 13.85%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">1.9-2.2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.86%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">1.2-2.1</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 54.88%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Anticipated rate of dividends (in %)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 14.04%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 13.85%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.86%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 54.88%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Share Price&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 14.04%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">$3.24-$9.07</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 13.85%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">$15.96-$26.40</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.86%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">$26.64-$38.40</div>
</td>
<td style="WIDTH: 0.07%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For information regarding share-based awards granted to employees and non-employees during the years ended December 31, 2018, 2017 and 2016, as well as the estimated fair value of the underlying ordinary shares on the grant date, see Note 10 to our audited consolidated financial statements presented elsewhere in this Annual Report.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Royalties provision</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Provision for royalties to an ASIC designer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In December 2007, we entered into an agreement for the development of an application specific integrated circuit, or ASIC, component to be used as an amplifier for the capture of signals at low frequencies from X-ray detectors contained in our product. The ASIC developer is entitled to receive royalties from us in the amount of &#8364;0.5 (approximately $0.57) for every ASIC component that we will sell, up to &#8364;200,000 (approximately $229,000). The net present value of the royalty liability to the ASIC designer is dependent upon our management estimates and assumption as to future product shipments and interest rates used to calculate the present value of the cash payments required to repay the royalties to the ASIC designer. In calculating the present value of future royalty payments to the ASIC designer, we used a discount factor of 17.6%, commensurate with our risk at the date of initial recognition of the liability. Any updates in the expected product shipments and the liability will be recorded to profit and loss each period. As of December 31, 2018, it was probable that we will be required to&#160;pay the above mentioned royalties, and accordingly, a liability for this reimbursement has been accounted for in our financial statements in the amount of $120,000.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Reimbursement liability to Check-Cap LLC unitholders</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">On May 31, 2009, we entered into an asset transfer agreement with Check-Cap LLC pursuant to which Check-Cap LLC transferred all of its business operations and substantially all of its assets to us. In connection with the transaction we undertook to reimburse the unitholders of Check-Cap LLC for any tax burdens that may be imposed on them due to the reorganization. The reimbursement liability is calculated assuming deemed royalties are paid to the U.S. unitholders of Check-Cap LLC under Section 367(d) of the Code, and is based in part on our forecasted sales with a cap calculated as the fair value of the share as determined at the date of the financial statements. The reimbursement liability is calculated by multiplying the estimated tax rate by the lowest of: (1) expected cash outflows discounted using a discount factor commensurate with the risk of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our company, and</font> (2) value of the shares held by U.S. unit holders of the Predecessor Entity as of December 31, 2018 <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">multiplied</font> by $2.1, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">the last reported sale price per share of </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">our</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff"> ordinary shares on the Nasdaq Capital Market on December 31, 2018</font>. Changes in the liability is recorded to profit and loss each period. As of December 31, 2018, the balance of the reimbursement liability totaled $65<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,000.</font> Due to the fact that we are still in the development stage and have not generated revenues, the sales forecast is highly subjective and may vary significantly in the future. As more information is gathered to assist our management in making forecasts, the liability will be updated.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Recent Accounting Pronouncements</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-02 &#8220;Leases (Topic 842)&#8221;. The purpose of this amendment requires the recognition of lease assets and lease liabilities by lessees for those leases previously classified as operating leases. The amendments in this ASU are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption was permitted. We do not believe that this guidance will have a material impact on our consolidated results of operations, financial position or disclosures.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In June 2018, the FASB issued ASU 2018-07, &#8220;Compensation&#8212;Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting&#8221;. The purpose of this amendment is to address aspects of the accounting for nonemployee share-based payment transactions. The amendments in this ASU are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption was permitted. We do not believe that this guidance will have a material impact on our consolidated results of operations, financial position or disclosures</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">JOBS Act Exemption</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The JOBS Act permits an &#8220;emerging growth company,&#8221; such as us, to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We chose to &#8220;opt out&#8221; of this provision and, as a result, we comply with new or revised accounting standards as required when they are adopted. This decision to opt out of the extended transition period under the JOBS Act was irrevocable.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zeb22202fc9a344aca7db1f8997a8a84a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Research and development, patents and licenses, etc.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For a description of our research and development programs and the amounts that we have incurred over the last three years pursuant to those programs, see Item 4B &#8220;Information on Our Company&#8212;Business Overview&#8212;Research and Development.&#8221;</div>

<br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">64</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9b1e7f374aa849059e67b2460c2de111" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Trend Information</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our results of operations and financial condition may be affected by various trends and factors discussed in Item 3D &#8220;Key Information&#8212;Risk factors,&#8221; Item 4 &#8220;Information on Our Company&#8221; and elsewhere in this Item 5 &#8220;Operating and Financial Review and Prospects&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0ae65865d24a4514ae983fc0128f3985" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">E.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Off-balance Sheet Arrangements</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We do not have any material off-balance sheet arrangements.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2e862ff8cebb4fc98f400b943041eb08" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">F.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Tabular Disclosure of Contractual Obligations</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following table summarizes our contractual obligations as of December 31, 2018:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z532cb228df1f47e3ac0d9d6da9c3304b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: middle; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="18">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Payments due by period</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: middle; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: middle; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="18">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(US$ in thousands)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Total</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Less than 1</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">year</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">1-3 years</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">4-5 years</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">More than 5</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">years</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Operating lease obligations<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup>:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">446</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">180</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">233</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">33</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Other long-term liabilities reflected on the Statements of Financial Position:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Royalties to ASIC designer<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">120</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">120</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Reimbursement liability to&#160;Check-Cap LLC unitholders</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160; (3)</sup></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">65</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">30</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">35</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 40%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Total&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">631</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">180</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">233</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">183</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">35</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 20.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -20.9pt">_____________________</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z505c71d8cf924ff0839606d54b54a67c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(1)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Operating lease obligations consist of payments pursuant to a lease agreement for office facilities as well as lease agreements for vehicles, which generally run for a period of three years.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za1986468212c4539a01aee85ff6754d9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(2)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">See Item 5B &#8220;Operating and Financial Review and Prospects&#8212;Liquidity and Capital Resources&#8212;Application of Critical Accounting Policies and Estimates&#8212;Royalties provision&#8212;Provision for royalties to an ASIC designer.&#8221;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf8cef1c3e52f41d9a8a81584aeaad815" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.06%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(3)</div>
</td>
<td style="WIDTH: 96.94%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">See Item 5B &#8220;Operating and Financial Review and Prospects&#8212;Liquidity and Capital Resources&#8212;Application of Critical Accounting Policies and Estimates&#8212;Royalties provision&#8212;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic"> Reimbursement liability to Check-Cap LLC unitholders</font>.&#8221;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM6" name="ITEM6"><!--Anchor--></a>ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb5ccc5fa276041e2bf4e31e805f1aa7c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Directors and senior management</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following table sets forth information for our executive officers and directors as of the date of this Annual Report. Unless otherwise stated, the address for our directors and executive officers is c/o Check-Cap Ltd., 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, 3009000, Israel.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3683d22166854ebdb5a460e20e6e659f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 35.4%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Name</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Age</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 51.41%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Position(s)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Alex Ovadia &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">57</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 51.41%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Chief Executive Officer</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.4%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Mira Rosenzweig<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>(1)</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">47</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 51.41%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incoming Chief Financial Officer</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Yoav Kimchy&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">58</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 51.41%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Chief Technology Officer</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Boaz Shpigelman&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">47</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 51.41%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Vice President, Research and Development</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Steven Hanley (2)(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">51</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 51.41%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Chairman of the Board of Directors</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Clara Ezed (4)(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">47</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 51.41%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Director</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Mary Jo Gorman (2)(3)(4)(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">59</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 51.41%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Director</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.4%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">XiangQian (XQ) Lin&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">35</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 51.41%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Director</div>
</td>
</tr>

<tr>
<td style="WIDTH: 35.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Yuval Yanai (2)(3)(4)(5)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 10.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">66</div>
</td>
<td style="WIDTH: 1.4%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 51.41%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Director</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">&#160;</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top" colspan="5">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"></div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5b80475b4764467a80ed051edfd350e6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(1)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">On February 28, 2019, we appointed Mr. Kochav as our Interim Chief Financial Officer. On March 18, 2019, we announced that Mira Rosenzweig will serve as our Chief Financial Officer, effective as of April 28, 2019. Concurrently with Ms. Rosenzweig&#8217;s appointment as our Chief Financial Officer, Mr. Kochav will discontinue serving as our Interim Chief Financial Officer.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6029d170eab241a688f39f1900f680db" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(2)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Member of our Nominating&#160;Committee.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z51d4cf778edb440e809c89c7a01cbca2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(3)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Member of our Financing Committee.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(4)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Member of our Compensation Committee.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6c27b841f30c4494bc28ae594b94642f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(5)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Member of our Audit Committee.</div>
</td>
</tr>
</table>
</div>

<br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">65</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Executive Officers and Directors</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Alex Ovadia</font> has served as our Chief Executive Officer since February 26, 2018.&#160; Mr. Ovadia has served as a member of the Board of Directors of our U.S. subsidiary, Check-Cap US, Inc., since March 2018. Prior to that, Mr. Ovadia served as our Chief Operating Officer and Israeli Site Manager since July 1, 2015, in addition to serving as our Vice President of Research and Development since January 2013.&#160; Mr. Ovadia has more than 25 years of experience leading global operations, in addition to worldwide management of complex projects.&#160; From 2001 to 2012, Mr. Ovadia served in various positions as global director and senior manager for CT research and development at Philips Healthcare &#8211; CT Systems.&#160; Mr. Ovadia was also appointed as a member of Global CT R&amp;D staff and as a member of management of Philips Medical System Technologies Ltd.&#160; Prior to that, from 1990 to 2001, Mr. Ovadia served as project/systems engineering manager for large scale military projects, mainly aircraft upgrades for U.S. and European governments performed by Elbit Systems Ltd.&#160; Mr. Ovadia holds a BSc degree in electrical engineering from the Technion-Israel Institute of Technology.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Niv Kochav</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, aged 48, has served as our Interim Chief Financial Officer since February 28, 2019, and will discontinue serving as our Interim Chief Financial Officer upon the appointment of Ms. Mira Rosenzweig as our Chief Financial Officer on April 28, 2019. Since 2016, Mr. Kochav serves as the Chief Financial Officer of PRS Geo-Tech Technologies Ltd. From 2014 to 2016, Mr. Kochav served as the Chief Financial Officer of Elbatech Group Ltd. Prior to that, Mr. Kochav served in a variety of financial roles including Chief Financial Officer of Scope Metals Group Ltd, Director of Finance of NDS Technologies Israel Ltd., and was an auditor at Somech-Haikin, KPMG. Mr. Kochav holds a BA in Accounting and Finance from the Academic College of Tel Aviv-Jaffa, Israel and an MBA from the College of Management in Rishon LeZion, Israel. Mr. Kochav is a certified public accountant in Israel.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Mira Rosenzweig </font>will serve as our Chief Financial Officer effective as of April 28, 2019. Ms. Rosenzweig has over 20 years of executive financial management experience, most recently serving as Chief Financial Officer of Entera Bio Ltd. (Nasdaq: ENTX) since May 2014.&#160; Prior to Entera Bio, from May 2013 to April 2014, Ms. Rosenzweig served as Chief Financial Officer of privately-held Paskal Technologies and, before that, from September 2008 to November 2011, as Vice President and Chief Financial Officer of Camtek Ltd. (Nasdaq: CAMT). Prior to that, Ms. Rosenzweig served in various finance roles including at Elron Electronic Industries Ltd. (TASE: ELRN). Ms. Rosenzweig began her career as a senior accountant at Luboshitz Kasierer, which is now part of Ernst &amp; Young. Ms. Rosenzweig holds a Bachelor of Arts in Accounting and Economics from the University of Haifa, Israel, and is a Certified Public Accountant (Israel).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Yoav Kimchy </font>has served as our Chief Technology Officer since our inception in April 2009 and served as a member of our board of directors from 2009 and until December 1, 2015. Dr. Kimchy founded Check-Cap LLC in December 2004, serving as its president and chief executive officer until March 2008, and as its president and chief technical officer since March 2008. Dr. Kimchy has also served as a member of the board of directors of Check-Cap Ltd. (Delaware), the manager of Check-Cap LLC, since December 2004. Between 2005 and 2012, Dr. Kimchy also served as our vice president of research and development. Between 2000 and 2003, Dr. Kimchy served as the vice president of research and development of V-Target Ltd. (Israel), a medical device company developing gamma imaging applications. Prior to that, from 1998 to 2000, Dr. Kimchy served as the Director of Cardiovascular Research at Impulse Dynamics Ltd. (Israel), a medical device company developing a unique therapeutic pulsing technology for chronic heart failure. From 1994 to 1998, Dr. Kimchy served as a systems engineer and algorithm specialist for an Israeli government contract project with the Israeli Navy. Dr. Kimchy also served as a lieutenant in the Israeli Navy. Dr. Kimchy holds a B.Sc. degree in physics and mathematics from the Hebrew University of Jerusalem, an M.Sc. degree in biomedical engineering from Tel Aviv University and a PhD from the Technion-Israel Institute of Technology.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Boaz Shpigelman</font> has served as our Vice President, Research and Development since March 2018.&#160; From 2012 to 2018, Mr. Shpigelman served as our director of development.&#160; From 2007 to 2012, Mr. Shpigelman served as R&amp;D&#160;Manager at Orsan Medical Technologies Ltd., which develops technologies for&#160;brain monitoring, with particular attention&#160;to intracranial pressure and its influence on cerebral perfusion. From 2003 to 2007, Mr. Shpigelman served as Vice R&amp;D Manager at GI-View, a medical company that developed a single use auto maneuvering colonoscopy. From 1993 to 2003, Mr. Shpigelman held various positions at Scitex/Creo, a company that developed devices for the graphic art field, initially as a hardware/software developer and subsequently as a director in the input division.&#160; Mr. Shpigelman holds a BSc in Electrical Engineering from the Technion-Israel Institute of Technology.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Steven Hanley</font>&#160;has served as a member of our Board of Directors since February 2015 and as the Chairman of our Board of Directors since September 2017, and has served as a member of our <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Nominating</font> Committee since <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">October</font> 2015 and as a member of our Financing Committee since June 2016.&#160; Mr. Hanley served as a member of our Audit Committee from March 2015 until December 2017 and as a member of our <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Compensation</font> Committee from <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">March</font> 2015 until March 2019. Mr. Hanley is currently the Co-Founder, board member and Chief Executive Officer of MediBeacon Inc., an optical diagnostic company based in St. Louis, Missouri formed upon acquiring assets and intellectual property from Covidien in 2012.&#160; Mr. Hanley is an experienced global business leader who has managed highly complex pharmaceutical and medical device operations with annual global revenue exceeding $1 billion.&#160; As the President of Covidien plc&#8217;s Imaging Solutions business unit, Mr. Hanley led a multifunctional organization that included sales, marketing, logistics, manufacturing, as well as research and development.&#160; Internationally, Mr. Hanley&#8217;s track record includes numerous new drug and device product introductions and sales force expansion in Eastern Europe, China and Latin America.&#160;Mr. Hanley is experienced working in different cultures and successfully navigating dynamic regulatory environments.&#160; Over his nearly 18 years with the Covidien family of companies, Mr. Hanley developed a large network of business leaders and clinicians to help determine market needs, commercial potential and product positioning.&#160; As a sales leader, Mr. Hanley called on radiologists, nuclear medicine physicians, cardiologists, as well as surgeons in specialties including general, orthopedic, and OB/GYN.&#160; Mr. Hanley is Principal and Founder of Neem LLC, which was founded in 2009 to focus on startup and entrepreneurial medical device and other life science companies with whom the firm works to bridge the gap between breakthrough technology and commercialization.&#160; Mr. Hanley is the Chairman of the Board of Managers for Daya CNS LLC, based in St Louis Missouri.&#160; In addition, Mr. Hanley is currently on the Advisory Board for Kogent Surgical LLC, based in St Louis Missouri.&#160; Mr. Hanley provided consultancy services to us on behalf of Neem LLC from November 2009 until December 31, 2014 and served as a Scientific Advisor to our company from June 2011 until his election to our Board of Directors in February 2015. Mr. Hanley holds B.A. and M.A. degrees in business administration from Marquette University.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">66</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Clara Ezed </font>has served as a member of our Board of Directors since June 2017, and has served as a member of our Audit Committee since December 2017 <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and as a member of our Compensation Committee since March 2019</font>. Ms. Ezed has served as VP, Legal &amp; Regulatory Affairs of Emas Pharma Ltd., a global contract research organization, since October 2013. From September 2009 to October 2013, Ms. Ezed served as VP, Regulatory Affairs &amp; Drug Safety of European Medical Advisory Services Ltd., a global contract research organization. Since 2011, Ms. Ezed has served as a director of a privately listed company, Sebaroyale Ltd, focused on the development and commercialization of a range of cosmeceuticals. Ms. Ezed, a lawyer and pharmacist with nearly 20 years&#8217; experience working in the pharmaceutical industry, has managed a large and varied portfolio working in regulatory and medical affairs, quality assurance, clinical operations and pharmacovigilance. Ms. Ezed holds a BSc. in Pharmacy from the University of Strathclyde, an MBA degree from Middlesex University, a Postgraduate Diploma in Pharmacovigilance from the University of Hertfordshire, a Postgraduate Diploma in Law from Nottingham University and a Postgraduate Diploma in Legal Professional Services from City Law School, London. Ms. Ezed is a member of the Bar of England and Wales.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Dr. Mary Jo Gorman</font>&#160;has served as a member of our Board of Directors (initially as an external director (within the meaning of the Israeli Companies Law and since June 2017, as an ordinary (non-external) director) and as a member of our Audit Committee and Compensation Committee since May 2015, and has served as a member of our Financing Committee since June 2016. Dr. Gorman serves as Managing Director at Prosper Capital, an early stage investment fund focused on women-led businesses. From 2006 to present, Dr. Gorman also serves as Founder of Advanced ICU Care, the largest telemedicine ICU services provider in the United States, in which she also served as Chairman and Chief Executive Officer from 2006 and 2014. From December 2016 to present, Dr. Gorman also serves as interim CEO and as a member of the audit committee of TripleCare, a U.S provider of telemedicine-based healthcare services to skilled nursing facilities. From 1999 to 2006, Dr. Gorman served at IPC-The Hospitalist Company (Nasdaq:IPCM), a leading national physician group practice, as Chief Medical Officer (2003-2006), Vice President of Medical Affairs (2001-2003) and Regional Medical Director (1999-2001). From 1996 to 1998, Dr. Gorman served as President of Inpatient Care Group, a hospitalist group in St. Louis, Missouri, which she had founded to provide hospitalist services to primary care physicians and hospitals and which was subsequently sold to IPC. From 1991 to 2008, Dr. Gorman served as President of Critical Care Services, Inc., a privately held corporation which she had founded and which was later sold to Advanced ICU Care. Dr. Gorman was awarded with the following awards: 2015 Distinguished Alumni Award, Southern Illinois University School of Medicine; 2013 Distinguished Alumni Award, Olin School of Business, Washington University; 2011 EY Entrepreneurial Winning WomenTM Class of 2011; 2009 Top 25 Influential Women in Healthcare by Modern HealthCare Magazine. Dr. Gorman holds a B.A. degree in Chemistry and Biology (Cum Laude) from St. Louis University, an M.B.A degree from Olin School of Business, Washington University and an M.D. from Southern Illinois University School of Medicine.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">XiangQian (XQ) Lin</font>&#160;has served as a member of our Board of Directors, since February 2015.&#160; Mr. Lin has served as the Group President and Chief Executive Officer of the Esco Group of Companies, a leading global life sciences and medical equipment manufacturer based in Singapore, since February 2011.&#160;Since 2014, Mr. Lin has also served as the Managing Partner of Esco Ventures, a corporate VC and venture creation arm of the Esco Group of Companies, focused on early stage investments in biotech and med-tech start-ups, since he founded it in August 2014. From January 1997 until February 2011, Mr. Lin held various positions, lastly as Vice President, of Esco Micro Pte Ltd., a family business which he re-engineered into a successful life sciences tools company when he established the Esco Biotech unit in 2000.&#160;From January 2007 to December 2010, Mr. Lin also served as the President of Esco Technologies, Inc., a wholly-owned U.S. subsidiary of Esco Micro Pte Ltd., which he established following a buy-out of a joint venture partner.&#160;Mr. Lin is the only non-U.S. member of the US NSF Standard 49 Joint Committee. Mr. Lin holds a BSc degree in Economics from the Wharton School, University of Pennsylvania.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Yuval Yanai</font>&#160;has served as a member of our Board of Directors since March 2015 (initially as an external director (within the meaning of the Israeli Companies Law) and since June 2017, as an ordinary (non-external) director) and has served as the Chairman of our Audit Committee and Compensation Committee since March 2015, as the Chairman of our Nominating Committee since October 2015 and as the Chairman of our Financing Committee since June 2016. Mr. Yanai served as Senior Vice President and Chief Financial Officer of Given Imaging Ltd. from September 2005 through March 2014. From October 2000 through August 2005, Mr. Yanai served as Senior Vice President and Chief Financial Officer of Koor Industries Ltd., one of Israel&#8217;s largest holding companies. Prior to that, from April 1998 to September 2000, Mr. Yanai served as Vice President and Chief Financial Officer of NICE Systems Ltd., an Israeli global provider of Insight from Interactions, and, from 1991 to April 1998, he served as the Vice President, Finance and Chief Financial Officer of Elscint Ltd., a former Israeli company engaged in the developing and manufacturing of medical imaging devices that was acquired by larger companies in this field. Mr. Yanai joined Elscint in 1985 and served as Corporate Controller and Corporate Treasurer through 1991. Mr. Yanai also serves as an external director (within the meaning of the Israeli Companies Law) of Haddasah Medical Organization, and serves as the Chairman of its finance and compensation committees and as a member of its donation committee.&#160; Mr. Yanai also serves as an external director (within the meaning of the Israeli Companies Law) of S&amp;P Global Maalot. Mr. Yanai also serves as an external director (within the meaning of the Israeli Companies Law) of Clal Biotechnology Industries and serves as the Chairman of its audit and financial reporting committees, and as a member of its compensation committee. Mr. Yanai also serves as the chairman of the board of directors of Endobetix Ltd., and as a member of the board of directors of Efranat Ltd. Nobio Ltd. and BRH Medical Ltd.&#160; Previously, Mr. Yanai served as an external director (within the meaning of the Israeli Companies Law) of Mazor Robotics Ltd. and Medical Compression Systems Ltd., as well as a director of Medigus Ltd., an Israeli company whose shares are listed on the Nasdaq Global Market. Previously Mr. Yanai served as a director of Macrocure Ltd., Citycon Oj, Starplast Industries Ltd., Adama Ltd. (formerly Makteshim-Agan Industries Ltd.), ECI Telecom Ltd., Equity One, Inc., BVR Systems Ltd., Tadiran Communication Ltd., The Elisra Group, Telrad Networks Ltd. and Medical Compression Systems (D.B.N) Ltd.&#160; Mr. Yanai holds a B.Sc. degree in Accounting and Economics from Tel-Aviv University.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">67</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Arrangements Concerning Election of Directors; Family Relationships</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We are not a party to, and are not aware of, any voting agreements among our shareholders. In addition, there are no family relationships among our executive officers and directors.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Scientific Advisors</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Certain of our officers and employees, including our chief executive officer, our chief technology officer and our clinical director, consult from time to time, on an individual, as needed basis with the individuals listed below with respect to matters of scientific relevance.&#160;We refer to these individuals as our Scientific Advisors. The amount of consulting services provided by our Scientific Advisors ranges from several hours a month to several hours a year. The names and biographies of the individuals who act as our Scientific Advisors are set forth below:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Dr. Walter L. Robb</font>&#160;has served as a member of the Board of Directors of our U.S. subsidiary, Check-Cap US, Inc., since June 2017 and served as a member of our Board of Directors from May 2009 until June 2017.&#160;Dr. Robb has served as a member of the Board of Directors of Check Cap Ltd. (Delaware) and a manager of Check-Cap LLC since February 2005. Dr. Robb is the general partner of each of Counterpoint Ventures Fund LP, established in 2004, and Counterpoint Ventures Fund II LP, established in 2011. Since 1993, Dr. Robb has served as a management consultant and president of Vantage Management, Inc. a private investment and consulting firm. Dr. Robb served as a member of the boards of directors of Celgene Corporation from 1992 to 2011, and has served as a member of the board of directors of Mechanical Technology, Inc. since 2000.&#160;Dr. Robb has also served as a director in several start-up companies over the last 20 years.&#160;Until 1993, Dr. Robb served as senior vice president and director for corporate research and development for General Electric, and served on General Electric&#8217;s Corporate Executive Council from 1986 to 1993.&#160; Dr. Robb was the director of GE Medical Systems from 1973 to 1986.&#160; In September 1994, Dr. Robb received the National Medal of Technology from President Clinton for leadership in the CT and MR Imaging Industry.&#160; Dr. Robb holds a BS degree in chemical engineering from Penn State University and an MS degree and PhD in chemical engineering, both from the University of Illinois.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Prof. Nadir Arber</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>is a full Professor of Medicine and Gastroenterology. He is a holder of the Yechiel and Helen Lieber chair for Cancer Research at Tel Aviv University, Sackler School of Medicine. Prof. Arber serves as the Director of the Integrated Cancer Prevention Center (ICPC) at Tel Aviv Sourasky Medical Center in Tel Aviv. He chaired the grants committee of the Sackler School of Medicine at Tel Aviv University. Prof. Arber is the Head of Cancer Research Center, Head of Djerassi Oncology Center. Prof. Arber, a noted expert in the field of early detection and prevention, has been serving as the principal investigator (PI) of several international, multicenter clinical trials in the field of early detection, prevention and therapy of gastrointestinal malignancies using NSAIDs and in particular, CRC. Prof. Arber has published more than 330 publications. Prof. Arber received a MD from the Hadassah School of Medicine of the Hebrew University of Jerusalem in 1987, an MSc degree from Sackler School of Medicine, Tel Aviv University in 1991 and a MHA degree from Rekanaty School of Management, Tel Aviv University in 1991. Prof. Arber has served as a Scientific Advisor to the Company since January 2012. We have entered into a consultation service agreement with Prof. Arber who is a leading investigator in our multicenter clinical study which is held at Tel Aviv Sourasky Medical Center and other sites.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Dr. Seth A. Gross</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;is the Director of Clinical Care and Quality&#160;at the NYU Langone Health. Dr. Gross is Chief of Gastroenterology at the NYU Langone Hospital Center. His areas of interest include CRC screening and gastrointestinal malignancies. Dr. Gross is an associate editor for Gastrointestinal Endoscopy. Dr. Gross is active in both the ACG and ASGE and serves on several committees. Dr. Gross is the former president at the NYSGE. Dr. Gross is the principal investigator in our pilot study being conducted at the NYU Langone Hospital Center. Dr. Gross has a M.D. degree from the School of Medicine at Tel Aviv University and completed his gastroenterology fellowship at the Mayo Clinic College of Medicine.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5ee2305956124098b87fed94f65815fc" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Compensation of Directors and Executive Officers</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The aggregate compensation paid and share-based compensation and other payments expensed by us to our directors and executive officers with respect to the year ended December 31, 2018 was $2.5 million. This amount includes approximately $489,000 set aside or accrued to provide pension, severance, retirement or similar benefits or expenses, but does not include business travel, professional and business association dues and expenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our industry. As of December 31, 2018, (i) options to purchase 61,864 ordinary shares granted to our directors and executive officers were outstanding under our 2006 Unit Option Plan, with a weighted average exercise price of approximately $51.10 per share, (ii) options to purchase 156,602 ordinary shares granted to our directors and executive officers were outstanding under our 2015 Equity Incentive Plan and the United States Sub-Plan to our 2015 Equity Incentive Plan, with a weighted average exercise price of approximately $5.86 per share; and (iii) 68,940 restricted share units awarded to our directors and executive officers were outstanding under our 2015 Equity Incentive Plan and the United States Sub-Plan to our 2015 Equity Incentive Plan.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">68</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">At our 2018 annual general meeting held on September 13, 2018, our shareholders approved, following the approval of our Compensation Committee and Board of Directors, the payment to each of our directors the following fees: (i) an annual fee of $25,000 for service on the Board of Directors and $2,500 for service on the Audit Committee; and (ii) a per meeting fee of $850 for each meeting of the Board of Directors or any committee thereof attended in person or via telephone. In addition, our shareholders approved an annual fee of (i) $10,000 for service as Chairman of the Board of Directors (other than an Active Chairman, who may be entitled to an increased fee in accordance with our Compensation Policy) and (ii) $5,000 for service as Chairman of the Audit Committee. Our directors also benefit from directors&#8217; and officers&#8217; indemnification and exculpation agreements as well as from our directors&#8217; and officers&#8217; liability insurance policy. The directors are also entitled to reimbursement of expenses (including travel, stay and lodging), subject to the Israeli Companies Law and the regulations promulgated thereunder, and in accordance with our company practices and our Compensation Policy for Executive Officers and Directors (the &#8220;Compensation Policy&#8221;).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We do not have any written agreements with any current director providing for benefits upon the termination of such director&#8217;s relationship with us.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">To our knowledge, there are no agreements and arrangements between any director and any third party relating to compensation or other payment in connection with their candidacy or service on our Board of Directors.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The table below sets forth the compensation paid to our </font>five most highly compensated office holders<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> (within the meaning of the Israeli Companies Law), in each case during or with respect to the year ended December&#160;31, 2018.&#160; We refer to the five individuals for whom disclosure is provided herein as our &#8220;Covered Executives.&#8221;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For purposes of the table and the summary below, &#8220;compensation&#8221; includes salary cost, consultancy fees, bonuses, equity-based compensation, retirement or termination payments, benefits and perquisites such as car, phone and social benefits, to the extent applicable, and any undertaking to provide such compensation. All amounts reported in the table are in terms of cost to us, as recognized in our financial statements for the year ended December 31, 2018, plus compensation paid to such Covered Executive following the end of the year in respect of services provided during the year. Each of the Covered Executives was covered by our directors&#8217; and officers&#8217; liability insurance policy and was entitled to indemnification and exculpation in accordance with indemnification and exculpation agreements, our articles of association and applicable law.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The exchange rate that we used to calculate the &#8220;Salary Cost&#8221; of our chief executive officer, former chief financial officer and chief technology officer, as presented in the following table, was NIS&#160;3.61 to US$1.00, and is provided herein for convenience (such exchange rate is based on the average of the last-day exchange rate of each of the 12 months during 2018, as published by the Bank of Israel).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb17e89e537e649708371d2833951c74c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom"></td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Salary Cost</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Bonus</font><sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup></div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Share-Based<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Compensation<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup></div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Total</font></div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Name and Principal Position</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="14">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">US$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Alex Ovadia - Chief Executive Officer (since February 2018); former Chief Operations Officer, Israeli Site Manager and Vice President, Research and Development (4)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">367,641</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">113,998</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">21,272</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">502,912</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Lior Torem &#8211; Former Chief Financial Officer and Vice President of Operations (5)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">316,136</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">90,483</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">51,029</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">457,649</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Yoav Kimchy - </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Chief Technology Officer</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">331,844</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">90,235</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">48,214</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">470,293</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Boaz Shpigelman -Vice President, Research and Development (since March 2018); former <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">director of development </font>(6)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">206,243</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">45,683</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">36,204</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">288,130</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Israel Hershko &#8211; Director of Quality Assurance and Regulatory Affairs (7)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">171,649</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">13,682</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">16,159</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">201,490</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">_______________</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze6f2f5d852044899b304ae2eafe503fb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(1)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#8220;Salary Cost&#8221; includes the Covered Executive&#8217;s gross salary plus payment of social benefits made by us on behalf of such Covered Executive. Such benefits may include, to the extent applicable to the Covered Executive, payments, contributions and/or allocations for savings funds, education funds, pension, severance, risk insurances, payments for social security and tax gross-up payments, vacation, car, medical insurances and benefits, convalescence or recreation pay and other benefits and perquisites consistent with our policies.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(2)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">Represents bonuses for 2018 awarded to the Covered Executives, consistent with our Compensation Policy.</font></div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(3)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Represents the share-based compensation expenses recorded in our consolidated financial statements for the year ended December 31, 2018 based on the fair value of the grant date of the equity awards, in accordance with accounting guidance for equity-based compensation.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(4)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Mr. Ovadia was appointed as our Chief Executive Officer on February 26, 2018.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(5)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Mr. Torem ceased to serve as our Chief Financial Officer and Vice President of Operations on February 14, 2019.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(6)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Boaz Shpigelman was appointed as our Vice President, Research and Development in March 2018. Mr. Shpigelman served as our <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Director</font> of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Development</font> from August 2012 to March 2018.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(7)</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Israel Hershko was appointed as our Director of Quality and Regulation Director on September 2017. Mr. Hershko is not considered an executive officer, and is included in the table above solely to satisfy disclosure requirements under the Israeli Companies Law.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">69</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">The following table sets forth information with respect to the options and RSUs granted to <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">the Covered Executives for the year ended December 31, 2018.</font><br style="LINE-HEIGHT: 1.25">
 &#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div>
<div id="DSPFPageHeader">
<div id="DSPFPageHeader"></div>

<table id="z4599f23d5a6444b18b1113f3c24870a7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0" border="0">
<tr style="HEIGHT: 55px">
<td style="WIDTH: 13%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Name</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">&#160;</td>
<td style="WIDTH: 7.67%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Date of&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Grant<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup></div>
</td>
<td style="WIDTH: 1.17%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">&#160;</td>
<td style="WIDTH: 10.86%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Security Type</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">&#160;</td>
<td style="WIDTH: 12.61%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Purchase&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> Price (in NIS)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">&#160;</td>
<td style="WIDTH: 21.52%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Number of Shares </div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Underlying Award</div>
</td>
<td style="WIDTH: 1.04%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 11.18%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Expiration Date</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Total Benefit&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (in US$)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Benefit&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>recognized&#160;in&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> 2018 (in US$)</div>
</td>
<td style="WIDTH: 0.98%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 13%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Lior</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Torem</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" rowspan="2">&#160;</td>
<td style="WIDTH: 7.67%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">July 30, 2018</div>
</td>
<td style="WIDTH: 1.17%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" rowspan="2">&#160;</td>
<td style="WIDTH: 10.86%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Options</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 12.61%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">$3.92</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 21.52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">29,632</div>
</td>
<td style="WIDTH: 1.04%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 11.18%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">July 30, 2028</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">77,472</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">21,734</div>
</td>
<td style="WIDTH: 0.98%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #deeaf6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 10.86%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">RSUs</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 12.61%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 21.52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">12,699</div>
</td>
<td style="WIDTH: 1.04%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 11.18%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">41,146</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">11,543</div>
</td>
<td style="WIDTH: 0.98%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #deeaf6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 13%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Yoav</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Kimchy</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" rowspan="2">&#160;</td>
<td style="WIDTH: 7.67%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">July 30, 2018</div>
</td>
<td style="WIDTH: 1.17%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" rowspan="2">&#160;</td>
<td style="WIDTH: 10.86%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Options</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">&#160;</td>
<td style="WIDTH: 12.61%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">$3.92</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">&#160;</td>
<td style="WIDTH: 21.52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">29,632</div>
</td>
<td style="WIDTH: 1.04%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 11.18%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">July 30, 2028</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">77,472</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">21,734</div>
</td>
<td style="WIDTH: 0.98%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 10.86%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">RSUs</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">&#160;</td>
<td style="WIDTH: 12.61%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">&#160;</td>
<td style="WIDTH: 21.52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">12,699</div>
</td>
<td style="WIDTH: 1.04%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 11.18%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">41,146</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">11,543</div>
</td>
<td style="WIDTH: 0.98%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 13%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Boaz</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Shpigelman</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" rowspan="2">&#160;</td>
<td style="WIDTH: 7.67%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">July 30, 2018</div>
</td>
<td style="WIDTH: 1.17%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" rowspan="2">&#160;</td>
<td style="WIDTH: 10.86%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Options</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 12.61%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">$3.92</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 21.52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">25,928</div>
</td>
<td style="WIDTH: 1.04%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 11.18%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">July 30, 2028</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">67,788</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">19,017</div>
</td>
<td style="WIDTH: 0.98%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #deeaf6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 10.86%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">RSUs</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 12.61%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ; BACKGROUND-COLOR: #cceeff">&#160;</td>
<td style="WIDTH: 21.52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">11,112</div>
</td>
<td style="WIDTH: 1.04%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 11.18%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">36,002</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">10,100</div>
</td>
<td style="WIDTH: 0.98%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #deeaf6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 13%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Israel </div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Hershko</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" rowspan="2">&#160;</td>
<td style="WIDTH: 7.67%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" rowspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">July 30, 2018</div>
</td>
<td style="WIDTH: 1.17%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" rowspan="2">&#160;</td>
<td style="WIDTH: 10.86%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Options</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">&#160;</td>
<td style="WIDTH: 12.61%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">$3.92</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">&#160;</td>
<td style="WIDTH: 21.52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">11,112</div>
</td>
<td style="WIDTH: 1.04%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 11.18%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">July 30, 2028</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">29,052</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">8,150</div>
</td>
<td style="WIDTH: 0.98%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 10.86%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">RSUs</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">&#160;</td>
<td style="WIDTH: 12.61%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BORDER-BOTTOM-COLOR: ">&#160;</td>
<td style="WIDTH: 21.52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">4,762</div>
</td>
<td style="WIDTH: 1.04%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 11.18%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">15,430</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 8%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">4,329</div>
</td>
<td style="WIDTH: 0.98%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>
</div>

<table id="ze2577f3d0d954ba2baa61aaffcf40f31" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 100%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">__________________________</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.07%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(1)</div>
</td>
<td style="WIDTH: 96.93%; VERTICAL-ALIGN: top">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">All options and RSUs granted to </font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">the Covered Executives</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> in fiscal year 2018 vest over a three-year period</font> commencing on their date of grant, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">such that</font> 33.33% of the award shall vest on the first anniversary of the date of grant and an additional 8.33% will vest at the end of each subsequent three-month period thereafter, subject to each executive officer&#8217;s continuing service in such capacity on each applicable vesting date<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Employment Agreements with Executive Officers</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have entered into written employment agreements with each of our executive officers.&#160;These agreements contain standard provisions for a company in our industry regarding non-competition, confidentiality of information and assignment of inventions.&#160;The enforceability of covenants not to compete in Israel and the United States is subject to limitations.&#160;For example, Israeli courts have recently required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts, such as the secrecy of a company&#8217;s confidential commercial information or its intellectual property.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We entered into an Employment Agreement dated as of December 27, 2012, as amended, with Alex Ovadia, or Mr. Ovadia&#8217;s Employment Agreement, pursuant to which Mr. Ovadia served as our Vice President of Research and Development, Israeli Site Manager and Chief Operations Officer until February 26, 2018. Effective as of February 26, 2018, Mr. Ovadia was appointed as our Chief Executive Officer and Mr. Ovadia&#8217;s Employment Agreement was amended accordingly, effective as of such date.&#160; The terms of Mr. Ovadia&#8217;s engagement in his capacity as our Chief Executive Officer were approved by our shareholders at the extraordinary general meeting of shareholders held on April 2, 2018. Mr. Ovadia&#8217;s Employment Agreement, as currently in effect, may be terminated by either us or Mr. Ovadia upon 90 days&#8217; prior notice to the other party. Pursuant to Mr. Ovadia&#8217;s Employment Agreement, we also have the right to immediately terminate Mr. Ovadia&#8217;s employment for &#8220;Cause&#8221; (as defined in Mr. Ovadia&#8217;s Employment Agreement). Pursuant to Mr. Ovadia&#8217;s Employment Agreement, Mr. Ovadia is entitled to a salary of $240,000 per annum, which is paid in NIS based on an exchange rate of $1= NIS 3.85.&#160; In addition, Mr. Ovadia may be entitled to an annual bonus of up to 30% of his annual salary subject to receipt of requisite approvals. Payment of the annual bonus shall be subject to the achievement of certain milestones determined by the Compensation Committee and Board of Directors.&#160; Mr. Ovadia&#8217;s Employment Agreement also contains confidentiality, intellectual property, and non-competition and non-solicitation provisions.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We entered into an Employment Agreement dated as of September 17, 2014, as amended from time to time, with Yoav Kimchy, or Mr. Kimchy&#8217;s Employment Agreement, pursuant to which Mr. Kimchy serves our Chief Technology Officer. Mr. Kimchy&#8217;s Employment Agreement may be terminated by either us or Mr. Kimchy upon 120 business days&#8217; prior notice to the other party. Pursuant to Mr. Kimchy&#8217;s Employment Agreement, we also have the right to immediately terminate Mr. Kimchy&#8217;s employment for &#8220;Cause&#8221; (as defined in Mr. Kimchy&#8217;s Employment Agreement) or if Mr. Kimchy is unable to perform his duties for a period of two consecutive months by reason of illness or accident. Pursuant to Mr. Kimchy&#8217;s Employment Agreement, Mr. Kimchy is entitled to a salary of NIS 941,400 ($260,776) per annum. In addition, Mr. Kimchy may be entitled to an annual bonus of up to 30% of his annual salary, subject to receipt of requisite approvals. Payment of the annual bonus shall be subject to the achievement of certain milestones determined by the Compensation Committee and Board of Directors.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">70</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We entered into an Employment Agreement dated as of March 30, 2018, with Boaz Shpigelman, as amended from time to time, or Mr. Shpigelman&#8217;s Employment Agreement, pursuant to which Mr. Shpigelman serves as our Vice President, Research and Development. Mr. Shpigelman&#8217;s Employment Agreement may be terminated by either us or Mr. Shpigelman upon 30 days&#8217; prior notice to the other party. Pursuant to Mr. Shpigelman&#8217;s Employment Agreement, we also have the right to immediately terminate Mr. Shpigelman&#8217;s employment for &#8220;Cause&#8221; (as defined in Mr. Shpigelman&#8217;s Employment Agreement). Pursuant to Mr. Shpigelman&#8217;s Employment Agreement, Mr. Shpigelman is entitled to a salary of NIS 540,540 ($149,734) per annum. Mr. Shpigelman&#8217;s Employment Agreement also contains confidentiality, intellectual property, and non-competition and non-solicitation provisions.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We entered into an Employment Agreement effective as of April 28, 2019 with Mira Rosenzweig, or Ms. Rosenzweig&#8217;s Employment Agreement, pursuant to which Ms. Rosenzweig will serve as our Chief Financial Officer. Ms. Rosenzweig&#8217;s Employment Agreement may be terminated by either us or Ms. Rosenzweig upon 90 days&#8217; prior notice to the other party.&#160; Pursuant to Ms. Rosenzweig&#8217;s Employment Agreement, we also <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">have</font> the right to immediately terminate Ms. Rosenzweig&#8217;s employment for &#8220;cause&#8221; (as described in Ms. Rosenzweig&#8217;s Employment Agreement).&#160; Pursuant to Ms. Rosenzweig&#8217;s Employment Agreement, Ms. Rosenzweig is entitled to a salary of NIS 660,000 ($<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">182,825</font>) per annum. In addition, Ms. Rosenzweig may be entitled to an annual bonus of up to 25% of her annual salary, based on <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">our</font> evaluation of Ms. Rosenzweig&#8217;s performance and subject to receipt of customary approvals.&#160; Ms. Rosenzweig&#8217;s Employment Agreement also contains confidentiality, intellectual property, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and </font>non-competition and non-solicitation provisions.<br style="LINE-HEIGHT: 1.25">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">Our agreements with our executive officers do not provide for benefits upon the termination of their respective employment with us, other than payment of salary and benefits during the required notice period for termination of these agreements, which varies under these individual agreements.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Agreements with Former CFO</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We entered into an Employment Agreement dated May 1, 2010, as amended, with Lior Torem, or Mr. Torem&#8217;s Employment Agreement, and also a Consulting Agreement dated as of September 9, 2012 with L.T. Factor Ltd., or the Consultant, of which Lior Torem is manager and sole shareholder, or the Consulting Agreement. Mr. Torem&#8217;s employment as our Chief Financial Officer ended on February 14, 2019. We refer to Mr. Torem&#8217;s Employment Agreement and the Consulting Agreement collectively as the &#8220;Torem Agreements.&#8221; Mr. Torem served as our Chief Financial Officer and Vice President of Operations pursuant to the Torem Agreements.&#160; The Torem Agreements allowed for termination by either us, the Consultant or Mr. Torem upon 90 days&#8217; prior notice to the other party. Pursuant to the Torem Agreements, Mr. Torem was entitled to a salary of NIS 881,640 ($249,208) per annum. In addition, Mr. Torem was entitled to an annual bonus of up to 25% of his annual salary, subject to receipt of requisite approvals. Payment of the annual bonus was subject to the achievement of certain milestones determined by the Compensation Committee and Board of Directors. The Torem Agreements also contained confidentiality, intellectual property, and non-competition and non-solicitation provisions.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zea46fe6a3cbb4559a42c202ccad55162" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Board Practices</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Board of Directors</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law, the management of our business, including strategy and policies, is vested in our board of directors. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors. Our chief executive officer is appointed by, and serves at the discretion of, our board of directors, subject to the employment agreement that we have entered into with him. All other executive officers are appointed by our chief executive officer, and are subject to the terms of any applicable employment agreements that we may enter into with them.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under our amended articles of association, our board of directors must consist of at least four and not more than eleven directors, including the external directors (if external directors serve on the board of directors).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our Board of Directors currently consists of five members, four of whom satisfy the independence requirements of the Nasdaq Listing Rules, such that we comply with the Nasdaq Listing Rule that requires that a majority of our board of directors be comprised of independent directors, within the meaning of Nasdaq Listing Rules.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">71</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our directors are elected by the general meeting of our shareholders by the vote of a majority of the ordinary shares present, in person or by proxy, and voting at that meeting. Each director will hold office until the first annual general meeting of shareholders following his or her appointment, unless the tenure of such director expires earlier pursuant to the Israeli Companies Law or unless he or she is removed from office as described below. In addition, our amended articles of association allow our board of directors to appoint directors (other than the external directors) to fill vacancies on our board of directors, for a term of office equal to the remaining period of the term of office of the director(s) whose office(s) have been vacated.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We rely on the exemption available to foreign private issuers under the Nasdaq Listing Rules and follow Israeli law and practice with regard to the process of nominating directors, in accordance with which our board of directors (or a committee thereof) is authorized to recommend to our shareholders director nominees for election.&#160; In October 2015, our Board of Directors established a non-independent Nominating Committee, whose role is to select and recommend to the Board of Directors for selection, director nominees, while considering the appropriate size and composition of the Board of Directors, the requirements applicable to all members of the Board of Directors and the criteria for the selection of new members of the Board of Directors.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law and our amended articles of association, nominations for directors may also be added to the agenda of a future general meeting of shareholders, at the request of any one or more shareholders holding at least 1% of our outstanding voting power. Any director nominated by a shareholder is required to certify to us, as required by all director nominees, that he or she meets all the requirements of the Israeli Companies Law for election as a director of a public company, and possesses the necessary qualifications and is able to dedicate sufficient time, to fulfill his or her duties as a director of our company, taking into consideration our company&#8217;s size and special needs.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt">Under the Israeli Companies Law, our board of directors must determine the minimum number of directors who are required to have accounting and financial expertise (as defined in regulations promulgated under the Israeli Companies Law). In determining the number of directors required to have such expertise, our board of directors must consider, among other things, the type and size of the company and the scope and complexity of its operations. Our board of directors has determined that the minimum number of directors of our company who are required to have accounting and financial expertise is one.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">External Directors</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law, companies incorporated under the laws of the State of Israel that are &#8220;public companies,&#8221; must appoint at least two external directors who meet the qualification requirements in the Companies Law.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">However, under a recent amendment to regulations promulgated under the Israeli Companies Law, Israeli companies whose shares are listed on certain stock exchanges outside of Israel (including the Nasdaq Capital Market) with no controlling shareholder (within the meaning of the Israeli Companies Law), such as ourselves, that satisfy the requirements of the laws in the foreign jurisdiction where the company&#8217;s shares are listed, as they apply to companies incorporated in such jurisdiction, with respect to the appointment of independent directors and the composition of the audit committee and compensation committee, may elect to exempt themselves from the requirements of Israeli law with respect to (i) the requirement to appoint outside directors and that one outside director serve on each committee of the board of directors authorized to exercise any of the powers of the board of directors; (ii) certain limitations on the employment or service of an outside director or his or her spouse, children or other relatives, following the cessation of the service as an outside director, by or for the company, its controlling shareholder or an entity controlled by the controlling shareholder; (iii) the composition, meetings and quorum of the audit committee; and (iv) the composition and meetings of the compensation committee.&#160; If a company has elected to avail itself from the requirement to appoint external directors and at the time a director is appointed all members of the board of directors are of the same gender, a director of the other gender must be appointed.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Following analysis of our qualification to rely on the exemption, our Board of Directors determined to adopt the exemption, subject to and effective as of the approval by our shareholders of a certain amendment to our articles of association, which was obtained at our 2017 annual general meeting held on June 22, 2017. If in the future we were to have a controlling shareholder, we would again be required to comply with the requirements relating to external directors and the composition of the audit committee and compensation committee under Israeli law.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Audit Committee</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our audit committee currently consists of Yuval Yanai, May Jo Gorman and Clara Ezed. Yuval Yanai serves as the Chairman of the audit committee.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Composition of the Audit Committee</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">According to the recent amendment to regulations promulgated under the Israeli Companies Law, Israeli companies whose shares are listed on certain stock exchanges outside of Israel (including the Nasdaq Capital Market) with no controlling shareholder (within the meaning of the Israeli Companies Law), such as ourselves, that satisfy the requirements of the laws of the foreign jurisdiction where the company&#8217;s shares are listed as they apply to companies incorporated in such jurisdiction in respect of the appointment of independent directors and the composition of the audit committee and compensation committee, may elect to exempt themselves from the requirements of the Israeli Companies Law with respect to (among other things) the composition, quorum and majority requirements at meetings of the audit committee. Following analysis of our qualification to rely on such exemption, our Board of Directors determined to adopt the exemption, subject to and effective as of the approval by our shareholders of a certain amendment to our articles of association, which was obtained at our 2017 annual general meeting held on June 22, 2017.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">72</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Nasdaq corporate governance rules, we are required to maintain an audit committee consisting of at least three independent directors, within the meaning of the Exchange Act and Nasdaq Listing Rules, each of whom must be able to read and understand fundamental financial statements, including the company&#8217;s balance sheet, income statement and cash flow statement (and one of whom has past employment experience in finance or accounting, requisite professional certification in accounting or other comparable experience or background that leads to financial sophistication) and none of whom has participated in the preparation of our or any of our subsidiary&#8217;s financial statements at any time during the prior three years.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the U.S. Securities and Exchange Commission and the Nasdaq Listing Rules. Our board of directors has determined that Mr. Yanai is an audit committee financial expert as defined by the U.S. Securities and Exchange Commission rules and has the requisite financial sophistication required by the Nasdaq Listing Rules.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Each of the members of the audit committee qualifies as an &#8220;independent director&#8221; within the meaning of Nasdaq Listing Rules and is &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, which is different from the general Nasdaq test for independence of board and committee members.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Audit Committee Role</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our board of directors adopted an audit committee charter, which became effective upon the listing of our securities on the Nasdaq Capital Market, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">as subsequently amended, </font>which sets forth the responsibilities of the audit committee consistent with the rules of the U.S. Securities and Exchange Commission and the Nasdaq Listing Rules, as well as the requirements for audit committees under the Israeli Companies Law, including the following:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8947e09c6fd54bae8f97b1817938a524" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors or shareholders for their approval, as applicable, in accordance with the requirements of the Israeli Companies Law;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">recommending the engagement or termination of the person filling the office of our internal auditor; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z448513cba42f4895a860dd2de8b4556c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors or shareholders for their approval, as applicable, in accordance with the requirements of the Israeli Companies Law.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the accountants are independent of management.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt">Under the Israeli Companies Law, our audit committee is responsible for:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z19491f7cce44499190a3d3ddcaefee59" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of directors to improve such practices;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 19.8pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z87d32d461b4c46dfb412ef06989a5e06" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest) and whether such transaction is extraordinary or material under Israeli Companies Law (see &#8220;&#8212; Approval of Related Party Transactions under Israeli Law&#8221;);</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z959d6a6d9e8d4398a97594716299367a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">determining whether a competitive process must be implemented for the approval of certain transactions with controlling shareholders or its relative or in which a controlling shareholder has a personal interest (whether or not the transaction is an extraordinary transaction), under the supervision of the audit committee or other party determined by the audit committee and in accordance with standards to be determined by the audit committee, or whether a different process determined by the audit committee should be implemented for the approval of such transactions;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 19.8pt; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">73</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9199b0134d12468686496abe6d7210a8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">determining the process for the approval of certain transactions with controlling shareholders or in which a controlling shareholder has a personal interest that the audit committee has determined are not extraordinary transactions but are not immaterial transactions;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za6f0c6ea9c124532a61645c75a589a51" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">where the board of directors approves the working plan of the internal auditor, to examine such working plan before its submission to the board of directors and proposing amendments thereto;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z29b40a0d4ffb4bad981ae04e3c730bfd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">examining our internal controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zafd3f372f55443579934de6b7f177935" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the compensation of our auditor; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc444a91f6d2b408c9a2499323219e07a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">establishing procedures for the handling of employees&#8217; complaints as to the management of our business and the protection to be provided to such employees.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Compensation Committee and Compensation Policy</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our compensation committee currently consists Yuval Yanai<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font> Mary Jo Gorman<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and Clara Ezed</font>. Yuval Yanai serves as the Chairman of the compensation committee.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Composition of Audit Committee</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">According to the recent amendment to regulations promulgated under the Israeli Companies Law, Israeli companies whose shares are listed on certain stock exchanges outside of Israel (including the Nasdaq Capital Market) with no controlling shareholder (within the meaning of the Israeli Companies Law), such as ourselves, that satisfy the requirements of the laws of the foreign jurisdiction where the company&#8217;s shares are listed as they apply to companies incorporated in such jurisdiction in respect of the appointment of independent directors and the composition of the audit committee and compensation committee, may elect to exempt themselves from the requirements of the Israeli Companies Law with respect to (among other things) the composition and meetings of the compensation committee. Following analysis of our qualification to rely on such exemption, our Board of Directors determined to adopt the exemption, subject to and effective as of the approval by our shareholders of a certain amendment to our articles of association, which was obtained at our 2017 annual general meeting held on June 22, 2017.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Nasdaq Listing Rules, we are required to maintain a compensation committee consisting of at least two directors, each of whom is an independent director within the meaning of the Nasdaq Listing Rules. Our compensation committee currently complies with the provisions of Nasdaq Listing Rules relating to composition requirements.&#160; &#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Compensation Committee Role</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our board of directors adopted a compensation committee charter, which became effective upon the listing of our shares on the Nasdaq Capital Market, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">as subsequently amended, </font>which sets forth the responsibilities of the compensation committee consistent with the Nasdaq Listing Rules and the requirements for compensation committees under the Israeli Companies Law, including the following:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd0b17f1a15b8467299cf716093ec2dba" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">recommending to the board of directors for its approval (i) a compensation policy; (ii) whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing compensation policy must in any case occur every three years); and (iii) periodic updates to the compensation policy. See &#8220;&#8212; Compensation Committee and Compensation Policy.&#8221; In addition, the compensation committee is required to periodically examine the implementation of the compensation policy;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z13032509cf82496ab8051589d2e6082c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the approval of the terms of employment and service of office holders (including determining whether the compensation terms of a candidate for chief executive officer of the company need not be brought to approval of the shareholders); and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5e6f3c077df14030bbc798c9b78f4670" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">reviewing and approving grants of options and other incentive awards to persons other than office holders to the extent such authority is delegated by our board of directors, subject to the limitations on such delegation as provided in the Israeli Companies Law.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Compensation Policy</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law, the duties of the compensation committee include the recommendation to the company&#8217;s board of directors of a policy regarding the terms of engagement of office holders, as such term is defined in the Israeli Companies Law, to which we refer to as a compensation policy, and any extensions and updates thereto. The compensation policy must be approved at least once every three years, first, by our board of directors, upon recommendation of our compensation committee, and second, by the shareholders by the Special Approval for Compensation (as defined below under &#8220;&#8212; Approval of Related Party Transactions under Israeli Law &#8212; Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions&#8221;).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">74</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our amended and restated Compensation Policy for Executive Officers and Directors, which was approved by our shareholders on June 22, 2017, serves as the basis for decisions concerning the financial terms of employment or engagement of our office holders, including exculpation, insurance, indemnification and any benefit, monetary payment or obligation of payment in respect of employment or engagement, including and any severance payment or benefit.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Compensation Policy must be determined and later reevaluated according to certain factors, including: (i) the advancement of a company&#8217;s objectives, business plan and its long-term strategy; (ii) the creation of appropriate incentives for executives, while considering (among other things) the company&#8217;s risk management policy; (iii) the size and the nature of the company&#8217;s operations; and (iv) with respect to variable compensation, the contribution of the office holder towards the achievement of the company&#8217;s long-term goals and the maximization of its profits, all with a long-term objective and in accordance with the position of the office holder.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In accordance with the Israeli Companies law, our Compensation Policy refers to the following factors:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1431ec1804bd4fea98760f27d699a58c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the knowledge, skills, expertise, professional experience and accomplishments of the relevant office holder;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1ece6c48623a48a68d5a32851dfc4bb4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the office holder&#8217;s roles and responsibilities and prior compensation agreements with him or her;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5a58652a15bc47d6af05d19fe1bf34d6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the ratio of the cost of the offered terms to the cost of compensation of the other employees of the company (including any employees employed through manpower companies), specifically to the cost of the average and median salaries of such employees and the impact of the disparities between them upon work relationships in the company;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z05e812c6fee94cbeb1f443a4b39e00f2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">with respect to variable compensation - the possibility of reducing variable compensation at the discretion of the board of directors, and the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z239399b3bf3f4143865f85eb7c60256a" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">with respect to severance compensation, the period of employment or service of the office holder, the terms of his or her compensation during such period, the company&#8217;s performance during such period, the person&#8217;s contribution towards the company&#8217;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, in according with the Israeli Companies Law, our Compensation Policy includes the following principles:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc89342fb8ecb4d7ea8f5507610f9bbdc" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the link between variable compensation (e.g., bonuses) and long-term performance and measurable criteria (i.e., variable compensation must be determined based on long-term performance and measurable criteria). Only &#8220;non-material&#8221; portion of variable compensation may be determined based on criteria that is not measurable, taking into account office holders&#8217; contribution to the company;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z01568145ce894f9fa869356b1c788869" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the ratio of variable to fixed compensation, and the ceiling for the value of variable compensation, which is determined at the time of payment, except that the ceiling for equity-based compensation is determined at the time of grant;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za0ba70e92e844273a5f557ba1ae62a98" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was required to be restated in the company&#8217;s financial statements;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb1d5bcf33c2047819c4a8e8594f4aef4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the minimum holding or vesting period for variable, equity-based compensation, while taking into account long-term objectives; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z4f8bfe77903f43cab492f39f1c0e5865" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">maximum limits for severance compensation.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Nominating Committee</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In October 2015, our Board of Directors established a non-independent Nominating Committee, whose role is to select and recommend to the Board of Directors for selection, director nominees, while considering the appropriate size and composition of the Board of Directors, the requirements of applicable law regarding service as a member of our Board of Directors and the criteria for the selection of new members of the Board of Directors.&#160; We rely on the exemption available to foreign private issuers under the Nasdaq Listing Rules and follow Israeli law and practice with regard to the process of nominating directors, in accordance with which our board of directors (or a committee thereof) is authorized to recommend to our shareholders director nominees for election.&#160; The Nominating Committee is currently comprised of the following directors: Yuval Yanai, Steven Hanley and Mary-Jo Gorman.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160; </font>Yuval Yanai serves as the Chairman of the Nominating Committee.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">75</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Financing Committee</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In June 2016, our Board of Directors established a financing committee, which currently consists of Steven Hanley, Yuval Yanai and Mary Jo Gorman.&#160;Our financing committee is responsible for the review, approval and oversight of any potential financings, including the negotiations of any potential financings, and to provide a recommendation to our Board of Directors concerning the approval of any potential financings.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Internal Auditor</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law, the board of directors of an Israeli public company must appoint an internal auditor recommended by the audit committee. An internal auditor may not be:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5bdd06515b9249f588a2109e6d5656d8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a person (or a relative of a person) who holds more than 5% of the company&#8217;s outstanding shares or voting rights;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zfc8edab8806c4317bd71de067634aec0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a person (or a relative of a person) who has the power to appoint a director or the general manager of the company;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze33a0244aa164f2f81bcdd1f81d5346b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">an office holder, within the meaning of the Israeli Companies Law (including a director and the general manager) of the company (or a relative thereof); or</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z4a3a3b0eb7434dd1a0359a4c62a99367" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a member of the company&#8217;s independent accounting firm, or anyone on his or her behalf.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The role of the internal auditor is to examine, among other things, our compliance with applicable law and orderly business procedures. The audit committee is required to oversee the activities and to assess the performance of the internal auditor as well as to review the internal auditor&#8217;s work plan. We have appointed Ms. Dana Gottesman Erlich of BDO as our internal auditor.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Approval of Related Party Transactions under Israeli Law</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Fiduciary Duties of Directors and Executive Officers</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Israeli Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table under &#8220;Management&#8212;Executive Officers and Directors&#8221; is an office holder under the Israeli Companies Law.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">An office holder&#8217;s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of care with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of care includes a duty to use reasonable means to obtain:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb084ece22f7d4c998171510e81a201fd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb406443835064d0a892e26968f2e1ee3" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">all other important information pertaining to any such action.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The duty of loyalty requires an office holder to act in good faith and in the best interests of the company, and includes, among other things, the duty to:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z27de7f9d092f452c9292584a1508b3d9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zdd6d2ca3bbd94adb9566625e34b34994" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">refrain from any activity that is competitive with the company;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z84c5b6f32e8b40f1a51d949c09b81abd" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb65477a598c840168632055524436b53" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder received as a result of his or her position as an office holder.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We may approve an act specified above which would otherwise constitute a breach of the office holder&#8217;s duty of loyalty, provided that the office holder acted in good faith, the act or its approval does not harm the company and the office holder discloses his or her personal interest a sufficient amount of time before the date for discussion of approval of such act.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">76</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Disclosure of Personal Interests of an Office Holder</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Israeli Companies Law requires that an office holder promptly disclose to the company any &#8220;personal interest&#8221; that he or she may be aware of and all related material information or documents concerning any existing or proposed transaction with the company. An interested office holder&#8217;s disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered. A personal interest includes an interest of any person in an act or transaction of a company, including a personal interest of such person&#8217;s relative or of a corporate entity in which such person or a relative of such person holds 5% or more of the outstanding shares or voting rights, is a director or general manager or in which he or she has the right to appoint at least one director or the general manager, but excluding a personal interest arising from one&#8217;s ownership of shares in the company. A personal interest includes the personal interest of a person for whom the office holder holds a voting proxy or the personal interest of the office holder with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such shareholder has no personal interest in the matter. An office holder is not, however, obliged to disclose a personal interest if it derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction. Under the Israeli Companies Law, an extraordinary transaction is defined as any of the following: a transaction other than in the ordinary course of business; a transaction that is not on market terms; or a transaction that may have a material impact on a company&#8217;s profitability, assets or liabilities.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Generally, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or the audit committee shall not be present at such a meeting or vote on that matter unless, with respect to an office holder, the chairman of the audit committee or board of directors (as applicable) determines that the office holder should be present during the discussions in order to present the transaction that is subject to approval (provided that the office holder may not vote on the matter). If a majority of the members of the audit committee or the board of directors (as applicable) has a personal interest in the approval of a transaction, then all directors may participate in discussions of the audit committee or the board of directors (as applicable) on such transaction and the voting on approval thereof. If a majority of the members of the board of directors has a personal interest in the approval of a transaction, shareholder approval is also required for such transaction.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Approval of Transactions with Officer Holders</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If it is determined that an office holder has a personal interest in a transaction that is not an extraordinary transaction, approval by the board of directors is required for the transaction, unless the company&#8217;s articles of association provide for a different method of approval. Further, so long as an office holder has disclosed his or her personal interest in a transaction, the board of directors may approve an act by the office holder that would otherwise be deemed a breach of his or her duty of loyalty, provided that the transaction is in the company&#8217;s best interest and the office holder acted in good faith. An extraordinary transaction in which an office holder has a personal interest requires approval first by the company&#8217;s audit committee and subsequently by the board of directors.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Compensation of Officers Other than the Chief Executive Officer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The compensation of an office holder (other than the chief executive officer) who is not a director generally requires approval first by the company&#8217;s compensation committee, then by the company&#8217;s board of directors, according to the company&#8217;s compensation policy. In special circumstances the compensation committee and board of directors may approve a compensation arrangement that is inconsistent with the company&#8217;s compensation policy, provided that they have considered the same considerations and matters required for the approval of a compensation policy in accordance with the Israeli Companies Law and such arrangement must be approved by a majority vote of the shares present and voting at a shareholders meeting on the matter, provided that either: (i) such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and shareholders who do not have a personal interest in such compensation arrangement present and voting on the matter, excluding abstentions; or (ii) the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the matter and who vote against the matter does not exceed 2% of the company&#8217;s aggregate voting rights. We refer to this as the Special Approval for Compensation. However, if the shareholders of the company do not approve a compensation arrangement with an executive officer that is inconsistent with the company&#8217;s compensation policy, the compensation committee and board of directors may, in special circumstances, override the shareholders&#8217; decision if each of the compensation committee and the board of directors discuss the arrangement again, analyze the shareholders&#8217; objection and provide detailed reasons for their decision.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">An amendment to an existing arrangement with an office holder (other than the chief executive officer) who is not a director requires only the approval of the compensation committee, if the compensation committee determines that the amendment is not material in comparison to the existing arrangement.&#160;However, according to a recent amendment to regulations promulgated under the Israeli Companies Law, an amendment to an existing arrangement with an office holder (who is not a director) who is subordinate to the chief executive officer shall not require the approval of the compensation committee, if (i) the amendment is approved by the chief executive officer and the company&#8217;s compensation policy determines that a non-material amendment to the terms of service of an office holder (other than the chief executive officer) may be approved by the chief executive officer and (ii) the engagement terms are consistent with the company&#8217;s compensation policy.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">77</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Compensation of Chief Executive Officer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The compensation of a public company&#8217;s chief executive officer generally requires the approval of first, the company&#8217;s compensation committee; second, the company&#8217;s board of directors and third (except for a number of exceptions), the company&#8217;s shareholders by the Special Approval for Compensation. However, if the shareholders of the company do not approve a compensation arrangement with a chief executive officer, the compensation committee and board of directors may, in special circumstances, override the shareholders&#8217; decision if each of the compensation committee and the board of directors discuss the arrangement again, analyze the shareholders&#8217; objection and provide detailed reasons for their decision.&#160;However, an amendment to an existing arrangement with a chief executive officer who is not a director requires only the approval of the compensation committee, if the compensation committee determines that the amendment is not material in comparison to the existing arrangement.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">According to a recent amendment to regulations promulgated under the Israeli Companies Law, the renewal or extension of an existing arrangement with a chief executive officer shall not require shareholder approval if (i) the renewal or extension is not beneficial to the chief executive officer as compared to the prior arrangement or there is no substantial change in the terms and other relevant circumstances; and (ii) the engagement terms are consistent with the company&#8217;s compensation policy and the prior arrangement was approved by the shareholders by the Special Approval for Compensation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Compensation of Directors</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Arrangements regarding the compensation of a director require the approval of the compensation committee, board of directors and (except for a number of exceptions) shareholders by ordinary majority, in that order. The approval of the compensation committee and board of directors must be in accordance with the compensation policy. In special circumstances, the compensation committee and board of directors may approve a compensation arrangement that is inconsistent with the company&#8217;s compensation policy, provided that they have considered the same considerations and matters required for the approval of a compensation policy in accordance with the Israeli Companies Law and that shareholder approval was obtained by the Special Approval for Compensation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">With respect to compensation of an officer (including chief executive officer) or director who is also a controlling shareholder, see &#8220;&#8212; Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder of a public company. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50% of the voting rights in the company. For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated. Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest, and the terms of engagement with a controlling shareholder or a relative thereof, directly or indirectly (including through a corporation controlled by a controlling shareholder), for the provision of services to the company and his or her terms of employment or service as an office holder or employment as other than an office holder, require the approval of each of (i) the audit committee or the compensation committee with respect to the terms of service or employment by the company as an office holder, an employee or service provider; (ii) the board of directors; and (iii) the shareholders, in that order. The shareholder approval requires one of the following, which we refer to as a Special Majority:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z74a7530cd14c452aa26b76eeb816d640" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a majority of the shares held by all shareholders who do not have a personal interest in the transaction and who are present and voting on the matter approves the transaction, excluding abstentions; or</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb44c1ca48ef942e0a287e570d169bea8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the shares voted against the transaction by shareholders who have no personal interest in the transaction and who are present and voting at the meeting do not exceed 2% of the voting rights in the company.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Each shareholder voting on the approval of an extraordinary transaction with a controlling shareholder must inform the company prior to voting whether or not he or she has a personal interest in the approval of the transaction, otherwise, the shareholder is not eligible to vote on the proposal and his or her vote will not be counted for purposes of the proposal.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">To the extent that any such transaction with a controlling shareholder is for a period of more than three years, approval is required once every three years, unless, with respect to any such extraordinary transactions, the audit committee determines that the duration of the transaction is reasonable given the related circumstances.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The compensation committee and board approval for arrangements regarding the terms of service or employment of a controlling shareholder must be in accordance with the company&#8217;s compensation policy. In special circumstances the compensation committee and board of directors may approve a compensation arrangement that is inconsistent with the company&#8217;s compensation policy, provided that they have considered the same considerations and matters required for the approval of a compensation policy in accordance with the Israeli Companies Law and that shareholder approval was obtained by the Special Majority.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">78</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Pursuant to regulations promulgated under the Israeli Companies Law, certain transactions with a controlling shareholder or his or her relative, or with directors, relating to terms of service or employment that would otherwise require approval of a company&#8217;s shareholders may be exempt from shareholder approval upon certain determinations of the audit committee and board of directors. In addition, disclosure of a personal interest in a private placement of a public company (including disclosure of any material fact or document) is required by (i) a shareholder holding 5% or more of the company&#8217;s issued and outstanding capital or its voting rights whose holdings will increase as result of the private placement and a shareholder who will hold 5% or more of the company&#8217;s issued and outstanding capital or its voting rights as a result of the private placement, if 20% or more of the company&#8217;s outstanding share capital prior to the private placement is issued in the private placement and the payment for which is not only in cash or listed securities or the transaction is not on market terms; and (ii) a person or entity that will become a controlling shareholder as a result of the private placement.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Shareholder Duties</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Pursuant to the Israeli Companies Law, a shareholder has a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at a meeting of shareholder with respect to the following matters:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z88703d0e313547a395a821809060769f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">an amendment to the company&#8217;s articles of association;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z715a5b9761954df9aa5886ab7c223a87" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">an increase of the company&#8217;s authorized share capital;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5b769341000f4091826700af62293b6e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a merger; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zfb42a665567149d6a046c319f43d916c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the approval of related party transactions and acts of office holders that require shareholder approval.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, a shareholder has a general duty to refrain from discriminating against other shareholders.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Certain shareholders have a duty of fairness toward the company. These shareholders include any controlling shareholder, any shareholder who knows that he or she has the power to determine the outcome of a shareholder vote and any shareholder who has the power to appoint or to prevent the appointment of an office holder of the company or other power towards the company. The Israeli Companies Law does not define the substance of the duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Exculpation, Insurance and Indemnification of Directors and Officers</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing such exculpation is included in its articles of association. Our amended articles of association include such a provision, to the fullest extent permitted by law. The company may not exculpate in advance a director from liability arising out of a prohibited dividend or other distribution to shareholders.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law and the Israeli Securities Law, 5728-1968, or the Israeli Securities Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of any such event or following an event, provided its articles of association include a provision authorizing such indemnification:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zff45e0ffcd3e4785ba485818406d518b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb22ff6203eb94157a5165862633a52f7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">79</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zeafe4c396f4249309daca17f366a0ead" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1bffc9529ee449c48df463baf15bb644" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation payments made to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Israeli Securities Law.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law and the Israeli Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company&#8217;s articles of association:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z4a9e4d20c5f043d8b1595341c22d9b00" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf522b469ca5945ef9ce5ca91331f84bc" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zdbf30423e9554a8a9c2b57cd8c20cdda" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a financial liability imposed on the office holder in favor of a third party; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3f47f434cc1147749ac5388291cc3b13" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder or certain compensation payments to an injured party imposed on an office holder by an administrative proceeding, pursuant to certain provisions of the Securities Law.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law, a company may not indemnify, exculpate or enter into an insurance contract for office holder liability, for any of the following:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf2663ac0073b43009aea5b7874b73a51" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc52ad7edf9da4f58b9b5338922ed96a6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2256efc779994b598caf6f87b0a4ce8d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">an act or omission committed with intent to derive illegal personal benefit; or</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z996a15e5ee2b4dbbb6a983d4a1d0d1a4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">a fine, monetary sanction or forfeit levied against the office holder.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to the chief executive officer and a director or (under certain circumstances), also by the shareholders. See &#8220;&#8212; Approval of Related Party Transactions under Israeli Law.&#8221; However, the insurance of office holders shall not require shareholder approval and may be approved only by the compensation committee, if the engagement terms are determined in the company&#8217;s compensation policy and that policy was approved by the shareholders by the Special Approval for Compensation, provided that the policy is on market terms and is not likely to materially impact the company&#8217;s profitability, assets or obligations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our amended articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted under the Israeli Companies Law and the Israeli Securities Law. We have obtained directors&#8217; and officers&#8217; liability insurance for the benefit of our office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have entered into indemnification and exculpation agreements with each of our current officers and directors exculpating them from a breach of their duty of care to us to the fullest extent permitted by the Israeli Companies Law and undertaking to indemnify them to the fullest extent permitted by the Israeli Companies Law and the Israeli Securities Law, to the extent that these liabilities are not covered by insurance. This indemnification is limited to events determined as foreseeable by our board of directors based on our activities, as set forth in the indemnification agreements. Under such indemnification agreements, the maximum aggregate amount of indemnification that we may pay to any and all of our currently serving or future officers and directors together may not exceed the higher of $5 million and 25% of our shareholders equity according to our most recent financial statements at the time of payment. In the opinion of the SEC, however, indemnification of directors and office holders for liabilities arising under the Securities Act of 1933, as amended, is against public policy and therefore unenforceable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">80</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9a15824e79114e5bbc5235ac8e819f06" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Employees</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As of December 31, 2018, we had 56 employees and independent contractors, all of whom were based in Israel, and of whom 6 persons were in administrative, accounting and human resources and 34 persons were in research and development. Under Israeli law, we and our employees are subject to protective labor provisions, including the length of the workday, minimum wages for employees, annual leave, sick pay, determination of severance pay and advance notice of termination of employment, as well as procedures for hiring and dismissing employees and equal opportunity and anti-discrimination laws. While none of our employees are party to any collective bargaining agreements, orders issued by the Israeli Ministry of Economy and Industry may make certain industry-wide collective bargaining agreements applicable to us. These agreements affect matters such as the length of the workday and week, recuperation pay, travel expenses and pension rights.&#160; We have never experienced labor-related work stoppages and believe that our relationships with our employees are a significant part of our operations and that we maintain a good and positive relationship with our employees.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Israeli law generally requires the payment of severance compensation by employers upon the retirement, death or dismissal of an employee. We fund our ongoing severance obligations by making monthly payments to insurance policies. All of our current employees have agreed that upon termination of their employment, they will be entitled to receive only the amounts accrued in the insurance policies with respect to severance pay. Furthermore, Israeli employees and employers are required to pay predetermined sums to the National Insurance Institute, which is similar to the U.S. Social Security Administration. These amounts also include payments for national health insurance.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, we have various consulting arrangements with experts in regulatory, research and clinical matters, including with physicians.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6448d51047934bcf8be268450cadeb18" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">E.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Share Ownership</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Share Ownership of Executive Officers and Directors</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For information concerning the beneficial ownership of our ordinary shares by our executive officers and directors, see the table in Item 7A. &#8220;Major Shareholders and Related Party Transactions&#8212;Major shareholders.&#8221; As of December 31, 2018, (i) options to purchase 56,521 ordinary shares granted to our directors and executive officers were outstanding under our 2006 Unit Option Plan, with a weighted average exercise price of approximately $50.31, (ii) options to purchase 156,602 ordinary shares granted to our directors and executive officers were outstanding under our 2015 Equity Incentive Plan and the United States Sub-Plan to our 2015 Equity Incentive Plan, with a weighted average exercise price of approximately $5.86 per share; and (iii) 68,940 restricted share units awarded to our directors and executive officers were outstanding under our 2015 Equity Incentive Plan and the United States Sub-Plan to our 2015 Equity Incentive Plan.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Option and Incentive Plans</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In connection with the transfer of all of the business operations and substantially all of the assets of Check-Cap LLC to us in 2009, we assumed the Check-Cap LLC 2006 Unit Option Plan, or the 2006 Plan. On June 23, 2015, our board of directors approved and adopted the Check-Cap Ltd. 2015 Equity Incentive Plan, or the 2015 Israeli Plan, and the Check-Ltd. 2015 United States Sub-Plan to Check-Cap Ltd. 2015 Equity Incentive Plan, or the 2015 U.S. Sub-Plan. The 2015 Israeli Plan and 2015 U.S. Sub-Plan are referred together as the 2015 Plan. As of such date, we ceased to grant options under the 2006 Plan and all equity-based awards made after such date shall be made under the 2015 Plan. Our shareholders approved the 2015 Plan at an extraordinary general meeting of shareholders held on August 13, 2015<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, and it was subsequently amended by our board of directors on July 30, 2018</font>.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The primary provisions of the 2006 Plan and 2015 Plan are described below.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">2006 Plan</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">General</font>.&#160; The 2006 Plan provided for the grant of options to purchase our ordinary shares to our employees, consultants and service providers. For the purpose of the 2006 Plan: (i) an &#8220;employee&#8221; means any person, including officers, directors or affiliates who are employed by us or by our affiliates; (ii) a &#8220;consultant&#8221; means any person who is engaged by us to render consulting or advisory services to us or to any of our entities provided that such services are provided in good faith and are (a) not in connection with the offer or sale of our securities in a capital raising transaction and (b) not directly or indirectly promoting or maintaining a market for our securities; (iii) a &#8220;service provider&#8221; means an employee, director, supplier or officer holder as defined in the Israeli Companies Law; and (iv) an &#8220;affiliate&#8221; means any entity which is directly or indirectly our parent or subsidiary.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">81</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Administration of the 2006 Plan</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font> Our board of directors has had the authority to administer the 2006 Plan and to grant options under the 2006 Plan, including, the authority to determine the persons to whom options would be granted, the number of shares subject to each option, the time or times at which the options would be granted, restrictions on the transferability of the options, and the schedule and conditions on which such options may be exercised.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Awards under the 2006 Plan.</font> The 2006 Plan provided for the grant of options pursuant to Sections 102 and 3(i) of the Israeli Income Tax Ordinance [New Version], 5721-1961, which we refer to as the Tax Ordinance. The 2006 Plan provides that Section 102 options may be granted only to employees who are Israeli residents and who do not own interests possessing more than 10% of the total combined voting power of all classes of our equity or the equity of our affiliates immediately before such option is granted. Options granted to optionees who are Israeli residents that are not intended to qualify as Section 102 Options are granted under Section 3(i) of the Tax Ordinance, which does not provide for similar tax benefits, and are referred to as Section 3(i) options. The 2006 Plan was submitted for the approval of the Israeli Tax Authority, which we refer to as the ITA, as required by applicable law.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Options granted to employees under the 2006 Plan were granted under Section 102(b)(2) of the Tax Ordinance, which permits the issuance to a trustee under the &#8220;capital gains track.&#8221; In order to comply with the terms of the capital gains track, all options granted under a specific plan and subject to the provisions of Section 102 of the Tax Ordinance, as well as the shares issued upon exercise of such options and other shares received subsequently following any realization of rights with respect to such options, such as share dividends and share splits, must be registered in the name of a trustee selected by the board of directors and held in trust for the benefit of the relevant employee, director or officer for a period of two years from the date of the grant. However, under this track, we are not allowed to deduct an expense with respect to the issuance of the options or shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Exercise Price; Vesting.</font> The exercise price of an option granted under the 2006 Plan has been determined by the board of directors or a committee appointed by it. The first option grant to an employee generally vested over a period of three years and nine months commencing on the date of grant, such that 8.33% vest on the first anniversary of the date of grant and an additional 8.33% vest on each subsequent three-month period thereafter, for 33 months. Additional options granted to an employee generally vest over a period of three years commencing on the three months anniversary of the date of grant, such that 8.33% is fully vested on the date of grant and an additional 8.33% vest on each subsequent three-month period thereafter, for 33 months.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Options Term; Termination of Employment or Service</font>.&#160; Options granted under the 2006 Plan generally expire within ten years of the grant date or upon the earlier termination of employment of, or services provided by, the optionee, as applicable, subject to the extended period of exercisability upon termination of employment or services, as applicable. Upon termination of the employment of or services rendered by an optionee, as applicable (other than for cause, disability or death), generally vested options may be exercised within three months after the date of such termination or within such shorter time period (not to be less than 30 days) or such longer time period (not to exceed five years) as our board of directors or a committee appointed by it shall determine, but in any event no later than the expiration date of the options. If the employment or services of the optionee are terminated because of death or disability (or if the optionee dies within three months after termination of employment or services other than for cause), the optionee&#8217;s options may be exercised by the optionee or the optionee&#8217;s legal representative or authorized assignee to the extent exercisable on the date of such termination or within 12 months thereafter or as otherwise determined by the board of directors or a committee appointed by it. If the employment or services of the optionee are terminated for cause, all outstanding options will, to the extent not previously exercised, be of no force and effect as of the date of termination, unless otherwise determined by the board of directors or a committee appointed by it.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">M&amp;A Transaction</font>.&#160; The 2006 Plan provides that in the event of a merger or consolidation of our company in which our company is not the surviving entity, an acquisition of all or substantially all of the outstanding capital of our company or the sale of all or substantially all of our assets, the optionee shall be provided the opportunity to (i) exercise his or her options in connection with the transaction and to receive in the transaction such consideration as the holder of ordinary shares shall receive in the transaction; or (ii) retain his or her options or receive a substitute option from the surviving company, if any.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As of December 31, 2018, we had granted options to purchase an aggregate 174,416 ordinary shares under the 2006 Plan, of which options to purchase an aggregate 25,783 ordinary shares had been exercised into our ordinary shares, options to purchase an aggregate 59,048 ordinary shares had been forfeited without having been exercised and options to purchase an aggregate 89,585 ordinary shares were outstanding with a weighted average exercise price of approximately $47.30 per share.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> As of December 31, 2018, no shares are available for future awards under the 2006 Plan.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">2015 Equity Incentive Plan</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Awards under the 2015 Plan.</font> Awards under the 2015 Plan may be options granted pursuant to Section 102 of the Tax Ordinance&#160; ( &#8220;Section 102 Options&#8221;) or Section 3(i) of the Tax Ordinance (&#8220;Section 3(i) Options&#8221;), &#8220;incentive stock options&#8221; (&#8220;ISOs&#8221;) within the meaning of Section 422 of the U.S. Internal Revenue Code of 1986, as amended, and options not intended to qualify as ISOs (&#8220;Non-statutory Stock Options&#8221;), stock appreciation rights (&#8220;SARs&#8221;), restricted stock awards (&#8220;RSAs&#8221;) and restricted stock units (&#8220;RSUs&#8221;), or any combination of the foregoing.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Unless the Administrator (as defined below) determines otherwise and subject to applicable law, Section 102 Options may be granted only to Israeli employees, executives and directors (excluding controlling shareholders) and Section 3(i) Options may be granted to consultants, controlling shareholders and non-Israeli employees, executives and directors, in each case of our company or any subsidiary. The Section 102 Options may be granted either pursuant to Section 102(c) of the Tax Ordinance, which are not required to be held in trust by a trustee, or pursuant to Section 102(b), which are required to be held in trust for a specified period to qualify for certain tax benefits. Options granted pursuant to Section 102(b) shall be designated to qualify for capital gain tax treatment in accordance with Section 102(b)(2) of the Tax Ordinance or ordinary income tax in accordance with Section 102(b)(1) of the Tax Ordinance and thereafter, only such type of Section 102(b) options shall be granted until the Administrator has determined otherwise in accordance with applicable law (which may not be prior to one year after the first grant of such type of Section 102(b) options).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">82</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Unless the Administrator determines otherwise and subject to applicable law, ISOs may be granted only to non-Israeli employees and Non-statutory Stock Options may be granted to non-Israeli employees and consultants, in each case of our company or any subsidiary. To the extent that the aggregate fair market value of the ordinary shares with respect to which ISOs are exercisable for the first time by a participant during any calendar year under all company plans exceeds $100,000, then unless the Administrator determines otherwise at any time and subject to applicable law, such options shall be treated as Non-statutory Stock Options.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Administration of the 2015 Plan</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font>The Plan 2015 will be administered by the Board of Directors or, subject to applicable law, a committee appointed by the Board of Directors (&#8220;Committee&#8221; and the &#8220;Administrator&#8221;). Subject to the provisions of the 2015 Plan and, in the case of a Committee, the specific duties delegated by the Board of Directors, and subject to the approval of any relevant authorities and compliance with all applicable laws, the Administrator shall have the full power and authority at its sole discretion, from time to time and at any time, among other things:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8a9ed90bf1924c499d511d90a464937f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">To determine whether and to what extent awards are to be granted to participants under the 2015 Plan and to select the eligible recipients of awards under the 2015 Plan;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3ae7f4017988469da97d84216deacc2b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">To approve forms of agreement for use under the 2015 Plan;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf9ba0b6ec54d4039883895269baaa7d2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">To determine the terms and conditions of any award under the 2015 Plan, including the exercise price, the time or times and the extent to which the awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any award or the ordinary shares relating thereto, based in each case on such factors as the Administrator, at its sole discretion, shall determine;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze4ddf31fe2064bb097a6e6494f92beae" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">To determine the fair market value of the shares covered by each award;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zddce2d8952d249c8b8e862115ff84c7d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">To make an election as to the type of Section 102 Option;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf94d6ede930e4adea8a3fe23d606f243" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">To prescribe, amend and rescind rules and regulations relating to the 2015 Plan, including rules and regulations relating to sub-plans established for the purpose of qualifying for preferred tax treatment under foreign tax laws;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zda2541d2086445ff8b5d0dd51ba9fc75" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">To authorize conversion or substitution under the 2015 Plan of any or all awards and to cancel or suspend awards, as necessary, provided the material interests of the participants are not harmed; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2495681489e046c8ad0d295c20ba0be6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">To construe and interpret the terms of the 2015 Plan and awards granted pursuant to the 2015 Plan;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z782832eb0fc647d29dbaea1e4d8f41f6" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">To alter, revise or otherwise adjust the terms of the 2015 Plan and the award agreement, as may be required pursuant to any applicable laws of local or foreign jurisdictions.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Term of Awards.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font>The term of each option shall be stated in the award agreement but in no event may it be more than ten years from the date of grant. Unless the Administrator determines otherwise and subject to applicable law, no ISO may be granted under the 2015 Plan to a grantee who possess more than 10% of the total combined voting power of our company or any of our affiliate (a &#8220;10% Shareholder&#8221;) unless the option terminates on a date that is not later than the day preceding the fifth anniversary of the date of grant. Unless otherwise specified in the applicable award agreement, the term of a SAR will be ten years.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Exercise Price.</font> The exercise price of any award under the 2015 Plan shall be determined by the Administrator, subject to applicable law. Unless the Administrator determines otherwise and subject to applicable law, in the case of ISOs and Non-Statutory Stock Options, the exercise price per share shall be no less than the fair market value per ordinary share on the date of grant and in the case of an ISO granted to a 10% Shareholder, no less than 110% of the fair market value per ordinary share on the date of grant.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Non-Transferability of Awards.</font> Unless the Administrator determines otherwise and subject to applicable law: (i) options and SARs may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the participant, only by the participant. For as long as options or shares purchased upon the exercise of options are held by a trustee on behalf of the participant, all rights of the participant with respect to such options and shares shall be personal, and may not be transferred, assigned, pledged or mortgaged, other than by will or laws of descent and distribution; (ii) RSUs may not be sold, pledged, transferred, assigned or encumbered; and (iii) RSAs may not be sold, transferred, pledged, assigned or otherwise disposed of during the restricted period, provided that the Administrator may provide for the lapse of such restrictions in installments and may accelerate or waive such restrictions in whole or in part.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">83</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<!--PROfilePageNumberReset%Num%84%%%-->
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Termination of Employment or Service.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Options and SARs</font>. If a participant ceases to be an employee or consultant, in the absence of specified period in the award agreement and unless the Administrator determines otherwise, such participant may exercise his/her options (to the extent vested on the date of such termination) or SARs within three months following such termination (but in no event later than the expiration date of the option or SAR). If a participant retires, he/she may continue to enjoy such rights with respect to awards under the 2015 Plan, on such terms and conditions as the Administrator may determine. If the participant&#8217;s employment or service is terminated as a result if his/her death or permanent disability, the participant (or, if the participant died, the participant&#8217;s estate or any person who acquired the right to exercise the option by bequest or inheritance), may exercise his/her options (to the extent vested on the date of such termination) and/or SARs within such additional period of time following such termination as specified in the award agreement (which may not be less than six months), or in the absence of a specified period in the award agreement, until 12 months following such termination or any longer period determined by the Administrator, but in no event later than the expiration date of the option or SAR.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">RSAs</font>. If a participant&#8217;s service of employment is terminated prior to the restricted period, subject to the terms of the award agreement or as otherwise determined by the Administrator, the participant&#8217;s restricted stock and any associated dividends that remain subject to forfeiture will then be forfeited automatically.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">RSUs</font>. If a participant&#8217;s service of employment is terminated prior to the RSU vesting, subject to the terms of the award agreement or as otherwise determined by the Administrator, the participant&#8217;s RSUs that remain subject to forfeiture will then be forfeited automatically.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">M&amp;A Transaction</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font> In the event of a Transaction (as defined in the 2015 Plan, which generally includes (among other things) a sale of all or substantially all of our assets or shares, a merger, consolidation or amalgamation with or into another company or a scheme of arrangement for effecting any of the foregoing or such other transaction determined as such by the Administrator, all subject to the conditions and limitations in the 2015 Plan), unless otherwise determined by the Administrator, in its sole discretion, any award granted under the 2015 shall be assumed or substituted by us or the successor company, under terms determined by the Administrator or the terms of the 2015 Plan applied by the successor company to such assumed or substituted awards, all in accordance with the terms of the 2015 Plan. Regardless of whether or not the awards are assumed or substituted, the Administrator may, at its sole discretion, among other things, provide for the exercise of any exercisable and vested awards, the cancellation of unexercised and unvested awards, the acceleration of unvested awards, or the cancellation of awards for payment in cash, shares or other property of our company or the acquiring company or other party to the Transaction, under such terms as the Administrator may determine, all in accordance with the terms of the 2015 Plan.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Term and Termination of the 2015 Plan</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">&#160;</font>The 2015 Plan became effective upon its adoption by our Board of Directors and shall continue in effect for a term of ten years. Our Board of Directors may at any time amend, alter, suspend or terminate the 2015 Plan. No amendment, alteration, suspension or termination of the 2015 Plan shall impair the rights of any participant, unless mutually agreed otherwise in writing between the participant and the Administrator.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As of December 31, 2018, we had granted options to purchase an aggregate 440,480 ordinary shares under the 2015 Plan, of which options to purchase an aggregate 111,881 ordinary shares had been forfeited without having been exercised and options to purchase an aggregate 328,599 ordinary shares were outstanding as of such date, with a weighted average exercise price&#160;&#160; of approximately $5.69 per share. In addition, as of December 31, 2018, we had issued 145,575 restricted share units under the 2015 Plan, of which 32,636 RSUs had been forfeited, 5,851 RSUs had vested, and 107,127 restricted share units were outstanding as of such date. As of December 31, 2018,&#160;496,786 ordinary shares are available for future awards under the 2015 Plan.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">84</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM7" name="ITEM7"><!--Anchor--></a>ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z92b07896f4ef4625a3990bc091086737" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Major shareholders</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of March 21, 2019 by (i) each person or entity known to us to beneficially own more than 5% of our outstanding ordinary shares; (ii) each of our current executive officers and directors individually; and (iii) all of our current executive officers and directors as a group.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The percentage of beneficial ownership of our ordinary shares is based on 8,235,810 ordinary shares, NIS 2.40 par value per share outstanding as of March 21, 2019. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting power or investment power with respect to securities. All options and warrants currently exercisable or exercisable into ordinary shares within 60 days of March 21, 2019 are deemed to be outstanding and beneficially owned by the shareholder holding such options or warrants for the purpose of computing the number of shares beneficially owned by such shareholder. Such shares are also deemed outstanding for purposes of computing the percentage ownership of the person holding the option or warrant. They are not, however, deemed to be outstanding and beneficially owned for the purpose of computing the percentage ownership of any other shareholder.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">This table is based upon information supplied by officers and directors and is believed to be accurate. Except as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all shares shown to be beneficially owned by them, based on information provided to us by such shareholders. Unless otherwise noted below, each shareholder&#8217;s address is: c/o Abba Hushi Avenue, P.O. Box 1271, Isfiya, 30090, Mount Carmel, Israel.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<table id="za7d5991b6cfb4a048ccabec154fd3fd9" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Ordinary Shares</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Beneficially Owned</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Name of Beneficial Owner</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Number</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Percent</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">5% or Greater Shareholders</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Barna Capital Group Ltd.(1)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">778,011</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9.4</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Intracoastal Capital LLC (2)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">701,201</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8.0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Donald Norman&#160;(3)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">623,600</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7.6</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Smotrich SARL-SPF(4)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">555,000</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6.7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Directors and Executive Officers</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Alex Ovadia</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Niv Kochav</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Yoav Kimchy&#160;(5)&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">64,431</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Boaz Shpigelman</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Steven Hanley&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Clara Ezed&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Mary Jo Gorman</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">XiangQian (XQ) Lin<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">&#160;</sup>(6)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">51,282</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Yuval Yanai&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">All director and executive officers as a group (9 persons) </div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">152,426</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.9</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
</tr>
</table>

<br style="LINE-HEIGHT: 1.25">
<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; FONT-WEIGHT: normal; FONT-STYLE: normal"><u>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </u></font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">* Less than 1% of our ordinary shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zac503a1f25394dcf9c0c62b6b2bc3b68" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(1)</div>
</td>
<td style="WIDTH: 96.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Based solely upon, and qualified in its entirety with reference to, Schedule 13G filed with the SEC on February 15, 2019.&#160;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(2)</div>
</td>
<td style="WIDTH: 96.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Based solely upon, and qualified in its entirety with reference to, Schedule 13G filed with the SEC on February 12, 2019.&#160; According to the Schedule 13G, (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (&#8220;Mr. Kopin&#8221;), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (&#8220;Mr. Asher&#8221;) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (&#8220;Intracoastal&#8221; and together with Mr. Kopin and Mr. Asher, collectively the &#8220;Reporting Persons&#8221;) have shared voting power over these ordinary shares.&#160; The Schedule 13G states such 701201 ordinary shares are comprised of (i) 216,705 ordinary shares held by Intracoastal and (ii) 484,496 ordinary shares issuable upon exercise of Series D warrants issued in connection with the February 2019 registered direct offering. According to the Schedule 13G, the<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>foregoing excludes 241,364 ordinary shares issuable upon exercise of Series D warrants issued in connection with the February 2019 registered direct offering because the warrant contains a blocker provision under which the holder thereof does not have the right to exercise the warrants to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder&#8217;s affiliates, and any other persons acting as a group together with the holder or any of the holder&#8217;s affiliates, of more than 4.99% of the ordinary shares. Without such blocker provision, each of the Reporting Persons may have been deemed to have beneficial ownership of 942,565 ordinary shares.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(3)</div>
</td>
<td style="WIDTH: 96.67%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Based solely <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">upon</font> a Non-Objecting Beneficial Owner list with a record date of March 15, 2019 obtained by the Company from Broadridge Financial Solutions, Inc. As of <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">such date</font>, the Company does not have information as to (i) whether beneficial ownership of any of these shares has been disclaimed, (ii) who holds voting and dispositive power over these shares, (iii) whether any other ordinary shares are beneficially owned, or (iv) whether these shares continued to be beneficially owned by such person and in such amounts since March 15, 2019.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(4)</div>
</td>
<td style="WIDTH: 96.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Based solely upon, and qualified in its entirety with reference to, Schedule 13G filed with the SEC on February 13, 2019.&#160; Based on the Schedule 13G, Mr. Alejandro Weinstein, Chalet les Ecureuils Ouest, Rte. de Zires 17, 3963 Crans-Montana, CH, is the ultimate beneficial owner of these ordinary shares and as such has the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(5)</div>
</td>
<td style="WIDTH: 96.67%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Includes: (i) 27,173 ordinary shares directly held by Yoav Kimchy</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> (ii) 10,520 ordinary shares subject to options held by Yoav Kimchy currently exercisable or exercisable within 60 days of March 21, 2019</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> (iii) 26,644 ordinary shares directly held by Sigalit Kimchy, the wife of Yoav Kimchy</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and (iv) 94 ordinary shares subject to options held by Sigalit Kimchy currently exercisable or exercisable within 60 days of March 21, 2019.&#160; Yoav Kimchy and Sigalit Kimchy have joint beneficial ownership over the shares beneficially held by them.</font></div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 3.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(6)</div>
</td>
<td style="WIDTH: 96.67%; VERTICAL-ALIGN: top">
<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Includes: (i) 14,429 outstanding ordinary shares<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font> (ii) 9,074 ordinary shares subject to options currently exercisable or exercisable within 60 days of March 21, 2019<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font> (iii) 6,945 ordinary shares issuable upon exercise of the Series A Warrants that are currently exercisable<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">,</font> and (iv) 20,834 ordinary shares issuable upon exercise of Long Term Incentive Warrants that are currently exercisable.</div>
</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">85</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As of March 21, 2019, based on information provided to us by our transfer agent in the United States and other information reasonably available to us, we had 54 holders of record of our ordinary shares in the United States. Such holders of record held, as of that date, 98.0% of our outstanding ordinary shares. The number of record holders is not representative of the number of beneficial holders of our ordinary shares, as 96.1% of our outstanding ordinary shares are recorded in the name of Cede &amp; Co. as nominee for the Depository Trust Company, in whose name all shares held in &#8220;street name&#8221; are held in the United States.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">None of our shareholders have voting rights different from the voting rights of other shareholders. To the best of our knowledge, we are not owned or controlled, directly or indirectly, by another corporation or by any government. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">To our knowledge, the only significant changes in the percentage ownership held by our more than 5% shareholders as reported in our annual reports on Form 20-F during the past three years are as follows: (i) the ownership percentage of Pontifax Funds decreased to under 5% in 2018 from 19.6% as of March 7, 2016, (ii) the ownership percentage of Shanghai Fosun Pharmaceutical Group Co. Ltd. </div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">decreased to under 5% in _2018 from 17.5% as of March 7, 2016, (iii) the ownership percentage of Quant Global Capital Advisors, LC decreased to under 5% in 2018 from 13.1% as of March 7, 2016, (iv) the ownership percentage of Yoav and Sigalit Kimchy decreased to under 5% during 2016 from 6.2% as of March 7, 2016, (v) the ownership percentage of Docor International B.V. decreased to under 5% in 2017 from 6.0% as of March 7, 2016, (vi) the ownership percentage of Guy Neev decreased to under 5% during 2016 from 5.4% as of March 7, 2016, (vii) the ownership percentage of Sabby Management, LLC increased to over 5% in 2017 and in the same year decreased to 5.2% and further decreased to under 5% in 2018, (viii) the ownership percentage of Armistice Capital, LLC increased to 5.5% in 2018 and in 2018 decreased to under 5%, (ix) the ownership percentage of Intracoastal Capital, LLC increased to 8.7% in 2019, (x) the ownership percentage of Smotrich SARL &#8211; SPF increased to 6.7% in 2019, (xi) the ownership percentage of Barna Capital increased to 9.9% in 2019, and (xii) the ownership percentage of Donald Norman increased to over 5% in 2018.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z97a36d228e394c91afcc6f1c21e86114" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Related Party Transactions</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt">Other than Mr. Densel&#8217;s Separation Agreement, the executive and director compensation, executive officer employment agreements, indemnification and exculpation arrangements and directors&#8217; and officers&#8217; liability insurance policy discussed in &#8220;Management,&#8221; and the transactions described below, since January 1, 2016, we have not been or are not a party to any transactions in which any of our directors, executive officers or holders of more than 5% of our share capital, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Pontifax Warrants</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">On October 14, 2014, we issued warrants to purchase an aggregate of 18,464 of our ordinary shares at an exercise price of NIS 2.40 per share, or the Pontifax Warrants, to the Pontifax Funds in consideration of their commitment to provide to us, for no consideration, the following services, if and to the extent requested by us: (i) business development services, in such scope and substance as shall be agreed between us and the Pontifax; and (ii) a representative designated by Pontifax to serve as the chairman of our board of directors.&#160;The Pontifax Funds subsequently agreed that the exercise price of fifty-percent of their warrants will increase to equal the price at which our ordinary shares are sold to the public in the initial public offering of our securities, or if units are sold in the initial public offering of our securities, the exercise price per share will increase to be equal to the effective price per share of the ordinary shares underlying the units sold to the public in the offering. The Pontifax Funds also agreed that such portion of their warrants would vest and become exercisable only upon the consummation of the initial public offering of our securities prior to their expiration date.&#160;The remaining warrants with an NIS 2.40 exercise price will vest on a quarterly basis in eight equal installments during a period of 24 months from issuance.&#160;In addition, the Pontifax Funds agreed to reduce the term of their respective warrants such that these warrants will now expire after eight years (instead of ten years) following their issuance, i.e., on October 14, 2022. Upon the closing of our initial public offering any unvested portion of the warrants became fully vested and exercisable. In September 2018, Pontifax exercised 9,232 of the Pontifax Warrants into 7,502 ordinary shares on a cashless basis.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Shareholders Agreement</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We entered into a shareholders agreement, dated as of March 17, 2011, to which each of the holders of our former preferred shares, including Pontifax (Cayman) II, L.P., Pontifax (Israel) II L.P., Pontifax (Israel) II- Individual Investors L.P., BXR Portfolio Limited (formerly named Eastern Petroleum Investment Company Limited), Docor International B.V., Spearhead Investments (Bio) Ltd., Jacobs Investment Company LLC and Emigrant Alternative Portfolios LLC, is a party, either as an original signatory or by virtue of a joinder thereto, and certain of the holders of our ordinary shares, including Yoav Kimchy and Sigalit Kimchy are parties.&#160; On October 14, 2014, the parties to such shareholders agreement and the lenders under the certain credit line agreement dated August 20, 2014, entered into an Amended and Restated Shareholders Agreement, or the Shareholders Agreement.&#160; Prior to the closing of our initial public offering, we amended the Shareholders Agreement to eliminate provisions related to information rights and matters related to the board of directors, such that the amended Shareholders Agreement consists primarily of the provisions regarding registration rights described below, and the undertaking discussed below under &#8220;&#8212;Transactions with Check-Cap LLC and the Members and Manager of Check-Cap LLC.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Demand Registration Rights</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">At any time after the closing of our initial public offering, at the request of, either (i) holders of a majority of our former Series D preferred shares (all of which converted into ordinary shares immediately prior to the closing of our initial public offering); or (ii) holders of a majority of our former Series C preferred shares (all of which converted into ordinary shares immediately prior to the closing of our initial public offering); or (iii) persons holding at least 20% of the ordinary shares issued upon conversion of the former preferred shares or in respect thereof, we must register any or all of such shareholders&#8217; ordinary shares. We are required to effect up to two such registrations for each former holder of our preferred shares, with respect to all of such person&#8217;s or entities&#8217; shares. We are required to give notice of a demand registration to the other holders of registrable securities that are entitled to registration rights and include their shares in such registration if they so timely request.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">86</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Piggyback Registration Rights</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">All of the former holders of our preferred shares that are a party to the Shareholders Agreement have the right to request that we include their registrable securities in certain registration statements that we file in connection with the public offering of our shares. We are required to give notice of our intention to effect such a registration to all holders of our registrable securities that are entitled to registration rights and include their shares in such registration if they so timely request.&#160;At the request of certain shareholders who exercised their piggyback registration rights pursuant to the Shareholders Agreement, we registered a total of 1,083,122 shares beneficially owned by such shareholders, or the Resale Shares, for resale, from time to time, by such shareholders pursuant to a Registration Statement on Form F-3 (Registration No. 333-211065), which was filed with the SEC on May 2, 2016 and declared effective on July 11, 2016, or the F-3 Registration Statement.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Registration Priority</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">To the extent it is not in our best interest for all of the former holders of our preferred shares to participate in any demand or piggyback registration, the shares to be included in the registration statement on behalf of the former preferred shareholders shall be allocated as follows: first, shares sought to be registered by the former holders of our Series D preferred shares; second, shares sought to be registered by the former holders of Series C preferred shares; third, shares sought to be registered by the former holders of our Series A preferred shares; and fourth, shares sought to be registered by the former holders of our Series B preferred shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Expenses</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have agreed to pay all expenses incurred in carrying out the above registrations, including the fees of one counsel chosen by the selling shareholders that are a party to the Shareholders Agreement. However, we shall not be required to pay any registration expenses in connection with any initiated registration that is subsequently withdrawn, other than a withdrawal due to a material adverse change not known to the holder of registrable securities at the time of such demand or request by us or the underwriters to reduce the size of the offering as a result of which the holders of at least a majority of the registrable securities elect to withdraw. A registration shall not count as a permitted registration until it has remained effective for a period of at least 120 days.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Registration Statement on Form F-3</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">On May 2, 2016, we filed the F-3 Registration Statement with the SEC. Pursuant to the F-3 Registration Statement, which became effective on July 11, 2016, we registered (among other things) (i) the Resale Shares, as described above, which include (a) ordinary shares issued upon conversion of our former preferred shares; (b) ordinary shares issuable upon exercise of the certain warrants that we issued to lenders under the credit line agreement we entered into on October 14, 2014 and (c) ordinary shares issuable upon exercise of the Series A Warrants and Long Term Incentive Warrants issued in the private placement consummated simultaneously with our initial public offering; and (ii) the offer and sale by us, from time to time, of up to 274,795 ordinary shares issuable upon exercise of the Series A Warrants and Long Term Incentive Warrants issued in our initial public offering.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Transactions with Check-Cap LLC and the Members and Manager of Check-Cap LLC</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">On May 31, 2009, we entered into an asset transfer agreement with Check-Cap LLC pursuant to which Check-Cap LLC transferred all of its business operations and substantially all of its assets to us. Our shareholders&#8217; holdings on the date of the asset transfer transaction reflected their interests as members of Check-Cap LLC. In the framework of the asset transfer agreement and under the Shareholders Agreement, we undertook to use commercially reasonable efforts to procure that distributions or advance funds are made to our shareholders holding (at the date of the transaction) ordinary shares, Series A preferred shares and/or Series B preferred shares (i.e., the shareholders who are also members of Check-Cap LLC), as would be necessary to eliminate the tax impact on such shareholders of the reorganization and the transfer of all of the business operations and substantially all of the assets from Check-Cap LLC to us. Notwithstanding the foregoing, we will not advance payments to such shareholders to address the fact that they will no longer receive a &#8220;pass through&#8221; of losses generated by us as they previously received while owning units of Check-Cap LLC. These advances, if and to the extent made, will be deducted from any distributions such shareholders are entitled to receive from us. We have reserved in our financial statements $65,000 as of December 31, 2018, $312,000 as of December 31, 2017 and $382,000 as of December 31, 2016 on account of such advances.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">In connection with the asset transfer agreement entered into in May 2009, we assumed the former obligation of Check-Cap LLC to distribute any proceeds it collects on the $1 million key man life insurance policy with respect to Yoav Kimchy, the Company&#8217;s chief technology officer and a former director, to the former holders of the Series A preferred units in an amount equal to their respective capital contributed to Check-Cap LLC, less any amounts previously distributed to them, plus any accrued and unpaid dividends due to them as of the date of distribution.&#160;On November 16, 2016, we cancelled the key man life insurance policy with respect to Yoav Kimchy.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Registered Direct Offerings</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">On August 8, 2016, we entered into a Securities Purchase Agreement with certain affiliates of Sabby Management LLC in connection with our registered direct offering of 53,635 ordinary shares at a price of $22.80 per share and pre-funded warrants to purchase 209,524 ordinary shares at a purchase price of $22.20 per pre-funded warrant. The pre-funded warrants had an exercise price of $0.60 per share, subject to certain adjustments and an expiration date of August 11, 2023, unless otherwise extended in accordance with the terms of the pre-funded warrants.&#160;The offering was consummated on August 11, 2016. We received gross proceeds from the August 2016 registered direct offering of approximately $5.9 million (including proceeds from the exercise of 47,917 pre-funded warrants at the closing of the offering).&#160;As of December 31, 2016, additional pre-funded warrants to purchase an aggregate 137,441 ordinary shares had been exercised, for additional proceeds of $82,500.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">As of January 23, 2017, all of the remaining pre-funded warrants to purchase an aggregate 24,167 ordinary shares had been exercised, for additional proceeds of $14,500.</font></div>

<br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">On May 30, 2017, we entered into a Securities Purchase Agreement with certain affiliates of Sabby Management LLC in connection with our registered direct offering of 112,460 ordinary shares at a price of $24.00 per share and simultaneous private placement of one-year warrants to purchase an aggregate of up to 112,460 ordinary shares. The warrants had an exercise price of $25.50 per share and were immediately exercisable.&#160;The offering was consummated on June 2, 2017. We received gross proceeds from the June 2017 registered direct offering of approximately $2.69. On June 2, 2018, all of the warrants issued in the offering expired.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">On November 20, 2017, we entered into a Securities Purchase Agreement with certain investors including certain affiliates of Sabby Management LLC in connection with our registered direct offering of 189,387 ordinary shares at a price of $13.20 per share and simultaneous private placement of five-year warrants to purchase an aggregate of up to 142,042 ordinary shares. The warrants have an exercise price of $15.00 per share and are immediately exercisable. The offering was consummated on November 22, 2017. We received approximately $2.5 million gross proceeds from the November 2017 registered direct offering, $999,900 of which represented the aggregate purchase price paid by certain affiliates of Sabby Management LLC. On April 25, 2018, 56,812 of the warrants issued in the offering were exercised into 13,574 ordinary shares on a cashless basis.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">In May 2018, we paid Sabby Management LLC $170,000 in settlement of a dispute regarding their rights over certain securities held by them.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 39.6pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">87</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Agreements with Hadar Kimchy and Sigalit Kimchy</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">On July 1, 2005, we entered into an agreement with Hadar Kimchy, as amended, according to which Hadar Kimchy provided us with marketing communication and graphical design services, in consideration for a monthly fee of NIS 13,680 ($3, 945).&#160; Such services were provided to us by Sigalit Kimchy, who is employed by Hadar Kimchy.&#160;The agreement terminated as of April 4, 2016.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">On April 4, 2016, we entered into an employment agreement with Sigalit Kimchy, according to which Ms. Kimchy serves as marcom and user interface lead, in a 50% part-time role (no less than 93 hours per month), for a monthly salary of NIS 11,200 ($2,988), plus up to 35 monthly overtime hours at a gross monthly rate of NIS 2,800 ($747), or an aggregate monthly salary of up to NIS 14,000 ($3,735).&#160;Ms. Kimchy is entitled to an education fund, managers&#8217; insurance or pension fund and reimbursement of monthly travel expenses.&#160;The employment agreement is for an indefinite term and may be terminated by either party upon 30 days prior written notice, and may be terminated by us with immediate effect for cause.&#160; Ms. Kimchy also entered into a confidentially, non-competition and intellectual property agreement.&#160; Sigalit Kimchy is the wife of Yoav Kimchy, our chief technology officer and a former director. For information regarding the beneficial ownership of our ordinary shares by Yoav Kimchy and Sigalit Kimchy, see Item 7A. &#8220;Major Shareholders and Related Party Transactions&#8212;Major shareholders.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Scientific Advisor</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Since May 2009, Dr. Walter L. Robb, a member of the board of directors of our U.S. subsidiary, Check-Cap US, Inc., since June 2017 and a former director of our company from May 2009 until June 2017, has provided us with consultancy services, on an as needed basis, with matters of scientific relevance, as a Scientific Advisor.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Agreements with Former CEO</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We entered into an Employment Agreement dated as of July 1, 2015, as amended, with William Densel, or Mr. Densel&#8217;s Employment Agreement, pursuant to which Mr. Densel served as President and Chief Executive Officer of our company and our subsidiary Check-Cap U.S., Inc. Mr. Densel&#8217;s employment with us as Chief Executive Officer of our company and our subsidiary Check-Cap U.S., Inc. ended on February 26, 2018. Mr. Densel&#8217;s Employment Agreement allowed for termination by either us or Mr. Densel upon not less than 90 days&#8217; prior written notice to the other party. Pursuant to Mr. Densel&#8217;s Employment Agreement, we also had the right to terminate Mr. Densel&#8217;s employment for &#8220;Cause&#8221; (as defined in Mr. Densel&#8217;s Employment Agreement) or if Mr. Densel was unable to perform his duties for an aggregate period of at least 90 days occurring in any 180 day period by reason of illness, injury or physical or mental impairment. Pursuant to Mr. Densel&#8217;s Employment Agreement, Mr. Densel was entitled to a salary of $350,000 per annum. In addition, Mr. Densel was entitled to an annual bonus of up to 50% of his annual salary, subject to receipt of requisite approvals. Payment of the annual bonus was subject to the achievement of certain milestones determined and approved by our Compensation Committee and Board of Directors. Mr. Densel&#8217;s Employment Agreement also contained confidentiality, intellectual property, non-competition and non-solicitation provisions. Mr. Densel&#8217;s Employment Agreement provided that in the event that his engagement with us is terminated by us without &#8220;Cause&#8221; (other than due to death or disability), he would be entitled to receive, during the six month period following the termination date, his annual salary of $350,000, payable monthly, and medical and dental insurance.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We entered into a Confidential Separation Agreement as of February 25, 2018 with Mr. Densel, or Mr. Densel&#8217;s Separation Agreement, pursuant to which Mr. Densel&#8217;s employment as our Chief Executive Officer and all positions he held with us or our U.S. subsidiary, Check-Cap U.S., Inc., ended as of February 26, 2018. Pursuant to the terms of Mr. Densel&#8217;s Separation Agreement, we paid Mr. Densel a lump sum equal to 90 days of his base salary and commencing as of the 91<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">st</sup> day after the separation date and for a period of six (6) months thereafter, shall pay to Mr. Densel his base salary. In addition, for a period of nine months from the separation date, we shall reimburse Mr. Densel for the cost of maintaining his health insurance coverage existing prior to the termination of his employment.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z459d161c779948b78c1732dfe9162865" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Interests of Experts and Counsel</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM8" name="ITEM8"><!--Anchor--></a>ITEM 8. FINANCIAL INFORMATION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z24af1e4319de4f0ab61e96c9696e7ecb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Consolidated Statements and Other Financial Information.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Consolidated Financial Statements</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">See Item 18 &#8211; Financial Statements.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">88</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Legal Proceedings</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">From time to time, we may be involved in litigation that arises through the normal course of business. As of the date of this filing, we are not a party to any material litigation nor are we aware of any such threatened or pending litigation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">There are no material proceedings in which any of our directors, officers or affiliates or any registered or beneficial shareholder of more than 5% of our ordinary shares, or any associate of any of the foregoing is an adverse party or has a material interest adverse to our interest.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Dividend Policy</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have never declared or paid dividends on our ordinary shares and currently do not intend to pay cash dividends on our ordinary shares in the foreseeable future.&#160;We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. See Item 3D &#8220;Key Information &#8211; Risk factors - Risks Related to the Company.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our ability to distribute dividends also may be limited by future contractual obligations and by Israeli law. The Israeli Companies Law restricts our ability to declare dividends. Unless otherwise approved by a court, we can distribute dividends only from &#8220;profits&#8221; (as defined by the Israeli Companies Law), and only if there is no reasonable concern that the dividend distribution will prevent us from meeting our existing and foreseeable obligations as they become due. Subject to the foregoing, payment of future dividends, if any, will be at the discretion of our board of directors and will depend on various factors, such as our financial condition, operating results, current and anticipated cash needs and other business and economic factors that our board of directors may deem relevant. See Item 10B. &#8220;Memorandum and Articles of Association&#8212;Dividend and Liquidation Rights.&#8221; The payment of dividends may be subject to Israeli withholding taxes. See Item 10E. &#8220;Additional Information&#8212;Taxation&#8212;Israeli Tax Considerations and Government Programs&#8212;Taxation of Our Shareholders&#8212;Taxation of Non-Israeli Shareholders on Receipt of Dividends.&#8221;&#160;Furthermore, if we pay a dividend out of income attributed to our Benefited Enterprise that was generated during the tax exemption period, we may be subject to tax on the grossed-up amount of such distributed income at the corporate tax rate which would have been applied to our Benefited Enterprise&#8217;s income had we not enjoyed the exemption. See Item 10E. &#8220;Additional Information&#8212;Taxation &#8211; Israeli Tax Considerations and Government Programs &#8212; Law for the Encouragement of Capital Investments, 5719-1959 &#8212; Tax Benefits Subsequent to the 2005 Amendment.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8206e5521c334af2b60a38c8d0f472a7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Significant Changes</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Except as disclosed elsewhere in this Annual Report, there have been no other significant changes since December 31, 2018, until the date of the filing of this Annual Report.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a id="ITEM9" name="ITEM9"><!--Anchor--></a>ITEM 9. THE OFFER AND LISTING</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd1b3d3b174f04e30aad60e1c947381b2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Offer and Listing Details</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our units were listed on the Nasdaq Capital Market on February 19, 2015 under the symbol &#8220;CHEKU.&#8221; Prior to that date, there was no public trading market for our securities. Our initial public offering was priced at $72.00 per unit on February 20, 2015. Each unit consisted of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share. Each unit was issued with one and one-half non-transferrable Long Term Incentive Warrants. Each whole Series A Warrant entitles the holder to purchase one ordinary share at an exercise price of $90.00. On March 18, 2015, the units separated and ceased to exist. Since such date, our ordinary shares, Series A Warrants and Series C Warrants have been listed on the Nasdaq Capital Market under the symbols &#8220;CHEK&#8221;, &#8220;CHEKW,&#8221; and &#8220;CHEKZ&#8221;, respectively. On April 4, 2018, we effected a 1-for-12 reverse stock split of our ordinary shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zedb3aaf44afc4392b8383c59f178c247" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Plan of Distribution</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb965422a19e84dc09c7f22aa8e1230dc" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Markets for Ordinary Shares</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">See &#8220;&#8212;Offer and Listing Details&#8221; above.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8491017daa614383ab5e7d338c6cd969" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Selling Shareholders</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zaca57bf13506458dac2700f1229cf552" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">E.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Dilution</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">89</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z26b5095b9b4949068efefc2e551969f5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">F.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Expenses of the Issue</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM10" name="ITEM10"><!--Anchor--></a>ITEM 10. ADDITIONAL INFORMATION</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0495261a0e7142b59fefeee112cb05ff" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">A.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Share Capital</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7c9c21fb7ff64a76a32ffaae981d4a0b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">B.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Memorandum and Articles of Association</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Registration Number and Purposes of the Company</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our registration number with the Israeli Registrar of Companies is 51-425981-1. Our purpose as set forth in our amended articles of association is to engage in any lawful activity.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Voting Rights and Conversion</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">All ordinary shares have identical voting and other rights in all respects.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Transfer of Shares</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our fully paid ordinary shares are issued in registered form and may be freely transferred under our amended articles of association, unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel, according to applicable Israeli law&#8217;s requirements.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our Board of Directors may, to the extent it deems necessary in its discretion, close the register of shareholders of registration of transfers of shares for a period determined by the Board of Directors, and no registrations of transfers of shares shall be made by us during any such period during which the register of shareholders is so closed.&#160; We shall notify shareholders with respect to such suspension of registration in such manner as shall be determined by our Board of Directors.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Election of Directors</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Under our amended articles of association, our board of directors must consist of not less than four but no more than eleven directors, including (if any) external directors (within the meaning of the Israeli Companies Law).&#160; Pursuant to our amended articles of association, each of our directors will be appointed by a simple majority vote of holders of our voting shares, participating and voting at an annual general meeting of our shareholders (subject to the special approval requirements under the Israeli Companies Law for the election of external directors, if any). </font>Our ordinary shares do not have cumulative voting rights for the election of directors.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Each director (other than external directors, if any) will hold office until the next annual general meeting following the annual general meeting at which they were elected and until his or her successor is elected and qualified, or until the occurrence of certain events, in accordance with the Israeli Companies Law and our amended articles of association, including his or her earlier resignation, death or removal by a vote of the majority of the voting power of our shareholders at a general meeting of until his or her office expires by operation of law. In addition, our amended articles of association allow our board of directors to appoint directors (other than external directors) to fill vacancies on the board of directors to serve for a term of office equal to the remaining period of the term of office of the directors(s) whose office(s) have been vacated.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Dividend and Liquidation Rights</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. Our amended articles of association do not require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Pursuant to the Israeli Companies Law, we may declare and pay dividends only if, upon the determination of our board of directors, there is no reasonable concern that the distribution will prevent us from being able to meet the terms of our existing and foreseeable obligations as they become due. Under the Israeli Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two most recent years legally available for distribution according to our then last reviewed or audited financial statements (less the amount of previously distributed dividends, if not reduced from the earnings), provided that the date of the financial statements is not more than six months prior to the date of distribution. In the event that we do not have retained earnings or earnings generated over the two most recent years legally available for distribution, we must seek the approval of the court in order to distribute a dividend. The court may approve our request if it is convinced that there is no reasonable concern that the payment of a dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to the nominal value of their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">90</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Exchange Controls</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of war with Israel.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Shareholder Meetings</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to in our amended articles of association as special general meetings. Our board of directors may call special general meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Israeli Companies Law provides that our board of directors is required to convene a special general meeting upon the written request of (i) any two of our directors or one-quarter of the serving members of our board of directors; or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding shares and 1% of our outstanding voting power or (b) 5% or more of our outstanding voting power.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Furthermore, the Israeli Companies Law requires that resolutions regarding the following matters be approved by our shareholders at a general meeting:&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc5b42d053063424c8514bb0fdde74654" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#183;</div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">amendments to our articles of association;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z17b852080d3c4c52a9cf2929df36d172" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">appointment, terms of service and termination of service of our auditors;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z302dc76a1913462b9a61561530eac6f4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">appointment of external directors<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">;</font></div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb3e91f0b292d4c2b8b883a399fedae70" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">approval of certain related party transactions;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z26692432f4364c06b0d705a5c057b346" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">increases or reductions of our authorized share capital;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf47f5cd760cc454197c524406fc9980b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">mergers; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z73bde6cb45514fcfa28e10c2372b5d19" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the exercise of our board of director&#8217;s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is essential for our proper management.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Subject to the provisions of the Israeli Companies Law and regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by the board of directors, which, as a company listed on an exchange outside Israel, may be between four and 40 days prior to the date of the meeting.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Israeli Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes, among other things, the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, an approval of a merger or the approval of the compensation policy, notice must be provided at least 35 days prior to the meeting.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law, our shareholders are not permitted to take action via written consent in lieu of a meeting.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Voting rights</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Quorum Requirements</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Pursuant to our amended articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general meeting. The quorum required for general meetings of our shareholders is at least two shareholders present in person, by proxy or written ballot, who hold or represent between them at least 25% of the total outstanding voting rights (or if a higher percentage is required by law, such higher percentage), within half an hour of the time fixed for the commencement of the meeting. A meeting adjourned for lack of a quorum is adjourned either to the same day in the following week at the same time and place or to such day, time and place as specified in the notice of the meeting or to such day, time and place as the chairman of the general meeting shall determine. At the reconvened meeting, at least two shareholders present in person or by proxy shall constitute a lawful quorum, unless the meeting of shareholders was convened at the demand of shareholders, in which case, the quorum shall be the presence of one or more shareholders holding at least 5% of our issued share capital and at least one percent of the voting power of our shares, or one or more shareholders with at least 5% of the voting power of our shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">91</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Vote Requirements</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our amended articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Israeli Companies Law or by our amended articles of association. Under the Israeli Companies Law, certain actions require a special majority, including: (i) approval of an extraordinary transaction with a controlling shareholder or in which the controlling shareholder has a personal interest and the terms of employment or other engagement of the controlling shareholder or a relative of the controlling shareholder (even if not extraordinary), requiring the approval described in Item 6C &#8220;Directors, Senior Management and Employees &#8212;Board Practices&#8212;Approval of Related Party Transactions under Israeli Law&#8212; Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions&#8221;; (ii) approval of a compensation policy, requiring the approval described in Item 6C &#8220;Directors, Senior Management and Employees&#8212; Board Practices&#8212; Compensation Committee and Compensation Policy&#8221;; and (iii) approval of executive officer compensation inconsistent with our office holder compensation policy or the compensation of our chief executive officer (subject to limited exceptions), requiring the approval described in Item 6C &#8220;Directors, Senior Management and Employees&#8212; Board Practices&#8212; Approval of Related Party Transactions under Israeli Law&#8212; Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, under the Israeli Companies Law the appointment of external directors requires the approval of a majority vote of the shares present and voting on the matter, provided that either: (i) such majority includes a majority of the shares held by all shareholders who are non-controlling shareholders and shareholders who do not have a personal interest in the election of the external director (other than a personal interest not deriving from a relationship with a controlling shareholder) that are voted at the meeting, excluding abstentions; or (ii) the total number of shares held by shareholders who are non-controlling shareholders and shareholders who do not have a personal interest in the election of the external director (other than a personal interest not derived from a relationship with a controlling shareholder) voted against the election of the external director does not exceed 2% of the aggregate voting rights in the company.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Furthermore, under the Israeli Companies Law the authorization of the chairman of the board to assume the role or responsibilities of the chief executive officer, or the authorization of the chief executive officer or his or her relative thereof to assume the role or responsibilities of the chairman of the board, for periods of no longer than three years each, is subject to receipt of the approval of a majority of the shares voting on the matter, provided that either (i) included in such majority are at least two-thirds of the shares of shareholders who are non-controlling shareholders and shareholders who do not have a personal interest in the resolution that are voted at the meeting on the matter (excluding any abstentions); or (ii) the total number of shares of shareholders specified in clause (i) who voted against the resolution does not 2% of the voting rights in the company.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Israeli Companies Law, which requires the approval of holders of 75% of the voting rights represented at the meeting and voting on the resolution.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Access to Corporate Records</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law, shareholders are provided access to: minutes of the general meetings of our shareholders; our shareholders register and principal shareholders register, articles of association and financial statements; and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be provided with any document in the company&#8217;s possession related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Israeli Companies Law. We may deny this request if we believe it has not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Modification of Class Rights</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law and our amended articles of association, the rights attached to any class of shares, such as voting, liquidation and dividend rights, may be modified or cancelled by adoption of a resolution by the holders of a majority of all shares as one class, without any required separate resolution of any class of shares, or otherwise in accordance with the rights attached to such class of shares, as set forth in our amended articles of association.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Registration Rights</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For a discussion of registration rights we have granted to our existing shareholders, please see Item 7B &#8220;Major Shareholders and Related Party Transactions&#8212;Related Party Transactions &#8212; Shareholders Agreement.&#8221;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">92</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Acquisitions under Israeli Law</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Full Tender Offer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">A person wishing to acquire shares of an Israeli public company, and who would as a result hold over 90% of the target company&#8217;s </font>voting rights or <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">issued and outstanding share capital, is required by the Israeli Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a Israeli public company, and who would as a result hold over 90% of the </font>target company&#8217;s voting rights or<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> issued and outstanding share capital of a certain class of shares of the company, is required to make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If (a) the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company, or of the applicable class, or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of the tender offer, or (b) the shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#8217;s issued and outstanding share capital or of the applicable class from shareholders who accepted the tender offer.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Special Tender Offer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Israeli Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company, if there is no other shareholder that holds 25% or more of the voting rights in the company, subject to exceptions. Similarly, the Israeli Companies Law provides that an acquisition of shares in an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions. No tender offer is required if the acquisition of shares: (i) occurs in the context of a private placement, that was approved by the company&#8217;s shareholders and whose purpose is to give the acquirer at least 25% of the voting rights in the company if there is no person who holds 25% or more of the voting rights in the company, or as a private placement whose purpose is to give the acquirer 45% of the voting rights in the company, if there is no person who holds 45% of the voting rights in the company; (ii) was from a holder of 25% or more of the voting rights in the company following which the purchaser will hold 25% or more of the voting rights in the company; or (iii) was from a holder of more than 45% of the voting rights in the company following which the purchaser will hold more than 45% of the voting rights in the company.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">A special tender offer must be extended to all shareholders of a company (but the offeror is not required to purchase shares representing more than 5% of the voting power attached to the company&#8217;s outstanding shares, regardless of how many shares are tendered by shareholders). A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by the offeror; and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser, its controlling shareholders, holders of 25% or more of the voting rights in the company or any person having a personal interest in the acceptance of the tender offer, or anyone on their behalf, including any such person&#8217;s relatives and entities under their control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it, at the time of the offer, and any person or entity under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Merger</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Israeli Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under the Israeli Companies Law are met, by a majority vote of each party&#8217;s shares, and, in the case of the target company, a majority vote of each class of its shares, voted on the proposed merger at a shareholders meeting. The board of directors of a merging company may not approve the merger if it determines that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">For purposes of the shareholder vote of a merging company whose shares are held by the other merging company or a person or entity holding 25% or more of any of the means of control of the other merging entity, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of shares voting on the matter at the shareholders meeting (excluding abstentions) that are held by parties other than the other party to the merger, or by any other person or entity who holds 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party, or any one on their behalf including their relatives or corporations controlled by any of them, vote against the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same Special Majority approval that governs all extraordinary transactions with controlling shareholders (as described in Item 6C &#8220;Directors, Senior Management and Employees&#8212;Board Practices&#8212; Approval of Related Party Transactions under Israeli Law &#8212; Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions&#8221;).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">93</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the valuation of the merging companies and the consideration offered to the shareholders.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Anti-Takeover Measures under Israeli Law</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Israeli Companies Law allow us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. No preferred shares are currently authorized under our amended articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended articles of association, which requires the prior approval of the holders of a majority of the voting power attached to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Israeli Companies Law and our amended articles of association as described above in &#8220;&#8212; Voting Rights.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Borrowing Powers</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Pursuant to the Israeli Companies Law and our amended articles of association, our board of directors may exercise all powers and take all actions that are not required under law or under our amended articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Changes in Capital</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our amended articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board of directors and an Israeli court.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8e0da860a26d4d148b2cec45cb809ea1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">C.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Material Contracts</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have not entered into any material contracts other than in the ordinary course of business and other than those described in Item 4. &#8220;Information on Our Company,&#8221; Item 7B &#8220;Major Shareholders and Related Party Transactions - Related Party Transactions&#8221; or elsewhere in this Annual Report.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z06298dd4f9d843ad8fdf59289712360f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">D.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Exchange controls</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in a state of war with Israel.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2e7436d967c246d38e8216adfb219f05" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">E.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Taxation</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following description is not intended to constitute a complete analysis of all tax consequences relating to our ordinary shares, Series A Warrants and Long Term Incentive Warrants, Series C Warrants and Series D Warrants (sometimes referred to collectively or individually as our &#8220;securities&#8221;).&#160; You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">94</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Israeli Tax Considerations and Government Programs</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following is a brief summary of the material Israeli tax laws applicable to us and certain Israeli Government programs that benefit us. This section also contains a discussion of material Israeli tax consequences concerning the ownership and disposition of our securities purchased by investors who are non-Israeli resident shareholders. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of such investors include residents of Israel or traders in securities who are subject to special tax regimes not covered in this discussion. Because parts of this discussion are based on new tax legislation that has not yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities or the courts will accept the views expressed in this discussion. The discussion below is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which change could affect the tax consequences described below.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">General Corporate Tax Structure in Israel</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Israeli resident companies are generally subject to corporate tax, currently at the rate of 23% (effective as of January 1, 2018 and thereafter, reduced from 24% for the 2017 tax year and 25% for the 2016 tax year) of a company&#8217;s taxable income. However, the effective tax rate payable by a company that derives income from an Approved Enterprise, a Benefited Enterprise a Preferred Enterprise or a </font>Priority Technological<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli resident company are subject to tax at the prevailing corporate tax rate.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Law for the Encouragement of Industry (Taxes), 5729-1969</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for &#8220;Industrial Companies.&#8221; The Industry Encouragement Law defines an &#8220;Industrial Company&#8221; as a company resident in Israel, of which 90% or more of its income in any tax year, other than income from defense loans, is derived from an &#8220;Industrial Enterprise&#8221; owned by it </font>and located in Israel or in the &#8220;Area&#8221;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">&#160;</font>(as such term is defined under Section 3A of the Israeli Income Tax Ordinance (New Version), 5721-1961, referred to as the Ordinance)<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose principal activity in a given tax year is industrial production.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following corporate tax benefits, among others, are available to Industrial Companies:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf597813a30af4a49918ededc3745ca47" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">amortization over an eight-year period of the cost of purchased know-how and patents and rights to use a patent and know-how which are used for the development or advancement of the Industrial Enterprise;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z27f600b0f4be437d968c7ae21c34e44d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 82.5pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -39.6pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zee9da0a1b3084476b365c54449286fd7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 5.93%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: Symbol, serif">&#183;</font></div>
</td>
<td style="WIDTH: 86.85%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">expenses related to a public offering are deductible in equal amounts over three years.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Eligibility for the benefits under the Industry Encouragement Law is not subject to receipt of prior approval from any governmental authority. We believe that we may qualify as an &#8220;Industrial Company&#8221; within the meaning of the Industry Encouragement Law; however, there can be no assurance that we will qualify as an Industrial Company or that the benefits described above will be available in the future.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Law for the Encouragement of Capital Investments, 5719-1959</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in production facilities (or other eligible assets).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The Investment Law has been amended several times in recent years, primarily: Amendment 60, effective April 1, 2005, referred to as the 2005 Amendment; Amendment 68, effective as of January 1, 2011, referred to as the 2011 Amendment; Amendment 71, effective as of January 1, 2014, referred to as the 2014 Amendment; and Amendment 73, effective as of January 1, 2017, referred to as the 2017 Amendment.&#160; Pursuant to the foregoing amendments, generally tax benefits that were granted in accordance with the provisions of the Investment Law prior to each such amendment remain in force; however, any benefits granted subsequent to the respective amendment are subject to the provisions of the Investment Law as amended.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Tax Benefits Prior to the 2005 Amendment</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Prior to the 2005 Amendment, a capital investment in eligible production facilities (or other eligible assets) could, upon application to the Investment Center of the Israeli Ministry of Economy (formerly named the Ministry of Industry, Trade and Labor), be designated as an &#8220;Approved Enterprise&#8221; and accordingly, entitled to certain tax benefits under the Investment Law. Each certificate of approval for an Approved Enterprise relates to a specific investment program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical characteristics of the facility or the asset. We do not have any Approved Enterprises.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">95</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Tax Benefits Subsequent to the 2005 Amendment</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Pursuant to the 2005 Amendment, a company whose facilities meet certain criteria set forth in the 2005 Amendment may claim certain tax benefits offered by the Investment Law (as further described below) directly in its tax returns, without the need to obtain prior approval. In order to receive the tax benefits, a company must make an investment which meets all of the conditions, including exceeding a minimum entitling investment amount, set forth in the Investment Law. Such investment allows a company to receive &#8220;Benefited Enterprise&#8221; status, and may be made over a period of no more than three years ending at the end of the year in which the company chose to have the tax benefits apply to its Benefited Enterprise, referred to as the &#8220;Year of Election.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The extent of the tax benefits available under the 2005 Amendment to qualifying income of a Benefited Enterprise depends on, among other things, the geographic location in Israel of the Benefited Enterprise. The location will also determine the period for which tax benefits are available. Under the &#8220;Exemption Track&#8221; the tax benefits include an exemption from corporate tax on undistributed income generated by the Benefited Enterprise for a period of two to ten years, depending on the geographic location of the Benefited Enterprise in Israel, and a reduced corporate tax rate of 10% to 25% for the remainder of the benefits period, depending on the level of foreign investment in the company in each year. The benefits period is for a duration of seven or ten years, depending on the location of the Benefited Enterprise, from the later of the first year in which the company generated taxable income from its Benefited Enterprise and the Year of Election, but in any event not more than 12 or 14 years from the Year of Election, depending on the location of the company. A company qualifying for tax benefits under the Exemption Track which pays a dividend </font>(as well as a deemed dividend, such as investments in subsidiaries, granting loans to related parties, repurchases of shares, acquisitions of securities/shares, capital reductions and additional events which reflect the transfer of funds out of the Benefitted Enterprise activity) <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">out of income derived during the tax exemption period by its Benefited Enterprise will be subject to corporate tax in respect of the amount of the dividend (grossed-up to reflect the pre-tax income that it would have had to earn in order to distribute the dividend) at the corporate tax rate which would have otherwise been applicable. Dividends paid out of income attributed to a Benefited Enterprise are generally subject to withholding tax at source at the rate of 15% or such lower rate as may be provided in an applicable tax treaty.&#160; </font>Applying reduced tax rates in accordance with a certain tax treaty is subject to the receipt in advance of a valid certificate from the Israel Tax Authority allowing for a reduced tax rate.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The benefits available to a Benefited Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law and its regulations. If a company does not meet these conditions, it may be required to refund the amount of tax benefits, as adjusted by the Israeli consumer price index, and interest, or other monetary penalties.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">We currently have one Benefited Enterprise program under the Investment Law, which, we believe, entitles us to certain tax benefits with respect to income to be derived from our Benefited Enterprise. We chose 2010 as the Year of Election. </font>We believe that we are located in the Zone A specified development zone and therefore, believe we are entitled to a 10-year benefit period, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">during which taxable income from our Benefited Enterprise program (once generated) will be tax exempt</font>, commencing with the year we will first earn taxable income relating to such enterprise, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">subject to a 14-year limitation from the Year of Election, and therefore, the tax benefit period will in any event end in 2023.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Tax Benefits under the 2011 Amendment and the 2014 Amendment</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The 2011 Amendment canceled the availability of the benefits granted to companies under the Investment Law prior to 2011 and, instead, introduced new benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise&#8221; (as such terms are defined in the Investment Law) as of January 1, 2011. The definition of a Preferred Company includes a company incorporated in Israel that is not wholly-owned by a governmental entity, and that, among other things, owns a Preferred Enterprise and is controlled and managed from Israel. Under the 2014 Amendment, effective as of January 1, 2014, a Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to its income derived by its Preferred Enterprise in 2014 and thereafter, unless the Preferred Enterprise is located in a specified development zone (referred to as &#8220;Zone A&#8221;), in which case the rate will be 9% for the 2014 tax year and thereafter and, pursuant to the 2017 Amendment (as discussed below), 7.5% from 2017 and thereafter. We believe our facilities are located in the Zone A specified development zone.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Dividends paid out of income attributed to a Preferred Enterprise are generally subject to withholding tax at source at the rate of 20% or such lower rate as may be provided in an applicable tax treaty. However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although, if such dividends are subsequently distributed to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may be provided in an applicable tax treaty will apply).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The 2011 Amendment also provided transitional provisions to address companies already enjoying existing tax benefits under the Investment Law. These transitional provisions provide, among other things, that unless an irrevocable request is made to apply the provisions of the Investment Law as amended in 2011 with respect to income to be derived as of January 1, 2011, a Benefited Enterprise can elect to continue to benefit from the benefits provided to it before the 2011 Amendment came into effect, provided that certain conditions are met.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We examined the possible effect, if any, of the provisions of the 2011 Amendment on our financial statements and decided not to apply the new benefits under the 2011 Amendment.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">96</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Tax Benefits under the 2017 Amendment</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The 2017 Amendment was enacted as part of the Economic Efficiency Law that was published on December 29, 2016, and became effective as of January 1, 2017. The 2017 Amendment provides new tax benefits for two types of &#8220;Technological Enterprises&#8221;, as described below, and is in addition to the other existing tax beneficial programs under the Investment Law.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The 2017 Amendment provides two new tax incentive tracks &#8211; the &#8220;Priority Technological Enterprise&#8221; track and &#8220;Special Priority Technological Enterprise&#8221; track (as such terms are defined in the Investment Law). The benefits available to a Priority Technological Enterprise or Special Priority Technological Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">A Priority Technological Enterprise is entitled (among other things) to a reduced corporate tax rate of 12% with respect to its income </font>which qualifies as &#8220;Preferred Technology Income&#8221;, as defined in the Investment Law, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">unless the Priority Technological Enterprise is located in a specified development zone (referred to as &#8220;Zone A&#8221;), in which case the rate will be 7.5%.&#160;A Special Priority Technological Enterprises is entitled to a reduced corporate tax rate of 6% with respect to its </font>Preferred Technology Income<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our company does not qualify as a Priority Technological Enterprise or Special Priority Technological Enterprise, within the meanings of the Investment Law.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The termination or substantial reduction of any of the benefits available under the Investment Law could materially increase our future tax liabilities.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Encouragement of Industrial Research and Development Law, 5744-1984)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Encouragement of Industrial Research and Development Law, 5744-1984), referred to as<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"> &#160;</font> the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law, research and development programs which meet specified criteria and are approved by the IIA (formerly the OCS) are eligible for grants.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law as currently in effect, the grants awarded are typically up to 50% of the project&#8217;s approved expenditures. The grantee is required to pay royalties to the State of Israel from the sale of products <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(and associated services) </font>developed <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">using IIA funding.</font> Regulations under the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law, as currently in effect, generally provide for the payment of royalties of 3% <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">or</font> 5% (and at an increased rate under certain circumstances) on sales of products and services based on technology <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">and know-how </font>developed using<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> IIA</font> grants, until 100% (which may be increased under certain circumstances) of the grant, linked to the U.S. dollar and bearing interest at the LIBOR rate, is repaid. The terms of the Israeli government participation require that products developed with IIA grants be manufactured in Israel, unless approval for transferring such manufacturing outside Israel is received from the IIA (however, only a notice to the IIA, as opposed to approval, is required for the transfer outside Israel of up to 10% of the manufacturing). Such approval may be provided by the IIA in connection with the approval of the grant application itself (as we requested in certain of our grant applications<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">),</font> in which case the royalty repayment rate is increased<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">, typically</font> by 1<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">%,</font> with respect to any such approved percentage.&#160; If manufacturing of IIA-funded products is transferred outside Israel (following IIA approval) in excess of the percentage approved by the IIA in connection with the grant approval, then the royalty repayment rate is increased by 1% and the royalty repayment amount with respect to such products may be increased to up to three times the amount of the grants received, depending on the percentage manufactured outside Israel (plus accrued interest).&#160; IIA prior approval is also required for the transfer of IIA-funded know-how to a third party outside of Israel (including by way of license), which we may not receive (and any such approval would be subject to <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">payment of a redemption fee, calculated according to a formula under the Innovation Law, which may be in the amount</font> of up to six times the amount of the grants received, plus accrued interest). Even following the full repayment of any IIA grants, we must nevertheless continue to comply with the requirements of the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law. If we fail to comply with any of the conditions and restrictions imposed by the <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Innovation</font> Law and regulations and guidelines thereunder, or by the specific terms under which we received the grants, we may be required to refund any grants previously received together with interest and penalties, and, in certain circumstances, may be subject to criminal charges.&#160;</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">As of December 31, 2018, we had received funding from the IIA (formerly the OCS) for the financing of a portion of our research and development expenditures in an aggregate amount of </font>approximately<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> $5.3 million.&#160;&#160;As of December 31, 2018, we had not paid any royalties to the IIA and had a contingent obligation to the IIA in the amount of </font>approximately<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> $5.6 million.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Taxation of our Shareholders</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Capital Gains Taxes Applicable to Non-Israeli Resident Shareholders</font>. A non-Israeli resident who derives capital gains from the sale of securities of an Israeli resident company will be exempt from Israeli tax so long as the securities (i) were not held through a permanent establishment that the non-resident maintains in Israel, (ii) were not received from a relative or in a tax free reorganization transaction and (iii) are not traded on the Tel Aviv Stock Exchange on the date of sale. However, non-Israeli corporations will not be entitled to the foregoing exemption if Israeli residents: (i) have a controlling interest of 25% or more in such non-Israeli corporation; or (ii) are the beneficiaries of, or are entitled to, 25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">97</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Additionally, a sale of securities by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. For example, under the Convention Between the Government of the United States of America and the Government of the State of Israel with respect to Taxes on Income, as amended, generally referred to as the United States-Israel Tax Treaty, the sale, exchange or other disposition of shares by a shareholder who (i) is a U.S. resident (for purposes of the treaty); (ii) holds the shares as a capital asset; and (iii) is entitled to claim the benefits afforded to such person by the treaty, is generally exempt from Israeli capital gains tax. Such exemption will not apply if, among other things: (i) the capital gain arising from such sale, exchange or other disposition is treated as industrial or commercial profits attributed to a permanent establishment in Israel, subject to certain conditions; (ii) the shareholder holds, directly or indirectly, shares representing 10% or more of the voting capital of the corporation during any part of the 12-month period preceding the disposition, subject to certain conditions; (iii) the capital gain arising from such sale, exchange or disposition is treated as royalties; or (iv) such U.S. resident is an individual and was present in Israel for 183 days or more during the relevant taxable year. In such case, the sale, exchange or disposition of our securities would be subject to Israeli tax, to the extent applicable; however, under the United States-Israel Tax Treaty, the taxpayer would be permitted to claim a credit for such taxes against the U.S. federal income tax imposed with respect to such sale, exchange or disposition, subject to the limitations under U.S. law applicable to foreign tax credits. The United States-Israel Tax Treaty does not relate to U.S. state or local taxes.&#160; The United States-Israel Tax Treaty is currently under review and subject to change.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">In some instances where our shareholders may be liable for Israeli tax on the sale of their securities, the payment of the consideration may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains </font>and to obtain an exemption from withholding tax certificate from the Israel Tax Authority<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> in order to avoid withholding at source at the time of sale.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Taxation of Non-Israeli Shareholders on Receipt of Dividends</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">. Non-Israeli residents are generally subject to Israeli withholding tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of residence (subject to the receipt of a valid certificate from the Israeli Tax Authority allowing for a reduced tax rate). With respect to a person who is a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or at any time during the preceding 12 months, the applicable withholding tax rate is 30%, unless such &#8220;substantial shareholder&#8221; holds such shares through a nominee company, in which case the rate is 25%. A &#8220;substantial shareholder&#8221; is generally a person who alone or together with such person&#8217;s relative </font>(as such term is defined in the Ordinance) <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">or another person who collaborates with such person on a permanent basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of the corporation. &#8220;Means of control&#8221; generally include the right to vote, receive profits, nominate a director or an executive officer, receive assets upon liquidation, or order someone who holds any of the aforesaid rights how to act, regardless of the source of such right.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">However, a distribution of dividends to non-Israeli residents is subject to withholding tax at source at a rate of 15% if the dividend is distributed from income attributed to an Approved Enterprise or a Benefited Enterprise and 20% if the dividend is distributed from income attributed to a Preferred Enterprise or </font>a Priority Technological <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Enterprise, unless a reduced tax rate is provided under an applicable tax treaty. We cannot assure you that in the event we declare a dividend we will designate the income out of which the dividend is paid in a manner that will reduce shareholders&#8217; tax liability.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Under the United States-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary shares who is a U.S. resident (for purposes of the United States-Israel Tax Treaty) is 25%. With respect to dividends paid to a U.S. corporation that held 10% or more of our outstanding voting capital throughout the tax year in which the dividend is distributed and the preceding tax year and provided that not more than 25% of the gross income of the paying corporation for such prior taxable year (if any) consists of certain interest or dividends, the maximum rate of tax withheld at source is 12.5%; provided, however, that if the paying corporation is an Approved Enterprise, the applicable withholding tax rate under such circumstances is reduced to 15%. We believe that the reference in the United States-Israel Tax Treaty to an Approved Enterprise under the Investment Law is deemed to include also a Benefitted Enterprise Preferred Enterprise and </font>Priority Technological Enterprise<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> under the Investment Law. The United States-Israel Tax Treaty is currently under review and subject to change.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">U.S. residents who are subject to Israeli withholding tax on a dividend may be entitled to a credit or deduction for U.S. federal income tax purposes in the amount of the taxes withheld, subject to detailed rules contained in U.S. tax legislation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Taxation of Non-Israeli Shareholders upon Exercise of Long Term Incentive Warrants</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.&#160;</font>While not free from doubt, the Long Term Incentive Warrants may be treated for Israeli income tax purposes as compensatory warrants (i.e., issued to compensate an original purchaser of units in our initial public offering for holding the ordinary shares underlying the units for a certain period of time after the closing date of the offering). In such case, a holder of Long Term Incentive Warrants may recognize ordinary compensation income for Israeli income tax purposes on the exercise of the Long Term Incentive Warrants.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Non-Israeli residents are subject to Israeli income tax only on income from sources in Israel, which is income accrued or derived in Israel. Therefore, to the extent that the Long Term Incentive Warrants may be treated as compensatory warrants for Israeli tax purposes, the ordinary compensation income on the exercise of the Long Term Incentive Warrants would not be subject to Israeli income tax to the extent such income is deemed to be attributable to the performance of services outside of Israel. Furthermore, according to the United States-Israel Tax Treaty, income received by an individual for his performance of labor or personal services shall be treated as income from sources within the country where the service was provided (i.e., with respect to U.S. residents (for purposes of the treaty), U.S. source income) and therefore, would be exempt from Israeli income tax.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">To the extent that the Long Term Incentive Warrants may be treated as compensatory warrants, the exercise of the Long Term Incentive Warrants may be subject to the withholding of Israeli tax at source by us and the warrants may not be exercised unless the withholding obligation has been fulfilled. Shareholders may be required to demonstrate that they are exempt from tax on such income in order to avoid withholding at source at the time of exercise<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">98</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Surtax</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Subject to the provisions of an applicable tax treaty, individuals who are subject to tax in Israel are also subject to an additional tax at a rate of 3% on annual income (including, but not limited to, dividends, interest and capital gain) exceeding NIS </font>649,560 <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">for 2019, which amount is linked to the annual change in the Israeli consumer price index.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Estate and Gift Tax</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Israeli law presently does not impose estate or gift taxes.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt">EACH HOLDER OF OUR SECURITIES IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY ISRAELI TAX LAWS AND ANY APPLICABLE TAX TREATIES.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">U.S. Federal Income Taxation</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following are certain material U.S. federal income tax consequences of the acquisition, ownership and disposition of our securities.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The discussion below of the U.S. federal income tax consequences to &#8220;U.S. Holders&#8221; will apply to a beneficial owner of our securities that is for U.S. federal income tax purposes:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9c8409364a2d4a9fbc0165bf23282371" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">an individual citizen or resident of the United States;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z63909ba6c418440e912f5326bf762baa" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">a corporation (or other entity treated as a corporation) that is created or organized (or treated as created or organized) in or under the laws of the United States, any state thereof or the District of Columbia;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8d21854458834c8694e023355418ec41" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">an estate whose income is includible in gross income for U.S. federal income tax purposes regardless of its source; or</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zab5e6b684ea9466bbd40739824fa5b55" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">a trust if (i) a U.S. court can exercise primary supervision over the trust&#8217;s administration and one or more U.S. persons are authorized to control all substantial decisions of the trust; or (ii) it has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">A beneficial owner of our securities that is described above is referred to herein as a &#8220;U.S. Holder.&#8221; If a beneficial owner of our securities is not described as a U.S. Holder and is not an entity treated as a partnership or other pass-through entity for U.S. federal income tax purposes, such owner will be considered a &#8220;Non-U.S. Holder.&#8221; Certain material U.S. federal income tax consequences of the acquisition, ownership and disposition of our securities applicable specifically to Non-U.S. Holders are described below under the heading &#8220;Non-U.S. Holders.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">This discussion is based on the Code, its legislative history, Treasury regulations promulgated thereunder, published rulings and court decisions, all as currently in effect. These authorities are subject to change or differing interpretations, possibly on a retroactive basis.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">This discussion does not address all aspects of U.S. federal income taxation that may be relevant to any particular holder based on such holder&#8217;s individual circumstances. In particular, this discussion considers only holders that own and hold our securities as capital assets within the meaning of Section 1221 of the Code, and does not address the potential application of the alternative minimum tax or the U.S. federal income tax consequences to holders that are subject to special rules, including:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd134591aa3b74ae0a61010676c84d4c1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">financial institutions or financial services entities;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8713a0b9772549d1b6e85d150bf2b356" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">broker-dealers;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0c3ed17a4f5842a4b817b45dccb92a5e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">persons that are subject to the mark-to-market accounting rules under Section 475 of the Code;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">99</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zbd7ce29be0e940ed852c25de86a6bee5" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">tax-exempt entities;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb52e7903a51b4263a0f2d4e962afa802" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">governments or agencies or instrumentalities thereof;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z827e38c196b244449e8d8a1aee698551" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">insurance companies;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z55f91da48e0549a1ad994185dcfd6c26" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">regulated investment companies;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd22c292fa235466ebdfb8343673a2a78" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">real estate investment trusts;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zaf5fa938bedc403fa50d321b65238849" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">certain expatriates or former long-term residents of the United States;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zfb669c9ff76e4ae994dc8de5b828d035" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">persons that actually or constructively own 5% or more of our shares;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z26f67d3e171a4b1da81bee74df2cf76e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">except as specifically discussed herein in respect of the Long Term Incentive Warrants, persons that acquired our securities pursuant to an exercise of employee options, in connection with employee incentive plans or otherwise as compensation;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb6bdb6b47ccf472cb6d5921acba0734f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">persons that hold our securities as part of a straddle, constructive sale, hedging, conversion or other integrated transaction;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7c6d157780394c398c29d518313a7834" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">persons whose functional currency is not the U.S. dollar;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9f0414ebdd70411f984144a2e9b3f8b7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">passive foreign investment companies; or</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z999a545484a642b6ae03c5d23c25154b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">controlled foreign corporations.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">This discussion does not address any aspect of U.S. federal non-income tax laws, such as gift or estate tax laws, or state, local or non-U.S. tax laws or, except as discussed herein, any tax reporting obligations applicable to a holder of our securities. Additionally, this discussion does not consider the tax treatment of partnerships or other pass-through entities or persons who hold our securities through such entities. If a partnership (or other entity classified as a partnership for U.S. federal income tax purposes) is the beneficial owner of our securities, the U.S. federal income tax treatment of a partner in the partnership generally will depend on the status of the partner and the activities of the partnership. This discussion also assumes that any distribution made (or deemed made) to a holder in respect of our securities and any consideration received (or deemed received) by a holder in connection with the sale or other disposition of our securities will be in U.S. dollars. In addition, as described in &#8220;Risk Factors &#8211; Risks Related to Taxation &#8211; There is a risk that we could be treated as a domestic (U.S.) corporation for U.S. federal income tax purposes by reason of the transactions related to our acquisition of all of the business operations and substantially all of the assets of Check-Cap LLC on May 31, 2009 (hereinafter sometimes referred to as the &#8220;reorganization&#8221;),&#8221; this discussion also assumes that we will be and have been treated as a foreign corporation for U.S. federal income tax purposes. Moreover, this discussion assumes that a holder owns a sufficient number of Series A Warrants, Series C Warrants, Series D Warrants and/or Long Term Incentive Warrants, such that the holder will not have a fractional warrant upon the exercise of a Series A Warrant, Series C Warrant, Series D Warrant and/or Long Term Incentive Warrant, as the case may be.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have not sought, and will not seek, a ruling from the IRS or an opinion of counsel as to any U.S. federal income tax consequence described herein. The IRS may disagree with the description herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt">EACH&#160;&#160;HOLDER OF OUR SECURITIES IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR SECURITIES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY STATE, LOCAL, AND NON-U.S. TAX LAWS, AS WELL AS U.S. FEDERAL TAX LAWS AND ANY APPLICABLE TAX TREATIES.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Characterization of the Long Term Incentive Warrants</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As discussed under &#8220;U.S. Holders &#8212; Exercise of Long Term Incentive Warrants&#8221; below, while not free from doubt, the Long Term Incentive Warrants may be treated for U.S. federal income tax purposes as compensatory warrants. Based on this characterization, no portion of the purchase price of a unit generally should have been allocated to the Long Term Incentive Warrants, and a holder of the Long Term Incentive Warrants may have ordinary compensation income for U.S. federal income tax purposes on the exercise of the Long Term Incentive Warrants, as described under &#8220;U.S. Holders &#8212; Exercise of Long Term Incentive Warrants&#8221; and &#8220;Non-U.S. Holders&#8221; below.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 45pt">Each holder is advised to consult its own tax advisor with respect to the risks associated with the Long Term Incentive Warrants (including alternative characterizations of the Long Term Incentive Warrants). The balance of this discussion assumes that the characterization of the Long Term Incentive Warrants as compensatory warrants will be respected for U.S. federal income tax purposes.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">100</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">U.S. Holders</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Taxation of Cash Distributions</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Subject to the passive foreign investment company, or PFIC, rules discussed below, a U.S. Holder generally will be required to include in gross income as ordinary income the amount of any cash dividend paid in respect of our ordinary shares. A cash distribution on our ordinary shares generally will be treated as a dividend for U.S. federal income tax purposes to the extent the distribution is paid out of our current or accumulated earnings and profits (as determined for U.S. federal income tax purposes). Such dividend generally will not be eligible for the dividends-received deduction generally allowed to U.S. corporations in respect of dividends received from other U.S. corporations. The portion of such cash distribution, if any, in excess of such earnings and profits will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in the ordinary shares. Any<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>remaining excess generally will be treated as gain from the sale or other taxable disposition of such ordinary shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">With respect to non-corporate U.S. Holders, any such cash dividends may be subject to U.S. federal income tax at the lower applicable regular long term capital gains tax rate (see &#8220;&#8212; Taxation on the Disposition of Ordinary Shares or Series A Warrants, Series C Warrants or Series D Warrants&#8221; below) provided that (a) our ordinary shares are readily tradable on an established securities market in the United States or we are eligible for the benefits of the United States-Israel Tax Treaty, (b) we are not a PFIC, as discussed below, for either the taxable year in which the dividend was paid or the preceding taxable year, and (c) certain holding period requirements are met. Therefore, if our ordinary shares are not readily tradable on an established securities market, and we are not eligible for the benefits of the United States-Israel Tax Treaty, then cash dividends paid by us to non-corporate U.S. Holders will not be subject to U.S. federal income tax at the lower regular long term capital gains tax rate. Under published IRS authority, shares are considered for purposes of clause (a) above to be readily tradable on an established securities market in the United States only if they are listed on certain exchanges, which presently include the Nasdaq Capital Market. Although our ordinary shares are currently listed and traded on the Nasdaq Capital Market, U.S. Holders nevertheless should consult their own tax advisors regarding the availability of the lower rate for any cash dividends paid with respect to our ordinary shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Dividends paid to a U.S. Holder with respect to our ordinary shares generally will be foreign source income, which may be relevant in calculating such U.S. Holder&#8217;s foreign tax credit limitations. Subject to certain conditions and limitations, Israeli tax withheld on dividends may be deducted from such U.S. Holder&#8217;s taxable income or credited against such U.S. Holder&#8217;s U.S. federal income tax liability. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends that we distribute generally should constitute &#8220;passive category income,&#8221; or, in the case of certain U.S. Holders, &#8220;general category income.&#8221; A foreign tax credit for foreign taxes imposed on distributions may be denied if a U.S. Holder does not satisfy certain minimum holding period requirements. The rules relating to the determination of the foreign tax credit are complex, and U.S. Holders should consult their tax advisors to determine whether and to what extent they will be entitled to this credit<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Adjustments with Respect to Warrants</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The terms of each Series A Warrant, Series C Warrant, Series D Warrant and Long Term Incentive Warrant provide for an adjustment to the number of ordinary shares for which the warrant may be exercised or to the exercise price of the warrant in certain events. An adjustment that has the effect of preventing dilution generally is not taxable. However, the U.S. Holders of the Series A Warrants, Series C Warrants and Series D Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the warrant holders&#8217; proportionate interest in our assets or earnings and profits (e.g., through a decrease in the exercise price of the Series A Warrants, Series C Warrants or Series D Warrants) as a result of a distribution of cash to the holders of our ordinary shares, which is taxable to the U.S. Holders of such ordinary shares as described under &#8220;&#8212; Taxation of Cash Distributions,&#8221; above. Such constructive distribution would be subject to tax as described under that section in the same manner as if the U.S. Holders of the Series A Warrants, Series C Warrants and Series D Warrants received a cash distribution from us equal to the fair market value of such increased interest. While not clear, the U.S. Holders of the Long Term Incentive Warrants may be subject to a similar tax treatment in respect of any such constructive distribution, or, alternatively, if such warrants are treated as compensatory warrants, such holders may be deemed to have additional compensation income either at the time of the adjustment or upon the exercise of the Long Term Incentive Warrants. U.S. Holders of Series A Warrants, Series C Warrants, Series D Warrants and Long Term Incentive Warrants are urged to consult their own tax advisors on these issues<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Taxation on the Disposition of Ordinary Shares or Series A Warrants, Series C Warrants or Series D Warrants</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Upon a sale or other taxable disposition of our ordinary shares or the Series A Warrants, Series C Warrants or Series D Warrants, and subject to the PFIC rules discussed below, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. Holder&#8217;s adjusted tax basis in the securities<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The regular U.S. federal income tax rate on capital gains recognized by U.S. Holders generally is the same as the regular U.S. federal income tax rate on ordinary income, except that long term capital gains recognized by non-corporate U.S. Holders generally are subject to U.S. federal income tax at a maximum regular rate of 20%. Capital gain or loss will constitute long term capital gain or loss if the U.S. Holder&#8217;s holding period for the securities exceeds one year. The deductibility of capital losses is subject to various limitations. Any such gain or loss that a U.S. Holder recognizes generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">101</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If an Israeli capital gains tax applies to any gains from the disposition of our ordinary shares or the Series A Warrants, Series C Warrants or Series D Warrants by a U.S. Holder, as discussed in &#8220;Israeli Tax Considerations and Government Programs &#8211; Taxation of our Shareholders&#8221; above, such tax may be treated as a foreign tax eligible for a deduction from such holder&#8217;s U.S. federal taxable income or a foreign tax credit against such holder&#8217;s U.S. federal income tax liability (subject to certain conditions and limitations). In addition, if such Israeli tax applies to any such gain, a U.S. Holder may be entitled to certain benefits under the United States-Israel Tax Treaty, if such holder is considered a resident of the United States for purposes of, and otherwise meets the requirements of, the United States-Israel Tax Treaty. U.S. Holders should consult their own tax advisors regarding the deduction or credit for any such Israeli tax and their eligibility for the benefits of the United States-Israel Tax Treaty.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Additional Taxes</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally may be subject to a 3.8% Medicare contribution tax on unearned income, including, without limitation, dividends on, and gains from the sale or other taxable disposition of, our ordinary shares or the Series A Warrants, Series C Warrants or Series D Warrants, subject to certain limitations and exceptions. U.S. Holders should consult their own tax advisors regarding the effect, if any, of such tax on their ownership and disposition of our ordinary shares or the Series A Warrants, Series C Warrants or Series D Warrants<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Exercise or Lapse of a Series A Warrant, Series C Warrant or Series D Warrant</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Subject to the PFIC rules discussed below, a U.S. Holder generally will not recognize gain or loss upon the exercise of a Series A Warrant, Series C Warrant or Series D Warrant for cash. An ordinary share acquired pursuant to the exercise of a Series A Warrant, Series C Warrant or Series D Warrant for cash generally will have a tax basis equal to the U.S. Holder&#8217;s tax basis in the Series A Warrant, Series C Warrant or Series D Warrant, as applicable, increased by the amount paid to exercise the Series A Warrant, Series C Warrant or Series D Warrant. The holding period of such ordinary share generally would begin on the day after the date of exercise of the Series A Warrant, Series C Warrant or Series D Warrant. If a Series A Warrant, Series C Warrant or Series D Warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis in the Series A Warrant, Series C Warrant or Series D Warrant<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The tax consequences of a cashless exercise of Series A Warrants, Series C Warrants and Series D Warrants are not clear under current tax law. A cashless exercise may be tax-free, either because it is not a realization event (i.e., not a transaction in which gain or loss is realized) or because the transaction is treated as a recapitalization for U.S. federal income tax purposes. In either tax-free situation, a U.S. Holder&#8217;s tax basis in the ordinary shares received would equal the U.S. Holder&#8217;s basis in the Series A Warrants, Series C Warrants or Series D Warrants surrendered. If the cashless exercise were treated as not being a realization event, the U.S. Holder&#8217;s holding period in the ordinary shares could be treated as commencing on the date following the date of exercise of the Series A Warrants, Series C Warrants or Series D Warrants. If the cashless exercise were treated as a recapitalization, the holding period of the ordinary shares received would include the holding period of the Series A Warrants, Series C Warrants or Series D Warrants, as applicable<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">It is also possible that a cashless exercise could be treated as a taxable exchange in which gain or loss is recognized. In such event, a U.S. Holder could be deemed to have surrendered a number of Series A Warrants, Series C Warrants or Series D Warrants, as applicable, with a fair market value equal to the exercise price for the number of Series A Warrants, Series C Warrants or Series D Warrants deemed exercised. For this purpose, the number of Series A Warrants, Series C Warrants or Series D Warrants deemed exercised would be equal to the amount needed to receive on exercise the number of ordinary shares issued pursuant to the cashless exercise of the Series A Warrants, Series C Warrants or Series D Warrants. In this situation, the U.S. Holder would recognize capital gain or loss in an amount equal to the difference between the fair market value of the Series A Warrants, Series C Warrants or Series D Warrants deemed surrendered to pay the exercise price and the U.S. Holder&#8217;s tax basis in such Series A Warrants, Series C Warrants or Series D Warrants deemed surrendered. Such gain or loss would be long-term or short-term depending on the U.S. Holder&#8217;s holding period in the Series A Warrants, Series C Warrants or Series D Warrants, as applicable. In this case, a U.S. Holder&#8217;s tax basis in the ordinary shares received would equal the sum of the fair market value of the Series A Warrants, Series C Warrants or Series D Warrants deemed surrendered to pay the exercise price and the U.S. Holder&#8217;s tax basis in the Series A Warrants, Series C Warrants or Series D Warrants deemed exercised, and a U.S. Holder&#8217;s holding period for the ordinary shares should commence on the date following the date of exercise of the Series A Warrants, Series C Warrants or Series D Warrants. There also may be alternative characterizations of any such taxable exchange that would result in similar tax consequences, except that a U.S. Holder&#8217;s gain or loss would be short-term.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Due to the absence of authority on the U.S. federal income tax treatment of a cashless exercise of Series A Warrants, Series C Warrants and Series D Warrants, it is unclear which, if any, of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a cashless exercise of Series A Warrants, Series C Warrants and Series D Warrants.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">102</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Exercise of Long Term Incentive Warrants</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">While not free from doubt, the Long Term Incentive Warrants may be treated as compensatory warrants (i.e., warrants issued to compensate an original purchaser of units in our initial public offering for holding the ordinary shares underlying the units for a certain period of time after the closing date of our initial public offering). Based on this characterization, a U.S. Holder of the Long Term Incentive Warrants generally would recognize ordinary compensation income on the exercise of the Long Term Incentive Warrants equal to the excess of the fair market value of the ordinary shares acquired pursuant to the exercise of the Long Term Incentive Warrants over the exercise price of the Long Term Incentive Warrants. In such case, a U.S. Holder&#8217;s tax basis in the ordinary shares received should be equal to their fair market value at the time of exercise, and the holding period of such ordinary shares should begin on the date of exercise.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Passive Foreign Investment Company Rules</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">A foreign (i.e., non-U.S.) corporation will be a PFIC if either (a) at least 75% of its gross income in a taxable year of the foreign corporation, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, is passive income, or (b) at least 50% of its assets in a taxable year of the foreign corporation, ordinarily determined based on fair market value and averaged quarterly over the year, including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends, interest, rents and royalties (other than certain rents or royalties derived from the active conduct of a trade or business), and gains from the disposition of passive assets.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We believe that we <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">were </font>a PFIC for the taxable year ended December 31, 2018<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> and may be a PFIC for the taxable year ending December 31, 2019</font>.&#160; <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">O</font>ur PFIC status for our current taxable year (2019) or any subsequent taxable year is uncertain and will not be determinable until after the end of such taxable year. Accordingly, there can be no assurance with respect to our status as a PFIC for our taxable year end<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">ing</font> December 31, 201<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">9</font> or any subsequent taxable year.</div>

&#160;&#160;&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If we are determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder of our ordinary shares or Series A Warrants, Series C Warrants or Series D Warrants, and, in the case of our ordinary shares, the U.S. Holder did not make a timely QEF election for our first taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) the ordinary shares, a purging election, a QEF election along with a purging election, or a mark-to-market election, each as described below, such holder generally will be subject to special rules for regular U.S. federal income tax purposes with respect to:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf2af9092a1324f3eac4ecc51a8c277d2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">any gain recognized by the U.S. Holder on the sale or other disposition of its ordinary shares or Series A Warrants, Series C Warrants or Series D Warrants; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1b1a2314c9be458f9d235f1caa28901e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">any &#8220;excess distribution&#8221; made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S. Holder that are greater than 125% of the average annual distributions received by such U.S. Holder in respect of the ordinary shares during the three preceding taxable years of such U.S. Holder or, if shorter, such U.S. Holder&#8217;s holding period for the ordinary shares).</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 86.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -42.9pt">Under these rules,</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0d8a69451a1c46ee8f3e718126afb05f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the U.S. Holder&#8217;s gain or excess distribution will be allocated ratably over the U.S. Holder&#8217;s holding period for the ordinary shares or Series A Warrants, Series C Warrants or Series D Warrants;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z24ec5dbd21d54263b3bf27e035680b82" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the amount allocated to the U.S. Holder&#8217;s taxable year in which the U.S. Holder recognized the gain or received the excess distribution or to the period in the U.S. Holder&#8217;s holding period before the first day of our first taxable year in which we qualified as a PFIC will be taxed as ordinary income;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zf7770a214cb2431a8c7616b10d6e00ee" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the amount allocated to other taxable years (or portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest ordinary tax rate in effect for that year and applicable to the U.S. Holder; and</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z05ff42a9b48c4681bce1d04fd5051100" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">the interest charge generally applicable to underpayments of tax will be imposed in respect of the tax attributable to each such other taxable year of the U.S. Holder.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Although a determination as to our PFIC status is made annually, an initial determination that we are a PFIC generally will apply for subsequent years to a U.S. Holder that held (or was deemed to hold) our ordinary shares or Series A Warrants, Series C Warrants or Series D Warrants while we were a PFIC, whether or not we meet the test for PFIC status in those subsequent years. If we are determined to be a PFIC in any taxable year, and then cease to meet the test for PFIC status in a subsequent taxable year, a U.S. Holder may be able to make a purging election to eliminate this continuing PFIC status with respect to its ordinary shares in certain circumstances. A purging election generally creates a deemed sale of such ordinary shares at their fair market value on the last day of our tax year during which we qualified as a PFIC (or, in the case of a purging election made in connection with a QEF election, the first day of our taxable year in which qualify as a QEF with respect to such U.S. Holder). Any gain recognized by the purging election generally will be treated as an excess distribution subject to the special tax and interest charge rules described above. As a result of the purging election, the U.S. Holder generally will increase the adjusted basis in its ordinary shares by the amount of gain recognized and will also have a new holding period in its ordinary shares for purposes of the PFIC rules.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">103</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In general, if we are determined to be a PFIC, a U.S. Holder may avoid the PFIC tax consequences described above with respect to the ordinary shares by making a timely QEF election (or a QEF election along with a purging election). Pursuant to the QEF election, a U.S. Holder generally will be required to include in income its pro rata share of our net capital gains (as long term capital gain) and other earnings and profits (as ordinary income), on a current basis, in each case whether or not distributed, in the taxable year of the U.S. Holder in which or with which our taxable year ends if we are treated as a PFIC for that taxable year. However, a U.S. Holder may make a QEF election only if we agree to provide certain tax information to such holder annually. At this time, we do not intend to provide U.S. Holders with such information as may be required to make a QEF election effective.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Alternatively, if a U.S. Holder, at the close of its taxable year, owns ordinary shares in a PFIC that are treated as marketable stock, the U.S. Holder may make a mark-to-market election with respect to such ordinary shares for such taxable year. If the U.S. Holder makes a valid mark-to-market election for the first taxable year of the U.S. Holder in which the U.S. Holder holds (or is deemed to hold) the ordinary shares and for which we are determined to be a PFIC, such holder generally will not be subject to the PFIC rules described above with respect to its ordinary shares as long as such shares continue to be treated as marketable stock. Instead, in general, the U.S. Holder will include as ordinary income for each year that we are treated as a PFIC the excess, if any, of the fair market value of its ordinary shares at the end of its taxable year over the adjusted tax basis in its ordinary shares. The U.S. Holder also will be allowed to take an ordinary loss in respect of the excess, if any, of the adjusted tax basis of its ordinary shares over the fair market value of its ordinary shares at the end of its taxable year (but only to the extent of the net amount of previously included income as a result of the mark-to-market election). The U.S. Holder&#8217;s adjusted tax basis in its ordinary shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale or other taxable disposition of the ordinary shares in a taxable year in which we are treated as a PFIC generally will be treated as ordinary income. Special tax rules may also apply if a U.S. Holder makes a mark-to-market election for a taxable year after the first taxable year in which the U.S. Holder holds (or is deemed to hold) our ordinary shares and for which we are determined to be a PFIC. Currently, a mark-to-market election may not be made with respect to warrants.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The mark-to-market election is available only for stock that is regularly traded on a national securities exchange that is registered with the U.S. Securities and Exchange Commission, including the Nasdaq Capital Market, or on a foreign exchange or market that is regulated or supervised by a governmental authority of the country in which the exchange or market is located and which (A) meets certain requirements, that are enforced by law, relating to trading volume, listing, financial disclosure,&#160; surveillance and other requirements that are designed to (i) prevent fraudulent and manipulative acts and practices, (ii) remove impediments to and perfect the mechanism of a free and open, fair and orderly market and (iii) protect investors and (B) has rules that effectively promote the active trading of listed stock. Although our ordinary shares are currently listed and traded on the Nasdaq Capital Market, U.S. Holders nevertheless should consult their own tax advisors regarding the availability and tax consequences of a mark-to-market election with respect to our ordinary shares under their particular circumstances.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">If we are a PFIC and, at any time, have a foreign subsidiary that is classified as a PFIC, a U.S. Holder of our ordinary shares generally should be deemed to own a portion of the shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge described above if we receive a distribution from, or dispose of all or part of our interest in, or the U.S. Holder were otherwise deemed to have disposed of an interest in, the lower-tier PFIC. A mark-to-market election generally would not be available with respect to such a lower-tier PFIC. U.S. Holders are urged to consult their own tax advisors regarding the tax issues raised by lower-tier PFICs.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">A U.S. Holder that owns (or is deemed to own) ordinary shares in a PFIC during any taxable year of the U.S. Holder may have to file an IRS Form 8621 (whether or not a mark-to-market election is or has been made) with such U.S.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"> &#160;</font> Holder&#8217;s U.S. federal income tax return and provide such other information as may be required by the U.S. Treasury Department.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The rules dealing with PFICs and purging and mark-to-market elections are very complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders of our securities should consult their own tax advisors concerning the application of the PFIC rules to our securities under their particular circumstances.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Non-U.S. Holders</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Cash dividends paid or deemed paid to a Non-U.S. Holder with respect to our ordinary shares generally will not be subject to U.S. federal income tax unless such dividends are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that such holder maintains or maintained in the United States).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, a Non-U.S. Holder generally will not be subject to U.S. federal income tax on any gain attributable to a sale or other taxable disposition of our securities unless such gain is effectively connected with its conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains or maintained in the United States) or the Non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year of such sale or other disposition and certain other conditions are met (in which case, such gain from U.S. sources generally is subject to U.S. federal income tax at a 30% rate or a lower applicable tax treaty rate).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">104</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Dividends and gains that are effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or business in the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that such holder maintains or maintained in the United States) generally will be subject to regular U.S. federal income tax at the same regular U.S. federal income tax rates as applicable to a comparable U.S. Holder and, in the case of a Non-U.S. Holder that is a corporation for U.S. federal income tax purposes, may also be subject to an additional branch profits tax at a 30% rate or a lower applicable tax treaty rate.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As in the case of a U.S. Holder, as described under &#8220;U.S. Holders &#8212; Exercise of Long Term Incentive Warrants&#8221; and &#8220; &#8212; Adjustments with Respect to Warrants,&#8221; a Non-U.S. Holder also may have compensation income for U.S. federal income tax purposes on the exercise of (or on certain adjustments in respect of) the Long Term Incentive Warrants. A Non-U.S. Holder may be subject to U.S. federal income tax (subject to reduction or elimination by an applicable income tax treaty) with respect to such compensation income to the extent such income is deemed to be attributable to the performance (or the refraining from the performance) of services in the United States or is otherwise considered to be U.S. source income for U.S. federal income tax purposes. Non-U.S. Holders are urged to consult their own tax advisors as to the U.S. federal income tax consequences that may arise with respect to the Long Term Incentive Warrants<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Backup Withholding and Information Reporting</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In general, information reporting for U.S. federal income tax purposes should apply to distributions made on our securities within the United States to a U.S. Holder (other than an exempt recipient) and to the proceeds from sales and other dispositions of our securities by a U.S. Holder (other than an exempt recipient) to or through a U.S. office of a broker. Payments made (and sales and other dispositions effected at an office) outside the United States will be subject to information reporting in limited circumstances. In addition, certain information concerning a U.S. Holder&#8217;s adjusted tax basis in its securities and adjustments to that tax basis and whether any gain or loss with respect to such securities is long term or short term also may be required to be reported to the IRS, and certain holders may be required to file an IRS Form 8938 (Statement of Specified Foreign Financial Assets) to report their interest in our securities.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Moreover, backup withholding of U.S. federal income tax, currently at a rate of 24%, generally will apply to dividends paid on our securities to a U.S. Holder (other than an exempt recipient) and the proceeds from sales and other dispositions of our securities by a U.S. Holder (other than an exempt recipient), in each case who:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0334d67ac1ce4a1face36c9a9e3d06d4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">fails to provide an accurate taxpayer identification number;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z18e04527dc124356bee40d5742e53423" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">is notified by the IRS that backup withholding is required; or</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zfbb8af2cadc4437d969399348a8daccb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">in certain circumstances, fails to comply with applicable certification requirements.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">A Non-U.S. Holder generally may eliminate the requirement for information reporting and backup withholding by providing certification of its foreign status, under penalties of perjury, on a duly executed applicable IRS Form W-8 or by otherwise establishing an exemption.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Backup withholding is not an additional tax. Rather, the amount of any backup withholding will be allowed as a credit against a U.S. Holder&#8217;s or a Non-U.S. Holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that certain required information is timely furnished to the IRS.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Holders are urged to consult their own tax advisors regarding the application of backup withholding and the availability of and procedures for obtaining an exemption from backup withholding in their particular circumstances.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9f815dd1017b4c33938346e89fbcc906" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">F.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Dividends and paying agents</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zce301f5ef1dd48fe889aa29fab686822" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">G.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Statement by experts</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5d0752e7368040d098669358604fac41" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">H.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Documents on display</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">You may inspect our securities filings, including this Annual Report and the exhibits and schedules thereto, without charge at the offices of the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may obtain copies of all or any part of the Annual Report from the Public Reference Section of the SEC, 100 F Street, NE, Washington, D.C. 20549 upon the payment of the prescribed fees. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding registrants like us that file electronically with the SEC. You can also inspect the Annual Report on this website.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">A copy of each document (or a translation thereof to the extent not in English) concerning our company that is referred to in this Annual Report is available for public view (subject to confidential treatment of certain agreements pursuant to applicable law) at our principal executive offices at Check-Cap Building, 29 Abba Hushi Avenue, P.O. Box 1271, Isfiya, 3009000, Israel.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">105</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z73d5c49f651d417dbf7e683d418dbe7d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 3.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">I.</div>
</td>
<td style="WIDTH: 96.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Subsidiary Information</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><a id="ITEM11" name="ITEM11"><!--Anchor--></a>ITEM 11.</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Exchange Rate Risk</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Some of our assets and liabilities are affected by fluctuations in the exchange rate between the U.S. dollar and the NIS and between the U.S. dollar and the Euro. For example, salaries and related expenses for Israeli employees are paid in NIS and some of our suppliers are located in Europe and require payment in Euros.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">During 2018, we entered into zero-cost collars to hedge against the risk of overall changes in exchange rates on future cash flow from payments of payroll and rent denominated in NIS. These contracts met the requirement for cash flow hedge accounting. During 2018, losses in the amount of $28,000 were reclassified when the related expenses were incurred and recognized in operating expenses. As of December&#160;31, 2018, we had had outstanding foreign exchange collars in the notional amount of $2.1 million with a fair value liability of $15,000.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As of December 31, 2018, our total assets and liabilities linked to the NIS amounted to $1.2 million and $1.5 million, respectively. A 10% depreciation of the dollar in relation to the NIS would cause an exchange rate loss of $29,000.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">As of December 31, 2018, we had no assets linked to the Euro and our total liabilities linked to the Euro amounted to $119,000. A 10% depreciation of the dollar in relation to the Euro would cause an exchange rate loss of $12,000.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">During the year ended December 31, 2018, the exchange rate between the U.S. dollar and the NIS increased by 8.1% and the exchange rate between the U.S. dollar and the EURO increased by 4.79%.&#160;During the year ended December 31, 2017, the exchange rate between the U.S. dollar and the NIS decreased by 9.83% and the exchange rate between the U.S. dollar and the EURO decreased by 12.33%. During the year ended December 31, 2016, the exchange rate between the U.S. dollar and the NIS decreased by 1.4% and the exchange rate between the U.S. dollar and the EURO increased by 3.21%.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Interest Rate Risk</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our obligation to pay royalties to the IIA is linked to LIBOR and we are therefore exposed to changes in LIBOR.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">In addition, we intend to invest our cash balances, including certain of the net proceeds from our May 2018 underwritten public offering and January 2019 registered direct offering pending their ultimate use, primarily in bank deposits and securities issued by the U.S. and Israeli governments. We are exposed to market risks resulting from changes in interest rates relating primarily to our financial investments in cash and deposits. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest income may decline in the future as a result of changes in the financial markets; however, we believe any such potential loss would be immaterial to us.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><a id="ITEM12" name="ITEM12"><!--Anchor--></a>ITEM 12.</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="PARTII" name="PARTII"><!--Anchor--></a>PART II</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><a id="ITEM13" name="ITEM13"><!--Anchor--></a>ITEM 13.</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><a id="ITEM14" name="ITEM14"><!--Anchor--></a>ITEM 14.</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">106</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"><a id="ITEM15" name="ITEM15"><!--Anchor--></a>ITEM 15.</font>&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">CONTROLS AND PROCEDURES</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">(a)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Disclosure Controls and Procedures.</font> Our management, including our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report (the &#8220;Evaluation Date&#8221;). Based on such evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that, as of the Evaluation Date, the Company&#8217;s disclosure controls and procedures are effective.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">(b)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</font>.&#160;Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act.&#160;Our management, including our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework and criteria established in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) as of the end of the period covered by this Annual Report.&#160;Based on that evaluation, our management has concluded that our internal control over financial reporting was effective as of December 31, 2018.&#160;As all internal control systems, no matter how well designed, have inherent limitations, our internal control over financial reporting may not prevent or detect misstatements.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">(c)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Attestation Report of Registered Public Accounting Firm</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">.</font>&#160;This Annual Report does not include an audit report on the effectiveness of our internal controls over financial reporting as of December 31, 2018 by our registered public accounting firm due to our status as an emerging growth company under the Jumpstart Our Business Startups Act of 2012.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">(d)</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; FONT-STYLE: italic">Changes in Internal Control Over Financial Reporting.</font><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>Based on the evaluation conducted by our Chief Executive Officer and our Chief Financial Officer pursuant to Rules 13a-15(d) and 15d-15(d) under the Exchange Act, our management has concluded that there was no change in our internal control over financial reporting that occurred during the year ended December&#160;31, 2018 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM16" name="ITEM16"><!--Anchor--></a>ITEM 16. [RESERVED]</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM16A" name="ITEM16A"><!--Anchor--></a>ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our Board of Directors has determined that Mr. Yuval Yanai, a member of our audit committee is an audit committee financial expert as defined by rules of the U.S. Securities and Exchange Commission and is an independent director under Nasdaq Listing Rules.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM16B" name="ITEM16B"><!--Anchor--></a>ITEM 16B. CODE OF ETHICS.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">We have adopted a Code of Business Conduct and Ethics that applies to all of our directors and employees, including our chief executive officer, chief financial officer, controller or principal accounting officer, or other persons performing similar functions, which complies with the &#8220;code of ethics&#8221; contemplated by Item 16B of Form 20-F promulgated by the U.S. Securities and Exchange Commission. A copy of our Code of Business Conduct and Ethics is available on our website at<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic"><u> http://ir.check-cap.com/corporate-governance</u></font>.&#160;Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report and is not incorporated by reference herein.&#160;If we make any amendment to the Code of Business Conduct and Ethics or grant any waivers, including any implicit waiver, from a provision of the code of ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the U.S. Securities and Exchange Commission.&#160; Under Item 16B of the U.S. Securities and Exchange Commission&#8217;s Form 20-F, if a waiver or amendment of the Code of Business Conduct and Ethics applies to our principal executive officer, principal financial officer, principal accounting officer or controller and relates to standards promoting any of the values described in Item 16B(b) of Form 20-F, we will disclose such waiver or amendment on our website in accordance with the requirements of Instruction 4 to such Item 16B.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM16C" name="ITEM16C"><!--Anchor--></a>ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">The following table represents aggregate fees billed to us for professional services rendered for fiscal years ended December 31, 2018 and 2017 by Brightman Almagor Zohar &amp; Co., a member firm of Deloitte Touche Tohmatsu, an independent registered accounting firm.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z345f7fc6e56047d7a9d44cda7c361faf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Audit Fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(1)</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">60,000</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">60,000</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Audit-Related Fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(2)</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">45,000</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,000</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Other Fees<sup style="vertical-align: text-top; line-height: 1; font-size: smaller">(3)</sup>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">25,481</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 19.8pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -8.8pt">Total&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">105,000</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">89,481</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">______________________</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1827652414d0491685125a6432eb8220" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 2.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(1)</div>
</td>
<td style="WIDTH: 97.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The audit fees for the years ended December 31, 2018 and 2017 were for professional services rendered for the audits of our financial statements, consents and in connection with certain of our filings with the U.S. Securities and Exchange Commission.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 2.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(2)</div>
</td>
<td style="WIDTH: 97.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Audit-related fees for the year ended December 31, 2018, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">are for services rendered by our auditors in connection with our May 2018 underwritten public offering. </font>Audit-related fees for the year ended December 31, 2017 are for services rendered by our auditors in connection with determining the number of Long-Term Incentive Warrants that were vested at February 24, 2016 and February 24, 2017.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 2.67%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(3)</div>
</td>
<td style="WIDTH: 97.33%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Other fees for the year ended December 31, 2017 were for services related to the application for an additional grant from the IIA (formerly the OCS).</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">107</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Audit Committee Pre-approval Policies and Procedures</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our audit committee has adopted a pre-approval policy for the engagement of our independent registered public accounting firm to perform certain audit and non-audit services. Pursuant to this policy, which is designed to assure that such engagements do not impair the independence of our auditors, the audit committee pre-approves annually a catalog of specific audit and non-audit services in the categories of audit services, audit-related services and tax services that may be performed by our independent registered public accounting firm. If a type of service, that is to be provided by our auditors, has not received such general pre-approval, it will require specific pre-approval by our audit committee. The policy prohibits retention of the independent registered public accounting firm to perform the prohibited non-audit functions defined in applicable SEC rules.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM16D" name="ITEM16D"><!--Anchor--></a>ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM16E" name="ITEM16E"><!--Anchor--></a>ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM16F" name="ITEM16F"><!--Anchor--></a>ITEM 16F. CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a id="ITEM16G" name="ITEM16G"><!--Anchor--></a>ITEM 16G. CORPORATE GOVERNANCE.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Under the Israeli Companies Law, companies incorporated under the laws of the State of Israel whose shares are publicly traded, including companies with shares listed on the Nasdaq Capital Market, are considered public companies under Israeli law and are required to comply with various corporate governance requirements relating to such matters as external directors, the audit committee, the compensation committee and an internal auditor.&#160;&#160;These requirements are in addition to the corporate governance requirements imposed by the Listing Rules of the Nasdaq Stock Market and other applicable provisions of U.S. securities laws to which we became subject (as a foreign private issuer) upon the closing of our initial public offering and the listing of our securities on the Nasdaq Capital Market.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold"> &#160;</font>&#160; Under the Listing Rules of the Nasdaq Stock Market, a foreign private issuer, such as us, may generally follow its home country rules of corporate governance in lieu of the comparable requirements of the Listing Rules of the Nasdaq Stock Market, except for certain matters including (among others) the composition and responsibilities of the audit committee and the independence of its members within the meaning of the rules and regulations of the U.S. Securities and Exchange Commission. We currently rely on this &#8220;home country practice exemption&#8221; solely with respect to the following items:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z608f59554f54454b83f31d3e2d8ef7af" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Nomination of our directors</font>. Israeli law and our amended articles of association do not require director nominations to be made by a nominating committee of our board of directors consisting solely of independent directors, as required&#160;&#160; under the Listing Rules of the Nasdaq Stock Market. We rely on the exemption available to foreign private issuers under the Nasdaq Listing Rules and follow Israeli law and practice with regard to the process of nominating directors, in accordance with which directors are recommended by our board of directors for election by our shareholders (other than directors elected by our board of directors to fill a vacancy).&#160; In October 2015, our Board of Directors established a non-independent Nominating Committee, whose role is to select and recommend to the Board of Directors for selection, director nominees, while considering the appropriate size and composition of the Board of Directors, the requirements of applicable law regarding service as a member of our Board of Directors and the criteria for the selection of new members of the Board of Directors.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Compensation of officers</font>. We follow Israeli law and practice with respect to the approval of officer compensation.&#160; While our compensation committee currently complies with the provisions of the Nasdaq Listing Rules relating to composition requirements and Israeli law generally requires that the compensation of the chief executive officer and all other executive officers be approved, or recommended to the board for approval, by the compensation committee (and in certain instances, shareholder approval is required), Israeli law includes relief from compensation committee approval in certain instances. For details regarding the approvals required under the Israeli Companies Law and regulation promulgated thereunder for the approval of compensation of the chief executive officer, all other executive officers and directors, see Item 6C &#8220;Directors, Senior Management and Employees&#8212; Board Practices &#8212; Approval of Related Party Transactions under Israeli Law &#8212; Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions&#8221;).</div>
</td>
</tr>
</table>

<div>&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">108</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<table id="z0bdf8a2f1b084e07ae4ec028537b5bd2" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Shareholder approval.</font>&#160;We will seek shareholder approval for all corporate actions requiring such approval under the requirements of the Israeli Companies Law, rather than seeking approval for corporate actions in accordance with Nasdaq Listing Rule 5635. In particular, under the Nasdaq Listing Rule, shareholder approval is generally required for: (i) an acquisition of shares/assets of another company that involves the issuance of 20% or more of the acquirer&#8217;s shares or voting rights or if a director, officer or 5% shareholder has greater than a 5% interest (or such persons collectively have a 10% or greater interest) in the target company or the assets to be acquired or the consideration to be received and the present or potential issuance of ordinary shares, or securities convertible into or exercisable for ordinary shares, could result in an increase in outstanding common shares or voting power of 5% or more; (ii) the issuance of shares leading to a change of control; (iii) adoption/amendment of a stock option or purchase plan or other equity compensation arrangements, pursuant to which stock may be acquired by officers, directors, employees or consultants (with certain limited exception); and (iv) issuances of 20% or more of the shares or voting rights (including securities convertible into, or exercisable for, equity) of a listed company via a private placement (and/or via sales by directors/officers/5% shareholders) if such equity is issued (or sold) at below the greater of the book or market value of shares. We will seek shareholder approval for all actions requiring such under the Israeli Companies Law.&#160;Under the Israeli Companies Law, the adoption of, and material changes to, equity-based compensation plans generally require the approval of the board of directors.&#160;For details regarding the approvals required under the Israeli Companies Law for the approval of compensation of the chief executive officer, all other executive officers and directors, see &#8220;Item 6C &#8220;Directors, Senior Management and Employees &#8212; Board Practices -Approval of Related Party Transactions under Israeli Law &#8212; Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions.&#8221; For details regarding the approvals required under the Israeli Companies Law for the approval of transactions with and compensation of controlling shareholders, see &#8220;Item 6C &#8220;Directors, Senior Management and Employees &#8212; Board Practices -Approval of Related Party Transactions under Israeli Law &#8212; Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions. &#8221; For details regarding the approvals required under the Israeli Companies Law for certain acquisitions of our shares and mergers, see Item 10B. &#8220;Memorandum and Articles of Association&#8212; Acquisitions under Israeli Law.&#8221;</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 7.22%; VERTICAL-ALIGN: middle">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.15%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#8226;</div>
</td>
<td style="WIDTH: 86.63%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-STYLE: italic">Quorum requirement.</font> Under our amended and restated articles of association and as permitted under the Israeli Companies Law, a quorum for any meeting of shareholders shall be the presence of at least two shareholders present in person, by proxy or by a written ballot, who hold at least 25% of the voting power of our shares (or if a higher percentage is required by law, such higher percentage) instead of 33 1/3% of the issued share capital required under the Nasdaq Listing Rules. If the meeting was adjourned for lack of a quorum, at the adjourned meeting, at least two shareholders present in person or by proxy shall constitute a quorum, unless the meeting of shareholders was convened at the demand of shareholders, in which case, the quorum shall be the presence of one or more shareholders holding at least 5% of our issued share capital and at least one percent of the voting power of our shares, or one or more shareholders with at least 5% of the voting power of our shares.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 43.2pt">Except as stated above, we currently intend to comply with the rules generally applicable to U.S. domestic companies listed on Nasdaq. We may in the future decide to use the foreign private issuer exemption with respect to some or all of the other Nasdaq corporate governance rules. Following our home country governance practices, as opposed to the requirements that would otherwise apply to a company listed on Nasdaq, may provide less protection than is accorded to investors under Nasdaq listing requirements applicable to domestic issuers.&#160; For more information, see &#8220; Item 3D &#8220;Key Information - Risk Factors Risks Related to the Company&#8221;- As a foreign private issuer, we are permitted, and intend, to follow certain home country corporate governance practices instead of otherwise applicable Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic U.S. issuers.&#8221;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><a id="ITEM16H" name="ITEM16H"><!--Anchor--></a>ITEM 16H. MINE SAFETY DISCLOSURE.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="PARTIII" name="PARTIII"><!--Anchor--></a>PART III</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a id="ITEM17" name="ITEM17"><!--Anchor--></a>ITEM 17.&#160;FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Not applicable.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a id="ITEM18" name="ITEM18"><!--Anchor--></a>ITEM 18. FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; TEXT-INDENT: 42.9pt">Our Financial Statements beginning on pages F-1 through F-31 are hereby incorporated herein by reference.&#160; These Financial Statements are filed as part of this Annual Report.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">109</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a id="ITEM19" name="ITEM19"><!--Anchor--></a>ITEM 19. EXHIBITS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff">Exhibit Index</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; BACKGROUND-COLOR: #ffffff">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5543e8428b0b451ca32c8fb50a59d20c" style="FONT-SIZE: 10pt; BORDER-TOP: medium none; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Exhibit No.</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Description</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001121/exhibit_1-1.htm">1.1</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001121/exhibit_1-1.htm">Amended and Restated Articles of Association of the Registrant (7)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-14.htm">2.1</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-14.htm">Form of Registrant&#8217;s Ordinary Share Certificate (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">2.2</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">Form of Series A Warrant Certificate (included in Exhibit 4.4) (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">2.3</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">Form of Long Term Incentive Warrant Certificate (included in Exhibit 4.4) (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">2.4</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_4-6.htm">Form of Warrant Agreement dated as of February 24, 2015 between Check-Cap Ltd. and American Stock Transfer &amp; Trust Company LLC, as Warrant Agent (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315002104/exhibit_4-1.htm">2.5</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315002104/exhibit_4-1.htm">Amendment No.1 dated as of June 24, 2015, to Warrant Agreement dated as of February 24, 2015 between Check-Cap Ltd. and American Stock Transfer &amp; Trust Company LLC, as Warrant Agent (8)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_1-1.htm">2.6</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000567/exhibit_1-1.htm">Form of 2014 Underwriter Warrants (1)</a></div>
</td>
</tr>

<tr style="HEIGHT: 15px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_4-2.htm">2.7</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_4-2.htm">Form of June 2017 Warrants (5)</a></div>
</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_4-2.htm">2.8</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_4-2.htm">Form of June 2017 Placement Agent Warrants (5)</a></div>
</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-1.htm">2.9</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-1.htm">Form of November 2017 Warrants (6)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-2.htm">2.10</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_4-2.htm">Form of November 2017 Placement Agent Warrants (6)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-13.htm">2.11</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-13.htm">Form of Ordinary Shares Warrant Certificate issued pursuant to a certain Credit Line Agreement dated as of August 20, 2014 (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-15.htm">2.12</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-15.htm">Forms of Ordinary Shares Warrant Certificate issued to the Pontifax entities (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-13.htm">2.13</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-13.htm">Form of Pre-Funded Warrant (9)</a></div>
</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-14.htm">2.14</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-14.htm">Form of Series C Warrant (9)</a></div>
</td>
</tr>

<tr style="HEIGHT: 20px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-15.htm">2.15</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001272/exhibit_4-15.htm">Form of Warrant Agent Agreement&#160; between Check-Cap Ltd. and American Stock Transfer &amp; Trust Company LLC, as Warrant Agent (9)</a></div>
</td>
</tr>

<tr style="HEIGHT: 23px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001462/exhibit_1-1.htm">2.16</a></td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891318001462/exhibit_1-1.htm">Underwriting Agreement, dated as of May 4, 2018, by and between Check-Cap Ltd. and H.C. Wainwright &amp; Co., LLC(10)</a></td>
</tr>

<tr style="HEIGHT: 20px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-1.htm">2.17</a></td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-1.htm">Form of February 2019 Series D Warrant (11)</a></td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-2.htm">2.18</a></td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-2.htm">Form of February 2019Pre-Funded Warrant (11)</a></td>
</tr>

<tr style="HEIGHT: 17px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-3.htm">2.19</a></td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_4-3.htm">Form of the February 2019 Placement Agent Warrant (11)</a></td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_10-1.htm">2.20</a></td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891319000303/exhibit_10-1.htm">Form of Securities Purchase Agreement dated as of February 4, 2019 by and between Check-Cap Ltd. (11)</a></td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-1.htm">4.1</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-1.htm">2006 Unit Option Plan and Amendments thereto (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-2.htm">4.2</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-2.htm">Amended and Restated Shareholders Agreement dated as of October 14, 2014 by and among Check-Cap Ltd. and the shareholders parties thereto (1)</a></div>
</td>
</tr>

<tr style="HEIGHT: 19px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000446/exhibit_10-3.htm">4.3</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315000446/exhibit_10-3.htm">Amendment to Amended and Restated Shareholders Agreement dated as of January 2015 by and among Check-Cap Ltd. and the shareholders parties thereto (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-4.htm">4.4</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-4.htm">Form of Series C-1 preferred shares purchase warrant (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-5.htm">4.5</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-5.htm">Forms of Series C-2 preferred shares purchase warrant (1)</a></div>
</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-9.htm">4.6</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-9.htm">Forms of Anti-Dilution Warrants (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-10.htm">4.7</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-10.htm">Asset Transfer Agreement, dated as of May 31, 2009 by and between Check-Cap Ltd. and Check-Cap LLC (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-11.htm">4.8</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-11.htm">The Agreement for ASIC Design and Development dated November 26, 2009 by and between Check-Cap Ltd. and Politechnico di Milano (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-12.htm">4.9</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"></td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891314003928/exhibit_10-12.htm">Form of Indemnification Agreement (1)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315002199/exhibit_99-3.htm">4.10</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891315002199/exhibit_99-3.htm">2015 Equity Incentive Plan and 2015 United States Sub-Plan to 2015 Equity Incentive Plan (2)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001597/exhibit_99-1.htm">4.11</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001597/exhibit_99-1.htm">Compensation Policy for Executive Officers and Directors (3)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891316006206/exhibit_10-2.htm">4.12</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891316006206/exhibit_10-2.htm">Placement Agent Agreement dated August 5, 2016 by and between Check-Cap Ltd. and Chardan Capital Markets LLC (4)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_10-1.htm">4.13</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_10-1.htm">Securities Purchase Agreement dated as of August 8, 2016 by and among Check-Cap Ltd. and the Purchasers named therein (4)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_10-1.htm">4.14</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317001696/exhibit_10-1.htm">Securities Purchase Agreement dated as of May 30, 2017 by and among Check-Cap Ltd. and the Purchasers named therein (5)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_10-1.htm">4.15</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89.21%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891317003232/exhibit_10-1.htm">Securities Purchase Agreement dated as of November 20, 2017 by and among Check-Cap Ltd. and the Purchasers named therein (6)</a></div>
</td>
</tr>
</table>

<div>&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">110</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<table id="z1aefc60bc14d421fa54cb1c510aed1dd" style="FONT-SIZE: 10pt; BORDER-TOP: medium none; FONT-FAMILY: 'Times New Roman', Times, serif; BORDER-RIGHT: medium none; WIDTH: 100%; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none" cellspacing="0" cellpadding="0" border="0">
<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891316004712/exhibit_8-1.htm">8.1</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="http://www.sec.gov/Archives/edgar/data/1610590/000117891316004712/exhibit_8-1.htm">List of Subsidiaries (12)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="exhibit_12-1.htm">12.1</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none"></td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="exhibit_12-1.htm">Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a)</a></div>
</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="exhibit_12-2.htm">12.2</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="exhibit_12-2.htm">Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a)</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="exhibit_13-1.htm">13.1</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="exhibit_13-1.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="exhibit_15-1.htm">15.1</a></div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><a href="exhibit_15-1.htm">Consent of Brightman Almagor Zohar &amp; Co., independent registered public accounting firm</a></div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">101.INS</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">XBRL Instant Document</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">101.SCH</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">XBRL Taxonomy Extension Schema Document</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">101.CAL</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">XBLR Taxonomy Extension Calculation Linkbase Document</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">101.DEF</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">XBRL Taxonomy Extension Definition Linkbase</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">101.LAB</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">XBRL Taxonomy Extension Label Linkbase</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 10%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">101.PRE</div>
</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 1%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">&#160;</td>
<td style="BORDER-TOP: medium none; BORDER-RIGHT: medium none; WIDTH: 89%; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; BORDER-LEFT: medium none">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">XBRL Taxonomy Extension Presentation Linkbase</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;__________________________________</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1f709e6f9ec4424db900ba07d4fac1d1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(1)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Registration Statement on Form&#160;F-1 of the Registrant (File No.&#160;333-201250).</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(2)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities Exchange Commission on July 6, 2015.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(3)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Form 6-K/A filed by the Registrant with the Securities and Exchange Commission on May 24, 2017.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(4)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on August 12, 2016.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(5)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on June 2, 2017.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(6)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on November 22, 2017.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(7)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Form 20-F filed by the Registrant with the Securities and Exchange Commission on April 4, 2018.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(8)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on June 24, 2015.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(9)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Registration Statement on Form&#160;F-1/A by the Registrant with the Securities and Exchange Commission on April 25, 2018.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(10)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on May 4, 2018.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(11)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Form 6-K filed by the Registrant with the Securities and Exchange Commission on February 6, 2019.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 8.26%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -18pt">(12)</div>
</td>
<td style="WIDTH: 91.74%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Incorporated by reference to the Annual Report on Form 20-F filed by the Registrant with the Securities and Exchange Commission on March 15, 2016.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">111</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25"><a id="SIGNATURES" name="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Annual Report on its behalf.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z06737cf4ee2142ed86ae84125bbcd7de" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">CHECK-CAP LTD.</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 43.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Date: March 28, 2019</div>
</td>
<td style="WIDTH: 6.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">By:</div>
</td>
<td style="WIDTH: 43.01%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">/s/ Alex Ovadia</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Name:</div>
</td>
<td style="WIDTH: 43.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Alex Ovadia</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Title:</div>
</td>
<td style="WIDTH: 43.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Chief Executive Officer</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">(Principal Executive Officer)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 43.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">By:</div>
</td>
<td style="WIDTH: 43.01%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">/s/ Niv Kochav</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Name:</div>
</td>
<td style="WIDTH: 43.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Niv Kochav</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Title:</div>
</td>
<td style="WIDTH: 43.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Interim Chief Financial Officer</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 43.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">(Principal Financial Officer</div>
</td>
</tr>

<tr>
<td style="WIDTH: 50%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 6.99%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 43.01%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">and Principal Accounting Officer)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">112</font></div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: left">
<div>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD.</div>

<div style="FONT-WEIGHT: bold; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2018</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CONSOLIDATED FINANCIAL STATEMENTS AS OF DECEMBER 31, 2018</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Table of Contents</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<table id="zfc884ad983b24527addb7e162389d154" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 84.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Page</div>
</td>
</tr>

<tr>
<td style="WIDTH: 84.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 84.5%; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; FONT-STYLE: normal">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><u><a href="#FIRM">Report of Independent Registered Public Accounting Firm</a></u></div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">F-3</div>
</td>
</tr>

<tr>
<td style="WIDTH: 84.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 84.5%; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; FONT-STYLE: normal">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><u><a href="#SHEETS">Consolidated Balance Sheets</a></u></div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">F-4</div>
</td>
</tr>

<tr>
<td style="WIDTH: 84.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 84.5%; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; FONT-STYLE: normal">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><u><a href="#OPERATIONS">Consolidated Statements of Operations</a></u></div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">F-5</div>
</td>
</tr>

<tr>
<td style="WIDTH: 84.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 84.5%; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; FONT-STYLE: normal">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><u><a href="#EQUITY">Consolidated Statements of Changes in Shareholders' Equity</a></u></div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">F-6</div>
</td>
</tr>

<tr>
<td style="WIDTH: 84.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 84.5%; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; FONT-STYLE: normal">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><u><a href="#FLOWS">Consolidated Statements of Cash Flows</a></u></div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">F-7</div>
</td>
</tr>

<tr>
<td style="WIDTH: 84.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr style="HEIGHT: 15px">
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-VARIANT: normal; WIDTH: 84.5%; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; FONT-STYLE: normal">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><u><a href="#STATEMENTS">Notes to Consolidated Financial Statements</a></u></div>
</td>
<td style="WIDTH: 15.5%; VERTICAL-ALIGN: top">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">F-8 - F-31</div>
</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-2</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 2pt; FONT-FAMILY: 'Times New Roman', serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">f</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><img style="HEIGHT: 39px; WIDTH: 164px" src="image0.jpg"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING <a id="FIRM" name="FIRM"></a>FIRM</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">To the Shareholders and the Board of Directors of Check-Cap Ltd.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Opinion on the Financial Statements</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We have audited the accompanying consolidated balance sheets of Check-Cap Ltd. and subsidiary (&#8220;the company&#8221;) as of December 31, 2018 and 2017, and the related consolidated statements of income, shareholders' equity, and cash flows for each of the three years in the period ended December 31, 2018, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Going Concern</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1B to the financial statements, the Company's accumulated losses and the additional funds needed to maintain its operation raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1B. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Basis for Opinion</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Brightman Almagor Zohar &amp; Co.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Certified Public Accountants</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">A Member Firm of Deloitte Touche Tohmatsu Limited</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Tel Aviv, Israel</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">March 28, 2019</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We have served as the Company's auditor since 2005.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-3</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CONSOLIDATED BALANCE <a id="SHEETS" name="SHEETS"></a>SHEETS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<table id="za4433e7568474409ae2c80c92d0bdf6d" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 20px">
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Note</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Current assets</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 15px">
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Cash and cash equivalents</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,572</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,997</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 16px">
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Restricted cash</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">350</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Short-term bank deposit</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,643</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Prepaid expenses and other current assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">3</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">419</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">406</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Total current assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">14,984</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,403</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Non-current assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Property and equipment, net</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">4</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">452</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">503</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total non-current assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">452</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">503</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Total assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15,436</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,906</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Liabilities and shareholders' equity</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Current liabilities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Accounts payable and accruals</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 20px">
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;Trade</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,113</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">608</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;Other</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">214</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">347</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Other current liabilities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">35</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Employees and payroll accruals</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">5</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">859</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">602</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Total current liabilities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,221</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,562</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Non-current liabilities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Royalties provision</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">7A</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">185</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">439</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Total non-current liabilities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">185</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">439</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Shareholders' equity</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">9</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Share capital</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,456</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">974</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Additional paid-in capital</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">72,888</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">57,643</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Accumulated other comprehensive loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(13</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Accumulated deficit</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(63,301</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(52,712</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Total shareholders' equity</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">13,030</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,905</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Total liabilities and shareholders' equity</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15,436</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,906</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The accompanying notes to the consolidated financial statements are an integral part of them.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-4</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CONSOLIDATED STATEMENTS OF <a id="OPERATIONS" name="OPERATIONS"></a>OPERATIONS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<table id="zc0b58ac419de4666a18bc500dea732f0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Note</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Research and development expenses, net</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">11</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,618</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,837</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,491</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;General and administrative expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">12</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,445</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,164</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,571</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">&#160; Operating loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">11,063</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,001</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,062</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Financial income, net</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">13</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">473</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">236</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">244</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Loss before income tax</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,590</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,765</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,818</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Taxes on income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(1</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,589</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Comprehensive loss:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 9pt">Net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,589</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 9pt">Change in fair value of cash flow hedge</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">13</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Comprehensive loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,602</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Loss per share:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Net loss per ordinary share (in USD)&#160;basic and diluted</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.61</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6.72</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7.31</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Weighted average number of ordinary shares outstanding - basic and diluted (in thousands)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">14</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,058</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,455</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,208</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The accompanying notes to the consolidated financial statements are an integral part of them.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-5</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' <a id="EQUITY" name="EQUITY"></a>EQUITY</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<table id="z704f75f6d8e44fdf85812bf92af85fd0" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">Number</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">Amount</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">Additional</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">paid-in capital</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">Other comprehensive loss</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">Accumulated</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">deficit</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: center" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">Total Shareholders&#8217; equity</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Balance as of December 31, 2015</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">984,292</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">599</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">46,164</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(34,115</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">12,648</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25">Changes during 2016:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25">Issuance of ordinary shares and pre-funded warrants in August 2016 registered direct offering, net&#160;of issuance&#160;expenses in an amount of $615 (2)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">53,635</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">32</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,227</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,259</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25">Exercise of warrants into ordinary shares</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">229,153</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">140</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(23</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">117</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25">Share-based compensation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,209</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,209</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25">Net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Balance as of December 31, 2016</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">1,267,080</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">52,577</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(42,941</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">10,407</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Changes during 2017:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Issuance of ordinary shares and warrants in June 2017 registered direct offering, net&#160;of issuance&#160;expenses in an amount of $399 (3)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">112,460</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">67</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,282</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,349</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Issuance of ordinary shares and warrants in November 2017 registered direct offering, net&#160;of issuance&#160;expenses in an amount of $378 (3)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">189,387</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">114</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,066</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,180</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Exercise of warrants into ordinary shares</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">35,474</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">22</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(8</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">14</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Share-based compensation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,033</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">726</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">726</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Balance as of December 31, 2017</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">1,605,434</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">974</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">57,643</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(52,712</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">5,905</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Changes during 2018:</font></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Issuance of ordinary shares in May 2018 in the Public Offering, net of issuance expenses in an amount of $2,381 (4)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,669,129</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,444</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15,343</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="LINE-HEIGHT: 1.25"></div>

<div style="LINE-HEIGHT: 1.25"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">17,787</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Exercise of warrants into ordinary shares</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">56,121</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">38</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(33</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Share-based compensation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(65</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(65</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Change in fair values of cash flow hedge</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(13</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(13</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(10,589</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(10,589</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 28%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -7.7pt">Balance as of December 31, 2018</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">5,330,684</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">3,456</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">72,888</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(13</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(63,301</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">13,030</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(1) All shares amounts have been retroactively adjusted to reflect a 1-for-12 share reverse split, see Note 1C.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(2) Includes pre-funded warrants to purchase 209,524 ordinary shares at a purchase price of $22.20 per pre-funded warrant, issued in connection with the registered direct offering. See Note 9C(2)(h).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(3) Issuance expenses include certain warrants with a value of $49,229 and $58,298 issued in connection with the June 2017 and November 2017 registered direct offerings, respectively. See Note 9C(2)(j).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">(4) Includes pre-funded warrants to purchase 450,909 ordinary shares at a purchase price of $5.49 per pre-funded warrant, issued in connection with the registered direct offering. See Note 9C(2)(k).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">The accompanying notes to the consolidated financial statements are an integral part of them.</font>&#160;</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-6</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CONSOLIDATED STATEMENTS OF CASH <a id="FLOWS" name="FLOWS"></a>FLOWS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<table id="z489399a3d92f437982c723843dd32d49" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">CASH FLOWS FROM OPERATING ACTIVITIES</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(10,589</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Adjustments required to reconcile net loss to net cash used in operating activities:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Depreciation and amortization</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">147</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">157</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">130</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Share-based compensation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(65</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">726</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,209</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Financial Expenses <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">(income), net</font></div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">67</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(165</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(56</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Changes in assets and liabilities items:</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Decrease (increase) in prepaid and other current assets<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font>and non-current assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(13</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(164</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">438</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Increase (decrease) in trade accounts payable, accruals and other current liabilities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">416</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">275</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(252</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Increase (decrease) in employees and payroll accruals</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">258</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(126</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(510</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Decrease in royalties provision</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(255</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(82</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(56</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Net cash used in operating activities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(10,034</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(9,150</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(7,923</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">CASH FLOWS FROM INVESTING ACTIVITIES</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">.</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Purchase of property and equipment</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(94</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(231</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(166</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Proceeds from (Investment in) short-term bank deposit</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(5,629</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,811</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Net cash provided by (used in) investing activities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(5,723</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(231</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">4,645</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">CASH FLOWS FROM FINANCING ACTIVITIES</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Exercise of warrants into ordinary shares</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">196</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">117</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Issuance of ordinary shares in the RD Offerings, net&#160;of issuance&#160;expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(30</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,379</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,307</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Issuance of ordinary shares in the 2018 Public Offering</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">17,792</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Net cash provided by financing activities</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">17,762</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">4,575</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">5,424</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Effect of exchange rate changes on cash and cash equivalents</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(80</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">164</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">55</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Net increase (decrease) in cash, cash equivalents and restricted cash</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">1,925</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">(4,642</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">2,201</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Cash, cash equivalents and restricted cash at the beginning of the year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">6,997</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">11,639</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">9,438</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">*</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Cash, cash equivalents and restricted cash at the end of the year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">8,922</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">6,997</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; LINE-HEIGHT: 1.25">11,639</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">*Reclassified</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Supplemental information for Cash Flow:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<table id="z1d25e8ae86c744f3adaf6d08dfb34084" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Supplemental disclosure of non-cash flow information</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Cashless exercise of warrants to purchase ordinary shares into ordinary shares</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">33</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">23</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Purchase of property and equipment</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Issuance expenses*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">30</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">47</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Supplemental disclosure of cash flow information</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 9.9pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -9.9pt">Cash paid for income taxes</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">* Represents warrants issued to placement agent as part of issuance expenses</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The accompanying notes to the consolidated financial statements are an integral part of them.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-7</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL <a id="STATEMENTS" name="STATEMENTS"></a>STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 1&#160;&#160; -&#160;&#160;&#160;GENERAL INFORMATION</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z67c30af030da4b7181b5bc3bb899119d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">A.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">General</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8f38780edcdf439f807249f56e0d5967" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">(1)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Check Cap Ltd. (together with its wholly-owned subsidiary, the &#8220;Company") was incorporated under the laws of the State of Israel. The registered address of its offices is 29 Abba Hushi Ave, Isfiya 3009000, Israel.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zca4bcb4f1e014a03be0c074aadc2eb69" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">(2)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Check-Cap Ltd has a wholly-owned subsidiary, Check-Cap U.S. Inc., incorporated under the laws of the State of Delaware on May 15, 2015.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z50decf95cce243bbba2312062e332ecd" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">(3)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company is a clinical-stage medical diagnostics company developing C-Scan&#174;, the first capsule-based system for preparation-free colorectal cancer screening (the "C-Scan system"). Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, the C-Scan system removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z90dc6a239ddb4e1eb401104e9fb94144" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">(4)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As described in Notes 9C(2)(b) and 9C(2)(d), on February 24, 2015 the Company consummated an Initial Public Offering in the United States (U.S.) (the "IPO") concurrently with a Private Placement (the "Private Placement").</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">On August 11, 2016, the Company consummated a registered direct offering of ordinary shares and pre-funded warrants (the "August 2016 RD Offering"). See Note 9C(2)(h).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">On June 2, 2017, the Company consummated a registered direct offering of ordinary shares and a simultaneous private placement of warrants (the "June 2017 RD Offering"). See Note 9C(2)(i).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">On November 22, 2017, the Company consummated a registered direct offering of ordinary shares and a simultaneous private placement of warrants (the "November 2017 RD Offering" and together with the August 2016 RD Offering and June 2017 RD Offering, the &#8220;RD Offerings&#8221;). See Note 9C(2)(J).</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">On May 8, 2018, the Company consummated an underwritten public offering of ordinary shares, pre-funded warrants and Series C warrants (the &#8220;May 2018 underwritten public offering&#8221;). See Note 9C(2)(k).</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">The Company's ordinary shares, Series A Warrants and Series C Warrants are listed on the NASDAQ Capital Market under the symbols "CHEK", "CHEKW" and CHEKZ&#8221; respectively.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb4bc759f3fa44c3186791e3a52a3a173" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right"></td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The consolidated financial statements of the Company as of and for the year ended December 31, 2018 include the financial statements of the Company and its wholly-owned U.S. subsidiary.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-8</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 1&#160;&#160; -&#160;&#160;&#160;GENERAL INFORMATION</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za8ce1020596942ea904a4da17ea1fa1f" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Going concern and management plans</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, recruiting management and technical staff, acquiring assets and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the Company's future operating losses and the timing of becoming profitable are uncertain. The Company has incurred losses of $10.6 million and $9.8 million for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, the Company's accumulated deficit was $63.3 million. The Company has funded its operations to date primarily through equity financing and through grants from the Israel Innovation Authority of the Ministry of Economy and Industry (the "IIA") (formerly the Office of the Chief Scientist of the Ministry of Economy and Industry (the "OCS)).</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Additional funding will be required to complete the Company's research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company's C-Scan system and to achieve a level of sales adequate to support the Company's cost structure.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings and other funding transactions. While the Company has been successful in raising financing in the past, there can be no assurance that it will be able to do so in the future on a timely basis on terms acceptable to the Company, or at all. Uncertain market conditions and approval by regulatory bodies and adverse results from clinical trials may (among other reasons) adversely impact the Company's ability to raise capital in the future.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company believes that current cash on hand will be sufficient to fund operations into February 2020.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of the C-Scan system, which will result in a negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company's ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during or before the end of 2019, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects and clinical trials, until it is able to obtain sufficient financing. If such sufficient financing is not received timely, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company's consolidated financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9f7072822e35459cb143c47b208ddb9c" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">C.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Reverse share splits</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Effective April 4, 2018, the Company's Board of Directors effected a reverse share split of 1-for-12 (i.e. 12 ordinary shares were combined into one ordinary share) (&#8220;Reverse Share Split&#8221;), in accordance with the approval of the Company's shareholders at an extraordinary general meeting of shareholders held on April 2, 2018. All references in the financial statements and notes to the number of shares, price per share and weighted average number of shares outstanding of our&#160;ordinary shares prior to the Reverse Share Split have been adjusted to reflect the Reverse Share Split on a retroactive basis unless otherwise noted.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-9</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">NOTE 2&#160;&#160; -&#160;&#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25">The Company`s consolidated financial statements are presented in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze5c6e403806041e48c31c15a2a60f4aa" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">A.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Use of estimates in preparation of financial statements</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zc88a45a73cc04184b0263ab1c7dbad97" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Principles of consolidation</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company's consolidated financial statements include the financial statements of Check-Cap Ltd. and its wholly-owned subsidiary, Check-Cap U.S., Inc. The Company's consolidated financial statements are presented after elimination of inter-company transactions and balances.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9aba636d358d49c2b6b1dda6a1cfc2d6" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">C.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Financial statements in U.S dollars</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company has not yet generated revenues and the majority of its expenses are in U.S. dollar (dollar or USD) or NIS, while none of these currencies is significantly material compared to the other.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Management judgment, in setting the dollar as the Company's functional currency, is based mainly on the following criteria: The Company's budget and other Company internal reports, including reports to the Company's Board of Directors and investors, are presented in dollars. Management uses these reports in order to make decisions for the Company. All of the Company's equity and debt financings were in dollars; and it is expected that a significant portion of the Company's future revenue will be in dollars. The financial statements are presented in dollars, which is the functional currency of the Company.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zcabfd4b36c704d3f8eefaafb96bb81fa" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">D.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Cash and cash equivalents</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Cash and cash equivalents include cash in hand, short&#8211;term deposits in banks and short-term highly liquid investment with an original maturity of up to three months, with a high level of liquidity that may be easily converted to known amounts of cash, and that are exposed to insignificant risk of change in value.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9b7149817935421b86dc0def4928f08d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">E.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Short-term bank deposit</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Short-term bank deposits are deposits with maturities of more than three months but less than one year. The short&#8211;term bank deposits are presented at their cost, including accrued interest, which approximates fair value.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z07aab22b9ab646b4a9f543cad0fc6115" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">F.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Cash flow hedges</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">As a matter of policy, the Company uses derivatives for risk management purposes, and does not use derivatives for speculative purposes. From time to time, the Company may enter into foreign currency zero-cost collars contracts to&#160;hedge&#160;foreign currency&#160;cash&#160;flow&#160;transactions. For&#160;cash&#160;flow&#160;hedges, unrealized gain or loss is recorded in Other comprehensive income (loss) until hedged item affects earnings. All of the Company&#8217;s hedges that are designated as hedges for accounting purposes were highly effective; therefore,&#160;no&#160;notable amounts of&#160;hedge ineffectiveness were recorded in the Company&#8217;s Consolidated Statements of Operations for either the settlement of&#160;cash&#160;flow&#160;hedges or the outstanding hedged balance.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-10</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 2&#160;&#160; -&#160;&#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z259188da6fd544fa833f3f10380cf26e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">F</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Cash flow hedges (cont.)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company uses zero-cost collars to hedge against the risk of overall changes in future cash flow from payments of payroll and rent denominated in New Israeli Shekel. As of December&#160;31, 2018, the Company had outstanding foreign exchange collars in the notional amount of $2.1 million. These options were set for a period of up to six months. The Company measured the fair value of the options in accordance with provisions of ASC No.&#160;820 (classified as level 2 of the fair value hierarchy). During 2018, losses in the amount of $28, were reclassified when the related expenses were incurred and recognized in operating expenses. The fair value of the Company&#8217;s outstanding collars at December&#160;31, 2018 amounted to liability of $15 and is included in in other current liabilities on the balance sheets, with the effective portion of the change in fair value, amounted $13 classified in accumulated other comprehensive income ("AOCI").&#160;</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5fd163dddc0d4963baf55566c27ba38b" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">G.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Property and equipment</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z9f83b17760684b19a0f2d2a3b5514446" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr style="HEIGHT: 14px">
<td style="WIDTH: 34.73%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 24.98%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold; TEXT-ALIGN: center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">Length of useful life</div>
</td>
<td style="WIDTH: 1.62%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 37.65%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold; TEXT-ALIGN: center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">Depreciation rate</div>
</td>
<td style="WIDTH: 1.02%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.73%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 24.98%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold; TEXT-ALIGN: center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">Years</div>
</td>
<td style="WIDTH: 1.62%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 37.65%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold; TEXT-ALIGN: center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
<td style="WIDTH: 1.02%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.73%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 24.98%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1.62%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 37.65%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1.02%; VERTICAL-ALIGN: bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.73%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Office furniture and equipment</div>
</td>
<td style="WIDTH: 24.98%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10-14</div>
</td>
<td style="WIDTH: 1.62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 37.65%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7-10</div>
</td>
<td style="WIDTH: 1.02%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.73%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Laboratory equipment</div>
</td>
<td style="WIDTH: 24.98%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3-7</div>
</td>
<td style="WIDTH: 1.62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 37.65%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15-33</div>
</td>
<td style="WIDTH: 1.02%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>

<tr>
<td style="WIDTH: 34.73%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Computers and auxiliary equipment</div>
</td>
<td style="WIDTH: 24.98%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3</div>
</td>
<td style="WIDTH: 1.62%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 37.65%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">33</div>
</td>
<td style="WIDTH: 1.02%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z619e8ff7b1b34163b20b6f63a53cfdbd" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">H.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Impairment of long-lived assets</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company's long-lived assets are reviewed for impairment in accordance with ASC 360-10 "Accounting for the Impairment or Disposal of Long-Lived Assets" whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December&#160;31, 2018, 2017 and 2016, no impairment losses were recorded.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7fbf76b04cef474781247913e453381e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">I.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Research and development costs</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Research and development costs are expensed as incurred and consist primarily of costs for personnel, subcontractors and consultants (mainly in connection with clinical trials) and materials for research and development and clinical activities. Grants received by the Company from the IIA and from Israel-United States Binational Industrial Research and Development Foundation (the "BIRD Foundation") are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from research and development expenses. Such grants are included as a deduction of research and development costs (since at the time received the Company expects to generate sales from these projects and pay the royalties resulting from such sales).</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">See Note 7B(1) below regarding the offset of grants received for participation in research and development expenses.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-11</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">NOTE 2&#160;&#160; -&#160;&#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zce17a6761f9d4712bb12bbd5a76aa7ff" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">J.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Contingent liabilities</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company accounts for its contingent liabilities in accordance with ASC No.&#160;450, "Contingencies". A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December&#160;31, 2018, and 2017, the Company is not a party to any ligation that could have a material adverse effect on the Company's business, financial position, results of operations or cash flows (see Note ).</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb01f5d74c62d4cea8f355bfbdae0d613" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">K.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Share-based compensation</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company recognizes expense for its share-based compensation based on the fair value of the awards granted. The Company&#8217;s share-based compensation plans provide for the award of stock options and restricted stock units. In accordance with ASC 718-10 "Compensation-Stock Compensation", the Company estimates the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's consolidated statement of operations.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company recognizes compensation expenses for the value of its awards granted based on the graded-vesting method over the requisite service period for each separately vesting portion of the award. Accounting Standards Update (&#8220;ASU&#8221;) 2016-09, Compensation-Stock Compensation (Topic 718) allows companies to account for forfeitures when they occur.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its share-based awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary shares, expected share price volatility and the expected option term. In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">In the years ended December 31, 2017 and 2016, expected volatility was calculated based on certain peer companies that the Company considered to be comparable.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No.&#160;110, as adequate historical experience is not available to provide a reasonable estimate.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-12</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 2&#160;&#160; -&#160;&#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd77571d0705f40c8ad02ba5d7c17ed71" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">L.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Income taxes</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company accounts for income taxes in accordance with ASC 740-10 "Accounting for Income Taxes." This Statement requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">In accordance with ASC 740, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered 'more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2018, and 2017, the Company had no unrecognized income tax positions and accordingly, there is no impact on the Company's effective income tax rate associated with these items.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z27d4cae0ccde4775874a598d7acc0943" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">M.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Fair value of financial instruments</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company measures its investments in money market funds (classified as cash equivalents) and its foreign currency net purchased options at fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -28.35pt"><font style="FONT-FAMILY: Times New Roman">&#9679; </font>Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -28.35pt"><font style="FONT-FAMILY: Times New Roman">&#9679; </font>Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -28.35pt"><font style="FONT-FAMILY: Times New Roman">&#9679; </font>Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -28.35pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-13</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 2&#160;&#160; -&#160;&#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont.)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6da57fa2119547269c8e0de514613449" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">N.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Comprehensive<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff"> loss</font></div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company accounts for comprehensive income in accordance with ASC No.&#160;220, &#8220;Comprehensive Income&#8221;. Comprehensive income generally represents all changes in shareholders&#8217; equity during the period except those resulting from investments by, or distributions to, shareholders. The Company&#8217;s comprehensive loss consists of net loss and unrealized gain or loss on the effective portion of cash flow hedges. These amounts are carried in accumulated other comprehensive loss on the consolidated statements of comprehensive income and are presented net of taxes.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z664f9f2680474ca7b9ff841747c00e19" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">O.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">Restricted Cash</div>
</td>
</tr>
</table>
</div>

<br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company has granted a pledge in favor of Bank Leumi Le-Israel B.M in the amount of $350 to secure certain payment obligations of the Company in connection with FOREX activities. This amount was classified as restricted cash balance on December 31, 2018.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">In January 2018, the Company adopted new guidance from the Financial Accounting Standards Board or the FASB that clarified how entities should classify certain cash receipts and cash payments on the statement of cash flows. As a result, the restricted cash balance that existed in prior periods is included as a component of cash and cash equivalents and restricted cash on the statement of cash flows in the relevant periods presented. &#160;</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt">
<table id="z951935bdf2094db4bc78c7416af2360c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="PADDING-BOTTOM: 2px" valign="bottom">
<div>&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="TEXT-ALIGN: center">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold; TEXT-ALIGN: center" valign="bottom" colspan="2">2 0 1 6</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td valign="bottom">
<div>&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 17px">
<td style="WIDTH: 64%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div>Cash and Cash equivalents</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">8,572</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div>6,997</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div>11,639</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div>Restricted cash included current assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div>350</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div>-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div>-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div>Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div>8,922</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">6,997</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">11,639</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze5eacba48bf745db850febfca3573593" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">P.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">New accounting pronouncements</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">ASU 2016-02, &#8220;Leases (Topic 842)&#8221; was issued by the FASB in February 2016. The purpose of this amendment requires the recognition of lease assets and lease liabilities by lessees for those leases previously classified as operating leases. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated results of operations, financial position or disclosures.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Accounting Standards Update (ASU) 2018-07, &#8220;Compensation&#8212;Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting&#8221; was issued by the Financial Accounting Standards Board (FASB) in June 2018. The purpose of this amendment is to address aspects of the accounting for nonemployee share-based payment transactions. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated results of operations, financial position or disclosures.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-14</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 3&#160;&#160; -&#160;&#160; PREPAID EXPENSES AND OTHER CURRENT ASSETS</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25">Composition:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z2f067121b5ac444390d19482d24af442" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 95%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Government institutions</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">178</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">89</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Prepaid expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">206</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">261</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Deposits</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">34</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">55</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Other assets</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">419</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">406</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 4&#160;&#160; -&#160;&#160; PROPERTY AND EQUIPMENT, NET</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Composition</font>:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z2a18379bcde34824b33dfba0ee3348be" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 95%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Cost:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Office furniture and equipment</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">186</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">157</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Laboratory equipment</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">644</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">626</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Computers and auxiliary equipment</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">388</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">339</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,218</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,122</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Accumulated depreciation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">766</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">619</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Property and equipment, net</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">452</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">503</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Depreciation expenses amounted to $147, $157 and $130 for the years ended December&#160;31, 2018, 2017 and 2016, respectively.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-15</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 5&#160;&#160; -&#160;&#160; EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3a8f70e7d63340688636546a2d8b7b02" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">A.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Composition:</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="zff8d3f796c354ec58fcdb1ce0f105b71" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold; BACKGROUND-COLOR: #ffffff" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold; BACKGROUND-COLOR: #ffffff" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold; BACKGROUND-COLOR: #ffffff" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 18px">
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Short-term employee benefits:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Benefits for vacation and recreation pay</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">162</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">235</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Liability for payroll, bonuses and wages</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">697</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">367</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">859</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">602</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2a18aa2f7f00414c802a5f04d073c942" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Post-employment benefits</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Pursuant to Israel's Severance Pay Law, 1963, Israeli employees are entitled to severance pay equal to one month's salary for each year of employment, or a portion thereof. All of the Company's employees elected to be included under Section 14 of the Severance Pay Law, 1963 ("Section 14"). According to Section 14, employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9e683e75f6a74bebad5d5d6e3b167b31" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">C.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Short-term employee benefits</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3ab7046bf1444da89dae809c5514685b" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">(1)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Paid vacation days</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">In accordance with the Yearly Vacation Law-1951 (the "Vacation Law"), the&#160;Company's employees are entitled to a certain number of paid vacation days for each year of employment. In accordance with the Vacation Law and its appendix, and as determined in the agreement between the Company and the employees, the number of vacation days per year to which each employee is entitled is based on the seniority of the employee.</div>

<br style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">The employee may use vacation days based on his or her needs and with the Company's consent, and to accrue the remainder of unused vacation days, subject to the provision of the Vacation Law. The vacation days utilized first are those credited for the current year and subsequently from any balance transferred from the prior year (on a "LIFO" basis). An employee who ceased working before utilizing the balance of vacation days accrued is entitled to payment for the balance of unutilized vacation days.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z43e9eb2751604aa5897e25286b9174e1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">(2)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Related parties</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">For information regarding short-term employee liabilities given to related parties, see Note 15.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-16</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 6&#160;&#160; -&#160;&#160; INCOME TAXES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0c66ad8bcdc2419c81bcb5f3d1bac98d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">A.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">The Company</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Check-Cap Ltd. is taxed according to Israeli tax laws:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd07f288927174025935b4f77ae84ca28" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">1.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Corporate tax rates in Israel</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">The Israeli corporate tax rate was 25% in the year 2016, 24% in year 2017 and 23% in year 2018 and onwards.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zcc6a31cc133f48bda3a275f1c1a7d1a1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">The Law for the Encouragement of Capital Investments, 1959 (the "Investments Law")</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">Under the Investments Law, including Amendment No. 60 to the Investments Law as published in April 2005, by virtue of the "Approved Enterprise" or "Benefited Enterprise" status, the Company is entitled to various tax benefits as follows:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z60f019a1dff344e5aa4fba2913a65355" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: justify; align: right">a)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Reduced tax rates</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">The Company has one Benefited Enterprise program under the Investments Law, which entitles it to certain tax benefits with respect to income to be derived from the Company's Benefited Enterprise. During the benefits period, taxable income from its Benefited Enterprise program (once generated) will be tax exempt for a period of ten years commencing with the year the Company will first earn taxable income relating to such enterprise. The Company chose 2010 as the year of election (the "Year of Election"). Due to the location of the Company's offices, the Company believes it is entitled to a 10 year benefit period, subject to a 14 year limitation from the Year of Election, and therefore, the tax benefit period will in any event end in 2023.</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -14.2pt"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z12bb4e0022674ecc885fc1c07645c018" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: justify; align: right">b)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Conditions for entitlement to the benefits</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">The benefits available to a Benefited Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law and its regulations.</div>

<div style="TEXT-ALIGN: left; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25; TEXT-INDENT: -14.2pt"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z39327366d04249878b7285417819fd9f" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: justify; align: right">c)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Amendment of the Law for the Encouragement of Capital Investments, 1959</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">The Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the "Capital Investments Law Amendment").</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">The Capital Investments Law Amendment set alternative benefit tracks to those in effect prior to such amendment under the provisions of the Investments Law.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">The benefits granted to the Benefited Enterprises will be unlimited in time, unlike the benefits granted to special Benefited Enterprises, which will be limited for a 10-year period. The benefits shall be granted to companies that will qualify under criteria set forth in the law; for the most part, those criteria are similar to the criteria that were set forth in the Investments Law prior to its amendment.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">Under the transitional provisions of the Investments Law, the Company is entitled to take advantage of the tax benefits available under the Investments Law prior to its amendment until the end of the benefits period, as defined in the Investments Law. The Company was entitled to set the "year of election" no later than tax year 2012, provided that the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company will be able to elect that the Investments Amendment applies to the Company, thereby making the tax rates described above available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable. The Company elected not to have the Capital Investments Amendment apply to the Company.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-17</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 6&#160;&#160; -&#160;&#160; INCOME TAXES (Cont.)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za10c00eb3a86482c98afa34a1e2d136d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">The Law for the Encouragement of Capital Investments, 1959 (the "Investments Law") (Cont.)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zef7988daf40749608f437c8ea0645f1d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: justify; align: right">c)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Amendment of the Law for the Encouragement of Capital Investments, 1959 (Cont.)</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">On December 22, 2016, the Knesset approved the 2017-2018 State budget, which includes amendment number 73 to the law for the Encouragement of Capital Investments. The amendment includes:</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">Adoption of tax benefits for high-tech preferred enterprises, based on the provisions and rules adopted by the Organization for Cooperation and Economic Development (the "GCOE"), creating new tax tracks of 7.5% for Development Area A and 12% for the rest of the country.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">Reduction of corporate tax rate for all preferred enterprises from 9% to 7.5%.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">Lowering the threshold for the conditions that were previously set in order to enter the track of a "special preferred enterprise" for very big enterprises entitled to a reduced tax rate of 5% in Area A or 8% in the rest of the country.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">Updating the definitions of preferred income, preferred enterprise etc.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">In accordance with the Income Tax Ordinance, as of December 31, 2018, all of Check-Cap Ltd.'s tax assessments through tax year 2013&#160;are considered final.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2963386a29d34defb4810b37bd0e538e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">3.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The Company recorded $6 and $8 current taxes for the years ended December 31, 2017 and 2016. The Company did not record current taxes for the year ended December 31, 2018, since it had no taxable income during this year.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zac6149ff784e435bb63975f3327c88f7" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Check-Cap U.S. Inc.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">Check-Cap U.S. Inc. is taxed according to U.S. tax laws.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">There are no NOL carry-forward of Check-Cap U.S. Inc.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">In December 2017, the Tax Cut and Jobs Act (the &#8220;Act&#8221;) was signed into law, which enacted significant changes to U.S. federal corporate tax and related laws. Some of the provisions of the Act affecting corporations include, but are not limited to: (i) a reduction of the U.S. federal corporate income tax rate from 35% to 21%; (ii) limiting the interest expense deduction; (iii) expensing of cost of acquired qualified property; and (iv) elimination of the domestic production activities deduction. The Company is currently evaluating the impact the Act will have on the future financial condition and results of operations and believe the Act will have a beneficial positive net impact. The Act did not have an effect on the financial results and position of the Company.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-18</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 6&#160;&#160; -&#160;&#160; INCOME TAXES (Cont.)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z8d0082e0440e442fa940ca7eaaca6848" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">C.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Deferred income taxes</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. Based on the Company's history of losses, the Company established a full valuation allowance.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="zd52c71ea93f8460e839c907ed0e43acf" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Carry forward tax losses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12,525</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">13,083</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Less valuation allowance</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(12,525</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(13,083</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z863965d34d7a4aaf970114b00d8eb4aa" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">D.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Reconciliation of the theoretical tax expense to actual tax expense</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision of full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">NOTE 7&#160;&#160; -&#160;&#160; COMMITMENTS AND CONTINGENT LIABILITIES</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z6e1a4adcf1e04bc98b4c193edf1b546f" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">A.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Royalties provision</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zea763a1fe1a2458ba235d0540986ed1d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">1.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Royalties to an ASIC designer</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">The Company has a liability to pay royalties for the development of an ASIC component which is used as an amplifier for the capture of signals at low frequencies from X-ray detectors contained in the capsule. The institution that developed the ASIC is entitled to receive royalties from the Company in the amount of &#8364; 0.5 ($0.57) for every ASIC component that the Company will sell, capped at &#8364; 200,000 (approximately $229). This royalty is considered as a liability.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">The royalties' liability is calculated based on estimated future sales generated by products which include the ASIC component. As of December 31, 2018, the Company believes that it will be required to pay the above mentioned royalties, and accordingly, recorded, as of December&#160;31, 2018, a provision in a total amount of $120.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zaf9aeede27744e1b9d4518173e213714" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Reimbursement liability to Predecessor Entity's unit holders</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">On May 31, 2009, the Company entered into an asset transfer agreement with Check Cap LLC (the "Predecessor Entity"), a company with the same shareholders as the Company at the time of transfer. According to the agreement, the Predecessor Entity transferred all of its business operations and substantially all of its assets to the Company, including development and consulting agreements, cash, property and equipment and intangible ownership rights, free of any debt.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">As part of the reorganization, the Company committed to reimburse the unit holders of the Predecessor Entity for any tax burdens that may be imposed on them due to the reorganization. The reimbursement liability is calculated assuming deemed royalties are paid to the U.S. unitholders of Check-Cap LLC under Section 367(d) of the Code, and is based in part on the Company&#8217;s forecasted sales with a cap calculated as the fair value of the share as determined at the date of the financial statements. The reimbursement liability is calculated by multiplying the estimated tax rate by the lowest of: (1) expected cash outflows discounted using a discount factor commensurate with the risk of the Company, and (2) value of the shares held by U.S. unit holders of the Predecessor Entity as of December 31, 2018 multiplied by $2.1, <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">the last reported sale price per share of the Company&#8217;s ordinary shares on the Nasdaq Capital Market on December 31, 2018</font>. Any updates in the contingent liability will be charged to earnings. As of December 31, 2018, the balance of the reimbursement liability totaled $65.</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z8128ce3a34ac44828bef74af40479fa4" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="6">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 14px">
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Royalties to an ASIC designer</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">120</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">127</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Reimbursement liability to Predecessor Entity's unit holders</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">65</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">312</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 76%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">185</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">439</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-19</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">NOTE 7&#160;&#160; -&#160;&#160; COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zba8305edc70c4f0fb3a7a76055ccc60b" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Commitments</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze036a6d6515b479693b809726a78f39f" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">(1)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Royalties</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">The Company's research and development efforts are financed, in part, through funding from the IIA (formerly the OCS) and the BIRD Foundation. Since the Company's inception through December&#160;31, 2018, the Company received funding from the IIA and the BIRD Foundation in the total amount of $5.3 million and $115, net, respectively.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">According to the terms of applicable law as currently in effect and the grants, the IIA is entitled to royalties equal to 3-5% (or at an increased rate under certain circumstances) of the revenues from sales of products and services based on technology developed using IIA grants, up to the full principal amount (which may be increased under certain circumstances) of the U.S. Dollar-linked value of the grants, plus interest at the rate of 12-month LIBOR. The obligation to pay these royalties is contingent on actual sales of the applicable products and services and in the absence of such sales, no payment is required. As of December 31, 2018, the Company had not paid any royalties to the IIA and had a contingent obligation to the IIA in the amount of $5.6 million.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">On July 13, 2014, the Company entered into a Cooperation and Project Funding Agreement with the BIRD Foundation and Synergy, pursuant to which the BIRD Foundation agreed to award a grant to Synergy and the Company in the maximum amount of the lesser of (i) $900; and (ii) 50% of the actual expenditures for the funding of a project entitled "Collection &amp; Analysis of Gastrointestinal Images for Diagnostic Adenomatic Polyps and Colorectal Cancer." The development work was to be performed over a 24-month period by Synergy (or a subcontractor on its behalf) and the Company.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">According to the terms of the grant, the BIRD Foundation is entitled to royalties equal to 5% of the gross revenues derived from the product funded by the project, up to 100%, 113%, 125%, 138% and 150% of the U.S. Consumer Price Index linked sum granted by the BIRD Foundation if repaid within one year, two years, three years, four years and five or more years, respectively. Under the terms of the agreement, if any portion of the product funded by the project is sold outright to a third party prior to full repayment of the grant to the BIRD Foundation, one-half of the sale proceeds will be applied to the repayment of the grant. If the funded product is licensed to a third party, 30% of all payments received under the respective license agreement must be paid to the BIRD Foundation in repayment of the grant.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">As of December 31, 2018, the Company, together with Synergy, had received funding from the BIRD Foundation in the aggregate amount of approximately $127. Based on the aggregate expenses that the Company incurred for such project, it refunded to the BIRD Foundation an amount of approximately $13. The Company shall not be receiving additional funding from the BIRD Foundation for the project, which is no longer active. As of December 31, 2018, we had not paid any royalties to the BIRD Foundation and had a contingent obligation to the BIRD foundation in the amount of $180.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5afd5e006aff4a239279d10236f709c2" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">(2)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Rental agreement</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">The Company leases approximately 900 square meters at a facility located in Isfiya, Israel under a lease agreement expiring on May 31, 2022. The Company has the right to terminate the agreement at any time, with 60 days prior written notice. The rental expenses recorded by the Company for the years ended December 31, 2018, 2017 and 2016 were $84, $83 and $78, respectively.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-20</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 7&#160;&#160; -&#160;&#160; COMMITMENTS AND CONTINGENT LIABILITIES (Cont.)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0ff6358d9b4746dfa9b70891af5c5db3" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Commitments (Cont.)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z44c34e2c4d1e41c585ccb17e4f32b2e9" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">(3)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Vehicle lease and maintenance agreements</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">The Company entered into several 32-36 months lease and maintenance agreements for vehicles, which are regularly amended as new vehicles are leased. The current monthly lease fees is approximately $14. The expected lease payments for the years ending December 31, 2019, 2020 and 2021 are approximately $100, $63 and $10, respectively.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating lease obligations as of December 31, 2018:&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z16b61586b1d74d23a7632da0884c427e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr style="HEIGHT: 15px">
<td style="WIDTH: 88%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Lease agreement for vehicles</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">22</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 88%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Lease agreement for office facilities lease</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">13</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr style="HEIGHT: 19px">
<td style="WIDTH: 88%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">35</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zcf92375279a34b03998534da5d0dfd91" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">C.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Legal</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">As of the date of the financial statements, the Company has not been and is not a party to any pending litigation.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">NOTE 8&#160;&#160; -&#160;&#160; FAIR VALUE MEASUREMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">In accordance with ASC No.&#160;820, the Company measures its money market funds and foreign currency derivative contracts at fair value. Money market funds are classified within Level&#160;1 or Level&#160;2. This is because these assets are valued using quoted market prices or alternative pricing sources and models utilizing market observable inputs. Foreign currency derivative contracts are classified within Level&#160;2 as the valuation inputs are based on quoted prices and market observable data of similar instruments.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The Company&#8217;s financial assets measured at fair value on a recurring basis, excluding accrued interest components, consisted of the following types of instruments as of the following dates:</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z302cda25c3ae4304bd1ffe17b3d54bea" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">December 31, 2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Fair value measurements using input type</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Level 1</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Level 2</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Total</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Cash equivalents:</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Money market funds</div>
</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,307</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,307</div>
</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Foreign currency derivative instruments</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(15</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(15</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total financial assets (Liabilities)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,307</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(15</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,292</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-21</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 9&#160;&#160; -&#160;&#160; SHAREHOLDERS' EQUITY</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z18e2fcd4b9124f08b3ab78199025e2c4" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">A.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">All share and per share amounts in the financial statements have been adjusted to reflect the Reverse Share Split.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1cdceb6f9ca845978d493ee9b4de82f8" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Ordinary shares</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zffd75b24281e4d02a6a32a031412a66a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">1.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The ordinary shares provide their owners with rights to receive dividends in cash and shares, and rights to participate at the time of distributing liquidation dividends. Additionally, the ordinary shareholders have the right to vote at shareholder meetings in a manner that each share provides one voting right to its holder.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z02e9edf268ab4c75902ade0c22fdb17c" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr style="HEIGHT: 12px">
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: normal; TEXT-ALIGN: justify; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Changes in ordinary share capital</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9be7f2abf21845838421f163fe6c35a6" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">a)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On May 11, 2010, the Company issued, free of charge, to all of its shareholders (except for certain ordinary shareholders), warrants to purchase an aggregate of 32,174 ordinary shares (hereafter- "Anti-dilution Warrants"). The Anti-dilution Warrants were issued in order to prevent the dilution of the holdings of such Company shareholders due to certain options granted to the Company's CEO (hereafter- "CEO options"). The Anti-dilution Warrants were subject to automatic exercise, without consideration (unless the holder thereof objected to such exercise), upon the exercise by the Company's CEO of the CEO Options. The fair value of the Anti-dilution Warrants on the grant date was immaterial. Anti-dilution warrants to purchase&#160;7,724 and 56 ordinary shares were exercised during the years ended December 31, 2018 and 2016, respectively. No such warrants were exercised during the year ended December 31, 2017. As of December 31, 2018, 7,246 Anti-dilution Warrants were outstanding.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z03610b82d7ba44919370ffcc2a7f4224" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">b)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On February 24, 2015, the Company consummated an IPO in the U.S. of 166,667 units at a public offering price of $72 per unit, before underwriting discounts and offering expenses. Each unit consisted of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share. Each unit was issued with one and one-half non-transferrable Long Term Incentive Warrants. Each whole Series A Warrant entitles the holder to purchase one ordinary share at an exercise price of $90. Upon vesting, each Long Term Incentive Warrant entitles the holder to purchase one ordinary share at an exercise price of $82.80.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">The Company granted the underwriters a 45-day over-allotment option to purchase up to 25,000 additional units (together with an accompanying 37,500 Long Term Incentive Warrants). The option to purchase additional 8,334 units was partially exercised on March 6, 2015. The units were separated into one ordinary share and one-half of a Series A Warrant to purchase one ordinary share on March 18, 2015, and the units ceased to exist as of such date. On April 6, 2015, the option to purchase additional 12,500 ordinary shares and 6,250 Series A Warrants was partially exercised. The Company received net proceeds from the IPO and partial exercise of the over-allotment option of approximately $10.8 million (net of issuance cost of approximately $2.9 million, including certain warrants with a value of $196 issued in connection with the IPO).</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb2f2f46800c9483cbf6ce93df36f5f53" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">c)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Immediately prior to the consummation of the IPO, certain members of the Company's management exercised options to purchase 25,624 ordinary shares granted to them under the 2006 Unit Option Plan.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-22</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 9&#160;&#160; -&#160;&#160; SHAREHOLDERS' EQUITY (Cont.)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z43a3406d7fa94d5cb22f16ef4ae9f157" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Ordinary shares (Cont.)</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze06815008da24cdc934f4ea6e9862650" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Changes in ordinary share capital (Cont.)</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7eb77cf2c95848f5bcb0d3f2e3fcb5b6" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">d)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On August 20, 2014, the Company entered into a certain credit line agreement, pursuant to which it obtained a credit line in an aggregate principal amount of $12 million from certain lenders and existing shareholders (the "Lenders").&#160;&#160;The credit line amount was deposited in an escrow account at the closing, which was consummated on October 14, 2014. The Company issued to each Lender at closing a warrant (collectively, the "Credit Line Warrants"), to purchase a number of the Company's ordinary shares constituting 2% of its share capital on a fully diluted basis (assuming conversion of all of the Company's convertible securities into ordinary shares at a 1:1 conversion rate) as of the closing for each $1 million (or portion thereof) extended by such Lender.&#160;&#160;The Company issued Credit Line Warrants ("CLA Warrants") to purchase in the aggregate 221,556 of its ordinary shares.&#160;&#160;The CLA Warrants are exercisable for a period of ten years at an exercise price of NIS 2.40 per share, and may be exercised on a net issuance basis.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">Under the terms of the credit line agreement, the Company directed that the entire credit line amount (that was in escrow) be invested in the Private Placement, consummated simultaneously with the consummation of the IPO on February 24, 2015. The Company issued to the Lenders 166,667 units at a price of $72 per unit, before issuance cost. Each unit consisted of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share. Each unit was issued with one and one-half non-transferrable Long Term Incentive Warrants. Each whole Series A Warrant entitles the holder to purchase one ordinary share at an exercise price of $90. Upon vesting, each Long Term Incentive Warrant entitles the holder to purchase one ordinary share at an exercise price of $82.80. The Company received net proceeds from the Private Placement of approximately $10.9 million (net of issuance cost of approximately $1.2 million, including certain warrants with a value of $125 issued in connection with the Private Placement).</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0b29997d98ad46dd91c861ccb10defa9" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">e)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">During the years ended December 31, 2018, 2017 and 2016, certain Private Placement investors exercised CLA Warrants to purchase an aggregate 22,501, 9,912 and 34,508 ordinary shares, respectively, on a cashless basis, which resulted in the expiration of 5,192, 243, and 761 CLA Warrants, respectively. As of December 31, 2018 and 2017, 7,389 and 35,082 CLA Warrants were outstanding, respectively.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z51ee299749d947c5b8c92622f2b57f37" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">f)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Upon the closing of the IPO, the Company issued warrants to purchase 8,334 ordinary shares at an exercise price of $90 to the IPO lead underwriter and warrants to purchase 1,250 ordinary shares at an exercise price of $60.72 to the Company's U.S. legal counsel.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2371cf9f7c0b418ebd5a7096f816a84a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">g)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On June 24, 2015, the Company entered into Amendment No. 1 to the Warrant Agreement, dated June 24, 2015, between the Company and American Stock Transfer &amp; Trust Company LLC, as Warrant Agent, to extend the Registration Due Date to the date which is 180 days following the date of closing of the Company's initial public offering (i.e., August 23, 2015) in order to allow the shareholders who were the original purchasers of IPO Units additional time to become the direct registered owners of the ordinary shares underlying the IPO Units. As of December 31, 2018, and December 31, 2017, 378,047 Long Term Incentive Warrants were outstanding.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-23</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 9&#160;&#160; -&#160;&#160; SHAREHOLDERS' EQUITY (Cont.)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z3604201e48cc4ee99fb57a987d2e6f1e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Ordinary shares (Cont.)</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z29d973f4466c46bd9ec47e1d443eea91" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Changes in ordinary share capital (Cont.)</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze3ede3e3f3154e6a903ea00c105c818c" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">h)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On August 11, 2016, the Company consummated a registered direct offering of 53,635 ordinary shares at a price of $22.80 per share and pre-funded warrants to purchase 209,524 ordinary shares at a purchase price of $22.20 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.60 per share, subject to certain adjustments and will expire on August 11, 2023, unless otherwise extended in accordance with the terms of the pre-funded warrants.&#160; The Company received gross proceeds from the August registered direct offering of approximately $5.9 million (including proceeds from the exercise of 47,917 pre-funded warrants at the closing of the offering).</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">On January 23, 2017, the remaining pre-funded warrants to purchase 24,167 ordinary shares were exercised, for additional proceeds of $14.5.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">As of December 31, 2018, and December 31, 2017, there were no outstanding pre-funded warrants.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zef7dbf0f65d04d5fbe085271694bd2c4" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">i)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On June 2, 2017, the Company consummated a registered direct offering of 112,460 ordinary shares at a price of $24.00 per share and a simultaneous private placement of one-year warrants to purchase 112,460 ordinary shares at an exercise price of $25.50 per share immediately exercisable. The Company received gross proceeds from the June registered direct offering of approximately $2.69 million. As of December 31, 2017, all the warrants issued in this offering were outstanding.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">On June 2, 2018, all of the warrants issued in this offering expired.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zfa85f6113bde45c09cc925cf132f33c1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">j)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On November 22, 2017, the Company consummated a registered direct offering of 189,387 ordinary shares at a price of $13.20 per share and a simultaneous private placement of five-year warrants to purchase 142,042 ordinary shares at an exercise price of $15 per share immediately exercisable. The Company received gross proceeds from the November registered direct offering of approximately $2.5 million.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">On April 25, 2018, 56,812 of these warrants were cashless exercised into 13,574 ordinary shares.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">As of December 31, 2017, all the warrants issued in this offering were outstanding.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">As of December 31, 2018, 85,228 of these warrants were outstanding.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb291166e27f448a8880a8d7d891df9cd" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 85.05pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 14.2pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">k)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">On May 8, 2018, the Company consummated an underwritten public offering (the &#8220;2018 Public Offering&#8221;) of 2,738,472 units (the &#8220;Units&#8221;), at a public offering price of $5.5&#160;per unit, and 450,909 pre-funded units (the &#8220;Pre-funded Units&#8221;), at a public offering price of $5.49&#160;per Pre-funded Unit. Each Unit consisted of one ordinary share of the Company and one Series C warrant to purchase one ordinary share of the Company. Each Pre-funded Unit consisted of one pre-funded warrant to&#160;purchase one ordinary share and one Series C Warrant to purchase one ordinary share. The exercise price of each pre-funded warrant included in the pre-funded unit was $0.01 per share. The Series C warrants have an exercise price of $</font>5.50 per share, are exercisable immediately and will expire five years from the date of issuance<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">.</font></div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 99.25pt; LINE-HEIGHT: 1.25">The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional&#160;478,407 ordinary shares and/or Series C Warrants to purchase up to an additional&#160;478,407&#160;ordinary shares at the public offering price. The underwriters&#8217; option was exercised in full on May 8, 2018.

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">The Company received gross proceeds from the 2018 Public Offering and exercise in full of the over-allotment option of approximately $20.2 million (before deducting underwriting discounts and commissions and other offering fees and expenses). During May 2018, the 450,909 pre-funded units were exercised in full in consideration of additional gross proceeds of $4.5.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">On February 6, 2019, the Company issued 1,881,500 units, at a purchase price of $2.58 per unit, and 1,024,876 pre-funded units, at a purchase price of $2.57 per pre-funded unit, in a registered direct offering. Each unit consisted of one ordinary share of the Company and one Series D Warrant to purchase 0.5 ordinary share of the Company. Each pre-funded unit consisted of one pre-funded warrant to purchase one ordinary share and one Series D Warrant to purchase 0.5 ordinary share. The exercise price of each pre-funded warrant included in the pre-funded unit was $0.01 per share. The Series D Warrants have an exercise price of $2.58 per ordinary share and are immediately exercisable </font>and will expire on the fifth anniversary of the original issuance date.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"> The Company received gross proceeds from the February 2019 registered direct offering of approximately $7.5 million (including proceeds from the exercise of 1,024,876 pre-funded warrants), or $6.6 million, net of issuance expenses in the amount of $927.</font></div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-24</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 10&#160;-&#160;&#160;SHARE-BASED COMPENSATION</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z25cfc124eedc4d6e9a2321314ffcb6e4" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">A.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">General</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z74b5d4383016474b8037fc59a31ba044" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">1.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In connection with the transfer of all of the business operations and substantially all of the assets of Check-Cap LLC to the Company in 2009, the Company assumed the Check-Cap LLC 2006 Unit Option Plan (hereafter: the "2006 Plan"). According to the 2006 Plan, the Company is authorized to grant options to purchase ordinary shares of the Company to employees, directors and consultants of the Company. The options granted according to the 2006 Plan are generally exercisable for 10 years from the grant date unless otherwise determined by the Company's Board of Directors, vest over a period to be determined by the Company's Board of Directors, and have an exercise price to be determined by the Company's Board of Directors.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7b0e0e81c8a041a28575dc3a18affb3f" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On January 15, 2015, the Board of Directors resolved to increase the number of ordinary shares by 4% of the Company's fully-diluted share capital (including the option pool) immediately following the consummation of the IPO. As a result, the number of the Company's ordinary shares reserved for issuance under the 2006 Plan increased by 80,646.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7dbf68fb85db4caaadde2eea87d4c795" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">3.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On April 6, 2015, the Company's Board of Directors resolved to increase the number of ordinary shares of the Company's reserved for issuance under the 2006 Plan by 143,212 shares.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb8f5bd11ec7f4136a397dbbc512fb3b5" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">4.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On August 13, 2015, the shareholders approved and adopted the Check-Cap Ltd. 2015 Equity Incentive Plan (the "2015 Israeli Plan") and the Check-Ltd. 2015 United States Sub-Plan to Check-Cap Ltd. 2015 Equity Incentive Plan (the "2015 U.S. Sub-Plan" and together with the 2015 Israeli Plan, the "2015 Plan").&#160;&#160;As of such date, the Company ceased to grant options under the 2006 Plan. All of the remaining shares authorized but unissued under the 2006 Plan were rolled over to the 2015 Plan.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z0841ad9eb5664bed8e33d443dcf3e15b" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">5.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On July 30, 2018, the Company's Board of Directors resolved to increase the number of ordinary shares of the Company's reserved for issuance under the 2015 Plan by 870,261 shares to 1,205,594 shares.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z7fb7344c22584c138caada4f3119cf0e" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Details of share-based grants made by the Company</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The following tables presents the grant dates, number of underlying shares and related exercise prices of awards granted to employees and non-employees during the years 2018, 2017 and 2016 as well as the estimated fair value of the underlying ordinary shares on the grant date:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z9c519caa83d04039befa20c8c13e6b3c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr style="HEIGHT: 34px">
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Grant date</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">No. of options</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Expiration date</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Exercise price</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Fair value on grant date</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Share based expenses (1)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">$ in thousands</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Vesting terms</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">February 29, 2016</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,642</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">March 1, 2026</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">28.44</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">24.12</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">40</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">May 4, 2016</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,608</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">May 4, 2026</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">34.68</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">17.40</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">132</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">August 4, 2016</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">404</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">August 4, 2026</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15.36</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">20.40</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">October 31, 2016</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">202</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">October 31, 2026</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">23.64</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15.84</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">February 27, 2017</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,964</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">February 27, 2027</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">27.96</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">14.40</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">28</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">May 9, 2017</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,580</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">May 9, 2027</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">25.86</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12.96</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">20</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">June 22, 2017 (4)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,041</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">June 22, 2027</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">22.32</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12.60</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">64</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(3</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">August 3, 2017</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">404</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">August 3, 2027</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">22.36</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12.36</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">November 2, 2017</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">853</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">November 2, 2027</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">20.76</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8.16</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">February 13, 2018</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,584</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">February 13, 2028</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10.44</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4.95</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">23</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">July 30, 2018 (6)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">231,819</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">July 30, 2028</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.92</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.61</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">605</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(5</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">September 20, 2018 (4)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">37,039</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">September 20, 2028</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.92</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.96</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">110</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(5</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">November 1, 2018</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">44,450</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 20%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">November 1, 2028</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.81</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.23</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">144</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(5</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-25</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">NOTE 10&#160;-&#160;&#160;SHARE-BASED COMPENSATION (Cont.)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zd55b75d3fb20466f80513e16b9b0eb01" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">B.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Details of share-based grants made by the Company (Cont.)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z809f846053a842dda1ade22a15a990a8" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Grant date</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">No. of RSUs and PSUs</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Expiration date</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Fair value on grant date</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Share based expenses (1)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Vesting terms</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 26%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">February 27, 2017</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,457</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 26%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">February 27, 2027</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.20</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">197</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">June 22, 2017 (7)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">17,448</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 26%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">June 22, 2027</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.88</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">393</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">August 3, 2017 (8)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">24,951</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 26%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">August 3, 2027</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.84</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">551</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(8</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">July 30, 2018 (6)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">79,844</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 26%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">July 30, 2028</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.24</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">251</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(5</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 26%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">September 20, 2018 (4)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15,875</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 26%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">September 20, 2028</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.65</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">58</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(5</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za1bbe5b8e048474ba78912dc03c5e61a" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">1.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Share based expenses are based on their fair value on grant date. The amount is charged to statement of operations over the vesting periods.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2af9db5fb8c74828bab62038e5272ee7" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The options vest over a period of four years commencing on the date of grant, such that 25% of the options vested on the first anniversary of the date of grant and thereafter, the remaining options vest in quarterly installments.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze62fd5c082614de2b33006e0fb9c9b9b" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">3.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The options vest over a period of three years commencing on the date of grant in quarterly installments.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2ad1038dcafa46e88c1dda4795c52ce4" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">4.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Options or RSUs granted to certain members of the Company's Board of Directors.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z21eeb720fde748f4ab904917e69e0fbb" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">5.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The options vest over a period of three years commencing on the date of grant, such that one third of the options vested on the first anniversary of the date of grant and thereafter, the remaining options vest in quarterly installments.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z270468f5bff1488f91fa8dcc73b1504d" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">6.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">Of the 231,819 options and 79,844 RSUs, 122,232 options and 50,796 RSUs, respectively, were issued to certain of the Company&#8217;s officers. The remaining options and RSUs were issued to employees and consultants.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zb553f7dac5634b15b829d94ab63a1524" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">7.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On June 22, 2017, the Company's shareholders approved the award of 11,302 and 6,146 RSUs to the Mr. Densel, who served as the Company&#8217;s CEO at such time, and to certain members of the Company's Board of Directors, respectively. The terms of the RSUs awarded to the Company&#8217;s former CEO provided that they shall vest over a period of four years commencing on the date of grant, such that 25% of the RSUs shall vest on the first anniversary of the date of grant and thereafter, the remaining RSUs will vest in quarterly installments.&#160; The RSUs granted to certain members of the Company's Board of Directors shall vest over a period of three years commencing on the date of grant in quarterly installments. The compensation expense was based on the fair value on the grant date, and was estimated at approximately $255 and $138 for the RSUs granted to the Company&#8217;s CEO and to certain members of the Company's Board of Directors, respectively. These amounts are charged to statement of operations over the vesting periods.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z9238a8ba778e4121803b654711205bf6" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">8.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On August 3, 2017, the Company's Board of Directors approved the award of 24,951 Performance Stock Units (&#8220;PSUs&#8221;) to certain of the Company's employees. The PSUs shall vest based on four pre-determined milestones, of which the first milestone (15%) in 2017, the second and third milestones in 2018 (22.5% each) and the forth milestone in 2019 (40%). The compensation expense was based on the fair value on the grant date, and was estimated at approximately $551. No expenses were recorded during the years ended December 31, 2018 and 2017 as the Company did not achieve the pre-determined milestones for these years, and estimates that it will not meet the remaining pre-determined milestone for year 2019.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1ec749a9703b43679d58bf13e86411d9" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">9.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">On February 26, 2018, upon the termination of the&#160;employment of Mr. Densel, the Company&#8217;s former CEO, options to purchase&#160; 49,965 ordinary shares&#160;and 11,302 RSUs were forfeited.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-26</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 10&#160; -&#160; SHARE-BASED COMPENSATION (Cont.)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2213e7b6d04849ba883e822561e6a8c8" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">C.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Options Fair Value</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 56.7pt; LINE-HEIGHT: 1.25">The parameters which were used in applying the model are as follows:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="zf7fb8786f239439bba62187a4e746f15" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">For the year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Expected volatility (1)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">104%-108</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">58%-60</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">59%-60</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Risk-free rate</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.67-3.15</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.9%-2.2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1.2%-2.1</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Dividend yield</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">0</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">%</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Expected term (in years)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5.5-7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5.5-7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5.5-7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Share price</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3.24 - $9.07</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15.96-$26.40</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">$</div>
</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">26.64-$38.40</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z1163da9b6ea94216b295b74ace7467ce" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; align: right">(1)</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options. In the years ended December 31, 2017 and 2016, due to lack of history of trading, expected volatility was calculated based on certain peer companies that the Company considered to be comparable.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff"></font>

<div id="DSPFPageHeader"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">&#160; </font></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff"></font>

<table id="z6816ec204b9c4a5e9b4d966b1cd275d5" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; TEXT-ALIGN: justify; align: right">D.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify">Effect of share-based compensation transactions on the Company's statements of operations</div>
</td>
</tr>
</table>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z35672c3e1afe4174b3344abfad185081" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">For the year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Research and development, net</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">234</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">116</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">234</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">General and administrative, net*</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(299</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">610</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">975</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(65</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">726</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,209</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; CLEAR: both; LINE-HEIGHT: 1.25">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;* Amount in 2018 is negative mainly, due to the forfeiture of the former CEO unvested options and RSU.&#160;</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z77a501962f6b4c53bbdf9a76f15331ea" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">E.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">A&#160;summary&#160;of the Company's option activity related to options granted to employees, service providers and directors, and related information under the 2006 Plan and the 2015 Plan is as follows:</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both; LINE-HEIGHT: 1.25">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-27</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>
</div>

<div>
<div style="LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 10&#160; -&#160; SHARE-BASED COMPENSATION (Cont.)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z1f162a2621b34f7c8805748b741fd9c1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year ended December 31, 2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Number</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Weighted average of exercise price</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(in $)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Weighted average remaining contractual life</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(in years)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Aggregate</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">intrinsic value</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">($ in thousands)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Options outstanding at beginning of year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">208,222</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">46.32</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7.11</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Options granted</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">318,094</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4.00</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Options forfeited</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(103,532</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">45.88</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Options outstanding at end of year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">422,784</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">15.54</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8.60</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Options exercisable at end of year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">101,040</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">46.18</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4.61</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z3f9cee9717bd4d038f6a3cb903ab3412" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year ended December 31, 2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Number</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Weighted average of exercise price</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(in $)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Weighted average remaining contractual life</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(in years)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Aggregate</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">intrinsic value</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">($ in thousands)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Options outstanding at beginning of year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">207,769</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">47.04</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7.39</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Options granted</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,842</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">23.88</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Options forfeited</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(9,389</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">39.24</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Options outstanding at end of year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">208,222</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">46.32</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7.11</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Options exercisable at end of year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">134,550</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">48.00</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5.99</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z0ace4bd5bd394d33b069d0e2fdee344f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom" colspan="4">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year ended December 31, 2016 </div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Number of options</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Weighted average of exercise price</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(in $)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Weighted average remaining contractual life</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(in years)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Aggregate</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">intrinsic value</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">($ in thousands)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Outstanding at the beginning of the year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">230,958</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">48.12</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7.99</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Granted</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,856</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">32.64</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Exercised</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Forfeited</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(33,045</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">50.52</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Outstanding at the end of the year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">207,769</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">47.04</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7.39</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 52%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Exercisable at the end of the year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">106,725</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">46.80</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6.34</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(2</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z44af405b9307457495639fc8f6e1bcfe" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">1.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The weighted average grant date fair values of options granted during the years ended December 31, 2018, 2017 and 2016 were $2.77, $12.48 and $18.60, respectively.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zbc8b418729d14c85b72bb91734b8b5f1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The aforementioned options are out of the money.</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z5e1d489c34374a74a84c6694a443eca1" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">3.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">As of December&#160;31, 2018, 2017 and 2016, there were $701, $346 and $766 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 Plan and the 2015 Plan, respectively. This cost is expected to be recognized over a period of up to 4 years.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25">A summary of the Company&#8217;s RSUs activity is as follows:</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="LINE-HEIGHT: 1.25">
<table id="zd4ce8dead8804c0e913f4df4941a299f" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: top; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Year ended December 31</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2018</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2017</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2016</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Number of RSUs</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Unvested at beginning of year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">44,473</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Granted</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">95,719</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">49,856</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Vested</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(4,818</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(1,033</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Forfeited</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(25,905</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(4,350</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: top; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Unvested at end of year</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">109,469</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">44,473</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z80ca516d1b124a1180177f0027f9da5b" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; align: right">1.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">The weighted average grant date fair values of RSUs awarded during the years ended December 31, 2018 and 2017 were $3.31 and $1.91. There were no RSU awards in the year ended December 31, 2016.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zed77e642c96f4fea883832ae5553ecf9" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">As of December&#160;31, 2018 and 2017, there were $263 and $287 unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2015 Plan, respectively. This cost is expected to be recognized over a period of up to 4 years.</div>
</td>
</tr>
</table>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-28</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 11&#160;&#160;-&#160;&#160;RESEARCH AND DEVELOPMENT EXPENSES, NET</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25">Composition:</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z12d494700c38415f9bf697b69bb0e9c1" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 95%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">For the year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Salaries and related expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,410</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,656</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,683</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Share-based compensation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">234</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">116</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">234</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Materials</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,508</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">614</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">596</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Subcontractors&#160;and consultants</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">311</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">456</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">320</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Depreciation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">138</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">147</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">121</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Cost for registration of patents</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">126</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">157</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">150</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Others</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,099</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">893</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">511</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,039</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,615</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Less participation of the IIA and BIRD Foundation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(208</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(202</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(1,124</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total research and development, net</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,618</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6,837</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">5,491</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 12&#160;&#160;-&#160;&#160;GENERAL AND ADMINISTRATIVE EXPENSES</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Composition</font>:</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z69b28d8c0cc6495b9051a676b3e9ccdc" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 95%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">For the year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Salaries and related expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,839</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,395</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,411</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Share-based compensation, net</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(299</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">610</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">975</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Professional services</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">833</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">414</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">354</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Office rent and maintenance</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">163</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">161</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">144</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Depreciation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Others</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">899</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">574</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">678</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total general and administrative</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,445</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,164</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,571</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 13&#160; -&#160;&#160;FINANCE INCOME (EXPENSES), NET</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Composition</font>:</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z98d88e3fb6ed4ba7a925df39aaedb081" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 95%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">For the year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Interest income on short-term deposits</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">243</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">66</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">139</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Bank fees and interest expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(7</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Changes in provision for royalties</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">255</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">82</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">56</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Exchange rate differences</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">(27</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">95</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">56</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Changes in derivatives fair value</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Total financing income</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">473</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">236</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">244</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="CLEAR: both; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-29</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 14&#160;&#160;-&#160;&#160;LOSS PER SHARE</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25">Basic loss per share is computed based on the weighted average number of shares outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares outstanding during each year, plus the dilutive potential of the ordinary shares considered outstanding during the year, in accordance with ASC 260-10 "Earnings per share".</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25">All outstanding options and warrants have been excluded from the calculation of the diluted loss per share for each period presented, since all such securities have an anti-dilutive effect.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25">The following table sets forth the computation of the Company`s basic and diluted net loss per ordinary share:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z1274829274e54485a10f554042ed880b" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 95%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">For the year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: center" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: center" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; TEXT-ALIGN: center" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Net loss</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">10,589</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">9,771</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">8,826</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Shares used in computing net loss per ordinary share, basic and diluted (in thousands)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">4,058</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,455</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1,208</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Net loss per ordinary share, basic and diluted</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2.61</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">6.72</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7.31</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25">Instruments that may potentially dilute the basic loss per share in the future, but were not included in the calculation of diluted loss per share, since their effect is anti-dilutive.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z2bbf2b74d5b6482ca4e2df90d71934d7" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 95%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">For the year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(number)</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Warrants and share options</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">3,457</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">914</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">849</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">7,515</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,369</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">2,057</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageBreakArea" style="MARGIN-BOTTOM: 10pt; MARGIN-TOP: 10pt; CLEAR: both">
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal">F-30</font></div>

<div id="DSPFPageBreak" style="PAGE-BREAK-AFTER: always">
<hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000" noshade="noshade">
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CHECK CAP LTD</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">(U.S. dollars in thousands, except share and per share data)</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">NOTE 15&#160; -&#160; RELATED PARTIES</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zfbf040ef4dd240988e052bb19702ffc3" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">A.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">Compensation to the non-executive directors:</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z427e8f9a29df48d5959574c6ebb3e41e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">For the year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Fees, including reimbursement of expenses</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">340</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">274</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">238</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Share-based compensation</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">113</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">179</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">252</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">453</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">453</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">490</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z86db018927b8464b96dffa3a837e7d58" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 28.35pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; FONT-WEIGHT: bold; align: right">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">B</font>.</div>
</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Transactions with related parties:</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="LINE-HEIGHT: 1.25">
<table id="z6a66edbc759b422d9f87d14627d91119" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 92%" cellspacing="0" cellpadding="0" align="right" border="0">
<tr>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="10">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">For the year ended December 31,</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 8</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 7</div>
</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; FONT-WEIGHT: bold; PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; FONT-WEIGHT: bold" valign="bottom" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">2 0 1 6</div>
</td>
<td style="VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom">&#160;</td>
<td style="VERTICAL-ALIGN: bottom" valign="bottom" colspan="2">&#160;</td>
<td style="VERTICAL-ALIGN: bottom; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Consulting fees, including share-based compensation and reimbursement of expenses (1) (2)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">47</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">57</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">67</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Key man life insurance premium (3)</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">-</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">1</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 2px solid; TEXT-ALIGN: right; BACKGROUND-COLOR: #ffffff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">12</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 2px; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>

<tr>
<td style="WIDTH: 64%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">47</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">58</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom">&#160;</td>
<td style="WIDTH: 9%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 4px double; TEXT-ALIGN: right; BACKGROUND-COLOR: #cceeff" valign="bottom">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25">79</div>
</td>
<td style="WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 4px; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff" valign="bottom" nowrap="nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; CLEAR: both; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="zae3e613dae714250a0ccca9d1e9ec088" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">1.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">On July 1, 2005, the Company entered into an agreement with Hadar Kimchy according to which Hadar Kimchy provided marketing communication and graphical design services to the Company in consideration for a monthly fee of NIS 10,260 ($3). On August 1, 2014, the monthly fee was increased to NIS 13,680 ($4).&#160;&#160;Such services were provided to the Company by Sigalit Kimchy, who is employed by Hadar Kimchy. On April 4, 2016, the agreement was terminated.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 85.05pt; LINE-HEIGHT: 1.25">On April 4, 2016, the Company entered into an employment agreement with Sigalit Kimchy, according to which Ms. Kimchy serves as marcom and user interface lead, in a 60% part-time role (no less than 112 hours per month), for a monthly salary of NIS 11,200 ($3), plus up to 35 monthly overtime hours at a gross monthly rate of NIS 2,800 ($1), or an aggregate monthly salary of up to NIS 14,000 ($4).&#160; Ms. Kimchy is entitled to an education fund, managers' insurance or pension fund and reimbursement of monthly travel expenses.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z16c381105fb840af9e4f72711ec74100" class="DSPFListTable" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 56.7pt"></td>
<td style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 28.35pt; VERTICAL-ALIGN: top; TEXT-ALIGN: justify; align: right">2.</td>
<td style="WIDTH: auto; VERTICAL-ALIGN: top; TEXT-ALIGN: left">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify">In connection with the asset transfer agreement entered into with the Predecessor Entity in May 2009, the Company assumed the former obligation of the Predecessor Entity to distribute any proceeds it collects on the $1 million key man life insurance policy with respect to Yoav Kimchy, the Company's chief technology officer and a former director, to the former holders of the Series A preferred units in an amount equal to their respective capital contributed to the Predecessor Entity, less any amounts previously distributed to them, plus any accrued and unpaid dividends due to them as of the date of distribution. On November 16, 2016, the Company cancelled the key man life insurance policy with respect to Yoav Kimchy.</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">NOTE 16&#160; -&#160; SUBSEQUENT EVENTS</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; MARGIN-LEFT: 28.35pt; LINE-HEIGHT: 1.25">On February 4, 2019, the Company consummated a registered direct offering. See Note 9.C.2.(l)</div>
</div>

<div>
<div id="DSPFPageNumberArea" style="TEXT-ALIGN: center"><font id="DSPFPageNumber" style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal"></font>&#160;</div>

<div style="FONT-SIZE: 8pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal; TEXT-ALIGN: center">F-31</div>
</div>

<div>
<hr style="BORDER-TOP: black 1px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 4px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
</div>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font id="DSPFPageNumber" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: normal; FONT-STYLE: normal"></font>&#160;</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>2
<FILENAME>exhibit_12-1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.5.0.0
    Copyright 1995 - 2019 Broadridge-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 1px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
<br>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"><u>Exhibit 12.1</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold">&#160;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Certification Pursuant to Rule 13a-14(a) of the Exchange Act</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">I, Alex Ovadia, certify that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">I have reviewed this Annual Report on Form 20-F of Check-Cap Ltd.;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">d.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the Annual Report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Date:&#160;March 28, 2019</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="ze64cf7520bc34fe1809f26936b6f050c" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">By:</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">/s/ Alex Ovadia</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Name:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Alex Ovadia</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Title:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Chief Executive Officer<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> (Principal Executive Officer)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<hr style="BORDER-TOP: black 1px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 4px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>3
<FILENAME>exhibit_12-2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.5.0.0
    Copyright 1995 - 2019 Broadridge-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 1px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"><u>Exhibit 12.2</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Certification Pursuant to Rule 13a-14(a) of the Exchange Act</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">I, Niv Kochav, certify that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">1.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">I have reviewed this Annual Report on Form 20-F of Check-Cap Ltd.;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">2.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">3.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">4.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The company&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">c.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">d.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the Annual Report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">5.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">The company&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">a.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; MARGIN-LEFT: 36pt; LINE-HEIGHT: 1.25"><font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">b.</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Date:&#160;March 28, 2019</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="z2ec2a4db89b748b7a39f3230d586788e" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">By:</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">/s/ Niv Kochav</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Name:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Niv Kochav</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 8%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Title:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 42%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Interim Chief Financial Officer<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>(Principal Financial Officer<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> and Principal Accounting Officer)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<hr style="BORDER-TOP: black 1px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 4px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
<br style="LINE-HEIGHT: 1.25">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>4
<FILENAME>exhibit_13-1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.5.0.0
    Copyright 1995 - 2019 Broadridge-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 1px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
<br>
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"><u>Exhibit 13.1</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">Certification Pursuant to 18 U.S.C. Section 1350</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Pursuant to U.S.C. Section 1350 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Check-Cap Ltd. (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">The Annual Report on Form 20-F for the year ended December 31, 2018 of the Company fully complies, in all material respects, with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<table id="za69a34665b534c4fba8a71b6560940fb" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; WIDTH: 100%" cellspacing="0" cellpadding="0">
<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%" colspan="2">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">CHECK-CAP LTD.</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 43%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">March 28, 2019</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">By:</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">/s/ Alex Ovadia</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Name:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Alex Ovadia</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Title:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Chief Executive Officer</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">(Principal Executive Officer)</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 43%">&#160;</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">March 28, 2019</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">By:</div>
</td>
<td style="VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 2px solid; WIDTH: 43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">/s/ Niv Kochav</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Name:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Niv Kochav</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Title:</div>
</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Interim Chief Financial Officer</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">(Principal Financial Officer</div>
</td>
</tr>

<tr>
<td style="VERTICAL-ALIGN: top; WIDTH: 50%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 7%">&#160;</td>
<td style="VERTICAL-ALIGN: top; WIDTH: 43%">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">and Principal Accounting Officer)</div>
</td>
</tr>
</table>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<hr style="BORDER-TOP: black 1px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 4px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
<br style="LINE-HEIGHT: 1.25">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>5
<FILENAME>exhibit_15-1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.5.0.0
    Copyright 1995 - 2019 Broadridge-->
</head>
<body style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-TOP: black 4px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 1px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: right; LINE-HEIGHT: 1.25"><u>Exhibit 15.1</u></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: center; LINE-HEIGHT: 1.25">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: justify; LINE-HEIGHT: 1.25">We consent to the incorporation by reference in Registration Statements on Form S-8 (No. 333-203384 and 333-226490) and&#160;in Registration Statements on Form F-3 (No. 333-211065 and <font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; BACKGROUND-COLOR: #ffffff">No. 333-225789)</font>, of our report dated March&#160;28, 2019, relating to the financial statements of Check-Cap Ltd. (the &#8220;Company&#8221;) appearing in this Annual Report on Form 20-F of the Company for the year ended December 31, 2018.&#160; </div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; LINE-HEIGHT: 1.25"><br>
</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">/s/ Brightman Almagor Zohar &amp; Co.</div>

<div style="LINE-HEIGHT: 1.25">_______________________________</div>
</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-WEIGHT: bold; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Brightman Almagor Zohar &amp; Co.<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font>Certified Public Accountants<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> A Member Firm of Deloitte Touche Tohmatsu</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">Tel Aviv, Israel<font style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif"><br>
</font> March 28, 2019</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman', Times, serif; TEXT-ALIGN: left; LINE-HEIGHT: 1.25">
<hr style="BORDER-TOP: black 1px solid; HEIGHT: 10px; BORDER-RIGHT: medium none; BORDER-BOTTOM: black 4px solid; COLOR: #ffffff; TEXT-ALIGN: center; MARGIN-LEFT: auto; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; MARGIN-RIGHT: auto" align="center">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>chek-20181231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CHEK 1218 20F.xfr; Date: 2019%2D03%2D26T22:03:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:chek="http://check-cap.com/20181231">
    <link:schemaRef xlink:href="chek-20181231.xsd" xlink:type="simple" />
    <xbrli:context id="D2016-01-01_To_2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2015-01-01_To_2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_ConsultingFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ConsultingFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_ConsultingFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ConsultingFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_KeyManLifeInsurancePremiumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:KeyManLifeInsurancePremiumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_FeesAndReimbursementMember_custom_NonExecutiveDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:FeesAndReimbursementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_FeesAndReimbursementMember_custom_NonExecutiveDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:FeesAndReimbursementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2016-01-01_To_2016-12-31_NonExecutiveDirectorsMember_ShareBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ShareBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_NonExecutiveDirectorsMember_custom_ShareBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ShareBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2016-01-01_To_2016-12-31_NonExecutiveDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_NonExecutiveDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_KeyManLifeInsurancePremiumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:KeyManLifeInsurancePremiumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2013-01-01_To_2013-12-31_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_OfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:OfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2016-01-01_To_2016-12-31_WarrantAndShareOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chek:WarrantAndShareOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_WarrantAndShareOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chek:WarrantAndShareOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2016-01-01_To_2016-12-31_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_TechnologyEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_DesignerRoyaltiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:DesignerRoyaltiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_PredecessorUnitHoldersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:PredecessorUnitHoldersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_OfficeOfTheChiefScientistMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:OfficeOfTheChiefScientistMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_BinationalIndustrialResearchAndDevelopmentFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:BinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_OfficeOfTheChiefScientistMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:OfficeOfTheChiefScientistMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_OfficeOfTheChiefScientistMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:OfficeOfTheChiefScientistMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_OfficeOfTheChiefScientistMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:OfficeOfTheChiefScientistMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_VehiclesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2016-01-01_To_2016-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2016-01-01_To_2016-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2016-01-01_To_2016-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2016-01-01_To_2016-12-31_PrivatePlacementMember_1">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2016-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2016-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2016-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2016-01-01_To_2016-12-31_IPOMember_1">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2016-12-31_CreditLineAgreementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:CreditLineAgreementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2016-12-31_PrivatePlacementMember_1">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2016-12-31_AntiDilutiveWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:AntiDilutiveWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2016-12-31_LongTermIncentiveWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:LongTermIncentiveWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2016-12-31_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_PrivatePlacementMember77625296">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-25to2016-12-31_custom_AntiDilutiveWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:AntiDilutiveWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-25</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_CreditLineAgreementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:CreditLineAgreementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_LongTermIncentiveWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:LongTermIncentiveWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-08-11_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-08-11</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-08-01to2016-08-11_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-08-01</xbrli:startDate>
        <xbrli:endDate>2016-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-23_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-01-23_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-01-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2015-01-01_To_2015-12-31_IPOMember_1">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_IPOMember_1">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2015-01-01_To_2015-12-31_CreditLineAgreementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:CreditLineAgreementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_CreditLineAgreementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:CreditLineAgreementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_LongTermIncentiveWarrantsMember_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:LongTermIncentiveWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2015-01-01_To_2015-12-31_OverAllotmentOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_PrivatePlacementMember_1">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2015-01-01_To_2015-12-31_OverAllotmentOptionMember_SeriesAWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:SeriesAWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2015-01-01_To_2015-12-31_AprilSixthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:AprilSixthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2015-01-01_To_2015-12-31_UnderwriterWarrantsMember_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:UnderwriterWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_UnderwriterWarrantsMember_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:UnderwriterWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="D2015-01-01_To_2015-12-31_LegalWarrantsMember_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:LegalWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_LegalWarrantsMember_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:LegalWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_SeriesAWarrantsMember_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:SeriesAWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_LongTermIncentiveWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:LongTermIncentiveWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_JanuaryFifteenthMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:JanuaryFifteenthMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="I2015-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-12-01to2016-12-22_custom_DevelopmentAreaAMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">chek:DevelopmentAreaAMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-12-01</xbrli:startDate>
        <xbrli:endDate>2016-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-12-01to2016-12-22_custom_RestOfTheCountryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">chek:RestOfTheCountryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-12-01</xbrli:startDate>
        <xbrli:endDate>2016-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-06-01to2017-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-06-01</xbrli:startDate>
        <xbrli:endDate>2017-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-11-01to2017-11-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-11-01</xbrli:startDate>
        <xbrli:endDate>2017-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_OverAllotmentOptionMember_custom_OrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:OrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-06-01to2017-06-02_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:OneYearWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-06-01</xbrli:startDate>
        <xbrli:endDate>2017-06-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-06-02_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:OneYearWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-06-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_custom_ThreeAugustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:ThreeAugustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_custom_ThreeAugustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:ThreeAugustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:TwentyTwoJuneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:TwentyTwoJuneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ThreeAugustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:ThreeAugustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ThreeAugustMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:ThreeAugustMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ThreeAugustMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:ThreeAugustMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ThreeAugustMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:ThreeAugustMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ThreeAugustMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:ThreeAugustMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate13Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate17Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate17Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate5Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate5Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate6Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate6Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate7Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate7Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate8Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate8Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate9Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate9Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate10Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate10Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate11Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate11Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate13Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate13Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_GrantDate17Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate17Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate15Member_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate15Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate16Member_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate16Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-11-01to2017-11-22_custom_RegisteredDirectOfferingMember_custom_FiveYearWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:FiveYearWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-11-01</xbrli:startDate>
        <xbrli:endDate>2017-11-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-11-22_custom_RegisteredDirectOfferingMember_custom_FiveYearWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:FiveYearWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-11-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-25to2016-12-31_custom_AntiDilutiveWarrantsMember_custom_OrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:AntiDilutiveWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chek:OrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-25</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_AntiDilutiveWarrantsMember_custom_OrdinarySharesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:AntiDilutiveWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chek:OrdinarySharesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:TwentyTwoJuneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:TwentyTwoJuneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-02-01to2018-02-26_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-02-01</xbrli:startDate>
        <xbrli:endDate>2018-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-02-01to2018-02-26_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-02-01</xbrli:startDate>
        <xbrli:endDate>2018-02-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_NonExecutiveDirectorsCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:NonExecutiveDirectorsCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GeneralTransactionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:GeneralTransactionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_TechnologyEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_TechnologyEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_TechnologyEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_TechnologyEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_OfficeEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_TechnologyEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:TechnologyEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_DesignerRoyaltiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:DesignerRoyaltiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_DesignerRoyaltiesMember_currency_EUR">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:DesignerRoyaltiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_PredecessorUnitHoldersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:PredecessorUnitHoldersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_BinationalIndustrialResearchAndDevelopmentFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:BinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_BinationalIndustrialResearchAndDevelopmentFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">chek:BinationalIndustrialResearchAndDevelopmentFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_AntiDilutiveWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:AntiDilutiveWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_AntiDilutiveWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:AntiDilutiveWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_LongTermIncentiveWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:LongTermIncentiveWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_CreditLineAgreementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:CreditLineAgreementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_PrivatePlacementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_PrivatePlacementMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_PreFundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:PreFundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_WarrantAndShareOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">chek:WarrantAndShareOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_currency_ILS">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:ILS</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_ConsultingFeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ConsultingFeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_KeyManLifeInsurancePremiumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:KeyManLifeInsurancePremiumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_FeesAndReimbursementMember_custom_NonExecutiveDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:FeesAndReimbursementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_NonExecutiveDirectorsMember_custom_ShareBasedCompensationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">chek:ShareBasedCompensationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_NonExecutiveDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">chek:NonExecutiveDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_VehiclesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_VehiclesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-04-25_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:OneYearWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-04-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:RegisteredDirectOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:OneYearWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-08_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-08_custom_PreFundedUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:PreFundedUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-08_us-gaap_CommonClassCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-05-07to2018-05-08_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-05-07</xbrli:startDate>
        <xbrli:endDate>2018-05-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-05-07to2018-05-08_custom_PreFundedUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:PreFundedUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-05-07</xbrli:startDate>
        <xbrli:endDate>2018-05-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-06_us-gaap_IPOMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-06_custom_PreFundedUnitsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">chek:PreFundedUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-06_us-gaap_CommonClassCMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-05to2019-02-06_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-05</xbrli:startDate>
        <xbrli:endDate>2019-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_TwoThousandFifteenPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">chek:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwentyTwoJuneMember_custom_CertainEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:TwentyTwoJuneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">chek:CertainEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate5Member_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate5Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate17Member_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate17Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_GrantDate11Member_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">chek:GrantDate11Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-05to2019-02-06_custom_PreFundedWarrantsOneMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:PreFundedWarrantsOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-05</xbrli:startDate>
        <xbrli:endDate>2019-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-08_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-06_custom_SeriesDWarrantsMember_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001610590</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">chek:SeriesDWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="usd">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPerShare">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="eur">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="ils">
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="ILSPerShare">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:ILS</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="EuroPerUnitSold">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:EUR</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>chek:Unit</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="USDPerUnitSold">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>chek:PerUnitSold</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <us-gaap:ProceedsFromWarrantExercises contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">117000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">196000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2016-08-01to2016-08-11_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember" unitRef="usd" decimals="-3">47917000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2018-01-01to2018-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="From2018-01-01to2018-12-31_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3">10900000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2017-01-01to2017-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">17792000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2018-01-01to2018-12-31_us-gaap_IPOMember" unitRef="usd" decimals="-3">10800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2018-05-07to2018-05-08_us-gaap_IPOMember" unitRef="usd" decimals="-3">20200000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2018-05-07to2018-05-08_custom_PreFundedUnitsMember" unitRef="usd" decimals="-3">4500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2019-02-05to2019-02-06_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-3">7500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="From2019-02-05to2019-02-06_custom_PreFundedWarrantsOneMember_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-3">6600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">5491000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">5491000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">6837000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">6837000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">7618000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">7618000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">3571000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="D2016-01-01_To_2016-12-31_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">3571000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">3164000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">3164000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">3445000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">3445000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2016-01-01_To_2016-12-31" unitRef="Shares" decimals="INF">9856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">9842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_custom_ThreeAugustMember" unitRef="Shares" decimals="INF">24951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember" unitRef="Shares" decimals="INF">6146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ThreeAugustMember" unitRef="Shares" decimals="INF">24951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate1Member" unitRef="Shares" decimals="INF">1642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate2Member" unitRef="Shares" decimals="INF">7608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate3Member" unitRef="Shares" decimals="INF">404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate4Member" unitRef="Shares" decimals="INF">202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate5Member" unitRef="Shares" decimals="INF">1964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate6Member" unitRef="Shares" decimals="INF">1580</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate7Member" unitRef="Shares" decimals="INF">5041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate8Member" unitRef="Shares" decimals="INF">404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate9Member" unitRef="Shares" decimals="INF">853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate10Member" unitRef="Shares" decimals="INF">4584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate11Member" unitRef="Shares" decimals="INF">231819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate13Member" unitRef="Shares" decimals="INF">44450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate17Member" unitRef="Shares" decimals="INF">79844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate15Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">17448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate16Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">24951</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Shares" decimals="INF">11302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">318094</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate5Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">7457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate17Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">79844</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31_custom_GrantDate11Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">1587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="D2016-01-01_To_2016-12-31" unitRef="USDPerShare" decimals="INF">32.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31" unitRef="USDPerShare" decimals="INF">23.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31" unitRef="USDPerShare" decimals="INF">4.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <chek:UnitsPurchased contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">25000</chek:UnitsPurchased>
    <chek:UnitsPurchased contextRef="I2015-12-31_IPOMember_1" unitRef="Shares" decimals="INF">166667</chek:UnitsPurchased>
    <chek:UnitsPurchased contextRef="AsOf2018-05-08_us-gaap_IPOMember" unitRef="Shares" decimals="INF">2738472</chek:UnitsPurchased>
    <chek:UnitsPurchased contextRef="AsOf2018-05-08_custom_PreFundedUnitsMember" unitRef="Shares" decimals="INF">450909</chek:UnitsPurchased>
    <chek:PricePerUnit contextRef="From2016-08-01to2016-08-11_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember" unitRef="USDPerShare" decimals="INF">22.20</chek:PricePerUnit>
    <chek:PricePerUnit contextRef="From2017-06-01to2017-06-02_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember" unitRef="USDPerShare" decimals="INF">25.50</chek:PricePerUnit>
    <chek:PricePerUnit contextRef="From2017-11-01to2017-11-22_custom_RegisteredDirectOfferingMember_custom_FiveYearWarrantsMember" unitRef="USDPerShare" decimals="INF">15</chek:PricePerUnit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" id="Foot-00-0" decimals="INF">3669129</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <chek:WarrantsIssuedNumber contextRef="D2015-01-01_To_2015-12-31_CreditLineAgreementWarrantsMember" unitRef="Shares" decimals="INF">221556</chek:WarrantsIssuedNumber>
    <chek:WarrantsIssuedNumber contextRef="D2015-01-01_To_2015-12-31_OverAllotmentOptionMember" unitRef="Shares" decimals="INF">37500</chek:WarrantsIssuedNumber>
    <chek:WarrantsIssuedNumber contextRef="D2015-01-01_To_2015-12-31_UnderwriterWarrantsMember_IPOMember" unitRef="Shares" decimals="INF">8334</chek:WarrantsIssuedNumber>
    <chek:WarrantsIssuedNumber contextRef="D2015-01-01_To_2015-12-31_LegalWarrantsMember_IPOMember" unitRef="Shares" decimals="INF">1250</chek:WarrantsIssuedNumber>
    <chek:WarrantsIssuedNumber contextRef="From2018-01-01to2018-12-31_custom_AntiDilutiveWarrantsMember" unitRef="Shares" decimals="INF">32174</chek:WarrantsIssuedNumber>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2018-01-01to2018-12-31_custom_NonExecutiveDirectorsCompensationMember">&lt;div&gt;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zd27f1b2e8cf94f8c8fe5df07cbc0a9ae" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif"&gt;Compensation to the non-executive directors:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z75a761be81b54da39c73600e9e13f034" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Fees, including reimbursement of expenses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;340&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;274&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;238&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Share-based compensation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;113&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;179&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;252&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;453&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;453&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;490&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2018-01-01to2018-12-31_custom_GeneralTransactionsMember">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z2f812836ffe643fea41001ecb1eb2712" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Transactions with related parties:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zdb5ea891c360443a84c7faae90afb35e" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Consulting fees, including share-based compensation and reimbursement of expenses (1) (2)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;47&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;57&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;67&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Key man life insurance premium (3)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;12&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;47&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;58&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;79&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">1209000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016-01-01_To_2016-12-31_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">975000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-01-01to2017-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">610000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">116000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">726000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-65000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">-299000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">13083000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">12525000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2017-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2018-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_OfficeEquipmentMember" unitRef="usd" decimals="-3">157000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_TechnologyEquipmentMember" unitRef="usd" decimals="-3">626000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">1122000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3">339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">1218000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31_us-gaap_ComputerEquipmentMember" unitRef="usd" decimals="-3">388000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31_us-gaap_OfficeEquipmentMember" unitRef="usd" decimals="-3">186000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31_us-gaap_TechnologyEquipmentMember" unitRef="usd" decimals="-3">644000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">619000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">766000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember">P14Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_us-gaap_TechnologyEquipmentMember_srt_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_us-gaap_TechnologyEquipmentMember_srt_MaximumMember">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_us-gaap_ComputerEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="AsOf2018-12-31_us-gaap_OfficeEquipmentMember_srt_MinimumMember" unitRef="Pure" decimals="INF">0.07</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="AsOf2018-12-31_us-gaap_OfficeEquipmentMember_srt_MaximumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="AsOf2018-12-31_us-gaap_TechnologyEquipmentMember_srt_MinimumMember" unitRef="Pure" decimals="INF">0.15</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="AsOf2018-12-31_us-gaap_TechnologyEquipmentMember_srt_MaximumMember" unitRef="Pure" decimals="INF">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage contextRef="AsOf2018-12-31_us-gaap_ComputerEquipmentMember" unitRef="Pure" decimals="INF">0.33</us-gaap:PropertyPlantAndEquipmentSalvageValuePercentage>
    <chek:RoyaltiesProvision contextRef="AsOf2017-12-31_custom_DesignerRoyaltiesMember" unitRef="usd" decimals="-3">127000</chek:RoyaltiesProvision>
    <chek:RoyaltiesProvision contextRef="AsOf2017-12-31_custom_PredecessorUnitHoldersMember" unitRef="usd" decimals="-3">312000</chek:RoyaltiesProvision>
    <chek:RoyaltiesProvision contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">439000</chek:RoyaltiesProvision>
    <chek:RoyaltiesProvision contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">185000</chek:RoyaltiesProvision>
    <chek:RoyaltiesProvision contextRef="AsOf2018-12-31_custom_DesignerRoyaltiesMember" unitRef="usd" decimals="0">120000</chek:RoyaltiesProvision>
    <chek:RoyaltiesProvision contextRef="AsOf2018-12-31_custom_PredecessorUnitHoldersMember" unitRef="usd" decimals="0">65000</chek:RoyaltiesProvision>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">13083000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">12525000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" id="Foot-01-0" decimals="INF">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" id="Foot-01-1" decimals="INF">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" id="Foot-01-2" decimals="INF">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" id="Foot-01-3" decimals="INF">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" id="Foot-01-4" decimals="INF">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" id="Foot-01-5" decimals="INF">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.0315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y6M0D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="USDPerShare" decimals="INF">26.64</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2016-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="USDPerShare" decimals="INF">38.40</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="USDPerShare" decimals="INF">15.96</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="USDPerShare" decimals="INF">26.40</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2016-08-11_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember" unitRef="USDPerShare" decimals="INF">22.80</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="I2015-12-31_IPOMember_1" unitRef="USDPerShare" decimals="INF">72.00</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2017-06-02_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember" unitRef="USDPerShare" decimals="INF">24.00</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2017-11-22_custom_RegisteredDirectOfferingMember_custom_FiveYearWarrantsMember" unitRef="USDPerShare" decimals="INF">13.20</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" unitRef="USDPerShare" decimals="INF">3.24</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" unitRef="USDPerShare" decimals="INF">9.07</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2018-05-08_us-gaap_IPOMember" unitRef="USDPerShare" decimals="INF">5.50</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2018-05-08_custom_PreFundedUnitsMember" unitRef="USDPerShare" decimals="INF">5.49</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2019-02-06_us-gaap_IPOMember_us-gaap_SubsequentEventMember" unitRef="USDPerShare" decimals="INF">2.58</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2019-02-06_custom_PreFundedUnitsMember_us-gaap_SubsequentEventMember" unitRef="USDPerShare" decimals="INF">2.57</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2019-02-06_us-gaap_CommonClassCMember_us-gaap_SubsequentEventMember" unitRef="USDPerShare" decimals="INF">0.50</us-gaap:SharePrice>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">209524</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">450909</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-05-08_us-gaap_IPOMember" unitRef="Shares" decimals="INF">478407</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-05-08_us-gaap_CommonClassCMember" unitRef="Shares" decimals="INF">478407</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-02-06_us-gaap_IPOMember_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">1881500</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-02-06_custom_PreFundedUnitsMember_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">1024876</us-gaap:CommonStockSharesIssued>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">5328700</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="D2016-01-01_To_2016-12-31_PrivatePlacementMember_1" unitRef="usd" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="D2016-01-01_To_2016-12-31_IPOMember_1" unitRef="usd" decimals="-3">615000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="D2015-01-01_To_2015-12-31_IPOMember_1" unitRef="usd" decimals="-3">2945000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2017-06-01to2017-06-30_us-gaap_WarrantMember" unitRef="usd" decimals="-3">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2017-11-01to2017-11-30_us-gaap_WarrantMember" unitRef="usd" decimals="-3">378000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2018-01-01to2018-12-31_us-gaap_IPOMember" unitRef="usd" decimals="-3">2381000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <chek:StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement contextRef="D2015-01-01_To_2015-12-31" unitRef="Shares" decimals="INF">166667</chek:StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement>
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="D2016-01-01_To_2016-12-31_CommonStockMember" unitRef="Shares" id="Foot-02-0" decimals="INF">229153</chek:StockIssuedDuringPeriodSharesWarrantsExercised>
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" id="Foot-02-1" decimals="INF">35474</chek:StockIssuedDuringPeriodSharesWarrantsExercised>
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_PrivatePlacementMember77625296" unitRef="Shares" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2015-02-25to2016-12-31_custom_AntiDilutiveWarrantsMember" unitRef="Shares" decimals="INF">56</chek:StockIssuedDuringPeriodSharesWarrantsExercised>
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="D2015-01-01_To_2015-12-31_OverAllotmentOptionMember_SeriesAWarrantsMember" unitRef="Shares" decimals="INF">6250</chek:StockIssuedDuringPeriodSharesWarrantsExercised>
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_OverAllotmentOptionMember_custom_OrdinarySharesMember" unitRef="Shares" decimals="INF">12500</chek:StockIssuedDuringPeriodSharesWarrantsExercised>
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2015-02-25to2016-12-31_custom_AntiDilutiveWarrantsMember_custom_OrdinarySharesMember" unitRef="Shares" decimals="INF">7724</chek:StockIssuedDuringPeriodSharesWarrantsExercised>
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2018-01-01to2018-12-31_custom_AntiDilutiveWarrantsMember_custom_OrdinarySharesMember" unitRef="Shares" decimals="INF">7724</chek:StockIssuedDuringPeriodSharesWarrantsExercised>
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" id="Foot-02-2" decimals="INF">56121</chek:StockIssuedDuringPeriodSharesWarrantsExercised>
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_IPOMember" unitRef="Shares" decimals="INF">56</chek:StockIssuedDuringPeriodSharesWarrantsExercised>
    <chek:StockIssuedDuringPeriodSharesWarrantsExercised contextRef="From2019-02-05to2019-02-06_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">1024876</chek:StockIssuedDuringPeriodSharesWarrantsExercised>
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">117000</chek:StockIssuedDuringPeriodValueWarrantsExercised>
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="D2016-01-01_To_2016-12-31_CommonStockMember" unitRef="usd" id="Foot-02-3" decimals="-3">140000</chek:StockIssuedDuringPeriodValueWarrantsExercised>
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="D2016-01-01_To_2016-12-31_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">-23000</chek:StockIssuedDuringPeriodValueWarrantsExercised>
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="D2016-01-01_To_2016-12-31_RetainedEarningsMember" unitRef="usd" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">14000</chek:StockIssuedDuringPeriodValueWarrantsExercised>
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-02-4" decimals="-3">22000</chek:StockIssuedDuringPeriodValueWarrantsExercised>
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">-8000</chek:StockIssuedDuringPeriodValueWarrantsExercised>
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">5000</chek:StockIssuedDuringPeriodValueWarrantsExercised>
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-02-5" decimals="-3">38000</chek:StockIssuedDuringPeriodValueWarrantsExercised>
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">-33000</chek:StockIssuedDuringPeriodValueWarrantsExercised>
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2016-01-01to2016-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodValueWarrantsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="D2016-01-01_To_2016-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_IPOMember" unitRef="Shares" decimals="INF">25624</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-05-07to2018-05-08_custom_PreFundedUnitsMember" unitRef="Shares" decimals="INF">450909</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="From2017-01-01to2017-12-31_us-gaap_PrivatePlacementMember77625296" unitRef="usd" decimals="-3">125000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="From2018-01-01to2018-12-31_us-gaap_IPOMember" unitRef="usd" decimals="-3">49229000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="From2018-01-01to2018-12-31_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3">58298000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2016-12-31_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">22.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare contextRef="AsOf2018-12-31_us-gaap_WarrantMember" unitRef="USDPerShare" decimals="INF">5.49</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="I2016-12-31" unitRef="Shares" decimals="INF">207769</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">208222</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">230958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">422784</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">109469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">44473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="D2016-01-01_To_2016-12-31" unitRef="Shares" decimals="INF">33045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">9389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">103532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="I2016-12-31" unitRef="usd" decimals="-3">-2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">-2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">-2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="I2016-12-31" unitRef="usd" decimals="-3">-2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">-2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">-2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="I2016-12-31" unitRef="usd" decimals="-3">2000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">2000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">2000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <dei:DocumentType contextRef="From2018-01-01to2018-12-31">20-F</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2018-01-01to2018-12-31">2018-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2018-01-01to2018-12-31">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="From2018-01-01to2018-12-31">Check-Cap Ltd</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2018-01-01to2018-12-31">0001610590</dei:EntityCentralIndexKey>
    <dei:EntityCurrentReportingStatus contextRef="From2018-01-01to2018-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:CurrentFiscalYearEndDate contextRef="From2018-01-01to2018-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="From2018-01-01to2018-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2018-01-01to2018-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:DocumentFiscalYearFocus contextRef="From2018-01-01to2018-12-31">2018</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2018-01-01to2018-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" id="Foot-03-0" decimals="-3">5259000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering contextRef="D2016-01-01_To_2016-12-31_CommonStockMember" unitRef="usd" id="Foot-03-1" decimals="-3">32000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering contextRef="D2016-01-01_To_2016-12-31_AdditionalPaidInCapitalMember" unitRef="usd" id="Foot-03-2" decimals="-3">5227000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering contextRef="D2016-01-01_To_2016-12-31_RetainedEarningsMember" unitRef="usd" id="Foot-03-3" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering contextRef="From2016-08-01to2016-08-11_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember" unitRef="usd" decimals="-3">53635000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering contextRef="From2017-06-01to2017-06-02_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember" unitRef="usd" decimals="-3">112460000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering contextRef="From2017-11-01to2017-11-22_custom_RegisteredDirectOfferingMember_custom_FiveYearWarrantsMember" unitRef="usd" decimals="-3">189387000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering contextRef="From2016-01-01to2016-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" id="Foot-03-4" xsi:nil="true" />
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="D2016-01-01_To_2016-12-31_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">1411000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">1395000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">4683000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">4656000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">4410000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SalariesWagesAndOfficersCompensation contextRef="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">1839000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:DepreciationNonproduction contextRef="D2016-01-01_To_2016-12-31_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">9000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="From2017-01-01to2017-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">10000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">121000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">147000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">138000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">10000</us-gaap:DepreciationNonproduction>
    <us-gaap:OtherCostAndExpenseOperating contextRef="D2016-01-01_To_2016-12-31_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">678000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="From2017-01-01to2017-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">574000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">511000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">893000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">1099000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating contextRef="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">899000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016-01-01_To_2016-12-31" unitRef="Shares" decimals="INF">2057</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="D2016-01-01_To_2016-12-31_WarrantAndShareOptionsMember" unitRef="Shares" decimals="INF">849</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_custom_WarrantAndShareOptionsMember" unitRef="Shares" decimals="INF">914</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">2369</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">7515</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31_custom_WarrantAndShareOptionsMember" unitRef="Shares" decimals="INF">3457</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2018-12-31_us-gaap_VehiclesMember" unitRef="usd" decimals="-3">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2018-12-31_us-gaap_VehiclesMember" unitRef="usd" decimals="-3">63000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2018-12-31_us-gaap_VehiclesMember" unitRef="usd" decimals="-3">10000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <chek:OperatingLeaseRentExpenseMonthly contextRef="From2018-01-01to2018-12-31_us-gaap_VehiclesMember" unitRef="usd" decimals="-3">14000</chek:OperatingLeaseRentExpenseMonthly>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2018-12-31_us-gaap_VehiclesMember" unitRef="usd" decimals="-3">22000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2018-12-31_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" unitRef="usd" decimals="0">13000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2018-12-31" unitRef="usd" decimals="0">35000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <chek:MaximumRoyaltyObligation contextRef="AsOf2018-12-31_custom_DesignerRoyaltiesMember" unitRef="usd" decimals="0">229000</chek:MaximumRoyaltyObligation>
    <chek:MaximumRoyaltyObligation contextRef="AsOf2018-12-31_custom_DesignerRoyaltiesMember_currency_EUR" unitRef="eur" decimals="0">200000</chek:MaximumRoyaltyObligation>
    <chek:MaximumRoyaltyObligation contextRef="AsOf2018-12-31_custom_BinationalIndustrialResearchAndDevelopmentFoundationMember" unitRef="usd" decimals="0">900000</chek:MaximumRoyaltyObligation>
    <chek:RoyaltiesPayablePercentageOfProductSales contextRef="AsOf2018-12-31_custom_OfficeOfTheChiefScientistMember_srt_MinimumMember" unitRef="Pure" decimals="INF">0.03</chek:RoyaltiesPayablePercentageOfProductSales>
    <chek:RoyaltiesPayablePercentageOfProductSales contextRef="AsOf2018-12-31_custom_OfficeOfTheChiefScientistMember_srt_MaximumMember" unitRef="Pure" decimals="INF">0.05</chek:RoyaltiesPayablePercentageOfProductSales>
    <chek:RoyaltiesPayablePercentageOfProductSales contextRef="AsOf2018-12-31_custom_BinationalIndustrialResearchAndDevelopmentFoundationMember" unitRef="Pure" decimals="INF">0.05</chek:RoyaltiesPayablePercentageOfProductSales>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="AsOf2018-12-31_custom_OfficeOfTheChiefScientistMember" unitRef="usd" decimals="-5">5600000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="AsOf2018-12-31_custom_BinationalIndustrialResearchAndDevelopmentFoundationMember" unitRef="usd" decimals="0">180000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <chek:RefundExpenses contextRef="AsOf2018-12-31_custom_BinationalIndustrialResearchAndDevelopmentFoundationMember" unitRef="usd" decimals="0">13000</chek:RefundExpenses>
    <chek:RoyaltiesPayablePerUnitSold contextRef="AsOf2018-12-31_custom_DesignerRoyaltiesMember" unitRef="USDPerUnitSold" decimals="INF">0.57</chek:RoyaltiesPayablePerUnitSold>
    <chek:RoyaltiesPayablePerUnitSold contextRef="AsOf2018-12-31_custom_DesignerRoyaltiesMember_currency_EUR" unitRef="EuroPerUnitSold" decimals="INF">0.50</chek:RoyaltiesPayablePerUnitSold>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">7403000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">14984000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">503000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">452000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">503000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">452000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">7906000</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">15436000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">608000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">1113000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">347000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">214000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">5000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">35000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">1562000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">2221000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">439000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">185000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockValue contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">974000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">3456000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">57643000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">72888000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">-52712000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">-63301000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">7906000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">15436000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingIncomeLoss contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">-9062000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">-10001000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-11063000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">-8818000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">-9765000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-10590000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">8000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-1000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">130000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">157000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">147000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">1209000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">726000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-65000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherNoncashIncomeExpense contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">56000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">165000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-67000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">-438000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">164000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">13000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">-252000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">275000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">416000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">-510000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">-126000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">258000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">-56000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">-82000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-255000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">166000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">231000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">94000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">-4811000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="From2017-01-01to2017-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:PaymentsForProceedsFromInvestments contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">5629000</us-gaap:PaymentsForProceedsFromInvestments>
    <chek:ProceedsFromIssuanceResisteredDirectOffering contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">5307000</chek:ProceedsFromIssuanceResisteredDirectOffering>
    <chek:ProceedsFromIssuanceResisteredDirectOffering contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">4379000</chek:ProceedsFromIssuanceResisteredDirectOffering>
    <chek:ProceedsFromIssuanceResisteredDirectOffering contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-30000</chek:ProceedsFromIssuanceResisteredDirectOffering>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">55000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">164000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-80000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="I2016-12-31" unitRef="usd" decimals="-3">11639000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">6997000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">8572000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <chek:WarrantsCashlessExercise contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">23000</chek:WarrantsCashlessExercise>
    <chek:WarrantsCashlessExercise contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">8000</chek:WarrantsCashlessExercise>
    <chek:WarrantsCashlessExercise contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">33000</chek:WarrantsCashlessExercise>
    <us-gaap:FairValueOfAssetsAcquired contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">8000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">15000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">3000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" id="Foot-03-5" decimals="-3">47000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="From2017-01-01to2017-12-31" unitRef="usd" id="Foot-03-6" decimals="-3">30000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="From2018-01-01to2018-12-31" unitRef="usd" id="Foot-03-7" xsi:nil="true" />
    <us-gaap:IncomeTaxesPaid contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">8000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">3000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">5000</us-gaap:IncomeTaxesPaid>
    <chek:GovernmentInstitutionalAssetsCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">89000</chek:GovernmentInstitutionalAssetsCurrent>
    <chek:GovernmentInstitutionalAssetsCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">178000</chek:GovernmentInstitutionalAssetsCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">261000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">206000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">55000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">34000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">1000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">1000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">406000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">419000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">235000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">162000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">367000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">697000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">602000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">859000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2016-01-01to2016-12-31_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" unitRef="usd" decimals="-3">78000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2017-01-01to2017-12-31_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" unitRef="usd" decimals="-3">83000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet contextRef="From2018-01-01to2018-12-31_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" unitRef="usd" decimals="0">84000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:SuppliesExpense contextRef="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">596000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">614000</us-gaap:SuppliesExpense>
    <us-gaap:SuppliesExpense contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">1508000</us-gaap:SuppliesExpense>
    <chek:SubcontractorsAndConsultantFees contextRef="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">320000</chek:SubcontractorsAndConsultantFees>
    <chek:SubcontractorsAndConsultantFees contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">456000</chek:SubcontractorsAndConsultantFees>
    <chek:SubcontractorsAndConsultantFees contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">311000</chek:SubcontractorsAndConsultantFees>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">150000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">157000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">126000</us-gaap:AmortizationOfIntangibleAssets>
    <chek:ResearchAndDevelopmentExpenseGross contextRef="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">6615000</chek:ResearchAndDevelopmentExpenseGross>
    <chek:ResearchAndDevelopmentExpenseGross contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">7039000</chek:ResearchAndDevelopmentExpenseGross>
    <chek:ResearchAndDevelopmentExpenseGross contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">7826000</chek:ResearchAndDevelopmentExpenseGross>
    <us-gaap:ProfessionalFees contextRef="D2016-01-01_To_2016-12-31_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">354000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2017-01-01to2017-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">414000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees contextRef="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">833000</us-gaap:ProfessionalFees>
    <us-gaap:LeaseAndRentalExpense contextRef="D2016-01-01_To_2016-12-31_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">144000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-01-01to2017-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">161000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2018-01-01to2018-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" unitRef="usd" decimals="-3">163000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">139000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">66000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">243000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">7000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">7000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">7000</us-gaap:InterestExpense>
    <chek:RoyaltyIncomeExpenseNonoperating contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">56000</chek:RoyaltyIncomeExpenseNonoperating>
    <chek:RoyaltyIncomeExpenseNonoperating contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">82000</chek:RoyaltyIncomeExpenseNonoperating>
    <chek:RoyaltyIncomeExpenseNonoperating contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">255000</chek:RoyaltyIncomeExpenseNonoperating>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">56000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">95000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-27000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">244000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">236000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">473000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="D2016-01-01_To_2016-12-31" unitRef="Shares" decimals="-3">1208000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="-3">1455000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="-3">4058000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="D2016-01-01_To_2016-12-31" unitRef="USDPerShare" decimals="INF">7.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-01-01to2017-12-31" unitRef="USDPerShare" decimals="INF">6.72</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-01-01to2018-12-31" unitRef="USDPerShare" decimals="INF">2.61</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:DebtInstrumentFaceAmount contextRef="I2015-12-31_CreditLineAgreementWarrantsMember" unitRef="usd" decimals="-3">12000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2015-01-01_To_2015-12-31_CreditLineAgreementWarrantsMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="D2015-01-01_To_2015-12-31_AprilSixthMember">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2016-08-01to2016-08-11_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember">2023-08-11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate1Member">2026-03-01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate2Member">2026-05-04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate3Member">2026-08-04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate4Member">2026-10-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate5Member">2027-02-27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate6Member">2027-05-09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate7Member">2027-06-22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate8Member">2027-08-03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate9Member">2027-11-02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate10Member">2028-02-13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate11Member">2028-09-20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate13Member">2028-11-01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate17Member">2028-07-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate15Member_us-gaap_RestrictedStockUnitsRSUMember">2027-06-22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate16Member_us-gaap_RestrictedStockUnitsRSUMember">2027-08-03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate5Member_us-gaap_RestrictedStockUnitsRSUMember">2027-02-27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate17Member_us-gaap_RestrictedStockUnitsRSUMember">2028-07-30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="From2018-01-01to2018-12-31_custom_GrantDate11Member_us-gaap_RestrictedStockUnitsRSUMember">2028-09-20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_custom_ThreeAugustMember" unitRef="USDPerShare" decimals="INF">22.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate1Member" unitRef="USDPerShare" decimals="INF">28.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate2Member" unitRef="USDPerShare" decimals="INF">34.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate3Member" unitRef="USDPerShare" decimals="INF">15.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate4Member" unitRef="USDPerShare" decimals="INF">23.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate5Member" unitRef="USDPerShare" decimals="INF">27.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate6Member" unitRef="USDPerShare" decimals="INF">25.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate7Member" unitRef="USDPerShare" decimals="INF">22.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate8Member" unitRef="USDPerShare" decimals="INF">22.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate9Member" unitRef="USDPerShare" decimals="INF">20.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate10Member" unitRef="USDPerShare" decimals="INF">10.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate11Member" unitRef="USDPerShare" decimals="INF">3.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate13Member" unitRef="USDPerShare" decimals="INF">3.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="AsOf2018-12-31_custom_GrantDate17Member" unitRef="USDPerShare" decimals="INF">3.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">-7923000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">-9150000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-10034000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">4645000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">-231000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-5723000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">5424000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">4575000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">17762000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <chek:ReductionInIncomeTaxRate contextRef="From2016-12-01to2016-12-22_custom_DevelopmentAreaAMember" unitRef="Pure" decimals="INF">0.05</chek:ReductionInIncomeTaxRate>
    <chek:ReductionInIncomeTaxRate contextRef="From2016-12-01to2016-12-22_custom_RestOfTheCountryMember" unitRef="Pure" decimals="INF">0.08</chek:ReductionInIncomeTaxRate>
    <chek:ReductionInIncomeTaxRate contextRef="From2018-01-01to2018-12-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.075</chek:ReductionInIncomeTaxRate>
    <chek:ReductionInIncomeTaxRate contextRef="From2018-01-01to2018-12-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.09</chek:ReductionInIncomeTaxRate>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">79000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2016-01-01to2016-12-31_custom_ConsultingFeesMember" unitRef="usd" decimals="-3">67000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2017-01-01to2017-12-31_custom_ConsultingFeesMember" unitRef="usd" decimals="-3">57000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2016-01-01to2016-12-31_custom_KeyManLifeInsurancePremiumMember" unitRef="usd" decimals="-3">12000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2016-01-01to2016-12-31_custom_FeesAndReimbursementMember_custom_NonExecutiveDirectorsMember" unitRef="usd" decimals="-3">238000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2017-01-01to2017-12-31_custom_FeesAndReimbursementMember_custom_NonExecutiveDirectorsMember" unitRef="usd" decimals="-3">274000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2016-01-01_To_2016-12-31_NonExecutiveDirectorsMember_ShareBasedCompensationMember" unitRef="usd" decimals="-3">252000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2017-01-01to2017-12-31_custom_NonExecutiveDirectorsMember_custom_ShareBasedCompensationMember" unitRef="usd" decimals="-3">179000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2016-01-01_To_2016-12-31_NonExecutiveDirectorsMember" unitRef="usd" decimals="-3">490000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2017-01-01to2017-12-31_custom_NonExecutiveDirectorsMember" unitRef="usd" decimals="-3">453000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2017-01-01to2017-12-31_custom_KeyManLifeInsurancePremiumMember" unitRef="usd" decimals="-3">1000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">58000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">47000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2018-01-01to2018-12-31_custom_ConsultingFeesMember" unitRef="usd" decimals="-3">47000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2018-01-01to2018-12-31_custom_KeyManLifeInsurancePremiumMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2018-01-01to2018-12-31_custom_FeesAndReimbursementMember_custom_NonExecutiveDirectorsMember" unitRef="usd" decimals="-3">340000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2018-01-01to2018-12-31_custom_NonExecutiveDirectorsMember_custom_ShareBasedCompensationMember" unitRef="usd" decimals="-3">113000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2018-01-01to2018-12-31_custom_NonExecutiveDirectorsMember" unitRef="usd" decimals="-3">453000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <chek:MonthlyRetainer contextRef="D2013-01-01_To_2013-12-31_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" unitRef="usd" decimals="-3">3000</chek:MonthlyRetainer>
    <chek:MonthlyRetainer contextRef="From2013-01-01to2013-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_currency_ILS" unitRef="ils" decimals="-3">10260000</chek:MonthlyRetainer>
    <chek:MonthlyRetainer contextRef="From2015-01-01to2015-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_currency_ILS" unitRef="ils" decimals="-3">13680000</chek:MonthlyRetainer>
    <chek:MonthlyRetainer contextRef="From2015-01-01to2015-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" unitRef="usd" decimals="-3">4000</chek:MonthlyRetainer>
    <chek:KeyManInsurancePolicy contextRef="AsOf2018-12-31_us-gaap_OfficerMember" unitRef="usd" decimals="-3">1000000</chek:KeyManInsurancePolicy>
    <chek:MonthlySalary contextRef="From2018-01-01to2018-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_currency_ILS" unitRef="ils" decimals="-3">11200000</chek:MonthlySalary>
    <chek:MonthlySalary contextRef="From2018-01-01to2018-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" unitRef="usd" decimals="-3">3000</chek:MonthlySalary>
    <chek:GrossOvertimeMonthlyRate contextRef="From2018-01-01to2018-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_currency_ILS" unitRef="ils" decimals="-3">2800000</chek:GrossOvertimeMonthlyRate>
    <chek:GrossOvertimeMonthlyRate contextRef="From2018-01-01to2018-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" unitRef="usd" decimals="-3">1000</chek:GrossOvertimeMonthlyRate>
    <chek:MaximumAggregateMonthlySalary contextRef="From2018-01-01to2018-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_currency_ILS" unitRef="ils" decimals="-3">14000000</chek:MaximumAggregateMonthlySalary>
    <chek:MaximumAggregateMonthlySalary contextRef="From2018-01-01to2018-12-31_us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" unitRef="usd" decimals="-3">4000</chek:MaximumAggregateMonthlySalary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="D2016-01-01_To_2016-12-31" unitRef="Pure" decimals="INF">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-01-01to2017-12-31" unitRef="Pure" decimals="INF">0.24</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-12-01to2016-12-22_custom_DevelopmentAreaAMember" unitRef="Pure" decimals="INF">0.075</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2016-12-01to2016-12-22_custom_RestOfTheCountryMember" unitRef="Pure" decimals="INF">0.12</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-01-01to2018-12-31" unitRef="Pure" decimals="INF">0.23</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-01-01to2018-12-31_srt_MinimumMember" unitRef="Pure" decimals="INF">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-01-01to2018-12-31_srt_MaximumMember" unitRef="Pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="I2016-12-31" unitRef="USDPerShare" decimals="INF">47.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-12-31" unitRef="USDPerShare" decimals="INF">46.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-12-31" unitRef="USDPerShare" decimals="INF">48.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-12-31" unitRef="USDPerShare" decimals="INF">15.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="D2016-01-01_To_2016-12-31" unitRef="USDPerShare" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="D2016-01-01_To_2016-12-31" unitRef="USDPerShare" decimals="INF">50.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31" unitRef="USDPerShare" decimals="INF">39.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31" unitRef="USDPerShare" decimals="INF">45.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2016-12-31_AntiDilutiveWarrantsMember" unitRef="Shares" decimals="INF">14969</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2016-08-11_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember" unitRef="Shares" decimals="INF">209524</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2017-01-23_custom_PreFundedWarrantsMember" unitRef="Shares" decimals="INF">24167</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2016-12-31_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember" unitRef="Shares" decimals="INF">137441</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2017-06-02_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember" unitRef="Shares" decimals="INF">112460</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2017-11-22_custom_RegisteredDirectOfferingMember_custom_FiveYearWarrantsMember" unitRef="Shares" decimals="INF">142042</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-12-31_custom_AntiDilutiveWarrantsMember" unitRef="Shares" decimals="INF">7246</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2016-08-11_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember" unitRef="USDPerShare" decimals="INF">0.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015-12-31_CreditLineAgreementWarrantsMember" unitRef="USDPerShare" decimals="INF">0.2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015-12-31_LongTermIncentiveWarrantsMember_PrivatePlacementMember" unitRef="USDPerShare" decimals="INF">82.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015-12-31_UnderwriterWarrantsMember_IPOMember" unitRef="USDPerShare" decimals="INF">90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015-12-31_LegalWarrantsMember_IPOMember" unitRef="USDPerShare" decimals="INF">60.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015-12-31_SeriesAWarrantsMember_PrivatePlacementMember" unitRef="USDPerShare" decimals="INF">90</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015-12-31_LongTermIncentiveWarrantsMember" unitRef="USDPerShare" decimals="INF">82.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_us-gaap_PrivatePlacementMember" unitRef="USDPerShare" decimals="INF">0.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_us-gaap_PrivatePlacementMember_currency_ILS" unitRef="ILSPerShare" decimals="INF">2.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-05-08_custom_PreFundedUnitsMember" unitRef="USDPerShare" decimals="INF">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2019-02-06_custom_PreFundedUnitsMember_us-gaap_SubsequentEventMember" unitRef="USDPerShare" decimals="INF">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-05-08_custom_SeriesCWarrantsMember" unitRef="USDPerShare" decimals="INF">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2019-02-06_custom_SeriesDWarrantsMember_us-gaap_SubsequentEventMember" unitRef="USDPerShare" decimals="INF">2.58</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <chek:ClassOfWarrantOrRightExpiration contextRef="I2016-12-31_CreditLineAgreementWarrantsMember" unitRef="Shares" decimals="INF">761</chek:ClassOfWarrantOrRightExpiration>
    <chek:ClassOfWarrantOrRightExpiration contextRef="I2016-12-31_LongTermIncentiveWarrantsMember" unitRef="Shares" decimals="INF">388980</chek:ClassOfWarrantOrRightExpiration>
    <chek:ClassOfWarrantOrRightExpiration contextRef="AsOf2017-12-31_custom_CreditLineAgreementWarrantsMember" unitRef="Shares" decimals="INF">243</chek:ClassOfWarrantOrRightExpiration>
    <chek:ClassOfWarrantOrRightExpiration contextRef="AsOf2017-12-31_custom_LongTermIncentiveWarrantsMember" unitRef="Shares" decimals="INF">378047</chek:ClassOfWarrantOrRightExpiration>
    <chek:ClassOfWarrantOrRightExpiration contextRef="AsOf2018-12-31_custom_LongTermIncentiveWarrantsMember" unitRef="Shares" decimals="INF">378047</chek:ClassOfWarrantOrRightExpiration>
    <chek:ClassOfWarrantOrRightExpiration contextRef="AsOf2018-12-31_custom_CreditLineAgreementWarrantsMember" unitRef="Shares" decimals="INF">5192</chek:ClassOfWarrantOrRightExpiration>
    <chek:ClassOfWarrantOrRightExpiration contextRef="AsOf2018-04-25_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember" unitRef="Shares" decimals="INF">13574</chek:ClassOfWarrantOrRightExpiration>
    <chek:WarrantsExercisedCashlessBasis contextRef="I2016-12-31_PrivatePlacementMember_1" unitRef="Shares" decimals="INF">34508</chek:WarrantsExercisedCashlessBasis>
    <chek:WarrantsExercisedCashlessBasis contextRef="AsOf2017-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">9912</chek:WarrantsExercisedCashlessBasis>
    <chek:WarrantsExercisedCashlessBasis contextRef="I2015-12-31_PrivatePlacementMember_1" unitRef="Shares" decimals="INF">82348</chek:WarrantsExercisedCashlessBasis>
    <chek:WarrantsExercisedCashlessBasis contextRef="AsOf2018-12-31_us-gaap_PrivatePlacementMember" unitRef="Shares" decimals="INF">22501</chek:WarrantsExercisedCashlessBasis>
    <chek:WarrantsExercisedCashlessBasis contextRef="AsOf2018-04-25_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember" unitRef="Shares" decimals="INF">56812</chek:WarrantsExercisedCashlessBasis>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2017-12-31_custom_CreditLineAgreementWarrantsMember" unitRef="Shares" decimals="INF">35082</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2016-12-31_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember" unitRef="Shares" decimals="INF">24167</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2018-12-31_custom_CreditLineAgreementWarrantsMember" unitRef="Shares" decimals="INF">7389</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2018-12-31_custom_PreFundedWarrantsMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2018-12-31_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember" unitRef="Shares" decimals="INF">85228</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2016-08-01to2016-08-11_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember" unitRef="usd" decimals="-3">5900000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2017-01-01to2017-01-23_custom_PreFundedWarrantsMember" unitRef="usd" decimals="-3">14500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2017-06-01to2017-06-02_custom_RegisteredDirectOfferingMember_custom_OneYearWarrantsMember" unitRef="usd" decimals="-3">2690000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2017-11-01to2017-11-22_custom_RegisteredDirectOfferingMember_custom_FiveYearWarrantsMember" unitRef="usd" decimals="-3">2500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants contextRef="From2016-01-01to2016-12-31_custom_RegisteredDirectOfferingMember_custom_PreFundedWarrantsMember" unitRef="usd" decimals="-3">82500000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-01-01to2016-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" decimals="INF">18.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" decimals="INF">12.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPerShare" decimals="INF">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2016-01-01to2016-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPerShare" xsi:nil="true" />
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate1Member" unitRef="USDPerShare" decimals="INF">24.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate2Member" unitRef="USDPerShare" decimals="INF">17.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate3Member" unitRef="USDPerShare" decimals="INF">20.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate4Member" unitRef="USDPerShare" decimals="INF">15.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate5Member" unitRef="USDPerShare" decimals="INF">14.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate6Member" unitRef="USDPerShare" decimals="INF">12.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate7Member" unitRef="USDPerShare" decimals="INF">12.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate8Member" unitRef="USDPerShare" decimals="INF">12.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate9Member" unitRef="USDPerShare" decimals="INF">8.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate10Member" unitRef="USDPerShare" decimals="INF">4.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate11Member" unitRef="USDPerShare" decimals="INF">2.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate13Member" unitRef="USDPerShare" decimals="INF">3.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate17Member" unitRef="USDPerShare" decimals="INF">2.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate15Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPerShare" decimals="INF">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate16Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPerShare" decimals="INF">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPerShare" decimals="INF">2.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPerShare" decimals="INF">1.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate5Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPerShare" decimals="INF">2.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate17Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPerShare" decimals="INF">3.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_custom_GrantDate11Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="USDPerShare" decimals="INF">3.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-3">346000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="I2016-12-31_EmployeeStockOptionMember" unitRef="usd" decimals="-3">766000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember_custom_ThreeAugustMember" unitRef="usd" decimals="-3">551000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember" unitRef="usd" decimals="-3">138000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ThreeAugustMember" unitRef="usd" decimals="-3">551000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2018-12-31_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember" unitRef="usd" decimals="-3">225000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-3">701000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3">263000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2017-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3">287000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwentyTwoJuneMember_custom_CertainEmployeesMember" unitRef="usd" decimals="-3">225000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember">P4Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_custom_ThreeAugustMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate1Member">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate2Member">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate3Member">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate4Member">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate5Member">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate6Member">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate7Member">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate8Member">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate9Member">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate10Member">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate11Member">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate13Member">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate17Member">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate15Member_us-gaap_RestrictedStockUnitsRSUMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate16Member_us-gaap_RestrictedStockUnitsRSUMember">P8Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate5Member_us-gaap_RestrictedStockUnitsRSUMember">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate17Member_us-gaap_RestrictedStockUnitsRSUMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_GrantDate11Member_us-gaap_RestrictedStockUnitsRSUMember">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember_custom_ThreeAugustMember" unitRef="Pure" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember" unitRef="Pure" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ThreeAugustMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" decimals="INF">0.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ThreeAugustMember_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" unitRef="Pure" decimals="INF">0.225</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember_custom_ThreeAugustMember_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" unitRef="Pure" decimals="INF">0.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="From2018-01-01to2018-12-31_custom_TwentyTwoJuneMember_us-gaap_ChiefExecutiveOfficerMember_us-gaap_ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" decimals="INF">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="D2015-01-01_To_2015-12-31_AprilSixthMember" unitRef="Shares" decimals="INF">143212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2015-01-01to2015-12-31_custom_JanuaryFifteenthMember" unitRef="Shares" decimals="INF">80646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">1205594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="From2018-01-01to2018-12-31_custom_TwoThousandFifteenPlanMember" unitRef="Shares" decimals="INF">870261</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2018-01-01to2018-12-31_us-gaap_IPOMember" unitRef="usd" decimals="-3">2900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2018-01-01to2018-12-31_us-gaap_PrivatePlacementMember" unitRef="usd" decimals="-3">1200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2019-02-05to2019-02-06_custom_PreFundedWarrantsMember_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-3">927000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="I2015-12-31_SeriesAWarrantsMember_PrivatePlacementMember" unitRef="usd" decimals="-3">1000000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="D2016-01-01_To_2016-12-31">P7Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2017-01-01to2017-12-31">P7Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2018-01-01to2018-12-31">P7Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="D2016-01-01_To_2016-12-31">P6Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2017-01-01to2017-12-31">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2018-01-01to2018-12-31">P4Y7M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2018-02-01to2018-02-26_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">49965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="From2018-02-01to2018-02-26_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">11302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <dei:EntityShellCompany contextRef="From2018-01-01to2018-12-31">false</dei:EntityShellCompany>
    <dei:EntityEmergingGrowthCompany contextRef="From2018-01-01to2018-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityVoluntaryFilers contextRef="From2018-01-01to2018-12-31">No</dei:EntityVoluntaryFilers>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2018-12-31_us-gaap_VehiclesMember_srt_MinimumMember">P32M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2018-12-31_us-gaap_VehiclesMember_srt_MaximumMember">P36M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">95719</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock contextRef="From2016-01-01to2016-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:WeightedAverageNumberOfSharesRestrictedStock contextRef="From2017-01-01to2017-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">49856</us-gaap:WeightedAverageNumberOfSharesRestrictedStock>
    <chek:NumberOfSharesRestrictedStockVested contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">-4818</chek:NumberOfSharesRestrictedStockVested>
    <chek:NumberOfSharesRestrictedStockVested contextRef="From2016-01-01to2016-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" xsi:nil="true" />
    <chek:NumberOfSharesRestrictedStockVested contextRef="From2017-01-01to2017-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">-1033</chek:NumberOfSharesRestrictedStockVested>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">25905</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="From2016-01-01to2016-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="From2017-01-01to2017-12-31_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="INF">4350</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:RestrictedCashCurrent contextRef="I2016-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2017-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:RestrictedCashCurrent contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">350000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2017-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">-13000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">-8826000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">-9771000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-10602000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3">4307000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3">-15000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">4292000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2017-01-01to2017-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">9000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:StockholdersEquity contextRef="I2016-12-31" unitRef="usd" decimals="-3">10407000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2016-12-31_CommonStockMember" unitRef="usd" id="Foot-02-6" decimals="-3">771000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2016-12-31_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">52577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2016-12-31_RetainedEarningsMember" unitRef="usd" decimals="-3">-42941000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">5905000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-02-7" decimals="-3">974000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">57643000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-52712000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31" unitRef="usd" decimals="-3">12648000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2015-12-31_CommonStockMember" unitRef="usd" id="Foot-02-8" decimals="-3">599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2015-12-31_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">46164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="I2015-12-31_RetainedEarningsMember" unitRef="usd" decimals="-3">-34115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">13030000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-02-9" decimals="-3">3456000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">72888000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-63301000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3">-13000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="I2016-12-31_CommonStockMember" unitRef="Shares" id="Foot-02-10" decimals="INF">1267080</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" id="Foot-02-11" decimals="INF">1605434</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="I2015-12-31_CommonStockMember" unitRef="Shares" id="Foot-02-12" decimals="INF">984292</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" id="Foot-02-13" decimals="INF">5330684</us-gaap:SharesOutstanding>
    <chek:StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering contextRef="D2016-01-01_To_2016-12-31_CommonStockMember" unitRef="Shares" id="Foot-04-0" decimals="INF">53635</chek:StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">1209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2016-01-01_To_2016-12-31_CommonStockMember" unitRef="usd" id="Foot-02-14" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2016-01-01_To_2016-12-31_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">1209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="D2016-01-01_To_2016-12-31_RetainedEarningsMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-65000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-02-15" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">-65000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2016-01-01to2016-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-01-01to2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent contextRef="From2017-01-01to2017-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-13000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-02-16" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent contextRef="From2018-01-01to2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3">-13000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent>
    <us-gaap:NetIncomeLoss contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">-8826000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="D2016-01-01_To_2016-12-31_CommonStockMember" unitRef="usd" id="Foot-02-17" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="D2016-01-01_To_2016-12-31_AdditionalPaidInCapitalMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="D2016-01-01_To_2016-12-31_RetainedEarningsMember" unitRef="usd" decimals="-3">-8826000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">-9771000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-02-18" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-9771000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-10589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-02-19" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3">-10589000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2016-01-01to2016-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1 contextRef="From2017-01-01to2017-12-31" unitRef="usd" id="Foot-05-0" decimals="-3">2349000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1 contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-05-1" decimals="-3">67000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1 contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" id="Foot-05-2" decimals="-3">2282000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1 contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" id="Foot-05-3" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1 contextRef="From2017-01-01to2017-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" id="Foot-05-4" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1 contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" id="Foot-05-5" decimals="INF">112460</chek:StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2 contextRef="From2017-01-01to2017-12-31" unitRef="usd" id="Foot-05-6" decimals="-3">2180000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2 contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-05-7" decimals="-3">114000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2 contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" id="Foot-05-8" decimals="-3">2066000</chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2>
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2 contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" id="Foot-05-9" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2 contextRef="From2017-01-01to2017-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" id="Foot-05-10" xsi:nil="true" />
    <chek:StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2 contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" id="Foot-05-11" decimals="INF">189387</chek:StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31" unitRef="usd" id="Foot-00-1" decimals="-3">17787000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="usd" id="Foot-00-2" decimals="-3">2444000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" id="Foot-00-3" decimals="-3">15343000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" id="Foot-00-4" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" id="Foot-00-5" xsi:nil="true" />
    <chek:GrantedRevenue contextRef="D2016-01-01_To_2016-12-31_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">1124000</chek:GrantedRevenue>
    <chek:GrantedRevenue contextRef="From2017-01-01to2017-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">202000</chek:GrantedRevenue>
    <chek:GrantedRevenue contextRef="From2018-01-01to2018-12-31_custom_OfficeOfTheChiefScientistMember" unitRef="usd" decimals="0">5300000</chek:GrantedRevenue>
    <chek:GrantedRevenue contextRef="From2017-01-01to2017-12-31_custom_BinationalIndustrialResearchAndDevelopmentFoundationMember" unitRef="usd" decimals="0">127000</chek:GrantedRevenue>
    <chek:GrantedRevenue contextRef="From2018-01-01to2018-12-31_custom_BinationalIndustrialResearchAndDevelopmentFoundationMember" unitRef="usd" decimals="0">115000</chek:GrantedRevenue>
    <chek:GrantedRevenue contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3">208000</chek:GrantedRevenue>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">2100000</us-gaap:DerivativeAssetNotionalAmount>
    <chek:DerivativeFairValueOfOptionOutstanding contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">15000</chek:DerivativeFairValueOfOptionOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="I2016-12-31" unitRef="Shares" decimals="INF">106725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">134550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">101040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="I2016-12-31" unitRef="USDPerShare" decimals="INF">46.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2017-12-31" unitRef="USDPerShare" decimals="INF">48.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-12-31" unitRef="USDPerShare" decimals="INF">46.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <chek:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree contextRef="D2016-01-01_To_2016-12-31">P7Y4M20D</chek:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree>
    <chek:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree contextRef="From2017-01-01to2017-12-31">P7Y1M9D</chek:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree>
    <chek:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree contextRef="From2018-01-01to2018-12-31">P8Y7M6D</chek:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate1Member" unitRef="usd" decimals="-3">40000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate2Member" unitRef="usd" decimals="-3">132000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate3Member" unitRef="usd" decimals="-3">8000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate4Member" unitRef="usd" decimals="-3">3000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate5Member" unitRef="usd" decimals="-3">28000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate6Member" unitRef="usd" decimals="-3">20000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate7Member" unitRef="usd" decimals="-3">64000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate8Member" unitRef="usd" decimals="-3">5000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate9Member" unitRef="usd" decimals="-3">7000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate10Member" unitRef="usd" decimals="-3">23000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate11Member" unitRef="usd" decimals="-3">110000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate13Member" unitRef="usd" decimals="-3">144000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate17Member" unitRef="usd" decimals="-3">605000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate15Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3">551000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate16Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3">551000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate5Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3">197000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate17Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3">251000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="From2018-01-01to2018-12-31_custom_GrantDate11Member_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3">58000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 1&amp;#160;&amp;#160; -&amp;#160;&amp;#160;&amp;#160;GENERAL INFORMATION&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z7fed8540e261424bbb89db86c4288be8" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;A.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;General&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z3c76648caeb0450cababdaef7e18da1a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;(1)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Check Cap Ltd. (together with its wholly-owned subsidiary, the &amp;#8220;Company") was incorporated under the laws of the State of Israel. The registered address of its offices is 29 Abba Hushi Ave, Isfiya 3009000, Israel.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z6422d35124a14843a368860224a40e56" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;(2)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Check-Cap Ltd has a wholly-owned subsidiary, Check-Cap U.S. Inc., incorporated under the laws of the State of Delaware on May 15, 2015.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z73d637c5bf22402b882b2405e3cb8054" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;(3)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The Company is a clinical-stage medical diagnostics company developing C-Scan&amp;#174;, the first capsule-based system for preparation-free colorectal cancer screening (the "C-Scan system"). Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, the C-Scan system removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z2633367b47664c3e8d2cb9f0db3f7186" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;(4)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;As described in Notes 9C(2)(b) and 9C(2)(d), on February 24, 2015 the Company consummated an Initial Public Offering in the United States (U.S.) (the "IPO") concurrently with a Private Placement (the "Private Placement").&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;On August 11, 2016, the Company consummated a registered direct offering of ordinary shares and pre-funded warrants (the "August 2016 RD Offering"). See Note 9C(2)(h).&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;On June 2, 2017, the Company consummated a registered direct offering of ordinary shares and a simultaneous private placement of warrants (the "June 2017 RD Offering"). See Note 9C(2)(i).&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;On November 22, 2017, the Company consummated a registered direct offering of ordinary shares and a simultaneous private placement of warrants (the "November 2017 RD Offering" and together with the August 2016 RD Offering and June 2017 RD Offering, the &amp;#8220;RD Offerings&amp;#8221;). See Note 9C(2)(J).&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;On May 8, 2018, the Company consummated an underwritten public offering of ordinary shares, pre-funded warrants and Series C warrants (the &amp;#8220;May 2018 underwritten public offering&amp;#8221;). See Note 9C(2)(k).&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;The Company's ordinary shares, Series A Warrants and Series C Warrants are listed on the NASDAQ Capital Market under the symbols "CHEK", "CHEKW" and CHEKZ&amp;#8221; respectively.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z7be91396531e41499ca4e38a4a6e1dde" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The consolidated financial statements of the Company as of and for the year ended December 31, 2018 include the financial statements of the Company and its wholly-owned U.S. subsidiary.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z3436b9bf69a743b99183b56a9a992de0" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;B.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Going concern and management plans&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, recruiting management and technical staff, acquiring assets and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the Company's future operating losses and the timing of becoming profitable are uncertain. The Company has incurred losses of $10.6 million and $9.8 million for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, the Company's accumulated deficit was $63.3 million. The Company has funded its operations to date primarily through equity financing and through grants from the Israel Innovation Authority of the Ministry of Economy and Industry (the "IIA") (formerly the Office of the Chief Scientist of the Ministry of Economy and Industry (the "OCS)).&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Additional funding will be required to complete the Company's research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company's C-Scan system and to achieve a level of sales adequate to support the Company's cost structure.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings and other funding transactions. While the Company has been successful in raising financing in the past, there can be no assurance that it will be able to do so in the future on a timely basis on terms acceptable to the Company, or at all. Uncertain market conditions and approval by regulatory bodies and adverse results from clinical trials may (among other reasons) adversely impact the Company's ability to raise capital in the future.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company believes that current cash on hand will be sufficient to fund operations into February 2020.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of the C-Scan system, which will result in a negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company's ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during or before the end of 2019, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects and clinical trials, until it is able to obtain sufficient financing. If such sufficient financing is not received timely, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company's consolidated financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zfa04a093fdd14f57b6cf8f3bff4e5e42" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;C.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Reverse share splits&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Effective April 4, 2018, the Company's Board of Directors effected a reverse share split of 1-for-12 (i.e. 12 ordinary shares were combined into one ordinary share) (&amp;#8220;Reverse Share Split&amp;#8221;), in accordance with the approval of the Company's shareholders at an extraordinary general meeting of shareholders held on April 2, 2018. All references in the financial statements and notes to the number of shares, price per share and weighted average number of shares outstanding of our&amp;#160;ordinary shares prior to the Reverse Share Split have been adjusted to reflect the Reverse Share Split on a retroactive basis unless otherwise noted.&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;NOTE 2&amp;#160;&amp;#160; -&amp;#160;&amp;#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt"&gt;The Company`s consolidated financial statements are presented in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z1b107627e34e43e781cf7cef0a3c7728" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;A.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Use of estimates in preparation of financial statements&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z051b52fa8e564bbaa7cf401067e3c8d0" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;B.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Principles of consolidation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company's consolidated financial statements include the financial statements of Check-Cap Ltd. and its wholly-owned subsidiary, Check-Cap U.S., Inc. The Company's consolidated financial statements are presented after elimination of inter-company transactions and balances.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z0e536f1fabd246a7bca985da6358f0ff" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;C.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Financial statements in U.S dollars&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company has not yet generated revenues and the majority of its expenses are in U.S. dollar (dollar or USD) or NIS, while none of these currencies is significantly material compared to the other.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Management judgment, in setting the dollar as the Company's functional currency, is based mainly on the following criteria: The Company's budget and other Company internal reports, including reports to the Company's Board of Directors and investors, are presented in dollars. Management uses these reports in order to make decisions for the Company. All of the Company's equity and debt financings were in dollars; and it is expected that a significant portion of the Company's future revenue will be in dollars. The financial statements are presented in dollars, which is the functional currency of the Company.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z3a263b11ad4e445da79a8bbc4290998e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;D.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Cash and cash equivalents&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Cash and cash equivalents include cash in hand, short&amp;#8211;term deposits in banks and short-term highly liquid investment with an original maturity of up to three months, with a high level of liquidity that may be easily converted to known amounts of cash, and that are exposed to insignificant risk of change in value.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zc2ad2db3bbae457a8532f133aa57190a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;E.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Short-term bank deposit&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Short-term bank deposits are deposits with maturities of more than three months but less than one year. The short&amp;#8211;term bank deposits are presented at their cost, including accrued interest, which approximates fair value.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z5cbc74d75c284622af96f671ae8330c9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;F.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Cash flow hedges&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;As a matter of policy, the Company uses derivatives for risk management purposes, and does not use derivatives for speculative purposes. From time to time, the Company may enter into foreign currency zero-cost collars contracts to&amp;#160;hedge&amp;#160;foreign currency&amp;#160;cash&amp;#160;flow&amp;#160;transactions. For&amp;#160;cash&amp;#160;flow&amp;#160;hedges, unrealized gain or loss is recorded in Other comprehensive income (loss) until hedged item affects earnings. All of the Company&amp;#8217;s hedges that are designated as hedges for accounting purposes were highly effective; therefore,&amp;#160;no&amp;#160;notable amounts of&amp;#160;hedge ineffectiveness were recorded in the Company&amp;#8217;s Consolidated Statements of Operations for either the settlement of&amp;#160;cash&amp;#160;flow&amp;#160;hedges or the outstanding hedged balance.&lt;/div&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company uses zero-cost collars to hedge against the risk of overall changes in future cash flow from payments of payroll and rent denominated in New Israeli Shekel. As of December&amp;#160;31, 2018, the Company had outstanding foreign exchange collars in the notional amount of $2.1 million. These options were set for a period of up to six months. The Company measured the fair value of the options in accordance with provisions of ASC No.&amp;#160;820 (classified as level 2 of the fair value hierarchy). During 2018, losses in the amount of $28, were reclassified when the related expenses were incurred and recognized in operating expenses. The fair value of the Company&amp;#8217;s outstanding collars at December&amp;#160;31, 2018 amounted to liability of $15 and is included in in other current liabilities on the balance sheets, with the effective portion of the change in fair value, amounted $13 classified in accumulated other comprehensive income ("AOCI").&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z43258e42ffa94d73b5a8850a4b787d41" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;G.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Property and equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z650bfb86e2314946955b5f01825ef12f" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr style="height: 14px"&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;Length of useful life&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;Depreciation rate&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;Years&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.02%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Office furniture and equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10-14&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7-10&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.02%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Laboratory equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3-7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15-33&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.02%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Computers and auxiliary equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;33&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.02%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="clear: both; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z878f598c2be74023b24dfc57c858b10f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;H.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Impairment of long-lived assets&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company's long-lived assets are reviewed for impairment in accordance with ASC 360-10 "Accounting for the Impairment or Disposal of Long-Lived Assets" whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December&amp;#160;31, 2018, 2017 and 2016, no impairment losses were recorded.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zcd46fa4c7ca745d097e6e140ff524d2e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;I.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Research and development costs&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Research and development costs are expensed as incurred and consist primarily of costs for personnel, subcontractors and consultants (mainly in connection with clinical trials) and materials for research and development and clinical activities. Grants received by the Company from the IIA and from Israel-United States Binational Industrial Research and Development Foundation (the "BIRD Foundation") are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from research and development expenses. Such grants are included as a deduction of research and development costs (since at the time received the Company expects to generate sales from these projects and pay the royalties resulting from such sales).&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;See Note 7B(1) below regarding the offset of grants received for participation in research and development expenses.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z39611cf098aa4a19bd6dedd02199f27b" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;J.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Contingent liabilities&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company accounts for its contingent liabilities in accordance with ASC No.&amp;#160;450, "Contingencies". A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December&amp;#160;31, 2018, and 2017, the Company is not a party to any ligation that could have a material adverse effect on the Company's business, financial position, results of operations or cash flows (see Note ).&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="za3d9811bb2e14883aa53c16b3d1df87e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;K.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Share-based compensation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company recognizes expense for its share-based compensation based on the fair value of the awards granted. The Company&amp;#8217;s share-based compensation plans provide for the award of stock options and restricted stock units. In accordance with ASC 718-10 "Compensation-Stock Compensation", the Company estimates the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's consolidated statement of operations.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company recognizes compensation expenses for the value of its awards granted based on the graded-vesting method over the requisite service period for each separately vesting portion of the award. Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2016-09, Compensation-Stock Compensation (Topic 718) allows companies to account for forfeitures when they occur.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its share-based awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary shares, expected share price volatility and the expected option term. In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;In the years ended December 31, 2017 and 2016, expected volatility was calculated based on certain peer companies that the Company considered to be comparable.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No.&amp;#160;110, as adequate historical experience is not available to provide a reasonable estimate.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/div&gt;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z74156c4b60254db69667b88159791230" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;L.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Income taxes&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company accounts for income taxes in accordance with ASC 740-10 "Accounting for Income Taxes." This Statement requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;In accordance with ASC 740, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered 'more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2018, and 2017, the Company had no unrecognized income tax positions and accordingly, there is no impact on the Company's effective income tax rate associated with these items.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z899c4d03750a4a47b4d730b3bd1a1b7f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;M.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Fair value of financial instruments&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company measures its investments in money market funds (classified as cash equivalents) and its foreign currency net purchased options at fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"&gt;&lt;font style="font-family: Times New Roman"&gt;&amp;#9679; &lt;/font&gt;Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"&gt;&lt;font style="font-family: Times New Roman"&gt;&amp;#9679; &lt;/font&gt;Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"&gt;&lt;font style="font-family: Times New Roman"&gt;&amp;#9679; &lt;/font&gt;Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z6bbb31e375064ab4bbff408ff3c970ef" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;N.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Comprehensive&lt;font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"&gt; loss&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company accounts for comprehensive income in accordance with ASC No.&amp;#160;220, &amp;#8220;Comprehensive Income&amp;#8221;. Comprehensive income generally represents all changes in shareholders&amp;#8217; equity during the period except those resulting from investments by, or distributions to, shareholders. The Company&amp;#8217;s comprehensive loss consists of net loss and unrealized gain or loss on the effective portion of cash flow hedges. These amounts are carried in accumulated other comprehensive loss on the consolidated statements of comprehensive income and are presented net of taxes.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zfcb6b8f1f9144a3ea8800c6f9367abad" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;O.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;Restricted Cash&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company has granted a pledge in favor of Bank Leumi Le-Israel B.M in the amount of $350 to secure certain payment obligations of the Company in connection with FOREX activities. This amount was classified as restricted cash balance on December 31, 2018.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;In January 2018, the Company adopted new guidance from the Financial Accounting Standards Board or the FASB that clarified how entities should classify certain cash receipts and cash payments on the statement of cash flows. As a result, the restricted cash balance that existed in prior periods is included as a component of cash and cash equivalents and restricted cash on the statement of cash flows in the relevant periods presented. &amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; text-indent: 36pt"&gt;&#13;&lt;table id="z5d79253cdc3c4130b5e286930e5812c3" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;2 0 1 6&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom"&gt;&#13;&lt;div&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr style="height: 17px"&gt;&#13;&lt;td style="width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;Cash and Cash equivalents&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif"&gt;8,572&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;6,997&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;11,639&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;Restricted cash included current assets&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;350&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;8,922&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;6,997&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;11,639&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="clear: both; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z6f0eab32db874209a8bdc3f763d8259d" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;P.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;New accounting pronouncements&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;ASU 2016-02, &amp;#8220;Leases (Topic 842)&amp;#8221; was issued by the FASB in February 2016. The purpose of this amendment requires the recognition of lease assets and lease liabilities by lessees for those leases previously classified as operating leases. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated results of operations, financial position or disclosures.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Accounting Standards Update (ASU) 2018-07, &amp;#8220;Compensation&amp;#8212;Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting&amp;#8221; was issued by the Financial Accounting Standards Board (FASB) in June 2018. The purpose of this amendment is to address aspects of the accounting for nonemployee share-based payment transactions. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated results of operations, financial position or disclosures.&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <chek:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 3&amp;#160;&amp;#160; -&amp;#160;&amp;#160; PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 28.35pt"&gt;Composition:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z1081dc66cfdc4f258ea43c74df680d86" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Government institutions&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;178&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;89&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Prepaid expenses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;206&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;261&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Deposits&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;34&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;55&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Other assets&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;419&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;406&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</chek:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="clear: both; line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 4&amp;#160;&amp;#160; -&amp;#160;&amp;#160; PROPERTY AND EQUIPMENT, NET&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 28.35pt"&gt;&lt;font style="font: bold 10pt Times New Roman, Times, serif"&gt;Composition&lt;/font&gt;:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z0032aba21dcd49e8ac554d4bd9c16663" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Cost:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Office furniture and equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;186&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;157&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Laboratory equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;644&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;626&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Computers and auxiliary equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;388&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;339&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,218&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,122&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Accumulated depreciation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;766&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;619&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Property and equipment, net&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;452&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;503&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; Depreciation expenses amounted to $147, $157 and $130 for the years ended December&amp;#160;31, 2018, 2017 and 2016, respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 6&amp;#160;&amp;#160; -&amp;#160;&amp;#160; INCOME TAXES&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z2fa582e916074cd48ad54e07674784ee" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;A.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;The Company&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Check-Cap Ltd. is taxed according to Israeli tax laws:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="ze927463fcb75405b86d5e989126eae06" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;1.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Corporate tax rates in Israel&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;The Israeli corporate tax rate was 25% in the year 2016, 24% in year 2017 and 23% in year 2018 and onwards.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z565f0507fb5844a0b62efd1b6f5fa364" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;2.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;The Law for the Encouragement of Capital Investments, 1959 (the "Investments Law")&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;Under the Investments Law, including Amendment No. 60 to the Investments Law as published in April 2005, by virtue of the "Approved Enterprise" or "Benefited Enterprise" status, the Company is entitled to various tax benefits as follows:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z0d99f75dd19e4c638ec41b06f7b90ccf" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: normal 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;a)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; font-weight: normal; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Reduced tax rates&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;The Company has one Benefited Enterprise program under the Investments Law, which entitles it to certain tax benefits with respect to income to be derived from the Company's Benefited Enterprise. During the benefits period, taxable income from its Benefited Enterprise program (once generated) will be tax exempt for a period of ten years commencing with the year the Company will first earn taxable income relating to such enterprise. The Company chose 2010 as the year of election (the "Year of Election"). Due to the location of the Company's offices, the Company believes it is entitled to a 10 year benefit period, subject to a 14 year limitation from the Year of Election, and therefore, the tax benefit period will in any event end in 2023.&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; margin-left: 99.25pt; line-height: 1.25; text-indent: -14.2pt"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z46d685e9f5534026a616707a76845519" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: normal 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;b)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; font-weight: normal; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Conditions for entitlement to the benefits&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;The benefits available to a Benefited Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law and its regulations.&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; margin-left: 99.25pt; line-height: 1.25; text-indent: -14.2pt"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z29470baacfec4f8c9090f1850eb9eefb" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: normal 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;c)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; font-weight: normal; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Amendment of the Law for the Encouragement of Capital Investments, 1959&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;The Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the "Capital Investments Law Amendment").&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;The Capital Investments Law Amendment set alternative benefit tracks to those in effect prior to such amendment under the provisions of the Investments Law.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;The benefits granted to the Benefited Enterprises will be unlimited in time, unlike the benefits granted to special Benefited Enterprises, which will be limited for a 10-year period. The benefits shall be granted to companies that will qualify under criteria set forth in the law; for the most part, those criteria are similar to the criteria that were set forth in the Investments Law prior to its amendment.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;Under the transitional provisions of the Investments Law, the Company is entitled to take advantage of the tax benefits available under the Investments Law prior to its amendment until the end of the benefits period, as defined in the Investments Law. The Company was entitled to set the "year of election" no later than tax year 2012, provided that the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company will be able to elect that the Investments Amendment applies to the Company, thereby making the tax rates described above available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable. The Company elected not to have the Capital Investments Amendment apply to the Company.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z600b6194f6134978ad5d50ff2c22ac19" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;2.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;The Law for the Encouragement of Capital Investments, 1959 (the "Investments Law") (Cont.)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zac96366cff684f818335ee6c4fc0fa53" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: normal 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;c)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; font-weight: normal; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Amendment of the Law for the Encouragement of Capital Investments, 1959 (Cont.)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;On December 22, 2016, the Knesset approved the 2017-2018 State budget, which includes amendment number 73 to the law for the Encouragement of Capital Investments. The amendment includes:&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;Adoption of tax benefits for high-tech preferred enterprises, based on the provisions and rules adopted by the Organization for Cooperation and Economic Development (the "GCOE"), creating new tax tracks of 7.5% for Development Area A and 12% for the rest of the country.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;Reduction of corporate tax rate for all preferred enterprises from 9% to 7.5%.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;Lowering the threshold for the conditions that were previously set in order to enter the track of a "special preferred enterprise" for very big enterprises entitled to a reduced tax rate of 5% in Area A or 8% in the rest of the country.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;Updating the definitions of preferred income, preferred enterprise etc.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;In accordance with the Income Tax Ordinance, as of December 31, 2018, all of Check-Cap Ltd.'s tax assessments through tax year 2013&amp;#160;are considered final.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z5a43e6c71d174d43b9fd6a0962cd046c" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;3.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; font-weight: normal; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The Company recorded $6 and $8 current taxes for the years ended December 31, 2017 and 2016. The Company did not record current taxes for the year ended December 31, 2018, since it had no taxable income during this year.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z876364cd714349059bf0ee4b9df9579d" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;B.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Check-Cap U.S. Inc.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Check-Cap U.S. Inc. is taxed according to U.S. tax laws.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;There are no NOL carry-forward of Check-Cap U.S. Inc.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;In December 2017, the Tax Cut and Jobs Act (the &amp;#8220;Act&amp;#8221;) was signed into law, which enacted significant changes to U.S. federal corporate tax and related laws. Some of the provisions of the Act affecting corporations include, but are not limited to: (i) a reduction of the U.S. federal corporate income tax rate from 35% to 21%; (ii) limiting the interest expense deduction; (iii) expensing of cost of acquired qualified property; and (iv) elimination of the domestic production activities deduction. The Company is currently evaluating the impact the Act will have on the future financial condition and results of operations and believe the Act will have a beneficial positive net impact. The Act did not have an effect on the financial results and position of the Company.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zd8327529467944d1a01bf115c3daf3fb" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;C.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Deferred income taxes&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. Based on the Company's history of losses, the Company established a full valuation allowance.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zdfa5e22d2d924a4ba967e406ae2ef8cd" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Carry forward tax losses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;12,525&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;13,083&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Less valuation allowance&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(12,525&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(13,083&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="clear: both; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zfe8cd346f416490bb9de3e9b0f294582" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;D.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Reconciliation of the theoretical tax expense to actual tax expense&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision of full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;NOTE 8&amp;#160;&amp;#160; -&amp;#160;&amp;#160; FAIR VALUE MEASUREMENTS&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;In accordance with ASC No.&amp;#160;820, the Company measures its money market funds and foreign currency derivative contracts at fair value. Money market funds are classified within Level&amp;#160;1 or Level&amp;#160;2. This is because these assets are valued using quoted market prices or alternative pricing sources and models utilizing market observable inputs. Foreign currency derivative contracts are classified within Level&amp;#160;2 as the valuation inputs are based on quoted prices and market observable data of similar instruments.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company&amp;#8217;s financial assets measured at fair value on a recurring basis, excluding accrued interest components, consisted of the following types of instruments as of the following dates:&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="za2d67b964ab94d169dfa6bf2084b886a" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31, 2018&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Fair value measurements using input type&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Level 1&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Level 2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Total&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Cash equivalents:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Money market funds&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,307&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,307&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Foreign currency derivative instruments&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(15&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(15&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Total financial assets (Liabilities)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,307&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(15&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,292&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 10&amp;#160;-&amp;#160;&amp;#160;SHARE-BASED COMPENSATION&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z7c972179bd2f4ab38d0e10e7740bd92e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;A.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;General&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z97000ff00ad046f9840c247325499abc" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;1.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;In connection with the transfer of all of the business operations and substantially all of the assets of Check-Cap LLC to the Company in 2009, the Company assumed the Check-Cap LLC 2006 Unit Option Plan (hereafter: the "2006 Plan"). According to the 2006 Plan, the Company is authorized to grant options to purchase ordinary shares of the Company to employees, directors and consultants of the Company. The options granted according to the 2006 Plan are generally exercisable for 10 years from the grant date unless otherwise determined by the Company's Board of Directors, vest over a period to be determined by the Company's Board of Directors, and have an exercise price to be determined by the Company's Board of Directors.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z616059d2d4184a4199a6a8b0a7a19492" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;2.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On January 15, 2015, the Board of Directors resolved to increase the number of ordinary shares by 4% of the Company's fully-diluted share capital (including the option pool) immediately following the consummation of the IPO. As a result, the number of the Company's ordinary shares reserved for issuance under the 2006 Plan increased by 80,646.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zb218e8639b384ca7a05c2d13795995d8" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;3.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On April 6, 2015, the Company's Board of Directors resolved to increase the number of ordinary shares of the Company's reserved for issuance under the 2006 Plan by 143,212 shares.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z5e4e59a841444c518deedabb45e8ca35" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;4.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On August 13, 2015, the shareholders approved and adopted the Check-Cap Ltd. 2015 Equity Incentive Plan (the "2015 Israeli Plan") and the Check-Ltd. 2015 United States Sub-Plan to Check-Cap Ltd. 2015 Equity Incentive Plan (the "2015 U.S. Sub-Plan" and together with the 2015 Israeli Plan, the "2015 Plan").&amp;#160;&amp;#160;As of such date, the Company ceased to grant options under the 2006 Plan. All of the remaining shares authorized but unissued under the 2006 Plan were rolled over to the 2015 Plan.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z243d6c7eac5643a592a29715f2f452f6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;5.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On July 30, 2018, the Company's Board of Directors resolved to increase the number of ordinary shares of the Company's reserved for issuance under the 2015 Plan by 870,261 shares to 1,205,594 shares.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z5d4c6204f82f46dbbd598138b1f8adcc" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;B.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Details of share-based grants made by the Company&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The following tables presents the grant dates, number of underlying shares and related exercise prices of awards granted to employees and non-employees during the years 2018, 2017 and 2016 as well as the estimated fair value of the underlying ordinary shares on the grant date:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z88a8a70b1f2645db8ae94013b5795614" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr style="height: 34px"&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Grant date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;No. of options&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Expiration date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Exercise price&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Fair value on grant date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Share based expenses (1)&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;$ in thousands&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Vesting terms&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 29, 2016&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,642&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;March 1, 2026&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;28.44&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;24.12&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;May 4, 2016&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,608&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;May 4, 2026&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;34.68&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;17.40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;132&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 4, 2016&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;404&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 4, 2026&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15.36&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;20.40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;October 31, 2016&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;202&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;October 31, 2026&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;23.64&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15.84&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 27, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,964&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 27, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;27.96&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;14.40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;28&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;May 9, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,580&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;May 9, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;25.86&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;12.96&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;20&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;June 22, 2017 (4)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5,041&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;June 22, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;22.32&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;12.60&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;64&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(3&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 3, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;404&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 3, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;22.36&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;12.36&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;November 2, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;853&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;November 2, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;20.76&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;8.16&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 13, 2018&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,584&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 13, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10.44&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4.95&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;23&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;July 30, 2018 (6)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;231,819&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;July 30, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.92&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2.61&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;605&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;September 20, 2018 (4)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;37,039&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;September 20, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.92&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2.96&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;110&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;November 1, 2018&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;44,450&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;November 1, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.81&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.23&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;144&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="clear: both; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zceb4452f4e784a36b5d61103a53b56a4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Grant date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;No. of RSUs and PSUs&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Expiration date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Fair value on grant date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Share based expenses (1)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Vesting terms&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 27, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,457&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 27, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2.20&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;197&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;June 22, 2017 (7)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;17,448&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;June 22, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1.88&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;393&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 3, 2017 (8)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;24,951&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 3, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1.84&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;551&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;July 30, 2018 (6)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;79,844&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;July 30, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.24&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;251&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;September 20, 2018 (4)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15,875&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;September 20, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.65&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;58&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z0dc06f5737784fbb84bd403149b6c4b5" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;1.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Share based expenses are based on their fair value on grant date. The amount is charged to statement of operations over the vesting periods.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z36ecf2eaf7b94b148a4f20154c6a7692" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;2.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The options vest over a period of four years commencing on the date of grant, such that 25% of the options vested on the first anniversary of the date of grant and thereafter, the remaining options vest in quarterly installments.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zd35ccfce8655477ca363a19c4ffc00f9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;3.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The options vest over a period of three years commencing on the date of grant in quarterly installments.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z37f0ba092f644150bdd7e4aa4f535286" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;4.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Options or RSUs granted to certain members of the Company's Board of Directors.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zbb63abf0cf864a6a8b9a5fd98830202f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;5.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The options vest over a period of three years commencing on the date of grant, such that one third of the options vested on the first anniversary of the date of grant and thereafter, the remaining options vest in quarterly installments.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zca27909ba468453ea129ee1067ab48f6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;6.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Of the 231,819 options and 79,844 RSUs, 122,232 options and 50,796 RSUs, respectively, were issued to certain of the Company&amp;#8217;s officers. The remaining options and RSUs were issued to employees and consultants.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z41b734a7e9de40839595f01d16850e7c" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;7.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On June 22, 2017, the Company's shareholders approved the award of 11,302 and 6,146 RSUs to the Mr. Densel, who served as the Company&amp;#8217;s CEO at such time, and to certain members of the Company's Board of Directors, respectively. The terms of the RSUs awarded to the Company&amp;#8217;s former CEO provided that they shall vest over a period of four years commencing on the date of grant, such that 25% of the RSUs shall vest on the first anniversary of the date of grant and thereafter, the remaining RSUs will vest in quarterly installments.&amp;#160; The RSUs granted to certain members of the Company's Board of Directors shall vest over a period of three years commencing on the date of grant in quarterly installments. The compensation expense was based on the fair value on the grant date, and was estimated at approximately $255 and $138 for the RSUs granted to the Company&amp;#8217;s CEO and to certain members of the Company's Board of Directors, respectively. These amounts are charged to statement of operations over the vesting periods.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z9ebf1a607d9843d0af1ff825d3481cb5" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;8.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On August 3, 2017, the Company's Board of Directors approved the award of 24,951 Performance Stock Units (&amp;#8220;PSUs&amp;#8221;) to certain of the Company's employees. The PSUs shall vest based on four pre-determined milestones, of which the first milestone (15%) in 2017, the second and third milestones in 2018 (22.5% each) and the forth milestone in 2019 (40%). The compensation expense was based on the fair value on the grant date, and was estimated at approximately $551. No expenses were recorded during the years ended December 31, 2018 and 2017 as the Company did not achieve the pre-determined milestones for these years, and estimates that it will not meet the remaining pre-determined milestone for year 2019.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zecd75dd973b6429bb073f150f1dc8019" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;9.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On February 26, 2018, upon the termination of&#13;the&amp;#160;employment of Mr. Densel, the Company&amp;#8217;s former CEO, options to purchase 49,965 ordinary shares&amp;#160;and 11,302&#13;RSUs were forfeited.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zd2a45ca7eccf40819e607d8c9afd0ebe" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;C.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Options Fair Value&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The parameters which were used in applying the model are as follows:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="za8ded490179145fc9b5c2a64a8d9cca1" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Expected volatility (1)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;104%-108&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;58%-60&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;59%-60&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Risk-free rate&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2.67-3.15&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1.9%-2.2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1.2%-2.1&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Dividend yield&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;0&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;0&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;0&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Expected term (in years)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5.5-7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5.5-7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5.5-7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Share price&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.24 - $9.07&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15.96-$26.40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;26.64-$38.40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zc8c9adea4a6f4511a31ef9643bc3f42f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;(1)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options. In the years ended December 31, 2017 and 2016, due to lack of history of trading, expected volatility was calculated based on certain peer companies that the Company considered to be comparable.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&lt;font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"&gt;&lt;/font&gt;&#13;&lt;div id="DSPFPageHeader"&gt;&lt;font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"&gt;&amp;#160; &lt;/font&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"&gt;&lt;/font&gt;&#13;&lt;table id="z0db7bdd3668f4b89a117104712adcd6e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;D.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Effect of share-based compensation transactions on the Company's statements of operations&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z5f621de7f3bd4e168919291a38d60b09" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Research and development, net&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;234&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;116&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;234&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;General and administrative, net*&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(299&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;610&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;975&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Total&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(65&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;726&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,209&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; clear: both"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &amp;#160;* Amount in 2018 is negative mainly, due to the forfeiture of the former CEO unvested options and RSU.&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z65d37a8354ee4a589fdb4cc9b20514dc" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;E.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;A&amp;#160;summary&amp;#160;of the Company's option activity related to options granted to employees, service providers and directors, and related information under the 2006 Plan and the 2015 Plan is as follows:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zab44d3db65d44b3790c923e5df7928f4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Year ended December 31, 2018&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Number&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average of exercise price&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in $)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in years)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Aggregate&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;intrinsic value&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;($ in thousands)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options outstanding at beginning of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;208,222&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;46.32&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.11&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options granted&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;318,094&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4.00&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options forfeited&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(103,532&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;45.88&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options outstanding at end of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;422,784&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15.54&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;8.60&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options exercisable at end of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;101,040&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;46.18&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4.61&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="clear: both; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z963140b0d9174374baecfce0a32e68b3" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Year ended December 31, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Number&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average of exercise price&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in $)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in years)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Aggregate&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;intrinsic value&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;($ in thousands)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options outstanding at beginning of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;207,769&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;47.04&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.39&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options granted&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;9,842&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;23.88&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options forfeited&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(9,389&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;39.24&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options outstanding at end of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;208,222&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;46.32&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.11&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options exercisable at end of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;134,550&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;48.00&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5.99&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zd7cd0a24132d42c1abf493587f05074d" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td colspan="4" style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Year ended December 31, 2016 &lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Number of options&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average of exercise price&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in $)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in years)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Aggregate&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;intrinsic value&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;($ in thousands)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Outstanding at the beginning of the year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;230,958&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;48.12&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.99&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Granted&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;9,856&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;32.64&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Exercised&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Forfeited&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(33,045&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;50.52&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Outstanding at the end of the year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;207,769&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;47.04&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.39&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Exercisable at the end of the year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;106,725&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;46.80&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;6.34&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="clear: both; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zaadb93eaa67b41efa80181154b198167" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;1.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The weighted average grant date fair values of options granted during the years ended December 31, 2018, 2017 and 2016 were $2.77, $12.48 and $18.60, respectively.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z5aa341f783874710a20d96c8621a3a09" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;2.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The aforementioned options are out of the money.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z9eba5ab88305454391f2e8cf491e5d3e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;3.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;As of December&amp;#160;31, 2018, 2017, and 2016, there were $701, $346 and $766 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 Plan and the 2015 Plan, respectively. This cost is expected to be recognized over a period of up to 4 years.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt"&gt;A summary of the Company&amp;#8217;s RSUs activity is as follows:&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z6e92aa6d530a46d98b047bb36a66bfce" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Year ended December 31&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2018&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2016&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Number of RSUs&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Unvested at beginning of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;44,473&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Granted&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;95,719&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;49,856&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Vested&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(4,818&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(1,033&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Forfeited&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(25,905&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(4,350&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Unvested at end of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;109,469&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;44,473&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z9dd477a7c526425d9a1dbe4a410d7fe4" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;1.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The weighted average grant date fair values of RSUs awarded during the years ended December 31, 2018 and 2017 were $3.31 and $1.91. There were no RSU awards in the year ended December 31, 2016.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z0f52939761bd42a38beed4dbde05ee13" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;2.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;As of December&amp;#160;31, 2018 and 2017, there were $263 and $287 unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2015 Plan, respectively. This cost is expected to be recognized over a period of up to 4 years.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 11&amp;#160;&amp;#160;-&amp;#160;&amp;#160;RESEARCH AND DEVELOPMENT EXPENSES, NET&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 28.35pt"&gt;Composition:&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z6ae27eed91ff42d6a21f6d62c5619b6f" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Salaries and related expenses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,410&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,656&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,683&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Share-based compensation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;234&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;116&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;234&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Materials&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,508&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;614&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;596&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Subcontractors&amp;#160;and consultants&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;311&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;456&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;320&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Depreciation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;138&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;147&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;121&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Cost for registration of patents&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;126&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;157&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;150&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Others&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,099&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;893&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;511&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,826&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,039&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;6,615&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Less participation of the IIA and BIRD Foundation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(208&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(202&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(1,124&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Total research and development, net&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,618&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;6,837&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5,491&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <chek:GeneralAndAdministrativeExpensesTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="clear: both; line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 12&amp;#160;&amp;#160;-&amp;#160;&amp;#160;GENERAL AND ADMINISTRATIVE EXPENSES&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 28.35pt"&gt;&lt;font style="font: bold 10pt Times New Roman, Times, serif"&gt;Composition&lt;/font&gt;:&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z8190ebefffad42d68e43f3991722a7ae" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Salaries and related expenses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,839&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,395&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,411&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Share-based compensation, net&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(299&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;610&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;975&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Professional services&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;833&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;414&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;354&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Office rent and maintenance&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;163&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;161&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;144&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Depreciation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;9&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Others&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;899&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;574&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;678&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Total general and administrative&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3,445&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3,164&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3,571&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</chek:GeneralAndAdministrativeExpensesTextBlock>
    <us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="clear: both; line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 13&amp;#160; -&amp;#160;&amp;#160;FINANCE INCOME (EXPENSES), NET&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 28.35pt"&gt;&lt;font style="font: bold 10pt Times New Roman, Times, serif"&gt;Composition&lt;/font&gt;:&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z10af8702d4f1459f8c68c9780ae3b3c8" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Interest income on short-term deposits&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;243&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;66&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;139&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Bank fees and interest expenses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Changes in provision for royalties&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;255&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;82&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;56&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Exchange rate differences&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(27&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;95&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;56&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Changes in derivatives fair value&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;9&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Total financing income&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;473&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;236&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;244&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 14&amp;#160;&amp;#160;-&amp;#160;&amp;#160;LOSS PER SHARE&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt"&gt;Basic loss per share is computed based on the weighted average number of shares outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares outstanding during each year, plus the dilutive potential of the ordinary shares considered outstanding during the year, in accordance with ASC 260-10 "Earnings per share".&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt"&gt;All outstanding options and warrants have been excluded from the calculation of the diluted loss per share for each period presented, since all such securities have an anti-dilutive effect.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt"&gt;The following table sets forth the computation of the Company`s basic and diluted net loss per ordinary share:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z0ff568004a344bd6843753f1ab80e1c4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Net loss&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10,589&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;9,771&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;8,826&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Shares used in computing net loss per ordinary share, basic and diluted (in thousands)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,058&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,455&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,208&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Net loss per ordinary share, basic and diluted&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2.61&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;6.72&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.31&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt"&gt;Instruments that may potentially dilute the basic loss per share in the future, but were not included in the calculation of diluted loss per share, since their effect is anti-dilutive.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z9881dccf01df42f7be4bf01e08e6520a" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(number)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Warrants and share options&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3,457&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;914&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;849&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,515&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2,369&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2,057&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 15&amp;#160; -&amp;#160; RELATED PARTIES&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zd27f1b2e8cf94f8c8fe5df07cbc0a9ae" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;A.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif"&gt;Compensation to the non-executive directors:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z75a761be81b54da39c73600e9e13f034" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Fees, including reimbursement of expenses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;340&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;274&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;238&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Share-based compensation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;113&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;179&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;252&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;453&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;453&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;490&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z2f812836ffe643fea41001ecb1eb2712" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&lt;font style="font: bold 10pt Times New Roman, Times, serif"&gt;B&lt;/font&gt;.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Transactions with related parties:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zdb5ea891c360443a84c7faae90afb35e" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Consulting fees, including share-based compensation and reimbursement of expenses (1) (2)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;47&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;57&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;67&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Key man life insurance premium (3)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;12&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;47&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;58&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;79&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z8dff4b29f3b74368ad4fa8b57068c4f6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;1.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On July 1, 2005, the Company entered into an agreement with Hadar Kimchy according to which Hadar Kimchy provided marketing communication and graphical design services to the Company in consideration for a monthly fee of NIS 10,260 ($3). On August 1, 2014, the monthly fee was increased to NIS 13,680 ($4).&amp;#160;&amp;#160;Such services were provided to the Company by Sigalit Kimchy, who is employed by Hadar Kimchy. On April 4, 2016, the agreement was terminated.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;On April 4, 2016, the Company entered into an employment agreement with Sigalit Kimchy, according to which Ms. Kimchy serves as marcom and user interface lead, in a 60% part-time role (no less than 112 hours per month), for a monthly salary of NIS 11,200 ($3), plus up to 35 monthly overtime hours at a gross monthly rate of NIS 2,800 ($1), or an aggregate monthly salary of up to NIS 14,000 ($4).&amp;#160; Ms. Kimchy is entitled to an education fund, managers' insurance or pension fund and reimbursement of monthly travel expenses.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zefcaae50acd445feb30ede342b08c033" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;2.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;In connection with the asset transfer agreement entered into with the Predecessor Entity in May 2009, the Company assumed the former obligation of the Predecessor Entity to distribute any proceeds it collects on the $1 million key man life insurance policy with respect to Yoav Kimchy, the Company's chief technology officer and a former director, to the former holders of the Series A preferred units in an amount equal to their respective capital contributed to the Predecessor Entity, less any amounts previously distributed to them, plus any accrued and unpaid dividends due to them as of the date of distribution. On November 16, 2016, the Company cancelled the key man life insurance policy with respect to Yoav Kimchy.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;NOTE 16&amp;#160; -&amp;#160; SUBSEQUENT EVENTS&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt"&gt;On February 4, 2019, the Company consummated a registered direct offering. See Note 9.C.2.(l)&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;table id="z1b107627e34e43e781cf7cef0a3c7728" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;A.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Use of estimates in preparation of financial statements&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z051b52fa8e564bbaa7cf401067e3c8d0" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;B.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Principles of consolidation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company's consolidated financial statements include the financial statements of Check-Cap Ltd. and its wholly-owned subsidiary, Check-Cap U.S., Inc. The Company's consolidated financial statements are presented after elimination of inter-company transactions and balances.&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccounting contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z0e536f1fabd246a7bca985da6358f0ff" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;C.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Financial statements in U.S dollars&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company has not yet generated revenues and the majority of its expenses are in U.S. dollar (dollar or USD) or NIS, while none of these currencies is significantly material compared to the other.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Management judgment, in setting the dollar as the Company's functional currency, is based mainly on the following criteria: The Company's budget and other Company internal reports, including reports to the Company's Board of Directors and investors, are presented in dollars. Management uses these reports in order to make decisions for the Company. All of the Company's equity and debt financings were in dollars; and it is expected that a significant portion of the Company's future revenue will be in dollars. The financial statements are presented in dollars, which is the functional currency of the Company.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z3a263b11ad4e445da79a8bbc4290998e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;D.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Cash and cash equivalents&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Cash and cash equivalents include cash in hand, short&amp;#8211;term deposits in banks and short-term highly liquid investment with an original maturity of up to three months, with a high level of liquidity that may be easily converted to known amounts of cash, and that are exposed to insignificant risk of change in value.&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zc2ad2db3bbae457a8532f133aa57190a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;E.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Short-term bank deposit&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Short-term bank deposits are deposits with maturities of more than three months but less than one year. The short&amp;#8211;term bank deposits are presented at their cost, including accrued interest, which approximates fair value.&lt;/div&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z5cbc74d75c284622af96f671ae8330c9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;F.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Cash flow hedges&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;As a matter of policy, the Company uses derivatives for risk management purposes, and does not use derivatives for speculative purposes. From time to time, the Company may enter into foreign currency zero-cost collars contracts to&amp;#160;hedge&amp;#160;foreign currency&amp;#160;cash&amp;#160;flow&amp;#160;transactions. For&amp;#160;cash&amp;#160;flow&amp;#160;hedges, unrealized gain or loss is recorded in Other comprehensive income (loss) until hedged item affects earnings. All of the Company&amp;#8217;s hedges that are designated as hedges for accounting purposes were highly effective; therefore,&amp;#160;no&amp;#160;notable amounts of&amp;#160;hedge ineffectiveness were recorded in the Company&amp;#8217;s Consolidated Statements of Operations for either the settlement of&amp;#160;cash&amp;#160;flow&amp;#160;hedges or the outstanding hedged balance.&lt;/div&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company uses zero-cost collars to hedge against the risk of overall changes in future cash flow from payments of payroll and rent denominated in New Israeli Shekel. As of December&amp;#160;31, 2018, the Company had outstanding foreign exchange collars in the notional amount of $2.1 million. These options were set for a period of up to six months. The Company measured the fair value of the options in accordance with provisions of ASC No.&amp;#160;820 (classified as level 2 of the fair value hierarchy). During 2018, losses in the amount of $28, were reclassified when the related expenses were incurred and recognized in operating expenses. The fair value of the Company&amp;#8217;s outstanding collars at December&amp;#160;31, 2018 amounted to liability of $15 and is included in in other current liabilities on the balance sheets, with the effective portion of the change in fair value, amounted $13 classified in accumulated other comprehensive income ("AOCI").&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z43258e42ffa94d73b5a8850a4b787d41" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;G.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Property and equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z650bfb86e2314946955b5f01825ef12f" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr style="height: 14px"&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;Length of useful life&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;Depreciation rate&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;Years&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.02%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Office furniture and equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10-14&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7-10&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.02%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Laboratory equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3-7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15-33&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.02%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Computers and auxiliary equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;33&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="clear: both; line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z878f598c2be74023b24dfc57c858b10f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;H.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Impairment of long-lived assets&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company's long-lived assets are reviewed for impairment in accordance with ASC 360-10 "Accounting for the Impairment or Disposal of Long-Lived Assets" whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December&amp;#160;31, 2018, 2017 and 2016, no impairment losses were recorded.&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zcd46fa4c7ca745d097e6e140ff524d2e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;I.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Research and development costs&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Research and development costs are expensed as incurred and consist primarily of costs for personnel, subcontractors and consultants (mainly in connection with clinical trials) and materials for research and development and clinical activities. Grants received by the Company from the IIA and from Israel-United States Binational Industrial Research and Development Foundation (the "BIRD Foundation") are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from research and development expenses. Such grants are included as a deduction of research and development costs (since at the time received the Company expects to generate sales from these projects and pay the royalties resulting from such sales).&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;See Note 7B(1) below regarding the offset of grants received for participation in research and development expenses.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;table id="z39611cf098aa4a19bd6dedd02199f27b" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;J.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Contingent liabilities&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company accounts for its contingent liabilities in accordance with ASC No.&amp;#160;450, "Contingencies". A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December&amp;#160;31, 2018, and 2017, the Company is not a party to any ligation that could have a material adverse effect on the Company's business, financial position, results of operations or cash flows (see Note ).&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="za3d9811bb2e14883aa53c16b3d1df87e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;K.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Share-based compensation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company recognizes expense for its share-based compensation based on the fair value of the awards granted. The Company&amp;#8217;s share-based compensation plans provide for the award of stock options and restricted stock units. In accordance with ASC 718-10 "Compensation-Stock Compensation", the Company estimates the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's consolidated statement of operations.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company recognizes compensation expenses for the value of its awards granted based on the graded-vesting method over the requisite service period for each separately vesting portion of the award. Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) 2016-09, Compensation-Stock Compensation (Topic 718) allows companies to account for forfeitures when they occur.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its share-based awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary shares, expected share price volatility and the expected option term. In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;In the years ended December 31, 2017 and 2016, expected volatility was calculated based on certain peer companies that the Company considered to be comparable.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No.&amp;#160;110, as adequate historical experience is not available to provide a reasonable estimate.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z74156c4b60254db69667b88159791230" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;L.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Income taxes&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company accounts for income taxes in accordance with ASC 740-10 "Accounting for Income Taxes." This Statement requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;In accordance with ASC 740, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered 'more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2018, and 2017, the Company had no unrecognized income tax positions and accordingly, there is no impact on the Company's effective income tax rate associated with these items.&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z899c4d03750a4a47b4d730b3bd1a1b7f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;M.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Fair value of financial instruments&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company measures its investments in money market funds (classified as cash equivalents) and its foreign currency net purchased options at fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"&gt;&lt;font style="font-family: Times New Roman"&gt;&amp;#9679; &lt;/font&gt;Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"&gt;&lt;font style="font-family: Times New Roman"&gt;&amp;#9679; &lt;/font&gt;Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"&gt;&lt;font style="font-family: Times New Roman"&gt;&amp;#9679; &lt;/font&gt;Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z6bbb31e375064ab4bbff408ff3c970ef" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;N.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Comprehensive&lt;font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"&gt; loss&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company accounts for comprehensive income in accordance with ASC No.&amp;#160;220, &amp;#8220;Comprehensive Income&amp;#8221;. Comprehensive income generally represents all changes in shareholders&amp;#8217; equity during the period except those resulting from investments by, or distributions to, shareholders. The Company&amp;#8217;s comprehensive loss consists of net loss and unrealized gain or loss on the effective portion of cash flow hedges. These amounts are carried in accumulated other comprehensive loss on the consolidated statements of comprehensive income and are presented net of taxes.&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zfcb6b8f1f9144a3ea8800c6f9367abad" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;O.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;Restricted Cash&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company has granted a pledge in favor of Bank Leumi Le-Israel B.M in the amount of $350 to secure certain payment obligations of the Company in connection with FOREX activities. This amount was classified as restricted cash balance on December 31, 2018.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;In January 2018, the Company adopted new guidance from the Financial Accounting Standards Board or the FASB that clarified how entities should classify certain cash receipts and cash payments on the statement of cash flows. As a result, the restricted cash balance that existed in prior periods is included as a component of cash and cash equivalents and restricted cash on the statement of cash flows in the relevant periods presented. &amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; text-indent: 36pt"&gt;&#13;&lt;table id="z5d79253cdc3c4130b5e286930e5812c3" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;2 0 1 6&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom"&gt;&#13;&lt;div&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr style="height: 17px"&gt;&#13;&lt;td style="width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;Cash and Cash equivalents&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif"&gt;8,572&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;6,997&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;11,639&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;Restricted cash included current assets&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;350&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;8,922&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;6,997&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;11,639&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="clear: both; line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z6f0eab32db874209a8bdc3f763d8259d" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;P.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;New accounting pronouncements&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;ASU 2016-02, &amp;#8220;Leases (Topic 842)&amp;#8221; was issued by the FASB in February 2016. The purpose of this amendment requires the recognition of lease assets and lease liabilities by lessees for those leases previously classified as operating leases. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated results of operations, financial position or disclosures.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Accounting Standards Update (ASU) 2018-07, &amp;#8220;Compensation&amp;#8212;Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting&amp;#8221; was issued by the Financial Accounting Standards Board (FASB) in June 2018. The purpose of this amendment is to address aspects of the accounting for nonemployee share-based payment transactions. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated results of operations, financial position or disclosures.&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <chek:ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z650bfb86e2314946955b5f01825ef12f" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr style="height: 14px"&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;Length of useful life&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;Depreciation rate&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;Years&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.02%"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Office furniture and equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10-14&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7-10&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.02%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Laboratory equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3-7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15-33&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.02%; background-color: #ffffff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Computers and auxiliary equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;33&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</chek:ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock>
    <chek:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;table id="z1081dc66cfdc4f258ea43c74df680d86" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&lt;tr&gt;&lt;td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Government institutions&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;178&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;89&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Prepaid expenses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;206&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;261&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Deposits&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;34&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;55&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Other assets&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;419&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;406&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</chek:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;table id="z0032aba21dcd49e8ac554d4bd9c16663" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&lt;tr&gt;&lt;td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Cost:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Office furniture and equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;186&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;157&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Laboratory equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;644&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;626&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Computers and auxiliary equipment&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;388&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;339&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,218&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,122&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Accumulated depreciation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;766&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;619&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Property and equipment, net&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;452&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;503&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <chek:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;table id="z730365e17d284dfb9afd51bea51cc4e0" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr style="height: 18px"&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Short-term employee benefits:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Benefits for vacation and recreation pay&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;162&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;235&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Liability for payroll, bonuses and wages&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;697&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;367&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;859&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;602&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</chek:ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zdfa5e22d2d924a4ba967e406ae2ef8cd" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Carry forward tax losses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;12,525&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;13,083&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Less valuation allowance&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(12,525&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(13,083&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OtherCommitmentsTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;table id="zde63b50cc0f04aefa2b3bba6731ebd6c" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr style="height: 14px"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Royalties to an ASIC designer&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;120&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;127&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Reimbursement liability to Predecessor Entity's unit holders&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;65&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;312&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;185&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;439&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:OtherCommitmentsTableTextBlock>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;Operating lease obligations as of December 31, 2018:&amp;#160;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z8d8f5993945949f99722c7756c6f5d95" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr style="height: 15px"&gt;&#13;&lt;td style="vertical-align: bottom; width: 88%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Lease agreement for vehicles&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;22&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Lease agreement for office facilities lease&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;13&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr style="height: 19px"&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 88%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;35&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The Company&amp;#8217;s financial assets measured at fair value on a recurring basis, excluding accrued interest components, consisted of the following types of instruments as of the following dates:&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="za2d67b964ab94d169dfa6bf2084b886a" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31, 2018&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Fair value measurements using input type&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Level 1&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Level 2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Total&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Cash equivalents:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Money market funds&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,307&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,307&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Foreign currency derivative instruments&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(15&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(15&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Total financial assets (Liabilities)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,307&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(15&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,292&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <chek:ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The parameters which were used in applying the model are as follows:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="za8ded490179145fc9b5c2a64a8d9cca1" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Expected volatility (1)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;104%-108&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;58%-60&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;59%-60&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Risk-free rate&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2.67-3.15&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1.9%-2.2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1.2%-2.1&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Dividend yield&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;0&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;0&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;0&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;%&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Expected term (in years)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5.5-7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5.5-7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5.5-7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Share price&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.24 - $9.07&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15.96-$26.40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;26.64-$38.40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zc8c9adea4a6f4511a31ef9643bc3f42f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;(1)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options. In the years ended December 31, 2017 and 2016, due to lack of history of trading, expected volatility was calculated based on certain peer companies that the Company considered to be comparable.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</chek:ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Effect of share-based compensation transactions on the Company's statements of operations&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;div style="line-height: 1.25"&gt;&lt;table id="z5f621de7f3bd4e168919291a38d60b09" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Research and development, net&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;234&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;116&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;234&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;General and administrative, net*&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(299&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;610&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;975&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Total&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(65&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;726&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,209&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; clear: both"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160; &amp;#160;* Amount in 2018 is negative mainly, due to the forfeiture of the former CEO unvested options and RSU.&amp;#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2018-01-01to2018-12-31_us-gaap_RestrictedStockUnitsRSUMember">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt"&gt;A summary of the Company&amp;#8217;s RSUs activity is as follows:&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z6e92aa6d530a46d98b047bb36a66bfce" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Year ended December 31&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2018&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2016&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Number of RSUs&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Unvested at beginning of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;44,473&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Granted&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;95,719&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;49,856&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Vested&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(4,818&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(1,033&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Forfeited&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(25,905&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(4,350&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Unvested at end of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;109,469&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;44,473&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z65d37a8354ee4a589fdb4cc9b20514dc" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;A&amp;#160;summary&amp;#160;of the Company's option activity related to options granted to employees, service providers and directors, and related information under the 2006 Plan and the 2015 Plan is as follows:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zab44d3db65d44b3790c923e5df7928f4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Year ended December 31, 2018&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Number&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average of exercise price&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in $)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in years)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Aggregate&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;intrinsic value&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;($ in thousands)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options outstanding at beginning of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;208,222&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;46.32&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.11&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options granted&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;318,094&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4.00&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options forfeited&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(103,532&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;45.88&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options outstanding at end of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;422,784&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15.54&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;8.60&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options exercisable at end of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;101,040&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;46.18&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4.61&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="clear: both; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z963140b0d9174374baecfce0a32e68b3" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Year ended December 31, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Number&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average of exercise price&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in $)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in years)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Aggregate&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;intrinsic value&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;($ in thousands)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options outstanding at beginning of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;207,769&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;47.04&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.39&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options granted&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;9,842&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;23.88&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options forfeited&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(9,389&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;39.24&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options outstanding at end of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;208,222&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;46.32&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.11&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Options exercisable at end of year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;134,550&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;48.00&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5.99&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zd7cd0a24132d42c1abf493587f05074d" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td colspan="4" style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Year ended December 31, 2016 &lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Number of options&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average of exercise price&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in $)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Weighted average remaining contractual life&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(in years)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Aggregate&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;intrinsic value&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;($ in thousands)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Outstanding at the beginning of the year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;230,958&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;48.12&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.99&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Granted&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;9,856&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;32.64&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Exercised&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Forfeited&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(33,045&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;50.52&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Outstanding at the end of the year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;207,769&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;47.04&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.39&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Exercisable at the end of the year&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;106,725&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;46.80&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;6.34&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <chek:ScheduleOfResearchAndDevelopmentExpensesNet contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;table id="z6ae27eed91ff42d6a21f6d62c5619b6f" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Salaries and related expenses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,410&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,656&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,683&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Share-based compensation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;234&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;116&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;234&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Materials&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,508&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;614&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;596&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Subcontractors&amp;#160;and consultants&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;311&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;456&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;320&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Depreciation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;138&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;147&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;121&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Cost for registration of patents&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;126&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;157&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;150&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Others&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,099&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;893&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;511&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,826&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,039&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;6,615&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Less participation of the IIA and BIRD Foundation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(208&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(202&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(1,124&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Total research and development, net&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,618&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;6,837&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5,491&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</chek:ScheduleOfResearchAndDevelopmentExpensesNet>
    <chek:ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;table id="z8190ebefffad42d68e43f3991722a7ae" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Salaries and related expenses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,839&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,395&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,411&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Share-based compensation, net&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(299&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;610&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;975&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Professional services&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;833&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;414&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;354&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Office rent and maintenance&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;163&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;161&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;144&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Depreciation&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;9&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Others&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;899&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;574&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;678&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Total general and administrative&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3,445&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3,164&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3,571&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</chek:ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;table id="z10af8702d4f1459f8c68c9780ae3b3c8" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&lt;tr&gt;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Interest income on short-term deposits&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;243&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;66&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;139&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Bank fees and interest expenses&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Changes in provision for royalties&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;255&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;82&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;56&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Exchange rate differences&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(27&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;95&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;56&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Changes in derivatives fair value&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;9&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Total financing income&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;473&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;236&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;244&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt"&gt;The following table sets forth the computation of the Company`s basic and diluted net loss per ordinary share:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z0ff568004a344bd6843753f1ab80e1c4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Net loss&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10,589&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;9,771&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;8,826&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Shares used in computing net loss per ordinary share, basic and diluted (in thousands)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,058&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,455&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,208&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Net loss per ordinary share, basic and diluted&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2.61&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;6.72&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7.31&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt"&gt;Instruments that may potentially dilute the basic loss per share in the future, but were not included in the calculation of diluted loss per share, since their effect is anti-dilutive.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z9881dccf01df42f7be4bf01e08e6520a" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;For the year ended December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 6&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;(number)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Warrants and share options&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3,457&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;914&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;849&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,515&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2,369&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2,057&lt;/div&gt;&#13;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <chek:DerivativeChangeInFairValueOfOptionOutstanding contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">13000</chek:DerivativeChangeInFairValueOfOptionOutstanding>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;The following tables presents the grant dates, number of underlying shares and related exercise prices of awards granted to employees and non-employees during the years 2018, 2017 and 2016 as well as the estimated fair value of the underlying ordinary shares on the grant date:&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z88a8a70b1f2645db8ae94013b5795614" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr style="height: 34px"&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Grant date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;No. of options&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Expiration date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Exercise price&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Fair value on grant date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom"&gt;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Share based expenses (1)&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;$ in thousands&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Vesting terms&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 29, 2016&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,642&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;March 1, 2026&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;28.44&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;24.12&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;May 4, 2016&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,608&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;May 4, 2026&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;34.68&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;17.40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;132&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 4, 2016&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;404&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 4, 2026&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15.36&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;20.40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;October 31, 2016&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;202&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;October 31, 2026&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;23.64&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15.84&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 27, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,964&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 27, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;27.96&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;14.40&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;28&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;May 9, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1,580&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;May 9, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;25.86&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;12.96&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;20&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;June 22, 2017 (4)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5,041&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;June 22, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;22.32&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;12.60&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;64&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(3&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 3, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;404&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 3, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;22.36&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;12.36&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;November 2, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;853&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;November 2, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;20.76&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;8.16&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 13, 2018&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4,584&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 13, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;10.44&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;4.95&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;23&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;July 30, 2018 (6)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;231,819&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;July 30, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.92&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2.61&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;605&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;September 20, 2018 (4)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;37,039&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;September 20, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.92&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2.96&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;110&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;November 1, 2018&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;44,450&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;November 1, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.81&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.23&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;144&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zceb4452f4e784a36b5d61103a53b56a4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Grant date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;No. of RSUs and PSUs&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Expiration date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Fair value on grant date&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Share based expenses (1)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;Vesting terms&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 27, 2017&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;7,457&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;February 27, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;2.20&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;197&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(2&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;June 22, 2017 (7)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;17,448&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;June 22, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1.88&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;393&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 3, 2017 (8)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;24,951&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;August 3, 2027&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;1.84&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;551&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;July 30, 2018 (6)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;79,844&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;July 30, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.24&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;251&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;September 20, 2018 (4)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;15,875&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;September 20, 2028&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;3.65&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;$&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;58&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;(5&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;)&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z0dc06f5737784fbb84bd403149b6c4b5" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;1.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Share based expenses are based on their fair value on grant date. The amount is charged to statement of operations over the vesting periods.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z36ecf2eaf7b94b148a4f20154c6a7692" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;2.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The options vest over a period of four years commencing on the date of grant, such that 25% of the options vested on the first anniversary of the date of grant and thereafter, the remaining options vest in quarterly installments.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zd35ccfce8655477ca363a19c4ffc00f9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;3.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The options vest over a period of three years commencing on the date of grant in quarterly installments.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z37f0ba092f644150bdd7e4aa4f535286" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;4.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Options or RSUs granted to certain members of the Company's Board of Directors.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zbb63abf0cf864a6a8b9a5fd98830202f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;5.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The options vest over a period of three years commencing on the date of grant, such that one third of the options vested on the first anniversary of the date of grant and thereafter, the remaining options vest in quarterly installments.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zca27909ba468453ea129ee1067ab48f6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;6.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Of the 231,819 options and 79,844 RSUs, 122,232 options and 50,796 RSUs, respectively, were issued to certain of the Company&amp;#8217;s officers. The remaining options and RSUs were issued to employees and consultants.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z41b734a7e9de40839595f01d16850e7c" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;7.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On June 22, 2017, the Company's shareholders approved the award of 11,302 and 6,146 RSUs to the Mr. Densel, who served as the Company&amp;#8217;s CEO at such time, and to certain members of the Company's Board of Directors, respectively. The terms of the RSUs awarded to the Company&amp;#8217;s former CEO provided that they shall vest over a period of four years commencing on the date of grant, such that 25% of the RSUs shall vest on the first anniversary of the date of grant and thereafter, the remaining RSUs will vest in quarterly installments.&amp;#160; The RSUs granted to certain members of the Company's Board of Directors shall vest over a period of three years commencing on the date of grant in quarterly installments. The compensation expense was based on the fair value on the grant date, and was estimated at approximately $255 and $138 for the RSUs granted to the Company&amp;#8217;s CEO and to certain members of the Company's Board of Directors, respectively. These amounts are charged to statement of operations over the vesting periods.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z9ebf1a607d9843d0af1ff825d3481cb5" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;8.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On August 3, 2017, the Company's Board of Directors approved the award of 24,951 Performance Stock Units (&amp;#8220;PSUs&amp;#8221;) to certain of the Company's employees. The PSUs shall vest based on four pre-determined milestones, of which the first milestone (15%) in 2017, the second and third milestones in 2018 (22.5% each) and the forth milestone in 2019 (40%). The compensation expense was based on the fair value on the grant date, and was estimated at approximately $551. No expenses were recorded during the years ended December 31, 2018 and 2017 as the Company did not achieve the pre-determined milestones for these years, and estimates that it will not meet the remaining pre-determined milestone for year 2019.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zecd75dd973b6429bb073f150f1dc8019" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;9.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On February 26, 2018, upon the termination of the&amp;#160;employment of Mr. Densel, the Company&amp;#8217;s former CEO, options to purchase 93,415 ordinary shares&amp;#160;and 11,302 RSUs forfeited.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">726000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3">726000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1033</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="D2016-01-01_To_2016-12-31" unitRef="usd" decimals="-3">2201000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2017-01-01to2017-12-31" unitRef="usd" decimals="-3">-4642000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">1925000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="I2016-12-31" unitRef="usd" decimals="-3">11639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2017-12-31" unitRef="usd" decimals="-3">6997000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2015-12-31" unitRef="usd" id="Foot-06-0" decimals="-3">9438000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">8922000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;As a result, the restricted cash balance that existed in prior periods is included as a component of cash and cash equivalents and restricted cash on the statement of cash flows in the relevant periods presented. &amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; text-indent: 36pt"&gt;&#13;&lt;table id="z5d79253cdc3c4130b5e286930e5812c3" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; text-align: center; vertical-align: bottom"&gt;2 0 1 6&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom"&gt;&#13;&lt;div&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr style="height: 17px"&gt;&#13;&lt;td style="width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;Cash and Cash equivalents&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif"&gt;8,572&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;6,997&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;11,639&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="width: 64%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;Restricted cash included current assets&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;350&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div&gt;-&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="width: 64%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div&gt;8,922&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;6,997&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;11,639&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-3">4307000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" unitRef="usd" xsi:nil="true" />
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">4307000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel1Member" unitRef="usd" xsi:nil="true" />
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-3">15000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2018-12-31_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3">15000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments contextRef="From2018-01-01to2018-12-31" unitRef="usd" decimals="-3">-28000</us-gaap:UnrealizedGainLossOnCashFlowHedgingInstruments>
    <us-gaap:ShortTermInvestments contextRef="AsOf2017-12-31" unitRef="usd" xsi:nil="true" />
    <us-gaap:ShortTermInvestments contextRef="AsOf2018-12-31" unitRef="usd" decimals="-3">5643000</us-gaap:ShortTermInvestments>
    <chek:EmployeeRelatedLiabilitiesTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&lt;div style="text-align: left"&gt;&lt;div&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 5&amp;#160;&amp;#160; -&amp;#160;&amp;#160; EMPLOYEE BENEFITS AND PAYROLL ACCRUALS&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z3a8f70e7d63340688636546a2d8b7b02" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;A.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif"&gt;Composition:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="zff8d3f796c354ec58fcdb1ce0f105b71" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr style="height: 18px"&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Short-term employee benefits:&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Benefits for vacation and recreation pay&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;162&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;235&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Liability for payroll, bonuses and wages&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;697&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;367&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;859&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;602&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z2a18aa2f7f00414c802a5f04d073c942" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt"&gt;B.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Post-employment benefits&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt"&gt;Pursuant to Israel's Severance Pay Law, 1963, Israeli employees are entitled to severance pay equal to one month's salary for each year of employment, or a portion thereof. All of the Company's employees elected to be included under Section 14 of the Severance Pay Law, 1963 ("Section 14"). According to Section 14, employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z9e683e75f6a74bebad5d5d6e3b167b31" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;C.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Short-term employee benefits&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z3ab7046bf1444da89dae809c5514685b" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;(1)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Paid vacation days&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;In accordance with the Yearly Vacation Law-1951 (the "Vacation Law"), the&amp;#160;Company's employees are entitled to a certain number of paid vacation days for each year of employment. In accordance with the Vacation Law and its appendix, and as determined in the agreement between the Company and the employees, the number of vacation days per year to which each employee is entitled is based on the seniority of the employee.&lt;/div&gt;&#13;&#13;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;The employee may use vacation days based on his or her needs and with the Company's consent, and to accrue the remainder of unused vacation days, subject to the provision of the Vacation Law. The vacation days utilized first are those credited for the current year and subsequently from any balance transferred from the prior year (on a "LIFO" basis). An employee who ceased working before utilizing the balance of vacation days accrued is entitled to payment for the balance of unutilized vacation days.&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z43e9eb2751604aa5897e25286b9174e1" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;(2)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Related parties&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;For information regarding short-term employee liabilities given to related parties, see Note 15.&lt;/div&gt;&#13;&#13;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</chek:EmployeeRelatedLiabilitiesTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&lt;div style="text-align: left"&gt;&lt;div&gt;&lt;div style="line-height: 1.25"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;NOTE 7&amp;#160;&amp;#160; -&amp;#160;&amp;#160; COMMITMENTS AND CONTINGENT LIABILITIES&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z6e1a4adcf1e04bc98b4c193edf1b546f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;A.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Royalties provision&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zea763a1fe1a2458ba235d0540986ed1d" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;1.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Royalties to an ASIC designer&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;The Company has a liability to pay royalties for the development of an ASIC component which is used as an amplifier for the capture of signals at low frequencies from X-ray detectors contained in the capsule. The institution that developed the ASIC is entitled to receive royalties from the Company in the amount of &amp;#8364; 0.5 ($0.57) for every ASIC component that the Company will sell, capped at &amp;#8364; 200,000 (approximately $229). This royalty is considered as a liability.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;The royalties' liability is calculated based on estimated future sales generated by products which include the ASIC component. As of December 31, 2018, the Company believes that it will be required to pay the above mentioned royalties, and accordingly, recorded, as of December&amp;#160;31, 2018, a provision in a total amount of $120.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zaf9aeede27744e1b9d4518173e213714" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;2.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Reimbursement liability to Predecessor Entity's unit holders&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;On May 31, 2009, the Company entered into an asset transfer agreement with Check Cap LLC (the "Predecessor Entity"), a company with the same shareholders as the Company at the time of transfer. According to the agreement, the Predecessor Entity transferred all of its business operations and substantially all of its assets to the Company, including development and consulting agreements, cash, property and equipment and intangible ownership rights, free of any debt.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;&#13;&lt;div id="DSPFPageHeader"&gt;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;As part of the reorganization, the Company committed to reimburse the unit holders of the Predecessor Entity for any tax burdens that may be imposed on them due to the reorganization. The reimbursement liability is calculated assuming deemed royalties are paid to the U.S. unitholders of Check-Cap LLC under Section 367(d) of the Code, and is based in part on the Company&amp;#8217;s forecasted sales with a cap calculated as the fair value of the share as determined at the date of the financial statements. The reimbursement liability is calculated by multiplying the estimated tax rate by the lowest of: (1) expected cash outflows discounted using a discount factor commensurate with the risk of the Company, and (2) value of the shares held by U.S. unit holders of the Predecessor Entity as of December 31, 2018 multiplied by $2.1, &lt;font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"&gt;the last reported sale price per share of the Company&amp;#8217;s ordinary shares on the Nasdaq Capital Market on December 31, 2018&lt;/font&gt;. Any updates in the contingent liability will be charged to earnings. As of December 31, 2018, the balance of the reimbursement liability totaled $65.&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z8128ce3a34ac44828bef74af40479fa4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;December 31,&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 8&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center"&gt;2 0 1 7&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td colspan="2" style="vertical-align: bottom; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr style="height: 14px"&gt;&#13;&lt;td style="vertical-align: bottom; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Royalties to an ASIC designer&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;120&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;127&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Reimbursement liability to Predecessor Entity's unit holders&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;65&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;312&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;185&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;439&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zba8305edc70c4f0fb3a7a76055ccc60b" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;B.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Commitments&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="ze036a6d6515b479693b809726a78f39f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;(1)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Royalties&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;The Company's research and development efforts are financed, in part, through funding from the IIA (formerly the OCS) and the BIRD Foundation. Since the Company's inception through December&amp;#160;31, 2018, the Company received funding from the IIA and the BIRD Foundation in the total amount of $5.3 million and $115, net, respectively.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;According to the terms of applicable law as currently in effect and the grants, the IIA is entitled to royalties equal to 3-5% (or at an increased rate under certain circumstances) of the revenues from sales of products and services based on technology developed using IIA grants, up to the full principal amount (which may be increased under certain circumstances) of the U.S. Dollar-linked value of the grants, plus interest at the rate of 12-month LIBOR. The obligation to pay these royalties is contingent on actual sales of the applicable products and services and in the absence of such sales, no payment is required. As of December 31, 2018, the Company had not paid any royalties to the IIA and had a contingent obligation to the IIA in the amount of $5.6 million.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;On July 13, 2014, the Company entered into a Cooperation and Project Funding Agreement with the BIRD Foundation and Synergy, pursuant to which the BIRD Foundation agreed to award a grant to Synergy and the Company in the maximum amount of the lesser of (i) $900; and (ii) 50% of the actual expenditures for the funding of a project entitled "Collection &amp;#38; Analysis of Gastrointestinal Images for Diagnostic Adenomatic Polyps and Colorectal Cancer." The development work was to be performed over a 24-month period by Synergy (or a subcontractor on its behalf) and the Company.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;According to the terms of the grant, the BIRD Foundation is entitled to royalties equal to 5% of the gross revenues derived from the product funded by the project, up to 100%, 113%, 125%, 138% and 150% of the U.S. Consumer Price Index linked sum granted by the BIRD Foundation if repaid within one year, two years, three years, four years and five or more years, respectively. Under the terms of the agreement, if any portion of the product funded by the project is sold outright to a third party prior to full repayment of the grant to the BIRD Foundation, one-half of the sale proceeds will be applied to the repayment of the grant. If the funded product is licensed to a third party, 30% of all payments received under the respective license agreement must be paid to the BIRD Foundation in repayment of the grant.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;As of December 31, 2018, the Company, together with Synergy, had received funding from the BIRD Foundation in the aggregate amount of approximately $127. Based on the aggregate expenses that the Company incurred for such project, it refunded to the BIRD Foundation an amount of approximately $13. The Company shall not be receiving additional funding from the BIRD Foundation for the project, which is no longer active. As of December 31, 2018, we had not paid any royalties to the BIRD Foundation and had a contingent obligation to the BIRD foundation in the amount of $180.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z5afd5e006aff4a239279d10236f709c2" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;(2)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Rental agreement&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;The Company leases approximately 900 square meters at a facility located in Isfiya, Israel under a lease agreement expiring on May 31, 2022. The Company has the right to terminate the agreement at any time, with 60 days prior written notice. The rental expenses recorded by the Company for the years ended December 31, 2018, 2017 and 2016 were $84, $83 and $78, respectively.&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z44c34e2c4d1e41c585ccb17e4f32b2e9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;(3)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Vehicle lease and maintenance agreements&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt"&gt;The Company entered into several 32-36 months lease and maintenance agreements for vehicles, which are regularly amended as new vehicles are leased. The current monthly lease fees is approximately $14. The expected lease payments for the years ending December 31, 2019, 2020 and 2021 are approximately $100, $63 and $10, respectively.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Operating lease obligations as of December 31, 2018:&amp;#160;&lt;/div&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&#13;&lt;table id="z16b61586b1d74d23a7632da0884c427e" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"&gt;&#13;&lt;tr style="height: 15px"&gt;&#13;&lt;td style="vertical-align: bottom; width: 88%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Lease agreement for vehicles&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;22&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;Lease agreement for office facilities lease&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;13&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&#13;&lt;tr style="height: 19px"&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 88%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif"&gt;35&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap"&gt;&amp;#160;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <dei:EntityExTransitionPeriod contextRef="From2018-01-01to2018-12-31">false</dei:EntityExTransitionPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;div&gt;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&lt;div style="text-align: left"&gt;&lt;div&gt;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;NOTE 9&amp;#160;&amp;#160; -&amp;#160;&amp;#160; SHAREHOLDERS' EQUITY&lt;/div&gt;&#13;&#13;&lt;div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z18e2fcd4b9124f08b3ab78199025e2c4" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;A.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;All share and per share amounts in the financial statements have been adjusted to reflect the Reverse Share Split.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&lt;br style="line-height: 1.25" /&gt;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z1cdceb6f9ca845978d493ee9b4de82f8" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 28.35pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;B.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify"&gt;Ordinary shares&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zffd75b24281e4d02a6a32a031412a66a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;1.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;The ordinary shares provide their owners with rights to receive dividends in cash and shares, and rights to participate at the time of distributing liquidation dividends. Additionally, the ordinary shareholders have the right to vote at shareholder meetings in a manner that each share provides one voting right to its holder.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z02e9edf268ab4c75902ade0c22fdb17c" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr style="height: 12px"&gt;&#13;&lt;td style="width: 56.7pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: normal 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"&gt;2.&lt;/td&gt;&#13;&lt;td style="vertical-align: top; font-weight: bold; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Changes in ordinary share capital&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z9be7f2abf21845838421f163fe6c35a6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;a)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On May 11, 2010, the Company issued, free of charge, to all of its shareholders (except for certain ordinary shareholders), warrants to purchase an aggregate of 32,174 ordinary shares (hereafter- "Anti-dilution Warrants"). The Anti-dilution Warrants were issued in order to prevent the dilution of the holdings of such Company shareholders due to certain options granted to the Company's CEO (hereafter- "CEO options"). The Anti-dilution Warrants were subject to automatic exercise, without consideration (unless the holder thereof objected to such exercise), upon the exercise by the Company's CEO of the CEO Options. The fair value of the Anti-dilution Warrants on the grant date was immaterial. Anti-dilution warrants to purchase&amp;#160;7,724 and 56 ordinary shares were exercised during the years ended December 31, 2018 and 2016, respectively. No such warrants were exercised during the year ended December 31, 2017. As of December 31, 2018, 7,246 Anti-dilution Warrants were outstanding.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z03610b82d7ba44919370ffcc2a7f4224" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;b)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On February 24, 2015, the Company consummated an IPO in the U.S. of 166,667 units at a public offering price of $72 per unit, before underwriting discounts and offering expenses. Each unit consisted of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share. Each unit was issued with one and one-half non-transferrable Long Term Incentive Warrants. Each whole Series A Warrant entitles the holder to purchase one ordinary share at an exercise price of $90. Upon vesting, each Long Term Incentive Warrant entitles the holder to purchase one ordinary share at an exercise price of $82.80.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;The Company granted the underwriters a 45-day over-allotment option to purchase up to 25,000 additional units (together with an accompanying 37,500 Long Term Incentive Warrants). The option to purchase additional 8,334 units was partially exercised on March 6, 2015. The units were separated into one ordinary share and one-half of a Series A Warrant to purchase one ordinary share on March 18, 2015, and the units ceased to exist as of such date. On April 6, 2015, the option to purchase additional 12,500 ordinary shares and 6,250 Series A Warrants was partially exercised. The Company received net proceeds from the IPO and partial exercise of the over-allotment option of approximately $10.8 million (net of issuance cost of approximately $2.9 million, including certain warrants with a value of $196 issued in connection with the IPO).&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zb2f2f46800c9483cbf6ce93df36f5f53" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;c)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Immediately prior to the consummation of the IPO, certain members of the Company's management exercised options to purchase 25,624 ordinary shares granted to them under the 2006 Unit Option Plan.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z7eb77cf2c95848f5bcb0d3f2e3fcb5b6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;d)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On August 20, 2014, the Company entered into a certain credit line agreement, pursuant to which it obtained a credit line in an aggregate principal amount of $12 million from certain lenders and existing shareholders (the "Lenders").&amp;#160;&amp;#160;The credit line amount was deposited in an escrow account at the closing, which was consummated on October 14, 2014. The Company issued to each Lender at closing a warrant (collectively, the "Credit Line Warrants"), to purchase a number of the Company's ordinary shares constituting 2% of its share capital on a fully diluted basis (assuming conversion of all of the Company's convertible securities into ordinary shares at a 1:1 conversion rate) as of the closing for each $1 million (or portion thereof) extended by such Lender.&amp;#160;&amp;#160;The Company issued Credit Line Warrants ("CLA Warrants") to purchase in the aggregate 221,556 of its ordinary shares.&amp;#160;&amp;#160;The CLA Warrants are exercisable for a period of ten years at an exercise price of NIS 2.40 per share, and may be exercised on a net issuance basis.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;Under the terms of the credit line agreement, the Company directed that the entire credit line amount (that was in escrow) be invested in the Private Placement, consummated simultaneously with the consummation of the IPO on February 24, 2015. The Company issued to the Lenders 166,667 units at a price of $72 per unit, before issuance cost. Each unit consisted of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share. Each unit was issued with one and one-half non-transferrable Long Term Incentive Warrants. Each whole Series A Warrant entitles the holder to purchase one ordinary share at an exercise price of $90. Upon vesting, each Long Term Incentive Warrant entitles the holder to purchase one ordinary share at an exercise price of $82.80. The Company received net proceeds from the Private Placement of approximately $10.9 million (net of issuance cost of approximately $1.2 million, including certain warrants with a value of $125 issued in connection with the Private Placement).&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z0b29997d98ad46dd91c861ccb10defa9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;e)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;During the years ended December 31, 2018, 2017 and 2016, certain Private Placement investors exercised CLA Warrants to purchase an aggregate 22,501, 9,912 and 34,508 ordinary shares, respectively, on a cashless basis, which resulted in the expiration of 5,192, 243, and 761 CLA Warrants, respectively. As of December 31, 2018 and 2017, 7,389 and 35,082 CLA Warrants were outstanding, respectively.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z51ee299749d947c5b8c92622f2b57f37" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;f)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;Upon the closing of the IPO, the Company issued warrants to purchase 8,334 ordinary shares at an exercise price of $90 to the IPO lead underwriter and warrants to purchase 1,250 ordinary shares at an exercise price of $60.72 to the Company's U.S. legal counsel.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="z2371cf9f7c0b418ebd5a7096f816a84a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;g)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On June 24, 2015, the Company entered into Amendment No. 1 to the Warrant Agreement, dated June 24, 2015, between the Company and American Stock Transfer &amp;#38; Trust Company LLC, as Warrant Agent, to extend the Registration Due Date to the date which is 180 days following the date of closing of the Company's initial public offering (i.e., August 23, 2015) in order to allow the shareholders who were the original purchasers of IPO Units additional time to become the direct registered owners of the ordinary shares underlying the IPO Units. As of December 31, 2018, and December 31, 2017, 378,047 Long Term Incentive Warrants were outstanding.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="ze3ede3e3f3154e6a903ea00c105c818c" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;h)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On August 11, 2016, the Company consummated a registered direct offering of 53,635 ordinary shares at a price of $22.80 per share and pre-funded warrants to purchase 209,524 ordinary shares at a purchase price of $22.20 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.60 per share, subject to certain adjustments and will expire on August 11, 2023, unless otherwise extended in accordance with the terms of the pre-funded warrants.&amp;#160; The Company received gross proceeds from the August registered direct offering of approximately $5.9 million (including proceeds from the exercise of 47,917 pre-funded warrants at the closing of the offering).&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;On January 23, 2017, the remaining pre-funded warrants to purchase 24,167 ordinary shares were exercised, for additional proceeds of $14.5.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;As of December 31, 2018, and December 31, 2017, there were no outstanding pre-funded warrants.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zef7dbf0f65d04d5fbe085271694bd2c4" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;i)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On June 2, 2017, the Company consummated a registered direct offering of 112,460 ordinary shares at a price of $24.00 per share and a simultaneous private placement of one-year warrants to purchase 112,460 ordinary shares at an exercise price of $25.50 per share immediately exercisable. The Company received gross proceeds from the June registered direct offering of approximately $2.69 million. As of December 31, 2017, all the warrants issued in this offering were outstanding.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 99.25pt"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;On June 2, 2018, all of the warrants issued in this offering expired.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zfa85f6113bde45c09cc925cf132f33c1" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;j)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt Times New Roman, Times, serif; text-align: justify"&gt;On November 22, 2017, the Company consummated a registered direct offering of 189,387 ordinary shares at a price of $13.20 per share and a simultaneous private placement of five-year warrants to purchase 142,042 ordinary shares at an exercise price of $15 per share immediately exercisable. The Company received gross proceeds from the November registered direct offering of approximately $2.5 million.&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;On April 25, 2018, 56,812 of these warrants were cashless exercised into 13,574 ordinary shares.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;As of December 31, 2017, all the warrants issued in this offering were outstanding.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;As of December 31, 2018, 85,228 of these warrants were outstanding.&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&lt;br style="line-height: 1.25" /&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="text-align: left; line-height: 1.25"&gt;&#13;&lt;table id="zb291166e27f448a8880a8d7d891df9cd" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%"&gt;&#13;&lt;tr&gt;&#13;&lt;td style="width: 85.05pt"&gt;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt"&gt;k)&lt;/td&gt;&#13;&lt;td style="vertical-align: top; text-align: left; width: auto"&gt;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, serif"&gt;On May 8, 2018, the Company consummated an underwritten public offering (the &amp;#8220;2018 Public Offering&amp;#8221;) of 2,738,472 units (the &amp;#8220;Units&amp;#8221;), at a public offering price of $5.5&amp;#160;per unit, and 450,909 pre-funded units (the &amp;#8220;Pre-funded Units&amp;#8221;), at a public offering price of $5.49&amp;#160;per Pre-funded Unit. Each Unit consisted of one ordinary share of the Company and one Series C warrant to purchase one ordinary share of the Company. Each Pre-funded Unit consisted of one pre-funded warrant to&amp;#160;purchase one ordinary share and one Series C Warrant to purchase one ordinary share. The exercise price of each pre-funded warrant included in the pre-funded unit was $0.01 per share. The Series C warrants have an exercise price of $&lt;/font&gt;5.50 per share, are exercisable immediately and will expire five years from the date of issuance&lt;font style="font: 10pt Times New Roman, Times, serif"&gt;.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;/div&gt;&#13;&#13;&lt;div style="line-height: 1.25"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt"&gt;The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional&amp;#160;478,407 ordinary shares and/or Series C Warrants to purchase up to an additional&amp;#160;478,407&amp;#160;ordinary shares at the public offering price. The underwriters&amp;#8217; option was exercised in full on May 8, 2018. &#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;The Company received gross proceeds from the 2018 Public Offering and exercise in full of the over-allotment option of approximately $20.2 million (before deducting underwriting discounts and commissions and other offering fees and expenses). During May 2018, the 450,909 pre-funded units were exercised in full in consideration of additional gross proceeds of $4.5.&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;&amp;#160;&lt;/div&gt;&#13;&#13;&lt;div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify"&gt;&lt;font style="font: 10pt Times New Roman, Times, serif"&gt;On February 6, 2019, the Company issued 1,881,500 units, at a purchase price of $2.58 per unit, and 1,024,876 pre-funded units, at a purchase price of $2.57 per pre-funded unit, in a registered direct offering. Each unit consisted of one ordinary share of the Company and one Series D Warrant to purchase 0.5 ordinary share of the Company. Each pre-funded unit consisted of one pre-funded warrant to purchase one ordinary share and one Series D Warrant to purchase 0.5 ordinary share. The exercise price of each pre-funded warrant included in the pre-funded unit was $0.01 per share. The Series D Warrants have an exercise price of $2.58 per ordinary share and are immediately exercisable &lt;/font&gt;and will expire on the fifth anniversary of the original issuance date.&lt;font style="font: 10pt Times New Roman, Times, serif"&gt; The Company received gross proceeds from the February 2019 registered direct offering of approximately $7.5 million (including proceeds from the exercise of 1,024,876 pre-funded warrants), or $6.6 million, net of issuance expenses in the amount of $927.&lt;/font&gt;&lt;/div&gt;&#13;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="#Foot-00-0" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-1" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-2" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-3" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-4" xlink:label="Foot-00_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-00-5" xlink:label="Foot-00_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-00_loc" xlink:to="Footnote-06" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-0" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-1" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-2" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-3" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-4" xlink:label="Foot-01_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-01-5" xlink:label="Foot-01_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-01_loc" xlink:to="Footnote-02" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-0" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-1" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-2" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-3" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-4" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-5" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-6" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-7" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-8" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-9" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-10" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-11" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-12" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-13" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-14" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-15" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-16" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-17" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-18" xlink:label="Foot-02_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-02-19" xlink:label="Foot-02_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-02_loc" xlink:to="Footnote-03" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-0" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-1" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-2" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-3" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-4" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-5" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-6" xlink:label="Foot-03_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-03-7" xlink:label="Foot-03_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-03_loc" xlink:to="Footnote-07" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-04-0" xlink:label="Foot-04_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-04_loc" xlink:to="Footnote-04" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-0" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-1" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-2" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-3" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-4" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-5" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-6" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-7" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-8" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-9" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-10" xlink:label="Foot-05_loc" />
      <link:loc xlink:type="locator" xlink:href="#Foot-05-11" xlink:label="Foot-05_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-05_loc" xlink:to="Footnote-05" order="1" />
      <link:loc xlink:type="locator" xlink:href="#Foot-06-0" xlink:label="Foot-06_loc" />
      <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Foot-06_loc" xlink:to="Footnote-01" order="1" />
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Reclassified</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-02" xml:lang="en-US">In the years ended December 31, 2017 and 2016, expected volatility was calculated based upon certain peer companies that the Company considered to be comparable. In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-03" xml:lang="en-US">All shares amounts have been retroactively adjusted to reflect a 1-for-12 share reverse split, see Note 1C.</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-04" xml:lang="en-US">Includes pre-funded warrants to purchase 209,524 ordinary shares at a purchase price of $22.20 per pre-funded warrant, issued in connection with the registered direct offering. See Note 9C(2)(h).</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-05" xml:lang="en-US">Issuance expenses include certain warrants with a value of $49,229 and $58,298 issued in connection with the June 2017 and November 2017 registered direct offerings, respectively. See Note 9C(2)(j).</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-06" xml:lang="en-US">Includes pre-funded warrants to purchase 450,909 ordinary shares at a purchase price of $5.49 per pre-funded warrant, issued in connection with the registered direct offering. See Note 9C(2)(k).</link:footnote>
      <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-07" xml:lang="en-US">Represents warrants issued to placement agent as part of issuance expenses</link:footnote>
    </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>chek-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CHEK 1218 20F.xfr; Date: 2019%2D03%2D26T22:03:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kw5w7xRiXgOn8uGbnRcSaqP6bP9xZ91yelBsmB0HQla3yEpnuxvdijymCtmIR0M -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:chek="http://check-cap.com/20181231" elementFormDefault="qualified" targetNamespace="http://check-cap.com/20181231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://check-cap.com/role/chek-dei" id="chek-dei">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/check-cbs" id="check-cbs">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-csoo" id="chek-csoo">
	  <link:definition>00000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-equity" id="chek-equity">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-equityp" id="chek-equityp">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-csocf" id="chek-csocf">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-info" id="chek-info">
	  <link:definition>00000007 - Disclosure - GENERAL INFORMATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-sigp" id="chek-sigp">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-peaoca" id="chek-peaoca">
	  <link:definition>00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-ppe" id="chek-ppe">
	  <link:definition>00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-stloan" id="chek-stloan">
	  <link:definition>00000011 - Disclosure - SHORT TERM LOANS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-ebapa" id="chek-ebapa">
	  <link:definition>00000012 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-itax" id="chek-itax">
	  <link:definition>00000013 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-cacl" id="chek-cacl">
	  <link:definition>00000014 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-fvm" id="chek-fvm">
	  <link:definition>00000015 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-sed" id="chek-sed">
	  <link:definition>00000016 - Disclosure - SHAREHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-sbp" id="chek-sbp">
	  <link:definition>00000017 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-raden" id="chek-raden">
	  <link:definition>00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-gaae" id="chek-gaae">
	  <link:definition>00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-fien" id="chek-fien">
	  <link:definition>00000020 - Disclosure - FINANCE INCOME (EXPENSES), NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-eps" id="chek-eps">
	  <link:definition>00000021 - Disclosure - LOSS PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-relp" id="chek-relp">
	  <link:definition>00000022 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000023 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-sigpp" id="chek-sigpp">
	  <link:definition>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-sigpt" id="chek-sigpt">
	  <link:definition>00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-peaocat" id="chek-peaocat">
	  <link:definition>00000026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-ppet" id="chek-ppet">
	  <link:definition>00000027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-ebapat" id="chek-ebapat">
	  <link:definition>00000028 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-itaxt" id="chek-itaxt">
	  <link:definition>00000029 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-caclt" id="chek-caclt">
	  <link:definition>00000030 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-fvmt" id="chek-fvmt">
	  <link:definition>00000031 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-sedt" id="chek-sedt">
	  <link:definition>00000032 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIENCY) (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-sbpt" id="chek-sbpt">
	  <link:definition>00000033 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-radent" id="chek-radent">
	  <link:definition>00000034 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-gaaet" id="chek-gaaet">
	  <link:definition>00000035 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-fient" id="chek-fient">
	  <link:definition>00000036 - Disclosure - FINANCE INCOME (EXPENSES), NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-epst" id="chek-epst">
	  <link:definition>00000037 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-relpt" id="chek-relpt">
	  <link:definition>00000038 - Disclosure - RELATED PARTIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-infod" id="chek-infod">
	  <link:definition>00000039 - Disclosure - GENERAL INFORMATION (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" id="SummaryOfSignificantAccountingPoliciesNarrativeDetails">
	  <link:definition>00000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-sosapd" id="chek-sosapd">
	  <link:definition>00000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" id="SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails">
	  <link:definition>00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Cash, Cash Equivalents and Restricted Cash) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-peaocad" id="chek-peaocad">
	  <link:definition>00000043 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-pped" id="chek-pped">
	  <link:definition>00000044 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-ebapad" id="chek-ebapad">
	  <link:definition>00000045 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-itaxd" id="chek-itaxd">
	  <link:definition>00000046 - Disclosure - INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-cacld" id="chek-cacld">
	  <link:definition>00000047 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails" id="FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails">
	  <link:definition>00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Schedule of Market observable data of similar instruments) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/ShareholdersEquityOrdinarySharesDetails" id="ShareholdersEquityOrdinarySharesDetails">
	  <link:definition>00000049 - Disclosure - SHAREHOLDERS' EQUITY (Ordinary Shares) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/Share-basedCompensationAwardsDetails" id="Share-basedCompensationAwardsDetails">
	  <link:definition>00000050 - Disclosure - SHARE-BASED COMPENSATION (Awards) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/Share-basedCompensationDetailsOfShare-basedGrantsDetails" id="Share-basedCompensationDetailsOfShare-basedGrantsDetails">
	  <link:definition>00000051 - Disclosure - SHARE-BASED COMPENSATION (Details of share-based grants) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails" id="Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails">
	  <link:definition>00000052 - Disclosure - SHARE-BASED COMPENSATION (Schedule of Parameters Used in Valuing Fair Value of Options) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-sbpced" id="chek-sbpced">
	  <link:definition>00000053 - Disclosure - SHARE-BASED COMPENSATION (Compensation Expense) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-sbpoad" id="chek-sbpoad">
	  <link:definition>00000054 - Disclosure - SHARE-BASED COMPENSATION (Option Activity) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-radend" id="chek-radend">
	  <link:definition>00000055 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-gaaed" id="chek-gaaed">
	  <link:definition>00000056 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-fiend" id="chek-fiend">
	  <link:definition>00000057 - Disclosure - FINANCE INCOME (EXPENSES), NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/LossPerShareScheduleOfLossPerShareDetails" id="LossPerShareScheduleOfLossPerShareDetails">
	  <link:definition>00000058 - Disclosure - LOSS PER SHARE (Schedule of Loss Per Share) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails" id="LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails">
	  <link:definition>00000059 - Disclosure - LOSS PER SHARE (Schedule of Anti-Dilutive Securities) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://check-cap.com/role/chek-relptrpd" id="chek-relptrpd">
	  <link:definition>00000060 - Disclosure - RELATED PARTIES (Transactions with Related Parties) (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="chek-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="chek-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="chek-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="chek-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
    <element id="chek_UnitsPurchased" name="UnitsPurchased" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_PricePerUnit" name="PricePerUnit" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="chek_WarrantsIssuedNumber" name="WarrantsIssuedNumber" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_RoyaltiesProvision" name="RoyaltiesProvision" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" name="StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" name="StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_OperatingLeaseRentExpenseMonthly" name="OperatingLeaseRentExpenseMonthly" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_MaximumRoyaltyObligation" name="MaximumRoyaltyObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_RoyaltiesPayablePercentageOfProductSales" name="RoyaltiesPayablePercentageOfProductSales" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="chek_RefundExpenses" name="RefundExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_RoyaltiesPayablePerUnitSold" name="RoyaltiesPayablePerUnitSold" nillable="true" xbrli:periodType="instant" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ProceedsFromIssuanceResisteredDirectOffering" name="ProceedsFromIssuanceResisteredDirectOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_WarrantsCashlessExercise" name="WarrantsCashlessExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GovernmentInstitutionalAssetsCurrent" name="GovernmentInstitutionalAssetsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SubcontractorsAndConsultantFees" name="SubcontractorsAndConsultantFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ResearchAndDevelopmentExpenseGross" name="ResearchAndDevelopmentExpenseGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_RoyaltyIncomeExpenseNonoperating" name="RoyaltyIncomeExpenseNonoperating" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ReductionInIncomeTaxRate" name="ReductionInIncomeTaxRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="chek_MonthlyRetainer" name="MonthlyRetainer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_KeyManInsurancePolicy" name="KeyManInsurancePolicy" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_MonthlySalary" name="MonthlySalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrossOvertimeMonthlyRate" name="GrossOvertimeMonthlyRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_MaximumAggregateMonthlySalary" name="MaximumAggregateMonthlySalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ClassOfWarrantOrRightExpiration" name="ClassOfWarrantOrRightExpiration" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_WarrantsExercisedCashlessBasis" name="WarrantsExercisedCashlessBasis" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_NumberOfSharesRestrictedStockVested" name="NumberOfSharesRestrictedStockVested" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering" name="StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1" name="StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" name="StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2" name="StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" name="StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantedRevenue" name="GrantedRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_DerivativeFairValueOfOptionOutstanding" name="DerivativeFairValueOfOptionOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GeneralAndAdministrativeExpensesTextBlock" name="GeneralAndAdministrativeExpensesTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" name="ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock" name="ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ScheduleOfResearchAndDevelopmentExpensesNet" name="ScheduleOfResearchAndDevelopmentExpensesNet" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock" name="ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="chek_DerivativeChangeInFairValueOfOptionOutstanding" name="DerivativeChangeInFairValueOfOptionOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_EmployeeRelatedLiabilitiesTextBlock" name="EmployeeRelatedLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="chek_PreferredSharesConversionMember" name="PreferredSharesConversionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_PreferredShareWarrantsConversionMember" name="PreferredShareWarrantsConversionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_NonExecutiveDirectorsMember" name="NonExecutiveDirectorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ConsultingFeesMember" name="ConsultingFeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_KeyManLifeInsurancePremiumMember" name="KeyManLifeInsurancePremiumMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FeesAndReimbursementMember" name="FeesAndReimbursementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ShareBasedCompensationMember" name="ShareBasedCompensationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_PontifaxFundsMember" name="PontifaxFundsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesAWarrantsMember" name="SeriesAWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_LongTermIncentiveWarrantsMember" name="LongTermIncentiveWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_DocorInternationalBVMember" name="DocorInternationalBVMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_EscoVenturesPteLtdMember" name="EscoVenturesPteLtdMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_CreditLineAgreementWarrantsMember" name="CreditLineAgreementWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_CounterpointVenturesFundTwoMember" name="CounterpointVenturesFundTwoMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_NonExecutiveDirectorsCompensationMember" name="NonExecutiveDirectorsCompensationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_WarrantAndShareOptionsMember" name="WarrantAndShareOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_PreferredSharesMember" name="PreferredSharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_BankLeumiCreditFacilityMember" name="BankLeumiCreditFacilityMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_DesignerRoyaltiesMember" name="DesignerRoyaltiesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_WarrantsSeriesCPreferredSharesMember" name="WarrantsSeriesCPreferredSharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_C2WarrantsMember" name="C2WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_C1WarrantsMember" name="C1WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesCPreferredShareWarrantsConversionMember" name="SeriesCPreferredShareWarrantsConversionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_PredecessorUnitHoldersMember" name="PredecessorUnitHoldersMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_OfficeOfTheChiefScientistMember" name="OfficeOfTheChiefScientistMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" name="BinationalIndustrialResearchAndDevelopmentFoundationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_WarrantsSeriesDPreferredSharesMember" name="WarrantsSeriesDPreferredSharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GeneralTransactionsMember" name="GeneralTransactionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesC2PreferredStockMember" name="SeriesC2PreferredStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesD4PreferredStockMember" name="SeriesD4PreferredStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesC1PreferredStockMember" name="SeriesC1PreferredStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesC3PreferredStockMember" name="SeriesC3PreferredStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesD1PreferredStockMember" name="SeriesD1PreferredStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesD2PreferredStockMember" name="SeriesD2PreferredStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesD3PreferredStockMember" name="SeriesD3PreferredStockMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_InvestorWarrantsMember" name="InvestorWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ServicesWarrantsMember" name="ServicesWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_AntiDilutiveWarrantsMember" name="AntiDilutiveWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_UnderwriterWarrantsMember" name="UnderwriterWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_LegalWarrantsMember" name="LegalWarrantsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_AprilSixthMember" name="AprilSixthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_OctoberTwentiethMember" name="OctoberTwentiethMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_OctoberFourteenthMember" name="OctoberFourteenthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FebruaryTwentyFourthTwoMember" name="FebruaryTwentyFourthTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_MarchFifteenthMember" name="MarchFifteenthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_MayNineteenthMember" name="MayNineteenthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_JuneFirstMember" name="JuneFirstMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_JanuaryFifteenthMember" name="JanuaryFifteenthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_MayFifteenthMember" name="MayFifteenthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_JuneSixthMember" name="JuneSixthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_JuneThirdMember" name="JuneThirdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_AugustThirteenthOneMember" name="AugustThirteenthOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_AugustThirteenthTwoMember" name="AugustThirteenthTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FebruaryEighteenthMember" name="FebruaryEighteenthMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_WarrantAwardsMember" name="WarrantAwardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FebruaryTwentyFourthOneMember" name="FebruaryTwentyFourthOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_VariousDatesMember" name="VariousDatesMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ShareBasedCompensationAwardTrancheFourMember" name="ShareBasedCompensationAwardTrancheFourMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_TweentyNineFebruaryMember" name="TweentyNineFebruaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FirstMarchMember" name="FirstMarchMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FourMayMember" name="FourMayMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FourAugustMember" name="FourAugustMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ThirtyOneOctoberMember" name="ThirtyOneOctoberMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_DevelopmentAreaAMember" name="DevelopmentAreaAMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_RestOfTheCountryMember" name="RestOfTheCountryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_OrdinarySharesMember" name="OrdinarySharesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_OneYearWarrantsMember" name="OneYearWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FiveYearWarrantsMember" name="FiveYearWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_TwentySevenFebruaryMember" name="TwentySevenFebruaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_NineMayMember" name="NineMayMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_TwentyTwoJuneMember" name="TwentyTwoJuneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ThreeAugustMember" name="ThreeAugustMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_TwoNovemberMember" name="TwoNovemberMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_CertainEmployeesMember" name="CertainEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate1Member" name="GrantDate1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate2Member" name="GrantDate2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate3Member" name="GrantDate3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate4Member" name="GrantDate4Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate5Member" name="GrantDate5Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate6Member" name="GrantDate6Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate7Member" name="GrantDate7Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate8Member" name="GrantDate8Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate9Member" name="GrantDate9Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate10Member" name="GrantDate10Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate11Member" name="GrantDate11Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate12Member" name="GrantDate12Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate13Member" name="GrantDate13Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate14Member" name="GrantDate14Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate15Member" name="GrantDate15Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate16Member" name="GrantDate16Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate17Member" name="GrantDate17Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GrantDate18Member" name="GrantDate18Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_VariousDatesIn2015Member" name="VariousDatesIn2015Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FindersWarrantsMember" name="FindersWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_PreFundedUnitsMember" name="PreFundedUnitsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_TwoThousandFifteenPlanMember" name="TwoThousandFifteenPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ForeignCurrencyDerivativeInstrumentsMember" name="ForeignCurrencyDerivativeInstrumentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_PreFundedWarrantsOneMember" name="PreFundedWarrantsOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesCWarrantsMember" name="SeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_SeriesDWarrantsMember" name="SeriesDWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="chek_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement" name="StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" name="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="chek_WarrantLiabilityReclassificationToEquity" name="WarrantLiabilityReclassificationToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="chek_AccountingPoliciesTable" name="AccountingPoliciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="chek_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ShortTermInvestmentInterestRate" name="ShortTermInvestmentInterestRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FutureFederalIncomeTaxRateNextYear" name="FutureFederalIncomeTaxRateNextYear" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="chek_FutureFederalIncomeTaxRate" name="FutureFederalIncomeTaxRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ForeignIncomeTaxRateMaximum" name="ForeignIncomeTaxRateMaximum" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="chek_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="chek_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="chek_RoyaltiesPayablePerUnit" name="RoyaltiesPayablePerUnit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ShareCapital" name="ShareCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ShareCapitalLessIssuanceCosts" name="ShareCapitalLessIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_RevenueFromCashCommission" name="RevenueFromCashCommission" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="chek_ResearchAndDevelopmentExpensesTable" name="ResearchAndDevelopmentExpensesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="chek_ResearchAndDevelopmentExpensesLineItems" name="ResearchAndDevelopmentExpensesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="chek_GeneralAndAdministrativeExpensesTable" name="GeneralAndAdministrativeExpensesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="chek_GeneralAndAdministrativeExpensesLineItems" name="GeneralAndAdministrativeExpensesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="chek_HourlyFeeUpToFiveHours" name="HourlyFeeUpToFiveHours" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="chek_HourlyFeeExceedingFiveHours" name="HourlyFeeExceedingFiveHours" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>chek-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CHEK 1218 20F.xfr; Date: 2019%2D03%2D26T22:03:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://check-cap.com/role/chek-dei" xlink:href="chek-20181231.xsd#chek-dei" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/check-cbs" xlink:href="chek-20181231.xsd#check-cbs" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-csoo" xlink:href="chek-20181231.xsd#chek-csoo" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-equity" xlink:href="chek-20181231.xsd#chek-equity" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-equityp" xlink:href="chek-20181231.xsd#chek-equityp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-csocf" xlink:href="chek-20181231.xsd#chek-csocf" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-info" xlink:href="chek-20181231.xsd#chek-info" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sigp" xlink:href="chek-20181231.xsd#chek-sigp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-peaoca" xlink:href="chek-20181231.xsd#chek-peaoca" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ppe" xlink:href="chek-20181231.xsd#chek-ppe" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-stloan" xlink:href="chek-20181231.xsd#chek-stloan" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ebapa" xlink:href="chek-20181231.xsd#chek-ebapa" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-itax" xlink:href="chek-20181231.xsd#chek-itax" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-cacl" xlink:href="chek-20181231.xsd#chek-cacl" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fvm" xlink:href="chek-20181231.xsd#chek-fvm" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sed" xlink:href="chek-20181231.xsd#chek-sed" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbp" xlink:href="chek-20181231.xsd#chek-sbp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-raden" xlink:href="chek-20181231.xsd#chek-raden" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-gaae" xlink:href="chek-20181231.xsd#chek-gaae" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fien" xlink:href="chek-20181231.xsd#chek-fien" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-eps" xlink:href="chek-20181231.xsd#chek-eps" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-relp" xlink:href="chek-20181231.xsd#chek-relp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/SubsequentEvents" xlink:href="chek-20181231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sigpp" xlink:href="chek-20181231.xsd#chek-sigpp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sigpt" xlink:href="chek-20181231.xsd#chek-sigpt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-peaocat" xlink:href="chek-20181231.xsd#chek-peaocat" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ppet" xlink:href="chek-20181231.xsd#chek-ppet" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ebapat" xlink:href="chek-20181231.xsd#chek-ebapat" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-itaxt" xlink:href="chek-20181231.xsd#chek-itaxt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-caclt" xlink:href="chek-20181231.xsd#chek-caclt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fvmt" xlink:href="chek-20181231.xsd#chek-fvmt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sedt" xlink:href="chek-20181231.xsd#chek-sedt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbpt" xlink:href="chek-20181231.xsd#chek-sbpt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-radent" xlink:href="chek-20181231.xsd#chek-radent" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-gaaet" xlink:href="chek-20181231.xsd#chek-gaaet" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fient" xlink:href="chek-20181231.xsd#chek-fient" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-epst" xlink:href="chek-20181231.xsd#chek-epst" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-relpt" xlink:href="chek-20181231.xsd#chek-relpt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-infod" xlink:href="chek-20181231.xsd#chek-infod" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="chek-20181231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sosapd" xlink:href="chek-20181231.xsd#chek-sosapd" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="chek-20181231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-peaocad" xlink:href="chek-20181231.xsd#chek-peaocad" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-pped" xlink:href="chek-20181231.xsd#chek-pped" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ebapad" xlink:href="chek-20181231.xsd#chek-ebapad" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-itaxd" xlink:href="chek-20181231.xsd#chek-itaxd" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-cacld" xlink:href="chek-20181231.xsd#chek-cacld" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails" xlink:href="chek-20181231.xsd#FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:href="chek-20181231.xsd#ShareholdersEquityOrdinarySharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/Share-basedCompensationAwardsDetails" xlink:href="chek-20181231.xsd#Share-basedCompensationAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/Share-basedCompensationDetailsOfShare-basedGrantsDetails" xlink:href="chek-20181231.xsd#Share-basedCompensationDetailsOfShare-basedGrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails" xlink:href="chek-20181231.xsd#Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbpced" xlink:href="chek-20181231.xsd#chek-sbpced" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbpoad" xlink:href="chek-20181231.xsd#chek-sbpoad" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-radend" xlink:href="chek-20181231.xsd#chek-radend" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-gaaed" xlink:href="chek-20181231.xsd#chek-gaaed" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fiend" xlink:href="chek-20181231.xsd#chek-fiend" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/LossPerShareScheduleOfLossPerShareDetails" xlink:href="chek-20181231.xsd#LossPerShareScheduleOfLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="chek-20181231.xsd#LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-relptrpd" xlink:href="chek-20181231.xsd#chek-relptrpd" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-dei" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/check-cbs" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesProvision" xlink:label="loc_chekRoyaltiesProvision" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_chekRoyaltiesProvision" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-csoo" xlink:title="00000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-equity" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-equityp" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-csocf" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaapOtherNoncashIncomeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashIncomeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInRoyaltiesPayable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInRoyaltiesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ProceedsFromIssuanceResisteredDirectOffering" xlink:label="loc_chekProceedsFromIssuanceResisteredDirectOffering" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_chekProceedsFromIssuanceResisteredDirectOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-info" xlink:title="00000007 - Disclosure - GENERAL INFORMATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sigp" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-peaoca" xlink:title="00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ppe" xlink:title="00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-stloan" xlink:title="00000011 - Disclosure - SHORT TERM LOANS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ebapa" xlink:title="00000012 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-itax" xlink:title="00000013 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-cacl" xlink:title="00000014 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fvm" xlink:title="00000015 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sed" xlink:title="00000016 - Disclosure - SHAREHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbp" xlink:title="00000017 - Disclosure - SHARE-BASED COMPENSATION" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-raden" xlink:title="00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-gaae" xlink:title="00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fien" xlink:title="00000020 - Disclosure - FINANCE INCOME (EXPENSES), NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-eps" xlink:title="00000021 - Disclosure - LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-relp" xlink:title="00000022 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sigpp" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sigpt" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-peaocat" xlink:title="00000026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ppet" xlink:title="00000027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ebapat" xlink:title="00000028 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-itaxt" xlink:title="00000029 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-caclt" xlink:title="00000030 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fvmt" xlink:title="00000031 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sedt" xlink:title="00000032 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIENCY) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbpt" xlink:title="00000033 - Disclosure - SHARE-BASED COMPENSATION (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-radent" xlink:title="00000034 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-gaaet" xlink:title="00000035 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fient" xlink:title="00000036 - Disclosure - FINANCE INCOME (EXPENSES), NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-epst" xlink:title="00000037 - Disclosure - LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-relpt" xlink:title="00000038 - Disclosure - RELATED PARTIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-infod" xlink:title="00000039 - Disclosure - GENERAL INFORMATION (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:title="00000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sosapd" xlink:title="00000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Cash, Cash Equivalents and Restricted Cash) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-peaocad" xlink:title="00000043 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GovernmentInstitutionalAssetsCurrent" xlink:label="loc_chekGovernmentInstitutionalAssetsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_chekGovernmentInstitutionalAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-pped" xlink:title="00000044 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ebapad" xlink:title="00000045 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-itaxd" xlink:title="00000046 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-cacld" xlink:title="00000047 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails" xlink:title="00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Schedule of Market observable data of similar instruments) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFairValueNetAssetLiability" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFairValueNetAssetLiability" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:title="00000049 - Disclosure - SHAREHOLDERS' EQUITY (Ordinary Shares) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/Share-basedCompensationAwardsDetails" xlink:title="00000050 - Disclosure - SHARE-BASED COMPENSATION (Awards) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/Share-basedCompensationDetailsOfShare-basedGrantsDetails" xlink:title="00000051 - Disclosure - SHARE-BASED COMPENSATION (Details of share-based grants) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails" xlink:title="00000052 - Disclosure - SHARE-BASED COMPENSATION (Schedule of Parameters Used in Valuing Fair Value of Options) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbpced" xlink:title="00000053 - Disclosure - SHARE-BASED COMPENSATION (Compensation Expense) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbpoad" xlink:title="00000054 - Disclosure - SHARE-BASED COMPENSATION (Option Activity) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-radend" xlink:title="00000055 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ResearchAndDevelopmentExpenseGross" xlink:label="loc_chekResearchAndDevelopmentExpenseGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_chekResearchAndDevelopmentExpenseGross" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_chekResearchAndDevelopmentExpenseGross" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense" xlink:label="loc_us-gaapSuppliesExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_chekResearchAndDevelopmentExpenseGross" xlink:to="loc_us-gaapSuppliesExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SubcontractorsAndConsultantFees" xlink:label="loc_chekSubcontractorsAndConsultantFees" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_chekResearchAndDevelopmentExpenseGross" xlink:to="loc_chekSubcontractorsAndConsultantFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaapDepreciationNonproduction" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_chekResearchAndDevelopmentExpenseGross" xlink:to="loc_us-gaapDepreciationNonproduction" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_chekResearchAndDevelopmentExpenseGross" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_chekResearchAndDevelopmentExpenseGross" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_chekResearchAndDevelopmentExpenseGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantedRevenue" xlink:label="loc_chekGrantedRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapResearchAndDevelopmentExpense" xlink:to="loc_chekGrantedRevenue" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-gaaed" xlink:title="00000056 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaapDepreciationNonproduction" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapDepreciationNonproduction" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGeneralAndAdministrativeExpense" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fiend" xlink:title="00000057 - Disclosure - FINANCE INCOME (EXPENSES), NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltyIncomeExpenseNonoperating" xlink:label="loc_chekRoyaltyIncomeExpenseNonoperating" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_chekRoyaltyIncomeExpenseNonoperating" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/LossPerShareScheduleOfLossPerShareDetails" xlink:title="00000058 - Disclosure - LOSS PER SHARE (Schedule of Loss Per Share) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000059 - Disclosure - LOSS PER SHARE (Schedule of Anti-Dilutive Securities) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-relptrpd" xlink:title="00000060 - Disclosure - RELATED PARTIES (Transactions with Related Parties) (Details)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>chek-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CHEK 1218 20F.xfr; Date: 2019%2D03%2D26T22:03:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://check-cap.com/role/chek-dei" xlink:href="chek-20181231.xsd#chek-dei" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/check-cbs" xlink:href="chek-20181231.xsd#check-cbs" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-csoo" xlink:href="chek-20181231.xsd#chek-csoo" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-equity" xlink:href="chek-20181231.xsd#chek-equity" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-equityp" xlink:href="chek-20181231.xsd#chek-equityp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-csocf" xlink:href="chek-20181231.xsd#chek-csocf" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-info" xlink:href="chek-20181231.xsd#chek-info" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sigp" xlink:href="chek-20181231.xsd#chek-sigp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-peaoca" xlink:href="chek-20181231.xsd#chek-peaoca" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ppe" xlink:href="chek-20181231.xsd#chek-ppe" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-stloan" xlink:href="chek-20181231.xsd#chek-stloan" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ebapa" xlink:href="chek-20181231.xsd#chek-ebapa" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-itax" xlink:href="chek-20181231.xsd#chek-itax" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-cacl" xlink:href="chek-20181231.xsd#chek-cacl" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fvm" xlink:href="chek-20181231.xsd#chek-fvm" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sed" xlink:href="chek-20181231.xsd#chek-sed" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbp" xlink:href="chek-20181231.xsd#chek-sbp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-raden" xlink:href="chek-20181231.xsd#chek-raden" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-gaae" xlink:href="chek-20181231.xsd#chek-gaae" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fien" xlink:href="chek-20181231.xsd#chek-fien" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-eps" xlink:href="chek-20181231.xsd#chek-eps" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-relp" xlink:href="chek-20181231.xsd#chek-relp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/SubsequentEvents" xlink:href="chek-20181231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sigpp" xlink:href="chek-20181231.xsd#chek-sigpp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sigpt" xlink:href="chek-20181231.xsd#chek-sigpt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-peaocat" xlink:href="chek-20181231.xsd#chek-peaocat" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ppet" xlink:href="chek-20181231.xsd#chek-ppet" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ebapat" xlink:href="chek-20181231.xsd#chek-ebapat" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-itaxt" xlink:href="chek-20181231.xsd#chek-itaxt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-caclt" xlink:href="chek-20181231.xsd#chek-caclt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fvmt" xlink:href="chek-20181231.xsd#chek-fvmt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sedt" xlink:href="chek-20181231.xsd#chek-sedt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbpt" xlink:href="chek-20181231.xsd#chek-sbpt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-radent" xlink:href="chek-20181231.xsd#chek-radent" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-gaaet" xlink:href="chek-20181231.xsd#chek-gaaet" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fient" xlink:href="chek-20181231.xsd#chek-fient" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-epst" xlink:href="chek-20181231.xsd#chek-epst" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-relpt" xlink:href="chek-20181231.xsd#chek-relpt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-infod" xlink:href="chek-20181231.xsd#chek-infod" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="chek-20181231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sosapd" xlink:href="chek-20181231.xsd#chek-sosapd" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="chek-20181231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-peaocad" xlink:href="chek-20181231.xsd#chek-peaocad" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-pped" xlink:href="chek-20181231.xsd#chek-pped" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ebapad" xlink:href="chek-20181231.xsd#chek-ebapad" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-itaxd" xlink:href="chek-20181231.xsd#chek-itaxd" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-cacld" xlink:href="chek-20181231.xsd#chek-cacld" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails" xlink:href="chek-20181231.xsd#FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:href="chek-20181231.xsd#ShareholdersEquityOrdinarySharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/Share-basedCompensationAwardsDetails" xlink:href="chek-20181231.xsd#Share-basedCompensationAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/Share-basedCompensationDetailsOfShare-basedGrantsDetails" xlink:href="chek-20181231.xsd#Share-basedCompensationDetailsOfShare-basedGrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails" xlink:href="chek-20181231.xsd#Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbpced" xlink:href="chek-20181231.xsd#chek-sbpced" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbpoad" xlink:href="chek-20181231.xsd#chek-sbpoad" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-radend" xlink:href="chek-20181231.xsd#chek-radend" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-gaaed" xlink:href="chek-20181231.xsd#chek-gaaed" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fiend" xlink:href="chek-20181231.xsd#chek-fiend" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/LossPerShareScheduleOfLossPerShareDetails" xlink:href="chek-20181231.xsd#LossPerShareScheduleOfLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="chek-20181231.xsd#LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-relptrpd" xlink:href="chek-20181231.xsd#chek-relptrpd" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-dei" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/check-cbs" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-csoo" xlink:title="00000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-equity" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement" xlink:label="loc_chekStockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:label="loc_chekStockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" xlink:label="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering" xlink:label="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1" xlink:label="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" xlink:label="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2" xlink:label="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" xlink:label="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_chekStockIssuedDuringPeriodValueWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueWarrantsExercised_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_chekStockIssuedDuringPeriodSharesWarrantsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesWarrantsExercised_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="loc_chekAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_60" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_60" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_60" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-equityp" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-csocf" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-info" xlink:title="00000007 - Disclosure - GENERAL INFORMATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sigp" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-peaoca" xlink:title="00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ppe" xlink:title="00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-stloan" xlink:title="00000011 - Disclosure - SHORT TERM LOANS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ebapa" xlink:title="00000012 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-itax" xlink:title="00000013 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-cacl" xlink:title="00000014 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fvm" xlink:title="00000015 - Disclosure - FAIR VALUE MEASUREMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sed" xlink:title="00000016 - Disclosure - SHAREHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbp" xlink:title="00000017 - Disclosure - SHARE-BASED COMPENSATION" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-raden" xlink:title="00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-gaae" xlink:title="00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fien" xlink:title="00000020 - Disclosure - FINANCE INCOME (EXPENSES), NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-eps" xlink:title="00000021 - Disclosure - LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-relp" xlink:title="00000022 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sigpp" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sigpt" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-peaocat" xlink:title="00000026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ppet" xlink:title="00000027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ebapat" xlink:title="00000028 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-itaxt" xlink:title="00000029 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-caclt" xlink:title="00000030 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fvmt" xlink:title="00000031 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sedt" xlink:title="00000032 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIENCY) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbpt" xlink:title="00000033 - Disclosure - SHARE-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock" xlink:label="loc_chekScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-radent" xlink:title="00000034 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-gaaet" xlink:title="00000035 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fient" xlink:title="00000036 - Disclosure - FINANCE INCOME (EXPENSES), NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-epst" xlink:title="00000037 - Disclosure - LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-relpt" xlink:title="00000038 - Disclosure - RELATED PARTIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_NonExecutiveDirectorsCompensationMember" xlink:label="loc_chekNonExecutiveDirectorsCompensationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekNonExecutiveDirectorsCompensationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralTransactionsMember" xlink:label="loc_chekGeneralTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekGeneralTransactionsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock_30" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-infod" xlink:title="00000039 - Disclosure - GENERAL INFORMATION (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:title="00000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sosapd" xlink:title="00000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AccountingPoliciesLineItems" xlink:label="loc_chekAccountingPoliciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AccountingPoliciesTable" xlink:label="loc_chekAccountingPoliciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_chekAccountingPoliciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="loc_us-gaapTechnologyEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapTechnologyEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShortTermInvestmentInterestRate" xlink:label="loc_chekShortTermInvestmentInterestRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_chekShortTermInvestmentInterestRate_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Cash, Cash Equivalents and Restricted Cash) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-peaocad" xlink:title="00000043 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-pped" xlink:title="00000044 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="loc_us-gaapTechnologyEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapTechnologyEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisposals_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisposals_120" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ebapad" xlink:title="00000045 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-itaxd" xlink:title="00000046 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DevelopmentAreaAMember" xlink:label="loc_chekDevelopmentAreaAMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_chekDevelopmentAreaAMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RestOfTheCountryMember" xlink:label="loc_chekRestOfTheCountryMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_chekRestOfTheCountryMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxDisclosureAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FutureFederalIncomeTaxRateNextYear" xlink:label="loc_chekFutureFederalIncomeTaxRateNextYear_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekFutureFederalIncomeTaxRateNextYear_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FutureFederalIncomeTaxRate" xlink:label="loc_chekFutureFederalIncomeTaxRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekFutureFederalIncomeTaxRate_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ForeignIncomeTaxRateMaximum" xlink:label="loc_chekForeignIncomeTaxRateMaximum_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekForeignIncomeTaxRateMaximum_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ReductionInIncomeTaxRate" xlink:label="loc_chekReductionInIncomeTaxRate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekReductionInIncomeTaxRate_110" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-cacld" xlink:title="00000047 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CommitmentsAndContingenciesLineItems" xlink:label="loc_chekCommitmentsAndContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CommitmentsAndContingenciesTable" xlink:label="loc_chekCommitmentsAndContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_chekCommitmentsAndContingenciesLineItems" xlink:to="loc_chekCommitmentsAndContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DesignerRoyaltiesMember" xlink:label="loc_chekDesignerRoyaltiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_chekDesignerRoyaltiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PredecessorUnitHoldersMember" xlink:label="loc_chekPredecessorUnitHoldersMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_chekPredecessorUnitHoldersMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OfficeOfTheChiefScientistMember" xlink:label="loc_chekOfficeOfTheChiefScientistMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_chekOfficeOfTheChiefScientistMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:label="loc_chekBinationalIndustrialResearchAndDevelopmentFoundationMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_chekBinationalIndustrialResearchAndDevelopmentFoundationMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekCommitmentsAndContingenciesTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currencyEUR_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyEUR_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekCommitmentsAndContingenciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdsAndLeaseholdImprovementsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdsAndLeaseholdImprovementsMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaapLeasesOperatingAbstract_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekCommitmentsAndContingenciesLineItems" xlink:to="loc_us-gaapLeasesOperatingAbstract_230" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesOperatingAbstract_230" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract_230" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesOperatingAbstract_230" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet_230" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesOperatingAbstract_230" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract_230" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract_230" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent_230" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract_230" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears_230" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract_230" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears_230" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OperatingLeaseRentExpenseMonthly" xlink:label="loc_chekOperatingLeaseRentExpenseMonthly_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesOperatingAbstract_230" xlink:to="loc_chekOperatingLeaseRentExpenseMonthly_230" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeasesOperatingAbstract_230" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_230" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="loc_us-gaapOtherCommitmentsAbstract_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekCommitmentsAndContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitmentsAbstract_230" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesPayablePerUnit" xlink:label="loc_chekRoyaltiesPayablePerUnit_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsAbstract_230" xlink:to="loc_chekRoyaltiesPayablePerUnit_230" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesPayablePerUnitSold" xlink:label="loc_chekRoyaltiesPayablePerUnitSold_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsAbstract_230" xlink:to="loc_chekRoyaltiesPayablePerUnitSold_230" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MaximumRoyaltyObligation" xlink:label="loc_chekMaximumRoyaltyObligation_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsAbstract_230" xlink:to="loc_chekMaximumRoyaltyObligation_230" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesProvision" xlink:label="loc_chekRoyaltiesProvision_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsAbstract_230" xlink:to="loc_chekRoyaltiesProvision_230" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantedRevenue" xlink:label="loc_chekGrantedRevenue_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsAbstract_230" xlink:to="loc_chekGrantedRevenue_230" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesPayablePercentageOfProductSales" xlink:label="loc_chekRoyaltiesPayablePercentageOfProductSales_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsAbstract_230" xlink:to="loc_chekRoyaltiesPayablePercentageOfProductSales_230" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsAbstract_230" xlink:to="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent_230" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsAbstract_230" xlink:to="loc_us-gaapOtherCommitmentsDescription_230" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RefundExpenses" xlink:label="loc_chekRefundExpenses_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsAbstract_230" xlink:to="loc_chekRefundExpenses_230" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails" xlink:title="00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Schedule of Market observable data of similar instruments) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:title="00000049 - Disclosure - SHAREHOLDERS' EQUITY (Ordinary Shares) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreFundedWarrantsMember" xlink:label="loc_chekPreFundedWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekPreFundedWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OneYearWarrantsMember" xlink:label="loc_chekOneYearWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekOneYearWarrantsMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FiveYearWarrantsMember" xlink:label="loc_chekFiveYearWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekFiveYearWarrantsMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AntiDilutiveWarrantsMember" xlink:label="loc_chekAntiDilutiveWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekAntiDilutiveWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_LongTermIncentiveWarrantsMember" xlink:label="loc_chekLongTermIncentiveWarrantsMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekLongTermIncentiveWarrantsMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CreditLineAgreementWarrantsMember" xlink:label="loc_chekCreditLineAgreementWarrantsMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekCreditLineAgreementWarrantsMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FindersWarrantsMember" xlink:label="loc_chekFindersWarrantsMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekFindersWarrantsMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_UnderwriterWarrantsMember" xlink:label="loc_chekUnderwriterWarrantsMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekUnderwriterWarrantsMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesAWarrantsMember" xlink:label="loc_chekSeriesAWarrantsMember_390" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekSeriesAWarrantsMember_390" xlink:type="arc" order="392" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OrdinarySharesMember" xlink:label="loc_chekOrdinarySharesMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekOrdinarySharesMember_410" xlink:type="arc" order="412" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_LegalWarrantsMember" xlink:label="loc_chekLegalWarrantsMember_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekLegalWarrantsMember_440" xlink:type="arc" order="441" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesCWarrantsMember" xlink:label="loc_chekSeriesCWarrantsMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekSeriesCWarrantsMember_570" xlink:type="arc" order="571" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreFundedWarrantsOneMember" xlink:label="loc_chekPreFundedWarrantsOneMember_630" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekPreFundedWarrantsOneMember_630" xlink:type="arc" order="631" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesDWarrantsMember" xlink:label="loc_chekSeriesDWarrantsMember_640" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekSeriesDWarrantsMember_640" xlink:type="arc" order="641" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RegisteredDirectOfferingMember" xlink:label="loc_chekRegisteredDirectOfferingMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_chekRegisteredDirectOfferingMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreFundedUnitsMember" xlink:label="loc_chekPreFundedUnitsMember_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_chekPreFundedUnitsMember_530" xlink:type="arc" order="531" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapCommonClassCMember_540" xlink:type="arc" order="541" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OrdinarySharesMember" xlink:label="loc_chekOrdinarySharesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_chekOrdinarySharesMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_580" xlink:type="arc" order="582" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareCapital" xlink:label="loc_chekShareCapital_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekShareCapital_660" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_660" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_660" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_chekStockIssuedDuringPeriodValueWarrantsExercised_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueWarrantsExercised_660" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaapStockholdersEquityPeriodIncreaseDecrease_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityPeriodIncreaseDecrease_660" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_660" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareCapitalLessIssuanceCosts" xlink:label="loc_chekShareCapitalLessIssuanceCosts_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekShareCapitalLessIssuanceCosts_660" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_660" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_660" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_chekStockIssuedDuringPeriodSharesWarrantsExercised_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesWarrantsExercised_660" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:label="loc_chekStockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_660" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_660" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_660" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_660" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsIssuedNumber" xlink:label="loc_chekWarrantsIssuedNumber_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekWarrantsIssuedNumber_660" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_660" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_660" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_660" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_660" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PricePerUnit" xlink:label="loc_chekPricePerUnit_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekPricePerUnit_660" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_UnitsPurchased" xlink:label="loc_chekUnitsPurchased_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekUnitsPurchased_660" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_660" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ClassOfWarrantOrRightExpiration" xlink:label="loc_chekClassOfWarrantOrRightExpiration_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekClassOfWarrantOrRightExpiration_660" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_660" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement_660" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_660" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_660" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsExercisedCashlessBasis" xlink:label="loc_chekWarrantsExercisedCashlessBasis_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekWarrantsExercisedCashlessBasis_660" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_660" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" xlink:label="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering_660" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_660" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants_660" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_660" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_660" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RevenueFromCashCommission" xlink:label="loc_chekRevenueFromCashCommission_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekRevenueFromCashCommission_660" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_660" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_660" xlink:type="arc" order="36" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/Share-basedCompensationAwardsDetails" xlink:title="00000050 - Disclosure - SHARE-BASED COMPENSATION (Awards) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_TwoThousandFifteenPlanMember" xlink:label="loc_chekTwoThousandFifteenPlanMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_chekTwoThousandFifteenPlanMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_TwentyTwoJuneMember" xlink:label="loc_chekTwentyTwoJuneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekTwentyTwoJuneMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ThreeAugustMember" xlink:label="loc_chekThreeAugustMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekThreeAugustMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_JanuaryFifteenthMember" xlink:label="loc_chekJanuaryFifteenthMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekJanuaryFifteenthMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AprilSixthMember" xlink:label="loc_chekAprilSixthMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekAprilSixthMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember_200" xlink:type="arc" order="203" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember_210" xlink:type="arc" order="213" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaapChiefExecutiveOfficerMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapChiefExecutiveOfficerMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CertainEmployeesMember" xlink:label="loc_chekCertainEmployeesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_chekCertainEmployeesMember_150" xlink:type="arc" order="153" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_300" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_300" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_300" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_300" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_300" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_300" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_300" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_300" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_300" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_300" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_300" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_300" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_300" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_300" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_300" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_300" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/Share-basedCompensationDetailsOfShare-basedGrantsDetails" xlink:title="00000051 - Disclosure - SHARE-BASED COMPENSATION (Details of share-based grants) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate1Member" xlink:label="loc_chekGrantDate1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate2Member" xlink:label="loc_chekGrantDate2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate3Member" xlink:label="loc_chekGrantDate3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate4Member" xlink:label="loc_chekGrantDate4Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate4Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate5Member" xlink:label="loc_chekGrantDate5Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate5Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate6Member" xlink:label="loc_chekGrantDate6Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate6Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate7Member" xlink:label="loc_chekGrantDate7Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate7Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate8Member" xlink:label="loc_chekGrantDate8Member_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate8Member_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate9Member" xlink:label="loc_chekGrantDate9Member_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate9Member_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate10Member" xlink:label="loc_chekGrantDate10Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate10Member_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate17Member" xlink:label="loc_chekGrantDate17Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate17Member_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate11Member" xlink:label="loc_chekGrantDate11Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate11Member_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate13Member" xlink:label="loc_chekGrantDate13Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate13Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate15Member" xlink:label="loc_chekGrantDate15Member_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate15Member_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate16Member" xlink:label="loc_chekGrantDate16Member_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate16Member_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_260" xlink:type="arc" order="262" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_320" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails" xlink:title="00000052 - Disclosure - SHARE-BASED COMPENSATION (Schedule of Parameters Used in Valuing Fair Value of Options) (Details)">
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AccountingPoliciesLineItems" xlink:label="loc_chekAccountingPoliciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AccountingPoliciesTable" xlink:label="loc_chekAccountingPoliciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_chekAccountingPoliciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_160" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_160" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_160" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_160" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_160" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_160" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_160" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_160" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_160" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_160" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_160" xlink:to="loc_us-gaapSharePrice_160" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbpced" xlink:title="00000053 - Disclosure - SHARE-BASED COMPENSATION (Compensation Expense) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbpoad" xlink:title="00000054 - Disclosure - SHARE-BASED COMPENSATION (Option Activity) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_NumberOfSharesRestrictedStockVested" xlink:label="loc_chekNumberOfSharesRestrictedStockVested_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" xlink:to="loc_chekNumberOfSharesRestrictedStockVested_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_110" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree" xlink:label="loc_chekSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_110" xlink:to="loc_chekSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_110" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_chekShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_110" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_110" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_110" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_110" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_110" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_110" xlink:type="arc" order="26" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-radend" xlink:title="00000055 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ResearchAndDevelopmentExpensesLineItems" xlink:label="loc_chekResearchAndDevelopmentExpensesLineItems" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ResearchAndDevelopmentExpensesTable" xlink:label="loc_chekResearchAndDevelopmentExpensesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_chekResearchAndDevelopmentExpensesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekResearchAndDevelopmentExpensesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense" xlink:label="loc_us-gaapSuppliesExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapSuppliesExpense_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SubcontractorsAndConsultantFees" xlink:label="loc_chekSubcontractorsAndConsultantFees_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_chekSubcontractorsAndConsultantFees_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaapDepreciationNonproduction_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapDepreciationNonproduction_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ResearchAndDevelopmentExpenseGross" xlink:label="loc_chekResearchAndDevelopmentExpenseGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_chekResearchAndDevelopmentExpenseGross_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantedRevenue" xlink:label="loc_chekGrantedRevenue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_chekGrantedRevenue_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_40" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-gaaed" xlink:title="00000056 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralAndAdministrativeExpensesLineItems" xlink:label="loc_chekGeneralAndAdministrativeExpensesLineItems" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralAndAdministrativeExpensesTable" xlink:label="loc_chekGeneralAndAdministrativeExpensesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_chekGeneralAndAdministrativeExpensesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_chekGeneralAndAdministrativeExpensesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapProfessionalFees_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaapDepreciationNonproduction_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapDepreciationNonproduction_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_40" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fiend" xlink:title="00000057 - Disclosure - FINANCE INCOME (EXPENSES), NET (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/LossPerShareScheduleOfLossPerShareDetails" xlink:title="00000058 - Disclosure - LOSS PER SHARE (Schedule of Loss Per Share) (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000059 - Disclosure - LOSS PER SHARE (Schedule of Anti-Dilutive Securities) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantAndShareOptionsMember" xlink:label="loc_chekWarrantAndShareOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_chekWarrantAndShareOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreferredSharesMember" xlink:label="loc_chekPreferredSharesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_chekPreferredSharesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-relptrpd" xlink:title="00000060 - Disclosure - RELATED PARTIES (Transactions with Related Parties) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="loc_us-gaapImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficerMember" xlink:label="loc_us-gaapOfficerMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapOfficerMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_NonExecutiveDirectorsMember" xlink:label="loc_chekNonExecutiveDirectorsMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_chekNonExecutiveDirectorsMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ConsultingFeesMember" xlink:label="loc_chekConsultingFeesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekConsultingFeesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_KeyManLifeInsurancePremiumMember" xlink:label="loc_chekKeyManLifeInsurancePremiumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekKeyManLifeInsurancePremiumMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FeesAndReimbursementMember" xlink:label="loc_chekFeesAndReimbursementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekFeesAndReimbursementMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareBasedCompensationMember" xlink:label="loc_chekShareBasedCompensationMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekShareBasedCompensationMember_190" xlink:type="arc" order="192" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MonthlyRetainer" xlink:label="loc_chekMonthlyRetainer_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekMonthlyRetainer_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_HourlyFeeUpToFiveHours" xlink:label="loc_chekHourlyFeeUpToFiveHours_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekHourlyFeeUpToFiveHours_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_HourlyFeeExceedingFiveHours" xlink:label="loc_chekHourlyFeeExceedingFiveHours_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekHourlyFeeExceedingFiveHours_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_KeyManInsurancePolicy" xlink:label="loc_chekKeyManInsurancePolicy_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekKeyManInsurancePolicy_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MonthlySalary" xlink:label="loc_chekMonthlySalary_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekMonthlySalary_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrossOvertimeMonthlyRate" xlink:label="loc_chekGrossOvertimeMonthlyRate_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekGrossOvertimeMonthlyRate_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MaximumAggregateMonthlySalary" xlink:label="loc_chekMaximumAggregateMonthlySalary_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekMaximumAggregateMonthlySalary_260" xlink:type="arc" order="9" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>chek-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CHEK 1218 20F.xfr; Date: 2019%2D03%2D26T22:03:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ConsultingFeesMember" xlink:label="chek_ConsultingFeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ConsultingFeesMember" xlink:to="chek_ConsultingFeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ConsultingFeesMember_lbl" xml:lang="en-US">Consulting fees, including share-based compensation and reimbursement of expenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_KeyManLifeInsurancePremiumMember" xlink:label="chek_KeyManLifeInsurancePremiumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_KeyManLifeInsurancePremiumMember" xlink:to="chek_KeyManLifeInsurancePremiumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_KeyManLifeInsurancePremiumMember_lbl" xml:lang="en-US">Key man life insurance premium [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FeesAndReimbursementMember" xlink:label="chek_FeesAndReimbursementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FeesAndReimbursementMember" xlink:to="chek_FeesAndReimbursementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_FeesAndReimbursementMember_lbl" xml:lang="en-US">Fees and Reimbursement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_NonExecutiveDirectorsMember" xlink:label="chek_NonExecutiveDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NonExecutiveDirectorsMember" xlink:to="chek_NonExecutiveDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_NonExecutiveDirectorsMember_lbl" xml:lang="en-US">Non-Executive Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareBasedCompensationMember" xlink:label="chek_ShareBasedCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationMember" xlink:to="chek_ShareBasedCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShareBasedCompensationMember_lbl" xml:lang="en-US">Share-Based Compensation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:to="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember_lbl" xml:lang="en-US">Sigalit Kimchy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficerMember" xlink:label="us-gaap_OfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficerMember" xlink:to="us-gaap_OfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficerMember_lbl" xml:lang="en-US">Yoav Kimchy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantAndShareOptionsMember" xlink:label="chek_WarrantAndShareOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantAndShareOptionsMember" xlink:to="chek_WarrantAndShareOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_WarrantAndShareOptionsMember_lbl" xml:lang="en-US">Warrant and Share Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development, net [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office furniture and equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="us-gaap_TechnologyEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TechnologyEquipmentMember" xlink:to="us-gaap_TechnologyEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TechnologyEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DesignerRoyaltiesMember" xlink:label="chek_DesignerRoyaltiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DesignerRoyaltiesMember" xlink:to="chek_DesignerRoyaltiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DesignerRoyaltiesMember_lbl" xml:lang="en-US">ASIC designer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PredecessorUnitHoldersMember" xlink:label="chek_PredecessorUnitHoldersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PredecessorUnitHoldersMember" xlink:to="chek_PredecessorUnitHoldersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PredecessorUnitHoldersMember_lbl" xml:lang="en-US">Reimbursement liability to Predecessor Entity's Unit Holders [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OfficeOfTheChiefScientistMember" xlink:label="chek_OfficeOfTheChiefScientistMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OfficeOfTheChiefScientistMember" xlink:to="chek_OfficeOfTheChiefScientistMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_OfficeOfTheChiefScientistMember_lbl" xml:lang="en-US">OCS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:label="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:to="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember_lbl" xml:lang="en-US">BIRD Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Office facilities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class Of Warrant Or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CreditLineAgreementWarrantsMember" xlink:label="chek_CreditLineAgreementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CreditLineAgreementWarrantsMember" xlink:to="chek_CreditLineAgreementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_CreditLineAgreementWarrantsMember_lbl" xml:lang="en-US">Credit Line Agreement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AntiDilutiveWarrantsMember" xlink:label="chek_AntiDilutiveWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AntiDilutiveWarrantsMember" xlink:to="chek_AntiDilutiveWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_AntiDilutiveWarrantsMember_lbl" xml:lang="en-US">Anti-Dilutive Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_LongTermIncentiveWarrantsMember" xlink:label="chek_LongTermIncentiveWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LongTermIncentiveWarrantsMember" xlink:to="chek_LongTermIncentiveWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_LongTermIncentiveWarrantsMember_lbl" xml:lang="en-US">Long Term Incentive Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer and auxiliary equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_ILS" xlink:label="currency_ILS" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_ILS" xlink:to="currency_ILS_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_ILS_lbl" xml:lang="en-US">ILS [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RegisteredDirectOfferingMember" xlink:label="chek_RegisteredDirectOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RegisteredDirectOfferingMember" xlink:to="chek_RegisteredDirectOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RegisteredDirectOfferingMember_lbl" xml:lang="en-US">RD Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreFundedWarrantsMember" xlink:label="chek_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PreFundedWarrantsMember" xlink:to="chek_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesAWarrantsMember" xlink:label="chek_SeriesAWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesAWarrantsMember" xlink:to="chek_SeriesAWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AprilSixthMember" xlink:label="chek_AprilSixthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AprilSixthMember" xlink:to="chek_AprilSixthMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_AprilSixthMember_lbl" xml:lang="en-US">April 6 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_UnderwriterWarrantsMember" xlink:label="chek_UnderwriterWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_UnderwriterWarrantsMember" xlink:to="chek_UnderwriterWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_UnderwriterWarrantsMember_lbl" xml:lang="en-US">Underwriter Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_LegalWarrantsMember" xlink:label="chek_LegalWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LegalWarrantsMember" xlink:to="chek_LegalWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_LegalWarrantsMember_lbl" xml:lang="en-US">Legal Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_JanuaryFifteenthMember" xlink:label="chek_JanuaryFifteenthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_JanuaryFifteenthMember" xlink:to="chek_JanuaryFifteenthMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_JanuaryFifteenthMember_lbl" xml:lang="en-US">January 15 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DevelopmentAreaAMember" xlink:label="chek_DevelopmentAreaAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DevelopmentAreaAMember" xlink:to="chek_DevelopmentAreaAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DevelopmentAreaAMember_lbl" xml:lang="en-US">Development Area A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RestOfTheCountryMember" xlink:label="chek_RestOfTheCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RestOfTheCountryMember" xlink:to="chek_RestOfTheCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RestOfTheCountryMember_lbl" xml:lang="en-US">Rest of the Country [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OrdinarySharesMember" xlink:label="chek_OrdinarySharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OrdinarySharesMember" xlink:to="chek_OrdinarySharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_OrdinarySharesMember_lbl" xml:lang="en-US">Ordinary Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OneYearWarrantsMember" xlink:label="chek_OneYearWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OneYearWarrantsMember" xlink:to="chek_OneYearWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_OneYearWarrantsMember_lbl" xml:lang="en-US">One-year warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">RSUs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ThreeAugustMember" xlink:label="chek_ThreeAugustMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ThreeAugustMember" xlink:to="chek_ThreeAugustMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ThreeAugustMember_lbl" xml:lang="en-US">August 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_TwentyTwoJuneMember" xlink:label="chek_TwentyTwoJuneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_TwentyTwoJuneMember" xlink:to="chek_TwentyTwoJuneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_TwentyTwoJuneMember_lbl" xml:lang="en-US">June 22 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="us-gaap_ChiefExecutiveOfficerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChiefExecutiveOfficerMember" xlink:to="us-gaap_ChiefExecutiveOfficerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Tranche One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share-based Compensation Award, Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate1Member" xlink:label="chek_GrantDate1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate1Member" xlink:to="chek_GrantDate1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate1Member_lbl" xml:lang="en-US">February 29, 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate2Member" xlink:label="chek_GrantDate2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate2Member" xlink:to="chek_GrantDate2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate2Member_lbl" xml:lang="en-US">May 04, 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate3Member" xlink:label="chek_GrantDate3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate3Member" xlink:to="chek_GrantDate3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate3Member_lbl" xml:lang="en-US">August 04, 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate4Member" xlink:label="chek_GrantDate4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate4Member" xlink:to="chek_GrantDate4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate4Member_lbl" xml:lang="en-US">October 31, 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate5Member" xlink:label="chek_GrantDate5Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate5Member" xlink:to="chek_GrantDate5Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate5Member_lbl" xml:lang="en-US">February 27, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate6Member" xlink:label="chek_GrantDate6Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate6Member" xlink:to="chek_GrantDate6Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate6Member_lbl" xml:lang="en-US">May 09, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate7Member" xlink:label="chek_GrantDate7Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate7Member" xlink:to="chek_GrantDate7Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate7Member_lbl" xml:lang="en-US">June 22, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate8Member" xlink:label="chek_GrantDate8Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate8Member" xlink:to="chek_GrantDate8Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate8Member_lbl" xml:lang="en-US">August 03, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate9Member" xlink:label="chek_GrantDate9Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate9Member" xlink:to="chek_GrantDate9Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate9Member_lbl" xml:lang="en-US">November 02, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate10Member" xlink:label="chek_GrantDate10Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate10Member" xlink:to="chek_GrantDate10Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate10Member_lbl" xml:lang="en-US">February 13, 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate11Member" xlink:label="chek_GrantDate11Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate11Member" xlink:to="chek_GrantDate11Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate11Member_lbl" xml:lang="en-US">September 20, 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate13Member" xlink:label="chek_GrantDate13Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate13Member" xlink:to="chek_GrantDate13Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate13Member_lbl" xml:lang="en-US">November 1, 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate17Member" xlink:label="chek_GrantDate17Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate17Member" xlink:to="chek_GrantDate17Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate17Member_lbl" xml:lang="en-US">July 30, 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate15Member" xlink:label="chek_GrantDate15Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate15Member" xlink:to="chek_GrantDate15Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_GrantDate15Member_lbl" xml:lang="en-US">June 22, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate16Member" xlink:label="chek_GrantDate16Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate16Member" xlink:to="chek_GrantDate16Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate16Member_lbl" xml:lang="en-US">August 3, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FiveYearWarrantsMember" xlink:label="chek_FiveYearWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FiveYearWarrantsMember" xlink:to="chek_FiveYearWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_FiveYearWarrantsMember_lbl" xml:lang="en-US">Five-year warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_NonExecutiveDirectorsCompensationMember" xlink:label="chek_NonExecutiveDirectorsCompensationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NonExecutiveDirectorsCompensationMember" xlink:to="chek_NonExecutiveDirectorsCompensationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_NonExecutiveDirectorsCompensationMember_lbl" xml:lang="en-US">Compensation to the Non-Executive Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralTransactionsMember" xlink:label="chek_GeneralTransactionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralTransactionsMember" xlink:to="chek_GeneralTransactionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GeneralTransactionsMember_lbl" xml:lang="en-US">Transactions with Related Parties [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="currency_EUR" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_EUR" xlink:to="currency_EUR_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_EUR_lbl" xml:lang="en-US">Euro [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Other Comprehensive Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Fair Value By Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreFundedUnitsMember" xlink:label="chek_PreFundedUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PreFundedUnitsMember" xlink:to="chek_PreFundedUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PreFundedUnitsMember_lbl" xml:lang="en-US">Pre funded Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="us-gaap_CommonClassCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassCMember_lbl" xml:lang="en-US">Series C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_TwoThousandFifteenPlanMember" xlink:label="chek_TwoThousandFifteenPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_TwoThousandFifteenPlanMember" xlink:to="chek_TwoThousandFifteenPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_TwoThousandFifteenPlanMember_lbl" xml:lang="en-US">2015 Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CertainEmployeesMember" xlink:label="chek_CertainEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CertainEmployeesMember" xlink:to="chek_CertainEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_CertainEmployeesMember_lbl" xml:lang="en-US">Certain Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreFundedWarrantsOneMember" xlink:label="chek_PreFundedWarrantsOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PreFundedWarrantsOneMember" xlink:to="chek_PreFundedWarrantsOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PreFundedWarrantsOneMember_lbl" xml:lang="en-US">Pre-funded Warrants one [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesCWarrantsMember" xlink:label="chek_SeriesCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesCWarrantsMember" xlink:to="chek_SeriesCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_SeriesCWarrantsMember_lbl" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesDWarrantsMember" xlink:label="chek_SeriesDWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesDWarrantsMember" xlink:to="chek_SeriesDWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_SeriesDWarrantsMember_lbl" xml:lang="en-US">Series D Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DocumentAndEntityInformationAbstract" xlink:label="chek_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DocumentAndEntityInformationAbstract" xlink:to="chek_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Transition period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">EntityVoluntaryFilers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term bank deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Trade</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employees and payroll accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesProvision" xlink:label="chek_RoyaltiesProvision" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesProvision" xlink:to="chek_RoyaltiesProvision_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RoyaltiesProvision_lbl" xml:lang="en-US">Royalties provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before income tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Taxes on income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive loss:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_lbl" xml:lang="en-US">Change in fair value of cash flow hedge</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Loss per share:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per ordinary share (in USD) basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of ordinary shares outstanding - basic and diluted (in thousands)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of preferred shares into ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of preferred shares into ordinary shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Reclassification of liability warrants to equity warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares in May 2018 in the Public Offering, net of issuance expenses in an amount of $2,381</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of ordinary shares in May 2018 in the Public Offering, net of issuance expenses in an amount of $2,381, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement" xlink:to="chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement_lbl" xml:lang="en-US">Issuance of ordinary shares in the Private Placement, net of issuance expenses in an amount of $1,225</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_lbl" xml:lang="en-US">Issuance of ordinary shares in the Private Placement, net of issuance expenses in an amount of $1,225, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" xlink:to="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering_lbl" xml:lang="en-US">Issuance of ordinary shares and pre-funded warrants in August 2016 registered direct offering, net of issuance expenses in an amount of $615</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering_lbl" xml:lang="en-US">Issuance of ordinary shares and pre-funded warrants in August 2016 registered direct offering, net of issuance expenses in an amount of $615, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1" xlink:to="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1_lbl" xml:lang="en-US">Issuance of ordinary shares and warrants in June 2017 registered direct offering, net of issuance expenses in an amount of $399</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1_lbl" xml:lang="en-US">Issuance of ordinary shares and warrants in June 2017 registered direct offering, net of issuance expenses in an amount of $399</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2" xlink:to="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2_lbl" xml:lang="en-US">Issuance of ordinary shares and warrants in November 2017 registered direct offering, net of issuance expenses in an amount of $378</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2_lbl" xml:lang="en-US">Issuance of ordinary shares and warrants in November 2017 registered direct offering, net of issuance expenses in an amount of $378</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="chek_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="chek_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants into ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="chek_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="chek_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants into ordinary shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" xlink:to="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xml:lang="en-US">Share-based compensation, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Capital investment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent_2_lbl" xml:lang="en-US">Change in fair values of cash flow hedge</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Issuance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US">Value or warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Pre-funded warrants to purchase ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Pre-funded warrants to purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Financial Expenses (income), net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities items:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Decrease (increase) in prepaid and other current assets and non-current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in trade accounts payable, accruals and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in employees and payroll accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:to="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRoyaltiesPayable_lbl" xml:lang="en-US">Decrease in royalties provision</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="us-gaap_PaymentsForProceedsFromInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_lbl" xml:lang="en-US">Proceeds from (Investment in) short-term bank deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants into ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ProceedsFromIssuanceResisteredDirectOffering" xlink:label="chek_ProceedsFromIssuanceResisteredDirectOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ProceedsFromIssuanceResisteredDirectOffering" xlink:to="chek_ProceedsFromIssuanceResisteredDirectOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ProceedsFromIssuanceResisteredDirectOffering_lbl" xml:lang="en-US">Issuance of ordinary shares in the RD Offerings, net of issuance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Issuance of ordinary shares in the 2018 Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental information for Cash Flow:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash flow information</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantLiabilityReclassificationToEquity" xlink:label="chek_WarrantLiabilityReclassificationToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantLiabilityReclassificationToEquity" xlink:to="chek_WarrantLiabilityReclassificationToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_WarrantLiabilityReclassificationToEquity_lbl" xml:lang="en-US">Reclassification of liability warrants to equity warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsCashlessExercise" xlink:label="chek_WarrantsCashlessExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantsCashlessExercise" xlink:to="chek_WarrantsCashlessExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_WarrantsCashlessExercise_lbl" xml:lang="en-US">Cashless exercise of warrants to purchase ordinary shares into ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of preferred shares into ordinary shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US">Issuance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL INFORMATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="us-gaap_ShortTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">SHORT TERM LOANS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Employee-related Liabilities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_EmployeeRelatedLiabilitiesTextBlock" xlink:label="chek_EmployeeRelatedLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EmployeeRelatedLiabilitiesTextBlock" xlink:to="chek_EmployeeRelatedLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_EmployeeRelatedLiabilitiesTextBlock_lbl" xml:lang="en-US">EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xml:lang="en-US">Research and Development [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseAbstract_lbl" xml:lang="en-US">General and Administrative Expense [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralAndAdministrativeExpensesTextBlock" xlink:label="chek_GeneralAndAdministrativeExpensesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralAndAdministrativeExpensesTextBlock" xlink:to="chek_GeneralAndAdministrativeExpensesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_GeneralAndAdministrativeExpensesTextBlock_lbl" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:to="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock_lbl" xml:lang="en-US">FINANCE INCOME (EXPENSES), NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates in Preparation of Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Financial statements in U.S dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US">Short-term bank deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:to="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_lbl" xml:lang="en-US">Cash flow hedges</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of credit risks</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Contingent liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value of financial instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsPolicyTextBlock" xlink:label="chek_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantsPolicyTextBlock" xlink:to="chek_WarrantsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_WarrantsPolicyTextBlock_lbl" xml:lang="en-US">Warrants to purchase preferred shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock" xlink:label="chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock" xlink:to="chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Depreciation Inputs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:label="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:to="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Employee Benefits and Payroll Accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTableTextBlock" xlink:label="us-gaap_OtherCommitmentsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTableTextBlock" xlink:to="us-gaap_OtherCommitmentsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Reimbursement Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US">Series D Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Changes in Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Summary of Fair Value Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityTableTextBlock_lbl" xml:lang="en-US">Summary of Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">Summary of Ordinary Share Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US">Summary of Awards Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock" xlink:label="chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock" xlink:to="chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Parameters Used in Valuing Fair Value of Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfResearchAndDevelopmentExpensesNet" xlink:label="chek_ScheduleOfResearchAndDevelopmentExpensesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfResearchAndDevelopmentExpensesNet" xlink:to="chek_ScheduleOfResearchAndDevelopmentExpensesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfResearchAndDevelopmentExpensesNet_lbl" xml:lang="en-US">Schedule of Research and Development Expenses, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock" xlink:label="chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock" xlink:to="chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock_lbl" xml:lang="en-US">Schedule of General and Administrative Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of Finance Income (Expense), Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Anti-Dilutive Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_2_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Reverse stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="us-gaap_DerivativeAssetNotionalAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssetNotionalAmount" xlink:to="us-gaap_DerivativeAssetNotionalAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAssetNotionalAmount_lbl" xml:lang="en-US">Notional amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" xlink:label="us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" xlink:to="us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments_lbl" xml:lang="en-US">Loss incurred</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DerivativeFairValueOfOptionOutstanding" xlink:label="chek_DerivativeFairValueOfOptionOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DerivativeFairValueOfOptionOutstanding" xlink:to="chek_DerivativeFairValueOfOptionOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DerivativeFairValueOfOptionOutstanding_lbl" xml:lang="en-US">Fair value of option outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DerivativeChangeInFairValueOfOptionOutstanding" xlink:label="chek_DerivativeChangeInFairValueOfOptionOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DerivativeChangeInFairValueOfOptionOutstanding" xlink:to="chek_DerivativeChangeInFairValueOfOptionOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_DerivativeChangeInFairValueOfOptionOutstanding_lbl" xml:lang="en-US">Change in fair value of option outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AccountingPoliciesTable" xlink:label="chek_AccountingPoliciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AccountingPoliciesTable" xlink:to="chek_AccountingPoliciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_AccountingPoliciesTable_lbl" xml:lang="en-US">Accounting Policies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AccountingPoliciesLineItems" xlink:label="chek_AccountingPoliciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AccountingPoliciesLineItems" xlink:to="chek_AccountingPoliciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_AccountingPoliciesLineItems_lbl" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShortTermInvestmentInterestRate" xlink:label="chek_ShortTermInvestmentInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShortTermInvestmentInterestRate" xlink:to="chek_ShortTermInvestmentInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShortTermInvestmentInterestRate_lbl" xml:lang="en-US">Short-term bank deposit, interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Length of useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:to="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage_lbl" xml:lang="en-US">Depreciation rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and Cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashCurrent_2_lbl" xml:lang="en-US">Restricted cash included current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GovernmentInstitutionalAssetsCurrent" xlink:label="chek_GovernmentInstitutionalAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GovernmentInstitutionalAssetsCurrent" xlink:to="chek_GovernmentInstitutionalAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GovernmentInstitutionalAssetsCurrent_lbl" xml:lang="en-US">Government institutions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_2_lbl" xml:lang="en-US">Depreciation expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisposals_lbl" xml:lang="en-US">Disposals amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Benefits for vacation and recreation pay</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Liability for payroll, bonuses and wages</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Employee benefits and payroll accruals</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Company [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_2_lbl" xml:lang="en-US">INCOME TAXES [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Carry forward tax losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FutureFederalIncomeTaxRateNextYear" xlink:label="chek_FutureFederalIncomeTaxRateNextYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FutureFederalIncomeTaxRateNextYear" xlink:to="chek_FutureFederalIncomeTaxRateNextYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_FutureFederalIncomeTaxRateNextYear_lbl" xml:lang="en-US">Tax rate in 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FutureFederalIncomeTaxRate" xlink:label="chek_FutureFederalIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FutureFederalIncomeTaxRate" xlink:to="chek_FutureFederalIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_FutureFederalIncomeTaxRate_lbl" xml:lang="en-US">Tax rate in 2018 and thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ForeignIncomeTaxRateMaximum" xlink:label="chek_ForeignIncomeTaxRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ForeignIncomeTaxRateMaximum" xlink:to="chek_ForeignIncomeTaxRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ForeignIncomeTaxRateMaximum_lbl" xml:lang="en-US">Foreign maximum tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ReductionInIncomeTaxRate" xlink:label="chek_ReductionInIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReductionInIncomeTaxRate" xlink:to="chek_ReductionInIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ReductionInIncomeTaxRate_lbl" xml:lang="en-US">Reduction in income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CommitmentsAndContingenciesTable" xlink:label="chek_CommitmentsAndContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CommitmentsAndContingenciesTable" xlink:to="chek_CommitmentsAndContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CommitmentsAndContingenciesLineItems" xlink:label="chek_CommitmentsAndContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CommitmentsAndContingenciesLineItems" xlink:to="chek_CommitmentsAndContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xml:lang="en-US">Leases:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US">Future payments:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OperatingLeaseRentExpenseMonthly" xlink:label="chek_OperatingLeaseRentExpenseMonthly" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OperatingLeaseRentExpenseMonthly" xlink:to="chek_OperatingLeaseRentExpenseMonthly_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_OperatingLeaseRentExpenseMonthly_lbl" xml:lang="en-US">Monthly lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Operating lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="us-gaap_OtherCommitmentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAbstract_lbl" xml:lang="en-US">Royalties:</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesPayablePerUnit" xlink:label="chek_RoyaltiesPayablePerUnit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesPayablePerUnit" xlink:to="chek_RoyaltiesPayablePerUnit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RoyaltiesPayablePerUnit_lbl" xml:lang="en-US">Royalties payable per unit sold</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesPayablePerUnitSold" xlink:label="chek_RoyaltiesPayablePerUnitSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesPayablePerUnitSold" xlink:to="chek_RoyaltiesPayablePerUnitSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_RoyaltiesPayablePerUnitSold_lbl" xml:lang="en-US">Royalties payable per unit sold</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MaximumRoyaltyObligation" xlink:label="chek_MaximumRoyaltyObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MaximumRoyaltyObligation" xlink:to="chek_MaximumRoyaltyObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_MaximumRoyaltyObligation_lbl" xml:lang="en-US">Maximum royalties payable</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantedRevenue" xlink:label="chek_GrantedRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantedRevenue" xlink:to="chek_GrantedRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantedRevenue_lbl" xml:lang="en-US">Funding</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesPayablePercentageOfProductSales" xlink:label="chek_RoyaltiesPayablePercentageOfProductSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesPayablePercentageOfProductSales" xlink:to="chek_RoyaltiesPayablePercentageOfProductSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RoyaltiesPayablePercentageOfProductSales_lbl" xml:lang="en-US">Royalty repayment, percentage of products sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Contingent liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="us-gaap_OtherCommitmentsDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Description</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RefundExpenses" xlink:label="chek_RefundExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RefundExpenses" xlink:to="chek_RefundExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RefundExpenses_lbl" xml:lang="en-US">Refund expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_2_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_2_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Money market funds</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Foreign currency derivative instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="us-gaap_FairValueNetAssetLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total financial assets (Liabilities)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_2_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FindersWarrantsMember" xlink:label="chek_FindersWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FindersWarrantsMember" xlink:to="chek_FindersWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_FindersWarrantsMember_lbl" xml:lang="en-US">Finders Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareCapital" xlink:label="chek_ShareCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareCapital" xlink:to="chek_ShareCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="chek_ShareCapital_lbl" xml:lang="en-US">Share capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of ordinary share upon exercise of stock options by employees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="us-gaap_StockholdersEquityPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:to="us-gaap_StockholdersEquityPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityPeriodIncreaseDecrease_lbl" xml:lang="en-US">Amount raised, gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareCapital" xlink:to="chek_ShareCapital_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="chek_ShareCapital_2_lbl" xml:lang="en-US">Subtotal</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareCapitalLessIssuanceCosts" xlink:label="chek_ShareCapitalLessIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareCapitalLessIssuanceCosts" xlink:to="chek_ShareCapitalLessIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="chek_ShareCapitalLessIssuanceCosts_lbl" xml:lang="en-US">Share capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="chek_StockIssuedDuringPeriodSharesWarrantsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_StockIssuedDuringPeriodSharesWarrantsExercised_2_lbl" xml:lang="en-US">Exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_2_lbl" xml:lang="en-US">Issuance of ordinary shares in the Private Placement, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Issuance of ordinary shares in the IPO, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Conversion of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsIssuedNumber" xlink:label="chek_WarrantsIssuedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantsIssuedNumber" xlink:to="chek_WarrantsIssuedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_WarrantsIssuedNumber_lbl" xml:lang="en-US">Warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Shares called by warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PricePerUnit" xlink:label="chek_PricePerUnit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PricePerUnit" xlink:to="chek_PricePerUnit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PricePerUnit_lbl" xml:lang="en-US">Price per unit</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_UnitsPurchased" xlink:label="chek_UnitsPurchased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_UnitsPurchased" xlink:to="chek_UnitsPurchased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_UnitsPurchased_lbl" xml:lang="en-US">Number of units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ClassOfWarrantOrRightExpiration" xlink:label="chek_ClassOfWarrantOrRightExpiration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ClassOfWarrantOrRightExpiration" xlink:to="chek_ClassOfWarrantOrRightExpiration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ClassOfWarrantOrRightExpiration_lbl" xml:lang="en-US">Expiration of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Issuance of ordinary shares in IPO, net of issuance expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Issuance of ordinary shares in the Private Placement, net of issuance expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsExercisedCashlessBasis" xlink:label="chek_WarrantsExercisedCashlessBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantsExercisedCashlessBasis" xlink:to="chek_WarrantsExercisedCashlessBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_WarrantsExercisedCashlessBasis_lbl" xml:lang="en-US">Warrants exercised on a cashless basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrant outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" xlink:to="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering_2_lbl" xml:lang="en-US">Issuance of ordinary Shares in RD Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US">Expiry date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds warrant from the registered direct offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds warrant from the exercise pre-funded warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RevenueFromCashCommission" xlink:label="chek_RevenueFromCashCommission" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RevenueFromCashCommission" xlink:to="chek_RevenueFromCashCommission_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RevenueFromCashCommission_lbl" xml:lang="en-US">Cash commission</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value of options on grant date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Fair value of warrants on grant date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Compensation cost not yet recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Period for recognizing compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Increase in shares available for grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Options expiring during period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">RSU's expiring during period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">No. of options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_2_lbl" xml:lang="en-US">Expiration date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Fair value on grant date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_lbl" xml:lang="en-US">Share based expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2_lbl" xml:lang="en-US">Vesting terms</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US">Black-Scholes-Merton option-pricing model assumptions:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Expected volatility, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Expected volatility, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Number of options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Outstanding at the beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:to="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesRestrictedStock_lbl" xml:lang="en-US">RSUs granted</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_NumberOfSharesRestrictedStockVested" xlink:label="chek_NumberOfSharesRestrictedStockVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NumberOfSharesRestrictedStockVested" xlink:to="chek_NumberOfSharesRestrictedStockVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_NumberOfSharesRestrictedStockVested_lbl" xml:lang="en-US">RSUs vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_lbl" xml:lang="en-US">RSUs forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Outstanding at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Exercisable at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted average of exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Outstanding at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and expected to vest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercisable at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Outstanding at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree" xlink:label="chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree" xlink:to="chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree_lbl" xml:lang="en-US">Outstanding at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Exercisable at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Outstanding at the beginning of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Outstanding at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Exercisable at the end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ResearchAndDevelopmentExpensesTable" xlink:label="chek_ResearchAndDevelopmentExpensesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ResearchAndDevelopmentExpensesTable" xlink:to="chek_ResearchAndDevelopmentExpensesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ResearchAndDevelopmentExpensesTable_lbl" xml:lang="en-US">Research and Development Expenses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ResearchAndDevelopmentExpensesLineItems" xlink:label="chek_ResearchAndDevelopmentExpensesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ResearchAndDevelopmentExpensesLineItems" xlink:to="chek_ResearchAndDevelopmentExpensesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ResearchAndDevelopmentExpensesLineItems_lbl" xml:lang="en-US">Research and Development Expenses [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Salaries and related expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense" xlink:label="us-gaap_SuppliesExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SuppliesExpense" xlink:to="us-gaap_SuppliesExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SuppliesExpense_lbl" xml:lang="en-US">Materials</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SubcontractorsAndConsultantFees" xlink:label="chek_SubcontractorsAndConsultantFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SubcontractorsAndConsultantFees" xlink:to="chek_SubcontractorsAndConsultantFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_SubcontractorsAndConsultantFees_lbl" xml:lang="en-US">Subcontractors and consultants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationNonproduction_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Cost for registration of patents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="us-gaap_OtherCostAndExpenseOperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCostAndExpenseOperating_lbl" xml:lang="en-US">Others</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ResearchAndDevelopmentExpenseGross" xlink:label="chek_ResearchAndDevelopmentExpenseGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ResearchAndDevelopmentExpenseGross" xlink:to="chek_ResearchAndDevelopmentExpenseGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="chek_ResearchAndDevelopmentExpenseGross_lbl" xml:lang="en-US">Research and development</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantedRevenue" xlink:to="chek_GrantedRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="chek_GrantedRevenue_2_lbl" xml:lang="en-US">Less participation of the NATI and BIRD Foundation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Total research and development, net</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralAndAdministrativeExpensesTable" xlink:label="chek_GeneralAndAdministrativeExpensesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralAndAdministrativeExpensesTable" xlink:to="chek_GeneralAndAdministrativeExpensesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GeneralAndAdministrativeExpensesTable_lbl" xml:lang="en-US">General and Administrative Expenses [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralAndAdministrativeExpensesLineItems" xlink:label="chek_GeneralAndAdministrativeExpensesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralAndAdministrativeExpensesLineItems" xlink:to="chek_GeneralAndAdministrativeExpensesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GeneralAndAdministrativeExpensesLineItems_lbl" xml:lang="en-US">General and Administrative Expenses [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Share-based compensation, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Office rent and maintenance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Total general and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income on short-term deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Bank fees and Interest expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltyIncomeExpenseNonoperating" xlink:label="chek_RoyaltyIncomeExpenseNonoperating" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltyIncomeExpenseNonoperating" xlink:to="chek_RoyaltyIncomeExpenseNonoperating_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RoyaltyIncomeExpenseNonoperating_lbl" xml:lang="en-US">Changes in provision for royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Exchange rate differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Changes in derivatives fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Revaluation of fair value of warrants to purchase preferred share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Total financing income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xml:lang="en-US">Basic and diluted net loss per ordinary share:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US">Preferred shares dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to ordinary shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Shares used in computing net loss per ordinary share, basic and diluted (in thousands)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Net loss per ordinary share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreferredSharesMember" xlink:label="chek_PreferredSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PreferredSharesMember" xlink:to="chek_PreferredSharesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PreferredSharesMember_lbl" xml:lang="en-US">Preferred Shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Transactions with related parties</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MonthlyRetainer" xlink:label="chek_MonthlyRetainer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MonthlyRetainer" xlink:to="chek_MonthlyRetainer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_MonthlyRetainer_lbl" xml:lang="en-US">Monthly retainer</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_HourlyFeeUpToFiveHours" xlink:label="chek_HourlyFeeUpToFiveHours" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_HourlyFeeUpToFiveHours" xlink:to="chek_HourlyFeeUpToFiveHours_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_HourlyFeeUpToFiveHours_lbl" xml:lang="en-US">Hourly fee, up to five hours per month</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_HourlyFeeExceedingFiveHours" xlink:label="chek_HourlyFeeExceedingFiveHours" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_HourlyFeeExceedingFiveHours" xlink:to="chek_HourlyFeeExceedingFiveHours_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_HourlyFeeExceedingFiveHours_lbl" xml:lang="en-US">Hourly fee, exceeding five hours per month</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_KeyManInsurancePolicy" xlink:label="chek_KeyManInsurancePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_KeyManInsurancePolicy" xlink:to="chek_KeyManInsurancePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_KeyManInsurancePolicy_lbl" xml:lang="en-US">Key man insurance policy</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MonthlySalary" xlink:label="chek_MonthlySalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MonthlySalary" xlink:to="chek_MonthlySalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_MonthlySalary_lbl" xml:lang="en-US">Monthly Salary</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrossOvertimeMonthlyRate" xlink:label="chek_GrossOvertimeMonthlyRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrossOvertimeMonthlyRate" xlink:to="chek_GrossOvertimeMonthlyRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrossOvertimeMonthlyRate_lbl" xml:lang="en-US">Gross Overtime monthly rate</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MaximumAggregateMonthlySalary" xlink:label="chek_MaximumAggregateMonthlySalary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MaximumAggregateMonthlySalary" xlink:to="chek_MaximumAggregateMonthlySalary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_MaximumAggregateMonthlySalary_lbl" xml:lang="en-US">Maximum aggregate monthly salary</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AccountingPoliciesLineItems" xlink:to="chek_AccountingPoliciesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_AccountingPoliciesLineItems_doc" xml:lang="en-US">Accounting Policies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AccountingPoliciesTable" xlink:to="chek_AccountingPoliciesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_AccountingPoliciesTable_doc" xml:lang="en-US">Accounting Policies [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" xlink:to="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_doc" xml:lang="en-US">Share of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AntiDilutiveWarrantsMember" xlink:to="chek_AntiDilutiveWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_AntiDilutiveWarrantsMember_doc" xml:lang="en-US">Anti-dilutive Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AprilSixthMember" xlink:to="chek_AprilSixthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_AprilSixthMember_doc" xml:lang="en-US">April 6 [2015]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AugustThirteenthOneMember" xlink:label="chek_AugustThirteenthOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AugustThirteenthOneMember" xlink:to="chek_AugustThirteenthOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_AugustThirteenthOneMember_doc" xml:lang="en-US">August 13, Issuance One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AugustThirteenthTwoMember" xlink:label="chek_AugustThirteenthTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AugustThirteenthTwoMember" xlink:to="chek_AugustThirteenthTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_AugustThirteenthTwoMember_doc" xml:lang="en-US">August 13, Issuance Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_BankLeumiCreditFacilityMember" xlink:label="chek_BankLeumiCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_BankLeumiCreditFacilityMember" xlink:to="chek_BankLeumiCreditFacilityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_BankLeumiCreditFacilityMember_doc" xml:lang="en-US">Credit line agreement with Bank Leumi [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:to="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_BinationalIndustrialResearchAndDevelopmentFoundationMember_doc" xml:lang="en-US">Israel-United States Binational Industrial Research and Development Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_C1WarrantsMember" xlink:label="chek_C1WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_C1WarrantsMember" xlink:to="chek_C1WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_C1WarrantsMember_doc" xml:lang="en-US">Warrants to purchase Series C1 convertible preferred shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_C2WarrantsMember" xlink:label="chek_C2WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_C2WarrantsMember" xlink:to="chek_C2WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_C2WarrantsMember_doc" xml:lang="en-US">Warrants convertible into Series C2 convertible preferred shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CertainEmployeesMember" xlink:to="chek_CertainEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_CertainEmployeesMember_doc" xml:lang="en-US">Certain Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ClassOfWarrantOrRightExpiration" xlink:to="chek_ClassOfWarrantOrRightExpiration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ClassOfWarrantOrRightExpiration_doc" xml:lang="en-US">Number of warrants or rights expired during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CommitmentsAndContingenciesLineItems" xlink:to="chek_CommitmentsAndContingenciesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_CommitmentsAndContingenciesLineItems_doc" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CommitmentsAndContingenciesTable" xlink:to="chek_CommitmentsAndContingenciesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_CommitmentsAndContingenciesTable_doc" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ConsultingFeesMember" xlink:to="chek_ConsultingFeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ConsultingFeesMember_doc" xml:lang="en-US">Consulting fees, including share based compensation and reimbursement of expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CounterpointVenturesFundTwoMember" xlink:label="chek_CounterpointVenturesFundTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CounterpointVenturesFundTwoMember" xlink:to="chek_CounterpointVenturesFundTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_CounterpointVenturesFundTwoMember_doc" xml:lang="en-US">Counterpoint Ventures Fund II LP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_CreditLineAgreementWarrantsMember" xlink:to="chek_CreditLineAgreementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_CreditLineAgreementWarrantsMember_doc" xml:lang="en-US">CLA Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DesignerRoyaltiesMember" xlink:to="chek_DesignerRoyaltiesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_DesignerRoyaltiesMember_doc" xml:lang="en-US">Royalties to an ASIC designer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DevelopmentAreaAMember" xlink:to="chek_DevelopmentAreaAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_DevelopmentAreaAMember_doc" xml:lang="en-US">Development Area A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DocorInternationalBVMember" xlink:label="chek_DocorInternationalBVMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DocorInternationalBVMember" xlink:to="chek_DocorInternationalBVMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_DocorInternationalBVMember_doc" xml:lang="en-US">Docor International B.V. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EmployeeRelatedLiabilitiesTextBlock" xlink:to="chek_EmployeeRelatedLiabilitiesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_EmployeeRelatedLiabilitiesTextBlock_doc" xml:lang="en-US">Disclosure for employee related liabilities.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_EscoVenturesPteLtdMember" xlink:label="chek_EscoVenturesPteLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_EscoVenturesPteLtdMember" xlink:to="chek_EscoVenturesPteLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_EscoVenturesPteLtdMember_doc" xml:lang="en-US">Esco Ventures Pte Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FebruaryEighteenthMember" xlink:label="chek_FebruaryEighteenthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FebruaryEighteenthMember" xlink:to="chek_FebruaryEighteenthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FebruaryEighteenthMember_doc" xml:lang="en-US">February 18 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FebruaryTwentyFourthOneMember" xlink:label="chek_FebruaryTwentyFourthOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FebruaryTwentyFourthOneMember" xlink:to="chek_FebruaryTwentyFourthOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FebruaryTwentyFourthOneMember_doc" xml:lang="en-US">February 24, Issuance One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FebruaryTwentyFourthTwoMember" xlink:label="chek_FebruaryTwentyFourthTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FebruaryTwentyFourthTwoMember" xlink:to="chek_FebruaryTwentyFourthTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FebruaryTwentyFourthTwoMember_doc" xml:lang="en-US">February 24, Issuance Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FeesAndReimbursementMember" xlink:to="chek_FeesAndReimbursementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FeesAndReimbursementMember_doc" xml:lang="en-US">Fees, including reimbursement of expenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FindersWarrantsMember" xlink:to="chek_FindersWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FindersWarrantsMember_doc" xml:lang="en-US">Finders Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FirstMarchMember" xlink:label="chek_FirstMarchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FirstMarchMember" xlink:to="chek_FirstMarchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FirstMarchMember_doc" xml:lang="en-US">First March [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FiveYearWarrantsMember" xlink:to="chek_FiveYearWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FiveYearWarrantsMember_doc" xml:lang="en-US">Five-year warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ForeignIncomeTaxRateMaximum" xlink:to="chek_ForeignIncomeTaxRateMaximum_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ForeignIncomeTaxRateMaximum_doc" xml:lang="en-US">Highest income tax rate applicable to foreign jurisdiction.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FourAugustMember" xlink:label="chek_FourAugustMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FourAugustMember" xlink:to="chek_FourAugustMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FourAugustMember_doc" xml:lang="en-US">Four August [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FourMayMember" xlink:label="chek_FourMayMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FourMayMember" xlink:to="chek_FourMayMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FourMayMember_doc" xml:lang="en-US">Four May [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FutureFederalIncomeTaxRate" xlink:to="chek_FutureFederalIncomeTaxRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FutureFederalIncomeTaxRate_doc" xml:lang="en-US">Tax rate to be applied in the next taxable year and thereafter.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_FutureFederalIncomeTaxRateNextYear" xlink:to="chek_FutureFederalIncomeTaxRateNextYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_FutureFederalIncomeTaxRateNextYear_doc" xml:lang="en-US">Tax rate to be applied in the next taxable year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralAndAdministrativeExpensesLineItems" xlink:to="chek_GeneralAndAdministrativeExpensesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GeneralAndAdministrativeExpensesLineItems_doc" xml:lang="en-US">General and Administrative Expenses [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralAndAdministrativeExpensesTable" xlink:to="chek_GeneralAndAdministrativeExpensesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GeneralAndAdministrativeExpensesTable_doc" xml:lang="en-US">General and Administrative Expenses [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralAndAdministrativeExpensesTextBlock" xlink:to="chek_GeneralAndAdministrativeExpensesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GeneralAndAdministrativeExpensesTextBlock_doc" xml:lang="en-US">Disclosure for general and administrative expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralTransactionsMember" xlink:to="chek_GeneralTransactionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GeneralTransactionsMember_doc" xml:lang="en-US">General Transactions [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GovernmentInstitutionalAssetsCurrent" xlink:to="chek_GovernmentInstitutionalAssetsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GovernmentInstitutionalAssetsCurrent_doc" xml:lang="en-US">Current assets related to government institutions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate10Member" xlink:to="chek_GrantDate10Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate10Member_doc" xml:lang="en-US">May 4, 2016 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate11Member" xlink:to="chek_GrantDate11Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate11Member_doc" xml:lang="en-US">August 4, 2016 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate12Member" xlink:label="chek_GrantDate12Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate12Member" xlink:to="chek_GrantDate12Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate12Member_doc" xml:lang="en-US">October 31, 2016 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate13Member" xlink:to="chek_GrantDate13Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate13Member_doc" xml:lang="en-US">February 27, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate14Member" xlink:label="chek_GrantDate14Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate14Member" xlink:to="chek_GrantDate14Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate14Member_doc" xml:lang="en-US">May 9, 2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate15Member" xlink:to="chek_GrantDate15Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate15Member_doc" xml:lang="en-US">June 22, 2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate16Member" xlink:to="chek_GrantDate16Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate16Member_doc" xml:lang="en-US">August 3, 2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate17Member" xlink:to="chek_GrantDate17Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate17Member_doc" xml:lang="en-US">November 2, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate18Member" xlink:label="chek_GrantDate18Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate18Member" xlink:to="chek_GrantDate18Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate18Member_doc" xml:lang="en-US">February 18, 2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate1Member" xlink:to="chek_GrantDate1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate1Member_doc" xml:lang="en-US">February 24, 2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate2Member" xlink:to="chek_GrantDate2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate2Member_doc" xml:lang="en-US">March 15, 2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate3Member" xlink:to="chek_GrantDate3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate3Member_doc" xml:lang="en-US">May 19, 2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate4Member" xlink:to="chek_GrantDate4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate4Member_doc" xml:lang="en-US">June 1, 2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate5Member" xlink:to="chek_GrantDate5Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate5Member_doc" xml:lang="en-US">August 13, 2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate6Member" xlink:to="chek_GrantDate6Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate6Member_doc" xml:lang="en-US">August 13, 2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate7Member" xlink:to="chek_GrantDate7Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate7Member_doc" xml:lang="en-US">August 13, 2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate8Member" xlink:to="chek_GrantDate8Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate8Member_doc" xml:lang="en-US">October 20, 2015 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate9Member" xlink:to="chek_GrantDate9Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantDate9Member_doc" xml:lang="en-US">February 29, 2016 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrossOvertimeMonthlyRate" xlink:to="chek_GrossOvertimeMonthlyRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrossOvertimeMonthlyRate_doc" xml:lang="en-US">Gross Overtime monthly rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_HourlyFeeExceedingFiveHours" xlink:to="chek_HourlyFeeExceedingFiveHours_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_HourlyFeeExceedingFiveHours_doc" xml:lang="en-US">Hourly fee paid for services exceeding five hours per month.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_HourlyFeeUpToFiveHours" xlink:to="chek_HourlyFeeUpToFiveHours_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_HourlyFeeUpToFiveHours_doc" xml:lang="en-US">Hourly fee paid monthly for up to five hours per month.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_InvestorWarrantsMember" xlink:label="chek_InvestorWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_InvestorWarrantsMember" xlink:to="chek_InvestorWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_InvestorWarrantsMember_doc" xml:lang="en-US">Investor Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_JanuaryFifteenthMember" xlink:to="chek_JanuaryFifteenthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_JanuaryFifteenthMember_doc" xml:lang="en-US">January 15 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_JuneFirstMember" xlink:label="chek_JuneFirstMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_JuneFirstMember" xlink:to="chek_JuneFirstMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_JuneFirstMember_doc" xml:lang="en-US">June 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_JuneSixthMember" xlink:label="chek_JuneSixthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_JuneSixthMember" xlink:to="chek_JuneSixthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_JuneSixthMember_doc" xml:lang="en-US">June 6 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_JuneThirdMember" xlink:label="chek_JuneThirdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_JuneThirdMember" xlink:to="chek_JuneThirdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_JuneThirdMember_doc" xml:lang="en-US">June 3 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_KeyManInsurancePolicy" xlink:to="chek_KeyManInsurancePolicy_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_KeyManInsurancePolicy_doc" xml:lang="en-US">Amount of key man insurance policy held.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_KeyManLifeInsurancePremiumMember" xlink:to="chek_KeyManLifeInsurancePremiumMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_KeyManLifeInsurancePremiumMember_doc" xml:lang="en-US">Key man life insurance premium</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LegalWarrantsMember" xlink:to="chek_LegalWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_LegalWarrantsMember_doc" xml:lang="en-US">Legal Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_LongTermIncentiveWarrantsMember" xlink:to="chek_LongTermIncentiveWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_LongTermIncentiveWarrantsMember_doc" xml:lang="en-US">Long Term Incentive Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MarchFifteenthMember" xlink:label="chek_MarchFifteenthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MarchFifteenthMember" xlink:to="chek_MarchFifteenthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_MarchFifteenthMember_doc" xml:lang="en-US">March 15 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MaximumAggregateMonthlySalary" xlink:to="chek_MaximumAggregateMonthlySalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_MaximumAggregateMonthlySalary_doc" xml:lang="en-US">Maximum aggregate monthly salary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MaximumRoyaltyObligation" xlink:to="chek_MaximumRoyaltyObligation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_MaximumRoyaltyObligation_doc" xml:lang="en-US">Maximum amount payable for royalties.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MayFifteenthMember" xlink:label="chek_MayFifteenthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MayFifteenthMember" xlink:to="chek_MayFifteenthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_MayFifteenthMember_doc" xml:lang="en-US">May 15 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MayNineteenthMember" xlink:label="chek_MayNineteenthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MayNineteenthMember" xlink:to="chek_MayNineteenthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_MayNineteenthMember_doc" xml:lang="en-US">May 19 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MonthlyRetainer" xlink:to="chek_MonthlyRetainer_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_MonthlyRetainer_doc" xml:lang="en-US">Amount of monthly retainer for services performed.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_MonthlySalary" xlink:to="chek_MonthlySalary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_MonthlySalary_doc" xml:lang="en-US">Monthly Salary.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_NineMayMember" xlink:label="chek_NineMayMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NineMayMember" xlink:to="chek_NineMayMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_NineMayMember_doc" xml:lang="en-US">May 9 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NonExecutiveDirectorsCompensationMember" xlink:to="chek_NonExecutiveDirectorsCompensationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_NonExecutiveDirectorsCompensationMember_doc" xml:lang="en-US">Non-Executive Directors Compensation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NonExecutiveDirectorsMember" xlink:to="chek_NonExecutiveDirectorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_NonExecutiveDirectorsMember_doc" xml:lang="en-US">Non-executive Directors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_NumberOfSharesRestrictedStockVested" xlink:to="chek_NumberOfSharesRestrictedStockVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_NumberOfSharesRestrictedStockVested_doc" xml:lang="en-US">Restricted stock unit vested.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OctoberFourteenthMember" xlink:label="chek_OctoberFourteenthMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OctoberFourteenthMember" xlink:to="chek_OctoberFourteenthMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_OctoberFourteenthMember_doc" xml:lang="en-US">October 14 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OctoberTwentiethMember" xlink:label="chek_OctoberTwentiethMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OctoberTwentiethMember" xlink:to="chek_OctoberTwentiethMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_OctoberTwentiethMember_doc" xml:lang="en-US">October 20 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OfficeOfTheChiefScientistMember" xlink:to="chek_OfficeOfTheChiefScientistMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_OfficeOfTheChiefScientistMember_doc" xml:lang="en-US">Office of the Chief Scientist of Israel's Ministry of Industry, Trade and Labor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OneYearWarrantsMember" xlink:to="chek_OneYearWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_OneYearWarrantsMember_doc" xml:lang="en-US">One-year warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OperatingLeaseRentExpenseMonthly" xlink:to="chek_OperatingLeaseRentExpenseMonthly_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_OperatingLeaseRentExpenseMonthly_doc" xml:lang="en-US">Monthly rent expense for operating leased assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_OrdinarySharesMember" xlink:to="chek_OrdinarySharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_OrdinarySharesMember_doc" xml:lang="en-US">Ordinary shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PontifaxFundsMember" xlink:label="chek_PontifaxFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PontifaxFundsMember" xlink:to="chek_PontifaxFundsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PontifaxFundsMember_doc" xml:lang="en-US">Pontifax Funds [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PreFundedWarrantsMember" xlink:to="chek_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PreFundedWarrantsMember_doc" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PredecessorUnitHoldersMember" xlink:to="chek_PredecessorUnitHoldersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PredecessorUnitHoldersMember_doc" xml:lang="en-US">Predecessor Entity's Unit Holders [Member[</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreferredShareWarrantsConversionMember" xlink:label="chek_PreferredShareWarrantsConversionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PreferredShareWarrantsConversionMember" xlink:to="chek_PreferredShareWarrantsConversionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PreferredShareWarrantsConversionMember_doc" xml:lang="en-US">Conversion of preferred share warrants to ordinary share warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreferredSharesConversionMember" xlink:label="chek_PreferredSharesConversionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PreferredSharesConversionMember" xlink:to="chek_PreferredSharesConversionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PreferredSharesConversionMember_doc" xml:lang="en-US">Preferred shares converted to ordinary shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PreferredSharesMember" xlink:to="chek_PreferredSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PreferredSharesMember_doc" xml:lang="en-US">Preferred Shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock_doc" xml:lang="en-US">Disclosure for prepaid expenses and other current assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PricePerUnit" xlink:to="chek_PricePerUnit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PricePerUnit_doc" xml:lang="en-US">Price per unit sold.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ProceedsFromIssuanceResisteredDirectOffering" xlink:to="chek_ProceedsFromIssuanceResisteredDirectOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ProceedsFromIssuanceResisteredDirectOffering_doc" xml:lang="en-US">Proceed from Issuance of ordinary shares in the RD Offering, net of issuance expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ReductionInIncomeTaxRate" xlink:to="chek_ReductionInIncomeTaxRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ReductionInIncomeTaxRate_doc" xml:lang="en-US">Reduction In Income Tax Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RefundExpenses" xlink:to="chek_RefundExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RefundExpenses_doc" xml:lang="en-US">Refund expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RegisteredDirectOfferingMember" xlink:to="chek_RegisteredDirectOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RegisteredDirectOfferingMember_doc" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ResearchAndDevelopmentExpenseGross" xlink:to="chek_ResearchAndDevelopmentExpenseGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ResearchAndDevelopmentExpenseGross_doc" xml:lang="en-US">The gross recognized cost of research and development during the period, before accounting for costs covered by grants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ResearchAndDevelopmentExpensesLineItems" xlink:to="chek_ResearchAndDevelopmentExpensesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ResearchAndDevelopmentExpensesLineItems_doc" xml:lang="en-US">Research and Development Expenses [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ResearchAndDevelopmentExpensesTable" xlink:to="chek_ResearchAndDevelopmentExpensesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ResearchAndDevelopmentExpensesTable_doc" xml:lang="en-US">Research and Development Expenses [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RestOfTheCountryMember" xlink:to="chek_RestOfTheCountryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RestOfTheCountryMember_doc" xml:lang="en-US">Rest of the Country [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesPayablePerUnit" xlink:to="chek_RoyaltiesPayablePerUnit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RoyaltiesPayablePerUnit_doc" xml:lang="en-US">Amount payable for royalties per unit sold.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesPayablePerUnitSold" xlink:to="chek_RoyaltiesPayablePerUnitSold_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RoyaltiesPayablePerUnitSold_doc" xml:lang="en-US">Amount payable for royalties per unit sold.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesPayablePercentageOfProductSales" xlink:to="chek_RoyaltiesPayablePercentageOfProductSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RoyaltiesPayablePercentageOfProductSales_doc" xml:lang="en-US">Royalties payable as a percentage of product sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesProvision" xlink:to="chek_RoyaltiesProvision_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RoyaltiesProvision_doc" xml:lang="en-US">Amount of the liability recorded to pay royalties.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltyIncomeExpenseNonoperating" xlink:to="chek_RoyaltyIncomeExpenseNonoperating_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RoyaltyIncomeExpenseNonoperating_doc" xml:lang="en-US">Ancillary revenue earned, net of expense during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:to="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock_doc" xml:lang="en-US">Tabular disclosure for employee related liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock" xlink:to="chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock_doc" xml:lang="en-US">Tabular disclosure for general and administrative expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock" xlink:to="chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of parameters used to calculate the fair value of options.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of prepaid expenses and other current assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock" xlink:to="chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the information used to calculate depreciation for property, plant and equipment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ScheduleOfResearchAndDevelopmentExpensesNet" xlink:to="chek_ScheduleOfResearchAndDevelopmentExpensesNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ScheduleOfResearchAndDevelopmentExpensesNet_doc" xml:lang="en-US">Tabular disclosure for the net expenses associated with research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesAWarrantsMember" xlink:to="chek_SeriesAWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesAWarrantsMember_doc" xml:lang="en-US">Series A Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesC1PreferredStockMember" xlink:label="chek_SeriesC1PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesC1PreferredStockMember" xlink:to="chek_SeriesC1PreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesC1PreferredStockMember_doc" xml:lang="en-US">Series C1 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesC2PreferredStockMember" xlink:label="chek_SeriesC2PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesC2PreferredStockMember" xlink:to="chek_SeriesC2PreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesC2PreferredStockMember_doc" xml:lang="en-US">Series C2 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesC3PreferredStockMember" xlink:label="chek_SeriesC3PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesC3PreferredStockMember" xlink:to="chek_SeriesC3PreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesC3PreferredStockMember_doc" xml:lang="en-US">Series C3 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesCPreferredShareWarrantsConversionMember" xlink:label="chek_SeriesCPreferredShareWarrantsConversionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesCPreferredShareWarrantsConversionMember" xlink:to="chek_SeriesCPreferredShareWarrantsConversionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesCPreferredShareWarrantsConversionMember_doc" xml:lang="en-US">Series C preferred share warrants converted to ordinary share warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesD1PreferredStockMember" xlink:label="chek_SeriesD1PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesD1PreferredStockMember" xlink:to="chek_SeriesD1PreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesD1PreferredStockMember_doc" xml:lang="en-US">Series D1 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesD2PreferredStockMember" xlink:label="chek_SeriesD2PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesD2PreferredStockMember" xlink:to="chek_SeriesD2PreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesD2PreferredStockMember_doc" xml:lang="en-US">Series D2 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesD3PreferredStockMember" xlink:label="chek_SeriesD3PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesD3PreferredStockMember" xlink:to="chek_SeriesD3PreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesD3PreferredStockMember_doc" xml:lang="en-US">Series D3 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesD4PreferredStockMember" xlink:label="chek_SeriesD4PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesD4PreferredStockMember" xlink:to="chek_SeriesD4PreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesD4PreferredStockMember_doc" xml:lang="en-US">Series D4 Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ServicesWarrantsMember" xlink:label="chek_ServicesWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ServicesWarrantsMember" xlink:to="chek_ServicesWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ServicesWarrantsMember_doc" xml:lang="en-US">Services Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_doc" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareBasedCompensationAwardTrancheFourMember" xlink:label="chek_ShareBasedCompensationAwardTrancheFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationAwardTrancheFourMember" xlink:to="chek_ShareBasedCompensationAwardTrancheFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ShareBasedCompensationAwardTrancheFourMember_doc" xml:lang="en-US">Fourth portion of share-based compensation award differentiated by a particular vesting feature, including, but not limited to, performance measure or service period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareBasedCompensationMember" xlink:to="chek_ShareBasedCompensationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ShareBasedCompensationMember_doc" xml:lang="en-US">Share-Based Compensation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareCapital" xlink:to="chek_ShareCapital_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ShareCapital_doc" xml:lang="en-US">Value of shares issued and total premiums for shares issued presented as the amount of share capital.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareCapitalLessIssuanceCosts" xlink:to="chek_ShareCapitalLessIssuanceCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ShareCapitalLessIssuanceCosts_doc" xml:lang="en-US">Amount of share capital raised, less the associated issuance costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShortTermInvestmentInterestRate" xlink:to="chek_ShortTermInvestmentInterestRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ShortTermInvestmentInterestRate_doc" xml:lang="en-US">Interest rate applied to short-term investment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement_doc" xml:lang="en-US">Number of new stock issued during the period as part of a private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering_doc" xml:lang="en-US">Issuance of ordinary shares and pre-funded warrants in the registered direct offering, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1_doc" xml:lang="en-US">Issuance of ordinary shares and pre-funded warrants in the registered direct offering, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2_doc" xml:lang="en-US">Issuance of ordinary shares and pre-funded warrants in the registered direct offering, Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="chek_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Number of shares issued upon the exercise of warrants during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement" xlink:to="chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement_doc" xml:lang="en-US">Equity impact of the value of new stock issued during the period as part of a private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" xlink:to="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering_doc" xml:lang="en-US">Issuance of ordinary shares and pre-funded warrants in the registered direct offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1" xlink:to="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1_doc" xml:lang="en-US">Issuance of ordinary shares and pre-funded warrants in the registered direct offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2" xlink:to="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2_doc" xml:lang="en-US">Issuance of ordinary shares and pre-funded warrants in the registered direct offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="chek_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SubcontractorsAndConsultantFees" xlink:to="chek_SubcontractorsAndConsultantFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SubcontractorsAndConsultantFees_doc" xml:lang="en-US">Fees for the services provided by subcontractors and consultants during the period.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ThirtyOneOctoberMember" xlink:label="chek_ThirtyOneOctoberMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ThirtyOneOctoberMember" xlink:to="chek_ThirtyOneOctoberMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ThirtyOneOctoberMember_doc" xml:lang="en-US">Thirty One October [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ThreeAugustMember" xlink:to="chek_ThreeAugustMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ThreeAugustMember_doc" xml:lang="en-US">August 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_TweentyNineFebruaryMember" xlink:label="chek_TweentyNineFebruaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_TweentyNineFebruaryMember" xlink:to="chek_TweentyNineFebruaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_TweentyNineFebruaryMember_doc" xml:lang="en-US">Tweenty Nine February [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_TwentySevenFebruaryMember" xlink:label="chek_TwentySevenFebruaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_TwentySevenFebruaryMember" xlink:to="chek_TwentySevenFebruaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_TwentySevenFebruaryMember_doc" xml:lang="en-US">February 27 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_TwentyTwoJuneMember" xlink:to="chek_TwentyTwoJuneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_TwentyTwoJuneMember_doc" xml:lang="en-US">June 22 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_TwoNovemberMember" xlink:label="chek_TwoNovemberMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_TwoNovemberMember" xlink:to="chek_TwoNovemberMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_TwoNovemberMember_doc" xml:lang="en-US">November 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_UnderwriterWarrantsMember" xlink:to="chek_UnderwriterWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_UnderwriterWarrantsMember_doc" xml:lang="en-US">Underwriter Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_UnitsPurchased" xlink:to="chek_UnitsPurchased_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_UnitsPurchased_doc" xml:lang="en-US">Number of units purchased, consisting of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share and one and one-half non-transferrable Long Term Incentive Warrants.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_VariousDatesIn2015Member" xlink:label="chek_VariousDatesIn2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_VariousDatesIn2015Member" xlink:to="chek_VariousDatesIn2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_VariousDatesIn2015Member_doc" xml:lang="en-US">Various dates in 2015 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_VariousDatesMember" xlink:label="chek_VariousDatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_VariousDatesMember" xlink:to="chek_VariousDatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_VariousDatesMember_doc" xml:lang="en-US">Various Dates [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantAndShareOptionsMember" xlink:to="chek_WarrantAndShareOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_WarrantAndShareOptionsMember_doc" xml:lang="en-US">Warrant and Share Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantAwardsMember" xlink:label="chek_WarrantAwardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantAwardsMember" xlink:to="chek_WarrantAwardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_WarrantAwardsMember_doc" xml:lang="en-US">Warrant Awards [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantLiabilityReclassificationToEquity" xlink:to="chek_WarrantLiabilityReclassificationToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_WarrantLiabilityReclassificationToEquity_doc" xml:lang="en-US">Reclassification of warrant liability to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantsCashlessExercise" xlink:to="chek_WarrantsCashlessExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_WarrantsCashlessExercise_doc" xml:lang="en-US">Cashless exercise of warrants into ordinary shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantsExercisedCashlessBasis" xlink:to="chek_WarrantsExercisedCashlessBasis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_WarrantsExercisedCashlessBasis_doc" xml:lang="en-US">Number of warrants exercised on a cashless basis.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantsIssuedNumber" xlink:to="chek_WarrantsIssuedNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_WarrantsIssuedNumber_doc" xml:lang="en-US">Number of warrants issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantsPolicyTextBlock" xlink:to="chek_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_WarrantsPolicyTextBlock_doc" xml:lang="en-US">Policy for the accounting practices applied to the classification of warrant instruments.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsSeriesCPreferredSharesMember" xlink:label="chek_WarrantsSeriesCPreferredSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantsSeriesCPreferredSharesMember" xlink:to="chek_WarrantsSeriesCPreferredSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_WarrantsSeriesCPreferredSharesMember_doc" xml:lang="en-US">Warrants to purchase Series C convertible preferred shares [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsSeriesDPreferredSharesMember" xlink:label="chek_WarrantsSeriesDPreferredSharesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantsSeriesDPreferredSharesMember" xlink:to="chek_WarrantsSeriesDPreferredSharesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_WarrantsSeriesDPreferredSharesMember_doc" xml:lang="en-US">Warrants to purchase Series D convertible preferred shares [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PreFundedUnitsMember" xlink:to="chek_PreFundedUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PreFundedUnitsMember_doc" xml:lang="en-US">Pre funded Units [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_TwoThousandFifteenPlanMember" xlink:to="chek_TwoThousandFifteenPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_TwoThousandFifteenPlanMember_doc" xml:lang="en-US">2015 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantedRevenue" xlink:to="chek_GrantedRevenue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_GrantedRevenue_doc" xml:lang="en-US">Revenue fron grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RevenueFromCashCommission" xlink:to="chek_RevenueFromCashCommission_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_RevenueFromCashCommission_doc" xml:lang="en-US">Cash commission.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DerivativeFairValueOfOptionOutstanding" xlink:to="chek_DerivativeFairValueOfOptionOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_DerivativeFairValueOfOptionOutstanding_doc" xml:lang="en-US">Fair value of option outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree" xlink:to="chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ForeignCurrencyDerivativeInstrumentsMember" xlink:label="chek_ForeignCurrencyDerivativeInstrumentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ForeignCurrencyDerivativeInstrumentsMember" xlink:to="chek_ForeignCurrencyDerivativeInstrumentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_ForeignCurrencyDerivativeInstrumentsMember_doc" xml:lang="en-US">Foreign currency derivative instruments [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_DerivativeChangeInFairValueOfOptionOutstanding" xlink:to="chek_DerivativeChangeInFairValueOfOptionOutstanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_DerivativeChangeInFairValueOfOptionOutstanding_doc" xml:lang="en-US">Change in fair value of option outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PreFundedWarrantsOneMember" xlink:to="chek_PreFundedWarrantsOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_PreFundedWarrantsOneMember_doc" xml:lang="en-US">Pre-funded Warrants one [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesCWarrantsMember" xlink:to="chek_SeriesCWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesCWarrantsMember_doc" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_SeriesDWarrantsMember" xlink:to="chek_SeriesDWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="chek_SeriesDWarrantsMember_doc" xml:lang="en-US">Series D Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GrantDate15Member" xlink:to="chek_GrantDate15Member_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GrantDate15Member_3_lbl" xml:lang="en-US">Legal Warrants [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_2_lbl" xml:lang="en-US">Common Stock, Value, Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" xlink:to="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2_3_lbl" xml:lang="en-US">StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" xlink:to="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares_3_lbl" xml:lang="en-US">Anti-Dilutive Warrants [Member] [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_2_lbl" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromInvestments" xlink:to="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromInvestments_2_lbl" xml:lang="en-US">Payments for (Proceeds from) Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_WarrantLiabilityReclassificationToEquity" xlink:to="chek_WarrantLiabilityReclassificationToEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_WarrantLiabilityReclassificationToEquity_3_lbl" xml:lang="en-US">Warrant Liability Reclassification to Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_2_lbl" xml:lang="en-US">Conversion of Stock, Amount Converted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_2_lbl" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock_3_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_2_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_2_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_2_lbl" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_GeneralAndAdministrativeExpensesTextBlock" xlink:to="chek_GeneralAndAdministrativeExpensesTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_GeneralAndAdministrativeExpensesTextBlock_3_lbl" xml:lang="en-US">General and Administrative Expenses [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_2_lbl" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" xlink:to="us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments_2_lbl" xml:lang="en-US">Unrealized Gain (Loss) on Cash Flow Hedging Instruments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_RoyaltiesPayablePerUnitSold" xlink:to="chek_RoyaltiesPayablePerUnitSold_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_RoyaltiesPayablePerUnitSold_3_lbl" xml:lang="en-US">Series D1 Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_2_lbl" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_2_lbl" xml:lang="en-US">Fair Value, Net Asset (Liability)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareCapital" xlink:to="chek_ShareCapital_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShareCapital_4_lbl" xml:lang="en-US">Share Capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ShareCapitalLessIssuanceCosts" xlink:to="chek_ShareCapitalLessIssuanceCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ShareCapitalLessIssuanceCosts_3_lbl" xml:lang="en-US">Share Capital Less Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_2_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="chek_ResearchAndDevelopmentExpenseGross" xlink:to="chek_ResearchAndDevelopmentExpenseGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="chek_ResearchAndDevelopmentExpenseGross_3_lbl" xml:lang="en-US">Research and Development Expense, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>chek-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CHEK 1218 20F.xfr; Date: 2019%2D03%2D26T22:03:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://check-cap.com/role/chek-dei" xlink:href="chek-20181231.xsd#chek-dei" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/check-cbs" xlink:href="chek-20181231.xsd#check-cbs" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-csoo" xlink:href="chek-20181231.xsd#chek-csoo" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-equity" xlink:href="chek-20181231.xsd#chek-equity" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-equityp" xlink:href="chek-20181231.xsd#chek-equityp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-csocf" xlink:href="chek-20181231.xsd#chek-csocf" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-info" xlink:href="chek-20181231.xsd#chek-info" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sigp" xlink:href="chek-20181231.xsd#chek-sigp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-peaoca" xlink:href="chek-20181231.xsd#chek-peaoca" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ppe" xlink:href="chek-20181231.xsd#chek-ppe" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-stloan" xlink:href="chek-20181231.xsd#chek-stloan" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ebapa" xlink:href="chek-20181231.xsd#chek-ebapa" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-itax" xlink:href="chek-20181231.xsd#chek-itax" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-cacl" xlink:href="chek-20181231.xsd#chek-cacl" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fvm" xlink:href="chek-20181231.xsd#chek-fvm" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sed" xlink:href="chek-20181231.xsd#chek-sed" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbp" xlink:href="chek-20181231.xsd#chek-sbp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-raden" xlink:href="chek-20181231.xsd#chek-raden" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-gaae" xlink:href="chek-20181231.xsd#chek-gaae" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fien" xlink:href="chek-20181231.xsd#chek-fien" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-eps" xlink:href="chek-20181231.xsd#chek-eps" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-relp" xlink:href="chek-20181231.xsd#chek-relp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/SubsequentEvents" xlink:href="chek-20181231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sigpp" xlink:href="chek-20181231.xsd#chek-sigpp" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sigpt" xlink:href="chek-20181231.xsd#chek-sigpt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-peaocat" xlink:href="chek-20181231.xsd#chek-peaocat" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ppet" xlink:href="chek-20181231.xsd#chek-ppet" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ebapat" xlink:href="chek-20181231.xsd#chek-ebapat" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-itaxt" xlink:href="chek-20181231.xsd#chek-itaxt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-caclt" xlink:href="chek-20181231.xsd#chek-caclt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fvmt" xlink:href="chek-20181231.xsd#chek-fvmt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sedt" xlink:href="chek-20181231.xsd#chek-sedt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbpt" xlink:href="chek-20181231.xsd#chek-sbpt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-radent" xlink:href="chek-20181231.xsd#chek-radent" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-gaaet" xlink:href="chek-20181231.xsd#chek-gaaet" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fient" xlink:href="chek-20181231.xsd#chek-fient" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-epst" xlink:href="chek-20181231.xsd#chek-epst" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-relpt" xlink:href="chek-20181231.xsd#chek-relpt" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-infod" xlink:href="chek-20181231.xsd#chek-infod" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="chek-20181231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sosapd" xlink:href="chek-20181231.xsd#chek-sosapd" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="chek-20181231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-peaocad" xlink:href="chek-20181231.xsd#chek-peaocad" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-pped" xlink:href="chek-20181231.xsd#chek-pped" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-ebapad" xlink:href="chek-20181231.xsd#chek-ebapad" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-itaxd" xlink:href="chek-20181231.xsd#chek-itaxd" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-cacld" xlink:href="chek-20181231.xsd#chek-cacld" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails" xlink:href="chek-20181231.xsd#FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:href="chek-20181231.xsd#ShareholdersEquityOrdinarySharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/Share-basedCompensationAwardsDetails" xlink:href="chek-20181231.xsd#Share-basedCompensationAwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/Share-basedCompensationDetailsOfShare-basedGrantsDetails" xlink:href="chek-20181231.xsd#Share-basedCompensationDetailsOfShare-basedGrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails" xlink:href="chek-20181231.xsd#Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbpced" xlink:href="chek-20181231.xsd#chek-sbpced" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-sbpoad" xlink:href="chek-20181231.xsd#chek-sbpoad" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-radend" xlink:href="chek-20181231.xsd#chek-radend" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-gaaed" xlink:href="chek-20181231.xsd#chek-gaaed" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-fiend" xlink:href="chek-20181231.xsd#chek-fiend" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/LossPerShareScheduleOfLossPerShareDetails" xlink:href="chek-20181231.xsd#LossPerShareScheduleOfLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails" xlink:href="chek-20181231.xsd#LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://check-cap.com/role/chek-relptrpd" xlink:href="chek-20181231.xsd#chek-relptrpd" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-dei" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DocumentAndEntityInformationAbstract" xlink:label="loc_chekDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/check-cbs" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaapShortTermInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapShortTermInvestments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaapAssetsNoncurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsNoncurrentAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesProvision" xlink:label="loc_chekRoyaltiesProvision" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_chekRoyaltiesProvision" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-csoo" xlink:title="00000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapNetIncomeLoss_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-equity" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement" xlink:label="loc_chekStockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueNewIssuesInitialPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:label="loc_chekStockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" xlink:label="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering" xlink:label="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1" xlink:label="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" xlink:label="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2" xlink:label="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" xlink:label="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_chekStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_chekStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="loc_chekAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-equityp" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-csocf" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaapOtherNoncashIncomeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:label="loc_us-gaapIncreaseDecreaseInRoyaltiesPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInRoyaltiesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromInvestments" xlink:label="loc_us-gaapPaymentsForProceedsFromInvestments" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsForProceedsFromInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ProceedsFromIssuanceResisteredDirectOffering" xlink:label="loc_chekProceedsFromIssuanceResisteredDirectOffering" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_chekProceedsFromIssuanceResisteredDirectOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapEffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantLiabilityReclassificationToEquity" xlink:label="loc_chekWarrantLiabilityReclassificationToEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_chekWarrantLiabilityReclassificationToEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsCashlessExercise" xlink:label="loc_chekWarrantsCashlessExercise" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_chekWarrantsCashlessExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="loc_us-gaapFairValueOfAssetsAcquired" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapFairValueOfAssetsAcquired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_us-gaapDebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-info" xlink:title="00000007 - Disclosure - GENERAL INFORMATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sigp" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-peaoca" xlink:title="00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="loc_chekPrepaidExpensesAndOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_chekPrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ppe" xlink:title="00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-stloan" xlink:title="00000011 - Disclosure - SHORT TERM LOANS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShortTermDebtTextBlock" xlink:label="loc_us-gaapShortTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapShortTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ebapa" xlink:title="00000012 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_EmployeeRelatedLiabilitiesTextBlock" xlink:label="loc_chekEmployeeRelatedLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_chekEmployeeRelatedLiabilitiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-itax" xlink:title="00000013 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-cacl" xlink:title="00000014 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fvm" xlink:title="00000015 - Disclosure - FAIR VALUE MEASUREMENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sed" xlink:title="00000016 - Disclosure - SHAREHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbp" xlink:title="00000017 - Disclosure - SHARE-BASED COMPENSATION">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-raden" xlink:title="00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:label="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_us-gaapResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-gaae" xlink:title="00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralAndAdministrativeExpensesTextBlock" xlink:label="loc_chekGeneralAndAdministrativeExpensesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_chekGeneralAndAdministrativeExpensesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fien" xlink:title="00000020 - Disclosure - FINANCE INCOME (EXPENSES), NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaapOtherNonoperatingIncomeAndExpenseTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeAndExpenseTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-eps" xlink:title="00000021 - Disclosure - LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-relp" xlink:title="00000022 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/SubsequentEvents" xlink:title="00000023 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sigpp" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="loc_us-gaapBasisOfAccounting" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccounting" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="loc_us-gaapMarketableSecuritiesPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:label="loc_us-gaapDerivativesMethodsOfAccountingHedgingDerivatives" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativesMethodsOfAccountingHedgingDerivatives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsPolicyTextBlock" xlink:label="loc_chekWarrantsPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_chekWarrantsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sigpt" xlink:title="00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock" xlink:label="loc_chekScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_chekScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaapScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-peaocat" xlink:title="00000026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_chekScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_chekScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ppet" xlink:title="00000027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ebapat" xlink:title="00000028 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:label="loc_chekScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_chekScheduleOfEmployeeRelatedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-itaxt" xlink:title="00000029 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-caclt" xlink:title="00000030 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsTableTextBlock" xlink:label="loc_us-gaapOtherCommitmentsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fvmt" xlink:title="00000031 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaapSeriesCPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesCPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaapSeriesDPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesDPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sedt" xlink:title="00000032 - Disclosure - SHAREHOLDERS' EQUITY (DEFICIENCY) (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbpt" xlink:title="00000033 - Disclosure - SHARE-BASED COMPENSATION (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock" xlink:label="loc_chekScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-radent" xlink:title="00000034 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfResearchAndDevelopmentExpensesNet" xlink:label="loc_chekScheduleOfResearchAndDevelopmentExpensesNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_chekScheduleOfResearchAndDevelopmentExpensesNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-gaaet" xlink:title="00000035 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock" xlink:label="loc_chekScheduleOfGeneralAndAdministrativeExpesesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_chekScheduleOfGeneralAndAdministrativeExpesesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fient" xlink:title="00000036 - Disclosure - FINANCE INCOME (EXPENSES), NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-epst" xlink:title="00000037 - Disclosure - LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-relpt" xlink:title="00000038 - Disclosure - RELATED PARTIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_NonExecutiveDirectorsCompensationMember" xlink:label="loc_chekNonExecutiveDirectorsCompensationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekNonExecutiveDirectorsCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralTransactionsMember" xlink:label="loc_chekGeneralTransactionsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekGeneralTransactionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-infod" xlink:title="00000039 - Disclosure - GENERAL INFORMATION (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplitConversionRatio1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:title="00000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeAssetNotionalAmount" xlink:label="loc_us-gaapDerivativeAssetNotionalAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDerivativeAssetNotionalAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments" xlink:label="loc_us-gaapUnrealizedGainLossOnCashFlowHedgingInstruments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnCashFlowHedgingInstruments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DerivativeFairValueOfOptionOutstanding" xlink:label="loc_chekDerivativeFairValueOfOptionOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_chekDerivativeFairValueOfOptionOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DerivativeChangeInFairValueOfOptionOutstanding" xlink:label="loc_chekDerivativeChangeInFairValueOfOptionOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_chekDerivativeChangeInFairValueOfOptionOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sosapd" xlink:title="00000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AccountingPoliciesTable" xlink:label="loc_chekAccountingPoliciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_chekAccountingPoliciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AccountingPoliciesLineItems" xlink:label="loc_chekAccountingPoliciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_chekAccountingPoliciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="loc_us-gaapTechnologyEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapTechnologyEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShortTermInvestmentInterestRate" xlink:label="loc_chekShortTermInvestmentInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_chekShortTermInvestmentInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage" xlink:label="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentSalvageValuePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Cash, Cash Equivalents and Restricted Cash) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaapRestrictedCashCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCashCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-peaocad" xlink:title="00000043 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GovernmentInstitutionalAssetsCurrent" xlink:label="loc_chekGovernmentInstitutionalAssetsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_chekGovernmentInstitutionalAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaapDepositsAssetsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_us-gaapDepositsAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-pped" xlink:title="00000044 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaapOfficeEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapOfficeEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TechnologyEquipmentMember" xlink:label="loc_us-gaapTechnologyEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapTechnologyEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisposals" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisposals" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-ebapad" xlink:title="00000045 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-itaxd" xlink:title="00000046 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaapDomesticCountryMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapDomesticCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DevelopmentAreaAMember" xlink:label="loc_chekDevelopmentAreaAMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_chekDevelopmentAreaAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RestOfTheCountryMember" xlink:label="loc_chekRestOfTheCountryMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_chekRestOfTheCountryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FutureFederalIncomeTaxRateNextYear" xlink:label="loc_chekFutureFederalIncomeTaxRateNextYear" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekFutureFederalIncomeTaxRateNextYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FutureFederalIncomeTaxRate" xlink:label="loc_chekFutureFederalIncomeTaxRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekFutureFederalIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ForeignIncomeTaxRateMaximum" xlink:label="loc_chekForeignIncomeTaxRateMaximum" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekForeignIncomeTaxRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ReductionInIncomeTaxRate" xlink:label="loc_chekReductionInIncomeTaxRate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekReductionInIncomeTaxRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-cacld" xlink:title="00000047 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CommitmentsAndContingenciesTable" xlink:label="loc_chekCommitmentsAndContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_chekCommitmentsAndContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CommitmentsAndContingenciesLineItems" xlink:label="loc_chekCommitmentsAndContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekCommitmentsAndContingenciesTable" xlink:to="loc_chekCommitmentsAndContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_DesignerRoyaltiesMember" xlink:label="loc_chekDesignerRoyaltiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_chekDesignerRoyaltiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PredecessorUnitHoldersMember" xlink:label="loc_chekPredecessorUnitHoldersMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_chekPredecessorUnitHoldersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OfficeOfTheChiefScientistMember" xlink:label="loc_chekOfficeOfTheChiefScientistMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_chekOfficeOfTheChiefScientistMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_BinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:label="loc_chekBinationalIndustrialResearchAndDevelopmentFoundationMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_chekBinationalIndustrialResearchAndDevelopmentFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekCommitmentsAndContingenciesTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currencyEUR" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyEUR" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekCommitmentsAndContingenciesTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekCommitmentsAndContingenciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdsAndLeaseholdImprovementsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VehiclesMember" xlink:label="loc_us-gaapVehiclesMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapVehiclesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaapLeasesOperatingAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekCommitmentsAndContingenciesLineItems" xlink:to="loc_us-gaapLeasesOperatingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaapOperatingLeasesRentExpenseNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapOperatingLeasesRentExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OperatingLeaseRentExpenseMonthly" xlink:label="loc_chekOperatingLeaseRentExpenseMonthly" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_chekOperatingLeaseRentExpenseMonthly" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesOperatingAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsAbstract" xlink:label="loc_us-gaapOtherCommitmentsAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekCommitmentsAndContingenciesLineItems" xlink:to="loc_us-gaapOtherCommitmentsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesPayablePerUnit" xlink:label="loc_chekRoyaltiesPayablePerUnit" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAbstract" xlink:to="loc_chekRoyaltiesPayablePerUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesPayablePerUnitSold" xlink:label="loc_chekRoyaltiesPayablePerUnitSold" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAbstract" xlink:to="loc_chekRoyaltiesPayablePerUnitSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MaximumRoyaltyObligation" xlink:label="loc_chekMaximumRoyaltyObligation" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAbstract" xlink:to="loc_chekMaximumRoyaltyObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesProvision" xlink:label="loc_chekRoyaltiesProvision" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAbstract" xlink:to="loc_chekRoyaltiesProvision" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantedRevenue" xlink:label="loc_chekGrantedRevenue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAbstract" xlink:to="loc_chekGrantedRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltiesPayablePercentageOfProductSales" xlink:label="loc_chekRoyaltiesPayablePercentageOfProductSales" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAbstract" xlink:to="loc_chekRoyaltiesPayablePercentageOfProductSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitmentsDescription" xlink:label="loc_us-gaapOtherCommitmentsDescription" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAbstract" xlink:to="loc_us-gaapOtherCommitmentsDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RefundExpenses" xlink:label="loc_chekRefundExpenses" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAbstract" xlink:to="loc_chekRefundExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails" xlink:title="00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Schedule of Market observable data of similar instruments) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueNetAssetLiability" xlink:label="loc_us-gaapFairValueNetAssetLiability" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueNetAssetLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/ShareholdersEquityOrdinarySharesDetails" xlink:title="00000049 - Disclosure - SHAREHOLDERS' EQUITY (Ordinary Shares) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreFundedWarrantsMember" xlink:label="loc_chekPreFundedWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OneYearWarrantsMember" xlink:label="loc_chekOneYearWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekOneYearWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FiveYearWarrantsMember" xlink:label="loc_chekFiveYearWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekFiveYearWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AntiDilutiveWarrantsMember" xlink:label="loc_chekAntiDilutiveWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekAntiDilutiveWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_LongTermIncentiveWarrantsMember" xlink:label="loc_chekLongTermIncentiveWarrantsMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekLongTermIncentiveWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CreditLineAgreementWarrantsMember" xlink:label="loc_chekCreditLineAgreementWarrantsMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekCreditLineAgreementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FindersWarrantsMember" xlink:label="loc_chekFindersWarrantsMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekFindersWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_UnderwriterWarrantsMember" xlink:label="loc_chekUnderwriterWarrantsMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekUnderwriterWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesAWarrantsMember" xlink:label="loc_chekSeriesAWarrantsMember" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekSeriesAWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OrdinarySharesMember" xlink:label="loc_chekOrdinarySharesMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekOrdinarySharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_LegalWarrantsMember" xlink:label="loc_chekLegalWarrantsMember" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekLegalWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesCWarrantsMember" xlink:label="loc_chekSeriesCWarrantsMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreFundedWarrantsOneMember" xlink:label="loc_chekPreFundedWarrantsOneMember" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekPreFundedWarrantsOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SeriesDWarrantsMember" xlink:label="loc_chekSeriesDWarrantsMember" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_chekSeriesDWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RegisteredDirectOfferingMember" xlink:label="loc_chekRegisteredDirectOfferingMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_chekRegisteredDirectOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaapPrivatePlacementMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapPrivatePlacementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaapOverAllotmentOptionMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapOverAllotmentOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreFundedUnitsMember" xlink:label="loc_chekPreFundedUnitsMember" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_chekPreFundedUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonClassCMember" xlink:label="loc_us-gaapCommonClassCMember" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapCommonClassCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_OrdinarySharesMember" xlink:label="loc_chekOrdinarySharesMember_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_chekOrdinarySharesMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtCurrencyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardDateAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareCapital" xlink:label="loc_chekShareCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekShareCapital" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_chekStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityPeriodIncreaseDecrease" xlink:label="loc_us-gaapStockholdersEquityPeriodIncreaseDecrease" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockholdersEquityPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareCapital" xlink:label="loc_chekShareCapital_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekShareCapital_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareCapitalLessIssuanceCosts" xlink:label="loc_chekShareCapitalLessIssuanceCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekShareCapitalLessIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_chekStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:label="loc_chekStockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekStockIssuedDuringPeriodSharesNewIssuesPrivatePlacement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsIssuedNumber" xlink:label="loc_chekWarrantsIssuedNumber" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekWarrantsIssuedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PricePerUnit" xlink:label="loc_chekPricePerUnit" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekPricePerUnit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_UnitsPurchased" xlink:label="loc_chekUnitsPurchased" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekUnitsPurchased" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ClassOfWarrantOrRightExpiration" xlink:label="loc_chekClassOfWarrantOrRightExpiration" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekClassOfWarrantOrRightExpiration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantsExercisedCashlessBasis" xlink:label="loc_chekWarrantsExercisedCashlessBasis" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekWarrantsExercisedCashlessBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" xlink:label="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekStockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RevenueFromCashCommission" xlink:label="loc_chekRevenueFromCashCommission" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_chekRevenueFromCashCommission" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/Share-basedCompensationAwardsDetails" xlink:title="00000050 - Disclosure - SHARE-BASED COMPENSATION (Awards) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_TwoThousandFifteenPlanMember" xlink:label="loc_chekTwoThousandFifteenPlanMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_chekTwoThousandFifteenPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_TwentyTwoJuneMember" xlink:label="loc_chekTwentyTwoJuneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekTwentyTwoJuneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ThreeAugustMember" xlink:label="loc_chekThreeAugustMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekThreeAugustMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_JanuaryFifteenthMember" xlink:label="loc_chekJanuaryFifteenthMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekJanuaryFifteenthMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AprilSixthMember" xlink:label="loc_chekAprilSixthMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekAprilSixthMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtCurrencyAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaapVestingAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapVestingAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaapVestingDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingAxis" xlink:to="loc_us-gaapVestingDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVestingDomain" xlink:to="loc_us-gaapShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaapTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualAxis" xlink:to="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaapChiefExecutiveOfficerMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapChiefExecutiveOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_CertainEmployeesMember" xlink:label="loc_chekCertainEmployeesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_chekCertainEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/Share-basedCompensationDetailsOfShare-basedGrantsDetails" xlink:title="00000051 - Disclosure - SHARE-BASED COMPENSATION (Details of share-based grants) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate1Member" xlink:label="loc_chekGrantDate1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate2Member" xlink:label="loc_chekGrantDate2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate3Member" xlink:label="loc_chekGrantDate3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate4Member" xlink:label="loc_chekGrantDate4Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate5Member" xlink:label="loc_chekGrantDate5Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate5Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate6Member" xlink:label="loc_chekGrantDate6Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate6Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate7Member" xlink:label="loc_chekGrantDate7Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate7Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate8Member" xlink:label="loc_chekGrantDate8Member" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate8Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate9Member" xlink:label="loc_chekGrantDate9Member" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate9Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate10Member" xlink:label="loc_chekGrantDate10Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate10Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate17Member" xlink:label="loc_chekGrantDate17Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate17Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate11Member" xlink:label="loc_chekGrantDate11Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate11Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate13Member" xlink:label="loc_chekGrantDate13Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate13Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate15Member" xlink:label="loc_chekGrantDate15Member" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate15Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantDate16Member" xlink:label="loc_chekGrantDate16Member" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_chekGrantDate16Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails" xlink:title="00000052 - Disclosure - SHARE-BASED COMPENSATION (Schedule of Parameters Used in Valuing Fair Value of Options) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AccountingPoliciesTable" xlink:label="loc_chekAccountingPoliciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_chekAccountingPoliciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_AccountingPoliciesLineItems" xlink:label="loc_chekAccountingPoliciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_chekAccountingPoliciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekAccountingPoliciesLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbpced" xlink:title="00000053 - Disclosure - SHARE-BASED COMPENSATION (Compensation Expense) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-sbpoad" xlink:title="00000054 - Disclosure - SHARE-BASED COMPENSATION (Option Activity) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesRestrictedStock" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_NumberOfSharesRestrictedStockVested" xlink:label="loc_chekNumberOfSharesRestrictedStockVested" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_chekNumberOfSharesRestrictedStockVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree" xlink:label="loc_chekSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_chekSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_chekShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_chekShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-radend" xlink:title="00000055 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:label="loc_us-gaapResearchAndDevelopmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ResearchAndDevelopmentExpensesTable" xlink:label="loc_chekResearchAndDevelopmentExpensesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapResearchAndDevelopmentAbstract" xlink:to="loc_chekResearchAndDevelopmentExpensesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ResearchAndDevelopmentExpensesLineItems" xlink:label="loc_chekResearchAndDevelopmentExpensesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesTable" xlink:to="loc_chekResearchAndDevelopmentExpensesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SuppliesExpense" xlink:label="loc_us-gaapSuppliesExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapSuppliesExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_SubcontractorsAndConsultantFees" xlink:label="loc_chekSubcontractorsAndConsultantFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_chekSubcontractorsAndConsultantFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaapDepreciationNonproduction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapDepreciationNonproduction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ResearchAndDevelopmentExpenseGross" xlink:label="loc_chekResearchAndDevelopmentExpenseGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_chekResearchAndDevelopmentExpenseGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrantedRevenue" xlink:label="loc_chekGrantedRevenue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_chekGrantedRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekResearchAndDevelopmentExpensesLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-gaaed" xlink:title="00000056 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseAbstract" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralAndAdministrativeExpensesTable" xlink:label="loc_chekGeneralAndAdministrativeExpensesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeneralAndAdministrativeExpenseAbstract" xlink:to="loc_chekGeneralAndAdministrativeExpensesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GeneralAndAdministrativeExpensesLineItems" xlink:label="loc_chekGeneralAndAdministrativeExpensesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekGeneralAndAdministrativeExpensesTable" xlink:to="loc_chekGeneralAndAdministrativeExpensesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekGeneralAndAdministrativeExpensesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensation" xlink:label="loc_us-gaapSalariesWagesAndOfficersCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapSalariesWagesAndOfficersCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaapProfessionalFees" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapProfessionalFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="loc_us-gaapDepreciationNonproduction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapDepreciationNonproduction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="loc_us-gaapOtherCostAndExpenseOperating" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapOtherCostAndExpenseOperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_chekGeneralAndAdministrativeExpensesLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-fiend" xlink:title="00000057 - Disclosure - FINANCE INCOME (EXPENSES), NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaapOtherIncomeAndExpensesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_RoyaltyIncomeExpenseNonoperating" xlink:label="loc_chekRoyaltyIncomeExpenseNonoperating" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_chekRoyaltyIncomeExpenseNonoperating" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherIncomeAndExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/LossPerShareScheduleOfLossPerShareDetails" xlink:title="00000058 - Disclosure - LOSS PER SHARE (Schedule of Loss Per Share) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaapEarningsPerShareReconciliationAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareReconciliationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails" xlink:title="00000059 - Disclosure - LOSS PER SHARE (Schedule of Anti-Dilutive Securities) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_WarrantAndShareOptionsMember" xlink:label="loc_chekWarrantAndShareOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_chekWarrantAndShareOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_PreferredSharesMember" xlink:label="loc_chekPreferredSharesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_chekPreferredSharesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://check-cap.com/role/chek-relptrpd" xlink:title="00000060 - Disclosure - RELATED PARTIES (Transactions with Related Parties) (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:label="loc_us-gaapImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapImmediateFamilyMemberOfManagementOrPrincipalOwnerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OfficerMember" xlink:label="loc_us-gaapOfficerMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapOfficerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_NonExecutiveDirectorsMember" xlink:label="loc_chekNonExecutiveDirectorsMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_chekNonExecutiveDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtCurrencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_ILS" xlink:label="loc_currencyILS" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyILS" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ConsultingFeesMember" xlink:label="loc_chekConsultingFeesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekConsultingFeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_KeyManLifeInsurancePremiumMember" xlink:label="loc_chekKeyManLifeInsurancePremiumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekKeyManLifeInsurancePremiumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_FeesAndReimbursementMember" xlink:label="loc_chekFeesAndReimbursementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekFeesAndReimbursementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_ShareBasedCompensationMember" xlink:label="loc_chekShareBasedCompensationMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_chekShareBasedCompensationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MonthlyRetainer" xlink:label="loc_chekMonthlyRetainer" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekMonthlyRetainer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_HourlyFeeUpToFiveHours" xlink:label="loc_chekHourlyFeeUpToFiveHours" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekHourlyFeeUpToFiveHours" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_HourlyFeeExceedingFiveHours" xlink:label="loc_chekHourlyFeeExceedingFiveHours" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekHourlyFeeExceedingFiveHours" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_KeyManInsurancePolicy" xlink:label="loc_chekKeyManInsurancePolicy" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekKeyManInsurancePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MonthlySalary" xlink:label="loc_chekMonthlySalary" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekMonthlySalary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_GrossOvertimeMonthlyRate" xlink:label="loc_chekGrossOvertimeMonthlyRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekGrossOvertimeMonthlyRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="chek-20181231.xsd#chek_MaximumAggregateMonthlySalary" xlink:label="loc_chekMaximumAggregateMonthlySalary" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_chekMaximumAggregateMonthlySalary" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0K!WH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.1L"@!^:,U6$N34H;- $M%-
M!IU !29IK'%-#4 2T4@-(30 ZBF@T$T .HI :6@ HHHH **** "BBB@ HHHH
M ***;F@!U%)2$T .HIF:>* "BD-)GF@!U%)29H =129XI,T .I,TUC@4Q7R:
M )J*0=*": %HIH-.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3-)NIDK;151KC!ZT 7MU&Z
MLX77O3OM/O0!H;J,U32?/>GM+@4 6=U&:IB;WI3-[T 6MU&ZJ1N/>F_:?>@#
M0!I:K0R;JLT %%%% !132:4&@!:*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3-+43MB@!^ZC=
M5*2XVGK1'<9[T 7LTFZJ_FU$T^.] %W=2YJB+CWJ59<B@"SFC-5&FP>M'G<=
M: +6X4NZLQ[K#=:FBGW=Z +U%,0Y%/H **** "BBFYH =1110 44AI,T .HH
MHH ***0T +130:=0 44&DH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHII- #J*04M !1110 4444 %%)2T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD:R,PF@#P[QHF$D->+7[?OV^M>X^.$Q#)7A=^?\ 27^M %8=:4YQ0O6G,.*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MIK4ZD- $8'->=_$?_CQ?Z5Z/7G/Q'_X\G^E 'S-JO_'T_P!362_-:NK_ /'T
M_P!:R.IH C(IM2L.*BH >IIYYJ,5(M  .*:QIS<5&30 Y30YIH-(30 E%%%
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M3=)]:\JQ7JWPM'^EI]: /I73U_T=/I5\54L1BV3Z5;H **** "BBB@ HHHH
M**** "D8X6EIDIPAH R+Z[\O/-<U>:V(R?FJ;7[OR]W->8ZWK)1V^:@#M)?$
M8'\?ZU4?Q*,_?_6O++CQ 0?O_K5%_$)_O_K0!Z]-XE!A(W]O6N(U;6=\Y.ZN
M5;Q Q7&_]:R;C52[YW4 =3<:GF(C=7':E<EY2<TYK\E#S65<3;VZT (9"3UI
MI)Q35.34N/EH VO"3'^U8_K7UKX0_P"05']*^2O"G_(6C^M?6G@__D%1_2@#
MI:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC!H T(_NTXG%"]*;(>* $#<TIZ5 K?-5@<B@!@'-2#I30.:?0 4444 %%%%
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M J.?_5'Z5)45Q_J6^E 'FOBN;:7YKQ7Q%=GS6Y[UZ[XRDVL]>&^(IOWS<]Z
M,.XN23UJFT[>M#MDU >M $WG-CK3#(<T <4QAS0!+YAQ49.329XI* )$/-6,
M_)553S4V[Y: -WPI_P A:/ZU]:>#_P#D%1_2ODKPG_R%H_K7UKX/_P"05']*
M .EHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCBA>M $PZ5'-TJ0=*CE'% $$?WJL-]VH(Q\U6".* &)UJ8=*C4<U)0 4444
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M\21R] 'AUX/WC5#'C%2Z@<2-5))<4 -NL51/6K,[YJKWH LQ=*EJNC8%/WT
M2G%0O2[ZB9J %B_UH^M=UX87]_']:X2'_6CZUWWA<?OH_K0!]'^#O^/%/I75
MXKE/!_\ QXK]*ZR@!,4M%% !1110!B>(?^/%_I7SUXO_ -=)]:^AO$/_ !XO
M]*^>?%_^NDH \LO/]>?K4:"I+S_7M]:C7@4 6H<9JV^-E9\;X-3M+\M %>;%
M0Q_>I\C9J-#\U %A_NU7[U.Q^6H<<T !ZBO5_A8/]+3ZUY1WKUKX6#_2T^M
M'TO9_P#'LGTJQ5>S_P"/9/I5B@ HHHH **** "BBB@ I,TM,8T /J&Y_U+?2
MI%-,N/\ 4M]* /&_' ^=Z\+U\?OS]:]X\;+EWKPGQ",7!^M &/$.*E(XI(1\
MM$AQ0!7)^>KD>/+JBQ^:K"2?)0!%)_K*D4?)43<M4@/RT 0./FI>U*PYI.U
M&]X2_P"0M']:^MO!_P#R"H_I7R3X2_Y"L?UKZV\'_P#(*C^E '2T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !VK
M@?'G_'H_TKONU<'X['^B-]* /FWQ!_KG^M<F[?,:Z[Q"/WS_ %KD&^^: ' Y
MI<4BBG&@"> 47*\4V%L4LS9% %(]:2G,.: * &T4XB@"@!M*#2D4V@!2:44V
MG 4 &:4-2&E H 7=1NIII0* #/-2+TJ+O4J]* %H/2C-!Z4 1'K4G:H_XJF
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MO7^M<<?OFNO\1-^]D^M<@?OF@!XIK4X4UZ $5L5)NS4 J1: $<4BBG-S0O%
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M HIN>:44 +1110 4444 %%(:3- #J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH .U<!X^.+-_I7
M?]J\^\?_ /'F_P!* /F_7VS-)]:Y5C\U=-KW^OD^M<N_WC0!(IH?I34-*YH
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MAOK4$8YH <R\5#CFKC+\M5L?-0 N.*?&>::W2B(_-0!8?[M5&-69#\M5#UH
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ML7ZTK"FQ_P"L'UH ]]^$G_+/\*]]B_U:_2O ?A)_RS_"O?HO]6OTH ?1110
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MO-2 4 .HHII8"@ 8UG7=SY>>:MR2@#K7,ZS>A W- #+O5A'GYJQY_$(4_?\
MUKE]9UC86^:N+O\ Q"58_/\ K0!ZI_PDJ_W_ -:#XE&/O_K7C/\ PD;?W_UH
M_P"$C;^_^M 'K$_B($_?_6H!XA']_P#6O*'\0D_Q_K4?]OG^_P#K0!Z^GB(?
MW_UJY%XD 'W_ -:\6'B _P!_]:F7Q$P_C_6@#VD>)5S]_P#6K,'B$,P^?]:\
M07Q&V?O_ *UJ6'B M(OS_K0![U8ZD)0/FK<AEWI7EV@ZKYB+\U=_I]T&C'-
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MN=BGFO-_%&M& M\U &SJ&O Y^?\ 6N0U36-V?FKEKCQ$6)^?]:QKS6"^?FH
MGUC42Q/S5Q][=L6/-6;R]\PGFL>9]QH 7[2WK1]I;UJM10!8^TMZFC[0WK5>
M@4 6A<-ZFE6Y;=U-0 <4G0T ;UC>,&7FNXT;4RNWYJ\S@EVD5NV.H&,CF@#W
M71]: 1?FKKK+60RCYJ\'T[7"H4;JZW3->+%1OH ]FM[X28YK3B;<N:X+2-1\
MS;\U=M92!H@<T 6'Z55(^>K9Y%0.M #T;BI :JAN:L*: %;I48ZU(W2HQUH
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M:'FK<"XKF_%-Y]GB;G% '%>*-2"!L-7D6O:@9"WS5U/B75?,+#=7G5_*9&-
M&7/(78TD0S2,G-/3B@!DPJM5M_FJNPQ0 *<5*K<57J130 ]FJ,FI,9IA6@ #
M5,CU!BG XH M=15:3@U,K<5"_)H <CX%/WYJ(+2]* %/-%)FC- "!L&M/3KK
M9,O-91J6V?;(* /6O#^I8V#=7J6@WX?8-U>!:1?>65YKTSPQJFZ:-=U 'ML!
MWVX-,5/WE,TM_,LU/M5G;\U $P^Y43U*.E,<4 11GYJCO_\ 5?A4R+\U0W_^
MJ/TH \B\?'_1I/I7SUJ'_'V_UKZ&\?C_ $63Z5\\ZA_Q]O\ 6@"J:04I% H
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M?-7S?X>NC%,O/>O8O#6I[M@W4 >QV4NX#FM0=*YK2+C>%YKI5^Z* %HHI":
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M21LF@#GI!ER:53MH/)IC4 2F2A?FJOFIX30 I^6H'.:FEJ#&: &45)LII7%
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M <4 ,E.3453.AIFV@!5%.(XI5%*>E $/0U*&XJ)NM H ?NYJ6-N:@Q4D?WJ
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MO$'^N?ZUR;#YS76>(/\ 7/\ 6N5_C- #6%- I[]*1.M ",*94KBHJ "BBB@
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M 4<4TCFI$Z4UNM  HI<XI5Z4US0 Z'_6BN]\+_Z^/ZUP,'^L%=[X7_U\?UH
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MW^7C7- 'NMHVZ%3[5+)TJII;;K53[5:EZ4 0J?FJ*^/[HTY#\]1W_P#J?PH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M# NV,5-0 AK"UJY\F(G/:MT]*XKQE<^1;L<]J /+/'>H>=&XS7B=WS,Q]Z]
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !VK@?'O_'H_P!*[[M7 ^/?^/1_I0!\W>(/]<_UKE?XS75>(/\
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MEA%1=:GB% #9J2(XI9JB0XH ED.:6*HR<U-&.* )$_UHKUOP+:"54XKR-/\
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MS7N6DMNM$/M7S1X,O?\ 3(USWKZ1T%MUA&?:@#6HHHH **** "BBB@ HHHH
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M&@"1CD4U3AA2]:3'- 'J7P[GVRI]:^AM%FWQK]*^:? LVR5/K7T)X;GWHG-
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M@"Y;'YA7K_PU :X3ZUXW V&%>P?#!\W*?6@#Z)M81]G7Z5/Y(HL_^/=?I4]
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M_I;_ %IDIRM,N&_TM_K2.V10!6:D6G-3>E $E1O3@::] "*>:LQU54\U9B-
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MT ?+OCC_ )"$GU-<#)]^N\\<G_B8R?4UP4A^:@!12-TI1TIK&@"(]:2E- H
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MW_'X_P!:^AO'Y_T63Z5\\W__ !]O]: *[=*:O6E8\4U>M #WZ5">M2L>*BH
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M8S4XGBHCUH 3O1BG*,TXKQ0!O^&O^/E?K7O?@X<QUX-X9'^E+]:]]\'K_JZ
M/5[7_4+]*E/2HK;_ %*_2GN< T >4_%/_CS?Z5\RW?\ Q]/]:^EOBBW^B/\
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M%_X24_W_ -:8?$C$_?\ UKSTW;C^(THNG/\ $: /0QXD;'W_ -::?$AS]_\
M6O/3=N/XC3?MC_WC0!Z,OB4@??\ UIW_  DK?W_UKSC[8_\ >-+]L?\ O&@#
MT&?Q&S1D;_UKE-1OS/(3FL@WC_WC47F%FY- %A_FYJ$GYL5)N^6JY/ST 3XX
MJ$_>J8'Y:B/WZ )5'&::7Q3Q]RJS]: )#)5S3SNF%9F:OZ8?WXH ];\%1_Z3
M&?<5] Z6,62?2O O!3CSXZ]]TS_CR3Z4 6UZU7OO]4:L+UJ"^_U9H \C^( _
MT63Z5\\7_P#Q]O\ 6OHCX@?\>DGTKYWOO^/Q_K0!68<4U1S3VZ4Q>M #F'%1
M5,_2H>] !5NW&:J5<MCB@!UPN!52/_6CZU<N#D540?O1]: />_A)_P L_P *
M]]C_ -6OTKP+X2?\L_PKWV/_ %:_2@!]1S?ZHU)4<_\ JF^E 'C'Q EVN]>%
M:W)ND;ZU[1\1Y,2/7AVJ-F0_6@#/2IPO%5T-6%/% #&.#3E&144A^:I8S\M
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M <QIE*:,4 )4D/\ K5^M1U)#_K5^M 'NWPS^XE>YZ?\ <6O#/AG]R.O<]/\
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M \TYJC[T 3"EI!TI: .<\4?\>3?2OGGQ:O[R3ZU]$>)AFR;Z5\^^+D^>3ZT
M>6W!Q.WUIC-Q3KO_ %[?6H#TH >AYJ1S\M0IUJ1^E $6>:D4U%4B4 *_2F**
M>W2D6@  ^85[9\)O];'7BO\ $*]I^$_^MCH ^BH/]2OTIS"FVY_<K]*DH C<
M8C;Z5XG\2QS)7MTG^K:O$_B5UDH \%U,?O&^M9/>MC5/]8WUK'/6@!ZFD)I!
M0: ' TA/- I#0 X'BD8T4AH ?#]\5W'AG_CXC^M</#_K!7<>&?\ CXC^HH ^
ME?!G_'@GT%==7(^#/^/!/H*ZZ@ HHHH 0TS'-24F* ,7Q!_QXO\ 2OGOQ?\
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M44 %%%% !1110 4444 ':N!\>_\ 'H_TKONU<#X]_P"/1_I0!\W>(/\ 7/\
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M[O\ "3_EG^%>^(?W:_2O _A)UC_"O>E_U:_2@"4&H[G_ %#?2G+3;G_4-]*
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M %D= 'T59']TOTJ[5"Q/[I?I5\=* &2_ZMOI7B'Q,',E>WR_ZMJ\3^)0YDH
M\%U$8=OK64>M:VI\.WUK)/6@!ZGBD8T@-(: )%/%-;K2 TAH D4\4QNM -(:
M 'P_?%=OX9_X^8_K7$0_ZP5V_AG_ (^8_K0!]+>"_P#CP3Z5UU<CX+_X\$^E
M==0 4444 %%%% &+X@_X\G^E?/GB\?O9/K7T)K__ !Y-]*^?_%X_>24 >27_
M /KVJLO6K-__ *]OK544 2$\5&:7/%-H *<O6FTHH D8\4U>M(32"@"0GFO6
M/A7_ ,?:?6O),\BO6_A7_P ?:?6@#Z:L_P#CV3Z58JO9_P#'LGTJQ0 4444
M%%%% !1110 4444 %17/^I;Z5+45S_J6^E 'C7CC[[UX7X@_US?6O=?''WWK
MPKQ!_KF^M '/]ZD!XJ*G T #=:;2FDH 45(#Q45.SQ0 -UIM!HH Z/PC_P A
M6/ZU];^#_P#D%1_2ODCPC_R%8_K7UOX/_P"05']* .EHHHH **** "BBB@ H
M[44=J /-OB2<6+_2OF'5GS=/]:^FOB8<6#_2OE_46S=O]: ,]NM.2AA0G6@"
M0]*C<T]NE1$T *II6--!H)H >E#T)2O0 L8H<4Z$4Z04 0A:"M3(M(ZT "'
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M:FI'YV^M9?>@!P%(:>HI&% " 4AJ11Q36'- " 4AJ11Q3&H =#_K!7;^&?\
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M3L4@J0#B@",TE.;K3: .C\(_\A6/ZU];^#_^05']*^2/"/\ R%8_K7UOX/\
M^05']* .EHHHH **** "BBB@ H[44=J /,/B=_QX/]*^7K_F\?ZFOJ'XG?\
M'@_TKY?OO^/U_K0!684U14K#BF 4 #=*B(J:HV% #!2FE44K"@ 0T,::*":
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M0\4 12]:AJ67K45 !1110 4444 %%%% !3T/-,IR]: +@/RU%GYJ0-Q3<\T
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MJ8]./2HV- #DI7Z4U*<] $8%*13XUS3F6@!BT,>:7I36H FB/%*YJ)#BAFH
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MWUKW?X@_ZEZ\(NO]>WUH B%!I5%*PH 92YI** %S1244 6H>E)-21'BB0Y-
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M5R_A^#;:QG':NIC&%% #ZRM5&8S]*U:SM17,9^E 'B'Q"7]R]>#W7^O;ZU]
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MS-.%:J0;CZ***LH****8!0**6FA!1115 %%%% !1110 4444 %%%% !1110
M4444 ':N!\>_\>C_ $KONU<#X]_X]'^E 'S=X@_US_6N3;[YKK/$'^N?ZUR3
M??- "$TY.M-(IR=: '/TJ,5(_2HQ0 $T T$4V@!Q-.A_UJ_6HZDA_P!:OUH
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ME4TKC%-2@!QIRB@"G#B@#1L4S(M>V> ;(2QIQ7B5B^)5^M?0'PSP\:4 =O\
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M*?Y15R&7-=,'J5%EX4ZHU;-25WP>AH%%% JUN M%%%:""BBB@ HHHH ****
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M#.U-<QFO&?B%'B!_I7M5\,H:\@^(D7^C/]* /GB[XN&^M1JU3WRXN&^M5,T
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M,44O0T >B>%=3^SJOS8KT"V\2!5'S_K7B-A?&$#FM0:XRC[U 'L?_"4#^_\
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M/G1KS71]J\]\'WZM$N6[5W<<RL.#0!#,F334;::LL 15*3AZ +\;9%.)YJ*
MY6G-UH E%+34Z4Z@ HI":89 .] $E,D.%J(W"CO5:XO$"'YA0 AE^?&:M)RM
M<_\ ;5,^-U;=M*&0<T 6 .:<>E I6Z4 0]ZD4U$>M.6@">J&H#]V:O"J5_\
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M1110 4444 %%%% !1110 4444 %%%% !VK@?'W_'H_TKONU>?^/_ /CS?Z4
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MNKUOPKJWFHN6H ]>ADWI4<B9:J6G70:,<U?WJ30!/",+3F'-,210.M*95]:
M)5Z4IZ5$)E]:&F7'6@!)'P*RKJ]V \U8NKD!#S7(ZMJ&P-\U %FZUH(3\U8]
MUXB !&_]:X[5M;*,WS5R5YXA.XC?^M 'IEOKH>Z'S]_6NYTK4!)&O-?.VFZV
M7O%^;O7KWAN_,D<?- 'IT+[E!J4]*HV+[H@:O]J (B*0#%28I",4 *#5._\
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MSFL:WO 5'-+=W@$).: (-2U$*K?-7G7B;4PT+C=6GK.I[0WS5YQKFI[PPW4
M<=K,^^9^>]<ZY^>M*_EWR-66W6@"Q">:GE;Y*IQM@U*[Y6@"'^*G-TI@^]3V
MZ4 $9P:L#D54!P:M0G)H 1UQ3H4WN/K3YA@5/IT>^0?6@#U[X70XE3CO7T#"
MO[E?I7A_PW@V2)Q7N</^J7Z4 .6GT@%+0 R7_5M]*\0^)@YDKV^7_5M7B?Q*
M',E '@>I#YV^M9?>M?4Q^\;ZUD'K0!*IXIK&D!H)H >IXIK=:0&D- $BGBF-
MUH!I#0!)#_K!7;^&O^/F/ZUP\/\ K!7<>&?^/B/ZB@#Z5\%_\>"?2NNKD?!G
M_'@GT%==0 4444 !IN>:4]*CSS0!FZW_ ,>C?2O"O&'62O==;_X\V^E>$^,/
MO24 >.ZC_P ?3?6JW:K6H?\ 'RWUJH>E #E/-68S5-3S5B-J )IC\M5H?OU-
M*?EJ&'[] %R492J)&#5]N4JJXH @:M_P]<>5*ISWK :K5E.8F'- 'N7AW60F
MWYJ[1?$ "#Y_UKP;2M8*$?-70?V^=OW_ -: /6?^$A']_P#6D/B$?W_UKR3_
M (2 _P!^FMXA/]_]: /4KCQ$,'Y_UKF]3UT.3\_ZUPL_B$\_/^M9=QK9<_>H
M [N#4]\@^;O7IW@^;S%7FO M,U O(O->V^ Y=Z)0!Z:OW12TU?NBG4 %1S?Z
ML_2I*9+_ *LT >:>+8\B2OGWQ:NVY;ZU]&^*(\I)7SQXS7%TWUH XU1S5I#\
MM0**DSQ0!')]ZGJ/EJ,_>J=!\E %=N&J<-\M0R?>H#<4 +GYZMAOW=40?FJ<
M-\M %BRDVW0/O7IWA[5/+5!NKR>-]L@-=%IVI&,J-U 'O5AKH6)?GK23Q /[
M_P"M>.VVN%8Q\]6%\0'/W_UH ]=/B 8^_P#K5:;Q$,??_6O+V\0';]_]:HS^
M(3_?_6@#T>[\0@@_/^M<]>:SOS\U</-KY/\ '^M5/[7+G[U 'J?AB\\V\'/>
MO8K$9MU/M7@/@>Y\R]3GO7T%IPS:)]* )2O%<-XWBW6S?2O0-M<;XPBW6[<=
MJ /FSQ%#MD?CO7)JN7-=]XJ@VL_%</$N93]: '!,"HY:N2+A:I2T -09IS+B
ME@&34DHP* *IJ>$9JNW6K-O0 ]A4:MMD%3R"JCG#4 >D>$]2\D*-U>N:)K(9
M5^:OG/2]0,)'->C^']9/R_-0![U97@E7K5EAN-<EH&H"2-<M75PR*PZT 78!
M@58JND@ I_G#UH EHJ+SAZT><OK0!(W2J4\^T'FII)UVGFL+4+L*K<T -N=2
M"$_-65/K87/S5S^JZIM9OFKDK_7"N[YZ: [:\\1C:1O_ %K-LM:$MZHW=Z\R
MO?$)W$;_ -:ET#63+J*#=WIH#Z6TJ7S+13[5; ^:LCPU)YFG(?:MH#FDP)EZ
M4ZD7I0:RDP"JEV<(:LYJE?G$1KGK/0.AS.HR=:YJ9LL:V=0DY:L*0Y8UXM5F
M39&W-+&O- J5%KCE(EC)1\M11+\U69!Q4<8YK'F(N3;<BH)1MJY&,U6O1A:V
MA(155^:T[)\$5BQM\U:5L^"*[J4BD=CITF<5T-N<@5R6ER<BNIM&R!7IT7J:
MP+]+2"EKOB:!1115 %%%% !1110 4444 %%%% !1110 4444 %%%% !VKS_Q
M_P#\>;_2O0.U<!X^'^B/]* /FK7A^_D^M<L_WC76:^/WTGUKDW^\: ')3GZ4
MU*<_2@!J]:<U1@T\<T (!014JK0RT $1Q4^:K XIX:@"4FJTIJ1FJ!SF@!E.
M IM2** &$4H%*PYIRCB@!5Z4^H^E/!XH ":A:GL:C-  *EC7FHE'-6XUXH L
MH<)44K4A; J!WH C/+5.B\5"O+5=5?DH B<_+51OO5/(U0]30!I:/#YEPHQ7
MLW@S3=LL;;:\K\+V_F7J#'>OH?PII@2&-MO:@#T+2X]EJ@]JOU!:KLA J>@
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MT$%:F@7<:?<1X6@ M+@JW6M+[6Q'6L.-MK5<C?- %XW+>M1/=-ZU$QXJM(]
M#Y;ICW-5C.Q/6F,V:8.M '2Z+(3(O-?0/P[.8T^E?/6B?ZQ?K7T'\.O]6GTH
M ]4#844]3FJ[-A14D1S0!-3)/N&GTR3[AH XGQ&F8I/I7SGXX&+MOK7TIX@3
M,,GTKYO\>+B[;ZT <0M*:1:<>E $7\564/R56/WJF4_+0!#+]ZFTY^6H XH
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M7EQ]_P#6D;7U'\?ZUY'%XD)7[_ZTR3Q*1_'^M-(9ZX?$*_W_ -:/^$A7^_\
MK7C;>)S_ '_UI/\ A*#_ ,]/UI"/8I/$*[3\_P"M8&HZZ&5OG_6O.F\3DC[_
M .M4+GQ 7!^?]: -K5M6W,WS5R&H7Y;=\U5KO5"Y/S5CSW1?/-- 5[NY8N>:
MU?"LQ.J1\]ZP)3N-;7A3_D*1_6D!]9^$#G2X_I72@<US?@[_ )!<?TKI@*;
M6F$T]NE0L:QD N:HZB<0FK6:HZF?W)KEK/070XS4'^=JR"<L:T+]OG:LU>7K
MQJID]R0"I$--(P*(SS7%+8F0^3I42'FGS'Y:@B;YJPN9ME]&Q5:].X4\M@5!
M(V^M(/4$4D7YJNQ'!%1!,5*G!KOI/4M'0:6_(KKK%L@5Q6G-@BNOTUL@5ZU#
M<T@;0Z4M(.E+7I+8U"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444
M':N!\>_\>C_2N^[5P'CX_P"B/]* /F_Q!_KI/K7(R??-=7KY_?2?6N4?[QH
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M5EM]RMOQ*F-2D/O6$3VH K..::*F=:B[T /4U(.*C44\T #'(J''-2#FG;*
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M[5U:'(H :5Q2 \U(W2HA]Z@";M5"^_U9J_VJA??ZLT >3?$ ?Z(_TKYWOO\
MC[?ZU]#_ ! /^BO]*^>+_P#X^W^M %=NE,7K3F/%-7K0 ]^E0]ZE8\5%0 5*
ME1@5(.* %>F1_P"L7ZTK&DC_ -8OUH ]\^$G_+/\*]]C_P!6OTKP+X2?\L_P
MKWV/_5K]* 'T444 1.>:%/%#BF@XH K7T.^%N.U>+>-[#,CG;7N4@W1&O-_%
MFG^;O.V@#YNUF$Q2GCO6-OQ79>*;/RIFX[UQDJ[30 F[)JP@RM5%ZU;C/RT
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M L:>?WJ_6OH7X8']W'7SYIJYE7ZU]#?#)<1QT >PK]P?2F,>:>OW!]*AD/-
M$J&GU%$:EH JWHS;/]*\ ^(-MNN'..]?05T,P-]*\7\<6N^1SB@#P+4HMDA^
MM9HZUT6N0;)FX[U@$8:@"S".*L%?EJM$>*L[OEH HR\/2@_+393\U(#Q0 U^
MM(O!IV,TX+0 X/Q3-W-*5XJ/O0!91LT\CBH4J4MQ0!&>M(:#UI.M #2:%/-*
MR\41KEJ /1OAP?\ B8)]:^I-*_X\8_\ =KYA^',>+]#[U]/Z5_QY1_[M %S%
M %*:0&@"O<P^8IKR[Q[8?N7PM>M$9%<5XOLO/A;CM0!\S:A;&.5N*P[FN^\3
M6'V<N<8K@)^6(H CA&33IA@4D?RTDS9H @QFF-Q4R#-,E7%  C4.]1J:1CS0
M \<TUAS4D8XI''- $D0XILG6G1]*1QDT (HH(H'%)FJ0WL2J.*C<<T]6XIK5
M+$,QQ49ZU(341ZT 2J.*4#FFJ>*4'FJ8$^/DJQI1VWJ_6JV[Y:?8/MNE/O0P
M/>?!\XVQC->R:9S;+]*\ \'7G[R-<U[WHK[K)3[5+ TL4[M4>[FGCI64F,CD
MZ5@ZQ_J6K??D5AZPO[EJXJBN#//KK_7-]:= ?FI+O_6M]:CA;#5Y\T83+\OW
M*J*,M4[OE*@3[U<55&8^1?EH@'S42'Y:+<_-7$R&2W"_+4=L/FJ:8Y6HH>&I
M1W)B27/W:HCEJMW#<543[U=M'<T1JV"\BNPTH=*Y734R177Z<N *]:B;0W-E
M>E.Q35Z4^O3I[&P 4M%%;B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW%>/>*M+/SX% 'D-\3DU4B%;6HV#(QXK+$>PT ,857?K5AS4#<T -4U.@S4
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MZUF8YH >HI&%/44,* &J.*1AS4BC IC=: % XIC"I!TIC]: %A_U@KMO#/\
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M:W^B)]* +I%1D8J6HWH %-/[5"IYJ8'B@#E_$>GBZC88S7C_ (DT40;CMKZ
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M:0W+(IU-%.%>G!&XM%%%;""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M[5Y_X_/^AO\ 2O0.U>??$#_CS?Z4 ?-NO-^_D^M<J_WC74:[_KW^M<N_WC0
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MQ[MS2 9JS):.I.13!&5ZB@!@2GC@4X 8ICG% $,IR:8!3F&:4#B@",\&ID;
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M0!QIXIE79K5E/2JK(10 @.*EW\57/%.#4 //6FD\4[M4;&@!IZTY.M,IR]:
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M 5#*@(-3TUAF@#B?$-AYP;BO,M:T L6^3]*]RO+02@\5S6H:*'!^6@#Y^O\
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M2M^RTL1$?+0!:TVU"*O%;B(%6J]O#L XJT>!0 H-.J)3S4HH **** "BBB@
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M[HJQLJ9!B@"O]D3^Z*/LB?W15NB@"I]D3^Z*<+91V%6:* (1"H[4\(!VI]%
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MH 9]E3^Z*AEM$/\ "*OYIA&: ,O[$O\ =%0RV2_W16QLICQ9H JV-N$(XK5
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M<*[(H!*6BE%;Q0A12TE+5%(****!A1110 4444 %%%% !1110 4444 %%%%
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M>K#BHE7YJ +*=*=2+TI: "BBB@ HHHH **** "BBB@ HHHH ***:30 ZD(I
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M1TJ-1S4@H CFZ5!']ZIY>E0H/FH M#I37IPZ4C"@""I$ZTA6G** )***:30
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M: %4U+VJ-14HH :!3J** "BBB@ HHHH **** $(H I:* "D(I:* &XI12T4
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MG"D[THH 6BBB@!#TJ+/-2MTJ''- $PZ4M(O2EH **** "BBB@ HHHH ****
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M %-3"H5'-3#I0 &FXYI]% #3TI@/-/;I48ZT 2]J;MIPI: & 4^BB@ HHHH
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M013J* (BM 6I,48H 0"G444 1N:0<T/UI4% #P*6BB@ HHHH **** "BBB@
MH-%% #,<TX4M% !2&EIN: $QS3A129H 4TW%.I* %HHHJ!A112TQ"4E+14V
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!****D I:**: ****8!1110
M4444 %%%% !24M)4M@% HI:$,****H04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 E%%%0QBT4E+5(04444P"BBB@ HHHH **** $H
MHHK-C"BBBF@%HHHJQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% "4445F,*6DI:M""BBBF 4444 %%%% !2&EI#28!0:*#6;&%%%%-
0 +1115H04444P"BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0V!WT# 2(  A$! Q$!_\0
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MCSC-4/;]:7CI^M %XW,8/6@W,8[U0Z>]. 7N: +GVJ+UI?M,>,YJAA0<]:4
M=<T#+OVJ+UI1<QGO5$JO44<'VH O?:$/0TOGIZU0Q^%')X_6@"[]I3IGFE$Z
M]S5+';]:3D<=: +WVA!U- G3UJC@CWI"#V-,#0-Q&.])]H0]#5  ]3^5+C/M
M0!?\]/6F_:4/0U1 />E_2D(O?:4Z9YI/M*=,\U2]OUI/\YHN,O?:4'4T?:4'
M4U2Z>])^M,"]]I3KGBC[2G7/%4NGO[4G^<4 7OM*'D&G"XC/>J&/P]J.OM2
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M*7:>N11VYZ4O&V@!NUCSN%+M)ZL*.W'2E&V@!NTG^(4NT]-PHXSP*!C/3F@
MVGIN%)M8?Q"E.,].:.,\B@!"GO2@ =.*4XI.W/2@!#S]?6@ 4[C;2=N.E  ?
M?FDVD]Q3EQ3>_% "[3TW"C:W3<*.,^])QGWH -I'\0H*GU%'UI3COS0 8QTX
MI#S]?6E[<]*7C;0 T**7Z\T=N.E*N* &[2>XI=IZ;A1QG@4#&>G- !M/3<*3
M:1_$*4XSTYHXSR* #:1_$*3:1SN%.;&*;]>E "[3UW"DV$\[A2\8]J3MQTH
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M KCH:/H<4<9Y%*<4@&[6'.X4N#UR*.W/2EXVT -VL>=PI<$_Q"CMQTI1M[4
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MX4NT]<BCMSTI>-M #=K'G<*7:3_$*.W'2E&* &[2?XA2[6Z;A1QG@4#&>G-
M!M;IN%)M8?Q"E.,].:.,\B@!"I]12@ =.*4XI.W/2@!#S]?6@ 4[C;2=N.E
M ??F@(/6E7%)WXXH$)MYZT; 3UI>,^]'&?>F,"N.AI-OIQ2_6@X[\T@ #'M2
M'!^OK2]N1Q2\;: $  H/OS1VXZ4HV]J &A!ZT;1GK2\9X% QGIS0 FP$]:4H
M!T-!QGIS1QGD4 &/0XI-K#G<*<V*3MSTH -IZ[A2;">=PIW&VD[<=* #:3_$
M*3:Q_B%.&*3C/ H -IZ;A1M/3<*48STYI#C/3F@ VL/XA1M([T<9Y%*VWO0
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MU)]U,T6U$ =:HS:EUP<54E**IRZY^M9DUW&N<C<?:KBF95'&QZI\/K@2EOF
M^M>G("5]:\=^&DHG9_W;#\*]F@XB Q7;36AYU9ZZ$S=*S9]VX\<5I'I6;/\
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MJ[5]!1M7T%"0&5M?=T-&U]W0UJ[5]!1M7T%,#*97SR#0RMW!K5VKZ"C:OH*
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MW1@:M23,^5D]%("".*6BX@HHHI@%%%% %2\D9%X-8*J\EP2.M:^I5FV_^LH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK/VA#TQ2?:4Z470AT,945,1D8J 72= >:/M2CJ:5P%EMU=3Q6<VGN&RIJ_\
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M]A1U/7%!'OBBP"8].M&?SH_2C_.: #Z]:,^O%'ZT?K0 <GK1T^E'3WH_SB@
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MO2=>](=@SZ"EYQ1^E)G/&:86#/YTHSCD4G^<TN>U(+!GUI.3UX%&/QHZ>],
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MQ0"/I3V@D[T?9GIV ;W_ *TF1G^M2>1)C':D^S/0 T_G2'WYJ06\@'%'V9Z
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MCC\J/TIWV:3-*;>0]:8$8(^E+W_K3C;24OD28QVH CR,_P!:4_G3OLSTHMY
M.* (S[\TN>/7VIWV9^U MY!2 CS^7I3@1CC\J4P2$TOV:3- #,^@Q2CZ8IS0
MR=Z7[/(1S3L SO\ UH[_ -:D\A^_2CR'[=*!$9^F:3([\U(+>04&W;M0,:2"
M.E)QC^E.%O(#Q2_9Y#]:0#05QTI!CZ4[[-)FE-O(>M #, TO^<T[[/)2^1)0
M.Y'Q1CVS3_LTE+Y$G:@!A]^:3 ^M/^SR&CR)!TH ;V_I28!I_P!GD-'V>04
M-_2@%0>E.\B3O2&VDH$-XST_&C(SR,^]/\B3&.U)]F>F TD$],T$COS3Q;R
M<4?9GI ,XQZ^U)V_I3Q;R \4OV>0_6@!@(QQ^5'Z4[[-)FE-O(>M,",$?2E[
M_P!:<;:2E\B3&.U $>1G^M*?SIWV9Z46\@'% $9]^:7C'K[4_P"S/2"WD!XI
M ,[?TI01CC\J?]GD/UI/LTF:8#?TI 1]*D-O(>M(;:2@!O?^M)D9_K4GD28Q
MVI/LST -/YTA]^:D%O(!Q1]F>@!G&/7VI.W]*>+>0'BE^SR'ZT@& C''Y4?I
M3OLTF:4V\AZTP&8!I?\ .:=]GDI?(DI#N1\48]LT_P"S24OD2=J &'WYI,#Z
MT_[/(:/(D'2@!O;^E)@&G_9Y#1]GD% #?TIH(SZ5(8).])]FDH$,)YZ?C0",
M\]?6I#!(!31;R$4 -)]LT9]>:D%O(!Q31;N::0"<8]?:D[?TJ06\@/%'V>0_
M6D P$8X_*CZ<4[[-)FE-O(>M,!@^F*._]:?]GD/6E\A^_2@"/O\ UH/TS4GD
M/VZ4@MY!0(C/OS2\8]?:GFW;M2"WD!XI#&=OZ4H(QQ^5/^SR'ZTGV:3-,!OZ
M4*5STIYMY#UI/LLE(!A89X% 89Y%2"U?O0;=NW2@!I()Z4A^F:-CC@4;&'2@
M [>OM1@X]O2D .?>G9/3O0 @Z>GM0!GIQ2[?7K29(ZT"#&.V*._3\:.>]+_*
MD,0@$]/QI#QVS2\_A2]N*!EBUJW52UQVJW5(3$;.*SIE^8FM$]*S9V.XC%,0
MU2,>]'&?FXH7IT_&@]?6I8QS8QR:;VYZ4X].F:"1CI2 ,+MIOTZ48[_I2Y_#
MVHN #IQS2)]ZD)/IBI8AN;I3 L1Q@\U-Y:TJ* *=5"&[!2X'I2T4 )@>E&!Z
M4M% "8'I1@>E+10 8'I28'I2T4 &!Z48'I110 F!Z4N!Z444 &!Z48'I110
M8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I28'I2T4 &*3 ]*6B@ P/2C ]*
M** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2
MC ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@
M P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/
M2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#
MTHP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THH
MH ,#THP/2BDR* # ]*7%%)D4 &!Z4N!Z444 &!Z48'I110 8'I1@>E%% !@>
ME&!Z444 &!Z48'I110 8'I1@>E)G%+0 8'I1@>E%)G- "X'I1@>E%% "8'I2
MXHHH 3 ]*7 ]*** $P/2EP/2BB@ P/2DP/2EHH ,#THP/2BB@ P/2C ]***
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M]:82O4=*0$'GM0 \W#CO2^=)CK324/W>::&!.!0!(9W ZT"=R.M-RG3/--W
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ME)![ 4E%   !VI20?X0*2FA2#G- #]G?%&1C[HHR?6F;3G.: '[-W.* 0.,
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MH ;WHI0"W2FMD=* %HH4$_6A@5^M !12*6[TM !1110 4444 %%%% !1110
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MM)10 W:<YS3\GUI/PHH **** "BBB@ IH4@]:=30V>,4  X;.<^U7HCE>E4
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M:K:#J<+PB(*!)["C0#I=4\2K8)Y9<>81ZUS4GB75)7WI-A![5E>(K2[?4%E
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MIM*2J#YC@TSS%SUH =M9ONG%&".#UI-P SFE!SS0 4444 %%-"X.<TNX9Q0
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M5FR\R'C%:1Z5FSAMYYH$+C"5&OTS3E)V]>*.O3BDQ@3^-'Z^U+C'0TF?3K0
M=OZ4F"><8]J7'YT;B.#UI, 'TQ5BW/S57Q_>YJS;_>IH3+=%%%4 'I5*XX/3
M-7#TJG/G/!Q0!"J]S^5/I!TI:>H!1P.@HHH :&)/2I2?E^[3*7<<8I ,W'.,
M5*IX^[FF4H8@8% #68@]*<A]LTE*"1TH 1SWQ2(23TIQ)/6DZ4 .8^V*;2EB
M>M)0 4444 %-8D=!FG44 *A]LTCGOBE!(Z4$D]: &H23TI['CIBF]*4L3UH
M8&)/2I2?E^[3*7<<8H 9N.<8J53Q]W-,I0Q P* &LQ!Z4Y#[9I*4$CI0 CGO
MBD0DGI3B2>M)TH <QXZ8J,,2>E/+$]:2@!Y/R_=J+<<XQ3]QQBDH >IX^[FF
M=Z4,0,"DH **** "BBB@!H8D]*E)^7[M,I=QQB@!FXYQBI5/'W<TRE#$# H
M:S$'I3D/MFDI02.E ".>^*1"2>E.))ZTG2@!S'VQ3:4L3UI* "BBB@ IK$CH
M,TZB@!4/MFD<]\4H)'2@DGK0 U"2>E/8^V*;TI2Q/6@!**** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !12@$]!24 (1D8I, #K3J*
M&KCL:4,#TI<#L*-N.<4 )N&<4M)@>E+0 4A8#J:>& '(IC<GY5S30!$A9B2>
M*S=7U$VJD9P*UT<*G(Q7&>(9C)<,HYYZ4T!I:5J373X!R,UT+(=F17->&[8^
M7NQBNE=CC&,4,"(* :6BBDP"D+ <9I-QSC%+@>E(!ZX(Y-(>O%)10 4=*0G
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M@#K3:* #R^^[\**;NYQ@U)E<>] #:*<"N.:;WH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "4NTXS24N3ZT )^%%%% "@[:.6-)10 I!'6DHR3UHH **** "BBB@ HHHH
M**** "F@MGFG4F0>] "#.[D<5>BQMXJACYNM7H1A* ):*** (Y<[>!6<Y._I
MS6A-]WKBL]_O]?QI,!XSCI3<^M*.G6@ >N:D!I+4[MS1D#OFDQGO3*#GMTH&
M<4#CO0>>AQ0!8MO:K@JG:\=:N4T)B'I6;.1O/'-:1Z5G3YW'@4 ,7&.G-#?>
MYH7..G%&<'CFDP''&.12'&.>E*<XXI,>G6D G;VIP*[:3/YT;2>:& @_V>*L
MVP^:J_UJQ;YW4T)ERBBBJ 0]*I7)&>>:O'I5*XZ_+S0!&O2EH'2EIH!****
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(6 ZTM.7'=<T
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M3S0P$Z^U6K?[U5OKS5BVSNIH3+E%%%4 AZ54FY//-6STJG<9)^7B@",G X%
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MNC)IN_)YX-%P*KZ#IY;?Y?-6((X+,?NTQ4HP1UYIK)ZTK@#M'=_(R\>XJO\
MV!IV_P PQC=^%6>W3%,.\GKQ3!CE$%L-L:=*0K#<#$JYI0 .M*=O\-%P*C:#
MI['<(QG\*F73K.)<!!3OF4\$T_R@PSDYH C-C;'D**5(HXONK@4'"-R34BE7
M'O0 &6-E*E>#UJB^B:9,VYHQD_2KC +P12?9P>68B@"&+2[*V.8DP14LEM;W
M";)4!!IY78OJ*;PXQG IW ICP[I:MO1!N_"K"PK"-H' Z5((-HRK$_C0)"_!
M'2E<!RD=^E(^/3BD.1TH&2.:0 F/2G-MQP*:>G%"Y[T@&KMSP*E;&W@<TPD+
M0)&/&.* $!(X(-/WH.&%*& '(&*8S1YZT .W1+T4FCY6ZCBHVE2'[O--2Y+'
MY10!*=HX'%.'W?O"H'$CG('-0M!<MT!H M8SR&'YT--&!CO5+[->#L:@EMKQ
MARN* --;N$''>G-<0GN,_6L!K>Z7M36CN=O?\Z -PW%N#\Q!_&E^VVV.,?G7
M->7=$\YI?(G7H3^= '1B\@SR1^=(;V '.1CZUR[0W)/&<_6D,-R!SG/UH ZH
M:A">A 'UIPO[<="/SKD-ER#CG\Z"ER.I/YT ==]MMO4?G1]MMO4?G7(8N/4_
MG2%;@CJ?SH ZXZA;= 1^=)]OMQP2#^-<D$GZ$G\Z=Y-QCY23^- '6K>V_=A^
M=*VH6X')'YUQX2X!ZG\Z7%QZG\Z .M%[ 3D$8^M/%_;@8R/SKDE$X&<G/UJ*
M::9!EB0?K0!UTE_;KSD?G35U6S/&1^=<#/>S'C<?SJF;V>,Y+'\Z /3%OK0G
MC'YTKZA;J.E>:+K4L?+,<?6I5\2@\,W'UH ] &IPYX%.;5(>_P#.N"&OQX^5
MLT#6@Q^]^M '??VI!CYN1]:C;5;8=*X4ZW&!]_GZTU=81FY?]: .\75;=NHX
MI3J=J/N\5Q2ZK">K_K0^HQG[KG\Z .S74DSP?UI6U.+\:XQ+V5N_%3>;*W7I
M0!UJ:I#ZC/UJ0ZK;C[W)^M<BJ.?XC^=/PZ]"2/K0!U)U: ]_UI/[6A(QFN4*
MD_=8_G3@C*."<_6@#J/[4M_\FE&K0@8!_6N3.\M]XY^M/5&ZECGZT =1_:D'
M^32C5H%/!'YURQS_ !,1^--52S?>/YT =C_:T&S.1^=<AK.IP27+ 'D^])=!
MT@)W''UKE9U>2[^\2,^M- =SH=Q L>6Q6Z=5@QCT]ZXS38RD&,G\ZL.K _>/
MYTP.I.J08ZC\Z7^TH,9R/SKD\,>C'\Z!O#?>/YTF!U7]J04HU. ^GYURI#=V
M.?K2$-W8C\:E@=5_:EOZC\Z/[5M_;\ZY0#U8_G1@Y^\<?6F!UG]JP Y_K1_:
MT)Y_K7*[CTW''UHW$<!C^= '5'5H#U(_.G'5(=O4?G7(D>C'\Z4YQ]\_G0!U
MO]J0[>HQ]:!JD.WJ/SKD/F_OG\Z< 2/OG/UH ZQ=4A(."/SIG]I6X.:Y<*R]
M6/YTA?LS'\Z .K;5;8KQU^M1_P!L0+]:Y;OG><?6CCKN./K0!U/]M0G[U1MK
M4*FN< 0]'/YTC*.S9H Z;^VHF'6FG68@,US6P#D,<_6G!5(Y:@#I!KD6WBD7
M7(OI7.%5QPU-V ]6Q0!TG]MH3\O%*NN1YYZUS84=VHQSUXH Z0ZY%N]Z<=9C
M/4US..>O%!'/#'\Z .E?6XAUIO\ ;:8R3Q7.$#L?UH(&.M '2_VY%M]J;_;:
M8R#Q7.8&.O-  QUH Z5=<BQQ3?[;0GY>*YQ0.YQ3MJ?WJ .A77(]W/6E.MQ%
MN:YEESWI N!@GB@#J/[7AH.N1)TKF  /NL2*>-A_B- '1'6UZL>*7^VH=N:Y
MQE'8TW*#[S4 =,NN18]J#K=NW3C\:YK,7]ZD/E'^,_G0!TG]MQDX7BG#68QR
M3S]:YDM$H^_^M-\Q,\N<?6@#J#K,9Y!Y^M UA#]X_K7+^8F>'./K1YB'HYQ]
M: .H_MB*D_ME<\GCZUS0>(_QG\Z0R1]%<_G0!U/]M1XQGBF?VRN>#Q]:YD/'
MT+G/UI2\0XWG/UH Z<:S&.AI#K*?PG]:Y?S$_B<_G1YB#JYQ]: .B_MQ0>M-
M.OKGCK7/EHSU;BDS'V;B@#H/[?'?DTC:\>YK"4PXX:D+QGA30!O'7CMZTG]N
M'&:PP(AR6IV8O[U &Q_;;'D'BGKKK8X-89>$<!N::'C'WCB@#=&N9/6E_MU>
MG>L)C#CEL4?N2/O4 ;HUX#CO2_V^._)K!_<@?>IN8_X6S0!OMKJG[W-+_P )
M"N,8.*P,PKU:E-S9QC._F@#=_MP=><5(NM*PSTKE9=1M\_(W-0&_'4&@#KGU
MMA]PXIJZZV>M<>^K&,?-55_$,8ZG% '??VT&[\THUC'&>:\U?Q.%/#<4Y/%?
MO0!Z.VLOGDT-JK.,EA^=><MXJ]#5=_%;G_5G/XT >EMXB%N/F8$?6JLOC&(=
M_P!:\U?7)K@]3^=31,TPRQ_6@#T!?&",<*>/K5B/Q&DAX/ZUYX%"M]XY^M68
MK@HPRWZT >B#75'(/ZU*NOQGC-<9#.I4;F_6K:1JW(8XH ZP:S >O6IEU"U8
M9/\ .N0V[> Q_.E#N!C<?SH [2.]MI.%(_.G[D/1A^=<4DTD?1C^=2K?3H<A
MB?QH [(J&7J#30 O;BN:AUB9#S_.KL6N@_?Q0!LAXQ_ ::?*;HI%4TUJ!N#C
MFK4=Q _.[K0 ^+:'QBB9\'BEX/*]*>L3-VXH ;!$)1EJAOKV.R3&1^=27-RE
MI$V3CBN'U'4)M0N"D1) -- /DW:Q>%#DKFNMTNR33[4#;T%4-!TDVZB9QR?6
MMF=\_*!1J UV$K;AT%/!5^G%,C4@8[TN&4\\4^@#FQC %,VC.:>6R,8I-IQF
MI 7Y<=.:85!.33]W&,4@4GD4 *N .136 )I0VVC!8\4 (H [<4K8/04<J:"=
MQH :% /%/.W' I""O6E+9&* &;1G-/\ EQTYI-IQFEW<8Q0 PJ">:>N .12!
M2>10&VT (P!-"@#MQ2X+'BCE30 -@]!30H'2G$[C05(ZT )1110 4444 %%%
M% !1110 4T-GC%.HH 8 "^,<U?B&%JA\V[I5Z'[@H EHHHH BFQMY%9[XW].
M*T)L[>!6>^=_3F@!PQCI2#';BG#..E-P3UXJ #OQ0,9]Z,XZT<GZ4P XS[TA
M]Z7D?2@DGI0!9MJMU4M1BK=- (>E9LWWSS6D>E9L^W>>.: &]5ZT 8[XH4C'
M3FCC/S<T,8O7OBE(XZT-C'(IOUZ5("]L9_&E XZTG&/:D[<=* %&1WS5BW'S
M57&.W%6+<_-30F7****H /2J5QR>N*NGI5*Y !Y&: (QTIP&3BFKTI:8"L,=
M\TE%% !M]!299#DG/M0LG/%*5,E2 H._G&!03$/^6@SZ5'=N;>S8]P*Y)-4=
MKO&3UJK =B6W?PXI,"DMI"\"EO2G'K18 )RN*:H*]Z"<4 YI6 7KR>:5BCC&
M*;VIJ[<\"@"16 &/TI<)U!P:9M&<TT[=W0YIW 5N3RU.V;Q][%(5!ZTM(!-H
M4T\;3P1^--HH 4C'0TH;UYIM% !3=ISG-.HH *, =*** #9N_BQ1RO -(6Q3
ME(ZF@!I4/U/XTH3R^AS0Q Y%(K T +]X\TYA\O6ABO:FT -4X/+9]JD*!AP<
M>U,V#.<4;\-2L FQU/WN*D^4CTIC2<\T%0W--@#*>WYTJCL32#?T/2G[ 1EC
MQ0 A /"G-((V'6HIKF&W&00/QJC)K0*D*: -)D5.6?-1/=PQC[XSZ5@M?3RO
MC)P:FAMQ*P+]Z5P+CW32-\G-2Q6LTW))6I[6VMXP.!FM1"N.,4P*46G[1\S9
MJREM&G05-10 W8H[4O YI::^-O- $4MRD?>J4VJ1J.@-)=JC*<"L&X&"<4[
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MO[4F//-(=5F/K73?V##_ '>*/[!MO[E%@.6.HS]LF@:E..3FNI70(<\**5M
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M<_C2'8ZS^S;G;_K#]*!IEUC_ %A%<;_PL*?/\7ZU(OQ!G[EOUH!HZY=,NO\
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M*!GO2GI4@-7Z8IU-7/<TZD 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !2'S'XP0*7O4NXHN6(Q0!"JI&<L*I7>JB/*J/QIE_>H%89'YUSEQ<,[
MG#<4 7Y)6NFZYS3H-(9^>N:SX)'C7Y35R#69H#@F@"Q+HDD8W+D^U5TM95?:
MX.*W;#5TN.'8?B:EU'R?(,B%2V.QH P+C9!$2.M<_<Z@6RN*GU.ZE\W;DUE2
M*2<L<T ,92QSTI\:MGI2J2W!Z591"/I3L3<>B'&<4UY-E.9G X/%1%3)0(JS
M2LYZ9J!D)ZC/M6@(2.E,,9SQUIH11%MN_AIXM0!DC'M5Q58-CO3WC.WYNM!%
MS+F50I %5[2U>6?[IZU:G7:XYK2TYHXR"V*8FRQ# 8HQ\N,4X@MU%76E1DX(
MIJ&/H2*+,15&%&,4TC!X7-76A0G((I/+0="* V*84'M1M'I5S9&>A&:-B ]1
MF@=BD5Q_#2;<]L5=VIWQFD95ZY!HL)%386XVXIL@"IR/QJT9T7@U2NY@R'!X
MI%HR+C#2$8_&GPJ$'W<TSEI/:KR0EDR#BI-$5IFXX%4Y*N2K@\54<$TBRE+U
MZ5%COBK3I^=1;3WIH>Y!MW=L4H!Z8Q4VPT;2.M,2(=N>WXTT@YQBK(C)I&C(
M[T@(54_W<U<M8=Q^[FF0HS=#Q6I:PL!Q0 ,NR,<4_3X3)= A>].D4]*T]'A_
M?*<<T =#9Q&*VR1VZ5DZA=LIQC%;[ML@_"N8U [WR3F@"LUQ*1G!J#[9(&YS
M4VX[<&JSC+4DT,G6Y=VZ?C4=[=O#"W&>*?#QCTJ#5&0V[X(Z5T029+9Y_JGB
M66"X8*">:JQ^*[C&=IK/U95^U/CUJL@!& *Z8Q1+-E_%<^>AH7Q3<?W36.54
M'D<TJ[>XK3V: V3XIG[*14,WB.>1<<BLUE7TINP#K0J8KED:S/N[_6I/[>NU
M&!GZU2V <]J=V]J?LD%RS_;UVQZM3_[<NU'\1JEMSR.*<A/0T>R07+/]OW0_
MO4?V_=_[7TJL5':E"@<T>R0^8L?V_=_[0H_MZZ;NPJN0#2!!1[)"N6_[:NP,
M[V%(?$%\.C-57;_>-(1ZGBCV2"Y:_P"$BU'J':E_X2+4#U=JK#&.U-P3]VCV
M07+P\17Z=)&-,/B/46/^L:J@1E[T?3K1[)!<MCQ'J"G[[4X^(;Y_^6C"J>S(
M]Z0)^='LD%RR=;O2<EV%._MZ[QC+#WJJ%S]Z@^_-'LD%RT-?NO4TIU^[_P!K
MZU2"#.>U/X ]J?LD*Y9_M^Z'4DTO]OW?^T:I;03Q3L8^[Q1[) 6O[>N_5C[4
MO]NW?JWTJG].M+M_.CV2"Y:_MZ[]6'M1_;MWZL*J?7DTNT_Q4>R07+?_  D-
MZ.[4H\0WG<M]:I'WYH )^E+V2"Y=/B&\[%OK2#Q%>GNQJGC'TH S]W@4>R07
M+_\ ;]VW4M2_\)'?(,*[50V^G%!3CCK1[)!<MGQ+J3' D?Z4O_"0:ECF1ZI@
M '/&:5G/3O1[)!<G_P"$@U'S!^\:NO\ #NJ7%Y*JOFN"82;QR*[?PA_KQN(-
M8U86*3.XN9([>TWE>0.M>?ZSXM>"1DCS7<ZZA_LUCGC%>+:J/],;)XS7'-#9
M-<:Y=WC$_,<U3VW$ASO(J2'A/DXIR>:Q/./K6#=B+C=]Q&.7)J2"20ODL3[4
MK0R,/O"B)&1^HS1%C3-VSW%,U)/G^[BH+*1@,'FK[C<N36JV+10P?2E4\TLI
MQU-1QYW]>* -&),@'%3XQQC-1P!MO'2I]C'D4AD)0CWI=N!DC-3!2:0*2<4"
M(MO&0/PI O<BIMISB@J<XH BVAN@Q2!,GIBIRI%!4@4 0[1TV_C2;.<8_&I]
MIQFC:<9H AV@<8S2%2#QS4X4D4P@YXH&BRF3'S6;=Q?O"0,UIQ E:JW2%<GO
M0!ENA*],52=>>F*T78DX-5)U(IAJ1P,=V.E:\* J*R8?O\FMBW/ I .*D<8H
M'IC-3["1FFB,]N* (BGMF@QX'3-6 II-N3B@"$+@9Q^%&,\XQ4NTYQ05/2@1
M'U[8I,;NV*D\LCKS2[<"AC(L=L?C2;3G%3;#C-&TXI"(=H'\.:9+$A7YAFK&
MQB>#Q370DXH YJ\A"R$A,U$GW<8Q[5UC:;$\>X@9KG[^W$,I"]:!%+R\MD<4
MYD/TIT>>_6G/N!'>F SR_:G^2"OW:>#D4[+8J6)LS9H]C<"NC\.W(1E#>HK'
M>,L:(Y7MCE#C%%Q7L>HWFK0VUHN&&<5YMK>M75Y.T<9)7/2K$37>L81&/%=)
MI?@YL!Y%Y/M1<+V//1:3.OF2*<TY+;G)%>JW'A5?)/RC\JXG7;./3G*\9H&8
M4J1J.@%5@?-;:%Z5*N+AN2#4VQ(!GBE<5QJ*BC!2H+BU!!DC7GUJP09.AXIR
M%T^4GY:+H";0_$%SI\JH<XS7L?A_Q'%>VZAB"<5XG/ &&Y.*T?#FIRV<^UVP
M,]S312/>&*XWJN<U 926^[CVIFAW\-Y9(-P+8]:M7$:ALK0A[$'FD<8IRJK<
MG@U& Q?DU(\;#!S3&20W$L+]\5N6FIE@%)K#C.[AC5E5V<@TQ'3HRR#.,^]*
MR%>E9%I=."!GBMA'+KG(H :23U-)1WHH **** "BBB@ HHHH **** "BBB@
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M6F7V01\+S0CMT8<5)*I#9Q2$ANU:+4H;Y8SE2<U*) !@FD +=!BFMP,%?QI
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M"M=<4R3G=8?;<LH'>L^-B1DU8O)VNYBV!M-0A0!BMXW)!ANZT -W-  %+BK
M3#9]J,-GKQ3J3%,0A#9XI>:,T=>M%@$.<<4 ''-.Q@4E !SBD4$'FEZ"@'/8
MT6 4L3P:-IQG-*=O:DHL,7<<8I I/.:7Y<>])18 I.:48[T46 2BEX[TN!U%
M%A#>>]%. S2$*.F:+ &T]<TE+1A??-%@#!/>E7/8TE%%@#!)ZT $'K1BDHL
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M6]&0RYYH :4QWYI4!Z$TDC+G'-.C7(R#^= "21G(.:=N)&*3ZYI0%7E<Y]Z
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MTD?N%Y[5H,P)Q0@&@$GB@@CK2=*7J>30 E%.90.AS3:0!1110 4444 %%%%
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MOUQ70Z;,2@R: -"1?FSCFA"1UIQ.><TT]* ',VZDIJC'?-.H **** "BBB@
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MYXJ1%!;CBG*#WQ4BQ'KTIV0$<FT)TYK#NF3S2,<UO7"L(STQ7/W"/YAX&*+
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MGZT<S"QT7V^USVQ2'4+7KQ7/?89_4Y^M--C/GYB?SHY@L=%_:=KV%']I6IZ
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M@K6^RCTYI1:=R* ,GRL]!2>3Z UL?9<]12?9B3RHH RA$3P!S2-!CJ.:VA;
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M (<@=*:"3U&*D;.>33: $P/2DW'.,4ZB@!,"D+$'&*=10 UC[9I8_E.32T4
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M:JJQ=QBKX4[1B@! NT9QFHI>1TJR,XYJ&0'/'6@1$F%[4XE7'W<4!3WIQ'%
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M<QZ__:^A]=L?TYJ-]<T5>B1_K7DXB?'W^?K33;R9Y?\ 6CZN@YCU3^W=&/\
M!&!4T&J:+=N$CBCW?C7D,D+[2-WZUL^#K)_[2!D;(SZUG.BD@N>SVVG6L,8N
M%4*.M-OO$%E;V[1F5<@5%K,QM?#N8^H6OG_6=8O9-292Y"Y]ZX)(=S<\7Z@+
MR])B;</:L"S1@<N,TT,[#=N&:MVNY^M<[,Y/N7 1LZ5%(<#^E2[2!QUJ&3)X
M)IHSTN:^B+F56]^E=5=S[;?&SM7-:"N&&370:BV(<>U7H;QL8'F[IC\N.:T[
M5-Q%9(!\[+=,UOZ?&7V^E47L:4"E5%6@^!C&:C$;*,=JD P.* %4CTI1UZ9I
M%!/0T#(/% !N.>GX49R>E'4^]!!!H 4D^F*,^V*0DGK2MNQR: #/M^-*#ST_
M&FY..:,G'% #R?09HW;?>HPQ'>@Y/2@$.;GGK5N!]J\_E5- <]:ER57)- &3
MK\XP>*Y2)M[YZ5N:])DD9KGH,ALF@9J1,<@8K9LP3CC\:Q[3,C@5T,"-&@)Z
M4"Z%U'VC&*G5ACIFJ08D\=*G4D#KB@9/Y@/:D#\U#N+=#1N/0'F@DFW\YIWF
M>U5]QZ=Z 2.IYH&6/,]J3S/:H2Y'7FF;SF@"V&.>F*&D]OQJ%78CD\4CD^O%
M #O.P?NYJ5)B!PM4PY!XJ0.Q'R\4A%E)SOJ#49?W!S3(L[SSS5759&$!&:0'
M.W5SB7BF+<$\]*SKR8B;K3!,<<FCS V#=G&*>EV:Q?-;UJ59' SNXH9)LK>'
M=5@71*XZUSOGMOZ\5H0R,4ZU#N2,OF.[.<UK>%9&%UP,US>I/(&&PXKIO \4
MDMU\Q%"8*YZSIK%K8$C'%7:IQ@PVX^8=*ADOE1#EQGZUHB[FCD5',Y5"16;;
MW4D[_?!'UJ34+Y+2U9I&'3UJK#.?U37)(79<$8/6L)]=9S]^N:\1^)/,N9$C
M;OZUDV]Z[)O9JF3L1)G;/JSX^_67=:D9#][-<^VHLQP&XI&F)&0:R<KF;99N
MKG;SFGZ7<^9= 9[UB7DCD<&K&B>8;I?7---#5CUO1Y-MO5N60L>F*R]&#>0-
MU:,I/>MH[&R0C/D8Q488YQBA=V>:DV\9S2 :3WJ1').!S4#!CT-6;2(Y&: )
M&B/!(JY;KL&127"X5=M36RDB@"=7/>G8##(XII&#2=#0 N"#S2E@1C%(6)'-
M, ;/- #\&EW#&,4FXXQ3,-GKQ0 _!]*2E#$# IK;B>* %P3THH4E?K0Q)^M
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M N.:86"GK3@V!T%(0#VH 5<'K2,0O0\4H..U!Y[4 (I#=Z5MH'%(,#M2DY[
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MC.5LS<>M=?H]L'53WQ7(09,RY'&:]#T6$"!&'I6EC1;#+E1$<=ZAC(8<U9U
MYE((JM$NU>!GZT +T[THP>M*N>P%)C)X'-  0,\=*3(S2C(/3FE/)Y&#0 A
M[&DI2".M)0 44NTXS0#QTH ;M!H)VT\9QP :0'V!H :G)YZ4MRVR$G/%.7KP
M*K:A+MA/\J .7U67>Y .:SHA@U:O9-TG09J% 2>10(U=&B$D_%=6T 6'CK6#
MX?0F?E0*ZJY&V'I3&9J+S4IQW.*;&WM22$EN*5PU'<=S2<9Y-*5P/6F@9Z4
M*<9XHSS1M_.D((^M "G'8T<8X--&<\BG9SV H <F,]>:),>O-)SCI^-1G)H$
M('&>:<SC'/%(L??K025Z*#]:0$L&">369KAQ W-;%I^\." *RO$2JD#8/X4
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M(%QBM#=O'2@!T0/7-2,,D'I4:G;4H8'[W6@+B_>'/%- YZXIQ(/44W(SSTH
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MSW6TC_M)N.,U7CMX6YIE(V=;OEU)PT?'TK.5=J]:0;4/R5(<8Z4F*3(R??\
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ME!C/0T#CO1P.U)P>M >A9MN>E7!5.V^6KE-"8AZ5FS;MYXK2/2LV;[Y^:AB
M']W35SV%+C*YS35^M Q^".G-)GTZT'GOBC]/>D 8_.EW8&".:3V_6E"C'6DP
M$Y/7BK-O]ZJO3WJS;#YJ:$RY1115 (>E4Y\YX&:NGI5*XY/7% $?..!0,]Z
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MFC- 7%HHHS0,**,T9H **3-&:!7%HI,T;A0%P/2LR\C7.5/-:6X8JC=@$>E
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MDZ=?>E_LI!UYH U/^$M4=2/TH'BU1U(Q65_92#T-+_9J?W: -0^+%/<8I/\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH ****8#@N1G--*,WW3BBD+8H
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MY9_*N[_L^W7L,_2E&GVY.2!GZ4 </_9"GD)C\*0Z8J]$/Y5W3:?;TW[!;MU
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M8YI](%QWI: "BBB@ I  .E+10 4444 %)2T4 +DTE%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1130N.] "?-
MNZU>A^X*H@@/G/-7XCE: )**** (IL[>#6>^?,Z\UH38V\FL]\;^O%)@/&<=
M:0+GK0,8ZT#'8T@#IUI#G\*-H[&C('UH* 9Q1SCBC@]Z3@=: +-IWJY5.V^:
MKE-"8AZ5FS??/RUI'I6;,/G/S4,0F3MQBFK],T\'Y*8OUQ0,>3[9I/U]J4CW
MQ2=?;WJ0#_.*,$\XQ[48X_K1DCC.?>A@ ^F*L6_WJKCZYJS;_>IH3+=%%%4
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M 3S244 *0 >*3O110 I '0T9-)10 4444 )D"GJI^E,P*=D],T !ZT#K244
M.93VYJ+E3ZU)DCH:2@ '2C&>E%&<=*  @CJ*50#U-!)/6DH <Q'0"F[QTV?C
M110 PG!^[FC>?[M/HH -N[MFC;GC%*"1T-&3ZT )M[8HVXXQ2Y.<YHR?6@!-
MNWM3023R*>22.33 "#UH =N'39^-)\V?N\4FTYSFG;^V: '!@!TIAW9X7-&1
MZT]>G7% #=Q7JN:"2W(7\*4KN.-V*3!3O^- " D<E:7?N_AQ2DD]324 (-W=
M<4OF9XV_C2Y)ZFDH 3YL_=X]:7?MXVYI=QZ9I* $.[LN:7=MZKFE"D]&Q2'Y
M>IH "2W(7\*0 GJ,4H^;HV/>EP5_BS0 FW;VQ28'I3C(1P1FDZ\T )@>E&!Z
M4M% "8'I00>RYI:4$CH: $7 ^\OX4-S]U?PHHR1TH 1>.JXIS$8X7%!)/4TG
M>@!J]?NXIVX=-GXTXJ .M-\OON_"@!=QZ;/QI-P'&S-+N/3-)0 A!/1<TN=H
MY7/M2'=V;%!!(ZT !.X<+^% R!ROX4#*CK2[L\DT  8'HN*7/^QCWI 0>AI<
MD]30 97'W>:3/^Q^-%+N/3-  "O=<T9Q_!NI*<OUQ0 @([K^%!/HN?:@KN.-
MV*3!3H<^] "YSU7'M0<$<+B@DGJ:2@! #GE<4N\9QL_&ER3U-)0 W!S]W\:=
MN XV9I=QZ9I* %S_ +&: 1W7\* 2.AI* $?'8?A0IXSM_"EHH -P;HN*0 YY
M7%+2Y)ZF@!-X/&S\:-_;;^-%% !OV\;<TUO]W-.IR@'OB@",]/NT9PO2GE-Q
MQNQ28V\9S0 @/<BC>#QMVTM(0#UH 0\<@4O4<G;2Y'8T$9ZT[ +N!&QEW+ZU
MEZCH-M=*S(H#$5ICCI2$'.0<4;@<(;;4=#G)0.Z$]JZ?3?$5O<1B.=E5^X-:
MX1)%Q* WUK U/PQ'<L7M\1MZBBX&X%5QYL)W#VIP^88?@^E<7'+?:'+M>5WC
M'O6_IVNP7P ; :@#4";/NC%*0>I%(Q.!M.X48_V\^U(!,#KBC ZXIS !<@U&
M.3UQ[4 .('<4Y67TS2A01R:;@ \4 !P3TI5P.U)10 K$'H,4W([TM)@4 +LQ
MSBG;AC&*3)Z9I* %"D]!069!]S-&XCH:-S>M #58N>E.!VGD4@XZ<44 .SEL
M@4CY[+29QTI<GUH :-W=<4M*23U-)0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !30Q)Z4ZDR#WH 0<MR,>]7HAA>M4,$M][\*O0C"4 2T444 13?=Z9K/?[_3
M\*T)ON]<5GO]_K^-)H!PZ=* ?;% Z?>H'US4@(2?3%'7J*7('?-)C/>F4&<=
M!1UZB@<=31UZ'% %BVXZ<U<%4[7CK5RFA,0]#69,1YAXYK3/2LV;.\Y%#$(
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MC9ANK5*"3YX^: %92M-#!NE)YCJ=K"G;5'(/6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I H'2EIH+9YH
M0$!N!S5^(DKS5$9W<CBKT6-O% $E%%% $4V-O(K/?&_IQ6C+G;P*SG)W].:3
M <,8Z4T<].*>,XZ4F?6D F :,@=N:"32]N:"A.#UZTG I>>W2@9Q0!8M?FZU
M<JG;>U7!30F(>E9TX.XG-:)Z5G3GYC0 Q>G7\*.IZXH4#'3FAOO<TF XCWQ2
M=?;WI3C'(I#C'/2D 8X_K29(XSGWH[>U.!7;0 @_.K-O]ZJH_P!GBK-L/FIH
M3+E%%%4 AZ53N!SUQ5P]*I7)&>>: &#I3NE-7I2TP%))ZTAZ444 ,4<_>S4N
MT8SFF!0.12;N<4@$(^;[U2A01UIFT9S2%L'% #B0#UI5 ;O32 W6EZ4 *V%[
MT@P3UI",CF@ #I0 ]E Z'--HHH **** "DR!UI:0J#UH <H#=Z&PO>DZ4A&1
MS0 HP3UI6 '>F@ =*6@!,@]Z?M&,YI@4 Y%+0 F1ZT\*",YIFT9S2T (<YX.
M*=GY<8YI5QW&::<9XH 5>O7%#CCK32=HR::,R'CI0 Y"%![TY"6)[8I?*V#<
M3@5D:IK"6T16(_,>.*:0!JFL)"C1H?G'%8UK83:C.)G<E2>E5[:RFU&[\QP=
MK'/(KL;2V6T@"*O(I@2VMO':0A4 7BE))/6F>82V&IY7 R:74 R?6DZ'(ZT4
M4@ G/6DP!TI:* "BBB@ HHHH 3('6G* W>FE0>M+TH 5L+WI!@GK2$9'-  '
M2@![*!T.:;110 4444 %)D#K2TA4'K0 Y0&[T-A>])TI",CF@!1@GK3F4#H<
MTP #I2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 N3ZT9)ZTE% !1110 4444
M )D#K0<GH<4%0W44$[10 =!R:7(/2DX84  =* %HHHH **** "BBB@ HHHH
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M9I4)8XQ3BBCMS3W CVG.<T\!<<MBD\Q.A'-,9"QR*FP#S@=Z2FA3_%3B0HH
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MB@!Z[L< 5&V[/ I:* %3/IS0^[TYI** !-V>13GSW%-HH **<0N.*CV\YS0
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MUI:4+N[TAX.* "C '2E R<4$;: $HHHH **** "BBB@ HHHH **** "BBB@
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MEP?2DH :5R<YIU+@^E)0 4444 %%%% "!@3@4[8O7/-)MQSBCS,\;?QH 3>
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M%ZYYI-X!I?,SQM_&C;WQ0 I.Z@J1UHP>PH)/>@!**** "BBB@ HHHH ****
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M/I2X-*1;!MRRH6^M-(=SD,/K3L M,+ GY6%.\R&+Y9I%S]:?&EHW*,I^AHL
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MV]J;0 NXXQ2[>,YIM% !2AB.E)10 H&X]:/NG@T+CO0<9XH "Q/6FX!-+UI
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M7)/6DH **** "BBB@ HHHH **** "BBB@ HHHH 4-MHP6/%-92>AQ3D'OB@
MY4T$[C2..V:1 0>M #BI'6DIS#WS3: "BBB@ HHHH **,@=:* "BBDR#TH 6
MBBB@ HHHH 4-MHP6/%-92>AQ3D'OB@ Y4T$[C2..V:1 0>M #B"O6E+9&*&'
M'7-1A2#UH ?M.,TN[C&*.,?>_"H]ISG- #PI/(I*<,8^]BFT %%%% !1110
MXMD8I-IQFF!2#UJ3C'WOPH -W&,4@4GD4S:<YS4@QC[V* &T449 ZT %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MIRX[BFTH;;0 C $T* .W%+@L>*.5-  V#T%-"@=*<3N-!4CK0 E%%% !1110
M 4444 %%%% !WIQVXX%-IQ;(Q0 S:,YI_P N.G-)M.,TN[C&* &%03DTM*%)
MY%)0 4444 %'>BB@!QVXX%,VC.:>6R,4FTXS0 ORXZ<TPJ"<FG[N,8I I/(H
M 5< <BFL 32AMM&"QXH 10!VXI6P>@HY4T$[C0 T* >*>=N.!2$%>M*6R,4
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M!]*%/&,?C1G!]:3&.;IUQ2=O3WI6/'2D_7VI( [?UI0!CK2=OZ4F"><8]J&
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M'K4;XQQS244  I/+!.=WX4M% "[B!2;L_P .*** % 4GGBEXSP?QIM% #RP
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M )1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHI@%%%% !2ABO0TE&U6^\<4 +UI*, <
M#I10 8)X%&UEZFBB@ HHHI %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 *6+#'6@
M(P.6/% "IR#DT$DT *7["F[&)R#@4H1?O9YH+$T !QC I*** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS5R,@KQ0 ^BBB@"*8@+SFL]_O=\5HRYVUGR?>J64@&,<4?3]:1:5B3UXH06
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M,L<XQ3JM>0N:# O:@"K15HP+V%'D+CIS0!5HJUY"XZ<T"!>XH JT5:$"]Z!
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M!+147GKZT>>O8T 2T5#YZ^M+YZ^M $M%0_:%]:7SU[F@"6BH?M"CJ:/M">M
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MP<>WI0.GI[4;CT[T8]>M- 'TXI00.U)]>:/K3 ."?N_C2$+GI^-+T^E'7Z4
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MN".AYHR>G>@8W:/I[4H'H,4N#W/-&2.M #=H],4 >@_&E^M'3Z4 (0.X_&C
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MZ4"$[]/QH_6EZ_2CZ4 (1Z\T8'U]J7Z<48].M PQQ_2DVCZ>U+G\Z,>O6@!
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MZ3Z\4N.<8_&E(([9IV 0X[\4G;GI2X(ZC-+@XZ4 )QCVI.W'2EP>OZ4N..E
M"#';FD^E+@GMB@?3%*X ,9]Z.,^]'/3'XT=\8_&GZ"$^O%*<=^*#D=LTG(ZC
M- "]N>E+QMH)XZ4G/7'X4 ';CI2KB@'CI2<GMB@8<9X- QGKS2J?;%(<YZ?C
M0 IQGKS2<9Y- Z]*5C[9H$!Q2=N>E'([9I2>.E !QMI.W'2EQQG'X4 \=*!@
MN*3C/'-+U[8I!],4  QGWHXS[T<],?C1WQC\:7H(3Z\4IQWXH.1VS2<CJ,TP
M%[<]*7C;03QTI.>N/PH .W'2E7% /'2DY/;% PXSQS0,9]Z!SVQ1STQ^-'J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44F12T %%)N'K2T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !129
M%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)*).5.13G+!?EZT /HJF]_' /WS 4MOJ-O='$3YHN!;HII)[4R6X2!-TA %
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A&:6B@#R7XK
M6K2H"#TKY_1U34'20=#7UKXGT$:M">,D#TKYN\6^%Y]*U"23R'VY[+732D0T
MS(DA1EW1':?45&)+V-<"=L57@G._8P*_6K3%OX7&/3-=D7<RE$1'F8'?(33#
M&[GES4B<<FD+YX'%;:$[">4R#*R\^E)YDW3>:<H&<DTK2(.W-)V)NV,&\CE\
M4Y?M,?,<I'TIH8$_-4C.R#Y32LBE<KR33,<2.:N6=E]H(Q+M)JN%$AR]*KO
M^8S@5I%(SG)I'1)X7EEMC()BV*QGM'LIP'&[FMW1M>E$?D,_!]ZTI[*"YP[
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MSD"LCQ=#()HY4!PO)JUH'B*%]L$C!2!CDT =CA2,5!=X2W;CM2"\M3R)H_\
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M,$H;'I7">("\L@5FR-U=%HNAW&F1.)6SFN>\4(\&'"-][TH Z+P]IL"6T<@
MW8KI-JD8(XKB?#?B*U:..!V"L!W.*ZMM3M1TF0_1J )G0*I"KC-<QK/AZYU
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M:79KSY4_>H K?9M7\GSR[@#G%;OAV^N2 LKG.>];LL@;168#^&N7TR1C=?\
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M+<XKOK=_,@5O45QUAX55)!)+(C-G/!%=E!&(H50= * )**** "BBB@ HHHH
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M+ZT /HIOF+ZT>8OK0 ZBF^8OK1O7UH =13/,7UH\Q?6BX#Z*9YJ9QFCS%]:
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MZ=HLULH\YR3]:WE7:H'I48F ^]3O,7UH ?13?,7UH\Q?6F ZBF[U]:3S%]:
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M+ZT /HIAE4=Z!(I&<T /HIGF+CK0)4/0T /HIGF+ZT>:F<9H ?13/,7UH,J
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M/% ";FZ_I2%WIW/XT;CT- ";F/M2%WIW/>CGO0&HW>V*-[8IV">O2C!'3I0
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MSUH_#\:/P_&@ ..]'UXHZ>]'ZT ';GI1V]J/U]J/\XH .W'2CZ<T?I[4?I0
MJXS2<9X/-+R>V*!P>GXT )QGD\TK8S0>3T_&CH>F: $/N:.W/2E)]LTGZ^U
M"=O:E&,<=*/\XH_3VH /IS0,=J/THZ^U !WXZTG&>>M+^'XT?A^-  <=Z0^_
M%+T]Z/UH .W/2D[>U+^OM1_G%  ,8XZ4?3FC]/:C]*  8[4=^.M'7VH_#\:
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MU[8H ._'6DXSSUI?P_&C\/QH #CO2'WXI>GO1^M !VYZ4G;VI?U]J/\ .*
M8QQTH^G-'Z>U'Z4  QVH[\=:0D^F*!]/QH0!QGGK2G'>DS[9]Z ?;- "_7BE
M.,4GZTN".<4"$[>U*,8HSQT_"C!ZXH&(/8T#';FE!]L4G7MB@ [\=:3C//6E
M_#\:/P_&@ ..](??BEZ>]'ZT ';GI2=O:E_7VH_SB@ &,<=*/IS1^GM1^E
M,=J._'6CK[4?A^- "<9YZTIQWH_#\:.GO0 A]^*7MSTH_6C]?:@!.WM2C&..
ME'^<4?I[4 'TYH&.U'Z4=?:@ [\=:3C//6E_#\:/P_&@ ..](??BEZ>]'ZT
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MQCOBEZ^WO00?X@:,''(.*+ )M]_QI?U]Z,''0XHP<< XH"XF/?-+T[YH /\
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MU?0444 &U?04;5]!110 ;%]!2>6OH*** %VKZ"D\M?0444 +M7T%&U?0444
M&U?04;5]!110 ;5]!1M7T%%% ">6OH*7:OH*** $V+Z"EVKZ"BB@ VKZ"C:O
MH*** #:OH*-J^@HHH -J^@HVKZ"BB@ VKZ"C:OH*** #:OH*-J^@HHH -J^@
MHVKZ"BB@ VKZ"C:OH*** #:OH*-J^@HHH -J^@HVKZ"BB@ VKZ"C:OH*** #
M:OH*-J^@HHH -J^@HVKZ"BB@ VKZ"C:OH*** #:OH*0HOH*** #8OH*-B^@H
MHH  B^@I=J^@HHH -J^@HVKZ"BB@ VKZ"C:OH*** $*+Z"C8OH*** #8OH*
MB^@HHH 7:OH*-J^@HHH -J^@HVKZ"BB@ VKZ"C:OH*** #:OH*-J^@HHH -J
M^@HVKZ"BB@ VKZ"C:OH*** #:OH*-J^@HHH 0HOH*-B^@HHH -B^@H"+Z"BB
M@!=J^@HVKZ"BB@ VKZ"C:OH*** #:OH*-J^@HHH -J^@HVKZ"BB@ VKZ"C:O
MH*** $V+Z"EVKZ"BB@!-B^@I=J^@HHH -H]!1M7T%%% !M'H*-J^@HHH   .
'@I:** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0O!W0# 2(  A$! Q$!_\0
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M0(>SXIN21FD^[R>:=D%>* !7SQ3JA4[6J3S!B@"12!UIQ&X9%0A\F@R;>*+
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M?-GBA^3QQ2)NSD]*63YCQQ2 =D;<4JD"F.P$>.])"WJ*$ \FC /2E9>]-&:
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MFF*X08-.W@<T@%"9%(!S1YF[I49?)P* )2V.O-&ZHLE>O-.R,9H%85AOZ<4
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M/>@!%([T<;J%QWI&('(H >5!'%-.%X[TU9,]*=O4\'K3$T-RH^]280\@4KJ
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ME&.*5I!3?<]* Z@NWO3MJ]:C;':F^9VI#W'MCM2#WI1@=:3C- 7'$XZ5'O\
MFIS8/2HF('UI@B0_-UI0AQQ4*OZU*)A2 4$CI4B@'D]:C+*W2I$88Q0!*N.]
M2 C/%1C%+WXI@R? (XIRX'6HE?TJ52IZTK B9<=Z<5SR*9D <THD':D.XH]J
MD''6F[AC(ZT!@>M,"2BDR * 0: 'X3''6A<=Z4[<4BX[U/D G&:=M!Z4T]:
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MI<C&:B)_O4A8XH!#F;TI#M(]Z92;QG% #PRKUJ/DMGM2LN:.@H!L?@$<5$^
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MQTI=V>E $J[<<U&^.])NQUIO/?I0 =_EZ5*2I7 ZU'].E)N!.!UI6&.W8ZT
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M!'-1D@4;@#2-@CFFM!#E(-/.W'%1C '%)N&>*; 4L >:0X(YIIQWZTG7KTI
M'3[M(';.*"V.!2\=1UH&+_O4F>QZ4QVP>:3/%.P$N0.E VYJ(,#THI6'H/E8
M"F[^/:FD!NM,Y'':@0\$'I1D9I 5%)\N<TQ#Z4-3,CO1F@5R="*E^6JJ^U2!
MN<&D)DX:I5?M4*X/6I.!TI#:)QCM2Y'>H0X[5(N#UI#)EP>M29 Z5#QBE#4
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MY/M2]1\U,XW4("5=O:@XSQUIO^[1QWZT '7[U-XS[4_M\U,XW4!L.*@CBDP
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M]:,#-)2CK0@)$ [5,  ,]ZB0 =*=4Z#) _K4@Q4"@'K4R@4,"90.QJ4 5$H
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MWYI=V[@U&4R<YIZ =Z # S3N%&0::0 :4J,<4 *,-R:7 IH48YHZ]>E(&B0
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M4$T1VURS9"&O=M+^#L#*#)C/O72P_"2Q11]V@#YH-C='G8:3[%>-QY9KZ?\
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MFD<Y&*BV#UI@2%\'Y>:/-_O<5$76+D'-5Y)6F;@<TP+1N#T%,\\U/8Z3?W;
M)"Q!]JZ"#P-J4HYMV_*@#E_M ]:/M ]:ZU_AWJ&W(@;\JB7X?:E@G[.WY4K(
M#F!+NJ08'>M:Y\(:M;YQ:OQ[5ERZ1JD!^>W8?A0U<+D;*#WI!'FHC'<Q'+H1
M2?:R.#188]B%.,T+)CI0$27YBU+Y07IS3$+G)S3P_P#>XINW SWJ)RS\$8H
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M%PPS55!CIS5A3Q2N!,O'2I5:HD/K4E)L/0>*0@YIT8J7 IC(T!IQ7FG=*.M
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M3FCWSS1D+[TF!US0 OWNO%/48%1Y#'TJ11VHL@'*VVI  QSFF%0.E*!QG--
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MS3!CF'O48P3BE^\,YIAX-""XK+CI2!L&C=33US1<0YV!%0;<M2NW- ;(Q1T
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M]X'9[E)9H^#SR*^@-+TB'3X55$ XJ#1M%BL+:-50 @5M4 &,=**** "BBB@
MHHHH **** "BBB@ J.6".48= ?K4E% '(:YX.M;^-R(ER?:O'O%7PX>+<T,9
M_"OH\@'K56YL(;A2'C4Y]J /BF_T6[L)RK1, #5?C&#P:^H_%'@"WO;>21(U
MW8["O!/$7@RZTV>1EC;&:3'<Y@#WIP /4U"_FP/M=2*D4!QUQ0(&X.!3T_=_
M-FHRI0\<T[/O189;2X)[U91R>]9><'-68I\\&@1J1S%>*L1R9.<UF+( .#4L
M,WS]:0TS6$IJQ%+5%9 1UI4D^?&:$A&F9>>M=7X-D!U2/ZUP[R8Z&NK\$29U
M>/GO3T&?1%L?]'3Z44EK_P >T?THIB/./BV<:.WTKYL!)D;MS7TK\6O^0.WT
MKYLX$I^M $OE;Q@G% @"=\T[^'KBHVE5>-V:3T D+*@ZU"\@/0TP02SOB,$Y
M]*Z'1O!UYJ+KF)P#2] .?BCFN7V(I-=OX8\"3:DRM(A_&O0O#OPK2-$ED S[
MUZ7I'A^#34 "+Q30'*^'OA[!9(CLBY%=S:Z=#;* J 8JX%"C &*6F @  XI:
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2('0J1UK
MA?%7A5)[>255&37>U#<P">,H>] 'S!JND26<S<$<U#;2[<*37K?C'PQYBLT:
M?E7D]]I\MI.001@U#&F:4+CL:M+DUD64G.":U4<#G-(;L6XCCK5I6!J@'W\"
MK<(PO6IL-(GV^]2*O?-,4 =ZE"9YS4W!H> #QFI!$/6H=OO4B^F:JP6'JN#U
MI^W)ZTU5QSFG8R>M%A+<>!@4M"C/&:D"@=Z6B+$5<<YJ0$4S;@]:<(]W>BQ-
M]1P )IS*!30N.*4\=Z0Q%ZU*1N[TQ4[YIQ7/>@74E4\8H(IJCM4H7%(>PB)W
MS4AI!3L9ZF@.@+UIS+@=:;BE(XZTP%"\=: N32JO&<TN=W'2@8]!CBI,;1G-
M1J,<9I[*,=: %P&YS1D$XI%7(ZT;.>M(-"0# I O.<TX# ZTT+SG- #B*5<9
MH(R*8%P<YIAJ2M@=Z;FFL-QZU(% 7K2$"@'J:,#/6HV&>AI0"1B@8]@/7-&P
M;:;L*]\T9]Z &LHIH?!Q3F^;O4)&#18+W'R=*9VHIV!CK56L *,]Z1A@TF<4
MPOVI6 4MBFXSR30 !R30RYYS0*X9#<49V\4Q5R>M##% P('6@ >M,SCO32-W
M.:3$*Q!XS2!<4P#)QFG9V\4(+",/>D"9ZTOO1U[TQ7&G@TE!ZXHI#N%(:7OU
MIK#/>@!"V>*3[G>EVTQEQWH!#P-W.:7;3%7 SFAGS30"DXXII^M,+'I0![U0
M[!CG.:"N10>N<TF=W%+<8P@@XH9<#K3B<<4UAQG-.X@"Y'6F.,\49]Z0\CK0
M@&9VT;J0_+Q3",<YI:$L1QN-*.!0!N&<TQGYQ5 F*S8IOOFF'ZT8XZTF.XK-
MFFCFC;FD(Q2OV <1BF=^M&?>E\O/.:0O4>HS3]HZ5&![T[=VS5 QP&WO4R#/
M.:A5?>I ,#.:3"Y849[U,J]JK1MN.*L#@4AW)U4#O3\BH%;!ZT_&[F@-25?F
M-3*,=Z@09-3J,<9H!$@^7FG?>/7% 3WIWE9YS0 Y!VJ3.WCK4:KSC-3!*!B*
M.<YI^<=Z3R\<YI?*W=Z0A1R:?Y8]:!%@=:<!CO0 PI@=:11D]:<5SWH">] "
M^U*JX[T@.#BGT:C&[?FSFI"V14>.>M/&* '!N.E-#<TXL-N*B"X/6D@)?>@<
M\4W\:51D]: L!'/6G8VC.::1@]:4K@9S36P"_>YS30,GK0%XZT 9-) .SMXI
M"!C.:1QCO48'/6F [..]%-9<GK2XXH 6D+8'6@8'>FE,GK2L F=]&>U*4XZU
M'CFF!)]VD9<C.:-N!UI"!ZT!=#,XH/--9<]Z<HH :JXI20*<V .M1,N><T["
MN&[?QFDQCC-(J\]:&';--(:=@8 #K2!01UI#'MY)IA&3G-(!Q^M)G ZT$ C&
M:B88[T"8\#GK44B9- .WO3^'&:!*]R+J,4 ;133][%&=O% ]1C$YI1@]Z5E&
M-V:A//>@![*#4?"^]&[M33]:$ I /-1L,]Z?CCK3&&>]'4$0$X.*0FG%><4;
M=M/U#4CVY.:1AD4^F.PIB(CQQ36..].)J%N.] :"'GO3&Y%/ !&<U'(>P-(1
M"P[9J)D YS3F)'%1'.>M- M /UI%;<<4A&3UIRJ/6F-@PQ2=*<>.^:C(QSF@
M2%8;JA88-/SGO36&:$/<52 *B8?-G-+C'>F-]:0M!&.:A<Y&*<W/>H';'&:8
M]")QM[U'FAW]ZBSSG-- [C9FJJY&W.:FN&##KBL]WYVYJE8DCFF]#561QC)-
M32(J\[JS[CH2#3L!%,P;/-4EC>2<(N3DU'*[NVU,FNR\(^');ZXC9HR03181
MN^!_!IOKA#(G7UKZ"\/Z%%I5L$"CI6;X7\,IIUO')@ XKKP,#%,!0,=****
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MSBD9>^::HR>M $P7C&::R^7SG-*.!UIC_6@!1\QSFI!]:A5>^:>1D=:3 ?\
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M8-CDU%&>]3;@XQ18!BJ2>M2D<<&F?=XIA8^M%@1,,@<G--((YS0AXH/')-"
M<C'UI6&:9][IQ4@&!28P0;1S3"#NSFE9L<4P@XSFG:XB8+GO28YQFH5SZXJ8
M?6AZ (P([TT*V>M*SXI5((I E81@3WI<<8S3)#Z5'D^M QS*1WI,FE5L=>:0
MG)IWL(8P)[TH&!UI&&>] 'RXS0V %B.],Y;FC&T\\T8SSTJ0#)/%!..":.O
MIC#%%PL2 #KFD;'7-1@GUIK9ZYI /+]J2F!NU/I@@HX-(1GO49!7O3L K+CG
M-(KXI!ECC-*5Q3\@$))-)S2C@TK,"*/("/>=V*=SBHRX!Z4>;188$$'.:,[N
M*0C(SFF=*=@)-V!BF-]:3?VIK/BD(0KD]:?VJ$DGFD,F>*87)"_.*8R\9S2
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<D*2##*#4E%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<]<T6 ?1418TX/D8IV 4G%( 2<YH^[UIN[GK0 ]@3TI-V!CO1DMTIA&#S0D
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M QNTL>M!4CI1DJ?:FL^>E AV_C%1Y)-%*"!0 X XSGBC&[I00<9SQ3,D=*
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M._I2L2:C.>U(74C(P:9(3BG.:A;/>JT*N@P2.M02<4K%NQJ)LMWI6N2,+]J
MIZFHR,&G'('6F K''0TPL::VX\YIA;C%.PQ78#K59RWKQ2R/@\U$233$-8L>
MAJ)\D=:5R15>64XXH"Y'(VSJ:IO<!FQ2R.3U-4WX.::0@N&(Z53F8>7GO4DL
MPQS6;)*TC[%IV"Y-:6LEW<J%!/-?1OP[\*(MA%.\?S #M7FOPW\-F_F5I$)Y
M]*^D=#L!862Q 8P*8C1AB$4:J!T%2444 %%%% !1110 4444 %%%% !1110
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M4;&SG/%!!/2E=# 9VTT*<\T[:0*100>30@$(;-!SVIQ1B<@TTJ>U%Q  <<T
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M@!<FD;..*"C$Y%(0V*+"%7..:0%L\GBE7.,4C1OUI@./(XIJAL\TT!J5B0*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT (-U2C.*0 GI3@#FA )M/>G &G;3WI.<T 21J>U/&0W-,0D4[=D^]"!$Q(
MYIZ GD5#M)ZU/&& I,9,N>U3+FH5SVJ9<]ZD9+SCF@9[4#_:HY_AZ4")4YZ4
MI!SS2)[4ISGFF"'C('/2C))XI!G'S=*7K]V@!^>*0MCK2XXI-N3S0'43)SGM
M2$ENE2E#M]J: !TH=AD."33@ O6GE1U%1E6- "MGMTI@#'I0%<-STJ3M\M B
M/G-*=W>CG=[TK;N] $>Q\Y[4I5FZ4_+8H7.>* &88#!ZTW:PZU(V<\TW<>]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^W:DSN^]0%Y]J0K]!P/]V@NPHR%^[33S30T2*_K3\C&:KTNXXQ28R0L3TI,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI,^E(6]*!DG!ZT;NW:H@W'-"DEN>E $PSVIV/3K0JMCY:0!MWO1=E*.@O/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#<0+.A5AP:\O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!A>)=-6_P!/>,("2/2O ?$F@RZ7.S*G4U],NH<8(KAO&'AX7T;,
MJ X'I2L,\&MY&!&<YK423CFHM5L7L;QDVXP:@BE+<&I8&DK$U*K8Z5524@8J
M9&]*AH=BTKTXMFJP)ZU*K9ZTA6)E)J3=CI4.\XQ2AB*:!,G4]ZE60G@U K9J
M1>3S0QDNXYXI^3BHPV*D#"EJ6B6(YZU>A8_A5) #R:N0D$XI-&D6:4,@ J5I
MR1@52&X?=YJ0%@,]Z5C5%@2'O3HI"'S57S"?O<5(LN*+%<UB[+</CY15%[AM
MW/6DDNV7A!FFPP2W$F=O6FD2V!GI=SN, 5L6N@--@LM;-MX>1<9%4HF,IG%F
MVN#]U":8;6Z8;?+->EQZ-"@^Z/RIPTJ -G:/RJN0CG/+O[(NF/,9JQ'X>G?J
MAKT\V4./NK^52+;1*O"C\J?*3SGF@\-2CHII&T"=1G8:].6*,?PC\J1HHCQM
M'Y4<H<[/*6TFZSCRS2'2+G&?+->IM9PGJJ_E2"RA*XVK^5'*',>3&SNH3G8:
M:6G!^92*]4DTB"3^$?E69=>&HFY %+E&I=SS]9'S\PQ4ZS "N@NO#[*#M2L:
MXTNXB;A#4<I5[E9WXRM1 LQY%3"WD0_,M2K'QR*&BKD:C Y%2H5Q3&]*@=F0
MX%*P]"<\M4,JU+$21GO4WV=I.HHL%KF=M<GIQ3P&7M6LMJ O(IC6P["F'+<S
MMAZT*"3R*NM 0.E1&,CM2N3R#58CBG$^E)M/I2X*]J Y!1DCWI4!)^88IRTY
MCZ\4KDV(R#NX'%/;Y5RO)I0W%(& /% 6&@DGD5(,^E& >:4$GC% FAP!]*:<
MU)N(&*3O3)U&#.*4$YY%/H*GTIE6&G/84HSWIZD@<"F.3V%($(5S2A3Z4BDG
MK4H8@=*; 0!AVIC9]*<TK#H*3)/)I6[@1X+=:<O'%.I #FE8&/Z=*4+WH Q3
MJ9-QZX/6I 2.!3$7/6IU2BY2'Q58 %1(OI3\$&D-C^6X-2*F*8K'O4RL<<4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9I>M0ME3UJ3S<=J809#0 Z+!]Z5V .,4U4\FG%=PS0 Q6*FGF3/:H\$4<^E
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MI7&ZM<LTC+G-=A>3^7;L,=JX2\DW7#'WJTQZ$4";N3Q5^/L *I(3V%:%H=S
M8IB;-O3+;=@D9K>:06\&:I::HCCR:AU:_"PD"@DR=8U7)(!KE99#+(34M_.9
M9#S4$;=L4##!3WJ,Y)J=FQVHR-N<4 1*FZG@[3C%)YA]*4/D]* "0$C@4HRJ
M9Q3M^T=,TN=W:@" ,9#C&*>/E.,4YB%Z"F"0D]* )"<#@5@ZJFX,:Z.)<CD5
MS6NSB,L!30F<OTF/UKIM*;]STKE8G,MP1CO76Z6-L0!%#;&C5MSA\FNUT++(
M,5QD*;F&*[WPY ?(!(J2M"'Q:VW3#GTKPS57#3GZU[9XZD$>F-SVKPF[FWS'
MZT,$(/E7-,+[J:7^6A?F%2 QF[8JO)GM4[]>E0.^WM0*Q#L.<YJ.6I6?C.*A
M9MW:FQ$+,<8J"1]O:IV<=*K3,!0,JS.<9JA)(3[5<E8;2:SG?>^*:U T= MC
M<ZM&F,@FOISP3H*VL$;[1R!7AO@;1WEU&&782,BOJ'1K80V40QCY13$::($7
M I]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYA"[<46 EC /O39/EZ"HU?RSGK3]V_FD D?[S@TQGV2;0M2#CI3&<+R132N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5#+&]*7K3MO>C[W2I&AFWGI3\!>O-.Q@8H"GO3N%AH&3FI !Z4NSN**@$,)
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MMADT4#DXIQ0J,TB1M!HHJD X)WH+ \ 4W)I0N:5@$P*.@I6&.*C .>:=P%I
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS 4+QS32,=>E+G:.:86)II,!'"$<"JH<J_R<&IV!)]J0[<=.::&D6K;4IH<
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#8T&,=!2,0>E*(QGFI-JXH0BN4!J-@!5HX/2F&+)YJ@:*H'//2E,:GD"K!B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %,F.(F/M3ZBN/]0_TH \W\27>Z5XP:YN
MSC^8EJU->(-^X'K5.V '6LY,:+<?!]JN( 1Q5= #TJP@QTJ&5<E7:.O6I*C&
M._6I5QWHN,4+WJ1 #TIF3T[5(N%Z4@';%[]:4*!UII))IZ@G[U ;$J8[5*4X
MXJ)0 >*L#I4L9"%;-3KCO24HQGFGT F4C'%(<=J%QVIVT=JFXT*F:G7=WJ ,
M%ZU/&_KTIEHLQ>U6E'%5%9?X:L+*N,4#:8]L=ZB?&.:D)4U&PS3=@1&JIVIY
MV8]Z38>U!3CFDBR)@#3D7!IP4#K3QCM2:&V-8$BH'2K51.RCK1829GRH>]49
M, UK2$/5"9%S03(I$ ]*3=L&#4FT*>*:4#<FJ,WV(U.X\T,GI3P%SQ37)%,F
MS&Y"].M-))IP7?TI3B/ANM 6L18/?I364$\5*RDC/:F@ 4BKB!!2,%'6G-G'
M%-"Y'S4$C<K3@%/2F[.?:E((^[180';GCK2A2?O4JJ.IIU R,Y!]J<N&Z4')
MIR+CI3$.X'UH# ]:#C'-"*#2&@XW>U2Y3'R]:@<$/@5*B4[ T'RYYJ10IZTT
MH,TN*0"X4'BG8!'%($-2!0.E)@-  ZU,F.]1[<]:=1<!S8SQ1A<<=:0*3TIV
MWB@+C:4+W-&,=:=D]^E)A<:V.U,"C.:D*@]*C;(%- (^.]1,^!3L_P!ZF[/,
M.!5)"&!P>E&\9Q5J+39&Z"K*Z0_7%5RBN94CXZ4@#N*WX=(#']X*O)I4*C&*
M.1CYD<HL+YXJW' Y'2ND&FPCM4@LHAVIN N9,YU;1SU%2BT<#@5T'V=/2E\E
M,8JE&Q+LSGA;N#P*7R'[]:W_ +.GI1]F0GI3<;DG/&*1>O2@9%= UK&PP143
M6,?85/+83BGN83I&XQWJ+[/&#R*VFT\#D"H7L&(Z5HI-&;HQ,Y404,?2I'M)
MD8DCBHF(7@T.3*5)(8343X/6G[E)XILE9-FT8(@8#\*9D=J<5;//2HVP.E26
MK(<=I'O4+;>]+FFL,]:-!-D?&?:D?;CB@@9II%)L3&#&:<XP.: O.:29N.:5
MPLR/C/%%(.E(V>U-,H1MM-5N>:7;D<U&1@T[BL/9_2H@033]I(INT T*P",P
M Q4)P34S 'K4+ KSVH&'"]*19!G ZT@5GZ=*<D()XZTO4M$H8=Z=OQ]*B92I
MYIR*3UZ4%)CS)GI0H4_6AD Z4+C/O1L XQKWJ-E].E6E3/6E:,8HN%V4U3TI
MV\J<4]@1]VF8!//6E<;'^:.],8L>G2G>6*:0P/M2L*Y7?FFB,'ZU88 CBH\8
M^M4KD,/+ '-+L].E2HI;[W2GF/ XI[$=2N$';K2[0.M2!.>*"OK1</(A9>.:
M9Y.>15@@8YIO/\/2AL%J5G4 5#M!ZU:=<U7;"]::0K$3HH'-57 [5:<<<]*K
M/CM0%BNX'XU'M'>IGQCWJ!CCK2#8@D%5R@JTRD_2HF4]JJPKE1U]*KNI/6KS
M*,>]5W&.M"0[HILGY57D [5=;]*K2*.U4@;*CJ-M8U\F^MR0?(165<+C)-5<
MEHD\,3M#JT2YXW5]0^&9@]E%S_"*^4=)E":S%C^]7TSX+N/,MHAGL*8CNJ*.
MU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !5*_=EA;'I5VL;6)F2)@/2@#S
M/6'WZBX'WLTV",K]^H-1D']HLP^]FI8Y68#=6<AFC&O<=*L 'M5&&4YQ5P,:
MS*)E49R:G4*:KJP/6I,XH'J38 I>E-7D5(N.] (>BBI#2#':G#'>DP$7K5@=
M*8J#K3Z2&.VDT*O/-/3.*=TI-B  "G-@#CK3!FG\8H"XU1N/-6$B;'/2F1X[
MU<CR>#TIFJ8U(SVJ98_SJ=$ Z4\*N?>FAN1$%]:3;S5@@"HSBE;L)2&@@4A9
M:0X[4S:,T[V*20I --Y!J08[T_:*+A>Q V<<54E#9S6EM%-:)2*+6!21D?-F
MH9,UI31!>E9\HP:&)E4HQIN,#!J?>.U(0#2(V95*G^&@*?XJL8"\U&Y#&FB;
MD>0/N=::P#'+]:4KMY6DZ_>ICW&MD#VIH4D\5)R>O2@@CI0(:P&W ZU& PZU
M-QVZT?[U("##Y]J>%)Z5)_*C_=IBL1X/2G 8ZTG.ZAL]Z %V]^U+_NT#=CVH
M'^S0 N!C!ZTT*P/%+W]Z<I/>@8H7N:>,]J7Y2G'6HU+!J )=I(I-ISQ4BL,<
MT?2@8JY YH/M2CWI0,]*0@7IS3@O/--((IJEB>>E(1+S_#3\<4+C'%(S@=*8
M <=Z:66F\N:N6]@TA!8<57*#*?)^Y3UMI9#TK<ATV-!TJTENB=!5*))C0:66
M_P!8*T(M+A3G%7L@5&\ZH.36BC8FXJ0JG04_BLZ6^_NFH#J#8QGFG87,:S.J
M]:C:ZC7J:R&NI'ZU QD8\]*-1<QLG481WIK:E#C@UBM'Z4T1#O3L)R-<ZBOK
M49U YX/%9_E8ZTWRVQQTHL+FN:O]HCUJ1-1CQR:Q/*8]*/+(ZT6'S6-\7T?K
M4HNXVZ&N<^84>9*#\O2BP^8Z=95;I3^*Y@7<R#CK4L>IRCAC2L.YO/$L@P:J
M2Z9$P)Q5:#4"6^8\5H+=QMT-*P[F!<:;(C$H*I2(T7^LKLOE<54N=.BG&2.:
M7*.YQSS$G Z4SK6O<Z0RL=@XK-FMGAZBH:*N0E>.*9DC[U1M*P;%&XMUJ;!H
MP/)IK';0V0.*:OS]:EH8TR'M33\W6E88; IDF4% QPXJ-WQTH4DCFE^4T!N,
MW,:;GUI6XX%(N,\TP'#=CBHWSVJ7GMTI" >G6A,1#@D<]:;AB?FZ5:"C'-1L
M!WZ4RD1@8^[TJ= I^[]ZH.<_+TJ:%<-GO2W*)O)W??J1;7VXJ1.>M6DR1@]*
M15KF>]O_ ':1;8@YQ6BR =*A?('%!7*0;2O6F$,3[4\[SUIZJ>](+6("@[4G
MV8GD"KRQ*>E3J@44T4D9\=LW\0I)+8@=*T2<5!*_!H(:,F2,KTH6+/)ZU/("
M3Q2H,"FF0R-4(ZTZI0N>M(5YXH,W8CV^E-('>I6QCBF%<T:!U(67/6HV!7I4
MS9J%L_A33 @9^>.M1/C^+K5AE4<CK4#[?XNM ,@?./:JSKZ5:/OTJ&3_ &:&
MP*K ?C4#KZU.V,^]1M[TP9 <_A43>U3-FH&]J>I)"V:@<$]:LMFH'SWIW"Q6
M<'\*JR_[-6G8]*KOCM0(J/G'-9MWG:<UI3'@XK-N,X.ZJ0(R].!_MF/']ZOI
M?P*I$$7T%?-.G,!K<?\ O5]->!V!MXL>@JA'H(Z44#I10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!BJA JS-UJL<=Z8^A"ZU7<>E6';L>E5I"!]WFJ%N596'K5.3WJY(JGG/-59
M/XJ$)LIRCBJ,I'8U>E.>.U4I44<YIH#/F4')K&O/O5MSXVFL*[)WCZT]16/1
M?A_#FYA..XKZ8TM MC']*^=?AU&"\)]Q7T=I_P#QYQ_2F#9:HHHIB"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME#<FE6#!Q5HX%,!YHU*L1-'CI4>SFK#OCI31MZYYI!8$3UJ8**:O-/IV&/4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@4M)R33@.YHN0V-9,BHR".*F9^*B9NPIB$QCD4T\GFG<+SFCAN:6@Q"W&*8
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M>>*8BJXXJK(N3S5UQ@9JI)R<T7$5I4^6J;@8X-7)7+#%49,KTYIC14D49ZU
MXS4[KSFH6!IW![%62JY7-6W0U Z^E->9.Q3:/YJAECXJZR<5 \>:8.YG-%FJ
MTT>P5HN *IS+OHU$9,R9R:Q[Y.>:Z"6+%86IU5Q'6^!I-M[",]Z^GM&<&QBP
M?X17RIX*D_T^$9[U]1Z!C[#$<_PU0&W1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBOE737":S&?]JOICP)<"2"(9["J ]%[44@Z4M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2@AKJ-R?6D;IUI=N*B<=\T70T1OS3> M 'F''2AH\<9H*N0.^#UJ(X;DU(T
MZ[JC,8Q]ZF2R&0CI51P,U9>+/>H6AQWH A(J-ES5CR::8?>A$E8Q9I/*Q[U9
MV \4OE[1ZTRK%!X\<U 8]U:#Q]Z@9:">I09.U021U=<C.*K2TPL9\RXJC(N:
MOS+WS5*3FGT&RA+QQ5";VYJ_..M46PN<\TT%M"C-&-I;-8USELBMFY4D$YK)
ME&[(JTB;&- ?*U%6ST->\?#S65#1KNZ5X-=1E)=P[5W7P\U-EO54MWJA'U+:
MSB>,&K%8OA^;SK13G/%;5 !1110 4444 %%%% !1110 4444 %%%% !1110
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MT!-O>G9 ///.:;MS2;#G.:D'S"E8!%_NT/%@9!I",'%/Q@<FGL%A@C^7-6+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8<DT*H IU%P)H^G6I!4*(3SFI0* L.R!29-&VG;=O-(&K J^].]J0<]*">U
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MQQQ0/4%;G%6$7%0B/!QWJS'\O6E8"15/6ID0MT-1CGD5+%FDQDH4CBIE4BF
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 444C-M7)H J7UT+:,L:\V\2:DTTK!6XKK/$NHHMN0#S7F%[,\\I(
M/>I8%<1%I=QJVJE:BB!JTN,<U)5A%0GK4RQ>E,VGM4D:MBI8TARD X[U9C)[
MU  #P!S5B)&7K2>P6+,8/4]*L#G[O%01Y!R>E3]?NTK(9*O3WJ15/>DCQCGK
M4RD=Z+6'8<@.<]JG'(XI$7C/:G=?NTA$B@U)RO6HU!J55/>BP#T0MS4XQ42Y
M XZ4]6R:+ 2"GX('-*H&*.1UZ4#'H14N01@5 .>E2*#VH: 4@@\TX' YI>!P
M:3&.3TH"XA.>E+N'2@D'I3#[460P=@.M1]\]J=M]:;C!]J+#N+][I4; ]*<6
M]*;F@9"RD=:0$BISCO43)W%/0!PE J59QT[U38'M2KQ2 OB0CJ:E$G&<UF-(
M1WIRS''7BDRKF@),GK4H?BLSSL]#4BRGUICL7_K2;N>*JB;'4TX2;N11<$BS
MNSTHSCK4(E H\T4KW"Q94B@X/2H$D%/+>],GEU'TX'UJ'?Q3EYH%8EQW[4=>
ME,+<=:;DGH: L2\=*4+ZTP9I3D=Z>@AV#FG5&&-.SGI0A-#J7I3><4F2.M K
M#\49IN[BFYSTHT"P^BF;L#%-W[>M [$G2FDYZ4TOFHR_I4C41Y%1ME><TQI3
MTS43,W<TM"TK;@[DGK3"Q/2HV)S3D(;BG=%IB$GO2;6ZDU8\JD\LT%<Q"IQ5
ME)#CBF^4*3I5)DN*98$Q7K4R7 Q5,$=Z,^E/F)]FF:(G!IX<&LK<P[T[SR%Q
MFJYB'1[&FR(W6HS;1'L*S?MI3J:>NI+W-5S&;I-%UK*$_P (IAT^#'W!FH/[
M5C'>FG68LXXIJ2)Y&.;3$;^&FC2D_NTHU>+U%/\ [6BQU%%T3:P#2X1_ *>N
MFP#^ 5&-6B/<4AU:/I3N/E+ L8/[HIXM85Z 51.IJ.<U&=0W'(-+F#E-58HT
MY&!2/,B]Q6--?N5^4U5^U2-U-+F"QNO?H@JE+J._E35#<S=33"ISQ0V-(LO>
MLXP#5=G)^]S2J@-.,?K472'9(A$8SFE*YZ5)[4H7(XJ6,K[#3@ O6I<<XH9,
M=:F^HR$KW%,J0@@^U! ;I0!%@4QU':I&!Z4U5/>A("'I14Q3- 4=ZH!BD5(Q
M '-&T'I1Y3#DTFKB& $G(J55S2"I5C)Z4AB<#BE53G-/$1'6I%7;UIH+# 2#
M5A'#<#K46W<>*F6(@9%&@6'$ ?>&30#CZ4[M@TFWG)Z4[##&[[M2*M"@8XIX
MZT"L-9,=:<$XR:5N.M&#C.>*0PV ]*;[4N?2DH ,8I,4H/K0: $-'.*,4N<4
M -HI"<4PMF@$A2WI0#GK30,T=#BF5H/QCDTPGGBI%]Z8^,\4A:,0D$5$V!3\
MTAP>M&E@T(@>>:"N1D4,I!S3<GM0+0C=L<5$6QUJ=@"/>H&7'6D&B(G&!FJK
MMFK+ _A4+IGI307*;^U0].M6V05"R>M&Q-BI)C&:H3'/2K\L9_"JKH*$!G2>
MG>J,^>]:LBKTQ522(=ZJXC'D4GFJCJ3FM:=  <5GNN3Q5(DRIEYQ5.6'UK5F
M2LZ=35)CL[&7-'@\=*H7&",+UK5E0D&LV6,Y-/=B,N6)2IW#FFZ;,;*Z#@XY
MJ6X;;Q6<^Y6SFGJ(^G_ACJZSZ>H9AG'K7IRL&7(KYB^'NO-:M'$'QD@=:^D-
M(F\^PC?/44P+]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %5[Q]ELQSVJQVKG];U#RHG3/:D!Q&NWQ>5U)[US6QG;(Z58U
M&<M<N3TS44+Y'%0RD."D#%2*#WIF\9J5&'>I0T2QY!YZ594@]*KYXIZY[46N
M46DV9Z<U.I&.:IKFIU![U(%A 2WM4VTCI446<U/DGI19@3(I(J5(F'6HD? Q
MWJ>-B>M2VPN/&\<9XJ5 :B^;=4T>:8%A"!UZU,".]0+BI*0KDVTL.*54(-,4
MG%/#D\507)U8=*<%)ZTQ%XIZ@CK4A<",=*-YZ"@AB>*<% IV'<!GO3MQZ4X$
M;:AP=V>U $H4D4G0T@8TC9/2DK@.IF#GFD&1UIA<@T]0N/9/2H6]*DR6'%1D
M\TM0N(,]Z.<T%L=::,DY[4[#N*RYZ5&1V[T]VQTI@;\Z+,5R-HV'6DPP'6I'
MSBHB&HLP4A,D&I!)Q[U P8]* & YI<I7,3ASW-/#GL>*I_-4;/(#P:=A\QIB
M7WH,N.]9ZR,:"[9I<K*YT::2X[TXRD]#67O<#K2>>_K32%SFNLOO4JS8'6L'
M[2V>#4J7#]S0TPYC8:0^M/C?WK(\]L=:%G?L:6H7-WS!C@TTN?6LH7#>M2+.
M>YI6872-+S0!S2B8=JS?.)-/63TIAH: ER:5G]:H_: ..])]HQUHU)T-#=Q4
M9D]*J"<D^U*7W?=H'<M>9Q4;/ZU7W,#BAB<<T:A=#_-.>#2^9FH-C$Y%+M/:
MBPTQY--&[/-)R.#4J*>]*P^9#/*9CQ4L<)!J9%J4+3L',-"\<TFWFI",4SD=
M:7**XC+Z5$5J8Y/2HV!I6:*3(2,&EQ@9H(/>FE6_"C4U&LU0N_&!UJ1D/:H7
M0T]47H5Y-W<U3=V!ZU9F#5ESLZD\U2;(DD3F5CWJO([9X/-4VG;M2>>>]%S&
M1,TLR_Q5+')*1RU54DW'FK* GI3NS)EE&D/0U.JN1DFHHD.:N)P,&E<+HC&[
MO4R@TH7!R:D&*+@-*;ABA8\=:D!STIV#WH5Q7!4I2G/%.&12@%NE&NX7&8XX
MZTHSCFG;>U&TCK2U BV<Y-*0>U3*E(XQTI6"Y%C\Z,'O3J#FE9B(V3O417TJ
M8Y'TII^;I3LQW1%BF[#3R#0,CK1J"&[#2;":=SGVI23CBF%R,##5/U%,QQ[T
M@#9H8[B^42<BI54CI31NI^2>E(5W<>!ZT;&[]*%R.M3*#WHU'<:B=ZF(.,"F
MX.>*> 33 :J^M2%.*0@BC)Q3 55)Z4NPTT$BG>9VH=Q7 Y'6@@XZTTDFH\MG
MVI:CN/VLW2C!Z49/:F[^?>C4+CMA7K3><TK.1UI@R3GM0KCN/.>U-W]J5LD<
M5'_.F*X\#/6D9#2KD=:&S^%)(+C5SVIK [J>N.U#=?>F',*H(ZTQSS2Y(ZTC
M#/(HL*XT#-(WRT;L&D+;J+!<B;- 4FE((Z]*3?Z4:A<8V:A;/>I6.:CSCK2U
M"Y$Z-C/:HJG9C^%1$;NE-!<JR9SQ4# ]ZN,M0/@=:=@O<J,I_"JTL9/W:M29
MS[57=J=@*#QX/-5I5XJ_(01[U3D![T6#8RIT8D^E4VC/:M.88-4I3GI31-RA
M*G%9LT1SS6G,3S6?(Y7K56&9\JXK/G3/2M*<EN16;.3VIDLRKB')YK-N8F X
MK5G)K.F)&<BJ$:'AF\-OJ,()_B%?6'A/4HY]*A4'G:*^.K2?R[Z-AV-?0_P[
MUQ9UBASV%,#V3M134.4!IU !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 !Z5SNL:7)=;MHZUT5)B@#RZ7P?=R2DX.*?'X-NE[&O
M3MHI:5AGFG_"'7&/N\TY?"-R.HKTFDP*GE"YYVOA.Y'45)_PBUP.@KT&BGRH
M+LX+_A&+@#I3X_#=QW%=U11RH+G&)X>F!Z5(V@3=A77T4<B'S')KH4@'3FGI
MHLP/2NIHI<B%=G.KI#]Q3SI3CH*WZ*?*@N82Z8X'2I$TY^XK9HI<B"YD?8'!
M]J<+ CM6K13Y$%S.6T8#I33:R9K3HI<B"YG"U<4XVS8J_13Y4%S.^RO2BU?O
M6A11RH.8SS:MVI/LKUHT4<B"YGBU;'-1M9,3TK4HI<B"YF"S<=*#9,:TZ*?*
M@N91L&/:F_87S6O12Y$%V8[V#GI0-.;'3FMBBGRH1B'3Y#1_9TE;=%'*@,(Z
M;)V%']F2$=*W:*.5#N8"Z9)GD4-I3D]*WZ*.5!<Y_P#LIQT%!TJ0]JZ"BGRH
M.8YT:5+GGI2-I$F>!71T460<QS@T=_2G#29/2NAHI<J"[.>_LJ3TIPTN05OT
M4<J#F9A_V:^/>A=.D[UN44N1#YF8XT]Z4V#]JUZ*.1!S,RA8'J1S1]@)ZBM6
MBCD0N9F8+$CM3OLA'2M&BGR(.9F?]D/7'-)]D8]:T:*7(@NS/^RL#[4IM3CB
MK]%/D0^9F:;-C3EM6'6M"BCD0<S*@A85*(\"IJ*.5!S,B,>:9Y1SS5BBCE0<
MS*YB]*88":MT4<B'SLH_9F-'V=JO44N1#]JS.:U?M2-9L5]ZTJ*?(A^UD84F
MFRMFL^71)W8^E=;12Y$)U9,XMO#LQZ"HSX<G]*[BDQ3Y$+G9Q*>'9P>E6$T.
M=377T4<J%S,YH:1,!Q4R:9(!S6_11R(5S$&G/W%+_9SYZ5M44<B"YDC3R.U.
M^PMZ5J44<J%<ROL+>E+]C<=*U**.1!<R_L;T\6;8Y%:-%+D0[F:+1\^U#V;'
MI6E11R(+F5]A;TH^PMZ5JT4*""YCFPD+>U+_ &>PZ"M>BGRH+F1_9[8Z<TS^
MSG[BMJBCD07,3^SGSTH.FOV%;=%+D07,4:<_<5)_9Y]*UJ*?(@N97V!O2C[
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MOH\Q*3DB@Q*1TH0CYG_X5#J6_<J'CVKMO!/@R_TB^5I0=H->Q"-0,8H$2@Y
MI@$8(0 ^E/HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
3 HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0L!VX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\43'_EJWYT ?1(URS/\ RT'YT'7;(?\ +4?G7SS_ ,)9*O\ RT/YTA\53/\
M\M#^= 'T-_;UE_SU'YTG]OV(_P"6J_G7SS_PDTW_ #T;\Z:?$<Y_Y:M^= 'T
M0-?LC_RU7\Z7^WK+_GJOYU\Z?\)/,G_+5OSH_P"$LF_YZ-^= 'T7_;UE_P ]
M1^=']O67_/5?SKYW'BB8_P#+1OSI#XIF'_+1OSH ^B?[>LO^>J_G2'7[$?\
M+5?SKYX7Q3,?^6C?G2-XDG/_ "U;\Z /H@:_8G_EJOYT'7[$?\M5_.OG4>)Y
ME_Y:M^=*?$TS?\M6_.@=CZ)&OV)_Y:K^=!U^Q'_+5?SKYU_X2>=?^6K?G2?\
M)/.W_+5OSI-B/HL:_8G_ ):K^=!U^Q'_ "U7\Z^=/^$GG7_EJWYTH\2SR?\
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M[>G_ .>C?G0!] _V]9?\]5_.C^WK+_GJ/SKY^.OSC_EJWYTW_A(I\_ZQOSH
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MBD;CI5,79/:@W..QH L@9ZU(J#M5$763TIXN]O44 6WC4CFHPBJ?EJ W7F<
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M35(W1':@71/:@"RR#M2",'K47VCVH\\^E RTL8'2E*#O587..U#76>U B1D
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MP?\ /,?E1]A@_N#\J /$#X)).?*/Y4H\%$?\LC^5>W?88/[@_*C[#!_<'Y4
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M_<'Y4?8+?_GF/RH \.'@IFZQ'\J>/!)'_+(_E7MWV&W_ .>8_*C[#!_<'Y4
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M;B/(04TF.Z/*QX+C8XV?I2GP,@&5C_2NV;4X(Y#E!5B+7+7H4%7RBYD>>_\
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M,AX$!Z1?I0? 7_3(_E7J,6J6D?#1BKL6H6<G_+,4 >.MX$(_Y9'\J:/ _/\
MJ_TKVQGM3'GRQ^59<UW:I+CRQ0)L\N7P-D?ZH_E2-X#_ .F1_*O8K26UD _=
MC\JTX[6W<9\L?E2:&F>"_P#"!G/^J/Y583P""O,1_*O=?L%O_P \Q^5#6=NJ
MY\L4P/!7\!D'B(_E2KX$]8OTKVBX>UB/,8_*J37MH#_JQ0!Y1_P@O'^J/Y5&
MW@)2>8_TKUO^T+3'^K%5I-0M=W""G839Y</ 8 XB_2D/@-<\Q_I7K<-U:LO^
MK%,FGM^R"IV#F/*5\$QKQY?Z4'P(K](_TKT26\@5ON"IK?5;4, 4%),JYYE_
MP@>.D1_*FGP*W_/(_E7MUD+:Z4$1C\JO?V?;_P#/,?E5W"YX%_P@C?\ /(_E
M2CP"#R8OTKWLZ?;8_P!6/RJK-:P*/]6/RHN(\/\ ^$("=(_TJO/X,(4L(CQ[
M5['/Y"MC8*=Y%O);M^['3TJ6!\Z:E9-I[$;<8K)\W>.:[OQ_$D<K[0!7G"O@
MFDB>HZ0D2#%=EX9;YDS7$&8;QFNN\/2;G3'K5%'NWA<C8N*[,=*X7PD3L3FN
MZ'W10 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !574/^/1_I5JJFH_\>;_2@#Y^\?R8N'^M><G#&O0?
MB"A^T/\ 6O-BQ4T 3E%Q4,+;;Q,>M&\D4V!2;M/K0!]"_#9LP1UZJ.@KRKX:
MKB".O51T% "T444 %%%% !1110 4444 %%%% !10>!6?=ZE'; [C0D!>,BKU
M-,-Q'_>%<5J?BZ&$GYA^=8G_  FL;'A_UK54VR7(]/\ M,?]X4X3(>AKR_\
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M'P];ELY%31Z+!'T-<6/B1:G^(?G2_P#"Q[7^\/SI_5Y#]O$[S[#%MQFJKZ)
M[[N*X[_A8EKC.X?G3&^)-HO\0_.CZO(7MX,[V#3HH>AJ]&%0<&O,_P#A9=I_
M>'YT\?$NT_O#\Z7U>0>WBCTSS%]::S*PQFO-#\1[4\[A^=-_X63:C^(?G3^K
M2!8B)Z!-813'DU6.BPGTKB/^%E6G]X?G4G_"S+/'WA^=)X>2'[>)V!T6#ID4
MG]@0,<BN)/Q)M6?AA^=:ECX_M92!N'/O1*A-(%6@SJ4T6)!Q2MHT34VQUJ*\
M *D<UJ(X<<5BXM;EJ2EL8K^'(7ZTQ?#$ ;-=!14V1:*EI8K:C"U<HHH&%0O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1R(7.R/:<=34;!O4U9\LTFT#K1R(:FV5@KCG)J>'4)K=P03Q4P*8Z5%(BD9
MI3BK%1D[G6:)XSN()$3<?SKV+PSK?VZ)2[=17S7 Q6Z7'K7L7@R:3RTYKS*U
M-,]&A(]<5PW0T^L^Q8LHR:T*X)*SL=RU"BBBI&%%%% !4%W_ ,>S_2IZANO^
M/=_I0!\^?$@MYTF!7E>,DYKUSXAJIEDXKRB5>3BG8" J-U;>DD"5.>]81SFM
M332?.3GO2:&?0'@0@HE>F+]T5Y9\/R=D>:]37[HH$+1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A.!63
MJTY6TD'M6LWW:P=9E M9![4 ?/7Q!?==/GUK@HF(-=MX]RUT^/6N+@7CF@";
M=D4ZV4F[3 [U"Q^;BM;2H \Z$CO0![I\. 1!'FO4@0!7E_@J>.UME)P,"MK5
M/'-G89#N./>@#M=Z^M&]?6O+S\3[#^^/SIA^*5@O_+0?G0!ZGYB^M'F+ZUY0
M?BG8'_EH/SH'Q4L/^>@_.DQV/5]Z^M&]?6O*O^%IV!_Y:#\Z>OQ4T\?\M!^=
M,EL]2WKZT;U]:\N_X6CIYZ./SI#\4; ?\M!^= 7/4MZ^M&\>M>6?\+2T_P#O
MC\Z/^%J:>/\ EH/SH*1ZGO7UI-ZGO7E9^*=@>D@_.@?%.P'_ "T'YT!8]*GM
M8INH%47T2W?LM<(/BGIY_P"6@_.G#XJZ<O60?G34F2T=L-"ME[+2-H=LW9:X
M=_BE8/TD'YTT?$^R7K(/SJN=DZ'>QZ+;QGC%7X+:.+IBO-/^%HV!_P"6@_.G
MK\5-/7K(/SI-ME)(]2R@'.*,Q^U>7-\5=.;HX_.FCXI6'_/0?G4A<]3W)[4N
M]?6O+/\ A:6G_P!\?G1_PM*P_OC\Z!GJ>]?6C>OK7EO_  M&P_OC\Z7_ (6C
M8#^,?G0!ZCO7UHWKZUY8WQ2L#T<?G31\4K =9!^= ['JN]?6CS%]:\K/Q3T\
M]''YT@^*5@.L@_.@=CU7>/6C>OK7EO\ PM/3S_&/SH_X6C8?WQ^= FCU+>OK
M1O'K7EG_  M&P_OC\Z>OQ2T\=7'YT"/4=P]:3>OK7F!^*>GD<./SIA^*-A_?
M'YT >I;U]:-Z^M>6?\+2T_\ OC\Z/^%I6']\?G0!ZGO7UHWCUKRS_A:5A_ST
M'YTY?BEIX_C'YT >I;AZTF]?6O,#\5-.Q]\?G3/^%I:?_P ]!^= 'J6]?6C>
MOK7EO_"TM/\ [X_.C_A:6G_WQ^= SU+>/6C>OK7EW_"TM//\8_.@_$^P_OC\
MZ8CU'>OK1O7UKRW_ (6E8?WQ^=)_PM+3_P"^/SH ]3WKZT;U]:\M'Q2L#_&/
MSI?^%GV/_/0?G0!ZCO7UHWKZUY;_ ,+2L/[X_.D/Q2T\?\M!^=# ]3WKZT;U
M]:\J_P"%JZ?_ ,]!^=.'Q2T_^^/SI >I[U]:-Z^M>6?\+2T_^^/SH_X6EI__
M #T'YT >I[U]:-Z^M>6?\+2T_P#OC\Z/^%I:?_?'YT >I[U]:-Z^M>6'XIZ>
M/^6@_.FGXK:>/^6@_.@#U7>OK1O7UKRK_A:VGG_EH/SIP^*>G_\ /0?G0!ZI
MN'K2;U]:\M_X6MIW3S!^= ^*>GD_ZP?G0(]3W#UI-Z^M>8?\+4T['WQ^=,/Q
M2T_/WQ^= SU+>OK2[AZUY6/BE89_U@_.I1\5-.Q]\?G0!Z=O7UHWKZUY:?BE
MIY/WQ^='_"T;#^^/SH ]2WCUHWKZUY=_PM+3_P#GH/SI/^%I6&?OC\Z!V/4]
MP]:3>OK7F ^*>G8^^/SI#\4+ \[Q^= CU'</6DWCUKS#_A:>G@??'YTP_%/3
M\_ZP?G2 ]3W#UJ.1UV'FO,Q\5-.Q]\?G39/B?8..)!^=,#J-<(-M)SVKP#QG
M_P ?#_6N^U'XAV4T3*''/O7F'B'58K^5F0]30!S61FI54$9J%HV8\5(D;#K0
M %RIP*<OS=:7@=:0^U [H1EQTIM2 C'-!7/2@0T/BG<&F$8H )Z4F [.WI2\
M-3=AI?+:@ SMZ4F<TI4CK2;333'83%."<<THP.M(S>E AC\=*5%W4G7K4J"F
M,<OR'-;VF:V;3'-<^YJ B0]#181Z&/%A(ZBD;Q(&ZD5Y\/.'<TQVG'\1IZ#2
M._;Q .Q%(/$/N*X)))AU8T\M*W1C28.QW?\ PD"^HJS!XF"#J*\W+3C^(T])
M)O[QJ6[".ZU#Q )P>17,7<XF)K-?SF_B-+&KC[QI78#L;32@[NM*XJ,*>U-
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MJTC;Y[4GV8>E-,7(4E>3^\:?YLO]XU:\C':D\L>E <A29Y?[QIGF2G^(U?\
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MGK\+-8ZE&_*ES,'!')+)GO4N5QG-=8/ACJP_@;\J#\+]9/16_*ESLE11R#3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/%1,U2L:B8K3)NB)C3-U/;%,)% "%13>]+@YI^WB@0T*.M.5SG%)Y;9]J>H
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M")N:814S(>U"IZU-SH:(12FI3'GH*%C(ZBI&D1JA-2!,5(%Q1TZT7%RD93-
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M6K+2 SARM4R;,I6WA^2YD\TL>:Z6QT=8%&0*T;2W$48&*L@8J#11L,CC$:X
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MH_TKP#Q[CSI/K7OVH_\ 'F_TKYW^(,C"XD^M 'FMT^&-1HV:<XW-S4D<8Q0
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M374Z@<YKF[H#)S7+-GO82.AE^26-.\LIUJ=<#I3B >M8-GM4DD0!=]!394V
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MU>QA;4[;3H_W(-:(&!5+3O\ 4"KU9MF\0HHHI%!1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCI1UZT7"P$BF$@4\@4P@&D4AA(-,IY %- H>QHAN:<#ZTI I ,TD!(&%.I@
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MU?Z4 >*>-E.^2O'-6R)3]:]>\<3E9)!7CVJ/ND/UH AMWXJUG(JC#TJQOP*
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MT5Y[X.(V)S7H2_=% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA/2DVXZU76[[9JPLBN.M92?8ZE,-P%)N6D<<\4@6D::"\]J<#CK3<XI0-U-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *IZE_QYR?2KE4-3/^AR?2@#YU^(3#[3)]
M:\Y)R:]%^(*@W,GUKSHC!H D4B@KGI2*H/>I0 * &# '--8BI&4&HF&* (<@
M,,UOZ.1YJ8]:Y_8"]='HL8\U/K0![5X.(\I*ZZ8CM7*^#X1Y2\UU=PH6@>A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ(^(IFYWM^=*XN4^F/\ A,;#'^L'YU')XUT]1_K!^=?-7_"2SCC<U,.O3/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M #U8 54E),HQZU9"Y%5I#MD'UH ]-\#/MV9KW/0W!1<5X)X,;)2O<_#WW%H
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M4TQEN DQC-$I(%2*,#%0W!PM(1GS2L3BJIR34DLF6J,'F@ VF@4\N,4U>30
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MZ5Y[XH3*2?2O0I?]6:X/Q-_JY/I0!\_^+1ME:N;M0#73>,1^^:N7M6VT 6)
MX^[3!N[U.9!Z5&3DT * Q'%5W'[P;JMI*%'2JTQWR#ZT =_X/(#)BO<_#A)1
M:\%\)/Y;)]:]U\,2[D6@#M!T%+2+]T4M !1110 4444 %%%% !1110 4444
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M1?NTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!7O.+=OI7D7C"8 R<UZY??\>S?2O%O&F=\G- 'DVMMNE/UK,B"XJ]JO\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *U]_QZO\
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M$%(-/QD8H -PS3U?-1^21S3@.U $A"XIG&:=L.*9CF@"3"XJ/ )IVPXIN.:
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M8/VE/K7T!\.H\PQUX#9,!<I]:^A/AR088Z /3XUP!4E(.@I: "BBB@ HHHH
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M+\4 623VIN&)J2'D<U(0!0! "PII)J8L*9MSS0!%O<=*4$GK4N5 Y%,)&>*
M%!/:FDG-/5ATI2N[F@!NXXJ,KD\U-D*.:C)R: )H<@\5J0$XYK.A8"M&$Y%
M$]%%% !1110 53OH@UL_TJY5:]_X]7^E 'S;\3%V3R8KS* G->H?$Y@)I*\M
MAD :@"RV[M0N>]2(ZD=*5B.U #<&F$8-3*P%1N030!IZ:["1<>M>Y> I&*IF
MO#=-8"1?K7N/@,@JE 'JT3945+447W14M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 6\A25?K7LG@*<D)7C49!E7ZUZYX$_@H ]ML6R@K1[5D:=]Q:UQTH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:_W33J9+]PT
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MYO. P%-:EDL;8R!6S%:P.OW173%(NYQ+B;/W33/,N!_ :[O^RX6.=HIYTJW
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M_=Q3,@CBDP: !G)IO/I4@(IV!0!'O('2CS#3CCI3=G.: %WD]:7"]::Q&,5
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M.M8*Z'ISR ;TKD=:UB\:Z*+(W)JWI6EZO> 2J[8ZT >@V'@W3;A1\R<UH/\
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M15^SOFMG!W8Q0!]->'+N![107'3UI^L:=;74+'>O->):9XS:U4#S2/QK;'Q
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MNPTF2M #A"%IK#%&\T8)H 4/BG8#5&1BGJC'I0 I.WI498DXJ7&W[U1MC/%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "HIUW1$5+2$9% '!>)-),L,A [5\^^,-/EAN6PAZ^E?6MU:)-$P(SFN
M \1>#(+M'81 GZ4 ?,D *\,,5:4*>]=;XD\&7=O(QAC( ]JXN?3KVU;#@C%
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M?'>HVBG/K0!HAU(ZBD8+US6<([@>M&RX]Z +^\+QFCY6[BJ!BG/K2>7< ]Z
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M,=!49^$"5[-10!XS_P *@3T%'_"H$KV:B@#QK_A4">E)_P *@2O9J* /&?\
MA4">@H_X5 E>S44 >,_\*@3T%*/A"@KV6B@#QW_A4:8Z"F'X0*:]EHH \9_X
M5 M'_"H%KV:B@#QG_A4">@H_X5 M>S44 >,_\*@3T%'_  J!:]FHH \8/P?4
MBFCX.KG->TT4 >.#X1J!BFGX0(:]EHH \9_X5 E'_"H%KV:B@#QG_A4"4?\
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MB@#QA/@^JU(WPC4U['10!XVOPB04K?")#VKV.B@#QL?"%!V%*WPB0]A7L=%
M'C8^$2BE;X1(>PKV.B@#QL?"%!2GX1(>PKV.B@#QL?"%!2GX1H:]CHH \:'P
MA04X_"-#V%>QT4 >-#X0H*<?A&A'05['10!XS_PJ!/2C_A4"U[-10!XT/A"@
M[4\_"-,=!7L5% 'C/_"H$]!1_P *@3VKV:B@#QG_ (5 E'_"H$]!7LU% 'C0
M^$*"GGX1ICH*]BHH \:/P@3T%)_PJ!/05[-10!XS_P *@3T%'_"H$]!7LU%
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M\@[5[110!XQ_PIY-V<"NBTCX>Q6&W*@XKT6B@#+LM*BM@ $''M6F% Z"EHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYYK1$?-3*O% &1]CV]J/LU:S1@BJ[1G/ H I?9?:C[*/2M%(^.:4Q^U %!8
M.U2_9P1TJQL I0* ,Z2#!Z4):;ATK2\D-UHV;>E &<;/!Z4HLLBK^PFEVD4
M9S6>.U-^R^U:1'K3=HS0!62U&.E,>U'I6BJC%(R4 9?V4>E/%D#VJ]L I0/2
M@#/:S [4W[+[5IE":3RZ ,W[+[4\6>15_P NEVD4 9KVNWM3%M\]JTV0'K49
MC]* *7V7VJ6.TJW''GK4A7'2@!L4.RK%1KFI* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ3Z8Q/:@!]%,4FGT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !112'I0 IJ,L*1FJ,L* 'XS3U7%5O,(/%2
M++0!/32P%1^92Y4T .WBDWBF'&:48H E!I"P%1Y]*7([T .WBC>*8<4WH: )
MP12,PJ+?BC<#0 [&>E/5<5&&H\R@";BFLP%1^91N!ZT +C=1TZT9QTII//-
M$P(-(6 IJ$4CD4 /5@:?5</BGB0>M $F!32P%-+^E)D'K0 [S*-XIAQVH4#O
M0!(&!I]- %.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7R3Z4GE&@ \VCS*7R3Z4GE&@ \RF&<4_RJ:;?-  )0:?]I5>M-$!':AK?-
MUTIZ4"8&H6M\'I4B1&@!_F"FF8"G^4?2FFWS0 "8&D,P%*(".@H-L3VH 03
MT[S:C,)7M4L<.[K0 !LT%L5(8]O2HRA- ">91YE+Y)J-HV':@!_F4Y9P#4&Q
M_2I8X"3R* -"VE#=*T$JA;QA*O*P'>@"6BHR_I0KT 244F:6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6!J19* ):0G%-WC'6F%\T /WC-/J( =<T[< .M #Z*A,E*)* ):*:&'K2Y%
M"T4A/%1[SF@"6BF@TN10 M%(34>\YH EHIH:ER* %HI,BC(H 6BDR*6@ HI,
MBEH **3(I: "BDR*6@ HHHH **3(I: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ***3(H 6BBB@ HHHH **C9B*5230 ^BHV8BE4D
MT /HJ-F(I5:@!]%1EZ56H ?149:F^8: )J:6 IGF&C[U  23TH!QUI/NTA.:
M %+4!JB8D4*2: )B<]*:<B@'%!;- "9-.#5$S8Z4*V>M $S-FD5JC9L4SS*
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M.),=309@>E5BY--!(H O1R$'FIC,,5G>8::TQ% %UWS3%8@U528L>:F+8&:
M)GEXZU%YF3Q4+.330<4 6Q(1U-+Y^> :K!MU+M YH G$C9ZU()?>J?F$4GFF
M@"]YOO2>;517)IY; H LB6I/-!%9QD-*DAS0!?!R:?D8JH)>*1I<=* +!)I-
MQ%5A.V:?YA(H E\VCS?>J[5$7- %WSCZT>:3WJF')J3.!F@"TI-2;^*H"=@<
M5()": +&XYZU()/>JGF&CS#0!;,M-\]:K;\TNT=: +0DS3P2:H[BM.%P10!<
M)-,W"J_GL:7=WH LYXI/,JOYK=,4!L]: +(8FER:@#XI?-H FR:>&XJMYAH\
MPT 3$G-.#<57$AJ0'- #BQS3@W%,HH <<FG!L=:9NI": )P::6J,-2'F@!_)
M/%/4&H@V*D#<4 /HJ,N:3>: ):*B\PTX-0 ^BHRYI5:@!]%1ES2JV: 'T49I
M,T +149<TJM0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1FF&*@",-SS4@=:40@TXP+CK0!&T@[5'DDU+Y0S2B,"@!@!'6G%^*>1D5&R
M4 ,WX/-+YJXXINT,<4>2 ,YH "2:* .U2%!B@"(\4F\4[&3BE\D 9H 3)-)2
M@=JD*#% $>329Q3AUQ3C&"* (Q+@\U()%85"T7-($V\T 3%#UJ,N%/-'G'I3
M)%!&: %:=5%4Y;Y%[U%.3TK(O"RJ2,T :#ZDN>M1-J:>M<?=ZA,CD &J9U&?
MT- ';MJ(/>D6^3/6N)_M*?T-*-2G'\)H [U;Y,=:8]_'ZUP_]JSXZ&F_VG/G
MH: .T-W\V0>*F34$'!-<0-5GZ;32G4)L9P: .Z^WH><TUM1C'>N";6+A3C!H
M_M.=NQH [<Z@I/!I5O >]<1_:,X_A-._M:=1T- '="\0#DT'4(QQFN#;6;C^
MZ:3^U)SS@T =U]M!/!IPO$QR:X,:Q.IQM-3IJTQ'0T =FUXN>#3UO$[FN(.J
MSYZ&G#5)O0T =R+M/6@W*>M<,=9G7L:3^W)_0T =J;@9X-/6X7N:X@:W/_=-
M/76)SV- '<"=?6FFX7UKC1K4P'0TTZU,>QH [59U]:E$Z8YK@_[=G4\ U.FM
MS,.0: .S:=>QI X-<:VM3 ]#4B:[+CH: .OW8[T;_>N/;7YAT!IRZ],>H- '
M7;_>FF0#O7(MK\PZ T#6YFZ@T =4TOH:%N,=37)-K4P[&HSK,Q/0T =H+@'O
M0;A?6N+&M3#L:&UJ8]C0!US3J>AIR7 '>N*;6IAT!I/[;G_NF@#MVNO0U";K
MU-<=_;<_H::=9G/\)H [,7([&AKP+U-<8-9G'\)IKZM._8T =F+X'O3Q?(.I
MKAUU2<=C0VJ3GL: .Y-\AZ&HS>J.IKB/[6G7L:/[6G;^$T =N+U3T-!O@.]<
M4NJ3C^$TK:I.?X30!V@O@>]2+>+W-<,-4G'8T_\ M>?T- ';/?(.AIJ7R$\F
MN).J3MV-,_M2X7^$T =XUTA'!I@O$7J:X7^V[C^Z:>NJSR?PF@#NO[3C'0T]
M=53^]7 R:A.HX!H@U&=CR#0!Z1%J"MT-7$N,]37$V%VYQUKHK>5F H V/-4T
M]9%'6J2=*G5<T 6MROTIC+CDTU!LYJ7(<8H A##/%/+8%(\07D4Q?F.* '!P
M:4G%.\D*,TFT-Q0 T..U.+4OD@<TFT'B@!F\$U(N*/) YH"\T /+#'%1LQIY
M08IFW)H :KC/-3%U IGD@<TFS/% #3+SQ3@_K3A .N:<8AC%  LB'BI-P S4
M0@ .<U(0",4 -\Y2<4[ QFHQ ,YJ7;QB@!N5S3LC%-\OG-/"YXH 9N7-.%+Y
M ZTH7'% "44_:,=:;QF@!*4,:?L&*9CF@!^012;.:55'K4F!B@"/( IH;FGE
M :!&* 'ATVU"S?-Q4WDKCK3?* -  .13=IS4ZH,4T\4 .0@+S4;.,TM,V9H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% $1!S3AG%/HH C(-*N:?10
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M/N?I36\--_<_2NY'7I4@0'M0!Y__ ,(N3_RS_2E'A@C^#]*[\H,=!3,<XVT
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MPT1_!^E*OADMT3]*[SRP_:G!!'VH X4>&"G5/TI#X;#=$_2N[.).U-\H+VH
MX(^%\?\ +/\ 2G1^&\?P?I7=[ W44>4%Z"@#BO\ A&LCE/TIA\,$?=3]*[?\
M*D3_ ': .-MM!EB/*UK0V)0#BMY\8Z5$%R>E &>+9NPJ1;=UK22,4LB@+Q0!
MFM&V*8J.#5]$W'D5*8!B@"AM8CF@1'/%7/*]J4)B@"H8WQ3=C"KQ&13?+]J
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M **** "BBB@ HHHH C8&E4&GT4 1L#2J#WI]% !1110 4444 %%%% !1110
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M (!$!VJ-XZMTTKF@"HD?-2F,8YJ4)BE*YH K&,=J%B/>K 3%.Q0!!Y ]*/)
M[58HH K^5[4")1VJQ32N: (&'I3 AS\U60E*5R* *Y08XI%5L\U8"8I2N10!
M%M4BFM&3TJ8)@T[% %01'-2K'4^** (C&*88\58I",T 5]HIPCJ0)S3J (FC
MXXJ#RR#5VD*YH KA13O+]JD"<T[% $/E^U'E^U3T4 0>72A34U% #-O%,VG-
M344 1^6*;L-344 1>6*38:FHH B\L8IOE<]*GHH 9MXIFTYJ:B@!H6EQ2T4
M)M%&T4M% ";11BEHH 3:*-HI:* $VBC%+10 FT48I:* $VBC:*6B@!-HHQ2T
M4 %%%% ";10!BEHH **** $VB@#%+10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image3.jpg
<TEXT>
begin 644 image3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0M!VX# 2(  A$! Q$!_\0
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MWHWN.]%P+F11D53W.>])O<=31<"[D49%4PSGO07<=Z8%S(HR*I[G/>@NX[T
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M3WN.]&7/>@"YD49%4][CO1N<]Z+@7,BC(JGO<=Z,N>],"YD49%4][CO1N<T
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M]:,CUJA^])ZT_,@'6F!<R/6C(]:SB\@/6GB1\=: +V1ZT9'K5#,OK2AW'4T
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M V*+ /P!UI"12A@>M! /2F *1WIQ /2HB"*-QH8T2<+2%@>U /K0=M)-@(&
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MHK':\DSP:5)YFH0&O168TDX%1?:9E/- &Q16?!<ENIJ\K9% #J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT4FX4;A0 M%-\Q?6C<* '44W>OK1O!H =12;A1N% "T4FX4;A0 M%)N%&X4
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M%[#Y1"Y--R?6G&@+FAR'RM '-.\TBCRZ!'2 <)?44;U/\(H*4S;BD"8I,?\
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M. )Z4 (1BFTX@CK3:!#@V*"V:2B@8H.*"V:52.]!P>E #>E+UI1@=:4D'I0
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M@*3VI^PBAC&'.*;3SN]*9M;TIB'#WI<@=*:%)[4XQD4KB#=ZT';2!">U+Y9
MH8#:.*4*3VI3&:8[C0?6GX':F!#GI3]A%*PAA!H'6G'=TQ2!3Z4QBDG%,!YI
MYW$8Q4>Q@<XI(9+SBF'%.&X\8I3&>M KC!UIWRXINPYZ4\QG%-B(SUI>*-IS
MTIWEG%(:&BGX7%-VMGI3O+-,&,-)3B&]*-A]* $W'%)WIP#>E.\L]<4@$&:7
MBCYNF*-A/- A-QI>"*:5([4;6]*=AV#;S2X % +=,4NPD4"(SUIXVXII0YZ4
M[RCBEJ,:<4#%*4/I2B,TV"&[C1G-!0CM0$/I0P0\9QQ3#UIXSTQ08R:0V,#&
MDSFE*$=J3:WI3)%"FC&.M.!8=J=L+4:C(N]/7;CFFE"#TIXC)%"0AK8[4S<,
MT]D([4SRB>U%QK4<&/:EZ]:0*1VHVL>U :(2GKCO3-K>E/$9-#V$2#':FG;W
MI0I I&0FI ;]*7CO2?,.U+M+4]0$+8Z4HPW6FF,CM2#<.U,!6 '2F\4IW'M2
MK&31<$--.7'>@QD4!#2U!L4J.U&T#K1\R]J,,W:D.XA [4# ZTX(136C)IDI
MW8$CM2C'>F!&':GA">U,IB'':@8[TK1D4@0FAB!L=J;]:<R$4!":0P!Q3L@]
M:0QD4@0FC<+BE1VIA!%2;2O:C!;M0(C!(Z4N2>M/\LBDV$T%)"#VH.>]/V%:
M,%NU B&G#WIQC(INUO2BUP'$+VI !WHVL.U*%)[4P D <4@;/6E,9%,*MGI2
MM<1* IHVBHP&':G_ #-VHLP$) Z4@;/6G&(TW8?2BP[#QMI214>PTH4FE8=@
M) Z4;O6@QFD"'TIK8D4[:;FG>6::$.>E- &10#3O+-($.>E+<=Q2%Q3*?Y9Q
M3=ASTHL(![4K9QS3A&10P)&,4#W(.,TX4AB.<XIZH?2G80<"E#&E\HXII5O2
ME:X[COE(IN.:3:WI3@&]*:T 7Y<4SO3_ "SBDV'/2DA"_+BFDT_RS3-K9Z4P
M#BDI_EG%-*GTI+48X;:<<]JCV&G MTQ18-AII,U)Y9/:F;#GI0M0N.^7%-.,
MT[RSBDV'/2A"%&VDW<TOEFFE2#TH =P1S33UXIPC.*:5.>E !Q29IXC)%(4(
M[4;CN*-M!/I0(S2%2.U" ;GFE#&G",FD*D=J $SGK24_RR:0H1VIH&)Q1N-.
M$9-(4([4MPN*"".::<9XIPC.*:5(/2@0JXQS2'&>*<(R12%"*$ +M[T[('2D
M$9-!4CM18:%R.](6QTH"$TA0BA Q00>M!..E C)I2A%'4$,)/>@,13_+)II0
MCM3N#%!!ZTC8[4H0FD9"*-A ,=Z4L!TI%0FE,9%+=@ (/6@X[4S:WI2@-Z4[
M##ZTN<=*-K'M2;6':@8A;UI5/I2^66ZTNPITI"T$;/>F5+@MVI#&1VH :N.]
M*P':@(32E"*+"(Z4,1TIP0GK2LH6GJ !L]:"!VIH />G<+TI=1@!ZTO':FEL
MT@('>C4 ;)ZTT+SQ4F=W6EP!1<!FWUH^E/SFE"@=Z+AL0L/6G0[<TZ0 BFQ)
MAJ:8B\O2EI%Z4M, IC]*?3)/NT 4W//6D'-,<-NIRYHL _8?6FXIV&IO.:@8
M[8?6DQS2X;%-YS30AP0GO2^7[TT$TA9J0Q^S'>@MQBH<N34@0XYIV$)Y98YS
M4R+CK462*D5^:>P%E0,4NT>E-0Y%/I@)@4;1Z4M% "8%&T>E+10 FT>E&T>E
M+10 F!1M'I2T4 )@4;1Z4M% ";1Z4;1Z4M%%@$P*-H]*6B@!,#THVCTI:* $
MP*-H]*6B@!,"C:/2EHH 3:/2C:/2EHHL FT>E&T4M% ";1Z4;1Z4M% ";1Z4
M;1Z4M% ";1Z4;1Z4M% ";1Z4;1Z4M% ";11M%+12L FT>E&T>E+13 3:/2C:
M/2EHHL FT>E&!2T4 )M'I1@>E+10 FT>E&!2T4 )M'I1M'I2T46 3:/2C I:
M* $VCTI-@]*=118!-H]*,"EHH 3:/2C:*6BBP";1Z48%+10 FT>E&!2T4 )M
M'I1M'I2T4 )M'I2;!Z4ZBBP";1Z48%+10 FT>E&!2T4 )M'I1@4M% ";1Z48
M%+10 FT>E&T>E+10 FT>E&!2T4 )M'I1M%+118!-H]*-H]*6BBP";1Z48%+1
M0 FT>E&!2T4 )M'I1@4M% ";1Z4;1Z4M% ";1Z48%+10 FT>E)M6G5#<OY<+
M-Z"@!Y,8ZD4!X_[P_.O/]9\3&UF*A\<U6L_$LD[K\Y_.@#TH;32X%8>G:D&B
M#.W:GW/B.UMCAF'YT ;.T>E&T>E<S_PF=CNQN'YUI6VN6]RN584 :FT>E)L'
MI5&3584&2PJA/XIM(/O,* -[:/2C KEO^$XL-VW</SK8L=9@O@"A'- &C@4;
M13#,H&<BJTFI11G!(HL!<VCTHVCTJM'?1R#@TDE_%&,DB@"UM'I33L'7%8-Y
MXIM+53N8<5R&I_$FSAEVA^_K0!Z< AZ8I<"N,\/>+(=3 VMG/O77K,&3(H >
M=O?%,,L*]74?C6'JNKK:JW->9>(/%ET&80RD?C0![/\ :+;_ )Z)^=*)H#T=
M?SKYZM]<UNY.5F:K?_"6:AIY'VB5OSH ]]#(W0@T[:/2O,O#GC>.ZVAWS^-=
M_:ZE%<J"IH O;1Z4;1Z50NM5AM?OFJ:^);5CC<* -O:/2C"BJ$6K0S#*D5A:
MWXOM=+!,C 8]Z .K^4TN!7FMO\4-.D?;O'YUT^F>*;74,;#UH Z/:/2C:/2L
M^;5H8%RQJH/$MJ3C</SH V]H]*-H]*HV^JPW'W2*O Y&: # HVBEHH 3:*-H
M]*6B@!,#THVCTI:* $VCTHVCTI:* $P*-H]*6B@!NP>E+M'I2T4 )@4;1Z4M
M% ";1Z4;1Z4M%%@$P*-H]*6B@!,"C:/2EHH 3 HVCTI:* $P*-H]*6B@!,"C
M:/2EHH 3:/2C:/2EHH 3 HVCTI:* &[!Z4NT>E+10 F!1M'I2T4 )@4;1Z4M
M% "8%&T>E+10 FT>E&T>E+118!,"C:/2EHH 3 HVCTI:* $P*-H]*6B@!,"C
M:/2EHH 3 HVCTI:* $VBC:/2EHI6 3:*-H]*6BBP"8'I1M'I2T4P$P*-H]*6
MB@!,"C:/2EHH 3 HVCTI:* $VBC:/2EHHL FT4;1Z4M%%@$VBC:*6BE8!,"C
M:/2EHI@)M'I1M'I2T4 )M'I1M'I2T4 -VCTHV#TIU% ";1Z4;1Z4M% ";11M
M%+12L FT>E&T>E+13 3:/2C:/2EHH 84%5IEJTV:K2@T,"!5.>M2^6<=:8 <
MU(,CK4CN1O&:8%([U.3NZ4W8:=P$ S3]GO3>1TI-S4!:P\I[TFW'>F'<>E(%
M?O2L%QS4Z+K3#FGQ=:8,N#I2T@Z4M,04Q^E/IDGW: *;_>I!2M]ZG;1BE<!N
M\TF:4\4VBP#@YIW!IE/"CKFI&(0>U-P:ER!Q05R*!D0-.W&FD8-+SZ4T(0\T
MJJ<TG>ITJA$L8XJ2FK3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J\Q%3,<55FRU $0?GBG%B:C5<&I
M0,U/F,;NQ3P^>M(5 I ,FDV XD8XIF:<5P.M(!DTPN&<=*<&SUI"H%(!DT@"
M0C'%)"6W4I4#O3XNM4F(MKTI:0=*6F 4R3[M/IDG2@"FWWJ<%..M,=ANI5:E
MJ C"F;3FILKBF'K1<8HHYHR*3-+08 G-2!N*1=O>GD#'%*XB/()J3C;4+<&E
MR<4T UG :IXSFH-H)YJ>,8JA%A:=35IU !1110 4444 %%%% !1110 4444
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M=P]: *[V,$ART8--_LZV_P">8_*K61ZTM %,Z9:G_EDOY4#3+4'(B7\JN44
M0K;1*,!0!52]TJVGB;,8)(]*T:CDD5%):@#RC7_!TEQ.3"N!GM2Z3X$QM\Y<
M_6NYO]9L+?/F$9%<[=>-K&W)V../>@#:L?".G0@%[="?I6[;Z;:6X_=1JOTK
MSQ?B38JX4R?K72:7XOL[T#:V<^] '4>6N,8JE<:+8W)S+ K9]15B"\CG&5-2
MF11WH R?^$7TD?\ +JGY5-'H.GQ_=MU'X5H"13WIV10!#':0Q#"( *KW&CV5
MR<RPJWU%7\CUII=1W% %"+1;&#_5P*/PJXD")]U0*>'4]Q2Y% $;V\<GWE!J
ME-H6GS_ZR!3]15YYE09-8][XEL[(XD8#\:  ^%M*[6J?E3D\,:8O_+LGY5!;
M>*[&Y.$<?G6M#?13#*F@ @TVUMO]5$%^@J9X(G^\H-9]]KMM9 ^8P&*YVZ\?
MZ=&<>8/SH Z>32;*3[T2FH?^$>TT_P#+NGY5A67BR"^/[I\Y]ZVXM24#+&@"
MU%I=G!]R)5I\EA:R_>136'J'B.&W!^:N?F\?VD!^>3]: .S;0].;K GY4@\/
MZ=_S[I^5<C;_ !#L)B )!^==)INO0WV-C9S0!<_L'3_^>"_E2?V!IYZVZ_E6
MFIRN:C>98^M %:+2;.'[D*C\*MK$B=!6=/J\,74TMMJD5PV%:@#3HIH8$9S5
M.[U2"S!,C#CWH O45SI\6V). X_.KEIK4%T1L:@#6HI@D7;G- D4]Q0 ^BC(
MJO/=QVXRYH L45BR>)+.,X+C\Z=!XAM)SA6'YT ;%)D>M9-YK,$$>XL*P)_&
M]E"Q#2#CWH [;-%<A8>,[*[?:K@GZUTMO>1S("IZT 6J*0'(IDDJQC)H DHK
M/EU:"+[QJH_B:R3JP_.@#;I-P]17*WGC&R13AQ^=8,WCZVB<YDX^M 'I&1ZT
MM>>V'Q LKB0+YG.?6NLL];M[E 5/6@#6HR*S+[5X;2'>YP,5S@\>Z?\ :/+\
MP9SZT =M16/9Z_:W:@HP.:L7FIQ6T/F,>,4 7\BC(KA[CX@:=#*8VD&1[U-:
M^-[&X8!9!^= '9TFX>M<]-XCMU@WANU<U=>/K6"4AI/UH ]&W#UHW#UKS0?$
MFP;Y1(,_6IX?'5LYSYG'UH ]%S17(V?C*RF(7>,_6NAMM0BN%RIZT 7:*0,"
M.*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!,5!* *L55N,]J (*7FFIG/-2DCM4M@,.:4 FDS1G'2E88XJ
M12 9-&X]Z,XZ4PL*5(I ,TA?UI XSQ19B%8%:6%^<4TDGK4D*C-- 7%Z4M(O
M2EI@%,?I3Z9)]V@"DZKNZT "D=?FZT**!MDFU<4SC-/V>],QS4 /VKBFFG;>
M.M,[U2:$%/!- 4=:4MBC0 P#UI<+49YI#FE88_"9ZU(GM5;RR3G-6(^*:0%A
M:=35IU,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0OAM=(BOY[?G0!UNFZ38JP,<@-=A9QK'$ IKG]-\,R68 :0G'O726\1B3!H
MR/$I(L'^E?._B*8_VDP9R!GUKZ(\39^P/CTKYR\1VLD^ILN".: +NDBR=AYL
MP'XUWFF6.C.@_P!(7/UKSW2_";7.";C;^-=KI7@39AC??^/4 =?9V%BC Q2
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MM*YXH \)U+7]7^T. CXS5G1?$.JK*"ROUK;U/9#*Q,(Z^E5]/FCFDP(@/PH
MMZGXCO'ML-GI7&R7\D\Q\QB,GUKN;[3?.ASMQQ7)7FB[7)!Q0!T/A7R!,I,G
M?UKV72983 @5\\5X!I-M+!*-I)YKU+PW/<'8&#8H ]+3&WBJ.H.J(<G%3P.1
M "?2N?\ $5TZPM@'I0!S/B'4EB5MC\UYS=ZY<-,P!.,^M=)-!+J5RR'/)JM?
M^$GMH?.VD\9H H:8DNI2!7SS776_P^AO8@S]ZY71+MK.\VNF #W%>FVWBFW@
MM5^9<XH R[/X:6MLX<'FNGL]$2R4 'I61_PG,9?"X-6X/$AO#@+U]J ,_P 9
M-LL&"GM7@[SS+J[')QN]:]W\10M<V;'!Y%>1W.DL+]CL/6@#L?#.I&-4WMC\
M:Z/7]7BDTLJLG.WUKSK,UG#E5/%4O[5N;N3R2&QTH YG69ISJ#,I;&?6MKPK
M--+=*K$]:MWNAOY'G%"3C/2JWAR5X=45/+/7TH ]IM=%2YTP%CU%<5K_ (3A
M#,V:]+TIB=*4X[5S'B)VV-A30!YA:>'8FOMFX]:] L_!4)LPX]*Y73VD_M09
M4]:]ATH!M.7<,<4 >;7.D?V9(74GBK.D^*98KD0[CCIUK<\311B%B&&:\QM7
M<:R ,XS0!]"Z/=&ZME<]Q6G7/^%R38+GTKH* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JTU6:K34F!77D\
MT\@#I357)IQ3'>DK@( #3BJTT+SUI2N.]'4887N:#M[&F[=W>E$/O3T 3:&Z
MTX1+ZTOE^]*$]Z38#6"@4L1&:&CSWHBBP>M-6 N#I2T@Z4M,04R3[M/IDG2@
M#/=6W4Y>!2/G=2B@=A<GUHZTNTTE2(=M;%-I_P V*::![BA3ZT[(J/+]J.>]
M"0,?MHR!30QIW!H$-SSQ4R5!WXJ9*:&6%IU-7I3J8@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#(U?3VO(BH':O-]9\+3P,TB@UZ_5:YLXKE<.!0!XQI%M<B["-GK7H4.
MBF>U&5[5K1>'K2*3>JC-:L<:QKM'04 <-/X/$A)V?I5)_ H;K'^E>D\4<4 >
M>6?@>."3=Y8_*MB;PTCV^P(.E=7Q10!P5IX.$%UY@3OZ5U2V&+81X[5I\44
M<E=>'/.<G;3;3PUY,N[;77T4 9<MANMO+QVKEKSPBTTI;;7>T<4 <)8^%'MY
M0VVNQLH/(B"U:XHH **** *6HVOVJ ICK7G.K> Y;F8NB\GVKU.DXH \5/@/
M5XS^Z=A4T/A+Q%&>)WQ7LF!Z"C ]!0!YMI_A_6HG!EE8UU<6GW!MMCDDXK>P
M*6@#SC5_"-S>$XSS7+-\,+A[C>R9&?2O;^*,"@#SG2/ <=H%+Q#(]JZG^PXE
MM3&J#I6]Q10!Y?J?@:2XN?,1>_I4EIX/NX5 YQ7I?%'% '"1^%),Y=<U<7PR
M N-E=AQ1Q0!Q'_"*_O VRM:'1S'!LQVKH>** .$O?"1N)M^WOZ5<M/#K0Q[=
MM=?Q10!Q[^&MTH8K6S:Z>;>#:HP<5K\44 <;J&D:A+<;HW(&:VM(M+BW0"4D
MUL<44 %036Z2H01UJ>B@#C-7\)QWFXB,9/M7&WW@34PQ^S%E'M7LM)@>E 'B
M,/@'6/,!D=CS79:-X7GMD E&:[S ]!2\4 <C<^&5F4Y2N<OO ;S,=J?I7J-)
MQ0!Y-#\/9%8$I^E;EOX8FM(#M&,"N]XI&4,I!H ^>/&FDW1F8#-4?#_A;5;G
M'ELPKWN^\.6EZ^Z10?PJ>PT2VL?]6H&/:@#RF/P%JK$&1F-=AH?A 6VW[0F2
M/45W6!Z"EXH IPZ?! F(T K#U?0/MI/RYKJ** .(M/"GDG.RNBM-/\A<8K5X
MHH XW7_#;ZB#M'6N'N/ .J(^8&9?I7M7%)@>@H \ST/P?>1E?MF6^M=Q::3#
M;)A$ -:G%+0!R6N>'3J&?ES4&C>%OL+@E,5VE'% $44010,5+110 QHU8<BL
M;4=)^T9VK6Y10!S-EH B;+K3-6\-17:$",5U-% 'DEWX$O%8FWROTK./@/5Y
M3^\=B*]KP*,#T% 'EVD> Y(&!F3/X5T;^$[<QX$0S]*Z[BEH \TU'P0\F?*7
M'X50L_ ]]#)DYQ7K/%&!0!RVDZ+-:[=_:MBZL!/%M(SQ6E10!Y]JW@YKK=L3
MK6;IO@6>WGW,O&?2O4^*3B@#B;GPP[P;57G%<W>>!+R5CMS7K?%)@4 >6Z-X
M%GMI@TRY&:]!L=)M[:)0$ (K1XI: &A !@"LS4M.%TA %:M% ''VOAHQ7&\K
MWK8N=(CFM]A7/%;%% 'G&I^"FD+- F#["N:G\"ZTSD+(VVO:^*,#T% 'CNF^
M!=2BE#2EB,UW.FZ ;=%W+R*ZG ]*6@#$NM*\Z'9CM7.R^#]\N[9^E=[1Q0!Y
M_/X-\R/;L_2J=MX#$<^\Q]_2O3.*3B@#C)_"BR6OE[.WI6+:> _(O?-\OOZ5
MZ=2<4 9UG8^1:B,CH*HZAHBW*D;>M=!10!P,/@_R[KS-G>MZY@-I8;1P0*Z#
MBH+F!9T*F@#Q[5WN;FY,8)P:-(\*2O<K,R]Z]&/AVW,V\KS6K;6$4"@ 4 0Z
M/:FUM@A'05ITBJ%'%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 U@:K2@U;JM.128$ !/2E((ZFFJW/%/.<
M<U-@&8)Z4NUAU-&<4\-GK3'<CY[4J[AWIYQVI!UYH&@.X]*%1^YI2P XH5SW
MH"XUPV.M$.[=R:61LCBFP[MU-"9?7I2TB]*6F(*8_2GTR3[M %-^M H?[U '
M%*XT+OIO>ES24@8\$T;1UHW<=*;0P'9/3%+MS2;L=J0MFD@&GBBBEQ37F @Z
MU.E0=ZF2J$6%Z4ZFKTIU !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% #6; K/N;XQ=*GG?&:RIXC,: %_M68_=!-/7
M4;@]5-265F%QN&:T_L\>/NB@#%DU*X7HIJK)KDZ=5(KH6M8R/NBLB_TP2?=%
M %1-=G?H":L+JER?X#18Z7L;YA6TEK&!]T4 9']I7/\ <-']I7/]PUM?9XO[
MHI#;Q_W10!AMJET.B&A=4NNZ&MS[-%_<%!MHO[@H QO[2N?[AH_M*Y_N&MD6
MT?\ =%!MX_[HH Q&U.Z'1#2+JET>J&MP6T?]T4?9HO[@H Q&U.Y'\!I%U2Z)
M^X:V_LT?]T4?9HO[@H Q6U.Y ^X::-4NC_ :W?LT?]T4GV:+^X* ,?\ M*Y_
MN&C^T[G^Z:V?LT?]T4UK6,_PB@#(_M.X_NFC^TKG^X:U5M$!^Z*D^SQ_W10!
MC?VE<_W#2KJ-R?X#6P+:/^Z*7R(_[HH R3?W&/NFJ\NK7"?PFM_R(_[HJC>V
MR%3A10!C#7;@G&TU9BU:X?\ A-1168,OW:UX+- H^44 4FU&X"Y"FH?[4NL_
M<-;HMX\?=%!MHO[@H QAJ=S_ '#1_:5S_<-;/V:/^Z*7[/'_ '10!B_VG<_W
M#2C4KD_P&M?[-'_=%+]FC_NB@#*.H7&/NFH_[2N?[AK9^SI_=%'V:/\ NB@#
M%.IW/]PTS^U+K/W#6[]FC_NBD^S1?W!0!C?VG<X^X:9_:EUG[AK=^S1_W11]
MFB_N"@#%_M.YQ]PTS^U+K/W#6[]FC_NBD^RQ?W!0!C?VG<X^X:9_:EUG[AK=
M^S1_W11]FB_N"@#$_M.YQ]PTPZK=?W#6[]FC_NBE^S1?W!0!@C5;K/W#4HU.
MY/\  :V/LL7]P4OV:/\ NB@#%?4[E1G8:JMKTZM@@UT,MK&Z8VBLN?1@S9 H
M JIKDK=C4ZZI<,.%-,CTK8_-:]O:HJ8*B@#,.IW/]PU&=4NL_<-;GV:/^Z*7
M[-%_<% &*-3N?[AI?[2N?[AK8^S1_P!T4OV>/^Z* ,;^T[G^X:3^T[K^X:VO
MLT?]T4OV>+^Z* ,/^T[K^X:/[3NO[AK;,,/]U:3R(?[HI"U,8:G<_P!PTO\
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M0 4444 %%%% !1110 4444 %%%% !1110 5#+M[U-44B@T 1Q[<\59'2H(T
M-3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $<A
M '-5U=-U2SCY:I(I\R@#37&.*6F1_=I] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2'I2TAH C.W-2#':F$+FGC% "T444 %%%% !11
M10 4444 %%%% !1110 4V1MJ$TZFR#<A% '.:EKB6I()K('BV,OC=6GJNDQ7
M&XM7+3Z+#',,>M5874[G3-26\4$'K5V<9%8N@VRQ(,5N2_=I 8MQP]:&GG@5
M2N=N_FKUAC Q18$S3HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M BM.VU))\8[T :5)D4SEAQ0 12 DI,BFD$TBJ10 _(%&X>M1NA(XIB1L#R:
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M* %R*6HBI!HW=J ),BEJ+!ZT;NU $F12U$%)-2 4 +112&@ R*6H]IS3L'%
M"Y%+494YIP!Q0 N12%ACK3'4XJLQ;.* )R1GK4B$>M555C4BY% %FBFK3C0
MF11D4PJ:38: ),BEJ+::-V* ),BEJ+!:G@$"@!<BEJ,J<TX @4 +D49%,933
M#D&@";(I&(VU& 30V0IH0&=>,.16++ CODD5H7Y.3S6.XDW<$ULHW$=!IRI&
MH^85:GE7'6L"W>11U-)-/)ZFI<; 6IU5VZUHZ>@ '-<^CLS#DUOZ=G S4L+,
MU:***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>;BK%5YJ3
M K@9-.*X[TT DTXJ14W&(!FG%1ZU'@T!3ZT]PL/"YIZJ!WJ+FE!-#0$I (IG
M"]ZC8DCBF@-GK1R@2,^:=%UJ/M4D76G81<'2EI!TI:8!3'Z4^F2?=H J-]ZE
M!&*:WWJ<%&*0#68TS>,T]A4>T9HL@) QQ2=:55I^U12;'88%-+TI<FFFA @W
M'-/W#%0G=Z4O-.R :=V[BK$7O5?)S5F.F%BPM.IJTZ@04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% "$9%59;&*4Y85;HH K16<<0^442644GWA5
MFB@"".UCB^Z*26TCE'(JQ10!A7.E GY%I;?25_C6MRB@#.^QB(?(*ISP%S\U
M:\A('%9MQ(P/2@!;2U0'I6FL2@=*HVCDFM+M0 F!5>9-U6:KRMB@!L,>#5KM
M5:)B35F@ HQ110 QEX-<)XM9U5MM=V[ "N6UVT%R#QFJB(\[TXW,DW4]:]!T
M2*4!=U9.GZ1Y4F=O>NOL8MBKQ3:&:<8P@I](O2EJ "BBB@ HHHH *0C-+10
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M4 )BEHHH AE48JNJKNJS+TJLOWJ=P+:J,4NT4+TIU(!,4;12T4 )BDVBG44
M%%%% !UINT4ZB@!,4FT4ZB@ HHHH **** "BBB@ HHHH .M,,8-/I#0!%L(-
M/5::2<U(N: #&*6BB@ HHHH *3:*6B@! ,4M%% !1110 4FT&EHH 3 %-?&T
MT^F./E-- 8MXH+5#%;JW45-></2V_(KHB] )H[5,=*9+:1^E3@L.E*06'-92
M0&3)$J-P*U+#H*S[@8>K]AT%3<#4HHHJ0"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *K359JM,*E@5P>>*<2>]-'!IXYZT#&4\'UH*CM2 >M "
ML1CBD7&>:4@ <4@ZT"''&.*:,9YI2 !Q2 9-  Y&.*2'=NIS*,<4Z+K33 MK
MTI:0=*6F 4R3[M/IDAXH IO]Z@4UW&ZE4TM1BG-,P<U+N%,R,U-PN.#8&*0G
MFG;ABF=Z8AV_CI29IVY<=*::$ X..E!4$9J.ER:=@&%L-BK$7-5]PSR*LQ\]
M*8%A:=35IU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%&:
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MO@F.:@L@F_BC5&V@UFV5PP?BJ3TL!UB_=%+5*"X=@,BK&\U#0$M%1;S1YAI
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MH9SMH AEDP:DA;-9=U.P>K5G*S"@#1HJ+<:>"30 ZBF,QH4DT /HIC,:%)-
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MDU)168#57%+@4M% "8%,,>:DHH 8$Q2.F14E(>E &7/;;FJS:Q;!1+]ZI8:
M)L"EHHH ,"BBB@ P**** "BBB@ Q1BBB@ Q3"F:?10 Q4Q3\444 %)@4M% #
M&0&A4Q3Z* $P*, =J6B@!I7-5)[;?5VF,": *,-IM-7/+XI54BI* &*F*"N:
M?10!&$Q2E,T^B@"-4Q4E%% !28%+10!FZ@,J:RK>#=)^-:NH'"FL^S<&7\:M
M; :T%L%45#?Q;TQ5^/[@JK>YVG%+J!BV]GB7/O6[!$%4<5E09$G/K6O$X*BJ
M8B<#BC H'2EK,84F!2T4 %(5S2T4 5I8\BJHA!:KTO2JZ_>H DC@Q5@* *1>
ME.H 3 HP*6B@ I,"EHH 3 HP*6B@ I,"EHH *3 I:* "DP*6B@ I",TM% $?
ME\T[;Q3J* (_+YIP7BG44 1-'D5 T7-7*:0,4 5A;BI5A H)(-2+0 H&*,"E
MHH *3 I:* "D(!I:* (S'S3@N!3J* (RF33@N*=10 4F*6B@!CCY36->)EC6
MT_W:RKK[U7$"I%9[CFM6W@V+BJ4+'-:41.VB06*%Y8"7FLYM/5.PK:G)K.EE
MQUJX["*JP!3Q6Q9# %90;<W%:UD#@5$KC-"BBBH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JO-5BJ\U)@5U&33BN.]-&<\4X@]Z0#:*2G*1W
MHN G-*IQ2DCM2+UHW 4MD4@.#2DC'%(,9YH 5F!%.BZTQ\$<4D(;=32 OCI2
MTB]*6F 4R3.VGTR0_+0!GN6W4Y<TCN=W2E6@!VXTW;DT[GTIO>IO88NTT=*=
MO..E-HO<0X;J?MXYIHDQ2[\B@8T]:<%!%,Y)J0=*; C(P:F0&H3G-3QMB@1,
MM.I <TM, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI
MI=1U- #J*0,#T-+0 44TNHZF@,#T- $$U4GZU=FS5*3@\T 6+:KPZ51MB*O4
M %5)U!JW5:;- #(% -62<"H(0<U.<8IH#/NF--M"<TEZ<=*;9,V>E5T%8UQT
MI:1>E+4#(I!FJ,R5H-5*>G<=QML!FM$=*S[<C=6@.E(0M%%% !1110 4444
M%%%% !1110 5')C'-25'(,T 1*%W587I5=$PU6!TH 6BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#TH-1LQH -YS4BG(J#O4R]*
M '4444 %-;I3J:XR* *<K#-1*S;N*?*G.:C4D'I6G01?ASCFI:BA.14M0QA3
M)/N&GTR3[II 8UP@\S-7;1@% JK<*=_2EA9@:TZ!8UE.:=4,))%35# ****0
M!1110 4AZ4M(>E %=PN:DCQVJ"7K4L- $]%%% !1110 4444 %%%% !1110
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M\L4>6*?10 SRQ3)(QCFIJBESB@"OY"$U*ELHY%1)G=5Q>E #/*&*;Y S4U%
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MIH#)NH]G2F6;-OY-37V0#5>R/SU3:L!MI]VG4U/NTZH **** "BBB@ HHHH
M*8Y '-/J*49% #5D4G@5,.E5$0[JMKTH 6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I#0:C;=0 NX9IXJ#O4R]* '4444 !J"8'
M::GJ&;.PTT!D2M^]Q6A:C*UF2_Z[\:T[3.VK>P[%P4M(*6LQ!1110 C?=JA,
MIS5]NE4)MV>*J(#$.#S5Z(Y%9H)W<U?@Z4,-"Q1114@%%%% !2'I2TAZ4 5)
M?O5+#37VYYJ2/':@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J)ZEJ-@30 B5+42J14M !1110 4444 %%%% !5"]S@XJ_5"]S
M@TT!0@R).36M$PVBL>$,7K6A4@"J8%D=*6D'2EJ (Y%W"LZZ3:"16K5"^'RF
MG<#/M7/F8S6Y%]P5S]N<35NPN"@H FHHHI %%%% $4I '-5E:/?P*LS#(JJB
M#?0!=3&WBG4U/NTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!#3"PJ2F% : &AEJ0&HMAS4BC% #J*** "BBB@ HHHH **** "BBB@
MJ&60!34K=*S[ACG%- 4;D;I.*OV*X JD8V9JT;5"HYJGL!<HHHJ $/2J=PP
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MK"B]!2F-3U%/HH C$*#M2^4OI3Z* &>4OI1Y2^E/HH C,*'M0(4':I** (S
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M* &>4OI1Y2^E/HH 9Y:^E+L%.HH C\E,YQ3M@QBG44 1&WC)R12B%!T%244
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M%/0=A,\T[<<=*;WI^X8J;"(L9-6(^*KD9-3Q\50V65IU-6G4Q!1110 4444
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M $J6HDJ6@ HHHH **** "BBB@"G=/M%9P/F-BKE_T-4+3F2K0%^WM]O-:"C
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MO<8.:NEJRM1EV@U2 A@'S\5JQ!L"N:@O"LG6MJUNRX%-@]#3%%-5@107 [U
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M^X#;J(H\]:IW=X5DP#5BTN X&36J>@(TXE '%35#&X(J7<*S8"T4W<*7<*0
M>E4KAU&<U9DE4*>:PKZ[4$\TT DP#-Q6A8*0!6"MT688-;NGN6 I,#4HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO-5BJ\U2P*P!)IVW
M'6D!.>*4EC2&-8$]*%C;/-.&13M[4[@-9"!Q2*#GFE+L>E-!;O3'<F[<4PAJ
M0$TNYN]+J+0C<&G0ALTUR:="6S5"+Z]*6D7I2T %,D.%I],DZ4 47D.[I0II
M79=W2@&@;';_ &IN:?N&*9GFH =O]J:3FGAACI321FJ2$ ^E2Y^6HA(.F*=@
MGFD/4B9R&Z5(LG%*=O>FD4Q!U/2IXU%0"51Q3U)8\4M1EL4M,3-/JA!1110
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M0:DC<-TJ"6-">34L*J.AH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *8RJ>M/IC8[T (JJ.E25&NWL:DH **** "BBB@ ICN%Z
MT^J5V^T4T!!=GS 0M06L#J^2*(Y=SUHQ#CI5 6$X44ZD'2EJ "BBB@ HHHH
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M:+B3DUN1XVBN:AF*R5KV\Y8"KD/<TZ*B5CBG>8*AB'T4SS!32]("6BH0U/\
M,&*& ^BF>8*/,% #ZJ77W:L;Q5*^?Y#BF@*D)'F]:UXL;!7-12L)NO>MJ";Y
M!5- BW(,BH @#=:9-<;5S5(7VY\"E8#97&.M.JC%(6&:L[^*5@):*AW'-.$@
MQ0T!)13/,%'F"D ^BF>8*/,% #Z*9Y@I#)0!)14.XYI=_%.P$M%0;CFG;^*+
M 2T5#N.:<)*&@)**9Y@I-^:0$E%1<]:4/CK0 \TPIGO09 !5=[D"@"<)[T\?
M6J'V@D]:E2;- %S-%0 DT[=CB@"6BHN31NQUH EHJ L<TX/Q0!+14!8TY7H
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M)GBG;FQS3MV.*0G(H!*Y%EMU6(O>J^X[NE6(CFJ$65IU-6G4 %%%% !1110
M4444 (1D5#+;HPRU3U7N7*Q-CTH SKA+)<AR*S9['3) 6)%<_K^H2Q2-C-<^
M-9G;Y<GF@#I+I],M7P'%6+*[M'(V,*Y0:9-J!WG=6A9Z<;1P"QH ]'TYT91M
M-:=<YHSD*,'-= C$B@!]%%% ",,C%95WIJ3G)%:U&* .=_L]H5.P5A:AI]Y(
M_P JFN^VCTI/+0]5% '):/:7,0 =36U+IJ3K\XYK3"*.BBG4 <3J&FW$+?Z.
MII^GZ5+.1]H6NQ**>JB@(HZ "@#,AL([4?**BN+=)OO5HS=*SII-IH +?38<
M]*T%L8UZ"H+23=6CVH C6)5'%5+J*%OOU?K/NXPV>:: R)H(5/RU;L$&1522
M,*>M7K#J*I@:RH,4;!3ATI:@!GEBCRQ3Z* &;!1L%/HH 9Y8H\L4^B@!GEBE
MVBG44 9>H1*P.:H6D$:R5J7J%@<50AC*/DU:V"YKQ* HQ4I0,*K0N, 9JT.E
M2P&")0>*<4!&*=12 C$*@\4XH"*=10!&(5!I)(E<8-2TC#- %,6,.<U,MLB]
M*>%&>M24 ,V"C8*?10 SRQ1Y8I]% #-@HV"GT4 ,V"C8*?10 S8*-@I]% #/
M+%'EBGT4 -V"E*@BEHH C\E<TOEC%/HH C\E<YI^T8I:* &[!1L%.HH 88P1
M4#V4;<FK5-89% %(6<"M5N-%5<"H3'\U3H,"@!=HJ&Y4&(BK%07!!C- '+SV
MR&ZS[UT&GH%C %9,L1,^?>MFR7""J; M% :38*?14@,\L4>6*?10 S8*=BEH
MH :4!I/+%/HH 3%1RQ@H:EIK_=- '.7EHK2]*N65F@ XI+D@/4EO*PZ"KZ :
M21A!Q3BH-,B<L.:EJ &>6*4J,8IU(>E %&:TA=LM4T$$<?W:;*F3UJ2%<4A7
M)2@-*% I:*8QC1!NM((E%244 ,V"CRQ3Z* &>6*-@I]% #-@HV"GT4 1F)30
M(E%244 ,V"C8*?10 S8*<% I:* &-&&ZT@B45)10!&8E-*L87I3Z* &E U0/
M M6:B>@")8%J81**1*EH 9L%&P4^B@!FP4;!3Z* &[!6=?J,&M.LV_Z&FMP,
MZVA5Y.:VH;9%4$5DV>?,K=3[@IR -@Q2;!3Z*D!GEBC8*?10 S8*/+%/HH 9
MY8H\L4^B@!NP55NHPRU<J"?I30&,MN!)FM*&-<"J_P#%5F(BK87)'MT=<&H%
ML(@V0*N?PTP$9ZU%P')"JCBG;!3ATI:0#=@I/+%/HH 9Y8H\L4^B@!GEBCRQ
M3Z* &>6*/+%/HH 9L%'EBGT4 ,V"CRQ3Z* &[!2>6*?10 SRQ1L%/HH 3%(4
M!IU% ##&,5"T$9JP>:8R4 5_(3/%2I HHP0:E6@ "@"C8,TZB@!,"D* TZB@
M!FP4;!3Z* &;!2[!3J* &,HQ6=<H"36FW2J4ZBJ0&9]EW-G%:EI#L%4_-*-@
M"M"W<L!38$^P4;!3J*BX#-@HV"GT4 0O K UCWE@C$\5NGI5.X"X.30!SXM0
MC<"MJP7 %9L\A5^!6CI[E@,B@#4HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JO-4S$BJTK$BDT!$,YXI3N[T@.*<6)%2AC:44TG%&XFJ!
M=R3)[4A+=Z0-BG!MU+J%[C1GM2Y;O2\+2;\T=0(FS3X=V:1^*="QSTJA%Y>E
M+2+TI: "F2=*?3)/NT 4W&6I0G%(_P!Z@$TM0$:H]IS4AI@!S1J,E4C&,4AI
MP(Q32:0#@PZ48SS3*< :!"=Z=CBEX[T'..*129$2 W2IX^:KDC/-3Q\]*H3+
M*TZFKTIU,04444 %%%% !1110 R1]B%O2N8UCQ*MFC@KG%=/(NY"*YK4]"%V
M3E<YH \LUSQ>LLY41'D^E-TRZ^U$/Y9_*NPN/ T#/O:,?E3X=,LM.&UD Q0!
M'9:M':Q;3%G\*J76J&XF&Q".?2M</IIZJ*MV\>F,P^04 7O#K%D7<#74 <5F
MZ>MNH'E#%:= !1110 4444 %%%% !1110 4444 5)WQ69,AD-:DP!K/E4YXH
M GLHBN.:TQTK.M W>M'M0 'I6==G /-:!Z5A:I(RYP:: JR$D]:OV':LJUDW
M-\U;UJ$P,53$7QTI:0=*6H&%%%% !1110 4444 %%%% #64'J*SKO" X%:=9
M]ZN151W J6LI+XS6RGW16+:IMDK90_**<@L/HHHJ "BBB@ ICT^F/0!'N(-2
M*]1@9-2A1B@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% "&F,]/-1L5H ;G)J5>E1=ZE7I0 CG"UGSSD'%:+_=K/N G-4@*RR*S\
MBM2W(V\5BB-O-XK8M00G-$@+-%%%2 4444 %%%% !1110 4R3[AI](1D4 8=
MTAWYJ:UD5< U;G@!4G%9$SF.3 ]:L#>C<,.*EK/L9"RBM"I8!2'I2TAZ4@*D
MN=U2PU%+]ZI8: )Z*** "BH7N%0\TJ3J_2@"6BD!S2T %%%% !1110 4444
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M/-:9Z51N%)!H RROS<UIV0&!BLJ;*M6E8$D"@#3HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ JO,.*L57FI,"NI -.+ U'WIX7/2DD E.
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MH:Q;B\*OC%5$"W&IW=*T8>E8T%ZQ/2M6"4LN:; LT5&7-)YE0!+147F&CS*
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M[C?+<GK4@1L=:0,:>&XH=Q$)B;=G-68_E'-0ECFI4YIH18!S2TU:=3 ****
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M:1G@U9,((I$C(/6IJ&!$L.VGE<TZBD P)BF2Q!QS4U,?ZTT!D75JHR<TRTB
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M10 56G8CI5FJMQTIH"GN9CUJQ O-5UX-6X2*I@6ATI:0=*6H **** "BBB@
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M;H,HJPLF:EB'T4UFP*C$X)Q2 FHIA?C-1^>,XH GHJ,29H\P4 244SS*3S*
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M*NX566##YS3I[D**II? OB@#508%.JO'< K4GF4 244P/FG9XH 6BF>91YE
M#Z*C\RCS* )**C\RE\R@!YYJM<#"5*9,"J=W= (::N!G[\3XK8MCE*YK[8IN
M,5T%G,#&*;!%VBF"2EW<5(#J*A,X!Q2^;QF@"6BH?/&<5(&R,T *1D5"8<G.
M:D+U#+-L7--("9%VBGUBOK4<;[35J'4TEZ&GRL#0HJ))@XXIQ?%*S ?14/GC
M-/63-(!]%,,E&^@!7^[69<-\U7Y9,(:P[J["R8JDA[%F/)(XK1@''2J%I.K
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M]]6K:+A!6:W^MK4M?N"E<"S1112 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "D/2EI#TH J2_>J6&HY>M20T[ 3T444@"BBB@ HHHH *C="14E(>E-,
M#+N/E-36K9[4VZQFG6N*MO0"_11VHK, HHHH *:>E.J&7-- 4+Q<TRU0T^8\
M\U);$'I6FR"[*FH/L%,TZ7<U/U*,L.*BTZ,JW-*^@['0+]VF/3U^[4;J3TK,
M0)4M0HA!YJ:@ HHHH *H7G2K]9]Z#BJCN!6MAEZU47BLBUR'K81OE%.0#Z**
M*@ HHHH **** "BBB@ HHHH **** "BBB@"*7I59?O59EZ567[U %Q>E.IJ]
M*=0 4444 %%%% !1110 4444 %07(RE3U%,I9*$!B%/WV:UK8X2LZ2!Q)FIX
M9=IP:T:"QI@YI:9&V13ZS **** "BBB@!DAPN:R9Y_FQFM.X/[LUSERS>=@>
MM4@+T>&:KVT"+I6=:1.V#FM/81$<TVPU,6>4B? />MBQ;<@S6-<1GS_QK7LA
MMC%.6P%[(HR/6J<TQ3G-4CJBH^TFER ;51RC*&HK:X$PR*EF/[LU('/W=NS2
MYW]ZOV, 51GFLR\F838SWK5TXEE&:J^@:F@B@#@4^D%+4 %%%% !1110 444
M4 (>E4+GO5\]*S[GO0!E31;FZUIZ?'M YK-E)W5I6!.!0!IT444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 57FJQ5><TF@*ZC)IQ7'>F+DGB
MGD'%2,C89I N.]*0:%R.M4@L/"YIQ3WI!STHP1UI=0$,>[O2>3CO2Y-.!]:'
M<&B)EI\*8/6B0@CBDA5MU-"+Z]*6D7I2TP"F2=*?3'Z4 4'SNI13G^]0*5Q[
MAS24N:2D#'?-3?K3]QQTIAYHL(7<:*3FBF,7<:,$TE.WT6L(;T-3)4.<FIHP
M:$!87I3J:M.I@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A
MZ4 (S!1DUG7.K06YPS8I]W.54UQ.L[I6)R:5P.Q@UJVEZ.*N"^B(SFO,K5Y(
M>A-7?[7F3CFJL!VL^L00GEJ6#5X)ONM7)P0KJ S(^*)8OL!_=L32 [-I5<<&
MJDB9/-9&G7TTF,@UHR7(7[QQ0!=ME %5K^3;FGVUW$?XQ5:_FA;^,4T!)8MO
M-:FP8K)TXIV.:T9;A8QR:H"=!BI:IPW*N>M6MZ^M*0#J*3</6C</6I 6BDW#
MUHW#UH 6BDW#UHW#UH 6BDW#UHW#UH 6BF[U]:7>OK0 M%)N'K2;U]: '44W
M>OK2[AZT +12!@>]&0* %HIN]?6EW#UH 6F/2[U]:8[KZT -7K4PZ56\Y,]:
MD69?6D@)J*;O7UHWKZTP!LXJE<YQ5[<#5:Z*A>:I,#-B_P!96K%G;6.LR++]
MX5IPW"E1@TV!<%%-#@CK1O7UJ '44F106 [T (SA!DU5DU&&+[S"DNY5V'!K
MEM1WL3M)JXQN!T+:[:@XWC\Z6/5H96PK5P!M;AI>C5JV%M+$P9LU?)8=CNXY
M ZY%/K*L[R-4"EQFM))%<9!K)IH0^BDR*-P]:0"T4FX>M-\Q<]: '&HSNIY8
M8S59[D XS3L!(0:BD#8I#<C'6HGN156 B\L;\FM& 86L]9D+=:T(6&WK2:#0
MFHIN]?6EW#UJ0%HIN]?6EW#UH 6BF[U]:7</6@!:*3(HR* %HI,BC(H 6BF[
MU]:7</6@!:*;O7UHWKZT .HIN]?6EW#UH 6D/2DWKZTC.N.M %>7K4D-5)YU
M#=:GMY PX-.X%NBDW#UHW#UI +12;AZTF]?6@!U%)N'K1D4 +36SBEW#UI-P
M(H H7 R:?; "H[J15/)J".[4'AJNV@S8!I:JPW"OWJQO'K4V$.HI-P]:-P]:
M0"U6F+=JGWC'6J%W="/O51W K2AB:GM%(JM'<I(>2*T8-G8U;>@#;B(,.:HG
M]R>*UG"XY-8]\P7.#4(:9<MKAG.":O$G%8=A.-W)K6,R[>M%M1,E4FI*IBY1
M>K 5*MW"?XQ0T!/13%E1NAIVX5( 35&\/%6FD3UJC<RIC@U2 BMA\]:J#BLJ
MV<;NM:J,-O6B0#Z*3</6DWKZU(#J*3</6DWKZT .HI,BC(H 6BDW#UI-Z^M
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M6G<"$Q,3UIWEG%2T4K@5S"V>M.$9QUJ:BD!7,+9ZTY8R.]344 1;#1L-2T4
M1;#1Y9J6B@"N86)ZTHB..M3T4 5VA8]Z;Y#>M6J* *OD-GK4@C([U-10!7:%
MCWIK0MMZU:I#TH Q;BR=GSNJU:6[(.33I@V[BIK?..: '-$Q[T+$1WJ>B@"!
MHF/>F>0WK5JB@"!8F'>G[#4E% %<Q,>].6,@=:FHH R+VQ>7.":R7LY(6Y)K
MK& Q61>[0:M.^@$=BC''-:?DMCK5.R85J \4M@(5B([T-$3WJ>BE<"OY38ZU
MCZC YS@FN@/2LZ[*#K5)W8&+:64C-U-;MO;-&!DU#;%2>*T5Z4Y-@1R1%AP:
MQKZV;UK?[5GWBYJ8[@9%K;/NZU?9&1>320,J'FFW<X(^4UKU$4;K>V=K&JD:
MSJWWFK3M4\UN:U4LH\?=I2=AV*%D[\;B:U"-Z\-5&[MV0?N^*IQ74D#?O"<5
MFEV MW2.N?FJDD3RMC=4DU^DXP*DLE.[-4%R>"Q9><U>6)@.M2I]T4ZHN!"T
M1/>FB%@>M6**0$+1$CK31"P/6K%% $7EFC8:EHH A:,GO31"P/6K%% $)C..
MM-$+ ]:L44 0F,XZTT0MGK5BB@"((:#&:EHH H3P,PZU32T;S,YK6EZ577[U
M #D@.WK2^0WK5A>E.H J^0WK2B%AWJS10!$(S08R14M% %8PMGK0(6!ZU9HH
M A\LXZTP0MNSFK-%%@&A3BF[#4E% %>6(LN*R9[%MV[-;IZ57F Q5)@9,0=6
MQDUHQ1LR]:JY7S*TH,;:& P0L#UIQ7 ZU)(VU<UDW5V1P#22 N%AG[U)*NZ,
MX:L)GN'?Y6-7+>*Y;J35;"*EQ9R/+PQJ:#3Y!SDUJQVQZL*L+'M'2JYAE..W
M=1C-2BV?.<U:! IXK-ML"-$(7%,:%B<YJQ12 BV';BJ%S9LV2#6I3),;::=@
M.<>%T?&35N.-S'U-2S;=]21XV\5HF.YAW%HYFSD]:U]/@94&32/LW\U?ML;>
M*<GH22>6:88F]:L45E<9"(SZTTPL3UJQ12 A6(@=::86)ZU8HH A6(@=:1HF
M/>IZ* *3V[E3S6+?:9*Y)#&NF/2J5PI- '+I;/ PR2:Z#32<"J4H7=R*T;';
M@8H TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KS58JO
M-28%;O2T*1GFG$C'%),!E+29 I=P/2@=@YI0,F@,!UIV]>U&P6N(5(%(!DT[
M=ZT%AVHU"UAK)CO3HL9Z5&ST^%P3328BZ.E+2+TI:8!3)/NT^F2#(H H.%W4
MJXH>/YNM*HH'8?A:9@9I^SCK3,<U #P%Q28%&SCK28YIH!X"TA6@)WS03VIZ
M@F-VI3NW'2F^6"<YIW08I"&[4)Y-2I@=*B\L$YS4J#;3N!86G4U:=3 ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH B
MDVX.:Y_4[DQD[36[,!@\US&J%0QYJD/H):3M(?FKH+0#BN>TU%D(YKIK>(*!
M3>PKEKM4$JD]*L=JADDVU #(E(ZU9[5!'+NJ>@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J*7..*EICT 0(6W597I4*]:F'2@!:***
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M5*X?% &;.%W<U>L0,#%9\OS-UK0L5P!0!I4444 %%%% !1110 4444 %%%%
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MI?/6@"6BHO/6D-P@H FHJ 7*&G>>M $M%0FX04@N4- $]%1>>M(;A!0!-14
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MO(PM9%YJL*$@F@"*7.ZM.PS@5@?VA%(W!K=TZ17 Q0!JT444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 57FJQ5>:I8%< DTI4BD&<\5)]:5A
MD)SVH&:D;':D&,\T:@(,TO-.)&.*0$9YI@)FE5B*5L8XIJXSS0 .VX4D*G=U
MI7QCBDAW;J:$7UZ4M(O2EI@%,?I3Z9(>* *C?>I=HQ4;M\U*I-(=A2#FD%/W
M^U,I"'Y.*;2[_:FDY- QVXTTG-**=L&*%H#&4[>:3'-.VC%%P&YR:E2H"2#T
MJ:/FGZ!8LKTIU-7I3J8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"-\D&L2^T[SVSBM^DV@]J ,>QL/)&,5'J&E+<9.*W  .U&T'M0!Q+
MPW-D<1(34D4%Q>']ZA%=>T$;=5% AC7HHH Q+:P, X%1W5@D_P!^MR0A1TK-
MN6)/ H JVNB0@\&M$:5&*2SSGFM,=*=P*T5HL8XJK>68EK3J"5P.M(#-M;$1
MFM$0\41.K=*L4 0?9Q2&U4U8HH K"T44[[.*GHH A^SBFFU4U8HH K"T44_[
M.*FHH KFU4T@M%%6:* (?LXIIME-6** *PM%%/\ LXJ:B@"'[.*:;935BB@"
MNMJJFGM"&&*EHH K"T4'-,FM@15RF/CO0!EBP7=5A+%15A2N>M3#I0!76T44
M\6X%344 1^4,4PVRFIZ* *PM%!IWV9<5/10!6^R+FG"W J>BBX$/D+2&V4]J
MGHIW8%<6J@T_R1C%2T4K@5_LJYS3_)&,5+10!6^R+G-.^S+BIZ* *WV1<YIQ
MM@1BIZ*+@95UHT5RI#=ZR5\%VPG\W/-=713N!2MK!+:+8M,EL58YJ^3BHV>A
M.P&>MDJM5V.$;<49!-3+TH<KA<@-HI.:=]F&,5/12 K?9%S3OLRXJ>B@"L;1
M2:<+914]% $'V<4?9Q4]% $'V<4?9Q4]% $'V<4?9Q4]% %8VBFE%LHJQ10!
M#]G%)]G%3T4 0?9Q2_9Q4U% %8VBFE-L N*L4'I0!B7.GAWS5NSM1$*LN4SR
M13T*GH: $:$&F_9Q4]% $'V<4?9Q4]% $/V<4PVJFK-% %7[&M.%JHJQ10!#
M]G%)]G%3T4 1K&%IDENLG6IZ* ,F?1(INM5?^$9@S7044 9EOH\=OTJZ( !4
MU% 7(&ME:A+<+4]% %>2U63K216BQ]*LT4 026XD'-4I=.7M6I3&8"@"A#9!
M35HVJD5('!J2E8"!+95I)+97'-6**+ 58[-4.14C0!ABIJ*8%86BBG?9UJ>B
M@"N;932"T459HH @^SBE^SBIJ* *YME-(+115FB@"N;930MJJFK%% $30@C%
M,%JH.:L44 1&$$8J(V:DU:HH J_8UH^QK5JB@"C+9KBJRV2;ZU),8Y-5U"[O
MO"@ 2T4"I/LXJ5>E.H @-LIIOV1<U9HH @^S+BF_9%S5FB@" 6X%'V<5/10!
M ;933?LBYJS10! +=11]G%3T4 0?9Q2^0*FHH KR6JR+@UFR:!#(^XUM44[L
M#)BT:*(Y%:"0!%P*FHHN!7:U4G-*+914]%("!K92*KO8*3FK](2/6E8#.^RX
MXIZV*GDU=RM*,=J8$"VJJ,4GV1<YJS10!$(0!BF-:JQS5BB@"N+913OLXJ:B
M@"#[.*/LXJ>B@"#[.*:;135FB@"N+912&T4U9HH KBV44AM%-6:* *XME%(;
M535FB@"D]BI4UA7^DJS&NI/2J=Q&"#0!RD>FK&PKHM-B" 8K.N<H_ K2TYB0
M* -6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J\U6*KS4
MF!7&0>*<23UIJG!IQ;(I7&-(I0 >M,)- )H D*C'%(!DTE.7FC8-!2HQQ30.
M>:>1@4T<FBX60,!BG1=:8XVBB%_FIB+PZ4M(O2EI@%,DZ4^F28Q0!1<C=0M*
M^W=0N*!L?N6F9YI_RXIG&:@!^Y<4WC-.^7%-.*:$.W"FEC1Q1MHL,;Y@SBG@
M$C-)A!UHW#M18+AO4'!%2H0>E180]>M/7KQ0@+2]*=3$SBGU0@HHHH ****
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MR/6C(]:Q UWCO2%KSWH O:A-Y<9(-84%^[7.-W>GW4=[*N,&LZ/3[Q9=VTT
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M P*R+>PG8@R UN6EN8@.* +U%%% !1110 4444 %%%% !1110 4444 %%%%
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MD>M@OM.*R(@?L^&/.*SO*D^U @G&: /0K659DS@59VKZ"L?2&980#Z5L*<T
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M0\SS8\D4 ;]KK)E?!%;L#+(@.!7#6:L)<UUEE(?+ H T]J^@HV+Z"D0Y%.H
M3:OH*-J^@I:* $VKZ"C:OH*6B@!-B^@HVKZ"EHH 3:OH*-J^@I:* $VKZ"C:
MOH*6B@!-J^@IK*H&<"GTUUW"@"I/<+$I/%9$NMB-\<8J[?VK>63FN)U02(Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX5[4=(B-.7281V% 'E'A?39-%9?,&,5ZAIVHK.J@&DGT""8\@5/9Z3':_=H
MT1TI:!P** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM I?M H FHJ#[0*/M H GHJO]J7-2"4$9HN!)14)G H^T"BX$U%0_:!1]H%
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M4/GBD^T"BX$]%0?:!2B<&@":BHC, ,TP72DXHN!8HJ+S1C--^T"E<">BH?M
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M5!Z4!,=:9N(Z4;V/6@+#F [4*N>M1MGM0K,.U#0B8Q^E1E2*>)#32Q/:DG8
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MI3PE+\OI0RDQ0_%(7'I2[:8<4!H+FEW\=*:!3LKBABU&9YI^_CI3<<T[*XI
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MZ4N3WI V*<&W4GN,;CTHP:?C'2FEB: &XI=I[THXH+$]J L'THR>]&<4%\T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4&1N]%P+@8&@L!5+S&[4>8W>@5RZ&!IU4=[]J7S7[T#+M-+ 52,LG:D#R=Z
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MIQ0 AX-/&"*81S2A30%V(P]*3O3\@=:-NZBX"!\4O!IN,44[A8=G%-)R:<&
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MA:@)G-. ..*:,4\,!0%AISFE ;M02#2;\4:L+"GWI-I/2@N.] ?THL F,=:
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G13 K?9J/L]6:*5@*K6N:06F.]6Z*8%;[-3TAVFIJ*  =**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image4.jpg
<TEXT>
begin 644 image4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0M!W@# 2(  A$! Q$!_\0
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MC.*8KC<: 5SQTH&T')I6 3>%ZTH< 8]:,*>M&%Q3 -XQB@8H&W\:,9Z4 *S
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY@I2X% #J*9O&:4N : '44T.":-XS0 ZBFAP:3S!0 ^BF[AC-)Y@H ?132X
MI-XS0 ^BFEP*3S!0 ^BF>8*4.#0 ZBF>8*/,% #Z*9Y@I2PQ0 ZBF[Q1O&:
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M$XI.<>U #MS8I-S4F>,4<\4@%RPZT9;I02>*.<YHN !GSBC<Q-+SU[TG.<T
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M0!7#<?6C/&*F$'RT>1\M,"'=QBA7W\8Z5-Y!VTI@PO'6D! IW9]J ^X_2IC
M>U!@YXI@1;OFS1N^;-3-#QQ0(.*0$.[!)IJ29R*G$')H6#&:8$ DVG%.+Y&*
ME%OQSUH\@[:5@(1)SMI=]2_9^/>@P<"BP6(!)N/3I2L_?%3&#D8H,&33 @\S
M^+%'F8YQ4_V?YO:@6_/-("%7_6EW;&VXZU/Y(H\G)R: (B^'"^M,=_FVXJQY
M7.>]'D@\]Z (">,4UY,8JPT/I2-;YQ3 CW]*0M\V:E,'(IWDTK 5F?:<XI5?
MG-3>1\W-.\D4 0^91OXQ4WDT>2*5@(-WRXIF_/R^E6_)%)Y SFJ K^9GBE+9
M-3& =J:\>.:0R(OCG%-+[N<4\E<]*:2JG..*2 7/%(9-O;K0W SVIV%V@GO0
M%QN_ ^M&_C'K2,0#3N-OO0T H;C%(31D;?>E)&V@ +<?2F>9GGTIY(('%'R^
ME/0!/-RM!DQ'G%!QG@4Y@/+Z4M 6PPM\N:7S,#I0A'>E;:G44,=Q WRT9^7%
M*I&WI29&W%%A"!_X:?NXIF :<"&X%(8@EW'ITI6;C-(2HY]*4$,,]JJPDQJG
M(S3M_&*1L;=PZ4(01DT@%#8'2F>;U&*EW+Z5&0#0%QZ_<IN[Y<4H;Y<4W>,;
M>]&HB12",5&#ES[4#VH'!H'8<6R1[4C/@[J0?>JP(@PZ4TA$"ODYIJR?.:M>
M2!1Y HL!7#8I/,P<8J<0=:!;\4 0;_X?6EW<8J7[/Q[TOD';0!!YF3C%/W^U
M2&WX&.M#0=*+ 1[Z-_-2&#D4>1\U%@(@WS9I=]2>3\U @Y-%@(0V,^])YFTX
MQ4X@.#0+?CGK18"/?1YGM4GD?)[TX0\46 K^;DGCI3?,SSCI5KR!1Y HL!7\
MWC.*%?)S5CR!1Y % %?=@YIV^I!!\U.\FCJ! &Q07R,5,L/K0T/%%M0(-W&*
M"W'TJ=8>*&@STHL!7\S=VIYDP*D-OTQ08,FBP$*ON.<4K28[5+Y&&XZ4>1EN
M:+ 5R^.?6E\S;QCK4XM_FYZ4XP TP(%? H+9&*F,'%"P\<TMP*V_^&E=\8XJ
M=H/2G" 8YH0%=GX!Q2"3<<U9\D4TP?-Q0!$TN.<4BOWJQY --:#THL!7+X;I
MUIQ;9CWJ5;?UI6@)(]J.H$6[=\M!;8,58$( ]Z#$".:5@*[M\H-!?CI4[PY4
M 4&$8Z4=!%<-N^:AY=J;L=*G\G' H\@$8/2BP:W($;<F_P!:3?M/UJP(<<#I
M2^0*-;C*Y?9^- ;CZU8,.135@]: (2^U.E*C;UJ<P@\4AAP.*8%<OD[<=*3S
M,]NE61!2&WYXH C63*9Q3?,W+TJ;R#G Z4[R0.E%@*K-M%*KX'3K4_D?-S3O
M(&*+,+E?=A331)^[/%64@P#F@0#% %</E,4GF9XQ5KR!CBD\@4@(%;?^%*&W
M#=Z5*8#VI/((/M3 A$F3FE+XYJQY IOD9;VHL!"K]Z0OM/2K/DBCR >HH @5
M\#ZTTR<[:L^2*/('6@"ONXQ2"7MBK#0Y'%(;?CBBP$*RY/2AG[U-]GY&*=Y
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M !4<@XJ2FN,J: *9 W8I609YZ4TC#<4[E^#4H8@P>#TI'.,#M2$;:4C>!1U
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]>: V,@TJD9YIIZT QT9PXJZ.E4H_OC-71TIH0M%%%, HHHH **** "BBB@
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MFO-_!$GV?7)%]32&>Q29VBH@,+[5+G="#[5'GY<4K@*J^M QS1NXQ4>XDFF
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M/'WLTO(#T362#IDW^X:\4@.W7,C^_7MFJ '39AWV'^5>'MN37AC^_3 ]VL)
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M,![4LGS#%(%^6F,0CD'TJ0X(S30N1FC'RYHT$*0-N<T8&.M)CY<TG:EU&..
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M>@- 'E>M:4+:Y\U/OCFO2O!DDYMD\P'&*DO_  <+N??NXKHM-TU;*W$8[#%
M'/>*)&FNXHTY'0UC:YH;0JEPB_P@G\J[2?2/.N?,)[U:O;%;JR,./X<4 <1X
M>\1);P-"[ -Z5!XMEDU#2Y-@R"IJW_P@C"\\T28&>E;P\/#[%Y+'/&*: \<L
M1<:<,A2-PQ5:6RFEOXY2AY;->MW/@U9E4 ]#3O\ A#URAS]VBX%25)?^$:
M.1'_ $JAX)2032F0$5W/]F#[!Y'^SBJEAHHL&=QWHN@/,O%BAO$^%Z\5ZGX;
M7;H\.?[HK@+[2VOO%\A.< #^9KTO3(/L]DD?H*&!<HHHI %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<OW:DIKC(H J'GDTPG-
M/DZTS%2&X[ VY[TWN*.E'<&C89>C_P!6**(_]6**H0.,H:I$8.*NR<(:I?,Q
MS28(6:+SK9D]17B=\K66OL>@WU[<K'[M>6^+=(E-X)88R3N[4#/1='/G:+;,
M.ZUGZMX9MM2E\QXP35GPT730[=).&"]ZU [;O:D(Y:'P9:QC'EC'TK5L-&BT
M^0/&H %:QD^:D+%C@]*8'->.+L0Z0YSU&*X#P78FYOVDQ_%78^/8I;C3Q'$"
M>1TJ#P)I;6P+2)@FD,[?;B.-?10*"#G%.DSGBF<[J!#X@?,JV.E5(\^95L=*
M: 6BBBF 4444 %%%% !1110!C76M)%*4[@U1U#71&(RN>13M8T\;MZ#DFLG5
M(H4M8MWW@M &LFO*;1V[@4[1]=6YF,)!R:Y[3/*D8HY^4UNV%G:Q7:O%C.*
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MZX^W[] '7;AZT;AZUR0UJ383OIJZZ^>7H Z_</6C</6N/;77!^_2?VY)_?H
M['</6C(]:X[^W9,XWTDWB(PQ9:3!H [+</6C</6N)@\2&9?ED!I[:Y+N&'H
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M0!V&X>M&1ZUR/]N.0,/]:8^NR;EP_P!: .QR/6C</6N/?7FXP]-37)3)DO\
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MFW.,=JZJF/&K_>&: .0M=$$=L[C.X"KVD6CJ[,V>/6N@6)0",<&E$:(#M %
M'GOB&W-UJ!BR0":W+'PW$;1<D]*SM3<#6,8[UV-B<VJ_2@#$_P"$7B)SDT__
M (1J+'4UT-% '.?\(S%G.33O^$:B]370T4 <]_PC46.II%\,0@YR:Z*B@#C-
M3\(PSYRQ%2Z;X4AAME4,3@5J:U>M;*P5<\5-HEPUQ8J[#!(H I?\(U%ZFC_A
M&HO4UT-% '/?\(U#ZFC_ (1J+U-=#10!SX\-Q YI1X<BSG-;]% '-7/A>&2-
MN2*Q[+P?!%<EE<FNWNF*6[D=A7.:5?N]\Z,IQF@"TOAR()C)IO\ PC47J:Z
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M/2J?AP&*^:+)(%=9>_\ 'NWTKE=#_P"0L_UH [.BBB@ HHHH **** "BBB@
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M[T :U%%% !1110 4444 ,D *'=TJC;0VHF)C W5:N]WV9]O7%<SI'VS[>_F
M[<T =:.E%(OW12T %%%% !1110 5G7=K:E@TBC.:T>U<KJS7C7"! =N\?SH
MZ>,*(P%Z4^H;7/V9-W7%34 %%%% !1110 55OEA>'$P!7WJU6/KOFFU(CSF@
M"Y80P)#^Y "Y[5<K!T W'D[90<9K>H **** "BBB@ I& 92#TI:1ONF@#-:T
MM/M88J-]:**%7 KF[H77]LQE0=F#FNBASY8SUH DHHHH **** "BBB@"G>00
M2C]Z ?K2V,4,4>(0 /:L[7#<<>2#^%2Z$)A;_O@<^] &O1110 4444 %%%%
M$<NW8=W2J%G!:+/(T2C<3S5B_P!_D'9UQ6!HPNEOIO,!V[N* .JHI%^[2T %
M%%% !1110 5ESVMH]QN=1OK3/0URFH?:_P"T/W8.W- '4Q*JQ@+TI]06>[[.
MN[KBIZ "BBB@ HHHH *P?$0S;O\ 2MZL#Q$<6[_2@!WA<8TN,>U;M8?A?/\
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MHO5W?WQ_.NS?[A^E<9JFTWJY_OC^= '76F/LR8]*GJ"T_P"/9,>E3T %%%%
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M'I137SL.* *,UM;-<AG4;ZO* % '2N7NVO/[57:#LS72P%C$N[KB@"6BBB@
MHHHH **** *%_#;2,OG $]LU-:0Q1+^Z  ]JQM>%P94\H'I5W1S-Y?[T'I0!
MJT444 %%%% !1110!!=X\EL^E<IHG_(8D^M=3>_\>[?2N5T/_D+/]: .SHHH
MH **** "BBB@ HHHH *:^,<TZFOC;S0P*LG44W<H/S=:<W6F$*?O=:GH K,O
M04G&!ZT;5QGO2\8&.M RY'_JQ11'_JQ15"$D_P!6:IAN"*N2\Q-5)(S@TGL
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M($[<B@"W/JACU!4(X-;<$HEC#"N6U]1'$DR?>JYX?NWELCNZB@#H-ZYQFE+
M=37+K>S?VF4R<;JFUJ_>#R57.6.* .B# C.: P/>L:UFD^P,['G%4M/U*26Z
MV'- '2EU!P32[AC.:Y/4]0FCOPBDXK5:X<Z:K\YVT 5]:U4VDB!1G)J[I=\+
MJ+)X-<[:.M]+(LW)'3-(99+.\5$)VDT =J6 &2: P/0UB:I=/%I1D4G.VG:5
M=/-:[FSG% &QO7.,TI8#J:Y2/4Y!J<D9)P&K1U.[>*W4KGF@#:W#&<T@=2<
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M?\0:Q<J'VL<5?\&7#3SY;.: /0Z*** "BBB@ HHHH **** "HY3A:DJ.7[M
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MA;SN6-"EKJ!SO_"?0V:A;F3#8[FNI\.^);;68B8W!Q[UY#\2O#DEE=$VX8@
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MF0VYR@ILNE02S>:P^:K]% '+>(H)OW440.W&*N:%IOV:%MPQO'-7[X0[U,A
M^M68'1D 0@T 46T6V:X$Q4;A4]SIT-TNUQP:N44 5+>PBMTVH.*B&DP"9I0H
MW$Y-:%% %*?38;@+O XIRV$2P&(#Y35NB@#G-3\.V<D#%E'2LKPU##!J#1Q]
MJ["\4- P/I7*Z)$(]6<Y[T =E1110 4444 %%%% !1110 5'+]VI*:XR*&!2
M<9/-'RCKUIS]:85W')I O(4A<9[TWO3RH HP, TD-ER/_5BBDC_U8HJA!+_J
MVJFG&5JY*,QG%4U1@328Q<?-BD R<4'(/O2 G-(!0N2:4#BG)WI&YZ4(&-4X
MI<\YI%ZT-UXI[@+U- .VD4XZTH(YS2#0*13DXI01@TT?>H0F/C_UQ6K@X%4H
MS^\]ZNKTJ@%HHHH **** "BBB@ HHHH **** "D/W32TC?=- '"ZJO\ Q-LY
M[UV-A_QZK]*X[5,_VO[9KL;#_CU7Z4 6J*** "BBB@ HHHH Q]5T^2Y)97(J
M;2K9X+=59LD"G7^IPV9VRG%36-U'=P"2(_*10!:HHHH **** "BBB@"*X0O
MRCN*PM.TR6&[9RY(K?E<1Q,[=!69::S:W%P8HS\PH U1P!2T@.1FEH ****
M"BBB@ [5S6I6$TEPK*Y W UTM8]WJ]K!*$D/).* -.W4K H/4"I:9$XDB5EZ
M&GT %%%% !1110 5EZS;/<6Q",0:U*I7UY%;1DR=* *^BVSV]J%=LG-:M4;"
M^ANDS$>*O4 %%%% !1110 4C#*D4M(S;5)/:@#G;G3Y7U1'#G&#6[$ODQ?,>
M@K/?5K87JPD_.1576=3 A:.)OF([4TK@4M3OWOW>V0D=J\_U3X8G4;\7+/U.
M:[K3(=DGFS#KZUU,'ERH"!6T9\@&)X6T!-'L(X@!\HQ72]J0*%'%+64I.3N
M4445(&3JUN\XPC$4NC6SV\.';/-37]]!:?ZTT[3[V&\CW1=*?0"[1112 ***
M* "BBB@""Y0R1$ XXK(T>SD@O)V=R0S9%;%Q,L,>Y^E4;#5+:[GD2(_,IP:
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M [5S6IZ.+B=7VDX8&NEK!U'4I()55%SE@* -FV3R[=%]!4M16[EX%8]2*EH
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M4 A-X8TX'G--;':A3S[4Q#E_UF:N+]VJ:_ZSVJXOW: %HHHI@%%%% !1110
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M)I64>7@4UA@TN?EQ0 [ \O!J)E!-2?>7%1LIS0@'J!MI,#;F@#*T$87-# 7
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M4M(?NGZ4 <'JA_XG'XUVEA_QZK]*XS5%/]L9]Z[*P_X]5^E %JBBB@ HHHH
M**** ,_4+V.V!WC-2:?<QW-NKQC (JCK-E)<YV#M4NC6TEK:JC=A0!JT444
M%%%% !1110 R9@D3,>@K)M-2MY;DQHH!K3ND+VSJ.I%<QI>EW$-^TC@[2: .
ML'(S2TB\*!2T %%%% !1110 5BWNIP6\JJZC)8"MKM7*:OI<]Q<(R X#@_K0
M!T\+AXE8="*DJ&U0QVR*>H%34 %%%% !1110 54O[A+>$NXR*MUEZY;27-F4
MC'- $FG7L=RF8Q@5H5BZ%926MOB0?-FMJ@ HHHH ***;(VR-F/84 9FN7R6E
MC(6./EKBO!TZ:GJ<Y'.WFN5^)_C=X;W[';2=!A@#6Q\(&>:.XE;[S)G]:UM9
M >ARWUO;WR0%1N(K6C<.H(KF[G39Y=72?!P :Z*!2L8!K("6BBB@ HHHH **
M** ,_4+N*WQY@S3["ZCN(\H,"J&M6<MS]P5)H=K+;0;9.N: -BBBB@ HHHH
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M+U'6F!=C^X**(_\ 5BBF 2#,9%4@ &Q5V3[AJD.6H>PQ<#?B@#G%-((- ZU
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M.WT^. Y45=HH H3:;'+/YIZYJPUNK1["*GHH KP6J0YP.M1O8QM-YF!FKE%
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MM(05-*22F* W';04QFHF7FG9.,4=: !1\M&/ES2@';FF]J+ +CY<TI'%-HH
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MO4BN:TFQO(;YVDSM)KJ)'"1EFZ"LZVU.WN)RD9!(ZT ::_=%+2#I2T %%%%
M!1110 'I7(:I8WTMVK1YVAP?UKKZS9M3MX90LC $G% %RU5EMD#=0.:FIJ,'
M0,O0TZ@ HHHH **** "LG7[>:>Q*PYW5K54OKI+6'>Y&* ,KP[:W-O!B?.<]
MZZ"J5A>Q746Y".M7: "BBB@"M?,5MV(ZXKS&TGD;7'#DD;J]$UJ\BM+)WD;
M ->=:,4OM89D.1FJ0'J%C_QYQX]*F<90@5':ILMD7T%2D@#)J0.2N["\;6HY
M4SY8!S746RLL0#=:JR:E:K<B(L-YJ\C!UR* '4444 %%%% !1110!@:]:W,^
M/(S4V@6\\%MB?.:T+F\@MO\ 6L!]:+2YCN$W1D$4 6:*** "BBB@ HHHH @N
ME9H6"=<5S^BV5W#J%P\V=K/D9KHYI5B3<QXJG::C;W$SHC E3@T 7QTI:**
M"BBB@ HHHH 0]#7(:K8WTM]NCSMS77DX&363-JD,5SL<CK0!>L$=+55?[P%6
M:9%(LD89>AI] !1110 4444 %87B X@?Z5NU@^(1FW<>U #O#!SIB'VK<K$\
M,#&EI]*VZ "FR?<-.ILGW#0!1Y!I1DGWI?O9I!D&I .2:5L8&*1^!D=:0<\T
M#Z"A><TK'TZ4I(' [TUL"CJ <X]J,'%&[*XI<Y&* $.>*#D=:&/2@G<* $Y;
MBGG 7'>D VC/>AL$9I:@- S2,3VIRG%# =J>H; ,[:;G J9 -M1LOY4;L!N<
MT[!QS0@%.;T[4=0&D$=:52-M+G(YI !C- "=J7/RX'6C *^]&W ]Z $YH&<<
M4#- X!HL *._:AAGD=*.=N* <+MHL W-"J023WIZKW-+D'(]* &I_K!5X=*H
M1Y\T5?'2FA"T444P"F2+O0BGTC,%7)H X'Q/I5PTH> '\*KZ1IUY;Q-*X.YN
M,UVT\D$QVL13(S;R'R%(^7F@9SFAZ/.=6:>X7*9)&:[95"J .@JFMS;P$)D
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MM7CMHUR#CM6Y:W,TNE&3'S<4 ;23*YX-!G0-C-8>F2W+SN)%(7'%07D]VEX
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MZ5S&B2++J3%/6N?\5:]J2RO D9V].E:'@EI))]T@PQH ]$7[HI:** "BBB@
MHHHH **** "HY<[:DID@RM %/&3FEW8-.(VGZTTKS4[@+QN]J:WWN*7C=BD/
M#<4(9=C_ -6**(_]6**H02?<-4@VTU=D^X:I8SS28Q3R<T#BFAMIR:4,,YI
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M*** .2\;QF?2)4#8)4US/@737AN]S9-7/&^LK"TMOSG)%;/A&(&U27'456R
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M "K>@Z(-,#$\DBDUK5TT^1 P/-7=,OUO8\J.U %MX%=LD4_8NW;CBG44 1)
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M1110!6O?]0WTKDM%C5M6?/K77W0!A;/I7(Z&3_;,@]Z .T P,"EHHH ****
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M;IM08I!90B?SMHWYSF@#,UJ>2- $SUI;)W%CN.<D5J2VT<WWQFE6"-4V <4
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MG\NV9?:L+1(/,O#,><5)XFNC'*8\]15KPPFZV=SUS6RT@!T0Z4445B 4444
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M%% !1110!6O?]0WTKE=#_P"0N_UKJKW_ %#?2N5T/_D+/]: .SHHHH ****
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MJTGAEC_=,"/:K58VAVAMK?!)Z]ZV: &NP12QZ"N2\2ZU"ML\0D&2.E=/??\
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M&&\\HIEL]:WNU8MSI:2W7F%1G- &K!()(@P[U+4<*;(PH[5)0 4444 %%%%
M!6%X@_U#_2MVL'Q#_P >[X]* '^&?^08GTK;K#\+Y_LN//I6Y0 4V3[AIU-D
MXC.: *61NZ4N[YJ:&4MQ3B1N]J0(8S8-.5N.:1BN>:4,H%'08AI?X<4H(P:,
MC;0(3.%Q2ELC%&1M]Z"1BE8!"<@4I;TI25P*;N4GB@8A-.QQFE([CI3<_E0
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MZMV[%]]L.QFVYH ZLNH&2P% =6&00:YW5$O&LH?*)W;>:?HWVK[ PE)+\]:
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M8&@#B]5 _M;WS78V'_'JOTKCM40_VOGWKLK#_CU7Z4 6:*** "BBB@ HHHH
MP==O9K;(C/:K6A7,ES8(\OWB*-2M(YVR[ 5/IT"P6ZJAR,4 7:*** "BBB@
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MU(W*F@#EY=0N5UN.(']V0<UTT9W(#67)91M>K+N&X5JH-JXH =1110 4444
M%%%% '/Z]>7%N1Y-6="N9;BVW2]:GOK5)OOD"I+"%(8]JG- %RBBB@ HHHH
M**** *M\[QP$IUQ6!H^H7-Q?3(^=JM@5TLR!XR#6=I]E'!<RNK EFS0!J+]V
MEHHH **** "BBB@!#T-<EJ6I745_Y<9XS77'I6)/8PO>;V<9STH TK)V>V5G
MZD59J.%0L8 J2@ HHHH **** "L+Q!_J'^E;M87B#_4/]* '>&?^08GTK;K$
M\,_\@Q/I6W0 4UP"A!IU,D_U9H I[5#<4N!NQVIHY;%+M^;&:D!=@)YZ4;%/
MX4O!XIM&H(4 8-'&VD R*-O&<T '&VE(&*3;\N<T8XZTEN,4@8%*$4+D4A7
M'-+C"XS38(16&<=J1L ^U*(L=Z"F>*!]07!IA"YYIP7M367)IB'J!MI.-OO0
M%^7K2;.^:0"\8]Z4XQ3=F.<T;,<YH DPN*4%<8J,KQC/6E$7'6@  4'VIQ5"
M*C*8&,T(,\9HL#' #F@ 8-(%SGGI0%X/-%P% &*%"]^M(%XZTW;SFA /(3/%
M*%3&:9LQSFD QGWIAH.0CS1BKPZ50B7$@J^.E,0M%%% !1110!0O["*Z3YUS
M7-7OA^UC_>%,9KI-3O/LL!;%<9J_B4RQ".-<L.PH WO#]I!!<9CZUTM>>^%]
M5E>] =",UZ AW*#ZT .I",C!I:* ,]]+@\YIMHW$=:YS5+:&>X6-QD!A_.NQ
M?[C?2N+U+Y+]3G^,?SH ZJQM8X;90H !%/\ L<>_=CFGVAS;)]*FH 9)$LBX
M(H6,*NT4^B@"!+9$<L!R:<\*NP)'2I:* &E 5VD<5G:C_HULSH,$"M.JU[")
MH"K' (H YC1[B6[O2)>E=6T"L@7' K)TZRAAF)1P36W0!'%"L0PHIC6J-,)2
M/F%3T4 1R1+(N"*$B5!@"I** (UB53D"DEB5^2*EI#TH Y>\N9X]42%!\A'-
M;]I&/*#$<FJLUO"]XLA<9%:,8 3 H CEMDE()'0U(8U,>PCBGT4 110)$,**
M;]F3S?,QS4]% $4L"S*%8<"B.!8UP!4M% '/ZPY@D1D'.:NZ:YN8<R4FHVL<
MS*7?&#5BQA6*/"MF@"<P*8]F.*(X5CZ"I:* (9;=)6!8=*>8P8]F.*?10!#%
M;I%G:,9IOV2/SO-Q\U6** *UZ@-LYQR%)%>>W>L2M<- [<$XKT:YQ]FDSTVF
MO*[^".351Y;@_-SBM*8':>&]-CCMQ(5Y;FN@E@25=K"H--B\NRA'^P*N5,G=
M@1QQ+''L XI%MT5]P'-2T5($4D"R$$CI3GC5X]AZ8I]% $4,"PIM4<5S_BX.
MMDIC&3SFNEK/U2&.:##MBJB]0.(\.;4O TG#&O08HU\O@<$5P#0"WOU*GC<*
M[ZT.;9/I6M7H)"K;H#G%/DC608(I]%8#&+&JIM XJ-;5$<L!R:GHH ADMTD8
M%ATJEJ[&WT\E.N:TZJZA$LUL48X&: ,/19FEE4MUS70&W0MG%9FGV<4,@*N#
MS6S0 PQJ5VD4V.%8U( ZU+10!#]G3S-^.:66!)1AA4M% #!&HCV <8Q59+"*
M)BRC!-7*0]* .9U"=_[62,?=XKH8XE,"C'45FW%I$]\)&<!@>E:R8V "@!B0
M*A.!UIOV5-^['-3T4 ,>,.A4C@TV*!8AA14M% $/V=/,WXYHFMTF4!AG%344
M <UKES-9F..+A<5<T4!TW$<D5)JEK%<,N]P,5-IUNL"_*V>* +4D"2=10(%$
M>S'%2T4 01VL<;;E'-*]NCMDBIJ* (FA5DVD<410+$I"CK4M% &5JFGP3PL7
M4=*P?#\21:BRIT%=5>IOMV'M7*Z&,:LX]Z .SHHHH **** "BBB@ HHHH *C
ME^[4E,D&10!5Z]:8QP>:E(&[Z4QTW'.:E )VI.].*\9IO>FAEZ/_ %8HHC_U
M8HIB!^4-4MOS8JZ_W#5,YW4 -9"W%"J>E.)(/O2#.:FPP /- !Q3ESDT'IQT
MH :IYIV?FS35Z\TN1N]J !AWI!FG;@>#TI 1WH 0@BA>N*4L"OO38LYYIB';
M3NQ5Q!A15<8W>]65^[0F M%%%, IKH'7!&:=10!E?V5&968H.3Z5-'IT2MG8
M./:K]% #$0(, 4_M110!R>K/*DW#$<U'?F9[*%E8C"\\UMZC8";! [UGZFT=
MM9I&W7;0!EV=S)+;RQ;CN(P.:MZ)%/#.PD8G/O659AT=Y1]T<FMK2[E9[CCL
M* ,S6+A;?4M[= :ZVPN5>R1QT(KS?QFMTUVP@SGVKL/#J7/]DH)LYVT =!#<
M+*Q /2B2Y6.0(3S6-I4=VM].9,[-WRU#JT=ZVHJ8<[.* .C:0*FXGBFQSJ_0
MUE70NO[*(7/F9%1:,EV(F\_.?>@#8^T+OVYI[RA%R37/.E[]ORN=NZK6J+=F
M "'.<4 5=9E>56:-C@>E2Z!?;K98W.6QWJG9[XK-Q>_>YZUG:8+@ZOF'/D9X
MH [:XN%@4$GK3EF#1;QTQ7/:\EZXC$.<9YK5LDE_LK:^?,V4 6H;E96(!Z4L
MDZHV":P-.AOH[MS)G;4NHQWC2@Q9Q0!M/.J1[^U$,ZRC(-94T=R=,QSYF*@T
M>.]5G\W..U &CJ5XL,++GDBN;TFZDCO6+L=I/'--UB/4#?$\^5FFR,CQ*MM_
MKAUQ0!VD<RM'D&HEO4:?R\\YK)TE;P0'SLU1A@OQK^XY\G=0!U$TZPC)H6=6
M3<*Q-=^U>6/*SUJ734N3IY\S.XCB@#4BNED. >]#W*I($)Y-86G0WR7#>9G;
MN-1ZI!J#:G&T.?+ YH Z5I0(]U<GJMV[SJ$8\,._O6S(ES_9I SYF*YFT)^U
MLMSUYQGUH ZRUOE$**3SBKDLRQQ;R>,9KCTMM0-RI3=Y>:V=66Z-B!'G.WF@
M#4M;I;E2R]J47*F8QYY%8?AM+I()!-GK5?R]0_MUV&?)P,4 =+-.L0!/<T_S
M!LW5B:TEV]M'Y.=V1FK%JMS]B(?.['% %Z*Z60X![UD^(+WR[=E4X-0:5#>I
M,_G9QN./SJAXE642,W.S- ,V/#\S260+GOWI^MW(2SD*MT%9VFNXT4-!]X$Y
MK@/$?B][2>6UF?#'C&:UA"^HD:WA:;[=K#ECG8<\UZ<SB* ,>@%>.> (KN?4
MC/'G8>37JVI),VG,L>=^VHGHP1;@N%FBW@\4UKI V,UE:%'=)8JL^=V.]4_(
MU WQ)SLS4C.BDNEC"D]Z4RAX6(/:L/5XKLQ0B'.0.:GLUNDL9/-SNV\4 9SW
MC_VVD88X(/>N@%VJ$*37'6TA_P"$@7S?O8.*U=4BO';=;9_"@#I3* F[/%,B
MN%E8@'I69(EW_9J@9\S'-9^@1Z@MS<?:<[=WRYH Z"6\2*783S4OGKLW9KE]
M2AOVU163/EY%7;P79L/W6=U &TDZN>#4?VQ/,V9YK(T=+T8,^:H^5?C5"3GR
M]U %[7[LPJ""1FGZ!<-+:EV.>M4/$8/EINZU)HZN-)81?>YQ0!OI>(\FT&GR
MW*Q8R:YC2TOA=9ES3]<CU%I$^S[L=\4 =0L@,6_MC-16]TL[, >E5+19_P"R
M=KY\S967H\5['=2&3.TT ;\ERJ2!":?)*(TW'I7.:G'?-?H8L[>]:%ZERVG8
M7._% %N6Y#V[,I[5S^CZ@PU*X1R3\_%6=/6XCMV^TYQ[UE6P5M5E,/\ >YH
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MPKJT&U *Y/PY;ZA%=;K@';[UUPZ4 %%%% #7_P!6WTKB=1!;4%_WQ_.NV?\
MU;?2N+OO^0BO^^* .OM!BV3Z5/4-K_Q[I]*FH **** "BBB@ JEJ08VK;3SB
MKM0W)01$OTQ0!R6@"X_M-][$C/<UV=8NGRV371$.-];5 !1110 4444 %-<$
MK@4ZD)P* .6NHYSK"*&.,&NEME*0@-UJA)-:_;U#8\S'%::D$<4 +1110 44
M44 %%%% '.Z^)3)&(R1S5[1E=8/G)-.U&2V1U\[&<\59LWB=/W?2@"S1110
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M9;DH%H UD0*@&*!$H;..:<.12T 130+,,&G)&$0*!TI]% "!0.U&U3U I:*
M$(&,8KD-1T^47BO&I^^*["LK4;Y+8K\N<L!0!=M8PMNF1SBI9(Q(FTBDA??$
MK>HJ2@"*&!800O>G>6N[=CFGT4 -9 _44H4 8Q2T4 -V#.0*R-=LC<VIVC)K
M9JK?3B" L1F@#(TRW:TTJ17'0&OG/QJUS?\ BV9(@2%?'%?0FI:Y''8<8RV1
MBN$T[PC]NU:6^;_EH^ZNFD["L;GPNM);>T/FICY/2O1RH88-9NDV"V$ 51VQ
M6G6-1IRT!#50*, 4NU<YP*6BH&,:,-C(Z4CQ@Q%<=:DI&.%S0!RTND-_;"3
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M)8C.!0!S&AV4\.H,[@@&NOK'L=12>8H%Q6Q0 4444 %%%% !36^[3J1C@9H
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MJ_[X_G77&X1@R@C.*Y#4>;]<]-X_G0!U]G_QZI]*GJ"T_P"/9/I4] !1110
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M-]TT 85UITLM^)=W -;4*E(P#7/W>I20ZHL.< FNAB;?&I]J 'T444 %%%%
M!1110!C:SI[7CH5/05:TVV>W3#'/%4-;U(VLL:JV,]:T--NOM$0.<\4 7J**
M* "BBB@ HHHH KW9 @;/I7*:,P&KN?>NKN\>0V?2N4T4!M7?TS0!V0.12T#@
M44 %%%% !1110 4444 %,D(VT^F28VTF!4<'=2]!@TO7K^%,.<T@$/6CTIY
MV\]:C[TT,OQ_ZL441_ZL44Q _*&J1 #<5=D_U9JB.6Q28"[=QP:<,'Y::>.*
M%!)J6,4 <T*,BD"G)H"G% #MHQ2",9SFDP<9I,FF!)M7UINP*>#48W;NM/YH
ML" @9P*4+S3=I7K3EY&*8GN*J@R8JXHP,533A\5<7[M" 6BBBF 4444 %%%%
M !1110 444A('4T +2'[I^E&1ZTA(VGF@#@M47_B=Y]Z[:P_X]5^E<?J28U?
M>?6NPL3FV7Z4 6:*** "BBB@ HHHH S=1L8KHG><5-I]LEK;JB'( K.URY:
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M78/6FD ]Z3!Z9I"I-.P[D@ VTFT%* I*T;3MS2N(-H"TI' I-IVYHP<4D I
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MS]WBF8QTH'T%YVYIN[(IW.W%(%XIB'*?6E/Z4PTN<C%)!U'9X.:0$8H'0YH
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MU=K*UWSOL#>2#NSVI -T_3K&!PT"*#GM5IM-@>3>R FN<T$WWVI1,#MS784
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M "BBB@ HHHH K7K[+=C[5R>BKC5G?U-=9>_\>[?2N5T/G5G'O0!V0.12T44
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M+2([]]SG%3Z?8I9PJB'( H NT444 %%%% !1110!%<,$A9SV%9&GZS!<7+1
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M09;'>K0X%- +1113 **** "BBB@ HHHH **** "D;[I^E+2'[I^E ' ZHO\
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M0,L<T :@.1FEHHH **** "BBB@!#P*YF_P!>>UO?+"YYKISTK(N-,@DN?,<
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M77]5;38HV5<[CBMJJ6H6<-TBB4 @'O0 FEW9N[1)",9%7J@M84AA5$& *GH
M**** "BBB@#-U+35O(BN,&N+U2[D\+C> 6R:]&K(UK2;?4+8K*@-7&5M ,+P
MWXK.K.@==N3BNS# ]#7GK:&VECS8. O/%:=AXAVX23)-4X7U0'8454M+U+E
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MWC^\N+@HXP,^M95(:Z =QKTMY&&^S@].U3Z!+<26*&X!W8YS66OB:V95$\B
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M.U<CJ]WJ$5T@B#;2X!_.NOJE=?9B1YA4'/>@":T9FMD+_>(YJ>F)C8-O2GT
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M-)>-#M/%2ZEK+6<:L%SD@5-%ID:7C2;!S3[[3TN H*@X(- #H;XRVIEQVS7
M:[XJ=KM[?8>N*]%2V5+?8!VKA=>T)1</+Y8SG- '3^%23I,9/]T5NUA^%QC2
MHQ_LBMR@ ILGW#3J;(<(2: *@&XYH8?Q4T.-W%.W#=[5 #,\T]N@ICX7FE5Q
MCFGJ I&!]:4?W::SBE!&WWH8P;@8I&.1BE)!7WH)&V@!,Y7'I0/6DS3B1F@
M)R*0<<TN1N]J=QU[4 (_W<TRG@\\]*C9@#0@'=*53D;:%(VTWI0 I&TXI.M.
MR"/>@D8HOH W%/7A<TF]:7<#TZ4:C&;MW-/Z+3L+C--W#/M1<0U3BE!P#2!@
M"<T C!HT 4'BFTX$8IM AR\\4 9)IH/-2C&VC89&G^L%7ATJBO\ K15X=*H0
MM%%% !1110 4444 %%%% !45Q'YD96I:* .9M=(DAU66=GRA P*I:L(VN55D
M!&\?SKL'4!6/M7%:BX&H+N_OC^= '665K"ENI2,#(J?[-%NW;!FFVG_'LGTJ
M>@!CPQR##J"*58U1=JC IU% %"[TR&?D( 3UK-/AFUD.9(U;ZBNAHJE)H#'M
M="MK=OEC4#TQ4][I\+VS*(QTK1J&YE2&(L_0"CG=[@<QI&D)#>LS*"*Z=K6%
MUPR BLVQU&VN;@I']ZMBDVV!%%;10C$:!1[4OD1[]^T;O6I**0#717&&&12+
M$BC 7 I]% $0MXE.0@S2301R+\R@U-378*N30!REU8,VJIL.$P<BNCL[6.&(
M849JE)?VJW 4_>K3@<21AEZ4 (UO$YRR FG-#&Z[64$>E/HH CC@CB&$4 4T
MVL)?<4&[UJ:B@"-H(W7:R@BE6&-%PJ@"GT4 <UKFGAIXWC&"#VK0TVV4PXD7
M/UI^HWMO;,HF[GBI[&XBGCS%TH G\F/9LVC;Z4B6\49RJ 5+10!$]M$[;F0$
MT\QJ4VD<>E.HH C2"*/[J 4TVL)DW[!N]:FHH JWMNLUK(I'\)KGM"LGCN9,
MGC-=1,ZI$S-T YK,L;^UEE98NH/- &B+>+(.P9]:5H(W^\H-2#D44 ,$2!=H
M48]*1((D;<J@&I** (GMXI#ED!-/,:E-I'R^E.HH C2".,?(H%8GB*R$\494
M88'K6_6=J=W#;(IEZ$\4 &FP*+%(W&<"KJPQH"%4#-16<T<T*M'T-6: (OLT
M6[=L&:<\*/\ >4&GT4 ,$2!=H48]*:MO$IRJ $U+10!$]O%(070$CI5'6;43
M:<T2C'-:=5KZ>.WMC)+]V@#F]#TYK:X4GUKJ#;Q%LE!FLZPU"UN7 BZYK6H
M88T(P1Q31;Q 8""I:* *TEC XYC%85YX6M[F4OL'Y5TU%4IM; <)+HTEH3L8
MA1V%-2_;3U("$GUKMWMT?J*JRZ5;2*<H*T]HGN(\V?69)M84NAQFO0+*^B>W
M52!C'2N>U73K:&Y*(@$G:HH=.U!4RN<5;Y6@.OAG@\P@ "IREN[9(!-</<6^
MI1J""V>]/BU"YB4"1FR.M0X+H,[DB)AM."*5(XU&% Q7$MKC;U^8^]:MKX@A
M6/+L:CD8'0"WB#;@@S2RP1RKM=00*RXM?MI3PU6QJ4)&=U+E8&%XALW,D2Q'
M:N.@K2T73UMH]Q')%/O;^T0H92.>E6[.YBF3]V1BERL"9X(W.64&E\E-FW:-
MOI2[USU%+D>M("-+>*,Y5 *&MXF;)0$U+10 PQ(R[2HQ2)#&@PJ@ U)10!0O
MK.W>%B\8/%<YH4*1ZH^P #-=3>_ZAOI7+:&3_:SCWH [*BBB@ HHHH ****
M"BBB@ J.7[M25'+]V@"HPP:0=:?TSFF5((>S ]!3.].R-OO3,C=BF@+\?^K%
M%$?W!13 23_5FJ2X+&KLO,9JD@Y(H =@;O:@ 9I".<4 9-3<!0!DTJ!>]-"\
MGFE XSFA,8_"YIIVTF,C-,V?-G-%@)$9<FA&7)IHBYSF@18SS1H%P8CM2)C-
M&S;WH09- AZ*#)[5<48'%4U^5\5<7[M- +1113 **** "BBB@ HHHH ****
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M!FL6PUDW,[($Z&@#?' Q12*<J#2T %%%% !1110 5E:S8B\B0$9P:U:R]:U
MV$*,%SN.* +-A;BWME4#H*M YJM87'VJT63&,BK"K@T .HHHH **** "J>IV
MPNK0QD=35RJ.JW?V*R,H&<&@"AIFEK:R @$8-;M86DZQ]M8 KC)K=H ****
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MHHH RM4LOM6.1^-2:5:_9H=N0?I5+79I8A^[)%/\.R326Y,I).3UH VZ***
M"BBB@ HHHH 9*@>-@>XK'TO3A;7L\F1\S9XK2O7*0$CKBN?T.>XEO[@2,2H?
MB@#J:*0=*6@ HHHH ****  ]*Y^[TOS;SS,CK6^WW37(ZG=W"7VU6.,T =5;
MIY<(7TJ6JUBS-;*6ZXJS0 4444 %%%% !6%X@_U#_2MVL+Q!_J'^E #O#/\
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M,BK=4-59TM&*'!Q0!G:5I7V6Y,F1S705R6A7D\MZR2,2!76T %%%% !1110
M4C#*XI:1NG% &+/IVZ^64$<5KPKMC -<]=W4T>JI&&.T@UT%N2T0)H EHHHH
M **** "BBB@#*U2R%TRG(X/>K&GV_D1XR*R]=GFBEC$;$9/:M#27D>'+DDT
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MH SM1B@DQYK8J33XXHXL1'(K+\0[\#;4OAQF:V^;U- &Y1110 4444 %%%%
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M01BC(V^] QCWH/ ]Z-!C1FE&>:7C;Q2 T )&<R@5?'2J2@!P15T=*H0M%%%
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M'-# ID?-2'Y3BI6P#2$*3SUJ;@AI(QSUI,C %.?:/K3>,#UH0%V/_5BBB/\
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MCBVLV:UZ ,!?#D(I1X<B!/O6]10!S_\ PC4-._X1R+;BMZB@#GO[!M[?YV.
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MF2NAP0#7!Z!J$EY.!(23[UZ1=6Z74#1.,J:RK/PW:6<F^-,&@#'>1SJ'E#.
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M@(]*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MR0X6GTR0X6A@5&'S4$8.*,\D4AZU(#L#=BFGAJ3FCO3&7H_]6**(_P#5BBF(
M20XC-4U<%O:KDHS&PJDB<FDP'X&[/:C*YI"P^[2!?6I&*",F@$8.: !S0 ,4
MT HZ>]-.0:>@!.::^,T ,#<U+U'%,V#K3LA>E #<_-4@9<5&P':A>M #E ,G
MM5Q?NU33[]7%^[30A:***8!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 V3_5M]*\WUBV6?56\U<C/>O26&5(KF=0TDRW>\#J
M:: P+C2K/S;<B->O/%)=P06]PAB4 CTKI#I.YH\CH:9=Z())%- SF)(8;VY_
M>J&8GO5N'2++#8B7('I6LFA;)MX%7HM*"Y/J*.@61Q%H@AU9DC& &KTZT_X]
M4SZ5RPT$QWYE /)S760+LA5?04A$E%%% !1110 4444 %%%% !1110 4444
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M-BAL@T@R32N!)&/WF*M@8%4TR'JXO2J0A:***8!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4TJ#VIU% ";1Z4A4$TZB@!-H
M]*,"EHH 3:/2EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIQBE<"YN&,T9JGYK8Q3O.8"F!:) HW"JAE)I/-)- %S<,XI:I>:<YH:=L<4
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M,XHW#.*I^:<YH\ULYHN!<W"C<*I&9@>*42MBF!<W#%&X8S5'SF'%.\UL8I7
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MWG-*"-M&1MQWH'H(!DTNW.?:FKG-/4XSF@"-7.['I3B<T #=FAL9XI]1#@H
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MN&#3FC+?+Z4U8SG%%K@)2C&*4(30$..E A.-OO1QM]Z4(=N<4;"!G%+J,0X
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MT4 )M%&T4M% ";11M&*6B@!-HHVBEHH 3:*-HI:* $VBC:*6B@!-HHVBEHH
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MH 3:*-HI:* $VBC:,4M% ";11M%+10 FT4;1FEHH 3:,T;12T4 )M%&T4M%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 A^Z?I7SO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\#!-6(-$CC<,0.*YN8Z4BIX>TI;2,'%=*.!BF1QK&H %/J6[E!1112 ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^^#0!GFD)^:F+J.5 6W49P>*16^8TBG$A)HZ#7F+N(IH&34G _&D'''K4H&
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M&XZ4A4YIW08-'0!%YXI>^*.VWO33QQ2"PX8/%.(!'TJ, FGGG\*86$QD<T(
M!FC.30WJ*!V!P.M(PP![TA!ZTYONBBXA"!Q3]HVTW:<4N#C%)CL)[4=>*#PN
M*0#-,5A#3B,C)I2,CZ4PMNZ=J!V# VYI> N:3!VYI<';FF(&QC-+PHI""!24
M /Z+3,_+BG=%Q2=%V]Z0"KR,&C&>*!R,4$\8H"PG!!]J ,KFFT]?NT]@$& N
M:7MFDP=N:5>!DT6 0'FG=/QI 0#]:"<#ZT@%Z<"D)YVT@;BDP30 [.>*7K^%
M- S2@YX':@+ >0<]J0=,TI^8<4WH: '8XS30>:D!P,U$G#DF@!0<&G'@<4SO
M3P>,&@!%/:C:-U&WYL4N,\4  P210F!FD0<FD[T .^]S3E )R:8OK2]]U(8[
M W9IJ_>-(&^;-+T.?6@0N,'CO2<#BCIU[TWO30"[1NQ2\'BC8?6FX)-,!W!_
M"@8/X4@!YIM(!_7FCMGO31P:4-\WM0 N<<TOT[TPG)I5..M (</E-(1N>@\<
M4 [>#0 '&=M,Z&G?>:E8;N!VH8".>E+UYIIY_"ESS0&HHY>D)P]+GYLTC#)W
M4: *<#FD(&100<4$'(I@! S1@;L4$'-(0=V* %;TI5Y'/:C&1CO0/Y4@ ^OI
M1PPYI&-( <9% #B HS0V-HIG.*4J<4!8=G:![T.<D4V@KR*& [C.*#Z=J0@[
ML4IZ8H <0-M,)R13NHI#ST[4@%<#&:9CY<TX_,.*;@[:: <,!<TGOZTF#MI<
M;1F@&+TZ49 XH5O6FL,&@!Q'..U QTH!R,=Z:00: ']>* V5(I.HP*:.#1T
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MYI,G-)N&:><;:+ )FFT\XP,4''% " X/M0<A\_PTIQN%*0"<=J!#!]\M_":
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M/>C (SWHN (<9IN>M)2@9&:+ )SBE ./:D![4X-S@]*+ -IW..:!C-+D'K0
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MTJV^,\U8HH K"VP3S3O(^7%3T4K#N5A;8'6C[/[U9HIBN5OL_O2&UR>M6J*
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@WV?WI1;X.:L44 0>1\V:#!\V:GHI6 11A<44M%,#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image5.jpg
<TEXT>
begin 644 image5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0M!VX# 2(  A$! Q$!_\0
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M@7LBC(JEN<]Z"[CO1<"[D>M&1ZUG&23L:<LC]S3 OY'K1D>M9[/)V-"R/W-
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M49)I0<4P8K$TB]:4MD=*0'!IB).O6FD#M2%B12 \TK#8[GO0<"C.12%?>@0
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M%AC6;!H#&D9E)YI57/2F2.\T#K2;MW2G;%[T[Y!THL@&A@.M(3D\4-BFYI6
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MA.* (?LXH^S"GM*%%0&\P<4 .^R+FG?9ABFBYS2_:* $^R+G-2"$ 8H67-2
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M-AC3 UJ*IPW:L.35H.".* '45!)*%[U5>Y;/!I :.::6 K/$LK=*"TM,#1#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4.] &5'"R'O5Q)"JU;$:XZ5%)#QD4P*$TK%J(D+$9IDT@C;!%3VTRF@"Y%&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRC/>NF#.6K8]5T]<1+S6JO2LO3Q^Y4^U::]*[(/0\RKN.HHHK0R"BDW"C<*
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M"W&=J?I67+X# /RQ_I6?LC3ZP>=3W_'6NE\(7F^X7ZUJ2^ F/_+,_E6UX?\
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M/88I<]*:"2:EV@BF;<'-%Q$@Y%-*XYS32^!302323 <7(&*9DYJ8 $4PI3N
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M)6BX6$(/>@$]J7.:3GM1T"PA)[THSVI.>]*"1THZ !SWH&>U!)/6@$CI3Z"
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M=[9QBI ,C- ;$1WFE'O3B2.U,.:+A<?S3>:3>_I2\]Z:%87YJ:<T_)]*9S2
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MG2EW'O1B@YHL&P8S1M-(#BG;\T7 3'I2@'O2=*7?F@&*0.U-"G-&<4[?GB@
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MZTO"TW8! O/-*0* ^:& J4,C-21=:9BI8@,U5Q%H=*6D'2EI@%-<<4ZFOTH
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M&F^5S5S%&T4 51":0Q&K>*-HH JBW)I?LYJUBBE8"J+<YIXAXJ>BAH"L;?-
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M[N!5R(DCFJZL :M1G(IJXA]%%%, HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BF
M<H.*EJM=$!30!R7B?7Y].@9HST%><6?Q)OY-2,3.=N<=:[#QD@FMW&>U>/PV
M'E:H7SWH ^@-%UYKN!6=N33O$FMR6-BTD1Y KA]%U%;>!1OZ5/KVI)>69CW]
MJ .4'Q,U,ZJ8=QVYQUKTGP_XBN;V-2Y/->,0:*&U,R^]>CZ5-]@MU([4 >IQ
M72K#ND.*JR^(+"$X>4#\:X&Z\5R-%Y0R*YJYDFO)"?,89]Z /88_$FGRMM68
M$_6M**XCF7<AR*\*AAELV\WS&/XULV?CJ6TQ%R<4 >O/*J#+&LJ_URVMD/[P
M UPUQXX>:"N2O];EO)""Y&?>@#MM0\;+&Y6.3]:IV?C*YFN -QVY]:X3[!YK
M;S(?SJ]:1BW8$-G% 'M.FZJDT 9VYJ^M["QP&%>2PZU) F 35VR\2%IP&?\
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M<$'I7E6A^)'\Q8BQKTG3I_/@#4 7:*** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MES>&[&9LL@_*@#PJ&&X9]N&_*M^PT.XN".#7J*^%=/5LB,?E5Z'2+:#[J@4
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M<=J0QH.#3^#4>*49[4["!EQ3HNM-.[O3HNM*X%Q>E+2+TI:: *8XXI],?I3
MIN@W4@%.<<]::*2&Q^%IG>G;/>FXYJ1#\+BF=Z=LXZTF.:: < M&['%($]Z-
MM"&* #2YQ2;/>DQ2&AP"DU9C Q554R>M6HQ@520F/HHHIB"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@,=*ED.:8F*0:"$^M 8#I3V7=31%CO2T&K6#=FDSBG>6/6D* =Z- %#9ZT'
MZ4@7/>@I@=:/0!!@GFG\#I3 O-+MQWHU 1GIT1&:B89I\*8/6JLA%X=*6D7I
M2T %,D!(I]-?I0!0>-]V<T $4]W.:3.:D8NUJ;S3OFIM(!VUJ;@T[YJ;FFA#
MMK8ZTG-+\U-S0@';6]:0@T;C2YH0T*JMGK5J/.*JKNS5J/.*$(?1115 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% %>Y#%>*XGQ)'-Y+<G&*
M[TJ#6-K-B)X" .U 'C-DC?VISZUZ+\JZ8,^E8$NA2Q79=4[UL6T,\D8B<<4
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M1G%-.L8[4 ;%%8W]L_[-']L_[- &S162-6SVI?[5]J -6BL<ZQ@]*<-7SVH
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M3P.U.>P4CI6G10!BC3/FZ5.-.3;]VM.B@#).FK_=I/[-'I6O10!E#3QZ4_\
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M?V:/[M.735[K6K10!E2:<I'"UDWNDS,#LKJZ@F) XH XB'1KP2<DXK:M]+D
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M)UJ]I:\"@#8!I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*:3BG4TD4 5I6S4:]:DEYJ)>#2$R7:#32H]:0Y;I3=C#J:0T."T%<=Z0 F@J
M11U& &32E !UI #05('6BX@"Y-/\L8ZTP YI2I'>@ :('O3HH@IZU$2?6I(L
MYHU N#@4M(.E+5 %,?I3Z8_2@"HYYI!0XYH I,:'?-BHRW-29.*C*\TK .!-
M/R*8 :,4,!QW=J93@QIV 10@&9:DI>]."C%%P$53FK48.*K!L' JS&<BFF(D
MHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44C' K,O+XQ
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M!UI,I C'Y5SK_#FU:XW&$=?2O4Z3 ]*KVT@V.-T[P/80*,Q#(]JVXO#UG&N
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M+#M3/MC>E6_*4]J3R4]* (H[@MVHDG*]JF$:CH*4QJ>HH @CN"W:J.H3.@.
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MANHYQE#7B>K>)+L7N%W8S7<^%=:$D"F9\''>@#NJ*S6U>V'_ "T%,.L6^/\
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MHHH **** "BBB@ JK=#*U:JK=9V\4 484/F=:U8_NUE0!O,K5C^[0 ^BBB@
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M<FBP#2:DBZU&:DBZT"+B]*6D7I2TT 4U^E.IK]*8%-U.::.M/=SGI3,\TKW
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M9L<"H8V?=T- &@6 IHD4U"Y)6HT#!J +FX"JMS(N.M.D9MM9MRSG/6@"2*9
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MJ2/1(X^BTG]L3_W#2?VQ-_SS- $O]D(?X:F318<<BJ+:U./^69_*F_VW<_\
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M7%&:8QM.[48HIH0T+\U7(A@54'6K<72@"6BBBF(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE<YJP))KHSTKGM4
M;!- !I(((KH1TK TILD<5OCI0 M%%% !1110 4444 %%%% !1110 4444 12
M*#4!7'2K+U79P*5T Z,G/2K Z57C?)JP.E,!:*** "BBB@ I&4&EHH YS7]*
M%Y$P"YR*\RU'0WTZ5I%4CG->WLH;J*YSQ!I:W43 *.13(E$X#P[K,HN!&Q.
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M@M0!C:I'F7\:TM'7 %<YJ.H>;-\A[UNZ$[,JYH Z,=**!THH **** "BBB@
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M[1 9%:;LVWI4H11T%+@>E &#>1/(WW:L6$!7&5K5,:GJ* BCH*  CY*YC68
MY.:Z=CQ7/:H-Q- &98:0DIZUT5OI"0@8-4]*7!%;XZ4 1) %%,EM!)5FB@"M
M%:"/H:2:S$O4U:HH HQZ>L9X-2FU!'6K-% %86@'>G?9Q4]% %8VH/>F_8E]
M:MT4 5A: =Z=]G%3T4 9]Q:[AQ5'[(P-;C8[U [*.PH STM"W6KL-H$YI\;
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M10!36Q56SFI_*&,5+10! ;<4?9QZU/10!!]G%!M@:GHH J_8QFGBW J>B@"
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MS;*\^4*35^5R8LBBYE)6,::-M^:EMN&J.1V\SFK%L%R*9"-:'[E2U'%C;4E
MPHHHH **** "HI4&VI:C=AB@"@8SYE7H1A:K?QU;CZ4 /HHHH **** "BBB@
M HHHH **** "BBB@!K_=K-F^_6D_W:H2LF_F@"6 '%6QFH(&7'%6* "BBB@
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MJ!?-YK0T<#:,4 ;O:BCM10 4444 %%%% !1110 4444 %%%% !1110 4444
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M[U7NHS V"<T :&CZ?$NW<P_&NZTV)$4;2*\]L=[.N&Q7=:,&"C+9H W:***
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M0<U4:PB!YH J^?G[M6;>23/)J2.SB!X-6DMU4<4 -D9BO%0H9-W-7/+%&P4
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M.M:GE#&*9]F7.: (T9O+R:KO,^_&:T/+&,5&;92<T 01LYJ;<V*D6(**78*
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M<H1^]/YT =3:Z"(F&)L_C75Z9;>2H^;-<197<VY=SYKM-)D+J,F@#:HH[44
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M5'Q+^-:&D-D"@#=[44=J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *8PI]-)Q0!4FR*C3+'FK,C+W%1<'I2N <**,[J0@CK2?2D.PXKBF'Z4
M\''6@D&@!JG%*6R.E XZT,013L(0'!I2V1TI!UIQ88I6 C-21=>E1,V*DA?)
MIV NCI2TB]*6F 4R3[M/IK=* *3GYJ QI[J,TS'-):@/^7%,)]*=M&*9WI:
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MG\-:/<V[J74XKI-/\*P60&,'%;L5LD8  '% #X4VQJ/:I*** "BBB@ HHHH
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MG?;R: -/<OK1D>M9929FR":MHKB/D\T 6-ZCN*7(/>L>=9_,X)JY;K)L^8T
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M"<+F@"CX>O8U"B<9/O7>V,\,BCRP!7FEVT23C[-TS78^&WD9%W4 =710.E%
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M):-R,^E '9^&H9$E4G.*[2_U%K2T!4\XKB[+49+5%_='CVJS-J<M^NS8?RH
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M2YSTKMX22*Y[0+3;&O&.*Z5$VB@!]%%% !1110 4R3[AI],D^X: .4U1F$O
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M;'KZUT?AKQCK%TRB1C^= 'T#D'O06 ZD5R^CZA<SQ@R9Z5A>+M;U"R5C;DT
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M2L>: /36<+UJ,W*#JPK"U*^EBL]ZGG%>6Z_XLU2V=Q$QX]Z /<%N$;HP_.I
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MEYOAE:R3^9QUKT,0MGK4GE_+BBP'(Z=X/MK'&,<5TL-K'%%L!&*<ULY/!I1
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MM-0R2PYK36PE+_?-:=K9R)C+&@#C[7X9VEO+Y@Q7366APV2@*1Q6UL.W%0O
MQ[T 5+NQCNXO+)'2N6O_ (=VEZ2S;>:[-+9E/6I6B8KC- 'GMA\,[*SG\Q2N
M<UV5EID5G&%!'%6_L[YZT/;N1@&@"&\M(KJ+82*Y+4/A_:WS$MCFNN2SD#9+
M&K7E';B@#SW3OAI9V-R)5*YSFNZM($L;<(".*?\ 9WSUI'MG9<9H HZG;1ZE
M&8F(YKC;CX76=S.9CMR:[A-/D#YW&KR1$+B@#B=.\ 6E@X9<<5U"VD4%OLW
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M>=U $R>]3#I4*5,.E "T444 %0SXV\U-4%Q]V@#)FV;J2 _/Q4<WWS3[?[]
M&U#]RI:BA^X*EH **** "BBB@!&SCBJLH>K=1R,,4[@4 'W\U?B^[53<-]6X
M^E("2BBB@ HHHH **** "BBB@ ZU!+;I(N"*GHH"QA7.APS$G8*H-X9A)_U8
MQ]*ZRC%0X)F;IIG)GPG9E<F(9^E9]QX<>(_N%Q7<L !FJ<DX#8I>S2(=)'"2
M6>J6XRK$ 5GRZI?VS8D<\5Z8(8YTP0.:RK_PY;3JQ(%'*"@T<9;>)T60"5N:
M['2=:@F48-<=J/AB-)<H.]2V=E=VJ_NU/%4KFBT/3(YTD'!J3(KSG^U-1MVP
M5.*TK3Q%(,><V*.8?,=K32N1BL6W\06K8#2#/UK3BOH)A\C U28]QDNG03??
M0&LZX\+:=,"6A!/TK<# ]*6GS,=CA;WP?",^1'CTXKG+SPUJ\1/V<L*]<P*0
MHI'05:J,5CQ?[-K]J?FD;BKUMK=]:D>>YXKT^?38I^H%9-SX4M9P<@52FNHS
M#L_&L$8 E;FM*/Q7;7!^1JS;SP3!DE%K,D\/3VH)B0\5I&,6P<K'<6VI0RCD
MBKGVJ#U%>27M[J=@#M5N*Y'4_'VK6;D$L,>]:?5^8GVC/HY)(GZ$5)Y<;>E?
M.&F?$[4&8!W/YUZ#HGCOSPOG28_&LY862#VC/1I=,MIOO(#51_#]D1Q&/RJ"
MT\1VDP'[T?G6M%>PS#Y6!KFE3MN6ILY;4/#[C/D+BL";2=8B/[MF%>H<&F-$
MK=A6?(:*J^IYA'_:\!_>.U:5OK<T&/-8\5V<VF12]0*S9_#5O)VHLS15(E2W
M\40<;C6I#KMO-T-8DWAB-,[!6?-IUS;?ZI33O8.6+U.XCO(WZ$5.) >]>=K<
MZE"?N&K4.LWB??!%+G$Z5]CO,U!,'/W:YF+Q"1]]L5;C\00-UD%/F)]C(U4#
M@\U92J$&HPS=&%7T92.#5&;BT2T444$A1110 4444 %%%% !1110 4444 %5
MKD$CBK-5KE]JT 4H8WW\UIQC"UF0S$R8K40Y6@=AU%%% @HHHH **** "BBB
M@ HHHH **** "H9]VSY:FJ*8D+0!E@7'F]>*U(,[.:SQ(WF5HPDE:+!8DHHH
MH **** "BBB@ HHHH **** "BBB@ IK_ ':=37^[0!0<-OJW!G'-5)"V^K<&
M<<T 34444 %%%% !1110 4444 %%%% !1110 4R3[AI],D^X: .7U,#S?QK0
MTD8 K,U0MYO'K6AH^=HS0!O=J*!THH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ IK9Q3J8QQ0!5F#5'&#GFI)F/:HXR2>:&!*5R.*85(J0YQQ
M31D]:@!HSVI2#CFASMZ5'O8GFJ >,]J"&[T#/:@EN]2P$IV3WIHS2\T[C$.*
MDBZU$:DBZTTP9<'2EI!TI:8@IKG IU-?I0!4=^:9GFG.>::.M)#8[?[4W/-/
MW#'2F=ZFS =O..E-/-/W#'2F&G8044N:2FAA2]J2G;3B@"(.0W2KT)R*I9 ;
MI5V$\4P):***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%&:* &N?E-<UJR%F-=*QXKG]389H 9HZ%2*Z0=*P-+8$BM\
M=* %HHHH **** "BBB@ HHHH **** "BBB@!CU P%3O5:12W2@!\:@'K5@=*
MJ11L#R:MCI0 M%%% !1110 4444 %%%% !1110 4444 12]*K#EJLR]*K#[U
M %E%&*E'2HD4XZU(* %HHHH *@N/NU/4%S]R@#$GX<T6[-OZ4LOW^:FMRN[I
M0!K0?<%2U'%]VI* "BBB@ HHHH 0U%(N1UJ4U#(IQ0!4V#?UJ]$,+5'8=_6K
MT0PM $E%%% !1110 4444 %%%% !1110 4444 -89%49;4,V<U>?[M9\I;?U
MH LQQB->#56YNF4$8JQ%DKR:AN-NTY%*PFC&ED623YA6K911LF-H/X5AW*DS
M?+ZUN:6I"#- D@N-(CF!^45CW7A029(.*ZVBBPVCSBY\-RVYW*S<>]5!J=YI
MC;0CD"O3G@C?[R@U3GTFUE4YB&?I2LT39]#D;+Q;,2!(I'UKH[+789P-S@5D
MW_A@R$F%=OTK$F\-ZA"<K(P J6VA7:/14NX9/NN#4P8'H:\WAO+G3>)68XK1
M@\8HA 8&FI7&I'<45@VGB.&YQT&:U8KR.0<,*I,JY8*@]143QQD8*C\JDWJ1
MP14$F>QJDQF1J&A17BM\HY]JX/6OAE'>L2 .:]4C]ZEVJW45M"O*.PK'B5M\
M($0YSBM6'X9FW&5<\>]>L"-1T%+L7TJGB9,$D>2S:%<Z;]PN<>]0KXDU#3C@
M0N<>U>M264$GWD!JI+H=C(.8%/X5#JWW"QP-KX^O&P'B8?45M6WC'S,;^*MW
MWA6&3/E1@?05@7'@N[)/EL1]*:Y!G7VNOV\V-TJC\:TDO[9_NRJ?QKRN7PGJ
MT/*S.*B5M0TP_O9'.*3@GL*]CU\/&_0@T-"C=5'Y5YK9^-/(P) 3BMF'QW ^
M/EJ728)W.HDL(W_@'Y51FT)).@ J&U\3PW&.@K5BOXI/XA^=2Z370T522.=G
M\*;\X;%95SX<DMLE68_C7?>8A'WA^=,:.)^N#4V1:JOJ><">ZL#PK'%3Q^++
MN/@QMQ7;2Z9;R_P"J,OA^%ND8_*E8UYX-:F?8>*6G($@V_6MV/5H& S(OYUS
MUUX9E.?)^7Z5E2:!J,)SYK4F[$\L'L=_'>PR='%6 ZGH:\XBENK _O&8XJS_
M ,)DMN,,#Q4NH@=#L=_N'K1N![UY\WC^%N,59M/&<,K#FA5$Q?5Y6.YHK%M=
M=BG P1S6DETC#[PJ[F3IR6Y8HJ,2J?XA3MZ^HIDV'44W</44N1ZT"%JM<H&'
M-6:JW6=O% %6*%0^<UHI@+65$K^9UK3C!VT 2T444 %%%% !1110 4444 %%
M%% !1110 5#.?EJ:HIB O- &6';S>E:D)^2L\2IYF,5HQ'*T7 DHHHH ****
M "BBB@ HHHH **** "BBB@ IK_=IU-8X% &?(YW]*MP$D5"\B!NE6(F!'% B
M6BBB@84444 %%%% !1110 4444 %%%% !3)/N&GTR3[AH Y35'(FZ=ZT=';*
MBL_5& EY'>M#1R"HH W>U%':B@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "FE<TZB@"K*N*C7K4\I%5\YZ5($A.*86)I>G6ER#2!6&$4GX5)T
MII8&G?4;$!Q06R.E (%.)!H>X#0>:<6R.E(, T%@:-@&&I(CS49J2+K3$7!T
MI:0=*6F 4U^E.IDGW: *CXS2 4/UH!H&.^7%1<YJ7 Q3>](!PVXYII]J=@8I
MII"&THI<48-.X[#EVU(<;:@I=S8Q4@-)7?5R'&*I;,MDU=A&!5B):*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@DN4C')J1R0IKF]4GD5
MB!F@"[<:U%&?O4MOK,,G\5<ZL,4_,K8J-A' W[MLT =Q%<+(.#3W? S6)I,I
M<#-:\KQA?F- &?=:JD!^8T6VL0R_Q5E:G';R,?G%5+2V /R'- '8K.DJ\5A:
MJA)XJ_9HRKR*RM9N#&30!9TE2"*Z =*X_3-1 (R:Z%+X,.#0!H4572X!ZFI/
M.3UH DHIGFJ>],>X1>IH FHJ!;J,_P 52"5#WH ?13/-4=Z3SD]: )**C\Y/
M6FF=?6@":BH!<+W-.%Q&>] $AQ5:4'^&DFN44=:I-?<\&@"W$),\U<'2LJ.]
M.>:N17 ?O0!:HJ-I0HR33%N$)ZT 3T5'YR <FFFX3L: )J*A$P]:<)D/>@"2
MBF&5!U-,-PG8T 345")AZT[SD]: )**9YJ'O095'>@!LO2JP^]2SW2 =:H?;
M/GX- &NF[%2"L^&\SU-7%G0CK0!+14?G)ZTAF7L: ):@N/N4OG#/6H+J=1'U
MH S)/O\ -36^W<*S)[P"0\U-:72,_P!Z@#HXL;:DJ"!QY8.:<9XP?O4 2T5%
MYZ8X--\]<]: )Z*C\U<<FF_:8LXW4 34UQD4QIE"Y!JC-J 7@&@"<H=U68Q@
M5BKJ+%\=JTH;D,N2: +=%0>>N>M/\U<=: )**@^TIGK3A,N,YH EHJ W* ]:
M<)TQUH EHJ#SUSUIXE7'6@"2BH#.,]:>)5QUH DHJ SKGK3UE4]Z 'MRM4)(
MF+\5:DE"J2#6//J;))@4 :T2D+S5:Z0[326]V9(\FJEY?A,C- S/G.V7GUK:
MTT@H*YN2<2RYSWKH-,8!!S0(UZ*9YBXZU$URBG[U %BBHEG1AP::UP@[T 3U
M&\*N,$4P3@]#2B=1U-)H"E<:+;3YW**Q[KPO!@E$YKIQ.A[T>8AI60G%'GMS
MHM] ?W ( J*-]4MC\Y/%>C$H1T%4;BT@ESG%"1+1RT&MS18\UJU;?Q%;'&]J
M+CP_;R@D$5@7^B>0"4SQ4N31DY-'8PZI;S#*$5(VIPQ_>:O'M0UR_P!+8K&K
M<5%:>)-1O"-ZM4NH+VS/:H]1BE^Z:LK(&[UY;9:Y+!CS"16[;>++=<!Y0/QI
M*J-5CN,TM8EEKUK<8VR@_C6JEPCCY36JDF;*2:)J*9N'K1O'K5#N->%7ZBJ%
MSH5I<YWH#5]I0.](LP/>CFL,YJX\(61SMC'Y5DW'A/9GRD_2N[:91WI!-&>N
M*UC5:%8\SET348/]4"*AVZU!W:O4CY;=A52:W@;[V!5^UON!YXFK:E#_ *UC
M5A/%QA_UKUUDNAVESG!'-8.H^"[5P3FFG!A<FLO&UHY 9_UKH+7Q#:7(&UAS
M[UYK<^$_(),.3]*JB+4[ _NXV.*?LHBN>S1W,<@X(ISQ)(.<5X_'XCUN'CRG
MXK2M?%^I9'G*P^M9RH]AIGH,^D6\WWE%8&H^%;>3.Q/TJ.T\71\>?(!]36FO
MBS2B/FN$_.LI47V-8U&CAKWP?-D^6GZ57M?#%_$_W3BO0CXGTANDZ?G4L.M:
M;,?DE0U'U=HV6*9RD.F7\(&T&KD::DG4FNM6:WD'R$&G^2C]A3<;#]M?<Y0W
M%\@Y)H74;I3\S&NEFLXR.U5/[,AD/:CE8<\7T,U-89?O-5J+7HQ]YJEDT*$C
MK58Z!#GK2LQ+D9?37;<C[U#ZM PZUDS:,L0RM9=Q!,F0H-)NPU3BSJ8M0@+<
M&M&.ZC8<&O.0UW&WRJ:G74M0CZ(U"D@=*+V/11(#WIV17G#>(=1C'W&I8O%-
M^6PRFJNC%TWT/1Z*XZV\0S-C?D5JPZW$1\[@4R7!HW**S!K5ICF4?G1_;EE_
MSV7\Z!<K-.BLY-:LW.%E!JPM["PR'%)L.5]BS155[R)!DL!4(U6V+8\P5/.'
M)(T**@2ZC<?*U/\ ,JD[BY625'*NY:8TP'>JTUW@<&F(/(&_-7(Q@5B-J#[N
M*L0WLC'FI0:FO14*2Y7)I//7/6J GHJ+SUQUJ/[0,]: +-%1><N,YJ/[6F<;
MA2N!9HJ,3*1G-(9T]:87):*C$R'O2^:GK0 ^BH_.3UI?,7UH ?36&13?.3UJ
M.6=0A(- $319;-6(EP*Q9=0D$F!5ZVNF=<M3L+4T:*@%RG=JD$JD9!I#'T5
MUR@.,T]958=: )**894'>D\Y?6@"2BH_.3UIAG7UIV GHJ$7">M/$J'H:0#Z
M*894'>F&=?6@":F2?<-5VNU4=:IW&IHJ$;J=@,G5-OF\^M:&CXVC%<[?WR23
M?>[UNZ&X91@T@.B[44#I10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !3&)%/IC"@"!SZTP8[4L@--2I8FAS"F#VIS4P$CI0-;$@SWIK8[4H)/
M6@J.U&@$=*!GI1@TH.* ' >M& >E(6S2!L46L C#%.A89IK'=3H4 :F@+J]*
M6D7I2TP"FOTIU,?I0!4<<TVE<\T@I,8M,W<T_8:;MYI7#0D"Y&<TP\4[::;0
MF(!3M_'2@)3N *; C[T[?QTI#UIP*XI6 ;G+5;BZ54QEN*MQ=*:86)****8!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 (PR*R[RQ\T'BM6D*@T
M <3=Z9(&^7-.L]#DD(+$UV#6\;=5IR0HGW10!GV>G?9EJ&_B=@<$ULTQHU;J
M* ."O+6??_%6GI$+KC<#72M90MU04Y+6)/NJ!0 U -G2N<UJ#S":ZAEP.*P-
M3(!.: ,C3]*9VZFNBM]+:,#+57TM@2*WATH I_8SZT?8V]35VB@"HMLP[U%-
M8M)_$:T** ,R/3F4_>-6%M6'>K=% %1K9CWIOV-O4U=HH I?8V]31]C;UJ[1
M0!GM8L>](MBP_B-:-% &5/8LPZU573V4\FMQES4+ +0!06R)JU#9E.<U-&P)
MJ<=* *\MN77&:@2Q96SFM"B@"F]HS#&:C2Q8'.XUH44 53;''6FBU8'K5RB@
M"F]JS#&:C6Q8-G=6A10!5^S''6F&S;U-7:* *:VC#N:5K8D8S5NB@#(GL&QU
MJFMBV_K6_(N15<1X:@"M%8D#K4XLVQUJTI&,5)0!2^QMZF@6C#O5VB@"K]F.
M.M5+NU8H>:U:@N?NT <C<6#-(>34EEIC)(#N-:$H&^GVY^:@#3AA/D[<U"UB
MQ;.XU<A^[4M %$6; =:46A!ZU=HH J-:DKC-5O[.??G<:U** *7V0[-N:H3Z
M8V=V:VS44@]: ,%+9E?&*TH;5BO6I-T8;I5N,@CB@"K]D.>M/-L<8S5JB@#.
M-BQ;.ZIA:D+C-6Z* ,YK!B<YIRV3 =:OT4 4OL9]:>+8XZU:HH IFT)/6G"V
M('6K5% %,VA)ZTY;8CO5JB@"K) 2A&:QY]/+2Y]ZZ%NE4Y'0-S3 AMK4K'BJ
M-[I1DR=U;*."O%5[C<5.#1<#EVL3%+UK?TZ$[!S6;/GS>:V-.^Z*0%LP$CK5
M233F=L[C6G10!1BLV0=32/9,QZU?HH I):%1UI'LV;O5ZB@=R@MDP_B-2K;$
M=ZM44"*WV<^M1M:,W<U=HH J);%1R:KW5F'4Y%:=1.!4N-R'"YYWK7A\3,2$
M_2L^VT;[./\ 5_I7IS6\3_>4&H6TZ%NB"LG1N9ND>6W^GROPB$?2LU?"EY<G
M(=Q7LBZ3;G[R"IDT^W3H@I>Q8*B>4V>EW>EXRSG%;EOX@GM\ HW'M7<R:?;/
MU050GT.W?[L8JE!Q*Y+&7;^)#+PPQ6I#J*2CEP/QK-F\/O\ \LQBLV;0M1'W
M'84]05T=:'B?_EJ/SIX5.T@_.N(6QU.#[TC5*+RZ@^^YHO8KF.S, ?HWZT@L
MS_>KE(O$GD_?)J_#XL@;BJ4PN=$EN5[U%/9M)T.*JP:[#-T(J^ETDG0BK4KE
M:$-O9-$<ELT74&\5<# ]Q4<B[N].X6,N.U53\R@U8^QP2C!B7\JL+#S4ZQ@4
M<S%8RY-$MW'^J7\JR[KPJDP.T 5UF*,52J-%6/,-1\ 3R@[)6'T-<)KG@_4=
M/W,DTAQZ&OHDJ#UK/O-*M[H$.@.:WA7:>HK'RA<S:K9N06EX/O6AHWB34(I
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M[S72TR3[AH \XO='>*;[QZUTF@0&-5R:BU,#S*O:5T% &Z.E%-'2G4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4UCBG4TD4 5I#FF)3Y2*C4
MX-2 ]N::.*<?FZ4W:1UH&@+9I <448H"PI?--I<9Z4NW%%[ (!FE*8H'/2@@
MT ,-21=:CZU-$IS3T$6ATI:0=*6F 4U^E.IKG H INIS30,4]WYIF>:E /\
MFIG>G;CZ4W/-%T [YJ;WI^\XZ4W/--6 7YJ:<T[<<=*3-) ,VM2X(ZT_>?2F
MDYIIC!3S5R+I5->M7(NE"$24444P"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** $;I7.ZLI)-="QXKGM4<AJ %TE2"*
MZ$=*Y_2FR170#I0 M%%% !1110 4444 %%%% !1110 4444 03%_X:IMYQ/-
M7)7*]!54SOG[M #X%<'FKHZ54AD9CR*MCI0 M%%% !1110 4444 %%%% !11
M10 4444 12YQQ54>9NYJQ.Y5>!5-;B0OC;0!<C4]ZF'2HXV)'(J44 %%%% !
M5>Y.$JQ5>Z&4H Q)V&XXHMMV^FSJ Y.:=;,=^,4 ;L'W!4U10?<%2T %%%%
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MNPI, ]JGD06//I=-O8?]4IJE)+K,/0-7IIC0_P (JO+91R?PC\J7);8EQ['
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M'FDXI*: 7-)2\4NTTT#$4\U;CZ53 PU7(NE""Y)1113$%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44A.!FJ%U?I""": +Q=1U84H=3T(KCKW4
M)W;]TQQ4MCJCQX$K4 =;15*VO4G'!J2:0J,T 6,CUHR/6N9O==6U;#&K&G:W
M'=8P: -YNE<YJWWC6^) R\5SVKQLQ.* 'Z3U%=$.E<YI",I&:Z,=* %HHHH
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MU7(NE4U S5R/I30[$E%%%,04444 %%%% !1110 4444 %%%% !1110 4444
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MWSDUU?A^\-PJDFO/D\(M:RC+$X/K7?>'++[.BBE*UM .J'2EI!TI:S&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4QB:?36- %:0^M1 \\5++S
M4:CFD)MC@<]:.!TI=N:3A:D:8A)[TF<=*=G=2%0*8Q0<]:"!VI!S2D8[T (
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M44 %%%% !3)#\M/ICXQS0!1,GSU=B.5JL3'OJU'C'% #Z*** "BBB@ HHHH
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M[W\:T-(/ IZ!H;@Z44#I10,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M;W8=>M9NIC>:MV-NRK\PJ/4+:1ONB@"'2_D(S70*X(ZUR*QW41X!JY%-=>]
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MKZHX\W\:T='.5%8QM+J9\N#6_I=NT0&13%U-<=*6BBD,**** "BBB@ HHHH
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MX02N,U8E#" <]JPKA6+G)H EBU1GEVD8%;-N8G4$D9KFA& <@\U,L\D(R":
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M=Z;O]*2D,4J3TI.E&\T[@BA!L,'6K<72JG\7%6XNE-"):***8!1110 4444
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M ,NTLF11N'-:2+M&*?10!%,F]<5FFP8R9(K7HH SWL4:+&VLB?1"SY"UT]%
M'-6^DR1OTK<MX/+3!%6:* #&**** "BBB@!",U#- &4X'-3T4 <]=:=.Q.S-
M4ETFZ\S)SBNNI,"@#,L[)HU&X<UH*FU>*DHH K.CFHFM=PZ<U>HH P[BPE8$
M#I61-X?>5\E:[.DVB@#E+70WB(^6N@LX#$H!JW@4M !1110 4444 %%%% ",
M,C%9]S8)*"=O-:-% ')7.DW.[]WD"K%IHQX,RYKI,#TI: *D-HD*X48JG>V]
MPX.PFM>B@#AKK1KZ63()K7TG3Y[<#S*Z' ]*7 H 8H(%/HHH **** "BBB@
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M:\LUN6%+HY0'F@!;?4;N]&[Y^:O0?;/,'#TS2-1@7:/)_2NTTZZMI,9A'Y4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %&,T44 -V*>PH\M/[HIU% "  4M%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)FEH **** "BBB
M@!ABC;JH-*L:+T4"G44 %%%% !1110 449HS0 4444 %%%% !1110 4444 ,
M:-6Z@&F&UA/6-?RJ:B@"-8(T^Z@'X5)110 4A /:EHH B>WB?[R _A2):PH<
MK&H^@J:B@ QBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8\:N,
M, :<3BF[Q0!#]A@SGRU_*I5@C7H@'X4_-+0  8Z4444 %%%% !1110 4444
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M2Y'>G84B@1!YV.,4\2Y[4I" \BC*"D ;_:F$\TXRIZ4S()XI@/#=L4NW=S2
MJ!2%N>* $(Q2?A4@8=Z7*T[L1%YN.,4X-NIQV'M2;?2A#%#8[4TG-.X'6FG!
MZ4+< \S;VHWYIN!0,4] N2!\#I36.33@5QS36QGBDQ"J^!TI"V>U*I4#FD8C
MM0 H;':D+9[4JE>]*2*!B!L=J0MFG K36(/2EJ @DQVH+Y[4HV]Z#M[4PT%#
M8[4%LT @=:0D=J.HA0V.U(S9[4H([TA(H; %;%*7SVH!%!([4+<8!L4%L]J
M1WI25[4=0W&;]O:G"7VH&WO2X4]*/4!?,]J86SVI^ .M-8BEU 0-BE+9[4@(
MIQ*T^H#=VWM2>9GM3@5[TAV]J+@ :G;QZ4T$4I*]J!#MX]*:6SVI 13N#TH
M:&YI2V>U*%QUH)':CJ S=BE\S/:E &>:#M[4,8@-*7]J08I25QQ0Q"!J4O[4
MBXSS3B5QQ0DV T'FG;^.E-&,TI*XH8PW4I?(Z4T=>:<2N* &;\4>=GM1D#K2
MAH_2F(4.:&?CI3MRTA*FI&1A^:D#^U, &:>2N*; /,'I07SVIG&:D!6A"(\\
MTN:?E:3*GI1J.XTMBF>9STJ392C8.U.Z"[&\XIF>>E3Y7%,WIZ4KC&K3M_M3
MMRT96AL0S/-.W^U'%&5Q0PM89FG[QCI3.,T[>F*$V F>:=OXZ4S(S3MZXQ2
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MRE]*=@*I;/:F\U<\I?2E\I?2@"ES1DU=\I?2D\I?2@"H 32E2!5L1J*78#2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0F!>WBE# U14R=Z?N<4[@6RP%)O%52[=Z8S/VH N[Q2A@:H!G[U(':E<"V6
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MP&[S'T&:>)B>HH!'<4NT'I2U :93Z49SUIW"]11C/2BXQ0<"HVY-/SMI"-U
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M0DFE5L4IP:$ T-BG;LU&3BE4;J&&P_=BFDD]J=]WK3P0: 9$#CM07S3GQ4=
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MY[T#/:FE\]: ^.E+4+CB#WIII2X/6FY':F ]<=Z&QVH7!ZT-CM2T$(N.]/\
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M]+]GJQ12L!4-IGO2K:XJU13 K?9Z7[/5BB@"H;3-*+7%6J* *WV>E^SU8HH
MK?9Z7[/5BB@"M]GI?L]6** *WV:E^SU8HHL!4-IGO2K:X[U:HH J&TS0+3%6
MZ* *AM,THM<5:HH JFUS2"TQWJW10!7^ST?9ZL44 5#:YH6TQ5NB@"J;7-(+
M3%6Z* *IM<T@M,5;HH JFUSWI!:8[U;HH JFUSWI!:8[U;HH K_9Z3[-5FB@
;"O\ 9Z3[-[U9HHL! (,5($Q3Z* "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image6.jpg
<TEXT>
begin 644 image6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0M!W@# 2(  A$! Q$!_\0
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M7(QFF%03Q^-+].E " C=GUI?N@^]-.,^U*#NX-%@%C(Z4XL%.*CQMI3@CWH
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MM+BA;JH%%:J*$7 HKI1P-W8.,K6>ZG=CM6B1D4SRQBF)%-5/I3MA;YCVJX$
M'2EVCTI6 H$,3G%&&':K^T>E)M7TI6 I;3FAE(.*O;1Z4;0>U.P%#!]*,-G.
M*O[1Z4FQ?2BP%(AB<XIIW#M6AM'I2;%]*+ 4<-Z4W#$XQ6CM'I2;%]*+#* 4
M^E(48G.*T=H]*-H]*+",]@P7(% #8SBK^Q?2C:OI0!GD-GI3L-C%7MB^E+M'
MI0D,H8;TIN&8].E:.T>E)L7THL%R@P;&<4AW #BM'8OI2;%]*!% @\8%+@XZ
M5="**"@(Z46'<SQN+=*?AO2KHC4=J=M'I181GX-&#Z5>\L;LXI=B^E*P&>0V
M>E.VGTJZ(P#TIVT>E.P&=\QXQ0 W/%:&Q?2C8OI18=S.",3G%/PP[5?VKZ4;
M1Z46$4-K>E(5.,8K0VCTHVCTHL!GA6 Z4?,<\5H;1Z4FQ?2BP[F?\VW.*52P
M&<=:O[%]*-B^E%@*&6# 8ZTYMRG:!UJ[L7TI=H]*5@,X;MQ&*%W9Z5H;%]*-
MB^E5T$46W$9Q3?F SBM'8OI2;%]*5AW*.&]*-I]*O[1Z4;1Z46$4-I]*4*2*
MO;1Z4;1Z46 H;3Z4;6]*O[1Z4;1Z46 S]K#M1M;TK0VCTHVCTHL!G_-G&*7:
MWI5[8OI2[1Z46 SBA)SB@A@.E:.U?2DV+Z4K#* 0]<=:7:WI5[8OI2[1Z4["
M,_YLXQ0-Q)R.E7]B^E&Q?2BP[E!@P&<4X*=F<5>V+Z4;1C&*+"*"AL]*62,]
M*O;1Z4;0>U*P&<BMG&*=M.:O;%]*7:/2G89G%#G.*4A@.E:&U?2C8OI181G@
M-CI3ANQC%7MH]*-H]*+ 9WS;L8IS!F XZ5>V+Z4NT>E%@,\JP'2D"MUQ6CM7
MTI-B^E%AW*&T^E 0CM6AM'I1M'I1810VGTHVGTJ_M'I1M'I18#/,9)SB@A@.
ME:&T>E)L7THL!GJA'..M!# XQ6AL7THV+Z4 4=IHV$]JO[1Z4;1Z46&F4-I]
M*38<YQ6AM'I1M'I1810VMZ4%3Z5?VCTHVCTHL!0V$\4A0^E:&T>E&T>E%AW,
M\H3VI=I]*O[1Z4;1Z46$9^PCM05.,8K0VCTHVCTHL!GA"!C% 0L>1TK0VCTH
MVKZ46&F9^UO2G[#LS5W:/2C:/2E81GJC9Z4YU(Y%7MH]*"H/:G8#-VM][%2%
M"%!QUJ[L7'2EVCTH&9^PGG%+AO2K^T>E&T>E%A%#:?2E&X#&*O;1Z4;1Z46
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@_>!JFG7]T?I3PPS56_G$4)H JVHS(P%63;%VJGI<H:1B:U]XH 2./8,5)3
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M  ';=3MS&FBE!QQ3 7+$9IK%B,4[=@4G/6D X;@F#U[4P,XZ]:=NS^%!R:-
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M)S3V.4HW*!30X)SVI *LG:A^HI!C- <;L'O2L XG<<4P\&G.X#8'6D)&*:3
M<#D9]*0'YLT+*N*0,-V>U"0QP/)IH.,^].##--+J#]:8W83=_#3M^!BD5U!P
M>M*Q!I6$,SS4F?DI"1Q1D9]J; 1>.:1C3@1F@,O.:!W&Y^7%!;*XIY*[<TFY
M<5)-QN>,T*><TN]32@J>1TJK-HKH(32!L TI90>:1V'&*0F*KX%,/)S3^-N*
M174G%*PA4;;VI'.>:"ZYI<C/M3'8!\HS2 X!I=P'7I0I&#1U$ ;C%#'(Q1D
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M#MQ[TA;<Y7TH:1>E-\Q5//6A("0-CCTIA;)S2>8&.11N5CD4(!_^U30V#07
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M)NYS33,N>.E*'4<GO2L !NM+OXQ3&8#FE212,4 2#YEI"W/3I33(.@I1(F*
M0C-FFY-.WKG/:F^:NZ@!P; I*7>H_&C>O2@ +<8I2>!2;EZ=Z:TJY ]*!C@?
MFIWF=J;O4\TT2KNS180\'K[TV@2KS0DB]#3>@#MWRXII/%*74G H)'% QF>,
MTY&[T[C.<<4FX YQ0 9QGWH#?+BE!&#Q29&.E*W409XI=_'2DR-O2@D8%*X6
M%+9.::QI2P!SBFLP/-4@' X&:=G<<5$6P!2AL&AA;4>QP,5&IRWTIY.:#C'
MH78!=W.:-^&S34/.:5B#TI#L.4]32*^ :!P/K2%<'ZT"%/)S2D<4W<,8I"^[
M@=J8,4M@YIKMQN]:F2/>N:7R#GGI4V=Q$2G"Y]: W&*G\GC%,\@T#0PGY,4W
M?D?2I?(;%.\C ICT(0VY=WI2*^3FIO)YP.E'D[6]J (<Y-28PM+Y!SFG/"QH
MU$0JVX[?2DWY;'I4_D$#CK31;G.:8$9;FEW_ #9J?R1BF^1\U&H$8;'XTA;
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M?!Z\56QCBG;?EQFBPB<7'/)IC3D-G-0A>>:>4W"@=B;S]PSGYJ:+AB<9J$(
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M>U0[,KC-(J8R:0*),;AL]:<9SLX/-0!=W)HP :&@)5N&+=:5YSV-0A1SBC:
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MK2,,C%' &* '^<S#K37D8+FD "T$ C%  )VP,&G23D8"GKUIBH :5XEZ@T6
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M7]T4 8:AL'CK2 E3C%;WV:/'05#):+LR!S0!E,,BD*;H\YZ4Z=2K[:09"XH
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MQ':DC^[2ALDBKN #.*8A/F>^:7S,'%*GW@U(#?M\^4,U+45N<Q"I: "BBB@
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M/X4AR3]*D\S/;I0 P9'/\5(>N1UIZG+[Z:W#[O6@ <MCBER=GO03C%&[YL4
M!)VBG#I110 S)#>U*I);VI6&1BF;B.,4 24$_+@]*:6Z8I6&X8H %YX;IVI"
M[#K^%!;< OI3G^;'M0 BL7Z]:1\BE4;7W4.W.<4 * 2**<K87ZU'N^;% "#.
M3FE4G)S3J0],T &.<TC9[4F[C/>I$.!TI ,;=^'>FX_[Y[U*#\K#UIH'[LKZ
MTP$7.>>E.I V1MQ0WW32 3)+>U"YW>U)&.#3Z8#&R3CM0>/E_A-*3@XI&Y^6
MD@#)(P>G:A<X-*3N7;Z4 \?2F@$4$\FE;.!BC=QFC=QFD -GBE P*0GI3J&
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M/45>KSWP7XHM[N".$N-V/6NX%[%C[PKTX5$T?&XC#SIS:L6J*9'*L@RI%*7
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M;KS1D'I2K^\R::BX;% "T@7!S3]HW8S33P<4 -(!(S3LY..]-(R0:51B3=0
MTC!XIT9'(]>M*O#$^M1QQX8\]: 'JJF3:3\M-8#?CM3_ "OX<TUD[4 .[4F1
MG%+T%'E_QYH :<-Q1@-^% 7G-"C% #C2$;J:QR=M/' Q0 T@9&:7 W TA&2#
M1CY@: %"X.:15VTZB@!",C%(0,8-.J,G<<>E $R@;>:C8D#BA3GBI-H*9H C
M5>]-Z'CO4S+A<U&%X- "*!NVG[M(>N.U/6/=\M,(RVWTH <I[&G4TKG'M3J
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M(U5:M?90>3UJ>WM.,DU,Z@_A639>Q3%LG7O0L(R:G"?-FK'V?"Y]:#2+,V4
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M97'ERN<9%54MDD&,552T:WOPP!"Y%>GAJ[YK'+C*$.0^B-'O!>64<GJ*OO\
M=KG/!S[M*C_W:Z.3.WBOH:;O%,^*JJTVD8-US<$=Z;VIUU_KSCK4;9X_6K,B
MY;9QD59!YYJM:'M5O W>U)@-VD$GUH+?)BG9SD?E2;<+DTKC!%.W-&#S2[OD
MXIH:C<!,FEP=N:0^O:C=D46 <>@I#D49-!.>M  !FCD&@'%*V.* $ZN#VH8\
MTO 84AQNH :O!YIP))I5QSF@ @^]%P$.0U &<T'K[T XH !D"C;QFCJ.*53V
M-,&)GCFFC(IQ&#2K@K[T@$<DQXK-;[YK1E&V+/>LYN6- AG+-D4YD<C(/%
M'2DWD'!Z50 8WP.:4JP&":-[=_PI"QQ\W6@!"I*XI1&KC"#![TJ9*TJG83B@
M!JQ+ <FHYK>WF/F,F2:?([.:=$H*X:@!D"HJ,@'RTV.VMXF)V#<3FG*,,P%
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M9DD9S0 ;R!MIN#G;3E.[G%.H C ).*>>!2T4 (IR*3[AR.<TI.T9HCX;)[T
M,.0<>M/ P*)1AL>M)N^7RZ &YW'FE7YCS2=>/2E'S'- "Y._% )+8IU-#9-
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M4RV19<YZ5 V5R,=*  #;Q2,<=*1<LV?2F[L/0!+U%1XP=O:G%L$8[TC')Q0
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MA*<9*YMV:KCFM)S"D>0!FL^V4"$D]:9<S#9@'FN"2N['%/<DFG5S@&H X,@
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M2JI3DTY^5XI -*\#FD(^;&:-IP.:4H1S1N [8/6AD# <]*9@XSFE(.!2 <%
M/6D<#/6FJI+[L\4.AWYS3MJ $>]+MYQFF!"#G/6G[3G%,0NSG&:0+G/-&#G%
M( <GFE=#'*N>](RX'6@ XS28.,U3$*L??-+L'K2<@?6F@'IFI&/>,&/K6:5'
MF,,]*T90?+P*S'0LYYZ46N(:5^:G4GEDG(/2DQ\V:H!U%%(>10 C#<*6/G(/
M&*6-21BFNIW<4 *4!^;/2@G]V#ZTA!R.:-OS'TH 0C:,]<TJC H"G)S0HQ0
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M1]]J7;\W7B@!,  -ZG%/>,)CG[U1LI+>U/))&#0 JH%.,]:4C!Q35!7J:6@
MHHI=O&: $H/(Q3).@IXZ4 , YV^M*R8&,T,>PZTF#MZT *PX!]*0#<<TG)_"
MG!OES0 ;?FS3N*8N2<TH4_-[T .S2(F7)S2;3MQ3><;: )"@8YSTIK' H(/'
M-(5YS0!<M/F6K(B'//6JML#VJQM89YZT@0]8@!UHQSBD4'I1M.<4A["[>O-
M7(SFDP>?:C!QFF %>.M!7@<T%3C-*5.!22$+L&.M(PR,>E!4YQFE="4 '6CJ
M W;OP,]*D &<^E1@$8&:613D$4# CYR<TG>C!QFF@'-,=R3;2;<MC-.'3'>F
MX.<4(0!>3STI3\PSZ4T DFG <YI: "C'-)LP<YZT[OFFAN32'>Q,J8A(S7DW
MC A=5;Z5ZP 1"V:\=\8DMK3 'M65;8Z,,[2,\.&C457DCYSFDCSL%3JA89KC
M1ZR5R*-.,FJ=SA7X/6KLBE3P:HO [.33-5H1I!O%6$CV#;FGPPMMQBK LG*#
MUI]2W(@-J6&14T5J2,GM5R*+"!3U%2E J\4"3,R6#G-0RCRX_J*T'7G-5+J$
MNG'I0]A-F&,/,1GO74Z/ .F:Y0Q-%.<GO74Z-)D=:EHS;.G$05!@TH7!S4,;
MD8R:DDE':E8.<EA_UX;/>M1R!&/>LB'+$-5UF(4<T6)YKLB<;&(]:IW 7D9J
M>=^V>:RY]V2,TTC1=S.NV\V3'3;5.4B0<\8J>Y!#<51F.7P.*&S4@D)0<576
M/[2X]JM3 "(YZU7L5*R$^]3<B1L6D#95,9%;TVE?9K/[3GH,U6TYDW("!FM[
M4F5M.:,$?=IJ1S2OT.$N(Q,Y:J%Q:[AFM01'S&SV-03H9,A:JY<7H<^^G!_F
MS71>'[R.Q0JP!YK/-I(&I5M70YSUJKEF]J&O[XS&B\&L2*/>-QJ=+8L,-UJ8
M6I0=:+A:Y5\DBM#3PML1*W:HB PQZ4DJMY1P:=R)QT/6O#6JI>6\850,@5MR
M1;7SFN+\"QD6L))["NV?@G/>NN#O$\6LK38S':D(YQ3E&T8/>FX.<59DRY']
MP44L8P@HJA"2?<.*I@MG%77^Z:I#(;-)@ SNJ*X!89JQ[BJURQ7@=*2 H8);
MGI0((U.X 9IX^[GM2 -G)'%4 B8"D'K5 @_:L=\UIA 1DUGY'V_\:B:=KCO9
M$VLJ6T\#OQ6#%^[MI<^E=%J;!K;%<Q<R8^1.C<&O Q6%E5EH<[QL:.YFQRMY
MG7C-:2PB9>1FJHM<'BK-I,R2;6' KR,3@)P6QVX;-X2ZD,]JT:' IUE8O(HR
M*O2'S1@5=M4$4 /\6*YZ5%K<>*QRELQD5A%MP4&:AETJ&0':@XJ_N(&1U- D
MV@[><UN]$<,<8[E"+2T2/[@JQ_9,93)0=*MQMO&#5C<<!<<5Y5:;3/0H8MM[
MG):AI3H"RKTJK"&C0;^M=O+ DJ8:LJYTF,@E>E91K-JS/46+TU,<HT^T)ZUL
M6]BB*K%1D4Z&P6$*16D4'EU$Y,R^L\S*#CY\]JBW#<:EE;#[148C&>:R4939
MI[1)794N.E8]QGS,5L:BZPQYS7+W5ZYDR*]?"Y=4DKV%',J<':YJ6Q^<8K<M
M@=O%<_I[;F4GJ:Z.W^5>.]<^,P\J;L:/$1J:H>WW:JG[U6W/RU3)^:N%092D
MEN2G[G'6H3N"G/6IP/EJ*7A">]7&E)O1$JM%%:<_+QUI(5+#GI3G7*YJ2#:4
M;'I70J$TBUB(I;D<D2["<<53N?DA)[8JW,Y$3#M63?3OY..U>KE^#G4>J.'%
M9E"$=S..9YMO7FI)M,<1;]O-%F 9@>];@+.FTBOL*>5M0V/DJV?N-31F!:QE
M) &ZYK7 QMVU'<VICPZCG-1&X,8YKP\9EDW.R1[V"SV$H:LGG)7FJ$L@P2>X
MIL][YAV@\5#@R_+VK3#Y-4M>PZ^>0B]&,C8E7![U7L@(=71SQQ5QXA$,U5<8
MD$HZBG7P,J70T691KT[)G=),)+=3G-,FES@ UGZ3<>;:[2>15H8.>>158565
MCY+,'[Y/$OS^U6C@ 5GB<HGO1]HD8#CO6\Z?,>8IM%FXD(P,]::JE4WGK32&
MD921TI;F79#BN6K3M%G51J>\5]V^;-667Y/EZU5MQN8'WK52%25_6OF<8G<^
MGP4]"IY7[@LXK(N83*_R"MZ\RH\M>AIEK9HW)KCY^4^BH5K(YE[*5%)8?2I+
M!FBF^>NN;34E7!K(OM+\ALH*TA5Y]#26)0KSC9D&L9T:2Y)[9J<NP;8U1/)L
M.5KNPV$G/H83S"G#J-G@4#)%9\J$Y Z5=$YD?:U++"%3(K>>'G2>IM#'1JQT
M95T)3'K4.>[5[&F3:KCTKQO2Y"-=@!_O5[%$W^B*?:OHLLE>)Y.)=Y7,BXS]
MI/K2.=P&WMUI;@YG)'6FC _'K7MHYMRW:-V[5:<@<G[M5K8+NP#69XGU&73[
M56C%2UU W1DJ".E)NP_/6N5T'Q*;RPN7<_-$*I6'B>6]UT6X^[@T= .[)51N
M/>F':_*8KDO%?B"73(5$?4URMIXYOEE4.ORL?2A"/5QG//2G%T ZBL_3=06^
MTP3@YXYK@==\975KJSVL(S@>E+<9Z5NWG@T\DA<&N"\,^(;Z[D(N$(&>.*[D
MON"D]2*8@R>E//S*,4S&:<"5I,!1D-BFMN,GM3BW[P>E+_$3VH&(I[&D.=U-
MSES2[B30%@YW4#/-*"=V:3.":+  SBCG'M2CI2CICM3$,;.*:F>]/8YX]*04
MACVSLYK*FW>8VVM21CY?O67(3YAIH0(6 YIC!MW%2 $C--W8;GI3 <.@HIHS
MS^E&2!SUH <&YP**CP?O=ZD'2@!ISNXHYW^U./'!HH #TIHSM- )R:%)/6@!
M,'9[T$' I]-8D$4 (<YS0,EL]J<_^STIHR/]V@!1G)H3(ZT DYI5)/6@ WY/
M/6EP*:JYEYZ4X]30 UL[N*=11UH 0G%*.:0KNI1P: &E3OP>E#@\8J1R&7(^
M]3%^8>_>@!P4D9I*4-@8I* &KG=S3J*:2=W% "MG'%(<[:5N!Q2'<5X% #E&
MY<BF$D-GM2JQ48'2D(+?2@!.^33L-MYIOL>U/W[NM #%#9YIS+Z4ZB@!A!R,
M4,3GG[M/I",C%  ?F7':D0$=:=T%-!)S0 ZFKG=DTJAB.>M(Q["@!00W%-YW
M8_AHP5(QWI] #=K=^G:@;CD'\*>6RN*8A.<^E  ,K\IZU(64C ZTPX9\]Z1<
M!LYH0 V<@TN"?F[4H4N, 58@MV;",.*8%95<GVJREJYY(JXEJ V/2K80 8IZ
M!8J16R[!D<U92)4Z"G@8%+4L!,4M%% !1110 4444 %%%% !1110 49'K52^
MO8[.!I'; %<--XTD^UA$.5W5C*O"+LRXTVU='HE%8^E:S%>H/F&[%:X.15PJ
M1EL2XM/4&4,.:C:(%2,5+15B,R>S/EDJ.:H-$ZC!ZUT) (Q5>6V5B30!C*,4
MUPV>*M7%NR<J*JC>#\PXH <N=O-(P)8$4,W&12Y^7CK0 F&9Q0^<X'44J/@\
M]:1N6R.M "8+].W6I.0F>U1JVSIWZT_)9,#I0 P?,2>U"@\BG ;5IW((- #5
MC.>>M$@(XIS.>HI Q;DT (HXHP.E*XQMV_C1VS0 =!31GFC=S[4!NOZ4 -R<
M8[T=L=Z.ISWI=K=<<T *<\4K' I1TYI&&1BA@6[,C&:LYR2/RJM:#C%6""#F
MI >%.WWIO/XTX/\ +3-W.:0P /-'.*4$\^] /%4(0YVT'/%*>F*0]!2U #G.
M*>20E-)YS2LV5H&,8,V,5( <C-(/E Q3B_S4,!N<-CM3<\TO!>@ 9.:  9SS
M3CZ#K29SSWH'7- ;B#.:5O4=*:#R<4Y>F*&"$4^O2D8?-FG8Y]J<0,"D XY^
MSM7COBQ2=;?Z5[)_RQ/TKR?Q1!NUIS[5G55T=.'>ISJ*<4\OMZ5;^S84<55E
MC^; KE:/5B]" DLV>U3PA<<T)%@<U8CA!I):FJ+%O;J5SBIY%"I@=:EM@%CY
MZTLJ#;N[FBPFS(<L'.*7YV.>U71 KG-*T*H,"F44,?-STH=/EI75@^ .*>%+
M#!H9+.;U")A(<5)IMTT6%)YK9NK$2*6Q7.7*M;R\4C-G=6DPGB3:<D=:T!$7
M8<<5RNBWK;5 _&NPA;(4CN*$(G6+8,@<579R6(S4TDQ''\-5F(ZBA F03*^_
MFJ4V[<?6KTLA/)J':)!GO0:19DSH2*R)VVR5N7G[K-8,R//(=@R,U!IS:%=W
M:1^#Q5RU@8<D5:LM)=RNY:WDTC:@)%%C*4]"A K( 15E[F1_E)-6EME"X[TT
MVA5=^*6QDUJ9<B$GY?QJ(18Y(JQ*?+<XIJD/UJS2*L0-&I^;%)';ESTXJYY:
M8QF@L(AQ3**\D?EC'>H,MT-2R3;SD]:KL],KJ(W7CK44KD#K2[F!R*BE(*$T
MPDM#T?P.Y,40SQQ7;2@[OQKAO @/D0GM@5W4I)-=5/X3Q,1\8U^HIASN]Z4D
MYI3SSWJSF+D?W!11']T458 YPIJENYS5U_NU3[Y[4F @;!J*XX0CUJ88'-0S
M$;3FA;@9S2;8MM98U[,WD[>E:CIO4XZUCC1R]SO'KFF!I+=EESBJ(F/VW=[U
MH"W 0#'052$.R\R>F:3V%)VB6-3EV6A;U%<S&_F.2>U;^N-ML\]JYV$C)K7#
MX=2=V?'YM7<678SN:E,&6-1QM\V!5H'=P*RQV&@T>7@\;-2W"!-IYJ^IPFZJ
M\6"*G'3VKY3$4N1Z'T5.LZBU'C@9]::OR''7-2C!6HT&"=WX5P2O8ZJ;)T&.
M*EW\@8J",Y:K>U< UX^(C)['IT+"O\P ]:8PPFVI&&<8[4R7A:Y()IZG=*2L
M1/\ *!]:F;[@]Z8,,.:ANYQ%&:[J&'E5>QR3Q$::YF59\)(3FJ;788D>E4Y[
MQI'* \U7;<00#S7T^ R:3LVCR<3G44K)D.J79E(7T-9#>M7;A<MD]JJ-]\>E
M?<87*81I['S]7-92GHRQ97>R51CO79:?B6/.>U< \@B8-[UKV&LE/DSUKP<S
MR7G=TCW,'G"C&TF=3<L$.,UG>:#)^-53<23,#FD2-RQ.>E>1'(Y=C:IGL>YJ
M-.!'GTK.N=0"QEO2JTSR;6 -9,Q?/)XKT<-D6NJ.6>>::,O_ -L%OEQUJS:W
M1"L<=161:1@R9(K<@C1D.!7?/(XI:HY99]+:XU[@R1E<53N_GBVUHF)5B/'-
M9UTP*8%=F RV--Z'DXG-YU-+E2TCVS@^E;L4F2.*Q[8?O0:UQC:"*]JI344>
M-5KMN[)+@!D K$U*+8N!WK:9_P!W67?,"O-<\<-&;NSIH8Z4=$8BH5;%783Q
M]*K?QU:BQ7HPPL(Q-JN+F]0F;SAZ8JG(,+5V48'%497&[%>/F>%3BVCULMQK
MV;.DT*#_ $<OGM5M%S(<U4T5R(/8U?F&P9'>OCE>$['HXNTE<5H PSFIA&J0
M@U3$K!>30YDE0;3WKTZ:31XDIV98-R <8JO<2^;Q2.A5<FH V7K#$05C?#S;
M9=M%VBM.#H:H 8A4CUJZARH KYO%45*5D?386JHK4&7>V#4D"X?:.U9VK:G'
M861S]_/6HM"UA+Q>OS9KAJ9;4<;I'KT\7%'3+SCVJCJ<JHG-7)W$-FTV>@S7
M"ZIK1N)_+0UUY?E4Y35T<V.QT:<6/G??.2*8\6 #ZTZW^:($]:DN#D*HK[_!
MY5&,5='Q&+S>;>C*GE?O U3,=T>WTI&&!BI H$.:X<SP$8JZ/1RC-9R=FS(M
MG\O7(#Z-7K]E+YUBI]J\@.!J\##LU>LZ-('L>.P%<. BHL^LY^=)E2==EP3Z
MTA''UJ2Y'^DGTJ(N.E>RF(M6@VFJWB:T^U::!Z9JS;9[U=D19+9@_3%)@>)1
M7[:-+>6__/7C^5;O@JP:;43='L*Y[QD$C\11J@X+\UZ5X(AB^P%E S@5*#H8
M/C1/.O%C/ K-O-#CBTV"4,,E<UH^/V,$HD'6N/AUJ>Y,4#,<=*=A'HG@Z1O[
M"F0]CC^=<F+!;SQC,'/&T?S->@:#8"UT$^KC=7ENLWTECXJE,9() Z?4T#/5
M;/18H8D9&'%:RC>H;^Z,5Q7AO5;F[50['&:[C:0JD=".:0#HN6--E;YL49QT
MHX)YHL >U*3\N*5L!Q]*0?,W% "*N:!US2J=A(-&06HZ@.Z?-3,\TN>?:@$9
M.:!" X7%.7E<4@QMH!XP.M #3UQ2J.,T&D!R.*+#',,KNK-?_6-6DQVPUF/R
M[4T(<&PN*B;YCCTH!*G!IV1N([TP /D8QTIK'>=WI2@C)IQ92.* &[OE!I0>
M,T@PRT[VH 8S;SN]*<IRN:0KSQTIW3B@!JG)(IQX&:,"B@!N[Y<T,W ]Z=@8
MQ30O/-  &VKM]:,_+Y=*PR/>E7 3GK0 U3QCTI5.:12"2*7A10 F[YL4ZFY&
M-U!;&/>@!QY&*11@8I:;N^;% #J0G S2TTC+Y[4 *HP/,_2ESY?S?WJ<SJ/]
MVHW8'Z=J '=>:;N^;%2*1MIF!G- "TUFVFE#9.*"!C)H 3=\N:4/M'3K0,%:
M7*KU%  ?W8V^M(K[1LI#\K?-SGI2-R<#K0 A^8X]* -QSZ4\# HX44 +13=P
MVYIP.1F@!I;#8I6.T9I"1NHD^[0 H.1FA&^;Z4+]VF=\CM0!*T@4[JB/#;O6
M@?,<]J>Q % "Y^7-(&R,TC, *0.,X% #Z:S8( H2-Y'P*LQV;,PSVH J[3NS
MBK,-D7.?6M)+5!U%3JBKT% %2"S\LYJT$ -/HIW ****0!1110 4444 %%%%
M !1110 44F::\BH,DT"NA]12R"-22:RKOQ!!;;LD<5S.I^+%E^2//)KCQ&(5
M.)<5<H^-=??=]D0?>SS7)6,+.^6-=)':KJDXDD&3[TR?2S V4&,5\MB,>W,]
M"BHV%T2Z>RO$!)()KTRQN1/"#[5YW9VPD/ ^8=*ZC1[DV\@@<\GI7;@L<W)(
MQKQ6YU -+35.12@YKZ6$KJYQBT4458#'0,*HW=K\G%:-(5##F@# ,11*BCZG
M-;LMNK+@"LRZLV096@"NR_QBD1MIW>O%(K'[IIX79\QZ'I0 QQL8#^]4F?+&
MSUIH(S\W/I3FD4#GK0 ,=R@>AI7?Y?I30<C-,)W'Z4 .4[A3J:GW\]J4\R9[
M4 /5L CUI"<H5I,9.*1OE;% ";/EQ3>OX4_=SBC@ T -!P=WI4BOD[L5%[]J
M>,8H &;YOK0>E.9, $TQAE>* +EH,BK><@CTJO9?<QWJ<_>.*@&-QQFEQQFE
M/(R*%X&3TIC$!P#[TF?EQ2Y'-  (QWI@)GY<4$\"G8_A[TC8X'I2 4\C-(1Q
MFC<,^U*S@C%  1@"DV_,!2@C'- /S<T:@)MYQ28Y(I6;GBFYYH >B\YIQ&#F
MD'J.E)N^:BS 2,<L?6E[$4@;!- Y&* 0HY&/2C[W'I33QQ2 G-("T/\ 5&O-
M?$,>=8<^U>E XB)]J\YU\_\ $V=CTQ4U-C:@[2,PPC9]:K&SYJT&+&K<079\
MPYKFL>E&1SMPFU]GI5B!,H#Z5)?*HF)J%'+<+VJ#=/0E:XPV/2I?,WK5=DYS
M3XS@Y[4#N30(<FG2KM.*F@95!SWJ"5_WF*+E)C/*##%(8N/I3SE:D5=R4"95
MSN&*Q;^QWR%JZ!8L9-0S0>8.E3<AZLPM+C,$K#WKL;*3$(KGH[?RICD=36[;
ML%C'TI:B1-<3Y0C%0)*& !/2I74.G'6L>02K,<'@4:C-65@:CWB)-Y/X56-Q
MMCR>PK'N;V25RJDXI@G8GU&Y$AXI=(A##YNYK,BCD9SN.:T[9C",#BC<N]SI
MHD2/ XJ5[U2I7'2N=%U)OP6I[RLW(/UIV,Y)ETSYDS[U)+>@QXQ68K,PZU%O
M99>>E38(H29LR?6I$A^6FJ!N)/?I4F_:N*:-+# O.*C;YB?:D:7G ZU 7.:H
M+$<ARV?2HW^[NIT@).13"<+S2+BABR=L=:@N#L!'K3F/-,E(\LANM"U+E'0]
M+\ M_HL(]A7=N<G%<!X .+>$>PKO9?F.%KLI['@XGXQN<G/I3=WSYIR#BD8
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MM+'&:BN1M&*FY!J&Z.[I2V R[DF.(L*P&O)C*!S@FNF*AUPW2H380L1A1FJ
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M<ETV/=(7-;W_ "R%8]B-I K7P=F>U?61I*$4CBQ#]XK,/GK:TQ21C-8<F?,
M'>MW2<@\UE6:L<.)^$Z6W3$(&:=,, 'TI%R81BEDSL&:\M[W/!J?$-1LBIU7
M>*JK][CI5R%217#C87@=.$E:9E:FGS+7=># ?[-D!/I7%7\;;^:[;PBI&FR
M=>*^44;5#]$RN5Z:+ESS<D U&RY'7I1<!OM)]:%5AG-=J/7+%M$<[@:L/ DQ
M_>*&'O45L>U62>:; 3R8XD 10 >U,%K"90^P;O6I><<TG*FDF(9)!$S?,H-.
M-LC(%P,>E+RU(@<$T +';10*0J@ ]:B^QPK+YP0;C4V25S2?-CVI7&*5P!S2
M[.>M-.>*/FSBAV 7;\V,TI7<?I33D&G%NF*+ *T>7!ST%1[<2'FGL_(Q33GK
M0@#85.<]:7;\V,TF2:,'-,0[;SUINS)Z]*/FSB@ \TA@%XI=ORYS28.*.=M
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MM]/V<FKJ0JIZ5*!B@"N+90:L  #%(V<<4J].: %HHHH **** "BBB@ HI"P
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M@_C ]:^DH854XGNTU9&Q9$G!K9S^X'I6/8_=Q6MR80O:IJ+4\W$?$5?^6O\
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MDDY%:B6BX&: ,E()#S@YJY;6F&RPK26)5[4[ ':@!JQA5QBG 8I:* "BBB@
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MG+@9%0AUN(,$C.*J02-;3X/0^M2\()5Y)%VUG<JT4O4]!5=R]I.'Z*31=O\
M,)DZCTIQD6\AVL0".:2PB)5=WN3W;>; "G/K264O[EHB>M4DG:)_+/W3Q1(_
ME2AUJ_JJ+]N[%B&4VUP3T!XJQYQ69)$/(-4IB)H]PZ]:=8ON#>9Q@<52PJ1I
M2Q,DSOM$U(31[';YNU;ZG(KR^SO'MKQ7!XKOM*OUNX0=PS]:PJTW%GUV78Q5
M(I/<U**0&C/-<YZ]Q:***!A1110 4444 %(0#2T4 5I[<.N<5FRVI4Y K;J*
M11Z4@.?;<&PW2EW#&WM6K-9JXS67<0-$^ #BF +[=*?C"DG\*9#D\-VI6<L2
M/2@&,RV*7)V^] 8@9[TN<C=WH!)@ 1S^=*?F%(Q. !WZTH&!0,MVF0,=JL@<
MDU7M<G@U8+=J1 H/&>]-W'K0*,9I&E@R:,G;2D8''>D'"XIDASMHR>*<O(P:
M;W^E%Q@2>]&>*<?F7-,I /S@#%-;[XQTH(X%+@;@*- $!P:3OFE(^;%)0 NX
MDTN3^-(.#FES@YH 3)%'.VD[YI<D+BF(5??I2$Y.*<I##!I .32VU8$\6?*.
M:XG7+A4U)@#SBNU1BT3<5YUK^%U9CGM6-1IHWHZ,9--\H(/)J@SN7XJ4'*T^
M%5-<TM#NBRJS29P*D"2D<@U<\M U.,J 8XXIHKF1!'!\GS#FI8X?;FGQR!AF
MAI=IR*8)DA3:.!30X08IAG)'UIIB+_C4^HTR.5V9OE^[4D0<+4\42*N&-2AH
M^F1Q3Z!S$"R.!SUJ,O(SY'6K!"L<BIX8UW;C287*JPRL,X-2"UYY%;,8B5.U
M4KF4*^%Q185R..%!QCBE>).I[57\YMV*9+.Q&/2D4I#Y9$ QD9JB\ASFHF+L
M^3FIEBW#)H+YNY2F=F/%5#YCY!'%; ME&?>FM"B\"BQ:FC'\AL8QQ2.N!@UI
ML548XJG(%))S05[1&80?,YJ1R0..M.8#?FFR,O7/-,?.B(9S4RC:,T* PXIV
MT[<8HL'.B&5S(,=J(AL'-.5<-CM4YC#K]*?+J-3*S$DU&Z<9[U(Y .3VJ%YQ
MCJ*3B7SH8/:H)03]*G5EZYHDV[2 :(QU(E-6/0_ X_T:''3 KLV.6(-<?X'P
MMI$!Z"NMESOKLAL>'B'[PX+@9HZCWINXT=.:I&)=C^X**(SE115B!SA353/.
MZK;_ '>:J=\]JE@(1WJO<J=M6%;FHKG[ASUH0&//&TL!C7[V*P1IMR;@<G@U
MTJ# SWJR##MX W50&6L#>4!W JJD#)=9)[ULDJ3E:S7/^F'TS5TMS&LFT<QK
M[B,EF]:H1ZJBP,H/.*F\87"1P-S7'V4QD8Y-?28:E>!\;F5&\KFK-)YS'GDU
M+'PM51PU6(6#'%>C&%M3R.6RL2,X9354??JPP]*@'^LXJMA11:B^5A6M XVX
MK)@(#?-6A9Y=\"N7$321/U=U)&C:PO/*(P#DFNXTNQ\E%R.?I6=H>G@(DA7F
MNHC0**^=Q-7F9];E67J"YF(8P5QBN8UVV,:.ZCBNL[51O;99X64C.17+"5F>
MKC,,JD+'GDKCRQZTH<(N#WJQJ.F3++\JG&:5-*N&0$J>*]2E57+J?$8K+)<^
MB*H7G-12GBKDEK)&NTCFL^0'.#VKJA53/-G@YQW*\K@"J9?=)FK,PW=*K'"/
MS7?3:L$86T(F=0>E26R_O :A=<G/:I;9B950=35U9)1-X4W/W4;<.3C J59P
M6*XK6TG32]N2R\U'<Z2\;,RKTKQY8A<UC=Y9)J]C'N/6LNZY7<.U:EQQE369
M(R[MIKNHS35SD^K.$A+4;#N-;%BC2*W!Z5D6(,UT$'3-=[I>E[(\E.HKEQ5=
M'I8? .JKF$?W2$,*RKO[I-=CJNG?Z,Q5?FKCKA@NY&ZBL\/45S+$X&5-V*L#
M[I!BMB)B1C!K&L8FEOXU7H3S7H-KI:>2"4&<4\1515#+Y54<X["-,FLF\?>#
M70ZM8O%)G;\E<]J@ "A/7FM<)),YJ^#=*5C);E\5:C^5147RYP>M31C<V*]-
MLQDM!LF215>;A@:N7  7BJ3#/)JX&D3*U%3L+>U<;J8R?QKL]0/R'Z5QFJ<'
M\:];#1YE9GNY>V5;._DMIAM<C\:]*\,>)H_*\N5\D>IKR5NO'6KEI<30?,K$
M4L1@(S/3KX:-17/3/%7B"(VQ2-OO>AKSY9_,G+GFJ<]])<'#L34EHPW\U6'P
M2I(B&'5.)?W<ECT(J ??JT0 ,GI5=L!Q76Y$^1KZ?]S'>MD$>1M[UC6/W/>M
ME1^X'K7#7/-KO4J,V)1[&MW3&!YK%8#>/UK:TO&*XZ\K1U.2O'FCH='%S&#1
M+QM'K2*=L(]*;(X+)7CNJE(\B5"?,2 A!S5B)]R\51D;?(JBMRUL6-GNVUR8
MFJFCLP^$D]3G]3R)%8=J[OP;)OTY\C'2N->+SM32(C/S8(KT31[1;2SPJXR*
M\*I&[N?992G&)7N&"WC9]*C^\6IUU_Q]$FDR ..]-6L>Z3VBGO5[J,56M".]
M6#RW%0WJ,:C?/CTJ20'&::!@[OSH+;AQTIW$"G R:3/S4Y$+5)''@G-(+D1_
MN]Z0@D;!U%32)\N1UIJ,J+\Q&ZK2'<;M+ #N*0H0*1KV&,G+#\ZKR:U:H.6%
M+E%<LB,D9H"$G%9Q\262\;Q3#K]LQRK"BS"YJ%"&Q3CTQWK,_MVV');FD_MZ
MU8_>%4HBN:2J32A<'=5!=:MO[PJ5=5MW/##%')<=RR#\^:>Q 'UJ-;F%N014
M@*D9)&#TJ7!A<9GY2*1?N 4_9D4@0[?>DXBYM;#>U(GK2D8XI1BC4O<;(1C-
M9Y(WMFM&09'M6<ZXD-22,)YI^1MQWI..],8]A32&Q?O=.U&<\CM1D8X_&EXS
MQTJT/H"L <GH:&89SZTAQGVI<CBGH2PQ\P-+(06S33G/M3N,\T,$)VS3<Y;=
MV%2OC  IHP.O2I .-WF=O2@X;\:3<-_^Q0S =/PH 0MY8V'DFE5@%V]Z08*_
M-][M0J\9/6@!0V<^U"G- QDXI<8H *1FVTI.!FDP&%  IW"AC@4N,=*",T *
M")%X&,5$>3GL*F7!&%_&D?:.E #5&/G[>E+'C))[TU&PW/W:5& 8YZ=J $+#
M=BE89&*" 3FEH 8'QQ4JD!<4S H')P*  M@4<L.!UJQ%:L6RPXJ[':KGI0!F
M1:?(3D]ZT8[/:F".:O!0!Q2T 1I$JCI4E%% !1110 4444 %%%% !1110 44
MUG"BLVZU:&WRK-R*3:1$IJ)>EN$C1F+#@9KF=0\40J&C!YZ=:P=7UYR6"2'!
MKFV9[B4/G.#DUS5*O1')5Q*2+]Q?RO>&0LQ0GIFG>4'82#'6H T9&#38GDCE
M^8_+7#.,I'G5,4:,F)(]@X-,MYOL_P"ZDY[9J"5R<%.M2F/?;Y_CQ6<:#N<\
ML2B*Y@D$@D4X7-6797AS&,%>M,2=9D\D'YJ=%MMCMEZ-Q75##G-/$! AFCW$
M_G2><OS)CD"JT_FI.6C)$>>U.=E"!N_>NNGATCDE69#%O\X[B<&I)&"2 $\5
M%(^<%.U0S%FB+9Y%=].FD<\G)D^X!L]C32<-GM54W D0*I^84-. N">:ZH*)
MS24F6'<(P<=!3)7X# ]ZJO.#&5)IHFPGS'BNN*B0J<GN:?F*\##^+'%,AG"0
MM$_)/0UE"Y*-R>O2DEN0>A^:JT*5)VL:"R-#)N)^6III%G3*\$5BM>J5VD\T
MB79Z*>M#28>S?4V(KD;3&W.:A:0PR;@>,UGR38A+ _-3$N"R_.:TC33$J1K2
MSJR@CK2+<!HRAZUD+.0^">*))]CA@>*T5$IT37@N@)-K=*DN+D!T*<#/-8[3
M J&4U,ERDB[<\T>Q#V+W-D3B6+Y3S6OH.K_8;@"5C@G'6N2BN/)?#'BKLD@E
MC5HSSFN6OA[HZ\'7G1E<];@U.&5 V\<^]3I>Q,<;Q^=>.C4KV)=HD8>E3QZM
M>QIEI&ZUYLJ%CZ&EF;>Y[&KJPR#FE+8-<MX6U<74 C=\N/6NI&#S7-*-F>U1
MK*I&Z'44G.:6I-@HHHS0 4444 %%%% !BH98%?M4U% &7/:D?=%4)08CDBNB
M*@]:IW=J)","A 9"L'.12GY3FII+9H'W8PM1*P:0D_=H8[B(V,Y[]*6G$K@_
MI35SCFFEH(N6S!AM'6ICP:@ML=NM62/6I=QI"]LTWWIR]/:D8=^U(=Q1T.:3
MHN*%/!I#]SWHL(.U)S2C[@]:4XP,4 Q!01WIQ]1TIF: Z"D'B@J=U!SQ2\YI
MB$VG.*3H:=SNI,9-(!_O3>K4X#)XZ4G"O0-#2N*5<8Q2@@DYII1NU AK @\4
M_P"\HQVHZ)SUIJ$D\4/5#+48_=D5QVL^&KB\U!ID/RD5V41&RGDBI<4.+:.%
MC\,SK'@TZ/PU.H-=QM%+@5/LD:>U9PW_  CEPPVYYJ%O"]R6ZUWVT YHXS0J
M2#VS.'C\,W"CK3F\-SDYKMA@B@X H]DA^WE<XM/#DP/-6UT"0+C^E=3Q1D9H
M]D@=>1QESX>N&X4XJN/#5T.=QKO,"DX/%'LD'MY''0:!,$YI[:+,O2NNP *3
M:K"CV2#V\CE5T2Y*_>-,_L&?/S'-=?@ 4AQFA4D'MY'*?\(_+BH_^$>E)KK\
MC.*7 %+V*#V\CD&\.29S@?E2MH,FW KKN#2$ "G[)#^L2../AZ;%1'PW.>]=
MMQ1QFCV2#V\CSV7PM<G@&HF\)7+ 8/2O1MJYH 6CV2']8D>9/X/N6;([>U0O
MX,NRV[/%>IA5QTI-BXZ4O9(?UF1YO9^#KE<EN_M5IO"4W3^E>@!0!Q1@&FJ:
M%]9D>;/X1GS@=?I2#PI<+Q_2O22JYS2;$/:G[-#6)D>77'@ZY?)'\JH'P3>%
ML_TKV#RT/:D\E .@I>R*^M2/)%\#WF.OZ4[_ (0F[ P3^E>M"-<=*0QIGI25
M-(7UEG->&=%ETZ",/V K=D/SU:R%XJLX#-Q6JC9'-.7,[C>"0:'I!UI7]J$!
M;C^X**(_N"BJ)%?[IJGN'0]*N.,J:IF'(ZTF WOQ3)QN3)J1%YQGI4=Q(,$4
MD!2&W;[U& ,]:;(3&"]8IU5A<;=O>J W,8X%4#S>%?>IXK@F,''6H(CYE[GW
MK2GN*7PGFOCJX8$IVW#^=8^G*-@;OBM'QV09R#_>'\ZS+%CY8"C)Q7U>#DE3
MNSYG,(.3T--7RV34T!7?\IJ*"SN)V'[L\UUFF>$)"GF-D9%%;&1B>3'"2ET.
M?=E53@]:IK,HDP36UK&B3V7*J3S6;8:'<7LRDH0":CZW'EN'U*5]B>TMIKF7
M"J2*['0-!9VS*I&!6EHGAX6RJ6'2NIA@6,8 KQ\5BW+1'M8++NLD,M;5;>,*
M.U6@*,<TM>8VWN?00@HJR$Q2%0:=12*:3*$VGI*<D4HLU5<8J[1BK4VC"6'A
M+H8\^DI(Q.*P=1T/RT9HQDUVV*AD@#@@UI"LT<5?+:<UHCR.ZMIX"?E.*SVR
M6^;BO4[W0UG4@=ZP;GP<64X)KTJ6-2ZGB5LG:>B.%>X3[H-=!X8TC[=<;V'"
M\TY/!,C7 R3P:[G0=&_LU,>U%?&WB;8/+;3U+UI8K;Q;0*=/:*Z$8ZBKM)BO
M)]H[W/H7AH<O+8XG5=%V1LZ#)KB;Z":.3[IS7LD]N)$*GO6#<^&EGF#5VT\6
MXQL>16RI2E='-^%]%>2X6252!UKT.* 1H%]*BLK%;5 H'2KF*YJM5S9Z6%PD
M:4;6*MS;B2,C%>=^(-*D@8O&I))KT[%9][IRW(Y'>G2K.!&*P4:NMCBO#&CL
M\PDE7&.:[Z. *@%16EDML,"K@&!4U:KDRL+A(TEJC'U>R$MNV!R!7G&IH89#
MYG !KUR5-Z$>M<?XB\.FZC+)U!S73A<1R:,X,QR]3]Y(\]9T+Y4\U;B@FV>8
MJYS6G8>$I6N,MG KK[;P\(H AKNGC;'CPRN4^AYW(&!Q(,54GD53M!XKT'4?
M"OG+E37(ZGX<FMVP 3730QL9-$U<M=/H<M?\H2.F*X[4N<YKLM34VZ&-NHKC
M-1.\U]/@IJ2NC?!QY78R5 +4\M@8%,QM:I50$;B:]A)6/96Q6D&TY%7K+!;)
M-5'7FK-HOS422L*>J-5N4QVJL>9%S5AAB("JS??6N1G(XFW8 8K9R!"/6L73
MR#WK7P/+SFN"M)7U/+KP=RM(VTYKH?#4#7EP$ R*YP_O;A8O[QKU'P/H1A7S
M3[5XV88A1B;X;#^T:1LP^'5: ;JJ7WAXHF4!)'2NY6(!0*1H%88(KYAXF5[G
MK2RF#1Y]8:'+)<9D4C%=9'8+%:;,=JU4MU0\"ED3Y3]*SE6<F;4\NC")YO-$
M+?Q!'_M/7H<&/LJX]*XC6(=FNVY]6KM(<+9KSVJ)&F$BHMHSYT#SG-0O@<>E
M)/<#[01FD0+(2=W2L['HHMVN-N3UJXG7BJMK'D^U.N[^VL%W/( :2BVPYBZ4
M^4Y[U7>YMK9#O< 5PVN_$:WLHY%1E;'O7G.I_$Y[O,:K@>M;QHM[D.:/:KSQ
M3I]HO^N7\ZYN]^(EM"6VRC'UKPG4/$DUVY^8@5D27EQ=-L4D]JT5%(CFN>TW
MGQ:$:ML<9!K#F^+=Y)_JN3]*X32/!]_JCC*N >>E>BZ'\(9'022,1]:AJQ>Y
MFKX^UN[;*1$@^U:=KJ>MW@!:%L'VKN],^'L5D@#'.*Z:ST*"WCVX'%0Y(=CS
MFST_49QEXV'X5O6.C7!7YP17<I;Q1I@**"4' 45/-<+'(2Z-*5R <U1ETJYC
M&54YKOT"XY%!BC8YP*I2"S/,)H[^(_*C?E6?/J>I6G\!Q]*]8DLHG["LV^\/
M1W:D# JU-$V9YFOC2]A^5QC'M5R'XB2<*YQBMG4?A_YH+*U<3J_@FXMG)3<<
M5M'ED1JCL[?QZK@ N*W;#Q7!-P[@5X3)!<6DN'##::M1:I)#\X)JG05A<UCZ
M$CU.TEP5D'/O5V/RY%RAS7@=IXKD@QFNHT[XAK#M1L5C*BRHU=3U.8;$YK+9
M]SM4&G>(K;5(1F11^-6V2,_,C!JQY;%I]2$<]:=M7KWI0H(S3 OS9S29=Q=H
M'/K0 ,<4 YXI,;1M]:FPQP16X[4C*,X]*0# Q3@,T7$PR.E&1G%,8<YHQA=_
M<T 2L !3.&% .10BX/6@!F,?+VIVW(%.=1T% X&* &LO>E4DCFEHH :H )H+
M'/'2FGY3]:.@QZT /(#"C(48H4;12[ XSGI0 U6]:=48^9OI4F10 (=I..],
M=OFQZTGW3D=Z5E#<YH 54W''\-#@9QZ4N[;'M')I1$T@STH 5=NWKS0$<]!5
MB*P,A#=,5H1VP6@#.CM2Q&15Q=/0$&K2H :?0 P1@+BG 8%+10 4444 %%%%
M !1110 4444 %%%,>14&6.*!-I#B<57GNHX4+.V *R=4UV*UB8JP)%<7>^*F
MNPT6,9[T/8Y*N)C$Z75?$L<:D1.":XR^UJ:Y=B>IK/DW,^_=FG+$)#N)K"5V
M>96Q>HQF,OWC5VW2-4.#VJ%[?"\&G0PLK;6X#=ZE4>8X*N)OU'^6#RAR:GB1
M7&'XQ4)Q:2X!W*.]!+.VX#@UTQPQY\\0[DV%#@9IYE,<F&^[494;-X/*TQG%
MS%M/!-:QPJ.=UVV/*")O.A.322S_ &H G@K5;[2+52IYXQ6=-J*6^6W#FATE
M$U@G,TFO@OR/P*J7.IP(ARXXKE]1UIY&81KGZ55M(+C4WV.K*#WK&5=0.Z&$
MNKLV9/$"*VU&!S2+K,K'9C@U%;^$'W>9N)QS6E:^'V,@#9%9/&V-_J<2HMQ(
M"6CY-02WT^>E=+'HWV4YZ@\4/H2/SNZTXXUMD2PL4<L;R8INQTH:]F9.171O
MH:(NS=UJM+I"A<!J[Z6(;1S3@HG-O?RDC(Z4"^E9P<5M-HJGDM49TE47=NZ5
MVP;9//&QF[V+9/>K*-C!S4QM%'>FR0K&5PW6NR%-LRDKBM-N&TTUW"KUJO.5
MC8'-5Y)PR]:[:5&Y4:1:\_/7M0;A67#&LLW/-#2!QNW5UJB;JC<TOM8 V@TU
M;HQ-N%8YG(:K*2AQ@FJ]BK#]B;:7'G1[F/2K5M>LOR_PUA)-M78.]7()A@+[
MURU:=SGJ4K&P;IF<$UK6:QW(VN<5C($>(G=R!1;WOD28)KBEAKF'OQ.HT^[_
M +*U%=A^4D5Z787:W,*L#VKQ^28/ LRG+ YKI?#'B-!((I"!QCFO.Q6&LKH]
M[+,4UHSTC--DD6-"S'@"J7]I6XAW^8,5RVN>*HD)@C8'/%>5+W4>]+$12.A.
MMVPEVEQ^=7H+N*<91LUYDD4D[>;N/K6K8:HUE(%/(KG534Q6*39Z"#FEJAI]
M\EU &##/I5^NA'9&2:"BBB@H**** "BBB@"*>$31[36?+8B-.*U:8Z;A0@.?
M:-P3D<#I2;^/>MF>W#J !69<VIB.:=P)K3&,]ZM]35.TX&<U;8!1P>M2R[BG
M@8[4 @\=J13D8HV\XI6($QC-  VT[&>/2DVX&: 0O 6FTI&5I"N .:8QV0..
MU-(Q]*7;S2\?=]*0#23Q2D_,#2\'CTHX;GTH ;GG- ;DTI  S2;,'.>M #PP
M!I#AFI-O.,T;?FQFBPA#P:59#CF@+DFDV\9ICN/P'&>],4;2:>@&,YI&P#P>
MM+J"%C<CCM3_ #.?:HB=JXI0-R47%<=YY!Q09V%,"C/TH;#4 2><2M-,I%,'
MRC-+LSS2U <DQ!I7F.:C*X.*7;SC-.X#Q-QS0)<\U$8]QZ]*<J>]#&/-P<T&
M; R*9Y8SUI%3)/-%Q7)//)X-!F*G IOECUI-N6Q3N!)Y[4PS'=1@'CTIIC&[
M=F@"7S#U[T-,<<4PX^]1T_&IN >>12^>6IIBR*01A5ZT7&/\TTX2\9J)5SFC
M;Q5/8+CC,<9%*)CBFJH(S0R8/6E<=P,Y#8IXEYQ49B'7- 7)HN [SVW$4\3'
M;GO3/+'K0%W4"%$Y88[TIEVU%M"29IS#)R*=@N2&;;TI//)J-E!XS0L8'&:+
M 2^><4>8<9-1!>:<?F&:5@N'FDFG+CK4>SC.:>.!UI]!(3 W4C\?2EQ@]:1N
M>*5QMV1;C^X**(QA!15"%?E353/&VK;_ '3BJ6ULYI,!0AS5>YA).:MMG''6
MJMSY@Y[4D!1E3<FVLUM*.\/@=:T,N9<_PU*TAQS5 ,$ 5 O?%5(TVWFWOFK@
M9CR>M4R2+HMWK2FP>QY+XZ1IKT1IU,@'ZUT/AGP=/(D<K#*XS5:ZTU]3U]5*
MY D!_6O7M)LUM;*-0 .,5WRQ3C3LCBE04GJ9EGH$43*QC7CVK<2W5%P% J?;
M2XKAG5E)ZFD,/&/0S;S3([B,@H#GVIECI$-O&!Y:Y'M6M12]I*UBOJ\+W&)&
M%' I]%%9W-DDM@HHHH&%%%% !1110 4444 )BD* CI3J*+BY41>2N<@"I ,4
MM%.XE%+8****104F*6B@+!1110 4444 )B@4M% K!3'C#C!%/HH!I/<@6V13
MD*!^%2!:?13NR5!(C* C!JE>:?'-&<J"?I6C2,,BJC-Q=T3.E&2U/"O'6GM:
MW#/C (KS2_4XS7OOQ'TGS],,D:_, 37S[J/F1NRMV-?:Y+B%.*/(G0Y)Z&?@
MYS4C*?+W=C44;;C@U*Q95Y^[7UBEH;<NA&>!SWJU9BJA.1S5FQ8M)L'6HJ5%
M%:DR3L:K1GRA5:0Y(/I5B0O%'\V<&J1WRS+''U8XKSJF(BM;G,HMR.F\-Z9+
MJMP(X_2NEU7PQ<Z9 '?D5T?PP\.^3;-<3)\_&,BO0]2T:#4(-DB@X'I7R&-S
M%JLTMCI^I<T;GSWI4+WFN01JI^5N:^@= LOLMDH(Y(%8>D>"+.SU%[CRP"#D
M<5V<:"- HZ"O,Q6*=70Z<+A?9ZCJ***X3O"FO]VG4A&10)['%Z[&5U>V/JW^
M-="<_P!G5F:]!NU&U..A_P :TKG,>F54GH<U*#C)LQC:/*Y8&F^4\#@EN!4L
M5PVSCKGFL#Q9KZ:;9$[L.13@KG0WH:&J>*[?2+8LYY^M>2^*_'+7TA,,C 'C
MK7-ZYX@OM3F*[F,>:Q?++??S7;3@MS)LDGGN+MBS2,0WJ:A\@HO/6I.1C8.!
M5BTMY;^Z6! 2QK=V2,[7*5O9O>S>4BG->C>%?AS<7.R9E&,]Q73^!_A['L%Q
M=Q<G'45ZI::?#I\0C@4 #VKCJU5LC6$>YFZ1X=MM/MD5HDW!0.E;L:QHF% %
M1EF8XH.Y17+*3:-4A6)!//6HT#<\TX'/6CD5%RDAW.,9IC+S1EB>.M!W'I^-
M T!X%'-*.3S0>O%&H6U$5&SG-/R8QS31O_"@!GZTN9DM#]P9<FJTUG%<*<H#
MGVJ4\'%(&*FM8S(<3@_$G@MKK?)"H'X5Y9J&G2:;*89!R*^EB%F3!Q@UPWB_
MPC#=(9HD&\YZ"NJG6Z,B<;(\3*[1GUJ(Q2=0U:.I:=/9W#QR# 4\50$C#AJ[
M(I-'+JB]IVMSV3[?,;CWKT3PYXSCE58I&).<<FO*=BLY8TT7,]G*'@)&.3BL
MZE,VA(^E(F$\2RHPP1F@ DYKR_PGXWDD6.">3@<')KU*%UN(A)$1M-<<H69N
MG=##&0<T^I"I(Y[5&Q["LFBD-)RV*=T%-"]SUH?/:HL, -WS=A0W]_L:$SCC
M[O>A^G'W.U  $(&<]:%4],T*S$8[=J;\^[B@"3:5X-*%W"D^;^+K2*67- #/
MNY6GJ,"D5"V6-/7&>: &.NZA4XQWH)PQ_2D#'IWH -ISY?>E92.,]*>"!U^_
M39&W?=Z]Z #RR?F%(T3$;LT@,FWCI3XDED&!TH B^[UJ6*U>9=PJ]%8AA\XJ
M[#"L2X H SX+!E(+5:6#YN!5L#%  !H %4*,"EHHH **** "BBB@ HHHH **
M** "BBB@!"<"@'(I":J7-XELI+$8%4E<SG4C!79/-,L<;,3T%<=K7B1 K1*3
MD\=:JZYXE)1D@?D\=:Y*0373;SGUK109XN,S&*T3))Y9I&,C.2I]ZKM 9Q\G
M!J>-PQ\ENO2F[)89,C[M#I-GBSQG,QL5N\; -SFIC"R29[59C G0LO5>33#.
MC+Y>?FIQH-G+.LV3-:,L8ESP.:CDNTFB,:##>M10W<I9HI#\N,"H]J02;CWZ
M5UPPQRU*KZ$\5LSVVQCEL=:D65 GDX^8"JKW3H^5/%0R.1\XZUO[+E,5)LF)
M:%B6/!J!W^;>IP*1Y_,C.3R*R)[F520#\M3.T36$;DE[>AP5'6L:6UFNCM5C
MS6A;VDEQ*"1UK:CTTQ -CFO-KSN>I07*S(TW0&C"B4 _6NJ@T>/R_P!VJ@@>
ME/AV>0!_RTQ3T>YA()SMKQZBDV>G&JD.MD$3[6%6)T7;O0#BD8+<1GR?OU#"
MSQ/LGZ'UKG=.17MD2'#1'/I6>"^YAGZ5=FS$"W\%9T]PHY7K5TX.YG*=Q9-R
M1G)YJAYC;^32RW3.O6JLDP5<]Z]BA$\^LRQ*&*Y!JG*6\LG-,^UNP(!JK-.X
M')^6O;P\3C2;9&\C'C-596=>K=>E-DF/4&L^YN9,CFO8HQ1V4J3)9G9ODSR:
MIRN0N,U!-<N#G/S=JIM<NYY->C2@CT*='0MF;BHO.8-G/%53,.H-0/.<Y!XK
MHY=#HC1--9P#S3UD/4&LGSB<5:CF]34N(2I:&U;7((VGK5\ A-V:P(Y5ZJ>:
MLK?.%VD\5S>RN<DZ+;-J*Z97'S<"II9?,(=3TK!-R<9!J:"][$\4_86.>5 Z
M*PO<,48Y!&!5A1)%,)$;'/8US:3.)=ZGY:THM1/ED,><<5YV*I*Q/*Z>QT,^
MN31VAA\QMQ]ZS+7S[JX5V8G!SR:SED:XDYZUU.D0Q)#EQS7SF(H.XYXEI&M!
M?I'$L1ZGBK>P20%AUK+EM2X+IVIUC=21S;)3\M<,<,TS&&,:=SIO#L[PW6UV
MX],UV\;@J#ZUYEYTJ7*R0'Y<CI77:?K*>6%D;G'K5N'+H>_@L;&2LSI**R&U
MNW4[=PS]:LP:C%-T(J+H]>-12V+U%,W@KG-5;G48;9<NPK.52,=S0NT5F0:O
M!.?E85H+(&7(-*-6+'9CZ*8SA1DD52FU:WA;:S#\ZOF0*+>Q?-4=07$6ZECU
M."495A^=1W=PDL. :+H?(T5[-2V3VJVJ$DBJEF&!XZ5=^93]:$R1NP@XI=IS
M2-NS[THW?C38T@(H"DTCANM*"V,U/4;V J12%3Q0^XJ#0<X&:?J2+@]*1D.*
M#G(J0@E/>D,BVDCBG*IH 84J9S38#2AW9H((ISDYIGS9YH0#MIS1@YQ1\V:.
M<^]'00@!R:,'&:!G)Q1SBA &"!F@(>I/6EPQ'M0=V*8T(Z$\9IZH0F*;A\9[
MT9?&.]%PL 4DFC8<YI/G[4[YL4":#;NYHQMX-("R_2D.XG)I,=A2IS1M.[%(
M<YH^;=[T70AP4YZTK*>U1DOGC\:>I8]:8"8(&:3!'/K3ADL?[O:D&<D'\*-
M%P>E)@[L4@+9Y_"EYS[T#$VDG@]*7:2*!G)HR<4FP&E#USQ3Q\HY[TSYL>U.
M&<?-^%(!>G'K32I)VTY0<<]>U+@XSWHV 8JGI2@'%-.[/%)\W;I3N(> <9H(
M/6F?-^%..>]%QAS2A#UI,&ERP.*&  $Y]J%]:0$Y- W'I1<0%"S[NU"<%@:<
M@8'':F8;>30F A4KG)I8P>F:,EJ<,CCO3N  $G%&TXI/FSQ1N-)NX=0P=N:1
M0<]:?@X]J8,AN:92%$9]:4^G>G@G%,Y_&L[ZDLMQ_<%%+']P9HK4 ?A:I-(1
MVJZYPIJG@?>I,!VX[0:ANF.W %3/]T5#<,%%2!EQL?-VMP*;YJ-(5R,"I)UW
MJ<<&L%1)]I*Y/6K Z&-E*$Y'%4-^ZZ_&E6-D3K4,65NPWO33 DTS1%&I&<CJ
M<]*Z]%VH!Z5#:JOE!@,&K%#=P"BBBD 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9'B"
MS%WIDJD9^0U\P^,+=K&^92I 9L<U]92()(V4]QBO(OB)X#&I*)H\ JV>*]?*
M\9[&5F85::>IX"),2 "IVD++AN *[W1_AD]W<[6;&*V]8^%)MM/W*W(&:^HC
MG-->ZV8>R=SQ[S&:0*.IZ5Z%X'\*MJDWF2HP 'I3= ^'[W>J('Z*>XKWOPUX
M;@TBU"A!G [5P8_.%RM1W+5*YYCXK\$+:Z;YD*,6 ["N)\-:%<77B"!)(FVA
MN>*^GKNQANH3&Z @C%9=AX:M;.X,JQ*#VXKQ%F4W!IL?U=)W1;T734T^S1%'
M4"M2D P !VI:\R4G)W9TI60F *6BBI&%%%% !1110!AZL,WUO[&K5_G^SJ=?
M6WFSQ/\ W33-3D\K3B<=*;U)L8UO$!&6[UR/BK16U214(./:NEM[UC_#QFK2
MR1R2(K(,M51=F)IGG%M\/(6B/RGGVJ4_#:$K]UORKU:%(XG";1R*N!8B<;!6
MBK-"4.IXTOPVA ;Y6_*M+0/AY!;:BLQ4Y'J*]2Q$,_(*,(HWJN*4JS:*4$10
MPK96RQQCI3U<GDTJMYAY%!&T_6N=N[*M8'.&!%(S%A1C8N#SFFA\G;BG8!H)
MW4\DDTX '\*.O/I28"#@9I-Q!^M.Z<^M!PO/K0 AX<#UI3UIK-N.:<?N4QIB
MAR>*&.RDC&!FACNI6 :>036'J.H302%5' K?'"_6JES8I/R0.::T Y.;Q1<6
MQQCBJ$_C1Y,HY7'UKH[WPJMTIP0,UR6I^ )"N%DZ5M"US)W.+\2:BES.74CG
MTKFF<,>M=5J'@V>!CEBV*YBZTZ:"0C:>*]"G.R,G%$>X>M,D/&!WJO()$;)!
MIAN2@Z5HY)F=F2VL[V4P=3WS7IVC>.FBTQ$+C(]Z\G\QY6VA3S72Z'X4N=2
M.\JM<U2QK"YZ"GCB>1L+@@UOZ5JT]WAG'6L+2? +0HK.^<5V=EI26<(  X%<
MLK&Z+9)V@TN<K2;\J.*>0 @/K6>[&1\K\H'!HY(V=A3D;(YI,_-BDP!3U'I0
MK'KBG4B-S2  Q;D]:1FP>*1S^\R*3H<^M $H;"XJ/)W>U.)^8#UI7(SY?ZT
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MVQI-,\N03Q2).B':3S6:;O:1@U')."V<T-)(UC1+<DS%R0>*(IAACGD5G/=
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MLCUJ-&R&2NN,U18Y-/+9..U1MBM4DD=D(V&G(I<Y7WII;- QCWJ7)(Z+#]P
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M>9]WD592,,,DUBZ)-BR4OR:U4F69L!L8JHC)21TIJJ.W-+);LQ!4YJQ!9/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@Q%.1BD;B@C:I'<TG5 .]&X#B<@49^;-(>@'I02,B@!V><TAZ@TBGFE(Y!H
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M;E&<>E:+2+$^".#Q7B33<CAJ8BPU2#&1WJ/<3&T9&,]Z?(AC=7[$U'=72;<
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M:S])NTN;1&3H16CP!2"X@/R]*%.10&!% - ,6D/2D YIU(0@X%!-+2,,T#W
M'-+2+S1CYLT !.#2'TI2<&@D4QH0>E*#1GG% - A,T9XI00:#@4 )FG#I2#%
M+2$-)[5')RN*D//%1R<C%,I$);YJ"?FS02"U)N&_-9IC+J<K10G*T50 _P!W
MFJ9/&!TJX_*U3 ^;':D H/'-5[G)JQP3BJ]RQ'- %(G"8_BH!XYIA);Y^]/'
M-,!CDD;AT%4V<.V!5^10J%1WJK%;A7S3 MK@1#UIK[NU.QBC-(!JGL>M!0DY
M6D;CD4[>47/K3MV 7M@U4N+A(00QXJVI!851U"U$Q-(": *X#+T-6&7! -5[
M5/+0+Z58=LX/I0 %<-SUI"&(^6G,VZ/=WI$? HL U,]Z<3@9IK-\W%"X>3;V
MIM 5;F[CX7OFI[<#;QWJA/9YGSSP:T(!L4>U&@$A7#<]:3 '-.+;FIC''XT
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M*H.XTJMA:-W&:0]!G<T#..*3/-*"0*H0KX\CFLIAF1L],UIMRF#TK/?AVI@
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MW4R0>M R#IQ3<?-B@@AJ,'=CO4#+J<+10GW:*H ?[IQ5+G/O5USA35(,=V:
M#)!H([BD8G/%*&(&*ECZ!EMN.U+DXYII<A<4XG*T:@(I;%#%@..M*'([4TL<
MYQ0 ;GXI9"05Q2;R.<=:1R<CBF&H_+,*8-P/-/5B!3#(2V,4K@"A\YQ3\MNH
M\P^E(&.[-%]1"@L#2,684;B#F@,5H (]PY(H3<6.:7?FG*W!S0,8A8!L_A0=
MQC_VJ;O))..E/WGR]V.:$ O)CQWIN#0'.,TF\[L8ZT ( Q?IQ3PF-Q]!2EMI
MP*1'8A@1V-&X'+ZYKSV/R[\'.!2^'_$1NY?+ED!8]!7/^+X0]Y%O; WU5T6
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MVI-YZ4X-@=*!";FW<T'<306R:"QSFD [HOO0W(R/QI"<\T*><'O0#%0D?2E
MW/GM3')!P.E.5B* ,?Q1>G3M,DE0X8+Q7DK^.[[>Z>:>OJ:]7\3V;:A8-'@]
M.U>9_P#"#CYYBK9SZ47U YVZU.6]F\YSEJTX/%]S80+''+C K.O; VMYY(!_
M*MJU\&B[MDEPV6&>E# ZOP7XAGU.3YWS7H4@)4$=:X;P?X=_LM^A_$5W)<AL
M8XQ0 WYL#-&3FE+$TFXYS0]!!DYIK[B>*D[9[TT-S]:!C5)W8[4ISNQVI3_K
M HZ&AB=VWTI@(I;//X4[G=3 Q8XQTJ3<>M(!O.:!GFEW'.::7(/ H8(49Q0,
MX]J QV]*3<>E"0 00<TI)(]Z;O)X]*%8DYHL KY, SUK-?=OXK4E8^5G%9;.
M5<\=::$-9"_;BJ\MFDA (X%6O,(XQUI&.!FF X((X%5>PI$"D9;K4>]J<H+'
M)XH .2^#TI+K:L/X4[)WX-07N?*./2@"SX?8F-L=,FNAKF_#1(A8?[1KI* "
MBBB@""YMUN(BC#((KR;QAX<G@N#)9Q$YY.!7L%0S6T<RD.@.?45C4I*2)E'F
M1\\0F_1]DRL #CFK4L[0#(.%%>K:KX7MWC>14&>O KSO5]&F$+J(VQ]*Y(PE
M"1Q5L.VC-CU%9AC<":29W[5S$RW-C.<*W7TK3M]1:6(%^& KV,-6MN>#B<,X
MLFE;J3]ZLF65E<XJZTH=\DU3F R<=Z]RC.+.:$;,JRS,:K><3P34S+@U7:,Y
MS77SV.R,4#3MTSQ5=YFP>:E*TB6Q?J*;JZ&B<44AYK-A0:V-,TJ69MQ0GFKE
MAIJ':6%=%:L+;A%!KDE*4C#$8I1C:)/I]H]HBX7  K?1UFCVN>*SHKO> K #
M-*\GEG"GBI5%O<\*I.4W<M%VMY!MX7-79XXGC$B8+8K)FG\R+ [4R&^9$P36
M=2DHZF/*V:L5P&AV.?FQ7+:M>R1NRH>#Q5BZOBA,@/S>E9J))>RY*DY-?/YC
MB%%6/H<GP]YILH&,J,H.3S5"6REDD+E3FNO^P)$HW=<52D91)M %?,2Q'O'Z
MOES5.*1RWV"9'#%3UKH;.!6MOF'S8K6AM%NHR"O09Z5!# 4FV$8P:RJ8BZ/<
M]NDC.@MRESDCC-3M8R&97"G;FM6XLSC*K^E:ZP(+'@ MBN9U^ISU,58R)(_W
M2^6. .:DL[![@ .IVFM32;(/$PD&,D]:E>4VDWDQKE0<9KFG5=[(XJF(;*JV
MD"?(<<4QK1)3P,@5>^R%V#MD9JR;985^7G-8^V:=T>=5J<QRNHZ4D\;(%R37
MG/B#19K)2ZQD#->R/&$EW8K)UVSBOK-U91G%?2Y3FSIM7/*K44W<\.,I'#4;
MA6SJFA/%*Q5&QGTK$FMIX\_(<?2OT7!9W"4=S@E2L/)R*0'UJ$;P/F!%&_N>
MU>M',8R,N34D+D58ME\R0 =<U60>8<UMZ?;!&5S4RQ7,C.K))&UI5J8F#%<"
MMX3!GP#Q63#<-@(!4X?RSUK"UW<\'$7DS1\]D;Y34OGDH6SR*S5G!SDU$UWS
M@&BR3.7ZO?4VTN6D@QGYL4ZWN3&W)K 74#&^0:FEN28]ZGDUSUII+0CZOJ;5
MU=Q!,AAFLV.[9YP ?EK*+RRN!S@UL6%F,<UY4Y<S*=.,%=FK&6('I6C;J00P
MZBJD( ^4]!5J*4(<5G&ES'%.H]BTS&7ANM/CN6B^3/!XJI).5<,O-2;2ZA^]
M:+#JYS2DR60F%U:+^(\U:V VYN'^\O>JR,GE,6(R!5.34F=&MQT-=,* US,M
M7%XTB;5--B5I(69^PXK.CDV$[CTJ%M7=<QKT/%;*DD-4I2-47[);/$I^8]JH
M+(0^2>36=]J87 :JM_J+QC*=:EU8P.BGA&]#8FNEB=<'J>:K7%TS2 (?E[US
M\E[)(,MD55EU:6(;0,U4<3!G=2P3V-EYBDA.:9),Q&:YJ35KASRII!J\VT@B
MNF&)B=2P,D;,TC;MW>HI+AB@P>:R#J;D<U&+\YS74J\6:QPK-U)2WWJ?YN#C
M/R=ZY\ZBQ'%6+:XGN?W:J3GTJ*F(BD/ZJS<DEB$.4(SVJYHME?ZI<!!&S)3_
M  OX;N-2OUCFC<1Y'.*]Q\.^&+;28@50$D=Q7BXO$KH==#!/J9/A3PM%:#SI
M(\/CO7<H@1< 4*BJ,  4ZO(E-RW/6I4E36@4445)J%%%,DD5%R30 ^D9@HR:
MS;G41&AVD9^M8ESK5PYVJ#0!M7>J0QG:'&16)=ZC<S2CR22GM4"V;71\QR<G
MK6A;VZVZ%>OUH H)%-<,?-!Q5673&BD,D:GBMQI.P%2>8"FT@<T 9^GRRYP_
M:KN\M(:1HUCC+]ZP9]6D@NV';% &X)"'*TK D].*QK/4&FGYZ$UN[ODQ0!8M
M,C(/W:G)?)]!TJ&W)VU8W$\$5.XQ$W'DU83-0%RJ\"IX"6&35(3)^<"@TUB>
M*44R6+VH-(:,T (2<4G.*4$F@G%,!,GBEYW4$\"C=S0,<:3M3=QW8IU(D%SC
MFE[4TG I0<B@H0TTYW4^EH)L S49W9IV3NQ1GF@M(09Q0<TZDSS3(>C =*0Y
MS2DD49.:!H44G.:=3-QS2*B.&<4ASBC/%.7D4#8G.*8=V[VJ0G%-)YH1+0WG
M=[4JYS3Z*+BL(<XIB@[LFGJ<T4#V#O36)S2T8H)N-&<T_M2$T"F%]1HSBEYQ
M3LTC<4#$YHYS3ATI,XH"]@&=U.YI,T9I!<*,T9HH$-.<\4O.:6D)YIC0'.Z@
M9S3N]-!ZTACJ2A232T""DH8D"B@+"#.ZHY,U-WJ)S0,K'=FCG=[T_=3,G=FH
M6XRZGW1FBA.5%%4 /PM4\C=FK<GW#5-.O- #A@-DTDF,\4H(W4%2:FPR.G"@
MC Q3CC:* &]\T%@&S3B,\BFX&:  CO1N'0CK1G)Q3G48!H ,<;>]! (P.M&?
MESWIN>]*P![4+PU.(R,BFK][FJ "<FE8@CBE&,FD7&#F@0WK2N<@ 4X ;<=Z
M  .M(8TXQQ0IP?:EVY.::>:?0!67N*5< 5)QLYIBD9YI ,5L28-2LZ[&P.U(
M0IZ=:4 %2/:@#S+QFKW$Z)'D-NJ/PLC65ZOG\D^M=1JNC/<ZC"ZK\H;)J'4-
M%E2ZCDB7  YQ1Y 9/B75K9HV38,U#X80SV%V!_$G'YT:IX;NKA=P3.36YX8T
M>:RMY4D7!9<"CT$>?:P)%9K$9W.<BK6A3EKB&V;.0P%=-=^&Y9=?CE,?RC-,
MT[PY+#K'F;,*&S3 [NR18+53CJ*Y+QK:+/:F:,@..AKL@!]G5.X%<3XFT^_N
M)@D6=AZB@#/\/32O!)'(Q("'J?:ETR;-M?CT7^M:^D:+-;VS;EPS*1^E5&TV
M33M/O6=<%UX_.BP[G+Z<B7>J^3QN)ZUU>N6H&GI%@<$5Q6EF2WU$S\C#=:]!
MEMY-1M$*#)X- CF+6W%OJ%NZC&&YK>UW58! L3+SBI/[$G^TPMMX4\U5\0:!
M<W,R-$O '- [F%X=?.L7#+]TQG^1K3M$\UYT'5JL:!X>N+6:221,;EQ5^#1Y
MX7D8+C/2@+G+J@TS6D:7G(KTK3KE+BQ5U'%<+>:%>7.IHY4D"NYTJV-MIZQ,
M,,#2L"+;$&D!YIP'Z4N!G/:@!A.6IQPPH&-U(RD4[ A .U.P",=Q0.1[TAR/
MK2L -C'%-7@\TY1GFD;&>*+:@!QG-*, &DQQD]*!S0 +P:5L=11M[4;>U,!%
M&>?2G<'GM31P<4K>W2D]Q"D@?-V- Q^?2@#CGI2$'/\ *@8C+@TN05Q1@]#1
MM[4  &>?2E89&12_3\:.^>U"$-4X/-,<X;ZU(,;_ &IS!338QBG<,=Z>N!Q2
M+A>M(#\Y-2 XA'R& -5YXX!"P$8_*G.2),CIWJ238]NV!VIH1XUXB\M/$!X&
M..*]-\-0POI4+%0<CTKRKQ5;S?\ "2D@';Q_.O4_">X:/"#Z4#-MECCX50*5
M<$<TP@[L'K0YPH ZT;@*Q&:,C.: ,J*"1N]J.@";OFI#US3L#.>U(PY%  /O
M FE&"YI'X(H3J: '*!N--+?-2$X<TN1NH0@SSF@$9-'&[VH&.<T  (QBD SQ
M3EQBF]#1U&A".:.G-+UHXS3"P/("F<5FO@NU:<@4)[5E$XE;/3-"$($X-*2#
M&$[B@MQBF]L=Z8 & (!%397((J-0#]:@NKE;;[QH GF.3D5%/S!^%+8SI=C>
MIRM%RA16ST[4 3>'/EB8'^\:Z&L#P[AH6/\ M&M^@ HHHH **** $90PP16?
M>Z5!/"RB-<D>E:-%)I,&KGFFJ>!6G9G5%_*N!U7PU/8W9XPH/I7T01D8-<7X
MMTAI0\J)QBIMR[''B,.I(\3NX'CRXSBLQ[\ [2#77R1*S&-A[5AW.CYE8A!S
MTKLH5Y(\6I3C"6ID-=KCI0LRLF,<U;DTB0?PTD=@R_*5YKUJ524D92JP2T(H
M8=YJ_%;@8XHCA,?!%3J=IYZ5U1A='-*;>Q9CPO2K44RQ?>YS5 SH3@&D>=>A
M-;4Z)SRBWN:<TV?F4XH6[#Q;<\UD^>1P3Q2B3!R#6KIV)5#0V(KH1_>J*:4
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MPT#X8W%I*'E (^E>PI:1(<JH%3@8%3/%2D4J2ZF1I&B6]A;J/*4..^*UP,#
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MN]:I 71<?+UI//!Z&J7(X]:105?K0!=DN %&#S2_:=P'-4C&<Y)II4JPYI6
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M*BGS!S0(N-/B0\\4GVDD')^E57&7VYI63C/I3 M)<$#)-.^T;N<U2^\N*4#
MQF@"X+CL#1YW/)JFJX[T$9& :0%LW0Z9H\_ Z\U1\L@]:>5Y'-%AEC[2<9SS
M3S<G8"#\U5=G\6::00<T:"+HFW+G/UI//]#51#M4\]:%7 ZT 7#<<=:/M&0.
M:ILN>,T 8&,T 7/M//6@7//6J6WG.:0_*<T("X;DYX/UJ19^Q/%44'4^M(QS
MQ3 N&X7?UXI?/[YJB(L]Z</3TH8R^)=X]Z>,XJC"V) :T,97=4@(!GKTIQ7
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M$#'>F6L?DJ0*<Q8MF@!2I./:D(VG-/'2FD$G':@! -QS2A>M !!QVH7.3F@
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MWF;AC'2@!&; XZTF3MIWEY^:B@!I)XIU-8X(HW?-B@ R=U.IN[YL4!LDCTH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8444G>@ Q3)EWQ,OJ*DI#R* 1\Z_%6T\C7!@<')_E7)6CXM@*]+^,%F6O5D
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M\M(^[M0!:M@1]*N $BJMF"1S5Q3C/Z5(TQA!!JQ!TJ Y(YZU/!Q30B>BBBF
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MS0N,\]:0<GFG8 .?6@!<@YI!C% 7OZT;<"@ ^7;[4;@ *,#;[4H52O)Z4 *
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M!$Q_%^%2<;:C8#%"GUH 7:,YI1\H('>@G'6@$'I0 T@ >U'R[?:G;0QP:1U
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MUT@Z5];@W>F=B=T0W7^H8>U8)&":Z"X_U35A.,28-=BW*3T$5NU ()(I&QG
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M %3\W6@!^/E\O^+UIK_-A1U'6@Y+<?>I I)X[=: %W!3BC:=V:5UWL"O:EH
M0-S@4UU)/%/P!S10 W:=F*;R>*DIK#N* ''@4SS<<4J@LV>U#Q?/N ^6@!0A
M^\3Q2.V!BE+8&*9VYZT $8/6G;@QQ3<X7;WIZC ]Z 'A@J4Q"@^<BEI,#&*
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M,^:U5$X[5IZ<?+M 3Z56E7*YJ4-ML>/2A;DRV.2M+![GQ [8XW&NHN])WV^
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MQZ=^M/(R^Z@?*K>](">S'[S Z5@?$+<-*C '&36U9R[9<5%XJL_MVF!1VS2
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M!BLQ/-.8D=*&.!F@<C- "$G(I#DMCM2L<$"G4 "G?\IZ"FDECG^[0&RV*=0
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M-#%HHHI %%%% !1110 5!=P+<6[HPSD5/01D8H ^6/BGX>.G:Q).JX$G->>
M!EYZU]3_ !%\*QZO:F0)EE7TKYEU&PDTS4)8)1C#D"I:-H2,MAAL#M3D?U[5
M::!2,CK5-QAR!2-+]2W'<[95=>U>O^ ]9CO81;MU %>)YP<"NI\&ZT-,U$EF
MPIQWK.<$=>'KN+L>^O:;3N[&HVC"GFI=,U*#4M/CD0@G%-E89.:Y)PLSV*-1
MR1 X6J4KA,U-++@D \UE7=THR,\UG>QVP5D9^IW_ ,C**Y=FW#)K3NW\V8@=
M":IRQ*IP*N+,*\KF!J &>E9RMCBMF]C&>:S1$FZMXGF58LLVG4"KRD;N*IVX
M 8>M753G--LSBK%Z&0;:O0., UFQ;3TK1B V\5+6ANB]&X YID\@Z&@<*,U$
M^">:DVBF590&4C%4]N'Q6J(0XXZU$;=0W(YJ6S91)+0# XK6BP.W%4K:-<#%
M:,:@=:D:B (!Z4QR*F4*2<U')M#8[TI&D8D$S[8"!Z5GP#?=)]:TK@*("#UQ
M4%E;[KJ/ [UI36ICB6DCV7PFNW3(_P#=KHJR- A$6GQ#_9%:]=T=CY:M\;"B
MBBJ,@J.4X6I*CE^[28%<./2F9&[/:G;03D=*;QN]J0%U/NBBA/NC%%4 /RIJ
ME@;L5=?E35(CG%)@2$ C%4;D#DU>V_+5&X7)S26X%,)O&:C:Y(/EU8W;.<5!
M+;\^8.]6!4N5)4@#K5W1#Y;*IJ2.%67#5%@6\^0>AHN!T_6BJUK,)$'-6:0!
M0>E%% '.^);,36,C8Y KR+4E\NU;/!Q7NUY )[=HSW%>)^.;8V/G*.@S7MY7
M55^5GAX_"\TN9&#H\^;G&:[.PVE&)/:O.="GS=#FO0M-@>="P["O9Q#21\SC
M,*V[I$5]""&:L65%3D'K6Y?Y16!%8;QESG-11<9')3@UHQFT CWJS'&!Q57.
M& JRS[$K?E214H-ER%0IJZA!%9D3Y .:MQ%G=0!7)6FD8K#RG*QM6Z9B!'6F
MJLB2$[36UI&E%HU=ORK7ETE&C.%'2O+J8A7.Z&42DKG'.PZ>M(,8QFM6?0F#
MDYJ,:(Y^7-*-=,QGE<D961FD9AU-; T)CQGI4-QHK8XK98A"662*","N[/(I
MT>[=P.M:5GH3,,DUM6^A*N":RJXE,Z*.3RDSF[>Q>2=05."?2NRTO3U@0#'6
MK4&GQQX^49J^B!1P*\^I5N?2X'+%2U8BQ@=J?BEHKFN>VHI;!11104%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!=Q"6$@
MUFV*B*Z9:V",C%8[QM'?%QT- GN:=QS"1ZBL)T"R8K9F8_9,^U89)=S0BD3(
M >*1@,D4Q<@XI6&2#0(FMD ;-7P,+FL^ _O16B.%S2:Z@,"XR?6G G&* >OO
M0#\M P4 G%&!DTB@DTNWK2 ,#:300-N:3^$FEQ\N:=T(0@8%/"#'6F,, 4#)
M.,T@%VC=BEE P*:00:4C>/I0-"*,R TKH V?6D7AJ<P[T^H#=@'/K2[1N I*
M!]ZD NT;L4  DT8^;% ')HT  !@TF!MS2@9&:3'RYIB$- 4#BE(P,T#TH&.D
M4>7BLJ109#[5JR+^[Q66T>Z1N>E"8ANW)S2X^;-*>!]*CS_%ZTP' #)H"\8I
MN<<^M*#M./6@ \L4J+OR#VIU'3I0 %!C/<5'SC=ZTX@DYIW% !M 7/<TT1@M
MS0 0:<>1Q0 T_*^T=*=2*,#FD89YH " 3FG5&/F.?2IMORYH 8%QGWIG0X%2
M=J:JXH -HVXH*Y ]J5AD8S2C@8H "@V[L\BD$8=-QZTOEEAG-1O,$^E #E7;
M05!.:BCE#L<'K4I_=G&>M #J.*;]YMM#+VSTH &4$\TT@+R*,%Z4)@\F@!67
M:FX=330=IXJ3KQ3&78=OK0 ^D(W4SG[M2#@8H :5R<T[(H/(IBK@]: %  .:
M=P130O)IOW3B@!5&YMO:G.H''I0HP/>FY+MB@!R*&&3U%)M^;-!4YXIU !49
M&TX]:DHH :$ .:;]\X-2J-QQ2$ &@!N-@IO;=WIS#)I63:N^@!G3FG*,<TBC
M/-'*GZT .8;ABD*_+]*=10!&HW'GM4E%% #0 #FG'D8IH7YJD9=M # ,#%!&
MZEHH :PXSZ4J*&7<>HI&'?TI%Y.: 'T4T+@YIU !2, :&&1BD(X% #N!4?\
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MI4,IW2")5S3<4@3.ZT'XB7,+"-B,?6O6- \607UNK22H&_WJ\6T'P-+J47G
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MCY!QZT8YV^E.)YZ4C<G IC$[_2G;RR].E-Z\#M3@1MH %&?F-.IN["YI/,%
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MJS116-S0**** "BBB@ HHHH **** "BBB@ HHHH *JWEC#>1%)$!R,<BK5%
M'A?Q ^'$+RRW$$9)/. M>&7FB7MI.RM X ]5-?<$]K%<#$B!L^HKBO$/@:WO
MRQAA09_V:6Q5[GR*\<J-AE(IN3VKVW6_A1=-*QC48/HM8"?">_YR._I3%L>:
M+%+)PBD_05:72[UEW>2^/]TU[-H/PJN4"F1 ?JM=XOP_B6R5/)3<!_=I6'&;
M6A\J2>=;OM?*D5JZ9K,UBP96)/UKT3QM\-[F*:2>)/E'. M>5R6=Q:RLKQ/Q
M[4G$VA6E%[GJ>A>,GFC5)6 ^IKNK2\AO(5*L#D=C7SA'=R0OP2M=QX6\5_90
MD<SD_4USSIGK8;&=&SUB1<';BH?* I++48=0"LC#GWJRZ\\=JY91:/;IU(R1
M6,8*]*2*W&>:DS\]/8@<BIL:M W[L "DZ\T?>%*O"XJ;!T&DD_+0,BEI=P/
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M U3T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $%W_ *AOI6".7..E;UW_ *AOI6&@&\^E #L#%1O]Y:>S /CM2/C&: )H
ML9XZU?0@)SUK/M<,V:OG&.O-2 *XR:>&3;FF>6NTG-(B@@C-&@T.#*QYZ4FY
M5)S^%.\M57K3=BMU[4)B'#&VF\9I.U+@8S3&*Q'%&Y<^U(P&!S1L7IGBD X%
M<YI2Z]Z8%7.,\42(#C%%@'[UW>](2I;CK3 F7&?2EV@/UHL@0IQQ1D;J4@>M
M)\I;K0 9&ZDW*#S2[1NZTW8&)]J!#P05YI RXQWH4#;2! >>]/H- 2N.*:N*
M<4 _&G+&H7- ,23:(\]JRY"/,-:D@4Q=>*RY /,-)7$(<9I>-WO2;<G-+M^;
M-4 $A3]:0D+3M@89/:H]N[K0 [C;[4$+CZT;?EQ1MZ>U  ,(-K?>/2AON8_C
M[TD@!<-W%/QN&\]30!'D]%_&G@#%(V%Y7OUIPY&: &L/EP*56'Y4N1C-- '.
M* "1@6RO2G YYIH7 Q1]T8'6@!01DXIA.3GM3E Q2 ?-@=* !<;\G[M.8KFA
MU"C':D(&!0 _"E/>F9_=;?XJ5C@4JH"NX]: &J<C%*2 <4B@9.*1@=] #R<"
MD#!NE!&1BD5=M #J1BNS ^]2TW;\V: &@XZ=>].8C>".G>E"@DXI@'S;1TH
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M &C&:<I!:F@#-*%V\T .?:.G2H5?YJD."*;L YH <6 H!STI&4,*487B@ W
M\4@Q@TH7!S2 #!YH $ W;C]WO2?QY[4[CRROK3.O!Z4 28W$4A 5@#UI0=I%
M(QW.#0 -CO00,9-# 'K1_#0 @( S2\,*3 VTHP!0 'I3,G&.]29%,? .1UH
M=C<@ ^\.M*0"05[=:0':NX=3P:7A>%_BZT -8[G!7I2Y"\FE*A>G>D8;ABE8
M!0R9HDP1\E,**.]. &WBK'N"<#FEDSD;:0G"CUH/;%38+ )=GWC4OGH4YZ5
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M*EF,K:')P>%\8)-;EII2VZ@8'%:@4"EK102..>)G+=C50*, 4ZBBK.<****
M"BBB@ HHHH *CF^[4E13?=I,"N/E;%(P^?%+T.#32#NQWI("ZG"BBA/NBBJ
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MF8F@#9_M),XS0-3C#<FLSREW9S2O:K@$'K0!?EU1-PVFC[>2N<UG?9AZU)L
M7;0!)+?N6 SP::<R<CK43Q#;D=J9%<".3:QQ0!,21\O>D*G\^M/X=MR\TO-
M$MLJJV35X$'Z51@^:3::O  ?+4O<+!QS2<;:,#GVHP-N:0Q>HXZTO0<?C2#@
M9I3TX[T -8@KQT[T@^YQTIVS V]CS1C V]J8#>U. !&.])2@8&:8," ![T9&
M!BE89&::1C'O2N(7C=[4AQN]J5A@BDQ3&AVX8YIO+&A0#F@<'-(!,[6QWI/>
MGE<_-WII':G<!5.5XZ4F:5!M7%)0 E.&-GO2&E &W-*^H#7.(O>LY\[S6C*/
MW616<QPQIK<5Q>U(5&,4TL=U+N^;%, 11SN_"E505)/7M2Q_-NS3 W6@ ^;:
M/6GCI2*<CFEH :<;N:?DXQ43 [Z&<JV* %"DGFG'IQ1GY<TBMGK0 JYQS36&
M#D4K' I0<K0 W><8'2EYV_[--/!P.E2?\L]O:@!JYQ[4U0P-/BP<@]J&. :
M$();VH7(//2DW'9GO3@<B@!#G=QTI&Z\]*?2'#"@!JC/7I3B?X1UHZ"F#.=Q
M[4 /V\8_CII)Z=QUHWDG?WI"><^M #P<BDYW>U*HP,TN10 444A.!0 -G'%
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M1Z5E:A$SN'0D8K5(VH?6EB$;(=XH BTQ3Y'S<FIV?8Y&.M,WJAPG I3@C<:
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MW>M77()XIOM1<"J;?D4&WPV*N8P1FD<C<!1<"NMOMS41AYJZK#)!I  V<=J
M*OV?*YHCML$L:N+@'VI00&/I0V!2>VYQZTY+;"8JP>33\C;[TFP*36^WF@V_
MF8]JM=1S0I':F!7%OLYIC6_._P!:NJ.YZ4C8S[4>0%3R.GO2_9JL\4\8*X[T
M= *0M_FQ0;4D]:M8P:>2,#%*X%,6F'S2&WVOGM5T,,T?*6H H^3N:I$@&[;5
MH!>:%*@TV!&(_+:I0<C/I0Q#=*!TX_&D%QP;Y<XI4EYH&-M0#B0GM0@9<\VD
M\[YL57W=: W'O0F!8\[YL4+-DD55R:,XJK@6S-@9IOG_ "YJMDD49XH LF?
M'O2^=\P%5CG HYS0!9\[YL4";)/M57)!I1DYQ1= 65FR*&FP*J@^E*'Q]Z@"
MP9\ >]*9OF JLWKVI,\T 7/-H\RJ@))I68]*0%KS.*3S:JJYS0S'/%*X%KS:
M/-JNI(ZT9(%.X%GS:/-JJ"2,=Z3<0:5P+7FTC38%5V;TH4YZTP+(EXI?,JH2
M0:<K?+BBX%H29-)YF#53<0:<SY%%P+/FTGFU64D\TN_YJ+@6/-I?-JLK=<TW
M<<T 6O-I1)FJQ;Y<=Z3<<#%*[ L^;3M_RYJH2<9%+N.S-,+EGS:3S:JY(%*&
MXHN!:\VCS:I[C3BW'%%P+)EXS2+-D56W'-!//%%P+?F4>;557ZYI"QS1<"WY
ME'FU6W_+BF[C0!;\VCS:J;C2J3U/2@"UYE*9,55#\TH?@YI@6/-J*:3*U#N-
M./S+28#0^XYQ1N^;.*1,9I>-_M2:&74.5%%"?=HJA _W:J87-6W&5(JGL._%
M2P%!!.#TJA=']YQ5_P KK6=<(^XD T("%O;K3]RE,9YIJQN?F*FA8'#YP>:H
M!5P.E,+9;':IO(8' !YIC6[*W - P&#QZ4[*L.>W2B.!LG@TTPOGH:5@T' (
M1GO3,#)I!%('Z&G>4X.<&G8!!C!H^7;BE$+],'FD,#],&@0, 8R#W%5+> 0R
M$CO5H)(3C!XIS1/C.T\>U ".<C'>D0"E6-S\Q!J0P,HW &@ RB\ ]>M0O&#)
M@=*<L#[^AJ=H6 S@T 5IUWQ;*I6]IB7<0>*TTB<]5I"C@\+0 F1G%#(F,CK2
M>4^<X--,<BG.#S0 [((Q4;#L.E3&!E7@'FFB)Q_": (9X!-&%;M1#$L?%2@2
M$D;32;)&R=IXH E^79[TS(Z4U8Y"<D'BG")P<X-  F,T2L /EH$3CL>:C\F3
M?C!H >L22#YZ7:!P*1ED4<*:D6-RA.#D4 -"HJY/6EC*L>:C\J1^H-.>!XUR
M >: $EVJ<+^-. 3RJ:MN[$9!YH>%U8* <&@ PH&:4MM&:0Q/MQ@\>U*D+R Y
M!XH 1/WIRU.8JIVBFF.1%X!I?(<Q[R#F@ 7':D(4GFB&.3=@@TLT+CD T *"
M *:<=30(G*#(-*8G(Z&@ W#I3BJA<]Z%MV"[L&DV/Z&@!H YIN,/D=*4QR*<
M 'FG")\8P?RH ,AN*1E!(SVH6%U.<&E,3DYP: %I,#.:78_H:-C^AH 3 &?>
MF9PW'2I#&Y&,&D\E\8P:  X(IJGG!_"D\N0G;@_E3FB?'0\>U #L\XI 0C9[
MTBQR$Y(--DB?K@T /W*6Y/6B0#'RTT0.1T-21POG!!H B501[T_@C%$D3HV0
M#2".0+G!H F@4 \=:NA1LSWK/@$F_)!K31"R9(H %*[2,T!4(IK1%>G>D2-N
ME38!PVCCM2 KGG\*4Q%CBD\HGCGBG8!>"M)D8]Z4(=N?2D\HCYO6@!?E[4?*
M3QTI/*(Y]:41$''K18 P-WM0=HI=AW8Q2>46//:D%@! 7WHW#'O2M#WIOE'&
M[UIVN $C'%"$=.U'E$?C2B(J<>M'0!KX!I4P1S2F(L<4",]/2CH <8YH&-OO
M1Y1(S1L.T'%%A@<<8IXVXII0@#CK04(.*+"$P-WM2X6CRSNQBD"$YI *,'K0
M< <4@0XSBE$9*YHL C8XH.,BG>6:0H0<8I@)@;CZ4F%).:=L.[&*01G)XI *
MN!0V#S2!#C.*-AVYQ1;4!"%P*-J@\4IC(Q[TI0YQB@!,+N]J7"TGEG=B@(3F
M@ &,4G&WWI0AQTHV';G% "@+BFD+GVI2AP*7RCB@6PC*H2@*A S1L)^6E$1
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M% ";11M%+10 FT9HP*6B@!-HHVBEHH 3:*-HI:* $VC-&T9I:* $P*-HI:*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MR;_4/_NFOFWXGR$ZVX/7-?2;C<C#U%?/_P 6M-,6J/*%]#6U'<3..TO4HT@6
M"7GC%$^J)YF(^,'M7.02EFRI^:IB&!+-UKTXI6,&CIO^$@_<[=QSCUJ"+60Q
MQ(21[USPRRY%+&233L*VIT4FO@ HI(!XZUB7TOG2*V#UJ !5G7?TW"NG73[:
MXM0R ;@*JRL95=$==X$C6*"&7'8&NAN-0+71"D]:R/"402TCC[XJZRK'>,7Z
M UQUT@P[NS<MM2\E06-2'5QYF_=\OUKE-5NV.W[.> ><52CU"1L)DUR.)W:'
MHMC+NN%D4]37:0G,2GVK@?"6ZZG59.@KT%5VJ .U9O<!:***0!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM IWG#&:IXI2<+[4P+?G#CWIWF"J6[BE#L:0%KSAG%'G#GVJFQ8<]Z 3C^=
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MS2[FSBE<"T)@<^U F&*J9;/%-^;/'2G<"\)01FD,P%55)#8IN6W'-'4+EPS
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M [<T[ +@;0:"H!%-IQ;)%( 8 -B@]A2,<FE)R * LQ6[4F3NS3FZK2-@,*$
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>M\G.:58,=ZGHHL!6^S^]'V>K-% "*-JXHI:* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image7.jpg
<TEXT>
begin 644 image7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0M!W<# 2(  A$! Q$!_\0
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M=%51(V>:89FS2N!=HS5596QS3/.;-,"[FC-4O-<4>:XH NYHJEYS>M.$QVT
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M@8A;C%+]Y<4AQMHR,<4[B +FA5YI2?2@\CBE< )R?I32><T=Z=@$Y% QK'-
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M3%)SBG9&W%&X;<4"%7D8II'-+N^7%&01BD T48HIQ((Q0,0G(Q2<TN:4L#3
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M[32[2>M6O*I?+HL,I[32[35ORJ/+HL(J%32;35SRZ/+H J;31M-6O*I?+H2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHX@ G%24 (W3FJ&0MP35Y_NUG1_->,I]* +C3A%S3HYA)TJ.XC&RH;4GS,4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ6&XU/E/2E#*!Q0 #(2JB0[;HR>M6]XQ1N6@!)1N2JUO#LF)JV6&*:SJ@S2
M29-]52&@/RCK5SS 0#2$J>HHL!''(QZBK!&Y<4WY12[AF@"E/#AL@41NX7&*
MN$J3S33M':F L63'S5%HBUWG%7U8=*3*[O>DP(Y8OW6!5:T9_-*D<5>W G%-
M&Q6X%,"6BFAP:-XS0 ZJES;A^:L;QFC>#0!1C+KQCI5B)-YW&I/D]*4,!TI6
M BN8_P!V2!S5. .0<@UHEP1S2#8.@I@4PA#[L5+.Q^SYQ5D!2*K7LBQPDT@*
M,(8-O YJR59^2*BLYTD8#%:7RCM3 (EVH*DIF\ 4>8* 'T4TN!2>8* 'T4S>
M*-XH ?13-XHWC- #Z*;O&<4;QG% #J*;O&<4;QF@!U%,WC- <&@!]%,\P4>8
M* 'T4SS!1Y@H ?13/,%'F"@!]%-WC&:-PQF@!U%,\P4>8* 'T4SS!1Y@H ?1
M32X%)Y@H ?13/,%'F"@!]%,\P4>8* 'T4SS!1Y@H ?13 X)HWC- #Z*:'!H#
M"@!U%-#B@.#0 ZBF[QBD\P4 /HIGF"CS!0 ^BF[AC-)Y@H ?132X HWC&: '
M44SS!1Y@H ?132X%!<"@!U%-WC-!<9H =13"X% <$T /HIA< T!P30 ^BF;Q
MF@.#0 ^BF>8,TH<&@!U%,\P4>8* 'T4SS!1Y@H ?13/,%'F"@!]%,\P4NX8S
M0 ZBF>8*/,% #Z*B:4"G%QC- #Z*9Y@H+@4 /HIGF"CS!0 ^BF>8* X)H ?1
M3=XSBD+@&@!]%,\P4>8* 'T4SS!1Y@H ?13 XQFFB4$F@"6BFAQBD\P4 /HI
MGF"CS!0 ^BF&0!<T@E!&: )**9Y@I2PQ0 ZBFEP!2>8* 'T4SS!1O&: 'T4T
MN!2;QF@!]%,+@&CS!0 ^BF>8*4.#0 ZBF;QFCS!0 ^BF>8*/,% #Z*9Y@I0X
MQF@!U%-##%)Y@H ?13/,%+N&,T .HIGF"CS!0 ^BF[QB@N * '44TN*"X H
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M,% #Z*:'!I-XS0 ^BF!P:/,% #Z*:'!I/,% #Z*:&&*3S!0 ^BF[QC-)Y@H
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M['.*&7!HN YF.:3S6Z4H.1MI-G.*+A83>:"YHV\XH"Y.*& ;WQS0DC$D&GD
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MQVH[[>U%P&C./:E!]:=_LTF!0.P@89YZ4 C-(!SBE R<4"%!]:;WHQS2J,T
M*#QS1D8YZTP]:7ZTP$HR:<%!&:3'RYHN(=G*^],/!IP&!FE(R,]Z0 #\O'6E
MSQQUJ,<&GG &:8"YSTZT9]/QI. ,T'U'>@ .#TH)':C[O2D88H3&+@$YH+#/
M%-5NU##% A6&>10OZ4*>U*>!B@88YSVHXW9[4 ]J,<XH0#6ZT TNT;L4F.:
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MI">:?C+<TDF U%PT%W?+BC=QBF44"'Y^7%*.1BDXV>]-!QTHT 7H:4<TF>]
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M>!F@+B[SBF@G-.X'-)P.:>R$("<FA6P: 0"?>@T7'8;(YSTI0WRXH^M'2@8
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M*5B!S3A@+FF U6/6E#$$T# .:%(!-%Q &Q2;B#P*4FE7&.::86#>::SGH**
M.:D=D*"<4$\8I3@#%)_!0]1";CMQ1DXQ1D;<4HP1B@0;SBD#DG&*.^*?@$<4
M%)#=Q8XKDO' S:'/I771CYZY/QR,VC8]*S:-*?Q'@MUQ=O\ 6F,2HI]V,WC_
M %I)!N48[5SRT/6IK0BW'.:F5R!FH5'.:DQGD5"-B19"QR:&;/- HI@0.2#D
M"F\L,D58VC/2D*CTIDLIL,<BHLD'-6W7FH9%XIID-7*TK<<53E)%73&1DFJD
MA&2*M&,D4W8@TN3BGLN.:9GBJ,F <CC'%.WX%"D8QWI",<4R;BJ<\&D9B#M'
M2@$!<=Z<KJ!S3V0AFXXQ2[CC%#$'I0!NXHL,"Q(IZ-QS1P1CTI,[CM%%A"D[
MC]*!\W7M3#P<4&F.P\?-^%*K<$>E-4X%"CDFD%@+&G*W%-ZG-'4YI"TN!/.>
M]*#CYN]!Z[NU-W?-[4]1L<>?F[TUONY[T[OGM3"?F]J0A <4[..:;GFBGN,4
M,<GWJ-R0:E4A1SWJ-L9I ,WFDR0<#O3N!0I"\'O3$UJ)DK1AV/ -31Q[VK9L
MK $ D47&B+3;8D!G&*T9&?/EH,BIMJC]VHP:T+2V5%!<9J2DB32;( "1AS4=
MXF92 *U8"#\JC%020;I#0-(I6<+%NE;,?RKTIL*+&O2GB49Z4[@2!LYS4;,2
M>E D&33\@TA7&[R!49G(ISL*AQO.11<:)?/++4#$ELXIVW%.WJ*&!*A 3<>*
MHWE\D8/S#/UJMJ&I+$I -<G>7KRN2&./K2&6M2U)G+!:R@O\1ZFD5CNW-S3B
M<]* '*<&G+;EG# =:2.,L16Y:6PVJ2*+ 0V]D2!Q6U:0"%.!3XD5 .*EDD6%
M/K18>EKE=Y_+S65=7KM+M'>I;B0EL#O1;V#2R!B* YBS8;\C@UT$(^7FJ]M;
MK#'R!3)[Q8OEIBYBXT2NV,TH54X%9!U90<9IC:LOK1<?,:\UP$0\UC3ZI@D9
M%4KO50RE0:PYKDN>IH:"1KR:HQ;K4$^J.4P#627)7K48<EL4"+#7\C$Y-1_:
M7.:B=<\BA"#2 0NS9R3303CJ:=*PR,4PL,YH$.4MC-2I.R_-48<%<T!@1F@5
MRVNH2)\PJW%K,BKGO65D;<TWW[4RC:?6Y&7WJK)J\HZ50&2<]J?@$4A7+ U>
M7-._MB;TJA@*W-2J5"].M(=R[_;4J\>M3PZ@6.2>M8Q&#]:52R'K3).JCN%8
M 9'-2F&-UX.:YI;LH ,FK]GJ&UP&)H&KEJ6Q.#@&LNXA=7V[3BNIBO(9% P*
MCGMXY>0!05N<J2R#%1B1G;:>E;=QIY8\"J$EFT9Z4V!68X^44$G&*:P*M@TX
M,&XJ1ADXI#FG$C&*:6!&*: 0G-*)#2=Z=LP,T"L7K:[( SVJ]]K\R,YK!$G<
M=JGCE)&0>*=@++D')J) V_.*02@MFKR*K)O H'8F10T7O0MMD\BB $-D]*U8
MU61< <T6),S8T!W(,U<64S1;7':K+0B,?,,U6DP.1Q0)G.ZM8E2712:PMS X
M(Y%=^L:3(58 \5RVJ:<UO<,^.&Y%-;D-&26-.WG%*Q [4Q6 IK<0 D<4_IQ3
M<]J7IP:8^HC$C@4*2#BE'!P:<V,8%*P";OFQ4JR8J$#MWH/I28)=38LI<GFK
M^-W2L.%R  #6U:R#9S2-%N/AD*28J>X;<M5F8>9^-3GYUI="BC(2*:C'-69$
MS58_>'M0M1HEQD5&4QS4F[(IK=,T RO(3FJLC$<U=;!&:K2+SFG<AE)SWIN?
MESWJ248YIBCY<T[DB$G&:"?EIVW R:;UIW%= HQSZTKX7I32<"D^M ;CP>*C
M/RGBC.VE''7O0( Y(QBFD[>E/(&.*;[47"PW?D8J,L3\N.*D(P*,C;[TQ$!)
M7@4\.=N*#BFY'2ADL4$D\T.3O3ZT2$;1BDR"8Q[TT*6Q]&?" YTQ<^M>I3-@
M<5Y=\(Q_Q*EKTYN3S5+4YY CEASQ2QMA\>](2,<4B?ZP51F7QTHI!THI@!Z5
M2?&[BKK=*I.,-28"8YXII!WCTHW[6Q3C)EP,4#'%>1Z4>W:ASQBDS\N*0A[?
M=XJ,'C%+N^7%- S1L%Q2302<4X<\4=>*$P&4N/6G#YOPI&;F@$Q0..::<YIV
M=U-+9.: N(<]Z<N,>](QS29[T '.:-O-+NYS0&YS0%V'.:=@8XZTW/S9H#8.
M: "@\4!L'-(3SF@=QQQQ2L..*8> #2[N*!7$[TYAZ4VE#<8H 3!(H P.*4'
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M!CBGRBN*..O2C SGM2$G%"$]*.4+ZB\9I"M!X-&31RCN H9><TG-.)XHY1W
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MBFXT_9@4IR*.31<0BKFE([T'(-)U-  .>:4C!S1CFEH$(.N:-N#FC.!0,]:
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M<4#0U5R:>PR*3Z4X'- #%7C-*!NYH[\=*">>*8 1S1M[TG4TO(.>U D!&.:
MN?FI&R>>U*IPM ,1E[TNSY:.<Y/2E#<\UFS2(T)M.:Y;QLFZU/TKJ&)+>V:Y
M?QHV+0_2L)O0Z:/Q(\3F3;=/]::\>0*>^3=29]:3G.#7$WJ>[3V(]G&*KO\
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M.*-P')H&-Z<T=.G>GY!I%X)S1<!.E!^7\:4\&G=J!H9TX]:7'%(WI2KP.:!
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M<4XB8[C%&!2[?EQ2@8%:K8S:&\"ES33R<4H&.*9(&E%(1F@"@0M-(!IU H
M.**.M H&%-V@G-.ZTE F%+VHQQ10"#M1VH-(>!0 HHH'3-% PI,#M2@=:0<4
M# 8[4N #0%I#P<4"LQ32 8I<48H$! )HZ"C'-!Y&*!B9XHXHV\8I-N1B@ '6
MCG=0.N*<!DT Q-H/6CI3B*;C)H"P;0>32\4I'%-VY- 6U%[4=J,48H$':DS2
MBDVY.:!VN+VII/I3NE)CG-"  HQGO12]*3'.: # %+Q01@4@7% !@ 4"E[8H
M48% 6#%'>CVHI &.:, FBC'-, P!28!I<48H$ Q1Q1BC%  *3 -+B@"@ HX)
MYHZTW'.:!["MC-'%!&>:3'.: '<4F!UHV\YH/ S0 O&* !30.].!H#9B=Z7%
M 7G-+T- [#< 4IH(Q1B@D#BDP.E*1@T8H 3 %!I<48YQ0 F.*!BE8=J11VH&
M!Q1@$4,.:51VH$-'6E'4YI<<T 9H'<,9ZT4$THYH 3&>312XR*0#C- A*"<"
ME XIC+QF@$*,$9[T<9I%7C-+M[TQL>*:^*6FLO>LY%P&J!D&N9\9C-J<>E=,
M!R*YWQ>/]$;Z5S5-F=5'XD>)W'%R_P!::3Z4MT<73_6D5>/K7%)GO4MA.^!T
MJ*3_ %@QTJP$P,4PQ5"-+#=HW ]J7 W>U/"?+BFA?FQ3'&(I].U1,N14W^S2
ME>,4KC:T*W3K3#SUZ5*4W'%#QX6J1!6XS4;#-2;"6Q2;<U:9FT5\$TH7=UJ9
M5S2[>"?2FF18JNH JO( ?K5IQGFJTB\YJT9214D6HB!CWJTPR,U T>3FK1BT
M5SQS4;XZCK5F2+Y.M5Q'@Y-,S:$;:%!'6@_,E))%@9S2@;5S0) .!Q2'VIRC
M(S2#Y#0 P,0:D&,4W9GFE^Z,>M WJ(3QQTIGTIY7"&H5XR*I"N2 <^U-8X/'
M2G _)BHSR*!#3R?:D'+;>U/QQBI(8=STF"5R>SB^;YA77:%IX#^8Z_+VK$L+
M3SY%4=C7;P1"&R"^U9MG1"!B:U*991$O(7BI='C$?)X-02I_I3G.>:T[2WW+
MNSC%1<Z$B\[%DYJFAQ-^-63)QCTJ&*/S)-WO2 T%0,N>]/" +SUJ6"+"Y-,E
M&6XJDR'8=$0$RU02W<:MC<,TR[D\J FN9DNF>XZUHGJ9LZ/SE=NO-2^4A&:R
M+/+.#5^><0QGFF*Z(;RY2-=JMS6%=7>[/-)<R,TI;UJE*A^]FI"Q"[$OGUJ&
M9\+Q4S'''K3#;EOQIH;*T$9FE  SS76V=JL%F,C'%9VG:=L<,:U=1E$$/ECT
MHW,VS*FG59L \9IXNOF !K*D;<Q.:FM 6E S39)TT4N(,D\8KF-4N6-P0#\M
M;]R?*L]OM7*7;;F-2-Z%)CNEYZ5%@!SZ5(1VI"N5IHAL8SXZ4S-&WG%*%Z^U
M:)DW&DBE7IS4?WF^E/Q0)B+@D[OPI,9/-*5R0:,4F =.*13^\P>E+UIQ7*9I
M @/WOEIP4 Y_BI%&Q-U2V\9GD%!5M2>*)I1P.:OVVG<Y9:OZ?IX7#&I[FX6(
M$"DV6EJ1I:6T8R<9I7GBB7"$5DS7;%^*0*7&<]:FY21+/>2D_*>*@^:8\U,L
M8 YI,B+\:395B%XPK #OUIVP*>.E*3DYJ-FYQ1<JPXN0<+TI=U(BT\IDXJ;C
ML-WGIVI-YS[4XQX&*!'D8IE6&>82V.U/ZTTQ8-/5<\4TQ-#*C[\U.8]QQ1Y.
M[\*+ZBY2%<]Z1E'>K/E4C0;AUH%RZD$;L@RO:KMMJ,BGYC5,+L%-(W].*=Q6
M.EBFM[E<R$9JI?6$,J9A&3[5BAVB[UHV.H^7]X9IBL94EI-$_*D"H7^7K77[
M8[V// )K,O-&P"P.:+BL<\2#TZTXC:,]Z?+;-;2DD4A4L,TS.VH8"KN7K4>\
MD\U+C Q33#W]:0EO84 =J<I(IJC;06QQ18&M1Y"XXJ)@>BTX#"X]:13M.*92
M+%J_E]ZZ"QU#<1$S?+7-T^.4Q.&!I#3.BU*Q62,R(,UAX\OAJZ33+M;J 1-Z
M52U33-C,Z]*-QW,A@&'-(V-N!2<D[?2E*4%#<\<U&0":FP",4GEXHN @Z<T@
M()YI?O4@7-(G<7.&XJVHW0FJBKGFKT'*8IW!K0Q[H;6-5>J^]:.H1X.:SD&>
M:I&;!<#ZT'U'6AEP<TF.-U-$"!B33T.3S2JO>@#F@I#@%##ZUIP$#&*S&3[I
M]ZT(5P!S4LI,U$/R<5"0 33E.U:0C)QZT&JV(';%-4;C3YH\40+@8HZ RS
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MC-&X8S0,8HP-M(8N01FDW@&E& *3:#S3$*,=:9O&:<N#Q2%!F@0I88I>,9I
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MJ,4$\8H$%)UI<X%(#N-!0['%-IU)C/- ,2G =Z*,T!881D[JDXVYI#10 TY
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M[M52_P V*UB9R[@:AD)SBI2XZ5')TJT9,CR3Q0.M.5Q33RW%.) TFD[4[K2
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MY!.>]-8@\&C;\V:CEXYI@V,; -5Y'QTJ5C\F:@9-PSFBUS*;:*\LI12<U?\
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M;V)IW)9D$Y&*0(.II=GS8IY7(HN3UL-4+WI7*XJ,\5'G<?I1<&284CGK5:1
M&J5AWII&X9H)('"]ZA.-W%2RKWJ+;QF@0F!UICXJ2F,F3FJ&"@8XJ-P/-3'K
M4JKMJ)AB9#[U1,CZ,^$V!I25Z<Y '%>8_"8?\2M3ZUZ:ZX%".>6Y$OM3D_U@
MI(_E/UIX&)![UH9%P=**!THI@#?=-4\_,0>O:KC?=-4^K$GM4L-1N<-@]:CN
M@?*.:<1EP:+D_N"?:HEL:TW[QPVIQ9NQQS34T\R)D+S4]\V;T5M6$*M ":YI
M:GKQJ<D;G,W%@R1DXYK%G0AB.]=OJB!(217$W3GSB:RDCNP]1R10FX!K,G?<
MV!6C<$\UGE &S631Z,!T*G@U<Z@8J"')Q5ORPH&*6PI,5%XIV,\T]5P*4+@8
MIIDC!FEP<\4]4IX7!Q1U%?48.#[5)Q^%-*_/BI%7M3L1(CQS[5(0 .:<(^<=
MJ1USQ186HPD8IJKSGM3]N1BGJO%%M!B @#%1J,$YJ0)ECFGF.FD3<8%]:KW*
M<&K9R!TJ!AO4YJTC*3,X1C!S5>6(8Z<U?=< U&(]ZECUH21EN4!&-F,?-3UC
M;&.]3"/YLXJS#%\VXBJL:1=BLL#8Y'-03P\<"M5U.>!431;NHK*6YJI&.81C
MIS40C.3[5JO  :KRQA%..XI-FJ5S(<@D@4L"'>,4K0E9..]7;> #!J6V:6L6
MHXB0IQ5U$.W%)"G %3%2IZ4]62WH,$)(SBG!,+4JDXQBD(YJD9N6A J\\T,,
M5,PP*8>5JC/F(=F>:='#SR*53AL'I4@/S8HL1.0^.R+G@4Z2P=1R.*V=)B64
M@&M*]M$6$GT%'+H1&KK8XPVI]*B:W8'D5J2D!B*@R&K/J=2EH4/LY]*/+(JZ
M>0:A/+<T%W96*\\T8YJTT8/-(L63FG<+D&#4;J2>.M73&!4$BE3D4T2Y%)D8
M'GK4;QY' JXP+#..:CV'TJKD;F?)'QTJ%H%QD#ZUIR0YYQ35M\CD4FQ\MS-6
M,=A44S <"M*6$1CBLV6/)I7*2(H 6E![=ZUHXU(! K/@CVR =C6O%&%'%(I(
M3R^.!2B/GGI4ZK@XIQ3YL4NHF5'0#I2)&2:M&/+8IRIM;%-"3*OD'=TXJ-X-
MIZ5?88--9-PZ4RBHL?K4B("#Q4NSC%*$VTFA;HA" 9R*@E09JYMS3&BS0@LC
M-DB^;.*A>V9SD"M)HR3R*>B +0298MR!AA2K$%/3FM%H\@FH5AS\QHUL!3^S
MDODBH'M\2YQQ6OY?'2HFBS0FRN4H,HV\"JKHXK7:W %0RP_+TIJ3,[&'(C,>
M*BD@7"DCIUK3E@*\XJO(G'UK6,F85(W1G32S1X:V)&WTKN_A_P".#:3""]F/
M)P,FN**^6VT<[JHWMNUG*D\).0<\5T1D>=5HW/KVQO([VT26(@AES4H5L^U>
M.?#KQRTUM%;W#A=OR\FO8K>ZCN8@T;!LCL:Z$]#R*E/ED/+ 494+FDV9-.*<
M8J[F7+J1EN_:G+DCBD?RXT^8@5G7FLVMG"Q\U 0/[U#DBU%LTB/6HGD7I7 7
M'CP?:?+213SCK75:1=G4(5D;N*CF17(UN:>>*Y[Q/_Q[-GTKH'&"![U@>*!F
MU/TK"=C>A\2/))0?M#Y]:;T!S4DW_'P_UJ(DG\*XI'T5'6(S'/-1N?FJ0FH\
M9.:SN:L6F$G=Q0Q(.*=CC/>@E#N=OO2<L-O>C=\N:6/[VZFBA"#T'6EV\>]#
M'#9IPYYH!I6(RI'(J16XIKG XJ-2<T")F8'I4,AR.*5A@4SFA$M:$502')XJ
MRXJLXP>*M&3(FZ5"R]Q4\@^6H_X.:TB9-$+<+FH3G.:G;E<4W:-N*LBVHW^'
MFH3UJ5^F*AQQ3)8F:8,YHSR:5>:"/(<#2C)--P:>GK0P0_H.>M"^_6CKR:<H
MSS29:0]3VI<<T;><T]AA,]Z1H$9^>M.V^\#WK-A7O6C >E92-*>YU%LVZ  >
ME1.<.:733N7'M3[B/#DBL3N6PR%SOK:A.5&*QD7:0:TX7*@8H1#+,RY0XK(C
ME,=UC/&:V7.$^M<W>2%+[ Z9JS-[FS<_O8\CTK+>/&3BM.!M\'X53G&TXI;C
M2*6PXSVJ59"$QFIQ#F#@5!Y9Z4@*4H9I<]J:R$"KGE_/@U%.O&*86*T65?)Z
M5JQ7("@$UF$86HUG;?@]*:):.L@E5X>?PK"U@G8U6;>X(C JEJS%HS6D3":.
M"O 1,Q/K5-CNZ5IWB;G-9Q38#6\6<LUJ5VC).<4QT[=ZLY^7-0%B6S5'.R(#
M9P>M. #&E9-YS4BQA1GO1<I)#T X ZUZ!I>19+]*X&,=#WKN]+9C:KQVK.;-
MZ<=2J8V>[;ZUI$?N@!UJ%4Q.QJP.M<[9Z5-:$4BG967,GS'%:TIP,5G3#!XI
M+<)HIMQ568YZ5>D3BJ,ORMBMDCF9&G IV<BF>PIZ  \T^A#$W@5%*>,]J=*O
MS<4PY*X-4B65\\Y[56E=H\D]*L/QQ4$X#QX-5!79C4V(+&W:^OD51GYJ^C/!
MNG&PTN%]N#MKQ7P)IIN-6^93@'TKZ'M$$-@D8'05WTXGEXB1-(^33"WK2$&E
M49'-=:V/.;'@C::BSAJ%)S3B@(W4P8$Y%(H]:%YZTIIA<#0#BBEH 3?\U*:;
MM^;-.H&-;)'%.!(6FL<4O5:$ TDLW%2MC:,5%&.30Q(/%,!V: V11U%-Z' J
M0%P<\4M*.E-).[% "<[O:I%QFFTW<=V* )&//%(#SS3<\XHQF@3%[^U+GBDH
M.*I($ !S2,IQ2ALCFD#ENM2V.2")B#@]:HZ_:BXTZ0$9)%72.=WI3Y%^T6K!
MO2LYK0UI2U/F_7[4VFI%<8R:KS']Q@?>KIO'UEY.I;P.]<CYA9,]Z\^JM3UZ
M4M"UI'-T >N:V]8/^@LHZXK TURMV#6SJDF;1CWQ6*-);G(29S1N!7'>B3.<
MU&<CD4]T2Q6SVHV$XQ^-/Q\N:%;%&MB1R<,*UH\-'Q60"2XK=M(OW/X5):9F
MS_>-2VJMU'2HKOY9BOO5NS'[DU9+1F:K)^\QGBLL#GCI5W53^_P*ICCBFC-B
M9PWM3AR<]JC()?VIZG!Q3$F* 2>:0+\W-*&YI <FD <@\U-;'$HSZU#U.*GM
M0&D&>U#&CO-$.8A]*75!C&?6F: <Q_2GZKEB/K4FB*,*YJ"[!#59BR*BNE+'
M)I%(GTPX>N@C^8<5SNGY#<UT,!PHJM!]"<' VT[/%*$RN[O01A,]Z.I+,_4)
M?W> >:Y^YRP-:MVVYB*SYTPN:+:DF)(N&XJ,M5F8 ,35)SAN*.HALIXXJ!7^
M:I9>E5E.&H%N6&)/(Z4H^Y3%/:I0O%%Q%.7/X4SG;4\J_-M[5"_'% G<B&=W
MM3B<4HIC9)Q5 )S^%,_Y:IGUI_7@U$Q/FH/>FB9'T=\)L_V6M>G2=*\P^$K9
MTI:].;YAS31S3W(Z<A^<9I$&[-*@_>5H9ET=**!THI@!Z538_-Q5QNE5&QNI
M,:&DC<*BO&_<GZ5-A=U17NT6S?2LV:4])'!:E.([T,:V].OE:W&*Y?6''V\+
MGCFKNGW"HH7-<\G9W/8C%25F:FIW :(BN,NG'G&M^^GR#SQ7.SD&4D]*PD^Y
MWT(I:(IRN.:H,WSU9G=0QYJLA5GK*YWQ\BY;D!>:LU!$% YJRNTT[!(<K;>M
M.)I" :>NWO1<AL1&QP:?N&:3Y:,#K09MZD@&:GB3=Q4*$8]ZF5MG-4).Y9^S
M_)[U3;!8KZ5-]K.<9JN&!D)IAJ(%YQ2[L'%.+#/'6E" \GK0#U)43S "*G2W
M+FF0$#BMFSMPQ!Q3CJ8U))&=+8G9G'2LB?Y7(]*[>XMU6$\=JXN_ $S >M6U
M8YN?F*+L#0&&W-(12;>>.E*P+0?''O\ F[5,!AL8I4PJ\5;M(!+("10:1E8C
M"!5W$57DQV%:T\ 08QQ5!D0'FID;P=RD\>!FJ,J$9)K5."2#TJE<!>?2H9TQ
M9FM&,]*L00GK32 6JY#C%!3)H!@U9(!%,CC&,U,HR:=C)C47"XQ2[,#I4VT#
MZU((QY9)ZU5C*9FN,&HV;C%6I%&*HRG'2JL8=1LD@VX'6I(Y P [U5# MS3H
MW4/UH$;^G7@A:M*XU%98BH]*YZ'!Y7K5HY*8'6A,26I6G;<Q(J!7ZU.<<YJE
M*VUN*R.F*9/Y@ZU!)*"V14;2#'6D0@M2N;K1%J++\U.!M^:HHL!@!TJX55NG
M2F)O0K/\PR*9M^7)JSM ;':F.%!P.E4C!LID!6SVIO&>E328J-!\WM5,2>HJ
MJ#VI'C"C@581!FB10:AHU3N94J]<UGNF#6G/Q554#'FD:$,*<]*OQ1D<&DAC
M3>*T4B7% =")$XQ4GE5.L8"YQ3U V'/6G8ER13\OYL4%<'%62O>DV C/>D*Z
M(/+XH\NK 4$>]*4XXH5QE;RJ9(F,5:QQ0RAJ=A<Q3\HMTI"F2*MD ' IS1+P
M11:PKE:6(%>!VJMY9S6DP7(%0R( W%2A,IE.*!'QG%6=H)I^U1Q3T&F53&-O
M2HS#QG%7-HS[4X*G0]*')%<UD9C+BFLH"\BK[1IN.>E0F-<^U%R;F9+$&SQ6
M<T)#-FMYT457>%,DFFB7L<S/&4?)IKX>/##-:UW A[50DA"K6L78RE"YE6[3
MV5X)(G*J#G ->M>%?B'%9P+%.S$].37E+N/,VFI@FP;X^M;*;1Y]7#\S/H6+
MX@6<F/>DN?B!:0YKY_BU&Z3N>*?)?W4QY)YJU5T.?ZDCU36/BA;,K1H3GZUY
M[JWBBYU$L(I7&?<UDK9&<[G!J=+%(SD"H=4Z:>%L5=*%V^H*7D8_-ZU]'^#U
M(TR+/7:*\(TN-1>+@=Z]^\, #38L=<"KA(Y\3!11L2<O7/\ B@_Z,?I71OC\
M:YOQ20+<_2E/8Y</\:/*)CFX?ZTUAQFGR8-PV/6E<#C%<,WJ?1TMBJU)GC-2
MN%IF%Q0K&MF,&#SBD(P<]JD4+GVI=H+8[4,BVI$!DY[5(I -#  X%+'@MSTH
M&(R<YIA;%3$@$YZ5",%SGI2$)N'?O2HG>A0NXYZ=J?%U(/2@!*C? &*M%5 S
M5=L$TP:*K XQ487'6K,F*CP-M-&$D59/O8J%^3@5/)C/O47&?>M$S(@V\XI#
MP<58;;C/\51-C&3UJEJ+<A<9%1,1C%3-4+XIID2(C2 \U(=M)A>U69BE@<4X
M\8IAV\8IW!Q28(>!NY%*.'%"X XJ0 'D5)HB48)#=J'&1FFH><'I4QQMI,T6
MPD?W:N6_!R:JKC%3QN *S9K Z+2I1OQ5Z9?GS6/H[YFZUOLH(R:R9UQV*NW&
M#5ZV8#K4:QJ14T05>M)#L6)#E:P;R(FZS6XSJ!4$D,;G=WJMB&B.V.V+!J*<
M9JRJJ%J*7&T^M,1) 5^SA2.<5 RC?TIT!^3!ZTKD#GO2$5)!AZA<;QBK#LI^
MM(JKBE<9FOQQ5=AEN*T+F->JU2(&:8FM"U VX*!VI=17=%^%%MM[5+<X:,U:
M,9HXN\CPYK,F7O6_?(NXXK'E5=K&M4V<E1&>W0U#TYJUA2IJL^.U:G.T"L"<
MU(HRV>U1QXJS&N3[57H)#XX\N#VKO=+ 6U&?2N)C*JPKL=*F4P@$]JQJ'72%
M;_CX8^]3CY1FF8'GDGI4HP3[5RR/1BM"O+S5)QCK6A<8'2J4A4]::U":T*;'
M&:S[@X.*TI *IRHK'FM(G+)6*:'UJ1@2.*"@%/ !7WK5&31"&QP:9(X J5E'
MXTQT!7-!+3*Q(?BJLZG*CWJR.'I0@DF4>]:4]S*IL>B_#JP!D5]HSCTKU7=M
M^3TKBO =NL<*$#M7<R*NXXZUZ=+8\+$-\PF\8J$OEN*=P33F5.U;HYD*<8&*
M:32C&0#3VV 46#H1]LT [N:,C/M2G:.E-,0=J/>@$9]J=\N?:F @.#DT*?FI
M&*T9% 6$8@&DW8_&G?*>M'R]_P *5PT#BE! '--R,TI(H&-+8.*44G!/-*<4
M" M@XI<BFG!I<@4QBD]J!UIWRXS2?+CWI7$-W#=BG;@1BF'&:4$4/N/J# GI
M2$$@>U2$KM]Z:"*%J TC/2CM2]Z<V,<4A7&9W5/&N5J(  5)$^' [4I(N+LS
MRGXCVV)FDQTKRV-P5W]J]N^(EHKV<CXZ"O$+8 P^U>=B#U<.RW8\W(<=*O:A
M-^Y(]JIV( N,=JGU/ C/IBL$K'3,PI9!498;<TK8-.558<T$#/,XIH.TY/>G
MLJ@T85E^E"!#HW"N >]=+:86#)]*YBV7=+\W;I736_RVY#>G%%BEH8UV<W)^
MM:5O@6A^E9TJAIV^M:*E8[)L\'%,3.<OG!G_ !JJQ^:IK@AYB?>HGQU[TT9[
M,>&4ICO3#Z4@(V^]*,8SWJK"8F<C%"^E+Q2C:#4BW 'G%/A;]\,>M,&,Y%3V
MB!IE^M)E([S05S#^%/U7AE^M2Z*@2 8]*CU;!8?6D:)%.##'-.GBWG<!P*=;
M*/PJ_P"4I7VIE,S8QL.['2M>TDW*#5"9%!XZ5;M<!.*!FF'P,]J9+(-A-1AQ
MT)J*YD B.#2MH2S-N6YS6=<SC9BK<CALY-9-P?F.>E,DIW,G>JC-BII>3[5"
MV,<T^A,ADCC%5PPS4V P.:B1!N)- 7)$'-6@P"564C-3G[E B"1P7Q5>7DXJ
M5UYSWJ!F^;WI#N-!QQ1N&:?A<9[U$^*HFXC.#TIC'YT^M+Q2-MWICKFFA/8^
MB_A'_P @M:]1DX%>8?"7 TI,5Z=*>E4CFEN-C.* 09!B@].*1/\ 6"J7<R+H
MZ44#I15 #?=JF5PWUJXW2J39W4F-!M^:HKV/_1FY[5)ALU#>[OL[#VK)FD-S
MS/6QMOASZU%:2$-UHU[<M\ ?>JD<F%P.M<\CVZ.IH7$NX[<UDW ^8KFIW+D9
MSS6?,S;CSS7.]ST:2*EPN3C-1Q)\W6I&RQ]Z8 <\5#9U1T-"--RCGI5F./=W
MZ53CW;1BKD62.*+D29*$S2LG'6F#-*-S4R&P5.]28XIAR#3@>*:(9(JX&:4M
MD8IH)Q1@]:JP*PHBR=V:-NPYS2J2.>U,.[=D]*8;CU3G=4E-AZ\]*1T;=D=*
M7419C7#KSUKJ]+0%!7&;F!7GI72Z/=@+AC5PWN<N)NUH:NID10GZ5PEW\T[?
M6NKU6Z#1XS7)R [V)]:MM7.6G>*U*K)SBD'R'9ZTZ7/;K42*Q//6AHZ"P$VG
M;FNFT>Q#H&KF%#!N:Z[0W_=J*21C)NVA'JEML5OI7/-'YAQG&*[#55WPMCKB
MN/N%=2=O6HDM3IP\FU=D$R8&,]*SYOFR/2K$I=AC/-4;C<%XZUG8[X$:'+8K
M0ACXS69""6K6AZ"A(J3+4)P,59BCYS59!WJY;G+@521A.1.EH9&!JX]A^Y+>
ME:6GVGF '%7[NR80':.U:Q1Y]2NE*QP4ZXS6?,ORYK3OK>196XXS6;+&^,4N
MAK&5S,<_-0AYHF@DWYJON,9YJ6-FW9N$/6MVSMUD!;/45Q27OEMEFXK7L]=2
M%?F?@BI9447;R,1L>:R)R!WIE]JJN<ANM9QN]_>H9U11:\SYL5(C?,!6?'O9
MZO11L7%%BY&K;QY6KB1X&W/6JT",$QWJ_! [1GCFK2N<\IZD7E_PU#)'CBK4
MB,@Q_%414E>>M4D2G<IM%N[TY(NU.96S@4JHQZ4R6QZ)DXILZ[%J>.)JAN02
M,>E1)%PD94_SFH%2II%(8U"0Q/%2="V+-M#O<'/2M,1XQS6;;1R!ABM6-&(R
M::1,F/VY3-,V_+FIPO%,*$-[51#=R/9\N:-ORYIY4]>U-&<^U)H0B1\YI[)@
M4 $'/:G!6-(I,C\K'/K3/+P?K4^TCK3,$FF$F,,&WG-*4XQ0X<'FG!& R:!(
MC:''>F>1N/6IRK,,4WRW4<]:+%:$?V?9WJ%H<OUJT%<KS3-IZ=Z5@N,$/&,T
MUH.V:F",*1@QX'6H:U)ZE9H<C&>E1F'(Q5MD8C ZT/&=@QUJXHM6L9SV^>*J
MW$> !Z5KE"1CO5*ZA-:)$LQ9H]WX55>,2@BM&>,D<5FMN1J1)B7MJ8I2V:DL
MWW)@U=N(3<<CFH(+1U?@<47%RIEJ.V#+FIH[1>M21VLK ;>E2-%(!@5/,7&"
M&@JG%,QO:@1.&^:K4,6[MS1=E<J2(],@Q>J?>O=_#*;-/C/M7B^EP%;T;AQF
MO:O#ZG[$GIBNBD>+CC:9><US'BN/-N>>U=,P8&N;\4Y^S-]*TGL<&'^-'E#+
MBX;ZTYX\#ZTUPPN7SZU(0>,UP3/I:2]TKLG.*3R]O&:G92/K415LTDS48(\'
M&:5EQQ3MK9HV,33N*PBQ9&<T&+'>I%RHYI),LORT7$T1E?,^7/2F>7GC/2@[
M@..M!#D<4":$5-[%?2I(AYAQTQ4.2#QU[U-NVXVT")3%O&,]*@>'!SGI4X)
MIDN2IQ3$T4Y%SS487(J0AJ@;=NXZ4T9R17E3]YFHV&TYJQ(#G-0E"6SVK1;&
M31&%R=U(R9.:FQCZ5!)G/M31FR-J@=<58(.*@=&SGM5D2(=F.<]:3;4A!Q3
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M' Q35)+4K*6Z4,AB[-_&:14V9YI@#J:=(3@4 D2VPWS#ZUT4O%L/I7/V2GS
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M2S8K9TN(-C([TV-&E;)Y-L<C'%9(_>W)SZUNW>U(,9[5D6\8WLU R/5I]B;
M>U<T5+$FM35)-\W7I5 \"JZF;8P+Q[T8X]Z<#QFD[9H) >O>EQQGO2=LT%R*
M!]!23CBFIUI>V:(_O4 D3P1!I1]:Z[3(!'M(%<U:I^]7'K77VHVHM24;\+ 1
M@"I"%[?C5.)MJC'>I&?:0 >M RPN.W2I,+MJ-.$I5;C% ^IF7V-_%55JS?\
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MD3 GH:U<LC\5DSH6I9<9%4I%Y)JUN.VJ-R[(WM07$AE7Y2:K("3FK(</&<5
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M\M12*N,C\:I&;17/S#-"\"D+#=4@QC-,1'N^;-/!_BI?EQFF=\]J8T3+\W-
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MUJ-F&[%6I(EQFJ<@&<T>0N@V3&/>H=P%.9LGFF%0>]4A"94T<=!1L IP4=:
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MW=JE92/I419MV.U,FS$P0WM3\$TT9W>U3*OK0.PBH: "&J7M4>#NH1,D5[F
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MNHSP73/"5]=1[G@D'_ 36_!\/I7CRT3_ /?)KZ9M?#UA!&%%NG _NBK0TFS
MP(4_[YIV,W(^3M1\#W5NI,<$A_X":YF32K^T<EH'&/537VJ^BV+_ 'H$/_ 1
M7*Z_X(MKU7$," G_ &10T4IGR>9I4/S BIX;GN37J^N?"6[RTB  >PK@]4\$
M7NGJQ(/%3RFGM7T*.B7&W4D.>K5]3>"R&TB%L]5%?*6F6$\5]'E3]ZOJ?P'D
M:/"#_=%'(0YMHZGI(36#XASY1K?*D.36)KR9A/TK*HM#?#?&CSTJ/.;'K4FS
M%/$!69B?6GLN!7FU-SZN@URH@<96JK1@ FKC#C%0,AVFL]+'05L96G!1MH\L
MTI!QBET$Q54'BADQQVI4!Z4K]-O>F0,(XQ3D%-?E0!3UY7'>J$V.^\<5+MPM
M+ F3BIPF0:=@N9[KEJ.@SZ58=,&H&(-2QC=Q?K4@7Y:15[TX?,<BDQD?>EQQ
M4A&&S0!DYI7&B'9SG%2J"!FI,"GHO>@!BDBI'DPM)C:<U"QPV>U-.P%6<$-N
M'>G1O@5*RC&3WJM("IJD3*UBQG<*I7,/''>K,3CO4DBAATK1,YIQN8$L&WM5
M"1.<5OW,7!XK+DAJKG.XF>XVC%5W/:K<PP=O>J[Q\5<60]&,6,$9J-AAL5,H
MP*8R$MFM$Q !D<TBKYC;6Z"G$<8H*X'%(+H5>"5["IX@$.14(^[4D9XJ6(V;
M&X,; YKT'P]J/FQ*K$5Y7#+AJZK1;TQ,G-*XIJ\;'J4D2RVY'7(KA-<T[R9C
M( <BNQTJ[69%R<T:QI7VJ,LH'2J:NCCIU?93LSAK"Y\Q!O.#5Y@#R*QKJVDL
MKL]0 :U+2421 FN>:/:ISYE<GC.*AECYW"I<?-FG'FH-+V=S.)(-3*N!N'>G
M21X.:!P.:$:MWU&XVG/K4H4 9%1N,8/K3D!QS18ACJKSIS5@(0:21?EI,:=F
M4/NG%/P,4%<4@!Z5!NM@5B/E[4OW3D4C+M%(/F&*$PMH;>G7H&U21^==3'#'
M=0X..E>>(KQR#FNKTG41PA/2NJG(\?'4'O$JZ]X7CEB9@OZ5Y3KFF&SD8;2
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M)B@8M)2TF*!!2T44#"DI:3% A*6C%&*8K!1110.P448HQ2 *6DQ2T (:***
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M0G %.&"*3 )IYC"KQWH3*;$#8/%2!MQ&W\:C"\U(%$8R*;8DBTLB@@"F3O\
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M !1110 4444  H-%% "8HQ2T4"L%)FEHH&%%%% "48I:*!6"D[TM% PHHHH
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M#?=-4#G?5]ONFJ)/STF $G-.5FW8II;FESEP:0%Q,[>:=34.5IU4 AH%+10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M0:* "BBB@ HHHH **** "BDS2T %%%% !1110 4444 %%%% !2"EHH ****
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MVWM0W3--6%I<C)8+QUH3<>M.#8-"MCM03<<,CI2X((Q2!^:D'2@&*#6??2$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%P)**;O&,TGF"BX#STJG*HW<59+C;58GYLFE<!  !6-KV!;M]*V".<UBZ_Q
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M-*?-X- K%PHIYJ*64*,9IBR<57F5LYS189',H;)]:+6V&[)I40EA]:T?LY1
M:0B"X"HHYK,NG#KC-6[W<1P:R9$8N!GO3$/MXANK4B4* !56"$@8JV%*=:&&
MH_:-U03, =H-*[X&*KE&=NM(!H'SU;7 6HA$<4[G&VF*Y/!"'?)K21!C%5K5
M?EJQ@[L47&,>( YJ6+BI%B,@P*4IY8H!C9I,"L^;]X#FIIY-QX[53DDYH0$#
MH IK/F4$$U>E;(XJE(I-(15BBW25I16BXS45G#NDS6KY!"TQ&?+: KQ5:>V
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M8-S"D.<YI_7FD/(S1<!-[9XJ3)VY[TP=,T[=\N:5P&;VS0I.XFC/.:0'!S3
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M.V$CCK5@H *>J#K2N5RD&SY?>G; 0 !S4VSFG"([@0.M%PY;$"P'(.*M8(
MJTD' XJ0V^!2N4D5@F%R*FMAOZ4OEDML ZUI65@RN,*>?:BY?*36EJ&(!%='
M8Z=MP0O%1V=@-RY%;PVQ)@5FR[(AVK%U%0^8SR\'Y:ED_>\41Q!#0F/00*=W
M-/Y'6G <U%-*%!% F1W$X1#DURVH2EY6R>.U:5Y<,Q([5AW3YS[4TB)&;<IS
M44<;9YJ9"TKX(K0@M"^,BK(L10V^8\D<T[[,S< 5J);;0 !5N&T!.2*-A6*-
ME8G'S+S6H\"0P[F'-61"L4>[IBL74=2W1E015(EV,O5+A7RJGFJ$&[\:24[S
MNSS5FTA+D9%5NR6T:-G&S$5MQP@(.*@L[8( :NNP44:BN1[ 35:XZ86I6DVG
MCO4;#]:=^X[F>(BS\BIV@7;P*M+$HYJ.?Y1@4A%8*%Z55N(RYR*O*N>M0R<-
MCM00RBL>.O2J%Y)ABH/%:%[*(DX-8?F-/<8/2@+%JRMVDE!(R*Z&*$*G2J>G
M0 8K8"<X[4T"*WE<\]*4)@U9(&,5$QQ0(BF.%JH[94U-*V[(-5FZ4!L9[C+$
M&K-M#M!+#Z4JQ!FR:LA<(?:CR'>Q1N!SBH4@)[<U9<;FR:LP1@C-%@O<DL+<
MA>1S4MVRI&1WJ5&V+FL^^EW*3FD(Q[R3.:Q)^7]ZT;E^M9^-SYIB8J*,4/C>
MGUJ55Q4,W$B_6FB&SW7X:\Z<F*]%8 BO-_ADW_$N6O2#P*T1RR(S2Q@EQ2D8
MZ4^+ -5<S99'2BEHJA"-]TU3!Y(-7&^Z:HD$/2: 4KSS2].*:2<T<YJ1BD$4
M['R5&Y8BG9;RO>FT K#,=,0$KBG GR\=Z:N1]:.@#MII-I)I?FI!G- "[30H
M.:3)H&:+@*Q&:7&3FHFW9XJ1<BAH0/2!<C-.8>E-&0*+C$[4]5[U#\V?:I,G
M% #^ASVI-O>F98G':GKGH: $'!YH8=Z".:0DF@ (X%!&*#GB@YHN I!IP7Y>
M::=QIZYVT,0WA1@TS%#;J1=W>FD,<!SBC'.*3D&EYW5-P'XXQ49':ER<TU@3
M30#@-U!]*!N44UB:8#@,TH%-7..*49[4D(7&: .*3FCG%,!0,G-.([TP$TTL
MV<4K#'L,\T8.W-)SBCG%&P@QQF@C S1SMHYQ1J ;<#-*IYI5.1@U& =_M0AC
MBN#01B@DT'/>@0I!XIW08IA)XH.<T,!<8.*7MCO3><T?-UH&2;/EQ28XQ2[C
MM]Z3/RY[T@&[3FD .<4N6S2#.:8"8.:1LG%.YS33G(I@AWI0_P W2B3/&VCM
M2'U$'2EV\9IK9R,4X9VT[" #BC&1FCG% SBE<0+P<TXCO4?S9]J4%LX[46&.
M4\T,O>F<[JD7/>CJ F,#FD*X_&DD)[=* 20*.H=!X^4<TW%&&-.7IS0"!<8Q
M32O.*7!ZT?-G- ,4# Q3=O.*.<T$G=0(-O.*>PPE,R<TYB2GO1< .-HH.-M(
M?NC'6FOG;@=:!7% W<4!<Y]J1,@4HS04 7-.44WF@9[4-@F.89Y%,V$\TN2.
M*86;.!0@'@'%."DBF_,!0&8#BBXA2I I4&.::2Q%&3BD,?M)YI"I%)N;%-RY
M/-,$/%8GB 'R3]*V5W!N:PO$>\PG'I6=1=#IH/WD>?.F)VSZT_< ,>M5)3+Y
M[9SUI<2G!P:\VI!MGTM"K&Q,W''K2H=HVGO4)$AYQS3<2YS@U'+H=BJQL7%^
M7@FIE;C&:S\RD=#FI%:7;WS0HV(E5B::/VS4ZM62K3 9J='E(]ZJS,W.+-(<
MTIYXJJ'D J1=Y&:GE9#FB3%(:0!\\"G,C]A2Y6/VB$IOWC2['/:CRG'04<K'
M[2(F.:7;GFCRY/2G!'':CE8>T0W'S5&R'=FK C8MTXIKQOGI1RL%41%CC--V
M]Z?Y<F>G%&QNF*.5E>T1%MYJ*2+G-3%),]*'CDV]*.5E*JC/N%VXJ:U;:1DT
MRXBD(Z&JH,RGO0HLF52+.EBD!7K4BCWK#MYY@.<U?BG?!W5HEH<SFKEB9-QK
M-N(2&S5]6=US4<JDQG/6AQ-(U$C'E3/'>H@NWBIIEESD"JLHEQD YK/EU-56
M31:CDYVYYJTC=LUCH)AR0<U8WS8R,YI\A?M8FNI%##/2LZ&2;/-6U,A%'(Q<
MZ'@&C&143^:.@JNSSAN,T^5@ZJ+#1$]#3H4([U"6E XIT;24N5DNK$NA<TUX
MC3X S59,#$=*5F"J(S&B[U&T&5S6A) X'2JC))G&.*?*RO:HIO;?+FH/)V]:
MOF.7/0XJL8Y2Y&#BJLQ.I$KO!WJ'R2O6K3I+TP:KR)-Z&DHLEU(E4Q;7)]:1
MH\#FGO',3T-02+/Z&JU)<XC&B-0F,@X/6IMLN.0:@*S9R0<T[,S<XD4D1!Q4
M97:,$U*ZS$9(.:JLMP3R#5),SE.(NSCK04XQGFHV6?L#4)%SGH:NS9DY1)=G
M.*:8]QP*B(N,]#FE"7"\X-"0N="^5GBHY8\K@=J:PN,Y -(R7&W.#5)$<R%1
M<]^E)(N_H>E5V6Y'W0:CQ=+U!JK,ER19 IK+D]:KXN3T!HVW/H:=B;H>ZX:F
M%><U$ZW&[.#BF%9\]#BA(5TBQCWI67Y<U5*W'8&@BY(Q@T<HKHM!?DSFD[=:
MK8N=NW!IA6Y]#0XB;2+F/>C9CG-546Y/4&AOM(X(-%@YD6OQIG3J:J!;HYX-
M-"W6>0:=@YD7L>_6@)@=:IXN<9(/M3E%R5S@TTAMHM[: G:J8^U=P:D"W.W.
M#FBUA.2+.W(Q1Y?&*K[+G'0YI0MSCH<TK,.<E\KG%-,7-1E;D#.#FD*W&,X-
M*P<Y)Y7/6FF(YZU&$NCT4T!+HG[IH5Q<R'M 3T-)Y!]::Z7.X8!J25)]@V@Y
MIH5T2>5N7--$7O4""Z Q@TY$NB?NFAH?,DRP(.]/6')S2I#<;>5-/$,X'W3B
MD7=">3S2^5Q3EBG)^Z:G2TG8_=-%@YD5!"2:F2U9JO1Z=.3]PXJ[#82C^$TF
M5SQ,U+!FJ[%IQVC(K5AL)/[M7HK)P/F6IU%S(QTLM@Y%-:WQQCK6Q+;/GA:(
M["1SRM-(I21F6^G'S 2*Z>QL%VC*C\JDM-/^0%EYJ\L3QG %38KF0AA$2]JB
MP7XS4DHE)Y%0-O7D=:5@YD3QQ8.":63 .W-4FN)5Y[U4ENI^H/-"0G-&D\H
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M-MYX7D&I))9QQS185T3%_G(S36.[C-5,RYS@YH FSP#03<D=<\5'Y=-<3D\
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M O6HW\'CKFN^PFW-1_)N]J+![4X-?!?.<U(O@T#G-=YA *3<E*P_:G!_\(<
MV<U+'X2 [UVN%')Z4BE0:+"]H<3+X.![U"O@H!NM>@;D[TFY,T6#VIPW_"'!
M?ESUI3X+&PC-=QE":4D=* ]JSSQ_ X9"N:A_X0$;<9KT@;<TOR9Q2L'M3S8>
M %'>D;P ",9KTH[!36*XXHL'.>;?\*_4CK4<GPZ5R.>E>G!DQ2[HZI(7M#G?
M#^D?V5 (Q_#6X)-QQCI3V*]J3:.HIV(;ZC6:EC_>.&Z8IRE6%1C_ %PV]*:1
M%R^.E% Z"BJ #TJFX ;BKC=*I."&^M "=Z"!FC&#B@@@U(QW?;VII7!IQ4@9
MH!R,=Z0 .>.U!..*&^5:3&]!BF%U< ,]:16W-M/2G=MM-"\T)@Q0O)]J"<TI
M/;TI?O4 ,))H).:5B#2$Y.:$("3G-.ZC--8@FEQD9H&)@;<T#CF@Y"9IHY&:
M+:@2'!&::#BEP=N:3;@9IB'%<C-(5XH5L4H//-(8W%*PQ2].?6FFG<!1P.*3
M)VD4J\#FG;<+2!D2IBG#KBE!P,4F: 0N!NQ1CYL4@Y-!X- A6&*53N&#0#N&
M*:>.*-QBL>U,Q4GWA2-]W% A%&:4"FKENE. S0,0#@TH'&:0#]*4#C- "#K0
M2<T#KFE)^:@&(QR<TG:E;DY%&WC- !CY<TNWY<TF#MS3AP,F@0@XI0><T@.#
MF@'YJ!C>].(VT$;>:3J:-P#N*4C!I",4M ",,&D(I2ISBG8XVT -R=N*%&:D
MV?+BF]L=Z+@(!\V*5>":0 YQ3NO HZ ,'S.<TAX-*%YQ37&30 $;C3B<CZ4@
M%.VYH 7[R\]JCZ"I!T--"Y&:%H +\RYI*5>*=Q]ZBX,:,@T9.ZER,YI,_-F@
M0'DTE.!&[-*1CF@8C#Y<T@;%*W"YI , 'UH"P4*2*=]T<TBG&: '@ +3 ><4
MJGC%'3CUI (5^:C;\V.U.Z<&D[;>] ";?FQ2,.U+@YQ0?2FAH3VIP.>#3**;
M%<<%YH &32#F@ Y-+J G>E49% 7- .#1N(0C!HV<YIY^8YI"PW4#$8DTNWY<
MTN,\TC'- #*<..:7;QFD!P<T .SCFFY.<T_IS3 1G- AS<K3!R:?TY/>D! I
M7'8" *3&Q>.]&"QIW08/>@+C$'-.88/%&-HI5.1BBP)L0#)I".<4X_*,4W!)
MJK!?J)[4N.,48YQ3NVWO2'=C,9XI1QQ0!SBG=>* N-ZFEZ4E*3F@+B[<\F@=
M#0QXXI.HH!W +GFBD7UIW7F@5QN.]&.<TN[YLTF?FS0FPN.XVYIN>*">:3'&
M: N.V\9%.!P*0<#)I&!ZTNH78I'<=Z:AQFG#Y1SWH7C- [LC YI^S:>.] .,
MTJG!YIZBNP8[1BFAB.*)#\V*-N#B@  YQ4F.W:HRISBG9VC% #6'.*% Z49S
M2<BBPQ^!2 9.*0 F@<&@0=Z:>33\;J;CF@!Z#/6D?AN*4G/ I-I!R:0:AC"Y
M[T(2PR>M!.329QS0 [MN[T$9&:0'=\W:C/.:!!CY<T$<9I1_>[4 \T#(\X-2
M'&*:R]Z"#BD IZ#%!XH' Y[TC BF%QQ'I2$8Z4*V!S0&X(-, #'I2D8/%-'2
MG ]C1L @Y--)P^.U*5/04WOM[T;E7'#DT,,4!2.*=UXI"&A=W6ER1Q06P,4O
MWA0A7 #/6D SUI,T9]*; 3%. XR:!SSZ4IY&12L TMS2Y.<U'_'FI,C<#18!
M",T#Y>:7/S9H89YH ",KGO0!M%*O R>E'O19"8C+D9I-O IXXYI.G-%@&L,"
MA6P:0Y)I2N*5ABL.101@XIN#D4K @T[ *1CI3<<TX'C!I0<#% #<<44-R,4@
MX&*90O?%*%!I,9XI0#THT$!%(%W'GM0?2EZ4 #'M2[>,T$;B,4/P*1/4!ANM
M*5 &13,';FD5BU-(8_J,FD R,TI&1D4B^M%@N*!@9H]Z#ZT@/.:+"U$R0V:?
MGC(IIZYH!QUHT&##O01@9%##O2@X'/>C00@;M2E>,BD(QS0K8'-.PQ 2!BDQ
M4BXVFF@]J5@$Z4X<FC&!BCH-O>BX7%9 5IB#!QVI2V%Q1GY:-0N&,MBE;IBF
MCFG?>XI;!<11GK28Y-/(^6F)\Q(]*87NP%. !ZT 9IN>:5AWT%,>>:;G!IQ?
MD4C+N.10*]QV RY--"C;12;#U[55@%(V+N'6E4Y7=WI.31TI-!8#SS0/EHHH
M&&,FG'Y!Q3>E# TF)@1S05Y%+C%*1@BF.R$88%(H.:5O2E! % ,1N!@4+D\4
M#YN*=D+Q18D;SG;VI-OS8I2PIN:+"']>#3=OS4[=D<4A/% Q^,C%-$8I<[A@
M4C-18 V"FA>#3OO#BCK^%(!%&!FD))-*1GD4T=:$ [WI>V>]+[TW=S18!IR3
M3B/EI<=Z!P<]J+!<:5XH*\4[&.:0'!YHL"$*\#% ) Q2AL9S2(PR:8#5!!.*
M=&/GIP(%(G^LIA8NCI10.E%, ;I5)R=W-76Z53=LO]*& WG-!SF@GG-!;G-2
M _)*X/6F#(-.Z_-0QP-U"V #R,&@<+@4@.1NI>@W4!8#TXZTT9S0&YH#8:D,
M<1QD?C35S3LX_&D!Q3 &QGB@@9%-[TTM@XHL(D8<\4<@4@-+NXQ0/H-)XQVI
M!P,4M-SSB@"5<G@]*,\X/2D#<8I ,F@!0O/-(PYI_7BD)[4 -.<"G <<TTGI
M[4,W2A@!SFGC)3FF$YJ0'*4F P 8YI!0?6FJ>:8#AD&@Y)I<\YI,_-F@ &0?
M>CDFC=\V:4-@YH$+]T<=:1L;?>AAQFFT *..E S0#@4H- Q!G!I5S^%)NX/O
M0#@8H8AQ SQ2,/2D!XI0W&*  #GVH8]ATI<_PT>U 7$YV4G)%.8X&*%;/% -
MB*/6@ 9-#-VH'S"D BG=G=1WI@.212]Z>PQQR>M'(-+NR1[4$Y.:?00[MSUI
MI)ZFDW9.:4_,,T@';OE]Z.V>]1@X.:<7S0 O;(ZTT$YH4X- /S&F <YI.]*&
MP:,\TACCCC%#' XIE% "\XXH&<4JGMZTI^48HN W!Q29.,4X-\N*9WQ0(<O7
MFG;?F]J8.N*?G^&@!H_UA':G']*;CYL4K-VH'<1LD<T<X%!.5H)R * '#D<T
M@ YS3<T9H#0<,8SWI1SR>M(!D9I,\YH 4D]Z3)SGO0S9- /.: ']L]Z"/ESW
MIF[YLU(7^6@0PXQ00-M))P,TT'C- #AQTH!/-(#2J<$^] 7%&>U)C)I0<4!L
M4#N+G!QVICCGB@TH; Q0 JY_"AAZ=*0-@8HW?+B@0<[:3!I=W&*7=QB@!,YX
M-*H&>:;2]:!BC))!Z4W!S3L[N/2E+TA7&#*FG-U!I0=]-=LT //S"F 8IR?=
MS0QRI-"8+S$SNIV,#WJ.,\$U)VS3N,9SFG]L]Z8#SFES\V:!"#.:,D&E!PU*
M1WI@!Y''6F]#2J<?C0RXYI#V!CQQ2#..*2E!P#0(%IV0#BF T4: /VC=[4F!
MNH0]J,?-BA#$;K0#V-!'.*2@5AS9I#G%*6R,4%N,4[ (<X%.4<<TA;('M06S
M3L H7UH ]:0MF@MR/:E8!".<]Z=GCGK32V6S2-RV:748_MGO37^YGO03DTE%
M@%7[G/6E.-OO33P*13Q3 >E(?O4*<&C/.:+"ZB D4HSFFL<&G*V!2L,<1TQ1
M(<D49VTSO0A7%P<48)% ; Q2AL"F@$3@8[4I'/M3:>#D8H !^E-84X_W:7KQ
M0%R,D]*4YQ2'@TK-E<4K !S@4'/>@G@4I.10,% QS28HZTO\&:!B4"F@\9H7
MGFF&H[)SGO1CYL]Z <'-&[YLTA#NV>]-)Q]:-WS9I#R<TA,>5RN:,8Z4 [12
MD\9H5Q",O&13 ,FI"V!3<[1]:=QW%/3Y?QIJGM0IQGWI*=@'$#=2$?O!Z4PL
M0<4_/RT6L ,.>.E.7T/2@'(Q03@8H 1LXP.E(<XI=WRXI"<C%&P#EZ<TO7@]
M*0'<,4UCVI *H&>:&.30.12#D_2@=TA<'(H/6G@Y'TIN<G- 7&D<T&G'YAFF
M@X.:!W'8&.>M--#<\TVA"N2)U-(/O'%-%*IP:+ '.ZA\\8I0V&S29^:@$QQ.
M,4K\BF2':13B<**-A78JXVX--*X^[3.:>&^7% Q 3BC/%*IXQ2XP=OK1<0T9
MQ[4H'/M3O]FD]J!W$/7VI,>M!]*4GY: 3%;[M(.G-(6^7%!.0*!#ASUH"\&@
M?,*4'(- :C4/RD4WH:$YR:?C/-(!I)S0,[^:,_-FG'D[J>X"LN12$?+[TN[C
M-(>FZ@2V \+35)SQ3F^[FFK\O-(:'D\>]- QR/QI V#FG9P,^M,!H)SQ3RH/
M2F*<&G_=_&@$-8 &@''':E8?,*8XVG%"L%]!S#TI4/&#2!L#%-IH8YA@\4*,
M]>E&[C%)N^7%  PY]J!3A\PQ3",&D%Q<&E;-+G(QZ4UFS0%P;-!).*"V:4GI
M[4(0O;GK1P5/K0?F&::*:&-!(&>]/'S+D]:,9&:%.&H&Q .U!%+GYLTA/.:!
M7#Z4I Q2>])GFD,4<=*)/:G?=&:C)YH6XKCESCBCF@-@4 X!]Z&(<E-8?/QT
MI0<"@-VH'<7OCM2;1N]J0\4X'(Q0 9YQVIS_ '>*8>#BE)R,4(+ ISP:1A3-
MW.*E!W#%,-AF.*:B\T_N:3-%QZ(4]*2+._FD)S3D^^*$#9='2B@=**9(-TJD
MY&^KI&1BJSP\TF!$6&:1F!Z5((>U+Y&#2 BW;>O2G,08\]J5HLMM[4S:=_EX
MXHL%AX($6:8'&.>E/\L_<[4GD_-M[4[ (I&<TA8 \T\1=J4P9I6 CWBE5U'6
MG>1GCTI3!FG:X"%DQ4>5SS4ODYI/(R<TAC2ZA:174BG-!D9I$@IV -PVX[TO
M&VG>1SFE\JD!'O&,=Z7<,<4OD<YH:/%/J(;FC-2"+C--:,B@=QC]L4XXP*"A
MP*4H?2A"$)%(S #BG&,C'%(8STQ0 P,"*$(S3O*(XQUH\HJ<8H =D;O:FMC-
M+L.[&*78=V* (R0.:"P S3S%DXQ2>43QCI1L TOQ1N &:=Y1/&.E'E9X]*8"
M4Y2,<TJQY'2@(3FD @Q@T#&VE"'!XH"';TI@(",4PM@T\(<9Q2>5GG%(!=XQ
MCO3-_P U'EG=G%'EG.<4[ 2$@K[U&&YQ3]AVYQ2>5CG%*X"DC%!("\4%#C.*
M<(OES2 B4C/%/.*8(R&Z5(8R.U4 AQQ2-CM3BAR.*"ASBE8!@('-.# GCI0T
M?.,4"+:<4 (V,\4+C-.V'=BC8=V*8!QNI!C<:4(=V,4!#GI0 G&:8S &GA"3
MTI/*W'ITI  90.:-RCK1Y1;MTH\HMVZ4 -+ &I 05YIOE$\^E."';TI@(",4
MWO3Q&<9Q1L.W-("/<-U2(ZYQWIOD\;J:$(;.*&K@/;AZ"012LI(SB@QG&<46
M 0XQ0V-HQ2E#MZ4%" *=@&#K3F(XQ2E",8I"A':D NX9XI"1F@QG.*"ASC%
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MEHH 3:,T;12T4 )M%&T4M% ";11M%+10 FT48%+10 FT4;12T4 )M%&T4M%
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MK'M[U"O!I9+HE3S7*XG1$UHY0]25SUM>$3A2W4UOH<J#4M6*'4444@"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<QXMT*/4]-E!3<Q!Q73TC*&&"*:=@/C[Q'X<O-(U%F2
M)E4DUAF:?=SG-?5OB?PA%K"<  UP$_PD^<L'_P _E772JV,W$\2\^?WH,TY]
M:]G'PF[[Z>?A-@9W?Y_*NGVRL2XZ'C'F2X!'6MO2+Z4L$)KTP?";C.^I;/X5
MF&;?OJ%5.6I!L;X4:1D/H3727-GN (%:NC>$?L,6,UM?V*,=:PJ5$S6C3:.&
M;3!(.5JJNA2/>KMC)7->AKHH6KEKIJ0]0#7.V=:T*>B:4EK"ORX.*W1P*0
M8%+4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS2^<OK5+&X[J6BX[%IIAC@THG7'6JE&*+B+8N%.>:!<*>]4PN#]:<4"<@T7
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M$'(S03B@$4$B@!0:,T@(HS0 $XI0>*3CO02!0 C-@TO:D)'>ER*8@IP; Q2
MC%*"-M2P0T\KBG*<)MIHYI"<-BF ZD[T,?DXZTTYVBF@'TE.R-GO3<@T@$#9
M.*=2<"C<#0,**,BC<!0(*#TS1D49H %/>@GO02!0"#0,5&YS0>31QFE4C/-
M#"V*4'C-#$9I4(HZ !Z4P#::=GFG C'-,3&T9HS3@1BD VD+?-BES2\8]Z %
MSQBHRQSBG9I?EQ[T; )3RW&*9FER,4 *6R,4W=VI-PI>,4##=F@'-'%!P!Q0
M M%(&!-!(H$!/%)N.,TN0:,"@8 Y&:6DHS3$(QP,TH.1FC@]:*0 3B@'BCCO
M02!0,0G%+1P:*$(0G!Q3NV*3BB@=QN=IQ3Z3CO2Y&*+@,W?-BG4<8S1FCJ T
M\G%.;E **0$$XHL $94"E;D+[44 YI:@.9LK3,T9!HR*8 &R*3J<T[BA< T
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MGHH KFV&*!; "K%%%@*YM@10+8 58HH KM; T?9AC%6** *QM0<4[[.*GHH
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%HH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image8.jpg
<TEXT>
begin 644 image8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0O!WD# 2(  A$! Q$!_\0
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M *:8Q2?;I3L@C.*0<BFYYI *#STI3P,4@..:0'BBX6%_A H)Y%&>,49SCVH
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M:EQQFF,0]:5?2FYI5ZXI *WI2%L'.*5CVHSWQ0 @;G.*-V.,=:7/.<49 [4
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M@T#$P=N:5>!]:=D8SVIH(YH 0#/%*3@@>E&<#WHR.* 89^8&A3R:7(W=*0$
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M^7WI"00* N'O2J>M(#S[4N0,T Q/X2*>P^04S/RTK-E<4"#(W T9^8FCC.:
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MY29SBE8"DSDD8'3K2[P.<<5<\I/3K1Y*8QBBP%0'()Q1G Z<U<\I .E&Q#3
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M+C&*3RU]*+ 57.. .:5<$=*LF-2<XI0BCM2L!3S\W3BC//2K?EKZ4>6OI3Z
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MBK?E+Z4>6OI3 IYR.1S2Y^7I5ORU]*/+7THL!3XSP*7=STXJWY:^E'E+Z4K
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTZ[C"MD4 7HW$B;A3ZJ63[HP*MT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2QP^XCL:NS?ZIOI5+3F&' ]: (ISMN3NZ=JLQ[C'_*H;],%6QWJQ;L B@^E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF@!]%1^:N,TOFKQ[T /HIGFKG%'FKS[4 /HIGFKC-'FK0 ^BF>:N<4>:N<4
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MGGB'P&\2%[:/@>E>P^8M12"*=&1@,&LI4TS:%643YFN-+N[9MI4\>U4Y',>
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MDDT?+C/>@ 8X^[^-&3C%.&TJ2.U(F",GI3 53D<_A3"Q#>].W 'G\*8?O>]
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MW 4^M"T!B'&!2\;A0<8%(?OCTI *3V[4S.#3FZ^U+M&,FJ 0\T@ZTO&WWI<
M@8_&D N!G/:CKQ^5&X9QVI>!S^5 $>2K4I"]>]"_,_-*ZY.%H 3!WY_AI?EW
M'TIWF1H-K$4?(1D&JL(;QBDXVCUI*=@%>.M2,&( XI%(//:DQVI4 'TI] '#
M'^%- Q(/6E_BH(.\'O2 ;G+&G$#&:11R:3.5([4P%4@]:7C'O2;<"CC;SUI
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M2U0F-<X4U38Y^E7'^[5)ACZ4F $8H S2$D]:=G"^]+<8'''ZT<;O:@X.#^=
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MC&#F@9SQ3MN ?TH7]:8#0"32D GVI,D&E8<9% "' (QTIS]12*.,FD;[V#0
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M%)@-(HI1@CFC@+GO2N,<..GXT8^;VI,X'UH4YXH 9R6-2+\JY[T@ YHZK1H
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MCM32,'VI1]WBDSP!0,4DG%(&^>E+<C-(!^\S3$+D\T*>U ;YB*-HW>U(8TD
MT[(9<]Z3:">>U'&V@0/P!BEP,B@@8'-'&X<T7&&!G%-.13^,TF0PY[4; (A/
M6C)&:%ZTK8% "9.VEY.*0-D8IXZ<T AN3GWIZC@GVIN?FS3E/#?2A;A8\1^)
MW_(?3_/I79_#G/\ 9H';/]*XWXG#_B?)_GTKM/AOC^S!_GM74_A,SMP.M-[T
MX<9-(>1D=:YC0<%&,TPD$\=*,\8]:1% .,T@%Z$4[.6S00&8#TI#\K@#K0,
M3DTW'>G@GFFYX(H)#FG'E<GK0.1S0>13 ;@;0:7C.*#C:*,<BD A&&I5&0:1
ML;C0AZT#%QA?>D4G!I201GO2(W:BX@')P:5NM!7'3I2$YQ0 N3N%+SFD).X4
M G=0,3%*#D8-*#CBFG - "K@9IQ;*"F#!!I3C:* #CBD(PU+QQ2\%L=J+@,Z
MTOW3FE &:0_,:8"@G.::>5Q2J=II">*0#\8CQ3-OS9I0<K[4_P!SUH 83\_O
M0.M)@E\TX@9% 7# W>U*, -2<;L9HXYH 3 VD]Z#C H_AI2.!0(3.!BALD"F
MU(.1S0,:<FE7@D=Z7@\TU3\Y/K0"%!/--(Q]*>>!Q2 @\4 )S37R!3F;GZ4X
MX9<]Z$[@,/1<4XXW@4F:=M7&XFE)C&@#)I5P 3WI% )ZT#;T)I6$&[))I%X-
M/P .*8P]*>HKDA VBDP ,TB]/FZ4-@D"DKAU&8W/FG'(( []:<0%Z=:.A!]:
M=P:$Q@4*!SFE;GCM2#!&/2FMQ*X<;3313L9!]:0@ >].^HQ2!D<TY\;!BF ;
MCBG<?=/:A@)]X4#@^](3SQ29PY/>D"%=<C^="\+MHW=?>CG%"&&#0>*7)P,]
MJ"01GO0 W/-.QS00-N12#IB@0]?O$4S)!IR_*2:,;AF@+C0QW9%*_P PI <<
MTYNF10,C VK[4YANVTA.Y<4Y<#&?PI@(#M8>M!SDXHQF0&@-R: V $[<4@IV
M?EIM+4!0=PR:7C YI!]VC QF@0I XI01G%(<<4AQNH&*QSQ1C ]Z%QW[4IZ9
M[T -4X./6E;[N!2$#&12J>QH$(3@ 4N3N!I'ZBG=Q0,802V:4=:7.&I&QGBF
M(=@;C3.].')Q0 ,'-*XQ <4I'(]Z3C;FE..* %X^[VIO0TK#N*3K1L"%#9:@
M$[C2#(:G].>] #<G::4<CFFAN"*"3MIB'GU-,Z\T[JO-(" N>](8-VIO>G-Z
MTB\GF@!RGY3FF@_-F@TJX SWH 7('XTCGGBDY)H88H <?]6/K36&7!I5Y'M2
MY'4]: $R=]!''% ))S2G@<4 (IR,&@ 9--I5[FFA%N+.P9J2HX3E*DI@-?[M
M4V(Z5<?[M4C@'K28T QBCC;G- P0:,#;UJ6 <<<TN!NZTFT#'/6EP-V,T[ &
M!SS2#&,YI0!SS28&W.:.HA2!C-+QTI#C;UI!@\]J=@'/@)0N,9--8@X&>*<5
M '6EL,3=SGUH(]* H(I05'&:  'M33U-+@;L9HP.:8"8&W/>E.,"DXVYS2G&
M!S2$! R.:7()P:3 R.: !GK0P'-CK3(P-Y)H R/>EX'UH&*<#CUII7:..E*0
M,9!I5VE,9H  =P^E-4X?FE  --;#-D=: 0]@-U&%!ZT8 I"H+8S2 7=1G*TJ
MJ"<4]HOER*M1L!&>4 I,@<4XC8N33/E)X-2T IQ]TG@4BE?7D4% 3R>*1(UW
M9!Z4UL YAD9[TW!'6E=PAW.<"F17MK<L41P67J,T /&,TB'+-GM3L#=CM2E5
M7J:EZ &[Y:4O\M,XVDYH.T*#F@0BC<:7 W$4HPIQ2,#NS2#4%[YI,T[''-,"
M@GWIH:)1C:::K@<'I3U3*FD\C(Q3L*^I&XW,"*>,#D]:<4VCGM49PS4K#0[?
MZ4BIS3.%/6GEP!@'BK3&QX8#(IHQR::N#WI0GRYI-DBLNY0U*%&*:K'&*<I7
MUJ6 W W8SQ32 Q^E.PN[K32H&2*:*2' <>]-3"DTJ9SDTW@L>:8K6).",9XH
M!'3TH&P+UIH )ZU"$!Y?=Z4YAGD4WC'7FG+@=3S3;&(>.E"D9R:48Z4Q@.@H
MBP3%/4TN,+0N,9/:D8@KFG<3%*YQC\:5@/+P*5 -M-X#]>*748+@K@]J3[K4
M?Q<5(J[^O6J2$1Y!Z=:0'GFIA!M.:B=?2DT&HH W=>*>P&,^E1H .IIQ(8=:
M30Q"<C-! XI. H.:7C /K0D N0#CM2!1SDTUDR*<Y"HHIN-@$ HR.U QCWI=
MHZCK0F/0/X: <C%+TX[4W !R>E)L0T\'%2*@(]Z0JK-NS1N_><4)W$+D*< ]
M:3Y0W/2E:/C-1@!N#0 \ '//TIAX.*.%;%*1EP31N,7 XI>-PYI&4+S1@9'-
M%["'O@+3. .3S2\,<$]*;* 6!% QP&5IZ@;:8I&/>EZ<#O0P&[1GVIP(/X4I
MV[<9I@ YI)Z@!.>:"!QS1@;<TI XYJ@%XZ=J8G+D=J=@;L9I!@&BX"C &:&P
M1FC@KG-)@;>M A5/:D. U2!1CK43@9'/>FACW4%E-!(#TX[0!DU& &ESFD@0
M*/F)IW'2@$ D4A7GB@&)WHQ\N:4+ZTG&TT )3L#<.:#@ <T8&X<T- +QG&:3
M YYHP-W6C@@T" 8 SWIIYIW&W-)\O8_6@!@&T5-P5%,(7.,\4HQZ]*!B=^*>
MG1OI0NW/)IP PV/2A;C9XC\3B/[=0?Y[5V?PW7.FC_/:N*^)R?\ $^3_ #Z5
MVWPV*C3 ,_YQ73+X3);G;X&#2# &?6EXP233< J#FN=EBL .E(N">:4@9%(0
M W%)@/*@<YI@YD!IP.[KVI%(\RA#!6&XTC 9XIP0;F--&"<=J %!!&#1@ 4C
M#;2\%<TP XQ1QFD(&.M! SUI7U 7 W=: !S2X&[K2 #GFCJ(3 V]>:1%QDTN
M!MSGFG1XP:!H0$=*:?E-.(&[KQ1@.<'M0 Y<,<FAL YI"-AXI0 W- #3C-&!
MD\\4$#=UHXSC- "#'/-+QMS2  YYI>-HYH0@...:,#=C-(0..:7 W8S2N,.#
MFD!PU+\HZFFX#-5 B3:#S48PW':E&02*:%P":20$C85!3<Y84-AEQF@;0.>M
M'0+#V(!XZTTXR#ZTSC?G-/XR,&G808&[K1@<\T8&[&:,#GFEL <;2<T<8%)Q
MM/-! QQ1<8-@4H(88IHPW&:?M H ;1WXZTY0#UIHP)#S3 5&'2DVC=[4;1GB
MEXSBIEL X@8J/D4[W/;I02&&[O2B(:",XIQP?ESP:<D(QFFNN#Q5M "J!Q2;
M 3GO3E&>M##:W% QH)4TY<$<TT$%N:=\GK2$(0&^7L*0#YJ7 ZYXI5(P10]-
M!B.1G-!QQ28^7GK4BQC H2"XWC.*0 <U(8OFXIFW&<U3740@X!-!Z9I!C83F
ME.-HJ4G<8# :EX+4FT%@!3)98K<YE; H0B0#')IH :0DTQ+RWN.(W!(]ZD 0
M<D\U5A@P':G#:4Q2$#MWH"@#KQ4#Z"L!MIH&1[TO4<_A2#Y1GO0MA !VHXSB
MG+MZTTJ-W'2@+AP3BE4C8<TFT \]*  1UIH0F!M![TI("X]:!C'7FD? [T#&
MXVCGI3G 8+CM0V&C I4 7&[\*8A4QGGK364!LBE('F@TK8+<&D,.!$::@!I6
MQMVTBX P:$ <;31QC.:,#'6C VCFEJ X@<<TF!NZTI XYI,#=UJF(:>M.XVY
M[T8'-&!MZT@$%#  \4X*I'6C"]*!C&(.,TXG!!IKJ PS3SM./7%,!A()]Z!U
MI-N'S3R!GK0(,#<>:."#1@9(S2 #GFD <;>M! XYI<#:#F@@?+1J O'3M3#P
M:=@9ZT #F@!5.YA2%@":;NVM3P@.3FC88U%&#Z4[@\=J:A&"*=@>M# 3C%)@
M;<TO!'6CC;UH$''%&!NZT$#CFC SC-   .:;3L#GFD&W'7F@!5.*1L=*4@<<
MTC8'>@8[ $8IC?,<T_(*\]*3 '7K0 @.#0K9.*5@/QI, =#3 7 SCM0 ,'FD
M&,\FE&,'FA;B+,'^K%2U%!_JQ4M,!K_=JD54GDU=?[IJ@^/6D-$FU0.M(0,=
M:0 $=:,#;UI6U 7 XYHP-W6@@<<T8&[&>*8@ '/-&!MZT8'/-'&W.>:$ ,!M
MZTU,;2M*P&WK0$"IFE<!WEJ%ZT94]33"VY0,]Z5D&\4>HQWRJ>#0%4<YHV+O
MZ\TC =,T )P3UXI<#GFD"J.]* .>: $P-O6E(&!S00-O6D(&!S0 N!N'-  S
MUHP-P&:,#/6@0HP.::0,[O6C QUHXQUH&/50%/--V@+D'BEXQC/6F,0H"YXH
M > #WI0BJV<TF %#9I#\PSWI7 <5!R<TU1EL48P/YTY<;N#510CC?$_BH:+&
MS;@,5Q]O\6B\^QW &?6L[XH,SL8]Q&7 _6L*T\ _:/#YOU+;QBNGE31-[GN?
MASQ';ZY;C;("WUK<,2J>M?/7P\U6XTSQ.;%V.!C@_C7T*&4P)(QX*@UE*.H)
MAMW?+VHV+%SFLFZ\3:79R^7+.JD>]3VFKV.IG$,H;'H:7*.XS7I6BTQI5ZX-
M>7>"-?N+KQ7?6[L=JOC]!7J'B0!=(8?[)KQKP"@'C34"/^>G/Y"A(#WD(#&K
M>U1G#G#'&.E07&I6UI&GG.%7'4FIXW@N(A+&X*GO4N(Q?+RF*#'E0*JOJ]I'
M<B$R#?Z9J2>^AMD$DC *:%$+E@H-O'6D.0 #5*36K"&/S'F4#ZTEIKMAJ$GE
M02JS#T-/E T#AA3%4AJ'^4J5IRME\U-@,#Q5KQT&V$@.,BO-C\791-M##&:Z
M#XND_P!GQ\XXY_6O/?#/@%-:L%N,D[AFMHQT(;=SUSPGXR@U]2K2#>.V:ZUT
MPN\5\V>%9)O#_C0V6Y@OF8&?I7TE;.9K)&_V:4XV*3$,>X C\:7RAT[53NM;
ML-/XFE53WR:99>(=-OFV03JQ]C67*.Y>PJC@].35236[-)Q;M* _3&:GNI([
M>TFF9OEV''Y5\_:EXG/_  F61*?+$F.OO51A<5SZ(0#KV-,,97)%4=+U:VO[
M!&CD!(&3S[4]M:M WDF0;CQC-'(.Y<V H#F@#D U#)>P6T :9PJGH2:2&_MK
MWFW<-MZX-2XCN66&&&*C9<'Y?QJO-J]G;2!9I0K=@35E71D\V,Y5N<U7**X!
M >,TNW;]*S;O7M-T]]L\ZJ?<U9M=5L=27;!*K$^AH<03+05=VX&D906RO6A5
M"MM)JC>ZQ8Z8VZ:55/N:GD"Y>51T;K3B$'!/-4+/6M/U%@T$RM]#5R<*K[R<
M"FH6 7;\WL:>8N*I?VQ89VF5<IUYJN_BG3!+Y?GKNZ8S0X@:B8&0::RCUXI8
MVCGC$J'*GO0<-\N>*FS AO)5M;9I,]!FO+M7^)K6%V\:N-RL0!7H?B$D:;(,
M\!:^=4T;^W?%+P[B27/'XUM%:"9Z+IOQ5-Q<1I*X 8@'FO4].OK>_M$EB<-N
M7)YKYYU_P%=:3:_:8%?*?-71_#7Q6^U;.=_F#%<$^]-PT!,]H /F$'[M.*C'
M%#L%3)^[C.:R[KQ%IEC_ *V=0?<UGR,9I^4"O/%)*5BBWD_*O4U5L]6M-3C#
M6\@;Z&J_BC4(=/T"X,CA6*\<TE%IA<EBUFSF?RDD!8\=:OR*K("3]*^?O#7B
M7.N(9I2(]_<U[M;745[;1-"VX8[5<X@3Q+N;)[5-MP:IWNH6NFQ[IY I [FJ
M5EXHTR]F\J.=2WIFL^03-8CYO:E*;_E["D!#_<.5/>HKF^@T^+?.X5?4T<H7
M)=N%]Z9D0QF5SC'6LN#Q1I=Q/Y8G4MG&,T>*-1AL](EEW@90XYJU#4+ER#6+
M6Y<QQR MZ9JZ(_EYKPCPQXF6/7V,LOR;NYKW*UO[>_A5H7!R.QIRA8$QQ0,X
M(/2APQ<8'%17=W;Z;&SS.%!]36=;^+-)DD\L7"%OK4* [FP,-P>U)L^;CI2!
MDF4/&<@U%/?VUF=LSA?J:3B%RQL!Z4U0,X)YK.;Q#IL9XG7)X'-7H7CFC\X-
M\IYIJ-D!(8PIR*:X.1CIWK,NO$^EV\_D/<*),XQFK]K=PW:YA8,#Z4[: 2[1
MN]J7:N.M-)Q(4["@ <_I6?48HQG&:& !&#2;1C/>EV@\U3 7:,]:;M!/)I>,
MXSQ2 #/6I . .M! QUHV@\YYHP,=:H"08"XS32BXZTAP!P:;]X#FDD \J'(Y
MZ4TX5_>GX %,*@MG/S4( V@'.>M.XZ=J9WP:<0!0 O!X]*3 VGFD '<TN!CK
M0(1E&!S2X&X<T$# YH(&>M,!<#=C/%!48ZTF!NZT<'K2 ,#;UI JYX-&!MI-
MH49SUIC'.JA>M*$ 4'-1G!7K4@P5'/2@!N/FS4B@8;GM3>/7FG*  >>U+J-G
MB7Q.(_MU!_GM79_#=!_9H.?\XKC/B>!_;R8/'_ZJ[7X;%?[- SW_ *5TOX3-
M;G;!00<TW: HQ3GP"<4@4$5SLM[ <<<T8&[&:"!GK1@;NM(0XJ *C4#S0:DX
M/!/2F$#S!@T(9)E<GFH\+GK2K&.>:8JC)!-%@)& <8IN!MZTH4>M&!MSF@&)
M@8ZTN!GK2'&.M+@9ZT:"# W=: !SS1@;CS2+U:CJ,,#;UHP!WZTY5!')IK =
MC0 [:I'6C"CO3 ,=Z7:#U- #OE8\FD! ; --QS3EC!.<\T ! SUI"H)ZTI S
MC-&!GK0(% P>:,#:#F@ 8/-)@;>M  0..:=@9ZTA XYHP-V,\46&)M#'KTI0
M%!SGF@ <\TW:#SWH E&WK33MV$9II V]:;L^0\T) 2!5"9S3=H;G-(.4VYIP
M  YHV 9CYLTX* >O6@@9SGFEP..:8,,#=UHP.>:,#=UXH '//2E<0F!M)SS2
M\8HP-N<\T$# YH2 :5"]ZEP"O6HI ,8S4F!Y?6AC#:H/6HR%WGFG<$=:157D
MYYH >@4 X--VC/6FJ ,X-%#6@[#LJ>":>D:],U%L!Y)Z5-$O&?:B*$>>>+/'
M1T*[$*L*Z#P?XACU_33+N!:O#?BTS'5WV,>*VO@SK#QS+:2,?F/?ZUT<FA-S
MT[Q7XD&AQ*RL =P'ZUK>'=3_ +8T\7.<\"O-_BRA^S(P)P9%_G77?#92OAL<
MYX']:SE"P7.L*@OQUH\K' Z5#<7D%BIEF<*/<UFKXMTIY?+6X0G/K2Y0N:^!
MG83P.E."[>::ICN(!+$<KZT!L@AN,4I(9( &7)KR_P 4?$4Z1?-;HPRIQ7IK
M_+ S#KBOFOQ'I_\ :WC)H68_-)C'X5<$)G=:7\5O-G5)G !]Z]3T_4(=3LDF
MC<'<.U?/'B'P%+I>G"\AW<#-=_\ "?6&N+1K>1LE#CFJE'0+GINW (J39\O%
M,DFB@C,DS;5]ZR/^$MTA)O+^TINSC&ZI25@N;2C:]<=\0]0DL=*$D9(/_P"J
MNN@N8+M \+!@?0UPOQ10_P!B*,=_\*F,=0N9WPWU>74[B43,?E'%>FR0@G(-
M>1?"Q%6XE.?X:]0?6K-+DV_FC>.HS5-#N7E50N,_6CV[5#)(B1>=N^0\DU%!
MJEG<_NX90S'WJ'$+EJ/+,<]!TI7!8\56DU*UMFV2N%)]ZJW/B33;-?GF4?C0
MHZ"3-(@ 4X;2N :K6=_:Z@NZ&0-D=C4Q3;]WFDT,<0"=IH*J!UIJ GEN*< #
MU-3<=AF!USS3]JD<FHR 'QFG. !P:;$*JJ.,\4, WX4U #WIY4 =:.HQ!CUY
MH "<YZT(@)SFD;&2,T=0'84]Z"BD=:8%VKG-*N#U- "\%:3C'6C V]:3:,9S
M1<!Q XYHP,]:"!QS1@;L9H$&!SS1@;>O-  YYH(&.M, P!C]:7:#WXI.,8S2
M$A1C-(8YPC8R:-@# YJ-AT.:?D,.O-%A"MM)ZTF!GK3,8?K3R!GK1U&&!N/-
M  YYHP,]:,#GF@0$#'6E"J1UIN!CK00..>M'0!<#=C-+@<\TUL#O0N#U-'0!
M0JL<GM2!@&(!I#P<4BJ"33&."J#P:=@=,TQ0,]:?@9ZTF F!CK28&WK3L#'6
MDP,=: 88''-&!NQF@@<<TG&[KQ0(4 <\T@0=<TN!SS2<8Z\T *0.*4JI7DTS
MBE(&<9XH&+A=N,\"D(#')/2DVKZ\4N!W/-/0 X)SGFEV@'K2!1G.>:&QV-(
M*@MC/%.VJ%ZTT8SR:<0NWK0MQ%B#_5BI:B@_U8J6J :_W35(JI.":NN,J15!
MUQQFD!(0H'6FX&WK32N><]*=CY0<TGH,4XXYHP,XS2;>G-+M^;&:!  .>:3
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MW0Y D/\ .NN^*R!?#S+Z@"AK45SQY_$NJZK;M'#N(4XXJ_X%U^]TWQ(L=VS
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MXR1%_6IE9.Y2=SY@LA=%@(\^9FOI+P!]JAT57N01@=Z\A\+:6ESXA2,]"_\
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MWN,TN/ESFDV;1G/6F@%" <9IW7\*8 2,9IRK[]*+#% YW9IZCJ<]J9CO3E&
M>>U+J-GB7Q0_Y#R+_GM7:?#8?\2P<_YQ7&?$]/\ B>IS_GBNR^&W&FC_ #VK
MH?PF2W.XQU.:;CY<YI?6DQ\H.:PU-!<8QS1CYL9H*].:0C#=:0#R,<YI NY]
MWI3<%N_2A3M:BS D"C)HV@*>:0=Z9@^4PSWI .SD8S28XS2*IQS1CY<YI["%
MQQG-'1AS2$?+UHVX.,T7&.(RYI .O-&/FQFD Z\]*&P%Q\N:".,YI,?+G-':
MF"%'/&:#P>M-&0*0Y-*P]"1N1FFJV#2X^7-,"G=FFD(>1SUHQSC-, /3-."X
M.,T@%4<'FC'RYS0!D'FC'RBA"%QC'O28^;&:"O3FC'S8S38 %R3S0/E--Z&D
MVDMFDADG YIO!&WUIH!SUI=NWO3L \1[1UHV[SG.*0?-WIO(H "N&X-.V].:
M:N0V32G)/% "X^;&:,=>:0#YL48Z\]*5Q!CY<TO0#FDQ\N<T$<#FD,&&.].!
M##%-=>,9I "!56T DV>]*!C/--'(SFFKG>?>E8  Y/-/[8I!'WS1CC&:EC$Q
MG-31_P"K/TJ%1@GVJ11D%L]JN))\Z^,CM\9#_?%=OXWTX7?@>.15RPA7G_@-
M<+XUCE/C %4)&\5[%]A^W^"HX6')B'\JZE.UB'J?,]C>N+V.W<GA@*^B_#"Y
M\'L!SD#^M?/6MZ-<:?KH*H<>8.WO7T7X#C9O"H5QR5''YTZCN@BCRJ-EMOB#
MN8]2O\S7L7BF=/\ A$R"PYB_I7C'CNQN=)\4+J,:,5R.GUI=:^(%QJ6G+8HA
MR8POZ5#2"S+/PH!?Q+)MZ?\ ZZ]_D^6):\B^#_A^6T/VN92"P[_2O7Y0,9]*
MSFRD1%<P%F]*^;_$=G]O\8M .\F/TKZ1F;=:M@<XKYZE64?$!<H<&7^E73=D
M#.UT'X;Q%4FD / /(KT^UL8K+3Q#&H&T=J9I8 T].WRBK*G<",U$I-L21\^>
M/G$'Q"MV?[O_ .JO:+*5&\*.V0!Y)_E7D_Q?T2<:FNI0J3L';Z"L^V^)$ZZ'
M]@V$,4V_I5WND!!H9\[QM(4[.W\Z](\>K_Q2<:M_GI7&_#+19KK49+^5#\S$
M\CU-=K\3E;^P%C0=/_K4V]16L<[\+!_IDF#VJ]\6]/S;1SXSDFL[X5+(MY)N
M!'%=S\0=/^W:0N!G -)/W@L> G5"=/\ L>[[PQBO<?A=8"V\-P$C!V"OGQ;1
MQXJCM><%\8_"OJ;PM9?8=&CCQC""KJ.R"VIX]\0CM\66;,>!)_0UZ%97D)\)
M2'<!A1_(UYQ\65:/58)DZJV?YUSZ^-;J+09+0(V3Q5+6*!$M@=WBQ"AS^]'\
MZ^CH,_8;?_KFO\J^=_ &F7%YK<=Q*AP6SS7T6@V6T2>B@5C4=RD.4Y&*1>.3
M3>E/^\,USM%7&D[C3B,#'K3!Q3F&!G-5H(-NT8I>HIN[*@4K_P )%(>X@.&H
MV<Y]:.L@-.SR:8(;U7;0HH*[:%&:6P"X^7.:;3@..M(1QFCH N,8YI"/FZTI
M7IS1M^;&:0"A<<YH;D9IC YZ]*7'RYS3 <F"#3MHV\FH0I!^M*V2N*+ .:/<
M!S0H ;K3,' YHVG<#3L YE_>9S2D<]:0T=Z+@.QSBF@9S3B.,4T#KS28 1\H
MYI=O3FC'&<T$=.:!!CYL9IW]*;CYL9I3S0 <-S31\IS2#(>E ^;-,I=A .>M
M/]O2FX^;%!R#2$QS<C-(!\N:,9&:3'RYH 4CISUHV_-C-&.G/6C'S8S0( O7
MFC'&:0#KSTI*.@QU.QQBF$<#FG8[4 (_  %-;E@:>5W#%-=<&A *"-]*5YZU
M&!AB:50<XSUIV!6'XR<9H*8!YIH7!QFC!.>>E BU!_JQ4M10?ZL5+3 :_*FJ
MF,C'I5M^5-4B"*3 4+[]*".,YIO-'-(!<8Q[TN/FQFF\TH!+4 +CKS2*<&@Y
M&:$Z9IC'8QS29XQ1NYIM(!>E*?FI.HHZ&@!P&T?6D*XH)R<T9P* %'(VT@'7
MVIHS3AR#0 F/ES01TII) I_0 F@!3\I%(/FH<Y< 4F#0/44#C-&.,T <9H!Q
M3$+T&/6AN%Q1T!IIR4 I(!WWE^E"C'--' %._P!JA@)GYLTN_+XI-V>/6D\O
M'&:$[#W.6U[PM'JC[F4'#9Z5LZ'8C3+/R0,8K1)XQBC(SG&*MR)$&1(3ZTVZ
MM(KJ!DD .:D_VJ;R3C-3<#S'5_AO'<W[2QJ ">PKH/#'@^#1FWL@W8XXKKRZ
MQ@ C-!^?#=,57-J%B&]B%U;F+':N8TGPJFG:I-=!<%VS77,0OS>M+D.AXQ0Y
M!8%;,>WL!7SQ\0TCNO$:HF,@X-?04J[;1\'G%>$77AZ[O_%,LK*VT2<<5I3D
M)H]8\!6WV70(AC&4%<[\6#LTC)/4C^==SHEM]ETZ&,\80"N-^)FGS:EIABB4
MGD=*+ZBL<+X0\)PZ]IKL ,YZ_G7?^%_!$6BWID*C(&<XJK\,-*FTJP>*4'DY
MY^IKT20C. .:4IA88OS+MQC%*ORC.>M(S'' H0%QS6+>I5C)US2$U: HPSQ7
M%?\ "MXF?[HQ]*]-X08ZTA8;.!6L9:"MJ<UX<\*6VE,S&,9'0XKIVQ]T#Y<4
MTME1BC?M'2I<M2C@?$7@6+4+AI509?VK*TGX;"UO [<CZ5ZJ'5AR*-RD<#FG
MS.P6*EA:+8VBVZCBN;\4^$8=6+/M&2/2NL4Y;!I>IY%)2U"QR7@WPQ_82AP*
MZ+6K)=1L9(2,[A5LR #"BG X([YI<SN2SAM \&Q:9=M+M S[5;\2^%8]9$>5
M!V>U=8^&?:!C%.! PI&:T=30+'.^&/#Z:-$2  :Z!U69&5QD&GLH/3BF%<'B
MH<QV/._$GP_CU"[,L2@9.>!2:!\/5L;E97YVG/2O1^$'(S3$F!?&W%/FT!(2
M,*T*PL.%&*XCQ1X'AU2;S$4 GVKN)3M.12I@KN(S2C(+'F.E?#E;.Y21AD@Y
MZ5Z*UIMT\08[8J\ AY J/S,R%2.*4I:@<;8^$TAUAKP* 2V>E:WB/1UU.S=6
M&<CI6ZV 00*85&[<>GI3YP,?PSHRZ3;D 8R*VI3D8%#G@;>*9NXQBH<]0&SP
M"Z@*'TQ7"ZEX BO+MI0HY/I7?QTXNH.*I3U"QY]I_P /K>WG5WC!P?2NYL[*
M*PMUC10,"II'&!@4T@R$'.*IS$DB.[MDO+4QR#<"*\_U[X>Q7C^9&@&#G@5Z
M.&"G;3\KCD4HS'8\Z\-^!5TZ;SF')QVKOBBBU%OV(QBG&0*.%I%3G?FES"L>
M=Z]\/HM0NWD" 9.>E=;X<T9=(LEA]*VF(;M49R[8' %5*3L.QS?BCPK#KD3-
ML&[Z5QEK\,O+N58_=!STKUHG:P]*-Z>E)2T"Q2T>Q72K-8!Z"LSQ/X;AUZU*
M,HSCTK?QE=U)S3N!YAHWPX2TN_.91A6]*]-BA3[&8 H"[<8J0. P4+0[['X[
MT7N!Y[K7@:/4+D,$'7/2NC\.Z$-(CC3^[6^[*,?+G-+D-Q3;$<[XL\*P:Y#N
MV#<!UQ7&:=\,TBOA*Z@J#TQ7JV<CGH*!(HZ+24AV(+&UCT^T2*-0,#M6%XD\
M/)K8R1FNBW9)![TB$1MM/0T<P&?HFGKIMNL8&-HINM:4NJ1L&'48K0=MS8'&
M*E5AMJ;ZZ >41_#4)J@F(RN[.,5Z3I>F0Z;; (H!QBKNY>NVF'+<>M7?00[=
MNHZ_A3?N+MI<Y K'J,#R,T$=.:0TI'2JV&&/FQFE.&XI,?-C-)WI"% XH(XS
M2 9&:2F HR:<R[0#1]T4W)*@4ACL[B,TYN#FF$\B@DDYH 0\\T _+B@'@TE,
M / I <BG$Y%(.E(!^<"D(^;K2-P :#]\#U% #L<XS28R#1CYJ0T &/ES1VI,
MT4 "C%/'S#Z4WM3EX%%P <-3U'WC[4P'+9I4Y+?2A;@SQ3XG_P#(=0?Y[5V/
MPX'_ !+!_GM7'?$\8UU!_GM79?#@?\2P#_/2NA_"9K<[9?F!HQ\H-(O0GTI1
MR@:L#04C!'-&,G%)WI2,&D =#1MW'=Z4OWOPI,D-0 I&.G>FD8%+GK2+]PYH
M =U7%-Q\N:4GY:0#Y<T +CY<T$<]:;FEP<T" C!H SGFE/7%(O>@8H'&:",#
MZTHZ9IAR<T]P'*01BD. :15-(RDFC01)]X9%-!P:%R#0>6S18!2N#2XY(S3<
MTH'6D, .#28^7-(N6S2XPM%P%(Z48^;&:"" #2#DTQ"A<FC[IS2=#03N-(8I
M7N*;U&*<#BFT!L*JTX#/- Y&*;D@T;@!/S4[A1]:1AWIHY.#2 7&6I0.M&WY
ML48SGVIW 3'RDTN.!S28^4FE/ H 0KBG=1BDS\N*">* $YH7AB:=][FD!^8G
M%""X@)S2[><9IO>C)Q0T O.<"G)PV#35;;U%.(R,]Z=Q'%W_ (02[U1KEE!^
M;/2NLMK816"V_HH%6 X7@K2\?>IJ0NIQ6K>!X;V82[!D,#TKJ-'L%T^S6$#
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M7W!3ZCB.4%24Q#7^[5+K(1Z5=?E:IJN'-)C!FQVZ4G##=BAB#Q2;MM*P#CP
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M9NY]*4<')IZ *#R:3^$BE!Z\4@(((I" G(Q28XYI>E*?F7- Q-HV@TI'-)C
M!I&RK 4(0\#!Q31\Q;VIV.<4BC!-%QC@<)29P#[TN<C--!Y(]: #.5Q03P*#
MPN*0G(% A=V6S0>N12=.:6,98F@:&THY)7TH[XH9=M.X"@<&E)_=BF@9!I?X
M!2!"=<4N.<48QCWHQ\V,T !.?PHW?-FD;@T 9&:+ .'7--S\I%"M@TAY!HL
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M]Z4L%Y)X-<_4MC I!Y/6AD+'%.;J.1S2D@#KS2$ &<#TZTC_ 'ABA>A.11D
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MM;GG=5-E+9P:2/.PY-%@N7#=-(,9Z4"\8C!8U3VE<MGK0@.: +?VB3.-U/\
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MS38SQFM^+_5**PMI^T\'O6];8,8'<4GW 2ZR+<^M8;(=Q)-;5X#Y)'>LA@:
M(U'>G$$G<*#R.*6,''M5 4[ACYJCWKJ],7_0USUKE;E<3)]:ZS3?^/-:0%K:
M*38OI3J* &[%]*7%+10 FT4;1C%+10 FT8Q1M&:6B@!I0$YH 'I3J04@#:,8
MHVBEHI@)M!--,2GM3Z* (O)7=TIWEJ>U/HH :$ [4NT9S2T4 )@4;1C%+10
MA4&DV+Z4ZB@!NQ?2EVC&*6B@!NP>E+M&<TM% ";1G-&T8I:* $VC&*-HI:*
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MIU !112!LF@!:0]*6B@!J#%.I%;-+0 4444 %-8$CBG49H 0=*6BB@ HHHH
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M_;XSD*>:I>8%EP?+-)X>!_ME_I_C56*\5U*$\U<\/JPU=R>F/\:; Z^BBBD
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M HHHH **** "BBB@ HHHH **** "D;..*6B@!!TYI:** "BBB@ HHIK9R,4
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MIQ28!.08B*Q#^[E)[5N2C,3$5B.,R'/2A )D')'6F[MO/\5*PVC*T* PR:;
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M>E,&X1[?XJ=G.[VIR<C=WIL!A.[:#U[TRYN8K6/+G%3;<.&K'UZ-IXL1]*:
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MT-O\L:TF!'<Y\LYK!ESOXKH;OF(^M<^_^L-) *F<>U '[PG^&@9V\=*7>BH
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M@NE,L)6FD!F:9<22!MY^7-;>@$?VLY'3'^-8EM'LE*K]WO6MH:.NJ/MZ;?\
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MC(SVH BQA<#\:<C%1M/2@_*WUIY&1B@""XR8SCTJ]X;;]R^?6J,S$(1[5?\
M#RYB8^] S=W?-BI*B7'FU+20@IC-@@4^F-MW#-,!]%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0(3YG/2IZCDP*&
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MI%X%+0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "DSFEJ-/O&@#/U)GQ@#BFV!.#D=JDU$OC@<5'8D\Y':F
M,\@^*!8ZXG'^>*Z[X<EO[+QCU_E7'_$UW.NID?YXKM/AS_R"LGW_ )5K]DDU
MY@PE8X[TPMN-23N3(PQWJ+!'-97&4-2C+;>.]00Q,$&16L\8E&6[56N/W:@J
M*0&KH<)4,?6N@B7:M8FA2%DK?H :5S3J** &NNY<5#%'Y;<58I%7% "T444
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M8"PC/6IL$&H-0_U*GO2 TO#;DEQCBNEKE_"[?ZP"NHH **** "BBB@ HHHH
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MBBB@ HIA;Y\4H)W=* '4444 %%%-<X% #J*8C;J?0 4444 %(5^;-+29YQ0
MM%%% !1110!A:W,8@,5FVCEI4([]:N:V=\FVJEBH1U%(#HDP8P*J3M@,#5A
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M#@S$Y/K0!LQ?ZXU9JI&^;LK[5;H **** "BBB@ HHHH **** "BBB@ HHHH
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M4#@TWP])MUIX^V/\: .R'%%%% !1110 A'-+110 4444 %-*Y.:=10 4444
M%%%% !1110 A&1B@# I:* "BBB@"-@=]2444 %%%% !2$9&*6B@! ,"EHHH
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M6@ HHHH **** "BBB@ HHHH :2=^*=32?GQ3J "BBB@ HHHH **** "BBB@
MHHHH **** "BBD8X4F@#%UHC:-O+5F63'S1D<BK=[(3<,3R*K6K9N<@=#2 W
MT<F/)'-59F)#5.&+*,"HY@/+.>* ,5OFW'WIE*>';ZTXKA<BJ2N -]W';%4=
M!?'B213TV_XU?QNB-9>G$KKIQQTYI >@#I2TR+_5K3Z "BBB@ HHHH ****
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M]OS$&]: *6IGY,5'I[9R,=JDU"F6)Y/':J$>/_% 9UU#_GM77_#@8TLGV/\
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M%U$<#BNET(8TU*YF:3SGC^M=18'R;-*0&C12*=R@TM !2,<"EHH 0=*6BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H
MYSB%C[5)4<I&W'K0!A2IN3>W>JUNP2Y  ZFM+4U"6RA:RX/EE0^M &^K84<5
M5NP2A(JP#^[ J*\;;$..U(## +;B>H-*K;>M*3@E\=^E1NX"EC5("8',#"LV
MU!&J8 YR.:F@O5ERHYQ5G25$FIOD=!FD!U4!_=+]*EJO;2!B5':K% !1110
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M"XZ5K4 49XA'(),=35Q,%0?:F3INC/MS4%I-N!!['% %O:,YQS2T44 %%%%
M!2'I2T'I0 R,8!I]-4YIU !1110 4U^G2G4UC@4 *.E+2#I2T %%%% !1110
M 4444 %%%% !32N2#3J* $8A1S5.! \K%AGGBFWESC*#K5FV7]TI[F@";H*A
MN5!B;Z5-5>Z_U+?2@#!MS_I+?6M8Y$8:LFV/^D'CO6P2#$*0$,I^3I5 'D\5
M?E.%QBJ /S8Q3 IW<KLA4<5SK6YCN?-(YSFNO,*OR15%[ 239QQF@"CO9KBV
MP.]=K9Y\@9]*Y8J(;Z!,9YKKX@/+7'I0!EH62Z?CJ:UE^Z/I4$T8^\!3H)/,
M7Z<4 2,<"A1@4ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1C@9I
M:* $!R*6BB@ HHHH **** "@]**9(VU": ,V=C)<%>V:THAMB JM#$)'\TBK
ME &9J3?)BHM/;(/TI=3)SC%%@>#]*KH(\=^)C?\ $_0_Y[5V?PZ_Y!>?7/\
M*N,^)1SX@3_/I7:?#XXTKCT/\JU?P@:URQ6Y*CN:4KSCIBE?YIV)'>H;J4J,
M 5B-%/4+TPNN.QIHN?M**U4[[=-@[>E%L2L:\4@.OTA@D!/M6S X=>#6#I"&
M2U?Z5HV):)S&>] &E1110 444BC% "T444 %%%% #=WS8IU1_P#+2I* "BBB
M@ HHIDF<#% #Z*0=*6@ HHHH **0\"HU)+YH EHHHH **** "BD8XI: "BBB
M@!DD@1235#K%,WK27TAW%5ISJ4L3[B@# D.9\#UK?LS^Y /:L'&V;\:W(#F-
M<4ACKAOE/%8,_#Y]3703C$1:N?DYE)H2$#3"!,$=:YB_5Y;X."0,UTDB><:H
MS6F9=@'0YS3 17PJ'N*Z6"=CIT;!:YQX]KID=#776*JU@IVT 6;20O$,U8JE
M:R?O77&,5=H :&R:5C@9I:* $!R*6BB@ HHHH 1CBD+=*=10 4444 %%%% $
M3N=^SUIRGG%*5R^:=0 4444 -+8-(SX-/IK+NH 0/D$T;OESBG 8&*7% " Y
M%+110 5%DEZEINWYLT .HHHH ;NY(JE-<'S57'>KK<*3[51C3S9LXZ4 1:DO
M[D$UD6_S3 >];6J#]R!6):MY<_/<TF!O)\L6,5%<G,?(Z"I$DW1XQ4-PVZ,C
M':DP,=OF+'T-9^H3[864=QBKKDJ6^M5YK/S$W$U: R]+0P[@3DL<UM:/-C49
M%QSM_P :S[>W*2G/2M'0H\ZTX[;?\:0&[8RE9F#<9K5JC<0A75EXP:MQMO0&
M@!]%%% #0V2:=110 4444 %%%% !1110 4444 (QP,T Y%+10 4444 %%%%
M#2V&Q3JC;[]24 %%%% !1110 4444 (QQ4;R[6YZ5+5.^;$9 ZT 01'=J$A
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M?H:3 WHAL7!J.Z(V'BIL[H^*K7#;HR,=JD$8Q&^0_6DZ'%*7V%CCO01D;JM
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M0-J(D87'6H[H_*<#I4JO@#BH)7RK<4MP,CB1'..0:C#[>*<G^M8=LTC#YJI
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M'6J>GX6W#'O5P,.3B@"U$04XJ2HXL%!BI* &R8VG-4>,\=*NRG"&J4;#&30
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M:@R1)G^&K6P$VY5&"/I5:\V^2>.:G;! JO=?Z@@TK ;VC8^S+@<UJUCZ(V8
M*V*0!1110 F[YL4M-!&^G4 %0W$(E0C'/:IJ* ,OR98%)S4BWZJH5AS5]E##
M!%9][9AER@Q0!<AE61<@BI:YZVDEA8@YP#6@FI*2%(H T:*8LBD Y%.W#UH
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M;WKC[PK*ET]PV8^*8UG=XX<_G0!KF11W%+YBX^\*Q7M[I$Y8TB6UV\?#G\Z
M-HR*!G<*KRWJ1C/6L]K*[*@;S^=.@T^;?^\.10!+_:RMD!33%DEFR%R,U=6Q
MA'.T?E4RPHG04 9 T^9Y\N<BM6.VC10 M2 C=BG4 (  ,"EHHH **** "BBB
M@ HHHH BG_U1KG;DC[0/K7228V'-<W<\WV.U &I"-L8^E$_,0 I;<Y3!ITV
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MD0R EAWK3BF66-6!ZT 24444 %%%% !112$@#)-  K9I:KM<HD98$'%4FUE
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M$C16YSS0!T]%<Y_PDT7W<<TT>)8\].E '2TF1ZUS4GB:,H2 >*KP^)EW\@T
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MLU[$J,VX<5!%J44ASN% &A15;[;%G[XIQNHP,[Q0!/15=;R)OXQ3?ML7]\4
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M%PS[A+Q]:46DK2?O),K]:YY-:FW'[V*1M9G+$@MTH ZZ.SM@/FVU9C2"'[I
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MWL5S:W4D4K '@]: -6&&-Y@ !BIY-.#OP*RK6Y=;@-GY<UT:/E ] &:VF[7
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M?6NG0AH@#TI  BBV?=%)LBQC;R*=QTICD \=:=@%\F*0\**S]0D2W;:!5\,
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M2_E2G3;-^D8X]JE@;=;@=\4Y00<"@"'['#C=M''%2+;0,IRHR!Z5/@!>:C!
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M8U1WJ"2V..E3D9^M-?!7;VH P88"DK$CC%3VJ.7^7UK46V3'(ZU)%#'$I]:
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MO488;L'MTI^1N]Z #*@T#;]ZD^4FFAE#X[4 *I4R$M0Y4T_$?)[8J)<'(H
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M<?C0(<'CI1<"($'BC<,XJ3R2ISZTOV<E<]Z+@1TW>IJ<Q$BF_9OFSVI7&1<
M9I!UYJ9H#Z<4Q86)Y%.X6N,8\\=:>.GR_P# JD\@X]Z:L3#/ZTKB(OEW_P"S
M3B1GC\*<8#CCI1Y!XI("*3&/>K]AMP<=<55: ]ZN6:A<_2JN!XU\3<#Q G^?
M2NR^';9TW';!_E7'?$XJ=?3'3_\ 579?#L*-*S]?Y5M;W1&U,/WK?6FXP..M
M/D(,C>N:C+@''\58]1L:.O-2?RIK$=J XZ'I0 N0W'Y4ARHQ0"O7\J7((YH
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M&>] ["GA,C\::@R,]J7>N,#\:0.H&/X:!#MGRL?RI(B!DMUH\SCVI RXQWH
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M?:@+B%1MI HS3\C..U-H'<7:"..M-"<G]:>I&/>@D#IWZT(3$"#\*4(O?\*
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M/I2C'-(N,\TO'- #1G=Q3W7&*08"D]Z5SD"@0GR[AZ4T]:=@;AZ4T]:.H#L
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MWWI,9%+@;?>D&<&A )PHIRD$<TW&12D8 I@ QNYZ4H^]QTI /FYI>C8% @.
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M"XAZTXC@$4K#(SWIA)R!0 #[^.U.V\FC W"G>QHW :!E3ZTF*0'!IYY&1UH
M3D+Q2<[10"<4?PCTH$#9-&SOWI[]J;D[J &BEQ0HQN]Z,G;B@8* <YI.E+@T
MH&5]Z  XQ2'[X':E(P*:XPPQ0 X ;J.#FD49ZTA!!H$%%. X]Z;0 IR4Q1D@
M#VI<G;BE/(% P!RV:5?XOI31D'WIR?Q?2A;@>)?$P8U]/3_]5=O\.#G3 /\
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MNO-#T :!E?>@T'Y9:?M&W(HN SM1DDBE4@C!I.] "Y.ZDR>:7=\V:3/7WHL
M G;BE).!29^6@Y(&:-A"_>7/>G%L+BF#BG-C% QC??XIX7-,;[PQ3PV!BC4!
MG0TH8[LTE ;!H>H#@3S1VQVH!ZTF[C%,!23Q1D[LTC'@4 _-FD X9YI!G!%
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M!Q0IY-"<$T"!<8YZ4%LGZ4XKD8[4BJ%//:AC$))-*0,9I=P+Y%+NC.5SR>M
M$:')Q3FSBF$;'QVIRMDX;I3L H7*^]+]T4C$!N*0_-S0 X\#BFY.T4JYQB@G
MMVI (2<BG].>](.>M1N6SQUH$+N;)P.M+NPN#222)!%N<XS4<4T=QT:F,G4[
MA3<X-*PV#BDX*Y[T@'-R,TTYSCM2G&!2/E7 [8IH:8=*"V33LYX-( .M*XF
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MP%S\N*">!0V *4$,O-( &",]Z#C'6CC&:"!C.:=@# W"CC.*"!N S1@;CS2
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MZ\4HQCDT(!TS1M!ZGI0 X 8YICX5E /6E_AS05!V\T@%P-W6@ 9/-&!NQF@
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M'YRF*$XI#A1CM2K@BET'<4X/-+'CYN>U-XS3T4#<<]J:!['B7Q07_B?)Z?\
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M"!MSFCC&<T<8Z\T@%(''-&!N]J"!QS1QG&>*!B?+S2C &>]-(&:4#*^],!W
M_&FN!LZ\4'&,"HR2!M[&FD!(X&U:=Y:Y!)[4QAD+GM3G/3![4@$8@G%/B 4\
M5&5 ^:I8@,<&C2X'G'Q%4,01V;/ZUSVA:K?P7<4<:$J3@UT/Q!(65 3P7Q^M
M:/A+1X)8Q(P&0,BF@8>,G=]!MY&X8DY_2L[P_$3X?NF!).S_  K:\=18TJ)
M. 37-:-JUK:Z+=0M(-Q7&,_2D!H>% 3>L">]8/B>%TU=C(2$)XK<\&S+->,^
M?ESUK2\4V-E=QL[. RCCFG8";PM%:BQ#PN"X7IFN"UK4'N-9:&1CM#_UK7\"
MW$BWLD.25#$#\ZYW4H3_ ,)*_F\*7QG\:.H%Y0(=;@:W;*[.<?A76^)KIAX7
MBYP6./Y5'IFC6(EB?S 25!ZU)XSB5-)C1?N*V?Y4@.8L?#"W.DR7+$Y.36_X
M#C$),?IBHM*UFUB\.R1NX# $8S4W@21)IVD4\&A =](.>*:O)Q3WP'P.],P-
M^,\4"%VXSFD &VG<,#[5'GG%"0P&,TYL#O1M Y!ZT,H/&:8A5(88/2E=@&&*
M:$"_2C:,Y/6D,0CYRU ()I3\QQWI"H3I3$2;5'>DZ]::N#WXIQ(((]*0%J+&
MSBGU%!_JQ4M4 U_NFJ>P$]:N/RIJBP[9I=1H4Q@C/I1CY0:3/%.V_+G-)H!=
MHVYIJ@%J4C ZTBC)ZT(!<#F@ $4@'7FE XSF@ *C%($"G&:5AQG-1X^7K30#
MG'/7BG(H(I&7,0&><TY![TN@"LH_&E  &*:/]<3GBD8$'@T;@&WYO:@ <^U*
M.1BDQUYZ4 )CY2:4J  :3'RYS3GZ"F(,#<!2 #=1CY@,TFW)ZT '(-/"@\DT
M9&,TF-PSFD,Y3QG#)<0"*,$AC@XIVB:%&GAI(F7D#N/:NE-M&X/F 'ZT]$5$
M\L#"BA@>::)ILUCXDF8*P0OZ5=\2:8]UJ;. >6]*[MK2 -O"C=ZTU[6.3YBH
M)HOH(XWQ%I'VC1[10I+(OI]:G\/6KP:/-"P//K76M;1R(JL 0*:+:-3M4 "F
M!YUHNCM!KYFVG[Q[5Z4.8E]A4*V,,;[P #4H'RYI#8FP#YJ<5!IO4T_;CO0"
M \#:*15#'GM1MYQFG!0#UH"XU\!\TFT YSUI2F9"<TC)COUI@.P"-N>*C8<X
MIZ)\O6D,>[O20  -N:4C"BD ^7K2E>!S3$&T;A1@%L48YQFC'S8S2N ;1@T
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MU7;IP.?\XKHE\)FMSM\98_6E90.E&.III'R@YK T%( Q1@;L9I&''6A5[9H
M4 <^U,'#YI^WKS30F3G-"$2  \TN%VXS38QC/-,=2 >:5AC@H]:3'RYH4<=:
M7''6F F/E!I2.:,<9S1CGK20@P-V*,#GVHQ\V,T*N2>:   ;<TFT*1SUI67
MZTFPOSGI0,K:RI_LF0)U/I7$^$='WWUS),IY?N/:N]>,2IY;=#26]I%:YV
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MN8\9YI=!#=F2>>E+CY>M 7 Z]*3;GYLT#'%>.M&.<9I"..M+MYQFA" +SC-
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M\T@$ Z\T%?XLTH&<TT&F@$'7K4C+M7.:8%YS2L<KMH :1N.<]*=VI,8%'6F
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M/S4W&!FG;=O.:0\C- @*].>M&WYL9H(Z>](/]9BC08H'7F@#(ZT=<^U-!Q0
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MG-R-PI%; -" 0#C%.QC%&?EQ3A\P'M3"XAY-*G\7THSS2J/O'VI#>QXI\3E
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MX=M 6%SE<4WG-.4?+B@GF@!FT[\T\C %&[YLTAY-%P#G-*.0?:E_V:0#K[4
M-IVW@4FWY<T[H/K0(8Z]LT_HN*:P(-*3D8H& &1FD!P:,D&E8?Q4,!O>E49.
M*2CF@0Y_04WM3EYY]*1O6@8>E+CY@,TA7I2X^8"BX@ YZT8P,TG1J<?F&: &
MD<9I0>,4WH*4' Q0,4GY<4UOFQ2YR,4=Z  <&D .^G9^;.* >3[T *3@8J-2
M>:>PQ34.[/M3 .U'-+[TI&!FE<!",'K0<T=33CZ4 ,I-I+9IYYH'RFF P<$T
M_/RXI.I)HS\N,4@#G%)FE;D"C;\N:  C S1WHI=O.* $ YH R":7')%(O(-
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M3FE)&*" !CN:,9&!1<!>HR.E+QCVI@..*<.F3TH 4+@$TPG*^]/Z Y[U'VH
M4'!H.,Y%.P&7CM35.#S0 HQT/>C;\V*&&#FDY+4 *!DTIZ<=*0 YH .V@ /W
M<TF<TI!VTW'- #CC:!0Q%+CMW%(1D<=J $7&:7(YI%(!YH(R?K0 ?PTIQ@<4
M$87'>EP&'% @/(R*5B-HIN./:@@XHL,:Q(:G#FFM]X TJCFF   &ER-V<<48
MS2+@=:0"Y'-' 7'>D(YS2C!&.]  2.*-PSTXI2HX]J0@'D4  (R: =PP>M"X
M'6D(VFBP@Y4TK<]*,@CWI&/I0,7^$4N#D9IO\(IQ!XH!"GGCO2'&?I28.[WI
MV-Q^E #&Y/%*&P.:5L*PIK#'- @XVFE."*3(V8[TI(V\4]@#(W=*0XW4+UYI
M6'>@!>G!ZT$XX[TT@YI<9.*0PSN! [=:4D+%3>F:,?+STH 4'Y,F@?,,&@CH
M*&^5<#K1H(3E>*.II<;EI0.],8*<4@(Q2'KF@$;>: 8X?,OO3,X-/53C-(V#
MTI #>HH(/% X&3TI">:!"@8;%)MR30,EJ4 Y- "+P>:4$ F@C(R*;BFM1CMW
MRD4@H*XI.AH <2,T'KF@X)S1D;CZ4@$'6G=>.]-# ''<TN#NH$(!C-+CY:7'
M6D[>U Q<X7FFDTIX'-(!GB@!201Q2 X-(>#BB@!V1N)H!'-(OWS3L!<T -XV
MXIPP1]*:!NXHZ'% "Y&[VH/44V@GD"F _!SCO2+UI#D&A>32 7MGM3:=@[32
M$8&: '=!31S2@Y&#1T&.] (4XR*3(W4O#8]J3C?0  C)%(<K2C')I.M%@%/(
MI%./I2DC%-'*YH <PZ'M2ORP'M0?NTA!!H %&&H.":3G- 4]: %W#=[4N  3
MZT@ '-(3G-%@%'(QWI>!2 C;[T$;L$=NM (#R>*>@P&^E1@X:I1]UCVQ0MP9
MXC\3?^0ZGK_^JNS^&Y']G?Y]*XKXF_-KR8_STKM?APN--7Z_TKH;]TA;G;+T
M8C@9I1]W/:@D!N.E!(7GL:YV7T#/-(>#01WHZFF [@\^E&1NS2"EXSGM2 0$
M9-'\)%&0,T#H?6@!< C%-I1[4I]: &D<9I=O(SUH.< T$'(HN $9;%(.#2G(
M:D SDT *PR,BA3D8-*.!GM0,<T )]T4A(.*=CC!ZTPC'% AV1NH!&XTB]:7(
MW46  1TI2=HQWIG>G_>&.] QJ'.:4-^5(%P#BE48&30P \<TH.>.](U-'6@!
M3UI<C<#1C=2#AN: '9&:813\8Y[4F1MH /X:7 (R*3C;3ASR* &*>>:<QQ@>
MO2D.,YH'O^% "$8/O0#NS^M+C)Q3DP,T= &C"C/:D/KZTYOF''2DQ@"CS #]
MW!ZT$C%(PP:=PPXI[" <\BDW<^U!.#01WI6 0TO!7% /!S3>E,8H.#2D_E2X
MW"FE>,T@%/:E'#C-)V%&#N H 4\L::#@^U !S0%[T !//M1FG  <FFD8H ,\
M 4XG./:F4YB.U, R-V:3^*E4=Z7 !^M*X#6'-"@TN.<4O48':F(93CTIM.(.
M*0Q-N&IQ&>.](?O =Z7!S3 0XR*0_>IV 3]*3(W&D @Z&CC;[TH(YI0,KB@0
MA(XH)_*@XX]J5AD9% PZ=:/;O3<T[!S[TK -Y#4X\CBDQDXHQQQ3 4<+D]*;
M1@[:=@*.: $)POO2+SR:4D$4O4<4; -_Y:#TI1C)H& <T \FF#%(PM'#+@4'
MI@TT>U( [48X!HQD9II;I0 ]N"*4 [C32O2G8.<=Z &'K2J<?2D/6G8XS0
M]:-WRX-*!@?6D(PN*! 2.*5AGFF-SC%.)X%,8 \X/2D88-)BEZG% A?O#'>D
M4&E (;%+U'%(8>_:@X[_ (4#@<]*0@Y% "DX'O2%N.*4],'K3:$ +][-*IP3
M1D;A0#R:!!_":,C;1_":."N* $.#R*,TN.,TF.,T#%/&*1#^\Q2XZ9I N'H
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M&)SMI0>,&C[JY(ZTS8R\GO56)%Z4HR0:3!;BE52 : $S3B#Q3=IZ]J<0>*-
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **0G S3!,A;;D9H DHI,CUI: "BDR/6HWG2-]K$9H EHIB2*YX-/H ****
M"BBB@ HHHH **,T9H **9YBYQD4K,%&2: '44Q95<\&GT %%%)D9Q0 M%-9P
MO6G=J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF&" *ZFF1H$4 "GU PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ79"SAV 8H T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNYIX&5S3%:PW%*<DTC9Q@4H]Z"K";N:1B6XI^T;CZ4W&.:5R=Q%!!]Z49YI
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M4IP!Q2;?G)[T =:& <[1Z4'.!2G.T4O.!0%AO*FG$9&133DFA<@F@0+][FE
M&::/]9[4Y<[CGI058,#;[T8^7WIH)P?K3FSM&.N: L@8>E"GC!Z4-28_*@5D
M##!S2_>/O0<D4T9!H 49YI!3QGFF]Z L%!XI!G//X4LF3]:+#'?PCUHZ'BD&
M0@]:1L[ACI0 [C=[4F .OX4#&[FD).:!,3I2K_\ KI.2:E7 &*$Q$\6-G%24
MR+&WBGU0#)?]6:HQOCZU>D^X:H #=0 K$YIX;Y<4TX%-&2<]J0R0D\4;CGI2
M;LX]J7)W9I (O!/O2C(.:82<T[)VT6 &;=2JY' IN#2'*G- #B6#9 H?.X8Z
M4FYL9QUI?F'&.M#0(5<L<=A2/GI0KE6VXHW,6Y% "*#Z4ASFG[CF@$\\4 )D
M[<4$GBDRV,8XI23@4, );.<<T!B#S2;FSG'-+R>U%@&G.:<2=M)[4ISM]J8"
M(QIY8GBD44?-NSBDPN)RHY[T8.*1RQ(P*=D[<8H$)G.*.0V::-V>GTI26/..
M:0Q03FE4]C2*2*;SNH0#F&/I3A\PS33G;2J2O%.PA,G=1D[@!2,6W<"@;@1Q
M0BDQV/WA!Z4W!#4$L6Z4!F)Y% A^3G/>F[B":7)W4UMQ/ HL =J<2<4W!Q3B
M3@4@#)W"C)W&D);.<<T MG..:+  S2)DN1VI03SQ2*65CQ30"'.6H7)7)H^8
MY.*/FV=.:8:!@EABG'*.*168=J'+%AQQ2 D )R:C&233]QVXQ48+ DD4!J.Y
M!H!.*0LQ' YI03MZ4- &>,4$GBFC=NZ<4Y\D=*+"#))S0#C(I$W#J.:0EMW
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MYO2G \8I@!;]*4D]>],YSS2Y(Y'6@!6)V@@<TN2" !Q3=[#!QUI6W#  ZTP
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D,XJY@4N!0(I;7SG%,*ON''6K^!Z48'I2L V-=J@4^BBF!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image9.jpg
<TEXT>
begin 644 image9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0P!V\# 2(  A$! Q$!_\0
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M7 O;U]:-Z^M4?QI/QI@7_,7UH\Q?6J0QW-*0.QHN!<\Q?6EW+ZU0_&E#D=*
M+N]?6CS%]:I%LTGXT 7MZ^M+N'K5#.#UI=YQ2; N[U]:-Z^M4>IZTF<=Z8%_
M>OK1O7UJAD>M'XTK@7]Z^M&]?6J%'XT[@7]Z^M'F+ZU0[T_"XZTKH"YO7UHW
MKZU1/L:3\:8%_>OK1O7UJAS2_C0!>\Q?6EW+ZUG_ (TX,10!=WKZTNX>M42Q
M- <T 7=Z^M+N'K5#//6EWMBE<"[O7UH\Q?6J.<]Z/QI@7MZ^M&]1WJD&(IV[
M/4TK@6_,7UH\Q?6J1QV--_&F!H;AZTF]?6J>\XII.>] %[>OK1O7UJEM--_&
M@"_O7UHWKZU0H_&@"_YB^M&]3WJA^-.#$=*3 N[U]:7</6J!8GK2[R*+@7=Z
M^M&]?6J).>]'XTP+V]?6CS%]:H?C10!?WKZT;U'>J0)%!8GK2 N^8OK1YB^M
M4/QH_&BX&AN'K2;U]:I;S2$Y[T7 O;U]:-Z^M4<&@''>F!?W#UI-ZGO50-GK
M1D#H:5P+F]?6D\Q?6J18FFTP+^]?6C>OK5#\:7F@"]O7UI=P]:H=#UI^]L4
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MO(^U1[QLH0B7S<@?>-,-RI'6LW[4IZFH9+I0.*N*D#E&Q>FN(^YJ*RO(Q>*
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M-*#S2ECCI180VC%%!S2V&.!QVH/-1[F'04H)/44;AH2!B!TII))I0QQTIK4
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M+3?(7.:EHH C,2FD$"BI:* &>6*/+%/HH B,*FE$2@5)10!%Y"YI?*7%244
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M,/[T 7LCUI:J1JY/.:L*I% "/G%9-U]^M63I65<_?HU GM5..M:"<#DUGV^
MF=U.>ZQ\H-) :&Y?6C(]:R\R.<C-6(@^><TP+M%(O2EH **** "D)P,TM,D.
M%- %6:YQQ5+#2/\ >HN)/GQ20)EP<T 6X[1L9S4ZVY'6IHAA*?0!7:WSTIT<
M)2IJ* "BBF,QQC% #MP'>C</6JCPLYSDBD\ID7[QH N9'K2UF>?L;&:LQW.:
M +5&:0,"*BF.!UH EW#UHW#UK+DG93P<U)"[R^M &AN'K1N'K5-E<>M,W$'D
MT :%%5$N.U65;<,T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW#UH 6BDR/6C</6@!:*3(]:-P]: %HI,CUHW#UH 6BDR/6C</6@!:*3(HR*
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MO?VIV%-!4]13>E+0 *&D /:ER:4>U,!"#WI5SVH(;N:0$]J$ -GO2#-*2>]
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MJWL%&Q:+ 5MI'2FL'/:K84"E*@T6 IJ''04C*QZBKH4"D* T6 I"-O2GB/\
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M *-Q[4@$Z&GY;'2FYS3OFQ3 9U-+M-)SFG\X^:BXA@!/2G!?6EX_AHY_BHN
MTX'0TH QR:0X[4J[>] "'%.0+FFM[4B_>I@7DQCBG4R/I3Z8!3) <4^F2#CK
M0!5<-GDTT ]C3G&#UIJ\]Z3 &!'4T GL:5A[T@7WI##FE"GUI<A>*,9YS1<!
MI%-VMZU(3@=*833"X"E^M(.:<5QWI-@(.>E2 'N:ASBI(VSWI 68ZDJ-*DJD
M(****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXZTWZ&CRR>=V* ;#&#3\-CK3?N\9I2,C[U&@@[TK XZU#L)/WJ?Y9 SNS3T
M50<\&E(/<TW&>^*781_%20";"W0T;".IIP'^U01[T7U 3%"XS3?+S_%4B1X/
M6GH!:CZ4^F(.*?3$%,DQBGTR3&.: *C 9ZT@ />E?;GBD7'>D $ =#F@ 'J:
M&V]J!M[T@ C%(,#O3CMI,1^M!22';N*CV GK3N!]*-R#OS0%Q0E*0 .M)OS0
M0M#N(B89J2)<4AQ3TI 64J2HTJ2J0@HHHI@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %6_)%NV/2O,-=ED\Y@":]1N4,D16
MN8N?#\=S/EUZF@#RM_-\S)+"KUE+*K##M^=>COX+LWCR <UF2>$/L[%HD--
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M8R>802.QK'T;PP880P4[A6E<G5+:(I&GRBG<1R3Z-):7I<2N<'UK7769K2(
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Q^E/IDF,<T 57
MSUIH />G,%SQ30!WI= '9"]#FFL%?J<4NT'I2>6/XJ6E@ *J]#FG?*1]ZF[5
M'0T;4/4T%#2@)ZTOE#KNHP*=A<=:!#1UQ3RHQUIO&:4[<<4V(0!?6EPO9J:
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MQG_"0@]C33XA^M+Z^B?[4@=<\=O)RP%,%O: \**Y9=?SZTO_  D2KU!JHX]
MLSB=DC1J,+THD,;KAL5QK>)E49YJLWB] <8-:?7(C_M.!V2P6ZMD*,U/NBQC
M%<'_ ,)>OH:D3Q:C'A32>,B"S*)V,UK:S_?4&DAM;6W/[M0*Y=/$2OV-*_B
M+ZTGC8@\RB=B)DH\]?6N+'B/_9-._M_/8U+QR%_:<#LOM"^M'VA?6N,_X2$#
ML:/[?SZTOK\0_M.)V?VA?6E\]?6N*_M_GH:>->^M']H1#^TX]3LO/7UH\]?6
MN-_M_P"M U[ZT?VA$/[3B=EYZ^M'VA?6N._M\>],/B#'8T+'18?VG$[3SU]:
M3[0OK7#OXDQZU%_PE:@XP:T6,BQ?VG$[[SU]:3[0OK7#+XH#=C4R^(P?X35/
M%Q17]HH[/SQZTOGKZUQW_"0CT--_X2#/8UE+'Q0?VC%'9?:%'>C[2A[UQO\
M;WKF@:\#ZU/]H1)>:11V?GKZT>>OK7'?V[]:0^(,>M4L=%E1S.#.S\Y?6G!\
MUQ\6OAF P:VK2_$J@UO#$*1TT\4IFP*6HHY-PJ6NE-,[$[H****8PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *CEZ5)3),8H I$C-*".]..">E&T+[U
M([B;@.E,,@[TXD>E V]QFA; -!!Z4\;>](<=ABC>!U%-[ '&:7Y<4W(/:G9&
M.E)B&\9IWR]J3C/2E+#'2@!A('6G*V?NT@QW%2#;V&*&T,8VT??I5Q_#0S =
M1FA?FZ<46$-8H/O#FE1N?EH+*.",TY%!.1Q3T&6DSMI],08%/IB"F2=.E/ID
MF<4 5&//2D4X[4KD]Q2+GM4@#'/;%*IQVH8D]: 2.@H 4@&HV;!QBG$GO2 T
M:C0 T[</2EPN.M,[T:"%!I2<CI2 @4N_/44#&[MIZ5(K[NU1G%/2AB+,=25&
ME24T 4444P"BBB@ HHHH **** "BBB@ HHHH **** "CM110!1NHPP/R9KE[
M_37DERJ$<^E=K@'M33$A_A% '(P:<\,!;:<@>E8M[JMY!*8T@8BO2#$I7&!5
M.32H)&R5'Y460'F[?:K\;6B89]JB_L2:P/VA4)/7&*].CTR&,\*/RJ62SBD3
M:5'Y4] /,XM=O93Y!MW '&:Z/1HY'8,X(SZUO#1+8-N"C\JM164</W15<W81
MDZG;J8C]*\M\3>&TOG;GK7K6IHQ0X%>>:X+]9#Y4)89KNPU9Q!G$6_PZ$HR'
M_2IC\,Y?X=Q_"N^T'[8P7S8<?A7>6$2E!N0?E794S"I!:"/ S\*YVYRWY41_
M"N=6SEORKZ+\F/\ N#\J/)C_ +@_*N?^UJH<J/ 3\,YO+Q\WY53D^%TY/&[\
MJ^BO)C_N#\J/)C_N+^5']JU0Y4?.(^%LX_O?E0WPOG[!ORKZ-\F+^XOY4>3%
M_<7\J/[5JARH^<D^&=PIZ-^5:$/PSF9>=P_"O??(B_N+^5+Y4?\ <'Y4?VK5
M%R'SO<_#"8MP&/X5$GPLGSGYORKZ-\F/^XOY4GDQ_P!Q?RH_M6J'(>"0?#F:
M/ PWY59F^'DYBZM^5>Y^3'_<'Y4>5'_<'Y4?VK5'RH^=9/AE/*_1ORIG_"J)
MQSEORKZ,\B+^XOY4ODQ_W%_*C^U:HN1'S>WPMN/]K\J!\+;GU;\J^C_(B_N+
M^5'D1?W%_*G_ &O5'R1/G(?"J<]2WY4O_"KYUX ;\J^BS'$/X%_*F[(?[B_E
M1_:]4AQB?.I^%<YYRWY4+\,KD-CYORKZ+VP_W%_*C9#_ '%_*E_:U0=HGS[_
M ,*MGVYW-^50O\,ISQAORKZ)VP_W5_*DV0_W%_*I_M:H.T3YT7X5W#'DM^5:
MMC\,Y;?!RWY5[MLA_NK^5+B+^Z*3S.HPT/&SX$FVX&[\JR;SX:SSMG+?E7O>
MV+^Z*39%_='Y4EF=0M2L>!P?#6:,8^;\JEE^'4VP_>_*O=]D7]T?E2%(<?=7
M\JK^U:B*]HCYNN/AU<F0@(WY4U/AG<YR=WY5]&O%;_W%_*H62 =%7\JT6<S1
MRU)H^?A\-IL8VL/PI'^&\R#/S'\*]ZFV ?*B_E6;+(W.(Q^58SSJ1Y]6JUL>
M(GX?2=\C\*8? #J?O$_A7KUTTG:(?E6>3<$\1?I7-+.Y=SD>(G?0X.S\%;
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MUHVOW!FMX8=19U4L+R,M1KA:EI%Z4M=458]%*R"BBBJ&%%%% !1110 4444
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MBBB@!&Z558-NJTW2JS!MW6@"5,XYJ6HT!Q4E D%%%% PHHHH **** "BBB@
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MS:T\#LR_,1^52S_#_,9((_*O10JKT %(67H2*8'CO_"!2I=]>,^E=79>"XQ
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M*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F28QS3Z9)C'-
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M'JELY_UJ_G4XNX#TD7\Z **:2B#A13FTM2.@JVU];+UE4?C47]IVN<"5?SH
MI+HB"3=M%:L,0B3:*6.5)!E6!J2@ HHHH *0]*6D;I0!SFK%1)R*M:81Y7'I
M5/5P?,_&K>E_ZG\* ([EE\[IWK2M.4&*R[H'S^G>M.S^X* +HZ4M(*6@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "F28Q3Z8YXH JM@G@4W%.
M9N>E-#8I##/I1GUI_#>U'"]LT@(Z*<>>V*-P Z4 ,J3(QTIAY-.W<=*!"9YI
M2PQTIO>G$\=*'<! 1GFE)!Z#%(#@]*=][MBD,9S2C-.X7WH^][4[@,-/13GK
M32,4)G/6F!<08%/IB=*?3$%,DSBGTR3..* *K$^E-!/I3F+9YIHSVI/8 8D]
M1BE4D=!FD;=WH!(Z5(Q2&/:F98'I4F\]Z0DDTQH48(YIA'-.VG&14>7!Z4 /
M&13B3W%-5C3FW8YH8AASVYI &)Y%&6'2I$9CUHNP)X@14U1I4E4(**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH HWD<
M3 [R!7)ZE:Z>7^=EKH-6CG93Y8KS?7+'67E/E(<5TTDV93.TTJUL0HV,OX5N
M*B*ORXQ7GF@VVKQ@>:A%=M;"Y\G##G%16B829.WE;N2,U8BV?PXK&EM[HRY
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M%6],SY7/I0!%<L?.Z=ZT;3E!FLVY<B;\:TK,Y04 7!TI:04M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %,D.!3Z9)G'% %5FR>E-^E#!LT D
M=*6XQ<$TOS#M2J_K379_X!4Z@!YZTF#V%(-Y^\*>-V.*?0!G.:?DXZ4TYS3O
MFQ0(;WIQ)QTIN#FG'=CD47&-&0>*=UZ\4T!L\4XAC2 0KZ<TF#WH(D'049?^
M*F"#-.0 GK3*>@7- ,MH!BG4U,8XIU4(*9)G'%/IDG2@"JRL3UH",*&!SUI
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MF9:@"Q15?S2O8T;RWK0!8HJ+><4TLW6@">BJ_G'I@TH8T 3T5$7)%,\PKZT
M6**K^:6Z T\,1UH EHJL\IST--$S>AH MT57#-UYH\XYQ@T 6**KEVQGFD$C
M$]Z +-%5B[#UH5V/K0!9HJOYI7M1O+>M %BBH@Y%*9,=J )**@,^3C!H#'K0
M!/36SVIOF>U0S,Q'RY% #G5SWI\88=36<R3$_?(JS;[U^\<T 7:*C\SVH\SV
MH DHJ L:9YK9QS0!:HJOO(YYH$I;C% %BBJ[%EYI!(Q]: +-%5_-*]C1O+4
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MR/O#FNITQF: %J - 4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %,?..*?3'Z4 57W9Y-- )Z4YP<]:8,^M(!2I'6E ;M2AL=>::06^Z<4
M@'YQUIC!S]T\4Y5V]>:0J3T;%(8T ]Z?AL=:;TZ\T[:3WIL!N2*-S4[R_>D*
M8[T: (0YZ&@"0=30,^M.VG^]0 T^8>AI0KXY-+M/K3L'^]1<"%D?/6A <\T\
M]>M*C#/2G<&6H_NT^FH1BG4Q!3)!QUI],DQB@"HZ\]:11[TK 9X-(H!ZT@!A
M[T!0>]! '0TGXTACBH'>D_&DI-H/>@:'!O>EP/[U)L.*9M]Z+"']32D8_BI
M/6G;1V-'4",DU)'2;?6G  =*'N(L)4E11YJ6J0!1110 4444 %%%% !1110
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M1(.@%1,%W=:D2@";:,=*38H["E'2EH 3 ]*,#TI:* $VCTHVCTI:* $P/2C
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M %%%% !1110 4444 %%%% $$NWO1%M[4L@!ZTL8 Z4 2T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-
MTJLVS?5ENE4V^_0!;3&.*=3(_NT^@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ()^E0Q8SS4\_2H(\
M9YH M+CM3Z8I'84^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7]_T[UJ67$8K,N9E\[J.M:=FX*#F@"Z*6D'2EH **** "BBB@ HHHH ****
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M[BAGG["K=% %17G[BD9[CL*N44 4M]Q_=H#W&?NU=HH JEYL=*:'N,\BKE%
M%4O/C@4BO/W%6Z* *VZ7TJ-C/G@5=HH J*9NXH?S<9 JW2'I0!DO)=[L!>*$
M-SGE:T">:<I6@"LK3D<BI!YH[59I: *VZ7THW2^E6:* *VZ7TIA>XSTJY10!
M K2;>1S43O<9X%7** *)DN<<+34DNMW*UH44 5@TV.E(SS]A5JB@#/:2Z[+0
MLEUW6M"B@"J&FQR*C8SYX%7J* *.ZXQC%)FX]*OT4 4M]Q_=HWW']VKM% %1
M7G[BAGG["K=% %17G[BD9Y\\"KE% %57FQR*7=+Z59HH K%YNPJ,O<9^[5VB
M@"EON/[M,>2Y_NUH4F : ,.=[LGA:GM///WA6@Z"EC % $>91T%,+W&>E7**
M *H>;'2HVDN>RU>HH SA+=Y^[3_,N/[M7J* *:O/W%*SS]A5NB@"HKS]Q2,\
M^>!5RB@"J'FQR*;ON,]*N44 5=\V.E-#W&>E7** *I>;' IJO/GD5<HH K;I
M?2C=+Z59HH IL\_84P&X)Y%7Z* ($W[>105;J*GHH K;I1T%&Z;TJS10! K2
M=Q2LTG85-10!6W2^E,9Y\\"KE% %0M,5Y%9\OGF3I6TW2JK(2] %:(3 =*F#
MW '2K2(,5)B@"EON/[M*KS]Q5RB@"MNE]*-TOI5FB@"FSS]A2![C^[5VB@"J
M'F[BEW2^E6:* *K--CI46;@'I5^B@"FKS]Q2L\_85;HH I;[C^[1ON/[M7:*
M *&;@]J<'N!VJ[10!5WS8Z4PO<9^[5VB@"EON/[M(6N#VJ]10!0!N!VJ17G[
MBK=% %;=+Z4;I?2K-% %;=+Z4;I?2K-% %;=+Z4C--Z5:HH Q[OS2/F%9ZF9
M6^0$UOW(4CD57@CC+<"@".TDN3]]:M,\_8595% X%.H H^9<?W:9YEWNQMXK
M1HH K*)"N2.:C+W / J[10!2WW']VD+7![5>HH H9N!VIV^X_NU=HH I;[C^
M[3U>;N*M44 5BTN.E19GSTJ]10!65I<=*1GF["K5% %-7GSR*21[@#Y15VB@
M"C')<G[RT]GG["K=% %+?<?W:-]QG[M7:* *N^;'2F[[C/2KE% %4O-CI3-]
MQG[M7:* *6^X_NTQI+KLM:%% %!9+DCE:S[U[S!VK6_4<B*5/% '!R?;S<C*
M<9KJ]+C;R1OX-4[GB; ]:T;,/M% %\# I:1<XYI: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *9)G%/J.0D"@"HP;- SVH9CGFA<]JGH I+=Q
M3*D(;O32*$.P +CFD.,\4X;>]-..U)@. 7%)CFD&*6F@L+A?6DX[TG%% #CM
M'2FYI>.U&/6A )2YI..U%--@!H7[U%/7;FGL(M1_=I]-3&.*=0 4Q^E/IC\B
M@"J^?6F@$]#2LN#UI%'O2Z # CJ:;Y9;H:>PQWS3-V.](!X 3KS2%B>E .?>
MDHL,*4#%)C-+Y>.=U-@A21CI3:<6'3%-I(0C>U*A*^]&S=WQ4D:!?>F,GC;/
M:I:8A'84^F(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH QM4U7[$I^4GZ5Q.I>*)F?Y XKT.ZMX) ?,V_C7+:GIVGE
MCEXUK2+1C.Z,_2_$K<"16-=E87GVI P!%<S9:5:D@HZGZ5U%C:K$@"FAV(A)
MME]33J0#%+69T(****!A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %(W2EI#TH JLK;NM2)2,1GK2K0!,.E+2#I2T %%%%
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M=F^K*8QQ0 HZ4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 444UL]J (I5S2Q+BFLQ'6GQL#TH EHHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHS3-XSC;0AC@O&302O84F31GVI!8;4B4PGVIZ47 M)3ZC2I*H04444 %%%%
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M7V6=&Y<F@#HXI4?I4N1678JX SFK4L<AZ,: +61ZT9'K5 12Y^\:F6*3'WJ
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MBBB@ HQ110 4444 %%%% "8%+110 8%%%% !1110 48HHH *,"BB@ HP***
M"DP*6B@"M.N>U+ ,=J>]*E $E&*** "BBB@ P**** #%%%% !1BBB@ I,"EH
MH *,"BB@ I,"EHH 3 I:** "BBB@ P**** "BBB@ Q1110 4444 (W2JK%=V
M-HJTW2J;??H G1 1FI0 *;']VGT %&*** "BBB@ Q28%+10 F!2T44 %%%%
M!BBBB@ HHHH *,"BB@ HQ110 48HHH **** "C%%% "8%+@444 %%%% $$PX
MJ!,9Y%3S]*BB7)H L)CL*DIH4"G4 )@4M%% "8%&!2T4 %)@4M% !1110 F!
M2T44 %&*** "BBB@ I, TM% "8'I1@'M2T4 & **** "DP*6B@!,"EQ110 4
MF >U+10 F!Z4V0#8>*?3)/N&@# NI )\;!UK4LB3&.,5E70?[1P.]:UEN\L9
M% %P4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1R]*DID
MF=O% %(@YZ4H)':G,6STI 3VJ>@QV<]1BF,^WH,T[K]ZFLI_AYI(!5DS_#2&
M0_W*09'44[>?2J ;N/7%'F-TVTN>:=EL=*3$,!YZ4YF./NTWG-/);'(H]1D:
MN<]*DW9[4P9[4[![T#$WXZ#-)NSVI>E%- Q-^/X:56R>F*:<]A2IUYH%L78_
MNT^F1_=I],04R3..*?3),XH J-NSS2+GM2L#W-(N>U2 K9[T+N[4,".M"@]C
M0 ASGF@%J?D=Z3;GD4,8T\TP!L\]*ER *833#0>,8XZT'/>F@'M3L'')H 81
MGI3TR.M-S3DYI,3W+,9J2HXZDIH HHHI@%%%% !1110 4444 %%%,>544DD4
M /HR*PK_ ,106JG/:N=7QU"UUL&>M '?T5CV&MQW2# /-:ZMN7- "T444 %%
M%% !1110 4444 %%%(: *-[,L:G-<'KFIJLA -=MJ$1937 :Y9YD/UJ9*Z.#
M$*Y=T:XCGP6KM+%1L&VN'T2VVXZ5W5@I5!40C9F=".I>6GT@%+6IZ26@4444
M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*1NE+2-TH K-OW4]*C8-NZU(E $PZ4M(.E+0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%(6Q0!&]*E12
M$MT-/B!'4T 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-=1;;%48-3"5V+#N[+@I:0$4M:GHH***3(H&+129HR* %HI,TN: "BDR*6@
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MJ:CDD38?FH P[IL3]>]:EFW[L5D77E&?[_>M:R \L8.: +HI:0=*6@ HHHH
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MBGJQ4(ZD:&;TJ8>9Z5,,4M=5CT$M" ^9CI4>)0>E6Z*916_>GJ*/WHZ"K-%
M[E7]Z>U&9O2K5% BK^]]*4&8=JLT4 5BTV.E,W7&>E7** *I:?' H1I\_,*M
M44 5Y&EQ\HJ(>>>HJ[10!5'FCM4@,F.E344 4W:?/ I@^T9Y%7Z* *A,V.E1
M_P"D \"K]% %-6N.XI^Z;TJS10!6W3>E&Z;TJS10!"#)CD5!,T^.!5VD.,4
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MPKZ64-\JDUS5(W9R5D78+=$^[BM&+@5CV#2,!N!%;,72G26HJ*)12T"BN@[
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I#TI:0]* (3UIR@^M-;K0N<]: )Q12#I2T %%%% !1110 4444 %%%%
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M>M(0UN.E"<]>*1L]J=&I/WJH"U$!V-35%&H%2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !12;AZBD9PHR30 ZD-0->1+U84+=
M1R<*:&*XLF.]4)I85/)%6YE9A63<VKLW2N>HSEJEZ&2)OND5>CQCBL:U@=,5
MK0@@<TZ;'29.*6BBMSJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "D;I2TC=* *S,V[I3TJ-MVZI$H F'2EI!TI:
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M;$*T8(KFYM-D6X!W]ZZ33E\N$ \T 7P,"EI!2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4R09%/J.7[M %5E(-( >U!?#<T[(;IQ4[ '3[U
M-(W?=.*=Y9/>FF(_WL4D,41MW-(8V[&E"$#[U(8V)^_3"XG(IX#$=::$QU-.
MQ@?>I 'EGUI"& Y-)R>]'EG^]3  "3UIVP^M,V$]#BE$;#^.@!VQAT-!SW-(
M4/\ ?I0G^UF@:&'?V-"YW<TYA[TB]::!ER/[M/ID?2GTR0J.0<=:DIDF,<T
M4V !ZT*,]\4K!<]: %J;#$8 =Z% />A@.U"@=Z0 >.]("#U-/PGK2;$]:8(7
MRP5ZU$4P>M2;\<=J 8SWIZB$%*P&.M.VIZTTA>QI,8U1D]:?G;T.:;Q3E0&B
MVH6)XFS4U11J%J6J$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %%%% !1110 C<"JK2@-BK+?=JBZ#S* +2.2.E2BF1 !:DH
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MHSTI5H F'2EI!TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,3(?XJ/.C'\5 $E(:;YR'O36G0#[PH &8>E-7K5=[E,]:6.Y5FQF@"Z.E+3
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MFIZT /HIGFIZT>:GK0 ^BF"13WI3(H[T .HIGFIZT>:GK0 ^BF[U]:3S5]:
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M=:FHH A^SK1]G6IJ* (?LZTAM4-3T4 0"U04AM$-6** (!;(*:]HA%6:0]*
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MM[TAQGBE&W'-(<9H$*-M297%1;T]*,YI6N,<=M,HXI1CO36P"?2E '>ER.U
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M?<-.ILGW#0!@77^O_&M.R_U8K,NO]?\ C6I9 ^6* +@I:04M !1110 4444
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M4NT>E $7GC.,4[S1C.*=L7TI=H]* (A."<8I3, .E/V+Z4NU?2@",3@]J&F
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M0K@4Z84MR84M%%=!U!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !2-TI:0YQQ0!68ONZ4]/>D8R9Z4Y5;O0!*.E+2#
MI2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!%(Q'1<T1L3U&*)"_841EOXA0!+1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (
MW2JS,=W2K+=*K$MNZ4 2HF1FI134SCFG4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#,Q X&:KK+)
MG[E3SLP'%51)-G@4 7(W8]1BI:KPM(?O"K% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R3[AI]-?[AH Y
MV[+_ &C@=ZU;+/EC-9]TY$_XUH6C@H,T 7ATI:1>E+0 4444 %%%% !1110
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M$8 J6HXZDIH04444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I#2TUJ&#(9:S;B\2$X:M)P<=:RKNT64\D5SS.2H36]RDWW:T8
MSQ67:VXBZ$5J1=**>XZ6Y-10**Z#J"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "D;..*6D/2@"J5GW\'BID#XYI"Q
M!ZTY9* )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH K3>9_":6'S/XC2R@]C2Q ]S0!-1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 (W3BJ;B7?P:N'I59@V[K0!)&'QS4U-3I3J "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH KW
M&<<56C$F>#5N?I4$0)- %B,/WJ6FJ#WIU !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4R3[AI],D^X: .?N
MXW,_!XS6G9)A!GK67=;_ +1P>];%B/W0S0!;'2EHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ IDF=O%/J.3I0!5;=GFD&>U!8YYI1STI;(8
M,&[TS#=JD((ZG--VENAQ20(0;N]+B3L:4*5ZFC:QZ-04-RW?K2XD/>C:?6C:
MX_BI"%"-2D,!S306Z9I2&QR:9(SYOX:=B3N:09SUIX8CKS1J,C)<=#2JQ[T/
MSTXH7CK3&*5<]*100W-+DTB_>H5Q-EV/[M/ID?2GTQ!3)!QUI],D Q0!488/
M6@<^U#!<\&D '<U/08,,=\T!0>]# =C0H!ZFE=@*0!2>7GG-/V+ZTP\=#3"[
M%Y'%)GWH'/6E"+US0QBX)I"N.]*2<=*90)L*D7ZTP 'K3P,=*&!8CJ2HHR>]
M2TT(****8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 -9@JY-4)
M-5AC?:6'YU;N5S$P'I7$:I:2^>6!:@#L8M0BDZ,/SI;F\6WBWDC%</9R2Q2@
M9-;%U(;BTV2':,=: )G\5P*Y7*_G5RTUR.Z. 1^=<,VC6C3%OM!SGUK7T^RB
MMR-LA-2VR&V==+(&7*FL.^$Q;Y=U:-NPV]<U5OKY8#VK&;9S5.X[3Q( -^?Q
MK:BZ5RZ:N['Y%%:EK>2..12IO4*;LS:%%4UFDQ]VGB9\\BNDZT[EFBH&E95R
M13%N2S8H&6J*BWG%-:5AT% $]%0I*3UI&D?/ H GHJ)9#CFFF5\\"@">BH#*
MP7I40GEW8V\4 7**A,C8X%-$KYY% %BBH#*W84"5NXH GHJN97["E$K=Q0!/
M146]O2CS#0!+141=@.!48F?/(H LT5%YAH\PF@"6BHO,/I0'8]J ):0]*;OX
MYJ&65P.!0 ]@/6D7&>M9DMVX:D@NI6?E>* -H=*6J_FMY>0.:8LTN>5H MT5
M$)":/,([4 2T5%O/I3&E<'I0!8HJL)9/2GB0]Z )J*BWMZ4AE;L* )J*KB5\
M\BE,K=A0!/14 E?N*=O;TH EHJ(R$4PRR=A0!8HJKYTGI3A+)W% %BBH#*V.
M!2"5\\B@"Q14!E;L*%E?N* )Z*@,K]A0)6QR* )Z*KF5\\"G>:V.E $U%5_-
MDSTIXD)H EHJ+>WI4<DCXX% $CIO[T1Q[>^:SY+J1#R*D@NW?M0!HT5")6QR
M*:99,\"@"Q14/FMCI3/.?/2@"S14/FMC@4T2OGD4 6**@,K=A0)7[B@">BH#
M*_84"5NXH GHJL9GSP*>)6Q0!-158RR>E'G2>E %FBJZR2'J*DW-Z4 245%O
M;TH\TT 2T5%YAHWMZ4 2T5$9"*9YLF>E %BBHA(31O;TH EHJ+S#1O([4 2T
M5 97["@2MW% $S=*K,!O^]2R2L%.!63+=.): -Q.E/K.M[J0@<5:\UL=* )Z
M*KB5\\BE,K=A0!/14 E?N*=O)[4 2T5$9"*897SP* +%%0^:V.E-\V3/2@"Q
M14/F'O2^8: ):*B\PT>8: ):*@,K]A0)6[B@">BJYE?L*3SI/2@"S15;SG]*
M/.?TH LT56$S]Q4@D)H EHJ+>WI3&F8=!0!8HJ!96/44AE?/ H L45#YK8Y%
M,\Y\]* +-%0^:V.E-\V3TH 6?I4<1P>:AN;ET7I5!;V1FZ4 ;X(-+6?;2NW4
M5;WD4 2T5%O;'2HS,X/2@"S140=B.E(TI H FHJNLKDXQ4CNP&0* )**@21F
M/(I9)&7H* )J*@61SVH,D@/2@">BH!*V.12>;)GIQ0!8HJ+S#CWIGFOGI0!8
MHJ RMC@4@E?N* +%%1>8309"* ):*KF5\\"E$K8Y% $]%5_-DSTIWFMCI0!-
M15?S9,]*4RMC@4 3T5 )7[BF23./NB@"U37^X:@CF<CYA5*]O9XP=BY% %:Y
M4>?U[UIV9Q&*Y&;4)6N0&&.:ZG3)"\ )H T!2T44 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4R09%/J.3I0!59 #UI />@]:!@]:708XC'?-
M-_2G=.G--8;NO%) A1]:7;[TT*1TH^M V+WI=O'6@"@A<=:0F,QSUIQ7'>F]
MZ<0N.M/00@&3UIX&/>HS2J3VH8Q6^E"G':D8D]:52<<"@!&YH4'-#$TY&.>E
M,1:CZ4^F(<BGTP"F28QS3ZCDQCFD!5(!/% 7'WJ&P3\O% !'WN:EC J#]VDQ
MCK003]SB@9'WZ $S2C%*5STIN,&BX7'[3BF=#4@<8IF,FJ7F&XH;UI<*>E(4
M(IN#VXI, 8%>M*ASTH.1]_FGQ[6^Z* L3QY[U+3$!%/JA!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% #7&5Q67=6#2YPM:U%)@<S'HT@FW
M%>*EU2P?[&1&/FQ70TUD5Q@BF!Y+)IFK"X8HAQFM_1]/U#</M"X%=M]CASG:
M*>(D7H*'J)HHQVH1:J7>FQW!^85J2MM%9%YJ:P-@@USST.6HD)!I,,?05J06
MD:#@5GVE^MQT!K6B;(IT[!2M<E5 !@4;!FE%+6YUC&C##!IBVR*<BIJ* $VC
M&*;Y8I]% #/+%."@4M% #2@I=HI:* &;!1Y8I]% #0@%*5!I:* &A *"@-.H
MH 0*!2% :=10 FT4FP9IU% ";13?+%/HH 9Y8I0H%.HH :5!I0H%+10 TH#2
M,J[<&GTU_NT 4VMX&?GK4R6L8Z"H6^_4\;'% $@0"G%0:!TI: &A *"H-.HH
M 0*!2% :=10 FT4FP9IU% ";1BDV#-.HH 0J#2! *=10 TH#2A0*6B@!I0&E
MVBEHH ;L%+M%+10 W8,TI4&EHH :$ H*@TZB@!H4"@H#3J* $VBDV#-.HH 3
M:,4FP9IU% ";0:38*=10!4GAC;[U+!%&OW:DD*#J*6,J?NB@!VP4[:*6B@!I
M04GEBGT4 -" 4I4&EHH :$ H*@TZB@!H4"@H#3J* &>6*/+%/HH 3:*38,TZ
MB@ Q1110 A4&F^6*?10 SRQ3MHI:* &[!FEVC%+10 W8,TI4&EHH :$ I2H-
M+10 T*!04!IU% #&1=O-4'@MS)SUK1;I5)FC\SD<T 3101A?EJ8(!21XV\4^
M@!-H-($ IU% #2H-*% I:* &E :4*!2T4 -V#-+M&*6B@!GEBCRQ3Z* &>6*
M/+%/HH :% H* TZB@! H%(4!IU% #/+%'EBGT4 ,\L4H0"G44 (5!IOEBGT4
M ,\L4[:!2T4 -* TGEBGT4 -""EP*6B@"I<Q(PYJK#;P[JO3@$5!$%!Z4 68
MXT4<4\H#2*1VI] "!0*38*=10 FT4WRQ3Z* &A *4J#2T4 -"@4I4&EHH 0*
M!2T44 -V#-+M&*6B@!FP9IVT4M% #0@%*5!I:* &A0*"@-.HH 0*!2%!3J*
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M9EU_K_QK4LE_=B@"X*6@44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 (WW>*HNDAD^[Q5UVVKFLR340LNW- %^-..:FJO#*9%!S4XH
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH JW7W:KVY.[BI[N5$7YJK6UU"S?*: -)2<<TZFJX8<4Z@
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M:7XQ2*5)YHW&!^M/2FL% XI8S1<"TE25''4E-""BBBF 4444 %%%% !1110
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MN#,N,T =G!.'0<U8JM;VRQJ#5F@ HHHH **** "BBB@ HHHH **** "BBB@
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MF1]*?5""F28QS3Z9(>* *C;<\4@QWI68$]*12!U%+H -CM2!E'6E8@]!BD#
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MMV9H [&BL&Q\21WH!5",UI/?HD)D/:@"Y17*7'C.""4H4)Q4EMXOM[A@-N*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M< .E-SS3#04[<<4VG97'2@8!YH0#*<KA>M*2.PINS<:!%N)PW2I:@A3;4]4
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1@444 %%%% !1110 F!Z4TQ*W44^B@!JH
M%Z"G444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !3)!D4^F/G'% %,J<\TH]J5PV>330#VI6'<<684TDFG]/O4
MPD=J0"4O-*".XI2I/2@!E+M.,TG2C<0*! .O%..['-,#9-/(;')I#&@D'BGA
MO[U- R>*=C'6G8!"^.E*&!ZTUL=A2C&.12LP$..U*CG-(<=J<A7-4(M(<BGT
MU,8XIU, IK]*=3)!QUH KN148YI649X-(J^M2.X%<>] S3LA?>CAO:BX!N'0
MBF%23D&E/% 84:#0X8QC%!3WHW\=*;DYH$P_"E''6EW'TH4C-&XQ"1Z4BMBG
MLJMWIH7;TYH$6(W!Z\5+D>M4BQ^E <BGL(N[AZT9'K5$L3WIV]L47 N;AZT9
M'K5')SUIQ=L47 N;AZT9'K5')SUH+-[T7 O9'K1D>M4E9ATH+,:+@7<CUHW#
MUJD)"*0L3WHN!>R/6C</6J8=L4<]<T7 N9'K1N'K5,LU-#$=Z+@7LCUHR/6J
M1<FD#$47 O9'K1D>M42Y-*&8"BX%W</6C(]:HEB33M[8HN!<W#UHR/6J.XYZ
MT[>V*+@7-P]:,CUJB&(-*68T7 NY'K1D>M40Y'>@N30!>R/6C</6J0=A2%B3
MUHN!>R/6C</6J8=J.>N:+@7,CUHW#UJF7:FAB#UHN!>R/6C</6J>\GO29(Z&
MBX%W</6C(]:HEB>]*)"*+@7=P]:,CUJB68T[<V*+@7-P]:,CUJCN.>M+YAQ1
M<"[N'K1D>M40QSUI2S$47 NY'K1D>M40Y'>@N3WHN!>R/6C</6J0<BD+$]Z+
M@7LCUHW#UJEYAI-QSUHN!>R/6C</6J>]L4T,V:+@7LCUHR/6J99C30Y'>BX%
M[(]:,CUJB7)H$A%%P+VX>M&1ZU1+$]Z=O;%%P+FX>M&1ZU1W'/6G;R11<"YN
M'K1D>M4^1R#06:BX%S(]:,CUJB'([T%R>]%P+V1ZT;AZU2#D4A8GO1<"]D>M
M&X>M4O,-)N.<YHN!>R/6C</6J7F'%)N(YS1<"]D>M&1ZU2+DT!F%%P+N1ZT9
M'K5,DGKQ1N*]Z+@7-P]:,CUJB6)[TOF'%%P+NX>M&1ZU1W'.<T[S#THN!<W#
MUHR/6J?/4&D+-1<"[D>M&1ZU1#D=Z"Y-%P+V1ZT;AZU2#D4A8GO1<"]D>M&X
M>M4A(:.O.:+@7<CUHW#UJF6:FACGK1<"]D>M&X>M4]S'KQ1RO0YHN!<R/6C(
M]:I,S'K0K,*+@7=P]:,CUJF<GJ:3<1QFBX%W</6C(]:I>^:4LV*+@7-P]:,C
MUJCDYZTI9L47 N[AZT9'K5$,1WH+DT7 O;AZT;AZU0Y]:,GUHN!?R/6C</6J
M7F&DW'.<T7 O9'K1N'K5+S#BDW'.<T7 O9'K1N'K5(NQ%(&([T7 O9'K1D>M
M4BY- <BBX%W</6C(]:HEB:4.1Q1<"[N'K1D>M4=QSG-+YAQ1<"[N'K1D>M40
MQSUIQ=L47 N;AZT9'K5$,PI2S&BX%W</6C</6J(8CO1N)[T7 O9'K1N'K5(2
M$"DW$GK1<"]D>M&X>M4][8INXYZT7 O9'K1N'K5/<Q'-)R.AHN!=W#UHR/6J
M)9J4.11<"[N'K1D>M4\EN^*3<1WHN!=W#UHR/6J.X^M+YC8HN!=W#UHR/6J.
MXYSFE\PFBX%W</6C(]:HAF%*6;O1<"[D>M&X>M4@S#IS2%F/6BX%[(]:-P]:
MI"0BDW$]Z+@7LCUHW#UJCO;% 8YZT7 O9'K1N'K5,NU-#$=Z+@7LCUHR/6J1
M<F@.11<"[N'K1D>M4\ENIHW,.G-%P+FX>M&1ZU1+'/6E\PXHN!=W#UHR/6J.
MXYZTXNV*+@7-P]:,CUJB&([TI<FBX%W(]:,CUJD&8=*"S'K1<"[D>M&X>M4A
M(12;B3UH O9'K1N'K5/>V*;N.<YHN!>R/6C</6J7F&D!;UHN!>W#UHR/6J)9
MN]*&8=*+@7<CUHR/6J19CUH#MBBX%W</6C(]:HECGK2^8V*+@7=P]:,CUJCD
MYZTNYL=Z+@7=P]:,CUJB&([TI<FBX%W(]:,CUJD&8=*"S'K1<"[D>M&X>M4@
MY%(6)/6BX%[(]:-P]:I>8<4FXYSFBX%[(]:-P]:I>8:0,1WHN!>R/6C(]:I%
MR:%9ATHN!=W#UHR/6J>2>IQ1N8=.:+@7-P]:,CUJB6.>M+YAHN!=W#UHW#UJ
MB23WI,GU-,"_N'K1D>M40Q'>E+DTK@7<CUHR/6J09ATH+,>M%P+N1ZT;AZU2
M#MCBD+'/6BX%[(]:-P]:I>8U)N.>M%P+V1ZT;AZU2\PD4@8@YS1<"]D>M&1Z
MU2+DT!F'2BX%W(]:,CUJBS,>O%*'(HN!=W#UHR/6J)8YZTGFMTHN.Q>+ =ZC
M=\C%5@QZYI=YQBAB!E.<YI ">])S3ASUXI# @COFD"Y]J?PO?--9LT +]WMF
MFEC2A\=J7 ;FC80SDFG>6<9I02.U/W#%)L9"%YIY4@4;^>E/+#%&H$7/TI0<
M=>:"V>U .*8Q&.>U*IP.E(QS2J2!TIDB-S2+UI6/K0IYH&7(^E/ID?2GTQ!4
M<F,<U)3),8YH J-M!XH!SUH;;GBD  ZU(6!@.U)BG'':D^M PVDTFP9I=Q'2
MC.: 08..*3H:?\V*9C)H0,7>2*3!/2EVGO1G'2C0 VGO1NQTI0V>M!QVH]0%
MR&ZTTX'2BC:3THM8!*?EL=*;C'6G\XH"PS/-+N)%-(.:>%/>BX#<X/%.W9ZT
M8!Z4TJ1UH ?T^[33GO302.E/R#]ZC4!E*,4I7/2DQB@!V6QTIO>G?-BF=Z '
M;CBFT[:<4VC0 HS3A[T'!Z4[@ P>M+R.E(,=Z7/I2 ..]&X]!1D'KUI"I[4
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MU'S=Q1EATI=S'K0'0<I(Z"D8DGD4J[NU(V[/-*P"@MC@4ASFG+OQQ36S32$
MS3MHQUJ/$F>!3P'H'H(5-)EAT&:>2W>D!;M0&@TLQZC%.4GL*&W=Z%+=J $;
M)/(I03CI2,3GFE&['%+0!#FF_-Z4XYS3@6%4P3&@-UQ3PS#M2[N/>FG=WI !
M=NPIA9CU%/&>U!)[T#=A%)':D)/<4X$]J:<YYIH3%!;'2D.<]*<"V.*0DYH
M7+8Z4WG-.R^*8<TD _)(Z4@R*;N?O2Y;M0,5B?2D4GL*0[^]*N[M2$#$GM2@
MG'2D;/>E&['% "$GTHWO_=H.<\T[+8JF"&'-)N;TIQ)I,/W% U80Y["A0Y[4
MOS#I2AV[T7%8,NO09I-S'J*DW,>E,.>]);@*"<=*0DYZ4H+8XI"3GF@0X,V.
ME-+'M3AOQQ2;6SFA#& N>U.VMZ4[>PH+L>E%V&H#([4N\]A3,OWI06[46&(2
M>XIP)QTIISWIPW8XIIZ$C#G/2G@MCI33G/-.!?%+0!O.:=N8=J;DYIWST,8A
MD/84FYS_  T<BGJY[T,! 6':FDGN*D))Z5&V[O2 56;' I"3GI3EW8XIISGF
MJ$+EL=*:V:?\V*;@YI(8P;\]*<214@W=Z'4XXHN"(MQ/44N#VH"/GFG@,.E.
MX,9@]Z<&(' I#GO2C=CBD(0DDTN3CI2'.:<-V*&P&\YIVXXZ4WG-.^;%-@-W
M'L*"S'J,49(-*6)ZT=1@"?2@DGJ*3YOX:/F[T=0  ]A28.:<"W:D.<\T=1#@
M3CI33UIWSXIG.: %PQ[4A##H*>"]!<TAC/F[BE /I07)I06[4^@7$.>XI03V
M%(=W>@%^U'0 .<T[+8Z4SYL\T\%\4A#.<]*?EL=*;SFG?/B@8P[NPI,OW&*<
M2PZ4FYSUICL)O8=!2[V;J,4AW=J!N[T" E^PS0,]Q4@W8XIISGFEN N3CI3<
MG-.^;%-YS2V =N;'2D!.>E+\V*:"<\4 /W''2F$MV%2#<>M*01TII@0@MW%/
M!/I2,6[TJ[L<4-@(2:-S_P!VD.<\TX;L4K@-YS3\G'2F9.:=\V* &$GL*5&?
MN*!G/%2@MWIW!#6+=A4?S=Q4Q)[5&=W>A V-RW89I1GN*<-W:@DYYI]0N+EL
M=*;SFG9;%,YS20AQ)QTIHSGI3_FQ31G/%%@%)/I3=S#H,TX[L<T@)'2FMAAN
M8]1BE!8=J"Q/6@%NU+H A)S3LMCI33G/-.!;%/H(9SGI3\MCI3><T[Y\4K ,
M.>U)ENXIPSFE.['--CN,.:<@+=:;ANU2H&[T/0-+#60]J9R*F;=VJ,YSS4[@
M*&;'2F\YIPW8XIO.: 'Y;'2FC.>E.R^*:"<T6 4DXZ4WYNPIY+8YINX]J:V
M0;CU%.R5[4N\]Z:V\]*!@3FE!..E,PW>GC=CBD(;SGI3MQQTI.<T[YL4V@&
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M=C1]F;UH C ;'!I"#4WV=O6C[.WK0DQD84]Z7(Z4OV=_[U+]F;UHL*Y&5-(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2 [S(/>EKG[">X 'F,35]M12,?-0!HT5C/K$8.<TP>(8 =I% &Y168FK1OR
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M[EY""33L!K44@Z4M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWH; GHJL9C3/.;/6@"Y157SSCK31,V>30!<HJMY_%'GT 6:*J-,W8T+,>YH
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MI@,/!HR?6E[TNP8SFD W-&3ZT8R:?@ 4 1TN*?PU+@+[TP(^:.:5CGM0/I0
MH!]:,KGIS2X]Z3(SBD&HN#CK321Z4[;QG-)[468#0,TI7%.&%YI&?-/T 0$>
ME!H'':@_2@!M+13@H(ZT -I=G'6CO3L<=:0$>.:6EQS3MH'>@!@&:4KB@MF@
M-CK1J !:7@4O#=\4TK0 ;<TF*4#WIVX=*$"&4X$'M2E1US3.E #BE-Y%*#BE
M+ ]J>H#<DT4H.*"<T )2Y- ;':D)S1< ZFG;..M-IV/>BX#>13@WK2%J2BX#
MB5/:FTH7/7B@J!WHO8 R12[QWI N>]!7'2C< )!Z4E+MI,47 **=L&.M)BBX
M"44NW'>@#-%P%! ZT$@]*"N.]-H *7)I0<#I2-S1<!,TAXI12[1CK0 P-DXQ
M4H7 S3 HS3\ =Z& C$'H*12!U%.R#2<#WI!<8_/3BE3@<\T_ ;VH^[VS1J A
M&>E- (:E).:<C<]* +4?W:?34/%.J@"F28Q3Z9)C'- %1@,]:1<=S2N%SQ2+
MCO4ZH!6 [&D 7N:&V]J!M[T-@!QVIHJ3Y*/DH ,G'2F9.:=O_*ERO7O0 9)'
M--8#L:=O'>FDKVI,8*,]32L!V-(N.]*VWM5*PA JGJ:" .E*-O>D..U" 3BG
M;^U V]Z:<4D,D 4G.:<V,5"&6G[LCFE8=AA^M* #UIQV4@V]Z?00%0.E  [F
M@X[4#;WHZ !P.E&%/4TAQVI1M[T/8!"<4T. >M..*-D=/0!P?-(0/6D( %-W
M+VI6"PX =S2G Z&D&.]*=O:CJ #!ZFD(':C*]Z,CM1U 4 =2:4MVI/EQS2<4
M+<0"-2<YJ0@!:8-HI"V>*-QB;@#P:?N#=:CV+G-.&.].RL#!@.QH4#N:#M[4
M#;WJ1 <=J4 8ZTAQVI1MQS3U 0B@8'>C(I?EH&&^FGZTN!2G;VH8"  ]:=D+
MTYIHQWH.WM28#LANO%-( Z4J[>](<=J:0A0!CDTG>E&WO0=M T+A?6D+]J3=
M'Z\TG!H2$&5SP:<,'K2;(QTI1M[T:6&(0!T-)3CM[4@V]Z.@"4X 8Y-(<=J4
M;>] "<9IP"CO3>,TOR4,0%^U(.*7Y:#M[4,8A8F@-@TH([T';VHL N0W7BFD
M 'B@;>]!QGBC80H [FD/M2C;CFD.*$ G'K2YHRF*.*:&&<4[.>M'R4F1WI!H
M+D+TI"V:#M[4@V]Z8@P3TIP4=S1N Z494]:F[&-/M2=*7(%&Y/QI@+O/I28%
M(2*;O%.P#P/6G<+TIH(/6E.WM1N(7(;KQ3"!VI05'WJ,KVI6&* ,=::<9IPV
M]Z0@9HU$. 7UH8\8I/EQ2<&A#T(\+NSFI.U&R.E&VG<$)]*/K2G;VH&.](=Q
M,XI0 >II#CM2C;CFBPKB'CI24I(SQ3OD[T -!]:=@=C36P*:'&>*=F X@T!L
M4H;(YH.WM2 7(;KQ32!V- V]Z#CM1;40 #N:=NQP*0;<<TAQGBBP#L*1G--P
M,TORXI.,TT N%'>DX;J:7Y:08SS20[AL4=#0 #U-!V]J!M[T=  X'0TH (Y-
M(=O:E&W'- AIZT\8QUIIQGBE^7%# 7?VHPO7--XS2_+BBPQ#2!L4H([TIV]J
M %R&Z\4U@!THRH^]1E3THMJ(3\:7-*-O>@[>U PPN.M-IWR4G&:$ ?C0#GK2
M_+BD&,\T!<7:O8T!1W-!V]J!CO1T#00X'0T  ]30<=J4;>]'00T@49'K0<9X
MI=J=Z0T(.:=M&.M)@9I?EQ3$(!SS2G Z&D!'>E^3M0,3.:3BG#;WI#M[4+<&
M* .YI#UXI1M[TAQGBG;40H QUI.,TORXI.,T(!V%QUIN1GFE^7%-P.]+4=QV
M5'0TN0W6F[4[4["]Z-+!8,A>E'#=333M[4HV]Z.@AI S2A5QUH.,\4ORXI#&
M]Z=M7'6DP,TORX]Z; :!S3^%Z&F#&>:> E+0 R&ZTT@#I3CL'6FDKVIK<!0!
MW-(3@\4HVXYI"!GBAW 7"D=:;CFG?+CFDXS2 7"XZTF<]:7Y<4F!FBP7'  =
M#2,3W%+E1TI-X_BIB&YIPP>II"5/2E&WO1;08AQGBE 7')I#C/%+\N.:!#>]
M.P,=:3C-+\N*8#1UIQP!P:08S2_+BD,;FG*3VI,KWI=ZC[M "-GO0&QVI<@]
M:0X[4;B'<'J:9WIWRXYI.,T(!V%QUIM+\M-.*%J,<5&.#33Q1N':E&#UI[!8
M17QTI2<]:"JCI3<CO2L M)1D'I3QMQS1<!M*..]'&:7Y<4, WGTIN:7C-.&R
MC80T8/6@@#I3CY8ZTTE>U'48E.#XH&WO2'':GU$.^4]33<#-&4[T<9XH0"X7
M'6D&,T["8I@QFD[@.*J!P:;3CMQQ3,@=:+C%IP /6F;E/2GC;WHL#$( Z4F!
M3B1VH^7O0]@T&T["XZTG%+\M A,"G?*O2F\9I3M[4,!=P/7BD('8T@QWH.WM
M1U 3\:<&Q2#;WH..U'48$Y- IFX TX'-.P(7CUI!UYIWRXI.*6X,7"]C24OR
M]J!CO0M@$SBE&#UH.WM3-RCK18"7H.*8U ?TI"Z]Z+  IVT>M-!!I^5% A-I
MS05'K1OH.WM0 @ [U(JKZU&".]/&WM0P=A2H[FF;MO2G'!ZTGR4K!<86S3E?
MGI2_)31C=Q5 7$.13Z9']VGTP"F28Q3Z0@'K0!28C/ I%QW%7?+7TH\M?2E8
M"DV.PH&.XJ[Y:^E'EKZ46 I[">E' ZBKNU?2DV+Z4K 4N_2ERN.E7/+7TH\M
M?2G8"CWZ4NT'H*N^6OI1L4=J&@*10B@*3TJ]M7TI-BCM18"I@#J*:>>@J[L4
M]J-B^E%AE''/2G;#BKFQ?2EVCTH$4-HSTIQ0@5<V+Z4NT>E,=S/[]*<..HJ[
MY:^E&Q?2E8"IM#=!32N.M70BCM1L4]J8BCCTIPV]Q5S8OI1Y:^E*PRD1Z"D
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JLVT=132N[I5O8I[4NQ?2F!0*X[4+][I5[8I[4>6OI0 D?2GT8Q10!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6818292144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Check-Cap Ltd<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Transition period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">EntityVoluntaryFilers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">5,328,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6818567456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,572<span></span>
</td>
<td class="nump">$ 6,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">350<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term bank deposit</a></td>
<td class="nump">5,643<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">14,984<span></span>
</td>
<td class="nump">7,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">15,436<span></span>
</td>
<td class="nump">7,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade</a></td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">214<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and payroll accruals</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,221<span></span>
</td>
<td class="nump">1,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RoyaltiesProvision', window );">Royalties provision</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Share capital</a></td>
<td class="nump">3,456<span></span>
</td>
<td class="nump">974<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">72,888<span></span>
</td>
<td class="nump">57,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(63,301)<span></span>
</td>
<td class="num">(52,712)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="nump">13,030<span></span>
</td>
<td class="nump">5,905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 15,436<span></span>
</td>
<td class="nump">$ 7,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_RoyaltiesProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the liability recorded to pay royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_RoyaltiesProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811229392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">$ 7,618<span></span>
</td>
<td class="nump">$ 6,837<span></span>
</td>
<td class="nump">$ 5,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,445<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
<td class="nump">3,571<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">11,063<span></span>
</td>
<td class="nump">10,001<span></span>
</td>
<td class="nump">9,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial income, net</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income tax</a></td>
<td class="nump">10,590<span></span>
</td>
<td class="nump">9,765<span></span>
</td>
<td class="nump">8,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">10,589<span></span>
</td>
<td class="nump">9,771<span></span>
</td>
<td class="nump">8,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">10,589<span></span>
</td>
<td class="nump">9,771<span></span>
</td>
<td class="nump">8,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent', window );">Change in fair value of cash flow hedge</a></td>
<td class="nump">13<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="nump">$ 10,602<span></span>
</td>
<td class="nump">$ 9,771<span></span>
</td>
<td class="nump">$ 8,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per ordinary share (in USD) basic and diluted</a></td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="nump">$ 6.72<span></span>
</td>
<td class="nump">$ 7.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of ordinary shares outstanding - basic and diluted (in thousands)</a></td>
<td class="nump">4,058<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819523168">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares [Member]</div></th>
<th class="th"><div>Additional paid-in capital [Member]</div></th>
<th class="th"><div>Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 46,164<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (34,115)<span></span>
</td>
<td class="nump">$ 12,648<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">984,292<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering', window );">Issuance of ordinary shares and pre-funded warrants in August 2016 registered direct offering, net of issuance expenses in an amount of $615</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,227<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering', window );">Issuance of ordinary shares and pre-funded warrants in August 2016 registered direct offering, net of issuance expenses in an amount of $615, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">53,635<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants into ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 140<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(23)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants into ordinary shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">229,153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,209<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent', window );">Change in fair values of cash flow hedge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,826)<span></span>
</td>
<td class="num">(8,826)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 771<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">52,577<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(42,941)<span></span>
</td>
<td class="nump">10,407<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,267,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1', window );">Issuance of ordinary shares and warrants in June 2017 registered direct offering, net of issuance expenses in an amount of $399</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 67<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,282<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1', window );">Issuance of ordinary shares and warrants in June 2017 registered direct offering, net of issuance expenses in an amount of $399</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">112,460<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2', window );">Issuance of ordinary shares and warrants in November 2017 registered direct offering, net of issuance expenses in an amount of $378</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">$ 114<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,066<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2', window );">Issuance of ordinary shares and warrants in November 2017 registered direct offering, net of issuance expenses in an amount of $378</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">189,387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants into ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(8)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants into ordinary shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">35,474<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">726<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,033<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent', window );">Change in fair values of cash flow hedge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,771)<span></span>
</td>
<td class="num">(9,771)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 974<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">57,643<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(52,712)<span></span>
</td>
<td class="nump">5,905<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,605,434<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares in May 2018 in the Public Offering, net of issuance expenses in an amount of $2,381</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">$ 2,444<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,343<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares in May 2018 in the Public Offering, net of issuance expenses in an amount of $2,381, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">3,669,129<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants into ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(33)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants into ordinary shares, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">56,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(65)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent', window );">Change in fair values of cash flow hedge</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,589)<span></span>
</td>
<td class="num">(10,589)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,456<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 72,888<span></span>
</td>
<td class="num">$ (13)<span></span>
</td>
<td class="num">$ (63,301)<span></span>
</td>
<td class="nump">$ 13,030<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Dec. 31, 2018</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5,330,684<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">All shares amounts have been retroactively adjusted to reflect a 1-for-12 share reverse split, see Note 1C.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents warrants issued to placement agent as part of issuance expenses</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Includes pre-funded warrants to purchase 209,524 ordinary shares at a purchase price of $22.20 per pre-funded warrant, issued in connection with the registered direct offering. See Note 9C(2)(h).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Issuance expenses include certain warrants with a value of $49,229 and $58,298 issued in connection with the June 2017 and November 2017 registered direct offerings, respectively. See Note 9C(2)(j).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">Includes pre-funded warrants to purchase 450,909 ordinary shares at a purchase price of $5.49 per pre-funded warrant, issued in connection with the registered direct offering. See Note 9C(2)(k).</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and pre-funded warrants in the registered direct offering, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and pre-funded warrants in the registered direct offering, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and pre-funded warrants in the registered direct offering, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodSharesNewIssuesRegisteredDirectOffering2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued upon the exercise of warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and pre-funded warrants in the registered direct offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and pre-funded warrants in the registered direct offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and pre-funded warrants in the registered direct offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTaxParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811324496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Value or warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Value or warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,298<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance expenses</a></td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Pre-funded warrants to purchase ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Pre-funded warrants to purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6806493072">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (10,589)<span></span>
</td>
<td class="num">$ (9,771)<span></span>
</td>
<td class="num">$ (8,826)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="nump">1,209<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Financial Expenses (income), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities items:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Decrease (increase) in prepaid and other current assets and non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in trade accounts payable, accruals and other current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">416<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase (decrease) in employees and payroll accruals</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">258<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="num">(510)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Decrease in royalties provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(255)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,034)<span></span>
</td>
<td class="num">(9,150)<span></span>
</td>
<td class="num">(7,923)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromInvestments', window );">Proceeds from (Investment in) short-term bank deposit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,629)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,811<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,723)<span></span>
</td>
<td class="num">(231)<span></span>
</td>
<td class="nump">4,645<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants into ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ProceedsFromIssuanceResisteredDirectOffering', window );">Issuance of ordinary shares in the RD Offerings, net of issuance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">4,379<span></span>
</td>
<td class="nump">5,307<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of ordinary shares in the 2018 Public Offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,792<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,762<span></span>
</td>
<td class="nump">4,575<span></span>
</td>
<td class="nump">5,424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(80)<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,925<span></span>
</td>
<td class="num">(4,642)<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,997<span></span>
</td>
<td class="nump">11,639<span></span>
</td>
<td class="nump">9,438<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the year</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,922<span></span>
</td>
<td class="nump">6,997<span></span>
</td>
<td class="nump">11,639<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash flow information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_WarrantsCashlessExercise', window );">Cashless exercise of warrants to purchase ordinary shares into ordinary shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Purchase of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Issuance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Represents warrants issued to placement agent as part of issuance expenses</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ProceedsFromIssuanceResisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceed from Issuance of ordinary shares in the RD Offering, net of issuance expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ProceedsFromIssuanceResisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_WarrantsCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of warrants into ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_WarrantsCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash balances in continuing operations held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash paid (received) associated with the acquisition or disposal of all investments, including securities and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809528560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL INFORMATION</a></td>
<td class="text"><div><div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 1&#160;&#160; -&#160;&#160;&#160;GENERAL INFORMATION</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z7fed8540e261424bbb89db86c4288be8" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">A.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">General</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z3c76648caeb0450cababdaef7e18da1a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">(1)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Check Cap Ltd. (together with its wholly-owned subsidiary, the &#8220;Company") was incorporated under the laws of the State of Israel. The registered address of its offices is 29 Abba Hushi Ave, Isfiya 3009000, Israel.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z6422d35124a14843a368860224a40e56" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">(2)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Check-Cap Ltd has a wholly-owned subsidiary, Check-Cap U.S. Inc., incorporated under the laws of the State of Delaware on May 15, 2015.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z73d637c5bf22402b882b2405e3cb8054" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">(3)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The Company is a clinical-stage medical diagnostics company developing C-Scan&#174;, the first capsule-based system for preparation-free colorectal cancer screening (the "C-Scan system"). Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, the C-Scan system removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation.</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z2633367b47664c3e8d2cb9f0db3f7186" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">(4)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">As described in Notes 9C(2)(b) and 9C(2)(d), on February 24, 2015 the Company consummated an Initial Public Offering in the United States (U.S.) (the "IPO") concurrently with a Private Placement (the "Private Placement").</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">On August 11, 2016, the Company consummated a registered direct offering of ordinary shares and pre-funded warrants (the "August 2016 RD Offering"). See Note 9C(2)(h).</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">On June 2, 2017, the Company consummated a registered direct offering of ordinary shares and a simultaneous private placement of warrants (the "June 2017 RD Offering"). See Note 9C(2)(i).</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">On November 22, 2017, the Company consummated a registered direct offering of ordinary shares and a simultaneous private placement of warrants (the "November 2017 RD Offering" and together with the August 2016 RD Offering and June 2017 RD Offering, the &#8220;RD Offerings&#8221;). See Note 9C(2)(J).</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">On May 8, 2018, the Company consummated an underwritten public offering of ordinary shares, pre-funded warrants and Series C warrants (the &#8220;May 2018 underwritten public offering&#8221;). See Note 9C(2)(k).</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">The Company's ordinary shares, Series A Warrants and Series C Warrants are listed on the NASDAQ Capital Market under the symbols "CHEK", "CHEKW" and CHEKZ&#8221; respectively.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z7be91396531e41499ca4e38a4a6e1dde" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt"></td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The consolidated financial statements of the Company as of and for the year ended December 31, 2018 include the financial statements of the Company and its wholly-owned U.S. subsidiary.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>


<div style="text-align: left; line-height: 1.25">
<table id="z3436b9bf69a743b99183b56a9a992de0" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">B.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Going concern and management plans</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since its inception, the Company has devoted substantially all of its efforts to research and development, clinical trials, recruiting management and technical staff, acquiring assets and raising capital. The Company is still in its development and clinical stage and has not yet generated revenues. The extent of the Company's future operating losses and the timing of becoming profitable are uncertain. The Company has incurred losses of $10.6 million and $9.8 million for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2018, the Company's accumulated deficit was $63.3 million. The Company has funded its operations to date primarily through equity financing and through grants from the Israel Innovation Authority of the Ministry of Economy and Industry (the "IIA") (formerly the Office of the Chief Scientist of the Ministry of Economy and Industry (the "OCS)).</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Additional funding will be required to complete the Company's research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company's C-Scan system and to achieve a level of sales adequate to support the Company's cost structure.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, additional equity financings and other funding transactions. While the Company has been successful in raising financing in the past, there can be no assurance that it will be able to do so in the future on a timely basis on terms acceptable to the Company, or at all. Uncertain market conditions and approval by regulatory bodies and adverse results from clinical trials may (among other reasons) adversely impact the Company's ability to raise capital in the future.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company believes that current cash on hand will be sufficient to fund operations into February 2020.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of the C-Scan system, which will result in a negative cash flow from operating activity. This has led management to conclude that substantial doubt about the Company's ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during or before the end of 2019, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects and clinical trials, until it is able to obtain sufficient financing. If such sufficient financing is not received timely, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection. The Company's consolidated financial statements do not reflect any adjustments that might result from the outcome of this uncertainty.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zfa04a093fdd14f57b6cf8f3bff4e5e42" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">C.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Reverse share splits</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Effective April 4, 2018, the Company's Board of Directors effected a reverse share split of 1-for-12 (i.e. 12 ordinary shares were combined into one ordinary share) (&#8220;Reverse Share Split&#8221;), in accordance with the approval of the Company's shareholders at an extraordinary general meeting of shareholders held on April 2, 2018. All references in the financial statements and notes to the number of shares, price per share and weighted average number of shares outstanding of our&#160;ordinary shares prior to the Reverse Share Split have been adjusted to reflect the Reverse Share Split on a retroactive basis unless otherwise noted.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6786670368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div><div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify">NOTE 2&#160;&#160; -&#160;&#160; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt">The Company`s consolidated financial statements are presented in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z1b107627e34e43e781cf7cef0a3c7728" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">A.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Use of estimates in preparation of financial statements</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z051b52fa8e564bbaa7cf401067e3c8d0" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">B.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Principles of consolidation</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company's consolidated financial statements include the financial statements of Check-Cap Ltd. and its wholly-owned subsidiary, Check-Cap U.S., Inc. The Company's consolidated financial statements are presented after elimination of inter-company transactions and balances.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z0e536f1fabd246a7bca985da6358f0ff" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">C.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Financial statements in U.S dollars</div>
</td>
</tr>
</table>
</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company has not yet generated revenues and the majority of its expenses are in U.S. dollar (dollar or USD) or NIS, while none of these currencies is significantly material compared to the other.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Management judgment, in setting the dollar as the Company's functional currency, is based mainly on the following criteria: The Company's budget and other Company internal reports, including reports to the Company's Board of Directors and investors, are presented in dollars. Management uses these reports in order to make decisions for the Company. All of the Company's equity and debt financings were in dollars; and it is expected that a significant portion of the Company's future revenue will be in dollars. The financial statements are presented in dollars, which is the functional currency of the Company.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z3a263b11ad4e445da79a8bbc4290998e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">D.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Cash and cash equivalents</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Cash and cash equivalents include cash in hand, short&#8211;term deposits in banks and short-term highly liquid investment with an original maturity of up to three months, with a high level of liquidity that may be easily converted to known amounts of cash, and that are exposed to insignificant risk of change in value.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zc2ad2db3bbae457a8532f133aa57190a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">E.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Short-term bank deposit</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Short-term bank deposits are deposits with maturities of more than three months but less than one year. The short&#8211;term bank deposits are presented at their cost, including accrued interest, which approximates fair value.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z5cbc74d75c284622af96f671ae8330c9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">F.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Cash flow hedges</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">As a matter of policy, the Company uses derivatives for risk management purposes, and does not use derivatives for speculative purposes. From time to time, the Company may enter into foreign currency zero-cost collars contracts to&#160;hedge&#160;foreign currency&#160;cash&#160;flow&#160;transactions. For&#160;cash&#160;flow&#160;hedges, unrealized gain or loss is recorded in Other comprehensive income (loss) until hedged item affects earnings. All of the Company&#8217;s hedges that are designated as hedges for accounting purposes were highly effective; therefore,&#160;no&#160;notable amounts of&#160;hedge ineffectiveness were recorded in the Company&#8217;s Consolidated Statements of Operations for either the settlement of&#160;cash&#160;flow&#160;hedges or the outstanding hedged balance.</div>
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company uses zero-cost collars to hedge against the risk of overall changes in future cash flow from payments of payroll and rent denominated in New Israeli Shekel. As of December&#160;31, 2018, the Company had outstanding foreign exchange collars in the notional amount of $2.1 million. These options were set for a period of up to six months. The Company measured the fair value of the options in accordance with provisions of ASC No.&#160;820 (classified as level 2 of the fair value hierarchy). During 2018, losses in the amount of $28, were reclassified when the related expenses were incurred and recognized in operating expenses. The fair value of the Company&#8217;s outstanding collars at December&#160;31, 2018 amounted to liability of $15 and is included in in other current liabilities on the balance sheets, with the effective portion of the change in fair value, amounted $13 classified in accumulated other comprehensive income ("AOCI").&#160;</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z43258e42ffa94d73b5a8850a4b787d41" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">G.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Property and equipment</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt">&#160;</div>

<div style="line-height: 1.25">
<table id="z650bfb86e2314946955b5f01825ef12f" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr style="height: 14px">
<td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">Length of useful life</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">Depreciation rate</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">Years</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1.62%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1.02%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Office furniture and equipment</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10-14</div>
</td>
<td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7-10</div>
</td>
<td style="vertical-align: bottom; width: 1.02%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Laboratory equipment</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3-7</div>
</td>
<td style="vertical-align: bottom; width: 1.62%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15-33</div>
</td>
<td style="vertical-align: bottom; width: 1.02%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Computers and auxiliary equipment</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3</div>
</td>
<td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">33</div>
</td>
<td style="vertical-align: bottom; width: 1.02%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>
</table>
</div>

<div style="clear: both; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z878f598c2be74023b24dfc57c858b10f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">H.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Impairment of long-lived assets</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company's long-lived assets are reviewed for impairment in accordance with ASC 360-10 "Accounting for the Impairment or Disposal of Long-Lived Assets" whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December&#160;31, 2018, 2017 and 2016, no impairment losses were recorded.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zcd46fa4c7ca745d097e6e140ff524d2e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">I.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Research and development costs</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Research and development costs are expensed as incurred and consist primarily of costs for personnel, subcontractors and consultants (mainly in connection with clinical trials) and materials for research and development and clinical activities. Grants received by the Company from the IIA and from Israel-United States Binational Industrial Research and Development Foundation (the "BIRD Foundation") are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from research and development expenses. Such grants are included as a deduction of research and development costs (since at the time received the Company expects to generate sales from these projects and pay the royalties resulting from such sales).</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">See Note 7B(1) below regarding the offset of grants received for participation in research and development expenses.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
<div style="text-align: left; line-height: 1.25">
<table id="z39611cf098aa4a19bd6dedd02199f27b" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">J.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Contingent liabilities</div>
</td>
</tr>
</table>
</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company accounts for its contingent liabilities in accordance with ASC No.&#160;450, "Contingencies". A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December&#160;31, 2018, and 2017, the Company is not a party to any ligation that could have a material adverse effect on the Company's business, financial position, results of operations or cash flows (see Note ).</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="za3d9811bb2e14883aa53c16b3d1df87e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">K.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Share-based compensation</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company recognizes expense for its share-based compensation based on the fair value of the awards granted. The Company&#8217;s share-based compensation plans provide for the award of stock options and restricted stock units. In accordance with ASC 718-10 "Compensation-Stock Compensation", the Company estimates the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's consolidated statement of operations.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company recognizes compensation expenses for the value of its awards granted based on the graded-vesting method over the requisite service period for each separately vesting portion of the award. Accounting Standards Update (&#8220;ASU&#8221;) 2016-09, Compensation-Stock Compensation (Topic 718) allows companies to account for forfeitures when they occur.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its share-based awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary shares, expected share price volatility and the expected option term. In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">In the years ended December 31, 2017 and 2016, expected volatility was calculated based on certain peer companies that the Company considered to be comparable.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No.&#160;110, as adequate historical experience is not available to provide a reasonable estimate.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</div>
<div style="text-align: left; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z74156c4b60254db69667b88159791230" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">L.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Income taxes</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company accounts for income taxes in accordance with ASC 740-10 "Accounting for Income Taxes." This Statement requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">In accordance with ASC 740, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered 'more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2018, and 2017, the Company had no unrecognized income tax positions and accordingly, there is no impact on the Company's effective income tax rate associated with these items.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z899c4d03750a4a47b4d730b3bd1a1b7f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">M.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Fair value of financial instruments</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company measures its investments in money market funds (classified as cash equivalents) and its foreign currency net purchased options at fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"><font style="font-family: Times New Roman">&#9679; </font>Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"><font style="font-family: Times New Roman">&#9679; </font>Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"><font style="font-family: Times New Roman">&#9679; </font>Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z6bbb31e375064ab4bbff408ff3c970ef" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">N.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Comprehensive<font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"> loss</font></div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company accounts for comprehensive income in accordance with ASC No.&#160;220, &#8220;Comprehensive Income&#8221;. Comprehensive income generally represents all changes in shareholders&#8217; equity during the period except those resulting from investments by, or distributions to, shareholders. The Company&#8217;s comprehensive loss consists of net loss and unrealized gain or loss on the effective portion of cash flow hedges. These amounts are carried in accumulated other comprehensive loss on the consolidated statements of comprehensive income and are presented net of taxes.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<div style="text-align: left; line-height: 1.25">
<table id="zfcb6b8f1f9144a3ea8800c6f9367abad" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">O.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify">Restricted Cash</div>
</td>
</tr>
</table>
</div>

<br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company has granted a pledge in favor of Bank Leumi Le-Israel B.M in the amount of $350 to secure certain payment obligations of the Company in connection with FOREX activities. This amount was classified as restricted cash balance on December 31, 2018.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">In January 2018, the Company adopted new guidance from the Financial Accounting Standards Board or the FASB that clarified how entities should classify certain cash receipts and cash payments on the statement of cash flows. As a result, the restricted cash balance that existed in prior periods is included as a component of cash and cash equivalents and restricted cash on the statement of cash flows in the relevant periods presented. &#160;</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; text-indent: 36pt">
<table id="z5d79253cdc3c4130b5e286930e5812c3" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="padding-bottom: 2px; vertical-align: bottom">
<div>&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; text-align: center; vertical-align: bottom">2 0 1 6</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom">
<div>&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr style="height: 17px">
<td style="width: 64%; background-color: #cceeff; vertical-align: bottom">
<div>Cash and Cash equivalents</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt Times New Roman, Times, serif">8,572</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div>6,997</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div>11,639</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="width: 64%; background-color: #ffffff; vertical-align: bottom">
<div>Restricted cash included current assets</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div>350</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div>-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div>-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="width: 64%; background-color: #cceeff; vertical-align: bottom">
<div>Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div>8,922</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">6,997</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">11,639</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="clear: both; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z6f0eab32db874209a8bdc3f763d8259d" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">P.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">New accounting pronouncements</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">ASU 2016-02, &#8220;Leases (Topic 842)&#8221; was issued by the FASB in February 2016. The purpose of this amendment requires the recognition of lease assets and lease liabilities by lessees for those leases previously classified as operating leases. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated results of operations, financial position or disclosures.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Accounting Standards Update (ASU) 2018-07, &#8220;Compensation&#8212;Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting&#8221; was issued by the Financial Accounting Standards Board (FASB) in June 2018. The purpose of this amendment is to address aspects of the accounting for nonemployee share-based payment transactions. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated results of operations, financial position or disclosures.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809586560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><div><div style="line-height: 1.25"></div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 3&#160;&#160; -&#160;&#160; PREPAID EXPENSES AND OTHER CURRENT ASSETS</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 28.35pt">Composition:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z1081dc66cfdc4f258ea43c74df680d86" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%">
<tr>
<td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="6" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Government institutions</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">178</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">89</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Prepaid expenses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">206</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">261</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Deposits</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">34</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">55</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Other assets</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">419</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">406</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6786670368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><div><div style="clear: both; line-height: 1.25"></div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 4&#160;&#160; -&#160;&#160; PROPERTY AND EQUIPMENT, NET</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 28.35pt"><font style="font: bold 10pt Times New Roman, Times, serif">Composition</font>:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z0032aba21dcd49e8ac554d4bd9c16663" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%">
<tr>
<td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="6" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Cost:</div>
</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Office furniture and equipment</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">186</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">157</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Laboratory equipment</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">644</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">626</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Computers and auxiliary equipment</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">388</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">339</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,218</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,122</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Accumulated depreciation</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">766</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">619</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Property and equipment, net</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">452</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">503</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Depreciation expenses amounted to $147, $157 and $130 for the years ended December&#160;31, 2018, 2017 and 2016, respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809585184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS AND PAYROLL ACCRUALS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Employee-related Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_EmployeeRelatedLiabilitiesTextBlock', window );">EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"><div style="text-align: left"><div><div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 5&#160;&#160; -&#160;&#160; EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z3a8f70e7d63340688636546a2d8b7b02" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">A.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif">Composition:</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="zff8d3f796c354ec58fcdb1ce0f105b71" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr style="height: 18px">
<td style="vertical-align: bottom; font-weight: bold; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Short-term employee benefits:</div>
</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Benefits for vacation and recreation pay</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">162</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">235</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Liability for payroll, bonuses and wages</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">697</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">367</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">859</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">602</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z2a18aa2f7f00414c802a5f04d073c942" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">B.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Post-employment benefits</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Pursuant to Israel's Severance Pay Law, 1963, Israeli employees are entitled to severance pay equal to one month's salary for each year of employment, or a portion thereof. All of the Company's employees elected to be included under Section 14 of the Severance Pay Law, 1963 ("Section 14"). According to Section 14, employees are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Payments in accordance with Section 14 release the Company from any future severance payments (under the above Israeli Severance Pay Law) in respect of those employees; therefore, related assets and liabilities are not presented in the balance sheet.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z9e683e75f6a74bebad5d5d6e3b167b31" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">C.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Short-term employee benefits</div>
</td>
</tr>
</table>
</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z3ab7046bf1444da89dae809c5514685b" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">(1)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Paid vacation days</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">In accordance with the Yearly Vacation Law-1951 (the "Vacation Law"), the&#160;Company's employees are entitled to a certain number of paid vacation days for each year of employment. In accordance with the Vacation Law and its appendix, and as determined in the agreement between the Company and the employees, the number of vacation days per year to which each employee is entitled is based on the seniority of the employee.</div>

<br style="line-height: 1.25" />
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">The employee may use vacation days based on his or her needs and with the Company's consent, and to accrue the remainder of unused vacation days, subject to the provision of the Vacation Law. The vacation days utilized first are those credited for the current year and subsequently from any balance transferred from the prior year (on a "LIFO" basis). An employee who ceased working before utilizing the balance of vacation days accrued is entitled to payment for the balance of unutilized vacation days.</div>

<div style="text-align: left; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z43e9eb2751604aa5897e25286b9174e1" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">(2)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Related parties</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">For information regarding short-term employee liabilities given to related parties, see Note 15.</div>

</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_EmployeeRelatedLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure for employee related liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_EmployeeRelatedLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6631394464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div><div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 6&#160;&#160; -&#160;&#160; INCOME TAXES</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z2fa582e916074cd48ad54e07674784ee" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">A.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">The Company</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Check-Cap Ltd. is taxed according to Israeli tax laws:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="ze927463fcb75405b86d5e989126eae06" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">1.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Corporate tax rates in Israel</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">The Israeli corporate tax rate was 25% in the year 2016, 24% in year 2017 and 23% in year 2018 and onwards.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z565f0507fb5844a0b62efd1b6f5fa364" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">2.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">The Law for the Encouragement of Capital Investments, 1959 (the "Investments Law")</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">Under the Investments Law, including Amendment No. 60 to the Investments Law as published in April 2005, by virtue of the "Approved Enterprise" or "Benefited Enterprise" status, the Company is entitled to various tax benefits as follows:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z0d99f75dd19e4c638ec41b06f7b90ccf" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: normal 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">a)</td>
<td style="vertical-align: top; font-weight: normal; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Reduced tax rates</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">The Company has one Benefited Enterprise program under the Investments Law, which entitles it to certain tax benefits with respect to income to be derived from the Company's Benefited Enterprise. During the benefits period, taxable income from its Benefited Enterprise program (once generated) will be tax exempt for a period of ten years commencing with the year the Company will first earn taxable income relating to such enterprise. The Company chose 2010 as the year of election (the "Year of Election"). Due to the location of the Company's offices, the Company believes it is entitled to a 10 year benefit period, subject to a 14 year limitation from the Year of Election, and therefore, the tax benefit period will in any event end in 2023.</div>

<div style="text-align: left; margin-left: 99.25pt; line-height: 1.25; text-indent: -14.2pt"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z46d685e9f5534026a616707a76845519" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: normal 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">b)</td>
<td style="vertical-align: top; font-weight: normal; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Conditions for entitlement to the benefits</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">The benefits available to a Benefited Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law and its regulations.</div>

<div style="text-align: left; margin-left: 99.25pt; line-height: 1.25; text-indent: -14.2pt"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z29470baacfec4f8c9090f1850eb9eefb" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: normal 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">c)</td>
<td style="vertical-align: top; font-weight: normal; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Amendment of the Law for the Encouragement of Capital Investments, 1959</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">The Investments Law was amended as part of the Economic Policy Law for the years 2011-2012, which was passed by the Israeli Knesset on December 29, 2010 (the "Capital Investments Law Amendment").</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">The Capital Investments Law Amendment set alternative benefit tracks to those in effect prior to such amendment under the provisions of the Investments Law.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">The benefits granted to the Benefited Enterprises will be unlimited in time, unlike the benefits granted to special Benefited Enterprises, which will be limited for a 10-year period. The benefits shall be granted to companies that will qualify under criteria set forth in the law; for the most part, those criteria are similar to the criteria that were set forth in the Investments Law prior to its amendment.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">Under the transitional provisions of the Investments Law, the Company is entitled to take advantage of the tax benefits available under the Investments Law prior to its amendment until the end of the benefits period, as defined in the Investments Law. The Company was entitled to set the "year of election" no later than tax year 2012, provided that the minimum qualifying investment was made not later than the end of 2010. On each year during the benefits period, the Company will be able to elect that the Investments Amendment applies to the Company, thereby making the tax rates described above available to the Company. An election to have the Capital Investments Amendment apply is irrecoverable. The Company elected not to have the Capital Investments Amendment apply to the Company.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z600b6194f6134978ad5d50ff2c22ac19" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">2.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">The Law for the Encouragement of Capital Investments, 1959 (the "Investments Law") (Cont.)</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zac96366cff684f818335ee6c4fc0fa53" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: normal 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">c)</td>
<td style="vertical-align: top; font-weight: normal; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Amendment of the Law for the Encouragement of Capital Investments, 1959 (Cont.)</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">On December 22, 2016, the Knesset approved the 2017-2018 State budget, which includes amendment number 73 to the law for the Encouragement of Capital Investments. The amendment includes:</div>

<div style="text-align: left; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">Adoption of tax benefits for high-tech preferred enterprises, based on the provisions and rules adopted by the Organization for Cooperation and Economic Development (the "GCOE"), creating new tax tracks of 7.5% for Development Area A and 12% for the rest of the country.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">Reduction of corporate tax rate for all preferred enterprises from 9% to 7.5%.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">Lowering the threshold for the conditions that were previously set in order to enter the track of a "special preferred enterprise" for very big enterprises entitled to a reduced tax rate of 5% in Area A or 8% in the rest of the country.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">Updating the definitions of preferred income, preferred enterprise etc.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">In accordance with the Income Tax Ordinance, as of December 31, 2018, all of Check-Cap Ltd.'s tax assessments through tax year 2013&#160;are considered final.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z5a43e6c71d174d43b9fd6a0962cd046c" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">3.</td>
<td style="vertical-align: top; font-weight: normal; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The Company recorded $6 and $8 current taxes for the years ended December 31, 2017 and 2016. The Company did not record current taxes for the year ended December 31, 2018, since it had no taxable income during this year.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z876364cd714349059bf0ee4b9df9579d" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">B.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Check-Cap U.S. Inc.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Check-Cap U.S. Inc. is taxed according to U.S. tax laws.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">There are no NOL carry-forward of Check-Cap U.S. Inc.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">In December 2017, the Tax Cut and Jobs Act (the &#8220;Act&#8221;) was signed into law, which enacted significant changes to U.S. federal corporate tax and related laws. Some of the provisions of the Act affecting corporations include, but are not limited to: (i) a reduction of the U.S. federal corporate income tax rate from 35% to 21%; (ii) limiting the interest expense deduction; (iii) expensing of cost of acquired qualified property; and (iv) elimination of the domestic production activities deduction. The Company is currently evaluating the impact the Act will have on the future financial condition and results of operations and believe the Act will have a beneficial positive net impact. The Act did not have an effect on the financial results and position of the Company.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zd8327529467944d1a01bf115c3daf3fb" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">C.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Deferred income taxes</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">In assessing the realization of deferred tax assets, the Company considers whether it is more likely than not that all or some portion of the deferred tax assets will not be realized. Based on the Company's history of losses, the Company established a full valuation allowance.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="zdfa5e22d2d924a4ba967e406ae2ef8cd" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Carry forward tax losses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">12,525</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">13,083</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Less valuation allowance</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(12,525</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(13,083</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="clear: both; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zfe8cd346f416490bb9de3e9b0f294582" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">D.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Reconciliation of the theoretical tax expense to actual tax expense</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The main reconciling item between the statutory tax rate of the Company and the effective rate is the provision of full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6588174000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"><div style="text-align: left"><div><div style="line-height: 1.25"></div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify">NOTE 7&#160;&#160; -&#160;&#160; COMMITMENTS AND CONTINGENT LIABILITIES</div>

<div style="text-align: left; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z6e1a4adcf1e04bc98b4c193edf1b546f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">A.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Royalties provision</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zea763a1fe1a2458ba235d0540986ed1d" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">1.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Royalties to an ASIC designer</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">The Company has a liability to pay royalties for the development of an ASIC component which is used as an amplifier for the capture of signals at low frequencies from X-ray detectors contained in the capsule. The institution that developed the ASIC is entitled to receive royalties from the Company in the amount of &#8364; 0.5 ($0.57) for every ASIC component that the Company will sell, capped at &#8364; 200,000 (approximately $229). This royalty is considered as a liability.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">The royalties' liability is calculated based on estimated future sales generated by products which include the ASIC component. As of December 31, 2018, the Company believes that it will be required to pay the above mentioned royalties, and accordingly, recorded, as of December&#160;31, 2018, a provision in a total amount of $120.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zaf9aeede27744e1b9d4518173e213714" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">2.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Reimbursement liability to Predecessor Entity's unit holders</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">On May 31, 2009, the Company entered into an asset transfer agreement with Check Cap LLC (the "Predecessor Entity"), a company with the same shareholders as the Company at the time of transfer. According to the agreement, the Predecessor Entity transferred all of its business operations and substantially all of its assets to the Company, including development and consulting agreements, cash, property and equipment and intangible ownership rights, free of any debt.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">
<div id="DSPFPageHeader"></div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">As part of the reorganization, the Company committed to reimburse the unit holders of the Predecessor Entity for any tax burdens that may be imposed on them due to the reorganization. The reimbursement liability is calculated assuming deemed royalties are paid to the U.S. unitholders of Check-Cap LLC under Section 367(d) of the Code, and is based in part on the Company&#8217;s forecasted sales with a cap calculated as the fair value of the share as determined at the date of the financial statements. The reimbursement liability is calculated by multiplying the estimated tax rate by the lowest of: (1) expected cash outflows discounted using a discount factor commensurate with the risk of the Company, and (2) value of the shares held by U.S. unit holders of the Predecessor Entity as of December 31, 2018 multiplied by $2.1, <font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff">the last reported sale price per share of the Company&#8217;s ordinary shares on the Nasdaq Capital Market on December 31, 2018</font>. Any updates in the contingent liability will be charged to earnings. As of December 31, 2018, the balance of the reimbursement liability totaled $65.</div>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z8128ce3a34ac44828bef74af40479fa4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr style="height: 14px">
<td style="vertical-align: bottom; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Royalties to an ASIC designer</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">120</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">127</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Reimbursement liability to Predecessor Entity's unit holders</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">65</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">312</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">185</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">439</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>



<div style="text-align: left; line-height: 1.25">
<table id="zba8305edc70c4f0fb3a7a76055ccc60b" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">B.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Commitments</div>
</td>
</tr>
</table>
</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="ze036a6d6515b479693b809726a78f39f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">(1)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Royalties</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">The Company's research and development efforts are financed, in part, through funding from the IIA (formerly the OCS) and the BIRD Foundation. Since the Company's inception through December&#160;31, 2018, the Company received funding from the IIA and the BIRD Foundation in the total amount of $5.3 million and $115, net, respectively.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">According to the terms of applicable law as currently in effect and the grants, the IIA is entitled to royalties equal to 3-5% (or at an increased rate under certain circumstances) of the revenues from sales of products and services based on technology developed using IIA grants, up to the full principal amount (which may be increased under certain circumstances) of the U.S. Dollar-linked value of the grants, plus interest at the rate of 12-month LIBOR. The obligation to pay these royalties is contingent on actual sales of the applicable products and services and in the absence of such sales, no payment is required. As of December 31, 2018, the Company had not paid any royalties to the IIA and had a contingent obligation to the IIA in the amount of $5.6 million.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">On July 13, 2014, the Company entered into a Cooperation and Project Funding Agreement with the BIRD Foundation and Synergy, pursuant to which the BIRD Foundation agreed to award a grant to Synergy and the Company in the maximum amount of the lesser of (i) $900; and (ii) 50% of the actual expenditures for the funding of a project entitled "Collection &#38; Analysis of Gastrointestinal Images for Diagnostic Adenomatic Polyps and Colorectal Cancer." The development work was to be performed over a 24-month period by Synergy (or a subcontractor on its behalf) and the Company.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">According to the terms of the grant, the BIRD Foundation is entitled to royalties equal to 5% of the gross revenues derived from the product funded by the project, up to 100%, 113%, 125%, 138% and 150% of the U.S. Consumer Price Index linked sum granted by the BIRD Foundation if repaid within one year, two years, three years, four years and five or more years, respectively. Under the terms of the agreement, if any portion of the product funded by the project is sold outright to a third party prior to full repayment of the grant to the BIRD Foundation, one-half of the sale proceeds will be applied to the repayment of the grant. If the funded product is licensed to a third party, 30% of all payments received under the respective license agreement must be paid to the BIRD Foundation in repayment of the grant.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">As of December 31, 2018, the Company, together with Synergy, had received funding from the BIRD Foundation in the aggregate amount of approximately $127. Based on the aggregate expenses that the Company incurred for such project, it refunded to the BIRD Foundation an amount of approximately $13. The Company shall not be receiving additional funding from the BIRD Foundation for the project, which is no longer active. As of December 31, 2018, we had not paid any royalties to the BIRD Foundation and had a contingent obligation to the BIRD foundation in the amount of $180.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z5afd5e006aff4a239279d10236f709c2" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">(2)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Rental agreement</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">The Company leases approximately 900 square meters at a facility located in Isfiya, Israel under a lease agreement expiring on May 31, 2022. The Company has the right to terminate the agreement at any time, with 60 days prior written notice. The rental expenses recorded by the Company for the years ended December 31, 2018, 2017 and 2016 were $84, $83 and $78, respectively.</div>



<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z44c34e2c4d1e41c585ccb17e4f32b2e9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">(3)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Vehicle lease and maintenance agreements</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">The Company entered into several 32-36 months lease and maintenance agreements for vehicles, which are regularly amended as new vehicles are leased. The current monthly lease fees is approximately $14. The expected lease payments for the years ending December 31, 2019, 2020 and 2021 are approximately $100, $63 and $10, respectively.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">
<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Operating lease obligations as of December 31, 2018:&#160;</div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">
<table id="z16b61586b1d74d23a7632da0884c427e" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr style="height: 15px">
<td style="vertical-align: bottom; width: 88%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Lease agreement for vehicles</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">22</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Lease agreement for office facilities lease</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">13</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr style="height: 19px">
<td style="vertical-align: bottom; padding-bottom: 4px; width: 88%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">35</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6630616432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><div><div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify">NOTE 8&#160;&#160; -&#160;&#160; FAIR VALUE MEASUREMENTS</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">In accordance with ASC No.&#160;820, the Company measures its money market funds and foreign currency derivative contracts at fair value. Money market funds are classified within Level&#160;1 or Level&#160;2. This is because these assets are valued using quoted market prices or alternative pricing sources and models utilizing market observable inputs. Foreign currency derivative contracts are classified within Level&#160;2 as the valuation inputs are based on quoted prices and market observable data of similar instruments.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company&#8217;s financial assets measured at fair value on a recurring basis, excluding accrued interest components, consisted of the following types of instruments as of the following dates:</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="line-height: 1.25">
<table id="za2d67b964ab94d169dfa6bf2084b886a" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31, 2018</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Fair value measurements using input type</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Level 1</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Level 2</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Total</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Cash equivalents:</div>
</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Money market funds</div>
</td>
<td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,307</div>
</td>
<td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,307</div>
</td>
<td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Foreign currency derivative instruments</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(15</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(15</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Total financial assets (Liabilities)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,307</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(15</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,292</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6632190368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"><div style="text-align: left"><div><div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 9&#160;&#160; -&#160;&#160; SHAREHOLDERS' EQUITY</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z18e2fcd4b9124f08b3ab78199025e2c4" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">A.</td>
<td style="vertical-align: top; font-weight: bold; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">All share and per share amounts in the financial statements have been adjusted to reflect the Reverse Share Split.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" /><br style="line-height: 1.25" /></div>

<div style="text-align: left; line-height: 1.25">
<table id="z1cdceb6f9ca845978d493ee9b4de82f8" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">B.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Ordinary shares</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zffd75b24281e4d02a6a32a031412a66a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">1.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The ordinary shares provide their owners with rights to receive dividends in cash and shares, and rights to participate at the time of distributing liquidation dividends. Additionally, the ordinary shareholders have the right to vote at shareholder meetings in a manner that each share provides one voting right to its holder.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z02e9edf268ab4c75902ade0c22fdb17c" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr style="height: 12px">
<td style="width: 56.7pt"></td>
<td style="font: normal 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">2.</td>
<td style="vertical-align: top; font-weight: bold; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Changes in ordinary share capital</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z9be7f2abf21845838421f163fe6c35a6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">a)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On May 11, 2010, the Company issued, free of charge, to all of its shareholders (except for certain ordinary shareholders), warrants to purchase an aggregate of 32,174 ordinary shares (hereafter- "Anti-dilution Warrants"). The Anti-dilution Warrants were issued in order to prevent the dilution of the holdings of such Company shareholders due to certain options granted to the Company's CEO (hereafter- "CEO options"). The Anti-dilution Warrants were subject to automatic exercise, without consideration (unless the holder thereof objected to such exercise), upon the exercise by the Company's CEO of the CEO Options. The fair value of the Anti-dilution Warrants on the grant date was immaterial. Anti-dilution warrants to purchase&#160;7,724 and 56 ordinary shares were exercised during the years ended December 31, 2018 and 2016, respectively. No such warrants were exercised during the year ended December 31, 2017. As of December 31, 2018, 7,246 Anti-dilution Warrants were outstanding.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z03610b82d7ba44919370ffcc2a7f4224" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">b)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On February 24, 2015, the Company consummated an IPO in the U.S. of 166,667 units at a public offering price of $72 per unit, before underwriting discounts and offering expenses. Each unit consisted of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share. Each unit was issued with one and one-half non-transferrable Long Term Incentive Warrants. Each whole Series A Warrant entitles the holder to purchase one ordinary share at an exercise price of $90. Upon vesting, each Long Term Incentive Warrant entitles the holder to purchase one ordinary share at an exercise price of $82.80.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">The Company granted the underwriters a 45-day over-allotment option to purchase up to 25,000 additional units (together with an accompanying 37,500 Long Term Incentive Warrants). The option to purchase additional 8,334 units was partially exercised on March 6, 2015. The units were separated into one ordinary share and one-half of a Series A Warrant to purchase one ordinary share on March 18, 2015, and the units ceased to exist as of such date. On April 6, 2015, the option to purchase additional 12,500 ordinary shares and 6,250 Series A Warrants was partially exercised. The Company received net proceeds from the IPO and partial exercise of the over-allotment option of approximately $10.8 million (net of issuance cost of approximately $2.9 million, including certain warrants with a value of $196 issued in connection with the IPO).</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zb2f2f46800c9483cbf6ce93df36f5f53" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">c)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Immediately prior to the consummation of the IPO, certain members of the Company's management exercised options to purchase 25,624 ordinary shares granted to them under the 2006 Unit Option Plan.</div>
</td>
</tr>
</table>
</div>



<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z7eb77cf2c95848f5bcb0d3f2e3fcb5b6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">d)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On August 20, 2014, the Company entered into a certain credit line agreement, pursuant to which it obtained a credit line in an aggregate principal amount of $12 million from certain lenders and existing shareholders (the "Lenders").&#160;&#160;The credit line amount was deposited in an escrow account at the closing, which was consummated on October 14, 2014. The Company issued to each Lender at closing a warrant (collectively, the "Credit Line Warrants"), to purchase a number of the Company's ordinary shares constituting 2% of its share capital on a fully diluted basis (assuming conversion of all of the Company's convertible securities into ordinary shares at a 1:1 conversion rate) as of the closing for each $1 million (or portion thereof) extended by such Lender.&#160;&#160;The Company issued Credit Line Warrants ("CLA Warrants") to purchase in the aggregate 221,556 of its ordinary shares.&#160;&#160;The CLA Warrants are exercisable for a period of ten years at an exercise price of NIS 2.40 per share, and may be exercised on a net issuance basis.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">Under the terms of the credit line agreement, the Company directed that the entire credit line amount (that was in escrow) be invested in the Private Placement, consummated simultaneously with the consummation of the IPO on February 24, 2015. The Company issued to the Lenders 166,667 units at a price of $72 per unit, before issuance cost. Each unit consisted of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share. Each unit was issued with one and one-half non-transferrable Long Term Incentive Warrants. Each whole Series A Warrant entitles the holder to purchase one ordinary share at an exercise price of $90. Upon vesting, each Long Term Incentive Warrant entitles the holder to purchase one ordinary share at an exercise price of $82.80. The Company received net proceeds from the Private Placement of approximately $10.9 million (net of issuance cost of approximately $1.2 million, including certain warrants with a value of $125 issued in connection with the Private Placement).</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z0b29997d98ad46dd91c861ccb10defa9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">e)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">During the years ended December 31, 2018, 2017 and 2016, certain Private Placement investors exercised CLA Warrants to purchase an aggregate 22,501, 9,912 and 34,508 ordinary shares, respectively, on a cashless basis, which resulted in the expiration of 5,192, 243, and 761 CLA Warrants, respectively. As of December 31, 2018 and 2017, 7,389 and 35,082 CLA Warrants were outstanding, respectively.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z51ee299749d947c5b8c92622f2b57f37" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">f)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Upon the closing of the IPO, the Company issued warrants to purchase 8,334 ordinary shares at an exercise price of $90 to the IPO lead underwriter and warrants to purchase 1,250 ordinary shares at an exercise price of $60.72 to the Company's U.S. legal counsel.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z2371cf9f7c0b418ebd5a7096f816a84a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">g)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On June 24, 2015, the Company entered into Amendment No. 1 to the Warrant Agreement, dated June 24, 2015, between the Company and American Stock Transfer &#38; Trust Company LLC, as Warrant Agent, to extend the Registration Due Date to the date which is 180 days following the date of closing of the Company's initial public offering (i.e., August 23, 2015) in order to allow the shareholders who were the original purchasers of IPO Units additional time to become the direct registered owners of the ordinary shares underlying the IPO Units. As of December 31, 2018, and December 31, 2017, 378,047 Long Term Incentive Warrants were outstanding.</div>
</td>
</tr>
</table>
</div>



<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="ze3ede3e3f3154e6a903ea00c105c818c" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">h)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On August 11, 2016, the Company consummated a registered direct offering of 53,635 ordinary shares at a price of $22.80 per share and pre-funded warrants to purchase 209,524 ordinary shares at a purchase price of $22.20 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.60 per share, subject to certain adjustments and will expire on August 11, 2023, unless otherwise extended in accordance with the terms of the pre-funded warrants.&#160; The Company received gross proceeds from the August registered direct offering of approximately $5.9 million (including proceeds from the exercise of 47,917 pre-funded warrants at the closing of the offering).</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">On January 23, 2017, the remaining pre-funded warrants to purchase 24,167 ordinary shares were exercised, for additional proceeds of $14.5.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">As of December 31, 2018, and December 31, 2017, there were no outstanding pre-funded warrants.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zef7dbf0f65d04d5fbe085271694bd2c4" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">i)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On June 2, 2017, the Company consummated a registered direct offering of 112,460 ordinary shares at a price of $24.00 per share and a simultaneous private placement of one-year warrants to purchase 112,460 ordinary shares at an exercise price of $25.50 per share immediately exercisable. The Company received gross proceeds from the June registered direct offering of approximately $2.69 million. As of December 31, 2017, all the warrants issued in this offering were outstanding.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 99.25pt">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">On June 2, 2018, all of the warrants issued in this offering expired.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zfa85f6113bde45c09cc925cf132f33c1" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">j)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On November 22, 2017, the Company consummated a registered direct offering of 189,387 ordinary shares at a price of $13.20 per share and a simultaneous private placement of five-year warrants to purchase 142,042 ordinary shares at an exercise price of $15 per share immediately exercisable. The Company received gross proceeds from the November registered direct offering of approximately $2.5 million.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">On April 25, 2018, 56,812 of these warrants were cashless exercised into 13,574 ordinary shares.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">As of December 31, 2017, all the warrants issued in this offering were outstanding.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">As of December 31, 2018, 85,228 of these warrants were outstanding.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zb291166e27f448a8880a8d7d891df9cd" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 85.05pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 14.2pt">k)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, serif">On May 8, 2018, the Company consummated an underwritten public offering (the &#8220;2018 Public Offering&#8221;) of 2,738,472 units (the &#8220;Units&#8221;), at a public offering price of $5.5&#160;per unit, and 450,909 pre-funded units (the &#8220;Pre-funded Units&#8221;), at a public offering price of $5.49&#160;per Pre-funded Unit. Each Unit consisted of one ordinary share of the Company and one Series C warrant to purchase one ordinary share of the Company. Each Pre-funded Unit consisted of one pre-funded warrant to&#160;purchase one ordinary share and one Series C Warrant to purchase one ordinary share. The exercise price of each pre-funded warrant included in the pre-funded unit was $0.01 per share. The Series C warrants have an exercise price of $</font>5.50 per share, are exercisable immediately and will expire five years from the date of issuance<font style="font: 10pt Times New Roman, Times, serif">.</font></div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 99.25pt">The Company granted the underwriters a 30-day over-allotment option to purchase up to an additional&#160;478,407 ordinary shares and/or Series C Warrants to purchase up to an additional&#160;478,407&#160;ordinary shares at the public offering price. The underwriters&#8217; option was exercised in full on May 8, 2018.

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify">The Company received gross proceeds from the 2018 Public Offering and exercise in full of the over-allotment option of approximately $20.2 million (before deducting underwriting discounts and commissions and other offering fees and expenses). During May 2018, the 450,909 pre-funded units were exercised in full in consideration of additional gross proceeds of $4.5.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify"><font style="font: 10pt Times New Roman, Times, serif">On February 6, 2019, the Company issued 1,881,500 units, at a purchase price of $2.58 per unit, and 1,024,876 pre-funded units, at a purchase price of $2.57 per pre-funded unit, in a registered direct offering. Each unit consisted of one ordinary share of the Company and one Series D Warrant to purchase 0.5 ordinary share of the Company. Each pre-funded unit consisted of one pre-funded warrant to purchase one ordinary share and one Series D Warrant to purchase 0.5 ordinary share. The exercise price of each pre-funded warrant included in the pre-funded unit was $0.01 per share. The Series D Warrants have an exercise price of $2.58 per ordinary share and are immediately exercisable </font>and will expire on the fifth anniversary of the original issuance date.<font style="font: 10pt Times New Roman, Times, serif"> The Company received gross proceeds from the February 2019 registered direct offering of approximately $7.5 million (including proceeds from the exercise of 1,024,876 pre-funded warrants), or $6.6 million, net of issuance expenses in the amount of $927.</font></div>
</div></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6630616432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><div><div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"></div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 10&#160;-&#160;&#160;SHARE-BASED COMPENSATION</div>

<div style="text-align: left; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z7c972179bd2f4ab38d0e10e7740bd92e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">A.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">General</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z97000ff00ad046f9840c247325499abc" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">1.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">In connection with the transfer of all of the business operations and substantially all of the assets of Check-Cap LLC to the Company in 2009, the Company assumed the Check-Cap LLC 2006 Unit Option Plan (hereafter: the "2006 Plan"). According to the 2006 Plan, the Company is authorized to grant options to purchase ordinary shares of the Company to employees, directors and consultants of the Company. The options granted according to the 2006 Plan are generally exercisable for 10 years from the grant date unless otherwise determined by the Company's Board of Directors, vest over a period to be determined by the Company's Board of Directors, and have an exercise price to be determined by the Company's Board of Directors.</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z616059d2d4184a4199a6a8b0a7a19492" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">2.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On January 15, 2015, the Board of Directors resolved to increase the number of ordinary shares by 4% of the Company's fully-diluted share capital (including the option pool) immediately following the consummation of the IPO. As a result, the number of the Company's ordinary shares reserved for issuance under the 2006 Plan increased by 80,646.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zb218e8639b384ca7a05c2d13795995d8" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">3.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On April 6, 2015, the Company's Board of Directors resolved to increase the number of ordinary shares of the Company's reserved for issuance under the 2006 Plan by 143,212 shares.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z5e4e59a841444c518deedabb45e8ca35" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">4.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On August 13, 2015, the shareholders approved and adopted the Check-Cap Ltd. 2015 Equity Incentive Plan (the "2015 Israeli Plan") and the Check-Ltd. 2015 United States Sub-Plan to Check-Cap Ltd. 2015 Equity Incentive Plan (the "2015 U.S. Sub-Plan" and together with the 2015 Israeli Plan, the "2015 Plan").&#160;&#160;As of such date, the Company ceased to grant options under the 2006 Plan. All of the remaining shares authorized but unissued under the 2006 Plan were rolled over to the 2015 Plan.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z243d6c7eac5643a592a29715f2f452f6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">5.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On July 30, 2018, the Company's Board of Directors resolved to increase the number of ordinary shares of the Company's reserved for issuance under the 2015 Plan by 870,261 shares to 1,205,594 shares.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z5d4c6204f82f46dbbd598138b1f8adcc" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">B.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Details of share-based grants made by the Company</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The following tables presents the grant dates, number of underlying shares and related exercise prices of awards granted to employees and non-employees during the years 2018, 2017 and 2016 as well as the estimated fair value of the underlying ordinary shares on the grant date:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z88a8a70b1f2645db8ae94013b5795614" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr style="height: 34px">
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Grant date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">No. of options</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Expiration date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Exercise price</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Fair value on grant date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Share based expenses (1)</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">$ in thousands</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Vesting terms</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 29, 2016</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,642</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">March 1, 2026</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">28.44</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">24.12</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">May 4, 2016</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,608</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">May 4, 2026</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">34.68</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">17.40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">132</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 4, 2016</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">404</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 4, 2026</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15.36</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">20.40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">8</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">October 31, 2016</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">202</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">October 31, 2026</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">23.64</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15.84</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 27, 2017</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,964</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 27, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">27.96</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">14.40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">28</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">May 9, 2017</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,580</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">May 9, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">25.86</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">12.96</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">20</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">June 22, 2017 (4)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5,041</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">June 22, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">22.32</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">12.60</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">64</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(3</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 3, 2017</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">404</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 3, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">22.36</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">12.36</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">November 2, 2017</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">853</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">November 2, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">20.76</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">8.16</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 13, 2018</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,584</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 13, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10.44</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4.95</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">23</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">July 30, 2018 (6)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">231,819</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">July 30, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.92</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2.61</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">605</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">September 20, 2018 (4)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">37,039</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">September 20, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.92</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2.96</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">110</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">November 1, 2018</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">44,450</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">November 1, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.81</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.23</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">144</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>
</table>
</div>

<div style="clear: both; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="zceb4452f4e784a36b5d61103a53b56a4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Grant date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">No. of RSUs and PSUs</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Expiration date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Fair value on grant date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Share based expenses (1)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Vesting terms</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 27, 2017</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,457</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 27, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2.20</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">197</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">June 22, 2017 (7)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">17,448</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">June 22, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1.88</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">393</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 3, 2017 (8)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">24,951</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 3, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1.84</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">551</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(8</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">July 30, 2018 (6)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">79,844</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">July 30, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.24</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">251</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">September 20, 2018 (4)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15,875</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">September 20, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.65</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">58</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z0dc06f5737784fbb84bd403149b6c4b5" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">1.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Share based expenses are based on their fair value on grant date. The amount is charged to statement of operations over the vesting periods.</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z36ecf2eaf7b94b148a4f20154c6a7692" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">2.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The options vest over a period of four years commencing on the date of grant, such that 25% of the options vested on the first anniversary of the date of grant and thereafter, the remaining options vest in quarterly installments.</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zd35ccfce8655477ca363a19c4ffc00f9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">3.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The options vest over a period of three years commencing on the date of grant in quarterly installments.</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z37f0ba092f644150bdd7e4aa4f535286" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">4.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Options or RSUs granted to certain members of the Company's Board of Directors.</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zbb63abf0cf864a6a8b9a5fd98830202f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">5.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The options vest over a period of three years commencing on the date of grant, such that one third of the options vested on the first anniversary of the date of grant and thereafter, the remaining options vest in quarterly installments.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zca27909ba468453ea129ee1067ab48f6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">6.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Of the 231,819 options and 79,844 RSUs, 122,232 options and 50,796 RSUs, respectively, were issued to certain of the Company&#8217;s officers. The remaining options and RSUs were issued to employees and consultants.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z41b734a7e9de40839595f01d16850e7c" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">7.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On June 22, 2017, the Company's shareholders approved the award of 11,302 and 6,146 RSUs to the Mr. Densel, who served as the Company&#8217;s CEO at such time, and to certain members of the Company's Board of Directors, respectively. The terms of the RSUs awarded to the Company&#8217;s former CEO provided that they shall vest over a period of four years commencing on the date of grant, such that 25% of the RSUs shall vest on the first anniversary of the date of grant and thereafter, the remaining RSUs will vest in quarterly installments.&#160; The RSUs granted to certain members of the Company's Board of Directors shall vest over a period of three years commencing on the date of grant in quarterly installments. The compensation expense was based on the fair value on the grant date, and was estimated at approximately $255 and $138 for the RSUs granted to the Company&#8217;s CEO and to certain members of the Company's Board of Directors, respectively. These amounts are charged to statement of operations over the vesting periods.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z9ebf1a607d9843d0af1ff825d3481cb5" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">8.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On August 3, 2017, the Company's Board of Directors approved the award of 24,951 Performance Stock Units (&#8220;PSUs&#8221;) to certain of the Company's employees. The PSUs shall vest based on four pre-determined milestones, of which the first milestone (15%) in 2017, the second and third milestones in 2018 (22.5% each) and the forth milestone in 2019 (40%). The compensation expense was based on the fair value on the grant date, and was estimated at approximately $551. No expenses were recorded during the years ended December 31, 2018 and 2017 as the Company did not achieve the pre-determined milestones for these years, and estimates that it will not meet the remaining pre-determined milestone for year 2019.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zecd75dd973b6429bb073f150f1dc8019" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">9.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On February 26, 2018, upon the termination of
the&#160;employment of Mr. Densel, the Company&#8217;s former CEO, options to purchase 49,965 ordinary shares&#160;and 11,302
RSUs were forfeited.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zd2a45ca7eccf40819e607d8c9afd0ebe" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">C.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Options Fair Value</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The parameters which were used in applying the model are as follows:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="za8ded490179145fc9b5c2a64a8d9cca1" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Expected volatility (1)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">104%-108</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">58%-60</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">59%-60</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Risk-free rate</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2.67-3.15</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1.9%-2.2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1.2%-2.1</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Dividend yield</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">0</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">0</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">0</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Expected term (in years)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5.5-7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5.5-7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5.5-7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Share price</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.24 - $9.07</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15.96-$26.40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">26.64-$38.40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zc8c9adea4a6f4511a31ef9643bc3f42f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">(1)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options. In the years ended December 31, 2017 and 2016, due to lack of history of trading, expected volatility was calculated based on certain peer companies that the Company considered to be comparable.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left"><font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"></font>
<div id="DSPFPageHeader"><font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff">&#160; </font></div>

<div style="text-align: left; line-height: 1.25"><font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"></font>
<table id="z0db7bdd3668f4b89a117104712adcd6e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">D.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Effect of share-based compensation transactions on the Company's statements of operations</div>
</td>
</tr>
</table>
</div>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z5f621de7f3bd4e168919291a38d60b09" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Research and development, net</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">234</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">116</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">234</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">General and administrative, net*</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(299</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">610</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">975</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Total</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(65</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">726</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,209</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; clear: both">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;* Amount in 2018 is negative mainly, due to the forfeiture of the former CEO unvested options and RSU.&#160;</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z65d37a8354ee4a589fdb4cc9b20514dc" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">E.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">A&#160;summary&#160;of the Company's option activity related to options granted to employees, service providers and directors, and related information under the 2006 Plan and the 2015 Plan is as follows:</div>
</td>
</tr>
</table>
</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</div>

<div style="line-height: 1.25">
<table id="zab44d3db65d44b3790c923e5df7928f4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Year ended December 31, 2018</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Number</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average of exercise price</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in $)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average remaining contractual life</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in years)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Aggregate</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">intrinsic value</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">($ in thousands)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options outstanding at beginning of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">208,222</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">46.32</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.11</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options granted</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">318,094</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4.00</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options forfeited</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(103,532</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">45.88</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options outstanding at end of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">422,784</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15.54</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">8.60</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options exercisable at end of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">101,040</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">46.18</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4.61</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>
</table>
</div>

<div style="clear: both; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="line-height: 1.25">
<table id="z963140b0d9174374baecfce0a32e68b3" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Year ended December 31, 2017</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Number</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average of exercise price</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in $)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average remaining contractual life</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in years)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Aggregate</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">intrinsic value</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">($ in thousands)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options outstanding at beginning of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">207,769</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">47.04</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.39</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options granted</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">9,842</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">23.88</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options forfeited</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(9,389</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">39.24</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options outstanding at end of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">208,222</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">46.32</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.11</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options exercisable at end of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">134,550</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">48.00</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5.99</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="line-height: 1.25">
<table id="zd7cd0a24132d42c1abf493587f05074d" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td colspan="4" style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Year ended December 31, 2016 </div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Number of options</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average of exercise price</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in $)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average remaining contractual life</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in years)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Aggregate</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">intrinsic value</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">($ in thousands)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Outstanding at the beginning of the year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">230,958</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">48.12</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.99</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Granted</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">9,856</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">32.64</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Exercised</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Forfeited</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(33,045</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">50.52</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Outstanding at the end of the year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">207,769</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">47.04</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.39</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Exercisable at the end of the year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">106,725</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">46.80</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">6.34</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>
</table>
</div>

<div style="clear: both; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zaadb93eaa67b41efa80181154b198167" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">1.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The weighted average grant date fair values of options granted during the years ended December 31, 2018, 2017 and 2016 were $2.77, $12.48 and $18.60, respectively.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z5aa341f783874710a20d96c8621a3a09" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">2.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The aforementioned options are out of the money.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z9eba5ab88305454391f2e8cf491e5d3e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">3.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">As of December&#160;31, 2018, 2017, and 2016, there were $701, $346 and $766 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 Plan and the 2015 Plan, respectively. This cost is expected to be recognized over a period of up to 4 years.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt">A summary of the Company&#8217;s RSUs activity is as follows:</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="line-height: 1.25">
<table id="z6e92aa6d530a46d98b047bb36a66bfce" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Year ended December 31</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2018</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2017</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2016</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Number of RSUs</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Unvested at beginning of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">44,473</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Granted</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">95,719</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">49,856</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Vested</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(4,818</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(1,033</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Forfeited</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(25,905</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(4,350</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Unvested at end of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">109,469</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">44,473</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z9dd477a7c526425d9a1dbe4a410d7fe4" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">1.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The weighted average grant date fair values of RSUs awarded during the years ended December 31, 2018 and 2017 were $3.31 and $1.91. There were no RSU awards in the year ended December 31, 2016.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z0f52939761bd42a38beed4dbde05ee13" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">2.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">As of December&#160;31, 2018 and 2017, there were $263 and $287 unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2015 Plan, respectively. This cost is expected to be recognized over a period of up to 4 years.</div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809517760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT EXPENSES, NET</a></td>
<td class="text"><div><div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 11&#160;&#160;-&#160;&#160;RESEARCH AND DEVELOPMENT EXPENSES, NET</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 28.35pt">Composition:</div>

<div style="line-height: 1.25">
<table id="z6ae27eed91ff42d6a21f6d62c5619b6f" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Salaries and related expenses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,410</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,656</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,683</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Share-based compensation</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">234</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">116</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">234</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Materials</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,508</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">614</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">596</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Subcontractors&#160;and consultants</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">311</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">456</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">320</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Depreciation</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">138</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">147</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">121</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Cost for registration of patents</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">126</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">157</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">150</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Others</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,099</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">893</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">511</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,826</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,039</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">6,615</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Less participation of the IIA and BIRD Foundation</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(208</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(202</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(1,124</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Total research and development, net</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,618</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">6,837</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5,491</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6630616432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_GeneralAndAdministrativeExpensesTextBlock', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="text"><div><div style="clear: both; line-height: 1.25"></div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 12&#160;&#160;-&#160;&#160;GENERAL AND ADMINISTRATIVE EXPENSES</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 28.35pt"><font style="font: bold 10pt Times New Roman, Times, serif">Composition</font>:</div>

<div style="line-height: 1.25">
<table id="z8190ebefffad42d68e43f3991722a7ae" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Salaries and related expenses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,839</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,395</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,411</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Share-based compensation, net</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(299</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">610</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">975</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Professional services</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">833</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">414</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">354</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Office rent and maintenance</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">163</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">161</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">144</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Depreciation</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">9</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Others</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">899</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">574</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">678</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Total general and administrative</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3,445</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3,164</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3,571</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_GeneralAndAdministrativeExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure for general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_GeneralAndAdministrativeExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809579200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE INCOME (EXPENSES), NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock', window );">FINANCE INCOME (EXPENSES), NET</a></td>
<td class="text"><div><div style="clear: both; line-height: 1.25"></div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 13&#160; -&#160;&#160;FINANCE INCOME (EXPENSES), NET</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 28.35pt"><font style="font: bold 10pt Times New Roman, Times, serif">Composition</font>:</div>

<div style="line-height: 1.25">
<table id="z10af8702d4f1459f8c68c9780ae3b3c8" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Interest income on short-term deposits</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">243</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">66</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">139</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Bank fees and interest expenses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Changes in provision for royalties</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">255</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">82</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">56</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Exchange rate differences</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(27</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">95</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">56</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Changes in derivatives fair value</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">9</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Total financing income</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">473</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">236</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">244</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the components of non-operating income or non-operating expense, including, but not limited to, amounts earned from dividends, interest on securities, gain (loss) on securities sold, equity earnings of unconsolidated affiliates, gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809568544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text"><div><div style="line-height: 1.25"></div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 14&#160;&#160;-&#160;&#160;LOSS PER SHARE</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt">Basic loss per share is computed based on the weighted average number of shares outstanding during each year. Diluted net loss per share is computed based on the weighted average number of shares outstanding during each year, plus the dilutive potential of the ordinary shares considered outstanding during the year, in accordance with ASC 260-10 "Earnings per share".</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt">All outstanding options and warrants have been excluded from the calculation of the diluted loss per share for each period presented, since all such securities have an anti-dilutive effect.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt">The following table sets forth the computation of the Company`s basic and diluted net loss per ordinary share:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z0ff568004a344bd6843753f1ab80e1c4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Net loss</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10,589</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">9,771</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">8,826</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Shares used in computing net loss per ordinary share, basic and diluted (in thousands)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,058</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,455</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,208</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Net loss per ordinary share, basic and diluted</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2.61</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">6.72</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.31</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt">Instruments that may potentially dilute the basic loss per share in the future, but were not included in the calculation of diluted loss per share, since their effect is anti-dilutive.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z9881dccf01df42f7be4bf01e08e6520a" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">(number)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Warrants and share options</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3,457</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">914</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">849</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,515</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2,369</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2,057</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6644526160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><div><div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">NOTE 15&#160; -&#160; RELATED PARTIES</div>

<div style="text-align: left; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zd27f1b2e8cf94f8c8fe5df07cbc0a9ae" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">A.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif">Compensation to the non-executive directors:</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z75a761be81b54da39c73600e9e13f034" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Fees, including reimbursement of expenses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">340</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">274</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">238</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Share-based compensation</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">113</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">179</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">252</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">453</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">453</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">490</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">
<div style="text-align: left; line-height: 1.25">
<table id="z2f812836ffe643fea41001ecb1eb2712" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"><font style="font: bold 10pt Times New Roman, Times, serif">B</font>.</div>
</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">Transactions with related parties:</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>
</div>

<div style="line-height: 1.25">
<table id="zdb5ea891c360443a84c7faae90afb35e" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Consulting fees, including share-based compensation and reimbursement of expenses (1) (2)</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">47</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">57</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">67</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Key man life insurance premium (3)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">12</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">47</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">58</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">79</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z8dff4b29f3b74368ad4fa8b57068c4f6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">1.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On July 1, 2005, the Company entered into an agreement with Hadar Kimchy according to which Hadar Kimchy provided marketing communication and graphical design services to the Company in consideration for a monthly fee of NIS 10,260 ($3). On August 1, 2014, the monthly fee was increased to NIS 13,680 ($4).&#160;&#160;Such services were provided to the Company by Sigalit Kimchy, who is employed by Hadar Kimchy. On April 4, 2016, the agreement was terminated.</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt">On April 4, 2016, the Company entered into an employment agreement with Sigalit Kimchy, according to which Ms. Kimchy serves as marcom and user interface lead, in a 60% part-time role (no less than 112 hours per month), for a monthly salary of NIS 11,200 ($3), plus up to 35 monthly overtime hours at a gross monthly rate of NIS 2,800 ($1), or an aggregate monthly salary of up to NIS 14,000 ($4).&#160; Ms. Kimchy is entitled to an education fund, managers' insurance or pension fund and reimbursement of monthly travel expenses.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zefcaae50acd445feb30ede342b08c033" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">2.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">In connection with the asset transfer agreement entered into with the Predecessor Entity in May 2009, the Company assumed the former obligation of the Predecessor Entity to distribute any proceeds it collects on the $1 million key man life insurance policy with respect to Yoav Kimchy, the Company's chief technology officer and a former director, to the former holders of the Series A preferred units in an amount equal to their respective capital contributed to the Predecessor Entity, less any amounts previously distributed to them, plus any accrued and unpaid dividends due to them as of the date of distribution. On November 16, 2016, the Company cancelled the key man life insurance policy with respect to Yoav Kimchy.</div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6639406656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div><div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify">NOTE 16&#160; -&#160; SUBSEQUENT EVENTS</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt">On February 4, 2019, the Company consummated a registered direct offering. See Note 9.C.2.(l)</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6806516912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates in Preparation of Financial Statements</a></td>
<td class="text"><div><div style="text-align: left; line-height: 1.25"><table id="z1b107627e34e43e781cf7cef0a3c7728" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">A.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Use of estimates in preparation of financial statements</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div><div style="line-height: 1.25"></div>

<div style="text-align: left; line-height: 1.25">
<table id="z051b52fa8e564bbaa7cf401067e3c8d0" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">B.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Principles of consolidation</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company's consolidated financial statements include the financial statements of Check-Cap Ltd. and its wholly-owned subsidiary, Check-Cap U.S., Inc. The Company's consolidated financial statements are presented after elimination of inter-company transactions and balances.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Financial statements in U.S dollars</a></td>
<td class="text"><div><div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z0e536f1fabd246a7bca985da6358f0ff" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">C.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Financial statements in U.S dollars</div>
</td>
</tr>
</table>
</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company has not yet generated revenues and the majority of its expenses are in U.S. dollar (dollar or USD) or NIS, while none of these currencies is significantly material compared to the other.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Management judgment, in setting the dollar as the Company's functional currency, is based mainly on the following criteria: The Company's budget and other Company internal reports, including reports to the Company's Board of Directors and investors, are presented in dollars. Management uses these reports in order to make decisions for the Company. All of the Company's equity and debt financings were in dollars; and it is expected that a significant portion of the Company's future revenue will be in dollars. The financial statements are presented in dollars, which is the functional currency of the Company.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Transactions and balances denominated in dollars are presented at their original amounts. Non-dollar transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10 "Foreign Currency Translation". All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><div><div style="line-height: 1.25"></div>

<div style="text-align: left; line-height: 1.25">
<table id="z3a263b11ad4e445da79a8bbc4290998e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">D.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Cash and cash equivalents</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Cash and cash equivalents include cash in hand, short&#8211;term deposits in banks and short-term highly liquid investment with an original maturity of up to three months, with a high level of liquidity that may be easily converted to known amounts of cash, and that are exposed to insignificant risk of change in value.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term bank deposit</a></td>
<td class="text"><div><div style="line-height: 1.25"></div>

<div style="text-align: left; line-height: 1.25">
<table id="zc2ad2db3bbae457a8532f133aa57190a" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">E.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Short-term bank deposit</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Short-term bank deposits are deposits with maturities of more than three months but less than one year. The short&#8211;term bank deposits are presented at their cost, including accrued interest, which approximates fair value.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives', window );">Cash flow hedges</a></td>
<td class="text"><div><div style="line-height: 1.25"></div>

<div style="text-align: left; line-height: 1.25">
<table id="z5cbc74d75c284622af96f671ae8330c9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">F.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Cash flow hedges</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">As a matter of policy, the Company uses derivatives for risk management purposes, and does not use derivatives for speculative purposes. From time to time, the Company may enter into foreign currency zero-cost collars contracts to&#160;hedge&#160;foreign currency&#160;cash&#160;flow&#160;transactions. For&#160;cash&#160;flow&#160;hedges, unrealized gain or loss is recorded in Other comprehensive income (loss) until hedged item affects earnings. All of the Company&#8217;s hedges that are designated as hedges for accounting purposes were highly effective; therefore,&#160;no&#160;notable amounts of&#160;hedge ineffectiveness were recorded in the Company&#8217;s Consolidated Statements of Operations for either the settlement of&#160;cash&#160;flow&#160;hedges or the outstanding hedged balance.</div>
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company uses zero-cost collars to hedge against the risk of overall changes in future cash flow from payments of payroll and rent denominated in New Israeli Shekel. As of December&#160;31, 2018, the Company had outstanding foreign exchange collars in the notional amount of $2.1 million. These options were set for a period of up to six months. The Company measured the fair value of the options in accordance with provisions of ASC No.&#160;820 (classified as level 2 of the fair value hierarchy). During 2018, losses in the amount of $28, were reclassified when the related expenses were incurred and recognized in operating expenses. The fair value of the Company&#8217;s outstanding collars at December&#160;31, 2018 amounted to liability of $15 and is included in in other current liabilities on the balance sheets, with the effective portion of the change in fair value, amounted $13 classified in accumulated other comprehensive income ("AOCI").&#160;</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and equipment</a></td>
<td class="text"><div><div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z43258e42ffa94d73b5a8850a4b787d41" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">G.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Property and equipment</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt">&#160;</div>

<div style="line-height: 1.25">
<table id="z650bfb86e2314946955b5f01825ef12f" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr style="height: 14px">
<td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">Length of useful life</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">Depreciation rate</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">Years</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1.62%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1.02%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Office furniture and equipment</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10-14</div>
</td>
<td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7-10</div>
</td>
<td style="vertical-align: bottom; width: 1.02%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Laboratory equipment</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3-7</div>
</td>
<td style="vertical-align: bottom; width: 1.62%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15-33</div>
</td>
<td style="vertical-align: bottom; width: 1.02%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Computers and auxiliary equipment</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3</div>
</td>
<td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">33</div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div><div style="clear: both; line-height: 1.25"></div>

<div style="text-align: left; line-height: 1.25">
<table id="z878f598c2be74023b24dfc57c858b10f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">H.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Impairment of long-lived assets</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company's long-lived assets are reviewed for impairment in accordance with ASC 360-10 "Accounting for the Impairment or Disposal of Long-Lived Assets" whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable. Recoverability of assets (or asset group) to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. During the years ended December&#160;31, 2018, 2017 and 2016, no impairment losses were recorded.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development costs</a></td>
<td class="text"><div><div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zcd46fa4c7ca745d097e6e140ff524d2e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">I.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Research and development costs</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Research and development costs are expensed as incurred and consist primarily of costs for personnel, subcontractors and consultants (mainly in connection with clinical trials) and materials for research and development and clinical activities. Grants received by the Company from the IIA and from Israel-United States Binational Industrial Research and Development Foundation (the "BIRD Foundation") are recognized at the time the Company is entitled to such grants, on the basis of the costs incurred and applied as a deduction from research and development expenses. Such grants are included as a deduction of research and development costs (since at the time received the Company expects to generate sales from these projects and pay the royalties resulting from such sales).</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">See Note 7B(1) below regarding the offset of grants received for participation in research and development expenses.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent liabilities</a></td>
<td class="text"><div><div style="text-align: left; line-height: 1.25"><table id="z39611cf098aa4a19bd6dedd02199f27b" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">J.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Contingent liabilities</div>
</td>
</tr>
</table>
</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company accounts for its contingent liabilities in accordance with ASC No.&#160;450, "Contingencies". A provision is recorded when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">With respect to legal matters, provisions are reviewed and adjusted to reflect the impact of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. As of December&#160;31, 2018, and 2017, the Company is not a party to any ligation that could have a material adverse effect on the Company's business, financial position, results of operations or cash flows (see Note ).</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><div><div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="za3d9811bb2e14883aa53c16b3d1df87e" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">K.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Share-based compensation</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company recognizes expense for its share-based compensation based on the fair value of the awards granted. The Company&#8217;s share-based compensation plans provide for the award of stock options and restricted stock units. In accordance with ASC 718-10 "Compensation-Stock Compensation", the Company estimates the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company's consolidated statement of operations.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company recognizes compensation expenses for the value of its awards granted based on the graded-vesting method over the requisite service period for each separately vesting portion of the award. Accounting Standards Update (&#8220;ASU&#8221;) 2016-09, Compensation-Stock Compensation (Topic 718) allows companies to account for forfeitures when they occur.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company selected the Black-Scholes-Merton option-pricing model as the most appropriate fair value method for its share-based awards. The option-pricing model requires a number of assumptions, of which the most significant are the fair market value of the underlying ordinary shares, expected share price volatility and the expected option term. In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">In the years ended December 31, 2017 and 2016, expected volatility was calculated based on certain peer companies that the Company considered to be comparable.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The expected option term represents the period of time that options granted are expected to be outstanding. The expected option term is determined based on the simplified method in accordance with Staff Accounting Bulletin No.&#160;110, as adequate historical experience is not available to provide a reasonable estimate.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><div><div style="text-align: left; line-height: 1.25"></div>

<div style="text-align: left; line-height: 1.25">
<table id="z74156c4b60254db69667b88159791230" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">L.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Income taxes</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company accounts for income taxes in accordance with ASC 740-10 "Accounting for Income Taxes." This Statement requires the use of the liability method of accounting for income taxes, whereby deferred tax asset and liability account balances are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">In accordance with ASC 740, the Company reflects in the financial statements the benefit of positions taken in a previously filed tax return or expected to be taken in a future tax return only when it is considered 'more-likely-than-not' that the position taken will be sustained by a taxing authority. As of December 31, 2018, and 2017, the Company had no unrecognized income tax positions and accordingly, there is no impact on the Company's effective income tax rate associated with these items.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value of financial instruments</a></td>
<td class="text"><div><div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z899c4d03750a4a47b4d730b3bd1a1b7f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">M.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Fair value of financial instruments</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company measures its investments in money market funds (classified as cash equivalents) and its foreign currency net purchased options at fair value. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"><font style="font-family: Times New Roman">&#9679; </font>Level 1. Observable inputs based on unadjusted quoted prices in active markets for identical assets or liabilities;</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"><font style="font-family: Times New Roman">&#9679; </font>Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt"><font style="font-family: Times New Roman">&#9679; </font>Level 3. Unobservable inputs for which there is little or no market data requiring the Company to develop its own assumptions.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 85.05pt; text-indent: -28.35pt">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive loss</a></td>
<td class="text"><div><div style="line-height: 1.25"></div>

<div style="text-align: left; line-height: 1.25">
<table id="z6bbb31e375064ab4bbff408ff3c970ef" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">N.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Comprehensive<font style="font: 10pt Times New Roman, Times, serif; background-color: #ffffff"> loss</font></div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company accounts for comprehensive income in accordance with ASC No.&#160;220, &#8220;Comprehensive Income&#8221;. Comprehensive income generally represents all changes in shareholders&#8217; equity during the period except those resulting from investments by, or distributions to, shareholders. The Company&#8217;s comprehensive loss consists of net loss and unrealized gain or loss on the effective portion of cash flow hedges. These amounts are carried in accumulated other comprehensive loss on the consolidated statements of comprehensive income and are presented net of taxes.</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<div style="text-align: left; line-height: 1.25">
<table id="zfcb6b8f1f9144a3ea8800c6f9367abad" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">O.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: justify">Restricted Cash</div>
</td>
</tr>
</table>
</div>

<br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company has granted a pledge in favor of Bank Leumi Le-Israel B.M in the amount of $350 to secure certain payment obligations of the Company in connection with FOREX activities. This amount was classified as restricted cash balance on December 31, 2018.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">In January 2018, the Company adopted new guidance from the Financial Accounting Standards Board or the FASB that clarified how entities should classify certain cash receipts and cash payments on the statement of cash flows. As a result, the restricted cash balance that existed in prior periods is included as a component of cash and cash equivalents and restricted cash on the statement of cash flows in the relevant periods presented. &#160;</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; text-indent: 36pt">
<table id="z5d79253cdc3c4130b5e286930e5812c3" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="padding-bottom: 2px; vertical-align: bottom">
<div>&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; text-align: center; vertical-align: bottom">2 0 1 6</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom">
<div>&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr style="height: 17px">
<td style="width: 64%; background-color: #cceeff; vertical-align: bottom">
<div>Cash and Cash equivalents</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt Times New Roman, Times, serif">8,572</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div>6,997</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div>11,639</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="width: 64%; background-color: #ffffff; vertical-align: bottom">
<div>Restricted cash included current assets</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div>350</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div>-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div>-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="width: 64%; background-color: #cceeff; vertical-align: bottom">
<div>Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div>8,922</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">6,997</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">11,639</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div><div style="clear: both; line-height: 1.25"></div>

<div style="text-align: left; line-height: 1.25">
<table id="z6f0eab32db874209a8bdc3f763d8259d" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="font: bold 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">P.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">New accounting pronouncements</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">ASU 2016-02, &#8220;Leases (Topic 842)&#8221; was issued by the FASB in February 2016. The purpose of this amendment requires the recognition of lease assets and lease liabilities by lessees for those leases previously classified as operating leases. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated results of operations, financial position or disclosures.</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Accounting Standards Update (ASU) 2018-07, &#8220;Compensation&#8212;Stock Compensation (Topic 718) Improvements to Nonemployee Share-Based Payment Accounting&#8221; was issued by the Financial Accounting Standards Board (FASB) in June 2018. The purpose of this amendment is to address aspects of the accounting for nonemployee share-based payment transactions. The amendments in this Update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company does not believe that this guidance will have a material impact on its consolidated results of operations, financial position or disclosures.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EEEE<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109999725-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809608768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock', window );">Schedule of Depreciation Inputs</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets at the following annual rates:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; margin-left: 56.7pt">&#160;</div>

<div style="line-height: 1.25">
<table id="z650bfb86e2314946955b5f01825ef12f" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr style="height: 14px">
<td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">Length of useful life</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">Depreciation rate</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 34.73%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 24.98%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">Years</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.62%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; text-align: center; width: 37.65%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1.02%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1.62%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1.02%">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Office furniture and equipment</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10-14</div>
</td>
<td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7-10</div>
</td>
<td style="vertical-align: bottom; width: 1.02%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Laboratory equipment</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3-7</div>
</td>
<td style="vertical-align: bottom; width: 1.62%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15-33</div>
</td>
<td style="vertical-align: bottom; width: 1.02%; background-color: #ffffff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 34.73%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Computers and auxiliary equipment</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 24.98%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3</div>
</td>
<td style="vertical-align: bottom; width: 1.62%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; text-align: center; width: 37.65%; background-color: #cceeff">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">33</div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">As a result, the restricted cash balance that existed in prior periods is included as a component of cash and cash equivalents and restricted cash on the statement of cash flows in the relevant periods presented. &#160;</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; text-indent: 36pt">
<table id="z5d79253cdc3c4130b5e286930e5812c3" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="padding-bottom: 2px; vertical-align: bottom">
<div>&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="border-bottom: #000000 2px solid; font-weight: bold; text-align: center; vertical-align: bottom">2 0 1 6</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom">
<div>&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr style="height: 17px">
<td style="width: 64%; background-color: #cceeff; vertical-align: bottom">
<div>Cash and Cash equivalents</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt Times New Roman, Times, serif">8,572</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div>6,997</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div>11,639</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="width: 64%; background-color: #ffffff; vertical-align: bottom">
<div>Restricted cash included current assets</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div>350</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div>-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div>-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="width: 64%; background-color: #cceeff; vertical-align: bottom">
<div>Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div>8,922</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">6,997</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">11,639</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the information used to calculate depreciation for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ScheduleOfPropertyPlantAndEquipmentDepreciationInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809520256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div><div style="line-height: 1.25"><table id="z1081dc66cfdc4f258ea43c74df680d86" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"><tr><td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="6" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Government institutions</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">178</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">89</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Prepaid expenses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">206</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">261</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Deposits</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">34</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">55</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Other assets</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">419</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">406</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6809605696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div><div style="line-height: 1.25"><table id="z0032aba21dcd49e8ac554d4bd9c16663" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"><tr><td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom"></td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="6" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Cost:</div>
</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Office furniture and equipment</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">186</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">157</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Laboratory equipment</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">644</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">626</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Computers and auxiliary equipment</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">388</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">339</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,218</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,122</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Accumulated depreciation</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">766</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">619</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Property and equipment, net</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">452</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">503</div></td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6800355904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Employee-related Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock', window );">Schedule of Employee Benefits and Payroll Accruals</a></td>
<td class="text"><div><div style="line-height: 1.25"><table id="z730365e17d284dfb9afd51bea51cc4e0" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"><tr><td style="vertical-align: bottom; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom"></td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr style="height: 18px">
<td style="vertical-align: bottom; font-weight: bold; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Short-term employee benefits:</div>
</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Benefits for vacation and recreation pay</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">162</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">235</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Liability for payroll, bonuses and wages</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">697</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">367</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">859</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">602</div>
</td>
</tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for employee related liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ScheduleOfEmployeeRelatedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6642933616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Taxes</a></td>
<td class="text"><div style="line-height: 1.25">
<table id="zdfa5e22d2d924a4ba967e406ae2ef8cd" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Carry forward tax losses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">12,525</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">13,083</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Less valuation allowance</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(12,525</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(13,083</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6800474560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsTableTextBlock', window );">Schedule of Reimbursement Liability</a></td>
<td class="text"><div><div style="line-height: 1.25"><table id="zde63b50cc0f04aefa2b3bba6731ebd6c" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"><tr><td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"></td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr style="height: 14px">
<td style="vertical-align: bottom; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Royalties to an ASIC designer</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">120</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">127</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 76%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Reimbursement liability to Predecessor Entity's unit holders</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">65</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">312</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 76%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">185</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">439</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left"><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;Operating lease obligations as of December 31, 2018:&#160;</div>
</div>

<div style="line-height: 1.25">&#160;</div>

<div style="line-height: 1.25">
<table id="z8d8f5993945949f99722c7756c6f5d95" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr style="height: 15px">
<td style="vertical-align: bottom; width: 88%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Lease agreement for vehicles</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">22</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 88%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Lease agreement for office facilities lease</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">13</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr style="height: 19px">
<td style="vertical-align: bottom; padding-bottom: 4px; width: 88%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">35</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=115931803&amp;loc=d3e12069-110248<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164451&amp;loc=d3e36991-112694<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about obligations resulting from other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6633876848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in Fair Value</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The Company&#8217;s financial assets measured at fair value on a recurring basis, excluding accrued interest components, consisted of the following types of instruments as of the following dates:</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="line-height: 1.25">
<table id="za2d67b964ab94d169dfa6bf2084b886a" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">December 31, 2018</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Fair value measurements using input type</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Level 1</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Level 2</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Total</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Cash equivalents:</div>
</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Money market funds</div>
</td>
<td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,307</div>
</td>
<td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,307</div>
</td>
<td style="vertical-align: bottom; text-align: left; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Foreign currency derivative instruments</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(15</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(15</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Total financial assets (Liabilities)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,307</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(15</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,292</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6801240496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Awards Granted</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The following tables presents the grant dates, number of underlying shares and related exercise prices of awards granted to employees and non-employees during the years 2018, 2017 and 2016 as well as the estimated fair value of the underlying ordinary shares on the grant date:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z88a8a70b1f2645db8ae94013b5795614" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr style="height: 34px">
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Grant date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">No. of options</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Expiration date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Exercise price</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Fair value on grant date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Share based expenses (1)</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">$ in thousands</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Vesting terms</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 29, 2016</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,642</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">March 1, 2026</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">28.44</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">24.12</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">May 4, 2016</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,608</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">May 4, 2026</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">34.68</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">17.40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">132</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 4, 2016</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">404</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 4, 2026</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15.36</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">20.40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">8</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">October 31, 2016</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">202</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">October 31, 2026</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">23.64</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15.84</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 27, 2017</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,964</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 27, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">27.96</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">14.40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">28</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">May 9, 2017</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,580</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">May 9, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">25.86</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">12.96</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">20</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">June 22, 2017 (4)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5,041</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">June 22, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">22.32</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">12.60</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">64</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(3</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 3, 2017</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">404</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 3, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">22.36</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">12.36</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">November 2, 2017</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">853</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">November 2, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">20.76</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">8.16</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 13, 2018</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,584</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 13, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10.44</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4.95</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">23</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">July 30, 2018 (6)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">231,819</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">July 30, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.92</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2.61</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">605</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">September 20, 2018 (4)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">37,039</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">September 20, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.92</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2.96</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">110</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">November 1, 2018</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">44,450</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 20%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">November 1, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.81</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.23</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">144</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="zceb4452f4e784a36b5d61103a53b56a4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Grant date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">No. of RSUs and PSUs</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Expiration date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Fair value on grant date</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Share based expenses (1)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Vesting terms</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 27, 2017</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,457</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">February 27, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2.20</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">197</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">June 22, 2017 (7)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">17,448</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">June 22, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1.88</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">393</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 3, 2017 (8)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">24,951</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">August 3, 2027</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1.84</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">551</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(8</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">July 30, 2018 (6)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">79,844</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 26%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">July 30, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.24</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">251</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">September 20, 2018 (4)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15,875</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: top; width: 26%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">September 20, 2028</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.65</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">58</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(5</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z0dc06f5737784fbb84bd403149b6c4b5" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">1.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Share based expenses are based on their fair value on grant date. The amount is charged to statement of operations over the vesting periods.</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z36ecf2eaf7b94b148a4f20154c6a7692" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">2.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The options vest over a period of four years commencing on the date of grant, such that 25% of the options vested on the first anniversary of the date of grant and thereafter, the remaining options vest in quarterly installments.</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zd35ccfce8655477ca363a19c4ffc00f9" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">3.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The options vest over a period of three years commencing on the date of grant in quarterly installments.</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="z37f0ba092f644150bdd7e4aa4f535286" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">4.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Options or RSUs granted to certain members of the Company's Board of Directors.</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zbb63abf0cf864a6a8b9a5fd98830202f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">5.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">The options vest over a period of three years commencing on the date of grant, such that one third of the options vested on the first anniversary of the date of grant and thereafter, the remaining options vest in quarterly installments.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zca27909ba468453ea129ee1067ab48f6" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">6.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">Of the 231,819 options and 79,844 RSUs, 122,232 options and 50,796 RSUs, respectively, were issued to certain of the Company&#8217;s officers. The remaining options and RSUs were issued to employees and consultants.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z41b734a7e9de40839595f01d16850e7c" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">7.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On June 22, 2017, the Company's shareholders approved the award of 11,302 and 6,146 RSUs to the Mr. Densel, who served as the Company&#8217;s CEO at such time, and to certain members of the Company's Board of Directors, respectively. The terms of the RSUs awarded to the Company&#8217;s former CEO provided that they shall vest over a period of four years commencing on the date of grant, such that 25% of the RSUs shall vest on the first anniversary of the date of grant and thereafter, the remaining RSUs will vest in quarterly installments.&#160; The RSUs granted to certain members of the Company's Board of Directors shall vest over a period of three years commencing on the date of grant in quarterly installments. The compensation expense was based on the fair value on the grant date, and was estimated at approximately $255 and $138 for the RSUs granted to the Company&#8217;s CEO and to certain members of the Company's Board of Directors, respectively. These amounts are charged to statement of operations over the vesting periods.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z9ebf1a607d9843d0af1ff825d3481cb5" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">8.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On August 3, 2017, the Company's Board of Directors approved the award of 24,951 Performance Stock Units (&#8220;PSUs&#8221;) to certain of the Company's employees. The PSUs shall vest based on four pre-determined milestones, of which the first milestone (15%) in 2017, the second and third milestones in 2018 (22.5% each) and the forth milestone in 2019 (40%). The compensation expense was based on the fair value on the grant date, and was estimated at approximately $551. No expenses were recorded during the years ended December 31, 2018 and 2017 as the Company did not achieve the pre-determined milestones for these years, and estimates that it will not meet the remaining pre-determined milestone for year 2019.</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zecd75dd973b6429bb073f150f1dc8019" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; text-align: justify; width: 28.35pt">9.</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">On February 26, 2018, upon the termination of the&#160;employment of Mr. Densel, the Company&#8217;s former CEO, options to purchase 93,415 ordinary shares&#160;and 11,302 RSUs forfeited.</div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock', window );">Schedule of Parameters Used in Valuing Fair Value of Options</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 56.7pt">The parameters which were used in applying the model are as follows:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="za8ded490179145fc9b5c2a64a8d9cca1" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Expected volatility (1)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">104%-108</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">58%-60</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">59%-60</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Risk-free rate</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2.67-3.15</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1.9%-2.2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1.2%-2.1</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Dividend yield</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">0</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">0</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">0</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">%</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Expected term (in years)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5.5-7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5.5-7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5.5-7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Share price</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3.24 - $9.07</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15.96-$26.40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">$</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">26.64-$38.40</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="text-align: left; line-height: 1.25">
<table id="zc8c9adea4a6f4511a31ef9643bc3f42f" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 56.7pt"></td>
<td style="font: 10pt Times New Roman, Times, serif; vertical-align: top; width: 28.35pt">(1)</td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options. In the years ended December 31, 2017 and 2016, due to lack of history of trading, expected volatility was calculated based on certain peer companies that the Company considered to be comparable.</div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation</a></td>
<td class="text"><div><div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">Effect of share-based compensation transactions on the Company's statements of operations</div>

<div style="font: bold 10pt Times New Roman, Times, serif; text-align: justify">&#160;</div>
<div style="line-height: 1.25"><table id="z5f621de7f3bd4e168919291a38d60b09" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%"><tr><td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"></td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Research and development, net</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">234</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">116</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">234</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">General and administrative, net*</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(299</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">610</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">975</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Total</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(65</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">726</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,209</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; clear: both">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;* Amount in 2018 is negative mainly, due to the forfeiture of the former CEO unvested options and RSU.&#160;</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div><div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="z65d37a8354ee4a589fdb4cc9b20514dc" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>

<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: 10pt Times New Roman, Times, serif; text-align: justify">A&#160;summary&#160;of the Company's option activity related to options granted to employees, service providers and directors, and related information under the 2006 Plan and the 2015 Plan is as follows:</div>
</td>
</tr>
</table>
</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="line-height: 1.25">
<table id="zab44d3db65d44b3790c923e5df7928f4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Year ended December 31, 2018</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Number</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average of exercise price</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in $)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average remaining contractual life</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in years)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Aggregate</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">intrinsic value</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">($ in thousands)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options outstanding at beginning of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">208,222</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">46.32</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.11</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options granted</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">318,094</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4.00</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options forfeited</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(103,532</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">45.88</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options outstanding at end of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">422,784</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">15.54</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">8.60</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options exercisable at end of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">101,040</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">46.18</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4.61</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>
</table>
</div>

<div style="clear: both; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="line-height: 1.25">
<table id="z963140b0d9174374baecfce0a32e68b3" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Year ended December 31, 2017</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Number</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average of exercise price</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in $)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average remaining contractual life</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in years)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Aggregate</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">intrinsic value</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">($ in thousands)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options outstanding at beginning of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">207,769</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">47.04</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.39</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options granted</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">9,842</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">23.88</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options forfeited</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(9,389</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">39.24</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options outstanding at end of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">208,222</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">46.32</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.11</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Options exercisable at end of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">134,550</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">48.00</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5.99</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both">&#160;</div>

<div style="line-height: 1.25">
<table id="zd7cd0a24132d42c1abf493587f05074d" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td colspan="4" style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Year ended December 31, 2016 </div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Number of options</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average of exercise price</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in $)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Weighted average remaining contractual life</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">(in years)</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; vertical-align: bottom">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">Aggregate</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">intrinsic value</div>

<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: center">($ in thousands)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Outstanding at the beginning of the year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">230,958</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">48.12</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.99</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Granted</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">9,856</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">32.64</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Exercised</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Forfeited</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(33,045</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">50.52</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Outstanding at the end of the year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">207,769</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">47.04</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.39</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 52%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Exercisable at the end of the year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">106,725</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">46.80</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">6.34</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(2</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div></td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt">A summary of the Company&#8217;s RSUs activity is as follows:</div>

<div style="line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="line-height: 1.25">
<table id="z6e92aa6d530a46d98b047bb36a66bfce" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: top; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Year ended December 31</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2018</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2017</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2016</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: top; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">Number of RSUs</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Unvested at beginning of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">44,473</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Granted</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">95,719</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">49,856</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Vested</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(4,818</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(1,033</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Forfeited</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(25,905</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(4,350</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: top; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Unvested at end of year</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">109,469</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">44,473</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of parameters used to calculate the fair value of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ScheduleOfParametersUsedInValuingFairValueOfOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6800439072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ScheduleOfResearchAndDevelopmentExpensesNet', window );">Schedule of Research and Development Expenses, Net</a></td>
<td class="text"><div><div style="line-height: 1.25"><table id="z6ae27eed91ff42d6a21f6d62c5619b6f" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"><tr><td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"></td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Salaries and related expenses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,410</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,656</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,683</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Share-based compensation</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">234</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">116</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">234</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Materials</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,508</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">614</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">596</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Subcontractors&#160;and consultants</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">311</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">456</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">320</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Depreciation</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">138</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">147</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">121</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Cost for registration of patents</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">126</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">157</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">150</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Others</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,099</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">893</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">511</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,826</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,039</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">6,615</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Less participation of the IIA and BIRD Foundation</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(208</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(202</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(1,124</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Total research and development, net</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,618</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">6,837</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">5,491</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ScheduleOfResearchAndDevelopmentExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for the net expenses associated with research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ScheduleOfResearchAndDevelopmentExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6801793152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and Administrative Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock', window );">Schedule of General and Administrative Expenses</a></td>
<td class="text"><div><div style="line-height: 1.25"><table id="z8190ebefffad42d68e43f3991722a7ae" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"><tr><td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"></td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Salaries and related expenses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,839</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,395</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,411</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Share-based compensation, net</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(299</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">610</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">975</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Professional services</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">833</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">414</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">354</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Office rent and maintenance</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">163</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">161</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">144</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Depreciation</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">9</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Others</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">899</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">574</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">678</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Total general and administrative</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3,445</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3,164</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3,571</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ScheduleOfGeneralAndAdministrativeExpesesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6800439072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE INCOME (EXPENSES), NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Finance Income (Expense), Net</a></td>
<td class="text"><div><div style="line-height: 1.25"><table id="z10af8702d4f1459f8c68c9780ae3b3c8" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%"><tr><td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom"><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Interest income on short-term deposits</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">243</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">66</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">139</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Bank fees and interest expenses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(7</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Changes in provision for royalties</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">255</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">82</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">56</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Exchange rate differences</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">(27</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">)</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">95</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">56</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Changes in derivatives fair value</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">9</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Total financing income</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">473</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">236</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">244</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6653382912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Loss Per Share</a></td>
<td class="text"><div><div style="line-height: 1.25"></div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt">The following table sets forth the computation of the Company`s basic and diluted net loss per ordinary share:</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z0ff568004a344bd6843753f1ab80e1c4" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Net loss</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">10,589</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">9,771</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">8,826</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Shares used in computing net loss per ordinary share, basic and diluted (in thousands)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">4,058</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,455</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1,208</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Net loss per ordinary share, basic and diluted</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2.61</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">6.72</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7.31</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Securities</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: justify; margin-left: 28.35pt">Instruments that may potentially dilute the basic loss per share in the future, but were not included in the calculation of diluted loss per share, since their effect is anti-dilutive.</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z9881dccf01df42f7be4bf01e08e6520a" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 95%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">(number)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Warrants and share options</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">3,457</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">914</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">849</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">7,515</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2,369</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">2,057</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6811219136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_NonExecutiveDirectorsCompensationMember', window );">Compensation to the Non-Executive Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><div><div style="text-align: left; line-height: 1.25"><br style="line-height: 1.25" />
</div>

<div style="text-align: left; line-height: 1.25">
<table id="zd27f1b2e8cf94f8c8fe5df07cbc0a9ae" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>

<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt Times New Roman, Times, serif">Compensation to the non-executive directors:</div>
</td>
</tr>
</table>
</div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>

<div style="line-height: 1.25">
<table id="z75a761be81b54da39c73600e9e13f034" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Fees, including reimbursement of expenses</div>
</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">340</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">274</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">238</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Share-based compensation</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">113</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">179</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">252</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">453</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">453</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">490</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td></tr></table></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_GeneralTransactionsMember', window );">Transactions with Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><div><div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left; clear: both"></div>

<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">
<div style="text-align: left; line-height: 1.25">
<table id="z2f812836ffe643fea41001ecb1eb2712" class="DSPFListTable" cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, serif; width: 100%">
<tr>
<td style="width: 28.35pt"></td>
<td style="vertical-align: top; text-align: left; width: auto">
<div style="font: bold 10pt/1.25 Times New Roman, Times, serif; text-align: left">Transactions with related parties:</div>
</td>
</tr>
</table>
</div>

<div style="text-align: left; line-height: 1.25">&#160;</div>
</div>

<div style="line-height: 1.25">
<table id="zdb5ea891c360443a84c7faae90afb35e" cellspacing="0" cellpadding="0" align="right" border="0" style="font: 10pt Times New Roman, Times, serif; width: 92%">
<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; vertical-align: bottom">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">For the year ended December 31,</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 8</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 7</div>
</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; font-weight: bold; padding-bottom: 2px; text-align: center; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: #000000 2px solid; font-weight: bold; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: center">2 0 1 6</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td colspan="2" style="vertical-align: bottom; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Consulting fees, including share-based compensation and reimbursement of expenses (1) (2)</div>
</td>
<td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">47</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">57</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">67</div>
</td>
<td style="vertical-align: bottom; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 2px; width: 64%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">Key man life insurance premium (3)</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">-</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">1</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: right; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 2px solid; text-align: right; width: 9%; background-color: #ffffff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">12</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 2px; text-align: left; width: 1%; background-color: #ffffff; vertical-align: bottom; white-space: nowrap">&#160;</td>
</tr>

<tr>
<td style="vertical-align: bottom; padding-bottom: 4px; width: 64%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif; text-align: left">&#160;</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">47</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">58</div>
</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom; white-space: nowrap">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 4px; text-align: right; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: left; width: 1%; background-color: #cceeff; vertical-align: bottom">&#160;</td>
<td style="vertical-align: bottom; border-bottom: #000000 4px double; text-align: right; width: 9%; background-color: #cceeff; vertical-align: bottom">
<div style="font: 10pt/1.25 Times New Roman, Times, serif">79</div>
</td></tr></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_NonExecutiveDirectorsCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_NonExecutiveDirectorsCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_GeneralTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_GeneralTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819968576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL INFORMATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 10,589<span></span>
</td>
<td class="nump">$ 9,771<span></span>
</td>
<td class="nump">$ 8,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 63,301<span></span>
</td>
<td class="nump">$ 52,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6635371952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">Notional amount</a></td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments', window );">Loss incurred</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_DerivativeFairValueOfOptionOutstanding', window );">Fair value of option outstanding</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_DerivativeChangeInFairValueOfOptionOutstanding', window );">Change in fair value of option outstanding</a></td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_DerivativeChangeInFairValueOfOptionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of option outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_DerivativeChangeInFairValueOfOptionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_DerivativeFairValueOfOptionOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of option outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_DerivativeFairValueOfOptionOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) related to derivatives designated as cash flow hedging instruments, recorded in results of operations to the extent that the cash flow hedge is determined to be ineffective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnCashFlowHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819456352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Length of useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Depreciation rate</a></td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Length of useful life</a></td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Depreciation rate</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Laboratory equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Length of useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Depreciation rate</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Laboratory equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Length of useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Depreciation rate</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and auxiliary equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Length of useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage', window );">Depreciation rate</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated as a percentage, the estimated or actual value of the asset at the end of its useful life or when it is no longer serviceable (cannot be used for its original purpose) divided by its [historical] capitalized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentSalvageValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6788692000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash equivalents</a></td>
<td class="nump">$ 8,572<span></span>
</td>
<td class="nump">$ 6,997<span></span>
</td>
<td class="nump">$ 11,639<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash included current assets</a></td>
<td class="nump">350<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 8,922<span></span>
</td>
<td class="nump">$ 6,997<span></span>
</td>
<td class="nump">$ 11,639<span></span>
</td>
<td colspan="2" class="nump">$ 9,438<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Reclassified</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6751389632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_GovernmentInstitutionalAssetsCurrent', window );">Government institutions</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 419<span></span>
</td>
<td class="nump">$ 406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_GovernmentInstitutionalAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current assets related to government institutions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_GovernmentInstitutionalAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6806607392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expenses</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="nump">$ 130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,218<span></span>
</td>
<td class="nump">1,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">766<span></span>
</td>
<td class="nump">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">644<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and auxiliary equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 388<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_TechnologyEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6639268368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Employee-related Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Benefits for vacation and recreation pay</a></td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Liability for payroll, bonuses and wages</a></td>
<td class="nump">697<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee benefits and payroll accruals</a></td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804698672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2016</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Carry forward tax losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,525<span></span>
</td>
<td class="nump">$ 13,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,525)<span></span>
</td>
<td class="num">(13,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ReductionInIncomeTaxRate', window );">Reduction in income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ReductionInIncomeTaxRate', window );">Reduction in income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=chek_DevelopmentAreaAMember', window );">Development Area A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ReductionInIncomeTaxRate', window );">Reduction in income tax rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=chek_RestOfTheCountryMember', window );">Rest of the Country [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ReductionInIncomeTaxRate', window );">Reduction in income tax rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ReductionInIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction In Income Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ReductionInIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=chek_DevelopmentAreaAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=chek_DevelopmentAreaAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=chek_RestOfTheCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=chek_RestOfTheCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6820139072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENT LIABILITIES (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>&#8364; / Unit </div>
<div>$ / PerUnitSold</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / Unit </div>
<div>$ / PerUnitSold</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating lease obligations</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Royalties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RoyaltiesProvision', window );">Royalties provision</a></td>
<td class="nump">185,000<span></span>
</td>
<td class="nump">$ 439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Office facilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="nump">84,000<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">$ 78,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating lease obligations</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_OperatingLeaseRentExpenseMonthly', window );">Monthly lease expense</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating lease obligations</a></td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term</a></td>
<td class="text">32 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">32 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Vehicles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=chek_DesignerRoyaltiesMember', window );">ASIC designer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Royalties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RoyaltiesPayablePerUnitSold', window );">Royalties payable per unit sold | $ / PerUnitSold</a></td>
<td class="nump">0.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_MaximumRoyaltyObligation', window );">Maximum royalties payable</a></td>
<td class="nump">$ 229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RoyaltiesProvision', window );">Royalties provision</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=chek_DesignerRoyaltiesMember', window );">ASIC designer [Member] | Euro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Royalties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RoyaltiesPayablePerUnitSold', window );">Royalties payable per unit sold | &#8364; / Unit</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_MaximumRoyaltyObligation', window );">Maximum royalties payable | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=chek_PredecessorUnitHoldersMember', window );">Reimbursement liability to Predecessor Entity's Unit Holders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Royalties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RoyaltiesProvision', window );">Royalties provision</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=chek_OfficeOfTheChiefScientistMember', window );">OCS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Royalties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_GrantedRevenue', window );">Funding</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Contingent liability</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=chek_OfficeOfTheChiefScientistMember', window );">OCS [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Royalties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RoyaltiesPayablePercentageOfProductSales', window );">Royalty repayment, percentage of products sold</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=chek_OfficeOfTheChiefScientistMember', window );">OCS [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Royalties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RoyaltiesPayablePercentageOfProductSales', window );">Royalty repayment, percentage of products sold</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=chek_BinationalIndustrialResearchAndDevelopmentFoundationMember', window );">BIRD Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Royalties:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_MaximumRoyaltyObligation', window );">Maximum royalties payable</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_GrantedRevenue', window );">Funding</a></td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RoyaltiesPayablePercentageOfProductSales', window );">Royalty repayment, percentage of products sold</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Contingent liability</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RefundExpenses', window );">Refund expenses</a></td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_GrantedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue fron grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_GrantedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_MaximumRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_MaximumRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_OperatingLeaseRentExpenseMonthly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly rent expense for operating leased assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_OperatingLeaseRentExpenseMonthly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_RefundExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refund expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_RefundExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_RoyaltiesPayablePerUnitSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable for royalties per unit sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_RoyaltiesPayablePerUnitSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_RoyaltiesPayablePercentageOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalties payable as a percentage of product sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_RoyaltiesPayablePercentageOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_RoyaltiesProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the liability recorded to pay royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_RoyaltiesProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=chek_DesignerRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=chek_DesignerRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=chek_PredecessorUnitHoldersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=chek_PredecessorUnitHoldersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=chek_OfficeOfTheChiefScientistMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=chek_OfficeOfTheChiefScientistMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=chek_BinationalIndustrialResearchAndDevelopmentFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=chek_BinationalIndustrialResearchAndDevelopmentFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6807300064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Schedule of Market observable data of similar instruments) (Details) - Recurring [Member]<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 4,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Foreign currency derivative instruments</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets (Liabilities)</a></td>
<td class="nump">4,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">4,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Foreign currency derivative instruments</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets (Liabilities)</a></td>
<td class="nump">4,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Money market funds</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Foreign currency derivative instruments</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total financial assets (Liabilities)</a></td>
<td class="num">$ (15)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6831311376">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SHAREHOLDERS' EQUITY (Ordinary Shares) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">22 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 06, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 08, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 02, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 11, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 22, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 25, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of warrants into ordinary shares | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement', window );">Issuance of ordinary shares in the Private Placement, shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_UnitsPurchased', window );">Number of units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of ordinary shares in IPO, net of issuance expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,792<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering', window );">Issuance of ordinary Shares in RD Offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds warrant from the exercise pre-funded warrants | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance expenses | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Value or warrants | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,298<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Issuance of ordinary shares in the Private Placement, net of issuance expenses | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_WarrantsExercisedCashlessBasis', window );">Warrants exercised on a cashless basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,501<span></span>
</td>
<td class="nump">9,912<span></span>
</td>
<td class="nump">34,508<span></span>
</td>
<td class="nump">82,348<span></span>
</td>
<td class="nump">34,508<span></span>
</td>
<td class="nump">22,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | ILS [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | &#8362; / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance expenses | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
<td class="nump">$ 2,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Value or warrants | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_UnitsPurchased', window );">Number of units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,738,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of ordinary shares in IPO, net of issuance expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,881,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_WarrantsIssuedNumber', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chek_PreFundedUnitsMember', window );">Pre funded Units [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_UnitsPurchased', window );">Number of units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of ordinary shares in IPO, net of issuance expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=chek_PreFundedUnitsMember', window );">Pre funded Units [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,024,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonClassCMember', window );">Series C [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonClassCMember', window );">Series C [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares called by warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,167<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds warrant from the registered direct offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,024,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of ordinary shares in IPO, net of issuance expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_PreFundedWarrantsMember', window );">Pre-funded Warrants [Member] | RD Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares called by warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_PricePerUnit', window );">Price per unit | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering', window );">Issuance of ordinary Shares in RD Offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiry date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 11,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds warrant from the registered direct offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds warrant from the exercise pre-funded warrants | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_OneYearWarrantsMember', window );">One-year warrants [Member] | RD Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares called by warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_PricePerUnit', window );">Price per unit | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ClassOfWarrantOrRightExpiration', window );">Expiration of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_WarrantsExercisedCashlessBasis', window );">Warrants exercised on a cashless basis</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering', window );">Issuance of ordinary Shares in RD Offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds warrant from the registered direct offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_FiveYearWarrantsMember', window );">Five-year warrants [Member] | RD Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares called by warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_PricePerUnit', window );">Price per unit | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering', window );">Issuance of ordinary Shares in RD Offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds warrant from the registered direct offering | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_AntiDilutiveWarrantsMember', window );">Anti-Dilutive Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_WarrantsIssuedNumber', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares called by warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,969<span></span>
</td>
<td class="nump">7,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_AntiDilutiveWarrantsMember', window );">Anti-Dilutive Warrants [Member] | Ordinary Shares [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_LongTermIncentiveWarrantsMember', window );">Long Term Incentive Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ClassOfWarrantOrRightExpiration', window );">Expiration of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,047<span></span>
</td>
<td class="nump">378,047<span></span>
</td>
<td class="nump">388,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388,980<span></span>
</td>
<td class="nump">378,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_LongTermIncentiveWarrantsMember', window );">Long Term Incentive Warrants [Member] | Private Placement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_CreditLineAgreementWarrantsMember', window );">Credit Line Agreement Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_WarrantsIssuedNumber', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ClassOfWarrantOrRightExpiration', window );">Expiration of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,192<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">5,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,389<span></span>
</td>
<td class="nump">35,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_UnderwriterWarrantsMember', window );">Underwriter Warrants [Member] | IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_WarrantsIssuedNumber', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Private Placement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants value | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_SeriesAWarrantsMember', window );">Series A Warrants [Member] | Over-Allotment Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_OrdinarySharesMember', window );">Ordinary Shares [Member] | Over-Allotment Option [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_LegalWarrantsMember', window );">Legal Warrants [Member] | IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_WarrantsIssuedNumber', window );">Warrants issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_PreFundedWarrantsOneMember', window );">Pre-funded Warrants one [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Issuance of ordinary shares in IPO, net of issuance expense | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=chek_SeriesDWarrantsMember', window );">Series D Warrants [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="14"></td></tr>
<tr><td colspan="14"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents warrants issued to placement agent as part of issuance expenses</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ClassOfWarrantOrRightExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights expired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ClassOfWarrantOrRightExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_PricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price per unit sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_PricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period as part of a private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodSharesNewIssuesPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued upon the exercise of warrants during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of ordinary shares and pre-funded warrants in the registered direct offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodValueNewIssuesRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_UnitsPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of units purchased, consisting of one ordinary share and one-half of a Series A Warrant to purchase one ordinary share and one and one-half non-transferrable Long Term Incentive Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_UnitsPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_WarrantsExercisedCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised on a cashless basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_WarrantsExercisedCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_WarrantsIssuedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_WarrantsIssuedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=chek_PreFundedUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=chek_PreFundedUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=chek_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=chek_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_OneYearWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_OneYearWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_FiveYearWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_FiveYearWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_AntiDilutiveWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_AntiDilutiveWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=chek_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=chek_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_LongTermIncentiveWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_LongTermIncentiveWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_CreditLineAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_CreditLineAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_UnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_UnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_LegalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_LegalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_PreFundedWarrantsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_PreFundedWarrantsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=chek_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=chek_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819227312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Awards) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 26, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,094<span></span>
</td>
<td class="nump">9,842<span></span>
</td>
<td class="nump">9,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422,784<span></span>
</td>
<td class="nump">208,222<span></span>
</td>
<td class="nump">207,769<span></span>
</td>
<td class="nump">230,958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_TwentyTwoJuneMember', window );">June 22 [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_TwentyTwoJuneMember', window );">June 22 [Member] | Tranche One [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_JanuaryFifteenthMember', window );">January 15 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_AprilSixthMember', window );">April 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of options on grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.77<span></span>
</td>
<td class="nump">$ 12.48<span></span>
</td>
<td class="nump">$ 18.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 701<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognizing compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,205,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options expiring during period</a></td>
<td class="nump">49,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options [Member] | August 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value of options on grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,469<span></span>
</td>
<td class="nump">44,473<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSU's expiring during period</a></td>
<td class="nump">11,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | June 22 [Member] | Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | June 22 [Member] | Certain Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | August 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | August 3 [Member] | Tranche One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | August 3 [Member] | Share-based Compensation Award, Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | August 3 [Member] | Share-based Compensation Award, Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=chek_TwoThousandFifteenPlanMember', window );">2015 Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">870,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_TwentyTwoJuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_TwentyTwoJuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_JanuaryFifteenthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_JanuaryFifteenthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_AprilSixthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_AprilSixthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_ThreeAugustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_ThreeAugustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=chek_CertainEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=chek_CertainEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=chek_TwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=chek_TwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6828209648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details of share-based grants) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">318,094<span></span>
</td>
<td class="nump">9,842<span></span>
</td>
<td class="nump">9,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate1Member', window );">February 29, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">1,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Mar.  01,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 28.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 24.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate2Member', window );">May 04, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">7,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">May  04,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 34.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 17.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate3Member', window );">August 04, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Aug.  04,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 15.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 20.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate4Member', window );">October 31, 2016 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Oct. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 23.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 15.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate5Member', window );">February 27, 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">1,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Feb. 27,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 27.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 14.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate5Member', window );">February 27, 2017 [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">7,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Feb. 27,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 2.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate6Member', window );">May 09, 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">1,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">May  09,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 25.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 12.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate7Member', window );">June 22, 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">5,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jun. 22,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 22.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 12.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate8Member', window );">August 03, 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Aug.  03,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 22.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 12.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate9Member', window );">November 02, 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Nov.  02,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 20.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 8.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate10Member', window );">February 13, 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Feb. 13,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 10.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 4.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate17Member', window );">July 30, 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">79,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jul. 30,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate17Member', window );">July 30, 2018 [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">79,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jul. 30,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate11Member', window );">September 20, 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">231,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Sep. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 2.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate11Member', window );">September 20, 2018 [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Sep. 20,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate13Member', window );">November 1, 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">44,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Nov.  01,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 3.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 3.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate15Member', window );">June 22, 2017 [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">17,448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Jun. 22,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=chek_GrantDate16Member', window );">August 3, 2017 [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">No. of options</a></td>
<td class="nump">24,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Expiration date</a></td>
<td class="text">Aug.  03,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value on grant date</a></td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Share based expenses</a></td>
<td class="nump">$ 551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting terms</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate7Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate7Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate8Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate8Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate10Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate10Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate17Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate17Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate11Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate11Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate13Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate13Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate15Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate15Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=chek_GrantDate16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=chek_GrantDate16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6831369888">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Schedule of Parameters Used in Valuing Fair Value of Options) (Details) - Options [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Black-Scholes-Merton option-pricing model assumptions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">104.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">59.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">108.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free rate, minimum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.67%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free rate, maximum</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.15%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Black-Scholes-Merton option-pricing model assumptions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="nump">$ 15.96<span></span>
</td>
<td class="nump">$ 26.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Black-Scholes-Merton option-pricing model assumptions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9.07<span></span>
</td>
<td class="nump">$ 26.40<span></span>
</td>
<td class="nump">$ 38.40<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In the years ended December 31, 2017 and 2016, expected volatility was calculated based upon certain peer companies that the Company considered to be comparable. In the year ended December 31, 2018, expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending on the grant date, equal to the expected term of the options.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804578032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="num">$ (65)<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
<td class="nump">$ 1,209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="num">$ (299)<span></span>
</td>
<td class="nump">$ 610<span></span>
</td>
<td class="nump">$ 975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6819456816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Option Activity) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the year</a></td>
<td class="nump">208,222<span></span>
</td>
<td class="nump">207,769<span></span>
</td>
<td class="nump">230,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">318,094<span></span>
</td>
<td class="nump">9,842<span></span>
</td>
<td class="nump">9,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited</a></td>
<td class="num">(103,532)<span></span>
</td>
<td class="num">(9,389)<span></span>
</td>
<td class="num">(33,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the year</a></td>
<td class="nump">422,784<span></span>
</td>
<td class="nump">208,222<span></span>
</td>
<td class="nump">207,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the year</a></td>
<td class="nump">101,040<span></span>
</td>
<td class="nump">134,550<span></span>
</td>
<td class="nump">106,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average of exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the year</a></td>
<td class="nump">$ 46.32<span></span>
</td>
<td class="nump">$ 47.04<span></span>
</td>
<td class="nump">$ 48.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">4.00<span></span>
</td>
<td class="nump">23.88<span></span>
</td>
<td class="nump">32.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">45.88<span></span>
</td>
<td class="nump">39.24<span></span>
</td>
<td class="nump">50.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the year</a></td>
<td class="nump">15.54<span></span>
</td>
<td class="nump">46.32<span></span>
</td>
<td class="nump">47.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the year</a></td>
<td class="nump">$ 46.18<span></span>
</td>
<td class="nump">$ 48.00<span></span>
</td>
<td class="nump">$ 46.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the beginning of the year</a></td>
<td class="text">7 years 1 month 9 days<span></span>
</td>
<td class="text">7 years 4 months 20 days<span></span>
</td>
<td class="text">7 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree', window );">Outstanding at the end of the year</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="text">7 years 1 month 9 days<span></span>
</td>
<td class="text">7 years 4 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the year</a></td>
<td class="text">4 years 7 months 10 days<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">6 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate intrinsic value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the beginning of the year</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Outstanding at the end of the year</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the year</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the year</a></td>
<td class="nump">44,473<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock', window );">RSUs granted</a></td>
<td class="nump">95,719<span></span>
</td>
<td class="nump">49,856<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_NumberOfSharesRestrictedStockVested', window );">RSUs vested</a></td>
<td class="num">(4,818)<span></span>
</td>
<td class="num">(1,033)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">RSUs forfeited</a></td>
<td class="num">(25,905)<span></span>
</td>
<td class="num">(4,350)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the year</a></td>
<td class="nump">109,469<span></span>
</td>
<td class="nump">44,473<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_NumberOfSharesRestrictedStockVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock unit vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_NumberOfSharesRestrictedStockVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6807154544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT EXPENSES, NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ResearchAndDevelopmentExpensesLineItems', window );"><strong>Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="num">$ (65)<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
<td class="nump">$ 1,209<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development, net</a></td>
<td class="nump">7,618<span></span>
</td>
<td class="nump">6,837<span></span>
</td>
<td class="nump">5,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development, net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ResearchAndDevelopmentExpensesLineItems', window );"><strong>Research and Development Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salaries and related expenses</a></td>
<td class="nump">4,410<span></span>
</td>
<td class="nump">4,656<span></span>
</td>
<td class="nump">4,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Materials</a></td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_SubcontractorsAndConsultantFees', window );">Subcontractors and consultants</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Cost for registration of patents</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Others</a></td>
<td class="nump">1,099<span></span>
</td>
<td class="nump">893<span></span>
</td>
<td class="nump">511<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_ResearchAndDevelopmentExpenseGross', window );">Research and development</a></td>
<td class="nump">7,826<span></span>
</td>
<td class="nump">7,039<span></span>
</td>
<td class="nump">6,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_GrantedRevenue', window );">Less participation of the NATI and BIRD Foundation</a></td>
<td class="num">(208)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
<td class="num">(1,124)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development, net</a></td>
<td class="nump">$ 7,618<span></span>
</td>
<td class="nump">$ 6,837<span></span>
</td>
<td class="nump">$ 5,491<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_GrantedRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue fron grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_GrantedRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ResearchAndDevelopmentExpenseGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross recognized cost of research and development during the period, before accounting for costs covered by grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ResearchAndDevelopmentExpenseGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_ResearchAndDevelopmentExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expenses [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_ResearchAndDevelopmentExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_SubcontractorsAndConsultantFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fees for the services provided by subcontractors and consultants during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_SubcontractorsAndConsultantFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6808747376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL AND ADMINISTRATIVE EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_GeneralAndAdministrativeExpensesLineItems', window );"><strong>General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation, net</a></td>
<td class="num">$ (65)<span></span>
</td>
<td class="nump">$ 726<span></span>
</td>
<td class="nump">$ 1,209<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative</a></td>
<td class="nump">3,445<span></span>
</td>
<td class="nump">3,164<span></span>
</td>
<td class="nump">3,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_GeneralAndAdministrativeExpensesLineItems', window );"><strong>General and Administrative Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Salaries and related expenses</a></td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">1,395<span></span>
</td>
<td class="nump">1,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation, net</a></td>
<td class="num">(299)<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="nump">975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Office rent and maintenance</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Others</a></td>
<td class="nump">899<span></span>
</td>
<td class="nump">574<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Total general and administrative</a></td>
<td class="nump">$ 3,445<span></span>
</td>
<td class="nump">$ 3,164<span></span>
</td>
<td class="nump">$ 3,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_GeneralAndAdministrativeExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General and Administrative Expenses [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_GeneralAndAdministrativeExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873854&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873831&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6752615200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCE INCOME (EXPENSES), NET (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income on short-term deposits</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Bank fees and Interest expenses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_RoyaltyIncomeExpenseNonoperating', window );">Changes in provision for royalties</a></td>
<td class="nump">255<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Exchange rate differences</a></td>
<td class="num">(27)<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Changes in derivatives fair value</a></td>
<td class="nump">9<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total financing income</a></td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_RoyaltyIncomeExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned, net of expense during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_RoyaltyIncomeExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6635676752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Schedule of Loss Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Basic and diluted net loss per ordinary share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 10,589<span></span>
</td>
<td class="nump">$ 9,771<span></span>
</td>
<td class="nump">$ 8,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing net loss per ordinary share, basic and diluted (in thousands)</a></td>
<td class="nump">4,058<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per ordinary share, basic and diluted</a></td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="nump">$ 6.72<span></span>
</td>
<td class="nump">$ 7.31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6800523216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Schedule of Anti-Dilutive Securities) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive instruments</a></td>
<td class="nump">7,515<span></span>
</td>
<td class="nump">2,369<span></span>
</td>
<td class="nump">2,057<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chek_WarrantAndShareOptionsMember', window );">Warrant and Share Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive instruments</a></td>
<td class="nump">3,457<span></span>
</td>
<td class="nump">914<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chek_WarrantAndShareOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=chek_WarrantAndShareOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6808331312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Transactions with Related Parties) (Details)<br> $ / shares in Units, &#8362; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="8">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>ILS (&#8362;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>ILS (&#8362;)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>ILS (&#8362;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transactions with related parties</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted | shares</a></td>
<td class="nump">318,094<span></span>
</td>
<td class="nump">318,094<span></span>
</td>
<td class="nump">9,842<span></span>
</td>
<td class="nump">9,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.88<span></span>
</td>
<td class="nump">$ 32.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_ConsultingFeesMember', window );">Consulting fees, including share-based compensation and reimbursement of expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transactions with related parties</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=chek_KeyManLifeInsurancePremiumMember', window );">Key man life insurance premium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transactions with related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember', window );">Sigalit Kimchy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_MonthlyRetainer', window );">Monthly retainer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_MonthlySalary', window );">Monthly Salary</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_GrossOvertimeMonthlyRate', window );">Gross Overtime monthly rate</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_MaximumAggregateMonthlySalary', window );">Maximum aggregate monthly salary</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember', window );">Sigalit Kimchy [Member] | ILS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_MonthlyRetainer', window );">Monthly retainer | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 13,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 10,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_MonthlySalary', window );">Monthly Salary | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_GrossOvertimeMonthlyRate', window );">Gross Overtime monthly rate | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_MaximumAggregateMonthlySalary', window );">Maximum aggregate monthly salary | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OfficerMember', window );">Yoav Kimchy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_chek_KeyManInsurancePolicy', window );">Key man insurance policy</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_NonExecutiveDirectorsMember', window );">Non-Executive Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transactions with related parties</a></td>
<td class="nump">453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">453<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_NonExecutiveDirectorsMember', window );">Non-Executive Directors [Member] | Fees and Reimbursement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transactions with related parties</a></td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_NonExecutiveDirectorsMember', window );">Non-Executive Directors [Member] | Share-Based Compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Transactions with related parties</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_GrossOvertimeMonthlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross Overtime monthly rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_GrossOvertimeMonthlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_KeyManInsurancePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of key man insurance policy held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_KeyManInsurancePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_MaximumAggregateMonthlySalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate monthly salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_MaximumAggregateMonthlySalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_MonthlyRetainer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of monthly retainer for services performed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_MonthlyRetainer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_chek_MonthlySalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly Salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">chek_MonthlySalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>chek_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_ConsultingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_ConsultingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_KeyManLifeInsurancePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_KeyManLifeInsurancePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_ImmediateFamilyMemberOfManagementOrPrincipalOwnerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_ILS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_ILS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_NonExecutiveDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=chek_NonExecutiveDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_FeesAndReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_FeesAndReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=chek_ShareBasedCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=chek_ShareBasedCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^5V$7C-W;?VQ\$90M_+H+^0502P,$%     @ )8I\3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M%- I3B_0_ I/+R;T J?/4/K,TV<3^BPH#R+FN, <%9@#^B(0@(@E+K! !1:
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M)X*?C1LN[5CUC40_,;(;FJ1L[-2V_P!02P,$%     @ )8I\3H]5]J!\ P
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M1F6._7";NOMV.EM.C=Z>YW-S=#V\;_X 4$L#!!0    ( "6*?$[#*//X,P,
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MI-P8RP4Q6<5H$<;\&)XD N7[/@.",2KU1\?^1K @!0LL&.ST2J!%0@'E8DS
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M_V#O,C,[:Z_ST=A7UP%X\J:D=@7MO.^/C+FJ \7=G>E!XY_&6,4]AK9EKK?
MZTA2DB6[W8$I+C0M\Y@[VS(W@Y="P]D2-RC%[<\32#,6=$]OB6?1=CXD6)GW
MO(6OX+_U9XL16U1JH4 [832QT!3T<7\\90$? =\%C&ZU)Z&3BS&O(?A4%W07
M#(&$R@<%CLL5GD#*((0V?LR:="D9B.O]3?U#[!U[N7 '3T:^B-IW!7V@I(:&
M#](_F_$CS/W<4S(W_QFN(!$>G&"-RD@7OZ0:G#=J5D$KBK]-J]!Q':<_V8VV
M34AF0K(0'B*!386B\_?<\S*W9B1V.ON>ARO>'Q,\FRHDXU'$?VC>8?9:[@]9
MSJY!:,:<)DRRQBP(ANI+B62KQ"GYAYZFV_QTTV(:^>D?%N^W!;)-@2P*9/_M
M<0MS^*L(6QVJ MO&<7*D,H..H[S*+A/[F,1+^0V?QOT+MZW0CER,QZN-%] 8
MXP&M[.YPACI\84L@H?%A^P[W=IJS*?"FGY\06]YQ^0M02P,$%     @ )8I\
M3DQ006VU 0  TP,  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL?5/1
M;IPP$/P5RQ\0W\$UN9X *9>J:J1$.J5J^^R#!:S87FJ;(_G[VH90FJ"^8.\R
M,SMKK[,!S;-M 1QY45+;G+;.=0?&;-F"XO8*.]#^3XU&<>=#TS#;&>!5)"G)
MDLWFFBDN-"VRF#N9(L/>2:'A9(CME>+F]0@2AYQNZ5OB232M"PE69!UOX#NX
M']W)^(C-*I50H*U 30S4.;W='HZ[@(^ GP(&N]B3T,D9\3D$]U5.-\$02"A=
M4.!^N< =2!F$O(W?DR:=2P;B<O^F_C7V[GLY<PMW*'^)RK4YW5-20<U[Z9YP
M^ 93/Y\HF9I_@ M(#P].?(T2I8U?4O;6H9I4O!7%7\95Z+@.XY\TG6CKA&0B
M)#-A'^NPL5!T_H4[7F0&!V+&L^]XN.+M(?%G4X9D/(KXSYNW/GLIMM<W&;L$
MH0ES'#')$C,CF%>?2R1K)8[)!WJ:KO/358MIY*?_6-RO"^Q6!7918/??'M<P
MG]\588M#56":.$Z6E-CK.,J+[#RQMTF\E+_P<=P?N6F$MN2,SE]MO( :T8&W
MLKGR,]3Z%S8'$FH7MC=^;\8Y&P.'W?2$V/R.BS]02P,$%     @ )8I\3B7M
M+\BT 0  TP,  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL?5/M;IPP
M$'P5RP\0<W#YT F0<JFJ5FJE4Z*VOWVP@!7;2VQSI&\?VQ!*6]H_V+O,S,[:
MZWQ$\VP[ $=>E=2VH)US_8$Q6W6@N+W"'K3_TZ!1W/G0M,SV!G@=24JR-$EN
MF.)"TS*/N9,I<QR<%!I.AMA!*6Y^'D'B6- =?4\\BK9S(<'*O.<M/('[UI^,
MC]BB4@L%V@K4Q$!3T/O=X;@/^ CX+F"TJST)G9P1GT/PN2YH$@R!A,H%!>Z7
M"SR E$'(VWB9->E2,A#7^W?UC[%WW\N96WA ^4/4KBOH'24U-'R0[A''3S#W
M<TW)W/P7N(#T\.#$UZA0VO@EU6 =JEG%6U'\=5J%CNLX_;E.9]HV(9T)Z4*X
MBW785"@Z_\ =+W.#(S'3V?<\7/'ND/JSJ4(R'D7\Y\U;G[V4N]LD9Y<@-&..
M$R9=8Q8$\^I+B72KQ#']BYYEV_QLTV(6^=EO%O]A8+\IL(\"^__VN(5)_RC"
M5H>JP+1QG"RI<-!QE%?996+OXRVR7_!IW+]RTPIMR1F=O]IX 0VB V\EN?(S
MU/D7M@02&A>VMWYOICF; H?]_(38\H[+-U!+ P04    "  EBGQ.4XC,F[0!
M  #3 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q]4]MNG# 0_17+
M'Q#O KEH!4C95%4KM=(J49MG+PQ@Q1=BFR7]^XP-H;1%?<&>X9PS9^QQ/AK[
MXCH 3]Z4U*Z@G??]@3%7=:"XNS(]:/S3&*NXQ]"VS/46>!U)2K)DM[MAB@M-
MRSSF3K;,S>"ET'"RQ U*<?OK"-*,!=W3C\2C:#L?$JS,>]["$_@?_<EBQ!:5
M6BC03AA-+#0%O=\?CEG 1\!/ :-;[4GHY&S,2PB^U@7=!4,@H?)!@>-R@0>0
M,@BAC==9DRXE W&]_U#_''O'7L[<P8.1SZ+V74'O**FAX8/TCV;\ G,_UY3,
MS7^#"TB$!R=8HS+2Q2^I!N>-FE70BN)OTRIT7,?I3YK-M&U",A.2A7 7Z["I
M4'3^B7M>YM:,Q$YGW_-PQ?M#@F=3A60\BO@/S3O,7LK];9JS2Q":,<<)DZPQ
M"X*A^E(BV2IQ3/ZAI^DV/]VTF$9^^H?%;%L@VQ3(HD#VWQZW,-=_%6&K0U5@
MVSA.CE1FT'&45]EE8N^3>"F_X=.X?^>V%=J1L_%XM?$"&F,\H)7=%<Y0AR]L
M"20T/FQO<6^G.9L";_KY";'E'9?O4$L#!!0    ( "6*?$[(:/7CM0$  -,#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;'U3[6Z<,!!\%<L/$-_!
M-7<Z 5(N595*K71*U.:W#Q:PX@]BFR-]^ZP-H;1%_8.]R\SLK+W.!F-?7 O@
MR9N2VN6T];X[,N;*%A1W-Z8#C7]J8Q7W&-J&N<X"KR))299L-K=,<:%ID<7<
MV1:9Z;T4&LZ6N%XI;G^=0)HAIUOZD7@43>M#@A59QQMX O^C.UN,V*Q2"07:
M":.)A3JG=]OC:1?P$?!3P. 6>Q(ZN1CS$H*O54XWP1!(*'U0X+A<X1ZD#$)H
MXW72I'/)0%SN/]2_Q-ZQEPMW<&_DLZA\F],#)174O)?^T0P/,/7SB9*I^6]P
M!8GPX 1KE$:Z^"5E[[Q1DPI:4?QM7(6.ZS#^2?<3;9V03(1D)AQB'386BLX_
M<\^+S)J!V/'L.QZN>'M,\&S*D(Q'$?^A>8?9:['=WV;L&H0FS&G$)$O,C&"H
M/I=(UDJ<DG_H:;K.3U<MII&?_F%QORZP6Q7818'=?WM<PQS^*L(6AZK -G&<
M'"E-K^,H+[+SQ-XE\5)^P\=Q_\YM([0C%^/Q:N,%U,9X0"N;&YRA%E_8'$BH
M?=CN<6_'.1L#;[KI";'Y'1?O4$L#!!0    ( "6*?$X2T\/5M@$  -,#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;'U3VVZ<,!#]%<L?$+- N]L5
M(&535:W42JM439^],( 5FZ&V6=*_KVU8@AJ4%]LS/N?,Q>-L1/UL6@!+7I3L
M3$Y;:_LC8Z9L07%SASUT[J9&K;AUIFZ8Z37P*I"49'$4?62*BXX66?"==9'A
M8*7HX*R)&93B^N\))(XYW=&;XU$TK?4.5F0];^ GV%_]63N++2J54- 9@1W1
M4.?T?G<\I1X? $\"1K,Z$U_)!?'9&]^JG$8^(9!06J_ W7:%!Y#2"[DT_LR:
M= GIB>OS3?U+J-W5<N$&'E#^%I5M<WJ@I(*:#](^XO@5YGH^4#(7_QVN(!W<
M9^)BE"A-6$DY&(MJ5G&I*/XR[:(+^SC=[-.9MDV(9T*\$ XA#IL"A<P_<\N+
M3.-(]-3[GOLGWAUCUYO2.T,KPIU+WCCOM=CM/V7LZH5FS&G"Q&O,@F!.?0D1
M;X4XQ6_H2;+-3S933 (_68<_1-L"Z:9 &@32=VO<P!S^KY*MFJI -V&<#"EQ
MZ,(HK[S+Q-['X5%>X=.X_^"Z$9TA%[3N:<,#U(@67"K1G9NAUOVPQ9!06W_<
MN[.>YFPR+/;S%V++/R[^ 5!+ P04    "  EBGQ.I&+[5+4!  #3 P  &0
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MVQ&D&0N:T&OB2;2=#PE6YCUOX1OX[_W)8L06E5HHT$X832PT!;U/#L=]P$?
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MRR1+<W8-0C/F-&&2%6:_(!BJ+R&2K1"GY#]ZFF[ST\T4T\A/U^'O#ML"V:9
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M,',YU_Z\T&)8VAI9>VOQ!U!+ P04    "  EBGQ.NS8$,+D!  #3 P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6QU4]MNW" 0_17$!X0UWFQ6*]M2
M-E&42JVT2M3VF;7'-@H7!_ Z_?L =APW=5^ &<XY<V'(!FU>; O@T)L4RN:X
M=:X[$&++%B2S5[H#Y6]J;21SWC0-L9T!5D62%(1N-CLB&5>XR*+O9(I,]TYP
M!2>#;"\E,W^.(/20XP1_.)YXT[K@($76L0:>P?WL3L9;9%:IN 1EN5;(0)WC
MV^1PW 9\!/SB,-C%&85*SEJ_!.-;E>--2 @$E"XH,+]=X Z$"$(^C==)$\\A
M W%Y_E!_B+7[6L[,PIT6OWGEVASO,:J@9KUP3WIXA*F>:XRFXK_#!82'ATQ\
MC%(+&U=4]M9I.:GX5"1[&W>NXCZ,-]?)1%LGT(E 9\(^QB%CH)CY/7.LR(P>
MD!E[W['PQ,F!^MZ4P1E;$>]\\M9[+P7=[3)R"4(3YCABZ *3S CBU><0="W$
MD?Y#3]-U?KJ:8AKYZ3+\_C\"VU6!;138_E7CS9<:US#[+T'(HJD23!/'R:)2
M]RJ.\L([3^PMC8_R"1_'_0<S#5<6G;7S3QL?H-;:@4]E<^5GJ/4_;#8$U"X<
M;_S9C',V&DYWTQ<B\S\NW@%02P,$%     @ )8I\3MOWX=^X 0  TP,  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL;5/;;IPP$/T5RQ\0LX9NMBM
MRJ:J4JF55JF:/'MA "N^$-LLZ=_7-H2@E!?;,S[GS,7C?-3FQ78 #KU)H6R!
M.^?Z(R&VZD R>Z-[4/ZFT48RYTW3$ML;8'4D24%HDNR)9%SA,H^^LRES/3C!
M%9P-LH.4S/P]@=!C@7?XW?'(V\X%!RGSGK7P&]R?_FR\11:5FDM0EFN%##0%
MOML=3UG 1\ 3A]&NSBA4<M'Z)1@_Z@(G(2$04+F@P/QVA7L0(@CY-%YG3;R$
M#,3U^5W]>ZS=UW)A%NZU>.:UZPI\P*B&A@W"/>KQ >9ZOF T%_\3KB \/&3B
M8U1:V+BB:K!.RUG%IR+9V[1S%?=QNLD.,VV;0&<"70B'&(=,@6+FWYAC96[T
MB,S4^YZ%)]X=J>]-%9RQ%?'.)V^]]UK2_=><7(/0C#E-&+K"[!8$\>I+"+H5
MXD3_HZ?I-C_=3#&-_'0=_K#?%L@V!;(HD*UKO$T^U;B%^5PE6355@FGC.%E4
MZ4'%45YYEXF]H_%1/N#3N/]BIN7*HHMV_FGC S1:._"I)#=^ACK_PQ9#0./"
M\=:?S31GD^%T/W\ALOSC\A]02P,$%     @ )8I\3D+&=7FX 0  TP,  !D
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M>(=G.\W99'C3SU^(+?^X^ -02P,$%     @ )8I\3I/,:H?' 0  . 0  !D
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M+]%J<*B-VQ[M7LWS.!M&#LM30];WKO@#4$L#!!0    ( "6*?$ZRRWM7#0(
M &H%   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;'U4[6Z;,!1]%<0#
MU& ^DD: 5!)-F[1)4:=UOQUR Z@V9K83NK>?;0BEP/H'V]?GG'NNL6_2<?$J
M*P#EO#':R-2ME&IW",FB D;D V^AT3L7+AA1>BE*)%L!Y&Q)C"+L>3%BI&[<
M++&QH\@2?E6T;N H''EEC(B_.5#>I:[OW@//=5DI$T!9TI(2?H+ZU1Z%7J%1
MY5PS:&3-&T? )76?_-TA,G@+>*FADY.Y8RHY<?YJ%M_.J>L90T"A4$:!Z.$&
M>Z#4"&D;?P9-=TQIB-/Y7?V+K5W7<B(2]IS^KL^J2MVMZYSA0JY4/?/N*PSU
M1*XS%/\=;D UW#C1.0I.I?TZQ54JS@85;861MWZL&SMV@_Z=MD[  P&/!#_^
ME! ,A."=$'Y*" =".".@OA1[-@>B2)8(WCFB_[LM,9?(WX7Z] L3M(=M]_3Q
M2!V]97B[2=#-" V8O,?@"<8?$4BKCRGP6HH<+^A!\#'#?@42?H0<EI X6'<1
MK!8:6'XP+2+ZCT"X*A!:@7 BL/%G!]5#8@MI^AQ>M'V<%;M$/6[F4H<E:+O%
M\;K?:-5OM/ ;S9SDT2))' 3>S,I^B8KPQL<S+VARXQB(TKYFZ13\VBCSWR;1
ML6$\87-C9_%<-Y+^W;_+]%WH!Q%EW4CGQ)5^#_;67CA7H$UZ#]IEI1O?N*!P
M46:ZT7/1/_]^H7@[=#8TMM?L'U!+ P04    "  EBGQ.FR&@%>T!   !!0
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MB6A2EU*,D?1[/Q#[%Z=[;/:FL4&W%>Z;*5Z9Z*W&NUV);M9HTAR\!B\TZ:Q
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M0PADD7M1 5"$)WQ$8".1>(ZJ8U"$I_8#^XV,S13AY00%[":2_(>JL%?(V"R
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M;^\YYWEM[&RD[)4W ,)Y[TC/<[<18M@CQ*L&.LP?Z "]7#E3UF$AA^R"^,
MUSJH(RCPO 1UN.W=(M-S1U9D]"I(V\.1.?S:=9C]/0"A8^[Z[L?$<WMIA)I
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MWWM[*8VP'-,[*]C1]D[=H!![XSXG]ELU#40S,+)NFZ.DZ] 6_P!02P,$%
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M]9;[6HFRLZ*EE-EK^\RKYGELW["THV$"[0BT)VC?EPA11XC>"<E% NL([)W
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M>#H?%E97AHL# TA'-A,8:?:)333#2+,[MM',W" '8!O-S/69$?MBQG"!8*!
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M/$B3+1LTPC2?^W<X$ (%M*>I2?X<0-K:J)@ZNXX!3&QT3B7<UV_CNDTGC R
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M8&N""$ <( ")"$#J(0 ?6E#G 0^A9"+T3SWH_R&!9U9B7"#3F C]4P_Z?TB
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MK9 E(V! PP5;4P'#%] JJN38ZGDX)+)F!$Q?0(NHDB-"E$Q: 2,:P JIYN$
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MI,IOA:*XLYPXK@19KAS#EWBNY!+3E1#7E539K@3XKJS/=(2)\TJJK%<PBIT
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MNPS;ZVHXH1MNFO)B3A^]VQ'H^G]02P,$%     @ )8I\3LKL/<LI P  !@T
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MB6?&)"B/P4*ULU3#?#A0.$N]S=2>VY%F#Y*U_;1&PR>C^ =02P,$%     @
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M ,,HX*)Q6CR21P29P-\DM97RA)MGA^3GFK^;+Y?(P4K_,7Z*;[.$I@6T+W9
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MNYU1(BGHV2S^4BH HWW@'Z=E$2=9#V0*1V*-5ZL"X00IS!9_W('P@FJ5#PK
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M@D2/"-X18 <%$2@7JALL\F9/RO905^[XC=KGB"(7VAX?BKDW:%_O'O7\)3X
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MP9(I, F05 @/ ". &^+^T)Q (\O3SVS6V.69=_ =Q/X]SM95LZ%;OE1<&"4
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M4C*7#4.P4Z."6S+?"O@"R)@H[-]G3TBSV!JQ3 M@N7BL2Y$+]?+R7;9"H*4
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M1"9J5XZ1Z*ID*V>N==^0!'TI?,.L:0]H'T*4CQ$!J%RFJG(T?0[Z4S;U2CG
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M]9.4D\E+.\Y(%S9CW[\>R= ^-VFX@1KV7/A1_DJ!BR;X*365V6U405D$#:I
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MCXG?]0];%CI$KNJ-TM'#83ZF<@O^_/KT1,H8 B!7C>-V9HKD%IJR(THVL&N
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ME7B>1ER,^K-@U* =BDU0GG+FB'B.^LA2^[]A1IWO7,?N?F_L"**6X5OQ"O9
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M5P<6?9@O!)B1D^\@U6I'ZG9'XV *LCY?<)E4''1:IC>:! E\X2 8U?W.?Q^
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M#(-!/Y*$H'#(>U42_H>BY[]%PI(%%/XEHK9;IECO$1-),5^: (+JQTAOXF^
MU&K$Y4TUJH<Y$>XBJ6;KVG5IL7@8KJO6,TS5,OH[42I:GCW#KPC[#">I&KH=
M^NG4?@6RL?>H?AU:Q_DYMEU6M4I :[O3?\KE9Z[.$4B0:FEI,?&VYMP:C:28
MS6"JZ^14SZD5PG]-F"Y-\0:R6_T2%CRUS2V#9H+0<+?-9(%%(/^2RQ:23LW1
MKQS=>:P<^W!H.M*@E0K:/>7YIB\KZ*$OF! /?0>6_7&=9AA(OD'-&08V12H9
MF_37(%&.7G?8MJVV7F)_C94@%+(F,Y@\"*(7*!. N>@.,O8B[O1HQN:'9R"G
M]5]W?EMP!7F3,M>UD,<&&55DZZ5)\9-JF7G5Q ;VKQOBM%Z!PI=2UT,D9ZXL
MO](V $?%DAD5 M8V.(VMFG/->MZLYR;'CY5E21<X4%7,V%+KD?F"($UACLW!
M]K.(H-'E,)R!VMP0J(M>7>*<GN':,-9=@E9%:N6C)#>KP!0"#28:2^4W223$
M5W?BR:9&B>HVJ1:2+Z71=5OM=_M[@M5J9_//,2IKG*CU.<?^OE1M#E6PL#]\
MW0W[4^\U*!>ONZ")PR\S^>4J+3]UJ;((IN&ALCKI#GKA"+X*>_ 0:&'T:X2_
MAO#K6ZF\XC^E2;;R< SUGUX =;@_EN;K90=DTE%WXOQ[+754T!;$VI/?]5_-
M>E2<)QR!HMM]%8W%6C'NC8?=5X,I_HD;.MWL.Q^!H*3A-"BEL]J&@T!-JM!R
MXR)J\5,2,62'R1H5:C+T:>),O6;1.[M1S:)U";8&(J!+K1+\.L?D2M+4-.TY
M1+>S<Z3*229=!*W.2]LBYLR3@T\"%J[(^V.2%-7&O(Z9VO1 86\2/<OM1+&%
MTD+:9+GV58>>DD,T7@K3J[:0L@H;.>SQF['CJJ6(.WFHO6@P]$*TP<%/\>6*
MLP([SW(JQ^>$GOTW[SB:S4!#'X=];P;:/%>[.AZCUCZ)T/08]6?^O_ES4;R%
M"6']2\Q^0N<"TDE4,:RV$4);=B;:PA)N=RI_LJ)-P$'WO+E/SBPC:EINJD>[
M/]N3-CMC9FZ]'H[E6Y5"W$JJ%A_KRG4OJM'2#8D0-%63>T%Q7&.I3TN'XOV\
M!Y.]<S*E>W].L, 2LD\LX<@-D2M^3:0XKSKU)PU?4E7C$!NS]"ZQB=1<9Z>E
M\!#(KNE2N/JQ:WON&)W=BF./L6+J?;K92+ %CNI%_6D019$W'*,A=-(+0[']
MNH?O#8!B]6=##V/0]9>:VP#1ZP^"T0#?'([0NM6R .EU3%,/066<3(=(3$=#
M$!W'?7=JVZU=>37LAT$?:"VL&HV*:+^D5_=<T^2?_)HFP60\\X:37G\(US28
M-5\3&A,B-,A;5V#=$@:.(V$8S- :>, =/0<>^^X($R9'<$=3!!E@F+-G[V@L
M=V2[:?ZAKLL]**08SE4IJ@\7T ?=98I[#_'8U-[?FVL:C;U!A'X3Y7=:47._
M=^:R!@. <239HWYO%#5-;C5&WPLE"_>6FEX-^^-@$HWPHJ=]#VY[R*]*I;TO
MU;.U(DJ,=E%:%Z?)]J&Z07/1W:@W 37J51CUAE-1F)%25+-5Q?8;8XRHZ06F
M>1$'P:L-4SU3,J.V!M1+J+X68K8F.^C5!/."7PV&THEW,J9""]Q_9+=!G>A^
M0UYM1YA8LCBFN1LZ285EM@H@%+1V+T*&.L^#^%==SZ>N%R59V8UXETL-;;7B
MFF6% Y.'?',]OXV1:UV&36**F1_$1#WBH42A*R0 !_,^*L&BD2ZB/VDR(,S1
MN#4*)B'@ .-8E_P[B$[#8!I.J9EFT!]P+TT+V:)1,.M3K\UA, "JA5_;4[O<
M9Q8,$<W4Y"]'$L=T^'+MF0%QT!N$@A.]6:AZ(*L4-IA">>K39]61,:'0\SGE
M-AY$JAYS-)W\UH#_=P7S:H#EU>)Z,;\Z^9'Z;;Y=_+0XN[C$DLK^XB\88KFX
M#OSSQ4WM+5N<MYO$?TM=YS $[?.P=1!.2G_?;U?5K^,LIDAB-Q:$K3\> #ZH
M%L-@#!@&_TX'WG7+53IZRP<IREBB+Q_4_7$X!#T?)K/[C-3<#"![AB!5(K_L
M>V\3.)DE][T%$6/JA<.)%T:AA[&S9+PI[,QVN%NLVHJCA*CXC.!AP.X+A&-<
M11\X\W0V\$8PQ2281AA<@4[N<3 .1]R:UQ1_M6/QI/E.I;X_T)$^T1B,E"!2
M$X*<I6K_MG7I8@5O E/"D033P<0;!<-96"OZ^WYQOKB:G]'US]]^.#T_O;ZY
MFM^<_K30$%![Q=(4YXZFZ"_$6OA<8'$$D'? S#;8_9V@+H2SF<&_@]D(_AW"
ME;5!'9]H10N^+/*[A+)"T'@B?9R\*?""(<#A '20"Z[N7JC^CU:U?2\<#^"_
MD"(37"#LX_]G"J:F,.=H,O3&DZE<^WVKMNX-@B%(>(,@!#D0\PC#6FGXT_/Y
M^<G"/ST_N?BP\(_5:7<:20XM 2,$L<8!3K=0YMKG+GF =>/WSO6KW.^IJA N
MO<4!H<J'O-AVR= D1=!*+QH.O#%@*S;!BS>?3,).M95\R?$3YA^KEK'IXTI4
M077F\*+1R)M&W@C-D4MZG/N)K5),1,!&7C!JA(,!F,%3UI"FTG=I,72X>Y0_
MG/K>5'T<M^BAA! -@/X-A]6C/[NXOO8O%U<<MU_]=A$7&ZHA? F'RM;(;^(<
M:+=T9\+N+J#D9)2O85)SR7?VJ&JL&>]!3:PQH8,J[LY23428H<06!(^>_U;B
MHC'/XK>94]K&D?./"N!BI?\<V0#6(U'VS(9Z=&(P;!A;07O05.\!VRA$XWXW
M[/M'^MKT+H\D#-8:U#:2N3F,5!Z=2^LG5ELK90FU6) *-Z\<J:Y))]*-1(!B
MT822FC2BPXO;U)E*>"H,/S8U@S^KCNZ]ILA2GU(\V$&U%3_4;NNL3U2#_\U5
MD)9BGFL !?<BOEUD.9=!@1P'H^D,E.S))/2FQ-6OI8:+^#AXN;B;/2L)&A9^
M[!H$AD$?M'S@1:,1&56G>A&'C<>A=^/>!(T$(,R?6HT0=#-?#;FZ"");'AJ1
M6!Q^U*L[H+AJT0?J.645F&J&)P4U',<E'2]1K[,AI??-=W;,>-WQ3"E"585?
M6X &%( W QX]'<Y 3!J!9!8% U# (CC^24U,NEJ<S6\6;_W+^=7-:5TD4LE6
ME]3#[,:V\3_')4<DA#NC8VJ5D\LEQG**@?X*&+;E9@-BEOYVZ'Y'5F^33.+V
M&R:CF+#$P;#O12"!1" =MXKE80CBS 2.<!2!;#W@_V9][XWGG @W3Y 3(TDX
M^05[.#%]N.\JVVE7!4D2;-DKQ5UC%RQ0 @!&QA/O3]2^8\-6OI1Z'F_(2Y"L
MT]W:QR9-H*^#,D"O3#TX@M D#G []GWUO>)-M?_ZC_$*3N%/Z7KY\.3F;+%S
MU?E>QP!QBQ&V3:[7NTVZ--L%A??Q@5Q\W%_8-!VMI]"Y^<9<MU/U;KI+=&G.
M$),.^O[QJP&7Z5$9,7;!7?LU+I"I\H!@6AID *H>#C+L8*()L1!9&!$9$^#D
M+A/[2J;W<99NY1@XDBO5(1F4:62?DU6?8VC7N;*.'@,(5/^P5=OS;5=H.>@K
MMUE=:,.%?BA[ZCI)T"(C%]PG7"1=WPZ[BI*D>@<"&=6PDXSI<?\U(5&7RI$5
M6,WR&#O.<7\%6%<(VA9PEX(),%U()ZC<:HDZTI.^6&0[?+$B]; M8S#2+^14
M^W:=R,B4[<W)NNH)U4^7BK@&4QHOY%19IRAB?0D\&2UD2#78&3BL(ZHT]\3#
M7^T$V#$Y-Y"BT]BCQN K%M$%#%</-5,!M1P@V=C51_<&0%-62XXKY:::3%>K
MA9T-(5:EREI#\W0C10+VI:Z*8]1J[)>W=DB'^703&13"GDQ^,Z6L4QEF[7^V
M*@U_:B%U>98NGQ3E)NL8SO%S'G_64.WZ8#'FYLYN"BV1HE(R2#:C>%A@^8/Q
M\TH/>%V>%4@N%G=-5,V$U&[S:(<;I(7=9%/E39)!B,Y$TY/ZX06,.W3\$L.&
M;5E2KLIKCE57)!<<H1>D:Q6A[(9:.)J>0,;MO;;J/JM(0M/T1TH)F7R&<6-9
M/KP8REW#3[_YWNJIYQ_?7"_^ZR.9 ']JZBQWO;LMX:@1P!>?#THC'V,:>758
MIT+%L*E"Q:'UJX!O) DWH9KU3GI1[SCKU'?UX</\ZF?_XIU_??K^_/3=Z<D<
MEC(_.;GX>'YS>O[>O[PX.ST!X<L_OL1#P\Y9U4$^<C& A0X*H_JPW&-!\/&=
M[E%UK4,YJL. ="<C)?9(C^Y(C=VN;CB$[=GGF(DC,E'8"U[_^_G\4C4,=^/D
M "#6\:?$6@WA*)(>%3F&:D/,<CJ'O&$U<KP601!,X)..>?!J9KJ/B6)B5RFP
MFI2VO5-##HZ*K&_4])IH6I+NZ&S79;&5;W[)CC;UY^S0Y6QH5.!WV4K,.$IS
MSDOKK&KX<\D%_Z7M.TJG $YLR:T^^J;GN4\O[:?MBAA<;UZ^0QV^^=))%VL]
M+-^MGH!)P&3_VE(-5,PVQV*E7(0A7:6 EX'U/&8"!V@'[+UX81ST)B8#GV*_
M_21+K0A'%FVZ2P61MKJ :[P%X0"-:+73?M<"_;!:?P5[BHL:^IV 9OG\6[4N
MLZCM/@&?9\LK;L0!+Q)VX[_F!2)<SC7RG>PE'KXGX_O'\A/8SL?KMQW\"1(/
ME77.2--3<%^J_JG+E/NEHO2>WF'AWFV&1)_='Q**9A@;%6, J<ETW_CK;G4O
MK;M1_-]N==5=7HH;/DLE"#9+*3.D&A,&U"J3!'B.YM+AP-J6LZ0B46G\?05.
M;F'Z9&O53C(:!_7.S 0=*QHI?52OJMP4\4W&7"G.'52@#BVM?+/.F>RX\32>
MLIK*+AE,=!'D@[1442_V,IQ4="LFG)/JV2%SNS7F6Y4%HY?R@R"@ZUDD8FM?
M<[7'NGU#%#HGD*@[G-N;O6FC!FWG8W6N9K-/#0@JZ^BY!@\;7^$ -KGH4]84
M58JP%9%-5U\6(H[AX9NN@&<K4;",G*#NZWZC* /+="WE=+4UGT@C&ERG S:X
MJGZ<)VK'M$.V:XGIU5J.?P^H(&P,5*!$BJ28Q5C*1;)%>4>6[I</&$4.^+*N
M'=7&[-S"_YANFYI;&J-;6TY%;+=C5=Z10I,E*NA-,?F@Y&+B9*VZ4(^[F9+O
MM-+6U&__1O$A^@*6"$HH&HK1)T,Q'>$/CF<&'[F--Y^4F4Z[;A[2>^H630TP
M!;.-4AUO#+@ $=PIPLO:(V?O<*OK0/43P %!N$>]#A[D<4E;4E91;"H2EVGV
MI+J[,!A]V@!CM 4+W)D2/1!9J7 ;[":1D@\V[A9I23'*XA:"S7+7XIIK!C-?
M]=[Q0-0)^2V?,S3H/VB3<A(IRQ/KG,J:8_T/ZSS(@FOL \AJV*F"I*)V3?49
M&Q 7PR-LLEWMWJO[AYL,$-O;53L, JX[+-?^D #7J/+P9M?4.P%7ZSTN;0/3
M;=G/P_J0JV80"W"\<.C:PUNS.E<][@J\7Q$X5WG" L&.:AVYKZ*6129P=!#)
M:SW_'<F.4C&>LPCM12#TD;F C06U-MA_2XJ\2T$H2Z%IIA4T/$^[K;^UU,=A
M$T]J,6U]QT<54+A-G%$PRSVW3F6[?5J:I!SXF!W"*&X4R0/:4ZA',1&78WR^
M P-MTXR'71%Q$]T!F)PXLIHXIX[WDJO3J,4&2U8#];=DO^).5B2_RT$SAQ7*
MP9X%6-\/'&.$YQ-@&!-<'<<M&I3F$TPW^ATJ3^9F)*6;QO6>V +PM2-N7QAB
M3#ZTE,Z.:#;(7YDFVM7+\$70L/U[<I[".MP"I 3#=1C1D!$3AQ+E30@2FO#0
M;[<TOF@1)\QJB(\]JG)Q%/CRA!5SQ':&@6@NUSI/ONA*0-</R:<DVU-A>.N(
MV*Z+5,%RHOSI2\/+V1<B0HE522_JA:88\PT)=<HI*NT0M[4N5,PNRO2K$$?W
M7(TP\=#4/U:-WB!?U&4++#4QC?K^L=6V'> YDY;M2LLUDSRD<$'%\N')E!+E
M<Q,AHUY*,)H&&F2MWO /TORC&ORBQ%&B%\H>J@/:J'LP@:_3(_6F\21J>>'6
M5:J; W1N" .DU3/C5#8 XN-8XYND8RU0T))P54R B,AM'<.!Z"*.=*78/P4H
M*^2N2M2&.9NM!69MK\*!;QTH7_=N+6E$^1Z">#2_.#G%\E=U,P$>KJ@)*#U1
MU%8MU HM!$T/^BT?([TD<9"8,[-EJ45I+WEE!1MA(J'YB\(G3(H4-[UG(;.(
M,7ZB2YW/ULGV(5^9Q#"3YPFDZ&Z'$?&?35DK9>?95E3%>+,A8PN* ]][9\GF
M'OMZW9DQ[A(G+HJS]3#DM_1>J\BJNQWP%*);SE%X(8CR0V\"\KQW%M_F\"JF
MB)GO!UV,V^L.!N1KW6U5ND^\^PKP%+O/>H-!]6Y. >+30E%P[+O2/:.BI7/:
M;?7Q'WN>^T:&;V0I%QZ@\W'UY?KW+/Q_3I,OB=0%,P.V1) ,)()D;EBE4F+M
MU12@1I? 0#F2I;:7(Z(A"5YVPB9?%" ,WUBF!< 6(OR2/EBAYS'Q=?[<,BX*
M2O\TM K-]N0WP=Z&_-M]D>\>.R0*H6PEX;7(I:B:_Y7Z0Y,(.9;:"!R;^Y!D
M*^4[(S*BB?GM$_;3(GM)6EI$8,\JE7N"&>1NHVI#)RO#+6O1P<94)&75>,$]
M_U0*X5GW6DLMY+O%$!M\T[KI6N1Q96L63X"_3%9YP_8LW 0^2^ZA9D:G%O[-
M[=1 Z+*V( S,D:[J$=(MD:U$U0[3"$Y[K0F0/(K_S->BV2'K(V;M\$JI_(P)
M0VN I.R)3;@E!S&AC%&BMS"C7D%[8I']8S&E-;2V6P*U):_]EF*<.Q)"*B'/
M$IO<L@6:1KTO^1,ILO#W'!6CJRQ7BOZ9;L<2D$P?L%37=>M+OA$3+DQPNEGM
M2EJEWQJE;H*:I<9D)=09ZUH6#FP+ 6'%R8Y2<#W A$WWTM-.2P%E:CI^TK4X
MUX<YZ2*#Q:H$O&K(VWJF1@ZZ-E.*?5>$E,IXY(?8"V3'$D-G;55?C1-P0-2%
MI'I%6=!KGIB:O)2]EO^5GL*Y0%IGP4\%JHI?@]@ OL,Q>SA&Q_*B3=Y@",QM
M@AH >ND+4VGV[JYD:>*^ D,$\4Y4>[HYY!AKFK_Q#EF27?6I/V* 5-.#CO0N
M^B&C";4B;WZGA7>BP([5^OTC/1?:X-#^9P4"V]HQ2=ILSKW-60FX)453;+I&
MP$6/ EDL'9!TQ7G\BQ1P[-%')#\&@@+C/1EQJ^?_N>+;Y4Z#;/( 9+#T$$=\
MX,!Q[%?&&"1&1<UL.(U]D]R#GL4:;& )>49[+0.9L=AEJ-F#U+SZ++7@G::'
MEN'?SIPFF8UEBD?.PI>XF%C :8<64-[.,PVXZAV04K;2\%!/'"J"!D6)GZ!;
M80\?!ZL:;PIL HY/:0SU1'U5P#RP+*PJDCW0WL-*B9O"EA6.2X5NG1KK^U.O
M-<BN6B>?":7V-6E0;XU]:RWB(IS>J</J:,-:N6L=^Q'TKE*%;&E!4Q??X>(2
M=IPRV@:+E$0F_G+'W0]/FS%R$DY)FK6#([M<O\?^Z*@2J&45<:ENF7TULA<Q
M=*@S:"SUQ H1FDUI&UW,%L9/J*@)'Y=SGA5%D\^"B\F4/I+BM6J%8$1'+G]5
M.GS0W+#6N<B9CPW>3=T"*<F15L'5\=&VN MJ_;(4:#75 S*^,+U;,@^[57P=
M6(,/@49V57VGJ@;9MAL3?%YRW .>EBX2U7"Z7*)?E)UK-$+0FCX^TD6J"D_S
MZX^ZP!.*J%T,O7H&KOSCF_PQ72(8=KB;:&E7"\D5PZ$EF\H6I;; @(0(2GBE
M13O01N7X2_PW6-*D>[W$KM1E]P-0Q+P9U)2WEBJR6$X<&[[EB)M( E^4W2.@
M,KR.%(FM- DK)J12LHJ68;L]8FFH2LOAP-1#2RY;M5M*4S#'KN.B>*5^3O53
M2HJU4TOF__I".;]U%1QI25._%G2OVW7#K4)[+-O'VUJ6O]*^+)7::5W7.E=:
M.GT>;"I4@G"3L1E/T*-!^@.J<7=GDY$WNRS#R&INP!SVV76ZPGO;)C98X'**
M%!.^M/#Q.4XS%@)SS1IC(\P9VYG4T-2EJ71B&DGZ::7^&A6B8BF>XDJV!=D
MGD#RQ&!#Y2,UCEG!CFI<BUE\QG:72M1B3!TU<"]DDP>IA1;-K!ZW%#^9IVN2
MC.0-;N.O=2'^#"-JS==[1'?[J19A?3)L-'3)!#?X:N^(<[FUB\8-A]N5FC89
M.5UQJ3O;V51=$WHWX:9 C5ZI\%3X7"Q'=G";WI>)76 '5S.L6MF#NHFW$3=-
M\!J10Y@07WXN%@_GT]8B8]U--C%C&0Q3Z!C +/XB^&]%EHA(K+T*]BJK&(N!
M*2!&"ZIJ6;I^3/7%XC8LN[Q9F"L8D4N KD)UM9+V,21BL4Y>FBW2M7.5Z#89
M<]AWQ4?1C+14U1A,0P8'4,KOTBW[F5D5@"_B3Z3E41M5'45\EV;JL!,0$38J
M+,.B=-:+8G6T'T=SD:5M6B3Y.W3Z=[/T$\A)773P=P&IOS-47"U-)E 76X(F
M&*NV.#'.19#%[32V3R]6O="?!R3#*>%@<,8Z( )*E1"1/:ER$$0]M29:E6>-
M(\<:D\@D0%..W@+4QL7M@]T",<*F'CSHJ )VJ(S.F*N^\J'G'?!6DP^Q]#G6
M146Q$#Q1U1@E'F%20EEU#U:C:SHZ9K/F[4<_CRKP:-6IV=J!%KZU>LJX [!+
MMRS'!(9'*[(@Q@@F :0HW]K&*:R<3,Y@H75D THY!%&G0UC4C\/U*;HN<Z(\
M-7F3H]"6) H"FW/X2A?H0M'H("5S8(D^_;1\4"8XMO\AK5;803EA8G?7L<UD
MX"2"_@BRA<[F5*H-"_[,!C"10>Q%?*G$#/1ZOO?_]5]FX\GLA]K/BL_4K#O.
MRMP2M3=LU)20[*_I&M#&YDWY+>I&Q']EN60.3C>U)W>;^K-$+YH67D.,<\X_
M-.Y,,D.U\N=&U^<>HUJ$]?]%#W/G878MBEG//VD:V/0HLT3*2B"#72!<=2N5
ML$PK_%M8!;H^'A'(<XH"=0RD-K[>/E'VDIVH@1)0X,S6;#%9UD]3O <EF]DD
MP9?S1IK#<(0(-OJPJ_$CC468XZ(XT'MMS]=L.I!P]8;K44*&B1(3_S.)2DU>
M'F4!PN"M@]PZ%^36L5^K2;5:A0!!52)[ . _YZ3&4OV'LV2W3N'?+CLV_#>]
M#PT1%8-1G\G<D@)CE(8DAB*3BU5KVM?@RWEW<;7XB^.((7%49B.MS"']EG&,
M[E>%-<!X-39,XHSJ4E>/KE'=QS;)%_]^ES).FFZ:FH<U6DXDU)H5VW?SZS=B
M.,6R*K36!X [(EQ(',L'XA.RE2=]9K0%8AV/JJ,N?F*"BQIB68VYM*%)7=OQ
MT.* JY42D@2\C;UQ;!JSPDF(32 0 Q>V)FP,:JU8*^G[_4M6T%0D6?(YMNP
M&C-ZU:1F7R<UJW6<5-;A38/1)/+&P6PV\<(P& ]F-BY(R*WL3X7(L(3M80DR
M4U2$8UBK^PP:-PIW^F73&&ULM@LKFT613ROS>64UYPY&AUD@=EGD&_A]V9PF
M==GS\'D[R,]Y'MC)1S'=19J=G"6D XFA;CJ,.L),./N8^T^(OY- .=TXS63'
M3+\EG)"1FG 4M-NZRBBRK:+"&35ZL_49^L#6:F!JC+Q-M $59\EXT99^X!("
M$X;%3ZH.-[(F@;14VSA)"]-L@CQSW$I;MUW5V$J6RK1$TX55]ISE(72%K#74
M(@GC0A7H97!>,27T.+='4R=IESG%ULDH\1$9$J?9(ZJ\VZJ/P836WB:95&TG
MQ07>T(2+=):JQ\:H"N+I,URKT1W3Y+D1]B[):N4SEF2 /[(=3[O]B2//*'LQ
ML?_HAV<,R:=K:E0@>F2.*0^J)+%T[7UC=^VUUK0'M ^AZ,>( -17@)NMT$7M
MA_Z4S=RK54$ILB4[I)7UW;60;*Q]V*9GQ3S=D.3?(?HW@>A?DA=[0^T?ZZFU
M2Y Y=UG"Y@$K6.^4U([# A]_#US\[0(7[0L[(2F I(Q%1=KY%LG\=R'MGU](
MN[Q:7,Y/WYHBC%B@\>+FQ\65?_+QZ@HS^.?7UXN;PR@"Y<>G5M5 7#JGD)S(
MSIOC9?<6_WF/^+N1P%? X"UKXUXXF7K3F:<FU>6+HO[8B\8AXB17 QP,O=&(
MRRNJDP_A?T,L\ML?UX_DXG)Q=?,S'<7BOSZ>4HE4+F%XV"%8-&^AD!/>3VH1
MWWNWC?5(OW^6?$RY)FDC[1@/A]XX&A]".:93H!U8&C,*L1Q9&$7>O(42>Y/Q
MV!N'LY9@=:Z<.1Q%WJA?HT:+#Y=G%S\O%OZ;Q?GBW>D-P]OE_.>KB[,S9$17
M'^=GA\':0HD;;]@2+RT])65ECCEI<?8R0+-2[[0P(W9^(/QZ'A0O/L=6N24X
MFB*1H)CXR0O'6$!_Y)UI4RC'R]'* G39[11N?(GO 6#'0#D&8^SS.O/&_:CF
M5N-RFC?SOQS,F,7C8CO$7@9[&#Z,R^8(EOBK1/%Z812,HI$7#H+^=,#E;8WA
ME*(DJ-;IL3R'%6SY4:R:U:W%_UU\^'!Z\X$JA" @G%R0&()4Y^QT_N;T[/3F
M4&'DRJGMHX_^($:V]RBN=#@E%Q^:7Y^>2)9:4L!Y].$_>,J9WAC!X9UZT9GO
M2@I]4H5OO/'(&X01X/+(&S;0:'N;%UH[9.7WH/U9;[&2:INRXF97#PHZI.#J
M D<$]LE#NLR0QD:-W^="K>*ETH%I0H 7X'4UC\S\],K_:7[V<>%_6(!^=;5@
M2&B[;JL)U0<KU?K4&,=_TJ!X@[6(TO_!@@W_?8:BX"DZA6HE:ZS2K&;TZD--
M-EXC?(O4J-VLC@L&!1*4D9#OX_&3FR*0\IQ-N;-&^(''Q&J<Z$8+5@W-IT<6
M7&U'E"FE8AY<L=1:[SGSS@X=TJ=9BBQ-7@2:!>X9<]9"^1E)+Z"J&/2]]Z'F
MWL+.TL& ^EWQSW=5+Y9)I[4W L\?AT@\U$^G,JXY\^,S8VSI6).IEX=!-*M1
M4RI@VWTSOUX@O?F 8L_\YO3BO)W*F(8%<XYXDT8!37!2J7*J1<NR$@8$MVLB
MK:SH**LUFTG@LWN5L*_<C;RKM5BEVI'ZDUIW@*9F&3%F:&0ZTLQH2O6HT?9@
MKGJXT_<-_;=56<YJY^V%L]&7-^+VW6XKK7VY9](J!B3B8>1]H)AUJQ?]E'NB
M1T/LO ) U#>-Y*4T(%9:[T_-)_3>8-@;4T_U";=T"P<1ORB5$M6[5B=X\W(X
MX@[P49]?EN;U%\MM[G2WP:KP[H>\Y@'V@:%AJ+GWH-(*7K<B#X/9>-C<BGPB
MG=>'TI%N:K8]TV^/IGWS";\'4TH/^QGOH+&5^;#CC8+^,*QU,H\B[ M$[X]Q
M7EC>\:#6T=P^M8'SKLQ-/T<\M:ZE)K.#7#6H?,BO]WL3?&W:"_''I')HX4"U
MG(=M#ZN?4S_SL,^P,NS-1G0-:N_5ENK2M[FAI[ITO1]CZ_IQ?[2WM?J 6PNT
MM%:7D?@6PSZ/9.K*J<T,@R%HG>[G,L(TY$:% X*#(8]0QU]N/8+"-K97J6+Q
MB]&V%4\5T$ZH?&\CT/8B0K79I!'H)AW QF XG-:@+L3V5K#7V8"KOKO0YA]/
MX<JH>6P=Z$)&L1%\=SQMO&QNR-UPUQ'1%7QQSR6'HV Z&;5=\ACA;#3E$<)>
M\Z&:CY@>IT5%)#&WHFRQW,:O_&7->Z-#^K+_XJ[4_P -V0>_<@/Z?7,-31=6
M$+!_A4;8/6_T*R_?OB@L,,--BO]QKFL,1\BC"QUVTE(87>ED S\$(A$-(N>!
M43^8S,;R@-TN**@VNF_N'&WJ)'!55'& U/=!AEC=B=<,ZPIW5C)ISYM(Z6F+
M[E6+L]H!*RV-LKD+,(T^#L(A[U6%J-O=A['J,BF5JTH!.;>[^%8 @BK?T!W^
M6KW&F4FHEYTF6"WMSJT6HZ:\M,1'/NUM"O^+*=55I4'XKPG[#">I&OJ9IO2_
M MG8>U2_#JW[31N21R,N.?(J'$QU?E/UG%HA_->$Z6KHUB]AP5.B!ZXX4R4(
M3=44&\D"BT#8/H92.-&5P^[MCU2/6657H1BHTZM:J>!WI:%C?-.7%?30%TR(
MU]J\O9*,Q-ADVJ^#\O^:_-QFZV4"-%,EW2)KLCK!J];%QZ!, .9B[EE'IQQQ
M>Q(S-C\\ SFM_[KSVX(KR)M8(+%2SD<G([^\ Z!+O_U5NN(,%JSE_9G#2UNO
M0.%+F=AN=SOU$N/Q)9$ 1UUCY4.7@+4-3F-3.A<>=<^;$40;Z7^L0M$I5VLK
M+,&J+DOF"U.>'SZQ.=A^%A%H7HS)+A)>[<\&P3 <U8P=N&?AG$0W=)O<NN/=
M=@_%1;Q.R!OS4<*/T>J(1V(9.,G42RMILC(]FC$8$0@85#0SUCIX4M @^8/H
M.+(::7YK_XU%0X89JG!A?_BZ&_:GWFM03EYW09.'7V;RRY5.<B+'."B[D^Z@
M%X[@J[ '#X$61[]&^&L(O[Z5#"-.>_)P#/7?PLF7LYKPCGJC[L3Y]]JD$XKV
MY7?]5[,>F0C#$2C*W5?16*P=X]YXV'TUF.*?N*'?TPI-6J&4LL=D51R*-\!"
M2Q'C<G[[S,-]"&:'4=EQ6 >Y2A:2MG37GO?NE*:M):NX0=.&9W\SRK45K6$_
MJ]T<\WUKFT!Z]M^J[0S9D'\\1E/"!'M;!E%_YO^;/Q=K@'!&3,[![AUHI.?:
M-8'5W<!*?3;.!RUQ[U0#W(J*4R\%XMP@X073/ZS13KV :X7U6SH)?U>J[%#=
M1=CJ'5O-.K6UJ\ DH[.B4*B*]EIVL^WR=F&+@UHJ'];-6.QT_]R]YO?W?%>]
MY@= 1/NSH3?$_NX-S>;#_B 8#?#-X<CN1[^GW?P0M.#)=(CT?33TL-'WX>WF
M^V'0!_(/JT8[*9IDGVLW/_DGOZ;F9N_5:T+["$8TV%=@W=(L&$R1K QF:. \
MX(Z> X]]=S08!J,1W-$4009X^.S9.[+[@2O/TS_4=;D'A13#N2K%,^ "^J".
M37'O(1Z;VOM[<TW4XAA=0<J5MJ+P,JM+^6  ,(X$?]3OC:*FR>6XS;0M4+)P
M;ZGIU; _#B;1""]ZVO?@MH?T:BTK"(7G__Y MU;ST/_>,+ZI8?RW-1@_,)"F
MI9Z;"NIKC&3[O4OX/VV7\&]H$GX0(#W?.;RFV_[>]?LWZ?I]T/5Q5HG*TH4A
M^#@[ORKZ_][.N[V=]T&W=(;)N[J_]P$12;_W7?Y[]%W>=T5S;'3\5K7$OM8]
ML^O5<WYOW;QY8>OF9SHWMZ*0DY\GA@SL/K30#9>-;Z1-,FUM [TWXM05M=H:
M21]DJVK:Q#]IU^B:.:C>0]H^+&3U;=?R?UOWZ3;Q[?3\W<75!PEM?9MLXQ0K
M2G>Q 1THH1(L>:,HXB])%3Q']$5XZU@3[1\>CKNG;5VRHEK^N-OTH\8LJ5N-
M%-3=7^Q'[(&62:(Y#MQM"7'8FR\Y*'4XU3'VY_AH2/?_C_\!J[\ '+1JRU:^
MO30VW4N-&I,9JP^%?39KU"^QDO-8?6#2Z_=?_X+-8E&</9L-A\WK"OM-\S9E
M2+WD: <MDXV^:;)GMC9IGFPP:)I,I7>U97>USO(2V/VV/-+.-Y >FS;4<D9:
MTS#WE)K9EX)9XQY_ETS,7Y!U^>+C:\F6K&=FNUF3#<A-NE<-?:TLRA=E3KYX
M(RJ],"#GR=9-I]Q+U1S"U+;!MO3&;Z17+Z( WYH6^>(S/#1GL;;Z U,7:QNI
MIDVJS@3<1ZPE*=--</PV@B'1C[5L7F?L]M[E;0F/=8;9G/%87Y.D8*9[:J*>
MNN4,JU]'C=0^&C9^^O]U=W6_;=PP_+G[*P[8L/;!<7QV["0K,,!-DS9=$AMV
M4V"/;G))#3AQ=XX3!-@?/U%?=Q))26?[:2_K$%,D]7$419$_D=M0;$_KYE2K
MB7W.HL+;Y'0\;/<)L9'=K4<J>TS]L1Z 'HH%FPU9KB33B4Q7-'$-X1J)66;]
MB2[%X8C<<A,+5SF/C_)_?__UJ#<X>)_MR_2ZW\2_XZ*$_YTN%\C!K3,X9!SH
M.LT@@>;H]'HBD_I C6;JG"G04H/O]0<RHGP!*IHQ$YC#3%!Q*6M\96TL8C"I
MO4;B__9-5[;RWTHG1V>M;J?;(?Z&PD&7\-H@O&XK.\]HX'^LPDV,*O6U*!_0
MU]75KQO&/LL4 ;T!P\PI@^9C)+9X6BP-!24MJ&7Q\THL(Z%!9&$9G4N?49H^
M0L#INEQNH9_[&22K5[7$B[!9I3B(S3[K]'VN'Z.3*?O;V9H^\N+G<9 ;4&>;
M<$12HRFA.I4A:,%P0OZ:OF/_62YA:UG)P45+C3PM>AI$=A;OGBP0NX,"9=8W
M9"O3ZZ>@2U7I7(->%4)G,G5L_C"'AVQJ)<WN06AB"\)MW\(N3I49VM((*M*Q
MJM4_FY)XF6)7\0>JJ^5C58'^00+EAKQG7,=-W/:DE''39ZMP%3>VY++X/&#I
MU8.J[!$7;E(^CRX^GDZF;^691!Q/WHU,>%_=+KAQJWV3WRLF1":ZMV*34WQO
M9QV5EWRL]]F*C?HO-ARO6>?(V?]C3;ZL'X68KK/EQ]H,U_?PA('C L3:7"V?
MK3N=*N?+3.C6[3EM:$K*\XEQIYR=..4@F;*_@1Z#A.[)':#[/C9'/TLQ=AIJ
MCB8Y 83(*C,R]/7:(GHHDC#W*O*9<3]]7>R]H<9+.OW\?+5:*V#:.\11!T'&
MTA@4<&Q7Z)T:-!FOM!H" A%JB(@Z'X\L:MS<D)H*#*)S)+NI92<VCA%<^(*1
M)%J/RZ5Z,U,/:@6H6TL<*_; 7A:WU<B']+"W )&9,,R0RZJBU&50F@NJH!TN
M>CHVFUIF!DAE[$6?&;-;!9 "D3) 2E7X*,B&RT5O!:AW%,DI\I2K>P[G%[R'
MA,;(_W"11GI09(4F^6/*<(]'=06G:^%(_+.6F5;/H6#1Z+DH]X:+Q5*];Z'3
MI#EJ.^2TLL+ES/2:545='!^6L(GJTT)FZ9RD$S3A/JZ^/]MK5I":07@(1P&I
M<A^9YA2Z N)-@\H1DR4,ZBH62H #)H;7?U?C(/C4#1W/0K_)ILY"H64L\1]>
M91$*YWW\\N:-.!4C,+C18[$GKV!?-M2R!CT1,)-GPBW=3HZ;P1%=6Q%R(=3S
M/WGO=BFT@C,^9&%!'DB*^*1&0@G>7"+W0RS@.8"J":]C:/&^HHH( 8^0T+B@
M]R4[=ZJVR2>XAI**EW(.%UN4^G7SR9B1X9;]MJW5?3#1BZ"@9H::6Q.-&5W(
MAU@W'+*3E&G%Y@7J-K?8$#YN9_!X2"\%V,7=0FYVTC,5J.26HE- G-2<(73M
M7BVU[WI^-9V%^9;7#B&_WBO*X'X.;%,:)*(^PB<_YL5=5B4]J0@K'\YSN@5^
MF,PM>RV>:H]T)8B%%)T;L3V.W%735)MO3O&[_RN3'%!KI -3Q%E6X3SU6<G"
ML)8RE&M>GUG57OZ#&S,Y2\1!;[[(!GR$F=;83"T;WR,R5E8NR@_ZA*O'5LW$
MJ8H6;WHY50HPWA)=4)6=TS/@*RZFV  3)+KB*&PWO7Z;*MVI*A&B=[#\4UCJ
MXM93"]F2RBPZ--$&S)>U"1_>EH&A:EDY7U_XV#H *A 7<KN4+E%'./D'9!I0
M58W9?#?1FXA?'2R_L]UM,BY*8NAK#WWB".XPQ8NF&%W.2N'$:Q\>7:]3^&.<
MR970/60@]""BHD):9%30*RC*1)Y&6"X^U"+OI]T\R0@?PP?!U_%V6SH3AYH1
M2F7F&<&I)50R)X?T.")=H3@RLET</8Z%#$@+*H:)F9=>A(V<EQ['Q0(5=F+J
MJ+AU=#@-K&-X7G*C$'+S7+P_?FP6;:!BF/3IK9[F'9MO D@P0-H&*D:M *>8
M$C[09'B:<GYTJ947$^[!-Z8V.Z)G@=\ ML%Q<?<'Y!OM!4(L3=Z)MV]=HNP'
M KNEI9Z37*,<@KQ#9AGUR628/IFY0XM3][=8',EX0.[@+IP,VP6 F4%M\_8Q
M9IBWNPE2:,T!QP;[&!3#;CLGTIL<I!O_5[+[#@(.8U<R+FNC%IO&9YI&H##-
ML&]V\MK\_QF3)]T&.0ZQ*<K<I,)CVW!%RVTF"Z-#$8P@D UKH^-5Q!LX\AZT
MS.Y<=Q]I CF/B6 /:!3HJ(^%>4 ^C($92%# 0VU@9 1P'E#8-(JN$6W!HVSX
M376E1)8KBY<=BT_O%8V[H3K0=E$8BR!=GEO" 4FH78?LT-#19 <^64[+[:?*
M':".D&0L_@AY'&=BBO(WA4=!_G3'+;)4-(K&-BN*31$T0 GH",B$A( %\)%*
MPTX@+D'<">03!(H18N@3Z'.7X *IEMBGXW$IKH0AI8 ID-U*P9)H7N(21Y8(
MU^"&X!_H5<.#,:#8*@47@>:%1XQ ICP"Y=!X]-(P%] 9Q,%=./=Q%]!"C>(N
MX'V& 5\(L*;Q%^@9]($8T&+WP!=XE(4&[D+U!SL=,1_B0R/,!7)I[QPN ?DY
MC9@U&6D.+,$=<R:13K2]Q4V%3="E?S(OX\0%O#B=E>!GU*8W:#J&=>B#4+*K
MR1N!<5!L8_<X&+L@5@,?S5LU>4Q-UI^3P0A94^\TEX1$RM1T42I-LTF;?D(U
M2]_1/4392^#6"W*+8@X@^^_!4/[++.G=(PYPJR\"/,">L>;W,W'&SOZ:/]S\
MX$NK3 %,"<M5[*3<[]+?0F4(GTJP-9 % 2\**,\7F)&W%:I 8&8=8$.](EDS
M^D<2!OWN5"F#X8[Q=($N!IA'.LNW_'LY>X[-F5D1M<4 D )H")OBIL3HA=9G
MQL]PBV6VX,B! A,\]U>KIS__ U!+ P04    "  EBGQ.<BZ^=W("  !\#0
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MVH&TX2!K0ZRNA6XIPRVQ?M+U'' \@NP.,&.-8K0#N<-!=@>,Z9J8D$,<9(>
M87!<34@G#K).@#A(+G)I8D)6<9"M D;"<34AJSC(5C$C85\^??3VE0D'N<1!
M=@F8#<<UA&3B(,OD3#8\E=.<%X'LXB+;Y5P.>^0T,2';N,BV >/8Z$=W(?>X
MR.X!X]@8$YP-PQZW@'&,F)B0>UQD]XSSV'.-R(6<XR([YTDP>Y8/DHW[^V?!
MR$58=%*58TA(->Y+SHA]\DQ,2#HNLG1@3-_$A*3C(DL'QKPTY[DAZ7C(TH%#
MI9E]/4@Z'K)TP% 9FF[T(.EXR-*!0^6HFI!T/&3IC$/E,WW( Y^]H#]\@5+E
MJ(B0<SQDYYQ-E4+O?'MO8D+J\9#5\]S,([E(FZVJ9//=#!@>)!\/6SYGPR]]
MD,W6Q(3DXV'+YRSF<!>9F)!\/&SYG,4<+D[S^24D'__%1CQ!O3^87=V'Y.-C
MSZ^=Q4P/>F,3$Y*/CRP?>&!F]DT?DH^/+!]X8#;"A"SD(UL(')B-7P$ WP%
MMM#3@=E1/F5!ZAV):G-NPX<LY"-;",*D56=B0A;RD2WTZSBRD54KAU>[6O)@
M8D(6\@<+34[O36V+G:J*;:(/T>KE&UENE@WI/XY/=SV_?]:RNR_+0"]+JZB6
MPYM._3Y.KY"]_Q=02P,$%     @ )HI\3C4#30$) @  ,R,  !H   !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\7:S6[:0!2&X5M!OH ,<WY(4H6LLLFV
MZ0U8,& 4L"W/5$WNO@Z;.E+BKPOTL0$AT#GOZI$UP\//=*S+H6MS<^CSXNUT
M;/.Z:DKI?X20-TTZU?FFZU,[?K/KAE-=QH_#/O3UYK7>IR#+Y2H,TQG5X\-T
MYN)YNZZ&YVVL%K_J89_*N@IOQ_"G&UYSDU+)X?P6;\8%XT_>^_0_Z[O=[K!)
M3]WF]RFUY8N*?PNJ\'60S <)/4CG@Y0>9/-!1@_R^2"G!ZWF@U;TH-OYH%MZ
MT-U\T!T]Z'X^Z)X>%)= QB4_"6'-USH"KB/?ZPC CGRQ(R [\LV. .W(5SL"
MMB/?[0C@CGRY(Z [\NV. ._(UUN WL+76X#><H5G;?2PS==;@-["UUN WL+7
M6X#>PM=;@-["UUN WL+76X#>PM=;@-["UUN!WLK76X'>RM=;@=YZA;,2=%C"
MUUN!WLK76X'>RM=;@=[*UUN!WLK76X'>RM=;@=[*U]N WL;7VX#>QM?;@-[&
MU]N WG:%LVYTV,W7VX#>QM?;@-[&U]N WL;7VX#>QM?;@-[&U]N!WL[7VX'>
MSM?;@=[.U]N!WL[7VX'>?H6[2G19R=?;@=[.U]N!WL[7VX'>SM?;)WKGIA[2
M]J4,AW:?+UWR:?BWE]X3N'-Y/Z;+9YRG?KM_HG09MZ1P?KVXS>>I'Q'ATW]D
M'O\"4$L#!!0    ( ":*?$Z;Z.7DWP$  - B   3    6T-O;G1E;G1?5'EP
M97-=+GAM;,W:74_",!0&X+]"=FM8Z1=^!+A1;]5$_T#=#FQA6YNV(/Y[NZ$F
M&DPT0O+>,+;3G?-N-,\5LZ=71V&T:YLNS+,J1G?%6"@J:DW(K:,N59;6MR:F
M4[]BSA1KLR(F)I,I*VP7J8OCV/?(%K,;6II-$T?7^^M]ZWEFG&OJPL3:=FS;
ME=^:CM\;YIZ:84VH:A?.TH)L=+M+74*Z-L]2-63L%Q.^W]B?I_ONM^1]7=*?
MHMGELBZHM,6F3;?DP7DR9:B(8MODH3*>RL?HZV[UGO?!^'AGVM28[1KV94%^
MNASQM:'# 8;*,2?'M"WHT*BAL/_D_QKXL1L*ZVGL?*KZ6!]XO!3I(54#ZQ<>
M\Q&IWSHEE;\:GEJ?[H=]L7X]?#_TPC^+@0V'_[WUX^40(#DD2 X%DD.#Y)B"
MY#@'R7$!DN,2) >?H 1!$96CD,I13.4HJ'(453D*JQS%58X"*T>15:#(*E!D
M%2BR"A19!8JL D56@2*K0)%5H,@J4&25*+)*%%DEBJP215:)(JM$D56BR"I1
M9)4HLDH4616*K I%5H4BJT*15:'(JE!D52BR*A19%8JL"D56C2*K1I%5H\BJ
M4635*+)J%%DUBJP:159]0EF'8]Z:NOLIR;.UZX_Y;/@CR^(-4$L! A0#%
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "6*?$YKQ?- @P(  +4)   8
M          "  ?@(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  EBGQ.CU7VH'P#  #(#P  &               @ &Q"P  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ )8I\3L,H\_@S P  ^ P
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M965T-RYX;6Q02P$"% ,4    "  EBGQ.%K2<'+4!  #3 P  &
M    @ '](@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M)8I\3M4M<I:V 0  TP,  !@              ( !Z"0  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( "6*?$[V[H0.M $  -,#   9
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M970Q-"YX;6Q02P$"% ,4    "  EBGQ.R&CUX[4!  #3 P  &0
M    @ %L,   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M "6*?$X2T\/5M@$  -,#   9              "  5@R  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ )8I\3J1B^U2U 0  TP,  !D
M             ( !130  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    "  EBGQ.MO)"=K4!  #3 P  &0              @ $Q-@  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "6*?$YZH&\JM@$
M -,#   9              "  1TX  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ )8I\3M*5Q &S 0  TP,  !D              ( !
M"CH  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  EBGQ.
M]4U(YK4!  #3 P  &0              @ 'T.P  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "6*?$Y _6%RM@$  -,#   9
M      "  > ]  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ )8I\3DC<3Q:) @  V0D  !D              ( !S3\  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  EBGQ.T4K!Q\8!   X!
M&0              @ &-0@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( "6*?$Z'I32&N $  -,#   9              "  8I$  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ )8I\3N1>:@.X
M 0  TP,  !D              ( !>48  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    "  EBGQ.B!,(@K<!  #3 P  &0
M@ %H2   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "6*
M?$[P:- 2N $  -,#   9              "  59*  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ )8I\3G9T1!/( 0  . 0  !D
M         ( !14P  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    "  EBGQ.8;Z*$K<!  #3 P  &0              @ %$3@  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( "6*?$ZB'E.0ZP$  &<%
M   9              "  3)0  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ )8I\3KLV!#"Y 0  TP,  !D              ( !5%(
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  EBGQ.V_?A
MW[@!  #3 P  &0              @ %$5   >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( "6*?$Y"QG5YN $  -,#   9
M  "  3-6  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M)8I\3I/,:H?' 0  . 0  !D              ( !(E@  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    "  EBGQ.;E K4=T!  #[!   &0
M            @ $@6@  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( "6*?$ZRRWM7#0(  &H%   9              "  31<  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ )8I\3ILAH!7M 0
M 04  !D              ( !>%X  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    "  EBGQ.X8(,8'L"  #+"0  &0              @ &<
M8   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( "6*?$Z_
MZS-<9@(  *H'   9              "  4YC  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ )8I\3F"HQU,' @  [04  !D
M     ( !ZV4  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "6*?$Z87R:()0(  )D'   9              "
M >]T  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ )8I\
M3EC<E=,/"@  /4$  !D              ( !2W<  'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    "  EBGQ.YNJZ:"<%  #2'   &0
M        @ &1@0  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( "6*?$X5@O8?K0@   8Z   9              "  >^&  !X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ )8I\3CZCO28  P  F@P
M !D              ( !TX\  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    "  EBGQ.R1/*&$L"   ^!P  &0              @ $*DP
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( "6*?$[JU=]O
M300   X5   9              "  8R5  !X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ )8I\3LKL/<LI P  !@T  !D
M ( !$)H  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  E
MBGQ.U#@88M,"  #F"@  &0              @ %PG0  >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( "6*?$[= Y^"< (  # (   9
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M.20! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  FBGQ.J1*B%.H$  #&)@
M#P              @ '6)@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M)HI\3C4#30$) @  ,R,  !H              ( ![2L! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ )HI\3IOHY>3? 0  T"(  !,
M             ( !+BX! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $,
,0P!'$@  /C !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>250</ContextCount>
  <ElementCount>248</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-dei</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/check-cbs</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-csoo</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-equity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-equityp</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-csocf</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - GENERAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-info</Role>
      <ShortName>GENERAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-sigp</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-peaoca</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-ppe</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-ebapa</Role>
      <ShortName>EMPLOYEE BENEFITS AND PAYROLL ACCRUALS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-itax</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-cacl</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-fvm</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-sed</Role>
      <ShortName>SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-sbp</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-raden</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-gaae</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - FINANCE INCOME (EXPENSES), NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-fien</Role>
      <ShortName>FINANCE INCOME (EXPENSES), NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-eps</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-relp</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-sigpp</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-sigpt</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sigp</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-peaocat</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-peaoca</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-ppet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-ppe</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-ebapat</Role>
      <ShortName>EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-ebapa</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-itaxt</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-itax</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-caclt</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-cacl</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-fvmt</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-fvm</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-sbpt</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sbp</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-radent</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-raden</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-gaaet</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-gaae</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - FINANCE INCOME (EXPENSES), NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-fient</Role>
      <ShortName>FINANCE INCOME (EXPENSES), NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-fien</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-epst</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-eps</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - RELATED PARTIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-relpt</Role>
      <ShortName>RELATED PARTIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-relp</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - GENERAL INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-infod</Role>
      <ShortName>GENERAL INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-info</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sigpt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-sosapd</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sigpt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Cash, Cash Equivalents and Restricted Cash) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Schedule of Cash, Cash Equivalents and Restricted Cash) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sigpt</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-peaocad</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-peaocat</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-pped</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-ppet</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-ebapad</Role>
      <ShortName>EMPLOYEE BENEFITS AND PAYROLL ACCRUALS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-ebapat</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-itaxd</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-itaxt</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-cacld</Role>
      <ShortName>COMMITMENTS AND CONTINGENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-caclt</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - FAIR VALUE MEASUREMENTS (Schedule of Market observable data of similar instruments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/FairValueMeasurementsScheduleOfMarketObservableDataOfSimilarInstrumentsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Schedule of Market observable data of similar instruments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-fvmt</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SHAREHOLDERS' EQUITY (Ordinary Shares) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/ShareholdersEquityOrdinarySharesDetails</Role>
      <ShortName>SHAREHOLDERS' EQUITY (Ordinary Shares) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sed</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - SHARE-BASED COMPENSATION (Awards) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/Share-basedCompensationAwardsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Awards) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sbpt</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - SHARE-BASED COMPENSATION (Details of share-based grants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/Share-basedCompensationDetailsOfShare-basedGrantsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details of share-based grants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sbpt</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SHARE-BASED COMPENSATION (Schedule of Parameters Used in Valuing Fair Value of Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/Share-basedCompensationScheduleOfParametersUsedInValuingFairValueOfOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Schedule of Parameters Used in Valuing Fair Value of Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sbpt</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - SHARE-BASED COMPENSATION (Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-sbpced</Role>
      <ShortName>SHARE-BASED COMPENSATION (Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sbpt</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - SHARE-BASED COMPENSATION (Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-sbpoad</Role>
      <ShortName>SHARE-BASED COMPENSATION (Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-sbpt</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-radend</Role>
      <ShortName>RESEARCH AND DEVELOPMENT EXPENSES, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-radent</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - GENERAL AND ADMINISTRATIVE EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-gaaed</Role>
      <ShortName>GENERAL AND ADMINISTRATIVE EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-gaaet</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - FINANCE INCOME (EXPENSES), NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-fiend</Role>
      <ShortName>FINANCE INCOME (EXPENSES), NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-fient</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - LOSS PER SHARE (Schedule of Loss Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/LossPerShareScheduleOfLossPerShareDetails</Role>
      <ShortName>LOSS PER SHARE (Schedule of Loss Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-epst</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - LOSS PER SHARE (Schedule of Anti-Dilutive Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/LossPerShareScheduleOfAnti-dilutiveSecuritiesDetails</Role>
      <ShortName>LOSS PER SHARE (Schedule of Anti-Dilutive Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-epst</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="chek-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - RELATED PARTIES (Transactions with Related Parties) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://check-cap.com/role/chek-relptrpd</Role>
      <ShortName>RELATED PARTIES (Transactions with Related Parties) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://check-cap.com/role/chek-relpt</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>chek-20181231.xml</File>
    <File>chek-20181231.xsd</File>
    <File>chek-20181231_cal.xml</File>
    <File>chek-20181231_def.xml</File>
    <File>chek-20181231_lab.xml</File>
    <File>chek-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001178913-19-000985-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178913-19-000985-xbrl.zip
M4$L#!!0    ( ":*?$[-=LO^+BP! **F%  1    8VAE:RTR,#$X,3(S,2YX
M;6SLO7MWHTBR+_K_7>M\!ZYGS][=:Y5<O$%5TWV6RH\>SU25?6Q7S^[S3]T4
MI*3<A4#-P[;FT]]\  ($$B"0D$2M-=.6!)D1D;^,C(R,C/C;_WZ;6]P+=#WD
MV+]<")?\!0=MPS&1/?WEXMO38/1T=7=WP?WO7__7_\/A?W_[?P<#[A9!R_S
M73O&X,Z>.!^YKV ./W"_01NZP'?<C]SOP K(-\Y_?WK\C#^R]C]P\J6HF-Q@
M4**UWZ%M.NZWQ[NXM9GO+SZ\?__Z^GII.R_@U7%_>)>&4ZZY)R=P#1BW=?7W
MFW]R@BCHG,C?7KY-,,W7P,<_B+PP_*MXS4OX_T3U610_\-('2?J_)7OQ@1]X
M<2_\&Q_^8Z__[6WL6N@#^7\.R]WV/KQYZ)>+!&.OTJ7C3M^+/"^\_^\OGY^,
M&9R# ;(]']@&O(C>LI#](^\]83@<OJ>_1H^N/4DZC_J0WI.?Q\!;M4P(W/#\
M&B7X5]./7T@^K+QG/Z8>1;F/JNQ1%#UJPLQS'C0NI\[+>_P#?E[0![PPD(3H
M<1=."DE6W^-?HP>1Y\BBH&WBCST1O1!X@RD B_B%"?#&].'PAQQB\"^N8T$O
M]QWZ2\Y+MF/;P3R?+M-WW_O+!7R/'QK@IZ"+C/B][2^E7\ TD*_SJ:._Y%!G
M.('MN\O\(0E_)*]IF=<"U\6ZI.B]\-><%SW77Z</?YE'V@RNX(T_&#\&!EA@
MK3"G#PLB?C2:MP3K'SPZHQ[AA*/3Y,.,@H<T,XA>N'SSS(OP9R*27RX\-%]8
M&//OHZ;8/#8<VX=O/H?,7RZN\=LJH8T7OC\[W^DG01RLNH_?@K:/_&7\;?P]
M,LDO$P1=CA()4R,;B>WJ[I\7OV*%(J@"KPSYO[W/OKSJ[GUN?V%O"XP*QURG
M D]OUR>J\-<50U%+J]_67L/*>O42Y7O5O9EZ)?H^14#T92C1S6)64F)6CE_,
M2ATQ*VV*^>YH\<L6*#\'B-$OS4CHUG7FJQGB.ZO^OAN!YSOS[U>.[066CPVI
M6PB]+W ^AN[!A+D"'IS.84(*\4\F)N9M82$#^8Q6SD3X2687ALO=AT=H89"9
M#QB@RV<7V!XP?/S Z UY%[\2)?HAC^N_O<_M($G<^WSJ3E*'A=#1$M#1>NAT
M$#I:'>AH>X#.!JWS3[C\ NS/: +OL#1=8JL_N'".@OFYP&B;!'IM5!%29#:.
M;/,1HODX<#U(9,)D%CWQU;%OWJ 1^.@%7B,7&K[CGHW:*A;/=J0U0(GW:9G\
M)4'8AE'IYT#%%;F? _T<.&W3HM"!L0G9WY]FP(6?@ ?-*V>^P,,%R'B<-.Q;
M ENS$W+3N/3*OZ+RWS0!PD?Z>=#/@W-< 'IL=\2@.#&]VN.J([CJGI[:CJO>
M!]9I'UCW($66/BFU]$DAHN[F<V@BW-,MF"-KR<1T/\'"!5.ZR[UW'UQD&V@!
MK/M7&[HGC;!<]16]4U-4!X6B5 >*4IM0''GW$QKFP/ 7"O?[_62"C'-&5TH
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MIROH^@#941[J$_&AM@.<RA20Y3]E[:P-0[.=/B.?[&3O;!.](#, 5C(Q6NY
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M6T.R& 9-2!9;%W@BQ@$&CW"*/+(?Q$:CB^?!_60"761/0X)780BW :G;\R]
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M29F[$NK1@J!6=*>F)"LF'CW#S:!>DEM7B_'Z\!D"#WJW 0F(#<LPA)$1WG4
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MAN7NOD:>83DDE?<SEM4GJWRMI8M?_]/R/YKHY3^G_L?P3\[SEQ;\Y6*"6_C
MC1W+Y 1^X;\7+D6%>T9SZ'%?X2OWZ,R!_8Y]\8[SH(LF'SG2Y0!8:&I_X"PX
M\2](NU_OGV\XX3_!?/'Q+X+*?US]Q0WROEW]]=O-UYO'T6?N[NOM_>.7T?/=
M_5="Y/N(X+\(4OA_:=(M9,/!C#HZ/W"$[HN(O[%;_ SW?M5HF5ZRS'[D"OJ-
MWO7)*0@-8_JW-H&FKL@\%%5!%N7Q>*P/S;&N&K*HZV.H7W#T?O$O%]=/#[>?
MD><_DW?QM]"RO 4PD#TE\1KT\P*89O0Y-79DV+:-V"LR_1EYE/]KAE@W_=&,
MV@[?$/5+25GXL63?^V;!"QD@;:/H!;H^,H 5B=9W%FE@D6PB:+*,:4]2,KK<
M3,O6QME ABV#P'?24BF>'U6F1L@!;?HWK"=<8*TC+H>/]YE!>4\1U1)J.S1;
M)$-355DW !SSLL(;8 S&)H 3#0JZ"030_=FBJ)=:YR;+3\+/>YXMNTR4JQG$
MZ]H56'"???.2^\EWII#$C^+N_1F'UW/N=>98UG+@O-H0LQ",/60BX"[?<?@Q
MCJTJNBCR'\EZ#.SEQ<_<*_ X9!N.NW!<$I#*D?+R+GW> J\>YTSHWW2I)1_N
M/!= ZY)[QE^Z<;@YAR&%UVCZ.*'#H9&/N&6/$X?<:#P&W-\#;X:XT0M\A]N8
MH"7@))[FW'L7M;DW!; :B?I+>F*Q;GONJ[(HFI(BB#(09%V6@*3JNLJ+^#->
M/A6UG_OUYKYX='-_$,Y];H9G+2B>[:N'OUT^77)WMG'YKM(LOX;X:VS6<X[-
M?0%+3E#><=AF5OHY6F3-2J8J:88RGN!IR8MC71?'^ \%2L98YQ6YGZ/UYJAT
M3'.4K(GARDI6/H#''-F4.L\'4\C-H4D^<7B63FT'OV>0JR/L>9-%@9.XYZO!
MDP'L$+R:_)&MWA/D>CYG@(476'! PUPX;XF7WSDW<5QNX<(%8.7)!Q,69F,Y
MY X8[@^W9N#9[AGX>Q+H@BT'W. %ZR=LY.+G2^Z;CRST;_( LFV'A4US@>6[
M8& YKYSI>)#[[X&+]0&P32Q3%UJ0YH.8SP,[3 .%A6/,;-SW%!&)D8Y"FKDI
MM?-]8A;8F.0Y>YZ\,F-N#B=P8U6$;*S-8/2),&-SQ%3QN06>1[@-&_@!WC58
M2V*+H'2;^&- Y.,['.:9Z#1L;5QS<ZP0DPV^PQH4&3,.M^)@);B8+3UD(&![
MY$7+<7XPR3K6<N%1EAUJ;8&Q37JRD(]9O,2ZTL-(8+VA^<)UL-!(%PM,"TGR
M!=\6&#80#P%M ZMAEU25IL^\(@M#!+\=FDXVQB,R V!1$O" 8HR@!6$ V=C<
M(I*&6'.;FT:7"3TUN/C5N4,*;LT)U# \_@PP97CI,&A=T#%P,8$N 7A Q.'A
M1>&-C?[8>856$EQD'7D!Y*(2)9IPA"5-?]K?XG",.SA1E21)U<8RV<@9$M1-
MT1@/)[PYEB::H/=67,T50CZF%6+D846/9RH:0Z()N*\.48?#*VR+_C3^F<XF
M]L'\^1W1C+=P[ ;8I.-$F1E@;&Z':P;6F5XPGU.##L_U.Y(1%BN$AV!L(8.+
MBPL@IF&)QQ<_2&T\C_N)6(8_ARO!W<,]W@KBY@Q6,M9:LBTEX![H]1G(/5C
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M!P,O"@T@MYW)?!^0N8^707]&ELN7T)R+@F_)&Y DY[#HUB-4FR ,*O8S 0+
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M=9SJ( )T/, T#5AJTJ2G&/X2V\(#,IX4(YF[L$4#R%*@ .)98>6""$"B1O(
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MAY]#RO!!9+CS\W_\M2K.KPE9_'85MQS62^Q\AB=C0Z.O($BO$X#T?_[O_Z7
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M [%'MPN^/M8)\QF0%)/"M%,^E Z@FF5@DPI8PQ'"Z& CAPT=/]!5W=C-UWB
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M&QG4?UT;[J[AHP:L?!#G_%< M\K^3]$7/Y4B2^+PE8*#.O]13Y"?)>&0[FM
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MTPA5$FE1Y.I6:)BN%LBCT<?OE>[(]LI5+I[US7*#EMN\97(N%^4SS7%C(6E
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MZ214&QW-H$3H"2'4.=Q)J 2H!*C )Z%C8*LY:IK6WR4]JVA2/UC^@S=Q+?M
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ME C+N3^)H&/ L1\?)D1]'(]IPW[:T*BR$-S'+,T6%+^17K]/@VQ.X4;U5T^
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M+X4G-G5NX^=&4/,+@I-7 YT_XX=%;-B7+$W(CSZ/RCY62I (!7"M4,'(T[7
M<VQ#4USD>(&OA[:E!XYFNA!@_'1^T)?!Y0?1+S0HF&9+:-_+U '&K;7PU,MO
M/TIJ9&TI+^<39DQ2)1FR8VBO&UDY+/0WRO/YHLH<BS\E9XN/V,NJ8%>+)\',
MYMDLK9BU6/@P3H)U\JV2/Z=*8XEI!Y:8H=@'37XH\NH8DP=JPFKZEIAWO,%!
MM!RC7-* $P#Q)WD?ZSZ5X:%1S2G-^*SJ/!M6*6SN$9U:E^]8A-@R1N@HIUGS
MC.Y5;K ET)H@TSK4E$97L_?0'B]_Q<-DG5@E$Q22+RT"IU6S#)R6/B#*!\%B
MA\O*.3-*'E:L4ME+08KSLJQO'.'[NC@P^48=;<QXD59+ERSHB,JZ/XNTGXUU
M23:5,"ESI/PX97P>IQ+OO9.?G$@;8R(G6ZZ]E@97UXRHLL6TMT_0DU]/*6%K
MQ<R52I_3!$]G<?J(L<0K4C "3^E+&?V_Z-L3PKQ/X/DY%?G75%S^/D]P"<W=
M\AYQ O4@R*C<H)P7/JSXW9?9]9+&6)ITWU4F0X,.!62X%QG>:-P>:I!6!JU_
MA__\]1OY-YC'^"8DWZ0UG1XINVQ!C&%J"+/RA>]IOJ?/ZTI=+XI!,?NN32OW
MF"JB&ARO8%6-C*&4N>58?51:1%2N\B6;29I!8P8F4G,^&$'>@B=\0>U(3A:(
MJLL+JCK7BC,L:G/-<QS.8[+'WN.%6)8[,"?5"U-:$8$S3B:4Z9T1,NY'Y2-*
M5N0!QPQ3\4+/L;"FJX9K6*YI>F9(\*.9.%2U4(PTB+4(-F-[!-M!T;GE*W5C
M8NN_/&'='\\@?I9OH+5PZ.KD9$Q<IZ4Y8*U\PLEM<<=H12JA"W%+@]^UF.K$
M6D70J:VE;D\LL\VU7-+!5"%VLHZ*6.O81J@]Z*'.]= _J<4*>F>0>N<7T#//
MU3,#5BE=:H>CA0,,3QMT*=C'F_;Q"_..J[^CCOPF#&D!M7">):P@X/+AOBO9
M/_KH^:VM<J$:1] (?:U=]\JBFW6R+]2V@HB;&F0@R]25<FFP"QYKY)\0,491
MD6:/@JB4-L?,6M$OVLI(>E*A=+!>@BB4UE=)-2]TO2N-(MXZC<A<H==+<P*C
MLB[-_&<41T@8]=+Z3M@Z:,%::7^-EA>I,92&Z,7[Q=JU>IVX]8X2T_(='\JB
MZ:39&\J?>L6S\"[9O5GK]Y+; R0:]U:JXJB!;UE^&/A&J)D.1H;NVT806HX2
M.%8?]U;5 7FA,7=BDX6;'4R<-0!AVY<SJ!7B#FLK<0>;WRY(HUZP" V.J29]
M9,<+(39'$5O'-C UE,VJ4_G93GPS,/GIGZ.O'_HC0,OST=(GHY^@BG8,"K0+
MJ'>:&-6U3H$)/+:8E6<&VSH2']?SI?%O-&HRX<',25Y$!2__T;)W08@4OQ%G
M';;D#+7;LJ<@*Q;PV3X^G5.FW7K.OG(@ITF;^TKI2Y1PZ4SL9$,!JIMC4-T\
M7V UQ>I)8H&*"?"Y!SXM=53X'/5)Y3UF27QP-!%(4CLS_?2VHO/$,/T GN."
MIVF."IXM[".[4C $/*ZP0(=V>89W)J'T9HP]?6<CH 5Y6*?%LC';LC#WO&$2
M\U@$L@"R<!JRT-/6V>.YK)OJDKT;G^TK"^$Z+99-;:AMN?M;41=]'01!&D :
MJ#0\X4IO;#WQ,R/*#PW^7J5NW1J3WGFXN*+H&O*0I@9^8+C80;YI&H'A!:ZO
M6I;52[7GKL+%6](P$*TM8+3V<<H"0[QVSPMWVE&Y4&<=,"1*9/=0P[C%\@A<
MI7FQ@4'S>3;[<4X*>PM"[Q==''$"'4AA1;I=D5&'"79",M2[SU[ :P2!+PD<
M"!H$? J,3[.O4N/"WEB)>SEU1)ZIWMW9 GK8Q?6?6P9$$ (^!<:GUI?5(^RI
M96 AA%T1D$$LE<@7PIV9H;K3EN-<X&@JD 9A.RV8-.A"!0L)>U*#V$*(IA)7
M773'="%KJE#;)T07@CST*@^JIHU?'D[O4'JYI<XFG$7!^FY/?=A66\XK@:UO
MD 9A.RV6-%AB):[ 6;0M1JM-1:Y916LXG((QWI[^,,P3,,5!&H3MM%C28"HM
M5E'9/U5M2XF4#]-9G#YB_!6S,]6G"'E1'!41[JDPBJTKNF5BU0XTQPA"ST5A
M8*H>1J;J^P96^LATTP[+=-LI[\^TX]I3.*V$-&_/@]M?0C<D7 CA:A W2VX@
MMO"A0Q5BU4\RO6Y4PBI.\IU 'AP 7Y?@ZSAKK^_]H!I&;=,YLY]G+P>H6%Z2
M;W=I5ER0=9Y*N+25)0\G.(R*?/@Y@4?N@;A):+ H BY*J]5[!;R\?%?J#:+U
M,ND>^>SFDKE?,^QGF/\Z0X\MJ97>+ST$O(<1]Y9%M=KRDHIQH0+X'!<^-;TO
M3FB1G1P#N_.K_+N/; LB6TV6QK%,WIS,<\P3/1[0;6O5;>#* ZX\: "!V_')
M&"X 01J$E0;=.@%I.,[N:H@=G'KT[ Y#Y  \TCDI2.=>C(6TK _LM5C&MV,>
M*P3/$"<$#^1!X%Z+)0^6LI^SY&44TOL&QZP21R]:>(]#G&4X^(Y^7C+&Z<ND
MO1B;)P)K:B@LHFN"$)E8TP(M<#4#&1YR+1L;BH6PAD/'#_J,KFGW"#Z&W;_W
MR]LCA?E +(^8UC:07@\_,.+$0V\@OF;P,#IAZNOJW6-0L!VAN]/;P:ZU"\RA
M$!$C?3+/HRQC=W4/* ND OV4XI2<(Z%FN$ W\-V16FBRJ8VK,#- =&00U67%
MT4<%T9.\R?J$\URZ1_&\#%&,X_0!)3Z&>RWPX[>I+\Y;W=/ZO=MJ94)>@X2!
MA+4K86UNR2<C8?WM^F-F)]U#"_47//82+21>K\4Z%UR(I']$B?\$:0!IV" -
MC=TGWA:VLF!^>6:LR6K("J^-GDZG44%I8WIB?PFPI7NFXOM*J!@(ATCS=,]#
MEJVKV LL?^CL+[N0U=XE%\1^0.P'Q'[ I3W$?D#LQ[!@!+$?HU"P$+< L1^]
MR5O5K?JL81S.2B2NB^YK^HAB>IR3BE1"B73Y[?I*"G!.GL)92^+;^^%>0'^#
MN,X$55-&==\.^!P;/OLJ+SZD>!#!R^Y\Q='4FV<YILY!*:Y91,@F]"7# ?9Q
MGJ>9]"$IR*=_R:5Y$A72'3E.X*Q'+I'^[H:A&,FQU(EUK& 1@6J1@# (VVFQ
MA$%7A:JL,22B+@C%@,OGD[Q\5AVAPBTA& /DH=_J5$>KM"Z0/+Q9V2\;427U
M1TL3T/ZV]E;R8XPR-I*[77M<X^=%F,ON^)2U:)89SE!!UN(31CG.;T*:SX#Q
M^RCWXS2?9ZU&MK2RW1_3@JAG@_R13(>4>N11EMB12RB7TE!J!DA(=-2_/F5_
M/ 66+>$^.UK=OY%:(A>!0T[@A*;KZJYANH8;NJZM:;YMFY9OA6;@FF(0VZQ=
M39C/OIIP'.%,5B9K$KK-,/<2,9)S?!<1L8=\U5/T_+96@5W /?0HCM]M0MUK
M(N"Z4*=A&/E8"HDRY:&E?%\!/R^XMEH\IAXK94E\S]::F> >;B;L.MX*:#N
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M<8T=$>/U!7?U_(,Y>L"G(XZ4=A<J;\A.:U>AIQD8+Q2Z /!/ 5Z5%7UP3DP
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M+N/Z^S,V^^.?>XE"$:_78IU0#;NMW(!65$I?;A60!Y ''CJ@'RLS%^0!Y&&
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MBN5B- S9,$^%5WM0 @GQ"^.U/CN,7W#@0A?@?CIP[RU8'. .<.]ZA&IO:6^
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M=R?*<]R1!0%4T<>@BJ:_ZZ;2D]0 *?EI(>T"< 8X YSU:04\P[#ZGA8H9@:
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MM?^![:JMN;=VG&Z[TWGI26:*MG':>_TVMCLWF2]3,LBV)A@< =WM?[]' FQ
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M2\DT[CF7F4WGI3]HR#;YY#]02P,$%     @ )HI\3JL#%P%Z-@  VJ4# !4
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MNCY@M/SC5?(IT8I/YQ>;Y__S8;OH>4T&2>BNUA[A]/41KZ<?W84"[\\WE$<
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MX]7YFSTM7D!V@7^\BG!<PK(*E#8>$[IW#?S$,_ODBNA:>3>I&)::9CS,\E
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M\8..(&ZFH?HH'O3O*HQE;$ X?JR)8WFFA]CH&E#YD>D#NX^$T8EGV2CK7LS
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M\R#65::Z,][(NOB!WTU]8I:X0(OC0U0LW4C;&D</"&=98B9ME;=64W51&(=
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MH8/>$(G0#N&C]F9X8!W?D"_'-&4\JQ.HUF4+ ESRW?),\HZT3H&'Z U;77[
MK:/D;"0F;2/T(_DJ/#S&40<X\&$=!Y##%PBDEDZ  Y9J3J^[_GI#6X,5$$W%
M9W(S"SQ10YO>SYU\Q@ 0ZM(-S-C4@S!IL+V'-$V^,U;PN=T 7 *+H%;4]1
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M+"X4N6@D(7O("8BMXC*]<YKD/EX.?,=]=)W8\MBV)-#\Q5J53/$4T51;-J-
M[)]N]#!%WN9DQH.[G@=]/W*C9YXU5/E!:FQ4-C@<(,5DHYT]JPICG6WB!O5
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M @%.(!P$*C:GG],?] 95\LG_!U!+ P04    "  FBGQ./,K SV5[  "\Z 8
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MV8B;*VV DCZ'N;URIM]?J2S[F>L>M_'.ST9TS]L )3T.TT$_,WGHT1:]<S[
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M,<[4<U!+RBTCI!";C&B( &*$#)>"$4P4E;)C,N(91Q%]3>7%:A/1%'+,!PG
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M_F4Z?U9S:/4%B[=O@8#FI,-K(6ZCE7K4<UX3#N,TQ4'I.H=QGK3]:=!#A!N
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MB^+DP^#+=BG <9+WCA5KY7VWU 8SK7:&++\APM]+9AG.^6/,,J!Q2'^A:5N
M^'UB=>]3O/;"X*HXF2A&'7$LV,B=L"I9MYU=8>,2NDN%]>2V*0F:/3ZH%J)C
MR0MA)IK]ZTLZ#M:\1#80$EH(\C<IO695'R%Q$I\V_PQUA$Q\GSZ"SNZ]+<W7
M17UNWT\WI)UW@]RZM>T*&W>$=*FP?H38E 1X*N@ 7[C*$)=#(\"UH4%FD@ C
MKR@7K7G!)_0OZ<:+,LF8J4TE4$?(]6H=)5N,YSAB]F>/<:$K8MS18*Z<?@RH
M]0$SWPC:DN^X**>(V^=M"9:H8CM4/L^3K1?1RA8#W[K91,5QN:NJB)ZQ;2W
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M?D+\*JZ+4J(,PP@JD]Q\S/!R$]V&2Y7AL]($D9!(K(I51J*=VNAD[(Y5V++
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MS(INZ61;D2:S3%J 2&8)5=@"($(PR-8$G\UQE;=<?5ICT!EG*:>!+U_-213
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MHC X&9\MI6M2N2C %:D!J+0?,A0R*4"3M.BX<*0]^*?:@@ XJ!85M?!0-:7
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MTM7IN3608QK ^S?T0/ZT)8K1]WE'KWK;-)3:R./JU"A@@-EA'378N-WU)HW
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M<^)A>9'^P$8AZY(M6KAURD@%P?!&AT[8>F!'@\0MCG,V>]"')SF.O5@?\GS
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M?34*8\G@N2J.>\KW0XHC8;4H,(Z8<.K/O$H5JZ/BP;IEG8;1(GS-GU6=T1(
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M*5G24XOO9<VS(O^/KS]E>0FI?HL2;,_'HOK]%U_?RWQE4]_1IQ'#.!!2AI'
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M=!#9IRD]8K(??1;_)1[K1^)?8##%D_\!4$L#!!0    ( ":*?$ZSVIJ/'TH
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MQAPI^H#6XQ4.H"<\]95/YCTG]*F_C'+$W)$%=:DTA$_=%PJG,2>*-IQPCN!
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M![*'8-=\..QHG>6KZR?F EMI^%:C//S4&@R*-1ZO4@.>G?]Y:?\(&+Y3"WM
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M.>MJ3\AWI0SK.O;,Q8:1:E;Y.Z*+:]Y<V!K'18F>Q@B):7SA#.9UR;^IY/<
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MHE*8BT<?(_2;.2PU],W_<6T_KL"D<*N\^IQ^@VOM6RQ!K+^RB@H0MU)M[E*
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M&<CVFU^W=_O5':^&3OSYQ$S\+?S39QLN@TN:9;@B$N-2( .@,HJ,W!D)5ZK
M&T/?/-LPG'8$URB2B"06$OJM%ZJ-KQYA.Q(ABKVV%CN5A'U$3VLW5_SC*.KI
M/3SJ*<_13A;*B".:Z9+&6)+&&!2SVO62N;"_C1;%FH,)F>"4QJU^#D?T@N'T
MQJUR#$FJXW9H*MU!U Q9U_D0#I$SJKYU@MIU6(@D=*[OLVV03!ETR<X_R.8O
M#Z23=OK\9$/*#AQ1>H(IJL+M%-UP0 T081A@J,+A)HR5C W/S+Z^(UOB!6L^
MU<RB!*1W4'>V?7<)DLERL@8H5W"<#3\0GX2.Q^;;G:^H3[FY$],M 0()[&[[
MDJX.E%J<P0%FMDN0>?4FHGPZ".UO*\C%E*U3B;\>,\_]?=;.QQ X A_#=W ?
M0QKCV^FZ3%UH_'IQ+V!U+^S60Y5?H- .AUEEYD!?(!7)2?RP<P&*"%6TQ8%8
MM;R)$,!W%CW+9UPZO+\\X+H\X'J[#[BLIB(TEJ?WA ^Y/J-,A+E2U)/ \^Z#
MD/_20(")XGN63UIBN\-<Z>\*?K\YF4)<=A[=I3Y,0DY?B5[OF+].' ],G\+8
M?@JJ=G-W(<[3BB_JWX8TF\C=RG/E($BF5L@;ERIKEJD]*M@K8A'5&^5L8_+K
MR%X=!ANJIB']-L^:1:H,--X5U/-LP]&U8 6S Y7EQ2?6CZ(-F=]MPGURM,KY
MIX& 0;@@M%H@]J9M_3'/-M:[UN[3F/GZF\S/Z2;CDR5WY=K?9J0\R.4UV>?O
MK2MX@K'.-D:[=8&3,OL-"%I#1F>ZMV&<ZOJYW.A[Z\^<G0[X]-D&EMNPVL%0
M7J3>IF?EC^LS\ %CDNM*#K;B7>GY;T"64_L[U?CT05' ?W1"$8?/P':UW+.2
M>UU@+\JPM_#XE;5IJ:_XE/7ZQ6<EWT*L+H)\A$3!HW94\86CM#CA72-X+M9K
M3]NXB=1$"HFO[#3T6Q=/! 6\+8J:%9G_S"Y!A8$SD I&;2E+FY.P7J+]?!2F
M?>S/9'=0$;ZCS;;<:\X#*OKG<+MG6?1K2<"92']3EZP=BZGAM*"Z<0[7F7;M
MJ%;DXVVHRKD<(S3<]U?G<+UZ%@>)B\=?SS%L1X.:S@NJ5N=PW6M7K=J1D+>Q
ML>3<S';4 CP!J/R?P[6P7?G7Q/RRJ?A1=SZG_"^.=W@G#7C-;OBS4)4P=V-\
MJFL$$/\1K<A/:E*?M)>)">&O"=G/;P,_(7SC>#P_ZK5" $\]&?!K$JPK-4S:
M6LI^VQQV0P\$3D_1C,U'5-/8VFR@THSVJ9^6-%ME]5M:QL5&EH@))A*6-YD,
M5/#17@C;6,8;P&YR&6_ Q3Z;+?4CZJ:IP,4V[W[I,/ QJ"R:NVM56KHFR4>W
M,+9S##XF]R3.Z^(GH8+5_DWF">3%F#>Z&KB6D_:=H6RK/8O=Y3),WHF<2O8;
M3 FJ&^W?9)Z=;C0&_HWH3CN6TS&+3F,7E[X)E?[VKS'M2+]1Z%I^5&<GGVOH
M\!):>Y*.\KE^7\SG.NE->]W)[<=.=WC7N>O]VAN,Q@^]X:S3^SO/[=J;_D=G
MV)NAR.5:G65;[=U6]6OS%"/-!"ZLQ,*[@GKBR"@( R)_X  1USCK:BU,2@<E
M+5P&:+*M@MFLB\X 74;6-U<=I"9V$,IP9'.]%/K0( M+VM1+H8_S+_0Q=3PG
MI"3ZS5DFT:FCQ8*Z)(SR!K3DW +J;2M;J=;657V@T. .#CR1U?IH7SF;@VJU
M@H<-%=^LUQX38B7VI8;6TFFVH+G51)NZF]H\N=EM6!#RA>(V\*.-%SM^?$^(
MZ.2@[&4MI60#_H,(P[1BWA'&5I<F3!T&_CH,YAM7ONU)NEA+%]E<992,P(%7
M=Q6$,?U7,LW1HL]XZR\I._QTHXC$LOH;BG[6LC>VL*.!6((#OE'\3$)>A2>[
M9&#TC=:$/XCREV+PY+VLY4%L#AV$'88V+>G$1=F[E13K9>)N_Y%'PZT+SI3Z
M.;*#V/&:F(4"/)/'YV0^8=/V*V]B>:MB(VLYZAKB5$WL^><\E+*DID/%8D:V
MY@LDB"&MZJ*=2SE&*Q'<R?U0O)/[T!OV)MU!<B77O7OH#_O3V:0[Z__:V]_*
MH;B04]1*5=_,@0=H=1V5?U1Z20?LB\,QK0G/T?(+H]/4C9WJ\Z5%11.F :I;
M.RV!U$%I<+FY0XO?Y>X.PQ+Y-N_N4%5W1W5_=X;5W=_Z#9[V7G^YPSN'.[RF
ML-:^Q;,([#@,%B2*DJ=<@GNAK&FYI=6[N*9@B0C' <N ,.EAM$TX/SVE>@F:
M6[VL:PJ0E 4X4'I#]W1-T3J3FSJ+5SUF;NF:XG:*RYZ3G!!JGPTLW]4U!1#(
MEC?@CEY0X1.1'XONZ/O^L#N\[77ZP]O10Z_SY<X'_16>IR&)YJ4'PH/N 1(?
MJ?I9=;ML213SDVTZO[X?$R8&$F+$/2S7DX>A4W*TR.G'L9#N9J5<.$L-;;M/
M:H)22:[->UE1]$/PZGCQ:TI@-EUF2P42 R6YS%1VLUV#7 \W&$V8-.H^" E=
M^K<;)D2^^SH+'7;D3ZS?#P[U!T$4W9 %:S-S7L3:IC6([<K>M32Q!IMPX/OH
MA\3QZ+_(?#?1D7]'0KI-+"V)ST39T78I[UHX MF! [M[AX;I0^WY/S;IYCQ:
M_.:$25D,B3;*N]FNJUU/_R"L./]XI?P^<;2!B-&6=+%=T+H6TDH6G/=QD"\Y
M8Q(F;O8I^_U\XY'1(O_3['Q7?5K\J7A:'(RFT\ZX-^E,/W8G[+2X&[,3+#I\
MU X;MI.,^Q6*HV//"7FVLSVUZD.CN(=%12U.:D+<P'>IEWH1]8D2];=\E%2A
M5=!=/:[@V&2')#OQ#JI#M'?+TG$SV\=)36 JB3S_[7*\F_8T#MP_[^B6\E0L
MR;4TWWH.MH+T;A ^ANW#J";J^NQ!J)+=+=NR>$C7++@-5JO 3XAY#CS&ZNC&
MB:@+5%K(0+;/IDW4&LXH'"@7$J&FY8Q'BX3N7(:T9.8\7)UZF_A@9Y7!KCN>
M[7.L)N;-V';^[Z^+[ ++A[*C[8-Q0V/K-(@C.3!U_9B^FW-*Z99,B;L):4Q)
M)#T[_:QS=DH^<)=]H'/XPN44U6:PY1&>93A[+ZZW8;)RSU2%AZ-MXNQ1;I$:
MT2.27=!BR]_!$4VMN5ZTS83&KU%:"N]L1LQ \K9E%QO9VA=PR(T9K2L&E+;&
M-"1O:1H2=/-:/8#\+8[1CUZDL1T^XG@W5#W#H;,BJJ=#ZIXX).4$&@@2FSQG
M&CY $D139!=;S)A/CW5I/F7A0R+>1][%MKL2*ISY. H($PSE\C@XSOB7Y8P7
MM+7M*JS#<2G9.)Q&#=> [BK8^))34DO#6[ZU:=LD;G<S/<:@0JPLI7$GWCH.
MU]51NC]\6T[D/NC.>G>=<7<RZ_,$$;F0H*CSB<;/G0GQ^#5)9^R$>#P'V:3X
MG/)13(#@775/%)X$T31O7H]^ W48: V'PTZ"0BST#VC1C,0-()@SX'BO[HD#
MUD8B7DH#I*(9R:D;1JK\$*TSQF<#=27U.$ZR^7FISJY5;7%@J"^Y$N!0Y;OH
MKU9D3MG<[IT5]5[38\)H\>#X3EH7:!2.0^J[=.UXHT\^"549,&H/:/M8*Y;4
MXD..9BS#<?;*4CVHT"PTLY:Z4A>C2O(,.1B&/*4".SKQ(]0=#4F2V5GJ9I#V
M@.J!128K:3 HZ5$8YZ2<_:LHX>Q'?^R>=@AL"=;DN 6.7:852Z%$6\XYU1B%
MB+A?+X/M-V[V!8[$C_M_<21^S"&Q^SG/VI+-B5_KBZR 7?/*UI81*G&UH!"R
MJ;>XS]?D?W\PE? [^:V]A#<RUE5S.4<.CLU4H*ZU3C)O;D&"D)L+Q<0'H\ZQ
MI:(;#B@!(@H#S.QE658-@_I+G@M):D15-[66M!O&M;(=):/8D,'Z-_+*#BL#
MNB!]]FTV29>,0[*BFY64X>INT$WD)&<X$/>AK#"$!(<\22U%5T^;,$I.CU(,
M9!U0'1Q W%>3;ZHH465B/"GGY5W -\1H> ]A 6[K*KEZC$:+W,_TK:W*02Q?
M^4*O/X 6EH1/AM3K(?#C9X^9AC$3/J%&E5IA\@!"^%Y)A%'&?@PVH??*ELW'
M]2RXIUO"?R#*Y"YJ;#N:I0Z;Y82;YG;OQ26$/\0!L[RJA^WW:(WX+F8!CDVB
M>COK\JBSU"E_\WIH,G9>DZKKGYQPGH6B)45SHKX_)B$-YJ(23[MSL8F/V7ZZ
M5G/7,<CX,Y&L2(O"PI._W@L)71JQ4P=U93$LIYR$[;=SIB2Q?:!LOL"4'NX/
MI]G H^ZK]$1?:FL[U4R=C4I*MEDS-\FB+V)QH0VF"U1-$_>83$,L3=;_$=..
MF*[(SK9F,Q9P5]P<J1]0RF@5\:;$V'FAJ\VJNUR&22X0D%C+^U@KJM=$S"%L
MT(IPSG[#_WAB6P[[R?\'4$L! A0#%     @ )HI\3LUVR_XN+ $ HJ84 !$
M             ( !     &-H96LM,C Q.#$R,S$N>&UL4$L! A0#%     @
M)HI\3C>9:?75%0  &?$  !$              ( !72P! &-H96LM,C Q.#$R
M,S$N>'-D4$L! A0#%     @ )HI\3M=W$].\$P  3>L  !4
M ( !84(! &-H96LM,C Q.#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( ":*?$ZK
M Q<!>C8  -JE P 5              "  5!6 0!C:&5K+3(P,3@Q,C,Q7V1E
M9BYX;6Q02P$"% ,4    "  FBGQ./,K SV5[  "\Z 8 %0
M@ ']C $ 8VAE:RTR,#$X,3(S,5]L86(N>&UL4$L! A0#%     @ )HI\3K/:
MFH\?2@  MO,$ !4              ( !E0@" &-H96LM,C Q.#$R,S%?<')E
:+GAM;%!+!08     !@ & (H!  #G4@(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
